{"meta":{"query_hash":"1a15f055c4fd","filters":{"topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment"},"cohort_total":893,"direct_labels_cover":0,"predictions_cover":893,"exported":893,"export_cap":100000,"truncated":false,"label_status":"direct model label, unvalidated","prediction_status":"machine_predicted_unvalidated (Codex and Gemma teacher distillation)","score_status":"score_only:v0-immature-baseline","snapshot":{"source":"OpenAlex, pinned release, all 482 partitions","release":"2026-06-24","frame_built":"2026-07-12"},"permalink":"https://metacan.xera.ac/q/1a15f055c4fd","api":"https://metacan.xera.ac/api/v1/cohort?topic=Myeloproliferative+Neoplasms%3A+Diagnosis+and+Treatment"},"results":[{"id":"W1117787078","doi":"10.1016/j.clml.2015.07.650","title":"Evolving Therapeutic Options for Polycythemia Vera: Perspectives of the Canadian Myeloproliferative Neoplasms Group","year":2015,"lang":"en","type":"article","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University Health Network; Centre Hospitalier de l’Université de Montréal; University of Alberta; McGill University; Princess Margaret Cancer Centre; Thunder Bay Regional Health Sciences Centre; McMaster University; Hôpital Maisonneuve-Rosemont; St. Paul's Hospital; Memorial University of Newfoundland; University of British Columbia; Lakehead University; University of Toronto; Western University; University of Windsor; Jewish General Hospital","funders":"World Health Organization","keywords":"Medicine; Polycythemia vera; Phlebotomy; Ruxolitinib; Internal medicine; Oncology; Myelofibrosis; Thrombosis; Disease; Pegylated interferon; Intensive care medicine; Immunology; Bone marrow; Ribavirin","score_opus":0.06055785830586164,"score_gpt":0.34054404136767774,"score_spread":0.2799861830618161,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1117787078","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97965735,0.0037484514,0.00017031399,0.0063125966,0.0010401515,0.0031467052,0.00016988156,0.000095730844,0.00565884],"genre_scores_gemma":[0.99276435,0.00018168696,0.0030632026,0.0015654843,0.00066679687,0.0007158438,0.000059480986,0.000076809105,0.0009063215],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9965697,0.00030713264,0.001056057,0.0007881214,0.00057827635,0.0007007135],"domain_scores_gemma":[0.99569947,0.0011406209,0.00037694475,0.0008698417,0.00095460186,0.0009585391],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00091727055,0.0004736224,0.0010017593,0.0001714534,0.0005344886,0.00008130149,0.00037259143,0.00043977282,0.000089581445],"category_scores_gemma":[0.0017670542,0.0003205716,0.0007340471,0.00047020547,0.00071567594,0.00017540186,0.000107417196,0.00033334157,0.00005324854],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0029350368,0.002114249,0.65846354,0.0001687192,0.0030262507,0.00012445303,0.009012142,0.000080208396,0.00060667266,0.10743625,0.02047291,0.1955596],"study_design_scores_gemma":[0.007949897,0.0017146133,0.96799135,0.00024109376,0.00054321653,0.00014468796,0.00225245,0.0015325387,0.0018833915,0.002747175,0.012605428,0.00039415996],"about_ca_topic_score_codex":0.006793501,"about_ca_topic_score_gemma":0.025254153,"teacher_disagreement_score":0.30952784,"about_ca_system_score_codex":0.0033950554,"about_ca_system_score_gemma":0.0067464937,"threshold_uncertainty_score":0.99992466},"labels":[],"label_agreement":null},{"id":"W137786602","doi":"10.1182/blood.v124.21.5567.5567","title":"Safety and Efficacy of Ruxolitinib Retreatment after Treatment Interruption in Patients Enrolled in an Open-Label, Multicenter, Expanded-Access Study in Myelofibrosis","year":2014,"lang":"en","type":"article","venue":"Blood","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; St. Paul's Hospital; Princess Margaret Cancer Centre","funders":"","keywords":"Ruxolitinib; Medicine; Myelofibrosis; Tolerability; Adverse effect; Internal medicine; Discontinuation; Placebo; Phases of clinical research; Anemia; Surgery; Clinical trial; Gastroenterology; Bone marrow; Pathology","score_opus":0.04587728601097647,"score_gpt":0.3566049150287874,"score_spread":0.3107276290178109,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W137786602","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99539304,0.00008597604,0.0000011505144,0.00005932735,0.000043184373,0.0041534114,0.000024866258,0.000009915568,0.00022912447],"genre_scores_gemma":[0.99840164,0.00016172523,0.0002642366,0.000055425873,0.000019386673,0.0009597297,0.000080124286,0.00002624336,0.000031512664],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9977984,0.0003340942,0.00075249636,0.00059292075,0.000223954,0.00029816537],"domain_scores_gemma":[0.9990986,0.00015487679,0.00015069258,0.00039054002,0.00006263394,0.00014266685],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002467246,0.00031880048,0.00084829505,0.00031429416,0.000029335752,0.00005225102,0.00011323393,0.000085837535,0.000061051454],"category_scores_gemma":[0.000070612135,0.00024027479,0.000033101518,0.00022963718,0.0000360817,0.000243034,0.00015670682,0.00009350219,0.000004788058],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0071577774,0.088805586,0.89102226,0.000034204077,0.00013023084,0.00004574269,0.0030772055,0.000003265929,0.00009837315,0.0000073799406,4.964534e-7,0.009617469],"study_design_scores_gemma":[0.15522636,0.01480555,0.82739407,0.00037236884,0.00016075144,0.000001360513,0.00020034554,0.00006278227,0.0016193263,0.00000476212,0.000007705641,0.00014461663],"about_ca_topic_score_codex":0.0013080307,"about_ca_topic_score_gemma":0.006865361,"teacher_disagreement_score":0.14806859,"about_ca_system_score_codex":0.0002879758,"about_ca_system_score_gemma":0.000040765437,"threshold_uncertainty_score":0.9798122},"labels":[],"label_agreement":null},{"id":"W1483638371","doi":"","title":"Detection of JAK2 V617F mutation in patients with myeloproliferative disorders using real-time PCR","year":2006,"lang":"en","type":"article","venue":"Clinical Cancer Research","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hôtel-Dieu de Québec","funders":"","keywords":"Biology; Essential thrombocythemia; Point mutation; ABL; Polycythemia vera; Mutation; Chronic myelogenous leukemia; Allele; Leukemia; Cancer research; Molecular biology; Genetics; Immunology; Gene; Tyrosine kinase","score_opus":0.07058238119344454,"score_gpt":0.4381847314717254,"score_spread":0.3676023502782808,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1483638371","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9970545,0.00008614037,0.00004560729,0.00035625682,0.000055053893,0.0012902308,0.000019676809,0.000015572443,0.001076915],"genre_scores_gemma":[0.9987864,0.00020239523,0.00040890393,0.000026565736,0.00014269933,0.00020655141,0.000046210134,0.00002679812,0.00015350664],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9974338,0.00040553167,0.00061864196,0.00043225085,0.0007571606,0.00035260574],"domain_scores_gemma":[0.9982682,0.00059088133,0.00014016971,0.00022259235,0.0006649356,0.00011326315],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00086505123,0.00014797851,0.00045550606,0.00024689254,0.00010479874,0.000016673139,0.000061174615,0.00013399842,0.00014525291],"category_scores_gemma":[0.00027220507,0.00010860781,0.000078551864,0.0006475666,0.00030886455,0.000101532045,0.000036738933,0.0004101248,0.000017271095],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.002713815,0.001489057,0.97949475,0.00005591117,0.00007235291,0.000011513339,0.00010940754,0.00022133678,0.000579722,0.000047128477,0.00006620846,0.0151387965],"study_design_scores_gemma":[0.00616804,0.0026382932,0.9843725,0.00023507774,0.00004245112,7.691435e-7,0.0000491356,0.0009889522,0.00506763,0.00024474275,0.00008715435,0.00010525246],"about_ca_topic_score_codex":0.004364567,"about_ca_topic_score_gemma":0.0030863679,"teacher_disagreement_score":0.015033544,"about_ca_system_score_codex":0.00038336223,"about_ca_system_score_gemma":0.0003807393,"threshold_uncertainty_score":0.65979487},"labels":[],"label_agreement":null},{"id":"W1488761450","doi":"10.1111/j.1440-1827.2011.02687.x","title":"Case of polycythemia vera with unusual organizing pneumonia mimicking the clinical features of military tuberculosis and possibly caused by the involvement of neoplastic megakaryocytes","year":2011,"lang":"en","type":"article","venue":"Pathology International","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"St Mary's Hospital Centre","funders":"","keywords":"Polycythemia vera; Pathology; Medicine; Tuberculosis; Pneumonia; Immunology; Internal medicine","score_opus":0.032444046149395105,"score_gpt":0.294634528414976,"score_spread":0.2621904822655809,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1488761450","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9972665,0.0010454337,0.0000292475,0.0009557716,0.00011061096,0.0002555337,0.00008087905,0.0000061056835,0.00024994466],"genre_scores_gemma":[0.99874526,0.0002616695,0.0005797825,0.00028172688,0.00004103306,0.000025513538,0.000025594523,0.000012116954,0.000027308088],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9989212,0.00012306166,0.00043657355,0.00021053964,0.00019360911,0.00011499069],"domain_scores_gemma":[0.9986944,0.0006557917,0.00020471022,0.00019163618,0.00020980404,0.000043609543],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002940025,0.00013978532,0.00031888802,0.00006690426,0.000059635142,0.0000022521688,0.000109530396,0.000073022864,0.00005770654],"category_scores_gemma":[0.00017111767,0.00007123282,0.000069182286,0.00008015512,0.0004950977,0.000035813187,0.000076074946,0.00017631825,6.7424105e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0006669706,0.00071392796,0.97341806,0.000050237035,0.0010662619,0.000663357,0.006593973,0.0000029597766,0.014173842,0.0006917331,0.00039819576,0.0015604763],"study_design_scores_gemma":[0.002282857,0.0015461246,0.86384183,0.00015170226,0.0004900105,0.0038368946,0.0016101555,0.000088661174,0.12592864,0.000111488764,0.00002200498,0.00008965326],"about_ca_topic_score_codex":0.000380475,"about_ca_topic_score_gemma":0.00027454135,"teacher_disagreement_score":0.1117548,"about_ca_system_score_codex":0.00002686278,"about_ca_system_score_gemma":0.00007468774,"threshold_uncertainty_score":0.290479},"labels":[],"label_agreement":null},{"id":"W1490058918","doi":"10.1158/1538-7445.am2014-2914","title":"Abstract 2914: Phosphoproteomic and transcriptional biomarkers predict response to SAR302503, a JAK2 inhibitor, in human acute myeloid leukemia preclinical models","year":2014,"lang":"en","type":"article","venue":"Cancer Research","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency; Canada's Michael Smith Genome Sciences Centre; Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Myeloid leukemia; Biomarker; Cancer research; NPM1; Leukemia; Medicine; Cancer; Myeloid; Biomarker discovery; Oncology; Biology; Immunology; Internal medicine; Gene; Proteomics","score_opus":0.07934854208616081,"score_gpt":0.4099494661520082,"score_spread":0.3306009240658474,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1490058918","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9906663,0.0007237473,0.00004495785,0.0055405055,0.00009649471,0.0019195459,0.00012288243,0.000038648068,0.00084695674],"genre_scores_gemma":[0.9960823,0.00068050524,0.000414205,0.00035446024,0.00024009102,0.0015529168,0.00004005344,0.000046099234,0.0005893886],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9966883,0.0004020133,0.0005261411,0.00079816254,0.00090787513,0.0006775081],"domain_scores_gemma":[0.9981664,0.0005678231,0.00004843714,0.00040012004,0.00024388898,0.00057335966],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002790818,0.00025905168,0.00049775623,0.0004664211,0.00021931209,0.00007305161,0.00016298088,0.00021805534,0.00035755365],"category_scores_gemma":[0.0002893583,0.00021816071,0.00010630237,0.0004274544,0.00029359572,0.00015698298,0.000092262206,0.0007230838,0.000034753204],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.044962313,0.001130669,0.06625617,0.00033551242,0.00082406885,0.0002623546,0.0035862925,0.00041708988,0.83864754,0.001575159,0.011254836,0.030748012],"study_design_scores_gemma":[0.014399332,0.0045139,0.8503993,0.0015119447,0.00010376523,0.00004024451,0.00019070138,0.0013830365,0.11855677,0.0015631088,0.006870124,0.00046775636],"about_ca_topic_score_codex":0.0014641772,"about_ca_topic_score_gemma":0.00065149006,"teacher_disagreement_score":0.78414315,"about_ca_system_score_codex":0.0011754856,"about_ca_system_score_gemma":0.0010050911,"threshold_uncertainty_score":0.88963354},"labels":[],"label_agreement":null},{"id":"W1559360333","doi":"10.1111/j.1365-2141.2011.08701.x","title":"Low prevalence of <i>JAK2</i> V617F mutation in patients with first unprovoked venous thromboembolism","year":2011,"lang":"en","type":"letter","venue":"British Journal of Haematology","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of British Columbia; McMaster University; Université de Montréal; Western University; Hôpital du Sacré-Cœur de Montréal; McGill University; Ottawa Hospital; Dalhousie University; University of Ottawa","funders":"Canadian Institutes of Health Research","keywords":"JAK2 V617F; Venous thromboembolism; Medicine; Internal medicine; Mutation; Genetics; Thrombosis; Biology; Gene","score_opus":0.008621205634112651,"score_gpt":0.21588955584631903,"score_spread":0.20726835021220638,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1559360333","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9809534,0.0022588538,0.000028306291,0.01506728,0.0003783207,0.000919127,0.00010598462,0.000009886337,0.0002788723],"genre_scores_gemma":[0.9649822,0.0025868472,0.0015633233,0.029948222,0.0004453484,0.000072300594,0.00018036956,0.000101863254,0.00011950074],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99746186,0.00017235022,0.0011106897,0.00032777307,0.0005516669,0.00037567256],"domain_scores_gemma":[0.9973352,0.00022876891,0.0013692314,0.00023286759,0.00074160774,0.00009230116],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00017290474,0.00031563814,0.0019622662,0.00031455528,0.00005219719,0.000016954105,0.00020112003,0.0005364906,0.00023755776],"category_scores_gemma":[0.0001843943,0.00027937331,0.0001908996,0.00015543959,0.0002291137,0.00013226795,0.000034359837,0.0011906519,0.000010664074],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0011984317,0.00677364,0.38157585,0.011309851,0.001712907,0.2723254,0.0012699432,0.000012518534,0.0000038204034,0.00004465953,0.31812808,0.0056448854],"study_design_scores_gemma":[0.015952969,0.009296209,0.80717087,0.023838632,0.0017690826,0.13240808,0.000036967755,0.0000033937647,0.001284164,0.00034185816,0.0073025012,0.00059525995],"about_ca_topic_score_codex":0.00014141262,"about_ca_topic_score_gemma":0.00018239403,"teacher_disagreement_score":0.42559505,"about_ca_system_score_codex":0.00012168597,"about_ca_system_score_gemma":0.0003615316,"threshold_uncertainty_score":0.99996585},"labels":[],"label_agreement":null},{"id":"W157430056","doi":"10.1182/blood.v122.21.396.396","title":"Long-Term Outcomes Of Ruxolitinib Therapy In Patients With Myelofibrosis: 3-Year Update From COMFORT-I","year":2013,"lang":"en","type":"article","venue":"Blood","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":28,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Ruxolitinib; Medicine; Myelofibrosis; Clinical endpoint; Internal medicine; Placebo; Population; Phases of clinical research; Intention-to-treat analysis; Randomized controlled trial; Surgery; Clinical trial; Gastroenterology; Bone marrow; Pathology","score_opus":0.012721526456808198,"score_gpt":0.24306618042054037,"score_spread":0.2303446539637322,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W157430056","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9980539,0.00014635916,0.0000019375523,0.00026515056,0.00003609432,0.0010011381,0.00007274159,0.000024266377,0.00039842058],"genre_scores_gemma":[0.99815774,0.00012426729,0.0008205078,0.00037511185,0.000027614642,0.00019051963,0.00022595291,0.000026614576,0.000051661926],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99888074,0.000032771648,0.00031218774,0.00025744387,0.00028712818,0.00022975238],"domain_scores_gemma":[0.9992583,0.00007446209,0.00011763671,0.00032653872,0.00011424938,0.0001088156],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000035073615,0.00020302836,0.0004960003,0.00007961495,0.00002506651,0.000017423261,0.0000733995,0.00006658037,0.0007549244],"category_scores_gemma":[0.000014556286,0.00012612995,0.000071778864,0.000099519544,0.000050299383,0.00009401417,0.000024586601,0.00008911286,0.000077012366],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0001681617,0.0037212237,0.99274653,0.000016496146,0.00040512197,0.000009650736,0.00017089047,2.300793e-7,0.000060767863,0.00006435524,0.000063512845,0.0025730347],"study_design_scores_gemma":[0.01890054,0.0011664266,0.9701978,0.00017542228,0.000111264424,6.847166e-7,0.000024870873,7.2063926e-7,0.009236184,0.00004363101,0.000019853533,0.00012258628],"about_ca_topic_score_codex":0.0002765381,"about_ca_topic_score_gemma":0.00005021346,"teacher_disagreement_score":0.022548739,"about_ca_system_score_codex":0.000019909108,"about_ca_system_score_gemma":0.000037312802,"threshold_uncertainty_score":0.8265893},"labels":[],"label_agreement":null},{"id":"W1624561907","doi":"10.4212/cjhp.v61i3.54","title":"Anagrelide-Induced Pneumonitis: Case Report and Review of the Literature","year":2008,"lang":"en","type":"article","venue":"The Canadian Journal of Hospital Pharmacy","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"Western University; London Health Sciences Centre","funders":"","keywords":"Anagrelide; Pneumonitis; Essential thrombocythemia; Medicine; Interstitial pneumonitis; Antithrombotic; Adverse effect; Adverse drug reaction; Drug; Internal medicine; Intensive care medicine; Dermatology; Pediatrics; Pharmacology; Polycythemia vera; Lung; Respiratory disease","score_opus":0.025139139386817007,"score_gpt":0.2953461331954643,"score_spread":0.2702069938086473,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1624561907","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.90884143,0.061771277,1.740694e-7,0.027978178,0.00034408437,0.00040386105,0.000020956508,0.0000020414832,0.00063802104],"genre_scores_gemma":[0.9837854,0.013798671,0.00003225179,0.0020198922,0.00019147238,0.000006160734,0.0000025369168,0.000012821086,0.00015080189],"study_design_codex":"case_report","study_design_gemma":"case_report","domain_scores_codex":[0.9989346,0.000083516934,0.00046207887,0.00010495422,0.00023715799,0.00017764166],"domain_scores_gemma":[0.9984409,0.000057593315,0.0003800068,0.00024018425,0.0004658351,0.0004154648],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00030260894,0.00014197637,0.0003448566,0.00007212661,0.00028042574,0.000020707794,0.00011171718,0.00002644317,0.00007429041],"category_scores_gemma":[0.00027836108,0.00006975551,0.0001839812,0.00023661455,0.00014375786,0.00010267741,0.000015460335,0.00037251815,0.0000018974341],"study_design_candidate":"case_report","study_design_consensus":"case_report","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000050460923,0.00018478226,0.21454392,0.001005683,0.000715366,0.7390344,0.0043724007,0.0000011181959,0.00017234973,0.00015610056,0.033352513,0.006410906],"study_design_scores_gemma":[0.0018604426,0.0007462306,0.07592155,0.008419656,0.00065953523,0.89469105,0.00013250633,0.0000034901266,0.004668789,0.00008932846,0.012645028,0.0001623727],"about_ca_topic_score_codex":0.0030492465,"about_ca_topic_score_gemma":0.0017671979,"teacher_disagreement_score":0.15565667,"about_ca_system_score_codex":0.00010758687,"about_ca_system_score_gemma":0.0011653854,"threshold_uncertainty_score":0.4609569},"labels":[],"label_agreement":null},{"id":"W1644692312","doi":"10.1002/ajh.23690","title":"How common are myeloproliferative neoplasms? A systematic review and meta‐analysis","year":2014,"lang":"en","type":"review","venue":"American Journal of Hematology","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":228,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Medical Research Council; Queen's University; Queen's University Belfast","keywords":"Incidence (geometry); Essential thrombocythemia; Medicine; Polycythemia vera; Meta-analysis; Publication bias; Myelofibrosis; Internal medicine; Demography","score_opus":0.03890305758919121,"score_gpt":0.3476482793114404,"score_spread":0.30874522172224916,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1644692312","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00001476955,0.99266595,0.000121977195,0.004889489,0.000044001023,0.002161352,0.00004427831,0.000015861771,0.00004233635],"genre_scores_gemma":[0.0005842162,0.99552846,0.0010137489,0.0020535667,0.00005560603,0.00048399204,0.000030056986,0.00006652736,0.00018382874],"study_design_codex":"systematic_review","study_design_gemma":"meta_analysis","domain_scores_codex":[0.9942859,0.0019546333,0.0023232815,0.0005317339,0.00048781998,0.0004166234],"domain_scores_gemma":[0.989174,0.0017812051,0.007313358,0.0007047836,0.00056167075,0.00046497205],"candidate_categories":["metaepi_narrow","metaepi_broad"],"consensus_categories":[],"category_scores_codex":[0.0008364566,0.0009304949,0.036643345,0.0008612394,0.000099008554,0.00007035843,0.00027784056,0.00020302378,0.00007997807],"category_scores_gemma":[0.00059630215,0.0004998303,0.0042614215,0.0011150663,0.00042067372,0.00008946683,0.00008143757,0.00079343625,0.000019084344],"study_design_candidate":"meta_analysis","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000015952597,0.00016916041,0.00012432762,0.6216224,0.37380537,0.00068474485,0.000058072685,1.1287335e-7,6.262098e-9,0.0005214422,0.00038925305,0.0026091773],"study_design_scores_gemma":[0.00029798222,0.0012071602,0.000005330889,0.082733996,0.87186056,0.020637274,0.00012122581,0.0000016112657,0.0000010555149,0.000018906505,0.022789685,0.00032523222],"about_ca_topic_score_codex":0.000008933138,"about_ca_topic_score_gemma":0.000031146057,"teacher_disagreement_score":0.5388884,"about_ca_system_score_codex":0.00012600615,"about_ca_system_score_gemma":0.0003013135,"threshold_uncertainty_score":0.9997453},"labels":[],"label_agreement":null},{"id":"W1766283728","doi":"10.1016/j.bbmt.2015.09.005","title":"Hematopoietic Cell Transplantation as Curative Therapy for Patients with Myelofibrosis: Long-Term Success in all Age Groups","year":2015,"lang":"en","type":"review","venue":"Biology of Blood and Marrow Transplantation","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":42,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Manitoba; University of Toronto; Ottawa Hospital; Princess Margaret Cancer Centre; University of Ottawa","funders":"National Cancer Institute","keywords":"Medicine; Myelofibrosis; Hematopoietic cell; Transplantation; Term (time); Hematopoietic stem cell transplantation; Oncology; Surgery; Haematopoiesis; Internal medicine; Stem cell; Bone marrow","score_opus":0.03375686149648907,"score_gpt":0.3241317274963144,"score_spread":0.2903748659998253,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1766283728","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.38252407,0.6126927,0.00008506149,0.000031292195,0.000070712485,0.003794992,0.00069462345,0.000019479994,0.0000870572],"genre_scores_gemma":[0.20560575,0.7840472,0.00028557653,0.000036654936,0.00002735813,0.00077053066,0.009178311,0.000034795772,0.000013814884],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9982459,0.00017890136,0.0006328659,0.00052294554,0.00016004014,0.0002593451],"domain_scores_gemma":[0.9989707,0.00026113662,0.00037212655,0.00014257683,0.00013943913,0.00011405129],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00015274387,0.00047167612,0.0015183588,0.0002456729,0.00004394066,0.000013711919,0.00007748982,0.00037231634,0.000012482215],"category_scores_gemma":[0.000004520181,0.00031353027,0.00017014665,0.00013598173,0.00012558026,0.000098202036,0.0000037386226,0.00015214575,0.0000020435502],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.009169104,0.00715253,0.39434052,0.13438475,0.0030559031,0.00045984483,0.008271691,9.682478e-7,0.00041956303,0.0007952482,0.000029372479,0.44192052],"study_design_scores_gemma":[0.22601421,0.09229105,0.39967334,0.14682864,0.081097715,0.001950045,0.00032438006,0.0000042087204,0.019868808,0.0012690185,0.024542373,0.006136204],"about_ca_topic_score_codex":0.000032099226,"about_ca_topic_score_gemma":0.00009811962,"teacher_disagreement_score":0.4357843,"about_ca_system_score_codex":0.000029519406,"about_ca_system_score_gemma":0.00016247497,"threshold_uncertainty_score":0.9999317},"labels":[],"label_agreement":null},{"id":"W1893542341","doi":"10.1111/ced.12708","title":"Acral keratoses and leucocytoclastic vasculitis occurring during treatment of essential thrombocythaemia with hydroxyurea","year":2015,"lang":"en","type":"article","venue":"Clinical and Experimental Dermatology","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Ottawa","funders":"","keywords":"Medicine; Dermatology; Psoriasis; Lesion; Adverse effect; Discontinuation; Vasculitis; Hydroxycarbamide; Pathology; Surgery; Chemotherapy; Internal medicine","score_opus":0.048168981028374296,"score_gpt":0.3584948222964119,"score_spread":0.3103258412680376,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1893542341","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9956785,0.0034037544,0.000009475313,0.00016460493,0.00009795189,0.00035545763,0.000010417502,0.000027563861,0.00025231126],"genre_scores_gemma":[0.9987778,0.00032834255,0.0005894573,0.000082522834,0.000086172455,0.0000797948,0.000019487596,0.000015495605,0.000020901682],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9987969,0.00007279487,0.00039190377,0.00037489136,0.00013045892,0.00023309293],"domain_scores_gemma":[0.9992467,0.00010376987,0.000091346155,0.00015717417,0.00004607175,0.00035491222],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000034196826,0.0002377366,0.0008247209,0.000047674865,0.00007565217,0.000014539148,0.00002806654,0.00012144652,0.00003548871],"category_scores_gemma":[0.000022888216,0.00015074784,0.0001051701,0.00005148765,0.0005271331,0.000072703886,0.00005715882,0.00007737511,0.000007753609],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0013914258,0.0013431518,0.9928351,0.00005648929,0.00054136885,0.00069308485,0.0009696821,0.0000031440045,0.0013503075,0.00027256392,0.000058772075,0.00048492392],"study_design_scores_gemma":[0.04094368,0.012327145,0.47526127,0.00023982339,0.000601038,0.009532935,0.0018421729,0.0004357452,0.45760953,0.00007958404,0.00066471635,0.00046236027],"about_ca_topic_score_codex":0.0000577601,"about_ca_topic_score_gemma":0.000014808031,"teacher_disagreement_score":0.51757383,"about_ca_system_score_codex":0.000053818985,"about_ca_system_score_gemma":0.00008688943,"threshold_uncertainty_score":0.61473185},"labels":[],"label_agreement":null},{"id":"W1944062703","doi":"10.1007/s11899-015-0287-9","title":"Social Media and Myeloproliferative Neoplasms (MPN)—Focus on Twitter and the Development of a Disease-specific Community: #MPNSM","year":2015,"lang":"en","type":"review","venue":"Current Hematologic Malignancy Reports","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":29,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"University of Texas MD Anderson Cancer Center; Incyte; National Cancer Institute; Gilead Sciences","keywords":"Social media; Medicine; Public relations; Citation; Focus group; Health care; Internet privacy; Political science; World Wide Web; Business; Computer science; Marketing","score_opus":0.1813166460235479,"score_gpt":0.373956349976804,"score_spread":0.19263970395325608,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1944062703","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0075890627,0.98720926,0.000012502778,0.00041727323,0.00046029565,0.0035105136,0.00004327322,0.00006065886,0.00069717795],"genre_scores_gemma":[0.02351231,0.97358185,0.00028194848,0.000045475026,0.00018673306,0.0018573137,0.00040659233,0.000070537484,0.000057220826],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99468046,0.0009439987,0.0021540064,0.0008738971,0.0008502546,0.00049737596],"domain_scores_gemma":[0.99538296,0.0012966809,0.0017075414,0.00083226885,0.0003427866,0.00043778002],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0014374327,0.0010343196,0.0044063134,0.0002558894,0.00055094395,0.00007139623,0.00017199013,0.00033966286,0.000048341735],"category_scores_gemma":[0.00048735604,0.0005494899,0.00044834934,0.0002991372,0.00079302804,0.000055921973,0.00036024288,0.0010329989,0.000015897816],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0006975096,0.0022918882,0.004146323,0.03348304,0.0014700423,0.0016700319,0.014454689,6.070255e-8,1.9779824e-7,0.015861694,0.00972717,0.91619736],"study_design_scores_gemma":[0.0042841034,0.00032780628,0.0014646751,0.041911807,0.0033870684,0.0030557304,0.00053348235,0.0000018188148,0.000051509738,0.008340019,0.9354799,0.0011620767],"about_ca_topic_score_codex":0.0000029201706,"about_ca_topic_score_gemma":0.000011189213,"teacher_disagreement_score":0.92575276,"about_ca_system_score_codex":0.00020373886,"about_ca_system_score_gemma":0.0010032268,"threshold_uncertainty_score":0.99969566},"labels":[],"label_agreement":null},{"id":"W1964442667","doi":"10.1016/j.ceca.2013.05.006","title":"Calreticulin for better or for worse, in sickness and in health, until death do us part","year":2013,"lang":"en","type":"article","venue":"Cell Calcium","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":13,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"Canadian Institutes of Health Research","keywords":"Thrombopoietin; Thrombopoietin receptor; Myelofibrosis; Biology; Janus kinase 2; Thrombocytosis; Haematopoiesis; Germline; Germline mutation; Erythropoietin receptor; Cancer research; Myeloproliferative Disorders; Signal transduction; Mutation; Immunology; Cell biology; Genetics; Stem cell; Platelet; Gene; Bone marrow","score_opus":0.04167832208289082,"score_gpt":0.3164435913433461,"score_spread":0.2747652692604553,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1964442667","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98775375,0.00070635765,0.0002871916,0.0075034173,0.00014706368,0.0032235193,0.000030573854,0.000014718108,0.0003334098],"genre_scores_gemma":[0.98862743,0.00013047906,0.0028463565,0.0032998293,0.00017706983,0.0027700248,0.00006562955,0.000031149528,0.0020520405],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9987475,0.000036612266,0.0003672095,0.00034562865,0.000099626115,0.00040339146],"domain_scores_gemma":[0.99921036,0.0003041683,0.000066947345,0.00016439262,0.00007479462,0.00017934386],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00019306676,0.00018154114,0.0004413264,0.00009592656,0.000049867383,0.000028272014,0.00003760892,0.00009864993,0.0002383927],"category_scores_gemma":[0.000060508206,0.00012580924,0.000056908455,0.00010283528,0.00003475226,0.000051692045,0.000019931837,0.0001033917,0.000024926381],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0013994923,0.0018037653,0.9378713,0.002207383,0.00006439374,0.000076191805,0.001483515,0.00003651901,0.0004536382,0.0005124026,0.036121078,0.017970363],"study_design_scores_gemma":[0.035916463,0.0039166883,0.6891938,0.0013118653,0.00015890402,0.000042448362,0.0006591059,0.004062195,0.03033713,0.0013581688,0.23220366,0.00083961524],"about_ca_topic_score_codex":0.00037610444,"about_ca_topic_score_gemma":0.0005009863,"teacher_disagreement_score":0.2486775,"about_ca_system_score_codex":0.00011827002,"about_ca_system_score_gemma":0.00012200963,"threshold_uncertainty_score":0.5130352},"labels":[],"label_agreement":null},{"id":"W1969209268","doi":"10.1097/00000372-200010000-00009","title":"Extramedullary Hematopoiesis in a Pyogenic Granuloma","year":2000,"lang":"en","type":"article","venue":"American Journal of Dermatopathology","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":14,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Kingston General Hospital","funders":"","keywords":"Pyogenic granuloma; Homing (biology); Extramedullary hematopoiesis; Medicine; Pathology; Haematopoiesis; Lesion; Granuloma; Stem cell; Biology","score_opus":0.004671642824119964,"score_gpt":0.25675199160907275,"score_spread":0.2520803487849528,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1969209268","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99334675,0.0016856054,0.00003625601,0.003397476,0.00006307713,0.0001443125,0.0000029800358,0.000012409305,0.0013111625],"genre_scores_gemma":[0.9929946,0.0017396621,0.0029615473,0.002119628,0.000078566416,0.000015986514,0.0000023993148,0.000021190439,0.000066421555],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9984711,0.00018564556,0.0006492375,0.00017182865,0.00021897512,0.0003032059],"domain_scores_gemma":[0.99912226,0.00013729853,0.00026432436,0.00019717168,0.0000890011,0.00018996197],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00020393195,0.00017855375,0.00082163734,0.00027733573,0.000035134373,0.000009498549,0.000101324644,0.000054174372,0.0006497212],"category_scores_gemma":[0.00004779284,0.00013754435,0.00020610841,0.0003428309,0.000258659,0.0000773919,0.00001210228,0.00028171123,0.00007369428],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0005799646,0.0007994897,0.86376804,0.000022810947,0.000099521036,0.012784112,0.0011030952,0.000014872874,0.0006704264,0.00013318482,0.000495629,0.11952884],"study_design_scores_gemma":[0.0045032087,0.00346619,0.7250373,0.0002610609,0.00023614854,0.25279978,0.00090096396,0.000032299304,0.0048082774,0.0004927695,0.007196091,0.000265934],"about_ca_topic_score_codex":0.000017198468,"about_ca_topic_score_gemma":0.000012473806,"teacher_disagreement_score":0.24001567,"about_ca_system_score_codex":0.0000863775,"about_ca_system_score_gemma":0.00014699488,"threshold_uncertainty_score":0.71139914},"labels":[],"label_agreement":null},{"id":"W1969785686","doi":"10.1097/moh.0b013e3283497f54","title":"The pathogenesis of essential thrombocythemia","year":2011,"lang":"en","type":"review","venue":"Current Opinion in Hematology","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":17,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency; Terry Fox Research Institute","funders":"Kay Kendall Leukaemia Fund","keywords":"Essential thrombocythemia; Biology; Pathogenesis; Genetics; Phenotype; Human genetics; Myeloproliferative Disorders; Mechanism (biology); Myelofibrosis; Bioinformatics; Polycythemia vera; Immunology; Gene","score_opus":0.14246494387948588,"score_gpt":0.4276597470132881,"score_spread":0.28519480313380224,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1969785686","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000041318122,0.9945215,0.00001612796,0.00004393019,0.0038053568,0.0012749888,0.000039795417,0.000017317661,0.00023964052],"genre_scores_gemma":[0.00008181532,0.99859434,0.00006187112,0.0000027566762,0.00022123508,0.0007904883,0.00019191712,0.000037876256,0.000017705093],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9977093,0.0002600508,0.0010907782,0.00044135968,0.00016750212,0.00033105494],"domain_scores_gemma":[0.99809796,0.00059307885,0.0005607785,0.0005638654,0.00009514495,0.00008917012],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00020947766,0.0004032422,0.0023938592,0.00019307426,0.00006711159,0.0000070960386,0.00020508746,0.00030835776,0.00014386736],"category_scores_gemma":[0.0001271069,0.00022901528,0.0005279658,0.00025943562,0.00021046223,0.000018967141,0.00011618872,0.0003541043,0.00008645483],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00003743618,0.0007873958,0.0028438717,0.040023003,0.00032893178,0.000009260363,0.000115887735,2.3294698e-8,2.4321173e-7,0.042662375,0.0019450696,0.9112465],"study_design_scores_gemma":[0.0005552907,0.00013038646,0.00032593665,0.02162395,0.00043431242,0.00035018657,0.000012659215,0.000001340946,0.00001994993,0.00017998987,0.97619253,0.0001734572],"about_ca_topic_score_codex":0.0000076119936,"about_ca_topic_score_gemma":0.0000042359247,"teacher_disagreement_score":0.97424746,"about_ca_system_score_codex":0.000086301254,"about_ca_system_score_gemma":0.00042998343,"threshold_uncertainty_score":0.9338972},"labels":[],"label_agreement":null},{"id":"W1971888832","doi":"10.1016/j.leukres.2010.07.015","title":"What are RBC-transfusion-dependence and -independence?","year":2010,"lang":"en","type":"letter","venue":"Leukemia Research","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":100,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"National Cancer Institute","keywords":"Independence (probability theory); Medicine; Erythropoiesis; Anemia; Intensive care medicine; Interval (graph theory); Transfusion therapy; Blood transfusion; Internal medicine; Statistics; Mathematics","score_opus":0.06272011493768677,"score_gpt":0.36454207019617724,"score_spread":0.3018219552584905,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1971888832","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.12762001,0.004180749,0.000009679702,0.85916466,0.001126557,0.0026319171,0.00006891364,0.00011244298,0.0050851065],"genre_scores_gemma":[0.104071245,0.096301936,0.0014446724,0.6722732,0.015457614,0.0028804136,0.0008986783,0.0005381157,0.106134124],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99312687,0.0003895808,0.0004606228,0.001441705,0.0033335194,0.0012477039],"domain_scores_gemma":[0.99594855,0.0013445846,0.00012788118,0.0011662348,0.0009791043,0.0004336318],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":["research_integrity"],"category_scores_codex":[0.0012117631,0.00058310427,0.0009564132,0.00065436854,0.00051166175,0.0005656393,0.0004173342,0.0035279528,0.0015278545],"category_scores_gemma":[0.00044125813,0.0004460426,0.00020228897,0.00047232446,0.00055721414,0.00036234452,0.00030726712,0.018138992,0.0006734915],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00018304962,0.00013799056,0.015801664,0.00081679865,0.00025596813,0.014696629,0.00047567041,3.7971958e-7,0.0007879573,0.000093068724,0.95428604,0.012464804],"study_design_scores_gemma":[0.0029704394,0.00083237287,0.014550662,0.0027529646,0.00018756364,0.0013732938,0.00050923374,0.00007366413,0.0054820077,0.0010836166,0.96952164,0.0006625361],"about_ca_topic_score_codex":0.0009999553,"about_ca_topic_score_gemma":0.0008360243,"teacher_disagreement_score":0.18689144,"about_ca_system_score_codex":0.0010571975,"about_ca_system_score_gemma":0.0018395944,"threshold_uncertainty_score":0.99979913},"labels":[],"label_agreement":null},{"id":"W1972944880","doi":"10.1182/blood-2013-08-523514","title":"Value of the peripheral blood film: megakaryocytic fragments misidentified by automated counter","year":2013,"lang":"en","type":"article","venue":"Blood","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"London Health Sciences Centre","funders":"","keywords":"Medicine; Polycythemia vera; Peripheral blood; Polycythemia rubra vera; Respiratory system; Internal medicine; Gastroenterology; Anesthesia","score_opus":0.006422099441546095,"score_gpt":0.23366418439696635,"score_spread":0.22724208495542025,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1972944880","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99493515,0.0005605466,0.0000027088147,0.000832666,0.00015175134,0.0009894657,0.000052317726,0.00010311794,0.002372278],"genre_scores_gemma":[0.99544036,0.000051108214,0.0002529632,0.00075854984,0.0000540391,0.00021876048,0.00004515359,0.000029007748,0.0031500538],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99856687,0.00007464587,0.00036271583,0.000290504,0.00043043713,0.00027485157],"domain_scores_gemma":[0.9990727,0.00006482027,0.00013616962,0.0004505177,0.00015281586,0.00012300059],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.000075754775,0.00022161803,0.00036790277,0.0000363158,0.000098327575,0.000042078,0.00014451865,0.00009975756,0.0012192449],"category_scores_gemma":[0.000058265377,0.00013552648,0.00016183754,0.00014425928,0.00008378091,0.00008220746,0.000061154955,0.00012712138,0.00011350865],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00008356328,0.011663642,0.7571778,0.0003308934,0.0038466905,0.000088195964,0.0013626305,0.000031372223,0.105858326,0.00032588324,0.118964426,0.0002665726],"study_design_scores_gemma":[0.017173776,0.00074371067,0.52903306,0.00043294093,0.0019958343,0.00015467755,0.0001463169,0.0022525142,0.4463922,0.00010393596,0.0012661477,0.00030483972],"about_ca_topic_score_codex":0.00033096317,"about_ca_topic_score_gemma":0.000011241046,"teacher_disagreement_score":0.34053388,"about_ca_system_score_codex":0.000039471764,"about_ca_system_score_gemma":0.00009202996,"threshold_uncertainty_score":0.99969375},"labels":[],"label_agreement":null},{"id":"W1978086164","doi":"10.1182/blood-2008-11-187419","title":"Enrichment of Sca1+ hematopoietic progenitors in polycythemic mice inhibits leukemogenesis","year":2009,"lang":"en","type":"article","venue":"Blood","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Health Sciences Centre; Sunnybrook Health Science Centre","funders":"","keywords":"Haematopoiesis; Progenitor cell; Polycythemia vera; Biology; Erythropoietin receptor; Cancer research; Erythropoietin; CD34; Leukemia; Immunology; Stem cell; Molecular biology; Cell biology; Endocrinology","score_opus":0.010184806966759595,"score_gpt":0.2534026142587871,"score_spread":0.24321780729202747,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1978086164","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.995331,0.0018545361,0.000002841175,0.00067232683,0.00003918764,0.00064315053,0.0000057278107,0.00002909088,0.0014221251],"genre_scores_gemma":[0.99843234,0.00016343764,0.0008763033,0.0002297069,0.00007598969,0.00007078642,0.000011853852,0.0000141894525,0.00012538044],"study_design_codex":"observational","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99880576,0.000031289495,0.00037309257,0.00027403008,0.0002651105,0.0002506878],"domain_scores_gemma":[0.9994603,0.000045730398,0.00009489937,0.00022662453,0.000058189613,0.00011429907],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000095539166,0.0001854998,0.00040186004,0.00015641242,0.00002702092,0.000006546063,0.000059220733,0.00007787815,0.00004729649],"category_scores_gemma":[0.000034657794,0.00015009058,0.000106650725,0.00028599298,0.000029156294,0.000035162713,0.000018149834,0.000081079896,0.00002663356],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0002515451,0.0109097855,0.7541829,0.00020335786,0.0002865313,0.00026281294,0.001448574,0.0000052876235,0.22531724,0.0005963936,0.00028380723,0.006251777],"study_design_scores_gemma":[0.004955179,0.000781493,0.124754995,0.00024646756,0.00021968313,0.00014978743,0.000083173705,0.0000044848757,0.8684938,0.000093258495,0.00009701868,0.00012064147],"about_ca_topic_score_codex":0.000029965151,"about_ca_topic_score_gemma":0.000010913974,"teacher_disagreement_score":0.64317656,"about_ca_system_score_codex":0.00007423156,"about_ca_system_score_gemma":0.00011978362,"threshold_uncertainty_score":0.6120516},"labels":[],"label_agreement":null},{"id":"W1978362421","doi":"10.1007/s12308-011-0118-4","title":"Emergence of JAK2-mutant primary myelofibrosis in myelodysplastic syndrome: rare case report, literature review, and implications for clonal progression","year":2011,"lang":"en","type":"article","venue":"Journal of Hematopathology","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen's University","funders":"Medical Center, University of Rochester; University of Rochester; University of Toronto; Mayo Clinic","keywords":"Myelofibrosis; Hematology; Medicine; Internal medicine; Oncology; Somatic evolution in cancer; Cancer research; Cancer; Bone marrow","score_opus":0.023682995444282567,"score_gpt":0.31693238629513415,"score_spread":0.29324939085085155,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1978362421","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9502285,0.046741802,0.00026581628,0.001573712,0.00011237172,0.0008835929,0.000058531747,0.0000059544845,0.00012969832],"genre_scores_gemma":[0.9704505,0.011358437,0.017684203,0.00025258213,0.00003571594,0.00015152026,0.00002531825,0.000018071398,0.000023648225],"study_design_codex":"observational","study_design_gemma":"case_report","domain_scores_codex":[0.99836147,0.0000770943,0.0010325073,0.00022269214,0.00012418315,0.0001820311],"domain_scores_gemma":[0.9982574,0.00014347426,0.0007922929,0.00021450678,0.0004565528,0.00013576046],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004837067,0.00016801755,0.0008405026,0.00021072569,0.000050707058,0.0000047602216,0.00005915809,0.00011462424,0.000057677564],"category_scores_gemma":[0.00035338453,0.00011341001,0.00013821333,0.00022391873,0.000083671,0.00010843653,0.000038319482,0.0002040489,5.599255e-7],"study_design_candidate":"case_report","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00083541,0.002043527,0.68401223,0.008687067,0.00021030541,0.28107274,0.0015972807,5.04043e-7,0.012749449,0.001391329,0.0021066957,0.0052934326],"study_design_scores_gemma":[0.001066022,0.0015682015,0.23137355,0.004460467,0.0004006384,0.7580754,0.000057370373,0.000002154029,0.0024359087,0.00039180164,0.0000839669,0.00008449389],"about_ca_topic_score_codex":0.0000012432413,"about_ca_topic_score_gemma":0.000003345415,"teacher_disagreement_score":0.47700268,"about_ca_system_score_codex":0.000030777577,"about_ca_system_score_gemma":0.00014566744,"threshold_uncertainty_score":0.4624726},"labels":[],"label_agreement":null},{"id":"W1981528863","doi":"10.1007/s12308-009-0025-0","title":"Highlights of 2008 in bone marrow biopsy pathology","year":2009,"lang":"en","type":"article","venue":"Journal of Hematopathology","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"St. Thomas Hospital","funders":"","keywords":"Bone marrow; Hematology; Medicine; Pathology; Biopsy; Internal medicine","score_opus":0.012820136814376819,"score_gpt":0.2792624773761322,"score_spread":0.26644234056175536,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1981528863","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9875739,0.003050503,0.00010413269,0.007765514,0.00019908969,0.00016331626,0.0000036143945,0.000006509481,0.0011333787],"genre_scores_gemma":[0.9936248,0.0006815124,0.0049195196,0.000540257,0.00011341917,0.0000040807863,0.0000026610355,0.000009884111,0.000103870356],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99833596,0.00013086821,0.0009134366,0.00016475018,0.00020789054,0.00024708748],"domain_scores_gemma":[0.9988331,0.00010053363,0.0005273292,0.00019887065,0.00022127313,0.000118857926],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00043859056,0.00016380276,0.0009969121,0.00045907358,0.00002097614,0.0000033286594,0.000078183286,0.00016385588,0.00012388222],"category_scores_gemma":[0.00015523696,0.000114132476,0.0001780349,0.00019538967,0.000088152,0.00006481038,0.000015664338,0.00025672955,0.000015051452],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.002095755,0.00648045,0.5625063,0.00018448614,0.00013460484,0.12414118,0.0020366998,0.0000245459,0.2675235,0.022027265,0.0042719385,0.008573275],"study_design_scores_gemma":[0.006326586,0.005185217,0.7787479,0.0003636916,0.00015571213,0.12586589,0.000113324924,0.000011651959,0.078117356,0.003574037,0.0013761581,0.00016245194],"about_ca_topic_score_codex":0.0000022751778,"about_ca_topic_score_gemma":0.000005093173,"teacher_disagreement_score":0.21624161,"about_ca_system_score_codex":0.00006550395,"about_ca_system_score_gemma":0.0001174602,"threshold_uncertainty_score":0.46541873},"labels":[],"label_agreement":null},{"id":"W1984143879","doi":"10.1016/j.bbmt.2013.10.018","title":"Reduced-Intensity Hematopoietic Cell Transplantation for Patients with Primary Myelofibrosis: A Cohort Analysis from the Center for International Blood and Marrow Transplant Research","year":2013,"lang":"en","type":"article","venue":"Biology of Blood and Marrow Transplantation","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":145,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"National Institute of Allergy and Infectious Diseases; National Cancer Institute; Office of Naval Research; National Heart, Lung, and Blood Institute; Takeda Oncology; Genentech; Health Resources and Services Administration; National Institutes of Health; U.S. Department of Defense; Onyx Pharmaceuticals; Kiadis Pharma; Therakos; Sigma-Tau Pharmaceuticals; Tarix Pharmaceuticals; StemCyte; Blue Cross and Blue Shield Association; Swedish Orphan Biovitrum; Teva Pharmaceutical Industries; WellPoint; HistoGenetics; Otsuka America; U.S. Navy; Osiris Therapeutics; Celgene; Amgen; Allos Therapeutics; Ariad Pharmaceuticals; Leukemia and Lymphoma Society; GlaxoSmithKline; Sanofi","keywords":"Medicine; Internal medicine; Myelofibrosis; International Prognostic Scoring System; Transplantation; Gastroenterology; Hematopoietic stem cell transplantation; Cohort; Hematopoietic cell; Relative risk; Confidence interval; Multivariate analysis; Oncology; Surgery; Bone marrow; Haematopoiesis; Stem cell; Myelodysplastic syndromes","score_opus":0.013126779896040735,"score_gpt":0.2571434271529251,"score_spread":0.24401664725688435,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1984143879","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9927728,0.0003017882,0.0010224056,0.00087061245,0.000088520275,0.0023721745,0.0024743134,0.000016404725,0.00008098822],"genre_scores_gemma":[0.9859219,0.0025170562,0.002584646,0.00016227138,0.00007105735,0.0007291494,0.007975536,0.000016834068,0.00002151881],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99861556,0.000093510265,0.00037289152,0.00046046116,0.00021061877,0.00024694187],"domain_scores_gemma":[0.99835545,0.00059219333,0.00012548693,0.00014228887,0.0006896153,0.00009496249],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00025071597,0.0002070182,0.00045937792,0.00016470416,0.00017096465,0.000027366243,0.00007640351,0.0001395068,0.000024801739],"category_scores_gemma":[0.000019237903,0.00013251204,0.00011980866,0.00013022505,0.00020019941,0.00010305698,0.000005888678,0.00010797239,7.1193955e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0029738285,0.00081042957,0.9530378,0.0005017344,0.0023890128,0.0000032999526,0.0016427416,0.0000012966502,0.037857056,0.000089336434,0.000079555764,0.00061388564],"study_design_scores_gemma":[0.009894354,0.0016054057,0.9275771,0.00022270814,0.007621194,0.000020055057,0.00011048794,0.00004354109,0.05251342,0.00018950984,0.000045385757,0.00015687641],"about_ca_topic_score_codex":0.00026648174,"about_ca_topic_score_gemma":0.00013103837,"teacher_disagreement_score":0.025460763,"about_ca_system_score_codex":0.00001281284,"about_ca_system_score_gemma":0.00004201768,"threshold_uncertainty_score":0.5403684},"labels":[],"label_agreement":null},{"id":"W1987578623","doi":"10.1002/1097-0347(200007)22:4<435::aid-hed17>3.0.co;2-5","title":"Subglottic stenosis secondary to extramedullary hematopoiesis in a patient with postpolycythemia myeloid metaplasia","year":2000,"lang":"en","type":"article","venue":"Head & Neck","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":13,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta Hospital; Alberta Cancer Foundation","funders":"","keywords":"Extramedullary hematopoiesis; Medicine; Radiation therapy; Myeloid; Metaplasia; Myelofibrosis; Radiology; Stenosis; Surgery; Pathology; Bone marrow; Haematopoiesis; Internal medicine","score_opus":0.010341623123698435,"score_gpt":0.25068180276956925,"score_spread":0.24034017964587082,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1987578623","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9842347,0.0008862973,0.000004438437,0.0041652606,0.00004763653,0.0013245129,0.00003778924,0.000082819686,0.009216548],"genre_scores_gemma":[0.99042255,0.00017054992,0.003642521,0.004212616,0.00005497467,0.0005501089,0.000050754243,0.0000643465,0.0008315807],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9977964,0.000070943126,0.0004843082,0.00060676923,0.00046068718,0.00058086513],"domain_scores_gemma":[0.99878013,0.00012529266,0.00006178761,0.00050963927,0.00007716637,0.00044600244],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00009257579,0.00039938468,0.0007424399,0.00021743971,0.000097674696,0.00004044928,0.000091457114,0.00011430269,0.003613651],"category_scores_gemma":[0.000028559494,0.0002945014,0.00012943918,0.00050962163,0.000056517754,0.0001121795,0.000030597017,0.00028382937,0.00057778315],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0069803316,0.0061302115,0.77966523,0.00071402424,0.0010494288,0.009166766,0.010535388,0.00014797806,0.0021963187,0.0004235357,0.01071655,0.17227425],"study_design_scores_gemma":[0.0073742876,0.0070684175,0.90972257,0.0017397978,0.00039105196,0.0020439557,0.00078864576,0.000056352565,0.039357204,0.00007181987,0.03060652,0.0007794061],"about_ca_topic_score_codex":0.00027273849,"about_ca_topic_score_gemma":0.00047330128,"teacher_disagreement_score":0.17149484,"about_ca_system_score_codex":0.0002535752,"about_ca_system_score_gemma":0.00023898996,"threshold_uncertainty_score":0.9999507},"labels":[],"label_agreement":null},{"id":"W1987587843","doi":"10.1038/sj.bmt.1704075","title":"Stem cell transplantation for myelofibrosis: a report from two Canadian centers","year":2003,"lang":"en","type":"article","venue":"Bone Marrow Transplantation","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":77,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University Health Network; Vancouver General Hospital; BC Cancer Agency; Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Myelofibrosis; Transplantation; Gastroenterology; Surgery; Internal medicine; Thrombocytosis; Splenectomy; Hematopoietic stem cell transplantation; Stem cell; Bone marrow; Platelet","score_opus":0.015437755599963993,"score_gpt":0.24928573750256325,"score_spread":0.23384798190259926,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1987587843","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97974026,0.00046864743,0.007761017,0.0008515782,0.0003830242,0.0019225178,0.0012645862,0.000085697066,0.0075226873],"genre_scores_gemma":[0.9885905,0.0006888108,0.005052995,0.00041204263,0.00007894424,0.0003892811,0.0041196193,0.000046660978,0.0006211379],"study_design_codex":"observational","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99828345,0.000077910336,0.00048584488,0.0004945539,0.00027202393,0.00038620422],"domain_scores_gemma":[0.9990408,0.00013679561,0.00012895296,0.00022534245,0.000116971576,0.0003511488],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00018488149,0.0002749137,0.0003560206,0.00018811076,0.00018000776,0.00004338394,0.000041137533,0.00011525426,0.00013377478],"category_scores_gemma":[0.000005766102,0.0002607198,0.00017635392,0.00014238336,0.000026542268,0.0001437537,8.2128923e-7,0.000098296194,0.000032795146],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.009003823,0.001407477,0.8226826,0.0033426706,0.0011839608,0.01107752,0.01439292,0.00056876213,0.100847594,0.0043522976,0.004436936,0.026703449],"study_design_scores_gemma":[0.029073976,0.0010934223,0.32187706,0.0009711967,0.0037700594,0.0025554819,0.00081108627,0.00037199492,0.6199546,0.0005365705,0.017852671,0.0011318878],"about_ca_topic_score_codex":0.014450081,"about_ca_topic_score_gemma":0.04583361,"teacher_disagreement_score":0.519107,"about_ca_system_score_codex":0.00021658844,"about_ca_system_score_gemma":0.00034673265,"threshold_uncertainty_score":0.9999845},"labels":[],"label_agreement":null},{"id":"W1987633474","doi":"10.1371/journal.pone.0075472","title":"Enu Mutagenesis Identifies a Novel Platelet Phenotype in a Loss-Of-Function Jak2 Allele","year":2013,"lang":"en","type":"article","venue":"PLoS ONE","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Ottawa; Ottawa Hospital; Ontario Institute for Cancer Research; Mount Sinai Hospital; Lunenfeld-Tanenbaum Research Institute; University of British Columbia; Hospital for Sick Children; Toronto Centre for Phenogenomics; University of Toronto","funders":"National Institute of Diabetes and Digestive and Kidney Diseases; Canadian Institutes of Health Research; Natural Sciences and Engineering Research Council of Canada; Heart and Stroke Foundation of Canada","keywords":"Phenotype; Biology; Mutant; Mutagenesis; Genetics; Mutation; Exon; Allele; Loss function; Locus (genetics); Janus kinase 2; Molecular biology; Cell biology; Gene","score_opus":0.04666011858984435,"score_gpt":0.24584658252172542,"score_spread":0.19918646393188108,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1987633474","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9966596,0.00036255852,0.00007121817,0.00076165376,0.00003730003,0.00082811347,0.000012380049,0.00003394957,0.0012332641],"genre_scores_gemma":[0.9964364,0.00034325002,0.0016985132,0.00021602448,0.0000885316,0.0003724444,0.00005696363,0.000023170978,0.0007646608],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99888355,0.00002240119,0.0003092793,0.00025459484,0.00032333506,0.00020686767],"domain_scores_gemma":[0.9993208,0.000093232695,0.00008984466,0.00023789227,0.00017235818,0.00008589072],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.000083311774,0.00015416421,0.00042001758,0.00022585335,0.00003513269,0.000019100013,0.00005014438,0.000084660634,0.0014355899],"category_scores_gemma":[0.00011046142,0.00012846102,0.000061504616,0.0002789636,0.000044045082,0.00011836238,0.000031824766,0.000102586426,0.00039811098],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0004935584,0.01881296,0.6178683,0.0007285506,0.0019377004,0.00007472297,0.0013297197,0.00002015379,0.35231754,0.00072540273,0.002005753,0.0036856562],"study_design_scores_gemma":[0.0044973255,0.0008235948,0.66530955,0.0005164971,0.00041058435,0.000008122486,0.00016580097,0.0005163784,0.3268356,0.00044570526,0.00025118023,0.00021964694],"about_ca_topic_score_codex":0.0005400192,"about_ca_topic_score_gemma":0.00012687434,"teacher_disagreement_score":0.047441278,"about_ca_system_score_codex":0.00005248235,"about_ca_system_score_gemma":0.00004009377,"threshold_uncertainty_score":0.9994772},"labels":[],"label_agreement":null},{"id":"W1989311770","doi":"10.1160/th09-12-0871","title":"Essential thrombocythaemia in a teenage girl resulting in acquired von Willebrand syndrome with joint haemorrhage and menorrhagia","year":2010,"lang":"en","type":"letter","venue":"Thrombosis and Haemostasis","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Children's Hospital","funders":"","keywords":"Medicine; Girl; Von Willebrand factor; Von Willebrand disease; Joint (building); Surgery; Platelet; Internal medicine; Genetics; Biology","score_opus":0.03305757364649337,"score_gpt":0.2815276508582415,"score_spread":0.24847007721174813,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1989311770","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.85665005,0.0012014243,0.0000061115325,0.13866575,0.00015536863,0.0020532932,0.00021355216,0.0000697173,0.0009847581],"genre_scores_gemma":[0.93319345,0.0043329946,0.0035640586,0.056239262,0.00058223243,0.00054339715,0.00087236025,0.000264006,0.00040825532],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9954171,0.00021836146,0.0010521957,0.0015784692,0.00070840085,0.0010254813],"domain_scores_gemma":[0.99812925,0.0003125252,0.0004196744,0.0007581357,0.00011499484,0.00026542062],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":["research_integrity"],"category_scores_codex":[0.00052053755,0.0010873711,0.0027056483,0.0007749146,0.00024921013,0.00020984295,0.00015550732,0.001666296,0.00036304406],"category_scores_gemma":[0.00008600169,0.00081789755,0.00016382732,0.00052690913,0.00053141237,0.00026674394,0.00022426134,0.0026454893,0.000015356614],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0027431075,0.003350996,0.58788407,0.010004374,0.004536326,0.06625366,0.015233008,0.0000122017655,0.007294709,0.00020872582,0.26967764,0.032801162],"study_design_scores_gemma":[0.03438277,0.0033951863,0.89882463,0.009877829,0.0030884722,0.005059907,0.0009253035,0.00038984758,0.009880281,0.00023005296,0.030706584,0.0032391134],"about_ca_topic_score_codex":0.0014801677,"about_ca_topic_score_gemma":0.0017866746,"teacher_disagreement_score":0.31094056,"about_ca_system_score_codex":0.00025610844,"about_ca_system_score_gemma":0.00021016148,"threshold_uncertainty_score":0.9996554},"labels":[],"label_agreement":null},{"id":"W1990418413","doi":"10.1111/ejh.12455","title":"How we manage <scp>JAK</scp> inhibition in allogeneic transplantation for myelofibrosis","year":2014,"lang":"en","type":"review","venue":"European Journal Of Haematology","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":15,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Ruxolitinib; Myelofibrosis; Medicine; Discontinuation; Janus kinase; Transplantation; Tofacitinib; Hematopoietic stem cell transplantation; Adverse effect; Stem cell; Constitutional symptoms; Internal medicine; Immunology; Oncology; Cytokine; Disease; Bone marrow","score_opus":0.04522550680314516,"score_gpt":0.30919926107075374,"score_spread":0.2639737542676086,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1990418413","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0031340613,0.98944974,0.0035572562,0.0011725125,0.0004039918,0.0013185424,0.000051964827,0.000019079169,0.00089287385],"genre_scores_gemma":[0.0037000165,0.99263495,0.0024824436,0.00015823664,0.00035726916,0.000060691975,0.00019978941,0.00011237762,0.00029420533],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99653053,0.0011607079,0.0013402045,0.00036542155,0.00024118247,0.00036197095],"domain_scores_gemma":[0.9971964,0.0008402591,0.0013722698,0.00023214874,0.00017432348,0.00018463284],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0009364534,0.00048100037,0.0030107014,0.000767736,0.000060697585,0.000050695046,0.00013105845,0.00017609193,0.000011446267],"category_scores_gemma":[0.00027317353,0.00034183357,0.0008239519,0.00021099098,0.00007283673,0.00009994792,0.00002375166,0.0004514201,0.00004960477],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00017905762,0.0008373254,0.00039172714,0.08384733,0.0018751486,0.046049915,0.00093869324,0.000007608166,0.000039638217,0.002175838,0.011824666,0.85183305],"study_design_scores_gemma":[0.0029294046,0.0014950095,0.00031153942,0.02313253,0.0027275588,0.030449696,0.000048125497,0.0000026028831,0.00012609089,0.00005721562,0.93859315,0.00012708352],"about_ca_topic_score_codex":6.646216e-7,"about_ca_topic_score_gemma":0.000009150557,"teacher_disagreement_score":0.9267685,"about_ca_system_score_codex":0.00011552595,"about_ca_system_score_gemma":0.0001228138,"threshold_uncertainty_score":0.9999034},"labels":[],"label_agreement":null},{"id":"W1991802905","doi":"10.1002/ajh.23169","title":"Unraveling the genetic underpinnings of myeloproliferative neoplasms and understanding their effect on disease course and response to therapy: Proceedings from the 6th international post‐ASH symposium","year":2012,"lang":"en","type":"article","venue":"American Journal of Hematology","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":20,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"Incyte; National Cancer Institute; National Heart, Lung, and Blood Institute; Sanofi; Bristol-Myers Squibb","keywords":"Medicine; Disease; Internal medicine","score_opus":0.01614833568897234,"score_gpt":0.2788131011693511,"score_spread":0.26266476548037876,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1991802905","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.95844424,0.001541968,0.00024052225,0.03915202,0.00012943771,0.00043132144,0.000017008062,0.0000059314366,0.0000375492],"genre_scores_gemma":[0.9960512,0.00053203205,0.0004273193,0.0027974364,0.00013849793,0.000024054936,0.0000018792524,0.000021505679,0.0000060798134],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99869794,0.00023375035,0.00037473868,0.00018134479,0.0002765048,0.00023573957],"domain_scores_gemma":[0.9966524,0.0023170805,0.00044796037,0.00012275935,0.00019982929,0.0002599477],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00059141865,0.0002196943,0.0005405368,0.00011110356,0.00015009564,0.00003480709,0.00012583088,0.00003447395,0.0000150094975],"category_scores_gemma":[0.00030479644,0.00010423632,0.00008803424,0.00013990678,0.00045430116,0.00007608294,0.000053659736,0.0002344765,0.0000013959473],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.016347822,0.00029486613,0.95377225,0.000017232049,0.0011197479,0.00004647325,0.016564757,0.000015281386,0.005959606,0.0024395315,0.00024408232,0.0031783434],"study_design_scores_gemma":[0.003991337,0.010805515,0.948925,0.0007177731,0.0004918849,0.0018458015,0.016691802,0.00014097513,0.015095374,0.0006008087,0.00045713678,0.00023656392],"about_ca_topic_score_codex":0.000023258428,"about_ca_topic_score_gemma":0.0000035927935,"teacher_disagreement_score":0.03760695,"about_ca_system_score_codex":0.00009715307,"about_ca_system_score_gemma":0.00013365161,"threshold_uncertainty_score":0.42506337},"labels":[],"label_agreement":null},{"id":"W1995082806","doi":"10.1038/leu.2012.109","title":"RET fusion genes are associated with chronic myelomonocytic leukemia and enhance monocytic differentiation","year":2012,"lang":"en","type":"article","venue":"Leukemia","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":96,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Institute of Cancer Research; Institut National Du Cancer","keywords":"Fusion gene; Chronic myelomonocytic leukemia; Cancer research; Biology; Haematopoiesis; Myeloproliferative neoplasm; Chromosomal translocation; Leukemia; Tyrosine kinase; ABL; Gene; Stem cell; Immunology; Genetics; Myelodysplastic syndromes; Signal transduction; Myelofibrosis; Bone marrow","score_opus":0.017099378474052566,"score_gpt":0.2591504653778369,"score_spread":0.24205108690378435,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1995082806","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9940594,0.0039777854,0.00016769515,0.00022583117,0.00013047461,0.0007310003,0.000012002042,0.00010203042,0.0005937765],"genre_scores_gemma":[0.9966434,0.001205017,0.00020180047,0.0002286896,0.00029777535,0.0002563213,0.00013536323,0.000044469685,0.0009871251],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9984724,0.00007453056,0.0002722886,0.0003758995,0.00031870895,0.00048615824],"domain_scores_gemma":[0.99896663,0.0001463855,0.00022404086,0.0003018065,0.00009806707,0.0002630567],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00013507232,0.0003152636,0.0004720296,0.000093013914,0.00018195332,0.00003928549,0.00005466815,0.00017568626,0.000119868426],"category_scores_gemma":[0.0000818013,0.00022767526,0.000063485546,0.00019208103,0.00007359351,0.00019782552,0.000051862844,0.00022327167,0.00005498348],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00027202212,0.0002308518,0.96576154,0.00019955798,0.00043609118,0.000051898238,0.00070447364,0.000059131235,0.005727983,0.0002346893,0.0006935077,0.02562827],"study_design_scores_gemma":[0.0032663087,0.0005579201,0.9483881,0.00061824924,0.00043114056,0.000050062205,0.00007112795,0.0024792394,0.043040305,0.000037877016,0.0007701269,0.0002895333],"about_ca_topic_score_codex":0.00008453149,"about_ca_topic_score_gemma":0.0002383632,"teacher_disagreement_score":0.03731232,"about_ca_system_score_codex":0.004493875,"about_ca_system_score_gemma":0.00043834173,"threshold_uncertainty_score":0.9993277},"labels":[],"label_agreement":null},{"id":"W1995667110","doi":"10.5489/cuaj.1389","title":"Extramedullary hematopoiesis in the adrenal: Case report and review of literature","year":2013,"lang":"en","type":"article","venue":"Canadian Urological Association Journal","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":21,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Extramedullary hematopoiesis; Medicine; Asymptomatic; Adrenalectomy; Adrenal gland; Biopsy; Pathology; Adrenal insufficiency; Histology; Haematopoiesis; Surgery; Internal medicine; Stem cell; Biology","score_opus":0.011029932820464234,"score_gpt":0.24901832069721863,"score_spread":0.2379883878767544,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1995667110","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.85551876,0.03981204,0.000002094785,0.102822386,0.0000564937,0.00050551863,0.000016528857,0.0000042836905,0.0012619192],"genre_scores_gemma":[0.9752155,0.010051273,0.00019594457,0.014282376,0.00009901798,0.000046354733,0.0000167839,0.000004539146,0.00008822271],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9988587,0.00020779214,0.00038987523,0.0001175202,0.00022400431,0.00020212316],"domain_scores_gemma":[0.9988115,0.00029639236,0.00023637197,0.00010077957,0.00028385542,0.00027113094],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00083475723,0.00009493867,0.000287293,0.0000875001,0.00009090001,0.000052703246,0.0000422449,0.000120586876,0.0005824586],"category_scores_gemma":[0.0016585717,0.0000519452,0.000081237624,0.00021023347,0.000022515384,0.00006933433,0.0000059846134,0.00038023444,0.00000660192],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000007419222,0.00011400139,0.87224716,0.00023097874,0.00010801881,0.072816916,0.00047068534,4.0792912e-7,0.000005492675,0.00034789866,0.050411247,0.0032397674],"study_design_scores_gemma":[0.00049059285,0.00023849298,0.7315321,0.0013447335,0.00011166949,0.25097284,0.00015354328,0.00001153407,0.00001027247,0.00061606726,0.014433353,0.0000848381],"about_ca_topic_score_codex":0.0008758848,"about_ca_topic_score_gemma":0.0006030831,"teacher_disagreement_score":0.17815591,"about_ca_system_score_codex":0.00023042485,"about_ca_system_score_gemma":0.0001932369,"threshold_uncertainty_score":0.63775134},"labels":[],"label_agreement":null},{"id":"W1996668420","doi":"10.1182/blood-2012-07-446260","title":"Polycythemia vera followed by hairy cell leukemia variant","year":2012,"lang":"en","type":"article","venue":"Blood","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Phlebotomy; Polycythemia vera; Myelofibrosis; Medicine; Ruxolitinib; Leukemia; Internal medicine; Gastroenterology; Bone marrow","score_opus":0.008880982484944273,"score_gpt":0.23178104689425566,"score_spread":0.2229000644093114,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1996668420","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9651288,0.0032422584,0.000046998408,0.00054680253,0.00025527383,0.000398577,0.00003414426,0.00008447451,0.0302627],"genre_scores_gemma":[0.9936905,0.0001476675,0.0013444781,0.00078401814,0.00038876373,0.00010361021,0.00007942125,0.00003579687,0.0034257614],"study_design_codex":"observational","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99883074,0.000033224205,0.00020972746,0.00023855537,0.0002484626,0.0004393168],"domain_scores_gemma":[0.99917394,0.00007781442,0.00006364226,0.00031766502,0.00003364986,0.00033330708],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00011492878,0.00021716452,0.0003138567,0.00004439345,0.000088841814,0.000018033896,0.00006165768,0.000115354946,0.0005185853],"category_scores_gemma":[0.000030327688,0.00016652032,0.00012652547,0.00010150932,0.000027355754,0.000087235756,0.000035051617,0.00015387534,0.00043845654],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00028189618,0.010575464,0.7499939,0.00015178179,0.0008920934,0.00045717502,0.0014454323,9.019101e-7,0.08163705,0.0010925943,0.15155938,0.0019123361],"study_design_scores_gemma":[0.017791342,0.0008694303,0.06258033,0.00011126732,0.0013750724,0.0003659318,0.00010846773,0.000019486766,0.8241113,0.00002819746,0.092183866,0.00045531732],"about_ca_topic_score_codex":0.000063102714,"about_ca_topic_score_gemma":0.0000032635241,"teacher_disagreement_score":0.74247426,"about_ca_system_score_codex":0.00011728313,"about_ca_system_score_gemma":0.00012693803,"threshold_uncertainty_score":0.67905015},"labels":[],"label_agreement":null},{"id":"W1998550373","doi":"10.1002/ajh.22094","title":"Published guidelines versus real‐life practice in the diagnosis and treatment of essential thrombocythemia","year":2011,"lang":"en","type":"article","venue":"American Journal of Hematology","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"St. Paul's Hospital; University of British Columbia; Vancouver General Hospital","funders":"","keywords":"Essential thrombocythemia; Medicine; Thrombocytosis; Myeloproliferative neoplasm; Bone marrow; Internal medicine; Hydroxycarbamide; Thrombosis; Biopsy; Hematologist; Gene mutation; Anagrelide; Oncology; Surgery; Myelofibrosis; Polycythemia vera; Mutation; Chemotherapy; Platelet; Disease; Gene","score_opus":0.07414932893291384,"score_gpt":0.37263746025234146,"score_spread":0.29848813131942764,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1998550373","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9847198,0.0018524338,0.000018714367,0.01108991,0.00013949689,0.00023524562,0.0000030723902,0.000004083947,0.0019372515],"genre_scores_gemma":[0.983691,0.010649731,0.0050130114,0.0004947607,0.00009092857,0.000043626183,0.0000021658445,0.000011363992,0.0000034646398],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9984505,0.00023732644,0.0007371973,0.00016083727,0.00022849474,0.00018562737],"domain_scores_gemma":[0.99710685,0.0013198825,0.0008292469,0.00022138857,0.000400491,0.00012212257],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00033073343,0.0001635494,0.00087378145,0.00015944506,0.00003316772,0.000010103894,0.000098971286,0.00004580572,0.00011337752],"category_scores_gemma":[0.0012389171,0.00008943531,0.00012146422,0.0002199278,0.00033944703,0.00014146781,0.000017910359,0.00011383995,0.0000022105155],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.008267216,0.006122585,0.90824425,0.000044001474,0.002290455,0.002211121,0.017770385,0.0000025060426,0.00011483106,0.0092825955,0.0042251097,0.04142494],"study_design_scores_gemma":[0.04851639,0.097613536,0.68622905,0.00070267596,0.006081528,0.023806816,0.078805566,0.0000564711,0.039652765,0.0009450887,0.016823294,0.0007668458],"about_ca_topic_score_codex":0.0008577395,"about_ca_topic_score_gemma":0.00010536173,"teacher_disagreement_score":0.22201522,"about_ca_system_score_codex":0.000051767955,"about_ca_system_score_gemma":0.00021858329,"threshold_uncertainty_score":0.36470658},"labels":[],"label_agreement":null},{"id":"W1999590101","doi":"10.1016/j.humpath.2011.01.006","title":"Extramedullary hematopoiesis involving the central nervous system and surrounding structures","year":2011,"lang":"en","type":"article","venue":"Human Pathology","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":31,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Sciences Centre; University of Manitoba","funders":"Canada Research Chairs","keywords":"Extramedullary hematopoiesis; Meninges; Central nervous system; Medicine; Pathology; Haematopoiesis; Myelofibrosis; Autopsy; Anemia; Bone marrow; Internal medicine; Biology; Stem cell","score_opus":0.048943748933428406,"score_gpt":0.2678914740843994,"score_spread":0.218947725150971,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1999590101","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9936442,0.0026582503,0.00003828047,0.0001282762,0.00019492861,0.0003568441,0.0000048948823,0.00007057675,0.0029037471],"genre_scores_gemma":[0.99867266,0.000095758944,0.0006341842,0.0002847069,0.00013655091,0.000060320148,0.000011309296,0.00002109636,0.00008341738],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9989156,0.00013294196,0.00022983486,0.0002819279,0.00011477079,0.00032491045],"domain_scores_gemma":[0.99940354,0.000088061824,0.000085466905,0.00027209084,0.00004088663,0.00010993324],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001582655,0.0001768762,0.00033090368,0.00006526284,0.0003190735,0.000024091238,0.00007059717,0.00010182416,0.00015467255],"category_scores_gemma":[0.00003436494,0.00010843808,0.00006249697,0.00005410014,0.00018856711,0.00004233681,0.00005911611,0.00015514475,0.000008952006],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00007311371,0.0001553307,0.7413121,0.00033492135,0.0001754043,0.0025591734,0.012309221,4.6613778e-7,0.0035016066,0.23737559,0.00047916724,0.0017239038],"study_design_scores_gemma":[0.0007625161,0.0003085939,0.9877536,0.00010714794,0.00017587564,0.0031408463,0.0025998105,0.000014541203,0.0033495051,0.0014837268,0.00017448484,0.00012930752],"about_ca_topic_score_codex":0.00008777152,"about_ca_topic_score_gemma":0.00008565222,"teacher_disagreement_score":0.24644154,"about_ca_system_score_codex":0.000072644696,"about_ca_system_score_gemma":0.000026280388,"threshold_uncertainty_score":0.44219765},"labels":[],"label_agreement":null},{"id":"W2000782581","doi":"10.1182/blood-2008-12-196014","title":"JAK2V617F mutation for the early diagnosis of Ph− myeloproliferative neoplasms in patients with venous thromboembolism: a meta-analysis","year":2009,"lang":"en","type":"review","venue":"Blood","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":176,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University","funders":"","keywords":"Medicine; Odds ratio; Confidence interval; Internal medicine; Mutation; Myeloproliferative neoplasm; Gastroenterology; Myelofibrosis; Polycythemia vera; Genetics; Bone marrow","score_opus":0.05452431246079667,"score_gpt":0.31760236844796996,"score_spread":0.26307805598717326,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2000782581","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.010260159,0.97807956,0.00003642804,0.00015874446,0.000042719596,0.010561208,0.00073930976,0.00002802481,0.00009382337],"genre_scores_gemma":[0.019411797,0.96408594,0.0012623294,0.00015683849,0.000106855456,0.013731505,0.0010722175,0.00010239718,0.00007010063],"study_design_codex":"meta_analysis","study_design_gemma":"meta_analysis","domain_scores_codex":[0.9965885,0.00027126045,0.001228425,0.00082534144,0.0006321981,0.00045424938],"domain_scores_gemma":[0.99598336,0.0015935516,0.000996126,0.00077030074,0.00051864266,0.00013803606],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0003476402,0.0008340478,0.007277267,0.0006102144,0.00014121136,0.00005641047,0.00023848968,0.00032061207,0.000119202836],"category_scores_gemma":[0.00017149768,0.00041993754,0.0026403565,0.0015270701,0.000103656814,0.000102406644,0.000036846966,0.0003682964,0.000012122674],"study_design_candidate":"meta_analysis","study_design_consensus":"meta_analysis","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0005350889,0.020122139,0.026496392,0.005500911,0.74437916,0.00010543107,0.0018939936,0.000059514263,3.499682e-8,0.00057726644,0.00012729185,0.20020278],"study_design_scores_gemma":[0.0054425844,0.0067113074,0.038300116,0.0011550176,0.9325302,0.00001347157,0.000029924313,0.0000063319303,0.00004134512,0.00005618592,0.015227889,0.00048558874],"about_ca_topic_score_codex":0.00014153126,"about_ca_topic_score_gemma":0.00031742852,"teacher_disagreement_score":0.1997172,"about_ca_system_score_codex":0.000114016206,"about_ca_system_score_gemma":0.00038829193,"threshold_uncertainty_score":0.99982524},"labels":[],"label_agreement":null},{"id":"W2000932571","doi":"10.1371/journal.pbio.1001576","title":"Self-Renewal of Single Mouse Hematopoietic Stem Cells Is Reduced by JAK2V617F Without Compromising Progenitor Cell Expansion","year":2013,"lang":"en","type":"article","venue":"PLoS Biology","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":85,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Cambridge Institute for Medical Research, University of Cambridge; NIHR Cambridge Biomedical Research Centre; Wellcome Trust; Kay Kendall Leukaemia Fund; Canadian Institutes of Health Research; National Institute for Health and Care Research; Cancer Research UK; Leukemia and Lymphoma Research","keywords":"Biology; Stem cell; Progenitor cell; Haematopoiesis; Transplantation; Cell biology; Carcinogenesis; Hematopoietic stem cell; Cancer research; Proto-Oncogene Proteins c-kit; Tyrosine kinase; Immunology; Genetics; Stem cell factor; Signal transduction; Cancer; Internal medicine","score_opus":0.02120817058012897,"score_gpt":0.2449372396106689,"score_spread":0.22372906903053993,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2000932571","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99676484,0.00056407886,0.000016274193,0.000498381,0.00010934585,0.0014071398,0.000042066113,0.00008995825,0.00050789013],"genre_scores_gemma":[0.9957693,0.00008492418,0.0029139528,0.00021480481,0.00008372338,0.00021441482,0.00005616804,0.0000391589,0.0006235105],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9984686,0.00011537603,0.0004466188,0.00045761093,0.00016104769,0.0003507817],"domain_scores_gemma":[0.9989182,0.00011195653,0.00021149474,0.0003523573,0.00022171707,0.00018431175],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000058573838,0.00027344833,0.0006559543,0.00007735514,0.00006993214,0.000015303951,0.00009729174,0.00020724139,0.00026464177],"category_scores_gemma":[0.000008914578,0.00020006344,0.00009867273,0.00008835953,0.00009270039,0.000046152178,0.00005710389,0.00012177672,0.00018379402],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000066890745,0.002564848,0.02382382,0.0002411775,0.00019224164,0.000003826214,0.0008636403,2.120527e-7,0.97009146,0.000013343864,0.0018495074,0.0002890069],"study_design_scores_gemma":[0.0019227101,0.0015294368,0.0001659825,0.000091552094,0.00017746288,0.000015168336,0.000156956,0.00012062717,0.9951734,0.000033719538,0.00043779952,0.00017521893],"about_ca_topic_score_codex":0.000074172814,"about_ca_topic_score_gemma":0.0000018860958,"teacher_disagreement_score":0.02508188,"about_ca_system_score_codex":0.000092019494,"about_ca_system_score_gemma":0.0000848379,"threshold_uncertainty_score":0.81583506},"labels":[],"label_agreement":null},{"id":"W2001821752","doi":"10.1038/ki.2011.360","title":"Perinephric extramedullary hematopoiesis","year":2012,"lang":"en","type":"article","venue":"Kidney International","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Ottawa","funders":"","keywords":"Extramedullary hematopoiesis; Medicine; Adipose capsule of kidney; Pathology; Myelofibrosis; Fascia; Soft tissue; Lymphatic system; Abdomen; Biopsy; Anatomy; Bone marrow; Haematopoiesis; Kidney; Biology; Internal medicine; Stem cell","score_opus":0.016900238007121454,"score_gpt":0.29651283306892934,"score_spread":0.2796125950618079,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2001821752","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.80608493,0.00057048124,0.00033214802,0.039432213,0.001928293,0.00037654597,0.00008644964,0.00012606553,0.15106288],"genre_scores_gemma":[0.98513484,0.000091177484,0.004578448,0.0055197366,0.00075542997,0.000095800984,0.0001709447,0.000016468295,0.0036371388],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.99916834,0.000013651894,0.00016615294,0.00013669426,0.00031066142,0.0002044811],"domain_scores_gemma":[0.99929994,0.00004409,0.000042116164,0.00013705259,0.0000903321,0.00038646752],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.000078209065,0.00012133274,0.00015065719,0.000090333844,0.000044416352,0.00001960014,0.000065696135,0.000048585513,0.006441786],"category_scores_gemma":[0.00021147866,0.00009607935,0.00009642056,0.00006668862,0.000030036923,0.00013341768,0.000036478166,0.00008758215,0.0006219424],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00006918994,0.0010286836,0.82497644,0.000032025564,0.00046578114,0.000038662794,0.00048027147,5.465267e-7,0.0012888532,0.02007193,0.14870298,0.0028446359],"study_design_scores_gemma":[0.0014931156,0.00008519941,0.3363007,0.0000725074,0.00008997921,0.00046946047,0.00008467591,0.000106217514,0.012060557,0.00013474301,0.64894974,0.0001530885],"about_ca_topic_score_codex":0.000010889204,"about_ca_topic_score_gemma":6.689521e-7,"teacher_disagreement_score":0.50024676,"about_ca_system_score_codex":0.00011219906,"about_ca_system_score_gemma":0.000076091834,"threshold_uncertainty_score":0.9944665},"labels":[],"label_agreement":null},{"id":"W2002302430","doi":"10.1182/blood-2005-09-3900","title":"X-inactivation–based clonality analysis and quantitative JAK2V617F assessment reveal a strong association between clonality and JAK2V617F in PV but not ET/MMM, and identifies a subset of JAK2V617F-negative ET and MMM patients with clonal hematopoiesis","year":2006,"lang":"en","type":"article","venue":"Blood","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":237,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal; Hôpital Maisonneuve-Rosemont","funders":"National Institute of Diabetes and Digestive and Kidney Diseases; National Cancer Institute","keywords":"Myelofibrosis; Essential thrombocythemia; Polycythemia vera; Biology; Allele; Granulopoiesis; Myeloid; Immunology; Genetics; Haematopoiesis; Bone marrow; Gene; Stem cell","score_opus":0.0156500770186828,"score_gpt":0.3003505325570687,"score_spread":0.28470045553838585,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2002302430","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9960992,0.0001597253,0.00030842677,0.0011613861,0.000011347394,0.00092908647,0.0011594227,0.00001887814,0.00015253457],"genre_scores_gemma":[0.9933741,0.00006842869,0.005540116,0.00013483089,0.000023165789,0.00013484534,0.0006634073,0.000021613034,0.00003950824],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9969814,0.00052150723,0.0007206242,0.0006965727,0.00077727466,0.00030265085],"domain_scores_gemma":[0.99651855,0.0019957009,0.000658835,0.00020375081,0.00047548112,0.0001476542],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0009808795,0.00037943092,0.0010778154,0.0003461407,0.00016201478,0.000101842525,0.000044305838,0.0001608087,0.000014879866],"category_scores_gemma":[0.00031418251,0.00031478706,0.000090665795,0.0005302789,0.00022714319,0.00033337006,0.00007346323,0.0002807291,2.933663e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0003790438,0.0014940072,0.9932839,0.00024756548,0.0019845273,0.000012005718,0.0005916219,0.000010604672,0.00036101043,0.0015227265,0.000022363556,0.00009056723],"study_design_scores_gemma":[0.009201522,0.0007696631,0.9763524,0.00022560077,0.0026845776,0.0000028460952,0.0003665791,0.00012382003,0.009513843,0.0004877593,0.0000048795127,0.00026650738],"about_ca_topic_score_codex":0.0029668966,"about_ca_topic_score_gemma":0.0033709535,"teacher_disagreement_score":0.016931554,"about_ca_system_score_codex":0.00018249916,"about_ca_system_score_gemma":0.00018370885,"threshold_uncertainty_score":0.99993044},"labels":[],"label_agreement":null},{"id":"W2005413834","doi":"10.1016/j.acvfr.2008.07.008","title":"Syndrome myéloprolifératif cause d'une ischémie périphérique chez un sujet jeune","year":2008,"lang":"fr","type":"article","venue":"Annales de Chirurgie Vasculaire","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"St Mary's Hospital Centre","funders":"","keywords":"Medicine; Gynecology","score_opus":0.02902711564297717,"score_gpt":0.2670078490677894,"score_spread":0.23798073342481224,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2005413834","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8400441,0.11747317,0.0001886938,0.03111405,0.0018495972,0.0017237145,0.00021110002,0.0003144383,0.007081181],"genre_scores_gemma":[0.89102685,0.06662721,0.0011067487,0.0024268206,0.0020141364,0.0005856108,0.00044527752,0.00026331263,0.035503995],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99317557,0.00060957315,0.0012999078,0.0015308995,0.0011186206,0.00226546],"domain_scores_gemma":[0.9956059,0.00040706282,0.00040063827,0.0016235199,0.00045477718,0.0015081294],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":["metaepi_narrow","insufficient_payload"],"category_scores_codex":[0.00076056935,0.0014356736,0.0020286008,0.00040642073,0.0010091658,0.00011107927,0.0004893438,0.0008904086,0.00432502],"category_scores_gemma":[0.0003305019,0.0012801861,0.0013309487,0.0012546859,0.000997867,0.00054150494,0.00023978914,0.0011844768,0.0028750086],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000746873,0.012174606,0.6347915,0.002906374,0.016873533,0.06665109,0.019758252,0.0010178725,0.00080113724,0.013846541,0.20051931,0.029912895],"study_design_scores_gemma":[0.009261441,0.0023609123,0.62132156,0.0030951754,0.002227904,0.04712444,0.0008118249,0.0009080967,0.01266895,0.00085976365,0.29745296,0.0019069581],"about_ca_topic_score_codex":0.0014895783,"about_ca_topic_score_gemma":0.0010584157,"teacher_disagreement_score":0.09693363,"about_ca_system_score_codex":0.00087117014,"about_ca_system_score_gemma":0.001515031,"threshold_uncertainty_score":0.9998393},"labels":[],"label_agreement":null},{"id":"W2005690253","doi":"10.1038/bmt.2014.131","title":"Allogeneic hematopoietic cell transplantation for myelofibrosis using fludarabine-, intravenous busulfan- and low-dose TBI-based conditioning","year":2014,"lang":"en","type":"article","venue":"Bone Marrow Transplantation","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":32,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Busulfan; Cumulative incidence; Fludarabine; Myelofibrosis; Transplantation; Internal medicine; Adverse effect; Total body irradiation; Regimen; Hematopoietic stem cell transplantation; Surgery; Incidence (geometry); Gastroenterology; Chemotherapy; Cyclophosphamide; Bone marrow","score_opus":0.01341866862874403,"score_gpt":0.24954263668910182,"score_spread":0.2361239680603578,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2005690253","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.91418797,0.00019385442,0.083383635,0.000416049,0.0001001863,0.0012541342,0.00019817834,0.000079919286,0.00018609772],"genre_scores_gemma":[0.9808887,0.00032209908,0.016002849,0.00043400523,0.00009960761,0.0002678224,0.0018943853,0.000054795935,0.000035698078],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99833006,0.00009719878,0.00047953954,0.00047769686,0.0002756033,0.00033990585],"domain_scores_gemma":[0.99901384,0.00032740942,0.00016385708,0.00016816963,0.00015096534,0.00017574764],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00025313944,0.000320926,0.00046078992,0.00019604882,0.0002909318,0.00006490511,0.000040910338,0.00015243432,0.000046200104],"category_scores_gemma":[0.000020511978,0.00030476207,0.00013050302,0.00014717411,0.00007583676,0.00013966198,0.00000263224,0.000105017185,0.000008212315],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.004521583,0.0012395373,0.06168892,0.010923947,0.00024435157,0.00019965717,0.0051873717,0.0042639985,0.9001998,0.0011696335,0.00007901369,0.010282201],"study_design_scores_gemma":[0.020508517,0.0020300855,0.20962329,0.0015233158,0.0026744986,0.0007295734,0.00020282288,0.023262424,0.73803973,0.00051055686,0.00011272518,0.0007824619],"about_ca_topic_score_codex":0.000057926838,"about_ca_topic_score_gemma":0.000048246755,"teacher_disagreement_score":0.16216005,"about_ca_system_score_codex":0.0000804335,"about_ca_system_score_gemma":0.00010608172,"threshold_uncertainty_score":0.99994045},"labels":[],"label_agreement":null},{"id":"W2007570437","doi":"10.1111/j.1365-2141.2012.09179.x","title":"Guideline for the diagnosis and management of myelofibrosis","year":2012,"lang":"en","type":"article","venue":"British Journal of Haematology","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":109,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency; Queen's University","funders":"Wellcome Trust","keywords":"Guideline; Medicine; Myelofibrosis; MEDLINE; Family medicine; Intensive care medicine; Internal medicine; Pathology; Political science","score_opus":0.03466921393699031,"score_gpt":0.32107679877100503,"score_spread":0.28640758483401474,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2007570437","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.92814726,0.060708486,0.0019584992,0.0078122537,0.0003316054,0.00071027427,0.00003187914,0.0000054121297,0.00029432596],"genre_scores_gemma":[0.95148593,0.029355537,0.018283006,0.0005544856,0.0001442834,0.000108136286,0.0000048294223,0.000014214725,0.000049562157],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9989243,0.000039219874,0.0006059687,0.00008115588,0.00015084121,0.00019848572],"domain_scores_gemma":[0.99890184,0.00034890242,0.00031088485,0.00009547684,0.00023157995,0.000111302536],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00045715683,0.0000912338,0.00049872196,0.00005404928,0.0000744615,0.000010814683,0.000064404005,0.000051589872,0.00010770662],"category_scores_gemma":[0.00010108508,0.000064821885,0.00014065295,0.00006171797,0.000097188844,0.0000691816,0.00003680806,0.00007850215,0.0000015521308],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0006136099,0.0021202634,0.4910034,0.0013042125,0.0036516371,0.003679221,0.0004251685,0.0000075582984,0.000097281365,0.013204134,0.17391346,0.30998006],"study_design_scores_gemma":[0.01115247,0.0021439653,0.4619917,0.002747833,0.00393072,0.2173419,0.0011990617,0.00006776626,0.014365428,0.00082754844,0.28393984,0.0002917827],"about_ca_topic_score_codex":0.000021586206,"about_ca_topic_score_gemma":0.000010573498,"teacher_disagreement_score":0.30968827,"about_ca_system_score_codex":0.000018557352,"about_ca_system_score_gemma":0.000020108142,"threshold_uncertainty_score":0.264336},"labels":[],"label_agreement":null},{"id":"W2008887843","doi":"10.1097/aap.0b013e3181e6ad5d","title":"Hyperviscosity of the Blood and Epidural Hematoma","year":2010,"lang":"en","type":"letter","venue":"Regional Anesthesia & Pain Medicine","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier Universitaire de Sherbrooke","funders":"","keywords":"Medicine; Epidural hematoma; Hematoma; Hyperviscosity; General surgery; Anesthesia; Surgery; Blood viscosity; Cardiology","score_opus":0.020540369108919546,"score_gpt":0.2426459943293618,"score_spread":0.22210562522044225,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2008887843","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.2210545,0.001609404,0.00000427349,0.77653074,0.000019727273,0.00068378274,7.930779e-7,0.000027489214,0.00006931233],"genre_scores_gemma":[0.020275047,0.0006640047,0.00028054448,0.97353673,0.0027639004,0.0001045834,0.00016188355,0.00006227714,0.002151049],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9971417,0.0004051723,0.00056141603,0.0005363564,0.0009925613,0.00036279988],"domain_scores_gemma":[0.9974533,0.0010590345,0.0003991161,0.0007040835,0.00022271887,0.00016177472],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0007709524,0.0005177058,0.001232759,0.00013748342,0.00014799627,0.000008139698,0.0002351349,0.00094441336,0.00020857019],"category_scores_gemma":[0.00016157067,0.0002675091,0.00026611998,0.0002015703,0.0009555233,0.00002891337,0.000025196226,0.002029363,0.00000828613],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000067133784,0.00023828173,0.06649961,0.00087745854,0.00038524624,0.0016689994,0.00021751111,7.5730135e-8,0.00040726416,0.00055957737,0.9286717,0.0004071341],"study_design_scores_gemma":[0.0020020718,0.00080053665,0.06480124,0.0023507162,0.0011320702,0.007480112,0.00003326755,0.000016838489,0.0006728313,0.00035759623,0.92010885,0.00024389288],"about_ca_topic_score_codex":0.00017536267,"about_ca_topic_score_gemma":0.00001843039,"teacher_disagreement_score":0.20077944,"about_ca_system_score_codex":0.000035205296,"about_ca_system_score_gemma":0.00018875064,"threshold_uncertainty_score":0.9999777},"labels":[],"label_agreement":null},{"id":"W2014534001","doi":"10.1182/blood-2013-06-510222","title":"JAK2V617F homozygosity drives a phenotypic switch in myeloproliferative neoplasms, but is insufficient to sustain disease","year":2014,"lang":"en","type":"article","venue":"Blood","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":89,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Canadian Institutes of Health Research; National Institute for Health and Care Research; British Heart Foundation; Cancer Research UK","keywords":"Runs of Homozygosity; Phenotype; Disease gene identification; Myeloproliferative Disorders; Biology; Genetics; Disease; Polycythemia vera; Medicine; Immunology; Internal medicine; Genotype; Gene; Exome sequencing","score_opus":0.009201383433220293,"score_gpt":0.2503553068151575,"score_spread":0.2411539233819372,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2014534001","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98930776,0.00043997297,0.0002718213,0.0063099754,0.000111180154,0.0017003923,0.00007240658,0.00009683701,0.0016896626],"genre_scores_gemma":[0.993081,0.000090494555,0.0013691767,0.0037500663,0.00023427997,0.0005397844,0.000053744512,0.000047888614,0.0008335887],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99727535,0.00016436014,0.0004969214,0.00085068546,0.0005382487,0.0006744527],"domain_scores_gemma":[0.99800116,0.0002177328,0.0001025598,0.00063423323,0.00023666902,0.0008076611],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00028025074,0.00045234722,0.000691565,0.00032783585,0.0001913063,0.00007262145,0.00016642168,0.000120491764,0.00021633515],"category_scores_gemma":[0.00047644586,0.0003726854,0.00016274097,0.00055824296,0.00007776376,0.00009868003,0.00014511116,0.00029029345,0.00030038023],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0008515728,0.009612867,0.9702889,0.00019664523,0.00029080012,0.00048601074,0.0059912317,0.00008282861,0.0010109858,0.006395276,0.0013365851,0.0034563292],"study_design_scores_gemma":[0.010798338,0.0018226454,0.9506301,0.00037137762,0.00046057755,0.0000402924,0.0006307801,0.0006446127,0.028404722,0.0007603675,0.0048266393,0.0006095152],"about_ca_topic_score_codex":0.00015715239,"about_ca_topic_score_gemma":0.00024457742,"teacher_disagreement_score":0.027393736,"about_ca_system_score_codex":0.00018181579,"about_ca_system_score_gemma":0.00033566245,"threshold_uncertainty_score":0.9998725},"labels":[],"label_agreement":null},{"id":"W2015114981","doi":"10.1182/blood-2010-07-294447","title":"Thrombospondin-1 is not the major activator of TGF-β1 in thrombopoietin-induced myelofibrosis","year":2010,"lang":"en","type":"article","venue":"Blood","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":19,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal","funders":"Ligue Contre le Cancer; Institut National de la Santé et de la Recherche Médicale; Association pour la Recherche sur le Cancer","keywords":"Myelofibrosis; Thrombopoietin; Megakaryocyte; Bone marrow; Thrombospondin 1; Spleen; Platelet; Cytokine; Transforming growth factor; Thrombospondin; Fibrosis; Immunology; Activator (genetics); Internal medicine; Biology; Medicine; Cancer research; Endocrinology; Haematopoiesis; Angiogenesis; Cell biology; Receptor; Stem cell","score_opus":0.019957638218732726,"score_gpt":0.2813375255812673,"score_spread":0.2613798873625346,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2015114981","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9902302,0.00004776103,8.859137e-7,0.005278511,0.00019480023,0.00074066484,0.00004084827,0.000024276722,0.0034420646],"genre_scores_gemma":[0.99779433,0.00004130172,0.0007531228,0.0008260367,0.00016185186,0.00014230669,0.000009774732,0.00003386713,0.00023740539],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99849,0.000053353375,0.0003832246,0.000367926,0.00038507223,0.00032046804],"domain_scores_gemma":[0.9987304,0.0002715881,0.00015254042,0.0006215188,0.00010224599,0.00012169803],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0002271028,0.0002523427,0.00053414545,0.00010659675,0.0000937289,0.000020788108,0.000167589,0.00017590424,0.0013054712],"category_scores_gemma":[0.00013953829,0.00015599457,0.00016983326,0.00030699227,0.000107288724,0.00007419182,0.000069789654,0.0004077855,0.00012017781],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00011236487,0.002099694,0.356033,0.00004825841,0.00032171342,0.000020628848,0.0014077441,4.2276938e-8,0.637752,0.0010253727,0.0004858774,0.00069327233],"study_design_scores_gemma":[0.002976948,0.00032569954,0.43703797,0.000057050223,0.00020838658,0.00001919912,0.000117970136,0.000002235959,0.55872816,0.00005095231,0.0003838845,0.00009153106],"about_ca_topic_score_codex":0.00029946753,"about_ca_topic_score_gemma":0.00028411465,"teacher_disagreement_score":0.081004955,"about_ca_system_score_codex":0.000024542089,"about_ca_system_score_gemma":0.0001453229,"threshold_uncertainty_score":0.99960744},"labels":[],"label_agreement":null},{"id":"W2016099956","doi":"10.1200/jco.2005.03.3571","title":"Paraneoplastic Erythropoietin-Induced Polycythemia Associated With Small Lymphocytic Lymphoma","year":2006,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Vancouver General Hospital; University of British Columbia; BC Cancer Agency","funders":"","keywords":"Medicine; Erythropoietin; Lymphoma; Chronic lymphocytic leukemia; Polycythemia vera; Internal medicine; Cancer research; Oncology; Leukemia","score_opus":0.09455510757676037,"score_gpt":0.3866879914780393,"score_spread":0.2921328839012789,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2016099956","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9876542,0.0002584086,0.00011074851,0.004990024,0.0007400647,0.00027723386,0.000004417167,0.000024988214,0.0059398967],"genre_scores_gemma":[0.9938308,0.00012531441,0.0023862512,0.0015109638,0.0014663567,0.000012708915,0.000011173707,0.000037210426,0.0006191986],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9959854,0.00043737743,0.002352362,0.0002961807,0.00051499606,0.0004136736],"domain_scores_gemma":[0.9916721,0.004904585,0.0021137279,0.00022208176,0.0006430642,0.00044442917],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0014761533,0.00028681615,0.0020957727,0.00014044992,0.000085570624,0.000019120804,0.00013668482,0.00050524547,0.00018499244],"category_scores_gemma":[0.0029267564,0.00017518054,0.0005250388,0.00022827504,0.00023234011,0.00006531699,0.0000310529,0.00047599073,0.000058287365],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.02089496,0.020588415,0.8183289,0.00007005977,0.004089056,0.01851846,0.0001540448,0.00018885432,0.0006964811,0.0008387858,0.013100932,0.10253104],"study_design_scores_gemma":[0.046622135,0.035886895,0.8941295,0.00048307664,0.0018195139,0.0032927196,0.00007522952,0.00018284339,0.0016338009,0.00035908446,0.015245297,0.00026988052],"about_ca_topic_score_codex":0.00010703126,"about_ca_topic_score_gemma":0.00029480868,"teacher_disagreement_score":0.102261156,"about_ca_system_score_codex":0.0010849141,"about_ca_system_score_gemma":0.0047678095,"threshold_uncertainty_score":0.84578896},"labels":[],"label_agreement":null},{"id":"W2016111806","doi":"10.1016/j.clml.2014.12.008","title":"Effects of Ruxolitinib Treatment on Metabolic and Nutritional Parameters in Patients With Myelofibrosis From COMFORT-I","year":2014,"lang":"en","type":"article","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":87,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"University of Texas MD Anderson Cancer Center; National Cancer Institute; National Institutes of Health; Incyte; Gilead Sciences; Sanofi; Genentech; Celgene; AstraZeneca; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Ruxolitinib; Myelofibrosis; Medicine; Placebo; Internal medicine; Clinical endpoint; Gastroenterology; Post-hoc analysis; Randomized controlled trial; Surgery; Bone marrow; Pathology","score_opus":0.013702949473495459,"score_gpt":0.2692774016353615,"score_spread":0.25557445216186603,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2016111806","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9975336,0.0002663501,0.000011695616,0.00016737131,0.000115662246,0.0013548122,0.00010428085,0.00003524352,0.00041094527],"genre_scores_gemma":[0.9952232,0.00033359777,0.002756009,0.00078566733,0.00012848726,0.0004182326,0.00027743063,0.000042218166,0.000035136884],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9973273,0.000282521,0.00086095906,0.000714589,0.00044095,0.00037365535],"domain_scores_gemma":[0.99553084,0.003301759,0.00027327344,0.0004152026,0.0001041945,0.0003747437],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00018367665,0.00042131395,0.0013325313,0.00015106998,0.00006643289,0.000022054994,0.0000859772,0.00023268926,0.000025987061],"category_scores_gemma":[0.00033570876,0.00028852248,0.0002356991,0.00018138713,0.0003074607,0.00007278625,0.00004114707,0.00012213188,0.000027558879],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0027537649,0.0027822503,0.72364306,0.000056480134,0.00035891827,0.000029309758,0.00005770749,0.0000044696176,0.000023572771,0.0010304205,0.00005518412,0.26920483],"study_design_scores_gemma":[0.03198386,0.0076860148,0.9483048,0.0006278123,0.0004349133,0.000003482387,0.000010210589,0.00010335513,0.008983926,0.0003624578,0.0012552772,0.00024391487],"about_ca_topic_score_codex":0.00027319626,"about_ca_topic_score_gemma":0.000029766516,"teacher_disagreement_score":0.26896092,"about_ca_system_score_codex":0.00038993626,"about_ca_system_score_gemma":0.00021630214,"threshold_uncertainty_score":0.99995667},"labels":[],"label_agreement":null},{"id":"W2016147458","doi":"10.1182/blood-2012-05-428177","title":"Myelodyspastic syndrome with complex cytogenetics","year":2012,"lang":"en","type":"article","venue":"Blood","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Western University","funders":"","keywords":"Medicine; Sepsis; Mean corpuscular volume; Oxaliplatin; Cytogenetics; Chemotherapy; Fluorouracil; Internal medicine; Gastroenterology; Hematologic Neoplasms; Colorectal cancer; Surgery; Oncology; Hemoglobin; Cancer; Biology","score_opus":0.030757309695348272,"score_gpt":0.2643453585681127,"score_spread":0.23358804887276444,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2016147458","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9933489,0.0005059429,0.000096086456,0.0003771057,0.0000455253,0.00035550262,0.000012799662,0.000051627892,0.005206494],"genre_scores_gemma":[0.9936922,0.000043805172,0.0053347214,0.00035988097,0.00013941618,0.00007523305,0.00003884143,0.00002659889,0.0002892745],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.999146,0.000020047555,0.00013323218,0.00015659379,0.0002211415,0.00032298584],"domain_scores_gemma":[0.9993683,0.000055397253,0.000040559215,0.00022873114,0.00005313557,0.00025389594],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000050939212,0.00015919202,0.000261568,0.0000477212,0.00006436304,0.000011426922,0.000037645063,0.00004447896,0.00041484184],"category_scores_gemma":[0.000018514169,0.00010682842,0.00004262223,0.000110763525,0.000047382942,0.000036910533,0.000021884063,0.00007601782,0.00025612506],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000039315797,0.0023099089,0.99480915,0.000044120767,0.00036591614,0.00026577836,0.00015366774,0.0000020693544,0.00078571064,0.0005545572,0.0002903651,0.00037941654],"study_design_scores_gemma":[0.004054512,0.0012432938,0.97691435,0.00007400804,0.00073825766,0.0029476078,0.000037415753,0.0000068761883,0.010013541,0.000011030352,0.0038105487,0.00014856222],"about_ca_topic_score_codex":0.0000074156274,"about_ca_topic_score_gemma":0.0000060604107,"teacher_disagreement_score":0.017894827,"about_ca_system_score_codex":0.000022455384,"about_ca_system_score_gemma":0.00004194431,"threshold_uncertainty_score":0.45422274},"labels":[],"label_agreement":null},{"id":"W2016406604","doi":"10.2147/ott.s53348","title":"Management of cytopenias in patients with myelofibrosis treated with ruxolitinib and effect of dose modifications on efficacy outcomes","year":2013,"lang":"en","type":"article","venue":"OncoTargets and Therapy","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":62,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"Incyte","keywords":"Ruxolitinib; Myelofibrosis; Medicine; Extramedullary hematopoiesis; Pharmacology; Intensive care medicine; Internal medicine; Oncology; Bone marrow; Haematopoiesis","score_opus":0.00958283741905231,"score_gpt":0.25374510316316334,"score_spread":0.24416226574411104,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2016406604","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9968984,0.00021100276,0.000001457702,0.00023799506,0.0000054993225,0.0016862284,0.000015410458,0.000008610789,0.00093537214],"genre_scores_gemma":[0.99846643,0.0006323621,0.0005004311,0.000048080972,0.0000033538709,0.0002059464,0.00003012072,0.000015863001,0.0000974343],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9992404,0.000042441705,0.0001955404,0.0002202952,0.00016915005,0.00013219449],"domain_scores_gemma":[0.9994571,0.00012266183,0.00009503529,0.0001879057,0.00006350545,0.00007375162],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000053930904,0.0001838293,0.00045935236,0.000088138986,0.00003454865,0.000010063396,0.000027590622,0.000033034594,0.000047728652],"category_scores_gemma":[0.0000031068946,0.000091132555,0.000029173061,0.000106665604,0.00007462331,0.0000472585,0.000009500469,0.000046355304,0.0000021275778],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0019825855,0.0012335412,0.9636009,0.000068347916,0.00034194518,0.0000045676347,0.0002113975,0.0000035385583,0.00006853421,0.0003252423,0.000010267298,0.032149132],"study_design_scores_gemma":[0.018287841,0.0076616164,0.969002,0.00028584673,0.000071901595,6.4839617e-7,0.000025910365,0.000010073675,0.004488381,0.000010296965,0.000067805595,0.0000876633],"about_ca_topic_score_codex":0.0001435305,"about_ca_topic_score_gemma":0.0000049708397,"teacher_disagreement_score":0.03206147,"about_ca_system_score_codex":0.000018478015,"about_ca_system_score_gemma":0.000007941124,"threshold_uncertainty_score":0.37162778},"labels":[],"label_agreement":null},{"id":"W2019329008","doi":"10.1016/j.clml.2014.04.004","title":"Clinical Features of Patients With Philadelphia-Negative Myeloproliferative Neoplasms Complicated by Portal Hypertension","year":2014,"lang":"en","type":"article","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":29,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"National Center for Advancing Translational Sciences; National Cancer Institute; National Institute on Aging","keywords":"Medicine; Portal hypertension; Internal medicine; Ascites; Thrombosis; Myeloproliferative neoplasm; Gastroenterology; Polycythemia vera; Incidence (geometry); Population; Cardiology; Myelofibrosis; Cirrhosis; Bone marrow","score_opus":0.019999368163987532,"score_gpt":0.2955877178174157,"score_spread":0.2755883496534282,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2019329008","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99177074,0.00019740949,0.00015066596,0.0016680397,0.00042113912,0.0020475034,0.00024062111,0.00017409462,0.003329765],"genre_scores_gemma":[0.99101305,0.00024034125,0.00313757,0.0035423236,0.00046113555,0.00023085564,0.00094959815,0.000121014506,0.000304112],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9933451,0.00072642433,0.0025578267,0.0015598873,0.001060284,0.0007505154],"domain_scores_gemma":[0.9920613,0.0033289937,0.0011714589,0.0011193673,0.0013686839,0.00095016],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0008961439,0.0008435164,0.0026104546,0.0001554035,0.00026290995,0.00004821812,0.00034907274,0.0007489055,0.0001835121],"category_scores_gemma":[0.0020283,0.0005736245,0.00068475347,0.00051672815,0.001292849,0.00020312333,0.00018875096,0.0006621445,0.00014331783],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0055975863,0.004341708,0.78625774,0.00008042051,0.0012838478,0.00012527908,0.00011016155,0.000006230684,0.00008197266,0.001170996,0.02995432,0.17098972],"study_design_scores_gemma":[0.019668167,0.007177253,0.9628609,0.00036952042,0.0006276118,0.00010285736,0.000053570886,0.00043230818,0.0020933615,0.00026019212,0.005762438,0.0005918413],"about_ca_topic_score_codex":0.000078596735,"about_ca_topic_score_gemma":0.000038339575,"teacher_disagreement_score":0.17660312,"about_ca_system_score_codex":0.00030733028,"about_ca_system_score_gemma":0.000804312,"threshold_uncertainty_score":0.9996715},"labels":[],"label_agreement":null},{"id":"W2020673901","doi":"10.1158/0008-5472.can-08-2534","title":"Consistent Up-regulation of Stat3 Independently of Jak2 Mutations in a New Murine Model of Essential Thrombocythemia","year":2008,"lang":"en","type":"article","venue":"Cancer Research","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Immunovaccine (Canada)","funders":"National Cancer Institute; National Heart, Lung, and Blood Institute; National Institutes of Health","keywords":"Essential thrombocythemia; Janus kinase 2; STAT3; Polycythemia vera; Myelofibrosis; Cancer research; Biology; Bone marrow; Hyperactivation; Thrombocytosis; Gene; Medicine; Platelet; Immunology; Genetics","score_opus":0.15815529313159693,"score_gpt":0.42582512310290316,"score_spread":0.26766982997130623,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2020673901","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99751085,0.00042181404,0.00019045499,0.0004213675,0.000029418854,0.0006421175,0.00006653802,0.000004342149,0.0007130681],"genre_scores_gemma":[0.99763566,0.00059214863,0.0005717973,0.000009117533,0.000030255782,0.00008523454,0.000035845183,0.000013088311,0.0010268652],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9983582,0.00007158874,0.00042417034,0.00019981264,0.0007441035,0.00020214988],"domain_scores_gemma":[0.99881816,0.00014329948,0.000116546726,0.00022846718,0.0005914925,0.000102031896],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00023025034,0.00009104437,0.00038662401,0.00030550294,0.00003852785,0.0000023281666,0.00006725991,0.00006224899,0.00041009468],"category_scores_gemma":[0.00009638836,0.00007779905,0.000072595685,0.00038599444,0.00027644305,0.000054740736,0.000047755588,0.00017131714,0.0000025574298],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0020456514,0.0020999475,0.40994996,0.0008571224,0.00051598775,0.000038939692,0.010507672,0.016690625,0.5452822,0.006167285,0.0023924063,0.0034522],"study_design_scores_gemma":[0.0051315627,0.0004311634,0.1823074,0.0003734004,0.000052491585,0.000010273924,0.0003239932,0.004418511,0.8060536,0.00079997163,0.000026022977,0.0000716167],"about_ca_topic_score_codex":0.0026630543,"about_ca_topic_score_gemma":0.0008389517,"teacher_disagreement_score":0.2607714,"about_ca_system_score_codex":0.00020346808,"about_ca_system_score_gemma":0.0018805581,"threshold_uncertainty_score":0.44902492},"labels":[],"label_agreement":null},{"id":"W2023351243","doi":"10.1016/j.bbmt.2012.03.009","title":"Allogeneic Hematopoietic Cell Transplantation for Advanced Polycythemia Vera and Essential Thrombocythemia","year":2012,"lang":"en","type":"article","venue":"Biology of Blood and Marrow Transplantation","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":20,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"National Institute of Allergy and Infectious Diseases; National Cancer Institute; Office of Naval Research; Celgene; Osiris Therapeutics; U.S. Navy; CellGenix; Genentech; Health Resources and Services Administration; Therakos; Kiadis Pharma; Sigma-Tau Pharmaceuticals; Medical College of Wisconsin; National Heart, Lung, and Blood Institute; Blue Cross and Blue Shield Association; Otsuka America; National Center for Advancing Translational Sciences; Teva Pharmaceutical Industries; WellPoint; Takeda Oncology; Amgen; Ariad Pharmaceuticals; Swedish Orphan Biovitrum; U.S. Department of Health and Human Services; Tarix Pharmaceuticals; U.S. Department of Defense","keywords":"Medicine; Cumulative incidence; Essential thrombocythemia; Internal medicine; Polycythemia vera; Gastroenterology; Transplantation; Myelofibrosis; Splenectomy; Regimen; Incidence (geometry); Surgery; Bone marrow; Spleen","score_opus":0.009568727586966199,"score_gpt":0.2642618550169002,"score_spread":0.254693127429934,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2023351243","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99434936,0.0030587937,0.0014095344,0.0002043519,0.000089578105,0.00055620854,0.00013882745,0.000018540739,0.00017480111],"genre_scores_gemma":[0.98875284,0.0070237736,0.0034677067,0.000074066156,0.0000668114,0.00009750603,0.0004794359,0.000013313308,0.000024517658],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9992798,0.000030525152,0.00022452298,0.00020307692,0.000059167833,0.00020289561],"domain_scores_gemma":[0.9995781,0.00013637976,0.00008357185,0.00006947955,0.000036188016,0.00009624545],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00009492378,0.00015454256,0.00029659396,0.000060843016,0.00007045743,0.0000040804603,0.000020843876,0.0001261475,0.000017897095],"category_scores_gemma":[0.0000042582383,0.00012619351,0.00005590397,0.000036925383,0.000094928306,0.00007863065,0.0000027510237,0.000049611357,8.715817e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0009400241,0.00030473436,0.13250905,0.0011518757,0.00015086,0.000004480206,0.0016287597,7.6283965e-7,0.8597661,0.0013114141,0.000007972614,0.0022239361],"study_design_scores_gemma":[0.006383533,0.0007483333,0.05678344,0.00010378339,0.0014624291,0.0002825128,0.00009044103,0.000004424599,0.9337497,0.00018527923,0.000070753165,0.00013539547],"about_ca_topic_score_codex":0.000010775275,"about_ca_topic_score_gemma":0.000008474629,"teacher_disagreement_score":0.075725615,"about_ca_system_score_codex":0.000005716533,"about_ca_system_score_gemma":0.000024755049,"threshold_uncertainty_score":0.51460224},"labels":[],"label_agreement":null},{"id":"W2024993554","doi":"10.1016/s0720-048x(99)00122-9","title":"MRI features of epidural extramedullary hematopoiesis","year":2000,"lang":"en","type":"article","venue":"European Journal of Radiology","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":30,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Montreal General Hospital","funders":"","keywords":"Extramedullary hematopoiesis; Medicine; Epidural space; Spinal cord compression; Haematopoiesis; Thalassemia; Spinal cord; Magnetic resonance imaging; Radiology; Surgery; Internal medicine","score_opus":0.011744676632199238,"score_gpt":0.25306913303667294,"score_spread":0.2413244564044737,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2024993554","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9667358,0.0048534865,0.00007444444,0.0035097671,0.00017599271,0.00010669235,0.0000054486086,0.000009151312,0.024529258],"genre_scores_gemma":[0.99108607,0.0021050898,0.004972709,0.0006384402,0.00040299664,9.133537e-7,0.0000045853417,0.000022872733,0.000766334],"study_design_codex":"not_applicable","study_design_gemma":"observational","domain_scores_codex":[0.99851394,0.00046641452,0.0005560837,0.00012327573,0.00015709395,0.00018319568],"domain_scores_gemma":[0.9991214,0.00016076607,0.00026672147,0.00017277554,0.000120438286,0.00015786922],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00047694865,0.00014364245,0.0005786467,0.00011432569,0.000036786765,0.0000054575603,0.00011691712,0.000035267232,0.0015075138],"category_scores_gemma":[0.00009595706,0.00009539343,0.000225026,0.00008482726,0.00014035718,0.000045410572,0.000012215232,0.0002436361,0.00005629202],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0061246087,0.002604242,0.24888922,0.0003194009,0.0039090314,0.025737619,0.004703259,0.00041354445,0.013955982,0.0039734743,0.39755386,0.29181576],"study_design_scores_gemma":[0.0053374716,0.0054621887,0.86244345,0.0003447157,0.0003972967,0.051391874,0.00017773133,0.000008028583,0.01110836,0.00014784528,0.06299093,0.00019012214],"about_ca_topic_score_codex":0.0000017618737,"about_ca_topic_score_gemma":5.4895355e-7,"teacher_disagreement_score":0.61355424,"about_ca_system_score_codex":0.000029766545,"about_ca_system_score_gemma":0.000059350976,"threshold_uncertainty_score":0.99940526},"labels":[],"label_agreement":null},{"id":"W2025104203","doi":"10.1073/pnas.98.3.986","title":"Mouse model of congenital polycythemia: Homologous replacement of murine gene by mutant human erythropoietin receptor gene","year":2001,"lang":"en","type":"article","venue":"Proceedings of the National Academy of Sciences","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":56,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University","funders":"National Heart, Lung, and Blood Institute; National Institutes of Health","keywords":"Erythropoietin receptor; Erythropoiesis; Biology; Erythropoietin; Mutant; Gene; Allele; Gene knockout; Mutation; Genetics; Internal medicine; Medicine","score_opus":0.04104582319891913,"score_gpt":0.3099410122183451,"score_spread":0.26889518901942594,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2025104203","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99447244,0.00029342293,0.0000028152692,0.00307614,0.000011011757,0.00041685058,0.0001561814,0.000008664541,0.0015624487],"genre_scores_gemma":[0.9951077,0.00031017303,0.0035910122,0.00014944702,0.000042186406,0.00003260293,0.0000028002419,0.000008149881,0.0007558925],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9976683,0.0000073066917,0.00062638463,0.00030359539,0.0012120758,0.00018231396],"domain_scores_gemma":[0.9986569,0.00006761157,0.0006973553,0.000022843511,0.00049067463,0.0000645682],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00069901167,0.00015330857,0.00038887525,0.00015179151,0.00012682004,0.0000058432033,0.00032191206,0.00010015605,0.000101054866],"category_scores_gemma":[0.00021546784,0.00009959701,0.00012228648,0.0003767627,0.0010021633,0.00012911281,0.000118114185,0.00013437912,9.960489e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00016993511,0.0006026324,0.021616861,0.000065900385,0.00010820242,3.2738456e-8,0.0002357134,0.00007298425,0.97307885,0.002579972,0.0013867702,0.000082120976],"study_design_scores_gemma":[0.0010340731,0.0006034576,0.0029377416,0.00007380905,0.00006743492,0.000025946501,0.00015686477,0.0006575131,0.9928937,0.0014272446,0.000040848437,0.00008135662],"about_ca_topic_score_codex":0.000027941438,"about_ca_topic_score_gemma":1.993131e-7,"teacher_disagreement_score":0.019814836,"about_ca_system_score_codex":0.00007913698,"about_ca_system_score_gemma":0.000066842265,"threshold_uncertainty_score":0.40614483},"labels":[],"label_agreement":null},{"id":"W2029070773","doi":"10.3816/clm.2009.s.032","title":"Molecular and Genetic Bases of Myeloproliferative Disorders: Questions and Perspectives","year":2009,"lang":"en","type":"review","venue":"Clinical Lymphoma & Myeloma","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":16,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Institute of Cancer Research; Institut National Du Cancer; Ligue Contre le Cancer; Fondation pour la Recherche Médicale; Institut National de la Santé et de la Recherche Médicale; AstraZeneca","keywords":"Essential thrombocythemia; Myelofibrosis; Polycythemia vera; Myeloproliferative Disorders; Loss of heterozygosity; Mutation; Pathogenesis; Genetics; Epigenetics; Biology; Exon; Bioinformatics; Medicine; Gene; Immunology; Allele","score_opus":0.05432203405575678,"score_gpt":0.3835875530794639,"score_spread":0.32926551902370715,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2029070773","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.01985789,0.976579,0.000033577053,0.00069289224,0.000086375585,0.0018712583,0.000105224775,0.00005761139,0.00071618485],"genre_scores_gemma":[0.012008186,0.98429984,0.0026593953,0.00026518374,0.00023375492,0.00027645068,0.000075867436,0.00007620782,0.00010512683],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9960032,0.00056992145,0.0015374317,0.0011717778,0.00033841003,0.00037923042],"domain_scores_gemma":[0.9966655,0.0014266715,0.0005732054,0.00061356154,0.00023831264,0.00048276866],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00025986144,0.0007728784,0.0036105292,0.00025293167,0.0001350897,0.000051368184,0.00013239609,0.0005710298,0.00005094456],"category_scores_gemma":[0.001054887,0.0005709728,0.00074839406,0.00031252686,0.00082752533,0.00008155802,0.00013915864,0.00030441734,0.000018475735],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00006576116,0.001256491,0.0035629054,0.0024540108,0.0009033045,0.00022441517,0.00013075185,1.1901959e-7,5.997353e-7,0.002385525,0.0001380201,0.9888781],"study_design_scores_gemma":[0.005615958,0.006791901,0.3435467,0.026186295,0.009837684,0.0017263342,0.00030015467,0.000036367677,0.000023868397,0.0015370792,0.60301924,0.0013784094],"about_ca_topic_score_codex":0.000025286841,"about_ca_topic_score_gemma":0.000014848843,"teacher_disagreement_score":0.9874997,"about_ca_system_score_codex":0.00012354378,"about_ca_system_score_gemma":0.0006978006,"threshold_uncertainty_score":0.9996742},"labels":[],"label_agreement":null},{"id":"W2029201301","doi":"10.1016/j.exphem.2008.11.008","title":"Bone marrow mesenchymal stromal cells of patients with myeloproliferative disorders do not carry the JAK2-V617F mutation","year":2009,"lang":"en","type":"article","venue":"Experimental Hematology","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":21,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Jewish General Hospital","funders":"Canadian Institutes of Health Research","keywords":"Mesenchymal stem cell; Bone marrow; Myeloproliferative Disorders; Mutation; Haematopoiesis; Phenotype; Cancer research; clone (Java method); Biology; Stromal cell; Molecular biology; Medicine; Immunology; DNA; Genetics; Stem cell; Gene","score_opus":0.006987173452030944,"score_gpt":0.25823504564157906,"score_spread":0.25124787218954814,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2029201301","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9941986,0.0011023027,0.000033657336,0.0015068538,0.00012717207,0.0012548062,0.000034828907,0.00003124885,0.0017105029],"genre_scores_gemma":[0.9980014,0.000016210284,0.0010416482,0.0005195586,0.000040192852,0.00017225747,0.00010536944,0.000022295999,0.0000810823],"study_design_codex":"observational","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99833935,0.000110552646,0.00041069777,0.00039806927,0.00040501868,0.00033631228],"domain_scores_gemma":[0.9991545,0.0001104845,0.00020620038,0.0002929757,0.00011503041,0.00012081755],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00006883989,0.0003073032,0.0005866961,0.00009050799,0.00015434535,0.00001514141,0.00008690344,0.00010902779,0.00027869674],"category_scores_gemma":[0.000016669987,0.00018766742,0.00011348299,0.00015368403,0.00024487596,0.00010195612,0.000032743967,0.00016114018,0.0000247781],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.010776128,0.015450186,0.81898415,0.00016770764,0.0012354639,0.00047727808,0.02263279,0.00007560613,0.025271447,0.09609628,0.003023012,0.0058099297],"study_design_scores_gemma":[0.0058171484,0.005059076,0.18072851,0.00006816758,0.00009625443,0.000102220714,0.0020054341,0.00005087888,0.8056013,0.00011080498,0.000136879,0.00022333783],"about_ca_topic_score_codex":0.000030112824,"about_ca_topic_score_gemma":0.000021141239,"teacher_disagreement_score":0.7803298,"about_ca_system_score_codex":0.0000973483,"about_ca_system_score_gemma":0.0000775335,"threshold_uncertainty_score":0.76528555},"labels":[],"label_agreement":null},{"id":"W2030258670","doi":"10.1016/j.reprotox.2011.11.003","title":"A systematic review of the fetal safety of interferon alpha","year":2011,"lang":"en","type":"review","venue":"Reproductive Toxicology","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":107,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"SickKids Foundation; Hospital for Sick Children; University of Toronto","funders":"","keywords":"Alpha (finance); Medicine; Alpha interferon; Immunology; Interferon; Surgery","score_opus":0.04856916376793197,"score_gpt":0.3425941610552795,"score_spread":0.29402499728734754,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2030258670","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000019383304,0.9874909,0.0000058996216,0.00026500723,0.0003963382,0.008435863,0.000070584305,0.000014977437,0.0033010596],"genre_scores_gemma":[0.00014873139,0.9973518,0.00011637736,0.00012873427,0.00012594931,0.0010113936,0.000035157933,0.000048304515,0.0010334995],"study_design_codex":"systematic_review","study_design_gemma":"systematic_review","domain_scores_codex":[0.9955377,0.0011849359,0.001979602,0.0007956037,0.00025424853,0.00024792572],"domain_scores_gemma":[0.9950997,0.00039308157,0.00211227,0.0018898745,0.00043241473,0.000072654984],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0010295396,0.000495867,0.0065475656,0.00011034131,0.000041178166,0.0000018381976,0.00032520693,0.00028146632,0.0005424908],"category_scores_gemma":[0.0022793666,0.00025041754,0.0012957309,0.0004140795,0.00034403775,0.00002856551,0.0002307587,0.00040882558,0.00007978842],"study_design_candidate":"systematic_review","study_design_consensus":"systematic_review","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000057772824,0.00067690964,0.000028160397,0.9764582,0.0025472594,0.00001004771,0.00009492478,1.204288e-8,0.00000401323,0.0014158598,0.0004366987,0.018270157],"study_design_scores_gemma":[0.00032690147,0.0010337762,0.000049649705,0.8855515,0.014637463,0.000816103,0.000014855351,8.6177515e-8,0.00028530916,0.000033485685,0.0970703,0.00018055704],"about_ca_topic_score_codex":0.000009826156,"about_ca_topic_score_gemma":0.0000034843335,"teacher_disagreement_score":0.0966336,"about_ca_system_score_codex":0.00030081873,"about_ca_system_score_gemma":0.0005551122,"threshold_uncertainty_score":0.9999948},"labels":[],"label_agreement":null},{"id":"W2031242160","doi":"10.1002/hon.902","title":"Improved survival in red blood cell transfusion dependent patients with primary myelofibrosis (PMF) receiving iron chelation therapy","year":2009,"lang":"en","type":"article","venue":"Hematological Oncology","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":33,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"St. Paul's Hospital; University of British Columbia","funders":"","keywords":"Medicine; Myelofibrosis; Internal medicine; Gastroenterology; Splenectomy; White blood cell; Blood transfusion; Anemia; Surgery; Bone marrow","score_opus":0.015490967396035928,"score_gpt":0.257920360962542,"score_spread":0.24242939356650609,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2031242160","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99009156,0.00024928502,0.00008906368,0.0021429926,0.00008206262,0.001439297,0.0000045850497,0.00007093245,0.0058302376],"genre_scores_gemma":[0.99526995,0.0008115855,0.002738675,0.00080648216,0.000037149417,0.0001389464,0.00011822652,0.000017249304,0.00006173744],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9980072,0.00023836517,0.00050570536,0.0005502768,0.00029879084,0.0003996623],"domain_scores_gemma":[0.9990547,0.00029371708,0.00017059989,0.00021885677,0.000104316445,0.00015784317],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002237349,0.00029241535,0.0008420448,0.00011133253,0.00008956063,0.000012576143,0.00007606205,0.0003836583,0.00021734608],"category_scores_gemma":[0.000049411952,0.00018534808,0.000095389434,0.00021150439,0.00005497098,0.000081410675,0.00001864085,0.00032451493,0.00001031],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.003773834,0.009755543,0.94459224,0.000050912065,0.000047252168,0.00020900134,0.00031149935,0.000008308778,0.017486598,0.00012504679,0.000031271138,0.023608517],"study_design_scores_gemma":[0.016861267,0.011667659,0.9525262,0.00007779795,0.00009097637,0.00004584302,0.000036471938,0.00003827144,0.018177487,0.00008801003,0.0001812794,0.00020874394],"about_ca_topic_score_codex":0.000026332524,"about_ca_topic_score_gemma":0.000081360384,"teacher_disagreement_score":0.023399772,"about_ca_system_score_codex":0.00026674298,"about_ca_system_score_gemma":0.00011200158,"threshold_uncertainty_score":0.75582755},"labels":[],"label_agreement":null},{"id":"W2036934905","doi":"10.1016/j.anicom.2011.04.008","title":"Traitement d’un kyste bronchogénique par thoracoscopie","year":2011,"lang":"fr","type":"article","venue":"Pratique Médicale et Chirurgicale de l Animal de Compagnie","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal","funders":"","keywords":"Medicine; Splenectomy; Thrombocytopenic purpura; Gynecology; Platelet; Immunology; Spleen","score_opus":0.039322576425748275,"score_gpt":0.302795171498236,"score_spread":0.2634725950724877,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2036934905","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8625987,0.03179656,0.008615078,0.023727497,0.00090991607,0.0030199662,0.0003749985,0.0004022985,0.068554945],"genre_scores_gemma":[0.9432736,0.01015892,0.031085158,0.009316551,0.0012910673,0.0012328711,0.000149549,0.0001712777,0.003321019],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9924997,0.0018971761,0.001463402,0.0012918565,0.0008031648,0.0020446947],"domain_scores_gemma":[0.99558604,0.0008745636,0.00045118644,0.0008087053,0.0002815055,0.001998022],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.0019368372,0.0010751305,0.001577702,0.00020523532,0.00041885825,0.00018243096,0.0005375607,0.00091808086,0.01672825],"category_scores_gemma":[0.00044230063,0.0009770866,0.00062942517,0.00047317252,0.0006960365,0.00036599167,0.0002860418,0.0018400572,0.00081199675],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0051020444,0.037426535,0.51910096,0.0029403921,0.003642245,0.014522125,0.024281738,0.00007294621,0.011451173,0.26377854,0.05320557,0.06447572],"study_design_scores_gemma":[0.008371463,0.007654441,0.7318068,0.0032365103,0.0014978785,0.0015698303,0.00074634317,0.004815894,0.071537025,0.0056479448,0.16147888,0.0016369746],"about_ca_topic_score_codex":0.00055782864,"about_ca_topic_score_gemma":0.00023878622,"teacher_disagreement_score":0.25813058,"about_ca_system_score_codex":0.0009261399,"about_ca_system_score_gemma":0.0013808707,"threshold_uncertainty_score":0.99996597},"labels":[],"label_agreement":null},{"id":"W2037615243","doi":"10.14740/jh190w","title":"Acquired β-Thalassemia as an Etiology of Microcytic Anemia in Primary Myelofibrosis","year":2015,"lang":"en","type":"article","venue":"Journal of Hematology","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Myelofibrosis; Microcytic anemia; Medicine; Thalassemia; Etiology; Anemia; Pathology; Internal medicine; Bone marrow","score_opus":0.026494966175325145,"score_gpt":0.3102270538971393,"score_spread":0.28373208772181413,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2037615243","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9950845,0.0014897367,0.000020538851,0.0016886228,0.00018497171,0.00018628583,0.0000024888047,0.000006487754,0.0013363354],"genre_scores_gemma":[0.99590325,0.00019896042,0.0032203142,0.00051318033,0.00007679597,0.000009266138,0.000010611687,0.000016416448,0.00005121227],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99830055,0.00018834067,0.0008631966,0.0001748723,0.00022521042,0.00024781917],"domain_scores_gemma":[0.998426,0.00021714032,0.0005305257,0.00020375029,0.00036492,0.0002576441],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004100629,0.00016786226,0.001079265,0.00033095374,0.000016206171,0.000004785277,0.000117346375,0.00022064181,0.000094347364],"category_scores_gemma":[0.00025604112,0.000124428,0.00012194722,0.00016259469,0.00012580764,0.00011101154,0.000035934943,0.00018270456,0.000022334965],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.002670624,0.0016907394,0.9518578,0.00024169368,0.00022300701,0.0023292887,0.0013124399,0.000020328791,0.032649968,0.0017334886,0.0041203713,0.001150255],"study_design_scores_gemma":[0.026071312,0.018992495,0.6056828,0.0010213403,0.00063948426,0.065954246,0.0016071653,0.00008170021,0.2733809,0.003829785,0.002311052,0.00042774263],"about_ca_topic_score_codex":0.000028521055,"about_ca_topic_score_gemma":0.00002233253,"teacher_disagreement_score":0.34617501,"about_ca_system_score_codex":0.00025198035,"about_ca_system_score_gemma":0.00071828684,"threshold_uncertainty_score":0.50740266},"labels":[],"label_agreement":null},{"id":"W2038771520","doi":"10.1016/j.celrep.2015.03.056","title":"Central Role of ULK1 in Type I Interferon Signaling","year":2015,"lang":"en","type":"article","venue":"Cell Reports","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":75,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; University Health Network","funders":"National Cancer Institute; University of Illinois at Chicago; Northwestern University; U.S. Department of Veterans Affairs","keywords":"ULK1; Interferon; Biology; Protein kinase A; Cancer research; Transcription factor; Cell biology; Mediator; Regulator; MAPK/ERK pathway; p38 mitogen-activated protein kinases; Kinase; Signal transduction; Gene; Immunology; Genetics","score_opus":0.0241437392744405,"score_gpt":0.26767672190002145,"score_spread":0.24353298262558096,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2038771520","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9799622,0.0010606741,0.00000692293,0.000062511535,0.00019188177,0.00021125551,5.4005073e-7,0.0000124258595,0.018491568],"genre_scores_gemma":[0.99905384,0.00003301266,0.0003042692,0.000044214026,0.00005345867,0.0000096539925,0.000018005956,0.00001093764,0.00047258905],"study_design_codex":"observational","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99916637,0.000018006367,0.0003143825,0.00017420594,0.00016584655,0.00016116307],"domain_scores_gemma":[0.9994404,0.000021484691,0.00011611576,0.0001801776,0.00010246298,0.000139377],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00013510358,0.00008930351,0.000236309,0.00005831479,0.0000077513,0.0000047544377,0.000018167679,0.000047640497,0.00010875853],"category_scores_gemma":[0.000076773045,0.00007078901,0.00004102299,0.00009721089,0.000017979459,0.000027379809,0.000019191415,0.0000745852,0.000009269466],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00018420807,0.00058192026,0.9739607,0.000041437648,0.0000267994,0.0013097227,0.0012724614,0.00012339484,0.020135803,0.00003642568,0.0007497334,0.0015774183],"study_design_scores_gemma":[0.0012504549,0.0011620572,0.07287542,0.00022015964,0.00007340994,0.00019501569,0.0006252933,0.00013614747,0.9151364,0.00041380766,0.007779735,0.00013208546],"about_ca_topic_score_codex":0.00010751163,"about_ca_topic_score_gemma":0.000020929408,"teacher_disagreement_score":0.90108526,"about_ca_system_score_codex":0.00009471438,"about_ca_system_score_gemma":0.00015979292,"threshold_uncertainty_score":0.2886692},"labels":[],"label_agreement":null},{"id":"W2042473102","doi":"10.1074/jbc.c600277200","title":"Erlotinib Effectively Inhibits JAK2V617F Activity and Polycythemia Vera Cell Growth","year":2006,"lang":"en","type":"article","venue":"Journal of Biological Chemistry","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":122,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"National Heart, Lung, and Blood Institute; National Institutes of Health; National Natural Science Foundation of China","keywords":"Polycythemia vera; Erlotinib; Myelofibrosis; Essential thrombocythemia; Cancer research; Janus kinase 2; Tyrosine kinase; Myeloproliferative Disorders; Cell culture; Tyrosine-kinase inhibitor; Bone marrow; Chemistry; Clonogenic assay; Medicine; In vitro; Pharmacology; Kinase; Internal medicine; Biology; Cancer; Biochemistry; Genetics; Receptor","score_opus":0.012364473173428897,"score_gpt":0.24288706798117418,"score_spread":0.23052259480774528,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2042473102","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99349993,0.0007221707,0.00002331825,0.00071218616,0.00003582639,0.00012519691,0.000010057829,0.000013587139,0.0048577],"genre_scores_gemma":[0.99864274,0.00021679871,0.00040670205,0.000107286236,0.00042143435,0.0000066269968,0.0000057517173,0.000008722419,0.0001839353],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99908704,0.00004028959,0.00028727454,0.00020268852,0.00018486784,0.0001978242],"domain_scores_gemma":[0.999087,0.00025997448,0.000258536,0.00007978761,0.00014013198,0.00017460785],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00018107961,0.00019406696,0.00045754708,0.000024600926,0.000059536913,0.000019465613,0.000052318024,0.00019622587,0.00010839305],"category_scores_gemma":[0.00014254496,0.00011605266,0.00015691156,0.0000789844,0.00010633925,0.000047945858,0.00003790872,0.00036145534,0.000004659607],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0006450032,0.0008371155,0.18905938,0.00008838656,0.00006027546,0.00020014167,0.000014508053,5.857313e-7,0.8075251,0.000015113696,0.0006079803,0.0009463869],"study_design_scores_gemma":[0.0018513231,0.00059595035,0.28528255,0.000067488465,0.000052151743,0.0004688094,0.000010010886,0.000003191477,0.7112452,0.00014321978,0.00019600491,0.000084098734],"about_ca_topic_score_codex":0.000015006884,"about_ca_topic_score_gemma":3.9745612e-7,"teacher_disagreement_score":0.09627994,"about_ca_system_score_codex":0.00009305807,"about_ca_system_score_gemma":0.00006073403,"threshold_uncertainty_score":0.47324902},"labels":[],"label_agreement":null},{"id":"W2043184084","doi":"10.1371/journal.pone.0043437","title":"Random Mutagenesis Reveals Residues of JAK2 Critical in Evading Inhibition by a Tyrosine Kinase Inhibitor","year":2012,"lang":"en","type":"article","venue":"PLoS ONE","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":28,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Waterloo; Ontario Institute for Cancer Research; University of Toronto","funders":"Canadian Institutes of Health Research; Leukemia and Lymphoma Society","keywords":"Janus kinase 2; Tyrosine-kinase inhibitor; Biology; Tyrosine kinase; Mutagenesis; Cancer research; Mutation; Kinase; Signal transduction; Genetics; Gene","score_opus":0.04543179980773363,"score_gpt":0.2873441073788219,"score_spread":0.24191230757108825,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2043184084","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99323237,0.0034199993,0.000018558332,0.0019083294,0.00003599302,0.0006949132,0.000060787614,0.000030449202,0.00059860526],"genre_scores_gemma":[0.99620193,0.0002912157,0.0025104121,0.00027813375,0.00025185733,0.00019298684,0.00007265252,0.00002758712,0.00017320162],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9984165,0.00013334396,0.0004592369,0.00022831465,0.0004194631,0.00034316062],"domain_scores_gemma":[0.9989132,0.00044796415,0.00007717408,0.00020119004,0.00015140645,0.00020900746],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00038908847,0.00017845717,0.0006195269,0.00015693498,0.000044976197,0.000011206377,0.000027324573,0.000107751184,0.0002805588],"category_scores_gemma":[0.001051089,0.00015138017,0.00007411448,0.00021624641,0.00007923225,0.00016182367,0.000029820849,0.00012810699,0.000046027646],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00072406477,0.009011284,0.44724962,0.000534127,0.00014366399,0.000035447065,0.0004693551,2.075299e-7,0.5398561,0.0003488692,0.0014038421,0.00022346046],"study_design_scores_gemma":[0.005314288,0.00045873926,0.0697717,0.0019352314,0.00038831445,0.000006863289,0.00007310467,0.000017769313,0.9217911,0.00007187702,0.00003414978,0.00013690811],"about_ca_topic_score_codex":0.00007057916,"about_ca_topic_score_gemma":0.000019550367,"teacher_disagreement_score":0.381935,"about_ca_system_score_codex":0.00012433903,"about_ca_system_score_gemma":0.000031929525,"threshold_uncertainty_score":0.61731046},"labels":[],"label_agreement":null},{"id":"W2045465329","doi":"10.1002/pbc.21659","title":"<i>JAK2 V617F</i> positive polycythemia Vera in a child with neurofibromatosis type I","year":2008,"lang":"en","type":"article","venue":"Pediatric Blood & Cancer","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Capital District Health Authority; Izaak Walton Killam Health Centre; Dalhousie University","funders":"","keywords":"Juvenile myelomonocytic leukemia; Medicine; JAK2 V617F; Neurofibromatosis; Polycythemia vera; Neurofibromin 1; Myeloproliferative neoplasm; Germline mutation; Neurofibromatosis type I; Blood cancer; Mutation; Myeloproliferative Disorders; Pediatrics; Oncology; Internal medicine; Cancer; Genetics; Haematopoiesis; Pathology; Myelofibrosis; Bone marrow; Stem cell; Biology","score_opus":0.01075027003476274,"score_gpt":0.23825990049221069,"score_spread":0.22750963045744793,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2045465329","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9861448,0.005956793,0.0000016429848,0.0018484916,0.0001398814,0.0006174962,0.000053432854,0.000064432876,0.0051730624],"genre_scores_gemma":[0.9877667,0.009431899,0.00031304464,0.0011825239,0.0006892141,0.0002457696,0.000031654967,0.000051453455,0.0002877337],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99843997,0.000042368603,0.00026717814,0.00047731292,0.0003649803,0.00040820654],"domain_scores_gemma":[0.9992197,0.00008994109,0.000103470295,0.00026468374,0.00011392527,0.00020827072],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000045205943,0.00029803472,0.0004847948,0.00018439892,0.00013138306,0.000012724526,0.00007570079,0.00009458695,0.00020789397],"category_scores_gemma":[0.000024610743,0.00022261795,0.00008439571,0.00080503966,0.000055697707,0.00009105898,0.00003358681,0.00028295108,0.000057652156],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0006275666,0.00090200023,0.9935696,0.00007596186,0.00019618607,0.001359323,0.00059140834,0.000012742518,0.00011812206,0.00003840752,0.002212462,0.0002962073],"study_design_scores_gemma":[0.0074790525,0.001990799,0.9706249,0.00021783996,0.0012824113,0.0018675594,0.000038441754,0.000012785659,0.015108573,0.000009724605,0.0009370269,0.00043087616],"about_ca_topic_score_codex":0.00065421587,"about_ca_topic_score_gemma":0.00010873893,"teacher_disagreement_score":0.022944704,"about_ca_system_score_codex":0.00009000158,"about_ca_system_score_gemma":0.00036403415,"threshold_uncertainty_score":0.9078097},"labels":[],"label_agreement":null},{"id":"W2045829353","doi":"10.1017/s0317167100007149","title":"Chorea in the Elderly with Mutation Positive Polycythemia Vera: A Case Report","year":2009,"lang":"en","type":"article","venue":"Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":16,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"London Health Sciences Centre","funders":"","keywords":"Chorea; Polycythemia vera; Mutation; Medicine; Psychology; Internal medicine; Genetics; Biology","score_opus":0.024684927614308554,"score_gpt":0.28533924881663836,"score_spread":0.2606543212023298,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2045829353","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9694467,0.00054293853,0.000016138107,0.026237722,0.00014961782,0.00028709706,0.000005203256,0.000007375821,0.0033072042],"genre_scores_gemma":[0.99267477,0.00008412854,0.0011562682,0.0059065274,0.00015318142,0.0000046511636,6.6684373e-7,0.000005571603,0.000014210931],"study_design_codex":"case_report","study_design_gemma":"case_report","domain_scores_codex":[0.9966244,0.00062984193,0.0006903128,0.00042964125,0.0007494881,0.0008763117],"domain_scores_gemma":[0.9974733,0.00043721026,0.0005498149,0.00014250194,0.00038210733,0.0010150438],"candidate_categories":["sts"],"consensus_categories":[],"category_scores_codex":[0.002899588,0.0002762122,0.00044257226,0.0006709979,0.0016083037,0.00046481588,0.0005944659,0.000117403084,0.00005183914],"category_scores_gemma":[0.00090127205,0.00013498419,0.000150068,0.0012808526,0.0024646425,0.0005769673,0.000010882487,0.0010220028,0.000001209845],"study_design_candidate":"case_report","study_design_consensus":"case_report","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00018142196,0.00007895853,0.33911002,0.0000016148051,0.000010491768,0.65176356,0.0008607248,0.0004197947,0.0000069254934,0.0005255903,0.00021319333,0.0068276855],"study_design_scores_gemma":[0.00043345784,0.10255054,0.2135235,0.000040231167,0.000043679942,0.68024,0.0003988735,0.00012823814,0.00006055909,0.0022633912,0.00020729878,0.00011024816],"about_ca_topic_score_codex":0.00212387,"about_ca_topic_score_gemma":0.08664581,"teacher_disagreement_score":0.12558651,"about_ca_system_score_codex":0.00024765427,"about_ca_system_score_gemma":0.002841602,"threshold_uncertainty_score":0.9996915},"labels":[],"label_agreement":null},{"id":"W2045908279","doi":"10.1038/leu.2008.115","title":"Familial essential thrombocythemia with spontaneous megakaryocyte colony formation and acquired JAK2 mutations","year":2008,"lang":"en","type":"article","venue":"Leukemia","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Dalhousie University","funders":"","keywords":"Megakaryocyte; Essential thrombocythemia; Polycythemia vera; Mutation; Hematology; Myelofibrosis; Cancer research; Myeloproliferative Disorders; Thrombocytosis; Genetics; Biology; Immunology; Haematopoiesis; Medicine; Gene; Platelet; Bone marrow; Stem cell","score_opus":0.01361377132491346,"score_gpt":0.2427615797508115,"score_spread":0.22914780842589805,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2045908279","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99414045,0.0001424282,0.00028552246,0.00033673103,0.000066669,0.0007358095,0.000020583804,0.000082367806,0.0041894615],"genre_scores_gemma":[0.9961696,0.0002468416,0.002054129,0.00035141196,0.00014420373,0.00018290301,0.0001447182,0.000023393965,0.00068278424],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9989041,0.00002895247,0.00022425575,0.00026069858,0.0003503126,0.00023165457],"domain_scores_gemma":[0.99934715,0.00008929195,0.000083043284,0.0001879353,0.00014409565,0.00014850238],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000053311775,0.00019950153,0.0003180829,0.000074026924,0.00027692365,0.000020990527,0.000039067145,0.00009404966,0.00009991152],"category_scores_gemma":[0.000036064303,0.00014846172,0.000049924318,0.00013241173,0.00016567568,0.00017276661,0.000022748756,0.00009469311,0.00004994915],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.031061733,0.0050459756,0.43423513,0.0019588615,0.005695136,0.11627254,0.07639215,0.0025844784,0.1873301,0.014632323,0.07001875,0.054772843],"study_design_scores_gemma":[0.03443127,0.0058805244,0.6165737,0.00059192546,0.0015599625,0.08317496,0.0013155189,0.009586467,0.22882353,0.00036830647,0.016411893,0.0012819567],"about_ca_topic_score_codex":0.00014076247,"about_ca_topic_score_gemma":0.00021480532,"teacher_disagreement_score":0.18233857,"about_ca_system_score_codex":0.0005641442,"about_ca_system_score_gemma":0.00038554452,"threshold_uncertainty_score":0.6054093},"labels":[],"label_agreement":null},{"id":"W2046610014","doi":"10.1016/j.leukres.2012.01.023","title":"RBC-transfusion guidelines update","year":2012,"lang":"en","type":"letter","venue":"Leukemia Research","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"National Cancer Institute","keywords":"Myelofibrosis; Medicine; Randomized controlled trial; Erythropoiesis; Thalidomide; Disease; Clinical trial; Anemia; Intensive care medicine; Ruxolitinib; Pediatrics; Internal medicine; Bone marrow; Multiple myeloma","score_opus":0.19294292271923746,"score_gpt":0.4371403201345239,"score_spread":0.24419739741528645,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2046610014","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.011020739,0.0042919274,0.000026941862,0.96300256,0.00059082924,0.0019357317,0.00010590174,0.00013061623,0.018894764],"genre_scores_gemma":[0.0046812445,0.017096497,0.003025743,0.86193126,0.029743258,0.0014494276,0.0035066518,0.00035737874,0.07820856],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99391806,0.00045928181,0.00068209256,0.000897047,0.0025148261,0.0015286742],"domain_scores_gemma":[0.9962803,0.0005742805,0.00009445377,0.0011589713,0.001529257,0.00036270588],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":["research_integrity","insufficient_payload"],"category_scores_codex":[0.0014258511,0.00054309715,0.00090427406,0.00065608503,0.00034290188,0.00010446001,0.00035026527,0.0013829109,0.003798549],"category_scores_gemma":[0.00042544483,0.00039246297,0.0003355544,0.0005327436,0.000240765,0.00010811101,0.0002129087,0.0051946216,0.00463669],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00012509938,0.00010068557,0.003212967,0.0003964974,0.00025535928,0.0018372757,0.00008874923,9.0845964e-7,0.00022384242,0.00010612345,0.9832413,0.010411195],"study_design_scores_gemma":[0.0017221939,0.00034079343,0.001261134,0.0006295026,0.00016975688,0.00019286196,0.000019405627,0.000048380916,0.0029630107,0.00017578316,0.99215394,0.0003232094],"about_ca_topic_score_codex":0.00091397506,"about_ca_topic_score_gemma":0.00006568889,"teacher_disagreement_score":0.101071306,"about_ca_system_score_codex":0.0020440202,"about_ca_system_score_gemma":0.0015771168,"threshold_uncertainty_score":0.9999135},"labels":[],"label_agreement":null},{"id":"W2050173346","doi":"10.1038/nm.3150","title":"Cholesterol efflux in megakaryocyte progenitors suppresses platelet production and thrombocytosis","year":2013,"lang":"en","type":"article","venue":"Nature Medicine","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":196,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Canadian Blood Services; St. Michael's Hospital","funders":"National Cancer Institute; National Heart, Lung, and Blood Institute","keywords":"Megakaryocyte; Thrombopoietin; Platelet; Endocrinology; Internal medicine; Medicine; Progenitor cell; Haematopoiesis; Biology; Cell biology; Stem cell","score_opus":0.009404481395037806,"score_gpt":0.27729981071117543,"score_spread":0.26789532931613763,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2050173346","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9724108,0.0024394947,0.000002072456,0.022063576,0.0004714019,0.0017474554,0.0000033171077,0.00006463874,0.00079723296],"genre_scores_gemma":[0.99556094,0.0009597678,0.00040532055,0.0013942285,0.0008211524,0.00040552526,0.000055322405,0.000030217101,0.00036750577],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99840283,0.00004987666,0.00033214255,0.0005062992,0.00040813372,0.00030072176],"domain_scores_gemma":[0.9991487,0.000115074676,0.0000815613,0.0002896697,0.00017108973,0.00019386072],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00017846469,0.00028676074,0.0005770138,0.00020320428,0.00006917774,0.000018747749,0.000059579685,0.00029368626,0.00033653664],"category_scores_gemma":[0.0004120372,0.00018047138,0.000047159516,0.00032216063,0.00016561024,0.00018585181,0.00003469106,0.00063566293,0.000031819374],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00013986925,0.0006156883,0.93339926,0.0004419349,0.00030875835,0.00004003373,0.001836147,0.000002806616,0.021215001,0.00012831745,0.029369945,0.012502236],"study_design_scores_gemma":[0.0037844093,0.00092532835,0.8023349,0.0008916986,0.00014793812,0.00028471183,0.00024316247,0.00004986618,0.1854403,0.00007145295,0.0056468532,0.00017938433],"about_ca_topic_score_codex":0.00019630711,"about_ca_topic_score_gemma":0.00009937978,"teacher_disagreement_score":0.1642253,"about_ca_system_score_codex":0.00010061771,"about_ca_system_score_gemma":0.000043754488,"threshold_uncertainty_score":0.73594093},"labels":[],"label_agreement":null},{"id":"W2055650463","doi":"10.1038/bmt.2014.323","title":"Allo-SCT for myelofibrosis: reversing the chronic phase in the JAK inhibitor era?","year":2015,"lang":"en","type":"review","venue":"Bone Marrow Transplantation","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":15,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"National Cancer Institute; Eisai; Incyte","keywords":"Medicine; Myelofibrosis; Ruxolitinib; Candidacy; Internal medicine; Hematology; Natural history; Oncology; Bone marrow","score_opus":0.07107719492778257,"score_gpt":0.3777670950010192,"score_spread":0.3066899000732366,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2055650463","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00040272018,0.9904295,0.00016818804,0.0014179322,0.0002672783,0.0062752697,0.00046100258,0.000035600962,0.00054250483],"genre_scores_gemma":[0.001735948,0.9912784,0.00038095354,0.00023676932,0.00061226694,0.002595946,0.00292541,0.000063084924,0.00017118733],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99758303,0.00036246766,0.0007468117,0.00047179923,0.00046604322,0.00036983282],"domain_scores_gemma":[0.99851424,0.0006119167,0.0002843862,0.00039687977,0.000100290716,0.00009230964],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0009434441,0.00048634567,0.001241696,0.00017440652,0.00021732316,0.00007391496,0.00016361833,0.00025548728,0.000031241056],"category_scores_gemma":[0.000037679496,0.00025443578,0.0004899746,0.00033967107,0.00006818426,0.00010309576,0.000008030757,0.0004120845,0.000034603127],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0006254995,0.00071490917,0.000035372224,0.027631603,0.00039317677,0.00021288972,0.0021965886,0.0000044301164,0.000029901454,0.000354898,0.006720562,0.9610802],"study_design_scores_gemma":[0.0066685393,0.0010945324,0.00006823986,0.017988384,0.0049939496,0.00049958425,0.000116528376,0.000035225978,0.00007128782,0.000040347844,0.96810555,0.00031783522],"about_ca_topic_score_codex":0.00004628664,"about_ca_topic_score_gemma":0.00025084618,"teacher_disagreement_score":0.961385,"about_ca_system_score_codex":0.000492559,"about_ca_system_score_gemma":0.00064178434,"threshold_uncertainty_score":0.99999076},"labels":[],"label_agreement":null},{"id":"W2056903619","doi":"10.1002/ajh.23138","title":"A novel mutation in MPL (Y252H) results in increased thrombopoietin sensitivity in essential thrombocythemia","year":2012,"lang":"en","type":"article","venue":"American Journal of Hematology","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":22,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"National Heart, Lung, and Blood Institute","keywords":"Thrombopoietin; Essential thrombocythemia; Medicine; Mutation; Plateletpheresis; Thrombopoietin receptor; Myelofibrosis; Platelet; Immunology; Internal medicine; Genetics; Biology; Haematopoiesis; Gene; Bone marrow","score_opus":0.014848053300557865,"score_gpt":0.30426786043168563,"score_spread":0.28941980713112775,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2056903619","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9967915,0.00018048582,0.00019085982,0.0021996782,0.00010233335,0.00022973953,0.0000072595235,0.000005671442,0.00029246233],"genre_scores_gemma":[0.9961101,0.00006905901,0.0033841194,0.00031032512,0.00008301023,0.000012110803,0.000012286803,0.000016310785,0.0000027097642],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9979861,0.00030591557,0.00087861595,0.00019055662,0.00023135782,0.00040748177],"domain_scores_gemma":[0.9984175,0.0006170993,0.00056158553,0.00014911756,0.00009784588,0.00015685495],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010064611,0.0001856215,0.0010666981,0.00047265546,0.000018879517,0.0000064331616,0.000048848226,0.00008096414,0.000026149757],"category_scores_gemma":[0.00049124967,0.00015156758,0.00009333766,0.00048778864,0.00020169995,0.00015904948,0.000026834216,0.00040726722,0.000010739299],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0018335246,0.0026254803,0.97940546,0.000029286342,0.00008709918,0.0017989622,0.0030647197,0.000041819636,0.008443273,0.0006374467,0.000097718126,0.0019351891],"study_design_scores_gemma":[0.008833951,0.0009066118,0.96058875,0.00035073917,0.000055214943,0.008373481,0.0016102961,0.00013313022,0.018893905,0.00007377248,0.000039103666,0.00014103502],"about_ca_topic_score_codex":0.0017215692,"about_ca_topic_score_gemma":0.002253133,"teacher_disagreement_score":0.018816723,"about_ca_system_score_codex":0.00020499973,"about_ca_system_score_gemma":0.00020670601,"threshold_uncertainty_score":0.61807466},"labels":[],"label_agreement":null},{"id":"W2057956646","doi":"10.1155/2013/615189","title":"A Case of Erythrocytosis in a Patient Treated with an Aromatase Inhibitor for Breast Cancer","year":2013,"lang":"en","type":"article","venue":"Case Reports in Hematology","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Hospital","funders":"","keywords":"Medicine; Exemestane; Erythropoietin; Internal medicine; Aromatase; Hyperuricosuria; Polycythemia vera; Hematology; Endocrinology; Erythropoiesis; Hematologist; Cancer; Breast cancer; Anemia","score_opus":0.01814109980351047,"score_gpt":0.290432494208213,"score_spread":0.2722913944047025,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2057956646","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99700445,0.0002705007,0.000005849353,0.00030595704,0.000046851063,0.0021589645,0.00013748735,0.0000203335,0.000049629445],"genre_scores_gemma":[0.9954058,0.000020173275,0.0009845649,0.00009381689,0.000020329151,0.0033822474,0.00005889621,0.000026671953,0.00000748071],"study_design_codex":"case_report","study_design_gemma":"case_report","domain_scores_codex":[0.99832976,0.000055118973,0.0007726728,0.00045389016,0.00009287123,0.0002956644],"domain_scores_gemma":[0.99879265,0.00014044778,0.00030796762,0.00038570896,0.00020434201,0.00016886636],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00009295621,0.00022118924,0.00076116325,0.00023685365,0.000035709272,0.0000071170352,0.000012795497,0.00013195457,0.00019228569],"category_scores_gemma":[0.00006407218,0.0001553963,0.000059043774,0.00022544754,0.00009849338,0.00009746911,0.00001924693,0.00009579256,0.0000013393311],"study_design_candidate":"case_report","study_design_consensus":"case_report","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00038486774,0.001408369,0.38324538,0.0002425955,0.00007950243,0.6104374,0.0005611608,0.0000125553515,0.000102116515,0.00007952442,0.00016256695,0.003283989],"study_design_scores_gemma":[0.0026435116,0.0013046988,0.010524038,0.00040722036,0.00012202582,0.9648359,0.00078036945,0.00031960313,0.01881662,0.000058873484,0.000028084736,0.00015908002],"about_ca_topic_score_codex":0.00609023,"about_ca_topic_score_gemma":0.006689308,"teacher_disagreement_score":0.3727213,"about_ca_system_score_codex":0.00015963681,"about_ca_system_score_gemma":0.00017104133,"threshold_uncertainty_score":0.9206646},"labels":[],"label_agreement":null},{"id":"W2059299524","doi":"10.1016/s0151-9638(04)93873-2","title":"Effets secondaires cutanéo-muqueux de l’hydroxyurée : étude prospective sur trois ans avec collaboration hémato-dermatologique","year":2004,"lang":"fr","type":"article","venue":"Annales de Dermatologie et de Vénéréologie","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hotel Dieu Hospital","funders":"","keywords":"Medicine; Dermatology; Stereochemistry; Chemistry","score_opus":0.01818196589755563,"score_gpt":0.3118909544879616,"score_spread":0.293708988590406,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2059299524","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8880715,0.021659,0.0031914632,0.07892446,0.0010824142,0.0026752802,0.00041451975,0.00083906064,0.003142301],"genre_scores_gemma":[0.95346445,0.024117649,0.009013585,0.010783672,0.00034903057,0.0014011257,0.00028641918,0.00016526719,0.00041882167],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9912596,0.0019239989,0.001510079,0.0015524763,0.00064796355,0.0031058968],"domain_scores_gemma":[0.993944,0.0024533875,0.0007158592,0.0011084466,0.00081394234,0.0009643971],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":["metaepi_narrow"],"category_scores_codex":[0.0013565951,0.0014243757,0.002120253,0.0005094795,0.00055420725,0.00035288834,0.00072882476,0.0018715877,0.00025787562],"category_scores_gemma":[0.004037481,0.0013384545,0.0006249486,0.0010796139,0.0010150993,0.0008777989,0.00032765887,0.001718278,0.0005319575],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.000765171,0.0036567897,0.89634573,0.00127971,0.0016894095,0.02256137,0.011755465,0.0039295885,0.001606882,0.034961704,0.019199254,0.0022489],"study_design_scores_gemma":[0.010862063,0.0024189698,0.6985536,0.0021127276,0.0011770548,0.021387236,0.004161457,0.0017342649,0.22075754,0.024480388,0.010484874,0.0018698045],"about_ca_topic_score_codex":0.0006303057,"about_ca_topic_score_gemma":0.0033150057,"teacher_disagreement_score":0.21915066,"about_ca_system_score_codex":0.004270774,"about_ca_system_score_gemma":0.00781348,"threshold_uncertainty_score":0.99985063},"labels":[],"label_agreement":null},{"id":"W2062144482","doi":"10.1136/bmj.39598.708333.db","title":"Independent drug watchdog in Canada under funding threat","year":2008,"lang":"en","type":"article","venue":"BMJ","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Plasmacytoma; Larynx; Biopsy; Malignancy; Dysphagia; Amyloidosis; Thyroid cartilage; Rare disease; Dermatology; Disease; Pathology; Surgery; Radiology; Internal medicine; Multiple myeloma","score_opus":0.0412584916509002,"score_gpt":0.28796865392052406,"score_spread":0.24671016226962386,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2062144482","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9799595,0.00027813113,0.000009273826,0.009173789,0.00018612426,0.0004995072,0.000005923762,0.00001587159,0.009871908],"genre_scores_gemma":[0.9954182,0.00014932723,0.0001765603,0.0013341698,0.0001310478,0.00010702802,0.000017836526,0.000015468468,0.002650348],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99887604,0.00003134624,0.00024274211,0.00022463927,0.00035100876,0.00027424746],"domain_scores_gemma":[0.99948543,0.00008494641,0.000044980676,0.00020123337,0.00003544429,0.00014795957],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000096172575,0.0001390546,0.00026890205,0.000059742386,0.000072805335,0.000005550085,0.000044392564,0.00003446915,0.00039763277],"category_scores_gemma":[0.000025965188,0.00010624948,0.000042678344,0.000119125696,0.00001906609,0.000039929982,0.000029024857,0.00013867616,0.000054319094],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000036103105,0.00012283915,0.96875316,0.000013523216,0.000055929606,0.0012572607,0.00029740974,0.00007878949,0.00003226887,0.00033253452,0.028576147,0.00044406526],"study_design_scores_gemma":[0.0018401183,0.00004110694,0.991603,0.00008387755,0.000024004265,0.0002667843,0.00038330973,0.00007201613,0.0023992793,0.00008307565,0.0030774537,0.00012593315],"about_ca_topic_score_codex":0.69897586,"about_ca_topic_score_gemma":0.91921,"teacher_disagreement_score":0.22023414,"about_ca_system_score_codex":0.0010426929,"about_ca_system_score_gemma":0.0011797969,"threshold_uncertainty_score":0.43537998},"labels":[],"label_agreement":null},{"id":"W2063420113","doi":"10.1182/blood-2010-12-325365","title":"Polycythemia vera with pancytopenia and red cell fragmentation","year":2011,"lang":"en","type":"article","venue":"Blood","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"London Health Sciences Centre","funders":"","keywords":"Pancytopenia; Polycythemia vera; Medicine; Platelet; Gastroenterology; Hemoglobin; Red Cell; Internal medicine; Immunology; Bone marrow","score_opus":0.016699529047031727,"score_gpt":0.21394869158590726,"score_spread":0.19724916253887553,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2063420113","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9799179,0.00024192326,0.000014947007,0.00018868384,0.000017389495,0.00030526923,0.000004756621,0.000024944511,0.019284181],"genre_scores_gemma":[0.9943048,0.00011574121,0.004785036,0.0001990195,0.0000358105,0.000064132946,0.00001571827,0.000013326404,0.00046646627],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9995099,0.000012049986,0.00009126876,0.00017280254,0.000102406964,0.00011158211],"domain_scores_gemma":[0.99970764,0.00001562262,0.000037234226,0.00012446023,0.000028545184,0.0000864873],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00002751608,0.00010036892,0.00014502107,0.000021825645,0.00004501749,0.000008617892,0.0000182821,0.000033601267,0.00024390029],"category_scores_gemma":[0.0000038837884,0.00006813107,0.000018004463,0.00004780845,0.000024040952,0.000043623182,0.000010360118,0.000051843872,0.00002480458],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0004140013,0.0016482983,0.9851651,0.0000563049,0.00018991993,0.00021125165,0.001909809,6.906161e-8,0.008338752,0.00025392705,0.00029022153,0.0015223272],"study_design_scores_gemma":[0.008263826,0.0013590466,0.53065526,0.000066314446,0.00039579067,0.00009813699,0.00012176516,0.0000025336583,0.45837727,0.00005512749,0.0005022192,0.000102707636],"about_ca_topic_score_codex":0.000039274564,"about_ca_topic_score_gemma":0.000013607635,"teacher_disagreement_score":0.45450985,"about_ca_system_score_codex":0.000010639416,"about_ca_system_score_gemma":0.000029701785,"threshold_uncertainty_score":0.27783045},"labels":[],"label_agreement":null},{"id":"W2063756127","doi":"10.1182/blood-2014-02-554634","title":"Integrated genomic analysis illustrates the central role of JAK-STAT pathway activation in myeloproliferative neoplasm pathogenesis","year":2014,"lang":"en","type":"article","venue":"Blood","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":428,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal; Hôpital Maisonneuve-Rosemont","funders":"National Cancer Institute; MPN Stichting; Leukemia and Lymphoma Society; American Society of Hematology","keywords":"Myeloproliferative neoplasm; stat; Pathogenesis; Cancer research; Allele; Gene expression profiling; Biology; JAK-STAT signaling pathway; Janus kinase 2; Genetics; Myeloproliferative Disorders; Gene; Signal transduction; Myelofibrosis; Gene expression; Immunology; STAT3; Tyrosine kinase; Bone marrow","score_opus":0.008681461745573745,"score_gpt":0.21954389572178853,"score_spread":0.2108624339762148,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2063756127","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99746376,0.00014949558,0.0002034323,0.00042655654,0.000030096018,0.00063363515,0.00005007202,0.00002819054,0.0010147642],"genre_scores_gemma":[0.99858946,0.000095757125,0.0006309243,0.00016172322,0.00007948695,0.00015223355,0.00019353314,0.000022915685,0.00007394339],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9982686,0.00023972543,0.0004905217,0.00038102933,0.00026962085,0.00035048643],"domain_scores_gemma":[0.9988493,0.0002838324,0.00020663746,0.00035331666,0.00018960415,0.000117327174],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00026008155,0.00027349326,0.0006161394,0.00027230836,0.00009302248,0.000029258275,0.00010912847,0.000119034514,0.000103213046],"category_scores_gemma":[0.00016067932,0.00017118931,0.00021349535,0.00090412964,0.00008551633,0.00007655155,0.000031954292,0.00017561117,0.00001180047],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00016191813,0.0013712051,0.88289934,0.000026081534,0.001417566,0.000008864107,0.0021794643,0.00036528707,0.1030844,0.0011616689,0.000010227518,0.0073139966],"study_design_scores_gemma":[0.0022578437,0.00030569607,0.7091942,0.000051761785,0.00088774646,0.00000638925,0.00084327854,0.0014997451,0.2844107,0.00013945879,0.00026728964,0.00013589079],"about_ca_topic_score_codex":0.00039330902,"about_ca_topic_score_gemma":0.00090819184,"teacher_disagreement_score":0.18132629,"about_ca_system_score_codex":0.000091507274,"about_ca_system_score_gemma":0.00018925901,"threshold_uncertainty_score":0.6980898},"labels":[],"label_agreement":null},{"id":"W2066998828","doi":"10.1016/j.beha.2014.07.007","title":"Controversies and dilemmas in allogeneic transplantation for myelofibrosis","year":2014,"lang":"en","type":"review","venue":"Best Practice & Research Clinical Haematology","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Myelofibrosis; Medicine; Ruxolitinib; Transplantation; Hematopoietic cell; Disease; Intensive care medicine; Hematopoietic stem cell transplantation; Curative treatment; Oncology; Stem cell; Internal medicine; Haematopoiesis; Bone marrow","score_opus":0.3021772936801469,"score_gpt":0.5879111118193305,"score_spread":0.28573381813918364,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2066998828","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0005684091,0.9858343,0.00012149004,0.006710303,0.00021302834,0.0053294827,0.00010212103,0.00002405075,0.001096791],"genre_scores_gemma":[0.00036983468,0.9932431,0.0026055304,0.0004912876,0.00027090457,0.0024007084,0.00033028668,0.000067545065,0.0002208073],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99212337,0.003748242,0.0017617496,0.0010794542,0.00052380166,0.00076341454],"domain_scores_gemma":[0.8945516,0.10355114,0.000501744,0.00048116606,0.0005424376,0.0003719218],"candidate_categories":["metaresearch","metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.006057874,0.00043962992,0.0041588275,0.0004902101,0.000176628,0.0000684989,0.00019146655,0.0010042391,0.000056354438],"category_scores_gemma":[0.03427674,0.00032604893,0.0005271712,0.00033101364,0.00062696147,0.00017697849,0.00010596256,0.0014662117,0.00017066837],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0021455174,0.0030355563,0.003160107,0.037137963,0.0011825806,0.0018029412,0.00010673641,1.065461e-7,3.1879313e-7,0.011265233,0.0036585543,0.93650436],"study_design_scores_gemma":[0.0037990073,0.004408023,0.00014360811,0.007828893,0.0026905683,0.0022281702,0.00008597313,0.000013341216,0.0000022422616,0.00017878324,0.9783817,0.0002396785],"about_ca_topic_score_codex":0.0001380454,"about_ca_topic_score_gemma":0.00028043738,"teacher_disagreement_score":0.97472316,"about_ca_system_score_codex":0.00015132094,"about_ca_system_score_gemma":0.00095104694,"threshold_uncertainty_score":0.9999192},"labels":[],"label_agreement":null},{"id":"W2068094128","doi":"10.1038/nm.2370","title":"Loss of JAK2 regulation via a heterodimeric VHL-SOCS1 E3 ubiquitin ligase underlies Chuvash polycythemia","year":2011,"lang":"en","type":"article","venue":"Nature Medicine","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":81,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hospital for Sick Children; Ontario Institute for Cancer Research; University of Toronto","funders":"National Cancer Institute; Howard Hughes Medical Institute","keywords":"Ubiquitin ligase; Suppressor of cytokine signaling 1; Ubiquitin; Regulator; Cancer research; Biology; Erythropoietin; Gene; Genetics; Suppressor","score_opus":0.022149055853440406,"score_gpt":0.2815944741512558,"score_spread":0.2594454182978154,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2068094128","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97338986,0.005590324,0.00029871313,0.0069761192,0.00059468264,0.00093025615,0.000025615036,0.000101733254,0.012092664],"genre_scores_gemma":[0.9947217,0.0003741454,0.001260495,0.0019218557,0.00057061535,0.000058851256,0.00020647974,0.000042874162,0.00084294734],"study_design_codex":"observational","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99794894,0.00007333128,0.0005576982,0.0004439281,0.00063417037,0.0003419493],"domain_scores_gemma":[0.9984665,0.00019062145,0.0003050367,0.00052819366,0.00026269117,0.000246988],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00028964382,0.0003512442,0.00079394237,0.0002518409,0.000082327635,0.000004248998,0.000120956254,0.00039498642,0.0015431384],"category_scores_gemma":[0.00030801474,0.00023401223,0.00012941853,0.00039657785,0.00035179348,0.00008057416,0.000043544012,0.000570478,0.000042426786],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.007926092,0.006269339,0.4418961,0.0025066347,0.0036448082,0.0017488474,0.025673462,0.0000068791087,0.3000967,0.020021258,0.08233101,0.10787887],"study_design_scores_gemma":[0.008004598,0.003661895,0.39128947,0.0013114329,0.00087625615,0.00046483113,0.00038102406,0.00009005571,0.58280396,0.0017794465,0.0089632245,0.00037380928],"about_ca_topic_score_codex":0.00018696664,"about_ca_topic_score_gemma":0.000053643962,"teacher_disagreement_score":0.28270727,"about_ca_system_score_codex":0.00011961651,"about_ca_system_score_gemma":0.000092337934,"threshold_uncertainty_score":0.99936956},"labels":[],"label_agreement":null},{"id":"W2069651950","doi":"10.1056/nejmoa043800","title":"Hydroxyurea Compared with Anagrelide in High-Risk Essential Thrombocythemia","year":2005,"lang":"en","type":"article","venue":"New England Journal of Medicine","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":921,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"St. Thomas Hospital","funders":"Wellcome Trust","keywords":"Anagrelide; Essential thrombocythemia; Medicine; MEDLINE; Internal medicine; Pediatrics; Polycythemia vera","score_opus":0.010730541253397808,"score_gpt":0.2652675867253772,"score_spread":0.2545370454719794,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2069651950","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97969437,0.0013708761,0.00035995076,0.016700726,0.00018455765,0.00022631414,0.000002907597,0.000012140129,0.0014481747],"genre_scores_gemma":[0.9907844,0.0012514617,0.0030209182,0.0005762764,0.004126589,0.000003050035,0.000013324331,0.00002162101,0.0002023408],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9981941,0.000091152186,0.00065743824,0.00018141764,0.00062000373,0.00025590518],"domain_scores_gemma":[0.99859697,0.0002464492,0.0004080743,0.00019068824,0.00017425542,0.000383568],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00051609776,0.00023246188,0.00089856033,0.00027873952,0.000045400575,0.000009733322,0.000093925904,0.00006709696,0.00051952444],"category_scores_gemma":[0.00015905428,0.00012533851,0.00006762918,0.00024142874,0.0001078235,0.00010938931,0.000013359579,0.0004924391,0.000012696203],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0061952397,0.0009447647,0.8513331,0.000055015604,0.0008279974,0.002415911,0.0035568944,0.0017155639,0.0015202138,0.0004097649,0.01761348,0.113412075],"study_design_scores_gemma":[0.317965,0.009463834,0.6129521,0.0024985871,0.0014824676,0.0045539974,0.00043559176,0.0005208642,0.008300186,0.00051211653,0.04098227,0.00033295265],"about_ca_topic_score_codex":0.0005477737,"about_ca_topic_score_gemma":0.0010874172,"teacher_disagreement_score":0.31176978,"about_ca_system_score_codex":0.00014728581,"about_ca_system_score_gemma":0.0002334245,"threshold_uncertainty_score":0.5688428},"labels":[],"label_agreement":null},{"id":"W2070009478","doi":"10.1002/ajh.20765","title":"Absence of FTL3 mutations in patients with <i>JAK2<sup>V617F</sup></i> mutation negative essential thrombocythemia","year":2006,"lang":"en","type":"article","venue":"American Journal of Hematology","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Essential thrombocythemia; Myeloproliferative Disorders; Mutation; Haematopoiesis; Janus kinase 2; Point mutation; Cancer research; Medicine; Tyrosine kinase; Myelofibrosis; Biology; Internal medicine; Immunology; Receptor; Genetics; Polycythemia vera; Gene; Stem cell; Bone marrow","score_opus":0.004263649426485132,"score_gpt":0.24554761506339826,"score_spread":0.24128396563691312,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2070009478","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9981962,0.000066718654,0.00051573594,0.0005561241,0.000029240091,0.00025327323,0.000011149065,0.0000059222916,0.00036567994],"genre_scores_gemma":[0.9936257,0.000014444879,0.0061532645,0.00010937632,0.000034933244,0.000013945574,0.000023273518,0.000015974747,0.000009061395],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99856764,0.000100194266,0.00065308425,0.00016506382,0.00031022666,0.00020377214],"domain_scores_gemma":[0.9982171,0.00030627073,0.0008196167,0.00012553955,0.00045596372,0.00007549519],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00009182244,0.00016251086,0.00076457835,0.00024100105,0.000038418453,0.0000060541524,0.0000677879,0.0000409989,0.00006330583],"category_scores_gemma":[0.000082844774,0.00011626139,0.00008759702,0.0003841467,0.00044172912,0.00011291069,0.000012535603,0.00018342413,0.0000052094383],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0007702926,0.0012951309,0.9916325,0.000032212498,0.00020765884,0.00027268552,0.0012345727,0.001395049,0.00009923019,0.0013255714,0.00016223462,0.0015728349],"study_design_scores_gemma":[0.007925641,0.0052366066,0.9676016,0.00036275192,0.00024183071,0.0009894362,0.001848173,0.00025009998,0.014523907,0.0008145277,0.000029309165,0.00017610431],"about_ca_topic_score_codex":0.00021182728,"about_ca_topic_score_gemma":0.00006751094,"teacher_disagreement_score":0.024030913,"about_ca_system_score_codex":0.00008536173,"about_ca_system_score_gemma":0.00020245618,"threshold_uncertainty_score":0.4741002},"labels":[],"label_agreement":null},{"id":"W2070330288","doi":"10.1182/blood-2010-01-266320","title":"A CK2-dependent mechanism for activation of the JAK-STAT signaling pathway","year":2011,"lang":"en","type":"article","venue":"Blood","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":133,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Western University","funders":"Army Research Office; National Center for Complementary and Integrative Health; Mayo Clinic; National Institute of Arthritis and Musculoskeletal and Skin Diseases; Tampereen Yliopisto; National Center for Research Resources; National Institute of Neurological Disorders and Stroke; National Institute of General Medical Sciences; National Cancer Institute; Canadian Cancer Society Research Institute; National Institutes of Health; Peking University; National Institute of Diabetes and Digestive and Kidney Diseases","keywords":"JAK-STAT signaling pathway; Suppressor of cytokine signaling 1; Janus kinase; stat; SOCS3; Cancer research; Tyrosine kinase 2; Signal transduction; Cytokine; Janus kinase 2; Myeloproliferative Disorders; Tyrosine kinase; Biology; Janus kinase 1; Cell biology; Polycythemia vera; Autophosphorylation; Phosphorylation; Immunology; STAT3; Platelet-derived growth factor receptor; Suppressor; Receptor; Protein kinase A; Growth factor; Biochemistry; Gene","score_opus":0.04027488913000221,"score_gpt":0.24918625933252792,"score_spread":0.2089113702025257,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2070330288","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99597466,0.000031356147,0.0012191829,0.00023254889,0.00007620724,0.0008828908,0.00002437036,0.000018102759,0.0015407059],"genre_scores_gemma":[0.99679154,0.000009476327,0.0024872147,0.00021392992,0.00005840224,0.00021326417,0.000008136555,0.000014894696,0.00020311262],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9993602,0.000023203103,0.00017279525,0.00015051989,0.00017011895,0.00012315389],"domain_scores_gemma":[0.9994616,0.000068481335,0.00010408589,0.00018613914,0.00013669857,0.000042991345],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00009297724,0.00009753052,0.0001705035,0.000030516743,0.00006360371,0.000004405128,0.000051615032,0.00004935132,0.000088865665],"category_scores_gemma":[0.000079025056,0.00005858443,0.00010228432,0.000056112378,0.000015222203,0.00003163995,0.000021047743,0.000052021584,0.000004477943],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00066019007,0.009895261,0.11022976,0.00044632165,0.0015601142,0.000029834748,0.008434009,0.000005310858,0.6888321,0.17516382,0.0002417615,0.0045015193],"study_design_scores_gemma":[0.0030852896,0.0005025799,0.0053932974,0.00011121155,0.00022541793,0.000009008832,0.00015611276,0.000016814598,0.9871997,0.0031779076,0.00006563158,0.000056983168],"about_ca_topic_score_codex":0.00003077132,"about_ca_topic_score_gemma":0.000010808577,"teacher_disagreement_score":0.29836765,"about_ca_system_score_codex":0.000019495641,"about_ca_system_score_gemma":0.0000662344,"threshold_uncertainty_score":0.23890036},"labels":[],"label_agreement":null},{"id":"W2070376678","doi":"10.1309/lw7q3739rbrmbxxp","title":"Comparative Evaluation of Three<i>JAK2</i><sup>V617F</sup>Mutation Detection Methods","year":2007,"lang":"en","type":"article","venue":"American Journal of Clinical Pathology","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":25,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta Hospital; Alberta Hospital Edmonton","funders":"","keywords":"Polymerase chain reaction; Molecular biology; Capillary electrophoresis; Biology; Concordance; genomic DNA; Molecular diagnostics; Restriction fragment length polymorphism; DNA; Genetics; Gene","score_opus":0.17372300235258326,"score_gpt":0.534490452042761,"score_spread":0.36076744969017777,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2070376678","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9205212,0.00029586535,0.07724268,0.00048656852,0.00029370651,0.00035225315,0.000003100995,0.000008886445,0.0007957428],"genre_scores_gemma":[0.94123703,0.00009741558,0.057866443,0.0004024124,0.00036048083,0.000010259151,0.0000057585435,0.000013507866,0.0000066904813],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9950796,0.0017583095,0.0020580494,0.00025710673,0.0006177734,0.00022916311],"domain_scores_gemma":[0.9925848,0.0031010697,0.0021402058,0.00021982648,0.0017266173,0.00022744632],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.011986393,0.00017891968,0.0014481156,0.00025618833,0.000052409276,0.000005529479,0.00008711544,0.00012992503,0.00009517273],"category_scores_gemma":[0.0027748907,0.0001319329,0.00039189862,0.00037546403,0.0006054792,0.00009369134,0.000021713753,0.00051578286,0.000012360697],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0022652324,0.001033155,0.1574413,0.000011183004,0.00048284826,0.00016726683,0.00094513065,0.0006194372,0.0019202896,0.00009503137,0.000048961723,0.8349702],"study_design_scores_gemma":[0.006089594,0.01731128,0.9474774,0.00009558691,0.0015031559,0.0014388578,0.0016513738,0.004666728,0.017659035,0.0015625852,0.00039348978,0.00015092948],"about_ca_topic_score_codex":0.000019537887,"about_ca_topic_score_gemma":0.000048263635,"teacher_disagreement_score":0.83481926,"about_ca_system_score_codex":0.00011245953,"about_ca_system_score_gemma":0.00031495708,"threshold_uncertainty_score":0.5380067},"labels":[],"label_agreement":null},{"id":"W2071819956","doi":"10.5430/jhm.v2n1p41","title":"Anagrelide induced acute pancreatitis in a patient with unknown etiology of bicytopenia and thrombocytosis","year":2012,"lang":"en","type":"article","venue":"Journal of Hematological Malignancies","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Thrombocytosis; Etiology; Medicine; Pancreatitis; Drug; Acute pancreatitis; Anagrelide; Internal medicine; Gastroenterology; Intensive care medicine; Pharmacology; Essential thrombocythemia; Platelet","score_opus":0.02187978611616249,"score_gpt":0.2746254143461622,"score_spread":0.25274562822999974,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2071819956","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9967137,0.0016091247,0.000020602432,0.0008826021,0.000046813497,0.00024633776,0.0000046428177,0.000005272671,0.0004709034],"genre_scores_gemma":[0.9951357,0.0009859519,0.003561337,0.0002528443,0.000026646929,0.00002055858,0.0000015658163,0.000008014195,0.0000073313718],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99870217,0.00009856901,0.0005839488,0.00012371805,0.00022776156,0.00026383414],"domain_scores_gemma":[0.9989112,0.0002447185,0.0003975619,0.00010411636,0.00018042028,0.00016198227],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00019396558,0.00017043269,0.0009883598,0.00015122954,0.00003128797,0.0000076208344,0.000049497292,0.000117270945,0.00007007552],"category_scores_gemma":[0.00015716859,0.000088994144,0.000084021995,0.00018103042,0.00013101887,0.0001253038,0.00004159381,0.0001798756,0.0000022319084],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0006290976,0.00089900504,0.9795911,0.00008193874,0.0003130107,0.0012042529,0.00079517125,0.0000012194818,0.0098204445,0.0055365083,0.00013059437,0.0009976869],"study_design_scores_gemma":[0.0026453864,0.0070182225,0.8881878,0.00068768486,0.0003256104,0.012974112,0.0004400966,0.0000027750882,0.08710097,0.00023852386,0.00024243272,0.0001363574],"about_ca_topic_score_codex":0.00002070684,"about_ca_topic_score_gemma":0.000016479751,"teacher_disagreement_score":0.09140324,"about_ca_system_score_codex":0.00004757481,"about_ca_system_score_gemma":0.000064613196,"threshold_uncertainty_score":0.3629076},"labels":[],"label_agreement":null},{"id":"W2075985296","doi":"10.1016/j.bbmt.2012.04.011","title":"Incidence and Risk Factors for Early Hepatotoxicity and Its Impact on Survival in Patients with Myelofibrosis Undergoing Allogeneic Hematopoietic Cell Transplantation","year":2012,"lang":"en","type":"article","venue":"Biology of Blood and Marrow Transplantation","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":40,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Medicine; Gastroenterology; Internal medicine; Hepatic veno-occlusive disease; Incidence (geometry); Liver transplantation; Myelofibrosis; Transplantation; Portal hypertension; Portal vein thrombosis; Hematopoietic stem cell transplantation; Surgery; Thrombosis; Cirrhosis; Bone marrow","score_opus":0.010700564622884857,"score_gpt":0.25037045277404346,"score_spread":0.2396698881511586,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2075985296","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99841106,0.00040539136,0.00012205684,0.000016517757,0.000025805208,0.0006991832,0.0002986222,0.000008581598,0.000012773896],"genre_scores_gemma":[0.9958445,0.0035964812,0.00026318926,0.0000111073805,0.000010955156,0.000038855676,0.00022242016,0.000010885782,0.0000016110827],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9992399,0.0000800881,0.00019630062,0.0002145991,0.00008034291,0.00018873182],"domain_scores_gemma":[0.9992837,0.00042524835,0.00010522716,0.000047852507,0.000038035058,0.00009997396],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00012765899,0.00017606001,0.00030257273,0.000101058875,0.00006572578,0.0000059021118,0.0000159995,0.00010554859,0.0000030679978],"category_scores_gemma":[0.00001103304,0.00011912793,0.000031212847,0.000053618256,0.000052281135,0.00010957424,0.0000025519134,0.00006242717,1.8228732e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0015691799,0.00034436988,0.9869929,0.0005014125,0.00010757933,0.000001438601,0.0016878432,0.0000031519894,0.008472101,0.00010434874,1.6458844e-7,0.00021552829],"study_design_scores_gemma":[0.005191987,0.002937744,0.90714204,0.00017621348,0.0005651145,0.0000086123755,0.00004560891,0.000006091636,0.083793,0.000025049978,1.791984e-7,0.00010836865],"about_ca_topic_score_codex":0.0001606985,"about_ca_topic_score_gemma":0.00015563863,"teacher_disagreement_score":0.07985085,"about_ca_system_score_codex":0.00001112821,"about_ca_system_score_gemma":0.000021070531,"threshold_uncertainty_score":0.4857896},"labels":[],"label_agreement":null},{"id":"W2077076503","doi":"10.2217/ijh.14.35","title":"Ruxolitinib for the Treatment of Disease-Related Splenomegaly or Symptoms in Adult Patients with Myelofibrosis","year":2014,"lang":"en","type":"article","venue":"International Journal of Hematologic Oncology","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; University of Alberta","funders":"","keywords":"Ruxolitinib; Myelofibrosis; Medicine; Constitutional symptoms; Myeloproliferative neoplasm; Anemia; Natural history; Disease; Internal medicine; Pediatrics; Intensive care medicine; Bone marrow","score_opus":0.01445894224092989,"score_gpt":0.3111262826682992,"score_spread":0.2966673404273693,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2077076503","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9923278,0.00018880947,0.00015900978,0.0060019065,0.00035097127,0.00061150803,0.000039006954,0.000005464283,0.00031552455],"genre_scores_gemma":[0.9976946,0.00037831938,0.0012960385,0.00031733865,0.000090897935,0.00010742433,0.000026703703,0.000011223426,0.00007744918],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99863094,0.0000782946,0.0006823614,0.00014675818,0.00030112607,0.00016051119],"domain_scores_gemma":[0.99702764,0.0012843765,0.0006021661,0.000117738025,0.00086598494,0.00010208073],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001387302,0.00015399273,0.0005818276,0.00017245181,0.000030686206,0.00000864082,0.00015071902,0.00007548925,0.00012824898],"category_scores_gemma":[0.0003094283,0.000068260975,0.00017427879,0.00007962721,0.000113729075,0.00005330981,0.00001340502,0.0000777874,0.0000037927812],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0132924635,0.0060686925,0.94307303,0.000034834462,0.001335128,0.00016560315,0.0004961146,0.00010686938,0.00001640203,0.00951846,0.00019693493,0.025695441],"study_design_scores_gemma":[0.037968144,0.037244823,0.90569717,0.00049652887,0.0007705879,0.00044097812,0.00023450961,0.00063815474,0.0011204254,0.0015032984,0.013717793,0.00016760961],"about_ca_topic_score_codex":0.0000139037775,"about_ca_topic_score_gemma":0.0000424537,"teacher_disagreement_score":0.03737591,"about_ca_system_score_codex":0.00034882143,"about_ca_system_score_gemma":0.00022549478,"threshold_uncertainty_score":0.27836016},"labels":[],"label_agreement":null},{"id":"W2077581083","doi":"10.14740/jocmr1916w","title":"Secondary Polycythemia and the Risk of Venous Thromboembolism","year":2014,"lang":"en","type":"article","venue":"Journal of Clinical Medicine Research","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":28,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Medicine; Venous thromboembolism; Intensive care medicine; Internal medicine; Thrombosis","score_opus":0.11135600012706787,"score_gpt":0.49267733372818623,"score_spread":0.38132133360111836,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2077581083","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.94366544,0.0052267876,0.0000591765,0.04094406,0.00032598377,0.00035696678,0.000002289796,0.000003498733,0.009415804],"genre_scores_gemma":[0.98416966,0.012492185,0.00038761078,0.00053562614,0.0022169014,0.000006055791,7.9451326e-7,0.000014553413,0.00017661764],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9950674,0.0017190778,0.0015262126,0.0001761183,0.0012470931,0.00026410652],"domain_scores_gemma":[0.98165417,0.015906967,0.00069637457,0.00035017545,0.0009799821,0.00041232436],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.01995082,0.00012603743,0.0015971784,0.00019486246,0.00012201045,0.00000907415,0.00018157411,0.00013051201,0.0002531415],"category_scores_gemma":[0.020102086,0.00005350663,0.00025101184,0.0002230726,0.002001431,0.0000454324,0.000081240614,0.0018681515,0.000008609244],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.010126686,0.0023487522,0.4738579,0.00044370716,0.0025065942,0.00021165758,0.0023708807,0.0000021751684,0.00029374103,0.011179391,0.028814979,0.46784353],"study_design_scores_gemma":[0.034080405,0.017968556,0.90467656,0.0015074856,0.0008531507,0.00058730325,0.0007124392,0.00023217307,0.001200567,0.013528514,0.024564654,0.00008820153],"about_ca_topic_score_codex":0.00009581019,"about_ca_topic_score_gemma":0.000008080108,"teacher_disagreement_score":0.46775532,"about_ca_system_score_codex":0.000025382005,"about_ca_system_score_gemma":0.00039209836,"threshold_uncertainty_score":0.988152},"labels":[],"label_agreement":null},{"id":"W2078157614","doi":"10.1038/sj.leu.2404527","title":"JAK3 mutations occur in acute megakaryoblastic leukemia both in Down syndrome children and non-Down syndrome adults","year":2007,"lang":"en","type":"letter","venue":"Leukemia","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":81,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Institut national de la recherche scientifique","keywords":"Acute megakaryoblastic leukemia; Down syndrome; Medicine; Leukemia; Mutation; Immunology; Pediatrics; Genetics; Biology; Gene; Psychiatry","score_opus":0.0069373402391127255,"score_gpt":0.24421775688056488,"score_spread":0.23728041664145216,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2078157614","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9630679,0.00058213493,0.00005354352,0.030588146,0.00047337465,0.0033351101,0.00074236933,0.000102391146,0.0010550546],"genre_scores_gemma":[0.8830506,0.0006343329,0.0013709447,0.10636245,0.00093339686,0.0012767472,0.0037960925,0.00024484584,0.0023305505],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9949186,0.00014096337,0.0012362679,0.0015800509,0.0008487557,0.0012754069],"domain_scores_gemma":[0.9976998,0.00067915936,0.0003592072,0.0008241326,0.0001029595,0.00033475566],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":["research_integrity"],"category_scores_codex":[0.0002962379,0.0011307133,0.0019229031,0.0014238287,0.00013341778,0.00009023883,0.00030388308,0.001487504,0.0003347205],"category_scores_gemma":[0.00012388505,0.0009233474,0.0002696514,0.0007813495,0.00026579585,0.00023713028,0.00016628612,0.002702031,0.00032110832],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0008818111,0.0005619122,0.42607495,0.001326106,0.0026466295,0.16820545,0.0015332084,0.00016089295,0.00005946626,0.00005200629,0.39428014,0.0042174147],"study_design_scores_gemma":[0.012574496,0.0012326345,0.9616713,0.0049153436,0.0007367788,0.011212421,0.000026575884,0.00027605405,0.000087388355,0.00013422304,0.006030586,0.0011021955],"about_ca_topic_score_codex":0.001701648,"about_ca_topic_score_gemma":0.00074037164,"teacher_disagreement_score":0.5355963,"about_ca_system_score_codex":0.004743106,"about_ca_system_score_gemma":0.0013118513,"threshold_uncertainty_score":0.9998088},"labels":[],"label_agreement":null},{"id":"W2078483041","doi":"10.1007/s11239-015-1218-2","title":"Anagrelide compared with hydroxyurea in essential thrombocythemia: a meta-analysis","year":2015,"lang":"en","type":"review","venue":"Journal of Thrombosis and Thrombolysis","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":16,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University","funders":"","keywords":"Anagrelide; Medicine; Essential thrombocythemia; Hydroxycarbamide; Internal medicine; Thrombosis; Hematology; Randomized controlled trial; Aspirin; Gastroenterology; Surgery; Chemotherapy; Platelet","score_opus":0.1725048037040988,"score_gpt":0.40455405793604765,"score_spread":0.23204925423194886,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2078483041","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.003461545,0.99419236,0.000057746678,0.00055110134,0.000090415684,0.00096033124,0.00010868144,0.00001903755,0.00055877323],"genre_scores_gemma":[0.013341837,0.98397034,0.0019688427,0.00011740507,0.00020756727,0.000103243474,0.000120348006,0.000102254664,0.000068164576],"study_design_codex":"meta_analysis","study_design_gemma":"meta_analysis","domain_scores_codex":[0.99414045,0.00050447485,0.0025502197,0.00083106325,0.0014042672,0.00056955416],"domain_scores_gemma":[0.99484396,0.00043723607,0.0025784527,0.0008229502,0.00069055636,0.0006268609],"candidate_categories":["metaepi_narrow","metaepi_broad"],"consensus_categories":[],"category_scores_codex":[0.0012887587,0.0011957075,0.019288627,0.0020789844,0.0001178647,0.00016758905,0.00034238442,0.00051719026,0.00061017275],"category_scores_gemma":[0.000069133435,0.0006503616,0.00582754,0.0027569646,0.00026464378,0.00028663376,0.00014182502,0.0010785805,0.000016865168],"study_design_candidate":"meta_analysis","study_design_consensus":"meta_analysis","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00013014991,0.002475529,0.003452808,0.0043896446,0.9737849,0.00062878395,0.000651028,0.00008668963,0.0000036492581,0.000116149095,0.002093591,0.012187031],"study_design_scores_gemma":[0.0022168432,0.0010584036,0.001684629,0.002063891,0.9113611,0.0004662761,0.00019224048,0.000028148112,0.000013848532,0.000060671966,0.08022967,0.00062430167],"about_ca_topic_score_codex":0.00013940012,"about_ca_topic_score_gemma":0.00032983022,"teacher_disagreement_score":0.07813608,"about_ca_system_score_codex":0.00046610172,"about_ca_system_score_gemma":0.00084480236,"threshold_uncertainty_score":0.99959475},"labels":[],"label_agreement":null},{"id":"W2081076752","doi":"10.1046/j.1365-2141.2000.01826.x","title":"Induction of remission after donor leucocyte infusion for the treatment of relapsed chronic idiopathic myelofibrosis following allogeneic transplantation: evidence for a ‘graft vs. myelofibrosis’ effect","year":2000,"lang":"en","type":"article","venue":"British Journal of Haematology","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":59,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Hospital","funders":"","keywords":"Myelofibrosis; Medicine; Transplantation; Haematopoiesis; Graft-versus-host disease; Stem cell; Disease; Internal medicine; Gastroenterology; Surgery; Bone marrow","score_opus":0.02444582817807832,"score_gpt":0.306062339335051,"score_spread":0.28161651115697267,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2081076752","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.95296526,0.04305809,0.0008078433,0.0010676981,0.00029795378,0.0017542368,0.00003306247,0.000009652297,0.000006192861],"genre_scores_gemma":[0.96413296,0.03320634,0.0018176093,0.00006027733,0.00019114806,0.00048700703,0.000018356544,0.000030933345,0.000055369004],"study_design_codex":"design_other","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9978134,0.00022230652,0.0010946239,0.00028070976,0.0003042992,0.00028464675],"domain_scores_gemma":[0.99769086,0.0011193359,0.00057074364,0.0002062009,0.0002758609,0.00013699374],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00058929133,0.000248456,0.0012239283,0.0001434812,0.00017579304,0.000019734716,0.00011073632,0.00021588309,0.00008684564],"category_scores_gemma":[0.00022862465,0.00017552591,0.00082263123,0.00016870863,0.000115100804,0.00017339642,0.000006868728,0.00012514548,0.0000014329764],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.081967734,0.0026303406,0.08066964,0.0062149754,0.0035365478,0.004329126,0.0030186975,0.0004306662,0.10764172,0.000055963385,0.0008291638,0.70867544],"study_design_scores_gemma":[0.03757538,0.06186261,0.16929632,0.02537168,0.007967716,0.055743523,0.00011643317,0.00032201517,0.63654983,0.0001633663,0.0045572296,0.0004738967],"about_ca_topic_score_codex":0.000069308735,"about_ca_topic_score_gemma":0.00008433266,"teacher_disagreement_score":0.7082015,"about_ca_system_score_codex":0.00021833582,"about_ca_system_score_gemma":0.00033851495,"threshold_uncertainty_score":0.7157739},"labels":[],"label_agreement":null},{"id":"W2082518775","doi":"10.1016/j.jchromb.2005.06.021","title":"High-performance liquid chromatography–mass spectrometry method for determination of anagrelide in human plasma","year":2005,"lang":"en","type":"article","venue":"Journal of Chromatography B","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BioPhage Pharma (Canada)","funders":"American Society of Hematology","keywords":"Chemistry; Chromatography; Anagrelide; Mass spectrometry; High-performance liquid chromatography; Extraction (chemistry); Liquid chromatography–mass spectrometry; Human plasma","score_opus":0.012229740932507107,"score_gpt":0.29873727149973295,"score_spread":0.28650753056722583,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2082518775","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9911952,0.00060189306,0.006609454,0.0005801073,0.00012894295,0.00052788854,0.00001415094,0.000017521243,0.00032482587],"genre_scores_gemma":[0.79603434,0.00044530985,0.20311294,0.00009982407,0.00022961886,0.000033345234,0.000008903791,0.00002704162,0.0000086844075],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9976632,0.000078510355,0.0011955767,0.00022917578,0.0005059292,0.00032762447],"domain_scores_gemma":[0.998109,0.00024151614,0.00089878036,0.00023328348,0.0003514513,0.0001659714],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00069065474,0.00027389952,0.0009407437,0.0019344114,0.000076623655,0.000019621564,0.00015726204,0.00014250056,0.00006599876],"category_scores_gemma":[0.000056524277,0.00021846802,0.0005457857,0.00095781527,0.000079843674,0.00030092619,0.000015252742,0.00024324612,0.0000014439247],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0035955505,0.0045649298,0.4241285,0.0015359161,0.001679247,0.00021416631,0.000984885,0.0003763366,0.52488583,0.0034773909,0.0012344307,0.033322815],"study_design_scores_gemma":[0.008448261,0.0075914394,0.21936756,0.00092889805,0.00038482464,0.00039894128,0.000084905616,0.0010058203,0.7605729,0.0003136224,0.0006638617,0.00023897429],"about_ca_topic_score_codex":0.0000142023355,"about_ca_topic_score_gemma":0.000024614645,"teacher_disagreement_score":0.23568706,"about_ca_system_score_codex":0.00010688403,"about_ca_system_score_gemma":0.0000935976,"threshold_uncertainty_score":0.8908867},"labels":[],"label_agreement":null},{"id":"W2083073031","doi":"10.1111/bjh.12985","title":"Use of <scp>JAK</scp> inhibitors in the management of myelofibrosis: a revision of the <scp>B</scp>ritish <scp>C</scp>ommittee for <scp>S</scp>tandards in <scp>H</scp>aematology <scp>G</scp>uidelines for <scp>I</scp>nvestigation and <scp>M</scp>anagement of <scp>M</scp>yelofibrosis 2012","year":2014,"lang":"en","type":"letter","venue":"British Journal of Haematology","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":38,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"Medical Research Council; Public Health Agency","keywords":"Ruxolitinib; Myelofibrosis; Medicine; Hazard ratio; Internal medicine; Calreticulin; Confidence interval; Hematology; Oncology; Biology; Bone marrow; Genetics","score_opus":0.02982384085572492,"score_gpt":0.2775194712061712,"score_spread":0.24769563035044628,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2083073031","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9021619,0.056845874,0.002951602,0.005818865,0.004772181,0.018356042,0.0052498486,0.0003826954,0.0034609728],"genre_scores_gemma":[0.6544998,0.14528409,0.059955016,0.06474387,0.014033929,0.01471782,0.010915792,0.0063195904,0.029530056],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.95717275,0.005767922,0.016636636,0.0058272667,0.007328216,0.007267183],"domain_scores_gemma":[0.9015496,0.06693833,0.018030249,0.00471344,0.006736278,0.0020321382],"candidate_categories":["metaresearch","metaepi_narrow","metaepi_broad","sts","scholarly_communication","open_science","research_integrity"],"consensus_categories":["metaepi_narrow","sts","research_integrity"],"category_scores_codex":[0.010967672,0.006090469,0.016360257,0.0062675816,0.0016124492,0.0012715211,0.0055929963,0.006518305,0.000028783223],"category_scores_gemma":[0.06557375,0.005593022,0.00540672,0.005230776,0.0046075936,0.002779252,0.0028608076,0.0072355294,0.00008149924],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000062822,0.004241833,0.045022972,0.019860925,0.00728742,0.006000411,0.008434408,0.0005776739,0.0018625833,0.0019366894,0.901417,0.0032952686],"study_design_scores_gemma":[0.027862469,0.007288249,0.03278524,0.03562881,0.011388106,0.024170807,0.03381183,0.0008332692,0.034931768,0.0046386113,0.7861739,0.00048696768],"about_ca_topic_score_codex":0.0011653947,"about_ca_topic_score_gemma":0.0013342374,"teacher_disagreement_score":0.24766208,"about_ca_system_score_codex":0.0014805316,"about_ca_system_score_gemma":0.0021267636,"threshold_uncertainty_score":0.9997872},"labels":[],"label_agreement":null},{"id":"W2083459234","doi":"10.3816/clml.2010.n.059","title":"Phase II Study of Obatoclax Mesylate (GX15-070), a Small-Molecule BCL-2 Family Antagonist, for Patients With Myelofibrosis","year":2010,"lang":"en","type":"article","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":87,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ontario Institute for Cancer Research; Princess Margaret Cancer Centre","funders":"","keywords":"Myelofibrosis; Medicine; Internal medicine; Anemia; Adverse effect; Gastroenterology; Cyclophosphamide; Rash; Surgery; Chemotherapy; Bone marrow","score_opus":0.028101131469983387,"score_gpt":0.3297646416348803,"score_spread":0.3016635101648969,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2083459234","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99241924,0.00007870701,0.000058320238,0.00019733587,0.0005873116,0.005435687,0.00022814503,0.00013471214,0.00086052675],"genre_scores_gemma":[0.9936135,0.00005646936,0.0031218433,0.000642597,0.0003548597,0.0013868243,0.0002952471,0.0001359933,0.00039265727],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99517065,0.00017887558,0.001871563,0.0012903865,0.00072576996,0.00076272595],"domain_scores_gemma":[0.99540025,0.0009875308,0.000751933,0.0012699941,0.00088249677,0.0007077731],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00059471175,0.0007238982,0.0017972117,0.00018642811,0.00043765255,0.000059689097,0.0003728965,0.00045736742,0.00008201716],"category_scores_gemma":[0.0006563284,0.00052578683,0.0005417772,0.0004388641,0.00043807953,0.0001387624,0.00022283994,0.00039364293,0.000046604793],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.014770713,0.04927507,0.503628,0.00019994278,0.0017783296,0.00019349884,0.000640886,0.0000023679959,0.00362709,0.00036181856,0.0020113103,0.42351097],"study_design_scores_gemma":[0.08139604,0.06599637,0.8374758,0.00020952467,0.0011337956,0.000023322807,0.00021223434,0.00022837789,0.0071691605,0.000053360294,0.005530482,0.0005715378],"about_ca_topic_score_codex":0.00015202191,"about_ca_topic_score_gemma":0.0001599115,"teacher_disagreement_score":0.42293945,"about_ca_system_score_codex":0.00035717397,"about_ca_system_score_gemma":0.0012294645,"threshold_uncertainty_score":0.9997194},"labels":[],"label_agreement":null},{"id":"W2084116711","doi":"10.1182/blood-2014-09-603043","title":"Nongenetic stochastic expansion of JAK2V617F-homozygous subclones in polycythemia vera?","year":2014,"lang":"en","type":"letter","venue":"Blood","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Canadian Institutes of Health Research; National Institute for Health and Care Research; Cancer Research UK; Wellcome Trust","keywords":"Polycythemia vera; Medicine; Genetics; Biology; Internal medicine","score_opus":0.01569287129768855,"score_gpt":0.2487397605156014,"score_spread":0.23304688921791283,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2084116711","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8969681,0.0032561256,0.00009464983,0.09591681,0.0004357343,0.0018218927,0.0000797036,0.00007188501,0.0013550913],"genre_scores_gemma":[0.9172372,0.00020659092,0.0005739142,0.078191526,0.0020535225,0.0003599187,0.00047232248,0.0001372269,0.00076776545],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9976903,0.00009904515,0.0005979596,0.00059787085,0.00055886386,0.00045593575],"domain_scores_gemma":[0.99856883,0.00031216384,0.00024920772,0.0006579832,0.000111005495,0.00010083499],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.000115699,0.00049010257,0.0011458838,0.00033623463,0.000037663653,0.000014123584,0.00014653623,0.00066204194,0.00022995243],"category_scores_gemma":[0.00008611709,0.00039777116,0.00022459812,0.0001839032,0.000089457324,0.000021804593,0.00005503333,0.0008120499,0.00009823999],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0012160438,0.009541632,0.11037677,0.006852208,0.003794802,0.02579964,0.0026094806,0.00013584219,0.00986968,0.00011161838,0.820258,0.009434279],"study_design_scores_gemma":[0.1486274,0.02706759,0.189959,0.02993388,0.022250341,0.012142786,0.0002506469,0.000653347,0.2760906,0.0014017056,0.283642,0.007980747],"about_ca_topic_score_codex":0.0001465472,"about_ca_topic_score_gemma":0.000042900712,"teacher_disagreement_score":0.536616,"about_ca_system_score_codex":0.000073907824,"about_ca_system_score_gemma":0.00021885145,"threshold_uncertainty_score":0.9998474},"labels":[],"label_agreement":null},{"id":"W2085000409","doi":"10.1080/10428190601043138","title":"Overexpression of SOCS-2 and SOCS-3 genes reverses erythroid overgrowth and IGF-I hypersensitivity of primary polycythemia vera (PV) cells","year":2007,"lang":"en","type":"article","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":16,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Women's College Hospital; University of Toronto; Health Sciences Centre; Mount Sinai Hospital; Sunnybrook Health Science Centre","funders":"Canadian Institutes of Health Research","keywords":"Polycythemia vera; Haematopoiesis; Progenitor cell; Myeloid; Biology; Immunology; Cancer research; Peripheral blood mononuclear cell; Population; Cytokine; Stem cell; Cell biology; Medicine; Genetics; In vitro","score_opus":0.009433284318129924,"score_gpt":0.22828275624695313,"score_spread":0.2188494719288232,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2085000409","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9883422,0.0062643974,0.00004535653,0.00012404445,0.0001530625,0.00065015326,0.00012501466,0.00006531366,0.0042304373],"genre_scores_gemma":[0.98959315,0.007013263,0.0019633188,0.0007303033,0.00020643714,0.000023023935,0.000059571397,0.00007615765,0.0003348005],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9967571,0.00011289429,0.0008869478,0.00091726787,0.0006544938,0.0006713356],"domain_scores_gemma":[0.99748003,0.000758289,0.00050836435,0.0005495606,0.00020074526,0.0005030147],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0004714662,0.00067842944,0.0014260103,0.00028475828,0.0002581879,0.000039955186,0.000107220134,0.00047980144,0.00003227407],"category_scores_gemma":[0.000080537975,0.0005731662,0.00022453268,0.00028395126,0.00074774737,0.00028194374,0.0002671235,0.00012818167,0.0000045837396],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.005363237,0.0007339166,0.08730246,0.0017695364,0.00066434033,0.0004369154,0.002026378,0.0000065972667,0.73077685,0.001005924,0.0015218671,0.16839199],"study_design_scores_gemma":[0.013849957,0.000883259,0.4535928,0.000928005,0.00042302316,0.0008803317,0.0006004392,0.0002087897,0.52531165,0.00013507248,0.002696363,0.000490316],"about_ca_topic_score_codex":0.0013619126,"about_ca_topic_score_gemma":0.000047494672,"teacher_disagreement_score":0.36629036,"about_ca_system_score_codex":0.0019767287,"about_ca_system_score_gemma":0.0014498928,"threshold_uncertainty_score":0.999672},"labels":[],"label_agreement":null},{"id":"W2087700674","doi":"10.1111/bjh.12274","title":"The clinical benefit of ruxolitinib across patient subgroups: analysis of a placebo‐controlled, Phase <scp>III</scp> study in patients with myelofibrosis","year":2013,"lang":"en","type":"article","venue":"British Journal of Haematology","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":94,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"National Cancer Institute; Incyte","keywords":"Ruxolitinib; Myelofibrosis; Medicine; Placebo; Internal medicine; Randomization; International Prognostic Scoring System; Population; Polycythaemia; Gastroenterology; Clinical trial; Surgery; Myelodysplastic syndromes; Bone marrow; Pathology","score_opus":0.01525759521435154,"score_gpt":0.31945351406109845,"score_spread":0.3041959188467469,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2087700674","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9964891,0.0012000373,0.00001685894,0.00012202079,0.00011594541,0.0018998309,0.00006574833,0.0000048702423,0.000085595464],"genre_scores_gemma":[0.99901766,0.0003861478,0.00026690724,0.00008547468,0.000028360135,0.00015236744,0.000016971137,0.000021436712,0.000024700243],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99539286,0.00047052524,0.0027364357,0.0003020692,0.00064807927,0.0004500165],"domain_scores_gemma":[0.9937144,0.0023875595,0.0019962427,0.00031345803,0.0013534701,0.00023488683],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009733957,0.0002473009,0.0029285864,0.00028988157,0.00011503801,0.00004426667,0.00020462889,0.00014126478,0.000044980643],"category_scores_gemma":[0.0010558286,0.00016235841,0.00057567057,0.0005677966,0.00032425963,0.00013588945,0.000075213895,0.0003730443,0.0000029724047],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0040404215,0.011724816,0.9575634,0.000033601,0.006253044,0.0012478161,0.0013346917,0.000035446097,0.0000047810763,0.00004740422,0.00032806484,0.017386533],"study_design_scores_gemma":[0.07965677,0.011116095,0.90121263,0.00036467746,0.0024581943,0.000904132,0.0038193727,0.00008552207,0.00022987831,0.000038773494,0.000044571574,0.00006936784],"about_ca_topic_score_codex":0.0004298924,"about_ca_topic_score_gemma":0.0012782605,"teacher_disagreement_score":0.07561635,"about_ca_system_score_codex":0.00005775711,"about_ca_system_score_gemma":0.00012450875,"threshold_uncertainty_score":0.6620784},"labels":[],"label_agreement":null},{"id":"W2090582630","doi":"10.3324/haematol.2010.029678","title":"Extent of hematopoietic involvement by TET2 mutations in JAK2V617F polycythemia vera","year":2011,"lang":"en","type":"article","venue":"Haematologica","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":25,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Institute of Cancer Research; National Cancer Institute; Institut National Du Cancer; Fondation de France; Ligue Contre le Cancer; Institut National de la Santé et de la Recherche Médicale","keywords":"Polycythemia vera; clone (Java method); Biology; Haematopoiesis; Somatic cell; Mutation; Progenitor cell; Cancer research; CD34; Germline mutation; Myeloproliferative neoplasm; Molecular biology; Genetics; Stem cell; Immunology; Myelofibrosis; Gene; Bone marrow","score_opus":0.0431385331944375,"score_gpt":0.27588322941015275,"score_spread":0.23274469621571525,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2090582630","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9881014,0.0008880596,0.00006736319,0.00072214135,0.000051536328,0.00065318675,0.000017463935,0.000038449052,0.009460401],"genre_scores_gemma":[0.9966443,0.00015938311,0.002394369,0.00026411668,0.000007426694,0.0002954077,0.00004318673,0.000013061609,0.00017871345],"study_design_codex":"observational","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99874747,0.000049344984,0.00045560228,0.00028546335,0.00021544707,0.00024668773],"domain_scores_gemma":[0.9993153,0.000092654176,0.00013159518,0.0002821203,0.00006393241,0.000114369075],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00010982847,0.0001825191,0.00051924284,0.00010547726,0.000044216507,0.0000050043527,0.00008042112,0.00009271461,0.0012742487],"category_scores_gemma":[0.00006479166,0.00013064146,0.000100551624,0.0001823911,0.00011333558,0.000038901286,0.00004313924,0.00011264225,0.000082515515],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0005122832,0.008281128,0.9429608,0.00050347624,0.00034195348,0.0009878431,0.00807981,0.000002658643,0.008543644,0.021897983,0.005605938,0.002282458],"study_design_scores_gemma":[0.005680726,0.0022428422,0.26917362,0.0007288376,0.00028763307,0.0005050566,0.0023602142,0.00007033435,0.7107545,0.005868457,0.0018785766,0.00044917795],"about_ca_topic_score_codex":0.00014029519,"about_ca_topic_score_gemma":0.000035255605,"teacher_disagreement_score":0.70221084,"about_ca_system_score_codex":0.000065843524,"about_ca_system_score_gemma":0.000055974226,"threshold_uncertainty_score":0.99963874},"labels":[],"label_agreement":null},{"id":"W2090897038","doi":"10.1159/000214503","title":"The World Federation of Hemophilia","year":2009,"lang":"en","type":"article","venue":"Haemostasis","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Canadian Hemophilia Society","funders":"","keywords":"Medicine; Factor IX; Internal medicine","score_opus":0.022171563734876474,"score_gpt":0.3104115755719574,"score_spread":0.2882400118370809,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2090897038","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8967488,0.0011235453,0.0000732273,0.04936125,0.00013726109,0.00071824435,0.000013871135,0.000051517774,0.051772296],"genre_scores_gemma":[0.99477386,0.00022783138,0.0007357238,0.0011172513,0.00006695486,0.000018225446,0.00001598306,0.0000058794885,0.003038286],"study_design_codex":"design_other","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9993447,0.000023863635,0.00019002758,0.0001244741,0.0001863494,0.00013059184],"domain_scores_gemma":[0.9994618,0.000113162154,0.000060324826,0.00021193911,0.00009417502,0.000058590835],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00009583319,0.000090474125,0.00017279411,0.000040056573,0.00017212245,0.000023001685,0.000035592984,0.000024591583,0.00012159667],"category_scores_gemma":[0.000061651524,0.000053266624,0.00007433262,0.00016086562,0.000034839275,0.000032047115,0.0000073340866,0.000059321,0.000029150762],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0003239532,0.00059042807,0.027711459,0.000020995203,0.00015986103,0.00004452442,0.0002805507,0.000007161948,0.0011072104,0.027671307,0.04501198,0.8970706],"study_design_scores_gemma":[0.0019320578,0.0009400544,0.20670249,0.00012989952,0.00018004414,0.000041359715,0.000112207556,0.00015876444,0.68168575,0.0021365788,0.10582952,0.00015128408],"about_ca_topic_score_codex":0.000009686207,"about_ca_topic_score_gemma":0.00009541835,"teacher_disagreement_score":0.8969193,"about_ca_system_score_codex":0.000041062493,"about_ca_system_score_gemma":0.000040447503,"threshold_uncertainty_score":0.21721499},"labels":[],"label_agreement":null},{"id":"W2091653318","doi":"10.1097/mph.0b013e3182346cc5","title":"Allogeneic Cord Hematopoietic Stem Cell Transplantation in an Infant With Primary Myelofibrosis","year":2012,"lang":"en","type":"article","venue":"Journal of Pediatric Hematology/Oncology","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"SickKids Foundation; Hospital for Sick Children","funders":"","keywords":"Medicine; Myelofibrosis; Cord blood; Hematopoietic stem cell transplantation; Umbilical cord; Transplantation; Stem cell; Pediatrics; Haematopoiesis; Disease; Cord; Surgery; Internal medicine; Immunology; Bone marrow","score_opus":0.02290612392771706,"score_gpt":0.298437561714545,"score_spread":0.2755314377868279,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2091653318","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9924927,0.004487053,0.0002865258,0.0008665315,0.00032730098,0.00049250294,0.000007317472,0.000018291681,0.001021827],"genre_scores_gemma":[0.99058354,0.0031122803,0.0050968276,0.00055224926,0.00051223487,0.000058190893,0.000019910281,0.000034704608,0.000030085768],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99734795,0.00036509507,0.0011031351,0.00024888178,0.0003746204,0.0005603271],"domain_scores_gemma":[0.9977375,0.00050975056,0.00081750576,0.00020931933,0.00024187371,0.00048400968],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007311697,0.00030160032,0.0012702553,0.00057968724,0.00006247973,0.000011056996,0.00013447794,0.0003642283,0.00009216482],"category_scores_gemma":[0.0000166166,0.00020874498,0.00015085163,0.0004008375,0.00008328018,0.00032719484,0.000021336418,0.00050026004,0.00003055707],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0024625775,0.003184449,0.98436356,0.0004749305,0.00011519302,0.00198775,0.002789139,0.000014632358,0.0009309029,0.00020537141,0.00052909064,0.0029423945],"study_design_scores_gemma":[0.017044276,0.021532305,0.9051308,0.00016124574,0.002712946,0.033933952,0.0017454,0.000014223719,0.014482833,0.0000644449,0.0026328764,0.0005446846],"about_ca_topic_score_codex":0.000010426737,"about_ca_topic_score_gemma":0.000045620567,"teacher_disagreement_score":0.07923275,"about_ca_system_score_codex":0.00044298926,"about_ca_system_score_gemma":0.0008705003,"threshold_uncertainty_score":0.85123736},"labels":[],"label_agreement":null},{"id":"W2093164294","doi":"10.1182/blood-2014-04-572545","title":"MPD-RC 101 prospective study of reduced-intensity allogeneic hematopoietic stem cell transplantation in patients with myelofibrosis","year":2014,"lang":"en","type":"article","venue":"Blood","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":149,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"National Cancer Institute","keywords":"Myelofibrosis; Hematopoietic stem cell transplantation; Medicine; Transplantation; Stem cell; Internal medicine; Regimen; Surgery; Gastroenterology; Oncology; Bone marrow; Biology","score_opus":0.00766578970528299,"score_gpt":0.21279811109286942,"score_spread":0.20513232138758644,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2093164294","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99752885,0.000024810426,0.000012482756,0.000032222335,0.00003009752,0.0016887678,0.000012047555,0.000019780991,0.0006509444],"genre_scores_gemma":[0.99946964,0.000013147187,0.00020594259,0.00003337413,0.000018401826,0.00016432186,0.000024919174,0.000021805114,0.00004844202],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99872565,0.00007524537,0.00031068502,0.00036099087,0.00033859408,0.0001888123],"domain_scores_gemma":[0.99926424,0.000054912234,0.0001302551,0.00025393398,0.0002131837,0.000083458865],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00009836759,0.00019882622,0.00048326165,0.00010609008,0.000044134064,0.000008082498,0.000049127877,0.00005608547,0.000018925708],"category_scores_gemma":[0.000006774257,0.0001428973,0.00004726677,0.0001933273,0.000030395373,0.000047753998,0.000012466264,0.0000965504,0.00001200041],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00080157205,0.01343331,0.9799608,0.00016851422,0.00016134712,0.000020544665,0.004193341,0.000009294208,0.00095443125,0.000020157817,0.0000062899003,0.00027039798],"study_design_scores_gemma":[0.015699219,0.006198498,0.8514078,0.00017794601,0.0005322363,0.000007714101,0.00042317595,0.0000034377904,0.12542494,0.00000835981,0.0000013006588,0.00011535935],"about_ca_topic_score_codex":0.000081467064,"about_ca_topic_score_gemma":0.00018836386,"teacher_disagreement_score":0.12855299,"about_ca_system_score_codex":0.000043819327,"about_ca_system_score_gemma":0.000033271852,"threshold_uncertainty_score":0.58271825},"labels":[],"label_agreement":null},{"id":"W2093724620","doi":"10.1182/blood-2012-05-399048","title":"Allogeneic hematopoietic cell transplantation for myelofibrosis in the era of JAK inhibitors","year":2012,"lang":"en","type":"review","venue":"Blood","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":105,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"National Cancer Institute","keywords":"Ruxolitinib; Myelofibrosis; Medicine; Transplantation; Internal medicine; Oncology; Constitutional symptoms; Hematopoietic stem cell transplantation; Hematopoietic cell; Regimen; Stem cell; Haematopoiesis; Bone marrow; Disease","score_opus":0.03791316878432824,"score_gpt":0.3062783403199888,"score_spread":0.26836517153566053,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2093724620","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0046107885,0.9916682,0.000010558519,0.00008172969,0.00008913257,0.00298245,0.0001550669,0.000010692452,0.0003913309],"genre_scores_gemma":[0.012885569,0.98405623,0.0006218278,0.000052120427,0.00019773905,0.0016298566,0.00047797905,0.000044136577,0.00003451608],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9984605,0.00013063946,0.00063999783,0.00027067415,0.00024053335,0.00025768604],"domain_scores_gemma":[0.9988487,0.00047343125,0.0002698661,0.0002951284,0.000046852794,0.00006604459],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00027850922,0.0003350456,0.0012635425,0.000111836554,0.00004011732,0.000010508441,0.00011095673,0.0002318101,0.000034430777],"category_scores_gemma":[0.0000142987865,0.00019211882,0.00051397894,0.000214708,0.000033833934,0.000030722942,0.00000926385,0.00021363236,0.000018017558],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00010261383,0.010748098,0.011322226,0.22308515,0.0012764905,0.00009782396,0.0042948895,6.294632e-7,0.00008185211,0.0006466271,0.00042399994,0.7479196],"study_design_scores_gemma":[0.012340482,0.002418156,0.0054483535,0.05259305,0.05306942,0.00085821556,0.00024788952,5.599737e-7,0.013170366,0.00008183761,0.85872495,0.0010467204],"about_ca_topic_score_codex":0.000016315647,"about_ca_topic_score_gemma":0.000018320812,"teacher_disagreement_score":0.8583009,"about_ca_system_score_codex":0.000032106895,"about_ca_system_score_gemma":0.00015557128,"threshold_uncertainty_score":0.78343785},"labels":[],"label_agreement":null},{"id":"W2095227834","doi":"10.1002/ajh.23181","title":"Introductory remarks for the THSNA meeting proceedings: Hemostasis and thrombosis at the cutting edge","year":2012,"lang":"en","type":"article","venue":"American Journal of Hematology","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Hemostasis; Medicine; Multidisciplinary approach; Medical education; Thrombosis; Family medicine; Political science; Internal medicine; Law","score_opus":0.01882364038494134,"score_gpt":0.30327249930597816,"score_spread":0.28444885892103683,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2095227834","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9581134,0.00743333,0.00007499691,0.03322365,0.00022403219,0.00037220964,0.0000025845204,0.0000075152784,0.00054829376],"genre_scores_gemma":[0.9939725,0.0008742569,0.003000849,0.0015080153,0.00054460915,0.00004337551,9.84642e-7,0.00002149636,0.000033903867],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.998849,0.000060899074,0.00042176511,0.00014314761,0.0001799183,0.0003452725],"domain_scores_gemma":[0.99741334,0.0014336826,0.00063484453,0.00013144112,0.00025413447,0.00013257621],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00087165553,0.00016096291,0.0005855816,0.000060034276,0.00032730345,0.000017182296,0.000097618904,0.000035484914,0.000041900494],"category_scores_gemma":[0.0007089688,0.00007491164,0.0001378763,0.00013482402,0.00046604546,0.0000866396,0.00006771371,0.0002130244,0.0000030244912],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00038129566,0.00023307286,0.93142486,0.00009463356,0.001053255,0.0000074183763,0.0056524626,0.0000010613232,0.001202206,0.0023196952,0.022772685,0.03485737],"study_design_scores_gemma":[0.008916702,0.009188726,0.49951917,0.001410486,0.0065896036,0.045497596,0.0951813,0.00028700524,0.14416826,0.0005486264,0.18771406,0.0009784653],"about_ca_topic_score_codex":0.000012094363,"about_ca_topic_score_gemma":0.000003965029,"teacher_disagreement_score":0.43190566,"about_ca_system_score_codex":0.00008187008,"about_ca_system_score_gemma":0.00005341953,"threshold_uncertainty_score":0.30548078},"labels":[],"label_agreement":null},{"id":"W2095750011","doi":"10.1182/blood-2002-07-2287","title":"Discrimination of polycythemias and thrombocytoses by novel, simple, accurate clonality assays and comparison with PRV-1 expression and BFU-E response to erythropoietin","year":2003,"lang":"en","type":"article","venue":"Blood","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":152,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; McGill University Health Centre","funders":"National Heart, Lung, and Blood Institute","keywords":"Polycythemia vera; Essential thrombocythemia; Erythropoiesis; Thrombocytosis; Biology; Haematopoiesis; Erythropoietin; Myelofibrosis; Immunology; Molecular biology; Bone marrow; Internal medicine; Stem cell; Genetics; Anemia; Medicine; Platelet","score_opus":0.024726970735725735,"score_gpt":0.3036710571190307,"score_spread":0.278944086383305,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2095750011","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99705344,0.0010023374,0.00024278843,0.0008361535,0.000009910427,0.00053264725,0.00007550707,0.000015146368,0.00023206629],"genre_scores_gemma":[0.996268,0.00016527635,0.003305712,0.00010021379,0.000011073994,0.000046057936,0.000027681865,0.000015411502,0.000060572223],"study_design_codex":"observational","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99895215,0.000119188626,0.00023415538,0.0003229,0.00021382917,0.00015778533],"domain_scores_gemma":[0.9991726,0.00031034302,0.00011387505,0.00016075058,0.00007650204,0.00016587887],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002714148,0.00018142533,0.00038784108,0.00005187852,0.000097878336,0.000027310296,0.000021417329,0.00006388656,0.000020324556],"category_scores_gemma":[0.00023769477,0.00012305091,0.000016603813,0.000090938534,0.000121083496,0.00007769128,0.00003504346,0.00007965904,5.6332726e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.002136468,0.0023046776,0.56660926,0.00018801176,0.00014197244,0.00001314737,0.001983067,0.000001262989,0.42483687,0.00034226192,0.00092465413,0.00051832164],"study_design_scores_gemma":[0.0060809604,0.0018398435,0.36338118,0.000245691,0.0002423492,0.00008785887,0.00070020783,0.000011056711,0.6264152,0.000037782436,0.0008195334,0.00013833871],"about_ca_topic_score_codex":0.000041541603,"about_ca_topic_score_gemma":0.000036772235,"teacher_disagreement_score":0.20322812,"about_ca_system_score_codex":0.000016410702,"about_ca_system_score_gemma":0.000045699817,"threshold_uncertainty_score":0.501787},"labels":[],"label_agreement":null},{"id":"W2095934415","doi":"10.3324/haematol.2014.120857","title":"Somatic calreticulin mutations in patients with Budd-Chiari syndrome and portal vein thrombosis","year":2015,"lang":"en","type":"article","venue":"Haematologica","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":42,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network","funders":"Institut National de la Santé et de la Recherche Médicale","keywords":"Budd–Chiari syndrome; Calreticulin; Medicine; Portal vein thrombosis; Thrombosis; Internal medicine; Gastroenterology; Inferior vena cava; Biology; Genetics","score_opus":0.02343537249997888,"score_gpt":0.260084234927091,"score_spread":0.2366488624271121,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2095934415","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9961034,0.00010147939,0.000019182162,0.0010376049,0.000032171447,0.0006956991,0.0000116824085,0.00004270753,0.0019560403],"genre_scores_gemma":[0.99729186,0.000011018795,0.0022414168,0.00016340417,0.0000050218764,0.00015529676,0.00008635382,0.00001252376,0.000033101507],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9989607,0.000051566087,0.0002593431,0.0002700268,0.00024981052,0.0002086089],"domain_scores_gemma":[0.99937946,0.00008214059,0.00008097723,0.0001690549,0.000091847854,0.00019650513],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00007946804,0.00017476604,0.00048682696,0.0000900037,0.000054123495,0.000019992696,0.000035558758,0.000081999824,0.0001490932],"category_scores_gemma":[0.00010866967,0.000107658074,0.000029530564,0.0001652253,0.00010703343,0.00006958698,0.00002907377,0.000107674794,0.000056726647],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000059877842,0.00090062886,0.99652493,0.000048279522,0.00007630163,0.0006795661,0.0005335161,0.000005912154,0.0000016322907,0.00083842233,0.00016980704,0.00016110983],"study_design_scores_gemma":[0.0037581422,0.0015269592,0.99286383,0.00017963065,0.00012198656,0.0004513587,0.0003123792,0.00010041358,0.0001137186,0.0004012806,0.00003380703,0.00013648815],"about_ca_topic_score_codex":0.00004403466,"about_ca_topic_score_gemma":0.000066651795,"teacher_disagreement_score":0.0036982642,"about_ca_system_score_codex":0.000043078715,"about_ca_system_score_gemma":0.00007148976,"threshold_uncertainty_score":0.43901688},"labels":[],"label_agreement":null},{"id":"W2098215007","doi":"10.1002/ajh.24098","title":"Myeloproliferative neoplasm patient symptom burden and quality of life: Evidence of significant impairment compared to controls","year":2015,"lang":"en","type":"article","venue":"American Journal of Hematology","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":51,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Queen's University; Public Health Agency; Queen's University Belfast","keywords":"Medicine; Myeloproliferative neoplasm; Internal medicine; Polycythaemia; Myelofibrosis; Quality of life (healthcare); Population; Gastroenterology; Bone marrow","score_opus":0.05208725393675259,"score_gpt":0.3397715469331797,"score_spread":0.28768429299642706,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2098215007","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9914728,0.0016491187,0.00039055402,0.0056249644,0.0000973226,0.0006456101,0.00001678056,0.0000064018423,0.000096456824],"genre_scores_gemma":[0.99489605,0.00015723577,0.004313986,0.00051601214,0.000059385042,0.000034566976,0.0000017018397,0.000014339979,0.0000066995253],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99691385,0.00047504238,0.0015320926,0.00024551194,0.00056204566,0.00027143172],"domain_scores_gemma":[0.99510765,0.0010795292,0.001667832,0.00025735277,0.0012019095,0.0006857036],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006711986,0.00024047928,0.002138787,0.00022492466,0.000030595136,0.000008261256,0.00011989878,0.000049968607,0.000020365318],"category_scores_gemma":[0.0012214016,0.00016909342,0.00016109498,0.00024887032,0.00046441794,0.000079652666,0.00006791347,0.00017601179,0.000004312062],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0128348665,0.0012999463,0.94465125,0.0002967422,0.0017542541,0.00019235472,0.01622871,0.00031547024,0.00889397,0.0020992146,0.0008226717,0.010610557],"study_design_scores_gemma":[0.030064126,0.11868461,0.6643805,0.004865174,0.0015242503,0.003681251,0.04947939,0.00047852754,0.12389933,0.00063181453,0.001217577,0.0010934772],"about_ca_topic_score_codex":0.00031438633,"about_ca_topic_score_gemma":0.000021550328,"teacher_disagreement_score":0.28027079,"about_ca_system_score_codex":0.0001138113,"about_ca_system_score_gemma":0.0006876039,"threshold_uncertainty_score":0.68954295},"labels":[],"label_agreement":null},{"id":"W2099846553","doi":"10.1186/1471-2350-11-54","title":"Quantitative assay for the detection of the V617F variant in the Janus kinase 2 (JAK2) gene using the Luminex xMAP technology","year":2010,"lang":"en","type":"article","venue":"BMC Medical Genetics","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":15,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal; Cégep de Chicoutimi; Université du Québec à Chicoutimi","funders":"Canadian Institutes of Health Research","keywords":"Biology; Molecular biology; Primer (cosmetics); Point mutation; Polymerase chain reaction; Assay sensitivity; Taq polymerase; genomic DNA; Gene; Genetics; Mutation; Medicine; Chemistry; Pathology","score_opus":0.042380343544633575,"score_gpt":0.3311178850510852,"score_spread":0.2887375415064516,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2099846553","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96026665,0.0014033711,0.026020855,0.009787321,0.00062888395,0.0017842097,0.00001718229,0.000012391548,0.0000791414],"genre_scores_gemma":[0.99246615,0.00024127377,0.0059165503,0.0007604649,0.00024828492,0.00031600706,0.0000036528734,0.000018248438,0.000029361036],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9982258,0.0002756196,0.0003930944,0.0002397135,0.00059750216,0.00026823985],"domain_scores_gemma":[0.99610305,0.0028207423,0.00017115693,0.0006659797,0.00017166427,0.00006741662],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0014433983,0.00017466437,0.00026289775,0.00006413328,0.00025377897,0.000016057358,0.0004122234,0.00024174679,0.00004906747],"category_scores_gemma":[0.0032444333,0.00006473282,0.00013542415,0.00042234402,0.0006051079,0.000011619015,0.00009840372,0.0005447747,0.0000033174833],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.001519819,0.004874953,0.26878908,0.00060503493,0.0014021525,0.00026585022,0.010580505,0.00077567715,0.5095071,0.047490884,0.0012174041,0.15297154],"study_design_scores_gemma":[0.008937226,0.0029615015,0.27182865,0.00044296126,0.001832532,0.0013984966,0.0061244043,0.20200725,0.48290205,0.0038372711,0.017213931,0.00051372644],"about_ca_topic_score_codex":0.00009654009,"about_ca_topic_score_gemma":0.0023513683,"teacher_disagreement_score":0.20123157,"about_ca_system_score_codex":0.000034919616,"about_ca_system_score_gemma":0.00040303875,"threshold_uncertainty_score":0.38841242},"labels":[],"label_agreement":null},{"id":"W2100242421","doi":"10.3109/10428194.2014.963082","title":"Pulmonary tuberculosis reactivation following ruxolitinib treatment in a patient with primary myelofibrosis","year":2014,"lang":"en","type":"letter","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":26,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Héma-Québec","funders":"","keywords":"Ruxolitinib; Myelofibrosis; Medicine; Tuberculosis; Pulmonary tuberculosis; Internal medicine; Oncology; Bone marrow; Pathology","score_opus":0.010706398558013006,"score_gpt":0.22411892115910517,"score_spread":0.21341252260109217,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2100242421","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9393715,0.0021222408,0.00001503946,0.035834815,0.000366486,0.003359202,0.00014270528,0.00031153776,0.018476434],"genre_scores_gemma":[0.7561324,0.0024015247,0.0013032686,0.2254212,0.0021384922,0.003971933,0.0056002135,0.00056446745,0.0024664442],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99247974,0.00041197843,0.0015229904,0.0024649065,0.0014523591,0.001668028],"domain_scores_gemma":[0.9962185,0.00088770234,0.00072833087,0.0014339822,0.00019607604,0.0005354044],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":["metaepi_narrow"],"category_scores_codex":[0.00025199822,0.0020759096,0.0029635648,0.0009442559,0.00041442038,0.00023045196,0.0002600887,0.0019238323,0.00006540886],"category_scores_gemma":[0.000068614514,0.0015898062,0.0007918614,0.00076042395,0.00025603973,0.0003915913,0.00016120229,0.0005651998,0.000083323444],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0047834027,0.0028425925,0.10024719,0.0030399296,0.005521401,0.07385726,0.0035363827,0.0000610647,0.0017255004,0.00014951736,0.1274143,0.6768215],"study_design_scores_gemma":[0.037744597,0.006677351,0.17830387,0.006305673,0.0037063654,0.014769855,0.00040582265,0.0009802575,0.0070343628,0.00018282265,0.74033237,0.0035566292],"about_ca_topic_score_codex":0.0051745917,"about_ca_topic_score_gemma":0.00010212243,"teacher_disagreement_score":0.6732648,"about_ca_system_score_codex":0.029813793,"about_ca_system_score_gemma":0.0045134737,"threshold_uncertainty_score":0.9993719},"labels":[],"label_agreement":null},{"id":"W2100293053","doi":"10.1016/j.bbmt.2009.10.025","title":"Outcome of Transplantation for Myelofibrosis","year":2009,"lang":"en","type":"article","venue":"Biology of Blood and Marrow Transplantation","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":265,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"National Cancer Institute; National Heart, Lung, and Blood Institute","keywords":"Medicine; Myelofibrosis; Transplantation; Sibling; Splenectomy; Surgery; Internal medicine; Retrospective cohort study; Disease; Hematopoietic stem cell transplantation; Bone marrow","score_opus":0.020213177795147065,"score_gpt":0.297935639872179,"score_spread":0.27772246207703194,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2100293053","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9957496,0.00045604556,0.0021630607,0.0005606532,0.00003927368,0.00047862798,0.00025134368,0.000013801912,0.00028762192],"genre_scores_gemma":[0.9919661,0.0024449446,0.004974129,0.000113710645,0.000023780422,0.000030109517,0.0004217996,0.0000049937007,0.000020377553],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99933684,0.000023055862,0.0003221712,0.00015993555,0.000054992837,0.00010300873],"domain_scores_gemma":[0.99961686,0.00011277752,0.0000974765,0.00006204194,0.000068649504,0.00004218237],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000088681176,0.00010498329,0.0003140408,0.000086510714,0.000031629952,0.0000017770025,0.000021437489,0.000097298594,0.0000108898685],"category_scores_gemma":[0.0000084630765,0.000082951905,0.00008114787,0.000050383896,0.000055704837,0.000037280406,6.917816e-7,0.000030957992,3.3215645e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0014613434,0.00040114924,0.36010513,0.00091948954,0.00017480379,0.0000055297105,0.00065391226,0.0000018355619,0.6174836,0.0066250623,0.000009949035,0.012158194],"study_design_scores_gemma":[0.0052512814,0.0030339484,0.41222417,0.00012570508,0.001308812,0.000071281116,0.000027172518,0.00001307545,0.57709223,0.00071920356,0.00004601736,0.00008708557],"about_ca_topic_score_codex":0.000018570176,"about_ca_topic_score_gemma":0.000013961787,"teacher_disagreement_score":0.052119043,"about_ca_system_score_codex":0.0000032087864,"about_ca_system_score_gemma":0.000017145581,"threshold_uncertainty_score":0.33826804},"labels":[],"label_agreement":null},{"id":"W2102934344","doi":"10.4314/ahs.v14i4.39","title":"Splanchnic venous thrombosis driven by a constitutively activated JAK2 V617F philadelphia-negative myeloproliferative neoplasm: a case report","year":2015,"lang":"en","type":"article","venue":"African Health Sciences","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University","funders":"","keywords":"Myeloproliferative neoplasm; Medicine; JAK2 V617F; Venous thrombosis; Splanchnic; Myeloproliferative Disorders; Thrombosis; Neoplasm; Essential thrombocythemia; Internal medicine; Myelofibrosis; Pathology; Polycythemia vera; Bone marrow","score_opus":0.08563932816265177,"score_gpt":0.36340030367487147,"score_spread":0.2777609755122197,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2102934344","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.944777,0.00065806316,0.00019236779,0.03406204,0.00049706356,0.003039807,0.00037988275,0.00025952727,0.01613421],"genre_scores_gemma":[0.9930178,0.00018117751,0.003530198,0.0024098516,0.00016726073,0.00042912376,0.00006762491,0.000027637434,0.00016935369],"study_design_codex":"observational","study_design_gemma":"case_report","domain_scores_codex":[0.9955764,0.0003199929,0.0008668589,0.0011711768,0.0010562286,0.001009386],"domain_scores_gemma":[0.99653155,0.00056619645,0.0006988403,0.00041743042,0.0005358862,0.0012501093],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.001123346,0.00050679536,0.0011468793,0.00030321255,0.001041397,0.00010877738,0.00021645293,0.00013973651,0.000085015876],"category_scores_gemma":[0.0008057433,0.00037874203,0.00013351945,0.0015542265,0.0015305474,0.00039740076,0.00010287192,0.0004073766,0.00008874609],"study_design_candidate":"case_report","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.002377464,0.016469402,0.44249117,0.00073852256,0.0033324703,0.12621832,0.14011228,0.00059812993,0.003177501,0.012352117,0.24204569,0.01008695],"study_design_scores_gemma":[0.040236726,0.08745581,0.11302212,0.004295379,0.0018338269,0.44488943,0.13738725,0.005996534,0.077009566,0.005012582,0.07589196,0.0069688307],"about_ca_topic_score_codex":0.003218188,"about_ca_topic_score_gemma":0.00056190486,"teacher_disagreement_score":0.32946905,"about_ca_system_score_codex":0.00086425676,"about_ca_system_score_gemma":0.004855489,"threshold_uncertainty_score":0.9998664},"labels":[],"label_agreement":null},{"id":"W2105235256","doi":"10.1586/17474086.2013.827413","title":"Practical management of patients with myelofibrosis receiving ruxolitinib","year":2013,"lang":"en","type":"review","venue":"Expert Review of Hematology","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":36,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"National Cancer Institute","keywords":"Ruxolitinib; Medicine; Myelofibrosis; Adverse effect; Extramedullary hematopoiesis; Anemia; Constitutional symptoms; Internal medicine; Randomized controlled trial; Clinical trial; Intensive care medicine; Bone marrow; Oncology; Disease; Haematopoiesis; Stem cell","score_opus":0.048357737867579915,"score_gpt":0.39484366910145563,"score_spread":0.3464859312338757,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2105235256","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000015873577,0.99205446,0.000030314926,0.0004376432,0.00011526088,0.0046333116,0.000031069,0.000020708741,0.002661329],"genre_scores_gemma":[0.000009041834,0.97184,0.02536995,0.00028276246,0.000037308848,0.0019129664,0.00035588534,0.00006853307,0.00012350883],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99653274,0.00031499556,0.0017028697,0.0005897197,0.00049350015,0.0003661636],"domain_scores_gemma":[0.99674064,0.0004717379,0.0013996162,0.0008434394,0.00037366888,0.00017088349],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00021352108,0.0006081019,0.005861697,0.00015116522,0.000034696564,0.0000053504664,0.0001589984,0.00024573863,0.0013574559],"category_scores_gemma":[0.00015708532,0.00034590473,0.00064326933,0.00030103713,0.00016128342,0.000064957305,0.00013807231,0.00024803623,0.00012522265],"study_design_candidate":"systematic_review","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000022308046,0.0010730877,0.0005354426,0.462372,0.0014799354,0.0000700254,0.000022702992,1.1647499e-9,2.3060489e-8,0.0042485786,0.014212537,0.5159634],"study_design_scores_gemma":[0.00052621815,0.00044880004,0.00012879234,0.35211486,0.002005257,0.00017763813,0.000010986897,7.500103e-8,0.000015079623,0.0000036920605,0.64438033,0.00018827809],"about_ca_topic_score_codex":0.000008145319,"about_ca_topic_score_gemma":4.4707818e-7,"teacher_disagreement_score":0.6301678,"about_ca_system_score_codex":0.00009927467,"about_ca_system_score_gemma":0.00020321667,"threshold_uncertainty_score":0.99989927},"labels":[],"label_agreement":null},{"id":"W2107055840","doi":"10.14740/jocmr2047w","title":"The Burden of JAK2V617F Mutated Allele in Turkish Patients With Myeloproliferative Neoplasms","year":2014,"lang":"en","type":"article","venue":"Journal of Clinical Medicine Research","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Medicine; Essential thrombocythemia; Allele; Myelofibrosis; Internal medicine; Polycythemia vera; Gastroenterology; Hematocrit; Genetics; Bone marrow; Biology; Gene","score_opus":0.08726541006998487,"score_gpt":0.4664245150321919,"score_spread":0.37915910496220706,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2107055840","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9691712,0.00049477816,0.000031576605,0.026338741,0.00020907332,0.0007633897,0.0000026367252,0.0000048982142,0.0029836947],"genre_scores_gemma":[0.99653983,0.0012090526,0.0004143487,0.00018754572,0.001274187,0.000024419616,0.00000917359,0.000026220923,0.0003152113],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99306995,0.0014528288,0.002287965,0.00029132603,0.0023953223,0.0005026246],"domain_scores_gemma":[0.9838112,0.010897512,0.0008032167,0.00040416844,0.0035625028,0.00052141794],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.010085708,0.00021411282,0.0013833407,0.00036492303,0.00014160822,0.000019911213,0.00031288914,0.00016874353,0.00014307693],"category_scores_gemma":[0.015596841,0.00009421261,0.00017340928,0.0007098443,0.0010473579,0.00009724155,0.00007682457,0.0017179203,0.000013500046],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.008891657,0.0016756887,0.9244121,0.00009520278,0.00064661575,0.00018232556,0.001499456,0.00006891679,0.000045853914,0.0006763322,0.011946844,0.049859066],"study_design_scores_gemma":[0.031192098,0.037629448,0.8985269,0.002102192,0.00018353628,0.000076181816,0.0014150598,0.0008861309,0.00091595034,0.0010776242,0.025837418,0.0001574773],"about_ca_topic_score_codex":0.00014220287,"about_ca_topic_score_gemma":0.000091347436,"teacher_disagreement_score":0.04970159,"about_ca_system_score_codex":0.00010410767,"about_ca_system_score_gemma":0.0006377483,"threshold_uncertainty_score":0.9926952},"labels":[],"label_agreement":null},{"id":"W2111872404","doi":"10.1517/14656566.2012.732998","title":"Ruxolitinib, an oral JAK1 and JAK2 inhibitor, in myelofibrosis","year":2012,"lang":"en","type":"review","venue":"Expert Opinion on Pharmacotherapy","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":45,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"Incyte; Massachusetts Medical Society","keywords":"Ruxolitinib; Medicine; Myelofibrosis; Clinical trial; Janus kinase; Anemia; Internal medicine; Oncology; Tolerability; Adverse effect; Pharmacology; Bone marrow; Cytokine","score_opus":0.17150415643462785,"score_gpt":0.46996782130591475,"score_spread":0.2984636648712869,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2111872404","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00040831324,0.994915,0.0000024031492,0.0004648462,0.0011644212,0.0021042102,0.00007891982,0.000096849675,0.0007650487],"genre_scores_gemma":[0.00022388835,0.992863,0.00053483865,0.0022563275,0.0019722204,0.0013360248,0.0004550589,0.00018064534,0.00017800562],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9968314,0.0004399289,0.00081125734,0.000861373,0.00043121228,0.0006247966],"domain_scores_gemma":[0.9984408,0.0002142247,0.00025275056,0.0004683285,0.000053598604,0.00057028345],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00031064943,0.0008889435,0.0021782343,0.00047607892,0.00010774016,0.000063706415,0.00014413045,0.0003997777,0.0011105112],"category_scores_gemma":[0.000011263867,0.00064063683,0.00036216655,0.0003046674,0.000089949885,0.00020818171,0.000038407485,0.0005406461,0.00013324288],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00022341516,0.0017586694,0.00038173265,0.0011887418,0.00026999903,0.000024084069,0.00066911225,6.072214e-8,0.000040785035,0.00033756107,0.0030095044,0.9920963],"study_design_scores_gemma":[0.0039612837,0.0010507075,0.00015830253,0.00653432,0.000077111086,0.00008853888,0.00003267297,0.000006809523,0.0005409996,0.000008776744,0.9869762,0.00056426646],"about_ca_topic_score_codex":0.000085983855,"about_ca_topic_score_gemma":0.0000048207385,"teacher_disagreement_score":0.9915321,"about_ca_system_score_codex":0.00031280765,"about_ca_system_score_gemma":0.00023425702,"threshold_uncertainty_score":0.9998026},"labels":[],"label_agreement":null},{"id":"W2112000215","doi":"10.3324/haematol.2013.087650","title":"Comparison of placebo and best available therapy for the treatment of myelofibrosis in the phase 3 COMFORT studies","year":2013,"lang":"en","type":"article","venue":"Haematologica","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":39,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"National Cancer Institute; Novartis Pharmaceuticals Corporation","keywords":"Medicine; Placebo; Adverse effect; Myelofibrosis; Quality of life (healthcare); Internal medicine; Surgery; Pathology; Bone marrow; Alternative medicine","score_opus":0.18569937186375002,"score_gpt":0.4288866127252391,"score_spread":0.24318724086148907,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2112000215","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9749355,0.019467255,0.000009770095,0.0021485223,0.00002569627,0.0029668936,0.000019442736,0.0000067798696,0.00042016816],"genre_scores_gemma":[0.9849796,0.012080112,0.0006161206,0.00012230009,0.000012686158,0.0020324124,0.000010203391,0.0000063283455,0.00014019711],"study_design_codex":"observational","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99914485,0.00006115283,0.00034818577,0.00016645508,0.00012839526,0.00015095905],"domain_scores_gemma":[0.9979629,0.0014865794,0.00018906107,0.00023937397,0.00009522485,0.000026892696],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001298627,0.00015507602,0.0007160726,0.00003696839,0.0001005085,0.000009641752,0.00006463264,0.000046445253,0.00013822765],"category_scores_gemma":[0.000054447763,0.000059001577,0.00008889551,0.00008893445,0.00021688773,0.00002596255,0.000011478839,0.000036119895,0.000008442805],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0020394619,0.017015884,0.91045856,0.00028463363,0.0012466045,0.000014271756,0.015248712,0.0000080908285,0.001070542,0.002060554,0.014239388,0.036313303],"study_design_scores_gemma":[0.08957989,0.12356494,0.23028693,0.0010096367,0.0020438682,0.00025581825,0.0677244,0.003597436,0.38383964,0.0016801928,0.095679596,0.0007376593],"about_ca_topic_score_codex":0.00013378508,"about_ca_topic_score_gemma":0.000049939983,"teacher_disagreement_score":0.6801716,"about_ca_system_score_codex":0.000022482234,"about_ca_system_score_gemma":0.000020475421,"threshold_uncertainty_score":0.24060145},"labels":[],"label_agreement":null},{"id":"W2112895187","doi":"10.1074/jbc.m113.476192","title":"Essential Role for the Mnk Pathway in the Inhibitory Effects of Type I Interferons on Myeloproliferative Neoplasm (MPN) Precursors","year":2013,"lang":"en","type":"article","venue":"Journal of Biological Chemistry","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":17,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; University Health Network","funders":"National Cancer Institute","keywords":"Kinase; Haematopoiesis; Polycythemia vera; Cancer research; Biology; Signal transduction; MAPK/ERK pathway; Myeloproliferative Disorders; Myeloproliferative neoplasm; JAK-STAT signaling pathway; Janus kinase 2; Gene knockdown; Cell biology; Immunology; Stem cell; Biochemistry; Apoptosis; Receptor tyrosine kinase; Bone marrow","score_opus":0.01542116421486131,"score_gpt":0.2637041953225607,"score_spread":0.24828303110769936,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2112895187","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99559015,0.0008797317,0.000023123717,0.0019630962,0.00015174146,0.0007145398,0.0000062218946,0.0000046523014,0.00066672894],"genre_scores_gemma":[0.9986367,0.00019415662,0.00012301122,0.0003929043,0.0004244287,0.00012941791,0.0000065517743,0.000008174709,0.00008461451],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99887747,0.0000975994,0.00044724465,0.00015817657,0.00022184354,0.00019765034],"domain_scores_gemma":[0.99749273,0.0017171793,0.00029663564,0.00016883604,0.0002447044,0.00007989472],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003034723,0.0001838517,0.00041547322,0.000027886448,0.00006169232,0.000020903499,0.00018729939,0.00016336513,0.00009949467],"category_scores_gemma":[0.00077067205,0.00007422314,0.00021184787,0.000109325105,0.00014783266,0.00003926571,0.000031966527,0.00041928756,0.00000698034],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0044250516,0.005284617,0.05382972,0.0006167825,0.0011140635,0.00017342456,0.004016546,0.00009324276,0.9024928,0.00042450678,0.006721771,0.020807458],"study_design_scores_gemma":[0.0023266098,0.003307876,0.03639885,0.00038976342,0.00007910325,0.000115056864,0.0008020922,0.00006857534,0.9547397,0.0004219217,0.0012457048,0.00010476289],"about_ca_topic_score_codex":0.000005334404,"about_ca_topic_score_gemma":0.0000015453279,"teacher_disagreement_score":0.052246865,"about_ca_system_score_codex":0.00006289185,"about_ca_system_score_gemma":0.00010578888,"threshold_uncertainty_score":0.3026732},"labels":[],"label_agreement":null},{"id":"W2121743767","doi":"10.1056/nejmoa1110557","title":"A Double-Blind, Placebo-Controlled Trial of Ruxolitinib for Myelofibrosis","year":2012,"lang":"en","type":"article","venue":"New England Journal of Medicine","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":2050,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"National Cancer Institute","keywords":"Ruxolitinib; Myelofibrosis; Janus kinase inhibitor; Placebo; Medicine; Janus kinase; Clinical trial; Janus kinase 2; Internal medicine; Double blind; Oncology; Pathology; Alternative medicine; Bone marrow; Receptor","score_opus":0.06223975921785737,"score_gpt":0.34868154807874013,"score_spread":0.2864417888608828,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2121743767","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97746694,0.0028500538,0.0006558604,0.010461618,0.0017416888,0.0031255218,0.0000074229497,0.000011223399,0.0036796562],"genre_scores_gemma":[0.98306644,0.00046348126,0.0019578417,0.00033905898,0.013132363,0.000106173924,0.0000151077165,0.000027185684,0.0008923615],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9975695,0.0000981431,0.0011968582,0.00013179236,0.0006451739,0.00035852913],"domain_scores_gemma":[0.9966873,0.0011966622,0.0008353077,0.00019453232,0.00046681202,0.0006194077],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0018545813,0.0002453973,0.0015787451,0.00029727168,0.000052922984,0.0000064942265,0.0000949078,0.000112123125,0.00038175844],"category_scores_gemma":[0.00085124245,0.00013617017,0.0003562644,0.0001478546,0.00008706431,0.00012107351,0.000013671825,0.00022841728,0.0000040710156],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.96280557,0.0009901702,0.0059576416,0.00009460775,0.00095916254,0.000018204595,0.001391642,0.0000034703744,0.0010562987,0.0012777847,0.006795826,0.01864962],"study_design_scores_gemma":[0.9462856,0.0137428455,0.00093087734,0.00049671106,0.001767191,0.00039840862,0.00016336868,0.000010568227,0.0041910606,0.00017736404,0.03173564,0.00010036195],"about_ca_topic_score_codex":0.00003801175,"about_ca_topic_score_gemma":0.000007528616,"teacher_disagreement_score":0.024939813,"about_ca_system_score_codex":0.000070411654,"about_ca_system_score_gemma":0.0003069913,"threshold_uncertainty_score":0.5552859},"labels":[],"label_agreement":null},{"id":"W2126532431","doi":"10.3324/haematol.2014.119545","title":"A pooled analysis of overall survival in COMFORT-I and COMFORT-II, 2 randomized phase III trials of ruxolitinib for the treatment of myelofibrosis","year":2015,"lang":"en","type":"article","venue":"Haematologica","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":253,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"National Cancer Institute; University of Texas MD Anderson Cancer Center","keywords":"Ruxolitinib; Medicine; Hazard ratio; Internal medicine; Myelofibrosis; Placebo; Survival analysis; Confidence interval; Crossover study; Proportional hazards model; Surgery; Pathology","score_opus":0.1259945300572344,"score_gpt":0.39007178443101137,"score_spread":0.26407725437377694,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2126532431","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99188477,0.0028060465,0.00030150294,0.00059372565,0.000050545023,0.003573129,0.00040969325,0.000011295095,0.00036929006],"genre_scores_gemma":[0.9960652,0.001676832,0.0011252962,0.000046739035,0.000016193067,0.00080267736,0.00018180539,0.000010031705,0.000075212],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99705535,0.00045930812,0.0016883506,0.0002775105,0.0002979438,0.00022154569],"domain_scores_gemma":[0.99324584,0.0050979354,0.00096326414,0.0003499198,0.0002207142,0.00012233706],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0020403108,0.0002578518,0.0050873416,0.00029081287,0.000050532326,0.0000064272454,0.00007583545,0.000115557785,0.00012321984],"category_scores_gemma":[0.0010355738,0.00012600237,0.0008786019,0.000353648,0.0003031916,0.000030057388,0.000031192227,0.000040579078,1.8939913e-7],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.67675847,0.02320636,0.18197092,0.0005704511,0.050214775,0.000085174586,0.011894346,0.00032686003,0.0014033405,0.04175377,0.000591236,0.011224299],"study_design_scores_gemma":[0.89753747,0.010121814,0.0126213385,0.00023597028,0.034513235,0.000021325865,0.0013609906,0.007119356,0.033833254,0.0013309593,0.0010433458,0.00026091287],"about_ca_topic_score_codex":0.00062298594,"about_ca_topic_score_gemma":0.00019420189,"teacher_disagreement_score":0.22077903,"about_ca_system_score_codex":0.000052961397,"about_ca_system_score_gemma":0.00010991532,"threshold_uncertainty_score":0.51382273},"labels":[],"label_agreement":null},{"id":"W2126593019","doi":"10.5858/2007-131-1719-topvtc","title":"Transformation of Polycythemia Vera to Chronic Myelogenous Leukemia","year":2007,"lang":"en","type":"article","venue":"Archives of Pathology & Laboratory Medicine","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":35,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"","keywords":"Polycythemia vera; Chronic myelogenous leukemia; Medicine; Leukemia; Bone marrow; Myeloproliferative Disorders; Fusion gene; Cancer research; Immunology; Internal medicine; Gastroenterology; Pathology; Biology; Genetics","score_opus":0.011426673238852837,"score_gpt":0.28342222861147975,"score_spread":0.27199555537262693,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2126593019","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98583144,0.0018000135,0.0025459367,0.001891122,0.00017144806,0.00064461457,0.000056577348,0.000032642747,0.007026181],"genre_scores_gemma":[0.9961021,0.0004014794,0.0022386897,0.00084597105,0.00022606312,0.000029248531,0.00006642854,0.000022928405,0.00006711483],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9982949,0.000083324376,0.00070224475,0.00027787956,0.00029976587,0.0003418928],"domain_scores_gemma":[0.99864197,0.00039408798,0.00020198151,0.0003737547,0.00014621351,0.0002420187],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004979883,0.0002222205,0.00071467535,0.00040419304,0.000054398497,0.0000010498071,0.00012250176,0.00010396614,0.00013022049],"category_scores_gemma":[0.00017855175,0.00016738879,0.0000818315,0.00036176216,0.0005308599,0.00004386574,0.000026859741,0.00019459602,0.000014480872],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0013218794,0.00033326633,0.036912292,0.00038831634,0.00021978881,0.0005579713,0.016005162,0.000023493993,0.9000744,0.0046246015,0.00032582547,0.039213],"study_design_scores_gemma":[0.0058841784,0.0073429835,0.3674443,0.0006605752,0.0003245675,0.00020958825,0.0009278954,0.000025329799,0.6110435,0.00022581297,0.0057261176,0.00018511552],"about_ca_topic_score_codex":0.000032494816,"about_ca_topic_score_gemma":0.00007618559,"teacher_disagreement_score":0.330532,"about_ca_system_score_codex":0.00014425526,"about_ca_system_score_gemma":0.00048525864,"threshold_uncertainty_score":0.6825917},"labels":[],"label_agreement":null},{"id":"W2126752501","doi":"10.1053/j.jvca.2009.01.031","title":"High Transoxygenator Pressure Gradient in a Patient With Polycythemia Vera","year":2009,"lang":"en","type":"article","venue":"Journal of Cardiothoracic and Vascular Anesthesia","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Foothills Medical Centre; Vancouver General Hospital","funders":"","keywords":"Polycythemia vera; Medicine; Thrombocytosis; Essential thrombocythemia; Leukocytosis; Myelofibrosis; Internal medicine; Polycythemia rubra vera; Polycythaemia; Gastroenterology; Ruxolitinib; Hematology; Myeloproliferative Disorders; Pathology; Bone marrow; Platelet","score_opus":0.005255235119026073,"score_gpt":0.2298458910871683,"score_spread":0.22459065596814223,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2126752501","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98837876,0.008947677,0.00020326313,0.0020357147,0.000021358583,0.00031640744,0.0000010574346,0.000007752479,0.00008801304],"genre_scores_gemma":[0.9963947,0.0013998006,0.0016240649,0.00043639835,0.00010065177,0.0000078478,0.0000019488305,0.000015307216,0.00001929402],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99868786,0.00009692644,0.00036454835,0.00018163977,0.0004647329,0.0002043014],"domain_scores_gemma":[0.9993071,0.000027878785,0.00014436347,0.00017273742,0.00013211559,0.00021580995],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00025270908,0.0002044326,0.0007134611,0.00015993838,0.000044489698,0.00002676308,0.000045950706,0.00008441698,0.000014259999],"category_scores_gemma":[0.000011497098,0.00012630445,0.00026444127,0.00015227181,0.000030077636,0.00010385243,0.0000028732045,0.00022867743,0.0000011022823],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.015343667,0.006642491,0.5453172,0.00087204523,0.009315255,0.076006114,0.015257445,0.0027374362,0.0039931107,0.0038960364,0.001570363,0.31904885],"study_design_scores_gemma":[0.008491129,0.009876705,0.9093888,0.0011101987,0.0021503614,0.02995833,0.0003864755,0.00006723566,0.01076951,0.00014956176,0.02723117,0.00042053382],"about_ca_topic_score_codex":0.000012706736,"about_ca_topic_score_gemma":0.0000017063858,"teacher_disagreement_score":0.3640716,"about_ca_system_score_codex":0.000057720597,"about_ca_system_score_gemma":0.00010393966,"threshold_uncertainty_score":0.51505464},"labels":[],"label_agreement":null},{"id":"W2127097590","doi":"10.1016/j.bbmt.2014.03.017","title":"Janus Kinase Inhibitors and Allogeneic Stem Cell Transplantation for Myelofibrosis","year":2014,"lang":"en","type":"review","venue":"Biology of Blood and Marrow Transplantation","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":21,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"National Cancer Institute; Medac; Incyte; Les Laboratories Pierre Fabre; Sanofi; Exelixis; Amgen; Ariad Pharmaceuticals; Gilead Sciences; Novartis; National Heart, Lung, and Blood Institute; Pfizer; Celgene; AstraZeneca; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Medicine; Myelofibrosis; Ruxolitinib; Transplantation; Context (archaeology); Janus kinase; Stem cell; Hematopoietic stem cell transplantation; Oncology; Internal medicine; Bone marrow","score_opus":0.023018239294073838,"score_gpt":0.28762640702049636,"score_spread":0.26460816772642254,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2127097590","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.033525467,0.96276987,0.00043802347,0.000055462573,0.00014219961,0.0019502777,0.0009968083,0.0000262493,0.00009566663],"genre_scores_gemma":[0.040785324,0.9547355,0.0011451782,0.000037045866,0.00010791685,0.00042404488,0.0026792327,0.0000354533,0.000050277602],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9983861,0.00014848784,0.00063971727,0.0005155726,0.000086912005,0.00022322177],"domain_scores_gemma":[0.99891424,0.00043889545,0.00032403422,0.00013022243,0.00006609968,0.000126524],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0001928971,0.00041149792,0.0014531362,0.00021626538,0.00008982557,0.000011125224,0.000044140863,0.00046509167,0.0000062812396],"category_scores_gemma":[0.0000041363433,0.00030950352,0.00025695495,0.00008016168,0.0001257045,0.000040246832,0.000005010478,0.00011412277,0.0000016111663],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00036984138,0.00029111924,0.0028509777,0.10922253,0.0007102085,0.000027069662,0.00040980396,2.1132266e-7,0.0045657726,0.00040265277,0.000027711176,0.8811221],"study_design_scores_gemma":[0.033962075,0.018516993,0.004840275,0.05502422,0.13609833,0.0030591507,0.0001697532,0.000015625707,0.13805391,0.00033137633,0.6069152,0.003013147],"about_ca_topic_score_codex":0.000023128792,"about_ca_topic_score_gemma":0.00002670508,"teacher_disagreement_score":0.878109,"about_ca_system_score_codex":0.000012560489,"about_ca_system_score_gemma":0.000089837784,"threshold_uncertainty_score":0.9999357},"labels":[],"label_agreement":null},{"id":"W2127116761","doi":"10.1007/s00247-004-1361-y","title":"Intracranial involvement in extramedullary hematopoiesis: case report and review of the literature","year":2004,"lang":"en","type":"review","venue":"Pediatric Radiology","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":34,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"SickKids Foundation; Hospital for Sick Children","funders":"","keywords":"Extramedullary hematopoiesis; Medicine; Headaches; Neuroradiology; Myelofibrosis; Radiology; Abdomen; Neurosurgery; Pathology; Neurology; Bone marrow; Surgery; Haematopoiesis","score_opus":0.021708443800472238,"score_gpt":0.3148856657487854,"score_spread":0.2931772219483132,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2127116761","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0017246875,0.99460113,0.0000011874007,0.0004842587,0.00034722086,0.0026792972,0.00005905049,0.000012942754,0.00009020586],"genre_scores_gemma":[0.00014849566,0.9979113,0.00031187787,0.000278184,0.000546374,0.0005622092,0.00016131261,0.000034370256,0.000045893765],"study_design_codex":"systematic_review","study_design_gemma":"case_report","domain_scores_codex":[0.997062,0.0003792426,0.0014567107,0.0005911597,0.00021370321,0.0002971575],"domain_scores_gemma":[0.99798286,0.00036327075,0.00078066404,0.0006438159,0.000102220605,0.00012719497],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00061967724,0.00047787864,0.002944023,0.00025213536,0.00005012625,0.000008819694,0.000123635,0.00047429756,0.000054462926],"category_scores_gemma":[0.0005290003,0.0002641676,0.0004742458,0.00073012535,0.00010996608,0.000029830722,0.000099802324,0.0006828084,0.000003900833],"study_design_candidate":"case_report","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000019724159,0.0005885143,0.008927828,0.6773706,0.00044393653,0.19978358,0.00030771294,2.0539295e-7,4.851462e-8,0.00032500387,0.0018776929,0.11035514],"study_design_scores_gemma":[0.0010526425,0.0002945452,0.00056094147,0.14553046,0.0049570687,0.7082841,0.000014590873,2.8473664e-7,5.5317986e-7,0.00009797474,0.13889776,0.00030908262],"about_ca_topic_score_codex":0.000038071754,"about_ca_topic_score_gemma":0.000024298204,"teacher_disagreement_score":0.53184015,"about_ca_system_score_codex":0.0002725439,"about_ca_system_score_gemma":0.001001976,"threshold_uncertainty_score":0.99998105},"labels":[],"label_agreement":null},{"id":"W2127139470","doi":"10.1073/pnas.0604902103","title":"Expression of TEL-JAK2 in primary human hematopoietic cells drives erythropoietin-independent erythropoiesis and induces myelofibrosis <i>in vivo</i>","year":2006,"lang":"en","type":"article","venue":"Proceedings of the National Academy of Sciences","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":32,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ontario Institute for Cancer Research; University of Toronto; University Health Network","funders":"National Cancer Institute; Terry Fox Foundation; Canadian Institutes of Health Research; Leukemia and Lymphoma Society; Genome Canada; Ontario Genomics; University Health Network; Ontario Genomics Institute","keywords":"Myelofibrosis; Haematopoiesis; Erythropoiesis; Erythropoietin receptor; Cancer research; Erythropoietin; Biology; Polycythemia vera; Nod; Immunology; Context (archaeology); Stem cell; Bone marrow; In vivo; Cell biology; Medicine; Internal medicine; Anemia; Endocrinology; Genetics","score_opus":0.019916625947236238,"score_gpt":0.2812956236517283,"score_spread":0.261378997704492,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2127139470","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9929936,0.00037599867,1.6763049e-7,0.0017340385,0.000011702997,0.00040202815,0.000014875252,0.0000061665237,0.004461406],"genre_scores_gemma":[0.9978298,0.00016791828,0.0017374111,0.000097627504,0.000034716926,0.000033545504,4.1755058e-7,0.0000067425985,0.00009182772],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9976668,0.000014165306,0.00062451005,0.00035020153,0.0011570931,0.00018724661],"domain_scores_gemma":[0.9991269,0.00016722805,0.00048871717,0.000015932286,0.00016215646,0.000039041548],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007138161,0.00016105357,0.00042457454,0.00034102128,0.00012102809,0.000016344567,0.00023912858,0.00011894084,0.000028796734],"category_scores_gemma":[0.00007695155,0.000104876104,0.00007942363,0.00061266054,0.000974617,0.0002769996,0.00014720736,0.00016149085,3.5184362e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000027274293,0.000371445,0.2364845,0.00022702607,0.000007331305,7.5728614e-8,0.0003453099,0.000016191656,0.75944704,0.002770324,0.0002622733,0.00004123201],"study_design_scores_gemma":[0.0005162456,0.000099178214,0.37960866,0.00052763853,0.000013646432,0.00000656733,0.00028243172,0.000008818462,0.61486965,0.003998425,0.0000106670805,0.00005807516],"about_ca_topic_score_codex":0.00007365643,"about_ca_topic_score_gemma":0.0000016395397,"teacher_disagreement_score":0.14457738,"about_ca_system_score_codex":0.00008080014,"about_ca_system_score_gemma":0.000048590417,"threshold_uncertainty_score":0.42767236},"labels":[],"label_agreement":null},{"id":"W2128759209","doi":"10.1016/j.thromres.2010.06.025","title":"Increased circulating procoagulant activity and thrombin generation in patients with myeloproliferative neoplasms","year":2010,"lang":"en","type":"article","venue":"Thrombosis Research","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":65,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Institute of Cancer Research; Institut National Du Cancer; Ligue Contre le Cancer","keywords":"Polycythemia vera; Thrombomodulin; Medicine; Thrombin generation; Essential thrombocythemia; Platelet-poor plasma; Coagulation; Internal medicine; Platelet; Gastroenterology; Thrombin; Thrombosis; Immunology","score_opus":0.06180590466389472,"score_gpt":0.35716333905039505,"score_spread":0.2953574343865003,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2128759209","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99582946,0.000023295925,0.000009390228,0.00066114345,0.000039879964,0.0023626126,0.00001629476,0.000036647853,0.001021272],"genre_scores_gemma":[0.9978617,0.00004386908,0.0012278784,0.000061878425,0.00011981114,0.00050002796,0.000105650724,0.000041380266,0.00003781889],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99716884,0.0003033132,0.00027521266,0.00067170116,0.000999055,0.00058185984],"domain_scores_gemma":[0.9984035,0.0002889794,0.000076052864,0.0003907178,0.0005610247,0.0002797259],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00087160215,0.00027459522,0.00052410574,0.00035166868,0.0003531803,0.000114585586,0.00008264866,0.00017418667,0.00019820462],"category_scores_gemma":[0.0003673157,0.00019731943,0.000038987346,0.00058342103,0.00028623763,0.00026685005,0.00009972739,0.00093638815,0.000031939453],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00033540098,0.0014701766,0.9033456,0.00006362887,0.00011460592,0.000018687184,0.0009246864,0.0000047033036,0.0903722,0.0007927466,0.00012533923,0.002432235],"study_design_scores_gemma":[0.0046182005,0.0012966559,0.931149,0.00009755226,0.000032236854,0.000012342701,0.00006811487,0.001885316,0.060546316,0.000073736504,0.000028943778,0.00019157444],"about_ca_topic_score_codex":0.0008244324,"about_ca_topic_score_gemma":0.002677672,"teacher_disagreement_score":0.029825881,"about_ca_system_score_codex":0.0001858217,"about_ca_system_score_gemma":0.00034466927,"threshold_uncertainty_score":0.80464524},"labels":[],"label_agreement":null},{"id":"W2132651778","doi":"10.1016/s1054-8807(03)00055-3","title":"Essential thrombocytosis causing a massive myocardial infarction","year":2003,"lang":"en","type":"article","venue":"Cardiovascular Pathology","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Ottawa","funders":"","keywords":"Thrombocytosis; Medicine; Myocardial infarction; Cardiology; Internal medicine; Infarction; Disease; Platelet","score_opus":0.016444675063178076,"score_gpt":0.2576584765220786,"score_spread":0.24121380145890056,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2132651778","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97474504,0.0050230674,0.0075615244,0.00033547802,0.0010441995,0.0007998127,0.000012142534,0.000102597005,0.010376135],"genre_scores_gemma":[0.99603593,0.0010787236,0.0017605086,0.00040928865,0.00036145045,0.00019981767,0.000046740566,0.000040249135,0.000067301444],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9979797,0.0004412049,0.00026596725,0.00055922574,0.0003593879,0.00039453112],"domain_scores_gemma":[0.99892324,0.000052547985,0.000060075352,0.00061973656,0.00018599402,0.00015840879],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004062718,0.00026217048,0.0008468247,0.0001436193,0.00017094072,0.000023630806,0.00003358724,0.00022326868,0.00017291929],"category_scores_gemma":[0.00023039855,0.00022889438,0.0010891558,0.00022244175,0.00013646319,0.00006938284,0.000032575088,0.00022069,0.00012639033],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.001108244,0.004158314,0.5785142,0.00072619773,0.08122442,0.054776054,0.007025056,0.005728931,0.11132069,0.038345873,0.0073041976,0.10976781],"study_design_scores_gemma":[0.02506548,0.0019398931,0.5473006,0.0002914703,0.015130768,0.029760472,0.0011527556,0.00015828795,0.18582204,0.0013430086,0.19025208,0.0017831363],"about_ca_topic_score_codex":0.000021377007,"about_ca_topic_score_gemma":0.0000034927377,"teacher_disagreement_score":0.18294787,"about_ca_system_score_codex":0.00017307038,"about_ca_system_score_gemma":0.00014909692,"threshold_uncertainty_score":0.9334042},"labels":[],"label_agreement":null},{"id":"W2138709799","doi":"10.1056/nejmoa1312542","title":"Somatic <i>CALR</i> Mutations in Myeloproliferative Neoplasms with Nonmutated <i>JAK2</i>","year":2013,"lang":"en","type":"article","venue":"New England Journal of Medicine","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":1737,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"NIHR Cambridge Biomedical Research Centre; Dipartimento di Medicina Sperimentale e Clinica, Università degli Studi di Firenze; Cambridge Institute for Medical Research, University of Cambridge; Medical Research Council; Canadian Institutes of Health Research; Associazione Italiana per la Ricerca sul Cancro; Università degli Studi di Firenze; Vlaamse regering; Leukemia and Lymphoma Society; University of Southampton; University of Salford Manchester; University Hospital Southampton NHS Foundation Trust; Cancer Research UK; Kay Kendall Leukaemia Fund; Wellcome Trust; KU Leuven; National Institute for Health and Care Research; Leukemia and Lymphoma Research","keywords":"Calreticulin; Myelofibrosis; Essential thrombocythemia; Janus kinase 2; Biology; Polycythemia vera; Exome sequencing; Mutation; Germline mutation; Frameshift mutation; Myeloproliferative neoplasm; Cancer research; Myeloproliferative Disorders; Myeloid leukemia; Germline; Myeloid; Genetics; Gene; Immunology; Endoplasmic reticulum; Bone marrow","score_opus":0.011980994047530702,"score_gpt":0.25440944841800295,"score_spread":0.24242845437047225,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2138709799","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9636116,0.00086536177,0.0005834202,0.03130169,0.00020990381,0.00082947244,0.0000028946038,0.000022165874,0.002573475],"genre_scores_gemma":[0.99191344,0.0003533787,0.0043849247,0.0016840355,0.0010168453,0.000046150424,0.000024316832,0.00003419155,0.0005427418],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9976643,0.00013248816,0.0009308353,0.00022658509,0.0006980088,0.00034782794],"domain_scores_gemma":[0.99772394,0.0005400364,0.00042931942,0.00020323243,0.0005467812,0.0005566808],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00041360737,0.00031861768,0.0009682373,0.0004147309,0.0000711662,0.000027232765,0.00010611151,0.00008688569,0.0008825829],"category_scores_gemma":[0.00036476334,0.00017358207,0.00007814438,0.0005276445,0.00016836141,0.00026927653,0.000015114603,0.0005169302,0.00005685035],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0039163744,0.0024318865,0.78036064,0.0003273998,0.0017819181,0.005825553,0.022680454,0.0011718377,0.012435878,0.0012660405,0.022784961,0.14501709],"study_design_scores_gemma":[0.40334842,0.028357083,0.49111396,0.007491855,0.0018625315,0.021705704,0.0044101365,0.0020188345,0.019353498,0.0065711234,0.012843357,0.00092350045],"about_ca_topic_score_codex":0.0003095886,"about_ca_topic_score_gemma":0.00026504986,"teacher_disagreement_score":0.39943203,"about_ca_system_score_codex":0.0001393797,"about_ca_system_score_gemma":0.00047398204,"threshold_uncertainty_score":0.9663664},"labels":[],"label_agreement":null},{"id":"W2142506642","doi":"10.1200/jco.2012.44.4489","title":"Effect of Ruxolitinib Therapy on Myelofibrosis-Related Symptoms and Other Patient-Reported Outcomes in COMFORT-I: A Randomized, Double-Blind, Placebo-Controlled Trial","year":2013,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":192,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ontario Institute for Cancer Research","funders":"Incyte; American Society of Clinical Oncology; Sanofi","keywords":"Ruxolitinib; Medicine; Myelofibrosis; Placebo; Quality of life (healthcare); Internal medicine; Physical therapy; Clinical trial; Randomized controlled trial; Bone marrow; Alternative medicine; Pathology","score_opus":0.063216412113048,"score_gpt":0.4266609432678403,"score_spread":0.3634445311547923,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2142506642","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9855899,0.00035449414,0.0000021885803,0.002238324,0.0009103692,0.008481663,0.000002359104,0.0000101942305,0.0024104933],"genre_scores_gemma":[0.99717665,0.00045276058,0.00012587539,0.0011956546,0.00020520043,0.00066055264,0.0000028806508,0.000028159497,0.00015227677],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9909469,0.0024754754,0.0054751877,0.00028781625,0.0005178312,0.00029678576],"domain_scores_gemma":[0.9727474,0.02243426,0.003934484,0.0002377752,0.00029764598,0.0003484217],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0064125606,0.0003405589,0.0067238114,0.00032050503,0.000034297394,0.000016742859,0.00009671381,0.0005650525,0.00040614264],"category_scores_gemma":[0.0043715364,0.00016861866,0.0013173851,0.00013278608,0.00033687623,0.00009023882,0.000027625385,0.0008000955,0.0000130552635],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.8145205,0.00457236,0.1479082,0.000016726768,0.003433068,0.000111345835,0.00017553761,0.000009027394,0.000020817268,0.00015773633,0.00010123725,0.028973486],"study_design_scores_gemma":[0.9001879,0.08093502,0.01665851,0.00018852278,0.0008630017,0.0000795253,0.000019771935,0.0000838306,0.00034791642,0.00014757886,0.00037375288,0.00011467799],"about_ca_topic_score_codex":0.00011836878,"about_ca_topic_score_gemma":0.0000151227405,"teacher_disagreement_score":0.1312497,"about_ca_system_score_codex":0.00009805093,"about_ca_system_score_gemma":0.00046666144,"threshold_uncertainty_score":0.68760693},"labels":[],"label_agreement":null},{"id":"W2143495581","doi":"10.5603/kp.2013.0049","title":"Thrombocytosis as a potential cause of a very late stent thrombosis in the left main coronary artery","year":2013,"lang":"en","type":"article","venue":"Kardiologia Polska","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Optech (Canada)","funders":"","keywords":"Medicine; Clopidogrel; TIMI; Cardiology; Percutaneous coronary intervention; Internal medicine; Myocardial infarction; Stent; Artery; Right coronary artery; Thrombosis; Conventional PCI; Coronary angiography","score_opus":0.026703161093932417,"score_gpt":0.27748983736069266,"score_spread":0.25078667626676027,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2143495581","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99091583,0.0003375244,0.00001660429,0.0043354016,0.00015818821,0.0014234419,0.000045046487,0.000039014234,0.0027289377],"genre_scores_gemma":[0.9965357,0.0006034479,0.00023446657,0.0019608736,0.00010426238,0.00030314957,0.000057977137,0.000023846978,0.00017626272],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9979677,0.00031863575,0.00048669204,0.00040309032,0.0003709913,0.0004528915],"domain_scores_gemma":[0.99882656,0.0002819761,0.00013026349,0.0005665234,0.000085889355,0.00010876326],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00032675418,0.00030315734,0.0007674587,0.00012778853,0.00008575432,0.000031180163,0.00019156115,0.00018223924,0.0007300792],"category_scores_gemma":[0.00008901395,0.00017876437,0.00028482437,0.00016176261,0.00020450827,0.00012010972,0.00009290221,0.00027830712,0.00035048573],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00023582023,0.0013216079,0.96493256,0.000091096765,0.0014839994,0.00093384023,0.0019883546,0.00009999084,0.014395804,0.0006653414,0.012186124,0.0016654825],"study_design_scores_gemma":[0.00192148,0.0012559041,0.9914115,0.00011858589,0.00030136236,0.0006537573,0.000920737,0.000063328764,0.0024592667,0.0005975169,0.0001220994,0.00017447968],"about_ca_topic_score_codex":0.00035328825,"about_ca_topic_score_gemma":0.00005587826,"teacher_disagreement_score":0.026478944,"about_ca_system_score_codex":0.00012909134,"about_ca_system_score_gemma":0.00012373431,"threshold_uncertainty_score":0.7993855},"labels":[],"label_agreement":null},{"id":"W2146142395","doi":"10.1056/nejmoa1412098","title":"Effect of Mutation Order on Myeloproliferative Neoplasms","year":2015,"lang":"en","type":"article","venue":"New England Journal of Medicine","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":575,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Canadian Institutes of Health Research; Cancer Research UK Cambridge Institute, University of Cambridge; National Institute for Health and Care Research; Cancer Research UK; Wellcome Trust","keywords":"Mutation; Myeloproliferative neoplasm; Progenitor cell; Janus kinase 2; Haematopoiesis; Essential thrombocythemia; Cancer research; Germline mutation; Polycythemia vera; Stem cell; Clonogenic assay; Medicine; Biology; Myeloid; Immunology; Myelofibrosis; Genetics; Cell culture; Bone marrow; Gene","score_opus":0.023865951811524053,"score_gpt":0.3214936602420776,"score_spread":0.29762770843055353,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2146142395","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9839008,0.0010886431,0.00044148922,0.010141191,0.00066305225,0.0004098025,0.000002732889,0.000010953435,0.0033413398],"genre_scores_gemma":[0.9958656,0.00020302812,0.0007390484,0.00053912326,0.002233638,0.0000061650708,0.000014437905,0.000020155532,0.00037883988],"study_design_codex":"design_other","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99789435,0.00026881203,0.00065533386,0.00015224257,0.0008539309,0.00017530994],"domain_scores_gemma":[0.99722594,0.00085456634,0.0004785664,0.00016064664,0.0007659199,0.00051433523],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013782347,0.00023447687,0.0009129338,0.0002827335,0.000030673895,0.000006094116,0.00007142827,0.00007998942,0.00017032384],"category_scores_gemma":[0.0022503461,0.00012328141,0.000091912196,0.00027592975,0.00009727666,0.00008257495,0.000010910693,0.00031086223,0.00001629404],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.043796543,0.0011160645,0.189539,0.00030657672,0.0018729883,0.0031963768,0.013788771,0.00094169506,0.00314643,0.001755656,0.05366693,0.68687296],"study_design_scores_gemma":[0.48627347,0.24916542,0.038206507,0.004065341,0.0025815736,0.008724701,0.0007524832,0.00054769986,0.18251982,0.0012833641,0.025445916,0.00043369632],"about_ca_topic_score_codex":0.0000541812,"about_ca_topic_score_gemma":0.000016202734,"teacher_disagreement_score":0.6864393,"about_ca_system_score_codex":0.00010937037,"about_ca_system_score_gemma":0.00038849784,"threshold_uncertainty_score":0.502727},"labels":[],"label_agreement":null},{"id":"W2146758637","doi":"10.1136/jcp.2007.054379","title":"Testing for JAK2 <sup>V617F</sup> mutation across specimen types yields concordant results","year":2008,"lang":"en","type":"letter","venue":"Journal of Clinical Pathology","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"","keywords":"Essential thrombocythemia; Polycythemia vera; Myelofibrosis; Bone marrow; Myeloproliferative Disorders; Medicine; Haematopoiesis; Pathology; Mutation; Myeloid; Biopsy; Internal medicine; Stem cell; Biology; Genetics; Gene","score_opus":0.15331672947257963,"score_gpt":0.4329790039287831,"score_spread":0.27966227445620345,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2146758637","genre_codex":"empirical","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.53529584,0.0009143217,0.0003020765,0.4571743,0.0023385268,0.0012813999,0.0004585221,0.000039673574,0.0021953334],"genre_scores_gemma":[0.19751565,0.0020912327,0.052869372,0.675464,0.06585225,0.00014813569,0.0008700687,0.0002656809,0.004923607],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9942816,0.00048615967,0.0035602457,0.000574458,0.0005298067,0.000567757],"domain_scores_gemma":[0.9846315,0.01056946,0.002786763,0.00039617947,0.0013851606,0.00023094435],"candidate_categories":["metaresearch","metaepi_narrow","research_integrity"],"consensus_categories":["research_integrity"],"category_scores_codex":[0.002168803,0.00043438625,0.0024042553,0.0001565418,0.00015326859,0.000031372594,0.00021801547,0.0015236719,0.00005194302],"category_scores_gemma":[0.01527328,0.00030521292,0.00089097384,0.00013821838,0.00034030605,0.00008403033,0.00006371086,0.0030356976,0.000061323466],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0028190352,0.0006607742,0.027973408,0.0001725196,0.0007869195,0.04365842,0.00061723666,0.00007422325,0.000030341082,0.0000091272605,0.9019462,0.021251822],"study_design_scores_gemma":[0.02204717,0.024356615,0.08414999,0.0011819322,0.0013940774,0.023416271,0.00014671928,0.00028820382,0.00020075525,0.00062341767,0.8416526,0.0005422807],"about_ca_topic_score_codex":0.000008536419,"about_ca_topic_score_gemma":0.000005217909,"teacher_disagreement_score":0.33778018,"about_ca_system_score_codex":0.00012337056,"about_ca_system_score_gemma":0.000674502,"threshold_uncertainty_score":0.99994},"labels":[],"label_agreement":null},{"id":"W2148900734","doi":"10.3899/jrheum.120305","title":"Dr. Mazzantini replies","year":2012,"lang":"en","type":"article","venue":"The Journal of Rheumatology","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Polymyalgia rheumatica; Medicine; Prednisolone; Methotrexate; Comorbidity; Glucocorticoid; Internal medicine; Surgery; Giant cell arteritis; Vasculitis; Disease","score_opus":0.025306036615834124,"score_gpt":0.29864157004529934,"score_spread":0.2733355334294652,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2148900734","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9850479,0.002901794,0.000085267835,0.009412253,0.00042758195,0.00009456863,8.204782e-7,0.000007836072,0.0020220145],"genre_scores_gemma":[0.9966404,0.00218316,0.00043908795,0.00038694916,0.00004037012,0.0000026526068,7.722159e-7,0.00001021808,0.000296388],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99907786,0.00012052197,0.00037566383,0.000044821172,0.00015895319,0.00022215607],"domain_scores_gemma":[0.99890417,0.00038138253,0.00029952556,0.0001810442,0.00011649775,0.0001173757],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006045867,0.00009700045,0.00039442774,0.00006876789,0.00006984348,0.0000044712974,0.00008209397,0.000052951877,0.00030771358],"category_scores_gemma":[0.00020867544,0.00004772203,0.00009602158,0.00006615723,0.00009199062,0.000070313654,0.000027249922,0.00019735922,0.00009906987],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00026991277,0.00024271636,0.97677565,0.000020630767,0.00025907112,0.000011462057,0.0010879668,0.0000010303537,0.00014720854,0.0045420877,0.015447419,0.0011948386],"study_design_scores_gemma":[0.005245866,0.0017825004,0.75179696,0.00041970322,0.00091153616,0.12275708,0.001690258,0.00001920214,0.011255821,0.0008348973,0.10306912,0.00021708783],"about_ca_topic_score_codex":0.000021946298,"about_ca_topic_score_gemma":0.0000052026016,"teacher_disagreement_score":0.22497873,"about_ca_system_score_codex":0.000021913867,"about_ca_system_score_gemma":0.00005924014,"threshold_uncertainty_score":0.3369248},"labels":[],"label_agreement":null},{"id":"W2152275695","doi":"10.1038/leu.2015.310","title":"Efficacy of ruxolitinib on hepatomegaly in patients with myelofibrosis","year":2015,"lang":"en","type":"letter","venue":"Leukemia","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"National Cancer Institute; University of Texas MD Anderson Cancer Center; National Institutes of Health; Incyte","keywords":"Ruxolitinib; Myelofibrosis; Medicine; Internal medicine; Hematology; Oncology; Intensive care medicine; Bone marrow","score_opus":0.01776370035701409,"score_gpt":0.2540666334176579,"score_spread":0.23630293306064382,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2152275695","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9555089,0.00007959424,6.850163e-7,0.03198241,0.00016090975,0.0019339271,0.00021089752,0.000046614892,0.010076073],"genre_scores_gemma":[0.7598041,0.0000424896,0.0005589357,0.2314994,0.001283296,0.0005748451,0.0034912443,0.00020245186,0.0025432017],"study_design_codex":"not_applicable","study_design_gemma":"observational","domain_scores_codex":[0.99741226,0.00008840547,0.00052330154,0.0005956564,0.0009279013,0.00045246157],"domain_scores_gemma":[0.9983614,0.00025837822,0.00029328393,0.0006662673,0.00027864095,0.00014204573],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00010067264,0.00050368253,0.001124724,0.0003636832,0.000025824225,0.000016737447,0.00013557338,0.0005920725,0.00013148636],"category_scores_gemma":[0.00010560703,0.00034816648,0.00015691292,0.00028350877,0.00009403578,0.00004405618,0.00004093733,0.0010746478,0.00014032242],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.001526334,0.00057704054,0.45021167,0.00029295817,0.0002670088,0.0003587837,0.00016519359,0.000009884825,0.0000014365805,0.000032121316,0.54402375,0.002533834],"study_design_scores_gemma":[0.019007552,0.0041284794,0.69450176,0.002336639,0.00032535143,0.00000644276,0.0000071724894,0.000008100507,0.00065776287,0.000025352567,0.27856088,0.0004345017],"about_ca_topic_score_codex":0.00022001515,"about_ca_topic_score_gemma":0.000014570816,"teacher_disagreement_score":0.26546285,"about_ca_system_score_codex":0.0014674398,"about_ca_system_score_gemma":0.00069614715,"threshold_uncertainty_score":0.99989706},"labels":[],"label_agreement":null},{"id":"W2154564841","doi":"10.1084/jem.20111694","title":"Genetic resistance to JAK2 enzymatic inhibitors is overcome by HSP90 inhibition","year":2012,"lang":"en","type":"article","venue":"The Journal of Experimental Medicine","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":162,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Pediatric Oncology Group","funders":"National Cancer Institute","keywords":"Janus kinase 2; Hsp90; Hsp90 inhibitor; Janus kinase; Cancer research; STAT5; Kinase; Protein kinase B; Biology; Heat shock protein; Signal transduction; Cell biology; Biochemistry","score_opus":0.018521875093958563,"score_gpt":0.30339319925608665,"score_spread":0.28487132416212807,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2154564841","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.95734614,0.028046528,0.000082467006,0.012150911,0.0004754538,0.0004725785,0.0000057556426,0.000009791272,0.001410385],"genre_scores_gemma":[0.9917562,0.0003974689,0.0007131084,0.0053575244,0.0011279081,0.000023217823,0.0000037176808,0.000026902373,0.0005939238],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9980603,0.0001176486,0.000670685,0.000112661844,0.0007297292,0.00030898832],"domain_scores_gemma":[0.99871635,0.00017221081,0.00030747158,0.00023815778,0.00011449111,0.00045132084],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00051266735,0.00022740493,0.0004930301,0.00013034146,0.00011153533,0.000007981555,0.00008973274,0.000053452633,0.00082178507],"category_scores_gemma":[0.0001064485,0.00012312272,0.000091805916,0.00021439671,0.00012624153,0.00013619942,0.00003812464,0.00020689113,0.00006324372],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0010516552,0.0012546537,0.018769586,0.000054968794,0.00024986998,0.00005285592,0.017271757,0.0000011986266,0.6419434,0.00013990575,0.3186482,0.00056195585],"study_design_scores_gemma":[0.0043376,0.0032304404,0.019281361,0.0013107229,0.0003312702,0.0006515976,0.0035236538,0.0000030559224,0.94962406,0.000054013894,0.017483423,0.00016877268],"about_ca_topic_score_codex":0.000020944906,"about_ca_topic_score_gemma":0.000001960756,"teacher_disagreement_score":0.30768067,"about_ca_system_score_codex":0.00029234623,"about_ca_system_score_gemma":0.000036687466,"threshold_uncertainty_score":0.899797},"labels":[],"label_agreement":null},{"id":"W2155971057","doi":"10.1016/j.clml.2015.09.001","title":"Effect of Red Blood Cell Transfusion Dependence on the Natural History of Myeloproliferative Neoplasm-Associated Myelofibrosis","year":2015,"lang":"en","type":"article","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":12,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Princess Margaret Cancer Centre","funders":"American Society of Hematology","keywords":"Medicine; Myelofibrosis; Myeloproliferative neoplasm; Natural history; Blood transfusion; Neoplasm; Internal medicine; Pathology; Bone marrow","score_opus":0.02921214319194814,"score_gpt":0.2926505366442652,"score_spread":0.26343839345231707,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2155971057","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9865511,0.0012484096,0.000005892949,0.00064719544,0.0010168626,0.0019131915,0.000043370328,0.00009075966,0.008483195],"genre_scores_gemma":[0.99646443,0.0004421052,0.00022771802,0.0006165247,0.00019252374,0.00029155854,0.00007414959,0.00007142694,0.0016195681],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9941506,0.0015042505,0.0017111446,0.0008764794,0.0012035891,0.0005539563],"domain_scores_gemma":[0.9916556,0.0053585833,0.0008799896,0.0009278592,0.0006767077,0.0005012644],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0023671119,0.0006437016,0.0018311586,0.00016833581,0.0001101588,0.000015715781,0.00040497616,0.000552394,0.00011226535],"category_scores_gemma":[0.0033805338,0.00039844724,0.000841762,0.00042929006,0.00067292014,0.0001257998,0.00011534976,0.0005551678,0.000068079076],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.035000667,0.009258863,0.55874306,0.0009908549,0.0038528563,0.0008639663,0.004315326,0.00008341922,0.049111396,0.0016401855,0.033899646,0.30223975],"study_design_scores_gemma":[0.022719638,0.018862698,0.6308115,0.0009222931,0.0015273796,0.00007635431,0.00013242027,0.00064367265,0.32176855,0.00009993972,0.0019304401,0.00050509325],"about_ca_topic_score_codex":0.00020292026,"about_ca_topic_score_gemma":0.00005533569,"teacher_disagreement_score":0.30173466,"about_ca_system_score_codex":0.0020096423,"about_ca_system_score_gemma":0.0026258454,"threshold_uncertainty_score":0.99984676},"labels":[],"label_agreement":null},{"id":"W2158156680","doi":"10.3324/haematol.2011.047811","title":"European Bone Marrow Working Group trial on reproducibility of World Health Organization criteria to discriminate essential thrombocythemia from prefibrotic primary myelofibrosis","year":2011,"lang":"en","type":"article","venue":"Haematologica","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":109,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; University Health Network","funders":"","keywords":"Myelofibrosis; Medicine; Essential thrombocythemia; Thrombocytosis; Bone marrow; Internal medicine; Pathology; Polycythemia vera; Platelet","score_opus":0.07262760918209814,"score_gpt":0.2989729651666889,"score_spread":0.22634535598459077,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2158156680","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98923045,0.00015083433,0.0002623908,0.0015268336,0.00035890503,0.0020331312,0.000032940734,0.00014663304,0.0062578525],"genre_scores_gemma":[0.9867098,0.000050331542,0.011755933,0.0008219063,0.00018229963,0.000076518045,0.00025372242,0.00005250717,0.0000970347],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9965688,0.0005251242,0.0008655512,0.0013359638,0.00034692948,0.00035765325],"domain_scores_gemma":[0.9976814,0.00017076202,0.0004055588,0.001378748,0.00012610189,0.00023747735],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00083501625,0.0003264515,0.0011119003,0.00015472216,0.0001578065,0.000029155324,0.00014830376,0.000073667434,0.0009323213],"category_scores_gemma":[0.00066123146,0.00023835717,0.00013510551,0.00047889812,0.00010105098,0.00007020713,0.00017882041,0.00016836388,0.0000955593],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.13973889,0.026023693,0.65560895,0.002755091,0.0014564339,0.0012144914,0.025320098,0.0000070921255,0.078854695,0.013430176,0.020262823,0.03532758],"study_design_scores_gemma":[0.012804236,0.004465329,0.85822177,0.0013411372,0.00027008553,0.00004609028,0.0001353605,0.0000044622916,0.12147406,0.0006581339,0.00022936211,0.00034995802],"about_ca_topic_score_codex":0.0001832913,"about_ca_topic_score_gemma":0.0000627635,"teacher_disagreement_score":0.20261285,"about_ca_system_score_codex":0.00016600195,"about_ca_system_score_gemma":0.00007708657,"threshold_uncertainty_score":0.999981},"labels":[],"label_agreement":null},{"id":"W2161021913","doi":"10.3324/haematol.2014.115840","title":"Efficacy, safety, and survival with ruxolitinib in patients with myelofibrosis: results of a median 3-year follow-up of COMFORT-I","year":2015,"lang":"en","type":"article","venue":"Haematologica","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":329,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"Stanford Cancer Institute; National Heart, Lung, and Blood Institute; University of Texas MD Anderson Cancer Center; Weill Cornell Medical College; University of California, Los Angeles; Monash University; Hollings Cancer Center, Medical University of South Carolina; Northwestern University; Incyte; NIH Clinical Center; Townsville Hospital and Health Service; Emory University; Huntsman Cancer Institute; University of Toronto; Tower Cancer Research Foundation; London Health Sciences Centre; Barbara Ann Karmanos Cancer Institute; Rush University; University of Louisville; Georgetown University; National Cancer Institute; Wake Forest University; Kaiser Permanente; Cleveland Clinic; George Washington University; University of Pennsylvania; Vanderbilt University; University of Southern California; Park Nicollet Foundation","keywords":"Ruxolitinib; Myelofibrosis; Medicine; Internal medicine; Oncology; Surgery; Bone marrow","score_opus":0.025920741236176364,"score_gpt":0.25619804275661573,"score_spread":0.23027730152043938,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2161021913","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99395883,0.00007313224,0.000007690863,0.00039388548,0.000036382113,0.00083622476,0.00009902887,0.000020628817,0.004574178],"genre_scores_gemma":[0.99788445,0.000061758066,0.0017868229,0.000032812546,0.000009205371,0.000035544723,0.000119426826,0.000016268725,0.00005368002],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.998366,0.00009325219,0.0005138778,0.00031845583,0.00046151906,0.00024688657],"domain_scores_gemma":[0.9987329,0.00024320882,0.00026303632,0.00029076007,0.00025501146,0.00021504826],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002471001,0.00021386347,0.0009332069,0.00011389812,0.000026303213,0.000005878685,0.000068888745,0.00009999642,0.000021281512],"category_scores_gemma":[0.00024457937,0.00012133138,0.000041753607,0.0002340451,0.00023188133,0.00004763173,0.00005050325,0.000105487896,0.0000043743244],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.024872076,0.0009852959,0.97097677,0.000103119586,0.00015219033,0.000086726446,0.0009409885,0.0000042220204,0.000003276826,0.0010447737,0.00017404913,0.00065653655],"study_design_scores_gemma":[0.047560323,0.0066100466,0.9425319,0.00071028847,0.00014156546,0.000033158605,0.00055401557,0.000008781849,0.0013836755,0.000048382717,0.00026928392,0.0001486013],"about_ca_topic_score_codex":0.00017233855,"about_ca_topic_score_gemma":0.0004300684,"teacher_disagreement_score":0.02844487,"about_ca_system_score_codex":0.000034975234,"about_ca_system_score_gemma":0.00012229086,"threshold_uncertainty_score":0.494775},"labels":[],"label_agreement":null},{"id":"W2162013503","doi":"10.1016/j.exphem.2006.11.012","title":"Polycythemia vera is not initiated by JAK2 mutation","year":2006,"lang":"en","type":"article","venue":"Experimental Hematology","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":199,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University","funders":"National Institute of Diabetes and Digestive and Kidney Diseases; National Cancer Institute; National Heart, Lung, and Blood Institute; National Institutes of Health; U.S. Department of Defense","keywords":"Polycythemia vera; Allele; Mutation; Somatic cell; Biology; Mutant; Erythropoietin; Haematopoiesis; Genetics; Mutation frequency; Germline mutation; Immunology; Stem cell; Gene","score_opus":0.01997845871133661,"score_gpt":0.3134519333722287,"score_spread":0.2934734746608921,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2162013503","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9825279,0.004252005,0.000035476376,0.0021622668,0.00015321918,0.00041055778,0.000036347963,0.000090227026,0.010331964],"genre_scores_gemma":[0.99577767,0.00001240989,0.000528304,0.0022532602,0.00006766646,0.00019156937,0.0003548814,0.000026587833,0.00078765565],"study_design_codex":"not_applicable","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9989078,0.000035964644,0.0002916177,0.000321619,0.00017805999,0.00026494486],"domain_scores_gemma":[0.99956477,0.0000592782,0.000077863704,0.00017255286,0.000035652563,0.00008988408],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00002915065,0.00020375584,0.00036268416,0.00006582816,0.000093041825,0.000013325534,0.000042488155,0.0001260236,0.0014796887],"category_scores_gemma":[0.000007583724,0.00017678006,0.00008243759,0.00009217696,0.00008599724,0.0000616982,0.000025982783,0.000092869144,0.00039579778],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0022569124,0.01017366,0.1534096,0.00013638087,0.00066274026,0.002651877,0.0035494461,0.0000021826015,0.3035296,0.13606472,0.3862597,0.0013031722],"study_design_scores_gemma":[0.003132341,0.00049097015,0.0030640578,0.000029269035,0.00003145962,0.00083121296,0.000219762,0.000056105207,0.9882038,0.00009280629,0.00370373,0.00014444649],"about_ca_topic_score_codex":0.00021582936,"about_ca_topic_score_gemma":0.0000063048938,"teacher_disagreement_score":0.68467426,"about_ca_system_score_codex":0.00013127648,"about_ca_system_score_gemma":0.000038028567,"threshold_uncertainty_score":0.9994331},"labels":[],"label_agreement":null},{"id":"W2170974745","doi":"10.3324/haematol.2014.118927","title":"Endogenous megakaryocytic colonies underline association between megakaryocytes and calreticulin mutations in essential thrombocythemia","year":2015,"lang":"en","type":"letter","venue":"Haematologica","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hotel Dieu Hospital","funders":"Université de Montpellier; Institut Gustave-Roussy; Centre National de la Recherche Scientifique; Institut National de la Santé et de la Recherche Médicale; Agence Nationale de la Recherche","keywords":"Calreticulin; Essential thrombocythemia; Myelofibrosis; Exon; Myeloproliferative Disorders; Mutation; Biology; Cancer research; Genetics; Polycythemia vera; Gene; Immunology","score_opus":0.05822365109552091,"score_gpt":0.2963325217382911,"score_spread":0.2381088706427702,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2170974745","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.6622666,0.0029513312,0.000025994565,0.32853535,0.00024745212,0.0022517275,0.0003245052,0.00019632523,0.0032006884],"genre_scores_gemma":[0.9529591,0.0006061386,0.00091820175,0.04038489,0.00097076735,0.0005017445,0.002883417,0.00007266632,0.00070308003],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.99688864,0.0003030022,0.000753118,0.00073171,0.0007001848,0.0006233215],"domain_scores_gemma":[0.99736595,0.0013808702,0.00045758672,0.00034010469,0.00029306015,0.0001624022],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00032973802,0.00056558196,0.0018031669,0.00028352364,0.00016214405,0.00008354423,0.00012676015,0.0012873642,0.00012927786],"category_scores_gemma":[0.00065761554,0.00043831312,0.0001685158,0.00027312,0.0001912205,0.00008005364,0.000104720486,0.0013119711,0.00010767192],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0002070103,0.00072335475,0.4947909,0.0012041096,0.003086559,0.016743131,0.0023725205,0.000026269747,0.000087796594,0.0006046174,0.4797408,0.00041293996],"study_design_scores_gemma":[0.059344333,0.01391619,0.28140947,0.0070522656,0.03470513,0.016536219,0.0027676472,0.0012613904,0.040842965,0.033074513,0.5003439,0.00874597],"about_ca_topic_score_codex":0.0002497398,"about_ca_topic_score_gemma":0.00015849812,"teacher_disagreement_score":0.29069248,"about_ca_system_score_codex":0.0010457892,"about_ca_system_score_gemma":0.000465871,"threshold_uncertainty_score":0.9998069},"labels":[],"label_agreement":null},{"id":"W2176736150","doi":"10.1016/j.bbmt.2015.10.005","title":"Outcomes of Allogeneic Hematopoietic Cell Transplantation in Patients with Myelofibrosis with Prior Exposure to Janus Kinase 1/2 Inhibitors","year":2015,"lang":"en","type":"article","venue":"Biology of Blood and Marrow Transplantation","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":142,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre; Princess Margaret Cancer Centre","funders":"National Cancer Institute; H. Lundbeck A/S; Juno Therapeutics; Incyte; CTI Biopharma; Agios Pharmaceuticals; Novavax; Karyopharm Therapeutics; MorphoSys; Celgene; Alexion Pharmaceuticals; Amgen; Ariad Pharmaceuticals; Teva Pharmaceutical Industries; Gilead Sciences; Sanofi; Spectrum Pharmaceuticals; Pfizer; AstraZeneca; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Medicine; Ruxolitinib; Myelofibrosis; Internal medicine; Adverse effect; Transplantation; International Prognostic Scoring System; Cytopenia; Hematopoietic stem cell transplantation; Gastroenterology; Calcineurin; Confidence interval; Oncology; Bone marrow; Myelodysplastic syndromes","score_opus":0.008503955860677247,"score_gpt":0.22242083012269084,"score_spread":0.21391687426201358,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2176736150","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9985584,0.00020217034,0.000085889784,0.00016748699,0.000028127955,0.0007603127,0.00011295471,0.000010146027,0.000074514384],"genre_scores_gemma":[0.9969968,0.00018869196,0.0023675296,0.000056960627,0.0000072908383,0.00006564504,0.00029518345,0.000012465768,0.0000094172065],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99908626,0.000055599572,0.00031364674,0.0002433807,0.00015488971,0.00014620116],"domain_scores_gemma":[0.9994856,0.000063543725,0.00011547301,0.00009796638,0.00012135557,0.00011604345],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00008724114,0.00017549789,0.0004143592,0.00016056892,0.0000208511,0.000002982007,0.000030504627,0.00009467966,0.000005598707],"category_scores_gemma":[0.0000053735075,0.00011473693,0.000030831423,0.00012648951,0.00007368922,0.000053829455,0.0000029110279,0.000051090934,0.0000010036343],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.002887826,0.0007993499,0.97903436,0.00047759112,0.000109884786,0.000022599592,0.002582368,0.000019842806,0.013032845,0.000035006007,0.000002271777,0.0009960429],"study_design_scores_gemma":[0.010704945,0.0056885784,0.7801731,0.00024353393,0.0005342398,0.0000155163,0.000117974865,3.4890618e-7,0.20240368,0.000010434132,0.000002643821,0.00010501024],"about_ca_topic_score_codex":0.00007911114,"about_ca_topic_score_gemma":0.00017139412,"teacher_disagreement_score":0.19886127,"about_ca_system_score_codex":0.000010924989,"about_ca_system_score_gemma":0.000060499253,"threshold_uncertainty_score":0.46788362},"labels":[],"label_agreement":null},{"id":"W218273434","doi":"10.1182/blood.v124.21.714.714","title":"Primary Analysis Results from an Open-Label Phase II Study of INCB039110, a Selective JAK1 Inhibitor, in Patients with Myelofibrosis","year":2014,"lang":"en","type":"article","venue":"Blood","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Alberta Cancer Foundation; University of British Columbia; St. Paul's Hospital; Princess Margaret Cancer Centre","funders":"","keywords":"Myelofibrosis; Medicine; Internal medicine; Ruxolitinib; Clinical endpoint; Polycythemia vera; Gastroenterology; Constitutional symptoms; Essential thrombocythemia; Anemia; Bone pain; Phases of clinical research; Extramedullary hematopoiesis; Abdominal pain; Bone marrow; Clinical trial; Disease; Haematopoiesis","score_opus":0.016291533542011793,"score_gpt":0.29013978478780006,"score_spread":0.27384825124578827,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W218273434","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9970253,0.000019629015,0.000006589642,0.000064183994,0.000020251337,0.0017965925,0.00025059542,0.000018805142,0.0007980569],"genre_scores_gemma":[0.9973994,0.000004657689,0.0014123211,0.000136542,0.000046445683,0.00021102576,0.00072546746,0.000027297488,0.000036853802],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9977331,0.00023575913,0.0005841661,0.0007166794,0.0004963659,0.0002338888],"domain_scores_gemma":[0.99845046,0.00016957405,0.00028651554,0.0006196464,0.00029739537,0.00017642893],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00025574892,0.00027864988,0.00094582414,0.00033006867,0.000112091155,0.00003156621,0.0001694013,0.000082249746,0.00002478865],"category_scores_gemma":[0.000114125476,0.00020261157,0.00004101454,0.0010637258,0.000039594244,0.00020454645,0.00016578285,0.00015354148,0.0000045918537],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.005944563,0.15205038,0.83289844,0.000011024299,0.0023186163,0.000015493919,0.0031233218,0.000007668915,0.00043432417,0.0000073222595,0.000045517387,0.0031433417],"study_design_scores_gemma":[0.14481229,0.052044515,0.79278886,0.00010057005,0.0030161836,3.679606e-7,0.00014544665,0.000054094085,0.006838766,0.000009167196,0.000015080456,0.00017463513],"about_ca_topic_score_codex":0.0023282615,"about_ca_topic_score_gemma":0.0032647431,"teacher_disagreement_score":0.13886772,"about_ca_system_score_codex":0.00008119691,"about_ca_system_score_gemma":0.000107728614,"threshold_uncertainty_score":0.826226},"labels":[],"label_agreement":null},{"id":"W2184990328","doi":"10.14740/jocmr2405w","title":"The Clinical Significance of IDH Mutations in Essential Thrombocythemia and Primary Myelofibrosis","year":2015,"lang":"en","type":"article","venue":"Journal of Clinical Medicine Research","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":14,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Medicine; Myelofibrosis; Essential thrombocythemia; Clinical significance; Primary (astronomy); Pathology; Internal medicine; Polycythemia vera","score_opus":0.3241612351385892,"score_gpt":0.5671299941982673,"score_spread":0.24296875905967807,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2184990328","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9620667,0.0032499447,0.00004633203,0.030675003,0.0004578066,0.0005371853,0.0000028472257,0.0000036625274,0.0029604887],"genre_scores_gemma":[0.98810995,0.008994352,0.0009757217,0.00021271282,0.0014752072,0.000017924383,0.0000030571703,0.000015454641,0.00019563956],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9934336,0.0014620738,0.0028635014,0.00025193568,0.0016635023,0.00032541496],"domain_scores_gemma":[0.9802378,0.01628201,0.0006780113,0.00031529122,0.0018066843,0.0006802193],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.02121859,0.00013409922,0.0012641075,0.00022684554,0.00008909654,0.000016329974,0.00021179797,0.00017620981,0.000041331317],"category_scores_gemma":[0.021811096,0.00006830777,0.00019887762,0.00048109793,0.0020739564,0.00009077976,0.00009916338,0.0014988916,0.0000066567413],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00375552,0.0015643608,0.910544,0.00011674375,0.0003569298,0.00028126172,0.00057024637,0.0000036037154,0.000442706,0.00078364444,0.017576795,0.064004235],"study_design_scores_gemma":[0.014188863,0.0120810345,0.9576576,0.0011882178,0.00020699,0.00015691778,0.0016431191,0.00010098718,0.0010786052,0.0032103169,0.008401825,0.00008554398],"about_ca_topic_score_codex":0.000060022627,"about_ca_topic_score_gemma":0.000037522983,"teacher_disagreement_score":0.063918695,"about_ca_system_score_codex":0.00009798714,"about_ca_system_score_gemma":0.0017534655,"threshold_uncertainty_score":0.9864286},"labels":[],"label_agreement":null},{"id":"W2191051211","doi":"10.1007/s11899-015-0296-8","title":"Myelofibrosis—When Do We Select Transplantation or Non-transplantation Therapeutic Options?","year":2015,"lang":"en","type":"review","venue":"Current Hematologic Malignancy Reports","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Medicine; Myelofibrosis; Transplantation; Ruxolitinib; Hematology; Internal medicine; Hematopoietic stem cell transplantation; Janus kinase; Oncology; Intensive care medicine; Disease; Bone marrow","score_opus":0.11694056028219584,"score_gpt":0.39379647031905823,"score_spread":0.2768559100368624,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2191051211","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00016933757,0.99188155,0.0006327026,0.00012911954,0.0012127175,0.0048792926,0.00014656511,0.00023450627,0.00071423926],"genre_scores_gemma":[0.0007703012,0.9919881,0.00094322866,0.000031431693,0.00022882044,0.0026440585,0.002840402,0.00011399194,0.0004396558],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9944998,0.0003347655,0.0022008754,0.0014101928,0.00087244174,0.00068194413],"domain_scores_gemma":[0.9966295,0.0002822543,0.0014432379,0.0008639542,0.0003855003,0.00039560173],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00056671485,0.0011801388,0.0036019438,0.0004516564,0.00020301554,0.00010816654,0.00016947591,0.0006272614,0.00054448575],"category_scores_gemma":[0.000058017806,0.0007368177,0.0008554251,0.0005956972,0.00010109418,0.00017695189,0.000029004044,0.0005861571,0.00017253424],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00020498963,0.0013126301,0.0015013015,0.09944886,0.0009691918,0.009335808,0.0006921481,0.0000013676524,0.0000028318884,0.00074464583,0.0041689663,0.88161725],"study_design_scores_gemma":[0.0012780642,0.00068449177,0.0001361771,0.071814924,0.010151558,0.046682417,0.000024822257,0.0000058896576,0.00013134805,0.0011841321,0.86692953,0.0009766408],"about_ca_topic_score_codex":0.000008845629,"about_ca_topic_score_gemma":0.0000086247055,"teacher_disagreement_score":0.8806406,"about_ca_system_score_codex":0.00038004736,"about_ca_system_score_gemma":0.001459809,"threshold_uncertainty_score":0.99950826},"labels":[],"label_agreement":null},{"id":"W2209063367","doi":"10.1182/blood.v124.21.712.712","title":"Phase 1b Dose-Escalation Study of Sonidegib (LDE225) in Combination with Ruxolitinib (INC424) in Patients with Myelofibrosis","year":2014,"lang":"en","type":"article","venue":"Blood","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":19,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Ruxolitinib; Medicine; Myelofibrosis; Internal medicine; Smoothened; Oncology; Gastroenterology; Bone marrow; Hedgehog signaling pathway","score_opus":0.009788318639597818,"score_gpt":0.2545714235835682,"score_spread":0.2447831049439704,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2209063367","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9975927,0.000010404117,0.000019012963,0.000089387024,0.000017122224,0.0016150658,0.0000069845705,0.000015469057,0.00063384813],"genre_scores_gemma":[0.99918944,0.0000034043173,0.0004074539,0.00003790442,0.00001789924,0.00021145862,0.00008429006,0.000022365914,0.00002580973],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.998617,0.0001118135,0.00036146757,0.00030354646,0.0004056736,0.00020051168],"domain_scores_gemma":[0.9992646,0.00009698896,0.00016483171,0.00023794326,0.000159889,0.00007575941],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00017142386,0.00018478924,0.00041815924,0.00022590661,0.000034647106,0.000012769824,0.000043631033,0.000055129993,0.000025354979],"category_scores_gemma":[0.00004809297,0.0001291244,0.000022783135,0.000341001,0.000033111955,0.00010852335,0.00001600977,0.00010813677,0.0000061864907],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0010213117,0.08492601,0.90912443,0.000045929224,0.00008140165,0.0000095415135,0.0010937314,0.000012298603,0.00004080338,0.00016712879,0.000005311852,0.003472084],"study_design_scores_gemma":[0.12876622,0.022323046,0.84575355,0.00027338087,0.0001732075,0.0000014641387,0.00018509592,0.00009183794,0.0022879427,0.000020910898,0.000011090716,0.000112222806],"about_ca_topic_score_codex":0.00024379032,"about_ca_topic_score_gemma":0.00096932444,"teacher_disagreement_score":0.12774491,"about_ca_system_score_codex":0.00005828397,"about_ca_system_score_gemma":0.000045297336,"threshold_uncertainty_score":0.526554},"labels":[],"label_agreement":null},{"id":"W2245424203","doi":"10.1200/jco.2009.27.15_suppl.7085","title":"Role of serum erythropoietin, erythropoietin-independent erythroid colony formation, and bone marrow assessment in the diagnosis of polycythemia vera in patients with JAK2 V617F mutation","year":2009,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"St. Paul's Hospital; University of British Columbia; BC Cancer Agency","funders":"","keywords":"Erythropoietin; Polycythemia vera; Medicine; Bone marrow; Hemoglobin; Internal medicine; Gastroenterology; Pathology","score_opus":0.025857141244275687,"score_gpt":0.3723206368833043,"score_spread":0.3464634956390286,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2245424203","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98510087,0.00039456907,0.000016939264,0.0131955985,0.000109777204,0.0006880921,0.000013355303,0.000002634507,0.0004781945],"genre_scores_gemma":[0.99585724,0.0010319205,0.0020338122,0.0009344107,0.00009156286,0.000023712084,0.000010770382,0.000010324293,0.0000062577533],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9957916,0.00056647224,0.002520699,0.00019782622,0.0006972525,0.00022610811],"domain_scores_gemma":[0.9954422,0.0015528587,0.002145474,0.00018999206,0.0005317724,0.00013771557],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0023425217,0.00019020967,0.0013830116,0.00022109976,0.000039014267,0.0000099665585,0.000113303126,0.00024916997,0.0000806312],"category_scores_gemma":[0.0006720457,0.00011349598,0.00017989764,0.0002556445,0.00021322515,0.00020415174,0.000028580775,0.00070039736,0.0000011669067],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.002678968,0.0072837314,0.94582516,0.000042497304,0.00012696255,0.00012707252,0.0010054206,0.00004383128,0.00003675164,0.00017583516,0.00038831856,0.04226547],"study_design_scores_gemma":[0.01658781,0.027272807,0.95244366,0.00032025573,0.00022189043,0.00011626878,0.0011794425,0.000062775136,0.0006911554,0.000471946,0.0005416906,0.000090315654],"about_ca_topic_score_codex":0.00004009705,"about_ca_topic_score_gemma":0.0002860732,"teacher_disagreement_score":0.042175155,"about_ca_system_score_codex":0.00023448863,"about_ca_system_score_gemma":0.0006125241,"threshold_uncertainty_score":0.46282318},"labels":[],"label_agreement":null},{"id":"W2268601368","doi":"10.6084/m9.figshare.1466941.v1","title":"Bleeding disorders study","year":2015,"lang":"en","type":"article","venue":"Figshare","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine","score_opus":0.08384974342962985,"score_gpt":0.33049423371407716,"score_spread":0.2466444902844473,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2268601368","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.6861794,0.0017104446,0.0000014741927,0.0039115036,0.00037098545,0.005870827,0.07139853,0.00059084455,0.22996601],"genre_scores_gemma":[0.9884825,0.0000023093555,0.00005451947,0.00020755213,0.00012656994,0.00046470144,0.01006254,0.000016140955,0.00058321864],"study_design_codex":"not_applicable","study_design_gemma":"observational","domain_scores_codex":[0.9993308,0.000016896092,0.0001035776,0.00018272722,0.0002197123,0.00014624636],"domain_scores_gemma":[0.9994874,0.000046823297,0.000030347328,0.0001546378,0.000094664974,0.000186155],"candidate_categories":["insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.00003241452,0.00010746571,0.00016191458,0.00004287906,0.000041920666,0.000021822983,0.000042584223,0.000031384665,0.052906275],"category_scores_gemma":[0.0004579416,0.00008065698,0.0000433486,0.00010824673,0.0000022679255,0.000052987765,0.00004312331,0.00007530541,0.0028801817],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000063746345,0.0015279278,0.21124575,0.00005696671,0.00017877958,0.00013514755,0.001791139,0.000009114177,0.000005046664,0.00001968051,0.77456295,0.0104037635],"study_design_scores_gemma":[0.009602731,0.004179068,0.6069758,0.001337391,0.00018120397,0.00004174002,0.0037837832,0.0002570043,0.0008733136,0.00010306072,0.37225163,0.00041330577],"about_ca_topic_score_codex":0.000010572198,"about_ca_topic_score_gemma":0.00003819043,"teacher_disagreement_score":0.40231133,"about_ca_system_score_codex":0.00006101393,"about_ca_system_score_gemma":0.000083128645,"threshold_uncertainty_score":0.9978962},"labels":[],"label_agreement":null},{"id":"W2275402064","doi":"10.1182/blood.v124.21.4583.4583","title":"Ruxolitinib Overcomes the Adverse Prognostic Effect of Anemia in Patients with Myelofibrosis (MF)","year":2014,"lang":"en","type":"article","venue":"Blood","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"St. Paul's Hospital; University of British Columbia","funders":"","keywords":"Ruxolitinib; Medicine; Myelofibrosis; Adverse effect; Internal medicine; Anemia; Proportional hazards model; International Prognostic Scoring System; Gastroenterology; Oncology; Bone marrow; Myelodysplastic syndromes","score_opus":0.003425780218566742,"score_gpt":0.20942185750895828,"score_spread":0.20599607729039154,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2275402064","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9971537,0.000055586952,0.0000018978353,0.00014211488,0.000028087217,0.0010951059,0.000013989687,0.000018575376,0.0014909601],"genre_scores_gemma":[0.9994134,0.000009890974,0.0001740117,0.0001028449,0.00003860708,0.00016960387,0.00003603714,0.000017907641,0.000037703823],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99895376,0.00013421808,0.0002098428,0.00020995956,0.0002829564,0.00020929101],"domain_scores_gemma":[0.99886245,0.0006290161,0.00009162957,0.0002795833,0.00006498245,0.00007233582],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00018177839,0.00017479622,0.00036843613,0.000061008315,0.00004009408,0.0000060562525,0.00006136132,0.00005183735,0.000053307736],"category_scores_gemma":[0.00025267966,0.00008673229,0.00006617705,0.00015829796,0.000068362904,0.00003742623,0.000025744075,0.00010118318,0.000018138706],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00034248136,0.0011146906,0.9962697,0.00014901966,0.000091806214,0.0000069830626,0.00014474605,0.0000026619668,0.000042133655,0.0001346709,0.00004627686,0.0016548261],"study_design_scores_gemma":[0.013249024,0.004467668,0.96683925,0.00034678177,0.00041858002,0.000004307508,0.000012928771,0.000007215413,0.014425901,0.000010585087,0.00013215168,0.00008559821],"about_ca_topic_score_codex":0.000035777783,"about_ca_topic_score_gemma":0.000018635244,"teacher_disagreement_score":0.029430445,"about_ca_system_score_codex":0.000021414176,"about_ca_system_score_gemma":0.000031118372,"threshold_uncertainty_score":0.353684},"labels":[],"label_agreement":null},{"id":"W2292390406","doi":"10.1182/blood.v122.21.4071.4071","title":"Baseline Characteristics and Symptom Burden in RESPONSE: A Randomized, Open-Label, Phase 3 Study of Ruxolitinib In Polycythemia Vera Patients Resistant to or Intolerant of Hydroxyurea","year":2013,"lang":"en","type":"article","venue":"Blood","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Phlebotomy; Medicine; Ruxolitinib; Polycythemia vera; Internal medicine; Hematocrit; Phases of clinical research; Myelofibrosis; Myeloproliferative neoplasm; Clinical trial; Gastroenterology; Surgery; Bone marrow","score_opus":0.022583394364637844,"score_gpt":0.31889456224638146,"score_spread":0.2963111678817436,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2292390406","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99379164,0.00009270548,0.000001967355,0.00050072774,0.00002707146,0.0053962898,0.000107226464,0.0000069353555,0.00007540983],"genre_scores_gemma":[0.9982701,0.000061856765,0.00047351152,0.00012555273,0.000025560677,0.00086575816,0.00004081136,0.000023188772,0.000113644],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99757046,0.0004742149,0.0010510847,0.0003564914,0.00030636293,0.00024136963],"domain_scores_gemma":[0.99808306,0.000939173,0.00024673686,0.00034539666,0.00021500744,0.00017063096],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00092315103,0.00023609828,0.0013283463,0.0002996733,0.00002549929,0.000026028825,0.0001271142,0.00006958473,0.00012328196],"category_scores_gemma":[0.001526238,0.00016216902,0.00003132978,0.00029748937,0.000056829933,0.00008148918,0.000139379,0.00012439158,0.0000052826013],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.6118291,0.06571976,0.2899391,0.00023930417,0.00051400554,0.0003141235,0.013019626,0.0000010761584,0.01410771,0.000039102066,0.00009960235,0.0041774805],"study_design_scores_gemma":[0.75685126,0.010307774,0.22457863,0.0009640576,0.00032877503,0.0000075262183,0.0006917328,0.00018114997,0.005816654,0.000013940964,0.000066980305,0.00019154069],"about_ca_topic_score_codex":0.0015456096,"about_ca_topic_score_gemma":0.00017881212,"teacher_disagreement_score":0.14502212,"about_ca_system_score_codex":0.000051562154,"about_ca_system_score_gemma":0.0001423438,"threshold_uncertainty_score":0.661306},"labels":[],"label_agreement":null},{"id":"W2294247703","doi":"10.1182/blood.v124.21.1859.1859","title":"Safety and Efficacy of Ruxolitinib in Patients with Low Platelets Enrolled in a Phase 3b Expanded-Access Study in Myelofibrosis (MF)","year":2014,"lang":"en","type":"article","venue":"Blood","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; St. Paul's Hospital; Princess Margaret Cancer Centre","funders":"","keywords":"Ruxolitinib; Medicine; Myelofibrosis; Tolerability; Internal medicine; Adverse effect; Clinical trial; Phases of clinical research; Clinical endpoint; Discontinuation; Placebo; Surgery; Bone marrow; Pathology","score_opus":0.010353132557740239,"score_gpt":0.28359723680859583,"score_spread":0.2732441042508556,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2294247703","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9974864,0.00005193666,0.0000022819659,0.000058117115,0.000016905733,0.002015548,0.000016836953,0.000011334677,0.00034061036],"genre_scores_gemma":[0.99956644,0.00003263072,0.00010395046,0.000053560543,0.000017459499,0.0001617492,0.000033957956,0.000020360814,0.000009878401],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9983988,0.00013817646,0.00053979945,0.00038608257,0.00027093783,0.00026621384],"domain_scores_gemma":[0.99920976,0.00025974022,0.0001266308,0.00024176328,0.000055094657,0.00010699222],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00024146118,0.00022130119,0.00075508014,0.0002797589,0.00002447903,0.000016660631,0.00007078865,0.00006699269,0.000036326015],"category_scores_gemma":[0.00013214293,0.00016157771,0.000031407355,0.0003326221,0.000041567833,0.00009128089,0.000054196338,0.00013791514,0.000001975358],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00463455,0.030562043,0.95914507,0.00007259585,0.000097002,0.000070201495,0.0015606605,0.000011884269,0.000056121746,0.000014637448,0.0000018920077,0.0037733456],"study_design_scores_gemma":[0.16114521,0.0042854836,0.8311298,0.00040467174,0.00007603244,0.0000026704058,0.00010715071,0.0000252018,0.0026868233,0.000006065143,0.000007907318,0.00012296576],"about_ca_topic_score_codex":0.00024971846,"about_ca_topic_score_gemma":0.00070492155,"teacher_disagreement_score":0.15651067,"about_ca_system_score_codex":0.00004394802,"about_ca_system_score_gemma":0.00005577323,"threshold_uncertainty_score":0.6588948},"labels":[],"label_agreement":null},{"id":"W2294536664","doi":"10.3109/10428194.2016.1146950","title":"Impact of ruxolitinib treatment on the hemoglobin dynamics and the negative prognosis of anemia in patients with myelofibrosis","year":2016,"lang":"en","type":"letter","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":38,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"St. Paul's Hospital; University of British Columbia","funders":"","keywords":"Myelofibrosis; Ruxolitinib; Medicine; Anemia; Hemoglobin; Internal medicine; Oncology; Bone marrow","score_opus":0.007914056492146979,"score_gpt":0.22774553025526542,"score_spread":0.21983147376311846,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2294536664","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96973526,0.00044217167,0.0000022841925,0.0229647,0.00007816945,0.0037495845,0.0011156752,0.000035939844,0.001876227],"genre_scores_gemma":[0.98161215,0.0012593457,0.00011736666,0.014411692,0.00034852306,0.0010180409,0.00046900343,0.00015528643,0.0006086017],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9953312,0.00048617,0.0011686485,0.0011224442,0.0009691366,0.0009223795],"domain_scores_gemma":[0.99448967,0.0027582196,0.0010729968,0.001088822,0.0003728162,0.00021747244],"candidate_categories":["metaepi_narrow"],"consensus_categories":["metaepi_narrow"],"category_scores_codex":[0.0003059684,0.0013264869,0.002361072,0.00038356337,0.00023032288,0.00007362951,0.00032038853,0.0008664607,0.00007187508],"category_scores_gemma":[0.0001570469,0.000557823,0.0005664933,0.0004995738,0.0016108287,0.00012594966,0.00014912005,0.00032948173,0.000007681557],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.017929867,0.0013934271,0.79107875,0.00093215966,0.004002605,0.00036687186,0.0029145826,0.000012655221,0.000026679096,0.002026061,0.028710216,0.15060611],"study_design_scores_gemma":[0.07994082,0.008509719,0.90021163,0.0034359586,0.0015242966,0.00014101643,0.0002000086,0.00037537407,0.002397103,0.00030188047,0.0021289696,0.0008332032],"about_ca_topic_score_codex":0.0036881955,"about_ca_topic_score_gemma":0.00013118572,"teacher_disagreement_score":0.1497729,"about_ca_system_score_codex":0.0109605845,"about_ca_system_score_gemma":0.0027419738,"threshold_uncertainty_score":0.9999486},"labels":[],"label_agreement":null},{"id":"W2313431637","doi":"10.1097/moh.0000000000000052","title":"Kit and Scl regulation of hematopoietic stem cells","year":2014,"lang":"en","type":"review","venue":"Current Opinion in Hematology","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":26,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute for Research in Immunology and Cancer; Montreal Clinical Research Institute; Université de Montréal","funders":"Canadian Institutes of Health Research; Health Research","keywords":"Stem cell; Haematopoiesis; Biology; Stem cell factor; Cancer research; Proto-Oncogene Proteins c-kit; Cell biology; Protein tyrosine phosphatase; Hematopoietic stem cell; Immunology; Signal transduction","score_opus":0.1031322513369175,"score_gpt":0.395106721421949,"score_spread":0.2919744700850315,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2313431637","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00017055954,0.9963604,0.000065573404,0.00007257831,0.0017987073,0.0014058785,0.000019860641,0.000019740277,0.000086672975],"genre_scores_gemma":[0.00083764,0.99837625,0.00010033457,0.000005246114,0.0001276702,0.00033123267,0.00015687082,0.00003480714,0.000029967969],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9977065,0.00024315943,0.0011093316,0.0005101942,0.00018917592,0.00024169247],"domain_scores_gemma":[0.99837655,0.00047095912,0.00057247013,0.00038967057,0.00007567065,0.00011465422],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00020989942,0.0003881996,0.0029083253,0.00036676743,0.000027814453,0.0000078234025,0.00007931516,0.00033621956,0.000081585815],"category_scores_gemma":[0.000029974279,0.00029327793,0.00024336192,0.00021685245,0.00011999841,0.000026624706,0.000075287455,0.0002856754,0.00005593152],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000023816809,0.0006187687,0.0035140573,0.24514562,0.00016394754,0.000004633106,0.00017607845,4.4690572e-7,7.474442e-7,0.029493064,0.0021984794,0.71866035],"study_design_scores_gemma":[0.0010888905,0.00022554224,0.00017936577,0.07228773,0.00037338224,0.0004616453,0.000013069308,0.000031006806,0.00008328873,0.00019904641,0.9248056,0.00025146393],"about_ca_topic_score_codex":0.00000274169,"about_ca_topic_score_gemma":9.834915e-7,"teacher_disagreement_score":0.92260706,"about_ca_system_score_codex":0.00008112259,"about_ca_system_score_gemma":0.0001556214,"threshold_uncertainty_score":0.99995196},"labels":[],"label_agreement":null},{"id":"W2316089822","doi":"10.1097/mbc.0000000000000446","title":"The impact of ruxolitinib on thrombosis in patients with polycythemia vera and myelofibrosis","year":2015,"lang":"en","type":"review","venue":"Blood Coagulation & Fibrinolysis","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":71,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University","funders":"","keywords":"Ruxolitinib; Myelofibrosis; Medicine; Polycythemia vera; Thrombosis; Internal medicine; Venous thrombosis; Confidence interval; Placebo; Relative risk; Gastroenterology; Surgery; Pathology","score_opus":0.03938946591631503,"score_gpt":0.34575189443647597,"score_spread":0.30636242852016093,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2316089822","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.3805555,0.61616415,7.320897e-7,0.000050842234,0.00003329816,0.0021923156,0.00023713973,0.00003096636,0.0007350607],"genre_scores_gemma":[0.21960276,0.77930516,0.000106626605,0.000010015046,0.00007229525,0.00024084336,0.00051002175,0.000073578354,0.00007867788],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9976151,0.00016686082,0.0007669313,0.00051486643,0.0005956773,0.00034056956],"domain_scores_gemma":[0.99795866,0.00041334593,0.00058463955,0.000620045,0.00024000359,0.00018328035],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00017947034,0.00056295533,0.0020801867,0.0003187785,0.0001098748,0.00005132687,0.000103859704,0.0002310191,0.000035116343],"category_scores_gemma":[0.000065749984,0.00029475676,0.00046067304,0.0005847636,0.00011244821,0.000073953044,0.00006323767,0.00022167728,0.0000127281955],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00044567822,0.0012686893,0.46092674,0.0016499618,0.0037189685,0.0000058801998,0.00018766224,0.000019362597,9.528663e-7,0.00017674638,0.00017220492,0.53142715],"study_design_scores_gemma":[0.006508661,0.004900645,0.9499703,0.011477989,0.0070579783,0.000016253063,0.000025425046,0.000016446245,0.00006374588,0.000027256152,0.019373808,0.0005614896],"about_ca_topic_score_codex":0.00020990537,"about_ca_topic_score_gemma":0.00001568826,"teacher_disagreement_score":0.53086567,"about_ca_system_score_codex":0.00026453077,"about_ca_system_score_gemma":0.00036118398,"threshold_uncertainty_score":0.99995047},"labels":[],"label_agreement":null},{"id":"W2317588514","doi":"10.1097/mbc.0000000000000473","title":"Postpartum haemorrhage in a woman with essential thrombocythemia carrying calreticulin mutation","year":2015,"lang":"en","type":"article","venue":"Blood Coagulation & Fibrinolysis","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Thrombosis and Atherosclerosis Research Institute","funders":"","keywords":"Essential thrombocythemia; Medicine; Pregnancy; Calreticulin; Obstetrics; Placental abruption; Platelet; Complication; Thrombosis; Plateletpheresis; Surgery; Internal medicine; Fetus; Biology","score_opus":0.02364332059070085,"score_gpt":0.27130927376907893,"score_spread":0.24766595317837808,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2317588514","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99618554,0.0002091459,0.00037779642,0.001116971,0.000048971917,0.0006515685,0.000009427755,0.00008543592,0.0013151155],"genre_scores_gemma":[0.99671537,0.00001447679,0.0024224855,0.00012947277,0.000125483,0.00013191644,0.00024117668,0.000031921416,0.00018772477],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99832505,0.00007575473,0.00037364074,0.00042653765,0.000504963,0.00029408277],"domain_scores_gemma":[0.9990507,0.000070980335,0.00014527238,0.0002983103,0.00022338175,0.00021136226],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00013263396,0.00024551433,0.0004716061,0.00022919386,0.00007530901,0.00005303776,0.00004975932,0.000100299534,0.000100175464],"category_scores_gemma":[0.00007428441,0.00020029873,0.00009071555,0.00048616,0.00005634109,0.00017194581,0.00003140145,0.00012737303,0.000048103735],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00086596934,0.0011152446,0.9784921,0.00012257328,0.0006125497,0.0012689179,0.0046731085,0.0040057525,0.0053457646,0.00058427843,0.00022770962,0.0026860377],"study_design_scores_gemma":[0.016178427,0.001730963,0.7869459,0.0004610494,0.0018629067,0.00084623887,0.0015256442,0.010099265,0.17944454,0.00014288494,0.00015711089,0.0006050994],"about_ca_topic_score_codex":0.0003399873,"about_ca_topic_score_gemma":0.00035505273,"teacher_disagreement_score":0.19154622,"about_ca_system_score_codex":0.00014719352,"about_ca_system_score_gemma":0.00018659835,"threshold_uncertainty_score":0.8167945},"labels":[],"label_agreement":null},{"id":"W23182984","doi":"10.1200/jco.2012.43.4589","title":"广东省中山市：“一号议案”推动农村卫生大发展","year":2008,"lang":"en","type":"article","venue":"中国医药指南","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"National Cancer Institute; Canadian Institutes of Health Research","keywords":"Computer science","score_opus":0.04178020504462482,"score_gpt":0.2736296065569402,"score_spread":0.23184940151231537,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W23182984","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.92861927,0.00056379463,0.000051245916,0.0027577807,0.00016987702,0.00033825767,0.000008158166,0.00010467695,0.06738692],"genre_scores_gemma":[0.9874156,0.00042945327,0.0012639763,0.0015676601,0.0002622444,0.00007972959,0.000031519783,0.000022098724,0.0089276815],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9990764,0.000020034247,0.00017514521,0.00024881779,0.00024047034,0.00023911466],"domain_scores_gemma":[0.9993754,0.000057622183,0.000037729897,0.00027990312,0.000070654896,0.00017867713],"candidate_categories":["insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.000050046165,0.00015301692,0.00027310607,0.000063751,0.00013239964,0.000007659812,0.000047071455,0.00006843103,0.0012188947],"category_scores_gemma":[0.00005050668,0.000113100505,0.00010757193,0.00012933945,0.000069427864,0.000048459275,0.000025020203,0.000117590746,0.0012467748],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00020959813,0.0014707107,0.85483474,0.00005880363,0.00032432948,0.0030704231,0.0011818644,0.0000056623453,0.0016915373,0.0042459792,0.12223456,0.010671765],"study_design_scores_gemma":[0.004303946,0.0010277173,0.68189454,0.00009827912,0.00014479055,0.0018096633,0.00007372647,0.000080522615,0.02775135,0.0002579006,0.28225058,0.0003070022],"about_ca_topic_score_codex":0.000039421433,"about_ca_topic_score_gemma":0.000010848469,"teacher_disagreement_score":0.17294024,"about_ca_system_score_codex":0.00006585525,"about_ca_system_score_gemma":0.00008891079,"threshold_uncertainty_score":0.9996941},"labels":[],"label_agreement":null},{"id":"W2320020197","doi":"10.1158/1538-7445.am2013-907","title":"Abstract 907: Efficacy of SAR302503, a JAK2 inhibitor, in primary human acute myeloid leukemia xenografts.","year":2013,"lang":"en","type":"article","venue":"Cancer Research","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network; BC Cancer Agency; Ontario Institute for Cancer Research","funders":"","keywords":"Medicine; Myeloid leukemia; Ruxolitinib; Transplantation; Leukemia; Myeloid; Stem cell; Bone marrow; Cancer research; Janus kinase 2; Myeloproliferative Disorders; Internal medicine; Pharmacology; Myelofibrosis; Biology; Receptor","score_opus":0.05848348975548139,"score_gpt":0.3956894276361967,"score_spread":0.3372059378807153,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2320020197","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98572016,0.0011782577,5.1680667e-7,0.0013811988,0.00009468749,0.0017558732,0.000025669486,0.000028575201,0.009815036],"genre_scores_gemma":[0.99560606,0.0012616497,0.00013522743,0.00018436289,0.00033577043,0.0011514144,0.00006511539,0.00004292361,0.0012174677],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9972899,0.00010908594,0.0005063091,0.0004942065,0.0009177563,0.0006827557],"domain_scores_gemma":[0.99836475,0.00030236263,0.000086961336,0.00049498025,0.00046193998,0.0002889847],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0005228962,0.00022583033,0.0005643991,0.00046813238,0.0001306745,0.000045945537,0.00019679968,0.00015740597,0.0018914059],"category_scores_gemma":[0.00009001403,0.00017799053,0.0001290242,0.00062875036,0.00029379985,0.0001493603,0.00014070161,0.0007409264,0.00024665208],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00086634094,0.0022061446,0.3130502,0.0008611245,0.0006474607,0.0003928878,0.0022993751,0.000023944063,0.56874526,0.0003984992,0.04973404,0.060774744],"study_design_scores_gemma":[0.0048186714,0.000755142,0.8524267,0.0006913157,0.000035960056,0.000007474574,0.00011255717,0.0000057199613,0.13814636,0.0000984526,0.002747348,0.00015427568],"about_ca_topic_score_codex":0.0050269878,"about_ca_topic_score_gemma":0.00035337504,"teacher_disagreement_score":0.53937656,"about_ca_system_score_codex":0.0014781716,"about_ca_system_score_gemma":0.0011181151,"threshold_uncertainty_score":0.999021},"labels":[],"label_agreement":null},{"id":"W2323647093","doi":"10.1136/annrheumdis-2014-eular.1808","title":"SAT0245 Decreased Use of Glucocorticoids in PTS with RA Who Initiated IV Abatacept and Previously Failed at Least One Biologic Agent: Results from the 2-Year Action Study","year":2014,"lang":"en","type":"article","venue":"Annals of the Rheumatic Diseases","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"St. Joseph’s Healthcare Hamilton; McMaster University; St. Joseph's Hospital","funders":"","keywords":"Medicine; Concomitant; Abatacept; Internal medicine; Surgery; Rituximab","score_opus":0.12985102030288045,"score_gpt":0.32204101857825984,"score_spread":0.1921899982753794,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2323647093","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99638706,0.0004681453,0.000006131492,0.0011255473,0.000030441157,0.0016995566,0.00022980596,0.000017993603,0.00003529786],"genre_scores_gemma":[0.99838036,0.001020066,0.000058659723,0.00023333133,0.000015086982,0.00011970346,0.000110069705,0.000016433512,0.000046285775],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9980566,0.0005347639,0.0005621522,0.00030139147,0.00034772512,0.00019738123],"domain_scores_gemma":[0.9972516,0.0014269396,0.00043370933,0.0006050972,0.00015059751,0.00013208325],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00027915696,0.00021550093,0.000601498,0.00005984363,0.00009515217,0.000028058528,0.000121296354,0.000044245917,0.00005867994],"category_scores_gemma":[0.0020117678,0.00010399417,0.000100599376,0.00020782526,0.00019225413,0.00010571132,0.00010018624,0.00007915856,0.0000056453237],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0039654947,0.0028601794,0.983292,0.00012866463,0.0007359259,0.0000055507967,0.0017482755,0.000055416283,0.000064038475,0.000036429206,0.00053479784,0.0065732454],"study_design_scores_gemma":[0.006294818,0.0013833985,0.98739827,0.0020284064,0.00050417683,0.0000017361126,0.0007312806,0.00033515523,0.0010655026,0.00012379729,0.000028114175,0.00010531862],"about_ca_topic_score_codex":0.0012838612,"about_ca_topic_score_gemma":0.00100459,"teacher_disagreement_score":0.006467927,"about_ca_system_score_codex":0.00002857973,"about_ca_system_score_gemma":0.00006667791,"threshold_uncertainty_score":0.4240759},"labels":[],"label_agreement":null},{"id":"W2326125948","doi":"10.1136/annrheumdis-2015-207259.116","title":"A5.10 Increases in serum cholesterol with baricitinib treatment are associated with favourable changes in apolipoprotein content and with improvement in DAS28-CRP in patients with rheumatoid arthritis","year":2015,"lang":"en","type":"article","venue":"Annals of the Rheumatic Diseases","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"","keywords":"Apolipoprotein B; Medicine; Internal medicine; Rheumatoid arthritis; Triglyceride; Endocrinology; Cholesterol; Apolipoprotein A1; Very low-density lipoprotein; Placebo; Lipoprotein; Pathology","score_opus":0.04040915596739722,"score_gpt":0.2509010163450564,"score_spread":0.21049186037765918,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2326125948","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9941103,0.0010695911,4.793766e-7,0.0014737247,0.000008220959,0.0030494838,0.00022053746,0.00001829179,0.000049401737],"genre_scores_gemma":[0.9976749,0.0008004998,0.000034915396,0.0002684565,0.0000038767494,0.0010306195,0.0000940563,0.000043223492,0.00004946702],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99767536,0.00020192111,0.0005354068,0.0004552821,0.00062738376,0.00050464366],"domain_scores_gemma":[0.99849415,0.0001630144,0.00045358104,0.00039560138,0.00022846047,0.0002651995],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00022118312,0.00045432177,0.0011018523,0.0003030096,0.000046825353,0.00004570531,0.00011081992,0.00006403176,0.000027989581],"category_scores_gemma":[0.00020446695,0.00023405583,0.000040105257,0.0005099984,0.00017643216,0.0001907761,0.00005382339,0.00012656412,0.0000013403095],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0034425375,0.006440761,0.9782365,0.00014585305,0.00030708156,0.00007328953,0.00093171786,0.00015490566,0.0000011666498,0.000012212989,0.000028808987,0.010225177],"study_design_scores_gemma":[0.029457835,0.008014133,0.9431892,0.016081156,0.000064712134,0.00000779128,0.0021816979,0.000090385474,0.0006039092,0.000036839185,0.000005560459,0.0002667969],"about_ca_topic_score_codex":0.008001202,"about_ca_topic_score_gemma":0.060764633,"teacher_disagreement_score":0.052763432,"about_ca_system_score_codex":0.00027641075,"about_ca_system_score_gemma":0.00025462566,"threshold_uncertainty_score":0.9986046},"labels":[],"label_agreement":null},{"id":"W2335372520","doi":"10.1093/neuonc/nou255.35","title":"ET-35 * PACRITINIB: A NOVEL JAK/STAT INHIBITOR WITH TRANSLATIONAL RELEVANCE FOR GBM","year":2014,"lang":"en","type":"article","venue":"Neuro-Oncology","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ontario Institute for Cancer Research; Hotchkiss Brain Institute; Ontario Brain Institute; University of Calgary","funders":"","keywords":"Ruxolitinib; STAT protein; Janus kinase; STAT3; JAK-STAT signaling pathway; stat; Cancer research; PTEN; Myelofibrosis; Medicine; Signal transduction; Biology; Pharmacology; PI3K/AKT/mTOR pathway; Oncology; Internal medicine; Tyrosine kinase; Receptor; Bone marrow","score_opus":0.028356472759601962,"score_gpt":0.3231796751110784,"score_spread":0.29482320235147647,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2335372520","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.84724396,0.00028563102,0.025164569,0.10144438,0.00096525555,0.003851649,0.00027824138,0.00024286445,0.02052345],"genre_scores_gemma":[0.9639931,0.00008969614,0.022741145,0.011557516,0.0005448871,0.0007633,0.00010888914,0.000056781155,0.00014472417],"study_design_codex":"bench_or_experimental","study_design_gemma":"not_applicable","domain_scores_codex":[0.9985627,0.0000921725,0.00030739346,0.00046794978,0.00023383851,0.0003359781],"domain_scores_gemma":[0.99729925,0.0020113585,0.00011045887,0.00021059063,0.00018901237,0.0001793525],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002040507,0.000226893,0.0004863422,0.00007617886,0.000107613945,0.000014740212,0.00005778925,0.00013917762,0.00008063812],"category_scores_gemma":[0.00037243374,0.00016980062,0.000102396574,0.00010856684,0.00011056715,0.00007762436,0.000014117448,0.00023315843,0.00002943343],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.014378362,0.010065297,0.08710397,0.0006878293,0.0007338194,0.0004617659,0.004382396,0.00034915472,0.51419204,0.10883144,0.040152162,0.21866174],"study_design_scores_gemma":[0.017779788,0.012032016,0.011614726,0.000113168666,0.000230728,0.00046458136,0.000077029516,0.0010080587,0.03307976,0.00045749175,0.9228777,0.00026490496],"about_ca_topic_score_codex":0.000009102716,"about_ca_topic_score_gemma":0.00018838682,"teacher_disagreement_score":0.8827256,"about_ca_system_score_codex":0.00008364055,"about_ca_system_score_gemma":0.0003417112,"threshold_uncertainty_score":0.69242686},"labels":[],"label_agreement":null},{"id":"W2336221715","doi":"10.1182/blood.v122.21.2964.2964","title":"Medical Complications In Patients With Myelofibrosis By Frequency Of Blood Transfusion and Iron Chelation Therapy","year":2013,"lang":"en","type":"article","venue":"Blood","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Group for Research in Decision Analysis","funders":"","keywords":"Medicine; Myelofibrosis; Incidence (geometry); Blood transfusion; Anemia; Myeloproliferative neoplasm; Internal medicine; Bone marrow","score_opus":0.006211802182032017,"score_gpt":0.21705327089185594,"score_spread":0.21084146870982393,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2336221715","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9969257,0.00047068286,0.000017840484,0.0011714881,0.0000067289416,0.0008803179,0.000018511153,0.000013137091,0.0004955951],"genre_scores_gemma":[0.99817854,0.0005596892,0.0007888755,0.00012805103,0.000009748253,0.0001877714,0.00012406678,0.000011609313,0.000011624206],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99916476,0.000030119121,0.00021999709,0.00019200082,0.00028220456,0.00011092968],"domain_scores_gemma":[0.999552,0.00005634003,0.00005673954,0.0001385668,0.0000915807,0.000104734165],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000046182875,0.00011097429,0.00020530581,0.00005628676,0.000036635054,0.000006484669,0.000032305186,0.0000794191,0.000266774],"category_scores_gemma":[0.00001717886,0.000074876916,0.000022448832,0.000115813404,0.00005806315,0.000068747904,0.000006261321,0.00007793879,0.000005318055],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000027903643,0.004138034,0.98445237,0.000024231225,0.00006985554,8.386393e-7,0.00023064365,1.0271112e-7,0.005018658,0.00009996805,0.000037293663,0.005900119],"study_design_scores_gemma":[0.011829333,0.001104382,0.9724967,0.00013974604,0.00010156984,0.000003427925,0.000014121674,0.000008816232,0.014169316,0.00004952078,0.000013657774,0.00006944937],"about_ca_topic_score_codex":0.00035075773,"about_ca_topic_score_gemma":0.00004405077,"teacher_disagreement_score":0.0119556915,"about_ca_system_score_codex":0.000008753124,"about_ca_system_score_gemma":0.000032194534,"threshold_uncertainty_score":0.30533922},"labels":[],"label_agreement":null},{"id":"W2336769806","doi":"10.1159/000384895","title":"Steroids and Hemophilia1","year":2015,"lang":"en","type":"book-chapter","venue":"Current studies in hematology and blood transfusion","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Montreal Children's Hospital; McGill University","funders":"","keywords":"Computer science","score_opus":0.12827533682052777,"score_gpt":0.37030268421184187,"score_spread":0.2420273473913141,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2336769806","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.26430246,0.70291317,0.0000061936807,0.0025416263,0.0011256672,0.0017527632,0.000059320486,0.00006340533,0.027235383],"genre_scores_gemma":[0.27371725,0.71322703,0.00018691429,0.00023014954,0.00029366466,0.0002618252,0.00012897381,0.000083668485,0.011870513],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.9985188,0.000028351273,0.00043859528,0.00059469836,0.00019001789,0.00022953427],"domain_scores_gemma":[0.9992809,0.00017635371,0.00008595633,0.0001919893,0.00012582306,0.00013893298],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00014715106,0.0004457027,0.0012625387,0.00018767061,0.00011635754,0.0000055251003,0.000036428926,0.00031199056,0.000048053626],"category_scores_gemma":[0.000033942313,0.0003311902,0.0000813601,0.00002845657,0.0004865854,0.000032008407,0.00009223156,0.00046789728,0.000009460503],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0021971336,0.0039502475,0.43788567,0.018093443,0.006615068,0.0044926433,0.013856115,7.7080244e-7,0.00006254041,0.35341713,0.014019569,0.14540967],"study_design_scores_gemma":[0.09664401,0.016548352,0.023725145,0.05180812,0.022899413,0.020733926,0.0019875616,0.000042850912,0.003081747,0.19392778,0.5629034,0.0056977044],"about_ca_topic_score_codex":0.0000027379037,"about_ca_topic_score_gemma":0.000070246315,"teacher_disagreement_score":0.5488838,"about_ca_system_score_codex":0.00003620792,"about_ca_system_score_gemma":0.000045996047,"threshold_uncertainty_score":0.999914},"labels":[],"label_agreement":null},{"id":"W2345645288","doi":"10.1038/leu.2015.233","title":"Indication and management of allogeneic stem cell transplantation in primary myelofibrosis: a consensus process by an EBMT/ELN international working group","year":2015,"lang":"en","type":"review","venue":"Leukemia","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":272,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Medicine; Transplantation; Myelofibrosis; Alemtuzumab; Stem cell; Hematopoietic stem cell transplantation; Internal medicine; Cytopenia; Oncology; Immunology; Bone marrow","score_opus":0.03782294263671929,"score_gpt":0.3153776842246661,"score_spread":0.2775547415879468,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2345645288","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.04013526,0.9549761,0.00003045538,0.000032156764,0.000103025865,0.0024505078,0.000115875184,0.000029687739,0.0021269643],"genre_scores_gemma":[0.018724993,0.977085,0.0006039014,0.000049392394,0.0000464393,0.000983538,0.0023428998,0.00004125802,0.00012259513],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9981171,0.00011830652,0.00067975593,0.0004999803,0.00040434982,0.0001804935],"domain_scores_gemma":[0.99909735,0.000064677915,0.00045308948,0.00020071017,0.00006408012,0.00012007958],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00027228118,0.0003333148,0.00096930354,0.00025242142,0.000027877591,0.000023972974,0.00012337475,0.00023128741,0.000011209163],"category_scores_gemma":[0.000001673946,0.00027562547,0.00008837009,0.00021407616,0.000051297502,0.00005576048,0.000026766862,0.00019746792,0.0000065512163],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00014932021,0.0003657792,0.0051833834,0.034316566,0.00037634966,0.00011815621,0.000550688,0.0000048333623,0.000012161685,0.000077791214,0.00013730486,0.9587077],"study_design_scores_gemma":[0.023011478,0.002665417,0.042063836,0.18640164,0.013372752,0.00083137664,0.001345784,0.00022562483,0.00088835246,0.00015844045,0.7265682,0.0024671066],"about_ca_topic_score_codex":0.000020741796,"about_ca_topic_score_gemma":0.00001316665,"teacher_disagreement_score":0.95624053,"about_ca_system_score_codex":0.0009567175,"about_ca_system_score_gemma":0.0003180229,"threshold_uncertainty_score":0.9999696},"labels":[],"label_agreement":null},{"id":"W2399733579","doi":"10.1186/s40164-016-0043-4","title":"Patient perspectives of a diagnosis of myeloproliferative neoplasm in a case control study","year":2015,"lang":"en","type":"article","venue":"Experimental Hematology and Oncology","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Queen's University; Queen's University Belfast; National Institute for Health and Care Research","keywords":"Medicine; Myeloproliferative neoplasm; Polycythemia vera; Essential thrombocythemia; Etiology; Internal medicine; Logistic regression; Myelofibrosis; Disease; Denial; Hematology; Medical record; Bone marrow","score_opus":0.026269811310591206,"score_gpt":0.3451570595030722,"score_spread":0.318887248192481,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2399733579","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9891557,0.0075345077,0.0000046670134,0.00046794888,0.000085995656,0.0016051421,0.00002294947,0.000010786091,0.0011122796],"genre_scores_gemma":[0.9983741,0.00005152313,0.0004945516,0.0001266611,0.000015466196,0.00091297337,0.000002425029,0.00001177049,0.000010532129],"study_design_codex":"observational","study_design_gemma":"qualitative","domain_scores_codex":[0.99839383,0.00035684012,0.00054972095,0.00034980028,0.00013763072,0.00021218056],"domain_scores_gemma":[0.998893,0.00042537978,0.00020581111,0.00015906375,0.00015108303,0.00016561642],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00019348042,0.00020645723,0.0010693033,0.00019392215,0.000039628674,0.0000022953461,0.000032758115,0.00015142211,0.00008822461],"category_scores_gemma":[0.00013517796,0.00016331991,0.00006545968,0.00013925633,0.00034172364,0.000052550367,0.000061037565,0.0001464889,0.0000034087327],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0022407442,0.013111448,0.8705785,0.000030697378,0.00034654402,0.00660735,0.10146648,0.000003373193,0.00019767704,0.003907066,0.000088747416,0.0014213504],"study_design_scores_gemma":[0.04229138,0.057292875,0.12310731,0.0001470764,0.00032256372,0.017537491,0.5676748,0.0001360213,0.19078289,0.00019686163,0.00017094852,0.00033973908],"about_ca_topic_score_codex":0.00023720959,"about_ca_topic_score_gemma":0.00039311705,"teacher_disagreement_score":0.7474712,"about_ca_system_score_codex":0.00020142399,"about_ca_system_score_gemma":0.00020836465,"threshold_uncertainty_score":0.66599923},"labels":[],"label_agreement":null},{"id":"W2401350370","doi":"10.18632/aging.100964","title":"SHIP prevents metastasis","year":2016,"lang":"en","type":"editorial","venue":"Aging","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Metastasis; Environmental science; Medicine; Internal medicine; Cancer","score_opus":0.018347490920618423,"score_gpt":0.3271608301484493,"score_spread":0.3088133392278309,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2401350370","genre_codex":"editorial","genre_gemma":"editorial","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"editorial","genre_consensus":"editorial","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0019904764,0.0020434805,0.000063562504,0.0014969993,0.9831135,0.0007457745,0.00029383294,0.00012379783,0.010128558],"genre_scores_gemma":[0.00827675,0.0011159886,0.0006029685,0.00017108924,0.9746514,0.000253494,0.00047610464,0.000093761686,0.01435842],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9980412,0.00007362052,0.00029977996,0.00051371916,0.00071668345,0.00035496417],"domain_scores_gemma":[0.99839926,0.00068481144,0.0001568011,0.00043294166,0.00014872078,0.00017749268],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00023517727,0.00035086847,0.0006647793,0.00013047774,0.00008659408,0.000037391706,0.000110505825,0.00030961554,0.000608551],"category_scores_gemma":[0.0004528523,0.0002270129,0.00023133033,0.00008070714,0.00003291893,0.0000622828,0.000075130854,0.00037464363,0.0004391773],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00003805878,0.00013718804,0.0026138204,0.00016289901,0.00067782856,0.00016910434,0.00007186214,5.2215224e-8,0.00002310988,0.0000429352,0.9801357,0.015927458],"study_design_scores_gemma":[0.0016849309,0.00017277885,0.00047093056,0.001341152,0.0007481519,0.0000066168122,0.000007569827,7.467515e-7,0.0016345526,0.00011965598,0.99359417,0.00021874503],"about_ca_topic_score_codex":0.000045334935,"about_ca_topic_score_gemma":0.000012677396,"teacher_disagreement_score":0.015708713,"about_ca_system_score_codex":0.00024191721,"about_ca_system_score_gemma":0.00028748863,"threshold_uncertainty_score":0.9257317},"labels":[],"label_agreement":null},{"id":"W2408677492","doi":"10.1177/014556130408300414","title":"Extramedullary Hematopoiesis Occurring as a Nasal Polyp in a Man with a Myeloproliferative Disorder","year":2004,"lang":"en","type":"article","venue":"Ear Nose & Throat Journal","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"St. Thomas Hospital","funders":"","keywords":"Extramedullary hematopoiesis; Medicine; Nasal polyps; Polypectomy; Stomach; Myeloproliferative Disorders; Pathology; Haematopoiesis; Dermatology; Cancer; Gastroenterology; Internal medicine; Stem cell","score_opus":0.006996655150618108,"score_gpt":0.2668359744176064,"score_spread":0.25983931926698833,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2408677492","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99056244,0.0019036409,0.0004410011,0.0043094913,0.00011954419,0.0006615864,0.000007246685,0.000048002265,0.0019470487],"genre_scores_gemma":[0.9921478,0.00049047073,0.0049576066,0.0017972462,0.00030109144,0.00009203096,0.00000816215,0.00006050019,0.00014510295],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99772775,0.00008961946,0.00049926864,0.00041835842,0.0006535532,0.000611457],"domain_scores_gemma":[0.99889326,0.00007641919,0.00018396864,0.00027030712,0.0001609141,0.00041513747],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00024296899,0.0004132787,0.000655438,0.00028598236,0.0003040879,0.000134497,0.00012255565,0.00012835114,0.00063580135],"category_scores_gemma":[0.00009883886,0.0002852995,0.0001718923,0.00036845123,0.00014269452,0.00029344857,0.000051725103,0.00080143235,0.00019429288],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0017505606,0.0032295445,0.95924205,0.00010283546,0.00084139634,0.012360898,0.013318327,0.00042308006,0.00050824496,0.00271989,0.0003764958,0.0051267073],"study_design_scores_gemma":[0.040245805,0.007969,0.8703712,0.0047168853,0.0005594737,0.040824376,0.008407258,0.000083896186,0.015773607,0.003975921,0.005706595,0.0013659812],"about_ca_topic_score_codex":0.00019253104,"about_ca_topic_score_gemma":0.0004956603,"teacher_disagreement_score":0.08887082,"about_ca_system_score_codex":0.00044356432,"about_ca_system_score_gemma":0.0006868086,"threshold_uncertainty_score":0.99995995},"labels":[],"label_agreement":null},{"id":"W2417685891","doi":"10.1182/blood-2015-09-671172","title":"Activation of the thrombopoietin receptor by mutant calreticulin in CALR-mutant myeloproliferative neoplasms","year":2016,"lang":"en","type":"article","venue":"Blood","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":281,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Aging","funders":"Division of Human Resource Development; Ministry of Education, Culture, Sports, Science and Technology","keywords":"Calreticulin; Thrombopoietin; Thrombopoietin receptor; Mutant; Megakaryocyte; Cancer research; Janus kinase 2; Phosphorylation; Mutation; Receptor; Biology; Molecular biology; Cell biology; Genetics; Haematopoiesis; Gene; Stem cell","score_opus":0.00973414097659781,"score_gpt":0.23880471385706328,"score_spread":0.22907057288046548,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2417685891","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98935694,0.00013663265,0.000050477687,0.008453172,0.00011328896,0.0010531455,0.0001122178,0.000028015585,0.00069610204],"genre_scores_gemma":[0.9984473,0.0002664231,0.00032482127,0.0003182253,0.00007893444,0.0001981731,0.000019171908,0.000028935572,0.00031803388],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9981815,0.00015933478,0.0005041776,0.00040225714,0.00043367883,0.00031903034],"domain_scores_gemma":[0.9988195,0.0003132338,0.00020861927,0.00038635862,0.00015583487,0.00011647471],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00020079261,0.00026375582,0.0004917415,0.0000720593,0.00007774217,0.000011059614,0.00012138553,0.00015117484,0.0005052186],"category_scores_gemma":[0.00039414334,0.00012859008,0.000129908,0.00032294585,0.00016347166,0.00008580375,0.000060263097,0.00017494839,0.000059048114],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00027742618,0.0027312397,0.2247529,0.00004941712,0.0002569536,0.000015385804,0.0012202989,0.0000016585386,0.76558185,0.0014486008,0.0014143046,0.002249971],"study_design_scores_gemma":[0.0067248647,0.0005384239,0.062975295,0.0005999231,0.00011406044,0.000023277444,0.00014637211,0.000010056127,0.9271166,0.00014706049,0.0014463194,0.00015774931],"about_ca_topic_score_codex":0.00009615197,"about_ca_topic_score_gemma":0.00007002417,"teacher_disagreement_score":0.16177762,"about_ca_system_score_codex":0.00014542906,"about_ca_system_score_gemma":0.0002071749,"threshold_uncertainty_score":0.5531789},"labels":[],"label_agreement":null},{"id":"W2418937816","doi":"10.3324/haematol.2016.143677","title":"Safety and efficacy of ruxolitinib in an open-label, multicenter, single-arm phase 3b expanded-access study in patients with myelofibrosis: a snapshot of 1144 patients in the JUMP trial","year":2016,"lang":"en","type":"article","venue":"Haematologica","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":158,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; St. Paul's Hospital; University of British Columbia","funders":"","keywords":"Ruxolitinib; Myelofibrosis; Medicine; Open label; Snapshot (computer storage); Oncology; Internal medicine; Clinical trial; Phases of clinical research; Bone marrow; Computer science","score_opus":0.08403487765658953,"score_gpt":0.3716524044608081,"score_spread":0.2876175268042186,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2418937816","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9929414,0.000034182747,0.0000017207161,0.0001302136,0.000047781807,0.0066105067,0.000063930245,0.0000072204184,0.00016308176],"genre_scores_gemma":[0.9992145,0.000037415404,0.00014141973,0.00008500392,0.00000801836,0.0004274425,0.0000689041,0.00001486269,0.0000024809435],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9973664,0.00050364615,0.00094112154,0.0004952954,0.00038687023,0.00030663828],"domain_scores_gemma":[0.99845827,0.00051223295,0.00037699495,0.00041507187,0.00014499662,0.00009246709],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003926274,0.00027253,0.00103926,0.00020343547,0.00004300961,0.000032157823,0.00031296696,0.00008812783,0.00007494278],"category_scores_gemma":[0.0003461734,0.00012879049,0.000027192375,0.0003311593,0.00014597556,0.0002592885,0.00017558584,0.00011546969,0.0000010052354],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.09324611,0.11287243,0.78703237,0.000048320682,0.00004505996,0.00004963908,0.0020087848,3.0321223e-7,0.00003624918,0.000043792945,0.000009091007,0.004607868],"study_design_scores_gemma":[0.3047995,0.029969836,0.663419,0.0005923272,0.000053123124,0.0000015606721,0.00037716355,0.00000414376,0.0006588114,0.000011027234,0.000007205577,0.000106269516],"about_ca_topic_score_codex":0.00019676768,"about_ca_topic_score_gemma":0.00071392197,"teacher_disagreement_score":0.2115534,"about_ca_system_score_codex":0.000071530136,"about_ca_system_score_gemma":0.000050254814,"threshold_uncertainty_score":0.5251924},"labels":[],"label_agreement":null},{"id":"W2461719129","doi":"10.1182/blood.v122.21.5248.5248","title":"Barriers To Diagnosis In Myeloproliferative Neoplasms","year":2013,"lang":"en","type":"article","venue":"Blood","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"St. Paul's Hospital; University of British Columbia","funders":"","keywords":"Medicine; Referral; Polycythemia vera; Abnormality; Demographics; Pediatrics; Internal medicine; Myelofibrosis; Essential thrombocythemia; Surgery; Family medicine; Bone marrow","score_opus":0.010305858376697664,"score_gpt":0.25086316624792243,"score_spread":0.24055730787122476,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2461719129","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98475087,0.0002802115,0.00000811941,0.0076911952,0.00009604644,0.001940184,0.000015094837,0.000068390764,0.0051499135],"genre_scores_gemma":[0.9884963,0.0001772701,0.002493168,0.0039278767,0.00012953472,0.0042126235,0.000015850394,0.00003603838,0.0005113465],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99833006,0.00006445785,0.00035483288,0.0004837906,0.00029855754,0.00046829175],"domain_scores_gemma":[0.99847454,0.00017638519,0.000048394337,0.0003314697,0.00014325426,0.00082595606],"candidate_categories":["insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.00010756421,0.00028352733,0.0004795645,0.00023778243,0.00009407551,0.000056791643,0.00009342251,0.000111501155,0.002835133],"category_scores_gemma":[0.0004862161,0.00022492469,0.00010148917,0.00043389847,0.000040819912,0.00013662971,0.00005848758,0.00018950694,0.0013443392],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0000413723,0.0008926769,0.9893553,0.000024252102,0.00016281962,0.00014916687,0.0013476342,0.000010538263,0.0006005147,0.00062916346,0.0044477195,0.0023388274],"study_design_scores_gemma":[0.007237413,0.0014269197,0.8878174,0.00024142656,0.00017496473,0.00007465565,0.0005472173,0.000047742193,0.09729237,0.00035568196,0.004394678,0.00038954173],"about_ca_topic_score_codex":0.0003398259,"about_ca_topic_score_gemma":0.00025404608,"teacher_disagreement_score":0.10153793,"about_ca_system_score_codex":0.000093255316,"about_ca_system_score_gemma":0.00018885148,"threshold_uncertainty_score":0.9994332},"labels":[],"label_agreement":null},{"id":"W2463828088","doi":"10.1182/blood.v122.21.108.108","title":"Update On The Long-Term Efficacy and Safety Of Momelotinib, a JAK1 and JAK2 Inhibitor, For The Treatment Of Myelofibrosis","year":2013,"lang":"en","type":"article","venue":"Blood","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":44,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Jewish General Hospital; Princess Margaret Cancer Centre","funders":"","keywords":"Myelofibrosis; Medicine; Anemia; Internal medicine; Phases of clinical research; Gastroenterology; Constitutional symptoms; Clinical trial; Surgery; Disease; Bone marrow","score_opus":0.019062296254904982,"score_gpt":0.26169491538944334,"score_spread":0.24263261913453835,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2463828088","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99224514,0.0016775395,0.000006884816,0.003503923,0.00003211245,0.002299445,0.00006232655,0.0000072435696,0.0001653719],"genre_scores_gemma":[0.99537975,0.0035853698,0.00021549135,0.00013502387,0.00007121481,0.00045839598,0.000015167957,0.000015647696,0.00012391634],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.999206,0.000033932392,0.00026423947,0.00020660284,0.00013826379,0.00015094942],"domain_scores_gemma":[0.9985741,0.0008756373,0.000114286115,0.00028458628,0.00008101735,0.00007037982],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00008415363,0.00017358297,0.0003470998,0.00003553478,0.000105619154,0.000016159638,0.00004214918,0.00004817409,0.0001014315],"category_scores_gemma":[0.00004374173,0.000076555574,0.0000841352,0.00006465627,0.00013646416,0.000025909794,0.00002062526,0.000037261274,0.0000069267016],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0015188435,0.011828944,0.88294566,0.00031429794,0.0027094553,0.000008752771,0.0027088623,0.0000025933316,0.009231295,0.0031076306,0.0006642909,0.08495939],"study_design_scores_gemma":[0.01019258,0.0043353476,0.84404767,0.0001702753,0.00072674896,0.000013090014,0.00006177403,0.000016020986,0.1396507,0.00003442114,0.00067714084,0.00007426181],"about_ca_topic_score_codex":0.000051918814,"about_ca_topic_score_gemma":0.000022268034,"teacher_disagreement_score":0.1304194,"about_ca_system_score_codex":0.000014778549,"about_ca_system_score_gemma":0.000024898798,"threshold_uncertainty_score":0.31218457},"labels":[],"label_agreement":null},{"id":"W2464396699","doi":"10.1080/17474086.2016.1208555","title":"Hematological disorders: a commonly unrecognized cause of acute stroke","year":2016,"lang":"en","type":"review","venue":"Expert Review of Hematology","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":88,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Heart and Stroke Foundation of Canada; American Heart Association","keywords":"Medicine; Stroke (engine); Etiology; Disease; Intensive care medicine; Venous thrombosis; Complication; Thrombosis; Pediatrics; Vascular disease; Internal medicine","score_opus":0.04934048004836651,"score_gpt":0.40804430130253555,"score_spread":0.35870382125416905,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2464396699","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000011754191,0.99283856,0.000045612534,0.0014761571,0.00024372514,0.0034119645,0.00030008046,0.000046247562,0.0016258719],"genre_scores_gemma":[0.000017849115,0.99565715,0.0017396712,0.000549241,0.00006672113,0.0014061091,0.0002906093,0.00007653833,0.00019610899],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99511874,0.00064398354,0.0025905077,0.0007456667,0.0004109311,0.00049020315],"domain_scores_gemma":[0.99546415,0.0012747255,0.0016622622,0.0011172041,0.0002492414,0.00023243696],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0003308914,0.00086681126,0.011781835,0.00024994634,0.000044820805,0.0000040768805,0.0003616366,0.00059147534,0.0017116835],"category_scores_gemma":[0.0004686552,0.0004548414,0.0020917878,0.0002882693,0.00039112996,0.000045964098,0.00020184652,0.0003555016,0.00020768697],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00006879657,0.0014961928,0.0003295727,0.29247555,0.0057890886,0.0003927827,0.00004627177,3.779834e-10,0.0000015198926,0.006121947,0.01860889,0.6746694],"study_design_scores_gemma":[0.001038297,0.0005194149,0.0000036662514,0.27682576,0.0033508597,0.0026397852,0.0000051512575,9.851532e-8,0.00008359859,0.00004471584,0.7152117,0.0002769916],"about_ca_topic_score_codex":0.000010723691,"about_ca_topic_score_gemma":0.000007025435,"teacher_disagreement_score":0.69660276,"about_ca_system_score_codex":0.00008933627,"about_ca_system_score_gemma":0.0004864415,"threshold_uncertainty_score":0.9997903},"labels":[],"label_agreement":null},{"id":"W2467728751","doi":"10.1182/blood-2016-02-698951","title":"Cooperation of germ line JAK2 mutations E846D and R1063H in hereditary erythrocytosis with megakaryocytic atypia","year":2016,"lang":"en","type":"article","venue":"Blood","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":55,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Faculty of Medicine and Dentistry, University of Alberta; Austrian Science Fund; Grantová Agentura České Republiky","keywords":"Context (archaeology); Germline; Cancer research; Erythropoietin; Mutation; STAT5; Erythropoiesis; Erythropoietin receptor; Cell biology; Biology; Signal transduction; Genetics; Medicine; Internal medicine; Gene","score_opus":0.011865529753330386,"score_gpt":0.24252917689663708,"score_spread":0.2306636471433067,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2467728751","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99677414,0.0005409734,0.00009293964,0.0016023307,0.00002393349,0.0004276565,0.00003226663,0.000019208868,0.00048653665],"genre_scores_gemma":[0.99782115,0.00032390383,0.0013453185,0.00011272318,0.000069713504,0.00010318212,0.000032053,0.000015394748,0.00017657605],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9992391,0.000029112516,0.0002346569,0.00021711804,0.00014497276,0.00013502839],"domain_scores_gemma":[0.9994349,0.00015199669,0.00006456713,0.00015262263,0.00011533755,0.00008057371],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000067486704,0.00013024488,0.00027875495,0.00009895769,0.000038734335,0.000006732595,0.00002394661,0.000055430497,0.00008670695],"category_scores_gemma":[0.000066173656,0.000074819305,0.000026003561,0.00015114913,0.00007952647,0.00009519434,0.000015059633,0.00005312452,0.000010609336],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0005817084,0.0035288858,0.96461004,0.0001841117,0.00056453905,0.00034866022,0.00096067076,0.00001962191,0.020244904,0.0013927518,0.0002532614,0.0073108473],"study_design_scores_gemma":[0.023573343,0.0034945107,0.72378224,0.0010002677,0.00075359613,0.0003855664,0.00014896144,0.000101970254,0.24611872,0.0001485192,0.00024055237,0.00025171964],"about_ca_topic_score_codex":0.00006769778,"about_ca_topic_score_gemma":0.00041567048,"teacher_disagreement_score":0.24082777,"about_ca_system_score_codex":0.000036933154,"about_ca_system_score_gemma":0.00012050463,"threshold_uncertainty_score":0.30510426},"labels":[],"label_agreement":null},{"id":"W2477786763","doi":"10.1017/cbo9781316017852.019","title":"Managing acute vascular events in patients with myeloproliferative neoplasms","year":2016,"lang":"en","type":"book-chapter","venue":"Cambridge University Press eBooks","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"St. Thomas Hospital","funders":"","keywords":"Vascular access; Medicine; Computer science; Content (measure theory); Internal medicine; Mathematics","score_opus":0.00982972918472539,"score_gpt":0.19633504680592773,"score_spread":0.18650531762120234,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2477786763","genre_codex":"other","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"other","genre_consensus":"other","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.031055884,0.00011102575,0.00013406768,0.00011920481,0.00014707458,0.002583191,0.00040930268,0.00010693142,0.96533334],"genre_scores_gemma":[0.024859741,0.00044711394,0.00021065137,0.00018934233,0.000096453965,0.000016125303,0.00026662374,0.00012272863,0.97379124],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","domain_scores_codex":[0.9975347,0.00005900635,0.00031629473,0.0009366207,0.0006574715,0.00049594376],"domain_scores_gemma":[0.99828994,0.00007750683,0.00027767924,0.0006802642,0.00034932184,0.00032526074],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00008018525,0.00073938916,0.0010189902,0.00042725564,0.00016586081,0.00001824051,0.0002307864,0.0003721779,0.000021793867],"category_scores_gemma":[0.0000072803423,0.00058309926,0.00027833655,0.000021890131,0.00017110976,0.00013827471,0.00023324539,0.0005038807,0.000048879334],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0074802362,0.00071637606,0.06789311,0.0005115093,0.010275461,0.004757278,0.0004173367,0.0000080841055,0.000013162577,0.89318293,0.005862705,0.008881807],"study_design_scores_gemma":[0.06862104,0.0049603255,0.15610838,0.010869514,0.008241032,0.00009054024,0.000081086946,0.0000647693,0.0013918615,0.0001265869,0.7454262,0.0040187025],"about_ca_topic_score_codex":0.00003727906,"about_ca_topic_score_gemma":0.000009495465,"teacher_disagreement_score":0.89305633,"about_ca_system_score_codex":0.00079906336,"about_ca_system_score_gemma":0.00022408467,"threshold_uncertainty_score":0.99966204},"labels":[],"label_agreement":null},{"id":"W2483061118","doi":"10.1007/s11899-016-0341-2","title":"Social Media and Myeloproliferative Neoplasms (MPN): Analysis of Advanced Metrics From the First Year of a New Twitter Community: #MPNSM","year":2016,"lang":"en","type":"article","venue":"Current Hematologic Malignancy Reports","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":22,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"National Cancer Institute; AOP Orphan","keywords":"Social media; Hematologic Neoplasms; Social media analytics; Myeloproliferative neoplasm; Health care; Medicine; Public relations; Interpersonal communication; Internet privacy; Internal medicine; Political science; World Wide Web; Computer science; Sociology; Myelofibrosis; Social science; Cancer","score_opus":0.06264256132008802,"score_gpt":0.3193700999007866,"score_spread":0.2567275385806985,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2483061118","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9912324,0.005132982,0.00025752722,0.0022005325,0.0002262921,0.0006266884,0.00008055401,0.000032273598,0.00021075683],"genre_scores_gemma":[0.9975655,0.0013687802,0.00065655966,0.00009378436,0.00007036309,0.00008765615,0.00009296132,0.000017289842,0.00004708726],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9975984,0.00016857158,0.0010185011,0.00042112535,0.00051369175,0.00027970472],"domain_scores_gemma":[0.99626654,0.0016585536,0.0009683941,0.000647837,0.0003113736,0.00014730313],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003817759,0.0003231227,0.0013734581,0.00025185404,0.00018498642,0.000014247899,0.00013125871,0.00014171652,0.00024492285],"category_scores_gemma":[0.0011388016,0.00016416922,0.00033118718,0.0009102101,0.00028577406,0.00007877261,0.0001570461,0.00022193554,0.000003831554],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00014800375,0.000572765,0.97920185,0.00012129095,0.0016168191,0.00011986257,0.0049863583,8.8706855e-7,0.00018749543,0.0016691863,0.0040425994,0.007332876],"study_design_scores_gemma":[0.0035657212,0.0003985479,0.9490213,0.0013153143,0.0050853053,0.00016462186,0.0013676364,0.00001845189,0.027249312,0.00680074,0.004579401,0.00043367225],"about_ca_topic_score_codex":0.000097450386,"about_ca_topic_score_gemma":0.00023969925,"teacher_disagreement_score":0.03018058,"about_ca_system_score_codex":0.000060456794,"about_ca_system_score_gemma":0.00015837912,"threshold_uncertainty_score":0.6694626},"labels":[],"label_agreement":null},{"id":"W2483116350","doi":"10.1136/jclinpath-2016-203940","title":"Novel germline mutations in the calreticulin gene: implications for the diagnosis of myeloproliferative neoplasms","year":2016,"lang":"en","type":"article","venue":"Journal of Clinical Pathology","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":12,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal; Hôpital Maisonneuve-Rosemont","funders":"","keywords":"Germline; Calreticulin; Germline mutation; Genetics; Biology; Mutation; Allele; Exon; Frameshift mutation; Janus kinase 2; Essential thrombocythemia; Somatic cell; Gene; Cancer research; Polycythemia vera; Immunology","score_opus":0.11948415077993188,"score_gpt":0.43294567995166033,"score_spread":0.3134615291717284,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2483116350","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.848099,0.00059791934,0.0141214095,0.13572416,0.00030991703,0.0009342835,0.00014216745,0.0000039500337,0.00006722207],"genre_scores_gemma":[0.98728454,0.0020765637,0.007443711,0.0022326638,0.0005106092,0.00038705996,0.0000071476834,0.000013812666,0.00004390665],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9973384,0.000303285,0.0017473465,0.00020152924,0.00020258805,0.0002068467],"domain_scores_gemma":[0.9821655,0.01577276,0.00091029814,0.00033332367,0.0007150132,0.000103102524],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002193054,0.00014985279,0.00073421275,0.00010144539,0.00009558981,0.000008729641,0.00022929005,0.00016401643,0.00004664235],"category_scores_gemma":[0.0061465534,0.00005788052,0.00045479366,0.00019474812,0.00041209994,0.000060017137,0.000028069428,0.0003152892,0.000005649982],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0009354885,0.0035708488,0.9333584,0.000023626104,0.00043773302,0.00008275593,0.00094342744,0.000063158215,0.0029416773,0.012674874,0.002569144,0.04239892],"study_design_scores_gemma":[0.0064050243,0.0024399476,0.9815611,0.0001003742,0.0004588498,0.0008012282,0.00015430248,0.000039102135,0.002185031,0.0027111543,0.003069146,0.00007471898],"about_ca_topic_score_codex":0.0000051186335,"about_ca_topic_score_gemma":0.000067066656,"teacher_disagreement_score":0.13918555,"about_ca_system_score_codex":0.000036970898,"about_ca_system_score_gemma":0.00032564337,"threshold_uncertainty_score":0.73584425},"labels":[],"label_agreement":null},{"id":"W2489680151","doi":"10.1017/cbo9781316017852.009","title":"The newly diagnosed patient with polycythemia vera","year":2016,"lang":"en","type":"book-chapter","venue":"Cambridge University Press eBooks","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"St. Thomas Hospital","funders":"","keywords":"Polycythemia vera; Medicine; Internal medicine","score_opus":0.01285945558918074,"score_gpt":0.1947223680931787,"score_spread":0.18186291250399794,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2489680151","genre_codex":"other","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"other","genre_consensus":"other","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0025758946,0.00044589804,0.00004061189,0.00038120034,0.00016527041,0.0012545929,0.00026731068,0.00010088363,0.9947683],"genre_scores_gemma":[0.010737143,0.0007504262,0.00007012608,0.00024881578,0.00017957579,0.0000119661745,0.000043848166,0.00007682163,0.9878813],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","domain_scores_codex":[0.9983344,0.000035347744,0.00021365796,0.0005687424,0.00046402455,0.0003837958],"domain_scores_gemma":[0.9980733,0.0003313309,0.00025636583,0.00077931787,0.00024395589,0.0003157405],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.000049705282,0.00052038115,0.0005435873,0.00009574869,0.00044582944,0.00004564751,0.00021815405,0.00026288355,0.00001687988],"category_scores_gemma":[0.000013935396,0.0003055522,0.0002462143,0.000008100093,0.00036470997,0.000045896555,0.00017553403,0.00037797273,0.000050088882],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.002355676,0.00008661136,0.00018142919,0.00007276737,0.0015196247,0.005688881,0.0001601492,4.6748832e-7,0.000037738995,0.8938272,0.06747496,0.028594468],"study_design_scores_gemma":[0.003592127,0.0008556153,0.00019348109,0.00074678025,0.0007029574,0.00012927012,0.00004542649,0.0000026012779,0.0015421943,0.000006022468,0.9918018,0.00038173885],"about_ca_topic_score_codex":0.00006737082,"about_ca_topic_score_gemma":0.000011076581,"teacher_disagreement_score":0.92432684,"about_ca_system_score_codex":0.00045807747,"about_ca_system_score_gemma":0.0003134864,"threshold_uncertainty_score":0.9999397},"labels":[],"label_agreement":null},{"id":"W2492177020","doi":"10.1017/cbo9781316017852.017","title":"Women and children with myeloproliferative neoplasms – special considerations","year":2016,"lang":"en","type":"book-chapter","venue":"Cambridge University Press eBooks","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"St. Thomas Hospital","funders":"","keywords":"Medicine; History","score_opus":0.017060721468321806,"score_gpt":0.20092798203472212,"score_spread":0.18386726056640032,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2492177020","genre_codex":"other","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"other","genre_consensus":"other","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.023865303,0.0001538813,0.000032667445,0.00024484386,0.00009446838,0.0016073827,0.0008207125,0.0001008375,0.9730799],"genre_scores_gemma":[0.016916994,0.0004137479,0.00028037743,0.00029321964,0.00083525135,0.000016984557,0.00009007846,0.00007552551,0.98107785],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","domain_scores_codex":[0.99821395,0.000039956187,0.00023049301,0.00077346497,0.00034805617,0.00039405588],"domain_scores_gemma":[0.998433,0.00015740519,0.00021473269,0.00043668787,0.0002968076,0.0004613434],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00006020453,0.0006011888,0.0008249693,0.00021437208,0.0003635352,0.000065700995,0.00008401382,0.0003321737,0.000110314286],"category_scores_gemma":[0.000017301501,0.0004665385,0.000120021716,0.000008778433,0.0005288387,0.000099397716,0.00015237818,0.0003862949,0.00003140846],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00074639946,0.000058796842,0.0013313529,0.000043617194,0.001858505,0.0009005637,0.0004126941,2.8216033e-7,0.00001602174,0.9742672,0.018759713,0.0016048414],"study_design_scores_gemma":[0.017913377,0.0034008438,0.014229022,0.0013619324,0.0023261234,0.0021998738,0.00014385185,0.00000850916,0.0019801143,0.00034602356,0.954007,0.0020833064],"about_ca_topic_score_codex":0.000018451523,"about_ca_topic_score_gemma":0.000014655619,"teacher_disagreement_score":0.9739212,"about_ca_system_score_codex":0.00045590708,"about_ca_system_score_gemma":0.0004313474,"threshold_uncertainty_score":0.9997786},"labels":[],"label_agreement":null},{"id":"W2493270785","doi":"10.1017/cbo9781316017852.021","title":"Familial myeloproliferative neoplasms – implications for patients and their families","year":2016,"lang":"en","type":"book-chapter","venue":"Cambridge University Press eBooks","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"St. Thomas Hospital","funders":"","keywords":"Content (measure theory); Computer science; Medicine; Mathematics","score_opus":0.02116233921041118,"score_gpt":0.22298031360023707,"score_spread":0.20181797438982588,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2493270785","genre_codex":"other","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"other","genre_consensus":"other","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.009522441,0.00023700045,0.00041650032,0.00037464447,0.00019650624,0.003408021,0.0059795165,0.00012619265,0.9797392],"genre_scores_gemma":[0.02587223,0.0013318745,0.00028812705,0.00028445316,0.00022718155,0.000058298156,0.00047778856,0.000088211,0.9713718],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","domain_scores_codex":[0.99845994,0.000025727908,0.00026945086,0.00075745967,0.00015008662,0.0003373506],"domain_scores_gemma":[0.99810606,0.0003371168,0.00022950386,0.0004453372,0.0005816875,0.0003003082],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.000049331746,0.00059067406,0.0007655534,0.00020402494,0.00036594318,0.00003313732,0.00014932986,0.0003813313,0.0000039663323],"category_scores_gemma":[0.00003307295,0.0004565748,0.0002852776,0.000008630169,0.00033623772,0.00008000516,0.0001855766,0.00021865251,0.000008148648],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0007714701,0.00011394835,0.0015033366,0.00016395122,0.0008747441,0.000016110775,0.00020634441,8.8231744e-8,0.000088624765,0.9643021,0.01713764,0.0148216095],"study_design_scores_gemma":[0.006820883,0.0012248079,0.0073312153,0.00047348323,0.0008021467,0.000023266219,0.0000699918,0.000012732809,0.001434111,0.00017564785,0.9809238,0.00070795167],"about_ca_topic_score_codex":0.000018096564,"about_ca_topic_score_gemma":0.0000058895994,"teacher_disagreement_score":0.96412647,"about_ca_system_score_codex":0.0002886611,"about_ca_system_score_gemma":0.00020505753,"threshold_uncertainty_score":0.9997886},"labels":[],"label_agreement":null},{"id":"W2497070607","doi":"10.1017/cbo9781316017852.006","title":"Accurately assessing risk in your myeloproliferative neoplasm patient","year":2016,"lang":"en","type":"book-chapter","venue":"Cambridge University Press eBooks","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"St. Thomas Hospital","funders":"","keywords":"Myeloproliferative neoplasm; Medicine; Intensive care medicine; Internal medicine; Myelofibrosis; Bone marrow","score_opus":0.04532203838441809,"score_gpt":0.26315193022835925,"score_spread":0.21782989184394116,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2497070607","genre_codex":"other","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"other","genre_consensus":"other","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.030475914,0.0003023177,0.00010326788,0.00011819622,0.00028122865,0.0016359473,0.0006575608,0.00012789258,0.9662977],"genre_scores_gemma":[0.07330726,0.0009210862,0.00032139715,0.00019714278,0.00022180143,0.00001609385,0.00010916296,0.000115988536,0.9247901],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","domain_scores_codex":[0.99718934,0.000135834,0.00051753334,0.0010495671,0.00054366834,0.0005640587],"domain_scores_gemma":[0.9976408,0.00027463093,0.0006001977,0.0006875263,0.00039042573,0.000406439],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00013419228,0.0008253697,0.0011614225,0.00047373626,0.00027590845,0.00008593292,0.00022221355,0.00062632654,0.00003168975],"category_scores_gemma":[0.00006394138,0.00070687005,0.00037931863,0.000023585395,0.00025082362,0.00021264564,0.0002993454,0.00091979187,0.00007860688],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0023418006,0.0005437544,0.0074457135,0.00045198167,0.002776121,0.014333959,0.0013483423,0.000012534752,0.00026201943,0.8589282,0.01942344,0.09213216],"study_design_scores_gemma":[0.008584033,0.0008970997,0.0078574885,0.0033704895,0.0013746857,0.0002094964,0.0002770053,0.00007478018,0.004579881,0.00005350496,0.97121465,0.0015069017],"about_ca_topic_score_codex":0.00013639002,"about_ca_topic_score_gemma":0.000019499295,"teacher_disagreement_score":0.95179117,"about_ca_system_score_codex":0.0010649302,"about_ca_system_score_gemma":0.0005492013,"threshold_uncertainty_score":0.99953824},"labels":[],"label_agreement":null},{"id":"W2503893926","doi":"10.1182/blood.v126.23.56.56","title":"PRM-151 in Myelofibrosis: Durable Efficacy and Safety at 72 Weeks","year":2015,"lang":"en","type":"article","venue":"Blood","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":35,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; St. Paul's Hospital; University of British Columbia","funders":"","keywords":"Myelofibrosis; Medicine; Bone marrow; Fibrosis; Internal medicine; Essential thrombocythemia; Gastroenterology; Ruxolitinib; Surgery; Polycythemia vera","score_opus":0.022584504499443842,"score_gpt":0.2630835879488786,"score_spread":0.24049908344943474,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2503893926","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98363286,0.002273785,0.00000236167,0.0018167057,0.000060032322,0.00059682166,0.000012384465,0.000044435645,0.0115606],"genre_scores_gemma":[0.996714,0.0004739633,0.0007179618,0.000277048,0.000097321514,0.00009460479,0.000033376775,0.000021883896,0.0015698598],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9988587,0.00004746572,0.00025274133,0.00032108347,0.00022265359,0.00029734726],"domain_scores_gemma":[0.99927104,0.000101360885,0.00005039069,0.00023902758,0.000058820442,0.00027936237],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00019456173,0.00017775646,0.0003546877,0.000076883414,0.00006792355,0.000017756756,0.000041022795,0.00009017877,0.00009564138],"category_scores_gemma":[0.00012901501,0.00013633558,0.00003934053,0.00014304885,0.000046863795,0.000059670994,0.00007557296,0.00010845601,0.00013001972],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00083451223,0.0030455363,0.98557806,0.00009639486,0.00021434862,0.00029561858,0.0012843695,0.0000063953516,0.0014992561,0.0005217823,0.0035616534,0.0030620676],"study_design_scores_gemma":[0.031067275,0.0014232958,0.9301308,0.00039273672,0.00027304413,0.00022602518,0.00014731896,0.000024542302,0.021786148,0.00010125413,0.014201252,0.00022630765],"about_ca_topic_score_codex":0.000085348256,"about_ca_topic_score_gemma":0.00014439676,"teacher_disagreement_score":0.055447266,"about_ca_system_score_codex":0.00009515726,"about_ca_system_score_gemma":0.00009182758,"threshold_uncertainty_score":0.55596036},"labels":[],"label_agreement":null},{"id":"W2510139173","doi":"10.1200/jco.2016.34.15_suppl.7012","title":"Long-term outcomes of ruxolitinib (RUX) therapy in patients (pts) with myelofibrosis (MF): 5-year update from COMFORT-I.","year":2016,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Ruxolitinib; Medicine; Myelofibrosis; Internal medicine; Oncology; Term (time); Pediatrics; Dermatology; Bone marrow","score_opus":0.0874416609574633,"score_gpt":0.41998745525088477,"score_spread":0.33254579429342146,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2510139173","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9927319,0.00011585993,0.000032589607,0.0057776086,0.00044650453,0.0003543292,0.000044547392,0.000005944432,0.0004906602],"genre_scores_gemma":[0.99398184,0.0019859776,0.0019749405,0.001656901,0.00026224,0.000011704849,0.000011378996,0.000023626495,0.00009136727],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9962582,0.00035587192,0.002366224,0.00025208647,0.00049730454,0.00027032287],"domain_scores_gemma":[0.9941208,0.0030145647,0.0018107855,0.0002744619,0.00045692682,0.00032248124],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009035283,0.00021940927,0.0021474184,0.00014550776,0.00002262102,0.00000629572,0.00016635488,0.00029357063,0.0006754077],"category_scores_gemma":[0.00081343134,0.000101241676,0.00040845724,0.00010257182,0.00024224637,0.0001324433,0.000042608357,0.00038192078,0.000028347773],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.007886119,0.0050061806,0.8358387,0.000007567101,0.00072634214,0.00015677136,0.000054161894,3.8699156e-7,0.000024615994,0.00008404092,0.00043190483,0.14978321],"study_design_scores_gemma":[0.041351475,0.02422933,0.93096644,0.00036695032,0.00019446386,0.000010653564,0.000017169383,5.7269665e-7,0.00067979435,0.00015881367,0.0019202539,0.00010410502],"about_ca_topic_score_codex":0.000032565997,"about_ca_topic_score_gemma":0.000106210966,"teacher_disagreement_score":0.1496791,"about_ca_system_score_codex":0.00015997479,"about_ca_system_score_gemma":0.0005887836,"threshold_uncertainty_score":0.73952407},"labels":[],"label_agreement":null},{"id":"W2511586498","doi":"10.3324/haematol.2016.151449","title":"The impact of anemia on overall survival in patients with myelofibrosis treated with ruxolitinib in the COMFORT studies","year":2016,"lang":"en","type":"letter","venue":"Haematologica","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":86,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; St. Paul's Hospital; Princess Margaret Cancer Centre","funders":"National Cancer Institute; University of Texas MD Anderson Cancer Center; National Institutes of Health; Incyte","keywords":"Ruxolitinib; Myelofibrosis; Polycythemia vera; Medicine; Anemia; Internal medicine; Overall survival; Myeloproliferative neoplasm; Gastroenterology; Bone marrow","score_opus":0.03352389522912173,"score_gpt":0.3046890616389881,"score_spread":0.2711651664098664,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2511586498","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9386419,0.00020690417,1.9022116e-7,0.056751452,0.000029106077,0.0018940594,0.00013697449,0.000020716905,0.0023186863],"genre_scores_gemma":[0.98181576,0.0003867538,0.000027746724,0.016613109,0.000110037145,0.0005681841,0.00023498114,0.00004105282,0.00020238696],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9973713,0.00039507847,0.00052804715,0.00048066562,0.00065854087,0.0005663707],"domain_scores_gemma":[0.99687034,0.0018583126,0.00039068007,0.000649706,0.00018767777,0.000043275453],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00025186635,0.0005730406,0.0014453428,0.0001490748,0.00011419218,0.00002514399,0.00022578452,0.0003147773,0.00004483529],"category_scores_gemma":[0.00010623105,0.00016612199,0.00017015864,0.00023123139,0.0003620953,0.000036817986,0.00004169017,0.00068973814,0.00001091372],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.002640665,0.0004863478,0.92849374,0.00012910215,0.00055334665,0.0010081156,0.0003176317,0.0000027134995,4.2492013e-7,0.00015314369,0.06587719,0.00033756203],"study_design_scores_gemma":[0.006302748,0.008036373,0.9797146,0.0019892165,0.00017718779,0.000052389067,0.000120677,8.059859e-7,0.000069372574,0.00008311128,0.0031941694,0.00025939464],"about_ca_topic_score_codex":0.00024687548,"about_ca_topic_score_gemma":0.0001434919,"teacher_disagreement_score":0.062683016,"about_ca_system_score_codex":0.00026368245,"about_ca_system_score_gemma":0.00011276266,"threshold_uncertainty_score":0.6774258},"labels":[],"label_agreement":null},{"id":"W2514348686","doi":"10.1017/cbo9781316017852.011","title":"Which patients are candidates for JAK inhibitors and how to manage patients on JAK inhibitor treatment","year":2016,"lang":"en","type":"book-chapter","venue":"Cambridge University Press eBooks","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"St. Thomas Hospital","funders":"","keywords":"Content (measure theory); Medicine; Internal medicine; Computer science; Mathematics","score_opus":0.015479068819409393,"score_gpt":0.20849127289850913,"score_spread":0.19301220407909975,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2514348686","genre_codex":"other","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"other","genre_consensus":"other","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.18956259,0.00009157964,0.000019983314,0.0008224711,0.0006306411,0.007727301,0.007166177,0.00013293138,0.7938463],"genre_scores_gemma":[0.14889652,0.00019710656,0.00007008967,0.0002178095,0.0002889073,0.00005712507,0.00055667263,0.0001017439,0.849614],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9979703,0.000032255448,0.00021617462,0.00096905715,0.0003924555,0.0004197771],"domain_scores_gemma":[0.9979638,0.00016428139,0.0002946675,0.0005038019,0.00054584804,0.0005276403],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.000041068382,0.0007262358,0.00084665325,0.00034844232,0.00026545546,0.000057866982,0.000121243356,0.0003571665,0.0000046681707],"category_scores_gemma":[0.00004313086,0.00057500455,0.00023110345,0.000015119675,0.00009020967,0.0000745783,0.00018074497,0.00015946437,0.000021180624],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.017255599,0.0035566075,0.124335356,0.0020132742,0.007608212,0.00088422664,0.001381911,0.000001986962,0.00008041982,0.21168135,0.5211454,0.11005562],"study_design_scores_gemma":[0.012315131,0.0051546223,0.008592818,0.0022536444,0.0010711568,0.0000022259483,0.000033165437,0.0000030170406,0.0039600586,0.0000042439515,0.96587056,0.0007393395],"about_ca_topic_score_codex":0.000050267045,"about_ca_topic_score_gemma":0.000057009318,"teacher_disagreement_score":0.44472516,"about_ca_system_score_codex":0.0009853747,"about_ca_system_score_gemma":0.000070262344,"threshold_uncertainty_score":0.99967015},"labels":[],"label_agreement":null},{"id":"W2521045502","doi":"10.3324/haematol.2016.148924","title":"A phase 1/2, open-label study evaluating twice-daily administration of momelotinib in myelofibrosis","year":2016,"lang":"en","type":"article","venue":"Haematologica","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":94,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; Jewish General Hospital; University of Toronto","funders":"National Cancer Institute; Gilead Sciences; European Hematology Association; American Society of Hematology","keywords":"Myelofibrosis; Medicine; Administration (probate law); Phase (matter); Phases of clinical research; Open label; Ruxolitinib; Internal medicine; Adverse effect; Clinical trial; Chemistry; Political science; Bone marrow","score_opus":0.18015390891044974,"score_gpt":0.4582531616756482,"score_spread":0.2780992527651985,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2521045502","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9932799,0.000104758605,0.00004494976,0.0018020271,0.000046473986,0.002446552,0.00002169431,0.000036934063,0.002216735],"genre_scores_gemma":[0.9959566,0.000040745064,0.0028683897,0.00013590432,0.000019138191,0.00074727356,0.000012335706,0.000016359443,0.00020323948],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9979676,0.00023434169,0.00070474687,0.00047003385,0.00035643709,0.00026682403],"domain_scores_gemma":[0.9986172,0.0004374604,0.0002817723,0.00037746585,0.0001701267,0.00011603057],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00059678615,0.00022286702,0.00079459866,0.00012917619,0.00007041837,0.00002743896,0.00017088605,0.00009296211,0.00039929728],"category_scores_gemma":[0.0006359984,0.0001268474,0.000049039038,0.0002860152,0.00007194824,0.00014338354,0.000119125056,0.0000835176,0.000067667504],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.012588023,0.123967506,0.69313407,0.0002600153,0.0005017899,0.0015906988,0.0026053174,8.44848e-7,0.054069053,0.004247289,0.0008190935,0.10621631],"study_design_scores_gemma":[0.2124568,0.152447,0.4518912,0.0022617246,0.0007120573,0.0006021943,0.002932763,0.0004000111,0.17391764,0.0011293001,0.00043491775,0.0008143795],"about_ca_topic_score_codex":0.000049447473,"about_ca_topic_score_gemma":0.00009899439,"teacher_disagreement_score":0.24124284,"about_ca_system_score_codex":0.00007457449,"about_ca_system_score_gemma":0.00017696776,"threshold_uncertainty_score":0.51726866},"labels":[],"label_agreement":null},{"id":"W2521639558","doi":"10.1182/blood.v126.23.2807.2807","title":"Demographics, Baseline Characteristics, and Disease Symptom Burden in RESPONSE-2: A Randomized, Phase 3 Study of Ruxolitinib in Polycythemia Vera Patients (pts) Who Are Resistant to or Intolerant of Hydroxyurea (HU)","year":2015,"lang":"en","type":"article","venue":"Blood","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Sciences Centre; Sunnybrook Health Science Centre","funders":"","keywords":"Medicine; Ruxolitinib; Internal medicine; Polycythemia vera; Phlebotomy; Myeloproliferative neoplasm; Thrombocytosis; Quality of life (healthcare); Anemia; Gastroenterology; Myelofibrosis; Bone marrow; Platelet","score_opus":0.01898396108697531,"score_gpt":0.2917810544879017,"score_spread":0.2727970934009264,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2521639558","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9955179,0.00038923402,0.0000039876786,0.0006783318,0.000041066734,0.0029539396,0.0003844959,0.000012807073,0.000018210627],"genre_scores_gemma":[0.99909174,0.00011552237,0.00012541962,0.00013369264,0.00005083254,0.00034333477,0.00006998181,0.000028813565,0.000040645544],"study_design_codex":"observational","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9971128,0.00062602916,0.0010602265,0.00043504976,0.00049102266,0.00027488574],"domain_scores_gemma":[0.99762404,0.0007561971,0.00032512334,0.0004073478,0.00032577344,0.00056151743],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012304748,0.00029165865,0.0014753793,0.00053486606,0.000025558682,0.000014330919,0.00009203064,0.00007350535,0.00001917349],"category_scores_gemma":[0.004747206,0.00021005179,0.00009062262,0.00041130555,0.00010225004,0.000054626023,0.00007795531,0.00014897429,0.0000015239798],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.37122294,0.014619262,0.6084457,0.00013491856,0.0002135184,0.00040058405,0.0043008174,0.0000021820274,0.0001525545,0.000014352988,0.00004684242,0.00044633736],"study_design_scores_gemma":[0.49897742,0.0044455864,0.4920691,0.0016078755,0.0006364862,0.0000035339604,0.001153111,0.00017504409,0.000629215,0.000025758676,0.00007061372,0.00020626013],"about_ca_topic_score_codex":0.00043862744,"about_ca_topic_score_gemma":0.00027642451,"teacher_disagreement_score":0.12775448,"about_ca_system_score_codex":0.000064376276,"about_ca_system_score_gemma":0.00027906866,"threshold_uncertainty_score":0.85656637},"labels":[],"label_agreement":null},{"id":"W2523935751","doi":"10.1182/blood.v114.22.1903.1903","title":"Diagnosis and Treatment of Essential Thrombocythemia: Assessment of Current Clinical Practice.","year":2009,"lang":"en","type":"article","venue":"Blood","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"St. Paul's Hospital; Vancouver General Hospital; University of British Columbia","funders":"","keywords":"Medicine; Essential thrombocythemia; Anagrelide; Cohort; Biopsy; Hematologist; Thrombosis; Medical history; Pediatrics; Internal medicine; Surgery; Polycythemia vera; Disease","score_opus":0.05866891199116746,"score_gpt":0.4357470174500861,"score_spread":0.3770781054589186,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2523935751","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9916704,0.004355537,0.000029865636,0.0011650815,0.000108902794,0.00068621157,0.000026860198,0.000015783638,0.0019413073],"genre_scores_gemma":[0.9765789,0.017861204,0.00518397,0.000068979694,0.00017567023,0.000083337975,0.000022704058,0.000009545299,0.000015685615],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9985615,0.00008827796,0.0005949242,0.00030067016,0.0002950547,0.00015955712],"domain_scores_gemma":[0.9987089,0.0004082297,0.00029317636,0.00027918586,0.00016796788,0.00014255747],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00017015233,0.00018437259,0.0007040154,0.000059713424,0.000033687993,0.000007961093,0.00003489188,0.0000825027,0.00006854728],"category_scores_gemma":[0.0001416477,0.00012977238,0.00018277718,0.00009209096,0.00008979913,0.00006139147,0.00001723328,0.0000914113,0.0000022354818],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00013580224,0.04527411,0.8381328,0.00007060813,0.0008583554,0.00007210056,0.00022190994,6.999944e-7,0.0006714078,0.0022220972,0.00019708335,0.11214301],"study_design_scores_gemma":[0.011973753,0.010118831,0.9144117,0.0002349821,0.0027813567,0.00006388647,0.00007055402,0.000016515378,0.055444572,0.00009269597,0.0046657478,0.00012541054],"about_ca_topic_score_codex":0.000013832861,"about_ca_topic_score_gemma":0.0000043042096,"teacher_disagreement_score":0.112017594,"about_ca_system_score_codex":0.000037976137,"about_ca_system_score_gemma":0.00016848679,"threshold_uncertainty_score":0.52919644},"labels":[],"label_agreement":null},{"id":"W2524036634","doi":"10.1093/ajcp/aqw131","title":"Laboratory Investigation of Myeloproliferative Neoplasms (MPNs)","year":2016,"lang":"en","type":"review","venue":"American Journal of Clinical Pathology","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":37,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Princess Margaret Cancer Centre; Jewish General Hospital; Canada's Michael Smith Genome Sciences Centre; University of British Columbia; Hôpital Maisonneuve-Rosemont; St. Paul's Hospital; McMaster University; McGill University; Centre Hospitalier de l’Université de Montréal; University of Toronto; University Health Network; Stem Cell Network","funders":"","keywords":"Standardization; Medicine; Health care; Myeloproliferative Disorders; Intensive care medicine; Diagnostic test; Medical physics; Pathology; Computer science; Pediatrics","score_opus":0.08176131846374197,"score_gpt":0.44546002469253715,"score_spread":0.3636987062287952,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2524036634","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.020373238,0.97654366,0.00009364545,0.00091731775,0.0009400782,0.0006907664,0.00014873616,0.000015461123,0.00027712135],"genre_scores_gemma":[0.0023843816,0.9917888,0.0037468213,0.0007308336,0.0011351976,0.00004277644,0.000024615203,0.00006848546,0.00007811038],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99167675,0.0023616117,0.00461607,0.0004957268,0.0005053695,0.0003444492],"domain_scores_gemma":[0.9857592,0.004373543,0.0075895097,0.0005112658,0.0012016086,0.0005649003],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0022770977,0.00054524513,0.0077738725,0.0004403598,0.00004452689,0.000009559442,0.000273835,0.00046048296,0.0001418606],"category_scores_gemma":[0.0030374965,0.00030927107,0.0015639091,0.00053411955,0.0018144043,0.00009810073,0.00007404716,0.0011742064,0.000093307535],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00031094896,0.00037629143,0.013388199,0.0011654637,0.0013417176,0.0009892063,0.00012632454,1.2719904e-7,0.0000048742554,0.00036645524,0.000987641,0.9809427],"study_design_scores_gemma":[0.0042835115,0.023241118,0.0100296615,0.02937422,0.0053338213,0.003524012,0.00011669409,8.7617576e-7,0.00009920094,0.00042844668,0.9229595,0.0006089195],"about_ca_topic_score_codex":0.0000025952072,"about_ca_topic_score_gemma":0.0000022374081,"teacher_disagreement_score":0.9803338,"about_ca_system_score_codex":0.00012438986,"about_ca_system_score_gemma":0.0031687927,"threshold_uncertainty_score":0.9999359},"labels":[],"label_agreement":null},{"id":"W2525487380","doi":"10.1182/blood.v120.21.2844.2844","title":"An Individual Patient Supply Program for Ruxolitinib for the Treatment of Patients with Primary Myelofibrosis (PMF), Post-Polycythemia Vera Myelofibrosis (PPV-MF), or Post-Essential Thrombocythemia Myelofibrosis (PET-MF).","year":2012,"lang":"en","type":"article","venue":"Blood","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Myelofibrosis; Medicine; Ruxolitinib; Essential thrombocythemia; International Prognostic Scoring System; Polycythemia vera; Constitutional symptoms; Internal medicine; Adverse effect; Bone marrow; Anemia; Gastroenterology; Surgery; Myelodysplastic syndromes","score_opus":0.013883091863626726,"score_gpt":0.2724081887448032,"score_spread":0.2585250968811765,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2525487380","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97558075,0.0010114405,0.00007208833,0.0005873361,0.0003460464,0.013671109,0.008425015,0.00021180346,0.00009439799],"genre_scores_gemma":[0.95458305,0.00030492168,0.024949607,0.0005115055,0.0006989303,0.011241547,0.007350238,0.00025249485,0.00010770243],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99483746,0.00013939061,0.0011931551,0.0010770101,0.0011542973,0.0015986566],"domain_scores_gemma":[0.9950438,0.0011146627,0.0007292689,0.0012557154,0.0011211315,0.00073543563],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0002582636,0.0011376954,0.001575728,0.00026014514,0.000670252,0.00016201557,0.00038827065,0.00030402996,0.00025374605],"category_scores_gemma":[0.000112312875,0.00065161806,0.0007548255,0.00042784307,0.00038506545,0.0005253203,0.00009814561,0.00018667674,0.000014726052],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.029712426,0.10198554,0.70264995,0.0013380239,0.008751733,0.000021779706,0.011411157,0.0000092504015,0.011202488,0.0003602535,0.0011614528,0.13139595],"study_design_scores_gemma":[0.033436857,0.08466596,0.6486055,0.00037618083,0.007840661,0.000072965784,0.0011113732,0.000024956456,0.21358676,0.000014256249,0.009327052,0.0009374621],"about_ca_topic_score_codex":0.00017868122,"about_ca_topic_score_gemma":0.00006711166,"teacher_disagreement_score":0.20238428,"about_ca_system_score_codex":0.00036104434,"about_ca_system_score_gemma":0.0006116431,"threshold_uncertainty_score":0.9995935},"labels":[],"label_agreement":null},{"id":"W2526339802","doi":"10.1182/blood.v114.22.3259.3259","title":"FTY720 but Not Its Immunosuppressive Phosphorylated Form FTY720-P Exerts Anti-Leukemic Activity towards Ph(+) and Ph(−) Myeloproliferative Disorders through Reactivation of the PP2A Tumor Suppressor.","year":2009,"lang":"en","type":"article","venue":"Blood","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal; Hôpital Maisonneuve-Rosemont","funders":"","keywords":"Protein phosphatase 2; Dasatinib; Progenitor cell; Cancer research; Haematopoiesis; Stem cell; Tyrosine kinase; CD38; Myeloid leukemia; Biology; Chemistry; CD34; Cell biology; Phosphorylation; Phosphatase; Signal transduction; Imatinib","score_opus":0.013232047141679592,"score_gpt":0.25437814394041364,"score_spread":0.24114609679873406,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2526339802","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99087983,0.0008827874,0.000024657234,0.003215124,0.00015855898,0.0020992768,0.0001552119,0.00008342962,0.0025010984],"genre_scores_gemma":[0.9973503,0.0010554596,0.00024713643,0.00070407335,0.00009920184,0.00019056855,0.000057058274,0.000045622528,0.00025062845],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.997532,0.00014276823,0.00053937436,0.0006973079,0.00056968984,0.00051885133],"domain_scores_gemma":[0.9982288,0.00020477273,0.00048479796,0.0006107052,0.0003280598,0.00014289613],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00016684586,0.0005497169,0.0008981686,0.000091991664,0.00033339602,0.000054350836,0.00020397095,0.00021122172,0.000074460375],"category_scores_gemma":[0.00033584074,0.00037253814,0.00024129437,0.00037591712,0.00019381782,0.00059432467,0.00011696843,0.00044606163,0.0000071812183],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0042207763,0.008134292,0.02964091,0.0003132043,0.0017495495,0.00009677145,0.0082702665,0.000033613607,0.93237907,0.0014429057,0.0006975196,0.013021109],"study_design_scores_gemma":[0.0066731763,0.001026148,0.30543977,0.00028519853,0.00044890985,0.000074630516,0.00016689119,0.000095618074,0.6849952,0.0003425217,0.00019814113,0.00025382166],"about_ca_topic_score_codex":0.00027284882,"about_ca_topic_score_gemma":0.000024920044,"teacher_disagreement_score":0.2757989,"about_ca_system_score_codex":0.00013971936,"about_ca_system_score_gemma":0.00031288445,"threshold_uncertainty_score":0.9998727},"labels":[],"label_agreement":null},{"id":"W2530902519","doi":"10.1182/blood.v126.23.2799.2799","title":"Safety and Efficacy of Ruxolitinib in an 1869-Patient Cohort of JUMP: An Open-Label, Multicenter, Single-Arm, Expanded-Access Study in Patients with Myelofibrosis","year":2015,"lang":"en","type":"article","venue":"Blood","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; St. Paul's Hospital; University Health Network; University of British Columbia","funders":"","keywords":"Medicine; Ruxolitinib; Myelofibrosis; Internal medicine; Tolerability; Clinical endpoint; Phases of clinical research; Median follow-up; Surgery; International Prognostic Scoring System; Clinical trial; Adverse effect; Chemotherapy; Bone marrow; Myelodysplastic syndromes","score_opus":0.05333994591219693,"score_gpt":0.32926492484195863,"score_spread":0.2759249789297617,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2530902519","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9960045,0.00006223686,0.0000012382567,0.000018849672,0.000034704713,0.0035297866,0.000055350854,0.000009780453,0.00028350708],"genre_scores_gemma":[0.9988071,0.000016180187,0.0008410394,0.00004207772,0.0000118203625,0.00014426392,0.00010305112,0.000028650393,0.0000058321166],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99792886,0.0002134997,0.00067488785,0.00048734684,0.0004422327,0.00025317335],"domain_scores_gemma":[0.99866545,0.00009168462,0.00025222034,0.0004301618,0.00029368285,0.00026677657],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00026071625,0.00024713072,0.0007654891,0.0001905281,0.00002940312,0.000037426074,0.00017721168,0.00006275074,0.000021078173],"category_scores_gemma":[0.000095612566,0.00018614609,0.000015418036,0.00027254713,0.00007898614,0.00035911065,0.0001855087,0.00010350169,9.666171e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.004572495,0.13298209,0.8563442,0.000044810018,0.00014137839,0.000024497613,0.003071943,0.000008569172,0.00013296548,0.000008550983,0.000002569479,0.0026659127],"study_design_scores_gemma":[0.08199299,0.03383445,0.8771887,0.0003392032,0.00023377192,0.000001874503,0.0006479302,0.000020409701,0.0055781947,0.0000026327666,0.0000060388047,0.00015381133],"about_ca_topic_score_codex":0.0010147137,"about_ca_topic_score_gemma":0.0015029286,"teacher_disagreement_score":0.09914763,"about_ca_system_score_codex":0.00007483435,"about_ca_system_score_gemma":0.000100334924,"threshold_uncertainty_score":0.7590817},"labels":[],"label_agreement":null},{"id":"W2531563325","doi":"10.1182/blood.v112.11.4122.4122","title":"Possible Selection for the Jak2 V617F Mutation in Bone Marrow Failure","year":2008,"lang":"en","type":"article","venue":"Blood","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Sciences Centre; University of Manitoba","funders":"","keywords":"Essential thrombocythemia; Myeloproliferative Disorders; Bone marrow; Medicine; Megakaryocyte; Bone marrow failure; Mutation; Anemia; Hematology; Myeloid; Polycythemia vera; Haematopoiesis; Pathology; Internal medicine; Immunology; Biology; Stem cell; Genetics; Gene","score_opus":0.018285054606670414,"score_gpt":0.25954804449136704,"score_spread":0.24126298988469663,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2531563325","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9940354,0.0006397269,0.00021902578,0.0036454976,0.000046801546,0.0008983047,0.0000065139325,0.000030455341,0.00047825315],"genre_scores_gemma":[0.99581224,0.00010474065,0.002399817,0.00025665222,0.00014365018,0.0004635091,0.0000336384,0.00001334035,0.00077242043],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9993958,0.000019749681,0.00014719261,0.00016110062,0.00012625815,0.0001499201],"domain_scores_gemma":[0.99961764,0.00012958168,0.000042277377,0.00009717074,0.00007391772,0.000039394352],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00008545397,0.00009396173,0.00014976079,0.00006273341,0.00013813177,0.00000974716,0.000023149412,0.000054774915,0.0000622794],"category_scores_gemma":[0.0000694012,0.000060771265,0.000058293594,0.0001748587,0.000022308148,0.00004817856,0.000005796507,0.000079884005,0.000020341997],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00028314698,0.002839896,0.9762183,0.0000875958,0.00031077705,0.00012475578,0.001804507,0.00010551909,0.0062518474,0.0009791169,0.0061631473,0.004831381],"study_design_scores_gemma":[0.01709565,0.0016985052,0.83885795,0.000116749055,0.0004845595,0.0013427675,0.0003108925,0.0013615384,0.12858854,0.0003414523,0.009586157,0.00021524311],"about_ca_topic_score_codex":0.00008698598,"about_ca_topic_score_gemma":0.0004980538,"teacher_disagreement_score":0.13736036,"about_ca_system_score_codex":0.000036980437,"about_ca_system_score_gemma":0.00007297906,"threshold_uncertainty_score":0.24781802},"labels":[],"label_agreement":null},{"id":"W2532116000","doi":"10.1182/blood.v104.11.4345.4345","title":"A New Polycythemia Syndrome: Congenital Polycythemia with High Erythropoietin and Propensity for Malignant Hypertension Due to Paraganglioma.","year":2004,"lang":"en","type":"article","venue":"Blood","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; University of British Columbia","funders":"","keywords":"SDHB; SDHD; Erythropoietin; Germline mutation; Internal medicine; Medicine; Endocrinology; Pheochromocytoma; Polycythemia vera; Cancer research; Biology; Mutation; Gene; Genetics","score_opus":0.014472883178507022,"score_gpt":0.226411136550702,"score_spread":0.21193825337219496,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2532116000","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9907582,0.00038399204,0.000342255,0.006186108,0.000062793595,0.0020403005,0.000042966796,0.00007642184,0.000106981264],"genre_scores_gemma":[0.97814685,0.000016959308,0.02036969,0.0007070546,0.00012257136,0.00019667104,0.000039842085,0.000053402142,0.00034696513],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9985279,0.000018818273,0.00023645065,0.00055067637,0.00026652717,0.00039966192],"domain_scores_gemma":[0.9989417,0.00006864255,0.0000704472,0.0003192021,0.00012506577,0.00047489555],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000088884735,0.0003216983,0.00062147074,0.00009963554,0.0001754479,0.00004299229,0.000058141344,0.00010718746,0.000040215404],"category_scores_gemma":[0.000059696016,0.00021062823,0.0000744025,0.00019354367,0.00006906833,0.00006338541,0.000055563953,0.00011840357,0.000037820642],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.03248902,0.031225627,0.31726897,0.0018025433,0.013426032,0.18912911,0.007952429,0.000066432855,0.3460601,0.016525615,0.017071562,0.026982557],"study_design_scores_gemma":[0.03858425,0.010390821,0.19180176,0.0007771225,0.001839261,0.061031744,0.000185071,0.0000030068516,0.6937067,0.00046355516,0.0005676381,0.000649077],"about_ca_topic_score_codex":0.00047178648,"about_ca_topic_score_gemma":0.00016631147,"teacher_disagreement_score":0.3476466,"about_ca_system_score_codex":0.0000609182,"about_ca_system_score_gemma":0.00026767323,"threshold_uncertainty_score":0.858917},"labels":[],"label_agreement":null},{"id":"W2538888658","doi":"10.1182/blood.v126.23.4074.4074","title":"Final Results of Anagrelide Controlled-Release (GALE-401) Safety, Efficacy and Pharmacokinetics in Subjects with Myeloproliferative Neoplasms (MPN)-Related Thrombocytosis","year":2015,"lang":"en","type":"article","venue":"Blood","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"inVentiv Health Clinical","funders":"","keywords":"Anagrelide; Medicine; Thrombocytosis; Pharmacokinetics; Cmax; Pharmacology; Myelofibrosis; Platelet; Polycythemia vera; Essential thrombocythemia; Bioequivalence; Internal medicine; Gastroenterology; Bone marrow","score_opus":0.02599791101880424,"score_gpt":0.27693187463176766,"score_spread":0.25093396361296344,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2538888658","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9897341,0.0018340844,0.000010610185,0.0015329261,0.000069444715,0.0020925158,0.00010164657,0.00005559302,0.004569092],"genre_scores_gemma":[0.9968645,0.0011840961,0.0011316855,0.00020347779,0.00007450189,0.00012783993,0.000101307036,0.000045382727,0.00026720925],"study_design_codex":"observational","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99722785,0.00020928713,0.00091754383,0.00061544636,0.0005772692,0.00045261593],"domain_scores_gemma":[0.9978689,0.0005821221,0.0003427693,0.00035542177,0.00039222912,0.0004585886],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00043976746,0.00045894735,0.0013045043,0.00026964556,0.00007347126,0.000029417533,0.00009804789,0.00016776953,0.000034255485],"category_scores_gemma":[0.00055639754,0.00032281358,0.00009936447,0.00054171734,0.00022311641,0.00010844701,0.00006627833,0.00034972883,0.00001733037],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.15507376,0.027812755,0.7688189,0.0005212745,0.0071769687,0.004171093,0.013510534,0.002009649,0.008233544,0.002038663,0.0032325452,0.007400281],"study_design_scores_gemma":[0.5343063,0.012091182,0.3442804,0.0012243427,0.0029895206,0.0006031613,0.00057469145,0.0013034485,0.101201974,0.00013193501,0.00058016035,0.000712932],"about_ca_topic_score_codex":0.00018494116,"about_ca_topic_score_gemma":0.00025147156,"teacher_disagreement_score":0.42453852,"about_ca_system_score_codex":0.00009070236,"about_ca_system_score_gemma":0.0004464001,"threshold_uncertainty_score":0.9999224},"labels":[],"label_agreement":null},{"id":"W2542401987","doi":"10.1002/jbmr.3026","title":"Bone Health in Patients With Hematopoietic Disorders of Bone Marrow Origin: Systematic Review and Meta- Analysis","year":2016,"lang":"en","type":"review","venue":"Journal of Bone and Mineral Research","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":58,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Shriners Hospitals for Children - Canada","funders":"Canadian Institutes of Health Research","keywords":"Medicine; Myelofibrosis; Multiple myeloma; Internal medicine; Bone marrow; Gastroenterology; Chronic myelogenous leukemia; Leukemia; Essential thrombocythemia; Polycythemia vera; Thalassemia; Bone density; Osteoporosis","score_opus":0.08143536199011582,"score_gpt":0.41017816192555023,"score_spread":0.3287427999354344,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2542401987","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0008984241,0.9931693,0.0000033527513,0.0028619785,0.0000106006055,0.002945499,0.000063858766,0.000001973499,0.000045015502],"genre_scores_gemma":[0.001086665,0.99759245,0.0002032538,0.000118784905,0.000022596596,0.0001758406,0.000027600887,0.00003270868,0.00074007426],"study_design_codex":"systematic_review","study_design_gemma":"systematic_review","domain_scores_codex":[0.99477696,0.0009548464,0.0023280396,0.00035583435,0.0011501703,0.00043417176],"domain_scores_gemma":[0.9963317,0.0006334514,0.0015714712,0.00038758083,0.0006617605,0.00041402088],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0036031448,0.00041312652,0.011391516,0.0015726945,0.000065212065,0.000029275589,0.00007483646,0.0001221006,0.00010410794],"category_scores_gemma":[0.00042607525,0.0001843704,0.00095284294,0.0011941929,0.0001619605,0.00010436126,0.00007053216,0.0005958296,0.0000030064891],"study_design_candidate":"systematic_review","study_design_consensus":"systematic_review","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00013306283,0.00093168835,0.001681395,0.946711,0.038705114,0.00013666764,0.00008526713,7.9193306e-8,1.7414818e-7,0.00007531498,0.0013792355,0.010161011],"study_design_scores_gemma":[0.004947112,0.006383148,0.0013316238,0.5583037,0.3955178,0.00054077903,0.000057262663,9.849011e-7,6.154867e-7,0.00006209716,0.032392096,0.00046277296],"about_ca_topic_score_codex":0.00007133151,"about_ca_topic_score_gemma":0.0001427044,"teacher_disagreement_score":0.3884073,"about_ca_system_score_codex":0.00019710996,"about_ca_system_score_gemma":0.0006140583,"threshold_uncertainty_score":0.77870125},"labels":[],"label_agreement":null},{"id":"W2543681710","doi":"10.1182/blood.v118.21.3849.3849","title":"An Expanded Multicenter Phase I/II Study of CYT387, a JAK- 1/2 Inhibitor for the Treatment of Myelofibrosis,","year":2011,"lang":"en","type":"article","venue":"Blood","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":36,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Jewish General Hospital; Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Myelofibrosis; Constitutional symptoms; Dosing; Internal medicine; Polycythemia vera; Multicenter study; Phases of clinical research; Gastroenterology; Adverse effect; Anemia; Surgery; Clinical trial; Bone marrow; Disease; Randomized controlled trial","score_opus":0.05319811628048467,"score_gpt":0.33065920913840763,"score_spread":0.277461092857923,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2543681710","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9960893,0.00046994642,0.000023179362,0.00003275017,0.00009080255,0.0030473054,0.000092720584,0.000014665739,0.00013937186],"genre_scores_gemma":[0.99711794,0.00015698514,0.0013716301,0.000029641364,0.00013330161,0.0010525506,0.0000250514,0.000023027673,0.00008989932],"study_design_codex":"observational","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9989478,0.00004729823,0.00038160858,0.00023270388,0.00018754396,0.00020303117],"domain_scores_gemma":[0.99900997,0.00012863133,0.00015830637,0.0004480867,0.00013813366,0.00011689183],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000087954024,0.0001991122,0.00045013666,0.00006250585,0.000099429206,0.0000045169713,0.0000679437,0.000048300393,0.00011754792],"category_scores_gemma":[0.000022892333,0.00010917208,0.00014899836,0.00008207973,0.00004996464,0.00005522279,0.0000152979,0.00002921212,0.0000025525007],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0045483746,0.4033497,0.51552725,0.000082446975,0.0023930287,0.000015871674,0.0396365,5.824942e-7,0.020991262,0.000068414054,0.00011523197,0.0132713225],"study_design_scores_gemma":[0.06700929,0.13183218,0.111455746,0.000068052985,0.002460081,0.0000069930497,0.0034569548,0.00003527868,0.6829673,0.0000047230624,0.00058603095,0.000117346564],"about_ca_topic_score_codex":0.00019710173,"about_ca_topic_score_gemma":0.00011535032,"teacher_disagreement_score":0.66197604,"about_ca_system_score_codex":0.000026189246,"about_ca_system_score_gemma":0.000039741433,"threshold_uncertainty_score":0.44519082},"labels":[],"label_agreement":null},{"id":"W2544907814","doi":"10.3324/haematol.2016.151126","title":"Primary analysis of a phase II open-label trial of INCB039110, a selective JAK1 inhibitor, in patients with myelofibrosis","year":2016,"lang":"en","type":"article","venue":"Haematologica","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":103,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; St. Paul's Hospital; Princess Margaret Cancer Centre","funders":"National Cancer Institute; University of Texas MD Anderson Cancer Center; National Institutes of Health","keywords":"Myelofibrosis; Open label; Medicine; Ruxolitinib; Internal medicine; Oncology; Clinical trial; Pharmacology","score_opus":0.02871582059334091,"score_gpt":0.3091379193859089,"score_spread":0.28042209879256796,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2544907814","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9960045,0.000052115298,0.0000315136,0.00032910708,0.000028139355,0.0019961414,0.00011892908,0.0000156949,0.0014238289],"genre_scores_gemma":[0.9977571,0.000040634164,0.0015932358,0.00010154302,0.000009880278,0.0003544536,0.00006810826,0.000013415635,0.00006167738],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.998142,0.00013809596,0.0006637048,0.00043451216,0.00038652032,0.00023518961],"domain_scores_gemma":[0.9984889,0.00029582522,0.00043682425,0.00035491656,0.0003211321,0.0001024011],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00019884539,0.00023518951,0.001571082,0.0004286576,0.000056688477,0.0000072874277,0.00014313663,0.00012301673,0.00013432342],"category_scores_gemma":[0.0002090252,0.0001195426,0.000113701295,0.0011856756,0.00014971399,0.0001223232,0.00016586506,0.00007936088,0.0000039111023],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.1604449,0.04479516,0.7740943,0.00010860522,0.0031033836,0.00006500406,0.0005664085,8.3047394e-7,0.001808173,0.000777623,0.00043902243,0.013796597],"study_design_scores_gemma":[0.4078527,0.049212772,0.5030409,0.0007219176,0.0024509733,0.000005587334,0.000041679607,0.000016660117,0.036189687,0.00010109596,0.000095606694,0.00027039586],"about_ca_topic_score_codex":0.00007566993,"about_ca_topic_score_gemma":0.000070747694,"teacher_disagreement_score":0.27105337,"about_ca_system_score_codex":0.00012563303,"about_ca_system_score_gemma":0.00017494496,"threshold_uncertainty_score":0.48748058},"labels":[],"label_agreement":null},{"id":"W2549351957","doi":"10.1182/blood.v108.11.4915.4915","title":"A Novel and Quantitative Assay To Detect JAK2 V617F Allele by Real-Time AS-PCR and Its Applicability to PV Initiating Mutation.","year":2006,"lang":"en","type":"article","venue":"Blood","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University","funders":"","keywords":"Allele; Biology; Allele frequency; Genetics; Polycythemia vera; Primer (cosmetics); Locked nucleic acid; Molecular biology; Point mutation; Mutation; DNA; Oligonucleotide; Immunology; Gene; Chemistry","score_opus":0.015234593508005594,"score_gpt":0.2833667801944113,"score_spread":0.2681321866864057,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2549351957","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9922544,0.0003032936,0.0006851826,0.0013089937,0.000009442971,0.001350533,0.00012958482,0.00005456722,0.0039040155],"genre_scores_gemma":[0.9742033,0.00002966002,0.024396684,0.0005236582,0.00005638338,0.00046293664,0.00007586105,0.000025530631,0.00022601105],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9987132,0.000058344587,0.0002810668,0.0004849317,0.00021592648,0.0002465266],"domain_scores_gemma":[0.9989189,0.00047243104,0.000069592184,0.00015218758,0.00015001539,0.00023690054],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00026964623,0.00020876467,0.00035804324,0.00007213776,0.00012788724,0.000041697323,0.000035519188,0.00007202547,0.00005407362],"category_scores_gemma":[0.0004192907,0.00017873387,0.000035490546,0.00018716892,0.000028183133,0.000063086205,0.00005165707,0.00008445015,0.00008204973],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0008737302,0.0067431014,0.098524876,0.00046352937,0.0010011723,0.00024847995,0.005630866,0.000067568435,0.8587961,0.006438994,0.0066881874,0.014523374],"study_design_scores_gemma":[0.017938938,0.00757287,0.4393326,0.00034778498,0.0009257324,0.00041516015,0.0007214112,0.00092338526,0.52647775,0.0010945958,0.0032354125,0.0010143183],"about_ca_topic_score_codex":0.0004493346,"about_ca_topic_score_gemma":0.00012421225,"teacher_disagreement_score":0.34080774,"about_ca_system_score_codex":0.000039521452,"about_ca_system_score_gemma":0.000047261226,"threshold_uncertainty_score":0.72885555},"labels":[],"label_agreement":null},{"id":"W2550662061","doi":"10.1182/blood.v112.11.4472.4472","title":"Methylation Status of SMURF2 and Correlation with Clinical Parameters in Patients with Multiple Myeloma","year":2008,"lang":"en","type":"article","venue":"Blood","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"DNA methylation; Biology; Methylation; Molecular biology; Cancer research; Epigenetics; SMAD; Transforming growth factor; CpG site; Gene; Cell biology; Gene expression; Genetics","score_opus":0.022715898433586647,"score_gpt":0.2677895507423681,"score_spread":0.24507365230878145,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2550662061","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9990672,0.00007857017,0.00008892906,0.000028353754,0.000016263937,0.0005580182,0.00000996969,0.0000100833495,0.00014259893],"genre_scores_gemma":[0.99387074,0.000106759246,0.005862084,0.000034998822,0.000008438428,0.000027708307,0.00006677624,0.000010744531,0.000011780474],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9991687,0.000053390213,0.00025583172,0.00019171409,0.0001928206,0.00013753735],"domain_scores_gemma":[0.99934876,0.00022690957,0.00011811409,0.000115527306,0.00009514773,0.00009555523],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000068615875,0.00010053199,0.00027087078,0.00006775828,0.000028992385,0.0000027591843,0.0000120031045,0.000053913594,0.000005763726],"category_scores_gemma":[0.00011272006,0.000064882115,0.000021226952,0.00011615082,0.00008407863,0.00006004202,0.0000075324947,0.0000872164,0.0000017687939],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0008854586,0.0018394395,0.99411416,0.000015245988,0.00012548616,0.000018148536,0.00033761968,0.00004656325,0.0000070381343,0.000012327366,0.000005988005,0.0025925518],"study_design_scores_gemma":[0.018813346,0.0030335193,0.97644824,0.00008646095,0.00015024634,0.000008639406,0.000027569133,0.00020140322,0.0011370443,0.000003981384,0.000020533209,0.00006904813],"about_ca_topic_score_codex":0.00008995064,"about_ca_topic_score_gemma":0.00010385796,"teacher_disagreement_score":0.017927887,"about_ca_system_score_codex":0.00001849435,"about_ca_system_score_gemma":0.000061555,"threshold_uncertainty_score":0.2645816},"labels":[],"label_agreement":null},{"id":"W2551356538","doi":"10.1182/blood.v118.21.1750.1750","title":"Results of Phase II Clinical Trial MPD-RC 101: Allogeneic Hematopoietic Stem Cell Transplantation Conditioned with Fludarabine/Melphalan in Patients with Myelofibrosis","year":2011,"lang":"en","type":"article","venue":"Blood","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Fludarabine; Myelofibrosis; Melphalan; Internal medicine; Essential thrombocythemia; Gastroenterology; Transplantation; Hematopoietic stem cell transplantation; Polycythemia vera; Surgery; Regimen; Bone marrow; Chemotherapy; Cyclophosphamide","score_opus":0.037058609019289014,"score_gpt":0.28498216602791193,"score_spread":0.24792355700862292,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2551356538","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9967402,0.000041311825,0.000023722845,0.000048539638,0.000056615634,0.0018444526,0.00023434969,0.000023709448,0.0009870798],"genre_scores_gemma":[0.9979332,0.00007563068,0.0010943807,0.000054092303,0.000046204277,0.00019152844,0.00050589786,0.000028819853,0.000070228154],"study_design_codex":"observational","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9979439,0.00013589613,0.00084478874,0.00044042314,0.00039323856,0.00024178748],"domain_scores_gemma":[0.99888057,0.00013146154,0.00033461791,0.00031532222,0.00017164885,0.00016640563],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00022431277,0.00025510267,0.00064983097,0.00013171688,0.00007064841,0.0000067847554,0.000070169546,0.00012735752,0.00009505823],"category_scores_gemma":[0.000012771495,0.00016955183,0.00009960534,0.00020616074,0.00010338194,0.000083208404,0.0000112065045,0.00013725834,0.000013280835],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.19857298,0.054982655,0.7404111,0.00025627963,0.0004923078,0.00019925556,0.0033278207,0.0000019617341,0.00039437786,0.000057612786,0.000060185568,0.0012434855],"study_design_scores_gemma":[0.45852703,0.043760326,0.42554957,0.00034355954,0.0010328182,0.000014299969,0.000084281404,0.0000018716083,0.0704876,0.0000074277896,0.000012764576,0.0001784566],"about_ca_topic_score_codex":0.000046964225,"about_ca_topic_score_gemma":0.00010306326,"teacher_disagreement_score":0.3148615,"about_ca_system_score_codex":0.000022748512,"about_ca_system_score_gemma":0.00012793053,"threshold_uncertainty_score":0.69141227},"labels":[],"label_agreement":null},{"id":"W2552245275","doi":"10.1182/blood.v126.23.3848.3848","title":"Prospective Next-Generation Sequencing Molecular Profiling of Myeloid Malignancies: Assessment of Information Benefit and Impact on Patient Care","year":2015,"lang":"en","type":"article","venue":"Blood","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ontario Institute for Cancer Research; Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"CEBPA; Myeloid leukemia; Medicine; DNA sequencing; Sanger sequencing; Myeloid; Oncology; Computational biology; Bioinformatics; Internal medicine; Gene; Biology; Genetics; Mutation","score_opus":0.031194010548905655,"score_gpt":0.286453979460118,"score_spread":0.2552599689112124,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2552245275","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9973341,0.00037187987,0.00012263861,0.000026491285,0.000029795146,0.00093899766,0.00004790597,0.000011945719,0.0011162339],"genre_scores_gemma":[0.99403894,0.000032082207,0.005618797,0.000044352775,0.000021892167,0.00010516647,0.00012898125,0.0000083267605,0.0000014720466],"study_design_codex":"observational","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9990819,0.00002232007,0.0003097245,0.00013477157,0.0003378089,0.00011347767],"domain_scores_gemma":[0.9989884,0.000019837415,0.00020104524,0.00014618266,0.00055194495,0.00009260526],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000089335954,0.0001383855,0.00027031483,0.000101860845,0.000029484485,0.000016728056,0.000020986565,0.000051791743,0.0000045300862],"category_scores_gemma":[0.000061768296,0.000099890065,0.000056356967,0.00010619772,0.000022414733,0.00016984418,0.000019846633,0.00006127194,8.758898e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00017362666,0.00084546395,0.77671313,0.00044886154,0.00048539063,0.000021979307,0.0117595205,0.0038289381,0.1943024,0.004831649,0.000012472634,0.006576567],"study_design_scores_gemma":[0.00311268,0.0053275838,0.0746652,0.00024637958,0.0002032651,0.000017277289,0.0025135304,0.0012012135,0.9125624,0.0000499932,0.0000037027662,0.00009682108],"about_ca_topic_score_codex":0.00008583186,"about_ca_topic_score_gemma":0.000006416478,"teacher_disagreement_score":0.71825993,"about_ca_system_score_codex":0.00024195992,"about_ca_system_score_gemma":0.00030037423,"threshold_uncertainty_score":0.40733987},"labels":[],"label_agreement":null},{"id":"W2553187946","doi":"10.1182/blood.v118.21.278.278","title":"Consistent Benefit of Ruxolitinib Over Placebo in Spleen Volume Reduction and Symptom Improvement Across Subgroups and Overall Survival Advantage: Results From COMFORT-I","year":2011,"lang":"en","type":"article","venue":"Blood","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":23,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Ruxolitinib; Medicine; Myelofibrosis; Placebo; Internal medicine; Gastroenterology; Surgery; Bone marrow; Pathology","score_opus":0.022704609610613855,"score_gpt":0.2660786291448861,"score_spread":0.24337401953427226,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2553187946","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9968843,0.0004136379,0.0000017596757,0.00014111023,0.00011712598,0.000778079,0.00064856926,0.000020593592,0.0009948313],"genre_scores_gemma":[0.99828666,0.0005104033,0.00054872053,0.000056835357,0.00007615184,0.00006545383,0.00018882369,0.000020734242,0.00024618598],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9984399,0.00003548232,0.0005295365,0.0004670739,0.00023742598,0.00029059034],"domain_scores_gemma":[0.99919343,0.00010402011,0.00019198682,0.0002813603,0.00007029441,0.00015889666],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00024134108,0.00022620313,0.00049665564,0.000059042493,0.000056079167,0.000018612847,0.00004072098,0.000107064654,0.00006986804],"category_scores_gemma":[0.00004911939,0.00019369287,0.00005769291,0.0000590117,0.00011804351,0.000099733625,0.00009030428,0.00013096933,0.0000023619498],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.002084177,0.0017736675,0.98448825,0.00008291256,0.0003626742,0.00007037256,0.0035051145,6.746745e-7,0.0050916355,0.0006962752,0.000046021014,0.0017982027],"study_design_scores_gemma":[0.02625158,0.0011925267,0.9446156,0.00020257419,0.00026488918,0.00003659962,0.0007727577,0.00003861411,0.026097443,0.0002090296,0.00013977555,0.00017858153],"about_ca_topic_score_codex":0.0036720373,"about_ca_topic_score_gemma":0.0008150747,"teacher_disagreement_score":0.039872643,"about_ca_system_score_codex":0.000047868914,"about_ca_system_score_gemma":0.000037350666,"threshold_uncertainty_score":0.7898566},"labels":[],"label_agreement":null},{"id":"W2554212826","doi":"10.1182/blood.v118.21.1951.1951","title":"Incidence, Risk Factors for Early Hepatotoxicity and Its Impact on Survival in Patients with Myelofibrosis Undergoing Allogeneic Hematopoietic Cell Transplantation","year":2011,"lang":"en","type":"article","venue":"Blood","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Medicine; Gastroenterology; Internal medicine; Myelofibrosis; Portal vein thrombosis; Polycythemia vera; Transplantation; Portal hypertension; Liver transplantation; Incidence (geometry); Liver function; Hepatic veno-occlusive disease; Cumulative incidence; Surgery; Hematopoietic stem cell transplantation; Thrombosis; Bone marrow; Cirrhosis","score_opus":0.0164703155606479,"score_gpt":0.24091360007786822,"score_spread":0.22444328451722032,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2554212826","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9984733,0.00004655011,0.000036437923,0.000006137003,0.000023688523,0.0011081471,0.00012588242,0.000020975733,0.00015891677],"genre_scores_gemma":[0.9993126,0.00013779548,0.00033920349,0.000016457017,0.000011526725,0.000092774935,0.000055898996,0.000025566527,0.000008214572],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99899024,0.000056626057,0.00020339736,0.00030283985,0.0002097762,0.00023712132],"domain_scores_gemma":[0.999326,0.00025894574,0.000104915816,0.000118339834,0.000057981317,0.00013385197],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00008810311,0.00022588967,0.00032064313,0.00011223307,0.00007767356,0.000013883013,0.00003588129,0.00007818682,0.000021864704],"category_scores_gemma":[0.000028192444,0.00014689397,0.000067184716,0.00011155005,0.000019400135,0.00009218393,0.0000073078195,0.000089496585,0.0000037112034],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00087407016,0.0018247068,0.9951287,0.00012988405,0.00012004254,0.000012234349,0.001695144,0.0000045908228,0.00012652448,0.00003669887,9.820083e-7,0.00004642613],"study_design_scores_gemma":[0.008020135,0.0046204003,0.9114217,0.00019023418,0.00033712035,0.0000024313476,0.00004707309,0.0000065207896,0.07518006,0.00003217704,2.0055049e-7,0.00014190328],"about_ca_topic_score_codex":0.00027728916,"about_ca_topic_score_gemma":0.00024731952,"teacher_disagreement_score":0.08370695,"about_ca_system_score_codex":0.00004324632,"about_ca_system_score_gemma":0.000054499207,"threshold_uncertainty_score":0.59901625},"labels":[],"label_agreement":null},{"id":"W2554373928","doi":"10.1182/blood.v114.22.1296.1296","title":"Quantitation of Changes in VWF and FVIII Following Elective Orthopedic Surgery in Normal Individuals.","year":2009,"lang":"en","type":"article","venue":"Blood","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen's University; Kingston General Hospital","funders":"","keywords":"Medicine; Partial thromboplastin time; Thromboelastography; Von Willebrand factor; Orthopedic surgery; Prothrombin time; Factor IX; Coagulation; Surgery; Internal medicine; Gastroenterology; Platelet","score_opus":0.016614150871145473,"score_gpt":0.27422340740085854,"score_spread":0.25760925652971306,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2554373928","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99722826,0.0011149317,0.0000019262022,0.0006943593,0.000025348927,0.00028647977,0.0000039380247,0.000008756701,0.00063601637],"genre_scores_gemma":[0.99910444,0.00039859719,0.00022866938,0.00016692135,0.000026534646,0.00003544202,0.000022160171,0.00000603212,0.000011219914],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99927855,0.00004686906,0.00020481016,0.00016224949,0.00015191217,0.0001556173],"domain_scores_gemma":[0.99961376,0.00018928744,0.00006087957,0.00006722368,0.000026381023,0.000042480955],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000245828,0.00009456973,0.0003207728,0.00029472183,0.000018960234,0.0000060006046,0.000014880997,0.00005547264,0.000009146376],"category_scores_gemma":[0.00014687485,0.00008323497,0.000041061077,0.000275012,0.000013321913,0.00006598655,0.000008069889,0.00008025931,0.0000013279356],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000037765007,0.00090423744,0.99184954,0.000031340176,0.000054070115,0.000099969024,0.0009942229,6.5573295e-7,0.0007009466,0.00029489014,0.000013500169,0.005018855],"study_design_scores_gemma":[0.002793979,0.0005087947,0.98240733,0.000264968,0.00008713176,0.000012814027,0.0001419297,0.0000063450357,0.013605696,0.000078192905,0.00002393379,0.00006890937],"about_ca_topic_score_codex":0.000094585324,"about_ca_topic_score_gemma":0.0011765144,"teacher_disagreement_score":0.012904749,"about_ca_system_score_codex":0.000017728747,"about_ca_system_score_gemma":0.00007441091,"threshold_uncertainty_score":0.33942235},"labels":[],"label_agreement":null},{"id":"W2555002983","doi":"10.1182/blood.v126.23.1604.1604","title":"The Impact of Anemia on Overall Survival in Patients with Myelofibrosis Treated with Ruxolitinib: An Exploratory Analysis of the Comfort Studies","year":2015,"lang":"en","type":"article","venue":"Blood","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; St. Paul's Hospital; Princess Margaret Cancer Centre","funders":"","keywords":"Ruxolitinib; Medicine; Anemia; Myelofibrosis; International Prognostic Scoring System; Internal medicine; Proportional hazards model; Survival analysis; Surgery; Gastroenterology; Myelodysplastic syndromes; Bone marrow","score_opus":0.035604383041803925,"score_gpt":0.2994456234511574,"score_spread":0.2638412404093535,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2555002983","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9989251,0.00011830799,1.9883514e-7,0.00004291875,0.000011507718,0.0004950341,0.000079564736,0.000009649607,0.00031775393],"genre_scores_gemma":[0.9997499,0.000038901093,0.000029262634,0.000021612661,0.000012029108,0.00005933868,0.00005076596,0.000016041678,0.000022151626],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99870074,0.00015711137,0.00028322122,0.00020636414,0.0004646438,0.00018792576],"domain_scores_gemma":[0.99868876,0.0001712829,0.00021254021,0.00046971423,0.0003563632,0.00010137117],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00019935702,0.00019981788,0.0006126057,0.000121141755,0.000057151054,0.000008409846,0.00008809978,0.00003840553,0.000005313658],"category_scores_gemma":[0.000059455735,0.000075586184,0.000121493315,0.00059533137,0.00015302269,0.00005777491,0.000026632706,0.00008492145,4.8488243e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.001679968,0.0028593875,0.9896115,0.000013054647,0.0038368595,0.0000053680096,0.0014672618,0.00030058337,0.000019256802,0.00005678937,0.00003390891,0.00011603087],"study_design_scores_gemma":[0.008617864,0.006723261,0.9781373,0.00013638899,0.0020354858,5.8794706e-7,0.0008403457,0.000019364354,0.0033965448,0.000007152377,0.0000029736746,0.00008270636],"about_ca_topic_score_codex":0.00034652336,"about_ca_topic_score_gemma":0.0007930994,"teacher_disagreement_score":0.011474206,"about_ca_system_score_codex":0.000097490454,"about_ca_system_score_gemma":0.0001474209,"threshold_uncertainty_score":0.3082315},"labels":[],"label_agreement":null},{"id":"W2556851306","doi":"10.1182/blood.v114.22.2516.2516","title":"A Sensitized Screen Uncovers a Novel Platelet Phenotype in a Loss-of-Function Jak2 Allele.","year":2009,"lang":"en","type":"article","venue":"Blood","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; Mount Sinai Hospital; Princess Margaret Cancer Centre; University of Toronto; Toronto Centre for Phenogenomics; Ontario Institute for Cancer Research","funders":"","keywords":"Transversion; Biology; Mutation; Molecular biology; Mutant; Genetics; Phenotype; Exon; Allele; Mutagenesis; Gene","score_opus":0.016266446433028076,"score_gpt":0.2545703167140906,"score_spread":0.2383038702810625,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2556851306","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9942301,0.00019604083,0.00020122014,0.00087508047,0.00003688236,0.00051624747,0.000021645144,0.00003694962,0.0038858352],"genre_scores_gemma":[0.9966701,0.000073533556,0.0021676046,0.00078928797,0.00008942681,0.000017349146,0.000077138604,0.000013168817,0.00010234261],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9989818,0.000024475772,0.0002772538,0.00026130542,0.00023701749,0.00021819343],"domain_scores_gemma":[0.9994589,0.00006847882,0.00008394435,0.0002089309,0.00008553829,0.00009417583],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000114047754,0.00017,0.0004052311,0.00012962033,0.000028126318,0.000008745592,0.00003367076,0.00009654854,0.00009120496],"category_scores_gemma":[0.00007368209,0.00013963443,0.00009304069,0.00023662813,0.000027241578,0.000052650295,0.000012420534,0.0001265931,0.00003185321],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.009280906,0.033318948,0.7914149,0.00024828146,0.0025048568,0.0025635893,0.0026156574,0.00032792304,0.10830355,0.0132641895,0.0028512576,0.03330592],"study_design_scores_gemma":[0.062517926,0.0049359696,0.85297346,0.00044669348,0.00076448434,0.00026666754,0.00015552921,0.00025216205,0.07352157,0.0007737999,0.0029694808,0.0004222364],"about_ca_topic_score_codex":0.00016747437,"about_ca_topic_score_gemma":0.00009188777,"teacher_disagreement_score":0.06155856,"about_ca_system_score_codex":0.000044631306,"about_ca_system_score_gemma":0.000096451426,"threshold_uncertainty_score":0.5694127},"labels":[],"label_agreement":null},{"id":"W2556952828","doi":"10.1182/blood.v110.11.3544.3544","title":"The JAK2 Kinase Inhibitor LS104 Induces Growth-Arrest and Apoptosis in JAK2V617F Positive Cells.","year":2007,"lang":"en","type":"article","venue":"Blood","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Erythropoietin receptor; Kinase; Janus kinase 2; Protein kinase B; Autophosphorylation; Biology; Molecular biology; Apoptosis; Cancer research; Cell biology; Signal transduction; Protein kinase A; Biochemistry","score_opus":0.008962523663792315,"score_gpt":0.2438089026847542,"score_spread":0.23484637902096187,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2556952828","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9925026,0.0013520317,0.0000028505617,0.002151512,0.00018304185,0.0005697586,0.000014899007,0.000025112797,0.0031981543],"genre_scores_gemma":[0.9980664,0.00075857225,0.00025399285,0.00042569812,0.0002692378,0.00007267704,0.0000133912135,0.000021235457,0.000118763055],"study_design_codex":"observational","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99873626,0.00005074953,0.00028812303,0.00032235938,0.00024180426,0.00036071608],"domain_scores_gemma":[0.99899787,0.00046858014,0.00007078346,0.00018476306,0.000092412556,0.00018561207],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003294479,0.00021011353,0.00026684202,0.00010792096,0.00018658895,0.000049968745,0.000060976887,0.000108846485,0.000014605168],"category_scores_gemma":[0.00010801336,0.00013581368,0.000058879927,0.00022974107,0.000117304946,0.00006637077,0.00005440122,0.0002188634,0.00002554344],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0008680574,0.007759403,0.8417813,0.00015789048,0.00073248905,0.0010887932,0.004217708,5.908408e-7,0.11639596,0.0047860225,0.0018612302,0.020350557],"study_design_scores_gemma":[0.003844516,0.00048165786,0.27941266,0.00015488183,0.00015091793,0.00002418729,0.00037042797,0.0000013860507,0.7147562,0.00010695427,0.0005603886,0.00013581521],"about_ca_topic_score_codex":0.00021502069,"about_ca_topic_score_gemma":0.0003111365,"teacher_disagreement_score":0.59836024,"about_ca_system_score_codex":0.000050670402,"about_ca_system_score_gemma":0.00005488308,"threshold_uncertainty_score":0.55383205},"labels":[],"label_agreement":null},{"id":"W2558228672","doi":"10.1182/blood.v106.11.3137.3137","title":"Cbl-Deficient Mice Display Erythropoietin Hypersensitivity and Enhanced Phosphorylation of Protein Kinase B/Akt.","year":2005,"lang":"en","type":"article","venue":"Blood","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ontario Institute for Cancer Research","funders":"","keywords":"Erythropoiesis; Erythropoietin; Erythropoietin receptor; Biology; Haematopoiesis; Protein kinase B; Cancer research; Signal transduction; Protein tyrosine phosphatase; Myeloid; Endocrinology; Internal medicine; Cell biology; Immunology; Anemia; Medicine; Stem cell","score_opus":0.00855326071563405,"score_gpt":0.2401275501575437,"score_spread":0.23157428944190964,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2558228672","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99557734,0.0007435413,0.000107362284,0.00097528484,0.000023255288,0.0007713438,0.000022733391,0.00002653231,0.0017525818],"genre_scores_gemma":[0.9959135,0.000081468046,0.0034992758,0.00009924687,0.00007424847,0.00007493044,0.00002315244,0.000014681114,0.00021948939],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99906856,0.000041426763,0.00022317354,0.0002797573,0.00021501583,0.00017209115],"domain_scores_gemma":[0.999458,0.00006060006,0.0001008955,0.00017526305,0.000106015046,0.00009922434],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00012250175,0.00015517372,0.0002871161,0.000048228914,0.000066610315,0.000009692588,0.000020342224,0.00006567222,0.000053380154],"category_scores_gemma":[0.00007967344,0.00012346085,0.00006037909,0.000100640136,0.00008036102,0.000050979306,0.000024744304,0.0000862023,0.000025493166],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0003906868,0.0066649164,0.02323972,0.00021162709,0.00023471934,0.000060098737,0.0015681349,0.000019856661,0.9331577,0.0010185413,0.000074967174,0.033359073],"study_design_scores_gemma":[0.003982003,0.0005467167,0.060987912,0.00017320456,0.00021420905,0.000032613163,0.00011949246,0.00010387424,0.93308616,0.0000112621165,0.0006275564,0.00011501437],"about_ca_topic_score_codex":0.00005528833,"about_ca_topic_score_gemma":0.000056206627,"teacher_disagreement_score":0.03774819,"about_ca_system_score_codex":0.000033491135,"about_ca_system_score_gemma":0.0000435414,"threshold_uncertainty_score":0.50345874},"labels":[],"label_agreement":null},{"id":"W2558311129","doi":"10.1182/asheducation-2016.1.543","title":"Myelofibrosis: to transplant or not to transplant?","year":2016,"lang":"en","type":"review","venue":"Hematology","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":45,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Myelofibrosis; Medicine; Hematopoietic cell; Transplantation; Ruxolitinib; Disease; Clinical trial; Treatment modality; Oncology; Internal medicine; Haematopoiesis; Stem cell; Bone marrow","score_opus":0.07049820686344827,"score_gpt":0.38116001560489415,"score_spread":0.3106618087414459,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2558311129","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00016031567,0.98854375,0.00041511134,0.0036713139,0.0005400793,0.0041682115,0.0010546299,0.00016253862,0.0012840745],"genre_scores_gemma":[0.0004224119,0.9910904,0.0011770044,0.002155734,0.00025237084,0.0022871043,0.00021264699,0.00013153777,0.002270769],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99655837,0.00018412631,0.0010561362,0.0010599857,0.00034009924,0.00080130267],"domain_scores_gemma":[0.9975573,0.00069071696,0.00016658487,0.0007309443,0.000083695915,0.0007707988],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.00015713269,0.00087267125,0.004510545,0.0004768364,0.000097283286,0.00001962766,0.0002602301,0.00063118455,0.0015879999],"category_scores_gemma":[0.00006613544,0.0004670653,0.00065694517,0.00035805206,0.000055743032,0.00003184288,0.00004018221,0.00029038585,0.0054904637],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0018461739,0.0008336046,0.00035499677,0.04117996,0.00212808,0.005902776,0.0011236332,1.006623e-7,0.000016191803,0.00689083,0.01911296,0.92061067],"study_design_scores_gemma":[0.0010643213,0.001027446,0.00005799268,0.055530895,0.0019287224,0.006603249,0.000008532626,1.3483447e-7,0.00040216927,0.00000746176,0.93285584,0.00051321945],"about_ca_topic_score_codex":0.000014552945,"about_ca_topic_score_gemma":0.000084847234,"teacher_disagreement_score":0.9200975,"about_ca_system_score_codex":0.00017288947,"about_ca_system_score_gemma":0.00052420737,"threshold_uncertainty_score":0.9997781},"labels":[],"label_agreement":null},{"id":"W2559151048","doi":"10.1182/blood.v108.11.3374.3374","title":"A Novel Role for Thrombin in Hematopoietic Stem/Progenitor Cell Homing.","year":2006,"lang":"en","type":"article","venue":"Blood","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Canadian Blood Services; University of Alberta","funders":"","keywords":"Cell biology; Thrombin; Stem cell; Homing (biology); Biology; Progenitor cell; Chemistry; Molecular biology; Immunology; Platelet","score_opus":0.012882848236441207,"score_gpt":0.23979198517829575,"score_spread":0.22690913694185455,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2559151048","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9946805,0.0013146115,0.00008328223,0.0003433386,0.000059159167,0.0011294009,0.000032148713,0.00003765317,0.0023198905],"genre_scores_gemma":[0.9948079,0.000014854893,0.003456806,0.00011051988,0.00017857853,0.00060458004,0.00003484179,0.000030669067,0.0007612476],"study_design_codex":"observational","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99900657,0.00001121844,0.00026657892,0.0002866784,0.00015363992,0.000275328],"domain_scores_gemma":[0.9995189,0.000094119096,0.00006185403,0.00020067515,0.000053433578,0.000071066985],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000082585575,0.00016928955,0.0003360949,0.00007528051,0.000048237885,0.000019341765,0.00005016121,0.000082650826,0.000033476248],"category_scores_gemma":[0.000009825645,0.00013915678,0.000111675,0.00011341553,0.000020078402,0.000032890417,0.000019257928,0.000072841736,0.00003704445],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00025440528,0.029713433,0.62486804,0.00062915735,0.00024181392,0.00016319171,0.0009568425,0.000012912231,0.33659682,0.0033427225,0.0023156726,0.0009050017],"study_design_scores_gemma":[0.020952208,0.00077628216,0.05868455,0.00015098322,0.00035464452,0.00013743788,0.00023816482,0.0000917427,0.9164136,0.00038806387,0.0015850626,0.0002272295],"about_ca_topic_score_codex":0.00011086806,"about_ca_topic_score_gemma":0.00010675493,"teacher_disagreement_score":0.5798168,"about_ca_system_score_codex":0.00004213345,"about_ca_system_score_gemma":0.00007427525,"threshold_uncertainty_score":0.5674649},"labels":[],"label_agreement":null},{"id":"W2559562829","doi":"10.1016/s1470-2045(16)30558-7","title":"Ruxolitinib for the treatment of inadequately controlled polycythaemia vera without splenomegaly (RESPONSE-2): a randomised, open-label, phase 3b study","year":2016,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":254,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Sciences Centre; Sunnybrook Health Science Centre","funders":"Novartis Pharmaceuticals Corporation","keywords":"Medicine; Polycythaemia; Ruxolitinib; Internal medicine; Polycythemia vera; Clinical endpoint; Myeloproliferative neoplasm; Randomized controlled trial; Pediatrics; Myelofibrosis","score_opus":0.16147605963586667,"score_gpt":0.4526537947164275,"score_spread":0.2911777350805609,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2559562829","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9412561,0.0011108342,0.00013235652,0.040202383,0.00023916444,0.015564099,0.00019566849,0.000033439213,0.0012659455],"genre_scores_gemma":[0.98420393,0.0012537964,0.0003227449,0.0011716305,0.0005380358,0.010004262,0.000011015725,0.000036029163,0.0024585251],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99726325,0.0009768902,0.00065605354,0.00039186023,0.00021411684,0.0004978315],"domain_scores_gemma":[0.98943895,0.009074833,0.00040855867,0.00077745126,0.00017282531,0.00012737194],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0018274601,0.00033125165,0.0021294018,0.00006940554,0.00027693447,0.000027264385,0.00038594738,0.00010006586,0.00018839755],"category_scores_gemma":[0.000582151,0.00011944914,0.0001847017,0.000109073626,0.00024017502,0.00005205218,0.00006370582,0.000092325674,0.00003064182],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9003091,0.01888389,0.010002546,0.00001939407,0.003543913,0.00010422305,0.0030063747,0.0000013322008,0.00376391,0.0014177873,0.0020908753,0.056856684],"study_design_scores_gemma":[0.8149011,0.06080186,0.008061018,0.000054375912,0.0018761286,0.000064758824,0.0005275814,0.00008398751,0.003660789,0.00018112375,0.10963235,0.00015488482],"about_ca_topic_score_codex":0.00017280699,"about_ca_topic_score_gemma":0.00018570098,"teacher_disagreement_score":0.10754148,"about_ca_system_score_codex":0.00046144731,"about_ca_system_score_gemma":0.00055138994,"threshold_uncertainty_score":0.48709947},"labels":[],"label_agreement":null},{"id":"W2559573030","doi":"10.1182/blood.v108.11.1297.1297","title":"Recurrent De Novo Mutations of EPOR Gene in Primary Congenital Polycythemia.","year":2006,"lang":"en","type":"article","venue":"Blood","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"McGill University; Université de Montréal; Centre Hospitalier Universitaire Sainte-Justine","funders":"","keywords":"Erythropoietin receptor; Proband; Mutation; Genetics; Biology; Point mutation; Gene; Molecular biology","score_opus":0.00986511976744703,"score_gpt":0.24692547316659078,"score_spread":0.23706035339914375,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2559573030","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99252516,0.0010181601,0.00002183331,0.00030743785,0.00003368506,0.00030977096,0.000045477518,0.000015349426,0.0057231123],"genre_scores_gemma":[0.99549234,0.00004533568,0.0038755503,0.00007149019,0.0000853343,0.00009019366,0.00013592243,0.00001138244,0.00019247501],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99929255,0.0000197092,0.0002527906,0.00014419937,0.00013412269,0.00015660646],"domain_scores_gemma":[0.99964935,0.000063515094,0.00006153288,0.00012425847,0.00004834089,0.00005299017],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00006129564,0.00009641706,0.0002138225,0.00008222195,0.000020526586,0.000004436292,0.000027741336,0.00004605333,0.00006299284],"category_scores_gemma":[0.000027746226,0.00008191846,0.00005981345,0.00011910051,0.000037262205,0.000023330014,0.000013149033,0.00006960523,0.000011415251],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0000957208,0.005449344,0.9553935,0.00005578237,0.00013971534,0.0003776742,0.00021755052,0.0000070663436,0.036113128,0.0004132954,0.0001614349,0.0015758226],"study_design_scores_gemma":[0.0057088174,0.00033423738,0.7056167,0.00005512905,0.0002000614,0.0002465855,0.000027126574,0.000009918239,0.2873764,0.0001511584,0.00019170734,0.00008211091],"about_ca_topic_score_codex":0.0001055754,"about_ca_topic_score_gemma":0.00009722192,"teacher_disagreement_score":0.2512633,"about_ca_system_score_codex":0.00006758103,"about_ca_system_score_gemma":0.00016387922,"threshold_uncertainty_score":0.33405378},"labels":[],"label_agreement":null},{"id":"W2559986076","doi":"10.1182/blood.v106.11.120.120","title":"The Transcriptional Profile of PV Displays Limited Similarity to EPO Stimulated Progenitor Cells: Evidence That JAK2 V617F Confers a Novel Program to Malignant Hematopoietic Stem Cells.","year":2005,"lang":"en","type":"article","venue":"Blood","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ontario Institute for Cancer Research","funders":"","keywords":"Erythropoietin; Haematopoiesis; Progenitor cell; Biology; Polycythemia vera; CD34; Stem cell; Mutation; Cancer research; Molecular biology; Immunology; Gene; Genetics","score_opus":0.05183238357207373,"score_gpt":0.29658073716076766,"score_spread":0.24474835358869393,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2559986076","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.986494,0.0007944412,0.00046780505,0.005151473,0.0001528251,0.0064846515,0.00021225114,0.000116931646,0.00012560641],"genre_scores_gemma":[0.99074304,0.00009848558,0.006216772,0.0004601352,0.000113890674,0.001776025,0.000027240176,0.00004510401,0.0005193121],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99744457,0.000084052124,0.0005833399,0.00059233437,0.00074809487,0.000547596],"domain_scores_gemma":[0.9981417,0.00032960565,0.00018050613,0.00050898344,0.0003778715,0.0004613244],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00030422854,0.0003810919,0.0005554694,0.00010455207,0.00020473359,0.00007770005,0.00022470597,0.00013896372,0.000100563404],"category_scores_gemma":[0.000060992294,0.0002487231,0.00022285423,0.0003822687,0.0001037624,0.000098266166,0.000061565195,0.00019968562,0.00008746322],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0030795166,0.03358373,0.06542969,0.001388125,0.0022192732,0.00021807296,0.007017138,0.0009286283,0.86718005,0.0014334136,0.0028860073,0.014636354],"study_design_scores_gemma":[0.004486585,0.0027465206,0.016234621,0.00095429044,0.0008101178,0.00006853445,0.0002901916,0.0013762146,0.96582353,0.000004706656,0.00686487,0.00033983364],"about_ca_topic_score_codex":0.000025871625,"about_ca_topic_score_gemma":0.000044861434,"teacher_disagreement_score":0.09864346,"about_ca_system_score_codex":0.0001014785,"about_ca_system_score_gemma":0.0002579675,"threshold_uncertainty_score":0.9999965},"labels":[],"label_agreement":null},{"id":"W2560056817","doi":"10.1182/blood.v128.22.3107.3107","title":"Safety and Efficacy of Ruxolitinib for the Final Enrollment of JUMP: An Open-Label, Multicenter, Single-Arm, Expanded-Access Study in Patients with Myelofibrosis (N = 2233)","year":2016,"lang":"en","type":"article","venue":"Blood","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; St. Paul's Hospital; University of British Columbia","funders":"","keywords":"Ruxolitinib; Medicine; Myelofibrosis; Internal medicine; Tolerability; Clinical endpoint; Discontinuation; Phases of clinical research; Clinical trial; Adverse effect; Expanded access; Placebo; Surgery; Bone marrow; Pathology","score_opus":0.0618019106275395,"score_gpt":0.3331993970182839,"score_spread":0.2713974863907444,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2560056817","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99518156,0.00009718636,0.000034188593,0.00020441985,0.000031748274,0.004244688,0.00012619073,0.000007638931,0.00007240661],"genre_scores_gemma":[0.99878013,0.000055559434,0.0006955337,0.00005421546,0.00002219793,0.00031287735,0.000020003577,0.00002176325,0.000037733927],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9986306,0.000081272054,0.00045460238,0.00034447983,0.0002719457,0.00021712862],"domain_scores_gemma":[0.9986281,0.000511221,0.00021910257,0.00035655758,0.00018916497,0.00009585011],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00021177901,0.00019499823,0.00049716997,0.000069804235,0.00007041926,0.00002677352,0.00019196236,0.000038292514,0.000033243206],"category_scores_gemma":[0.00009705315,0.00009358264,0.000026552363,0.00010723801,0.00008793821,0.0001581071,0.00014241962,0.00004405463,5.3171146e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.007752262,0.06645521,0.9089505,0.00006113606,0.0003664107,0.0000032673809,0.00071747915,8.5396147e-7,0.0006962745,0.000041568095,0.000008622165,0.014946393],"study_design_scores_gemma":[0.11861363,0.021339832,0.8433968,0.0004129221,0.00043106524,0.000001152424,0.00017231141,0.0000055282744,0.0154726105,0.0000053348444,0.000048862876,0.00009993945],"about_ca_topic_score_codex":0.000108460066,"about_ca_topic_score_gemma":0.00013055543,"teacher_disagreement_score":0.11086137,"about_ca_system_score_codex":0.00003521503,"about_ca_system_score_gemma":0.0000552943,"threshold_uncertainty_score":0.38161892},"labels":[],"label_agreement":null},{"id":"W2562579323","doi":"10.1182/blood.v120.21.1733.1733","title":"Improvement in Weight and Total Cholesterol and Their Association with Survival in Ruxolitinib-Treated Patients with Myelofibrosis From COMFORT-I","year":2012,"lang":"en","type":"article","venue":"Blood","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":25,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Ruxolitinib; Myelofibrosis; Medicine; Internal medicine; Placebo; Gastroenterology; Weight loss; Body mass index; Cachexia; Hypocholesterolemia; Anemia; Cholesterol; Surgery; Obesity; Cancer; Bone marrow; Pathology","score_opus":0.005645359044309663,"score_gpt":0.19691509941011726,"score_spread":0.1912697403658076,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2562579323","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9986707,0.00015572758,0.0000012463706,0.0001158334,0.000022428614,0.00069549016,0.00009526273,0.000014167268,0.00022917216],"genre_scores_gemma":[0.99934,0.000052679727,0.00014801318,0.000079041834,0.00004470876,0.00013629251,0.00015218531,0.000018641118,0.000028424472],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9990498,0.000044996472,0.0001939717,0.00023500583,0.00019322289,0.0002830406],"domain_scores_gemma":[0.99951494,0.000105325285,0.000096399446,0.00011200054,0.000042625765,0.00012870347],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000103791164,0.0001960717,0.00034094608,0.00007091011,0.000033801272,0.00002324961,0.000016951695,0.000075210664,0.00001599568],"category_scores_gemma":[0.000012839025,0.00011889086,0.000014796863,0.00009983015,0.000023121618,0.00013320746,0.000025125313,0.00010506189,0.0000014552185],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00023943673,0.001867168,0.9940727,0.000017306638,0.00018882906,0.000004159053,0.00076892617,1.8250284e-7,0.00026554242,0.000014070118,0.0000031484005,0.0025585843],"study_design_scores_gemma":[0.017236013,0.0011293833,0.9652144,0.00017835289,0.00013538942,0.000002356644,0.00012247483,0.0000067663973,0.015821114,0.000005545812,0.000023050608,0.00012515759],"about_ca_topic_score_codex":0.0005991,"about_ca_topic_score_gemma":0.0006769752,"teacher_disagreement_score":0.02885825,"about_ca_system_score_codex":0.00009811536,"about_ca_system_score_gemma":0.000018793093,"threshold_uncertainty_score":0.48482284},"labels":[],"label_agreement":null},{"id":"W2563730090","doi":"10.1182/blood.v124.21.713.713","title":"Phase 2 Trial of PRM-151, an Anti-Fibrotic Agent, in Patients with Myelofibrosis: Stage 1 Results","year":2014,"lang":"en","type":"article","venue":"Blood","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":38,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; St. Paul's Hospital; University of British Columbia","funders":"","keywords":"Medicine; Myelofibrosis; Bone marrow; Essential thrombocythemia; Internal medicine; Gastroenterology; Fibrosis; Anemia; Ruxolitinib; Clinical endpoint; Polycythemia vera; Clinical trial","score_opus":0.01691741954328189,"score_gpt":0.27841635164952866,"score_spread":0.26149893210624675,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2563730090","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9969109,0.00002339971,0.000012488499,0.00008187255,0.000068669244,0.0015744212,0.00012672793,0.000029408713,0.0011720804],"genre_scores_gemma":[0.9982921,0.000016978243,0.0010240285,0.00006469687,0.00010236115,0.000101270554,0.00025044286,0.000027343007,0.000120790886],"study_design_codex":"observational","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9983224,0.00012881059,0.0004897405,0.0003992514,0.00039855854,0.00026123927],"domain_scores_gemma":[0.9989347,0.00008628797,0.00021148978,0.0004794601,0.000116543975,0.00017155368],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00023916326,0.0002146295,0.000531911,0.00014216616,0.000039450522,0.000015306714,0.000074288975,0.00007808286,0.000040678435],"category_scores_gemma":[0.00015976594,0.00015008393,0.00006515486,0.0002022433,0.000054242268,0.000104815954,0.000022726212,0.00010184545,0.000012916892],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.10957472,0.0982145,0.77922857,0.00030542893,0.00046371517,0.00006659434,0.0011291717,0.000016951306,0.0008981689,0.00034754985,0.00020045231,0.009554209],"study_design_scores_gemma":[0.51774853,0.032228097,0.42924476,0.00038924455,0.00027950003,0.0000016721913,0.000031600033,0.00003069641,0.019503467,0.000009842717,0.00036993463,0.00016268679],"about_ca_topic_score_codex":0.000051505478,"about_ca_topic_score_gemma":0.000039843097,"teacher_disagreement_score":0.4081738,"about_ca_system_score_codex":0.000026120524,"about_ca_system_score_gemma":0.000071472336,"threshold_uncertainty_score":0.61202455},"labels":[],"label_agreement":null},{"id":"W2566533640","doi":"10.1080/10245332.2016.1267830","title":"Relationship between<i>JAK2V617F</i>mutation, allele burden and coagulation function in Ph-negative myeloproliferative neoplasms","year":2016,"lang":"en","type":"article","venue":"Hematology","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; University Health Network","funders":"National Natural Science Foundation of China","keywords":"Essential thrombocythemia; Polycythemia vera; Allele; Medicine; Internal medicine; Mutation; Gastroenterology; Myelofibrosis; Coagulation; Immunology; Biology; Genetics; Bone marrow; Gene","score_opus":0.03086170962692747,"score_gpt":0.29128710196365276,"score_spread":0.2604253923367253,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2566533640","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98514897,0.0002320902,0.0026623053,0.009856387,0.000091564034,0.0008494702,0.000017454531,0.00006282792,0.0010789435],"genre_scores_gemma":[0.9978274,0.000038168466,0.0009476421,0.00018799155,0.00020524557,0.000281328,0.000088108245,0.000025650284,0.00039843257],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9982865,0.0002040187,0.00049922935,0.00048460948,0.0002049525,0.0003206871],"domain_scores_gemma":[0.9976,0.0016919413,0.00017540346,0.0001994613,0.00018160524,0.00015157096],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00022899831,0.00024699076,0.00054297544,0.0002611874,0.00015798344,0.000014680894,0.00003561914,0.0002291114,0.00012777976],"category_scores_gemma":[0.0006213572,0.00017261923,0.00005336832,0.00025646688,0.00017056447,0.00021663986,0.000030896677,0.00015976773,0.00013998024],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00027916933,0.00006689531,0.96033186,0.000046934274,0.00007998774,0.000049321996,0.0014837357,0.00000522793,0.00013288016,0.033881165,0.00026919477,0.0033736173],"study_design_scores_gemma":[0.004836336,0.0005702367,0.9731178,0.00014503687,0.00012090916,0.00024705,0.00036408164,0.00009751386,0.004768767,0.015127292,0.0004153799,0.00018958226],"about_ca_topic_score_codex":0.00010071578,"about_ca_topic_score_gemma":0.0004808582,"teacher_disagreement_score":0.018753873,"about_ca_system_score_codex":0.00022160761,"about_ca_system_score_gemma":0.00017024613,"threshold_uncertainty_score":0.7039208},"labels":[],"label_agreement":null},{"id":"W2566934960","doi":"10.1182/blood.v110.11.3539.3539","title":"The Presence of the JAK2V617F Mutation in Primary Myelofibrosis and Its Allele Burden in Polycythemia Vera Predict Chemosensitivity to Hydroxyurea.","year":2007,"lang":"en","type":"article","venue":"Blood","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre","funders":"","keywords":"Polycythemia vera; Phlebotomy; Myelofibrosis; Medicine; Essential thrombocythemia; Internal medicine; Univariate analysis; Gastroenterology; Cohort; Bone marrow; Myeloproliferative neoplasm; Multivariate analysis","score_opus":0.007405824369477488,"score_gpt":0.23800485384100395,"score_spread":0.23059902947152647,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2566934960","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9947419,0.00042218415,0.0000046161886,0.002275068,0.00003267318,0.00089050166,0.0000095845335,0.000008957171,0.001614488],"genre_scores_gemma":[0.99937063,0.00009819331,0.00011858549,0.00014531669,0.00006790712,0.000052702624,0.000006989634,0.000010891499,0.00012880162],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9989221,0.00006254653,0.0002665872,0.00022597025,0.00027870215,0.00024410934],"domain_scores_gemma":[0.9991412,0.00043999383,0.00007177562,0.00021845897,0.000049889364,0.00007865148],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004934157,0.00012756977,0.00022594845,0.00005994617,0.00007115935,0.000010369395,0.00007066714,0.00006705367,0.0000035819305],"category_scores_gemma":[0.00026949836,0.00007593476,0.00003984181,0.00026822652,0.000054409775,0.000048569156,0.000077536635,0.00013274,0.0000025185807],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00056559336,0.00092980976,0.919988,0.00010860629,0.000105613304,0.00010780827,0.004485244,0.000042106658,0.06401668,0.00014989077,0.00010649588,0.009394183],"study_design_scores_gemma":[0.0020834233,0.00018752096,0.75924325,0.00015927672,0.000042650638,0.000031481075,0.00012102692,0.000080305246,0.23786232,0.000027368797,0.000106201456,0.00005518939],"about_ca_topic_score_codex":0.000330036,"about_ca_topic_score_gemma":0.00084161427,"teacher_disagreement_score":0.17384565,"about_ca_system_score_codex":0.000094588504,"about_ca_system_score_gemma":0.00011083346,"threshold_uncertainty_score":0.30965295},"labels":[],"label_agreement":null},{"id":"W2568124169","doi":"10.1182/blood.v106.11.374.374","title":"Activated JAK2 Signaling in Primary Human Hematopoietic Cells Drives Erythropoietin-Independent Erythropoiesis and Myelofibrosis.","year":2005,"lang":"en","type":"article","venue":"Blood","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; Ontario Institute for Cancer Research; University of Toronto; University Health Network","funders":"","keywords":"Erythropoiesis; Myelofibrosis; Haematopoiesis; Erythropoietin; Polycythemia vera; Biology; Context (archaeology); Janus kinase 2; Stem cell; Cancer research; Essential thrombocythemia; Immunology; Bone marrow; Medicine; Signal transduction; Internal medicine; Cell biology; Endocrinology; Anemia","score_opus":0.010475370284824242,"score_gpt":0.2472205926312528,"score_spread":0.23674522234642856,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2568124169","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9945406,0.00092773995,0.000009589921,0.0014446345,0.000049857375,0.00075007975,0.0000122368265,0.000077595876,0.002187698],"genre_scores_gemma":[0.99429965,0.00043196869,0.003978983,0.0004477867,0.00019007787,0.00012928122,0.000044765256,0.000057023437,0.00042045722],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99778706,0.000092956005,0.0005500238,0.00064428616,0.00043404082,0.000491634],"domain_scores_gemma":[0.9990093,0.00015509603,0.00014978954,0.00035903387,0.0000777829,0.00024896726],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00020000072,0.00039757628,0.0007115994,0.00023144047,0.00020711726,0.00006492187,0.00009071083,0.00018393538,0.00050922466],"category_scores_gemma":[0.000024929968,0.00034146127,0.00013050136,0.00023943833,0.00016629286,0.00016487556,0.00010532829,0.00029399246,0.00008805184],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00009075103,0.0037961944,0.21865244,0.00021944742,0.00030332152,0.00020268044,0.0013934328,0.000016386433,0.773863,0.00017710832,0.0002481008,0.0010371296],"study_design_scores_gemma":[0.006561314,0.0004868479,0.19486694,0.0003431913,0.0002902944,0.00013797951,0.0002448975,0.000005645408,0.79634446,0.000056229845,0.00036013089,0.00030208786],"about_ca_topic_score_codex":0.00008616612,"about_ca_topic_score_gemma":0.00009277619,"teacher_disagreement_score":0.023785496,"about_ca_system_score_codex":0.00016297739,"about_ca_system_score_gemma":0.00009260639,"threshold_uncertainty_score":0.99990374},"labels":[],"label_agreement":null},{"id":"W2569321033","doi":"10.14740/jh305w","title":"The Clinical Course and Prognosis of Patients With Essential Thrombocythemia Treated With Hydroxyurea and Low-Dose Aspirin in an 11-Year Follow-Up","year":2016,"lang":"en","type":"article","venue":"Journal of Hematology","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Essential thrombocythemia; Medicine; Aspirin; Internal medicine; Oncology; Polycythemia vera","score_opus":0.014905453136266407,"score_gpt":0.30608218214192406,"score_spread":0.29117672900565766,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2569321033","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99812776,0.00021278427,0.0000075069916,0.0012076435,0.00004369843,0.00036501067,0.0000061020373,0.0000038724643,0.000025642457],"genre_scores_gemma":[0.99932176,0.00026225508,0.00029469893,0.000042452935,0.00003146739,0.000013583427,0.0000025432498,0.000015655512,0.00001559863],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9986829,0.00013723664,0.00058159383,0.00018259637,0.0002257879,0.00018987822],"domain_scores_gemma":[0.99856174,0.00039215415,0.0004574837,0.0001495672,0.0002768825,0.00016218289],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00027992236,0.00015842757,0.00071614096,0.00007330544,0.000047351663,0.0000110662095,0.000057420937,0.00010051205,0.000015668651],"category_scores_gemma":[0.000074021074,0.000062514926,0.000052538297,0.000079939084,0.00038666368,0.000105856314,0.000022223761,0.00013946703,7.7999965e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0039658775,0.0012354224,0.9916267,0.000034655153,0.0003177731,0.00017482704,0.000119455035,1.5097645e-7,0.00007777466,0.00028412955,0.00009017066,0.0020731045],"study_design_scores_gemma":[0.022122739,0.0068595884,0.96560436,0.0005686162,0.0003512107,0.0003817813,0.00011812238,0.0000067918186,0.0037947488,0.000053021093,0.000056592737,0.00008240862],"about_ca_topic_score_codex":0.000008979082,"about_ca_topic_score_gemma":0.00031221073,"teacher_disagreement_score":0.02602228,"about_ca_system_score_codex":0.00002207098,"about_ca_system_score_gemma":0.00014628288,"threshold_uncertainty_score":0.25492847},"labels":[],"label_agreement":null},{"id":"W2569343261","doi":"10.1182/blood.v120.21.432.432","title":"Lille Scoring System Rather Than DIPSS Is a Better Predictive of Overall Mortality After Allogeneic Hematopoietic Cell Transplantation (HCT) for Primary Myelofibrosis Using Reduced Intensity Conditioning: A Report From the Center for International Blood and Marrow Transplant Research (CIBMTR)","year":2012,"lang":"en","type":"article","venue":"Blood","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Medicine; Cumulative incidence; Internal medicine; Busulfan; Fludarabine; Myelofibrosis; Transplantation; International Prognostic Scoring System; Melphalan; Hematopoietic cell; Confidence interval; Hematopoietic stem cell transplantation; Incidence (geometry); Gastroenterology; Surgery; Chemotherapy; Haematopoiesis; Bone marrow; Cyclophosphamide; Stem cell; Myelodysplastic syndromes","score_opus":0.043626951125734184,"score_gpt":0.30639597598328255,"score_spread":0.2627690248575484,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2569343261","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9940247,0.00044185456,0.00084556243,0.0002659363,0.00024397268,0.002014108,0.002032431,0.000021543636,0.00010986833],"genre_scores_gemma":[0.995672,0.000079193785,0.0020393108,0.0001655837,0.00043347204,0.00082069007,0.0007283611,0.00003617339,0.000025239808],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9982335,0.00009969151,0.0004925941,0.0004208815,0.00041915322,0.0003341953],"domain_scores_gemma":[0.9985365,0.00033304296,0.00019341843,0.0002744039,0.0005414679,0.0001211573],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005409291,0.00021759204,0.00042053696,0.000078545796,0.00016089254,0.00003587579,0.00007751239,0.000114012044,0.000022970547],"category_scores_gemma":[0.00004506171,0.00015631718,0.0001899775,0.00006187053,0.00010265013,0.00015276839,0.000028819384,0.00013663356,6.7031687e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0014171214,0.0011874898,0.93227446,0.0007512756,0.0012835227,0.000048106212,0.005340537,0.0000012427964,0.057589423,0.00002150629,0.000067941386,0.00001738588],"study_design_scores_gemma":[0.005467915,0.00029646515,0.6853502,0.0010140652,0.0019687077,0.00025527322,0.0003174805,0.000058508023,0.30505648,0.00004020791,0.000037125425,0.00013757191],"about_ca_topic_score_codex":0.0001406672,"about_ca_topic_score_gemma":0.000017733546,"teacher_disagreement_score":0.24746707,"about_ca_system_score_codex":0.000081451115,"about_ca_system_score_gemma":0.000075456235,"threshold_uncertainty_score":0.637443},"labels":[],"label_agreement":null},{"id":"W2569817649","doi":"10.1182/blood.v112.11.3717.3717","title":"Random Mutagenesis Reveals Residues of JAK2 Critical in Evading Inhibition by Tyrosine Kinase Inhibitors","year":2008,"lang":"en","type":"article","venue":"Blood","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ontario Institute for Cancer Research","funders":"","keywords":"Biology; Janus kinase 2; Myeloid leukemia; Mutation; Tyrosine kinase; Mutagenesis; Polycythemia vera; Protein kinase domain; Point mutation; Cancer research; Molecular biology; Mutant; Genetics; Kinase; Signal transduction; Gene; Immunology","score_opus":0.018512999396775996,"score_gpt":0.27505668358676694,"score_spread":0.25654368418999096,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2569817649","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99463904,0.002950112,0.000016509388,0.0010237063,0.000053128384,0.00047844808,0.000043128304,0.000030486803,0.0007654356],"genre_scores_gemma":[0.9979174,0.00056316605,0.0009110721,0.00018812304,0.00012241365,0.000090748144,0.00005787279,0.000023259678,0.00012594511],"study_design_codex":"observational","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9985502,0.00010906605,0.00048715563,0.00029741786,0.00030770508,0.00024847785],"domain_scores_gemma":[0.9991335,0.00033841113,0.00007476714,0.00019375955,0.00012305478,0.00013646724],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002191945,0.00018187359,0.00051737006,0.0001642045,0.00007257867,0.0000073872066,0.000029658318,0.000108780936,0.00011432976],"category_scores_gemma":[0.0006139682,0.0001528923,0.00010594723,0.00025323487,0.00012582567,0.000083585735,0.000024013978,0.00011328745,0.000017944534],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0005367038,0.004659712,0.7594422,0.00024174672,0.00010423408,0.0009766814,0.00060700264,0.000002394948,0.22779348,0.00026789797,0.0049998574,0.00036810437],"study_design_scores_gemma":[0.013796353,0.0005944259,0.115802586,0.00063182146,0.00021306965,0.00014838921,0.00006176645,0.000005939598,0.8683998,0.000083242194,0.00011921585,0.00014336598],"about_ca_topic_score_codex":0.0001391682,"about_ca_topic_score_gemma":0.000033995842,"teacher_disagreement_score":0.6436396,"about_ca_system_score_codex":0.0000487095,"about_ca_system_score_gemma":0.00006140965,"threshold_uncertainty_score":0.62347674},"labels":[],"label_agreement":null},{"id":"W2571322676","doi":"10.1182/blood.v110.11.4661.4661","title":"A Rare Case of JAK2 V617F Positive Polycythemia Vera in a Child with Neurofibromatosis Type I.","year":2007,"lang":"en","type":"article","venue":"Blood","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Izaak Walton Killam Health Centre; Dalhousie University","funders":"","keywords":"Juvenile myelomonocytic leukemia; Polycythemia vera; Medicine; Neurofibromatosis; Pathology; Immunology; Gastroenterology; Haematopoiesis; Stem cell; Biology; Genetics","score_opus":0.007231242780039169,"score_gpt":0.2473051650984693,"score_spread":0.24007392231843014,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2571322676","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9916223,0.00037741964,0.000004968134,0.00034725576,0.000024013116,0.00045304408,0.000023452856,0.0000214288,0.0071260845],"genre_scores_gemma":[0.99883616,0.00003509826,0.00078219955,0.0001896949,0.00004616238,0.000018254852,0.000020861093,0.000023209866,0.000048368005],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99913394,0.000024494051,0.00022365704,0.00023766691,0.00015334065,0.00022686973],"domain_scores_gemma":[0.9994122,0.00010257194,0.00007317194,0.00020881474,0.00008268085,0.00012055384],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00008105242,0.00016370689,0.00032245117,0.00013524128,0.0000416264,0.000006398177,0.000032407832,0.00006371269,0.000051098366],"category_scores_gemma":[0.00003724911,0.000118546894,0.000051182273,0.0003339181,0.000044147022,0.000038875623,0.000020297835,0.0001308189,0.00001153325],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0018614171,0.004350032,0.9268998,0.00013055991,0.00047217114,0.057289295,0.0018458101,0.0000021152198,0.0050539705,0.0005948495,0.000083908315,0.001416076],"study_design_scores_gemma":[0.01225194,0.0036250888,0.51205367,0.00075142924,0.00050369755,0.030089986,0.00038470686,0.000005663569,0.44005415,0.000014372889,0.00006008063,0.00020519289],"about_ca_topic_score_codex":0.00025438514,"about_ca_topic_score_gemma":0.00023321706,"teacher_disagreement_score":0.43500018,"about_ca_system_score_codex":0.00002965821,"about_ca_system_score_gemma":0.00006469019,"threshold_uncertainty_score":0.48342022},"labels":[],"label_agreement":null},{"id":"W2573703208","doi":"10.1182/blood.v110.11.2536.2536","title":"JAK2 617V&amp;gt;F Mutation Correlates with Arterial Thrombosis in Essential Thrombocythemia.","year":2007,"lang":"en","type":"article","venue":"Blood","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"","keywords":"Essential thrombocythemia; Bone marrow; Internal medicine; Medicine; Exact test; Gastroenterology; Odds ratio; Chromosome abnormality; Pathology; Immunology; Biology; Polycythemia vera; Genetics; Chromosome; Karyotype","score_opus":0.014924077069046839,"score_gpt":0.28026888743361683,"score_spread":0.26534481036456997,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2573703208","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99392754,0.00011470659,0.00030275912,0.00027609995,0.00015985628,0.00055393286,0.000009190296,0.00005884664,0.004597094],"genre_scores_gemma":[0.9969868,0.000056287492,0.0021777218,0.00013826186,0.00032314265,0.000059032347,0.00012206056,0.000030039826,0.00010667178],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99869734,0.00002773486,0.00031262147,0.0003349201,0.00029899887,0.00032836228],"domain_scores_gemma":[0.9993757,0.000105616484,0.00009597882,0.00022006272,0.00008165504,0.00012099455],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00017249404,0.00021705953,0.00038200116,0.00013256763,0.00007711924,0.000028866882,0.000046425786,0.00012210883,0.0004145218],"category_scores_gemma":[0.00004070202,0.0001604352,0.00006497388,0.00024134527,0.00007257644,0.00008902053,0.000018310267,0.00015431819,0.000111655754],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0010595566,0.007234151,0.926149,0.00009835368,0.00073142804,0.0008037993,0.0029904493,0.000022172087,0.056940205,0.0013871595,0.0005958724,0.0019878515],"study_design_scores_gemma":[0.019977776,0.0011746365,0.7862405,0.0003735778,0.00075391686,0.00036458133,0.00028127438,0.000020843221,0.18979862,0.000196706,0.0004922066,0.00032532314],"about_ca_topic_score_codex":0.000051166564,"about_ca_topic_score_gemma":0.00041514714,"teacher_disagreement_score":0.13990846,"about_ca_system_score_codex":0.000062059495,"about_ca_system_score_gemma":0.00007849712,"threshold_uncertainty_score":0.6542358},"labels":[],"label_agreement":null},{"id":"W2576052929","doi":"10.1182/blood.v110.11.1095.1095","title":"Impact of Conditioning on the Outcome of Allografting in Myelofibrosis with Myeloid Metaplasia: Better Survival with Reduced Intensity Approach in Patients ≥50 Years.","year":2007,"lang":"en","type":"article","venue":"Blood","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Hospital; Hamilton Health Sciences; Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Myelofibrosis; Internal medicine; Fludarabine; Gastroenterology; Transplantation; Surgery; Myeloid; Bone marrow; Cyclophosphamide; Chemotherapy","score_opus":0.020401874767260887,"score_gpt":0.2681464875268918,"score_spread":0.24774461275963092,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2576052929","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99843633,0.000013349119,0.000015335438,0.00007655749,0.000013632851,0.00062207045,0.000017569506,0.000008718986,0.0007964593],"genre_scores_gemma":[0.99801695,0.0000022853012,0.0017922092,0.00006544564,0.000016368313,0.000031535656,0.00004947393,0.000020190386,0.000005546063],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99865407,0.000066591485,0.00041829576,0.00024887518,0.0003574954,0.00025465674],"domain_scores_gemma":[0.999137,0.00022531519,0.00021312971,0.00023463032,0.00013045092,0.000059470887],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004279437,0.00018894247,0.00057010195,0.00020569934,0.000026508102,0.00000722403,0.00006272482,0.000064896194,0.000017576975],"category_scores_gemma":[0.000075192795,0.00010185181,0.00009034957,0.00035552963,0.00009670778,0.00004760408,0.000023983986,0.00022195785,0.0000011910686],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0010307886,0.002620822,0.99424046,0.000032919073,0.00037771263,0.000025931262,0.00068483764,0.000030645777,0.00072420656,0.000045132398,0.000004531027,0.00018203452],"study_design_scores_gemma":[0.0068142284,0.0023854473,0.97751784,0.00022318568,0.00017806188,0.000008923169,0.00026062995,0.000006407232,0.0125049595,0.000004210914,8.9469756e-7,0.000095229225],"about_ca_topic_score_codex":0.00038484612,"about_ca_topic_score_gemma":0.00013994989,"teacher_disagreement_score":0.016722616,"about_ca_system_score_codex":0.00007480439,"about_ca_system_score_gemma":0.000045171095,"threshold_uncertainty_score":0.41533962},"labels":[],"label_agreement":null},{"id":"W2577857478","doi":"10.1182/blood.v118.21.5170.5170","title":"A Ruxolitinib Individual Supply Program for Patients with Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis","year":2011,"lang":"en","type":"article","venue":"Blood","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Ruxolitinib; Myelofibrosis; Medicine; Discontinuation; International Prognostic Scoring System; Internal medicine; Anemia; Adverse effect; Clinical endpoint; Placebo; Polycythemia vera; Essential thrombocythemia; Clinical trial; Gastroenterology; Surgery; Myelodysplastic syndromes; Bone marrow; Pathology","score_opus":0.01629583205061588,"score_gpt":0.2501240779281107,"score_spread":0.23382824587749482,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2577857478","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9868909,0.00029490388,0.000031816548,0.0003745953,0.00024110166,0.0072338735,0.002863883,0.0004051581,0.0016637853],"genre_scores_gemma":[0.9403128,0.00013053854,0.047328297,0.0011861583,0.00049620663,0.0044157994,0.005334085,0.00028146605,0.00051462604],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9947431,0.000108650274,0.0010140043,0.0014396147,0.0012004238,0.0014941829],"domain_scores_gemma":[0.99627274,0.00033385752,0.00049379683,0.0010238291,0.0011070464,0.00076874497],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00022730068,0.0011154163,0.0014614699,0.00033460418,0.0004992441,0.00019015612,0.0004486699,0.00047328862,0.0011720721],"category_scores_gemma":[0.00017043165,0.00077659363,0.0005267649,0.0005173463,0.00038599438,0.00047305116,0.00024618025,0.00040452572,0.00013005859],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.01929073,0.034611788,0.90303403,0.0013099555,0.00432505,0.00014918044,0.0038550184,2.5061624e-7,0.0074532474,0.0005256765,0.0024976996,0.022947362],"study_design_scores_gemma":[0.02855075,0.025824495,0.8397575,0.00072439795,0.0033253373,0.00015611811,0.00025731773,0.0000025825304,0.09807254,0.00003858631,0.0023109126,0.0009794785],"about_ca_topic_score_codex":0.00021511783,"about_ca_topic_score_gemma":0.00009707596,"teacher_disagreement_score":0.09061929,"about_ca_system_score_codex":0.00019579958,"about_ca_system_score_gemma":0.0009682692,"threshold_uncertainty_score":0.999741},"labels":[],"label_agreement":null},{"id":"W2584019337","doi":"10.1182/blood.v108.11.4916.4916","title":"In Vitro Erythroid Cell Expansion Analysis in Polycythemia Vera.","year":2006,"lang":"en","type":"article","venue":"Blood","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University","funders":"","keywords":"Polycythemia vera; Erythropoiesis; Biology; Transferrin receptor; Immunology; Erythropoietin; Population; Peripheral blood mononuclear cell; Reticulocyte; Stem cell; Cell biology; Andrology; Transferrin; Medicine; Internal medicine; In vitro; Endocrinology; Genetics; Anemia","score_opus":0.005810812428491745,"score_gpt":0.2336819355414297,"score_spread":0.22787112311293795,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2584019337","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9940247,0.0007692288,0.000009276333,0.0006217835,0.000027913258,0.00024702118,0.0000103171915,0.000017978942,0.0042717876],"genre_scores_gemma":[0.9980929,0.00008148331,0.00075871695,0.00023153335,0.000090487876,0.000067195855,0.00008659308,0.000013405566,0.00057772256],"study_design_codex":"observational","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9989668,0.000035705747,0.00027786926,0.00029158025,0.00018898548,0.00023903546],"domain_scores_gemma":[0.99957997,0.00005923458,0.000048311955,0.00023069516,0.00002277769,0.00005900906],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000084398,0.00015062178,0.00039647287,0.0003652799,0.00002391673,0.000010957489,0.0000383972,0.00007795674,0.00015845227],"category_scores_gemma":[0.000011063747,0.00012435297,0.00012198471,0.00069274387,0.000018074614,0.000049712664,0.00001879388,0.000120615485,0.000048352995],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00019958882,0.005527612,0.87711674,0.000028736538,0.00016158103,0.00072703516,0.00021978373,0.000060972852,0.115216844,0.000045330125,0.00039953593,0.00029624777],"study_design_scores_gemma":[0.006304067,0.0001231813,0.3711083,0.000026334457,0.0005158112,0.0000116883275,0.000038378326,0.00009763254,0.6212463,0.000059041846,0.00035799944,0.000111320565],"about_ca_topic_score_codex":0.0010094417,"about_ca_topic_score_gemma":0.00059805985,"teacher_disagreement_score":0.5060294,"about_ca_system_score_codex":0.00007687525,"about_ca_system_score_gemma":0.000050360875,"threshold_uncertainty_score":0.5070967},"labels":[],"label_agreement":null},{"id":"W2584614183","doi":"10.1182/blood.v120.21.178.178","title":"Phase I/II Study of CYT387, a JAK1/JAK2 Inhibitor for the Treatment of Myelofibrosis","year":2012,"lang":"en","type":"article","venue":"Blood","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":22,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Jewish General Hospital; Princess Margaret Cancer Centre","funders":"","keywords":"Myelofibrosis; Medicine; Constitutional symptoms; Internal medicine; Gastroenterology; Polycythemia vera; Phases of clinical research; Anemia; Essential thrombocythemia; Surgery; Clinical trial; Bone marrow; Disease","score_opus":0.03913227367097902,"score_gpt":0.327461189414224,"score_spread":0.28832891574324493,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2584614183","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9947214,0.0019099449,0.000012575469,0.00022481127,0.000117426294,0.0026728394,0.00010533806,0.000012273638,0.00022335042],"genre_scores_gemma":[0.9974074,0.00023570043,0.0006183839,0.000030164056,0.0003079117,0.0010921515,0.000019098254,0.00002137424,0.0002678436],"study_design_codex":"observational","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9989509,0.000035292047,0.00036563395,0.00017926023,0.00022813224,0.00024076086],"domain_scores_gemma":[0.99894017,0.0002990448,0.00015580944,0.00037388847,0.00011810862,0.000113001],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001166272,0.00019143232,0.00048474252,0.000061633735,0.00011765403,0.000004506765,0.000052005737,0.000048658527,0.0000994625],"category_scores_gemma":[0.000038610815,0.000103960956,0.00018871977,0.00012440271,0.000045714165,0.000043220643,0.000020684836,0.00003083017,0.00000602984],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0015358279,0.4334216,0.48920777,0.00014626085,0.0038558005,0.000008520797,0.018859742,0.0000017910446,0.021169025,0.00028574013,0.0007270287,0.030780893],"study_design_scores_gemma":[0.08299181,0.115220055,0.086295776,0.00009410796,0.0052479994,0.000018127992,0.0022357209,0.000015840747,0.6959269,0.000009236967,0.011773606,0.00017080798],"about_ca_topic_score_codex":0.00009936309,"about_ca_topic_score_gemma":0.000045830537,"teacher_disagreement_score":0.6747579,"about_ca_system_score_codex":0.00003686756,"about_ca_system_score_gemma":0.000045726978,"threshold_uncertainty_score":0.42394048},"labels":[],"label_agreement":null},{"id":"W2584660382","doi":"10.1182/blood.v116.21.5054.5054","title":"LY2784544, a Novel JAK2 Inhibitor, Decreases In Vitro Growth of Hematopoietic Human Progenitors From JAK2 V617F Positive Polycythemia Vera Patients","year":2010,"lang":"en","type":"article","venue":"Blood","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Polycythemia vera; Peripheral blood mononuclear cell; Haematopoiesis; In vitro; Myeloid; Immunology; Progenitor cell; Medicine; CFU-GM; Pharmacology; Biology; Molecular biology; Andrology; Internal medicine; Stem cell; Biochemistry","score_opus":0.007086816488903168,"score_gpt":0.2374670101542736,"score_spread":0.23038019366537044,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2584660382","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.997704,0.00012779316,0.0000029727344,0.00015371447,0.0001624571,0.0009792418,0.00025411023,0.00003864823,0.0005770435],"genre_scores_gemma":[0.9970772,0.000009325753,0.0018831005,0.00013479554,0.00023807629,0.00020271701,0.00038488267,0.00004717784,0.000022724062],"study_design_codex":"observational","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9981548,0.00004086519,0.00052400754,0.00048055913,0.00044795725,0.00035176644],"domain_scores_gemma":[0.9987763,0.00018560844,0.00019854933,0.00035164482,0.00023130733,0.00025658065],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00007713406,0.00033747448,0.0006178639,0.00018561774,0.00008576042,0.000022021733,0.000117185904,0.00018675234,0.000104920065],"category_scores_gemma":[0.00019416874,0.0002813793,0.00017454091,0.00022913414,0.000120148536,0.00009424166,0.00007454384,0.0003126618,0.000022285338],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00031302177,0.010404939,0.6230116,0.000048390597,0.00026268902,0.000062822466,0.00072516425,3.3006344e-8,0.36469984,0.00023267805,0.00004904698,0.00018980804],"study_design_scores_gemma":[0.009404695,0.00051881274,0.3200718,0.00020719029,0.00029498604,0.00001922708,0.000053575877,0.0000020992743,0.6691308,0.00011835874,0.000013890892,0.0001645404],"about_ca_topic_score_codex":0.0010094636,"about_ca_topic_score_gemma":0.00014550371,"teacher_disagreement_score":0.304431,"about_ca_system_score_codex":0.000057923542,"about_ca_system_score_gemma":0.00013946068,"threshold_uncertainty_score":0.9999638},"labels":[],"label_agreement":null},{"id":"W2584897115","doi":"10.1182/blood.v112.11.1748.1748","title":"Improved Survival in Red Blood Cell Transfusion Dependent Patients with Primary Myelofibrosis (PMF) Receiving Iron Chelation Therapy.","year":2008,"lang":"en","type":"article","venue":"Blood","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia Hospital; St. Paul's Hospital","funders":"","keywords":"Medicine; Deferasirox; Myelofibrosis; Internal medicine; Gastroenterology; Myelodysplastic syndromes; Blood transfusion; Thalassemia; Bone marrow; International Prognostic Scoring System; Surgery; Pediatrics","score_opus":0.010570215473079589,"score_gpt":0.2029129414743136,"score_spread":0.192342726001234,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2584897115","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99576575,0.0003928505,0.000021623458,0.00017580645,0.000075857795,0.0014121161,0.00001663706,0.000060539478,0.0020787944],"genre_scores_gemma":[0.99624604,0.0017213075,0.0012230559,0.0001023423,0.000072638744,0.00016845514,0.00020671479,0.00005022395,0.00020923385],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99820703,0.000101586425,0.00038276374,0.00050060364,0.0004773712,0.00033065825],"domain_scores_gemma":[0.9992308,0.0000898147,0.00012735152,0.00030006698,0.00011622156,0.00013573084],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00013777861,0.00029999725,0.00044545403,0.00013796441,0.00014588726,0.000014938799,0.0000665607,0.00014670672,0.00009510065],"category_scores_gemma":[0.000018260516,0.00022356726,0.00008799268,0.00023601623,0.000037137754,0.0001372048,0.000020167849,0.00021306341,0.000007547787],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00081197685,0.0077368673,0.9524666,0.00006567736,0.000113150585,0.000061646184,0.0008371715,0.0000066172815,0.03555917,0.0000016869798,0.000008724936,0.002330698],"study_design_scores_gemma":[0.028423078,0.002100947,0.8533194,0.00012422452,0.00019911192,0.000017413431,0.000026100586,0.000012546358,0.11553819,0.0000025437855,0.0000272014,0.00020924999],"about_ca_topic_score_codex":0.00020736115,"about_ca_topic_score_gemma":0.00016818376,"teacher_disagreement_score":0.099147215,"about_ca_system_score_codex":0.00008952849,"about_ca_system_score_gemma":0.00011698554,"threshold_uncertainty_score":0.9116808},"labels":[],"label_agreement":null},{"id":"W2586674273","doi":"10.1182/blood.v124.21.3521.3521","title":"Difficulties in Establishing the Cause of Thrombocytopenia Among Ambulatory Patients Referred to Hematology: An Agreement Study","year":2014,"lang":"en","type":"article","venue":"Blood","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"St. Joseph’s Healthcare Hamilton; St. Joseph's Hospital; McMaster University","funders":"","keywords":"Medicine; Pediatrics; Hematology; Internal medicine; Thrombotic microangiopathy; Medical diagnosis; Referral; Etiology; Ambulatory; Disease; Family medicine; Pathology","score_opus":0.023159619081572054,"score_gpt":0.2839802824027618,"score_spread":0.26082066332118975,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2586674273","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9979525,0.000040400002,0.0000022252475,0.00015450423,0.0000851342,0.0014369513,0.0000063982375,0.000018159333,0.0003036907],"genre_scores_gemma":[0.9993853,0.000005489452,0.00013962176,0.00014661961,0.000036133802,0.00021751357,0.000020111514,0.000015584666,0.000033645214],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.998591,0.0001896923,0.00037445425,0.00030486824,0.00032476886,0.00021523099],"domain_scores_gemma":[0.99902344,0.00017139637,0.000109841705,0.00047117058,0.00011104368,0.00011313476],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002917726,0.00017345558,0.0004802921,0.000096786505,0.00007414934,0.000025774207,0.00012874392,0.000051146006,0.000029271669],"category_scores_gemma":[0.00025348828,0.00010495892,0.000041485604,0.00015596836,0.0000476287,0.000102520564,0.00009082854,0.00011820695,0.00001035894],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00006064381,0.0077082342,0.98614407,0.00002304995,0.00016792199,0.00002237441,0.0051998426,0.000013285912,0.000106801934,0.00013490267,0.00013083627,0.00028801456],"study_design_scores_gemma":[0.006021658,0.0021892989,0.98437166,0.000103876075,0.00022894552,0.000002678536,0.0016688979,0.000014608494,0.005252772,0.000009214444,0.00003623568,0.000100154524],"about_ca_topic_score_codex":0.0004443722,"about_ca_topic_score_gemma":0.003279632,"teacher_disagreement_score":0.005961014,"about_ca_system_score_codex":0.000040627794,"about_ca_system_score_gemma":0.000026085927,"threshold_uncertainty_score":0.42801005},"labels":[],"label_agreement":null},{"id":"W2587294303","doi":"10.1182/blood.v128.22.1262.1262","title":"Retrospective Study of High Hemoglobin Levels in 56 Young Adults","year":2016,"lang":"en","type":"article","venue":"Blood","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Hôpital Fleurimont; Université de Sherbrooke; Centre Hospitalier Universitaire de Sherbrooke","funders":"","keywords":"Hematocrit; Medicine; Etiology; Retrospective cohort study; Hemoglobin; Population; Pediatrics; Hematology; Observational study; Internal medicine","score_opus":0.014169943929773918,"score_gpt":0.25755261545655445,"score_spread":0.24338267152678053,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2587294303","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9974823,0.00008606277,0.0000049316272,0.00031695937,0.00006758949,0.00085869536,0.0000386726,0.000021471036,0.0011233385],"genre_scores_gemma":[0.999282,0.000031271633,0.00015527804,0.000029953875,0.000075590826,0.00012786641,0.000002607769,0.000014803529,0.0002805977],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9989388,0.000046766607,0.00027386178,0.00030425028,0.00025593958,0.00018037051],"domain_scores_gemma":[0.99941784,0.000045754412,0.00008290959,0.0002689759,0.00011605901,0.000068444686],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000098389704,0.00014130032,0.00039841136,0.000091058166,0.000022516688,0.000003904265,0.0000510465,0.000051755113,0.0001632336],"category_scores_gemma":[0.00010809626,0.00008449936,0.000058004152,0.00016331875,0.000028045848,0.000046983,0.000033465843,0.00006502392,0.000029481587],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00020248714,0.008092306,0.9870605,0.000016748218,0.00024364894,0.00016474532,0.0012703675,1.2385942e-7,0.0013052495,0.0003666116,0.00005863849,0.0012185731],"study_design_scores_gemma":[0.023825845,0.003085302,0.93971854,0.00027431632,0.00015041229,0.000019763333,0.00032917224,5.0505366e-7,0.032374512,0.00012653637,0.000009204681,0.000085886866],"about_ca_topic_score_codex":0.000511812,"about_ca_topic_score_gemma":0.00093377143,"teacher_disagreement_score":0.047341958,"about_ca_system_score_codex":0.00009169901,"about_ca_system_score_gemma":0.0000441985,"threshold_uncertainty_score":0.3445784},"labels":[],"label_agreement":null},{"id":"W2587685665","doi":"10.1182/blood.v128.22.lba-5.lba-5","title":"Results of the Persist-2 Phase 3 Study of Pacritinib (PAC) Versus Best Available Therapy (BAT), Including Ruxolitinib (RUX), in Patients (pts) with Myelofibrosis (MF) and Platelet Counts &lt;100,000/µl","year":2016,"lang":"en","type":"article","venue":"Blood","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":37,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Ruxolitinib; Medicine; Internal medicine; Population; Adverse effect; Myelofibrosis; Clinical endpoint; Randomization; Intention-to-treat analysis; Randomized controlled trial; Gastroenterology; Phases of clinical research; Clinical trial; Bone marrow","score_opus":0.04798725098813239,"score_gpt":0.2931100426966477,"score_spread":0.2451227917085153,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2587685665","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99392426,0.00025714966,2.0510298e-7,0.00015656122,0.00006903769,0.00096542743,0.00033508227,0.000010721191,0.004281539],"genre_scores_gemma":[0.9990965,0.00036828037,0.00006298706,0.000032526852,0.000036790458,0.00006538407,0.000016272315,0.000022996253,0.00029824086],"study_design_codex":"observational","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9985694,0.00008462101,0.0003838767,0.00032693718,0.00040189084,0.00023326257],"domain_scores_gemma":[0.9989208,0.0002744321,0.00019333896,0.00035197355,0.00017743169,0.00008204988],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00016575654,0.00020198573,0.0004220379,0.00009189149,0.00007812666,0.000010238313,0.00008913597,0.00006511865,0.00014323309],"category_scores_gemma":[0.0001278265,0.00010626975,0.00004895493,0.00019921255,0.00011357641,0.000067919376,0.000054819015,0.00008218943,0.000013357689],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.009867222,0.024726728,0.9424865,0.00008910141,0.0007538883,0.000035568137,0.0031931428,4.0498512e-7,0.0018904789,0.00005386088,0.0012036645,0.01569944],"study_design_scores_gemma":[0.4275134,0.04215147,0.38559455,0.0020335235,0.00077620527,0.000015913782,0.0023509443,0.000005982926,0.13228667,0.00001680543,0.006755717,0.00049882557],"about_ca_topic_score_codex":0.00017840242,"about_ca_topic_score_gemma":0.000095544165,"teacher_disagreement_score":0.5568919,"about_ca_system_score_codex":0.000048982387,"about_ca_system_score_gemma":0.000059893646,"threshold_uncertainty_score":0.43335548},"labels":[],"label_agreement":null},{"id":"W2588698611","doi":"10.1182/blood.v114.22.2916.2916","title":"Thrombotic Complications and Risk of Myeloid Transformation in 164 Elderly Patients with Essential Thrombocythemia.","year":2009,"lang":"en","type":"article","venue":"Blood","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"St. Paul's Hospital; University of British Columbia","funders":"","keywords":"Medicine; Essential thrombocythemia; Myelofibrosis; Thrombosis; Internal medicine; Venous thrombosis; Surgery; Myeloid leukemia; Myeloproliferative neoplasm; Polycythemia vera; Pediatrics; Bone marrow","score_opus":0.006320464987302755,"score_gpt":0.23338135870590535,"score_spread":0.22706089371860258,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2588698611","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9970258,0.00009859404,0.00014938462,0.00036015562,0.000007487546,0.000605496,0.00002758704,0.000014665853,0.0017108631],"genre_scores_gemma":[0.9985701,0.00024255886,0.0010183151,0.00005163167,0.000009584951,0.000026386955,0.00007186137,0.000006307469,0.0000032812961],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9993467,0.00002370941,0.00021344266,0.00014696339,0.00015623994,0.00011294185],"domain_scores_gemma":[0.99961215,0.000038558417,0.00008207261,0.00013712562,0.00007677381,0.000053343298],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000044159307,0.00010658109,0.00023687634,0.00006841423,0.000046471225,0.00000795517,0.000025712823,0.000041557003,0.000014100713],"category_scores_gemma":[0.000011882435,0.00007651571,0.00002805296,0.00011803982,0.000041429415,0.000079496494,0.0000033955198,0.00008018593,0.0000032078208],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000077011195,0.0036790362,0.98706144,0.000040642186,0.00015178915,0.0000023349564,0.0012253217,0.00001010786,0.0006726822,0.00082754524,0.000010812308,0.006241305],"study_design_scores_gemma":[0.0077129146,0.0015231341,0.9785917,0.000119960816,0.00034410236,0.0000069822963,0.000055811386,0.000030567713,0.011333879,0.0001954764,0.00001518449,0.00007028771],"about_ca_topic_score_codex":0.0000392779,"about_ca_topic_score_gemma":0.00006828545,"teacher_disagreement_score":0.010661197,"about_ca_system_score_codex":0.000015439424,"about_ca_system_score_gemma":0.000030917974,"threshold_uncertainty_score":0.312022},"labels":[],"label_agreement":null},{"id":"W2589065286","doi":"10.1182/blood.v110.11.4655.4655","title":"Familial Essential Thrombocythemia Showing Spontaneous Megakaryocyte Colony Formation and Acquired JAK2 Mutations without a Germline Mutation in C-MPL or TPO.","year":2007,"lang":"en","type":"article","venue":"Blood","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Izaak Walton Killam Health Centre; Dalhousie University","funders":"","keywords":"Essential thrombocythemia; Megakaryocyte; Thrombopoietin; Thrombopoietin receptor; Polycythemia vera; Germline mutation; Biology; Mutation; Germline; Genetics; Myeloproliferative Disorders; Immunology; Thrombocytosis; Gene; Platelet; Haematopoiesis; Stem cell","score_opus":0.018356280245539213,"score_gpt":0.2928085827134607,"score_spread":0.2744523024679215,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2589065286","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.996778,0.0001714601,0.0007809468,0.00025348522,0.00009110156,0.0009863231,0.000018417999,0.000064168766,0.0008560747],"genre_scores_gemma":[0.9958043,0.000082344035,0.0033431752,0.00018531847,0.0001748533,0.00009169992,0.00017554569,0.000025389092,0.000117391966],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9985373,0.000043138098,0.00046840266,0.00029427608,0.0003526566,0.00030424792],"domain_scores_gemma":[0.9992535,0.00020543732,0.000120682314,0.00014944254,0.00013847265,0.00013242943],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003177978,0.00021116136,0.00037245452,0.00020352619,0.00013713037,0.000037920952,0.00003947396,0.0001220281,0.000064382366],"category_scores_gemma":[0.00018317784,0.00017016823,0.000057511374,0.00023688997,0.000051679082,0.00022142459,0.000026114463,0.000103729966,0.000014844292],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.016828211,0.014580026,0.48812938,0.0012827993,0.0019831695,0.04991743,0.041897632,0.00030846227,0.33851108,0.0020417417,0.0003538861,0.044166192],"study_design_scores_gemma":[0.043323085,0.002818625,0.6017686,0.0007164609,0.0016139351,0.015011129,0.002294118,0.004330811,0.3266971,0.00026431747,0.00047035416,0.00069144793],"about_ca_topic_score_codex":0.000116883064,"about_ca_topic_score_gemma":0.0023674306,"teacher_disagreement_score":0.11363923,"about_ca_system_score_codex":0.00013282799,"about_ca_system_score_gemma":0.00013505347,"threshold_uncertainty_score":0.6939259},"labels":[],"label_agreement":null},{"id":"W2589237569","doi":"10.1186/s13045-017-0417-z","title":"Long-term treatment with ruxolitinib for patients with myelofibrosis: 5-year update from the randomized, double-blind, placebo-controlled, phase 3 COMFORT-I trial","year":2017,"lang":"en","type":"article","venue":"Journal of Hematology & Oncology","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":427,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"National Cancer Institute; Incyte","keywords":"Ruxolitinib; Medicine; Placebo; Myelofibrosis; Internal medicine; Randomized controlled trial; Population; Adverse effect; Clinical endpoint; Surgery; Pathology; Bone marrow","score_opus":0.03706328763014617,"score_gpt":0.3607162889532588,"score_spread":0.32365300132311264,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2589237569","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.981016,0.00061801693,0.00033244723,0.0076525873,0.0006862181,0.009047818,0.00008063742,0.000014592455,0.0005516796],"genre_scores_gemma":[0.9932414,0.00048156217,0.002598553,0.0005543439,0.0006968546,0.0021239624,0.00012746727,0.000050186773,0.00012564322],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9970184,0.00039351368,0.0012908498,0.00039711304,0.00038969197,0.0005104381],"domain_scores_gemma":[0.991873,0.0031561265,0.0033979502,0.0006491172,0.00062701636,0.00029675508],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007826844,0.00048633304,0.003791041,0.00013758872,0.0005679564,0.00009103011,0.00032919456,0.00029368175,0.00019945843],"category_scores_gemma":[0.00033798648,0.00020912109,0.0006683623,0.000043078493,0.00067862327,0.00018425344,0.000046411966,0.0003310748,0.000015924663],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.877329,0.006135759,0.10490894,0.000019513205,0.0064006844,0.0004961859,0.0002794787,0.0000016130633,0.0000033958117,0.0013007583,0.00055031583,0.0025743602],"study_design_scores_gemma":[0.94412327,0.04277953,0.0026750606,0.00026067137,0.0064780484,0.0006578089,0.000096023556,0.000011357966,0.0005167343,0.000121392506,0.00209031,0.00018978577],"about_ca_topic_score_codex":0.00004846359,"about_ca_topic_score_gemma":0.00029513348,"teacher_disagreement_score":0.10223388,"about_ca_system_score_codex":0.00029618724,"about_ca_system_score_gemma":0.00085408107,"threshold_uncertainty_score":0.8527711},"labels":[],"label_agreement":null},{"id":"W2589631417","doi":"10.1182/blood.v118.21.3624.3624","title":"Efficacy of SAR302503, a JAK2 Inhibitor, in the Treatment of a Primary Xenograft Model of Human Acute Myeloid Leukemia,","year":2011,"lang":"en","type":"article","venue":"Blood","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; BC Cancer Agency; Hospital for Sick Children; Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Myeloid leukemia; Medicine; Myeloid; Leukemia; Transplantation; Haematopoiesis; Myelofibrosis; Stem cell; Cancer research; Nod; Ruxolitinib; Pharmacology; Bone marrow; Immunology; Internal medicine; Biology; Endocrinology","score_opus":0.044340039342035856,"score_gpt":0.2744695478423681,"score_spread":0.23012950850033226,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2589631417","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9930889,0.00060540426,0.000005959401,0.00004965984,0.000016295868,0.0009791455,0.000049925362,0.000010923272,0.005193792],"genre_scores_gemma":[0.9974514,0.0006002416,0.0015525628,0.000055625333,0.000034554614,0.0001500719,0.000039726187,0.000018830337,0.000096976044],"study_design_codex":"observational","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99864846,0.00006176942,0.0005536792,0.00023662933,0.00030060735,0.00019882488],"domain_scores_gemma":[0.99905044,0.00010255812,0.0002262647,0.00047095073,0.000088932386,0.000060881644],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00012225346,0.00021475615,0.0007151889,0.00015146843,0.00003084153,0.0000025509196,0.00011299551,0.00008955177,0.000033089655],"category_scores_gemma":[0.000012785971,0.00013060891,0.00022871632,0.00019177799,0.00012909462,0.00003608629,0.000024198625,0.00007693089,0.000002781877],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0026215194,0.11443838,0.5266151,0.00072953454,0.004493428,0.00031369954,0.085002854,0.000052909072,0.24837302,0.0033595115,0.00027935862,0.0137206875],"study_design_scores_gemma":[0.023472972,0.010469485,0.2315341,0.00030638176,0.0017814415,0.000026523412,0.0002754889,0.00005890598,0.7316703,0.00021009921,0.000044652283,0.00014963337],"about_ca_topic_score_codex":0.0004186426,"about_ca_topic_score_gemma":0.00008415478,"teacher_disagreement_score":0.48329732,"about_ca_system_score_codex":0.000096066105,"about_ca_system_score_gemma":0.00022958602,"threshold_uncertainty_score":0.5326077},"labels":[],"label_agreement":null},{"id":"W2590943925","doi":"10.1111/bjh.14508","title":"The <scp>JAK</scp>2 blocker <scp>TG</scp>101209 is a potent inhibitor of clonogenic progenitor cell growth in patients with chronic myeloid leukaemia","year":2017,"lang":"en","type":"letter","venue":"British Journal of Haematology","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"Austrian Science Fund","keywords":"CFU-GM; Progenitor cell; Clonogenic assay; Progenitor; Myeloid; Cancer research; Medicine; Cell; Stem cell; Biology; Cell biology","score_opus":0.0073944042852346435,"score_gpt":0.22014401739104578,"score_spread":0.21274961310581114,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2590943925","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9635737,0.017546227,0.000006464006,0.015159108,0.0010466899,0.001980169,0.0002175298,0.000020034067,0.000450071],"genre_scores_gemma":[0.9606683,0.007873277,0.0008621507,0.02244293,0.004531373,0.0004237689,0.00030681447,0.00037726862,0.0025141193],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9939015,0.00045867424,0.0021453307,0.0007955689,0.0014184829,0.001280431],"domain_scores_gemma":[0.99278206,0.00108097,0.0034276284,0.0007512431,0.0016125619,0.0003455489],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.0005472895,0.0008673395,0.0029293734,0.00048674128,0.0004016785,0.00018752206,0.000830212,0.0012584846,0.00003193973],"category_scores_gemma":[0.00084962475,0.00064726337,0.00079245254,0.00023714498,0.00068183895,0.00021680852,0.00021528304,0.003292294,0.000050137238],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0001027965,0.0011775367,0.23228125,0.0010863383,0.0016131697,0.05355451,0.0003134901,0.0000012991533,0.000038835504,0.000008927514,0.7082556,0.0015662516],"study_design_scores_gemma":[0.044619642,0.014250454,0.28253126,0.014546138,0.004699148,0.18494958,0.00031063045,0.000015152627,0.053627856,0.00033194234,0.3994772,0.0006409737],"about_ca_topic_score_codex":0.00019248016,"about_ca_topic_score_gemma":0.00020581778,"teacher_disagreement_score":0.30877838,"about_ca_system_score_codex":0.0006565738,"about_ca_system_score_gemma":0.0017342832,"threshold_uncertainty_score":0.99959785},"labels":[],"label_agreement":null},{"id":"W2591871775","doi":"10.1182/blood.v128.22.3110.3110","title":"A Pooled Overall Survival (OS) Analysis of 5-Year Data from the COMFORT-I and COMFORT-II Trials of Ruxolitinib for the Treatment of Myelofibrosis (MF)","year":2016,"lang":"en","type":"article","venue":"Blood","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Ruxolitinib; Medicine; Myelofibrosis; International Prognostic Scoring System; Internal medicine; Clinical endpoint; Clinical trial; Hazard ratio; Placebo; Surrogate endpoint; Crossover study; Surgery; Confidence interval; Myelodysplastic syndromes; Bone marrow; Pathology","score_opus":0.12174213721891605,"score_gpt":0.35179578534296735,"score_spread":0.2300536481240513,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2591871775","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9817152,0.001708556,0.00012568563,0.0014958484,0.000053109936,0.0014028,0.01336805,0.000008541167,0.00012219237],"genre_scores_gemma":[0.9950959,0.0030959498,0.000691211,0.00005470844,0.00011970245,0.00014700771,0.0006395112,0.00001762824,0.00013839858],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99804324,0.00018868655,0.0008901885,0.00034894713,0.00033356855,0.00019538437],"domain_scores_gemma":[0.9921237,0.0059404727,0.00059419294,0.0011283623,0.0001354965,0.0000777382],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008001067,0.00022042084,0.0015030878,0.000084693645,0.00009673902,0.000009708067,0.00021598589,0.00007456791,0.00030998577],"category_scores_gemma":[0.00042656402,0.00008638428,0.00044204007,0.00018997568,0.00018188421,0.00004797651,0.00009785399,0.000028600902,6.7419546e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.002397069,0.0059431423,0.9252108,0.00006819471,0.043502335,0.0000032373887,0.00116354,0.0000040149434,0.008814039,0.0023568075,0.00079634984,0.009740502],"study_design_scores_gemma":[0.042580176,0.004917624,0.7687737,0.00030507642,0.07264254,0.0000025329975,0.00048553463,0.00029096412,0.10146331,0.00033242814,0.007990372,0.00021575148],"about_ca_topic_score_codex":0.0011216588,"about_ca_topic_score_gemma":0.00064667437,"teacher_disagreement_score":0.15643708,"about_ca_system_score_codex":0.000022614091,"about_ca_system_score_gemma":0.000098327546,"threshold_uncertainty_score":0.35226485},"labels":[],"label_agreement":null},{"id":"W2592146876","doi":"10.1182/blood.v128.22.4264.4264","title":"Distribution and Impact of Comorbidities on Survival and Leukemic Transformation in Myeloproliferative Neoplasm (MPN)-Associated Myelofibrosis (MF)","year":2016,"lang":"en","type":"article","venue":"Blood","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University Health Network; University of Toronto; Princess Margaret Cancer Centre","funders":"","keywords":"Myelofibrosis; Medicine; Comorbidity; Myeloproliferative neoplasm; Internal medicine; Polycythemia vera; Proportional hazards model; Population; International Prognostic Scoring System; Survival analysis; Cancer; Oncology; Myelodysplastic syndromes; Bone marrow","score_opus":0.01626958853424984,"score_gpt":0.26803980581992337,"score_spread":0.2517702172856735,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2592146876","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9976589,0.00013837291,0.00002770549,0.00056122657,0.000029907704,0.0004956878,0.0004975537,0.000024875038,0.0005657797],"genre_scores_gemma":[0.9987799,0.00087106833,0.000023724264,0.00001986855,0.000025473342,0.00006211262,0.00015953547,0.000013224277,0.000045102668],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9989082,0.000097316544,0.00032943723,0.00022887407,0.00021480054,0.00022132332],"domain_scores_gemma":[0.9992639,0.00030849522,0.00011341783,0.00011023041,0.00009706385,0.00010690988],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000183528,0.00021202337,0.00045230478,0.00010493512,0.00006330754,0.000016415084,0.00002549896,0.00011512678,0.000027113168],"category_scores_gemma":[0.00013408206,0.00013047314,0.00007544159,0.00014126897,0.00010725088,0.00014895659,0.000013466932,0.00009079224,0.0000036259362],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00060318416,0.0012608,0.9750765,0.00008440847,0.00043997288,0.000017232465,0.0016482915,0.0000031160137,0.01248638,0.0017481566,0.000075846125,0.006556123],"study_design_scores_gemma":[0.010564628,0.0018964433,0.93413055,0.0004836196,0.0001455558,0.000025253354,0.00019254135,0.000037486392,0.052198756,0.00017504282,0.000014768741,0.00013532818],"about_ca_topic_score_codex":0.0002040259,"about_ca_topic_score_gemma":0.00018357938,"teacher_disagreement_score":0.040945914,"about_ca_system_score_codex":0.00020278858,"about_ca_system_score_gemma":0.00011034395,"threshold_uncertainty_score":0.53205407},"labels":[],"label_agreement":null},{"id":"W2592509843","doi":"10.1097/mph.0000000000000809","title":"Monocyte Chemoattractant Protein-1 (MCP-1) as a Potential Therapeutic Target and a Noninvasive Biomarker of Liver Fibrosis Associated With Transient Myeloproliferative Disorder in Down Syndrome","year":2017,"lang":"en","type":"article","venue":"Journal of Pediatric Hematology/Oncology","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Pediatric Oncology Group","funders":"","keywords":"Medicine; Monocyte; Pathogenesis; Biomarker; Fibrosis; Chemotaxis; Liver fibrosis; Immunology; Pathology; Internal medicine; Receptor; Biology","score_opus":0.020109241127633667,"score_gpt":0.29191684414379065,"score_spread":0.271807603016157,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2592509843","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9888509,0.003872358,0.0001407531,0.0054517593,0.000110911424,0.001251466,0.000022935643,0.000009741054,0.0002891961],"genre_scores_gemma":[0.99611604,0.001569513,0.0018604476,0.00014822566,0.00007844901,0.00011718382,0.000008261099,0.0000346367,0.0000672445],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99723697,0.00033024506,0.0011098897,0.00039586663,0.00044269304,0.0004843119],"domain_scores_gemma":[0.99667305,0.00042510976,0.0019106138,0.00028570386,0.00042648034,0.00027905832],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0006778341,0.00039626512,0.0018033528,0.00046923177,0.00020150736,0.000033437376,0.00020470886,0.00046580503,0.00012037631],"category_scores_gemma":[0.00044474332,0.00026727217,0.00023059906,0.00022835737,0.00039367005,0.0002463113,0.00006714989,0.0005961517,0.0000046840205],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00954434,0.008990045,0.92606974,0.0005691161,0.0038750705,0.032755256,0.005344317,0.0000321712,0.0064871935,0.00054202287,0.0002922056,0.0054984973],"study_design_scores_gemma":[0.021090312,0.014201531,0.93500733,0.00042338553,0.0019464493,0.017441453,0.0006393568,0.0002545216,0.007752551,0.00034786836,0.00046579403,0.000429451],"about_ca_topic_score_codex":0.000070035814,"about_ca_topic_score_gemma":0.00016197302,"teacher_disagreement_score":0.015313802,"about_ca_system_score_codex":0.00031341639,"about_ca_system_score_gemma":0.0012951386,"threshold_uncertainty_score":0.99997795},"labels":[],"label_agreement":null},{"id":"W2592583156","doi":"10.1182/blood.v126.23.1600.1600","title":"Circulating Cytokines and Markers of Iron Metabolism in Myelofibrosis Patients Treated with Momelotininb: Correlatives from the Ym-387-II Study","year":2015,"lang":"en","type":"article","venue":"Blood","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Jewish General Hospital; Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Medicine; Myelofibrosis; Internal medicine; Anemia; Gastroenterology; Thrombocytosis; Cytokine; Wilcoxon signed-rank test; Bone marrow; Proinflammatory cytokine; Ruxolitinib; Immunology; Mann–Whitney U test; Platelet; Inflammation","score_opus":0.01807539859597501,"score_gpt":0.23955891928596687,"score_spread":0.22148352068999186,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2592583156","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99768007,0.0005328845,0.0000011794598,0.00012551314,0.000029140994,0.0010896099,0.000044231663,0.000020508047,0.00047688896],"genre_scores_gemma":[0.9993357,0.000028085211,0.0003419757,0.000038024897,0.000036209163,0.000110065164,0.000050595572,0.00002288233,0.000036480305],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9986975,0.00015533996,0.000320907,0.00031770047,0.00033285958,0.00017568831],"domain_scores_gemma":[0.999092,0.00025489458,0.00016936105,0.00023223447,0.00014533327,0.000106182015],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00016046896,0.0002209912,0.00048889976,0.00007083666,0.000079434154,0.000015041422,0.000055743112,0.000051867803,0.000016519904],"category_scores_gemma":[0.00016694036,0.00012161847,0.000036906516,0.00025488157,0.00008258097,0.00008040853,0.000064664186,0.000107405525,0.0000016629947],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00054095645,0.003155978,0.9882322,0.000010137359,0.00040228554,0.000027579968,0.00653994,0.00001089567,0.00011304117,0.000010492959,0.000024023471,0.0009325026],"study_design_scores_gemma":[0.01729437,0.0028688272,0.97444516,0.00016041908,0.0007683553,0.0000051614074,0.0028357843,0.000047235153,0.0014250763,0.000012484882,0.000019117837,0.00011798494],"about_ca_topic_score_codex":0.0010836469,"about_ca_topic_score_gemma":0.00023568668,"teacher_disagreement_score":0.016753413,"about_ca_system_score_codex":0.000023532442,"about_ca_system_score_gemma":0.00004938252,"threshold_uncertainty_score":0.49594572},"labels":[],"label_agreement":null},{"id":"W2593028116","doi":"10.1182/blood.v120.21.4255.4255","title":"Cost-Effectiveness of Ruxolitinib Versus Best-Available Therapy for Medical Treatment of Myelofibrosis: Canadian Societal Perspective","year":2012,"lang":"en","type":"article","venue":"Blood","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Novartis (Canada)","funders":"","keywords":"Ruxolitinib; Medicine; Myelofibrosis; Reimbursement; Cohort; Internal medicine; Cost effectiveness; Health care","score_opus":0.08230238664045916,"score_gpt":0.36072881519931166,"score_spread":0.27842642855885247,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2593028116","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98370665,0.0065424666,0.000013085798,0.00034001068,0.00022297374,0.0026582256,0.0003692387,0.000017424518,0.0061299093],"genre_scores_gemma":[0.99639374,0.0011795782,0.00067808334,0.000045085653,0.00023539811,0.0012023152,0.00009494285,0.000031444222,0.00013939948],"study_design_codex":"observational","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99856955,0.00009962645,0.00027171784,0.0002623063,0.0003252291,0.00047157527],"domain_scores_gemma":[0.998116,0.000689031,0.00010230194,0.00024064702,0.00031968422,0.0005323234],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002943049,0.00023383649,0.0006314615,0.000096753356,0.00008453011,0.000004217582,0.00006368665,0.00016975348,0.0005412076],"category_scores_gemma":[0.00016188469,0.0001731964,0.00029766932,0.000132811,0.00013546334,0.00006427053,0.000009782977,0.000058200007,0.000024424484],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0083254175,0.041493636,0.8931712,0.0005817946,0.010171805,0.000048896283,0.008138152,0.0000028552356,0.0053573227,0.019920247,0.00079598866,0.011992689],"study_design_scores_gemma":[0.096827485,0.025290957,0.18038495,0.00057022774,0.0023412295,0.00007061216,0.003446059,0.000028417875,0.6759999,0.00011825011,0.0144609045,0.00046106498],"about_ca_topic_score_codex":0.016830955,"about_ca_topic_score_gemma":0.0022280116,"teacher_disagreement_score":0.71278626,"about_ca_system_score_codex":0.00041656173,"about_ca_system_score_gemma":0.0009897351,"threshold_uncertainty_score":0.98971605},"labels":[],"label_agreement":null},{"id":"W2593644059","doi":"10.1182/blood.v126.23.4073.4073","title":"Impact of Disease Duration upon Symptom Burden Amongst Patients with Myeloproliferative Neoplasms (MPNs)","year":2015,"lang":"en","type":"article","venue":"Blood","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hôpital Maisonneuve-Rosemont","funders":"","keywords":"Medicine; Myeloproliferative neoplasm; Myelofibrosis; Polycythemia vera; Essential thrombocythemia; Internal medicine; Cohort; Anemia; Disease; Leukopenia; Pediatrics; Bone marrow","score_opus":0.012136897239527105,"score_gpt":0.2598161557736921,"score_spread":0.247679258534165,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2593644059","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9971039,0.00015897398,0.000024387416,0.00025735056,0.00006208199,0.0012142622,0.00013395741,0.000054152577,0.0009908939],"genre_scores_gemma":[0.9985859,0.000028727234,0.00040394635,0.000045656434,0.00015879002,0.00016571238,0.00043569517,0.000038721686,0.00013685346],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9982482,0.00007405534,0.0003825253,0.0003831907,0.00061670877,0.00029527867],"domain_scores_gemma":[0.9980014,0.000070146394,0.00023209682,0.00037279955,0.0006995996,0.00062393484],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00009758935,0.00032206654,0.00048779938,0.00012914218,0.000069408125,0.000032531658,0.000072208204,0.00007848502,0.00009423394],"category_scores_gemma":[0.00014248144,0.00020414469,0.00014713487,0.00024473463,0.00006914618,0.00020098027,0.00003447937,0.00012197655,0.000048984974],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0018966445,0.0032753085,0.9917867,0.00004134819,0.0007631146,0.000052718333,0.0010254391,0.00009698843,0.000089168105,0.00020499973,0.0003685215,0.00039903098],"study_design_scores_gemma":[0.015947796,0.0053561977,0.9728965,0.00019382781,0.00078078645,0.000009992797,0.00007761237,0.00012930491,0.004273964,0.000049500995,0.000060234488,0.00022429191],"about_ca_topic_score_codex":0.00015202964,"about_ca_topic_score_gemma":0.000037027985,"teacher_disagreement_score":0.018890228,"about_ca_system_score_codex":0.00014796284,"about_ca_system_score_gemma":0.000548289,"threshold_uncertainty_score":0.83247787},"labels":[],"label_agreement":null},{"id":"W2594826311","doi":"10.1200/jco.2009.27.15_suppl.e16109","title":"Risk factors for thromboembolic events in testicular cancer patients receiving chemotherapy","year":2009,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"London Health Sciences Centre; Western University","funders":"","keywords":"Medicine; Chemotherapy; Germ cell tumors; Incidence (geometry); Cancer; Testicular cancer; Internal medicine; Retrospective cohort study; Cisplatin; Surgery","score_opus":0.08483301536177637,"score_gpt":0.46246818487871977,"score_spread":0.3776351695169434,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2594826311","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9946093,0.00022827428,0.000051966683,0.0037360087,0.00064451084,0.0004960933,0.0000073493247,0.0000049043906,0.0002215884],"genre_scores_gemma":[0.9923549,0.0026780881,0.0020514724,0.0023575185,0.00049977336,0.000014014386,0.0000041983326,0.000012779367,0.000027222139],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99754006,0.0002194344,0.0015800728,0.00018266065,0.00024951066,0.00022827329],"domain_scores_gemma":[0.9959882,0.0019948464,0.0012904702,0.00010483,0.00037852602,0.00024312019],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011117717,0.000150895,0.0014072527,0.0001037722,0.000037380483,0.0000034632803,0.00008439508,0.00025694957,0.00007697869],"category_scores_gemma":[0.005021512,0.00009504672,0.000407008,0.00010939716,0.000037174923,0.00007367867,0.000008268807,0.0004929242,0.0000028184247],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0008154513,0.0050113504,0.87930644,0.0000068317513,0.0001940096,0.000018442724,0.00015705095,0.000025380805,0.000018294893,0.000014397821,0.00076037075,0.113671996],"study_design_scores_gemma":[0.014748687,0.016096516,0.96319765,0.00015618087,0.00025501673,0.0000063332277,0.000024423187,0.00006274669,0.00019932992,0.0007374198,0.004436697,0.00007901179],"about_ca_topic_score_codex":0.00003678512,"about_ca_topic_score_gemma":0.00006463171,"teacher_disagreement_score":0.11359299,"about_ca_system_score_codex":0.00027346963,"about_ca_system_score_gemma":0.00056919164,"threshold_uncertainty_score":0.60115814},"labels":[],"label_agreement":null},{"id":"W2595165795","doi":"10.1182/blood.v106.11.119.119","title":"Characterization of Distinct Molecular Signatures in Myeloproliferative Diseases with the JAK2V617F Mutation and Wild Type JAK2.","year":2005,"lang":"en","type":"article","venue":"Blood","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hôpital Maisonneuve-Rosemont","funders":"","keywords":"Biology; Mutation; Gene; Polycythemia vera; Point mutation; Molecular biology; Gene expression profiling; Myeloproliferative Disorders; Genetics; Allele; Phenotype; Gene expression; Immunology","score_opus":0.005338461280016435,"score_gpt":0.2287456310499443,"score_spread":0.22340716976992786,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2595165795","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9964767,0.0006077655,0.000050397815,0.0020085368,0.000009775701,0.00056127174,0.000024826131,0.000013326645,0.00024736658],"genre_scores_gemma":[0.99905896,0.000073422765,0.00022828559,0.000332749,0.000055741104,0.00007963179,0.00010770251,0.00001299944,0.000050525654],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9993519,0.000047586887,0.00014507964,0.0001799978,0.00016967671,0.00010576306],"domain_scores_gemma":[0.99958426,0.00006211355,0.00008131422,0.00011690741,0.000103769475,0.000051632043],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0000448989,0.00012605518,0.00019868884,0.000055625933,0.00004326333,0.00001505055,0.000028082215,0.000039655955,0.000030679053],"category_scores_gemma":[0.000047305497,0.00007214296,0.000021615264,0.00016978142,0.000065453714,0.00007049256,0.000012833992,0.000078569035,0.0000019404736],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0011035227,0.0034797958,0.8690304,0.00017404906,0.00057455985,0.00031915907,0.0032897126,0.00013207975,0.11063198,0.0021062056,0.00006275103,0.009095748],"study_design_scores_gemma":[0.002933828,0.000650551,0.84813356,0.00012492506,0.00029322164,0.000025293397,0.000065864326,0.00014883456,0.14728373,0.000022971852,0.00022427301,0.00009296212],"about_ca_topic_score_codex":0.000010786888,"about_ca_topic_score_gemma":0.000055896497,"teacher_disagreement_score":0.036651753,"about_ca_system_score_codex":0.000016227235,"about_ca_system_score_gemma":0.000057434703,"threshold_uncertainty_score":0.29419044},"labels":[],"label_agreement":null},{"id":"W2596168750","doi":"10.1182/blood.v128.22.1126.1126","title":"Exploring the Potential of JAK1/2 Inhibitor Ruxolitinib with Reduced Intensity Hematopoietic Cell Transplantation (HCT) for Myelofibrosis: Stage I Results of a Prospective Trial Conducted through the Myeloproliferative Disorders - Research Consortium (MPD-RC)","year":2016,"lang":"en","type":"article","venue":"Blood","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Ruxolitinib; Myelofibrosis; Medicine; Internal medicine; Transplantation; Fludarabine; Regimen; Hematopoietic stem cell transplantation; Clinical trial; Surgery; Busulfan; Gastroenterology; Oncology; Bone marrow; Chemotherapy; Cyclophosphamide","score_opus":0.07615313580450668,"score_gpt":0.31191312948285355,"score_spread":0.23575999367834688,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2596168750","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98835003,0.000105289626,0.00022581928,0.0032725225,0.00015974358,0.0067951824,0.0005206533,0.000033768985,0.00053700624],"genre_scores_gemma":[0.9959029,0.0004040966,0.0005630201,0.00003360309,0.00022689381,0.0025287012,0.000054472253,0.000042034637,0.00024429648],"study_design_codex":"randomized_trial","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9970229,0.00036500668,0.000802648,0.00057653413,0.00076566846,0.0004672239],"domain_scores_gemma":[0.99645615,0.0012898594,0.00041407332,0.0005287879,0.0012181838,0.00009296076],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00078506884,0.00030935477,0.00067569537,0.000106090134,0.00033868907,0.000028488348,0.00016925455,0.00009349929,0.00001654658],"category_scores_gemma":[0.0004830911,0.00013817598,0.00019972798,0.00040007732,0.00080850086,0.00023492947,0.000044611184,0.00026884902,0.0000030144422],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.5380516,0.012036301,0.010472864,0.0019126219,0.0035152175,0.000080830294,0.07888095,0.000026107906,0.3443118,0.008481719,0.0006094703,0.0016204881],"study_design_scores_gemma":[0.10511736,0.007437999,0.023503521,0.0007118855,0.0007531102,0.000028837034,0.0077786217,0.0000035236442,0.8538784,0.00052966154,0.00007893228,0.00017818209],"about_ca_topic_score_codex":0.00018931314,"about_ca_topic_score_gemma":0.00013443247,"teacher_disagreement_score":0.50956655,"about_ca_system_score_codex":0.00006913137,"about_ca_system_score_gemma":0.0004370792,"threshold_uncertainty_score":0.5634653},"labels":[],"label_agreement":null},{"id":"W2596303874","doi":"10.1200/jco.2012.30.15_suppl.6624","title":"Adverse events (AEs) and the return of myelofibrosis (MF)-related symptoms after interruption or discontinuation of ruxolitinib (RUX) therapy.","year":2012,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Medicine; Discontinuation; Ruxolitinib; Myelofibrosis; Internal medicine; Adverse effect; Surgery; Gastroenterology; Bone marrow","score_opus":0.10272816596117287,"score_gpt":0.446228553385707,"score_spread":0.34350038742453415,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2596303874","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99361306,0.0011613573,0.000030875668,0.0036707295,0.00063177256,0.0004010824,0.00000799056,0.0000030525089,0.0004800944],"genre_scores_gemma":[0.9960408,0.002319612,0.0005751302,0.0004520584,0.00036518395,0.00001975584,0.0000043558875,0.000011881935,0.00021120631],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9964578,0.00072947284,0.002218353,0.00011725928,0.00030653825,0.00017055616],"domain_scores_gemma":[0.9947387,0.0024440428,0.0021127118,0.00015767483,0.00036141512,0.0001854834],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0027713818,0.00013847284,0.0012693484,0.00008912547,0.000024076762,0.0000019770732,0.00007459419,0.00026378478,0.00034721836],"category_scores_gemma":[0.0015978571,0.00006345232,0.00043671473,0.00009927578,0.00030068212,0.0001658636,0.000039726718,0.0003911806,0.0000050538824],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.028202612,0.0029548004,0.877016,0.000029480141,0.0010983836,0.000016639246,0.0017307537,0.000001018246,0.00014496096,0.00033477013,0.0001561787,0.08831441],"study_design_scores_gemma":[0.022108836,0.01052478,0.96198213,0.00038510552,0.00068191445,0.00013624557,0.00050120545,0.000045051216,0.0006617067,0.00021628902,0.002690375,0.00006638486],"about_ca_topic_score_codex":0.000012962462,"about_ca_topic_score_gemma":0.000010864939,"teacher_disagreement_score":0.08824802,"about_ca_system_score_codex":0.000060199167,"about_ca_system_score_gemma":0.00024371421,"threshold_uncertainty_score":0.38017976},"labels":[],"label_agreement":null},{"id":"W2596382835","doi":"10.1182/blood.v110.11.4653.4653","title":"Transfusion Dependence in Patients with Primary Myelofibrosis Has a Negative Impact on Survival Independent of Decreased Myelopoiesis.","year":2007,"lang":"en","type":"article","venue":"Blood","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"St. Paul's Hospital; University of British Columbia","funders":"","keywords":"Medicine; Myelofibrosis; Internal medicine; Gastroenterology; International Prognostic Scoring System; Bone marrow; Anemia; Splenectomy; Myelodysplastic syndromes; Surgery; Spleen","score_opus":0.012010795410853866,"score_gpt":0.24613943428432689,"score_spread":0.23412863887347302,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2596382835","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9966038,0.000065005384,0.000079520585,0.000100174504,0.00003867932,0.001200264,0.000052880154,0.000026801017,0.0018328951],"genre_scores_gemma":[0.9986374,0.0000516035,0.0009899426,0.000112015405,0.000029424733,0.000048455928,0.00007930308,0.0000331435,0.000018726907],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9977392,0.00008476964,0.00046197136,0.00044228326,0.00087420933,0.00039754223],"domain_scores_gemma":[0.9986494,0.00040383058,0.00016445607,0.00031529943,0.0002132832,0.00025373395],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00034563476,0.00033461067,0.0006475003,0.00028601452,0.0000740127,0.000016549922,0.00009081998,0.00013372382,0.00011971532],"category_scores_gemma":[0.00008998627,0.00021917683,0.00014180057,0.00042304827,0.000099746336,0.00009834271,0.000024337169,0.00022341598,0.000009436906],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.006534222,0.008150307,0.9797877,0.00006977188,0.0003302168,0.00010855661,0.00069996313,0.000011984357,0.0011535151,0.000034206543,0.000008689471,0.003110862],"study_design_scores_gemma":[0.019562257,0.0047802036,0.89706063,0.0004334258,0.00023082565,0.000007030144,0.000090066234,0.0000022032455,0.07762167,0.00002072009,0.000006205067,0.00018478805],"about_ca_topic_score_codex":0.0007436148,"about_ca_topic_score_gemma":0.00096858,"teacher_disagreement_score":0.082727104,"about_ca_system_score_codex":0.00022288617,"about_ca_system_score_gemma":0.000309168,"threshold_uncertainty_score":0.89377713},"labels":[],"label_agreement":null},{"id":"W2596571051","doi":"10.1182/blood.v118.21.5146.5146","title":"Clinical Burden and Progression of Myelofibrosis in a Controlled Study Population of Placebo-Treated Patients (COMFORT-I)","year":2011,"lang":"en","type":"article","venue":"Blood","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Medicine; Myelofibrosis; Placebo; Ruxolitinib; Population; Internal medicine; Clinical trial; Surgery; Pathology; Bone marrow","score_opus":0.03565850352619703,"score_gpt":0.32898378470369327,"score_spread":0.29332528117749623,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2596571051","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99696237,0.00009187686,4.381048e-7,0.00001089626,0.000022850032,0.002496355,0.000009712552,0.000010872324,0.00039461468],"genre_scores_gemma":[0.9992135,0.00004089044,0.0004982392,0.0000055195933,0.000021421078,0.00016487687,0.000029865276,0.000010697529,0.000014990968],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99863076,0.00014375283,0.00069234666,0.00021577813,0.00020732654,0.00011003307],"domain_scores_gemma":[0.99925804,0.0001286979,0.00027353887,0.00016296898,0.00010597545,0.00007075025],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00026336478,0.00012510437,0.0007041587,0.000110230234,0.000018274512,0.0000025014924,0.000029912486,0.000077632285,0.00003560962],"category_scores_gemma":[0.00015666337,0.000083886574,0.00007351243,0.00010987507,0.0000378076,0.000036869544,0.000031540727,0.00006556173,8.606993e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0043423525,0.010722966,0.97815347,0.000047120255,0.00029260755,0.000011424379,0.0008343729,1.6376339e-7,0.00006921331,0.0000144424175,0.0000026610287,0.005509197],"study_design_scores_gemma":[0.07264692,0.00601115,0.91854763,0.0002327704,0.0005025272,0.0000011950636,0.00011161614,0.000028199618,0.0018457497,0.000013819347,0.0000014482014,0.00005698206],"about_ca_topic_score_codex":0.00043313086,"about_ca_topic_score_gemma":0.00008998009,"teacher_disagreement_score":0.06830457,"about_ca_system_score_codex":0.0000112424505,"about_ca_system_score_gemma":0.000020262962,"threshold_uncertainty_score":0.34207952},"labels":[],"label_agreement":null},{"id":"W2603194473","doi":"10.1002/ajh.24740","title":"Monocytosis in polycythemia vera: Clinical and molecular correlates","year":2017,"lang":"en","type":"article","venue":"American Journal of Hematology","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":55,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"","keywords":"Monocytosis; Leukocytosis; Medicine; Chronic myelomonocytic leukemia; Internal medicine; Gastroenterology; Myelofibrosis; Univariate analysis; Myeloid; Neutrophilia; Myelodysplastic syndromes; Bone marrow; Multivariate analysis","score_opus":0.021558517347115398,"score_gpt":0.35488325895712824,"score_spread":0.33332474161001285,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2603194473","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98959327,0.0010444323,0.000059671034,0.0086097,0.00012434665,0.00008620918,8.9968967e-7,0.00000311943,0.0004783509],"genre_scores_gemma":[0.996331,0.0009766695,0.0019894857,0.00063365616,0.00004132969,0.000004420711,4.5557334e-7,0.000010893251,0.00001209071],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99896723,0.00008914712,0.000519296,0.00014836874,0.000107302876,0.00016865821],"domain_scores_gemma":[0.9987152,0.00023198662,0.0005832067,0.00022989124,0.00007303256,0.00016664261],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002424745,0.000116347364,0.000838966,0.000103375714,0.000060752976,0.000016682015,0.000097781165,0.000057034693,0.000024430621],"category_scores_gemma":[0.0003717308,0.00008440887,0.0001172098,0.000039022038,0.00060830987,0.000057347614,0.000045203346,0.00028291938,0.0000075427874],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0003863439,0.0002216761,0.9755821,0.000007658016,0.00019266775,0.001853993,0.00010371771,5.872429e-7,0.000102153026,0.0012386878,0.00019178305,0.020118615],"study_design_scores_gemma":[0.0050764475,0.0036446634,0.9741372,0.0002624784,0.0002293477,0.0086244205,0.00033256382,0.00007127785,0.006064669,0.00074537797,0.00067628623,0.00013525796],"about_ca_topic_score_codex":0.000043048505,"about_ca_topic_score_gemma":0.00001095957,"teacher_disagreement_score":0.019983357,"about_ca_system_score_codex":0.00002341069,"about_ca_system_score_gemma":0.00009507971,"threshold_uncertainty_score":0.34420937},"labels":[],"label_agreement":null},{"id":"W2604146377","doi":"10.1111/ejh.12891","title":"Is allogeneic stem cell transplantation for myelofibrosis still indicated at the time of molecular markers and <scp>JAK</scp> inhibitors era?","year":2017,"lang":"en","type":"article","venue":"European Journal Of Haematology","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hotel Dieu Hospital","funders":"","keywords":"Myelofibrosis; Medicine; International Prognostic Scoring System; Ruxolitinib; Internal medicine; Univariate analysis; Transplantation; Autologous stem-cell transplantation; Oncology; Stem cell; Overall survival; Gastroenterology; Myeloid leukemia; Hematopoietic stem cell transplantation; Myelodysplastic syndromes; Multivariate analysis; Surgery; Bone marrow","score_opus":0.01402502677181484,"score_gpt":0.24811725934685375,"score_spread":0.23409223257503892,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2604146377","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.995207,0.001323898,0.00017702905,0.001648128,0.000103639795,0.00038872476,0.000043216936,0.0000054603097,0.0011029134],"genre_scores_gemma":[0.9979111,0.00065147644,0.0006695309,0.0003397975,0.000045930225,0.0000059216836,0.000012005088,0.000033711607,0.00033053817],"study_design_codex":"observational","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9985505,0.00031424448,0.0005608274,0.00018504019,0.00019529973,0.00019413044],"domain_scores_gemma":[0.99815303,0.00033007172,0.0009474685,0.0002557526,0.00017757868,0.00013610611],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005600226,0.0001787248,0.0005361343,0.00011469803,0.00018356297,0.000025704601,0.00016707474,0.000055780307,0.00003060178],"category_scores_gemma":[0.00008017998,0.00011277441,0.00017845276,0.000038235077,0.00024722336,0.00006298892,0.000035501227,0.00015030454,0.000020414704],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0031491863,0.0010926019,0.50326985,0.0019116512,0.0038214477,0.013615405,0.016206406,0.00005462349,0.402142,0.00026396083,0.03216715,0.022305747],"study_design_scores_gemma":[0.00569861,0.0022429198,0.25662515,0.00035489775,0.0010432228,0.004976089,0.00023218586,0.00002780906,0.72510993,0.000023543304,0.0035814561,0.00008416848],"about_ca_topic_score_codex":0.0000024122216,"about_ca_topic_score_gemma":0.0000018434466,"teacher_disagreement_score":0.32296798,"about_ca_system_score_codex":0.000027867185,"about_ca_system_score_gemma":0.00005452784,"threshold_uncertainty_score":0.45988068},"labels":[],"label_agreement":null},{"id":"W2608237902","doi":"10.1016/j.cyto.2015.08.143","title":"ID: 116","year":2015,"lang":"en","type":"article","venue":"Cytokine","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network; University of Toronto","funders":"","keywords":"PI3K/AKT/mTOR pathway; Signal transduction; Interferon; Biology; MAPK/ERK pathway; Cell biology; Cancer research; ULK1; Kinase; Protein kinase B; Protein kinase A; Immunology","score_opus":0.056882614608510386,"score_gpt":0.30937165579938886,"score_spread":0.25248904119087845,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2608237902","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9067459,0.0006739974,0.00010063802,0.006296153,0.0002673474,0.00038513754,0.000020576266,0.00011497459,0.08539527],"genre_scores_gemma":[0.9944509,0.000044259326,0.0010319041,0.0012094218,0.00030712792,0.00005010705,0.000061515915,0.000015432777,0.0028293054],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.99935156,0.000014406836,0.00012287723,0.0001641454,0.00019167364,0.0001553441],"domain_scores_gemma":[0.9993991,0.000025558491,0.000026890442,0.00020633877,0.00009564273,0.0002464565],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0000820095,0.0001051618,0.00020268088,0.000043866497,0.000026391044,0.000010470118,0.00003257443,0.000041652333,0.00033940945],"category_scores_gemma":[0.00008280121,0.000073639465,0.00004146962,0.00009236317,0.000027585478,0.00003512595,0.000023325596,0.00006910027,0.00078038435],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0006640933,0.0018762862,0.59477895,0.00007093999,0.00039872492,0.0011557507,0.0010505867,0.00001577969,0.0036759193,0.011719142,0.35192782,0.03266602],"study_design_scores_gemma":[0.007841143,0.0015617766,0.121665016,0.00008592346,0.00018353989,0.00027759658,0.00015210232,0.00012412228,0.049429104,0.0006889342,0.81775856,0.00023220333],"about_ca_topic_score_codex":0.000026176085,"about_ca_topic_score_gemma":0.000009356542,"teacher_disagreement_score":0.47311392,"about_ca_system_score_codex":0.00008028444,"about_ca_system_score_gemma":0.000086423934,"threshold_uncertainty_score":0.9999976},"labels":[],"label_agreement":null},{"id":"W2612853764","doi":"10.1182/blood.v128.22.3118.3118","title":"Clinical Outcomes with Ruxolitinib (RUX) in Patients with Myelofibrosis (MF) Stratified By Transfusion Status: A Pooled Analysis of the COMFORT-I and -II Trials","year":2016,"lang":"en","type":"article","venue":"Blood","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Medicine; Myelofibrosis; Ruxolitinib; Anemia; Internal medicine; Placebo; Blood transfusion; Bone marrow","score_opus":0.021164645303813127,"score_gpt":0.29838522585240107,"score_spread":0.27722058054858795,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2612853764","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99750644,0.00006991924,0.00002609391,0.00065224845,0.00001884039,0.0011685443,0.00040890073,0.000012311168,0.00013671609],"genre_scores_gemma":[0.9989787,0.00021172853,0.00038385086,0.00015205785,0.000011211913,0.00008647436,0.000058093377,0.000015820706,0.00010208891],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9978596,0.0002884473,0.0008102785,0.00036932016,0.000425959,0.00024637813],"domain_scores_gemma":[0.9982261,0.00085854676,0.00031141212,0.00034481668,0.000112378984,0.00014676845],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00047177353,0.00022425425,0.0012746799,0.0001337221,0.00007283542,0.000011773073,0.00006021429,0.0000940909,0.00009728056],"category_scores_gemma":[0.00020805243,0.000083820945,0.0002171916,0.00042930729,0.00014152993,0.00005890324,0.000025179603,0.00009271718,5.07098e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0013402426,0.0037076618,0.9862047,0.00001853926,0.0038740365,0.0000027725616,0.00024953636,6.2084945e-7,0.00016931344,0.00004659573,0.00003469168,0.0043513263],"study_design_scores_gemma":[0.031423073,0.0028773092,0.95439476,0.00022711924,0.00793753,5.7426513e-7,0.00006455964,0.0000029056034,0.0028965669,0.000008374816,0.000051662155,0.000115539195],"about_ca_topic_score_codex":0.00016257631,"about_ca_topic_score_gemma":0.0007367645,"teacher_disagreement_score":0.031809878,"about_ca_system_score_codex":0.000023257833,"about_ca_system_score_gemma":0.000101302285,"threshold_uncertainty_score":0.3418119},"labels":[],"label_agreement":null},{"id":"W2614976199","doi":"10.1182/blood-2017-02-769240","title":"CD34+ megakaryocytes and megakaryocytic fragments in myelodysplastic syndrome","year":2017,"lang":"en","type":"article","venue":"Blood","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"","keywords":"Megakaryocyte; Peripheral blood; CD34; Platelet; Hemoglobin; Medicine; Myelodysplastic syndromes; Immunology; Internal medicine; Haematopoiesis; Biology; Bone marrow; Stem cell; Cell biology","score_opus":0.015114092523464198,"score_gpt":0.2720122154795686,"score_spread":0.2568981229561044,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2614976199","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99329245,0.0009171837,0.0000027272263,0.0010002065,0.00009415447,0.0004886652,0.000011774968,0.00003176502,0.0041610687],"genre_scores_gemma":[0.99801755,0.00040805864,0.00070729817,0.00016761175,0.00005650169,0.00012375905,0.000012656951,0.000024728015,0.00048185812],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9987777,0.000027216984,0.00025100802,0.0003914197,0.0002393606,0.00031329584],"domain_scores_gemma":[0.99885654,0.00012220306,0.000105432744,0.00068321853,0.000037102356,0.0001955111],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00011713422,0.00022659171,0.00044988963,0.00012200759,0.00023298078,0.00009324502,0.00015806308,0.00009393283,0.000092699716],"category_scores_gemma":[0.00034260683,0.00018091984,0.00005613372,0.000051213057,0.00011052055,0.00015602664,0.00015971961,0.00016051662,0.000083242296],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000085402855,0.0011805372,0.99416196,0.00010576758,0.00024810588,0.0023924385,0.00014972135,0.0000012594336,0.00032815532,0.00045055497,0.00009548832,0.00080058957],"study_design_scores_gemma":[0.009280105,0.0006275604,0.9842259,0.00038253155,0.000315004,0.00077006477,0.000030402416,0.000071447466,0.0035202303,0.00037392328,0.00023026684,0.00017253008],"about_ca_topic_score_codex":0.00011367748,"about_ca_topic_score_gemma":0.00007913309,"teacher_disagreement_score":0.009936045,"about_ca_system_score_codex":0.00004930084,"about_ca_system_score_gemma":0.00007380955,"threshold_uncertainty_score":0.73776966},"labels":[],"label_agreement":null},{"id":"W2724175224","doi":"10.1182/blood.v128.22.1949.1949","title":"Effects of Long-Term Ruxolitinib (RUX) on Bone Marrow (BM) Morphology in Patients with Myelofibrosis (MF) Enrolled in the COMFORT-I Study","year":2016,"lang":"en","type":"article","venue":"Blood","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Medicine; Myelofibrosis; Ruxolitinib; Internal medicine; International Prognostic Scoring System; Population; Bone marrow; Gastroenterology; Essential thrombocythemia; Polycythemia vera; Surgery; Myelodysplastic syndromes","score_opus":0.008084472802540894,"score_gpt":0.23883888654796523,"score_spread":0.23075441374542432,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2724175224","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99627537,0.00007739138,0.0000012977129,0.00031179583,0.00004018613,0.0029363758,0.00001707071,0.000013352791,0.00032716515],"genre_scores_gemma":[0.9989161,0.000028874994,0.000038391267,0.00024978642,0.00003134819,0.00062712154,0.000017385753,0.000024198931,0.0000668081],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9982753,0.0002598802,0.00038643664,0.00036120994,0.0003984124,0.00031876424],"domain_scores_gemma":[0.99864596,0.0006864082,0.00014365966,0.00039317476,0.00005895868,0.00007186508],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002207178,0.0002467962,0.00062540977,0.00018913875,0.000034419976,0.000007330389,0.0001067358,0.00007943539,0.00006451602],"category_scores_gemma":[0.00010202501,0.00011488902,0.00006621512,0.00021749291,0.00007456529,0.000039180333,0.00003619395,0.0001284652,0.000018557905],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.001618574,0.022479286,0.9718894,0.00008003034,0.00018566482,0.0005735233,0.0006857481,3.111361e-7,0.0005579737,0.000043780026,0.00003133298,0.0018544146],"study_design_scores_gemma":[0.055285174,0.009670483,0.91663456,0.00053277804,0.00023830801,0.00001210154,0.000049218295,1.7890373e-7,0.01745004,0.000009548487,0.0000031302386,0.000114460054],"about_ca_topic_score_codex":0.00005113107,"about_ca_topic_score_gemma":0.00016105328,"teacher_disagreement_score":0.05525478,"about_ca_system_score_codex":0.000050979073,"about_ca_system_score_gemma":0.00004317142,"threshold_uncertainty_score":0.46850383},"labels":[],"label_agreement":null},{"id":"W2727129020","doi":"10.1016/j.clml.2017.06.031","title":"Distribution and Impact of Comorbidities on Survival and Leukemic Transformation in Myeloproliferative Neoplasm-Associated Myelofibrosis: A Retrospective Cohort Study","year":2017,"lang":"en","type":"article","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; Public Health Ontario; University of Toronto","funders":"","keywords":"Myelofibrosis; Myeloproliferative neoplasm; Medicine; Retrospective cohort study; Cohort; Internal medicine; Overall survival; Oncology; Neoplasm; Myeloproliferative Disorders; Transformation (genetics); Survival analysis; Pathology; Bone marrow; Biology","score_opus":0.03255570675065547,"score_gpt":0.35152802420942897,"score_spread":0.3189723174587735,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2727129020","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99489206,0.00008706846,0.000008960568,0.00024028472,0.00019227459,0.0026509808,0.00036166536,0.000053179803,0.001513551],"genre_scores_gemma":[0.9983978,0.00068974786,0.000027029504,0.000046491765,0.00010695928,0.00035952908,0.0002671417,0.000037995018,0.00006727328],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9963749,0.00044570665,0.0013057941,0.0008135924,0.0006011313,0.0004588969],"domain_scores_gemma":[0.9971795,0.0007730028,0.000731638,0.0006446099,0.0003528072,0.00031844297],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0014312845,0.0005208906,0.0017517922,0.00015080144,0.00045337336,0.00014215757,0.00016233578,0.0003746424,0.000023332774],"category_scores_gemma":[0.0017144795,0.00041105732,0.00029163426,0.0001789496,0.0006604129,0.00038910576,0.00010614077,0.00037687962,0.00000909751],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.001927791,0.0013057407,0.96584994,0.000041810123,0.0007790658,0.00007753097,0.0009775931,0.0000063749576,0.00005976673,0.0006584887,0.000083919265,0.028231962],"study_design_scores_gemma":[0.014118373,0.0064729103,0.97598255,0.0004465225,0.0003449383,0.000034446013,0.0007089262,0.00082676555,0.0004142856,0.0003079858,0.000010598878,0.00033167706],"about_ca_topic_score_codex":0.0015880502,"about_ca_topic_score_gemma":0.0007881738,"teacher_disagreement_score":0.027900284,"about_ca_system_score_codex":0.0025622768,"about_ca_system_score_gemma":0.0007510603,"threshold_uncertainty_score":0.9998341},"labels":[],"label_agreement":null},{"id":"W2731773124","doi":"10.7326/m17-1378","title":"Are Antiplatelet Agents Beneficial in Essential Thrombocythemia? Maybe Yes, Probably No","year":2017,"lang":"en","type":"letter","venue":"Annals of Internal Medicine","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Essential thrombocythemia; Thrombocytosis; Myelofibrosis; Polycythemia vera; Myeloproliferative Disorders; Internal medicine; Gastroenterology; Splenectomy; Acute leukemia; Janus kinase 2; Anagrelide; Leukemia; Platelet; Bone marrow; Spleen","score_opus":0.07778514947883874,"score_gpt":0.3695268998171323,"score_spread":0.2917417503382936,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2731773124","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.3725029,0.0022164085,0.000007411281,0.6046474,0.0022178316,0.001446271,0.00023575136,0.000045402703,0.016680649],"genre_scores_gemma":[0.42538604,0.0040945928,0.00010215912,0.5410178,0.019030407,0.0001917889,0.000911593,0.00020075381,0.009064867],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99587935,0.00010835795,0.0012594422,0.000826197,0.0012066305,0.00072000286],"domain_scores_gemma":[0.9961998,0.0001784374,0.001744261,0.00092260784,0.0007565323,0.00019839984],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00039799864,0.00075814885,0.0024562154,0.0005209267,0.000086780405,0.000032524975,0.0005517732,0.00080600736,0.0016633973],"category_scores_gemma":[0.00090777443,0.00054002047,0.00038289966,0.000121219695,0.00041792472,0.0001151161,0.00016931907,0.0017777535,0.00018733925],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00071919814,0.00045177506,0.03050254,0.0011913291,0.0009567364,0.01487815,0.00027512884,0.0000013089416,0.00017618613,0.000022325443,0.9497808,0.0010445119],"study_design_scores_gemma":[0.00914248,0.003635111,0.057386056,0.037255485,0.00070896535,0.0007709407,0.00008270115,0.000077664394,0.011173372,0.00039445542,0.87855315,0.00081962673],"about_ca_topic_score_codex":0.0012829558,"about_ca_topic_score_gemma":0.000085598454,"teacher_disagreement_score":0.07122767,"about_ca_system_score_codex":0.00010015939,"about_ca_system_score_gemma":0.00016283077,"threshold_uncertainty_score":0.99970514},"labels":[],"label_agreement":null},{"id":"W2740659633","doi":"10.7326/m17-0284","title":"Benefits and Risks of Antithrombotic Therapy in Essential Thrombocythemia","year":2017,"lang":"en","type":"review","venue":"Annals of Internal Medicine","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":52,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hamilton Health Sciences","funders":"Regional Medical Associates of Hamilton","keywords":"Medicine; Antithrombotic; Randomized controlled trial; Aspirin; Observational study; Internal medicine; Relative risk; Incidence (geometry); Thrombosis; Dipyridamole; Surgery; Confidence interval","score_opus":0.3560672215737615,"score_gpt":0.4998974063024021,"score_spread":0.14383018472864056,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2740659633","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.030294327,0.9666633,0.000002080415,0.0004844373,0.00022742925,0.0008280488,0.00004396513,0.000006894742,0.0014495236],"genre_scores_gemma":[0.037796266,0.9615218,0.00004482242,0.0001435185,0.00029659944,0.00004239073,0.00003611365,0.000040326286,0.00007817072],"study_design_codex":"design_other","study_design_gemma":"systematic_review","domain_scores_codex":[0.9976265,0.00009355147,0.0011810338,0.00041669418,0.00042533648,0.00025692687],"domain_scores_gemma":[0.9975571,0.00033864233,0.0011402259,0.0005422178,0.00026664673,0.00015516714],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00045366128,0.00046057813,0.0040711183,0.00042147128,0.000030114552,0.000007995117,0.0002371907,0.00024446263,0.00024251115],"category_scores_gemma":[0.00037327234,0.0002746332,0.00034097,0.00011867281,0.00046816477,0.000058047463,0.00008332177,0.0003749999,0.000005936756],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00015455145,0.00044120807,0.008453524,0.007787452,0.0012506982,0.00010559451,0.00022666068,2.1436993e-7,0.0000118104435,0.00033824274,0.00068104616,0.980549],"study_design_scores_gemma":[0.009247121,0.011722206,0.05838652,0.5798904,0.0027424821,0.0007289816,0.00008805397,0.000008737709,0.0035829192,0.00024667155,0.33263406,0.0007218811],"about_ca_topic_score_codex":0.00096393895,"about_ca_topic_score_gemma":0.000053578286,"teacher_disagreement_score":0.9798271,"about_ca_system_score_codex":0.000023844646,"about_ca_system_score_gemma":0.00016597359,"threshold_uncertainty_score":0.99997056},"labels":[],"label_agreement":null},{"id":"W2744846745","doi":"10.1007/s00277-017-3082-y","title":"The impact of myeloproliferative neoplasms (MPNs) on patient quality of life and productivity: results from the international MPN Landmark survey","year":2017,"lang":"en","type":"article","venue":"Annals of Hematology","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":144,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"St. Paul's Hospital; University of British Columbia","funders":"National Cancer Institute; Novartis Pharmaceuticals Corporation; Incyte; Ariad Pharmaceuticals","keywords":"Medicine; Quality of life (healthcare); Myelofibrosis; Disease; Essential thrombocythemia; Polycythemia vera; Myeloproliferative neoplasm; Disease burden; Physical therapy; Internal medicine; Family medicine; Bone marrow","score_opus":0.12870162063342272,"score_gpt":0.4048097733120325,"score_spread":0.2761081526786098,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2744846745","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9814904,0.0005629062,0.0000018120027,0.015562414,0.00013498419,0.00047445818,0.00090722594,0.0000044169574,0.0008614224],"genre_scores_gemma":[0.9989565,0.000636726,0.000037182766,0.00018092606,0.000048707672,0.000030306204,0.00007835348,0.000008876931,0.00002240473],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9980882,0.00041440842,0.0006917985,0.00030434752,0.0003243476,0.00017689475],"domain_scores_gemma":[0.9940133,0.003541025,0.001074561,0.0007699694,0.000520522,0.00008059206],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.001033307,0.00017789048,0.0007159795,0.0000387714,0.00018966153,0.00002145149,0.00022361522,0.00008265003,0.000016395586],"category_scores_gemma":[0.008453814,0.00008494031,0.0001487655,0.00004250155,0.00048543143,0.0000608067,0.00012712038,0.00014318172,0.0000021555825],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.007402828,0.00068839267,0.9791708,0.000020723257,0.0011667279,0.000005268697,0.0012285424,0.000007791638,0.00030117473,0.0029327404,0.004514879,0.002560147],"study_design_scores_gemma":[0.0017493734,0.0011639815,0.94628185,0.00009484202,0.000020869502,0.000009084777,0.000117434734,0.00003880724,0.049617715,0.0007357005,0.00010331536,0.00006703801],"about_ca_topic_score_codex":0.0052730846,"about_ca_topic_score_gemma":0.0017073139,"teacher_disagreement_score":0.04931654,"about_ca_system_score_codex":0.000010618644,"about_ca_system_score_gemma":0.00019993311,"threshold_uncertainty_score":0.9998984},"labels":[],"label_agreement":null},{"id":"W2754624442","doi":"10.14740/jh335w","title":"Two Novel Monoallelic Calreticulin Mutations in a Patient With Essential Thrombocythemia","year":2017,"lang":"en","type":"article","venue":"Journal of Hematology","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Calreticulin; Essential thrombocythemia; Mutant; Mutation; Cancer research; Myeloproliferative Disorders; Thrombopoietin receptor; Myeloproliferative neoplasm; Medicine; Thrombocytosis; Germline mutation; Gene; Biology; Immunology; Genetics; Myelofibrosis; Endoplasmic reticulum; Polycythemia vera; Haematopoiesis; Thrombopoietin","score_opus":0.018751335360701626,"score_gpt":0.3187906458751747,"score_spread":0.3000393105144731,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2754624442","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9932339,0.00020966753,0.00037682196,0.0047286297,0.000113565795,0.00020149186,0.0000026640753,0.00000363192,0.0011296321],"genre_scores_gemma":[0.9944116,0.000045783163,0.0052774274,0.00015207668,0.000062268395,0.000017701917,0.0000025388506,0.000011081811,0.000019533856],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9990672,0.00002511623,0.0004212816,0.00012401903,0.00019164821,0.00017075906],"domain_scores_gemma":[0.99888694,0.00008554398,0.0005025277,0.00021866165,0.00019691857,0.000109376364],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00008932579,0.0001211682,0.00052819017,0.00012081319,0.00010466876,0.000021368078,0.00008495211,0.00005822104,0.00008878435],"category_scores_gemma":[0.00013724256,0.00007633595,0.00008300722,0.000038263923,0.00012236409,0.00008679274,0.000026728481,0.00021779265,0.000010730637],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0021080743,0.00585644,0.930251,0.00015167597,0.0012108822,0.019124115,0.0043381173,0.00041356724,0.007791581,0.024671307,0.00096392573,0.0031193276],"study_design_scores_gemma":[0.061223794,0.009892871,0.5974399,0.0023478353,0.001328673,0.1271745,0.0024529733,0.0012589099,0.19179596,0.0023474565,0.0020462784,0.000690889],"about_ca_topic_score_codex":0.000055183238,"about_ca_topic_score_gemma":0.0002489182,"teacher_disagreement_score":0.33281112,"about_ca_system_score_codex":0.000070790586,"about_ca_system_score_gemma":0.00020827238,"threshold_uncertainty_score":0.31128898},"labels":[],"label_agreement":null},{"id":"W2759277150","doi":"10.1186/s13045-017-0527-7","title":"Long-term survival in patients treated with ruxolitinib for myelofibrosis: COMFORT-I and -II pooled analyses","year":2017,"lang":"en","type":"article","venue":"Journal of Hematology & Oncology","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":298,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"Novartis Pharma; Genentech; AOP Orphan; CTI Biopharma; Incyte; Baxalta; Ariad Pharmaceuticals; Gilead Sciences; Pfizer; Celgene; AstraZeneca; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Ruxolitinib; Medicine; Myelofibrosis; Internal medicine; Hazard ratio; Randomized controlled trial; International Prognostic Scoring System; Clinical endpoint; Anemia; Hematology; Placebo; Survival analysis; Proportional hazards model; Clinical trial; Subgroup analysis; Surgery; Confidence interval; Bone marrow; Myelodysplastic syndromes; Pathology","score_opus":0.0497649413758295,"score_gpt":0.3819046456399105,"score_spread":0.332139704264081,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2759277150","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9959515,0.00043700924,0.00003315945,0.0023414597,0.0001446388,0.0005552035,0.00001297428,0.000006659825,0.000517421],"genre_scores_gemma":[0.99821156,0.00018784632,0.0011241088,0.00022791648,0.00007773624,0.000053633907,0.000020317499,0.000019936719,0.000076950484],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99843574,0.00011768375,0.00069531414,0.00023892723,0.0001743969,0.0003379592],"domain_scores_gemma":[0.99777174,0.00040018678,0.0009886815,0.00024874543,0.00039475854,0.00019586062],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00028546524,0.000229512,0.0014791689,0.00026215505,0.00026000012,0.000022632656,0.00012972132,0.00021836204,0.000037459362],"category_scores_gemma":[0.00026255357,0.00014585447,0.00013836399,0.000056412544,0.00025845692,0.00013474457,0.000059966198,0.0002232823,0.0000015304745],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.003991577,0.0017885235,0.989266,0.000076481934,0.0008727773,0.00069308816,0.00015620746,0.0000010690311,0.00009874493,0.00039346388,0.0001662262,0.002495863],"study_design_scores_gemma":[0.02005192,0.014038066,0.96073085,0.00025599438,0.0009152264,0.0012073513,0.000065400614,0.0000087274175,0.002265432,0.00006142451,0.00028059824,0.00011898476],"about_ca_topic_score_codex":0.00003207506,"about_ca_topic_score_gemma":0.00036469608,"teacher_disagreement_score":0.028535105,"about_ca_system_score_codex":0.0001517476,"about_ca_system_score_gemma":0.000253261,"threshold_uncertainty_score":0.5947773},"labels":[],"label_agreement":null},{"id":"W2760217744","doi":"10.1182/bloodadvances.2017009530","title":"Impact of genomic alterations on outcomes in myelofibrosis patients undergoing JAK1/2 inhibitor therapy","year":2017,"lang":"en","type":"article","venue":"Blood Advances","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":66,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network; University of Toronto","funders":"","keywords":"Myelofibrosis; Ruxolitinib; Hazard ratio; Internal medicine; Medicine; Mutation; International Prognostic Scoring System; Oncology; Myeloid; Proportional hazards model; Univariate analysis; EZH2; Multivariate analysis; Gastroenterology; Bone marrow; Gene; Myelodysplastic syndromes; Confidence interval; Biology; Genetics","score_opus":0.021548198773284902,"score_gpt":0.33064449314742783,"score_spread":0.30909629437414293,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2760217744","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99741936,0.0004687179,0.0000018941217,0.000306065,0.00010983455,0.00051944936,0.000050217517,0.000012527268,0.0011119308],"genre_scores_gemma":[0.99795765,0.0011944924,0.00050167483,0.00007584783,0.00006106903,0.00007867804,0.000023456616,0.00001666837,0.00009044538],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9990898,0.000025998834,0.00027869391,0.00023923906,0.00018207847,0.000184183],"domain_scores_gemma":[0.9991111,0.00016176989,0.0002187738,0.00036905776,0.00006744181,0.00007183741],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000046123885,0.00018292961,0.00039317913,0.00010517822,0.00016789605,0.000038862127,0.00008839283,0.000041139134,0.000060110673],"category_scores_gemma":[0.00012180392,0.00012083731,0.00014940479,0.000035990455,0.000052522904,0.00021034066,0.000025018411,0.00007294397,0.000016084357],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00015844073,0.0020216557,0.9884581,0.000018512983,0.00019450646,0.000006039397,0.00017768652,0.00005609305,0.0014713656,0.00010582149,0.00002179248,0.0073099663],"study_design_scores_gemma":[0.0064315037,0.002675141,0.9734593,0.00016865905,0.000038277947,0.0000010078171,0.000015978902,0.0000063801217,0.016890492,0.000098534125,0.00011244736,0.000102251775],"about_ca_topic_score_codex":0.000080112004,"about_ca_topic_score_gemma":0.00019692436,"teacher_disagreement_score":0.0154191265,"about_ca_system_score_codex":0.00007259667,"about_ca_system_score_gemma":0.00009058733,"threshold_uncertainty_score":0.49276024},"labels":[],"label_agreement":null},{"id":"W2761565001","doi":"10.1182/blood.v128.22.4339.4339","title":"Impact of Bone Marrow Fibrosis in MDS Patients Treated with Azacitidine","year":2016,"lang":"en","type":"article","venue":"Blood","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Sciences Centre; Sunnybrook Health Science Centre; University of Toronto","funders":"","keywords":"Medicine; Myelofibrosis; Azacitidine; Internal medicine; International Prognostic Scoring System; Myelodysplastic syndromes; Chronic myelomonocytic leukemia; Bone marrow; Gastroenterology; Surgery; Oncology","score_opus":0.009351642600387447,"score_gpt":0.24635067494992058,"score_spread":0.23699903234953312,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2761565001","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99835026,0.00007398809,0.0000019200188,0.00014326414,0.0000071046093,0.00039474972,0.000098930264,0.000018615707,0.0009111715],"genre_scores_gemma":[0.9993433,0.000075119264,0.00019740684,0.000018399327,0.000020990385,0.0000675793,0.00003943368,0.000019188516,0.00021859501],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9991404,0.0000273019,0.00023184206,0.00020678746,0.00018916249,0.00020453843],"domain_scores_gemma":[0.9994173,0.00007031102,0.00008583994,0.00020545503,0.000111753165,0.0001093407],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00004136204,0.00016380676,0.00038640352,0.00012365512,0.000015764132,0.000003914209,0.000025847214,0.000053414144,0.00029503217],"category_scores_gemma":[0.00004529791,0.00007782315,0.00009200889,0.00018835667,0.000042059582,0.000054715078,0.000013195444,0.000038536735,0.000018556182],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0005077604,0.003661383,0.98408175,0.000024083296,0.00025366683,0.000052791027,0.000056073353,3.1268306e-7,0.0094574895,0.00001322012,0.00012339074,0.0017680828],"study_design_scores_gemma":[0.01649818,0.004538862,0.8800459,0.00041180756,0.00016161181,0.00001368001,0.000003268431,9.481519e-7,0.0982126,0.000005806925,0.000022384262,0.00008499008],"about_ca_topic_score_codex":0.00019523552,"about_ca_topic_score_gemma":0.000055817905,"teacher_disagreement_score":0.104035884,"about_ca_system_score_codex":0.0000719775,"about_ca_system_score_gemma":0.000059241298,"threshold_uncertainty_score":0.32303953},"labels":[],"label_agreement":null},{"id":"W2761968036","doi":"10.1016/j.exphem.2017.09.011","title":"Determination of complex subclonal structures of hematological malignancies by multiplexed genotyping of blood progenitor colonies","year":2017,"lang":"en","type":"article","venue":"Experimental Hematology","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"Cambridge Institute for Medical Research, University of Cambridge; Blood Cancer UK; Wellcome Trust; Bloodwise; Leukemia and Lymphoma Society; National Institutes of Health; Cancer Research UK; Medical Research Council; Wellcome","keywords":"Genotyping; Biology; DNA sequencing; Computational biology; Mutation; Genetics; DNA; Genotype; Gene","score_opus":0.04148595602939695,"score_gpt":0.341847786026761,"score_spread":0.30036182999736405,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2761968036","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9950197,0.0038662269,0.00002119858,0.00012837515,0.000077651755,0.0005739355,0.000068003865,0.000013402916,0.0002315379],"genre_scores_gemma":[0.989376,0.000021031823,0.010380212,0.000021115167,0.000016291748,0.00009985289,0.00005284298,0.00001302249,0.00001964397],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99874973,0.000053825555,0.0005419778,0.00024162701,0.00022051495,0.00019234786],"domain_scores_gemma":[0.9987707,0.00012229923,0.0005964179,0.000301853,0.00014456548,0.000064121865],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00005904655,0.00018839721,0.00084626715,0.0000642959,0.0001245064,0.000006468746,0.00014753528,0.00013584054,0.00018738811],"category_scores_gemma":[0.000107397726,0.00014796341,0.00013500203,0.00003098434,0.0007086739,0.000055194363,0.0001034463,0.000060076614,0.0000014840091],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0004450542,0.001419968,0.2609081,0.00029988418,0.00019421661,0.000044284694,0.0006621716,1.7283706e-7,0.7076351,0.02812045,0.00010748025,0.0001631162],"study_design_scores_gemma":[0.0025911273,0.001071218,0.04870233,0.00009562563,0.0000960312,0.00036880258,0.00037062238,0.00004719107,0.9463817,0.0001494807,0.00002937503,0.00009648424],"about_ca_topic_score_codex":0.000058356232,"about_ca_topic_score_gemma":0.000010017511,"teacher_disagreement_score":0.23874661,"about_ca_system_score_codex":0.000021631877,"about_ca_system_score_gemma":0.000048583206,"threshold_uncertainty_score":0.6033773},"labels":[],"label_agreement":null},{"id":"W2766904819","doi":"10.1016/j.leukres.2017.10.016","title":"JAK2V617F detection and allele burden measurement in saliva vs. peripheral blood in patients with myelofibrosis","year":2017,"lang":"en","type":"article","venue":"Leukemia Research","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"DNA Genotek","keywords":"Saliva; Myelofibrosis; Medicine; Concordance; Internal medicine; Gastroenterology; Peripheral blood; Allele; Bone marrow; Biology; Genetics","score_opus":0.04390164215939978,"score_gpt":0.3152982846775243,"score_spread":0.2713966425181245,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2766904819","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9963982,0.00011707955,0.0000021982266,0.0008351355,0.0000280865,0.0010312718,0.000002818924,0.000009833096,0.0015753581],"genre_scores_gemma":[0.99908286,0.0001415717,0.00018563418,0.000030037167,0.00008998344,0.000230166,0.000008870668,0.000025025249,0.00020582696],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9975474,0.00015736671,0.0002226171,0.00044866712,0.001107483,0.00051646767],"domain_scores_gemma":[0.9988344,0.000059913735,0.00005566451,0.00046822504,0.00040296308,0.00017887482],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00084739295,0.00017214128,0.00031742064,0.0002395829,0.00032696791,0.00011966141,0.00012328246,0.00011160681,0.00006398342],"category_scores_gemma":[0.00034655494,0.00012883368,0.00002673137,0.00017787356,0.00016681703,0.0001510884,0.00011755923,0.00043641796,0.00001652243],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0018326472,0.00037742517,0.9817563,0.00008104426,0.0000698661,0.000075392694,0.0008012899,0.00001301324,0.0012174286,0.000019644174,0.000060020302,0.013695892],"study_design_scores_gemma":[0.011351948,0.0025037276,0.9773206,0.00033696878,0.000023577662,0.0000052233386,0.000118712866,0.00019330978,0.0075792274,0.000025688387,0.00041824192,0.00012274581],"about_ca_topic_score_codex":0.0068980795,"about_ca_topic_score_gemma":0.009519321,"teacher_disagreement_score":0.013573146,"about_ca_system_score_codex":0.0020655869,"about_ca_system_score_gemma":0.00047458094,"threshold_uncertainty_score":0.9997151},"labels":[],"label_agreement":null},{"id":"W2768676673","doi":"10.1182/blood.v128.22.4267.4267","title":"The Impact of Myeloproliferative Neoplasms (MPNs) on Patients' Quality of Life and Productivity: Results from the International MPN Landmark Survey","year":2016,"lang":"en","type":"article","venue":"Blood","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"St. Paul's Hospital; University of British Columbia","funders":"","keywords":"Medicine; Quality of life (healthcare); Polycythemia vera; Essential thrombocythemia; Myelofibrosis; Bristol-Myers; Absenteeism; Demography; Productivity; Myeloproliferative neoplasm; Internal medicine; Bone marrow; Psychology","score_opus":0.034217428626846694,"score_gpt":0.304659878616368,"score_spread":0.2704424499895213,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2768676673","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9935329,0.00014976141,0.0000032249798,0.0029610998,0.00011107672,0.0005991048,0.0021311296,0.000009538366,0.000502152],"genre_scores_gemma":[0.9991752,0.00029928543,0.00003867094,0.00007162053,0.00014163941,0.00004160732,0.00010868868,0.000012359628,0.00011093938],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9981499,0.00039741784,0.00050603726,0.00033433447,0.00045142087,0.00016093919],"domain_scores_gemma":[0.99417007,0.0044595343,0.00038284226,0.00045347732,0.0004392944,0.000094782525],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00097526395,0.00018565777,0.00039266906,0.0000319968,0.00010039982,0.000020731912,0.0001337457,0.000057133377,0.00002663139],"category_scores_gemma":[0.0058644055,0.00006944876,0.00011214958,0.000096081276,0.00018750643,0.00006076705,0.00007110633,0.000101389334,0.000005773517],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0040024016,0.0016505175,0.98739016,0.0000053054105,0.0010206472,0.0000010302331,0.0005701098,0.0000010447069,0.0006165936,0.00023247035,0.0012183114,0.0032914246],"study_design_scores_gemma":[0.009509053,0.0010792062,0.97421473,0.00009786809,0.000056448105,0.0000010632211,0.000036488513,0.0000039229267,0.014667196,0.00015747349,0.00009784222,0.00007869675],"about_ca_topic_score_codex":0.0019104391,"about_ca_topic_score_gemma":0.001002843,"teacher_disagreement_score":0.014050603,"about_ca_system_score_codex":0.000042472406,"about_ca_system_score_gemma":0.00019091624,"threshold_uncertainty_score":0.7020665},"labels":[],"label_agreement":null},{"id":"W2768722269","doi":"10.1038/leu.2017.330","title":"Long-term efficacy and safety of momelotinib, a JAK1 and JAK2 inhibitor, for the treatment of myelofibrosis","year":2017,"lang":"en","type":"letter","venue":"Leukemia","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":78,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; Jewish General Hospital","funders":"","keywords":"Myelofibrosis; Ruxolitinib; Term (time); Medicine; Internal medicine; Oncology; Bone marrow","score_opus":0.02789968569867325,"score_gpt":0.29448953559155167,"score_spread":0.2665898498928784,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2768722269","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8651893,0.012076148,0.000036552727,0.11338363,0.00044561477,0.007170464,0.0010465108,0.00003602294,0.00061573694],"genre_scores_gemma":[0.8666728,0.058676086,0.0026238272,0.042341422,0.0085744755,0.004761782,0.002513783,0.0004470238,0.013388809],"study_design_codex":"not_applicable","study_design_gemma":"observational","domain_scores_codex":[0.9982419,0.000046058703,0.00055806077,0.00053692184,0.00029719283,0.0003198633],"domain_scores_gemma":[0.9972412,0.0012117543,0.00052046403,0.00078181917,0.0001485582,0.00009622153],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00010954088,0.0004898464,0.0012431456,0.00011065171,0.00020417893,0.000037912872,0.00012154855,0.000487999,0.000040208608],"category_scores_gemma":[0.00008280506,0.0002853422,0.00026334767,0.00004791472,0.00038671357,0.00004158763,0.00005464509,0.0002624032,0.0000025781128],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.006389005,0.0021303666,0.30679077,0.007953692,0.0094973445,0.000693283,0.0043532806,0.0000057834577,0.0016362746,0.00019254582,0.34100616,0.31935152],"study_design_scores_gemma":[0.022698736,0.0076629063,0.5190185,0.002288057,0.0039729583,0.00015025688,0.000027645245,0.000039138256,0.018284475,0.000034229462,0.42533064,0.0004925021],"about_ca_topic_score_codex":0.00015215494,"about_ca_topic_score_gemma":0.000030387655,"teacher_disagreement_score":0.318859,"about_ca_system_score_codex":0.00033659214,"about_ca_system_score_gemma":0.00027189177,"threshold_uncertainty_score":0.9999599},"labels":[],"label_agreement":null},{"id":"W2778096288","doi":"10.1038/s41408-017-0035-6","title":"Risk factors for arterial versus venous thrombosis in polycythemia vera: a single center experience in 587 patients","year":2017,"lang":"en","type":"article","venue":"Blood Cancer Journal","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":147,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"University of Calgary; Mayo Clinic","keywords":"Medicine; Venous thrombosis; Internal medicine; Thrombosis; Polycythemia vera; Cardiology","score_opus":0.0634775556548781,"score_gpt":0.34844780470417197,"score_spread":0.28497024904929386,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2778096288","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9972267,0.00016463007,0.000004464627,0.00025132496,0.0015104758,0.0005540786,0.00010151825,0.000006185768,0.00018059417],"genre_scores_gemma":[0.9985709,0.000511464,0.00016401181,0.00005441709,0.00042029683,0.00023240219,0.000010855935,0.000021746086,0.000013877461],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99878097,0.000034864355,0.0003239334,0.00024990458,0.00023961591,0.0003707131],"domain_scores_gemma":[0.99916637,0.00007537937,0.0002958482,0.0002273425,0.000081648366,0.00015339664],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000080584905,0.0001923587,0.0003873873,0.00009636054,0.00029660593,0.00011434724,0.0001384423,0.00007828398,0.00013607656],"category_scores_gemma":[0.00019982351,0.00014908068,0.00011623518,0.000043231197,0.000056151115,0.00019197272,0.00003440877,0.00022686044,0.0000024450196],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0014015799,0.0027424751,0.9878214,0.000012065477,0.00016222092,0.00003636709,0.0036746198,0.000004368399,0.0005120655,0.0000032577605,0.00013226071,0.0034972953],"study_design_scores_gemma":[0.032067467,0.0020852303,0.9521943,0.0003294395,0.00015529823,0.000012903518,0.0003106816,0.000012607798,0.011749691,0.000020182097,0.0009003228,0.00016191923],"about_ca_topic_score_codex":0.0006030662,"about_ca_topic_score_gemma":0.0011176147,"teacher_disagreement_score":0.035627164,"about_ca_system_score_codex":0.0003586142,"about_ca_system_score_gemma":0.00013418561,"threshold_uncertainty_score":0.60793334},"labels":[],"label_agreement":null},{"id":"W2778275419","doi":"10.1016/s2352-3026(17)30237-5","title":"Momelotinib versus best available therapy in patients with myelofibrosis previously treated with ruxolitinib (SIMPLIFY 2): a randomised, open-label, phase 3 trial","year":2017,"lang":"en","type":"article","venue":"The Lancet Haematology","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":315,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Ruxolitinib; Medicine; Myelofibrosis; Internal medicine; Clinical endpoint; Anemia; Clinical trial; Phases of clinical research; Intention-to-treat analysis; Janus kinase inhibitor; Surgery; Gastroenterology; Janus kinase; Bone marrow","score_opus":0.11587736312776528,"score_gpt":0.37323862342992187,"score_spread":0.25736126030215656,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2778275419","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98164046,0.00022767656,0.0000030974804,0.0027760305,0.0001401348,0.007576644,0.00005878023,0.000050320366,0.0075268866],"genre_scores_gemma":[0.99530834,0.00051660504,0.00045868338,0.0004949636,0.00017317479,0.0022249243,0.00014138708,0.00006411266,0.00061781396],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9975234,0.00028801264,0.0004987899,0.0006243167,0.0003133896,0.0007520874],"domain_scores_gemma":[0.99712545,0.0005358399,0.00050980545,0.0014536178,0.00019550262,0.00017980824],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00043082674,0.0004489796,0.0021524713,0.00008905321,0.00048449228,0.0001917005,0.0006410302,0.00015622978,0.00038151184],"category_scores_gemma":[0.00023348155,0.00022609605,0.000059116173,0.00014588771,0.00039025542,0.00021293745,0.00013567969,0.00030404225,0.00016481214],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.75083715,0.0049989442,0.23706076,0.000049909737,0.0005355105,0.00025151923,0.00026168133,7.783832e-7,0.0000120629475,0.00047230686,0.0021327322,0.0033866293],"study_design_scores_gemma":[0.9516559,0.02521544,0.017717531,0.0003481806,0.0003646058,0.000065446315,0.00004172769,0.000019104984,0.001236718,0.000030849013,0.0030071547,0.0002973058],"about_ca_topic_score_codex":0.00041187144,"about_ca_topic_score_gemma":0.00038010103,"teacher_disagreement_score":0.21934323,"about_ca_system_score_codex":0.00009810919,"about_ca_system_score_gemma":0.00024208766,"threshold_uncertainty_score":0.9219929},"labels":[],"label_agreement":null},{"id":"W2778847088","doi":"10.1182/blood.v128.22.4281.4281","title":"Aside from the Allelic Burden of JAK2-V617F, Acquisition of Mutations in Myeloid Gene Panel Is Associated with the Transformation of Myeloproliferative Neoplasm into Secondary AML","year":2016,"lang":"en","type":"article","venue":"Blood","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Myeloid; Myeloproliferative neoplasm; JAK2 V617F; Mutation; Gene; Biology; Allele; Genetics; Medicine; Cancer research; Oncology; Bone marrow; Immunology; Myelofibrosis","score_opus":0.014545971677427504,"score_gpt":0.23782583951757602,"score_spread":0.22327986784014853,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2778847088","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9894449,0.0003294995,0.00018593848,0.008144934,0.000019398352,0.0009217038,0.0003983582,0.000012400634,0.0005428685],"genre_scores_gemma":[0.9986788,0.0002337377,0.00036259487,0.00025814935,0.000047662274,0.0001685516,0.00018528255,0.000017697786,0.000047514124],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9985019,0.0001812386,0.00055455824,0.0002092677,0.00038772018,0.00016534394],"domain_scores_gemma":[0.99819255,0.00076312944,0.00037373882,0.0002831438,0.00033992596,0.000047494872],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00026315523,0.00019172076,0.00046500398,0.00008971497,0.00007856475,0.0000075860207,0.00011375787,0.00010379528,0.00017327564],"category_scores_gemma":[0.00009623237,0.0000889546,0.00010567062,0.0002770709,0.00019405519,0.00013573177,0.000019198555,0.0001251412,0.000005480867],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0018246417,0.0051268702,0.28211632,0.00027504147,0.0067611453,0.00005744968,0.24216805,0.0001988354,0.4268134,0.0018850589,0.0005831352,0.032190055],"study_design_scores_gemma":[0.008644627,0.000739513,0.44665188,0.0005187118,0.0005541754,0.000011934728,0.0022944568,0.000054210956,0.539796,0.00056855514,0.00005721747,0.00010871353],"about_ca_topic_score_codex":0.0007550936,"about_ca_topic_score_gemma":0.0009369753,"teacher_disagreement_score":0.2398736,"about_ca_system_score_codex":0.000058640933,"about_ca_system_score_gemma":0.00023406543,"threshold_uncertainty_score":0.36274633},"labels":[],"label_agreement":null},{"id":"W2799990614","doi":"10.14740/jh375w","title":"Retrospective Study of High Hemoglobin Levels in 56 Young Adults","year":2018,"lang":"en","type":"article","venue":"Journal of Hematology","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":true,"ca_institutions":"Université de Sherbrooke","funders":"","keywords":"Medicine; Hematocrit; Etiology; Retrospective cohort study; Phlebotomy; Internal medicine; Population; Hemoglobin; Cohort; Aspirin; Gastroenterology; Surgery; Pediatrics","score_opus":0.018192052181828094,"score_gpt":0.3022637562406245,"score_spread":0.28407170405879645,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2799990614","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.997768,0.00023900555,0.000025341014,0.00071696186,0.0003129952,0.00035430395,0.0000040439786,0.0000042054066,0.0005751846],"genre_scores_gemma":[0.99903035,0.000027537299,0.00063431007,0.00008211732,0.00016356504,0.00000923356,6.4038437e-7,0.000011271164,0.000040970892],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99855244,0.000101556936,0.000723841,0.00016297735,0.00027525407,0.00018395168],"domain_scores_gemma":[0.99864864,0.00006795019,0.00048147832,0.00017020945,0.0005469433,0.000084778636],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00025297198,0.0001351418,0.0009063059,0.00024968083,0.000029759729,0.000003912629,0.00008006587,0.00008649201,0.00021185525],"category_scores_gemma":[0.00021775912,0.00009451419,0.000102605205,0.0002026989,0.00008671272,0.00006263493,0.00003097805,0.00021855,0.000013460962],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0011718284,0.0030135722,0.9882694,0.00003424074,0.00035153917,0.0010623507,0.003355453,8.6920954e-7,0.0002007197,0.0015381867,0.0006701222,0.0003317298],"study_design_scores_gemma":[0.010362081,0.01191185,0.9594958,0.00030101213,0.00013742958,0.0028387276,0.0016758555,0.000009890178,0.012549405,0.00061289466,0.00003123053,0.00007384936],"about_ca_topic_score_codex":0.00014391684,"about_ca_topic_score_gemma":0.0006872677,"teacher_disagreement_score":0.028773613,"about_ca_system_score_codex":0.00014657968,"about_ca_system_score_gemma":0.0001078938,"threshold_uncertainty_score":0.38541767},"labels":[],"label_agreement":null},{"id":"W2801874036","doi":"10.1016/j.thromres.2018.04.027","title":"Antiplatelet use in patients with essential thrombocythemia: A survey of opinion and Canadian practice","year":2018,"lang":"en","type":"letter","venue":"Thrombosis Research","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Impact; Princess Margaret Cancer Centre; Hamilton Health Sciences; University of Toronto; McMaster University; Population Health Research Institute","funders":"Hamilton Health Sciences Foundation; Hamilton Health Sciences; Heart and Stroke Foundation of Canada","keywords":"Essential thrombocythemia; Medicine; Expert opinion; Family medicine; Opinion survey; Internal medicine; Opinion leadership; Intensive care medicine; Political science; Platelet; Public relations","score_opus":0.11803493431805429,"score_gpt":0.3959210781924427,"score_spread":0.2778861438743884,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2801874036","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9236879,0.0001384129,8.2439226e-7,0.07232788,0.0001300022,0.0020943477,0.0006702428,0.000012402305,0.00093798863],"genre_scores_gemma":[0.9675448,0.001622802,0.0005804686,0.024866642,0.00063511566,0.00017228433,0.0042279507,0.00015698478,0.00019297579],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9951783,0.0010987911,0.0004704963,0.00079905,0.0015427878,0.000910576],"domain_scores_gemma":[0.9945871,0.0019630333,0.00018340551,0.0006965108,0.0022872693,0.00028265474],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0014815218,0.00038526815,0.0010445981,0.00096746406,0.00016389928,0.000113520495,0.00018014222,0.0007455091,0.00028525808],"category_scores_gemma":[0.0014857422,0.00028987156,0.000050760933,0.00082778884,0.00062156655,0.00027224727,0.00013468224,0.0020168961,0.00004744452],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0004818169,0.00043523323,0.66366464,0.00025726584,0.00045892925,0.00013474213,0.00022796971,1.3625392e-7,0.0000082445185,0.00000754281,0.33421385,0.00010960144],"study_design_scores_gemma":[0.003363181,0.0021886337,0.95655674,0.0009958756,0.00008819362,0.000012817397,0.000025822384,0.0000062962645,0.00029752823,0.0000054029097,0.036216084,0.00024344314],"about_ca_topic_score_codex":0.40770513,"about_ca_topic_score_gemma":0.15561919,"teacher_disagreement_score":0.29799777,"about_ca_system_score_codex":0.00053161767,"about_ca_system_score_gemma":0.0014074589,"threshold_uncertainty_score":0.99995536},"labels":[],"label_agreement":null},{"id":"W2802200411","doi":"10.1007/s00277-018-3352-3","title":"Bilateral adrenal hemorrhage as a manifestation of extramedullary hematopoiesis in a patient with primary myelofibrosis","year":2018,"lang":"en","type":"letter","venue":"Annals of Hematology","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Manitoba","funders":"","keywords":"Myelofibrosis; Extramedullary hematopoiesis; Medicine; Hematology; Haematopoiesis; Internal medicine; General surgery; Pathology; Bone marrow; Stem cell; Biology","score_opus":0.025721789281286253,"score_gpt":0.28750729572604655,"score_spread":0.2617855064447603,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2802200411","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8598751,0.0010581785,0.000010906475,0.13583325,0.00008604245,0.001011246,0.000112194386,0.000024738376,0.0019883765],"genre_scores_gemma":[0.7835442,0.0003929852,0.003625064,0.21007521,0.0002638882,0.00044845225,0.0013437689,0.00012007492,0.00018638889],"study_design_codex":"not_applicable","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9970281,0.00018064538,0.001085153,0.0006092189,0.0005731958,0.00052367937],"domain_scores_gemma":[0.9978359,0.00033801948,0.00080716977,0.00054549024,0.00037846505,0.00009495802],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00012263941,0.0005086239,0.0018833021,0.000598229,0.000033672954,0.0000091608845,0.00013478879,0.0006925024,0.0003589676],"category_scores_gemma":[0.000070945316,0.00037861563,0.00025208818,0.00028340032,0.00034088676,0.00008140034,0.000072575334,0.0005302809,0.000030720304],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.006301952,0.005426214,0.11113494,0.0259492,0.0033223291,0.085383646,0.0051472946,0.000007095168,0.0017950307,0.0011067752,0.7486742,0.0057513057],"study_design_scores_gemma":[0.012668751,0.03885691,0.06661936,0.01809951,0.0020423033,0.05968317,0.0006836166,0.0000904162,0.762076,0.003036399,0.03349045,0.0026531152],"about_ca_topic_score_codex":0.0001878408,"about_ca_topic_score_gemma":0.000035293124,"teacher_disagreement_score":0.76028097,"about_ca_system_score_codex":0.000040571074,"about_ca_system_score_gemma":0.0003694523,"threshold_uncertainty_score":0.9998666},"labels":[],"label_agreement":null},{"id":"W2802748326","doi":"10.1097/hs9.0000000000000044","title":"Clinical Utility of Next‐generation Sequencing in the Management of Myeloproliferative Neoplasms: A Single‐Center Experience","year":2018,"lang":"en","type":"article","venue":"HemaSphere","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":31,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Princess Margaret Cancer Centre; University Health Network","funders":"European Hematology Association; Bristol-Myers Squibb","keywords":"Medicine; Myeloid; Oncology; Internal medicine; Myelofibrosis; DNA sequencing; Bioinformatics; Gene; Biology; Genetics; Bone marrow","score_opus":0.1708202741207578,"score_gpt":0.36932847587103346,"score_spread":0.19850820175027567,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2802748326","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9878242,0.0002688657,0.00028909458,0.00030544947,0.00014456939,0.00083863316,0.0000079283145,0.000012430983,0.010308806],"genre_scores_gemma":[0.9929632,0.0001710355,0.0060333107,0.00040379225,0.00016341379,0.0001339718,0.00001719484,0.000011931599,0.00010214883],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99807304,0.00018530244,0.0007632547,0.00037166517,0.00038863212,0.00021812905],"domain_scores_gemma":[0.9989189,0.0001235872,0.00021441965,0.00045652466,0.00022197214,0.00006460037],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00045001548,0.00018427239,0.00044538057,0.00003523217,0.00006347735,0.000015611507,0.000121019584,0.00009227573,0.00049832347],"category_scores_gemma":[0.000060646194,0.00011914203,0.00012816314,0.00028174015,0.00030229613,0.000114571136,0.000054343178,0.00013709211,0.000014517723],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0008228398,0.0033449403,0.9203704,0.0005350121,0.00050158653,0.00017507604,0.024856877,0.000007659661,0.0069471155,0.006017476,0.001470758,0.034950253],"study_design_scores_gemma":[0.0139137935,0.0076322607,0.5448128,0.003388029,0.00056825037,0.00025527924,0.045763247,0.013116232,0.364021,0.00066601805,0.005114896,0.00074819976],"about_ca_topic_score_codex":0.000062773965,"about_ca_topic_score_gemma":0.00029167303,"teacher_disagreement_score":0.3755576,"about_ca_system_score_codex":0.000092664406,"about_ca_system_score_gemma":0.00010001836,"threshold_uncertainty_score":0.54562926},"labels":[],"label_agreement":null},{"id":"W2803381821","doi":"10.1007/s00277-018-3365-y","title":"Ruxolitinib for the treatment of inadequately controlled polycythemia vera without splenomegaly: 80-week follow-up from the RESPONSE-2 trial","year":2018,"lang":"en","type":"article","venue":"Annals of Hematology","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":60,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Sciences Centre; Sunnybrook Health Science Centre","funders":"Novartis","keywords":"Ruxolitinib; Medicine; Hematocrit; Polycythemia vera; Internal medicine; Hematology; Anemia; Myelofibrosis; Surgery; Bone marrow","score_opus":0.12358916082952978,"score_gpt":0.3813806818075789,"score_spread":0.25779152097804914,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2803381821","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.95998037,0.0032859875,0.00007234743,0.032014493,0.00047486057,0.0035321976,0.00023100687,0.000019324947,0.00038942552],"genre_scores_gemma":[0.99586004,0.000582026,0.00022881111,0.0012852469,0.00046771826,0.0010768079,0.000047042868,0.000029116361,0.000423194],"study_design_codex":"randomized_trial","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99792266,0.0003220333,0.0007881568,0.00033990067,0.00023928068,0.00038796413],"domain_scores_gemma":[0.9915915,0.006836247,0.00048746078,0.0006598037,0.0003274832,0.00009749729],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004925707,0.00029135685,0.0014589408,0.00007493445,0.00018206122,0.000011989371,0.00018221462,0.0001525177,0.0002114507],"category_scores_gemma":[0.00091090554,0.0001373317,0.0005586649,0.000106185056,0.0004876428,0.000031762647,0.000024946414,0.00007603298,0.000021576647],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9451178,0.0033741572,0.016153082,0.000036233694,0.0048091547,0.000030139403,0.0042116465,7.110796e-7,0.0015275631,0.0103459405,0.009944198,0.004449415],"study_design_scores_gemma":[0.4167392,0.058137953,0.01625536,0.00022281162,0.0022098143,0.000091825415,0.0011717231,0.0001974637,0.42737746,0.0032543014,0.074015126,0.0003269565],"about_ca_topic_score_codex":0.00040214503,"about_ca_topic_score_gemma":0.00017550786,"teacher_disagreement_score":0.52837855,"about_ca_system_score_codex":0.00002601209,"about_ca_system_score_gemma":0.00030164694,"threshold_uncertainty_score":0.5600224},"labels":[],"label_agreement":null},{"id":"W2804153282","doi":"10.1093/jcag/gwy016","title":"Esophageal Variceal Hemorrhage Secondary to Post-Polycythemic Myelofibrosis","year":2018,"lang":"en","type":"article","venue":"Journal of the Canadian Association of Gastroenterology","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Dalhousie University","funders":"","keywords":"Myelofibrosis; Medicine; Internal medicine; Esophagus; Esophageal varices; Cardiology; Gastroenterology; Bone marrow; Portal hypertension; Cirrhosis","score_opus":0.0064879631355258096,"score_gpt":0.23150846796555014,"score_spread":0.22502050483002434,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2804153282","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96094096,0.000014937167,0.000027673956,0.03723839,0.0006976731,0.0002017799,0.00009357268,0.0000034563418,0.00078156503],"genre_scores_gemma":[0.98690385,0.000004364359,0.0011547948,0.0106823025,0.000448171,0.0000042929023,0.0000055238943,0.0000147442315,0.0007819609],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9984997,0.00017439153,0.0005075254,0.00012398887,0.00032865492,0.0003657653],"domain_scores_gemma":[0.99779034,0.00007708522,0.0006957664,0.00017952376,0.0008297173,0.0004275618],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00051329774,0.0001338649,0.00044238017,0.0002897243,0.00013605085,0.000016715287,0.00018681485,0.00011599968,0.00034639932],"category_scores_gemma":[0.00027785185,0.000096718155,0.000229792,0.00015053761,0.000060745147,0.00006344586,0.00003393258,0.00027902692,0.000031107687],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0008496266,0.00013196754,0.9791483,0.000016578788,0.00059406727,0.000059414073,0.00045810602,0.000006648786,0.0019295495,0.000053387423,0.016174898,0.0005774487],"study_design_scores_gemma":[0.0025696058,0.005117695,0.9855919,0.000055272252,0.00032685226,0.0005211985,0.00006656309,0.000016472994,0.0042072744,0.000053925974,0.0014221186,0.000051162722],"about_ca_topic_score_codex":0.0026327022,"about_ca_topic_score_gemma":0.1380225,"teacher_disagreement_score":0.1353898,"about_ca_system_score_codex":0.0014658486,"about_ca_system_score_gemma":0.00075977633,"threshold_uncertainty_score":0.87770635},"labels":[],"label_agreement":null},{"id":"W2806323598","doi":"10.1016/j.leukres.2018.06.001","title":"The real-world outcomes of treating Polycythemia Vera: Physician adherence to treatment guidelines","year":2018,"lang":"en","type":"article","venue":"Leukemia Research","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Population Health Research Institute; McMaster University","funders":"Heart and Stroke Foundation of Canada; American Society of Hematology","keywords":"Medicine; Polycythemia vera; Internal medicine; Myeloproliferative neoplasm; Cohort; Retrospective cohort study; White blood cell; Myelofibrosis; Bone marrow","score_opus":0.1747975853204603,"score_gpt":0.477876164278517,"score_spread":0.3030785789580567,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2806323598","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9509193,0.00020022843,0.000008373357,0.006468077,0.000112461814,0.0011500848,0.00002074529,0.000042009287,0.041078765],"genre_scores_gemma":[0.97284,0.00049247715,0.001567307,0.00038638886,0.00059018703,0.00048389146,0.000012546317,0.000035852958,0.023591325],"study_design_codex":"observational","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9973655,0.00016469887,0.0005132994,0.0004445239,0.0008625853,0.0006494392],"domain_scores_gemma":[0.9967082,0.0011135575,0.000093953364,0.000777037,0.0010509016,0.00025634322],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006488496,0.0002491251,0.00051321497,0.00021410051,0.0005398537,0.00005475414,0.00022493913,0.00006175214,0.00010009578],"category_scores_gemma":[0.000545473,0.00013334648,0.00016017602,0.00076037925,0.00032593953,0.00004870129,0.00012379585,0.00019357621,0.00031102815],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0014142554,0.0006686418,0.52682453,0.000057423655,0.00085775746,0.000084298335,0.0024859484,0.000011206768,0.011353894,0.0068604383,0.021943506,0.4274381],"study_design_scores_gemma":[0.006517706,0.013911857,0.4474523,0.0007062742,0.00019237657,0.000010382964,0.0015676072,0.00081654085,0.44918582,0.0007775458,0.078451686,0.00040988217],"about_ca_topic_score_codex":0.00674667,"about_ca_topic_score_gemma":0.0047925147,"teacher_disagreement_score":0.43783194,"about_ca_system_score_codex":0.0015748895,"about_ca_system_score_gemma":0.0008398905,"threshold_uncertainty_score":0.9998675},"labels":[],"label_agreement":null},{"id":"W2876645126","doi":"10.1182/blood-2018-03-842161","title":"Concurrent JAK2 mutation and isolated del(5q) associated with marrow fibrosis and small hypo/monolobated megakaryocytes","year":2018,"lang":"en","type":"article","venue":"Blood","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"","keywords":"Mean corpuscular volume; Hemoglobin; Platelet; Medicine; Megakaryocyte; Internal medicine; Anemia; Mean corpuscular hemoglobin; Gastroenterology; Immunology; Pathology; Biology; Haematopoiesis; Genetics","score_opus":0.014407507337810316,"score_gpt":0.23238097441988328,"score_spread":0.21797346708207296,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2876645126","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.997123,0.0010975682,0.000040906085,0.0005828679,0.000043249674,0.0005580698,0.000039812665,0.00009255463,0.00042194885],"genre_scores_gemma":[0.99865955,0.00020724937,0.00051757664,0.00019159535,0.000056207933,0.000057523317,0.0001422689,0.000025162473,0.00014287463],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9989573,0.00006326503,0.0002150271,0.000365362,0.00015248271,0.00024660781],"domain_scores_gemma":[0.9991822,0.00015782082,0.00011820635,0.00013193677,0.00023914262,0.00017068649],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000092510185,0.00023008948,0.00034672697,0.00007626888,0.00016191154,0.00004825707,0.000029629282,0.00011701831,0.00005616296],"category_scores_gemma":[0.0001244664,0.00016646965,0.00002938975,0.00018382732,0.00015544411,0.00006697668,0.000030113557,0.00010342889,0.000012221958],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00042188776,0.0019522829,0.97597736,0.00008761283,0.0018850547,0.00025660335,0.0013444987,7.9706876e-7,0.0071764668,0.00020506432,0.0004621875,0.010230195],"study_design_scores_gemma":[0.017909873,0.0074436422,0.8815509,0.0005622234,0.0016726413,0.00034770154,0.00014203081,0.0012090509,0.08843777,0.00007818476,0.00027866245,0.00036732468],"about_ca_topic_score_codex":0.000083353516,"about_ca_topic_score_gemma":0.00028431037,"teacher_disagreement_score":0.09442645,"about_ca_system_score_codex":0.00003979242,"about_ca_system_score_gemma":0.000060247243,"threshold_uncertainty_score":0.6788435},"labels":[],"label_agreement":null},{"id":"W2888479936","doi":"10.1016/j.exphem.2018.06.205","title":"Using Zebrafish to Model JAK1-A634D Gain-of-Function Mutation in Familial Eosinophilia","year":2018,"lang":"en","type":"article","venue":"Experimental Hematology","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; Dalhousie University","funders":"","keywords":"Zebrafish; Biology; Myeloid; Haematopoiesis; Cancer research; Hypereosinophilia; Ruxolitinib; Eosinophilia; Eosinophil; Mutation; Immunology; Bone marrow; Stem cell; Genetics; Myelofibrosis; Gene","score_opus":0.05159859847395672,"score_gpt":0.3603386447041082,"score_spread":0.3087400462301515,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2888479936","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9946598,0.00046759716,0.0020573686,0.00023319518,0.00028930962,0.0006188392,0.000006097035,0.000027255792,0.0016405626],"genre_scores_gemma":[0.99211586,0.0000026274504,0.0069326865,0.00065587315,0.000095359595,0.00010259896,0.000023412817,0.000021294365,0.000050291907],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9988469,0.00004583216,0.00036360696,0.00033089714,0.00017065194,0.00024215307],"domain_scores_gemma":[0.99951524,0.000035068988,0.00007697282,0.00018500585,0.00008127489,0.0001064205],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00006898866,0.00017202173,0.0004090376,0.00019539983,0.000062458465,0.000005605222,0.000044133736,0.00011314472,0.00016171577],"category_scores_gemma":[0.000029659745,0.00015897826,0.000062959116,0.00018352091,0.000106884836,0.000073882664,0.000045651406,0.00007294394,0.00006637225],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0068124253,0.0077498904,0.17541681,0.00021876929,0.00038306197,0.00046839745,0.018005168,0.0016116798,0.64365745,0.14086504,0.0023025742,0.0025087416],"study_design_scores_gemma":[0.002661968,0.0020879263,0.005262614,0.0001144417,0.00003640027,0.00019913845,0.00070612767,0.020334158,0.968009,0.0003983236,0.000042526957,0.0001473699],"about_ca_topic_score_codex":0.00012239057,"about_ca_topic_score_gemma":0.000055875564,"teacher_disagreement_score":0.32435158,"about_ca_system_score_codex":0.00019324283,"about_ca_system_score_gemma":0.00007657348,"threshold_uncertainty_score":0.64829457},"labels":[],"label_agreement":null},{"id":"W2888686509","doi":"10.1016/j.jmoldx.2018.07.002","title":"Clinical Significance of DNA Variants in Chronic Myeloid Neoplasms","year":2018,"lang":"en","type":"review","venue":"Journal of Molecular Diagnostics","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":55,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Sciences North","funders":"Association for Molecular Pathology","keywords":"Clinical significance; Medicine; DNA; Biology; Genetics; Cancer research; Internal medicine","score_opus":0.05001394621180254,"score_gpt":0.37908277562101717,"score_spread":0.3290688294092146,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2888686509","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.003324398,0.99378943,0.00035445055,0.000100591475,0.00083976955,0.0012158661,0.00006704083,0.0000067165724,0.00030175512],"genre_scores_gemma":[0.0016085623,0.99434274,0.002757987,0.00013380057,0.00093716977,0.000050889164,0.000036053498,0.00009520101,0.000037577338],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99428576,0.00060049194,0.003422861,0.00045619757,0.0008020762,0.0004325921],"domain_scores_gemma":[0.99296,0.0026484907,0.002739888,0.00061595434,0.0006502801,0.00038540695],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0012856339,0.0005980315,0.0044355365,0.00051592727,0.000030481044,0.000025194342,0.00038265146,0.00063545565,0.00011953646],"category_scores_gemma":[0.0038517776,0.00043635283,0.0014794135,0.0005327065,0.00024491257,0.000062618994,0.0001030266,0.0011356317,0.00006096978],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00022098079,0.0040993276,0.006360785,0.020337014,0.0041414583,0.01444457,0.000093560826,0.000025978905,0.000040750227,0.0005105922,0.007800608,0.9419244],"study_design_scores_gemma":[0.004780579,0.0077447793,0.0034352145,0.09026185,0.0077456147,0.001526194,0.00001269958,0.000016744378,0.00067284046,0.00016828954,0.88302255,0.000612638],"about_ca_topic_score_codex":0.000008532191,"about_ca_topic_score_gemma":0.000016245765,"teacher_disagreement_score":0.9413117,"about_ca_system_score_codex":0.000648216,"about_ca_system_score_gemma":0.003909483,"threshold_uncertainty_score":0.99980885},"labels":[],"label_agreement":null},{"id":"W2889471460","doi":"10.1016/j.clml.2018.07.297","title":"Management of Polycythemia Vera: A Survey of Canadian Physician Practice Patterns","year":2018,"lang":"en","type":"article","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Princess Margaret Cancer Centre; St. Michael's Hospital; Toronto General Hospital; University of Toronto; University Health Network","funders":"","keywords":"Polycythemia vera; Family medicine; Medicine; Internal medicine","score_opus":0.05114154268951311,"score_gpt":0.35426591931080276,"score_spread":0.30312437662128966,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2889471460","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96789,0.0001814697,0.00002920193,0.00083995593,0.00040864598,0.00076897064,0.00021077532,0.000029553625,0.029641392],"genre_scores_gemma":[0.9948271,0.0006216097,0.0017420917,0.0018423923,0.00031659656,0.00007348488,0.00013994216,0.00004855808,0.00038824673],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9968466,0.0003266968,0.0012220914,0.000602636,0.00049488636,0.00050709094],"domain_scores_gemma":[0.99626267,0.0010086416,0.0005397992,0.0008659946,0.000758304,0.0005645669],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0010257779,0.00032566523,0.0009745559,0.0002817813,0.00010284025,0.000016480035,0.00024720537,0.00023955682,0.00019335814],"category_scores_gemma":[0.00056837517,0.0002781317,0.0002847449,0.00076626445,0.00040858318,0.00011574772,0.00010945714,0.0001534332,0.00019202336],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0015050571,0.001081456,0.48002288,0.00019355539,0.0015960017,0.0005304341,0.00019439026,7.183464e-7,0.00007240471,0.0017571759,0.0041227858,0.5089232],"study_design_scores_gemma":[0.0038056567,0.0015757222,0.97203195,0.0005201991,0.000453275,0.000037930196,0.00014863595,0.000063267915,0.0051517356,0.000039799343,0.015955407,0.00021641096],"about_ca_topic_score_codex":0.09451647,"about_ca_topic_score_gemma":0.026428878,"teacher_disagreement_score":0.50870675,"about_ca_system_score_codex":0.00068764604,"about_ca_system_score_gemma":0.0014092312,"threshold_uncertainty_score":0.9999671},"labels":[],"label_agreement":null},{"id":"W2891311699","doi":"10.1016/j.bbmt.2018.09.001","title":"Ruxolitinib Therapy Followed by Reduced-Intensity Conditioning for Hematopoietic Cell Transplantation for Myelofibrosis: Myeloproliferative Disorders Research Consortium 114 Study","year":2018,"lang":"en","type":"article","venue":"Biology of Blood and Marrow Transplantation","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":58,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"Medical Research Council; National Cancer Institute; Cancer Research UK; Incyte; Baxalta; Blood Cancer UK; Gilead Sciences; American Society of Hematology","keywords":"Ruxolitinib; Medicine; Myelofibrosis; Hematopoietic cell; Transplantation; Myeloproliferative Disorders; Hematopoietic stem cell transplantation; Oncology; Haematopoiesis; Bone marrow transplantation; Internal medicine; Stem cell; Bone marrow","score_opus":0.033959172633475476,"score_gpt":0.34007683218389023,"score_spread":0.30611765955041476,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2891311699","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99092954,0.00056352234,0.0023385936,0.0007440061,0.0001335106,0.0042099417,0.00079897366,0.00003868364,0.00024323547],"genre_scores_gemma":[0.99344033,0.002124085,0.0012829717,0.00013057183,0.00010462271,0.0014079773,0.0014117494,0.000027260208,0.000070425645],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99827063,0.00018857438,0.0004748708,0.0005344837,0.00016737677,0.0003640394],"domain_scores_gemma":[0.9984127,0.0006323264,0.00015472404,0.00014137788,0.000548975,0.00010987786],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005378041,0.00024464345,0.00052673963,0.00016748566,0.0004206484,0.000020042358,0.000060256432,0.00017283008,0.000020811249],"category_scores_gemma":[0.00003650155,0.00020411573,0.00011802197,0.000131028,0.00040101158,0.000087562265,0.000004538614,0.00011330137,0.0000015790654],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.013107769,0.0029784173,0.14662291,0.0011075166,0.0008857354,0.0000070163405,0.016252536,7.5849914e-7,0.81497175,0.0015938894,0.00085586455,0.0016158285],"study_design_scores_gemma":[0.020848934,0.01687853,0.040004104,0.0002003821,0.00107112,0.000050092996,0.0025656172,0.000028868479,0.9165466,0.0013056333,0.00022505691,0.00027506825],"about_ca_topic_score_codex":0.00007080119,"about_ca_topic_score_gemma":0.00011031442,"teacher_disagreement_score":0.1066188,"about_ca_system_score_codex":0.000016496722,"about_ca_system_score_gemma":0.00010338693,"threshold_uncertainty_score":0.8323598},"labels":[],"label_agreement":null},{"id":"W2891596347","doi":"10.1186/s13045-018-0661-x","title":"A phase Ib study to assess the efficacy and safety of vismodegib in combination with ruxolitinib in patients with intermediate- or high-risk myelofibrosis","year":2018,"lang":"en","type":"letter","venue":"Journal of Hematology & Oncology","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":30,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen Elizabeth II Health Sciences Centre","funders":"Fondazione Regionale per la Ricerca Biomedica; F. Hoffmann-La Roche","keywords":"Ruxolitinib; Vismodegib; Myelofibrosis; Medicine; Internal medicine; Hematology; Oncology; Phases of clinical research; Clinical trial; Bone marrow","score_opus":0.022472772919080175,"score_gpt":0.33131442023480595,"score_spread":0.3088416473157258,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2891596347","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9416677,0.000058902755,0.000037540343,0.05561579,0.00020700363,0.0023300503,0.000032465883,0.000004926374,0.000045656423],"genre_scores_gemma":[0.9795716,0.00008881878,0.0008286944,0.01906456,0.00020355648,0.00013066051,0.000047191486,0.000044526983,0.000020393694],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99636424,0.001012382,0.0013500449,0.0003992319,0.00048374492,0.00039036231],"domain_scores_gemma":[0.9950526,0.0022367479,0.0016318818,0.0003147923,0.00064576074,0.0001182704],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007595635,0.00040703503,0.0023396227,0.0007562899,0.00006238073,0.000013454812,0.0002104433,0.00043021108,0.000053861684],"category_scores_gemma":[0.0003930008,0.00019973729,0.00007026058,0.00034235689,0.00035473466,0.00008385293,0.00009034917,0.0014690451,0.0000029981359],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.039841976,0.018857429,0.91649806,0.00016968495,0.0011485366,0.0033767396,0.0037198365,0.000005329461,0.0000022401002,0.000035953613,0.014284219,0.0020600068],"study_design_scores_gemma":[0.090852104,0.14399455,0.7569203,0.0012772251,0.0010475504,0.0007827032,0.00060783944,0.0000055741316,0.000109553126,0.00003193755,0.004162206,0.000208451],"about_ca_topic_score_codex":0.00010035905,"about_ca_topic_score_gemma":0.00083220867,"teacher_disagreement_score":0.15957776,"about_ca_system_score_codex":0.0004009659,"about_ca_system_score_gemma":0.0006423596,"threshold_uncertainty_score":0.81450504},"labels":[],"label_agreement":null},{"id":"W2891720308","doi":"10.1200/jco.2017.35.15_suppl.7001","title":"Phase 3 randomized trial of momelotinib (MMB) versus best available therapy (BAT) in patients with myelofibrosis (MF) previously treated with ruxolitinib (RUX).","year":2017,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":15,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Myelofibrosis; Clinical endpoint; Anemia; Internal medicine; Gastroenterology; Ruxolitinib; Randomized controlled trial; Surgery; Bone marrow","score_opus":0.13005416151927524,"score_gpt":0.4476270528897659,"score_spread":0.31757289137049066,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2891720308","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99018097,0.00023270793,0.000006527447,0.0013256395,0.0005468139,0.0025118366,0.000017106735,0.0000075544417,0.0051708315],"genre_scores_gemma":[0.99471456,0.0021975543,0.0018175645,0.00020887665,0.0005037433,0.00010292053,0.000019186413,0.000038347498,0.00039726438],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.994502,0.000928577,0.0031190554,0.00036740044,0.00068807293,0.0003948663],"domain_scores_gemma":[0.98837286,0.004660297,0.0049304194,0.00056196516,0.0010256876,0.00044879297],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0032241398,0.00034513717,0.0045854338,0.00019739887,0.00011332698,0.000033728873,0.0002720972,0.00036828365,0.00043683965],"category_scores_gemma":[0.004434114,0.00018064777,0.0006159909,0.000122012156,0.00070068054,0.00022772286,0.000040323514,0.0006751805,0.000022362748],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.7529768,0.027191428,0.18356703,0.00002036687,0.0015232932,0.00021504665,0.00008322611,0.0000027234655,0.000005448614,0.000031798074,0.00036479678,0.034018047],"study_design_scores_gemma":[0.76508653,0.18420495,0.046002526,0.0004012401,0.000983601,0.000014719434,0.000024731124,0.000015052059,0.00038922994,0.00001421983,0.002728456,0.00013473733],"about_ca_topic_score_codex":0.00014253765,"about_ca_topic_score_gemma":0.00009418887,"teacher_disagreement_score":0.15701352,"about_ca_system_score_codex":0.00017409622,"about_ca_system_score_gemma":0.001604313,"threshold_uncertainty_score":0.7366602},"labels":[],"label_agreement":null},{"id":"W2892126810","doi":"10.1200/jco.2018.36.15_suppl.7042","title":"Mutant IDH (mIDH) inhibitors, ivosidenib or enasidenib, with azacitidine (AZA) in patients with acute myeloid leukemia (AML).","year":2018,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":32,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Medicine; Nausea; Azacitidine; Internal medicine; Gastroenterology; Neutropenia; Febrile neutropenia; Myeloid leukemia; Toxicity","score_opus":0.04641121958465396,"score_gpt":0.38688004272316784,"score_spread":0.3404688231385139,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2892126810","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9926341,0.000074946496,0.00005376474,0.004534093,0.00072180486,0.0006563539,0.000013502392,0.0000164418,0.0012949788],"genre_scores_gemma":[0.98966295,0.00041353935,0.0051396284,0.0024982335,0.0019236173,0.000026429481,0.0000123452,0.00004867848,0.00027457497],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9951875,0.00039232423,0.002630364,0.00044142336,0.00085142674,0.000496964],"domain_scores_gemma":[0.9942947,0.0016082275,0.0018650845,0.00033039786,0.0012377539,0.0006638475],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013942977,0.00037253712,0.0023702325,0.0002798511,0.000087090666,0.00002497916,0.00018941358,0.00044680512,0.0004295258],"category_scores_gemma":[0.0013232732,0.00018728396,0.00027199084,0.00039629437,0.0005620534,0.00026857766,0.00007039558,0.0011677099,0.00005796388],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.053642206,0.004144709,0.9039304,0.000026451455,0.0014481237,0.006449404,0.0002501617,0.00000621447,0.000118844575,0.00007155256,0.0040417304,0.0258702],"study_design_scores_gemma":[0.04658999,0.12649055,0.8020273,0.00074210967,0.0009984017,0.0011698938,0.000105995576,0.000017271192,0.004071618,0.0000793419,0.017436245,0.00027130745],"about_ca_topic_score_codex":0.00005439972,"about_ca_topic_score_gemma":0.0011118492,"teacher_disagreement_score":0.122345835,"about_ca_system_score_codex":0.00077915675,"about_ca_system_score_gemma":0.004163176,"threshold_uncertainty_score":0.7637219},"labels":[],"label_agreement":null},{"id":"W2895089040","doi":"10.5737/23688076284269275","title":"Néoplasies myéloprolifératives – Partie 1 : survol du diagnostic et du traitement des NMP « classiques »","year":2018,"lang":"fr","type":"article","venue":"Canadian Oncology Nursing Journal","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"London Health Sciences Centre; Princess Margaret Cancer Centre","funders":"","keywords":"Gynecology; Medicine; Humanities; Philosophy","score_opus":0.0344648497618146,"score_gpt":0.3360210406413334,"score_spread":0.3015561908795188,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2895089040","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.56682396,0.062510274,0.0014938418,0.2782986,0.017698817,0.0015642911,0.00028842437,0.00008670888,0.07123514],"genre_scores_gemma":[0.95908684,0.022025399,0.0019345651,0.0060305786,0.00867224,0.00012866195,0.000049617563,0.000102369675,0.0019697037],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.99426955,0.0016169237,0.0010391783,0.00064003625,0.0004366266,0.00199769],"domain_scores_gemma":[0.99233204,0.0027115461,0.00047396455,0.00031210668,0.0010596563,0.0031106914],"candidate_categories":["metaepi_narrow","sts","insufficient_payload"],"consensus_categories":["sts"],"category_scores_codex":[0.0015022566,0.0007090549,0.0011221675,0.0006502133,0.0018399592,0.0003151239,0.00027877538,0.00059889804,0.004789666],"category_scores_gemma":[0.0032424529,0.00064610573,0.00030289564,0.0003984348,0.0040840055,0.000510217,0.000028407427,0.0011205621,0.00048826117],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.00031150653,0.0019920683,0.3902083,0.00008399559,0.0011574912,0.0056755817,0.026347714,0.00003173937,0.000070309325,0.011720561,0.27699006,0.28541067],"study_design_scores_gemma":[0.005061739,0.011403939,0.44328028,0.00844769,0.0012903538,0.009795262,0.0057609947,0.00060293335,0.0014054836,0.004407934,0.50779796,0.0007454199],"about_ca_topic_score_codex":0.006149697,"about_ca_topic_score_gemma":0.2606676,"teacher_disagreement_score":0.39226294,"about_ca_system_score_codex":0.013847389,"about_ca_system_score_gemma":0.013518326,"threshold_uncertainty_score":0.99959904},"labels":[],"label_agreement":null},{"id":"W2895179707","doi":"10.5737/23688076284282287","title":"Néoplasies myéloprolifératives (NMP) – Partie 2 : Guide infirmier sur la conduite à tenir devant les symptômes de NMP","year":2018,"lang":"fr","type":"article","venue":"Canadian Oncology Nursing Journal","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"London Health Sciences Centre; Princess Margaret Cancer Centre","funders":"","keywords":"Gynecology; Medicine; Humanities; Political science; Art","score_opus":0.029270590979973227,"score_gpt":0.34984285723287684,"score_spread":0.3205722662529036,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2895179707","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.5886637,0.09686206,0.00069524243,0.16188371,0.011720381,0.001137047,0.0003018827,0.000086679196,0.13864931],"genre_scores_gemma":[0.9470219,0.008815032,0.0043568495,0.0058177873,0.007958265,0.00008924485,0.000041003706,0.0001504954,0.025749398],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9942653,0.0013296079,0.0010923111,0.000617906,0.00040741722,0.0022874218],"domain_scores_gemma":[0.9935373,0.001358041,0.00051320234,0.00038710213,0.0010346873,0.003169646],"candidate_categories":["metaepi_narrow","sts","insufficient_payload"],"consensus_categories":["sts"],"category_scores_codex":[0.0014777132,0.0007076023,0.0011962437,0.0007094839,0.0016383575,0.00030013733,0.00032965222,0.0009640246,0.0038476838],"category_scores_gemma":[0.0013982165,0.0006405935,0.00031399934,0.00038031835,0.00314161,0.00042171264,0.000034949368,0.0014939484,0.0004297408],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.00032085032,0.0009533558,0.19306897,0.00007678374,0.0014037282,0.0071630306,0.014545975,0.000039935665,0.00052248006,0.006491162,0.40071177,0.37470198],"study_design_scores_gemma":[0.0042129876,0.0037772127,0.07776203,0.006356813,0.0011003038,0.016897975,0.003852737,0.0007041886,0.0033235815,0.0015859791,0.87981755,0.0006086742],"about_ca_topic_score_codex":0.009022328,"about_ca_topic_score_gemma":0.110574886,"teacher_disagreement_score":0.47910574,"about_ca_system_score_codex":0.011554224,"about_ca_system_score_gemma":0.024277555,"threshold_uncertainty_score":0.9996614},"labels":[],"label_agreement":null},{"id":"W2895246380","doi":"10.5737/23688076284262268","title":"Myeloproliferative neoplasms (MPNs) – Part 1: An overview of the diagnosis and treatment of the “classical” MPNs","year":2018,"lang":"en","type":"article","venue":"Canadian Oncology Nursing Journal","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":16,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; London Health Sciences Centre; Jewish General Hospital; Juravinski Hospital","funders":"","keywords":"Polycythemia vera; Essential thrombocythemia; Myelofibrosis; Medicine; Quality of life (healthcare); Myeloproliferative Disorders; Health professionals; Intensive care medicine; Health care; Internal medicine; Bone marrow; Nursing","score_opus":0.0962874443278591,"score_gpt":0.3671634798524968,"score_spread":0.2708760355246377,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2895246380","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9457729,0.004898455,0.0000037682303,0.044598658,0.0011930192,0.000755774,0.00007367166,0.000006235818,0.0026975502],"genre_scores_gemma":[0.99342036,0.0037069812,0.00031427274,0.0014284814,0.00065695145,0.00006504503,0.000004300584,0.000024795998,0.00037881744],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9982007,0.0003938533,0.00047445745,0.00026230153,0.0002502889,0.00041839416],"domain_scores_gemma":[0.99802667,0.00023091215,0.00035314058,0.0003927552,0.00034469867,0.0006518164],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00021438,0.00025271252,0.00063969573,0.000136142,0.0006058697,0.000027418997,0.00016619256,0.00018638185,0.00030431538],"category_scores_gemma":[0.00015884874,0.00012927766,0.0002120313,0.00027708005,0.0011795339,0.00008162163,0.000016664584,0.00024686533,0.0000044865556],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00034069704,0.0024952756,0.62928283,0.000034330264,0.0009022853,0.00013490807,0.013135741,0.0000065164163,0.00032411818,0.0062816706,0.025827382,0.32123423],"study_design_scores_gemma":[0.0052067135,0.012430033,0.7564563,0.002540085,0.0013275513,0.0021757858,0.0012898375,0.00020843439,0.019732332,0.0013806841,0.19697733,0.0002748893],"about_ca_topic_score_codex":0.0010944866,"about_ca_topic_score_gemma":0.049112026,"teacher_disagreement_score":0.32095936,"about_ca_system_score_codex":0.002059188,"about_ca_system_score_gemma":0.0035509975,"threshold_uncertainty_score":0.9682392},"labels":[],"label_agreement":null},{"id":"W2895297534","doi":"10.5737/23688076284276281","title":"Myeloproliferative neoplasms (MPNs) – Part 2: A nursing guide to managing the symptom burden of MPNs","year":2018,"lang":"en","type":"article","venue":"Canadian Oncology Nursing Journal","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"Juravinski Hospital; Princess Margaret Cancer Centre; London Health Sciences Centre; Jewish General Hospital","funders":"","keywords":"Polycythemia vera; Essential thrombocythemia; Medicine; Myelofibrosis; Quality of life (healthcare); Myeloproliferative Disorders; Health professionals; Myeloproliferative neoplasm; Intensive care medicine; Nursing; Health care; Bone marrow; Internal medicine","score_opus":0.01976132827071432,"score_gpt":0.344142305879099,"score_spread":0.3243809776083847,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2895297534","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.5643867,0.0024006378,0.0016618976,0.28726366,0.0047509572,0.0018250331,0.000062620355,0.000061975545,0.13758649],"genre_scores_gemma":[0.98402023,0.00024342103,0.004609796,0.005638267,0.003539309,0.000054029646,0.00001471047,0.000065059874,0.0018151568],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99726254,0.00027402097,0.0007124842,0.0004092886,0.00039051927,0.0009511532],"domain_scores_gemma":[0.9968799,0.00027704547,0.000297515,0.00040552518,0.0007335536,0.0014064773],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00067849533,0.00033910305,0.0006989515,0.00058597996,0.0010374404,0.00009508586,0.00024177904,0.0002147516,0.0005351665],"category_scores_gemma":[0.00032609302,0.00024763538,0.00018687133,0.00049713306,0.000755164,0.00012084677,0.000018243232,0.00059920695,0.00012393027],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0008206439,0.000637258,0.01041626,0.000026825739,0.0010805799,0.001804973,0.05138485,0.00015382754,0.001091019,0.008447498,0.5120013,0.412135],"study_design_scores_gemma":[0.00983295,0.014509949,0.053949714,0.016149303,0.0022382005,0.02533001,0.02525164,0.0032891156,0.009954541,0.0054691704,0.83277315,0.001252285],"about_ca_topic_score_codex":0.0018744055,"about_ca_topic_score_gemma":0.009252265,"teacher_disagreement_score":0.41963354,"about_ca_system_score_codex":0.005272045,"about_ca_system_score_gemma":0.005194691,"threshold_uncertainty_score":0.9999976},"labels":[],"label_agreement":null},{"id":"W2896678815","doi":"10.1182/bloodadvances.2018021469","title":"The mutational landscape of accelerated- and blast-phase myeloproliferative neoplasms impacts patient outcomes","year":2018,"lang":"en","type":"article","venue":"Blood Advances","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":75,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; University Health Network; Toronto General Hospital; Princess Margaret Cancer Centre","funders":"European Hematology Association","keywords":"Medicine; Mutation; Myeloproliferative Disorders; Internal medicine; Genetics; Biology; Gene","score_opus":0.013784527794097277,"score_gpt":0.31572397991956763,"score_spread":0.30193945212547035,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2896678815","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9922325,0.0038179501,0.00001478441,0.0015951155,0.00014476794,0.0005680634,0.000068167355,0.000028422373,0.0015302425],"genre_scores_gemma":[0.9971366,0.0009956828,0.0010513414,0.00042349155,0.000107200816,0.000110670146,0.000031742056,0.000015770063,0.00012753584],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9987226,0.000050288916,0.00036509233,0.00027768314,0.00032674396,0.00025758886],"domain_scores_gemma":[0.998639,0.00045888277,0.00019797219,0.00018305024,0.00036676103,0.00015432986],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00009720269,0.00022329214,0.0003678208,0.00006494691,0.000294879,0.00004433572,0.000058205896,0.00004891673,0.00009393467],"category_scores_gemma":[0.00023656317,0.00012097011,0.00006737454,0.00015938157,0.00028558515,0.00016949969,0.0000398079,0.00009270387,0.00001455812],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0014336475,0.0024839868,0.92437387,0.00009300831,0.001235189,0.00009987947,0.0038253993,0.000015511132,0.0019911777,0.00436351,0.0009956565,0.059089165],"study_design_scores_gemma":[0.019801501,0.014600304,0.5670278,0.00032297752,0.0006740938,0.00036255945,0.002487634,0.00048512968,0.37324595,0.0014417367,0.019031454,0.0005188429],"about_ca_topic_score_codex":0.000008663855,"about_ca_topic_score_gemma":0.000115963485,"teacher_disagreement_score":0.37125477,"about_ca_system_score_codex":0.0000141496475,"about_ca_system_score_gemma":0.00012782423,"threshold_uncertainty_score":0.49330178},"labels":[],"label_agreement":null},{"id":"W2900220084","doi":"10.1182/blood-2018-99-111349","title":"Hepcidin Suppression By Momelotinib Is Associated with Increased Iron Availability and Erythropoiesis in Transfusion-Dependent Myelofibrosis Patients","year":2018,"lang":"en","type":"article","venue":"Blood","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Myelofibrosis; Hepcidin; Medicine; Anemia; Ruxolitinib; Erythropoiesis; Internal medicine; Gastroenterology; Blood transfusion; Bone marrow","score_opus":0.007465237073062167,"score_gpt":0.22755221059686007,"score_spread":0.2200869735237979,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2900220084","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9975085,0.00016580542,0.0000028609873,0.0005032785,0.000040645755,0.00096119015,0.00023573764,0.000048552254,0.0005333987],"genre_scores_gemma":[0.9987816,0.0002424852,0.00018063962,0.00029659917,0.00003228403,0.0001260759,0.00018878486,0.000032801385,0.00011868584],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9981071,0.00014675663,0.00035702993,0.00058763585,0.00046709384,0.0003344219],"domain_scores_gemma":[0.9990277,0.00017353822,0.00010581545,0.00028983023,0.00018307133,0.00022002964],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00020730284,0.00028646062,0.0004923192,0.00009387548,0.00015824892,0.000028495842,0.000057913585,0.0001626734,0.0006758677],"category_scores_gemma":[0.00016333887,0.00020365581,0.00005294089,0.00022581636,0.00017418088,0.00010516609,0.00004216402,0.0001442198,0.00002152695],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0004921886,0.005948754,0.98435205,0.000049187092,0.0001356474,0.000016243313,0.0010272698,4.320976e-8,0.0059205815,0.0000020082166,0.0013112918,0.0007447269],"study_design_scores_gemma":[0.0147578325,0.0026397402,0.8121029,0.0003230666,0.000283588,0.0000059126687,0.00009306135,0.000013339878,0.16946702,0.000011452963,0.00010778884,0.00019429806],"about_ca_topic_score_codex":0.00086628104,"about_ca_topic_score_gemma":0.0006613699,"teacher_disagreement_score":0.17224915,"about_ca_system_score_codex":0.00011510714,"about_ca_system_score_gemma":0.00006746425,"threshold_uncertainty_score":0.83048433},"labels":[],"label_agreement":null},{"id":"W2901102397","doi":"10.4274/tjh.galenos.2018.2018.0267","title":"A Case of SF3B1-Positive Myelodysplastic/Myeloproliferative Neoplasm with Ring Sideroblasts and Thrombocytosis","year":2019,"lang":"en","type":"article","venue":"Turkish Journal of Hematology","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Western University","funders":"","keywords":"Thrombocytosis; Medicine; Myeloproliferative neoplasm; Myelodysplastic syndromes; Internal medicine; Pathology; Myelofibrosis; Platelet; Bone marrow","score_opus":0.01036648995093659,"score_gpt":0.25487958827423546,"score_spread":0.24451309832329887,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2901102397","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9963101,0.00078559143,0.0002303299,0.0007364702,0.00012723812,0.0005228458,0.000016066848,0.000011584234,0.0012597879],"genre_scores_gemma":[0.99511033,0.00015801376,0.004372693,0.00020117925,0.00005886971,0.000013422262,0.0000036254453,0.000032224238,0.00004966136],"study_design_codex":"observational","study_design_gemma":"case_report","domain_scores_codex":[0.9982067,0.00012409088,0.0007570821,0.00029652368,0.00028925407,0.00032635193],"domain_scores_gemma":[0.99746966,0.0007602088,0.00070640846,0.00019651772,0.000617001,0.00025018826],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00021083538,0.00032049173,0.0014253338,0.00028711843,0.00007954719,0.00002146355,0.000068556896,0.00014872183,0.00013801792],"category_scores_gemma":[0.0001242903,0.0002123782,0.00013027279,0.00019092257,0.00022312069,0.0001896506,0.000056569206,0.00038375682,0.000016587199],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.006740465,0.002039663,0.87403953,0.0013667088,0.0059246602,0.06486052,0.011596954,0.00021858697,0.00983701,0.019423071,0.0005322442,0.003420592],"study_design_scores_gemma":[0.01448726,0.010603223,0.07300832,0.002394409,0.0012931497,0.70941424,0.0029717372,0.0003661447,0.18449357,0.00043382143,0.00009586869,0.00043826885],"about_ca_topic_score_codex":0.000023137964,"about_ca_topic_score_gemma":0.000052472362,"teacher_disagreement_score":0.80103123,"about_ca_system_score_codex":0.00007294975,"about_ca_system_score_gemma":0.00025176533,"threshold_uncertainty_score":0.8660532},"labels":[],"label_agreement":null},{"id":"W2901686792","doi":"10.1182/blood-2018-99-117559","title":"Tobacco Use in the Myeloproliferative Neoplasms: Patient Behavior, Opinions, and Care","year":2018,"lang":"en","type":"article","venue":"Blood","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Myeloproliferative neoplasm; Snuff; Smokeless tobacco; Population; Family medicine; Chewing tobacco; Demographics; Tobacco use; Internal medicine; Myelofibrosis; Environmental health; Demography; Pathology; Cancer","score_opus":0.02337470025487498,"score_gpt":0.27581004930028713,"score_spread":0.25243534904541215,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2901686792","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9959123,0.00093652285,0.0000014431157,0.0007122944,0.0001020492,0.0012405738,0.00006176646,0.000027469208,0.0010055463],"genre_scores_gemma":[0.99686736,0.0002117375,0.0010111098,0.001009998,0.00016794083,0.00058060884,0.00009723003,0.000018312297,0.000035684025],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9987982,0.00010302188,0.00025506565,0.0003526258,0.00023099578,0.00026007544],"domain_scores_gemma":[0.99917656,0.00015560442,0.000058799338,0.00033457702,0.00016796,0.00010649512],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00007635755,0.0002144632,0.00026929006,0.0000876382,0.00017310398,0.00007372394,0.00006591801,0.00008676581,0.000057063873],"category_scores_gemma":[0.00009617364,0.00013265848,0.00005506561,0.00018072625,0.00013031617,0.000109637745,0.000052209016,0.00016718314,0.000036041514],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000073589224,0.0013262047,0.9786841,0.000015543721,0.00006956236,0.00018565086,0.012802396,1.5974683e-7,0.000066671055,0.001095476,0.0005608618,0.0051197344],"study_design_scores_gemma":[0.004683416,0.0026337118,0.97062,0.00015153158,0.00029727622,0.00026475848,0.0049232775,0.0000038617936,0.010153739,0.000028157292,0.0060427827,0.00019752444],"about_ca_topic_score_codex":0.00017366248,"about_ca_topic_score_gemma":0.0008942175,"teacher_disagreement_score":0.010087067,"about_ca_system_score_codex":0.000039901992,"about_ca_system_score_gemma":0.00008617521,"threshold_uncertainty_score":0.54096556},"labels":[],"label_agreement":null},{"id":"W2902915646","doi":"10.1136/jclinpath-2018-205527","title":"JAK2-tree: a simple CBC-based decision rule to guide appropriate JAK2 V617F mutation testing","year":2018,"lang":"en","type":"article","venue":"Journal of Clinical Pathology","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":16,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Calgary Laboratory Services; University of Calgary","funders":"Lundbeckfonden; Gentofte Hospital","keywords":"JAK2 V617F; Simple (philosophy); Decision tree; Mutation; Computer science; Bioinformatics; Medicine; Genetics; Biology; Data mining; Gene","score_opus":0.09725493739790528,"score_gpt":0.454514800958479,"score_spread":0.3572598635605737,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2902915646","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9792649,0.00006960232,0.013901285,0.00399375,0.0008072797,0.00035293683,0.0000068790005,0.000021781803,0.0015815917],"genre_scores_gemma":[0.8551736,0.000020629954,0.13845208,0.00458613,0.001640737,0.000013820874,0.000007574878,0.00002561237,0.00007980435],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9964045,0.00034587935,0.0021148762,0.0003572287,0.00045409738,0.00032341815],"domain_scores_gemma":[0.9936749,0.0032585715,0.00092490925,0.00031716027,0.0013600844,0.00046441634],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.0023058914,0.00020876508,0.0009973916,0.0002201056,0.000112165486,0.000024131257,0.00014844407,0.00024507823,0.00021888602],"category_scores_gemma":[0.017973838,0.00014290588,0.00032253438,0.0002852817,0.0001607927,0.000078505815,0.000059602804,0.0004555583,0.00028618917],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0025807319,0.0015754766,0.5429089,0.000025611276,0.00013403535,0.003159831,0.00016572807,0.0001224708,0.0025384119,0.000059420923,0.008171033,0.43855837],"study_design_scores_gemma":[0.012050506,0.020439781,0.9362791,0.00046339733,0.0004387466,0.0016329302,0.00011594494,0.0017229049,0.0058190287,0.003845215,0.016936367,0.00025603082],"about_ca_topic_score_codex":0.000012864747,"about_ca_topic_score_gemma":0.00004439606,"teacher_disagreement_score":0.43830234,"about_ca_system_score_codex":0.000092576774,"about_ca_system_score_gemma":0.0004798432,"threshold_uncertainty_score":0.9902982},"labels":[],"label_agreement":null},{"id":"W2904677338","doi":"10.1182/blood-2018-99-115362","title":"PRM-151 in Myelofibrosis: Efficacy and Safety in an Open Label Extension Study","year":2018,"lang":"en","type":"article","venue":"Blood","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":48,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"St. Paul's Hospital; University of British Columbia","funders":"","keywords":"Medicine; Myelofibrosis; Ruxolitinib; Internal medicine; Essential thrombocythemia; Bone marrow; Fibrosis; Surgery; Gastroenterology; Polycythemia vera","score_opus":0.05360718723972167,"score_gpt":0.35552935264706864,"score_spread":0.30192216540734695,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2904677338","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99619466,0.00029743378,8.189846e-7,0.00040586345,0.00003650258,0.0021339874,0.0000051910515,0.000020455813,0.00090506946],"genre_scores_gemma":[0.9984838,0.00008341643,0.000815254,0.00026039884,0.00008193656,0.00016245767,0.000014142245,0.000019813842,0.00007878326],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99873513,0.0001212251,0.00029370488,0.0004664454,0.00016395062,0.00021954067],"domain_scores_gemma":[0.99933416,0.00007756477,0.000046621048,0.00034242653,0.00007030904,0.00012891329],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00032888143,0.00016515118,0.00038872092,0.00011644649,0.00007246208,0.000045885663,0.0000990924,0.00006262036,0.000058157082],"category_scores_gemma":[0.000084651576,0.00012563216,0.000009842526,0.00022951876,0.00004944212,0.0001416726,0.00015276838,0.000110253684,0.000028413904],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00093210477,0.021210432,0.9652229,0.000017751603,0.000058305308,0.00019652763,0.0023795585,2.7396567e-7,0.002159822,0.00007920169,0.0000613812,0.0076817665],"study_design_scores_gemma":[0.035924356,0.007873405,0.9526094,0.00030384,0.00010059826,0.000021928332,0.00032943016,0.000026718284,0.0025159551,0.000032777985,0.00013874518,0.00012283784],"about_ca_topic_score_codex":0.00029357235,"about_ca_topic_score_gemma":0.0022409726,"teacher_disagreement_score":0.03499225,"about_ca_system_score_codex":0.000036520472,"about_ca_system_score_gemma":0.00005999239,"threshold_uncertainty_score":0.51231307},"labels":[],"label_agreement":null},{"id":"W2905016588","doi":"10.1182/blood-2018-99-118299","title":"Pregnancy Outcomes in Patients with Myeloproliferative Neoplasms: A Systematic Review and Meta-Analysis","year":2018,"lang":"en","type":"review","venue":"Blood","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Mount Sinai Hospital; Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Medicine; Pregnancy; Essential thrombocythemia; Systematic review; Pediatrics; Myelofibrosis; Meta-analysis; Polycythemia vera; Obstetrics; MEDLINE; Internal medicine; Bone marrow","score_opus":0.04454477695995088,"score_gpt":0.31853800400413357,"score_spread":0.2739932270441827,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2905016588","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000085443906,0.98581016,0.0000018869298,0.00009195281,0.000013937743,0.013495776,0.0002991286,0.00003786497,0.00016386565],"genre_scores_gemma":[0.000092042705,0.9922924,0.0005123397,0.00034945112,0.000011761838,0.0054615582,0.00036702023,0.00008238554,0.0008310127],"study_design_codex":"systematic_review","study_design_gemma":"meta_analysis","domain_scores_codex":[0.9955686,0.00058796984,0.0016928443,0.0010785592,0.00064479146,0.00042724362],"domain_scores_gemma":[0.9968476,0.00044301397,0.001031005,0.0010857319,0.00034565123,0.0002469631],"candidate_categories":["metaepi_narrow","metaepi_broad"],"consensus_categories":[],"category_scores_codex":[0.00031272706,0.0011378828,0.018349357,0.0005816677,0.000083288425,0.000060606635,0.00017536413,0.00026081252,0.0002434387],"category_scores_gemma":[0.00030994497,0.00054148305,0.002062677,0.0011967093,0.00009586682,0.00010143578,0.000092715076,0.00034117486,0.00007760311],"study_design_candidate":"meta_analysis","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000004215473,0.0016067487,0.009769011,0.61538655,0.37289715,0.000062270425,0.00007561156,1.4444312e-8,1.83501e-10,0.000031948177,0.000016794504,0.0001496645],"study_design_scores_gemma":[0.0017072555,0.0006911379,0.00092666526,0.16457637,0.8310483,0.000022811118,0.0000043954137,1.3334711e-7,2.662179e-7,0.0000026677517,0.00061146123,0.00040853507],"about_ca_topic_score_codex":0.000013838218,"about_ca_topic_score_gemma":0.00009934816,"teacher_disagreement_score":0.45815116,"about_ca_system_score_codex":0.00009911217,"about_ca_system_score_gemma":0.00023931275,"threshold_uncertainty_score":0.99970365},"labels":[],"label_agreement":null},{"id":"W2905519397","doi":"10.1093/eurheartj/ehy566.p6072","title":"P6072Characterization of major and clinically relevant non-major bleeding in the APEX trial","year":2018,"lang":"en","type":"article","venue":"European Heart Journal","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"","keywords":"Medicine; Apex (geometry); Anatomy","score_opus":0.04696634321809596,"score_gpt":0.3434381612602658,"score_spread":0.2964718180421698,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2905519397","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9918918,0.000058135534,0.00008023785,0.0039114775,0.00029256422,0.0004204916,0.0000026933928,0.000006208467,0.0033363958],"genre_scores_gemma":[0.99572605,0.00021238405,0.0011292346,0.0011116258,0.0016973593,0.000004141338,0.000003781733,0.000018831766,0.00009657762],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99850065,0.00035824627,0.0005672137,0.00015623917,0.0002505999,0.00016703083],"domain_scores_gemma":[0.9991854,0.00024962914,0.00019838083,0.00013982393,0.00012244924,0.00010436309],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0018214743,0.00011072849,0.0002762998,0.00009488302,0.00013407791,0.000055559867,0.00006742022,0.00002913094,0.00012194823],"category_scores_gemma":[0.00040706736,0.0000648873,0.00007884884,0.00012043184,0.00009004171,0.00008176068,0.00003195375,0.00027687268,0.00005017081],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.024603132,0.0020067103,0.89789325,0.000092194416,0.0003083734,0.0008008274,0.0075707217,9.416808e-7,0.03987485,0.00026531328,0.008390006,0.018193701],"study_design_scores_gemma":[0.027809884,0.005655807,0.95619005,0.00042218127,0.00011375572,0.0008149674,0.00019429732,0.00008194785,0.0012619183,0.000032739074,0.007327164,0.00009526304],"about_ca_topic_score_codex":0.0000029053467,"about_ca_topic_score_gemma":0.0000026171388,"teacher_disagreement_score":0.058296848,"about_ca_system_score_codex":0.000020247726,"about_ca_system_score_gemma":0.000060662987,"threshold_uncertainty_score":0.26460275},"labels":[],"label_agreement":null},{"id":"W2907303596","doi":"10.1182/blood-2018-99-119002","title":"Survival Advantage to Allogeneic Transplant in Patients with Myelofibrosis with Intermediate-1 or Higher DIPSS Score","year":2018,"lang":"en","type":"article","venue":"Blood","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Medicine; Transplantation; Myelofibrosis; International Prognostic Scoring System; Internal medicine; Adverse effect; Proportional hazards model; Surgery; Bone marrow; Myelodysplastic syndromes","score_opus":0.013722650090068289,"score_gpt":0.2441999052133536,"score_spread":0.23047725512328532,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2907303596","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9978081,0.000025326068,0.000020704594,0.00025328773,0.00010877773,0.0009696929,0.00009011716,0.000043023876,0.00068097987],"genre_scores_gemma":[0.99768555,0.000021725751,0.0009701492,0.0005230575,0.00013878172,0.00020027086,0.00010568307,0.000047771642,0.0003070149],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99852234,0.00003992383,0.00023433585,0.00045051432,0.00037336696,0.00037950661],"domain_scores_gemma":[0.99922234,0.000056244637,0.000054426222,0.00029478586,0.00012209176,0.00025009993],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00005772387,0.00028753481,0.0004386845,0.00013282616,0.000054745342,0.000020001107,0.00008965281,0.000067986184,0.00035064633],"category_scores_gemma":[0.000009965354,0.00015514801,0.00003790336,0.0002826823,0.000088358385,0.00006994133,0.000025579402,0.00010310589,0.000074529504],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0048784483,0.0025232045,0.99042004,0.000050029208,0.0002470164,0.00024358965,0.0005610003,5.967028e-7,0.00020487823,0.000027303104,0.00005917536,0.0007847259],"study_design_scores_gemma":[0.01508511,0.010421266,0.9592313,0.00062189973,0.00029914465,0.000011960991,0.000043986995,5.074322e-7,0.013600689,0.0000014865008,0.00045697147,0.00022562937],"about_ca_topic_score_codex":0.000037227397,"about_ca_topic_score_gemma":0.0012266554,"teacher_disagreement_score":0.031188685,"about_ca_system_score_codex":0.000050122664,"about_ca_system_score_gemma":0.00008196142,"threshold_uncertainty_score":0.63267523},"labels":[],"label_agreement":null},{"id":"W2907355714","doi":"10.1182/blood-2018-99-119201","title":"Results from Ongoing Phase 1/2 Clinical Trial of Tagraxofusp (SL-401) in Patients with Intermediate or High Risk Relapsed/Refractory Myelofibrosis","year":2018,"lang":"en","type":"article","venue":"Blood","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Medicine; Refractory (planetary science); Regimen; Myelofibrosis; Internal medicine; Interleukin-3 receptor; Clinical trial; Oncology; Cohort; Malignancy; Stage (stratigraphy); Gastroenterology; Myeloid; Bone marrow; Biology","score_opus":0.02825834787298184,"score_gpt":0.31896612430573273,"score_spread":0.2907077764327509,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2907355714","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99708056,0.000027613722,0.000008366075,0.00008827323,0.00046756177,0.0012491206,0.0007491968,0.000031213956,0.00029808265],"genre_scores_gemma":[0.99658453,0.00021231943,0.0017803601,0.00013385754,0.00072275073,0.0000828259,0.0003470712,0.000039268944,0.00009699606],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9970607,0.0002726172,0.0012146605,0.0006474597,0.00048285472,0.0003217183],"domain_scores_gemma":[0.9971899,0.0010861796,0.00064506126,0.00060794066,0.00023652613,0.00023443463],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00045060666,0.0002998909,0.0008791742,0.00015723874,0.000066504595,0.000018371333,0.00012401615,0.00020938608,0.00023591207],"category_scores_gemma":[0.0012900258,0.000188687,0.00014582984,0.00025232838,0.00024278546,0.00011033721,0.00006951574,0.00034879553,0.0000743938],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.23888496,0.023882808,0.7204845,0.000016746517,0.0005846418,0.00006612139,0.0004968208,2.1417905e-7,0.00003803945,0.000005922623,0.0004863183,0.015052914],"study_design_scores_gemma":[0.39751467,0.035627443,0.5611274,0.0003893792,0.00059079647,7.1091216e-7,0.000027556385,0.00000670458,0.0041743116,0.000015690202,0.00037733576,0.0001479479],"about_ca_topic_score_codex":0.00068540435,"about_ca_topic_score_gemma":0.0009491706,"teacher_disagreement_score":0.15935704,"about_ca_system_score_codex":0.00005760342,"about_ca_system_score_gemma":0.00021998567,"threshold_uncertainty_score":0.7694433},"labels":[],"label_agreement":null},{"id":"W2907581136","doi":"10.1182/blood.v130.suppl_1.5272.5272","title":"The Real-World Treatment of Polycythemia Vera: Adherence to Treatment Guidelines and Outcomes","year":2017,"lang":"en","type":"article","venue":"Blood","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Juravinski Cancer Centre; McMaster University","funders":"","keywords":"Medicine; Polycythemia vera; Phlebotomy; Internal medicine; Aspirin; Hazard ratio; Thrombocytosis; Guideline; Thrombosis; Cohort; Retrospective cohort study; Surgery; Pediatrics; Confidence interval","score_opus":0.08085762637258775,"score_gpt":0.38188358250009796,"score_spread":0.3010259561275102,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2907581136","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9861931,0.0009258482,0.000001256322,0.007177556,0.00010506353,0.0008294706,0.00003658311,0.000021750506,0.004709323],"genre_scores_gemma":[0.98495436,0.004783032,0.0012211339,0.000106895495,0.00013033459,0.00033785604,0.000007155475,0.000017599756,0.008441644],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9989666,0.000020438523,0.0003262967,0.0002866392,0.0001776248,0.00022241328],"domain_scores_gemma":[0.9985892,0.0001851348,0.00015917886,0.00077371916,0.00011681831,0.00017591263],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00006534685,0.00024267359,0.0004881963,0.000046655776,0.00039221783,0.00005880523,0.00009275997,0.000036986818,0.000027998087],"category_scores_gemma":[0.00011538497,0.00011811879,0.00012619587,0.00003795044,0.00009291907,0.00003555885,0.000040393894,0.000023618619,0.000021224418],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00015093565,0.001370652,0.9246663,0.000009419153,0.0006916913,0.00005406656,0.0003437965,3.633946e-7,0.00045582588,0.0007074952,0.00023576347,0.0713137],"study_design_scores_gemma":[0.007817389,0.005351943,0.8926958,0.00009350547,0.0006979616,0.000016872124,0.00006923126,0.000006180415,0.07609764,0.00007588815,0.016948642,0.00012899007],"about_ca_topic_score_codex":0.002655723,"about_ca_topic_score_gemma":0.0035426628,"teacher_disagreement_score":0.07564181,"about_ca_system_score_codex":0.00008802817,"about_ca_system_score_gemma":0.00009509614,"threshold_uncertainty_score":0.48167446},"labels":[],"label_agreement":null},{"id":"W2908211253","doi":"10.1016/j.bbmt.2019.01.002","title":"Impact of High-Molecular-Risk Mutations on Transplantation Outcomes in Patients with Myelofibrosis","year":2019,"lang":"en","type":"article","venue":"Biology of Blood and Marrow Transplantation","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":62,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"National Center for Advancing Translational Sciences; National Cancer Institute; National Heart, Lung, and Blood Institute","keywords":"Medicine; Myelofibrosis; Internal medicine; Oncology; Transplantation; International Prognostic Scoring System; Cohort; Hematopoietic stem cell transplantation; Disease; Framingham Risk Score; Myelodysplastic syndromes; Bone marrow","score_opus":0.004051658614116382,"score_gpt":0.23814463694497867,"score_spread":0.2340929783308623,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2908211253","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9985671,0.00003710307,0.00007502769,0.000054810593,0.000025623654,0.0006291923,0.00050863595,0.000008335638,0.000094155024],"genre_scores_gemma":[0.9979461,0.000374323,0.00064312224,0.000020307058,0.0000030890305,0.000029140538,0.0009681319,0.000009764629,0.0000060136827],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9992361,0.00007242149,0.00026276536,0.000205905,0.00010746493,0.00011532538],"domain_scores_gemma":[0.99950266,0.00014659621,0.00014154214,0.00009451138,0.00007334071,0.000041362393],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000059309168,0.00014524741,0.00037208074,0.00018041053,0.000019230356,0.000002394266,0.000022983602,0.000089660265,0.000029546496],"category_scores_gemma":[0.000006913881,0.00009602918,0.00006963811,0.00009977419,0.000058690137,0.000050686434,0.0000013811198,0.00006860474,0.0000019319382],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0020567616,0.0008263448,0.9767137,0.00018606475,0.0003534304,0.000005618268,0.0004347092,0.0000756284,0.017742587,0.00045099578,3.7966282e-7,0.0011537565],"study_design_scores_gemma":[0.01079992,0.00577299,0.93313825,0.00017620898,0.000619217,0.0000052327646,0.000013239738,0.000004573064,0.04930236,0.00008399381,1.9598711e-7,0.000083833904],"about_ca_topic_score_codex":0.00032152195,"about_ca_topic_score_gemma":0.00007164934,"teacher_disagreement_score":0.043575488,"about_ca_system_score_codex":0.000011766795,"about_ca_system_score_gemma":0.000036470872,"threshold_uncertainty_score":0.39159563},"labels":[],"label_agreement":null},{"id":"W2911986426","doi":"10.1182/blood-2018-99-118889","title":"AML-Fated Clones Arise in Stem and Progenitor Cells in Myelofibrosis Patients Several Years Prior to AML Diagnosis","year":2018,"lang":"en","type":"article","venue":"Blood","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sunnybrook Health Science Centre; University of Toronto; Princess Margaret Cancer Centre; Health Sciences Centre; University Health Network","funders":"","keywords":"Myelofibrosis; Myeloid; Myeloid leukemia; Biology; clone (Java method); Cancer research; CD34; Stem cell; Bone marrow; Immunology; Gene; Genetics","score_opus":0.011462270574794155,"score_gpt":0.24440863269196084,"score_spread":0.23294636211716668,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2911986426","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9977163,0.00013659478,7.9885234e-7,0.000283993,0.00013052353,0.001551465,0.000052507694,0.00003228663,0.00009553286],"genre_scores_gemma":[0.99762243,0.00013353424,0.0011462172,0.00029372133,0.00012213862,0.00051413866,0.000019829959,0.000031545314,0.00011646948],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99852526,0.00006950864,0.00035192506,0.00045076924,0.0002477044,0.00035483253],"domain_scores_gemma":[0.999304,0.000087398555,0.000065232474,0.00021809981,0.000101702055,0.00022355243],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00009880553,0.00022366442,0.00040714355,0.00023063445,0.000043061336,0.000034748085,0.00006374801,0.00011338832,0.00005719087],"category_scores_gemma":[0.000046144072,0.00019404734,0.00004855185,0.00037146136,0.00005206395,0.00007823131,0.000076826764,0.000110114546,0.00012054149],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00021847808,0.0029203848,0.9871771,0.000047644862,0.00007477414,0.00008209908,0.0017162997,0.000001053125,0.00063811184,0.0000058989935,0.0004341605,0.0066840127],"study_design_scores_gemma":[0.0072575076,0.0015599747,0.90740895,0.00027477404,0.000102097714,0.000004512,0.00007904217,0.00001592553,0.08212483,0.0000056188755,0.0009821622,0.00018458109],"about_ca_topic_score_codex":0.00026042614,"about_ca_topic_score_gemma":0.00042963444,"teacher_disagreement_score":0.08148672,"about_ca_system_score_codex":0.00008529012,"about_ca_system_score_gemma":0.000058065452,"threshold_uncertainty_score":0.7913021},"labels":[],"label_agreement":null},{"id":"W2912061124","doi":"10.1182/blood-2018-99-115350","title":"Ruxolitinib for the Treatment of Inadequately Controlled Polycythemia Vera without Splenomegaly: 156-Week Follow-up from the Phase 3 Response-2 Study","year":2018,"lang":"en","type":"article","venue":"Blood","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Sciences Centre; Sunnybrook Health Science Centre","funders":"","keywords":"Phlebotomy; Ruxolitinib; Medicine; Polycythemia vera; Clinical endpoint; Myelofibrosis; Internal medicine; Surrogate endpoint; Hematocrit; Gastroenterology; Phases of clinical research; Clinical trial; Bone marrow","score_opus":0.05647221275066861,"score_gpt":0.34353198903802135,"score_spread":0.28705977628735274,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2912061124","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9876646,0.0014436663,0.00004623885,0.0033275897,0.0002567749,0.0065224622,0.00036115508,0.000040718227,0.0003368033],"genre_scores_gemma":[0.99478084,0.00014228614,0.0002395597,0.0004025857,0.0007284156,0.0023368055,0.000049872415,0.000046560115,0.0012730972],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99799335,0.00027895637,0.00055820105,0.00043826754,0.00035930338,0.00037190272],"domain_scores_gemma":[0.9952028,0.0033542062,0.000258047,0.00081997825,0.00023001252,0.00013496602],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000490888,0.0003610828,0.0009439907,0.000058839905,0.00035994282,0.00004478465,0.00018338546,0.00007595257,0.00021578204],"category_scores_gemma":[0.0003793311,0.00016480626,0.0003747447,0.00013557616,0.00019956486,0.00003900377,0.000026784464,0.00008515483,0.00003722244],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.3991754,0.1361587,0.3455282,0.000039595256,0.027540293,0.00021237308,0.047544215,0.0000015824867,0.012343153,0.0007752856,0.0028613391,0.027819874],"study_design_scores_gemma":[0.60200673,0.107283905,0.1145456,0.00014839185,0.013241939,0.000033587585,0.005674491,0.00018947895,0.11794575,0.000228347,0.038281742,0.0004200139],"about_ca_topic_score_codex":0.0005227923,"about_ca_topic_score_gemma":0.00034384665,"teacher_disagreement_score":0.23098257,"about_ca_system_score_codex":0.00009124887,"about_ca_system_score_gemma":0.0002686267,"threshold_uncertainty_score":0.67206043},"labels":[],"label_agreement":null},{"id":"W2912062763","doi":"10.1182/blood-2018-99-109740","title":"3,023 Mayo Clinic Patients with Myeloproliferative Neoplasms: Risk-Stratified Comparison of Survival and Outcomes Data Among Disease Subgroups","year":2018,"lang":"en","type":"article","venue":"Blood","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":33,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal; Hôpital Maisonneuve-Rosemont; Jewish General Hospital","funders":"","keywords":"Medicine; Myelofibrosis; Polycythemia vera; Essential thrombocythemia; Internal medicine; Population; International Prognostic Scoring System; Myelodysplastic syndromes; Bone marrow","score_opus":0.033849180491706904,"score_gpt":0.31555831732710066,"score_spread":0.2817091368353938,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2912062763","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99659085,0.00021664026,0.0000356336,0.00018599784,0.00013864228,0.0012050462,0.0008396739,0.00005133889,0.000736163],"genre_scores_gemma":[0.9971805,0.0000956942,0.0013747864,0.00006710776,0.00012827093,0.00007050712,0.00087700743,0.000041142932,0.00016494888],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99752057,0.00017160363,0.00064327073,0.0007459844,0.00057588395,0.0003426748],"domain_scores_gemma":[0.9973415,0.00044070318,0.0004440625,0.0009964557,0.00036513346,0.00041211382],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00026173572,0.0003857241,0.00095166115,0.00010064792,0.00020364061,0.00004563389,0.00019620251,0.00010171743,0.00015122523],"category_scores_gemma":[0.00034431063,0.00025638795,0.00007248754,0.00019131848,0.0005016741,0.00021812724,0.00017848163,0.00022861632,0.000037323578],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0009477389,0.004396874,0.9919233,0.000091930626,0.0009621263,0.000021438698,0.00062672567,4.1558468e-7,0.000005797839,0.00012873113,0.00022666427,0.0006683036],"study_design_scores_gemma":[0.011857008,0.002346902,0.982037,0.00018647399,0.0015971579,0.000001576701,0.00028954278,0.00016163045,0.00113834,0.000040610892,0.00008840758,0.00025535782],"about_ca_topic_score_codex":0.0001129631,"about_ca_topic_score_gemma":0.00082613406,"teacher_disagreement_score":0.010909269,"about_ca_system_score_codex":0.00002001007,"about_ca_system_score_gemma":0.00015699967,"threshold_uncertainty_score":0.99998885},"labels":[],"label_agreement":null},{"id":"W2912646751","doi":"10.21037/hbsn.2019.01.06","title":"Long term follow-up after liver transplantation from a JAK2 mutation positive donor","year":2019,"lang":"en","type":"article","venue":"HepatoBiliary Surgery and Nutrition","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Western University","funders":"","keywords":"Essential thrombocythemia; Myelofibrosis; Janus kinase 2; Medicine; Calreticulin; Polycythemia vera; Mutation; Myeloproliferative neoplasm; Germline mutation; Exon; Transplantation; Cancer research; Internal medicine; Immunology; Gene; Genetics; Bone marrow; Biology","score_opus":0.011285981357346661,"score_gpt":0.22817659589125486,"score_spread":0.2168906145339082,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2912646751","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99590313,0.0019388805,0.0000853477,0.0003370185,0.00028263923,0.0010383083,0.0001983056,0.000047572375,0.00016879178],"genre_scores_gemma":[0.99055094,0.006071287,0.00014817646,0.0004329489,0.00013295058,0.00036357975,0.0021692629,0.000019920635,0.00011093538],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9988427,0.000107510095,0.00027635874,0.00039812722,0.00019020881,0.00018505786],"domain_scores_gemma":[0.9990913,0.0004822299,0.00007417851,0.00014117322,0.000093299444,0.00011776384],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00011578028,0.0001999042,0.00036008324,0.00014009037,0.00006869308,0.000033747307,0.000015635847,0.00012873951,0.00042306157],"category_scores_gemma":[0.000012930591,0.00017625444,0.00015761185,0.00011018082,0.000033954253,0.00033767062,0.000007137455,0.00010646747,0.000108711814],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.003831249,0.0006313395,0.9813851,0.0004851324,0.0001276255,0.00102338,0.0006929641,1.2506064e-7,0.001019112,0.000020071102,0.00017705036,0.010606847],"study_design_scores_gemma":[0.0028632989,0.00030905675,0.97179633,0.0010692484,0.0002842483,0.00020012214,0.00005881404,0.00012285466,0.022924136,0.000100931466,0.00008049875,0.0001904351],"about_ca_topic_score_codex":0.00020056471,"about_ca_topic_score_gemma":0.00016688567,"teacher_disagreement_score":0.021905024,"about_ca_system_score_codex":0.00006518704,"about_ca_system_score_gemma":0.00003779628,"threshold_uncertainty_score":0.71874475},"labels":[],"label_agreement":null},{"id":"W2912665906","doi":"10.1182/blood-2018-99-119088","title":"Myelofibrosis Is Initiated and Sustained By Rare Multipotent Stem Cells","year":2018,"lang":"en","type":"article","venue":"Blood","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; University Health Network","funders":"","keywords":"Myelofibrosis; Myeloid; Biology; Progenitor cell; Haematopoiesis; Stem cell; Cancer research; Myeloproliferative neoplasm; Bone marrow; CD34; Immunology; Genetics","score_opus":0.019564278486328714,"score_gpt":0.2544280399630079,"score_spread":0.23486376147667917,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2912665906","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9956067,0.00078137196,0.000019434667,0.001167453,0.00006079131,0.0006687927,0.00011450492,0.000071058974,0.0015098769],"genre_scores_gemma":[0.9962245,0.00026945423,0.00053249917,0.0011905086,0.00012806914,0.00008525444,0.000037782174,0.000028001168,0.0015039144],"study_design_codex":"observational","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99892414,0.000038393384,0.00021493662,0.00035033067,0.00019877555,0.00027343558],"domain_scores_gemma":[0.99923146,0.00006794139,0.00006282245,0.00023265585,0.00019117487,0.00021396807],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000063342195,0.00020505834,0.00030474216,0.0000594359,0.00012921791,0.000034960816,0.00004166839,0.00009804524,0.00029193645],"category_scores_gemma":[0.000013763852,0.0001564139,0.000059293747,0.00012892278,0.0000939782,0.000051949733,0.00004795007,0.000077176126,0.000102197206],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0008898273,0.008453731,0.6994203,0.00055649877,0.0024876816,0.00060267403,0.006332678,2.1265315e-7,0.14983161,0.0002697681,0.10748533,0.023669707],"study_design_scores_gemma":[0.009847998,0.0018545769,0.02217942,0.00013918347,0.00047392698,0.00003840136,0.0005663945,0.000055675213,0.951908,0.000015370348,0.012703226,0.00021783031],"about_ca_topic_score_codex":0.000043359938,"about_ca_topic_score_gemma":0.0000095390815,"teacher_disagreement_score":0.8020764,"about_ca_system_score_codex":0.000030960357,"about_ca_system_score_gemma":0.000049258266,"threshold_uncertainty_score":0.63783735},"labels":[],"label_agreement":null},{"id":"W2913378115","doi":"10.14309/00000434-201710001-01982","title":"Role of the JAK2 V617F Mutation in Inflammatory Bowel Disease-associated Thromboembolism: Case Report and Review of the Literature","year":2017,"lang":"en","type":"article","venue":"The American Journal of Gastroenterology","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"","keywords":"Medicine; Internal medicine; Gastroenterology; Inflammatory bowel disease; Colonoscopy; Abdominal pain; Ulcerative colitis; Thrombosis; Disease; Colorectal cancer","score_opus":0.006878667381540804,"score_gpt":0.2690465043195864,"score_spread":0.2621678369380456,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2913378115","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9867827,0.0029909615,0.0000013224998,0.00978908,0.00008330148,0.00030469184,0.000017292574,0.0000013353658,0.000029299057],"genre_scores_gemma":[0.9961778,0.0025070019,0.00003750272,0.001203086,0.000043916905,0.000009475252,0.0000017826283,0.000008757385,0.00001067574],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9984625,0.00046402155,0.00059331895,0.00010627484,0.00022538382,0.00014848622],"domain_scores_gemma":[0.9966045,0.00008633675,0.0024805833,0.00049538666,0.0002609257,0.00007224353],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00061716285,0.00012311254,0.00062057684,0.000046204408,0.000112459755,0.000012058527,0.00021264306,0.000021876316,0.0000068531567],"category_scores_gemma":[0.00060765503,0.000054378703,0.00018842351,0.00007182766,0.0006331823,0.000063497304,0.00009402544,0.00028306176,1.5199355e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00092094915,0.00018740476,0.99399835,0.00016181933,0.00024987524,0.0026543008,0.0007234697,0.0000066806006,0.00017175217,0.000024512576,0.00014659157,0.0007542914],"study_design_scores_gemma":[0.0009717305,0.0011152017,0.97339267,0.0033605932,0.00036383647,0.020218598,0.0002212827,0.000012403024,0.00014606952,0.0001456944,0.000026699374,0.000025225687],"about_ca_topic_score_codex":0.000049465805,"about_ca_topic_score_gemma":0.000101935555,"teacher_disagreement_score":0.020605687,"about_ca_system_score_codex":0.000047834717,"about_ca_system_score_gemma":0.00010635854,"threshold_uncertainty_score":0.23329866},"labels":[],"label_agreement":null},{"id":"W2913960189","doi":"10.1155/2019/9656387","title":"Polycythemia Vera Presenting as Cardiac Arrest: Novel Management Strategies","year":2019,"lang":"en","type":"article","venue":"Case Reports in Cardiology","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Sciences Centre; University of Toronto; Sunnybrook Health Science Centre","funders":"","keywords":"Medicine; Cardiology; Polycythemia vera; Myocardial infarction; Internal medicine; Acute coronary syndrome; Intensive care medicine","score_opus":0.015233750058962785,"score_gpt":0.2949531353749875,"score_spread":0.27971938531602475,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2913960189","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8827321,0.0006356566,0.000032086165,0.00018301811,0.0015825361,0.0010409037,0.000006632472,0.000048336617,0.11373874],"genre_scores_gemma":[0.997363,0.00021656483,0.0004504759,0.00011462597,0.00033898774,0.00024683875,0.000048500035,0.000029657549,0.0011914016],"study_design_codex":"observational","study_design_gemma":"case_report","domain_scores_codex":[0.99814326,0.000070529924,0.00050643104,0.00064029003,0.00021778172,0.00042168942],"domain_scores_gemma":[0.9988257,0.00013159381,0.00015486895,0.000699443,0.00006711384,0.00012123533],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00036928218,0.0002522747,0.0007873313,0.00015276426,0.000055473713,0.00002883569,0.000032160195,0.00016103749,0.000095260824],"category_scores_gemma":[0.000055517048,0.00021199907,0.00023907743,0.0001490446,0.00006996774,0.000081051694,0.0001060253,0.0002346227,0.000069561276],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00008214138,0.00012614432,0.5417805,0.00017522491,0.0008796406,0.45046058,0.00023550937,0.00054252095,0.00075387955,0.0030741831,0.000729405,0.0011602874],"study_design_scores_gemma":[0.005609901,0.0009691283,0.41768876,0.00058176176,0.0012148303,0.44472504,0.0064490964,0.000155806,0.0056473375,0.0016058729,0.11422612,0.0011263572],"about_ca_topic_score_codex":0.00015307193,"about_ca_topic_score_gemma":0.000008992293,"teacher_disagreement_score":0.124091715,"about_ca_system_score_codex":0.00018346233,"about_ca_system_score_gemma":0.00014903683,"threshold_uncertainty_score":0.86450714},"labels":[],"label_agreement":null},{"id":"W2916182471","doi":"10.1182/blood-2018-99-111479","title":"Updated Results from an Open-Label, Multicenter, Expanded Treatment Protocol (ETP) Phase (Ph) 3b Study of Ruxolitinib (RUX) in Patients (Pts) with Polycythemia Vera (PV) Who Were Hydroxyurea (HU) Resistant or Intolerant and for Whom No Alternative Treatment (Tx) Was Available","year":2018,"lang":"en","type":"article","venue":"Blood","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"McMaster University; University of British Columbia","funders":"","keywords":"Medicine; Discontinuation; Ruxolitinib; Population; Internal medicine; Clinical endpoint; Gastroenterology; Surgery; Clinical trial; Pediatrics; Myelofibrosis; Bone marrow","score_opus":0.05792644211943544,"score_gpt":0.3666678888084303,"score_spread":0.3087414466889949,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2916182471","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.898059,0.000021835589,0.0000021853868,0.00009301874,0.0000497734,0.099358894,0.001846272,0.000040436295,0.0005285615],"genre_scores_gemma":[0.92769146,0.000030702508,0.0016265202,0.00007297202,0.00014429056,0.06830928,0.0010600172,0.000086539985,0.0009782158],"study_design_codex":"nonrandomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9962337,0.00024628537,0.001119245,0.0013189007,0.0004873174,0.000594553],"domain_scores_gemma":[0.99735504,0.00024906264,0.00057572033,0.0009167193,0.0005118162,0.0003916674],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0001964975,0.0007474483,0.001401291,0.00019519057,0.00028268568,0.00015138224,0.00023180053,0.00013957101,0.00021827522],"category_scores_gemma":[0.00008919459,0.00044823095,0.000055295935,0.0002042694,0.00017623257,0.00030621994,0.000113110014,0.00011710058,0.000021674738],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.36454973,0.37506223,0.21954903,0.00012513067,0.004603017,0.00048938417,0.023541227,0.0000022293186,0.0032584646,0.000016943179,0.0005125416,0.008290086],"study_design_scores_gemma":[0.6024927,0.27258685,0.021716332,0.0009980556,0.0012640146,0.0000063376733,0.0010625308,0.0006838186,0.09518081,0.000009902327,0.0034926743,0.00050597236],"about_ca_topic_score_codex":0.006827194,"about_ca_topic_score_gemma":0.007138721,"teacher_disagreement_score":0.23794296,"about_ca_system_score_codex":0.00047191815,"about_ca_system_score_gemma":0.00038670996,"threshold_uncertainty_score":0.9997969},"labels":[],"label_agreement":null},{"id":"W2916868222","doi":"10.3747/co.26.4385","title":"Secondary Polycythemia in a Sarcoma Patient: A Commentary about Cediranib","year":2019,"lang":"en","type":"article","venue":"Current Oncology","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"McGill University Health Centre","funders":"","keywords":"Medicine; Vascular endothelial growth factor; Cancer research; Prostate cancer; Colorectal cancer; Sorafenib; Sunitinib; Irinotecan; Bevacizumab; Cancer; Tyrosine-kinase inhibitor; Tyrosine kinase; Lung cancer; Placental growth factor; Platelet-derived growth factor receptor; Pharmacology; Oncology; Internal medicine; Growth factor; Receptor; VEGF receptors; Chemotherapy","score_opus":0.039470838963486486,"score_gpt":0.3586254098038415,"score_spread":0.31915457084035503,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2916868222","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97816074,0.00397228,0.0000029891185,0.0058220145,0.0012028844,0.0011000005,0.00004107652,0.000036639023,0.009661354],"genre_scores_gemma":[0.99484694,0.00045204745,0.00021146685,0.0037963644,0.000169326,0.000215526,0.00019612754,0.000023052837,0.00008916322],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.9985486,0.00011326687,0.00039548616,0.0003803688,0.00018374292,0.00037848178],"domain_scores_gemma":[0.9991979,0.00019401165,0.00010794109,0.00028501867,0.000049383274,0.00016575718],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00010923597,0.00022076863,0.0005659644,0.00017255466,0.000038025908,0.000008327345,0.000079722726,0.00011955723,0.0018074696],"category_scores_gemma":[0.000023765193,0.00018087855,0.000114201546,0.0001577839,0.000060178147,0.00006181907,0.00008534848,0.0004479603,0.00040806326],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0005171352,0.0030775159,0.72274137,0.00013885667,0.00008457578,0.0002923178,0.001228536,8.617976e-7,0.00035445997,0.00025267035,0.016915068,0.25439662],"study_design_scores_gemma":[0.011637048,0.0033662778,0.29580513,0.000348525,0.00007831596,0.00021682928,0.000369947,0.000107798194,0.0019085142,0.0001439276,0.68578595,0.00023172301],"about_ca_topic_score_codex":0.000050176375,"about_ca_topic_score_gemma":0.00010712119,"teacher_disagreement_score":0.6688709,"about_ca_system_score_codex":0.00053795584,"about_ca_system_score_gemma":0.00020563207,"threshold_uncertainty_score":0.99910504},"labels":[],"label_agreement":null},{"id":"W2917495513","doi":"10.1016/j.mayocp.2018.08.022","title":"3023 Mayo Clinic Patients With Myeloproliferative Neoplasms: Risk-Stratified Comparison of Survival and Outcomes Data Among Disease Subgroups","year":2019,"lang":"en","type":"article","venue":"Mayo Clinic Proceedings","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":163,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal; Hôpital Maisonneuve-Rosemont; Jewish General Hospital","funders":"Novartis","keywords":"Medicine; Disease; Internal medicine; Oncology","score_opus":0.035282675129042214,"score_gpt":0.3236939776750977,"score_spread":0.2884113025460555,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2917495513","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99324405,0.00020548998,0.000009324216,0.00048607402,0.00031679397,0.0027319763,0.0005589178,0.000101255864,0.0023460963],"genre_scores_gemma":[0.9960441,0.00025909036,0.0009525125,0.00019187364,0.00010325407,0.00013804175,0.00072255894,0.00008146472,0.0015070922],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99560636,0.00007579608,0.0014045181,0.0013763033,0.0009631691,0.0005738524],"domain_scores_gemma":[0.9959125,0.00088686554,0.001152162,0.0008089743,0.0006471906,0.0005923351],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00083313836,0.0006471027,0.0018320258,0.00018480953,0.00018585885,0.00010587115,0.0003918314,0.00022806697,0.00047470847],"category_scores_gemma":[0.00088045624,0.00045239207,0.00016625537,0.00034271256,0.00039879262,0.00057104195,0.0003632063,0.00063343236,0.00018184105],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0024611286,0.0019312609,0.9910153,0.00046148352,0.00073609187,0.000008153188,0.0010250745,7.5834356e-7,0.0000064839583,0.0002102495,0.0010881021,0.001055923],"study_design_scores_gemma":[0.010473519,0.0025220788,0.9823352,0.0005173207,0.0009702604,0.0000016777908,0.0014509109,0.0006301081,0.00017852797,0.00011203265,0.0003487592,0.0004595979],"about_ca_topic_score_codex":0.00008369387,"about_ca_topic_score_gemma":0.00010694569,"teacher_disagreement_score":0.008680084,"about_ca_system_score_codex":0.00007568599,"about_ca_system_score_gemma":0.00025287006,"threshold_uncertainty_score":0.99979275},"labels":[],"label_agreement":null},{"id":"W2920231006","doi":"10.1182/blood-2018-99-112124","title":"A Zebrafish JAK1-A634D Gain-of-Function Model Provides New Insights into the Pathogenesis of Familial Hypereosinophilia","year":2018,"lang":"en","type":"article","venue":"Blood","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; Izaak Walton Killam Health Centre; Dalhousie University","funders":"","keywords":"Hypereosinophilia; Biology; Gain of function; Ruxolitinib; Eosinophil; Zebrafish; Haematopoiesis; Eosinophilia; Cancer research; Immunology; Bone marrow; Mutant; Stem cell; Genetics; Gene; Myelofibrosis","score_opus":0.02077045516594838,"score_gpt":0.24901792908593406,"score_spread":0.22824747391998568,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2920231006","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9956907,0.00093864684,0.00042318023,0.0005912956,0.00011825912,0.0006742227,0.000008208674,0.000029480912,0.0015260126],"genre_scores_gemma":[0.9963668,0.0001612798,0.0022347365,0.00038655248,0.00039670133,0.00007113955,0.000014760589,0.000023956727,0.00034409878],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99879825,0.000055005123,0.00036102702,0.00028966542,0.00032557396,0.00017047428],"domain_scores_gemma":[0.9989459,0.0000944516,0.00015209067,0.00041857007,0.00027665382,0.000112349546],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00009661904,0.00019454228,0.0003782594,0.00008665399,0.00010893269,0.000010066391,0.00009848803,0.000099377714,0.000045391873],"category_scores_gemma":[0.00012006824,0.00011697369,0.00014208231,0.00020773584,0.00016154711,0.00006722958,0.000050590068,0.00008010683,0.000020431824],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0022915737,0.00917951,0.1874321,0.0005398985,0.0023012601,0.000048001806,0.023248788,0.00012575918,0.7091465,0.009049945,0.0048829466,0.051753726],"study_design_scores_gemma":[0.0107656345,0.0060237874,0.1769894,0.00042787474,0.0027100737,0.000031749183,0.0005054066,0.0037107999,0.79037726,0.005821655,0.0022748844,0.0003614596],"about_ca_topic_score_codex":0.0003156852,"about_ca_topic_score_gemma":0.00022896817,"teacher_disagreement_score":0.081230775,"about_ca_system_score_codex":0.00002504807,"about_ca_system_score_gemma":0.00030547293,"threshold_uncertainty_score":0.4770049},"labels":[],"label_agreement":null},{"id":"W2921129431","doi":"10.1111/bjh.15839","title":"<scp>UK</scp> results from the myeloproliferative neoplasms (<scp>MPN</scp>) landmark survey on the symptom, emotional and economic burden of <scp>MPN</scp>","year":2019,"lang":"en","type":"letter","venue":"British Journal of Haematology","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"Medical Research Council; Cancer Research UK","keywords":"Presenteeism; Medicine; Absenteeism; Disease burden; Quality of life (healthcare); Productivity; Burden of disease; Disease; Demography; Gerontology; Physical therapy; Family medicine; Internal medicine; Psychology","score_opus":0.02177184820432684,"score_gpt":0.2481609981325034,"score_spread":0.22638914992817655,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2921129431","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9183061,0.0068320846,0.000024155457,0.06265788,0.0018543169,0.0017151693,0.0058216667,0.000032497162,0.0027561423],"genre_scores_gemma":[0.7898784,0.023574581,0.00078748335,0.15470563,0.012940503,0.00027826475,0.006431256,0.0005729224,0.010830932],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99130034,0.0023772037,0.002740515,0.0012262173,0.0012051809,0.0011505684],"domain_scores_gemma":[0.95451814,0.039996352,0.003205266,0.0009426615,0.0010142061,0.00032338712],"candidate_categories":["metaresearch","metaepi_narrow","research_integrity"],"consensus_categories":["research_integrity"],"category_scores_codex":[0.002322631,0.0011329774,0.0037135063,0.00041350396,0.0004700064,0.00033163076,0.0009738298,0.0015400527,0.00011571059],"category_scores_gemma":[0.008683732,0.0007905158,0.000797613,0.0002527875,0.0008616824,0.00020460646,0.00030655786,0.004028109,0.00023280374],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000108156884,0.0002435196,0.048160937,0.00014093594,0.0032982987,0.010047325,0.0014166101,0.00011244937,0.000014369107,0.00020961823,0.9359962,0.0002516265],"study_design_scores_gemma":[0.01762529,0.0035329151,0.43113053,0.0068909135,0.002104006,0.098725766,0.0016841377,0.0002587216,0.001883273,0.0015401035,0.43428743,0.0003369076],"about_ca_topic_score_codex":0.002139123,"about_ca_topic_score_gemma":0.0011935568,"teacher_disagreement_score":0.50170875,"about_ca_system_score_codex":0.00031660628,"about_ca_system_score_gemma":0.0012248607,"threshold_uncertainty_score":0.99975616},"labels":[],"label_agreement":null},{"id":"W2924768710","doi":"10.1097/hs9.0000000000000233","title":"AXL Inhibition Extinguishes Primitive JAK2 Mutated Myeloproliferative Neoplasm Progenitor Cells","year":2019,"lang":"en","type":"article","venue":"HemaSphere","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Discovery Centre","funders":"Blood Cancer UK; Medical Research Council; Bloodwise; Cancer Research UK","keywords":"Myeloproliferative neoplasm; Essential thrombocythemia; Polycythemia vera; Myeloid leukemia; Cancer research; Thrombopoietin receptor; Janus kinase 2; Myeloproliferative Disorders; Myelofibrosis; Tyrosine kinase; Stem cell; Haematopoiesis; Myeloid; Medicine; Polycythaemia; Biology; Immunology; Internal medicine; Receptor; Bone marrow; Thrombopoietin; Genetics","score_opus":0.0072144557509660635,"score_gpt":0.23445714613808136,"score_spread":0.22724269038711528,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2924768710","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9526554,0.00033454134,0.000036445523,0.00071502937,0.0004217694,0.002757211,0.00004387188,0.0002208653,0.04281488],"genre_scores_gemma":[0.9875635,0.000079258476,0.0033259545,0.00079133897,0.0003976319,0.00046625076,0.00018087146,0.000082831124,0.0071123526],"study_design_codex":"observational","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99753976,0.00011591275,0.00049963914,0.0007655511,0.00052393664,0.0005551742],"domain_scores_gemma":[0.9983717,0.0002055468,0.00021427404,0.00042036688,0.00048401504,0.00030409356],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.00015359379,0.00048300583,0.0007053919,0.00007982283,0.00016177437,0.0000734248,0.000068629066,0.00023523533,0.002859322],"category_scores_gemma":[0.00010945392,0.00038797487,0.0002245085,0.00032889144,0.000089738285,0.00018787042,0.000067850066,0.0003484827,0.0024731932],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0033170448,0.007183152,0.5788128,0.0020256424,0.0030245369,0.003002899,0.01595476,0.000161229,0.3210686,0.006892093,0.026914403,0.03164286],"study_design_scores_gemma":[0.00641612,0.0015606978,0.03548733,0.0007089083,0.00026219836,0.00024802875,0.0016314508,0.00030435744,0.94199485,0.0001866689,0.010606715,0.0005926678],"about_ca_topic_score_codex":0.00003809988,"about_ca_topic_score_gemma":0.000038915325,"teacher_disagreement_score":0.62092626,"about_ca_system_score_codex":0.00026998634,"about_ca_system_score_gemma":0.00030655906,"threshold_uncertainty_score":0.9998572},"labels":[],"label_agreement":null},{"id":"W2932982370","doi":"10.14740/gr1137","title":"Thrombocytosis as a Rare Paraneoplastic Syndrome Occurring in Hepatocellular Carcinoma: A Case Report","year":2019,"lang":"en","type":"article","venue":"Gastroenterology Research","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Thrombocytosis; Medicine; Hepatocellular carcinoma; Pathology; Dermatology; Gastroenterology; Internal medicine; Platelet","score_opus":0.047146914437223034,"score_gpt":0.3494665351151198,"score_spread":0.3023196206778968,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2932982370","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99626154,0.00018499461,0.000010367299,0.00082432554,0.00015383649,0.0017210742,0.00001588852,0.000039806826,0.0007881631],"genre_scores_gemma":[0.99846816,0.000022143557,0.00015740434,0.00028240835,0.000045095174,0.00051946833,0.00004927507,0.000040645715,0.00041538934],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.996271,0.00047482952,0.0005604813,0.00088494644,0.0006347171,0.0011739946],"domain_scores_gemma":[0.9982373,0.0003448864,0.00008613727,0.0007427349,0.00024061168,0.00034828868],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.0010162608,0.00028940305,0.00081610953,0.0006407379,0.00013432911,0.00003373645,0.00014704074,0.00017968964,0.00091698894],"category_scores_gemma":[0.0002777853,0.00024884538,0.00015080824,0.0003933523,0.00019426532,0.00009304903,0.00022718529,0.0009084693,0.00086111686],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00063398236,0.00043776003,0.61904716,0.0001052639,0.00009368416,0.37905326,0.000203752,0.0000068820996,0.00023630941,0.000031574764,0.000126741,0.000023588245],"study_design_scores_gemma":[0.0041886717,0.003197296,0.58411694,0.00017103014,0.000047182108,0.40664363,0.0003340332,0.00063330226,0.0004447709,0.000038861115,0.000091507616,0.00009279434],"about_ca_topic_score_codex":0.00095012254,"about_ca_topic_score_gemma":0.00040159305,"teacher_disagreement_score":0.034930274,"about_ca_system_score_codex":0.00034751045,"about_ca_system_score_gemma":0.00024796487,"threshold_uncertainty_score":0.99999636},"labels":[],"label_agreement":null},{"id":"W294061672","doi":"10.1016/j.cyto.2013.06.143","title":"140","year":2013,"lang":"en","type":"article","venue":"Cytokine","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"","keywords":"Biology","score_opus":0.013370583274798018,"score_gpt":0.2539867094732359,"score_spread":0.24061612619843792,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W294061672","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9475995,0.00019536121,0.000047401347,0.0071798596,0.00008955193,0.00046410412,0.0000046982473,0.00006800763,0.044351574],"genre_scores_gemma":[0.99260736,0.000062602994,0.001101787,0.0015651869,0.00018050187,0.00017382648,0.000026600866,0.000013158055,0.004269009],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.999453,0.000009219238,0.0001143012,0.0001502784,0.00011962058,0.00015359247],"domain_scores_gemma":[0.9995513,0.00003204013,0.000022355647,0.0001891042,0.00007920989,0.00012601519],"candidate_categories":["insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.000026799222,0.00009595207,0.00017192395,0.000038215,0.000037452846,0.000015632217,0.00002807126,0.000036722675,0.0044107414],"category_scores_gemma":[0.0000348668,0.00006526921,0.00005307246,0.00007697321,0.000024913956,0.00004817785,0.00001768899,0.000063449974,0.0028020148],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00008670951,0.0013889446,0.66510725,0.00009078696,0.00035189174,0.0002229494,0.00034050577,0.0000033162764,0.027399926,0.0074298303,0.21791181,0.0796661],"study_design_scores_gemma":[0.002476538,0.00057106157,0.8051174,0.000066294495,0.0000809722,0.00009996458,0.000039745373,0.00012353942,0.06350746,0.00053742755,0.12723008,0.00014949433],"about_ca_topic_score_codex":0.00005196843,"about_ca_topic_score_gemma":0.000003941156,"teacher_disagreement_score":0.1400102,"about_ca_system_score_codex":0.00003730596,"about_ca_system_score_gemma":0.000024434923,"threshold_uncertainty_score":0.9979744},"labels":[],"label_agreement":null},{"id":"W2943873971","doi":"10.5539/gjhs.v11n6p106","title":"Assessment of Clinical Outcome of Patients With Primary Myelofibrosis Treated With Ruxolitinib in the Real-World Practice","year":2019,"lang":"en","type":"article","venue":"Global Journal of Health Science","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"Mustansiriyah University","keywords":"Myelofibrosis; Ruxolitinib; Medicine; Internal medicine; Hematology; Anemia; Bone marrow","score_opus":0.043609883062132634,"score_gpt":0.43615426073431923,"score_spread":0.3925443776721866,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2943873971","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9905328,0.000059647864,0.00001770678,0.0021217645,0.0000861161,0.0007494333,0.000021723194,0.000002624802,0.006408179],"genre_scores_gemma":[0.99025387,0.00014555799,0.008388754,0.0011674565,0.000020908117,0.000004805156,0.0000041288545,0.0000047488857,0.000009767542],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99599534,0.00025824644,0.0015462559,0.00023741837,0.0016458704,0.00031689275],"domain_scores_gemma":[0.9959045,0.00043777653,0.0021274139,0.00030837595,0.0010174271,0.00020448858],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0038285023,0.00014562004,0.0009033589,0.00014988708,0.000064129,0.00001708784,0.00025611074,0.000030843687,0.000015914608],"category_scores_gemma":[0.00017373251,0.000067636705,0.00008321389,0.001108091,0.00033632427,0.00031293894,0.000034088283,0.00025907878,0.0000013983018],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0010071928,0.0018459305,0.99347574,0.000119637625,0.00004882233,0.000021337823,0.000057432615,0.000027055637,0.0000035840815,0.00083904696,0.00003950756,0.002514744],"study_design_scores_gemma":[0.004750022,0.008445626,0.985613,0.0005393532,0.00007969303,0.000064269516,0.00024141792,0.000013469417,0.000029544986,0.000008342871,0.0001584706,0.000056791505],"about_ca_topic_score_codex":0.00050073414,"about_ca_topic_score_gemma":0.00006476029,"teacher_disagreement_score":0.008371048,"about_ca_system_score_codex":0.00042672592,"about_ca_system_score_gemma":0.0026397938,"threshold_uncertainty_score":0.46828806},"labels":[],"label_agreement":null},{"id":"W2946051233","doi":"10.1111/bjh.15954","title":"Next generation sequencing redefines a triple negative essential thrombocythaemia as double‐positive with rare mutations on <i><scp>JAK</scp>2 </i>V617 and <i><scp>MPL</scp></i> W515 hotspots","year":2019,"lang":"en","type":"letter","venue":"British Journal of Haematology","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"Institut National Du Cancer","keywords":"Medicine; Genetics; Biology","score_opus":0.03528295247028962,"score_gpt":0.2704517237881554,"score_spread":0.2351687713178658,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2946051233","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.95798737,0.0052890866,0.0001712701,0.02996541,0.001132148,0.002086862,0.00039816785,0.000055028362,0.0029146792],"genre_scores_gemma":[0.78412634,0.007890648,0.0051236902,0.18775952,0.0072320085,0.00050588715,0.0026377044,0.00048768392,0.0042365305],"study_design_codex":"not_applicable","study_design_gemma":"case_report","domain_scores_codex":[0.99512976,0.00054427324,0.0014173018,0.0009975197,0.001052746,0.0008583731],"domain_scores_gemma":[0.9938714,0.002068312,0.0019367143,0.0003984676,0.0014242514,0.000300854],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.0003406948,0.0008901497,0.0028231165,0.0006389649,0.0004925485,0.00044588544,0.00025209447,0.0011358161,0.000050894003],"category_scores_gemma":[0.0008764793,0.0008043615,0.00043263065,0.00042221643,0.000477351,0.00051901233,0.000087599736,0.0026891206,0.00006601288],"study_design_candidate":"case_report","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000273735,0.00046220253,0.0023955866,0.00067156064,0.0031804787,0.19729987,0.0025310505,0.00010367228,0.0018978937,0.0002836985,0.7899618,0.0009384447],"study_design_scores_gemma":[0.027046345,0.007180839,0.005174893,0.009531446,0.0045540747,0.84964824,0.0023443794,0.00015014263,0.059305552,0.0006321919,0.033868525,0.0005633701],"about_ca_topic_score_codex":0.0006023378,"about_ca_topic_score_gemma":0.0004912577,"teacher_disagreement_score":0.75609326,"about_ca_system_score_codex":0.0003756931,"about_ca_system_score_gemma":0.0014261442,"threshold_uncertainty_score":0.99961174},"labels":[],"label_agreement":null},{"id":"W2946944964","doi":"10.1186/s13104-019-4321-1","title":"Incidence of myeloproliferative neoplasms in Calgary, Alberta, Canada","year":2019,"lang":"en","type":"article","venue":"BMC Research Notes","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":12,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Alberta Health Services; Calgary Laboratory Services; University of Calgary; University of Saskatchewan","funders":"Canadian Institutes of Health Research","keywords":"Incidence (geometry); Medicine; Polycythemia vera; Pediatrics; Internal medicine","score_opus":0.06246342511319721,"score_gpt":0.3635923870726751,"score_spread":0.3011289619594779,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2946944964","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.990058,0.00037759292,0.000010960787,0.0013838538,0.00008855462,0.0013905853,0.000011765359,0.0000072703842,0.0066714142],"genre_scores_gemma":[0.9962108,0.00012646665,0.0009673308,0.00015325115,0.00005238756,0.00019946505,0.00002645594,0.000022590413,0.002241222],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9970908,0.0002931061,0.0004205859,0.00046045904,0.0011527558,0.0005822933],"domain_scores_gemma":[0.9947801,0.0039552916,0.000070749644,0.0004627827,0.00049496884,0.00023608848],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00068482466,0.00019545658,0.0005406932,0.00027230365,0.00006615242,0.000019790834,0.00016835947,0.00009595089,0.0007178423],"category_scores_gemma":[0.0021745916,0.00015016373,0.00006674021,0.00062096113,0.00013267805,0.00009977056,0.00012610834,0.0004366418,0.00013551918],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0003938257,0.00025752492,0.9931341,0.00019428278,0.00004714976,0.00008046939,0.0005023512,0.00005501057,0.0011979811,0.0025418005,0.00074976217,0.0008457735],"study_design_scores_gemma":[0.002250376,0.0008548105,0.92144513,0.00044004217,0.000012407427,0.00002577722,0.00029057605,0.0015682305,0.07155555,0.00023264234,0.0011603498,0.00016409156],"about_ca_topic_score_codex":0.82674766,"about_ca_topic_score_gemma":0.9573069,"teacher_disagreement_score":0.1305593,"about_ca_system_score_codex":0.00047982307,"about_ca_system_score_gemma":0.003588062,"threshold_uncertainty_score":0.785987},"labels":[],"label_agreement":null},{"id":"W2949764170","doi":"10.1097/01.hs9.0000564104.83392.dc","title":"PS1460 LONG-TERM FOLLOW UP OF JAK INHIBITOR (JAKI) TREATED PATIENTS WITH MYELOFIBROSIS: IMPACT OF MOLECULAR ENHANCED INTEGRATED SCORING SYSTEMS AND TYPE OF JAKI THERAPY FAILURE ON SURVIVAL","year":2019,"lang":"en","type":"article","venue":"HemaSphere","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Toronto General Hospital; Princess Margaret Cancer Centre","funders":"","keywords":"Myelofibrosis; Term (time); Medicine; Ruxolitinib; Internal medicine; Oncology; Physics","score_opus":0.014467297131724972,"score_gpt":0.26835723356450547,"score_spread":0.2538899364327805,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2949764170","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99721223,0.00074835593,0.000015599851,0.000011013479,0.00012466812,0.0014342936,0.00005941135,0.000021679725,0.00037275304],"genre_scores_gemma":[0.9993646,0.00011581491,0.00010445851,0.000007027845,0.00001839452,0.00004099827,0.000116987016,0.000048603826,0.00018308958],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9984468,0.00008478881,0.00045403407,0.0003599983,0.00042343602,0.00023094041],"domain_scores_gemma":[0.9984584,0.00008645688,0.00036217575,0.00039804305,0.0005753469,0.00011960604],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000074482676,0.00034433036,0.0009547302,0.00008599595,0.00002229372,0.000012324605,0.000057126123,0.00013899527,0.00018308897],"category_scores_gemma":[0.000029934743,0.00020998507,0.00015014739,0.00034754348,0.000064702785,0.00007370159,0.00002026746,0.000120373355,0.000006619134],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00392768,0.0007720687,0.87775695,0.00045081344,0.0009214592,0.00001149707,0.00032381725,0.000055559507,0.11430757,0.000048980124,0.00002873023,0.001394875],"study_design_scores_gemma":[0.009203213,0.008938112,0.5293247,0.002949358,0.00013101129,0.0000033139204,0.00016557684,0.000022320779,0.44909528,0.0000010499906,0.00000465376,0.00016139138],"about_ca_topic_score_codex":0.00030606473,"about_ca_topic_score_gemma":0.00004167091,"teacher_disagreement_score":0.34843224,"about_ca_system_score_codex":0.00009337033,"about_ca_system_score_gemma":0.0001307302,"threshold_uncertainty_score":0.8562943},"labels":[],"label_agreement":null},{"id":"W2951500503","doi":"10.1097/01.hs9.0000564124.13888.22","title":"PS1465 SAFETY AND EFFICACY OF RUXOLITINIB (RUX) IN PATIENTS WITH MYELOFIBROSIS (MF) AND ANEMIA (HB &lt;10 G/DL): RESULTS AT WEEK (WK) 24 OF THE REALISE TRIAL","year":2019,"lang":"en","type":"article","venue":"HemaSphere","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"St. Paul's Hospital; University of British Columbia","funders":"","keywords":"Medicine; Myelofibrosis; Anemia; Internal medicine; Clinical endpoint; Gastroenterology; Ruxolitinib; Polycythemia vera; Regimen; Dosing; Surgery; Clinical trial; Bone marrow","score_opus":0.01047886968490293,"score_gpt":0.22865220476873951,"score_spread":0.21817333508383657,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2951500503","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.991763,0.00026355652,2.1661637e-7,0.00044945866,0.000086048276,0.0019233936,0.00022172743,0.000010858225,0.0052817683],"genre_scores_gemma":[0.9973592,0.00015263144,0.00026020632,0.00006330432,0.0000340165,0.00003087129,0.00009178525,0.000025973337,0.001981993],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.998255,0.00010436229,0.0005870368,0.0004144644,0.00039854468,0.00024057936],"domain_scores_gemma":[0.9985446,0.00040709283,0.0003089384,0.00048325877,0.00013265791,0.00012346856],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00018245952,0.00024226925,0.0006637515,0.000039421226,0.00005454294,0.000008654042,0.00006764809,0.00012931906,0.00031853383],"category_scores_gemma":[0.00017396317,0.00014252945,0.000076010394,0.00019886323,0.00015529996,0.000056982783,0.00010513749,0.00013013545,0.00000824037],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.15808028,0.0017262795,0.83126545,0.0004961571,0.00014879736,0.000009997011,0.0017877641,0.000011585169,0.0003011316,0.00031157778,0.0021414775,0.0037195182],"study_design_scores_gemma":[0.12593973,0.0038957167,0.8616565,0.00091579347,0.00015156984,0.00000599877,0.00014812293,0.0000110554965,0.0052106506,0.000015476846,0.0019000848,0.00014934274],"about_ca_topic_score_codex":0.00013399027,"about_ca_topic_score_gemma":0.00019420477,"teacher_disagreement_score":0.032140553,"about_ca_system_score_codex":0.00008438231,"about_ca_system_score_gemma":0.00008817557,"threshold_uncertainty_score":0.58121824},"labels":[],"label_agreement":null},{"id":"W2952050362","doi":"10.1097/01.hs9.0000567332.39511.c6","title":"PB2213 SPLANCHNIC VEIN THROMBOSIS IN MYELOPROLOFERATIVE NEOPLASMS; A PROSPECTIVE ANALYSIS OF THROMBOSIS OUTCOME","year":2019,"lang":"en","type":"article","venue":"HemaSphere","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"St. Thomas Hospital","funders":"","keywords":"Medicine; Thrombosis; Thrombocytosis; Thrombus; Portal vein thrombosis; Prospective cohort study; Polycythaemia; Internal medicine; Budd–Chiari syndrome; Myelofibrosis; Polycythemia vera; Radiology; Splenic vein; Surgery; Gastroenterology; Portal hypertension; Bone marrow; Platelet; Inferior vena cava; Cirrhosis","score_opus":0.027074326728748103,"score_gpt":0.3238680065348369,"score_spread":0.2967936798060888,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2952050362","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97882354,0.0003145949,0.000030740743,0.00062243885,0.00012564416,0.0018364701,0.00007552348,0.00006479434,0.018106256],"genre_scores_gemma":[0.9962104,0.00014542733,0.0015848922,0.0003356401,0.00004017553,0.00035316072,0.00009765651,0.00004623556,0.0011864173],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9971188,0.000117737254,0.0008730302,0.00081719545,0.0005699418,0.00050330744],"domain_scores_gemma":[0.99822974,0.0003259132,0.0003095846,0.0007061102,0.00025894758,0.00016972242],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00026480234,0.00046337786,0.0019672927,0.00042259626,0.00005888416,0.000024865503,0.00014470478,0.00024301282,0.0043844567],"category_scores_gemma":[0.00010838576,0.0003647468,0.00051499676,0.0020911728,0.000105874555,0.00017402461,0.00008490817,0.00036461418,0.00027200175],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00021606004,0.0011658779,0.9877219,0.000186005,0.0035883375,0.000027393886,0.002033933,0.00018145028,0.0019896699,0.002468935,0.00020522173,0.00021520127],"study_design_scores_gemma":[0.0033219988,0.0009922591,0.98033535,0.00022245952,0.0019494252,0.0000063911307,0.00096355774,0.0007373969,0.010847047,0.00012991087,0.00017270217,0.00032149817],"about_ca_topic_score_codex":0.0003202258,"about_ca_topic_score_gemma":0.0015112879,"teacher_disagreement_score":0.017386857,"about_ca_system_score_codex":0.0004002824,"about_ca_system_score_gemma":0.00017703777,"threshold_uncertainty_score":0.99988043},"labels":[],"label_agreement":null},{"id":"W2952592194","doi":"10.1097/01.hs9.0000564128.13888.1d","title":"PS1466 CYTOREDUCTION FOR THE TREATMENT OF ESSENTIAL THROMBOCYTHEMIA: A SYSTEMATIC REVIEW","year":2019,"lang":"en","type":"review","venue":"HemaSphere","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University","funders":"","keywords":"Medicine; Randomized controlled trial; Essential thrombocythemia; Anagrelide; Internal medicine; Observational study; Aspirin; Relative risk; Placebo; Hydroxycarbamide; Surgery; Polycythemia vera; Chemotherapy; Confidence interval; Pathology","score_opus":0.08401434338757563,"score_gpt":0.39626701586450297,"score_spread":0.31225267247692734,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2952592194","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000003852863,0.97830623,0.000049208862,0.00016911008,0.00038867551,0.020631773,0.00011464482,0.000029185005,0.00030733543],"genre_scores_gemma":[0.000008187304,0.98714346,0.0002424246,0.00005686599,0.0003638698,0.008845379,0.00027546976,0.00008425841,0.002980117],"study_design_codex":"systematic_review","study_design_gemma":"systematic_review","domain_scores_codex":[0.99764603,0.00013368574,0.0011418927,0.00048331695,0.00033259694,0.00026245438],"domain_scores_gemma":[0.9969809,0.00080512156,0.00090433884,0.0010372938,0.00018904227,0.00008332766],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00018345828,0.00060712075,0.0055583487,0.000039810395,0.00008586748,0.000016732474,0.0001329696,0.00025203303,0.00038147246],"category_scores_gemma":[0.00010190546,0.00027542748,0.0019189081,0.00020863149,0.00006141784,0.000030196139,0.000017696868,0.000121341,0.00015467979],"study_design_candidate":"systematic_review","study_design_consensus":"systematic_review","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000015664573,0.0006722928,0.0000018156326,0.93718815,0.0030575686,0.000007486804,0.000070558104,1.6030668e-7,3.936474e-7,0.00022901062,0.0025109588,0.056245934],"study_design_scores_gemma":[0.00071767345,0.0009185498,4.389762e-7,0.5414057,0.047058128,0.00020172393,0.000041789663,0.00000344712,0.000046320325,0.0000047234244,0.40943706,0.00016447985],"about_ca_topic_score_codex":0.000010773808,"about_ca_topic_score_gemma":0.000006692263,"teacher_disagreement_score":0.4069261,"about_ca_system_score_codex":0.00042777043,"about_ca_system_score_gemma":0.0004499265,"threshold_uncertainty_score":0.9999698},"labels":[],"label_agreement":null},{"id":"W2952994283","doi":"10.1097/01.hs9.0000561608.73874.6a","title":"S832 A PHASE 2A STUDY OF THE LSD1 INHIBITOR IMG‐7289 FOR THE TREATMENT OF MYELOFIBROSIS","year":2019,"lang":"en","type":"article","venue":"HemaSphere","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"","keywords":"Medicine; Myelofibrosis; Ruxolitinib; Bone marrow; Myeloid; Internal medicine; Progenitor cell; Chronic myelomonocytic leukemia; Gastroenterology; Pharmacology; Oncology; Myelodysplastic syndromes; Immunology; Stem cell; Biology","score_opus":0.02639573131401898,"score_gpt":0.3162784913377868,"score_spread":0.28988276002376784,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2952994283","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9919953,0.0013274123,0.0000099436975,0.0007519287,0.00022816019,0.004911227,0.00008356926,0.000013760616,0.0006787299],"genre_scores_gemma":[0.9964292,0.0001476894,0.00019947092,0.00007684145,0.00012330814,0.0007610276,0.000009876145,0.000027192937,0.0022254155],"study_design_codex":"observational","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99881285,0.00005041149,0.00036948605,0.00026922335,0.0003030852,0.00019492526],"domain_scores_gemma":[0.9985237,0.00039269085,0.00019993036,0.0006754937,0.00014734651,0.000060826664],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00008389754,0.00021618126,0.00052445754,0.00001999158,0.00009347015,0.000008686641,0.0001000144,0.00005887466,0.00051422557],"category_scores_gemma":[0.000030154895,0.00009649836,0.00028627727,0.00016946245,0.000057178055,0.000029551393,0.00002856346,0.000050837894,0.000019043884],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0041736737,0.06401797,0.8080921,0.0006804181,0.003737029,0.00001702246,0.01916207,0.00008412325,0.023131007,0.0010305081,0.007246021,0.06862805],"study_design_scores_gemma":[0.07972416,0.066348344,0.17430915,0.0006875824,0.0033376783,0.000027492864,0.017343499,0.00056626945,0.59189236,0.00010788755,0.06521796,0.00043758628],"about_ca_topic_score_codex":0.00015054313,"about_ca_topic_score_gemma":0.00015346658,"teacher_disagreement_score":0.633783,"about_ca_system_score_codex":0.00009425411,"about_ca_system_score_gemma":0.000096912656,"threshold_uncertainty_score":0.563041},"labels":[],"label_agreement":null},{"id":"W2954564366","doi":"10.1200/jco.2019.37.15_suppl.7058","title":"Results from ongoing phase 1/2 clinical trial of tagraxofusp (SL-401) in patients with intermediate or high risk relapsed/refractory myelofibrosis.","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta Hospital; Alberta Hospital Edmonton; Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Refractory (planetary science); Internal medicine; Monocytosis; Myelofibrosis; Discontinuation; Interleukin-3 receptor; Phases of clinical research; Gastroenterology; Anagrelide; Clinical trial; Oncology; Leukemia; Bone marrow; Platelet; Essential thrombocythemia","score_opus":0.08061642482235527,"score_gpt":0.43866887677173166,"score_spread":0.3580524519493764,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2954564366","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99388725,0.00006047062,0.000014393387,0.001083915,0.003304744,0.0010875518,0.00015989046,0.000009425347,0.0003923862],"genre_scores_gemma":[0.99287736,0.0013965783,0.0032594693,0.000823243,0.0013986817,0.000012401634,0.00006491294,0.000035293484,0.0001320701],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.98960936,0.0017014785,0.0070109107,0.0005412153,0.00078435254,0.00035270583],"domain_scores_gemma":[0.9746578,0.016885499,0.0067173643,0.0005136014,0.0006691736,0.0005566075],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.0051223277,0.00031765673,0.0037254135,0.00024532923,0.000031029762,0.000012413099,0.00024950563,0.0007325511,0.00033396843],"category_scores_gemma":[0.01327851,0.00017854627,0.00069761544,0.00022485924,0.00031237784,0.00020783953,0.00009430519,0.0020396472,0.00005632501],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.4173985,0.018466972,0.4812882,0.000011997541,0.00064784486,0.00022698098,0.000096436364,0.0000062376403,0.000004093473,0.000006961704,0.0010531498,0.0807926],"study_design_scores_gemma":[0.34376544,0.1414848,0.5090673,0.00036652514,0.00047883482,0.000004124704,0.000040583127,0.000019857416,0.00003834186,0.000045539302,0.0045873253,0.00010134502],"about_ca_topic_score_codex":0.00015047647,"about_ca_topic_score_gemma":0.00025771148,"teacher_disagreement_score":0.123017825,"about_ca_system_score_codex":0.00023987023,"about_ca_system_score_gemma":0.0020271216,"threshold_uncertainty_score":0.9950331},"labels":[],"label_agreement":null},{"id":"W2955358464","doi":"10.1158/1538-7445.sabcs18-4912","title":"Abstract 4912: A snapshot of myeloproliferative neoplasms in the United States: Analysis of the “myMPN” patient registry","year":2019,"lang":"en","type":"article","venue":"Clinical Research (Excluding Clinical Trials)","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"St. Thomas Hospital","funders":"","keywords":"Snapshot (computer storage); Computer science; Medicine; Database","score_opus":0.5550935003392555,"score_gpt":0.5987014889231944,"score_spread":0.043607988583938884,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2955358464","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98696494,0.00027936895,0.0000071182094,0.00678093,0.00050807,0.003509905,0.00017396844,0.000014234865,0.0017614447],"genre_scores_gemma":[0.9942469,0.00354295,0.00015812505,0.0011659858,0.00027632545,0.0001878093,0.00023786908,0.000032127373,0.00015188692],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9747024,0.013619005,0.007120422,0.0011325276,0.0026083153,0.00081733783],"domain_scores_gemma":[0.8132452,0.17833537,0.0027841614,0.002949376,0.0020965536,0.0005893744],"candidate_categories":["metaresearch","research_integrity","insufficient_payload"],"consensus_categories":["metaresearch"],"category_scores_codex":[0.06602666,0.0003976025,0.003735742,0.000802926,0.00017876743,0.00006428939,0.00093552144,0.0006116282,0.0009937623],"category_scores_gemma":[0.13632734,0.00019732436,0.0025380396,0.005114882,0.0014960276,0.00008795051,0.0004265817,0.0029565392,0.000057335135],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0047731968,0.0052227476,0.97209835,0.00016691211,0.0042502484,0.000050020884,0.001068686,0.0004969952,0.00010733686,0.0017892332,0.0044674263,0.0055088694],"study_design_scores_gemma":[0.008298701,0.0042400276,0.9709704,0.0010496309,0.0015071296,0.0000031455784,0.0022747107,0.0034496055,0.00090321235,0.001038174,0.0060258047,0.00023948753],"about_ca_topic_score_codex":0.0004955866,"about_ca_topic_score_gemma":0.00026343693,"teacher_disagreement_score":0.16471636,"about_ca_system_score_codex":0.00015997149,"about_ca_system_score_gemma":0.0010492472,"threshold_uncertainty_score":0.9999195},"labels":[],"label_agreement":null},{"id":"W2956909849","doi":"10.1200/jco.2019.37.15_suppl.7056","title":"A phase II study of cpi-0610, a bromodomain and extraterminal protein inhibitor (BETi) alone or with ruxolitinib (RUX), in patients with myelofibrosis (MF).","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta; Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Myelofibrosis; Internal medicine; Ruxolitinib; Anemia; Gastroenterology; Oncology; Bone marrow","score_opus":0.0526204380176043,"score_gpt":0.4045944892902081,"score_spread":0.3519740512726038,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2956909849","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99655885,0.000050643983,0.0000052407095,0.00093476137,0.000106751155,0.0021341108,0.000012637093,0.000004919385,0.00019208797],"genre_scores_gemma":[0.99606377,0.000026528358,0.003185406,0.00026077946,0.00018155607,0.000060379032,0.0000046109176,0.000025827037,0.00019113303],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99591213,0.00055151485,0.0022513028,0.00035742603,0.0006329691,0.0002946729],"domain_scores_gemma":[0.996161,0.0009831162,0.0017444453,0.00023213017,0.00050021795,0.00037910196],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0014163054,0.00026419465,0.0022750332,0.00020332176,0.00004466523,0.000011349102,0.00009962331,0.00022606128,0.00017177984],"category_scores_gemma":[0.0005118786,0.00013681535,0.00012091554,0.00021892427,0.00019765414,0.00015901864,0.000065144966,0.0006351738,0.0000040707687],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.090908565,0.06472824,0.81587905,0.00009130945,0.00051628775,0.0010149439,0.0007503835,0.0000024040337,0.0001916186,0.000015080887,0.00010027042,0.025801852],"study_design_scores_gemma":[0.110909544,0.37914395,0.507484,0.00066287495,0.0003106167,0.000119094504,0.00044942732,0.00000957564,0.00041795627,0.000012752088,0.00037111214,0.00010904268],"about_ca_topic_score_codex":0.000040539,"about_ca_topic_score_gemma":0.00025191222,"teacher_disagreement_score":0.31441572,"about_ca_system_score_codex":0.00011643599,"about_ca_system_score_gemma":0.0010174903,"threshold_uncertainty_score":0.55791676},"labels":[],"label_agreement":null},{"id":"W2964353176","doi":"10.1200/jco.2012.30.15_suppl.tps6640","title":"An open-label, multicenter, expanded access study assessing the safety and efficacy of oral ruxolitinib administered to patients with primary myelofibrosis (PMF), post-polycythemia myelofibrosis (PPV MF) or post-essential thrombocythemia myelofibrosis (PET-MF).","year":2012,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Ruxolitinib; Myelofibrosis; Essential thrombocythemia; Internal medicine; Polycythemia vera; Clinical endpoint; Constitutional symptoms; Anemia; International Prognostic Scoring System; Gastroenterology; Phases of clinical research; Bone marrow; Clinical trial; Myelodysplastic syndromes; Disease","score_opus":0.12906822328021123,"score_gpt":0.4904048516542319,"score_spread":0.3613366283740207,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2964353176","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9918757,0.0001402864,0.000072711,0.00312852,0.00086081197,0.0034112218,0.00015017769,0.000027504173,0.00033307847],"genre_scores_gemma":[0.98352057,0.00022761659,0.012092405,0.0031741573,0.0006342202,0.000089408364,0.0000894088,0.00010572473,0.00006648518],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99104345,0.0017742495,0.0042433194,0.000785101,0.001239456,0.00091442524],"domain_scores_gemma":[0.9870941,0.0050830296,0.003543831,0.00090401,0.0018529933,0.001522047],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0034693093,0.0007228852,0.003843269,0.00028384445,0.00041751703,0.00030451472,0.0010597174,0.00039607292,0.00029618441],"category_scores_gemma":[0.0025662028,0.0003908766,0.0003243802,0.0004885494,0.00057628256,0.0016742721,0.0008712393,0.0010181498,0.00001040822],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.081798494,0.044329748,0.8145267,0.0001198557,0.0019518781,0.00012966676,0.0018732739,0.0000032462067,0.003009956,0.000016787626,0.00027602646,0.051964372],"study_design_scores_gemma":[0.053941753,0.0732638,0.86500883,0.00056116766,0.0023041952,0.00020110277,0.0013723383,0.000011739214,0.0019735224,0.0000034003024,0.0009737489,0.00038439388],"about_ca_topic_score_codex":0.00022655605,"about_ca_topic_score_gemma":0.00017814168,"teacher_disagreement_score":0.05157998,"about_ca_system_score_codex":0.00042479858,"about_ca_system_score_gemma":0.0020581502,"threshold_uncertainty_score":0.9998543},"labels":[],"label_agreement":null},{"id":"W2965517009","doi":"10.2147/imcrj.s217568","title":"&lt;p&gt;What cardiologists should know about essential thrombocythemia and acute myocardial infarction: report of two cases and advanced heart failure therapies considerations&lt;/p&gt;","year":2019,"lang":"en","type":"article","venue":"International Medical Case Reports Journal","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institut universitaire de cardiologie et de pneumologie de Québec","funders":"","keywords":"Medicine; Cardiogenic shock; Cardiology; Myocardial infarction; Internal medicine; Thrombocytosis; Essential thrombocythemia; Heart failure; Revascularization; Platelet","score_opus":0.01705014902538764,"score_gpt":0.33038740626451174,"score_spread":0.3133372572391241,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2965517009","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.978618,0.0057827136,0.00009122125,0.012610807,0.0019514348,0.00045115605,0.00002207122,0.000028422839,0.00044417413],"genre_scores_gemma":[0.99123067,0.005241425,0.0016801286,0.0006080439,0.00097009295,0.000046653247,0.000055996956,0.000024347886,0.0001426474],"study_design_codex":"case_report","study_design_gemma":"case_report","domain_scores_codex":[0.9967135,0.00012727245,0.0011130957,0.0004915031,0.001301099,0.0002535124],"domain_scores_gemma":[0.9972041,0.0006623831,0.00060187414,0.0002831538,0.0008036832,0.0004447875],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00085758907,0.0002954056,0.00079258665,0.00018930793,0.00019681481,0.00017750694,0.000039016533,0.00020444805,0.0012506319],"category_scores_gemma":[0.0014809694,0.0002169773,0.00024001465,0.00008101383,0.0003951452,0.0004657692,0.00009557462,0.00047890164,0.0000035368794],"study_design_candidate":"case_report","study_design_consensus":"case_report","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0004903019,0.00043979252,0.31877723,0.00007437447,0.0052006347,0.6428408,0.0006233631,0.00005555383,0.012864243,0.0017327642,0.0070197666,0.009881166],"study_design_scores_gemma":[0.0025033443,0.00045412342,0.027118249,0.0005632739,0.00035259238,0.94263804,0.0001603147,0.00006825152,0.0023248503,0.0005322133,0.023096379,0.00018835044],"about_ca_topic_score_codex":0.000028511675,"about_ca_topic_score_gemma":0.00007528112,"teacher_disagreement_score":0.29979727,"about_ca_system_score_codex":0.00013542538,"about_ca_system_score_gemma":0.00057575677,"threshold_uncertainty_score":0.99966234},"labels":[],"label_agreement":null},{"id":"W2965831517","doi":"10.1002/cncr.32417","title":"Identification of significant geographic clustering of polycythemia vera cases in Montreal, Canada","year":2019,"lang":"en","type":"article","venue":"Cancer","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":14,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Ottawa; McGill University","funders":"Fonds de Recherche du Québec - Santé; Canadian Dermatology Foundation","keywords":"Polycythemia vera; Medicine; Identification (biology); Traditional medicine; Internal medicine","score_opus":0.01133622664098716,"score_gpt":0.26197824418589927,"score_spread":0.2506420175449121,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2965831517","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9979496,0.00094677164,0.0000049322125,0.00025169228,0.00012753053,0.0003547594,0.000074361575,0.0000033325168,0.00028701985],"genre_scores_gemma":[0.9991543,0.0004099514,0.000012534608,0.000061715466,0.000020411948,0.00007266674,0.000013071698,0.00000786362,0.00024743407],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99928695,0.000015229033,0.00027881734,0.0001494003,0.00016026574,0.00010934485],"domain_scores_gemma":[0.9995118,0.000066444205,0.00012600858,0.00018097085,0.000072081064,0.000042740245],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000054743392,0.00008038999,0.00026248893,0.00007491543,0.0000095792075,0.0000024400981,0.000035642963,0.000028946157,0.00021787065],"category_scores_gemma":[0.000019017112,0.00006648292,0.00003843681,0.00013299481,0.000023346609,0.000025464593,0.000011150849,0.00004713929,0.0000017383002],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0001423549,0.00010111853,0.96759087,0.00019367803,0.0000736231,0.000028799597,0.0001588321,0.0003324427,0.027808152,0.000020893478,0.00033789806,0.0032113672],"study_design_scores_gemma":[0.0008620741,0.000108090666,0.86734116,0.00024947268,0.00005053171,0.0000050366007,0.00013968878,0.0005984696,0.13038673,0.0000063557486,0.00019012329,0.00006227805],"about_ca_topic_score_codex":0.6154641,"about_ca_topic_score_gemma":0.6468539,"teacher_disagreement_score":0.102578565,"about_ca_system_score_codex":0.00015305268,"about_ca_system_score_gemma":0.00028754695,"threshold_uncertainty_score":0.38709655},"labels":[],"label_agreement":null},{"id":"W2972452355","doi":"10.1111/ejh.13327","title":"Reduced‐intensity conditioning allogeneic transplant with dual T‐cell depletion in myelofibrosis","year":2019,"lang":"en","type":"article","venue":"European Journal Of Haematology","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Medicine; Myelofibrosis; Internal medicine; Cumulative incidence; Cyclophosphamide; Gastroenterology; Graft-versus-host disease; Incidence (geometry); Surgery; Transplantation; Bone marrow; Chemotherapy","score_opus":0.011424199007215082,"score_gpt":0.22568699275825554,"score_spread":0.21426279375104046,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2972452355","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99451756,0.00022400977,0.0002119769,0.001070474,0.00015912608,0.00020641969,0.0000034725545,0.000010214037,0.0035967578],"genre_scores_gemma":[0.99791056,0.00010548475,0.0014663495,0.0003267801,0.000055733555,0.0000020510572,0.000015718582,0.000026477222,0.00009081774],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9986308,0.00029066447,0.0004957848,0.0001852069,0.00018793254,0.0002096074],"domain_scores_gemma":[0.9992089,0.000076199205,0.00029403743,0.00013696839,0.00016369892,0.00012018935],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00035270234,0.00015889507,0.00060077576,0.0001907137,0.000038032267,0.000011274512,0.000059369442,0.000034595938,0.00017439091],"category_scores_gemma":[0.000019654304,0.00010897422,0.000097145705,0.00010288612,0.00006326873,0.000069452726,0.000012970453,0.0002618313,0.00012460655],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0018178741,0.00051666825,0.9212874,0.00011214705,0.00021547437,0.033069815,0.0014394239,0.00015080023,0.04041196,0.00027693328,0.00047846252,0.0002230008],"study_design_scores_gemma":[0.007129458,0.0039963806,0.84682024,0.0007675106,0.00023298709,0.07017922,0.00045805675,0.000026142008,0.069652766,0.00001755557,0.0005415514,0.00017812061],"about_ca_topic_score_codex":0.000006015105,"about_ca_topic_score_gemma":0.000012337004,"teacher_disagreement_score":0.07446719,"about_ca_system_score_codex":0.0000589957,"about_ca_system_score_gemma":0.000081908984,"threshold_uncertainty_score":0.44438398},"labels":[],"label_agreement":null},{"id":"W2978151740","doi":"","title":"Acute cerebrovascular event in a dog with polycythemia vera.","year":2018,"lang":"en","type":"article","venue":"PubMed","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Ataxia; Psychiatry","score_opus":0.011105641368611082,"score_gpt":0.24471701488113592,"score_spread":0.23361137351252484,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2978151740","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9903114,0.00014618627,0.00004269986,0.0023143962,0.00008995622,0.0013041106,0.000005941749,0.000041034706,0.005744282],"genre_scores_gemma":[0.99484116,0.00006403284,0.00034062567,0.0007223676,0.00021192573,0.0026628964,0.000015080242,0.000023034518,0.0011188594],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9988305,0.000027490689,0.00017402736,0.00030630286,0.00026697144,0.0003946832],"domain_scores_gemma":[0.9993801,0.000027732654,0.000042906337,0.00030371532,0.00005812853,0.00018739147],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001363932,0.00016575943,0.00029058923,0.00010094158,0.000045469536,0.000017189843,0.00005514375,0.00005723691,0.00012334193],"category_scores_gemma":[0.000026134494,0.000109027,0.0000730128,0.00022348441,0.00007507109,0.000054538526,0.000027577595,0.00010769704,0.000076565644],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00078263436,0.00097530155,0.92852736,0.000036602098,0.0011359428,0.00035693374,0.0005901338,0.0000019556005,0.00008969903,0.00042677356,0.002402955,0.06467372],"study_design_scores_gemma":[0.0050980025,0.00038410822,0.9564608,0.000052798685,0.00020607664,0.00012898422,0.000026324686,0.000018725492,0.026953744,0.000042438547,0.010488582,0.00013945154],"about_ca_topic_score_codex":0.0000700127,"about_ca_topic_score_gemma":0.00015301279,"teacher_disagreement_score":0.06453427,"about_ca_system_score_codex":0.00018386653,"about_ca_system_score_gemma":0.000058656307,"threshold_uncertainty_score":0.4445992},"labels":[],"label_agreement":null},{"id":"W2979242992","doi":"10.1182/blood.v128.22.2301.2301","title":"Impact of Genomic Alterations on Outcomes in Myelofibrosis Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplantation","year":2016,"lang":"en","type":"article","venue":"Blood","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network; Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Medicine; Myelofibrosis; Ruxolitinib; Hematopoietic stem cell transplantation; Oncology; Internal medicine; Transplantation; Cohort; Cancer; Bone marrow","score_opus":0.01415079610792921,"score_gpt":0.26121368671327877,"score_spread":0.24706289060534956,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2979242992","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.998814,0.00005064504,0.000039100352,0.00015063623,0.0000304233,0.0004797074,0.00008998229,0.000014536949,0.0003310031],"genre_scores_gemma":[0.99933416,0.0002267235,0.00016944259,0.000040372317,0.000012517447,0.000067169385,0.000033910612,0.000018181709,0.00009752888],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9990892,0.000046001267,0.00031691615,0.00021151637,0.00016517163,0.00017122895],"domain_scores_gemma":[0.9993675,0.00024075543,0.000096230586,0.0001762885,0.0000453585,0.00007391399],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000044129338,0.00015885566,0.00030682073,0.00014151656,0.000033528573,0.000007414843,0.00003823922,0.000052306234,0.000070973234],"category_scores_gemma":[0.00000793665,0.00009316438,0.00014056335,0.00006965481,0.000017452523,0.000052450232,0.000007023346,0.000037529164,0.000044476757],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00009086794,0.002635304,0.97602767,0.00007726221,0.00014741952,0.000011372118,0.0004895847,0.000022154094,0.01979334,0.00006970989,0.000009577188,0.0006257338],"study_design_scores_gemma":[0.008500865,0.0015685178,0.9010974,0.00022215142,0.00016702405,0.0000046284154,0.000014839043,0.0000015818831,0.08831263,0.000022947645,0.0000013708764,0.00008604585],"about_ca_topic_score_codex":0.00002493398,"about_ca_topic_score_gemma":0.00006309898,"teacher_disagreement_score":0.07493028,"about_ca_system_score_codex":0.00011024496,"about_ca_system_score_gemma":0.00009250345,"threshold_uncertainty_score":0.37991333},"labels":[],"label_agreement":null},{"id":"W2979499925","doi":"10.1182/blood.v122.21.4090.4090","title":"Myeloproliferative Neoplasm Quality Of Life (MPN-QOL) Study Group: Observational Study Of Quality Of Life and Symptomatic Response In Myelofibrosis Patients Receiving Undergoing Treatment With Conventional Therapy, The Measures Trial and Allogeneic Stem Cell Transplant, The Symptoms Trial","year":2013,"lang":"en","type":"article","venue":"Blood","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Medicine; Myeloproliferative neoplasm; Myelofibrosis; Quality of life (healthcare); Internal medicine; Clinical trial; Prospective cohort study; Randomized controlled trial; Observational study; Physical therapy; Surgery; Bone marrow","score_opus":0.08535212569603451,"score_gpt":0.30497268848416986,"score_spread":0.21962056278813535,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2979499925","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9882308,0.0005126186,0.000007860324,0.0002702269,0.00006041815,0.0108135315,0.00007473942,0.000013614778,0.000016163114],"genre_scores_gemma":[0.99786353,0.00020520264,0.00006478911,0.00006247934,0.00004716503,0.0016900168,0.000025585538,0.000026613066,0.000014618208],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99298954,0.0034515185,0.00172863,0.00051727344,0.001061558,0.00025145238],"domain_scores_gemma":[0.9928708,0.0051941993,0.0009827014,0.00044690247,0.00036013112,0.0001452608],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0020406977,0.00041318272,0.001348857,0.0001388187,0.00020211478,0.0000408272,0.00014226162,0.00009882076,0.000018215418],"category_scores_gemma":[0.00026910752,0.00021380404,0.00014736176,0.0002788863,0.00023031664,0.00013560835,0.00004501203,0.00014952813,4.5310867e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.17992811,0.023828007,0.779699,0.00012435066,0.0019690623,0.000001238622,0.013282825,0.00001609671,0.00062458415,0.000044189903,0.000001478162,0.00048100812],"study_design_scores_gemma":[0.29236516,0.027907416,0.67289984,0.00011652817,0.00035275234,0.0000011179621,0.0056399433,0.000012680725,0.00055823463,0.0000148496165,6.9006086e-7,0.0001307677],"about_ca_topic_score_codex":0.0012160421,"about_ca_topic_score_gemma":0.0016559138,"teacher_disagreement_score":0.11243705,"about_ca_system_score_codex":0.00006947497,"about_ca_system_score_gemma":0.00047378658,"threshold_uncertainty_score":0.8718676},"labels":[],"label_agreement":null},{"id":"W2979544688","doi":"10.1182/blood.v124.21.3180.3180","title":"Comparison of the Impact of Two Different Definitions of Red-Cell Transfusion Dependence on the Natural History of Myeloproliferative Neoplasm (MPN)-Associated Myelofibrosis (MF)","year":2014,"lang":"en","type":"article","venue":"Blood","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network; Leukemia & Lymphoma Society of Canada; Princess Margaret Cancer Centre; University of Toronto; Ontario Institute for Cancer Research","funders":"","keywords":"Medicine; Myelofibrosis; Natural history; Myeloproliferative neoplasm; Internal medicine; Essential thrombocythemia; Cohort; Red Cell; Gastroenterology; Polycythemia vera; Bone marrow","score_opus":0.03439543966203235,"score_gpt":0.2862136202716494,"score_spread":0.2518181806096171,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2979544688","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9943953,0.00048460352,0.000014978654,0.00030089988,0.0001283042,0.0007928373,0.00011771138,0.00001295714,0.0037523739],"genre_scores_gemma":[0.99943674,0.00019413292,0.00009777138,0.000041714615,0.000023921119,0.00006184342,0.000031106178,0.000021817295,0.000090985755],"study_design_codex":"observational","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.997806,0.00037777878,0.00073437387,0.000261556,0.00059802807,0.00022227403],"domain_scores_gemma":[0.997261,0.001054951,0.0007337312,0.0005026576,0.00037154258,0.0000761155],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00023354944,0.00028804792,0.0009076804,0.0001035847,0.00008597497,0.0000034917066,0.00020097286,0.00011359881,0.00010748756],"category_scores_gemma":[0.00029218633,0.00014547756,0.00051997055,0.00021483829,0.00026963386,0.00003643011,0.000045834087,0.00031807477,0.0000018846562],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00047294248,0.010599369,0.72753894,0.00016854335,0.000840577,0.0000012654609,0.00437685,0.00012168705,0.25225177,0.0026248319,0.0006394918,0.0003637229],"study_design_scores_gemma":[0.0041144397,0.0019926904,0.4723712,0.00047747922,0.0005648846,0.0000037046832,0.00013103311,0.00036659784,0.51968706,0.00018816836,0.0000071180716,0.00009563665],"about_ca_topic_score_codex":0.0004519926,"about_ca_topic_score_gemma":0.00028323202,"teacher_disagreement_score":0.26743525,"about_ca_system_score_codex":0.00021453461,"about_ca_system_score_gemma":0.0002707782,"threshold_uncertainty_score":0.5932403},"labels":[],"label_agreement":null},{"id":"W2979748361","doi":"10.1182/blood.v126.23.825.825","title":"Phase 1b/2 Study of the Efficacy and Safety of Sonidegib (LDE225) in Combination with Ruxolitinib (INC424) in Patients with Myelofibrosis","year":2015,"lang":"en","type":"article","venue":"Blood","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":32,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Ruxolitinib; Medicine; Myelofibrosis; Internal medicine; Phases of clinical research; Janus kinase inhibitor; Oncology; Gastroenterology; Surgery; Bone marrow; Toxicity; Janus kinase","score_opus":0.015993639499208036,"score_gpt":0.26365822068121864,"score_spread":0.2476645811820106,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2979748361","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99784017,0.000040713097,0.0000011686935,0.00010615954,0.000012956371,0.0016893725,0.000013283234,0.0000043939244,0.00029180877],"genre_scores_gemma":[0.9997254,0.000006258189,0.00013497252,0.000019796105,0.00000602506,0.00006620063,0.000013399963,0.0000119400775,0.000015997193],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9989459,0.00009392488,0.0002960598,0.00019152496,0.00034538252,0.00012719042],"domain_scores_gemma":[0.9993119,0.00009078386,0.00015143043,0.00021680769,0.00016127029,0.00006776229],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00015571162,0.00013023076,0.00035713345,0.000092489325,0.000022007274,0.000004999331,0.000045932047,0.0000336702,0.0000050992626],"category_scores_gemma":[0.00006862856,0.00007176452,0.000014797199,0.00027522532,0.00006475811,0.00005063017,0.000031467185,0.00008297189,5.536817e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0022707405,0.060815,0.9328652,0.00003608256,0.00009818403,0.000006832717,0.0027404695,0.0000060777134,0.0000184069,0.00008146521,0.00000575892,0.0010557822],"study_design_scores_gemma":[0.16279908,0.013644072,0.81996286,0.00031155444,0.00017342578,0.0000019366644,0.00052259094,0.0000070410388,0.0025012852,0.00000890549,0.0000073459933,0.00005989453],"about_ca_topic_score_codex":0.00023789583,"about_ca_topic_score_gemma":0.00058372144,"teacher_disagreement_score":0.16052833,"about_ca_system_score_codex":0.0000368287,"about_ca_system_score_gemma":0.00008667582,"threshold_uncertainty_score":0.29264724},"labels":[],"label_agreement":null},{"id":"W2979946483","doi":"10.1182/blood.v118.21.3842.3842","title":"Associations Between Improvements in Myelofibrosis (MF) Symptoms and Quality of Life Measures with Splenomegaly Reduction in COMFORT-I: A Randomized, Double-Blind, Phase III Trial of the JAK1 and JAK2 Inhibitor Ruxolitinib Versus Placebo in Patients with MF,","year":2011,"lang":"en","type":"article","venue":"Blood","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Ruxolitinib; Medicine; Myelofibrosis; Placebo; Quality of life (healthcare); Internal medicine; Clinical trial; Bone pain; Phases of clinical research; Randomized controlled trial; Anemia; Adverse effect; Surgery; Gastroenterology; Physical therapy; Bone marrow; Pathology","score_opus":0.05957677631218394,"score_gpt":0.2992773968094112,"score_spread":0.23970062049722723,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2979946483","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9947931,0.000066836124,0.00000176765,0.000057832334,0.00005348384,0.004693986,0.00013374344,0.000006390474,0.0001928179],"genre_scores_gemma":[0.9992601,0.000032061434,0.00013091647,0.0000091051315,0.00004302898,0.00043064688,0.00007109361,0.00001541609,0.000007584171],"study_design_codex":"observational","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9978796,0.0002810146,0.0008951205,0.00030238804,0.00043497948,0.00020685601],"domain_scores_gemma":[0.99868315,0.00029761525,0.00058353395,0.00020572243,0.00013398519,0.00009597077],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008867004,0.00020883094,0.0010635926,0.0002100936,0.000045398207,0.000009368427,0.00005188047,0.000107033484,0.0000056998106],"category_scores_gemma":[0.0002011548,0.00012982069,0.00006399635,0.00030480215,0.00018375345,0.0001188302,0.00003868226,0.00016407884,1.2034718e-7],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.47431988,0.0030653104,0.5205025,0.000034086206,0.00037525978,4.1570127e-7,0.001359996,6.182031e-7,0.00003296889,0.00006225686,6.654855e-7,0.00024607437],"study_design_scores_gemma":[0.62432796,0.0021944817,0.36963582,0.00017264298,0.00036587406,1.7216601e-7,0.00014856648,0.0000013530946,0.003061371,0.000010043789,5.222996e-7,0.00008118638],"about_ca_topic_score_codex":0.0027690595,"about_ca_topic_score_gemma":0.0014663719,"teacher_disagreement_score":0.15086667,"about_ca_system_score_codex":0.00008789648,"about_ca_system_score_gemma":0.00017768661,"threshold_uncertainty_score":0.5293934},"labels":[],"label_agreement":null},{"id":"W2980063723","doi":"10.1182/blood.v122.21.394.394","title":"Phase 3 Study Of Pomalidomide In Myeloproliferative Neoplasm (MPN)-Associated Myelofibrosis With RBC-Transfusion-Dependence","year":2013,"lang":"en","type":"article","venue":"Blood","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":27,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Pomalidomide; Myelofibrosis; Medicine; Internal medicine; Randomization; Placebo; Anemia; Gastroenterology; Clinical endpoint; Surgery; Randomized controlled trial; Bone marrow; Thalidomide; Pathology; Multiple myeloma","score_opus":0.013092591579987867,"score_gpt":0.26569894429509877,"score_spread":0.2526063527151109,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2980063723","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99416375,0.00012304887,0.000012831495,0.00042255703,0.00004448343,0.0036199219,0.00002986558,0.00006619193,0.001517365],"genre_scores_gemma":[0.99762684,0.000105930536,0.00060980173,0.0001480665,0.00004089202,0.001127275,0.000033614033,0.000048036083,0.00025954715],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9973575,0.0001948791,0.0006839827,0.0006235763,0.00066858943,0.00047149512],"domain_scores_gemma":[0.9984127,0.00027258616,0.00023030097,0.00043245978,0.0004074864,0.0002444622],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00021456151,0.000415994,0.0009402619,0.000268662,0.00011623338,0.000040705036,0.00013541512,0.00014574028,0.00036813648],"category_scores_gemma":[0.00014226497,0.0002968146,0.00010107122,0.0006617135,0.00008810037,0.00022631498,0.000046722085,0.0002934906,0.000058360496],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0007533629,0.05650052,0.92170817,0.00005384875,0.00095303264,0.00035845255,0.006062254,0.000016287404,0.011837852,0.000058391677,0.000075796306,0.0016220611],"study_design_scores_gemma":[0.09481891,0.018954374,0.78230435,0.0005540472,0.0008216533,0.00009739581,0.0037771608,0.00010791726,0.09804198,0.00006838465,0.000019008352,0.00043480808],"about_ca_topic_score_codex":0.002280661,"about_ca_topic_score_gemma":0.002444409,"teacher_disagreement_score":0.13940379,"about_ca_system_score_codex":0.00009605852,"about_ca_system_score_gemma":0.00021988826,"threshold_uncertainty_score":0.9999484},"labels":[],"label_agreement":null},{"id":"W2980301706","doi":"10.1182/blood.v120.21.800.800","title":"Long-Term Outcome of Ruxolitinib Treatment in Patients with Myelofibrosis: Durable Reductions in Spleen Volume, Improvements in Quality of Life, and Overall Survival Advantage in COMFORT-I","year":2012,"lang":"en","type":"article","venue":"Blood","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":34,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Ruxolitinib; Medicine; Myelofibrosis; Clinical endpoint; Internal medicine; Placebo; Randomized controlled trial; Quality of life (healthcare); Intention-to-treat analysis; Anemia; Surgery; Gastroenterology; Bone marrow; Pathology","score_opus":0.027013929775404608,"score_gpt":0.3025728459730689,"score_spread":0.27555891619766426,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2980301706","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9979569,0.00023302561,5.768699e-7,0.00006634736,0.000049817845,0.0013364935,0.0001232172,0.00000635798,0.00022728133],"genre_scores_gemma":[0.99915695,0.00011758656,0.000249721,0.000023383504,0.000018001156,0.00021488359,0.00011644664,0.00001893682,0.000084116655],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9980261,0.000127306,0.00091505033,0.00028433377,0.0002698783,0.0003773734],"domain_scores_gemma":[0.9992254,0.00008450841,0.00024184534,0.00026255695,0.000047408415,0.0001382757],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00029419726,0.00023276554,0.00083641073,0.000286574,0.000016432263,0.0000055283576,0.000045648994,0.00008244159,0.00003585256],"category_scores_gemma":[0.000062811974,0.00018180399,0.000051844563,0.00024162067,0.000061006715,0.00018754587,0.00003904055,0.000114940405,0.0000011470191],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00069694413,0.014995264,0.9824652,0.00023373627,0.00011077192,0.00000842651,0.0007403437,0.0000042243105,0.0002252633,0.000094379,0.0000011085885,0.0004243589],"study_design_scores_gemma":[0.030257829,0.0012320774,0.96588236,0.00027583673,0.0000704957,0.0000011192755,0.00021890562,0.0000026153718,0.0019083184,0.0000074634895,0.0000035162852,0.00013948213],"about_ca_topic_score_codex":0.0035572539,"about_ca_topic_score_gemma":0.00523507,"teacher_disagreement_score":0.029560883,"about_ca_system_score_codex":0.00018145621,"about_ca_system_score_gemma":0.000074037765,"threshold_uncertainty_score":0.7413752},"labels":[],"label_agreement":null},{"id":"W2980580253","doi":"","title":"Plasma levels of H- and L-ficolin are increased in axial spondyloarthritis: Potential improvement of early disease identification","year":2018,"lang":"en","type":"article","venue":"The Journal of Rheumatology","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Medicine; Axial spondyloarthritis; Identification (biology); Disease; Internal medicine; Gastroenterology","score_opus":0.014722561866853326,"score_gpt":0.26842138062124177,"score_spread":0.25369881875438843,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2980580253","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9982017,0.00045417313,0.000079617676,0.0007941407,0.00013804133,0.00027691183,0.000041737625,0.000002318224,0.000011315524],"genre_scores_gemma":[0.9993416,0.0004885549,0.00009206378,0.000030133626,0.000020654805,0.0000063141642,0.0000021590322,0.000008479701,0.000010045827],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99863964,0.00014328545,0.000758332,0.00009738949,0.00022874837,0.00013260446],"domain_scores_gemma":[0.9984754,0.0001531916,0.00078461703,0.00016051822,0.00032055474,0.00010576239],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005093247,0.000105710154,0.000482238,0.00018078367,0.000039928167,0.000005404837,0.00008635024,0.000055967845,0.000086334534],"category_scores_gemma":[0.00022077197,0.00007040216,0.00006971403,0.000099215395,0.00027124552,0.000066406355,0.000033785847,0.00011847123,0.0000027008844],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0055051045,0.0007108259,0.9614701,0.00015012288,0.00022714978,0.0000550716,0.0010251857,0.000007633663,0.02462072,0.00046576883,0.00008589833,0.00567641],"study_design_scores_gemma":[0.005514999,0.0017041799,0.96614105,0.00050518854,0.00019884763,0.0006313916,0.00030173082,0.00016112605,0.024337087,0.00043087514,0.000015576725,0.000057958594],"about_ca_topic_score_codex":0.0002446955,"about_ca_topic_score_gemma":0.00018667565,"teacher_disagreement_score":0.0056184516,"about_ca_system_score_codex":0.000030432882,"about_ca_system_score_gemma":0.00014558452,"threshold_uncertainty_score":0.28709167},"labels":[],"label_agreement":null},{"id":"W2980607362","doi":"10.1182/blood.v118.21.1260.1260","title":"The Influence of Bleeding on Trigger Changes for Platelet Transfusion in Chemotherapy-Induced Thrombocytopenic Patients","year":2011,"lang":"en","type":"article","venue":"Blood","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre hospitalier universitaire de Québec; Centre Hospitalier de l’Université de Montréal","funders":"","keywords":"Medicine; Platelet transfusion; Platelet; Internal medicine; Transfusion medicine; Hematology; Chemotherapy; Population; Blood transfusion; Surgery","score_opus":0.035938626489297174,"score_gpt":0.27078325994329205,"score_spread":0.23484463345399487,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2980607362","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99769694,0.000071119095,5.8583333e-7,0.00034412585,0.00003952907,0.0012679154,0.000007992464,0.0000103945285,0.0005613737],"genre_scores_gemma":[0.9986229,0.00076223584,0.000092559996,0.00020364815,0.000026426154,0.00024941063,0.0000056844997,0.000015590138,0.000021566919],"study_design_codex":"observational","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99927646,0.000018966226,0.00019564814,0.00017911186,0.00015264913,0.00017717511],"domain_scores_gemma":[0.9995076,0.00014406085,0.00007398417,0.00015550437,0.00007785294,0.00004099792],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00013360266,0.00012255834,0.00025780877,0.00005991772,0.00006529478,0.0000051018706,0.00006540344,0.00006394387,0.000024889008],"category_scores_gemma":[0.000044843287,0.0000725705,0.00005738535,0.000102198544,0.000023743161,0.000031439635,0.000007742553,0.0000732655,0.0000033923998],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0047333688,0.013841467,0.8072362,0.0002774766,0.00080950605,0.000024895458,0.016283054,0.0000036347756,0.08944622,0.0015970126,0.000102299746,0.06564487],"study_design_scores_gemma":[0.009931811,0.0025052675,0.49167392,0.00017894902,0.000059562368,0.0000015261644,0.00005857566,0.0000029701666,0.49524972,0.000051068087,0.00022261335,0.00006403422],"about_ca_topic_score_codex":0.00005988433,"about_ca_topic_score_gemma":0.0001157386,"teacher_disagreement_score":0.4058035,"about_ca_system_score_codex":0.00002332525,"about_ca_system_score_gemma":0.000028522098,"threshold_uncertainty_score":0.29593393},"labels":[],"label_agreement":null},{"id":"W2980652520","doi":"10.1016/j.thromres.2019.09.016","title":"P6. Abstract Title: Risks and Benefits of Antithrombotic Therapy in Polycythemia Vera: A Systematic Review","year":2019,"lang":"en","type":"review","venue":"Thrombosis Research","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University","funders":"","keywords":"Medicine; Antithrombotic; Polycythemia vera; Observational study; Aspirin; Randomized controlled trial; Thrombocytosis; Context (archaeology); Phlebotomy; Intensive care medicine; Systematic review; Internal medicine; Cochrane Library; MEDLINE","score_opus":0.4772274457903885,"score_gpt":0.5181349147482093,"score_spread":0.04090746895782077,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2980652520","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00045496083,0.9892875,7.160258e-8,0.00009828828,0.000050127728,0.0047529764,0.000045266886,0.000011394732,0.0052994415],"genre_scores_gemma":[0.0013008144,0.9976794,0.000028789616,0.00003684075,0.000044713903,0.00041688437,0.00005081664,0.00005641142,0.00038533332],"study_design_codex":"systematic_review","study_design_gemma":"systematic_review","domain_scores_codex":[0.99739856,0.00033363936,0.0007799755,0.0004328314,0.00070449046,0.0003505284],"domain_scores_gemma":[0.99800724,0.0007990731,0.00023388829,0.0006720855,0.00017829314,0.00010942625],"candidate_categories":["insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.0012284926,0.00032405966,0.0035558739,0.00038804716,0.00003882457,0.000023368057,0.00017908213,0.00023225155,0.0009675845],"category_scores_gemma":[0.00028568655,0.00020337861,0.000271712,0.00057658425,0.00011328516,0.00003644839,0.00008241286,0.000618304,0.00085484225],"study_design_candidate":"systematic_review","study_design_consensus":"systematic_review","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000005859909,0.0003153391,0.0002438754,0.93376046,0.00056593,0.000012043654,0.00004124303,4.4127667e-8,0.0000014720114,0.00018621355,0.0016919287,0.0631756],"study_design_scores_gemma":[0.0005763048,0.00048199025,0.0029732033,0.9696471,0.0011295187,0.00003784292,0.000011264369,0.0000015802144,0.000019625028,0.0000115978055,0.024893101,0.0002168662],"about_ca_topic_score_codex":0.00010065042,"about_ca_topic_score_gemma":0.0000074231452,"teacher_disagreement_score":0.06295873,"about_ca_system_score_codex":0.00018590924,"about_ca_system_score_gemma":0.00039087696,"threshold_uncertainty_score":0.99994564},"labels":[],"label_agreement":null},{"id":"W2980775163","doi":"10.1016/j.jalz.2019.06.2835","title":"P2‐428: MYELOPROLIFERATIVE CONDITIONS IN OLDER ADULTS WITH MAJOR NEUROCOGNITIVE DISORDERS: IS THERE AN ASSOCIATION?","year":2019,"lang":"en","type":"article","venue":"Alzheimer s & Dementia","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Red Deer Regional Hospital; Alberta Health Services","funders":"","keywords":"Neurocognitive; Dementia; Medicine; Cognition; Psychiatry; Thrombocytosis; Pediatrics; Internal medicine; Disease; Platelet","score_opus":0.009570229557451512,"score_gpt":0.26523882037089225,"score_spread":0.25566859081344073,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2980775163","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98399615,0.004415041,0.000010134151,0.0027456528,0.000121885794,0.002932673,0.00012833276,0.00006649713,0.005583618],"genre_scores_gemma":[0.9955528,0.0001657993,0.0003731821,0.0024454421,0.00007472523,0.00081754895,0.0003490667,0.000056060966,0.00016537201],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99789214,0.00014418931,0.00037410742,0.00066616246,0.0004653518,0.0004580304],"domain_scores_gemma":[0.99883366,0.00015527116,0.00021141338,0.0003341193,0.00028635006,0.0001792073],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00013034108,0.00036197004,0.0004683701,0.00015187085,0.00014016265,0.00006237262,0.000095691066,0.0001310974,0.003493849],"category_scores_gemma":[0.000021649119,0.0002829007,0.00009976865,0.00031089265,0.000047957823,0.00038010592,0.00003901042,0.00026820478,0.0006658921],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00031693597,0.0016220332,0.9830772,0.000014496754,0.007322873,0.000037401664,0.0035641878,0.000002974457,0.000035651025,0.00029168715,0.0011582555,0.0025562586],"study_design_scores_gemma":[0.009002618,0.0013913874,0.97520006,0.0002370739,0.005815411,0.000009185555,0.0016284421,0.00013922376,0.005021449,0.00014547499,0.001053086,0.00035659928],"about_ca_topic_score_codex":0.000244265,"about_ca_topic_score_gemma":0.0013807309,"teacher_disagreement_score":0.011556637,"about_ca_system_score_codex":0.000043027,"about_ca_system_score_gemma":0.0001464565,"threshold_uncertainty_score":0.99996233},"labels":[],"label_agreement":null},{"id":"W2981049338","doi":"","title":"Polycythaemia Vera Presenting As A Porta Hepatis Mass.","year":2020,"lang":"en","type":"article","venue":"PubMed","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hospital for Sick Children","funders":"","keywords":"Medicine; Polycythaemia; Portal vein thrombosis; Polycythemia vera; Porta hepatis; Surgery; Pancytopenia; Thrombocytosis; Phlebotomy; Thrombosis; Gastroenterology; Internal medicine; Bone marrow; Platelet","score_opus":0.03752451368725193,"score_gpt":0.24759704665423127,"score_spread":0.21007253296697934,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2981049338","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9356392,0.00045828446,0.000025756455,0.022570156,0.00014778227,0.0014960765,0.000016341572,0.00013669475,0.0395097],"genre_scores_gemma":[0.99161434,0.00010330313,0.00039709097,0.0040558213,0.0003978385,0.0017877505,0.00004304122,0.000028906292,0.0015718767],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9986631,0.000030524257,0.00024631812,0.00035065936,0.00031644898,0.00039294074],"domain_scores_gemma":[0.9991489,0.000068461355,0.000079398385,0.00019235405,0.000049825063,0.0004610541],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000079918136,0.00017142671,0.00031690672,0.000041429736,0.00006831082,0.000038033486,0.00006642421,0.00006510649,0.00036991987],"category_scores_gemma":[0.00034770972,0.00013975389,0.00011200563,0.0001779991,0.000028635237,0.00007574319,0.00004333408,0.00015077121,0.0001861313],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0001725963,0.00016386507,0.93287045,0.000071454095,0.00030974502,0.0011020829,0.00041729992,0.0000020540947,0.000112306385,0.00049616705,0.012114917,0.052167088],"study_design_scores_gemma":[0.0019484428,0.00012918407,0.95129764,0.000018153203,0.00017958193,0.000054585387,0.000052751788,0.00013822003,0.014862298,0.000117621865,0.031031858,0.00016967367],"about_ca_topic_score_codex":0.00010062768,"about_ca_topic_score_gemma":0.000007270376,"teacher_disagreement_score":0.05597516,"about_ca_system_score_codex":0.00006481037,"about_ca_system_score_gemma":0.000055738597,"threshold_uncertainty_score":0.56989986},"labels":[],"label_agreement":null},{"id":"W2981172339","doi":"10.1182/blood-2018-99-111592","title":"Outcomes of Patients with Low Variant Allele Fraction JAK2V617F: A 5-Year Retrospective Analysis","year":2018,"lang":"en","type":"article","venue":"Blood","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; St. Paul's Hospital; Canada's Michael Smith Genome Sciences Centre; BC Cancer Agency; Leukemia & Lymphoma Society of Canada","funders":"","keywords":"Medicine; Internal medicine; Cumulative incidence; Population; Gastroenterology; Incidence (geometry); Retrospective cohort study; Cohort","score_opus":0.005193319382316779,"score_gpt":0.2368822388728625,"score_spread":0.2316889194905457,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2981172339","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99688756,0.000012746601,0.00021928253,0.0001409015,0.0000271848,0.0003536282,0.000047645073,0.000023019425,0.0022880298],"genre_scores_gemma":[0.99757206,0.000011564667,0.0019624291,0.000100296544,0.00006457989,0.000037509908,0.00008331492,0.000013874419,0.00015438325],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99901545,0.00002713934,0.00019928775,0.00026692462,0.00034113627,0.00015006795],"domain_scores_gemma":[0.999043,0.00003980847,0.00014498299,0.00028456526,0.00040572204,0.00008193662],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00006338809,0.00014145674,0.00047796222,0.00014830139,0.000060225662,0.0000092616565,0.000036316207,0.000056348956,0.00057462306],"category_scores_gemma":[0.00006688111,0.000090499736,0.00012334572,0.00040573152,0.000060168535,0.0000568179,0.000016899474,0.00007179274,0.000039418916],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0001835504,0.0034030385,0.9911266,0.000011174934,0.0046595205,0.000014360118,0.0001776466,9.0461975e-7,0.000028750215,0.00018703518,0.000102745005,0.00010466777],"study_design_scores_gemma":[0.0056203525,0.0019164172,0.9837092,0.000020516876,0.0032929666,0.0000016010351,0.000038108734,0.000017881679,0.005173472,0.00003183023,0.00008961212,0.000087996385],"about_ca_topic_score_codex":0.000094894465,"about_ca_topic_score_gemma":0.00014184859,"teacher_disagreement_score":0.0074173617,"about_ca_system_score_codex":0.000052261108,"about_ca_system_score_gemma":0.00004151406,"threshold_uncertainty_score":0.6291719},"labels":[],"label_agreement":null},{"id":"W2983883026","doi":"10.1182/blood-2019-122919","title":"Systematic Literature Review of the Economic Burden and Cost of Illness in Patients with Myelofibrosis","year":2019,"lang":"en","type":"article","venue":"Blood","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Myelofibrosis; MEDLINE; Systematic review; EconLit; Family medicine; Internal medicine; Bone marrow","score_opus":0.0033529788702524902,"score_gpt":0.20625138231941714,"score_spread":0.20289840344916465,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2983883026","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.982535,0.014765182,8.659694e-8,0.00013492895,0.000026917765,0.002115173,0.000033920413,0.0000016987966,0.00038709794],"genre_scores_gemma":[0.99550664,0.0041821683,0.00003978724,0.0000764666,0.000009822636,0.000087798035,0.000011998064,0.000007692698,0.00007761649],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99936974,0.000049945713,0.00027446836,0.0001232782,0.000113241265,0.00006933654],"domain_scores_gemma":[0.99942005,0.000062969906,0.00017083946,0.00025372973,0.000065791544,0.00002664124],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000088830406,0.00009385189,0.00049652276,0.0000328561,0.000009866222,0.0000045476563,0.00004297479,0.00003124022,0.00003810635],"category_scores_gemma":[0.000028343089,0.000046105393,0.000042600313,0.00008911804,0.000022418191,0.00003084478,0.000022539985,0.000046818346,0.000005700516],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0000362541,0.00019437283,0.881827,0.117143534,0.00014650391,0.0000013041789,0.00035396105,0.0000011989328,0.00002382483,0.00011800417,0.00001834821,0.00013571649],"study_design_scores_gemma":[0.0051244805,0.00045541683,0.6483331,0.34276986,0.00045801594,0.00000960839,0.00003783382,0.0000048964403,0.0026966033,0.0000029436944,0.000033214954,0.000074069925],"about_ca_topic_score_codex":0.000014180322,"about_ca_topic_score_gemma":0.000009955302,"teacher_disagreement_score":0.23349391,"about_ca_system_score_codex":0.000023564438,"about_ca_system_score_gemma":0.000036851357,"threshold_uncertainty_score":0.18801235},"labels":[],"label_agreement":null},{"id":"W2984908450","doi":"10.1182/blood-2019-125183","title":"Factors Associated with Health Care Resource Utilization in Myeloproliferative Neoplasms: A Population-Based Cost Study","year":2019,"lang":"en","type":"article","venue":"Blood","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Health Sciences Centre; Institute for Clinical Evaluative Sciences; Sunnybrook Health Science Centre; Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Population; Polycythemia vera; Disease burden; Essential thrombocythemia; Health care; Cohort; Myelofibrosis; Internal medicine; Pediatrics; Environmental health; Bone marrow","score_opus":0.045304747024475865,"score_gpt":0.30745085778094183,"score_spread":0.262146110756466,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2984908450","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9944534,0.00023579599,0.0000083245695,0.00034279632,0.000036063746,0.0043845247,0.000060752333,0.00008632983,0.00039202315],"genre_scores_gemma":[0.9976434,0.0000035538396,0.000057201596,0.00047431112,0.000024095061,0.0002825529,0.0013803908,0.000043951753,0.000090561494],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9979997,0.00025780802,0.00040322513,0.00050448824,0.00048807435,0.00034669615],"domain_scores_gemma":[0.99888057,0.00025104106,0.00021592923,0.000308347,0.00017861165,0.00016548287],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00016592567,0.00030947055,0.00063590135,0.00022648877,0.0001266215,0.00003574825,0.00005897317,0.00009487549,0.00009222307],"category_scores_gemma":[0.0001415197,0.0002208748,0.00006018633,0.00054077426,0.000017190972,0.00007386431,0.00001652993,0.00020315137,0.00001204214],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0001661771,0.0037665055,0.9884237,0.000047930047,0.0002142805,0.000022066906,0.0067511313,0.0002603594,0.0000037366003,0.000040948144,0.000027245536,0.00027592733],"study_design_scores_gemma":[0.015302537,0.0036172075,0.9728539,0.00035065293,0.00014813835,0.0000014533696,0.0065584,0.00018411854,0.0007112857,0.0000016828237,0.000073050636,0.00019756949],"about_ca_topic_score_codex":0.00038901813,"about_ca_topic_score_gemma":0.005152651,"teacher_disagreement_score":0.015569788,"about_ca_system_score_codex":0.00044646012,"about_ca_system_score_gemma":0.00043232224,"threshold_uncertainty_score":0.90070134},"labels":[],"label_agreement":null},{"id":"W2985271579","doi":"10.1182/blood-2019-124739","title":"Baseline Mutational Status of Patients with Myelofibrosis and Anemia in the Realise Trial and Impact on Outcome","year":2019,"lang":"en","type":"article","venue":"Blood","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"St. Paul's Hospital; University of British Columbia","funders":"","keywords":"Myelofibrosis; Medicine; Ruxolitinib; Internal medicine; Clinical endpoint; Anemia; Essential thrombocythemia; Surrogate endpoint; Polycythemia vera; Adverse effect; Gastroenterology; Thrombocytosis; Clinical trial; Bone marrow; Platelet","score_opus":0.012504991271558307,"score_gpt":0.28133805204773327,"score_spread":0.26883306077617497,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2985271579","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9984276,0.00007499808,4.7680734e-7,0.00016279821,0.000013973606,0.00090213626,0.00015904316,0.000003526766,0.00025543247],"genre_scores_gemma":[0.9994021,0.000048414255,0.00017670174,0.00014881954,0.000023216826,0.000035275854,0.00014419614,0.0000073223805,0.000013941761],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9992592,0.00005587441,0.00017853241,0.00015065323,0.00022888882,0.00012686595],"domain_scores_gemma":[0.9993915,0.00030605675,0.00006768068,0.00012157586,0.000048311627,0.000064853055],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00012778952,0.000106427025,0.00023109774,0.000058634334,0.000017681748,0.000009488372,0.00001733833,0.00003119525,0.00005558026],"category_scores_gemma":[0.0000690431,0.00005082178,0.000025245463,0.00007626211,0.000028292861,0.000031601263,0.000007990983,0.00006305028,0.0000020358411],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00888962,0.0013939537,0.98832977,0.00003562882,0.000054023112,0.000008796155,0.00031101366,0.0000040406358,0.00001690532,0.00007478942,0.000035893732,0.0008455901],"study_design_scores_gemma":[0.07414079,0.0045678173,0.92068404,0.000054770735,0.00012304798,0.000004211801,0.000053333682,0.000011140098,0.00027437008,0.00001012712,0.00002745564,0.000048877304],"about_ca_topic_score_codex":0.00012385624,"about_ca_topic_score_gemma":0.000022841863,"teacher_disagreement_score":0.067645684,"about_ca_system_score_codex":0.000016979853,"about_ca_system_score_gemma":0.000045328838,"threshold_uncertainty_score":0.20724522},"labels":[],"label_agreement":null},{"id":"W2986040087","doi":"10.1182/blood-2019-128211","title":"Preliminary Report of MANIFEST, a Phase 2 Study of CPI-0610, a Bromodomain and Extraterminal Domain Inhibitor (BETi), in Combination with Ruxolitinib, in JAK Inhibitor (JAKi) Treatment Naïve Myelofibrosis Patients","year":2019,"lang":"en","type":"article","venue":"Blood","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":25,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; McMaster University","funders":"","keywords":"Ruxolitinib; Medicine; Myelofibrosis; Tofacitinib; Myeloproliferative neoplasm; Janus kinase; Internal medicine; Venetoclax; Cancer research; Bone marrow; Leukemia; Cytokine","score_opus":0.010544082203607513,"score_gpt":0.2641798675588689,"score_spread":0.2536357853552614,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2986040087","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99540496,0.00011591699,0.0000010416838,0.00006804897,0.000047405432,0.0039386805,0.000051132636,0.0000141812525,0.00035860526],"genre_scores_gemma":[0.99856246,0.000024744615,0.0006293883,0.0000115533785,0.000029563436,0.0005046193,0.00012362475,0.000033843164,0.00008019092],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9975337,0.00017310442,0.0009238015,0.0005857327,0.0004907899,0.00029291608],"domain_scores_gemma":[0.99875253,0.00015123718,0.0004293268,0.00038711645,0.00015190018,0.00012789493],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00025033078,0.00034424633,0.0008679253,0.00035995652,0.00003144076,0.000013546958,0.0000529463,0.00011210616,0.000027786324],"category_scores_gemma":[0.000035966048,0.0002611286,0.00006608662,0.0003037246,0.00007315599,0.00013317945,0.000049694812,0.000116749805,0.0000026486032],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.003296133,0.07362337,0.9123667,0.00025752213,0.0002045947,0.0015331273,0.0047348114,0.0000020808109,0.0027698134,0.00004153614,0.000008674765,0.0011616444],"study_design_scores_gemma":[0.091901995,0.06404431,0.80715936,0.0009288018,0.00031779727,0.00028792766,0.0019268773,0.00001829233,0.03315871,0.00003575583,0.000014116412,0.00020605295],"about_ca_topic_score_codex":0.00043158248,"about_ca_topic_score_gemma":0.00023035001,"teacher_disagreement_score":0.10520733,"about_ca_system_score_codex":0.00015140214,"about_ca_system_score_gemma":0.00014650082,"threshold_uncertainty_score":0.9999841},"labels":[],"label_agreement":null},{"id":"W2986211227","doi":"10.1182/blood-2019-127119","title":"MANIFEST, a Phase 2 Study of CPI-0610, a Bromodomain and Extraterminal Domain Inhibitor (BETi), As Monotherapy or \"Add-on\" to Ruxolitinib, in Patients with Refractory or Intolerant Advanced Myelofibrosis","year":2019,"lang":"en","type":"article","venue":"Blood","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":45,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Jewish General Hospital; McMaster University; Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Ruxolitinib; Myelofibrosis; Bromodomain; Medicine; Internal medicine; Refractory (planetary science); Phases of clinical research; Oncology; Pharmacology; Clinical trial; Chemistry; Biology; Biochemistry","score_opus":0.010333862447035776,"score_gpt":0.2845839353661351,"score_spread":0.2742500729190993,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2986211227","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9954991,0.000044523433,0.000002311204,0.000097656346,0.00004965756,0.003959441,0.00005973891,0.000022473658,0.00026509474],"genre_scores_gemma":[0.997115,0.000024097404,0.0015573443,0.00033556295,0.000052757994,0.00051645,0.000021781354,0.000055191656,0.0003218155],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9977884,0.00013542883,0.0005438631,0.0006584668,0.00050552114,0.0003682794],"domain_scores_gemma":[0.99879485,0.00019965137,0.00018393104,0.00044783432,0.00011174035,0.00026198226],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00015021654,0.00039204932,0.0007978619,0.000254909,0.000053392094,0.000026744043,0.00008816874,0.000089883135,0.00038419597],"category_scores_gemma":[0.000039476083,0.00023854099,0.00004818754,0.00028566943,0.000043814773,0.00011504778,0.000039239974,0.00016872684,0.000036055942],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.06468765,0.05450607,0.85729444,0.00019303718,0.00042276643,0.0007742458,0.0071181534,0.000004831001,0.0053516477,0.00003766789,0.00004664872,0.009562864],"study_design_scores_gemma":[0.14988129,0.12781216,0.70292574,0.0011554604,0.00019514619,0.000059199607,0.0018650158,0.000003952822,0.0152914915,0.000016615168,0.00039114055,0.00040276075],"about_ca_topic_score_codex":0.00011200325,"about_ca_topic_score_gemma":0.000338889,"teacher_disagreement_score":0.15436865,"about_ca_system_score_codex":0.00008156541,"about_ca_system_score_gemma":0.00015242488,"threshold_uncertainty_score":0.9727419},"labels":[],"label_agreement":null},{"id":"W2986606277","doi":"10.1182/blood-2019-124186","title":"Megakaryocyte-Driven Myelofibrosis Leads to Progressive Osteosclerosis in G6b-B Knockout Mice","year":2019,"lang":"en","type":"article","venue":"Blood","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University","funders":"","keywords":"Osteosclerosis; Bone marrow; Myelofibrosis; Megakaryocyte; Medicine; Extramedullary hematopoiesis; Haematopoiesis; Internal medicine; Conditional gene knockout; Endocrinology; Knockout mouse; Pathology; Biology; Receptor; Stem cell; Phenotype","score_opus":0.011696817313044448,"score_gpt":0.2583691168683439,"score_spread":0.24667229955529946,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2986606277","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9908953,0.0006412425,0.000001685765,0.0020947203,0.00013086974,0.0020210738,0.00003161604,0.0000830556,0.0041004806],"genre_scores_gemma":[0.99447566,0.000077952674,0.0027285337,0.0009884705,0.00013666632,0.0005898159,0.000046092995,0.000053656106,0.00090315606],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9980104,0.00006785809,0.00039537007,0.0006325516,0.00039052198,0.0005032958],"domain_scores_gemma":[0.99891865,0.00012582199,0.00009803054,0.00043612186,0.00012614834,0.00029522963],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00010318311,0.00032576386,0.00062522513,0.0002349454,0.000057051646,0.000040855146,0.0001407091,0.000147726,0.00048015555],"category_scores_gemma":[0.00007484746,0.00026751513,0.00015314946,0.00044579525,0.000043311327,0.0001063082,0.00010971631,0.0001991626,0.001509159],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0003030069,0.0022286547,0.92443585,0.00012080509,0.00020412866,0.00013174601,0.0011752989,0.000013611618,0.06867649,0.00017890101,0.00062892825,0.0019026046],"study_design_scores_gemma":[0.008618957,0.0026131582,0.63745403,0.0007739043,0.00028943268,0.00005443463,0.00019442526,0.00002556507,0.34802082,0.000008843535,0.0016161101,0.0003303305],"about_ca_topic_score_codex":0.000083051214,"about_ca_topic_score_gemma":0.000086910055,"teacher_disagreement_score":0.28698182,"about_ca_system_score_codex":0.00012281316,"about_ca_system_score_gemma":0.0001235063,"threshold_uncertainty_score":0.9999777},"labels":[],"label_agreement":null},{"id":"W2988198068","doi":"10.1182/blood-2019-130923","title":"HSCs Fated to Progress to Blast Phase Can be Detected in Myelofibrosis Patients Several Years Prior to Leukemic Transformation","year":2019,"lang":"en","type":"article","venue":"Blood","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Sunnybrook Health Science Centre; University of Toronto; Princess Margaret Cancer Centre; Health Sciences Centre; University Health Network","funders":"","keywords":"Myelofibrosis; Myeloid leukemia; Biology; clone (Java method); Germline mutation; Myeloid; Mutation; Somatic cell; Genetics; Leukemia; Cancer research; Bone marrow; Gene; Immunology","score_opus":0.009582577477515187,"score_gpt":0.26604903559907406,"score_spread":0.2564664581215589,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2988198068","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9947609,0.0000107248015,0.000016140197,0.0011487524,0.00008319388,0.0036406238,0.00015085815,0.00006258626,0.00012627266],"genre_scores_gemma":[0.99698406,0.0000040011605,0.0012304594,0.0009279082,0.000031069147,0.00050396007,0.00017666309,0.0000311001,0.000110752044],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9985677,0.000038150785,0.00034054415,0.00034856627,0.0003417644,0.00036329383],"domain_scores_gemma":[0.9992175,0.000025486597,0.000043663735,0.00022679256,0.00013684784,0.00034970124],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00006648583,0.00021114644,0.00033624383,0.00028314572,0.000036054083,0.000031973756,0.00007927818,0.00008207607,0.00008283367],"category_scores_gemma":[0.00004399671,0.00018927133,0.000052145322,0.0005857172,0.0000092257715,0.00007872998,0.000028678664,0.00010103693,0.00018672345],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0028754692,0.008959041,0.85679364,0.00022000198,0.0003446133,0.000076235454,0.025107298,0.00018666431,0.038032643,0.000023664237,0.00075600983,0.0666247],"study_design_scores_gemma":[0.02258294,0.0055470085,0.827166,0.00038111518,0.00013245243,0.000007660901,0.00015447768,0.000081023565,0.14213608,0.0000013463106,0.0015172211,0.00029264358],"about_ca_topic_score_codex":0.0001563804,"about_ca_topic_score_gemma":0.00045062898,"teacher_disagreement_score":0.104103446,"about_ca_system_score_codex":0.00023291055,"about_ca_system_score_gemma":0.000121030986,"threshold_uncertainty_score":0.7718261},"labels":[],"label_agreement":null},{"id":"W2988772156","doi":"10.1182/blood.2019002804","title":"Reducing the burden of MPN","year":2019,"lang":"en","type":"letter","venue":"Blood","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen's University","funders":"","keywords":"Medicine","score_opus":0.019381403932945313,"score_gpt":0.2577189647935971,"score_spread":0.2383375608606518,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2988772156","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.08873484,0.0016744357,0.0000013787256,0.8885774,0.00034990825,0.0011129322,0.000065261265,0.000029896622,0.019453954],"genre_scores_gemma":[0.18714182,0.00089797535,0.0008670051,0.73645383,0.0256493,0.00042172786,0.0008545837,0.0002188319,0.047494937],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9987859,0.00005719631,0.0002733781,0.00029882096,0.00036336685,0.00022130735],"domain_scores_gemma":[0.99875796,0.0002933367,0.00017901153,0.00064498873,0.00009981411,0.00002492005],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000094033254,0.00023030944,0.0005410378,0.000067795845,0.00004042131,0.0000134962165,0.00012787318,0.00031566186,0.00035578592],"category_scores_gemma":[0.00006831765,0.00012791312,0.00020698897,0.00007983653,0.00005429884,0.000014534974,0.00004674604,0.0006910162,0.00018482984],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000011533346,0.00019105196,0.001794058,0.00034751982,0.00088216685,0.00029717435,0.00045356943,0.0000030877093,0.00030533943,0.000019781599,0.9952329,0.0004618389],"study_design_scores_gemma":[0.0026527701,0.0005279415,0.0011657699,0.0008973959,0.0019451604,0.00019233368,0.000045648834,0.000008287978,0.01469475,0.00002846257,0.97766036,0.0001811382],"about_ca_topic_score_codex":0.00020377322,"about_ca_topic_score_gemma":8.670385e-7,"teacher_disagreement_score":0.15212357,"about_ca_system_score_codex":0.000025396754,"about_ca_system_score_gemma":0.00015066676,"threshold_uncertainty_score":0.5216146},"labels":[],"label_agreement":null},{"id":"W2990454217","doi":"10.1002/ajh.25688","title":"Chronic neutrophilic leukemia: 2020 update on diagnosis, molecular genetics, prognosis, and management","year":2019,"lang":"en","type":"review","venue":"American Journal of Hematology","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":44,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hôpital Maisonneuve-Rosemont","funders":"","keywords":"Leukocytosis; Monocytosis; Medicine; Myeloproliferative neoplasm; Hepatosplenomegaly; Disease; Chronic myelomonocytic leukemia; Immunology; Bone marrow; Bioinformatics; Cancer research; Oncology; Myelodysplastic syndromes; Internal medicine; Myelofibrosis; Biology","score_opus":0.018840278390420205,"score_gpt":0.3197540739869434,"score_spread":0.3009137955965232,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2990454217","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0040254937,0.99227893,0.000011499284,0.0016960192,0.00025546644,0.0015224188,0.000017681108,0.000013297995,0.00017918022],"genre_scores_gemma":[0.0042470437,0.993443,0.0008881328,0.00069443235,0.00025206726,0.00031937737,0.000036425958,0.00009595524,0.000023574205],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9969907,0.00031952496,0.0012232081,0.00058550766,0.00039536593,0.00048571854],"domain_scores_gemma":[0.9971778,0.00028323458,0.0015845823,0.0004832249,0.00013749406,0.00033366831],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00018291803,0.0006663822,0.0043514087,0.0004296892,0.000053408297,0.000029267183,0.00025051483,0.00019218109,0.00008082621],"category_scores_gemma":[0.000031430252,0.0004617684,0.00067387347,0.00032722627,0.0003279201,0.000032905784,0.00013326372,0.0007225195,0.00013017902],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000060613598,0.00033167933,0.0021482748,0.009785156,0.0034588154,0.005142622,0.000024075154,0.0000038786197,3.7014948e-7,0.0015067179,0.0028842667,0.97465354],"study_design_scores_gemma":[0.0015843958,0.007251038,0.00039407815,0.016042804,0.006977901,0.0107711535,0.000024425988,0.0000032236592,0.000065028704,0.000039601935,0.9564444,0.00040198368],"about_ca_topic_score_codex":0.000005292399,"about_ca_topic_score_gemma":0.000002491589,"teacher_disagreement_score":0.97425157,"about_ca_system_score_codex":0.0005946384,"about_ca_system_score_gemma":0.00061417057,"threshold_uncertainty_score":0.9997834},"labels":[],"label_agreement":null},{"id":"W2992727443","doi":"10.1002/anr3.12030","title":"Laparoscopic hepatectomy in a patient with uncontrolled polycythaemia vera","year":2019,"lang":"en","type":"article","venue":"Anaesthesia Reports","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University","funders":"","keywords":"Polycythaemia; Medicine; Phlebotomy; Polycythemia vera; Surgery; Thrombosis; Blood transfusion; Bloodletting; Internal medicine","score_opus":0.0046026753738737155,"score_gpt":0.21873086714272427,"score_spread":0.21412819176885056,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2992727443","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9910713,0.00035087604,0.0000016273755,0.00085368595,0.00008032431,0.0013984758,7.5583205e-7,0.000051147355,0.006191812],"genre_scores_gemma":[0.9980146,0.000068588866,0.00031555007,0.0007734903,0.000025338664,0.00026285916,0.000019735937,0.000031042557,0.0004887492],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9983939,0.00004399833,0.0004307719,0.0004612255,0.00035199733,0.00031811863],"domain_scores_gemma":[0.9990641,0.000031910164,0.000190328,0.0005018698,0.00006737876,0.0001444095],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000116476396,0.00023936915,0.00064116385,0.00014345095,0.000034001212,0.000020663803,0.000029657356,0.00008403127,0.000205437],"category_scores_gemma":[0.000024745284,0.00015936834,0.00008661365,0.00023562451,0.000027487957,0.00007333368,0.000015033272,0.00015068932,0.000072439674],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0004899644,0.00040895122,0.97388977,0.00002756968,0.00008880372,0.020693738,0.00024299786,0.00002580426,0.0001408224,0.000093126255,0.00014707918,0.0037513662],"study_design_scores_gemma":[0.010427061,0.0057072416,0.95464665,0.0006360909,0.00016877663,0.0046523754,0.00014926388,0.000120419405,0.01163184,0.00012092359,0.01131659,0.00042274594],"about_ca_topic_score_codex":0.0005960573,"about_ca_topic_score_gemma":0.0002770823,"teacher_disagreement_score":0.019243103,"about_ca_system_score_codex":0.00018701349,"about_ca_system_score_gemma":0.00024406692,"threshold_uncertainty_score":0.64988524},"labels":[],"label_agreement":null},{"id":"W2994888696","doi":"10.14740/jmc3388","title":"Triple Therapy When Thrombotic Risk Exceeds Bleeding Risk: Polycythemia Vera in a Patient With Atrial Fibrillation and Subacute Stent Thrombosis","year":2019,"lang":"en","type":"article","venue":"Journal of Medical Cases","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Medicine; Percutaneous coronary intervention; Conventional PCI; Aspirin; Atrial fibrillation; Polycythemia vera; Internal medicine; Warfarin; Thrombosis; Cardiology; Clopidogrel; Regimen; Surgery; Myocardial infarction","score_opus":0.024318806967270512,"score_gpt":0.28749323431033397,"score_spread":0.26317442734306346,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2994888696","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99372095,0.0033390485,0.000022134418,0.0020267167,0.00029000334,0.00051426934,0.0000123285,0.000008439982,0.00006613541],"genre_scores_gemma":[0.9842543,0.014520688,0.0005139542,0.00015144228,0.000522213,0.0000026600403,0.0000045678144,0.000020169171,0.000009997962],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9975108,0.00016260134,0.00062048534,0.0002108644,0.001258606,0.00023665147],"domain_scores_gemma":[0.9982417,0.00060678547,0.0005495752,0.00013334457,0.00013619108,0.00033239092],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00068614475,0.000209797,0.0007134796,0.00018959142,0.000069648224,0.00003970162,0.00006188308,0.00014196457,0.0006880456],"category_scores_gemma":[0.00045573694,0.00012024685,0.00018141426,0.00015136538,0.0000715761,0.00015129666,0.000029868163,0.00045349187,0.0000057612706],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0025439668,0.00020239878,0.96629834,0.000033914366,0.0004961435,0.0007180828,0.0018262507,0.000053990465,0.000077315344,0.00001782382,0.0005151329,0.027216634],"study_design_scores_gemma":[0.033043936,0.025012033,0.9255109,0.002004668,0.0010004222,0.0051695397,0.0025303306,0.001427567,0.0017505484,0.0001552519,0.0020579535,0.0003368443],"about_ca_topic_score_codex":0.00030222163,"about_ca_topic_score_gemma":0.000051780524,"teacher_disagreement_score":0.04078744,"about_ca_system_score_codex":0.00016740248,"about_ca_system_score_gemma":0.00028182476,"threshold_uncertainty_score":0.7533617},"labels":[],"label_agreement":null},{"id":"W2995622226","doi":"10.1159/000504740","title":"Avoiding the Thorns of the Gifted Red Rose: Case Report of Late Diagnosis of Polycythemia Rubra Vera in a Sibling Bone Marrow Transplantation Donor for a Patient with Chronic Myeloid Leukemia","year":2019,"lang":"en","type":"letter","venue":"Acta Haematologica","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; Health Sciences Centre; Sunnybrook Health Science Centre","funders":"","keywords":"Medicine; Polycythemia rubra vera; Bone marrow transplantation; Sibling; Polycythemia vera; Bone marrow; Myeloid leukemia; Transplantation; Chronic myeloid leukaemia; Immunology; Surgery","score_opus":0.01996873778988468,"score_gpt":0.2543217617436371,"score_spread":0.2343530239537524,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2995622226","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.93067026,0.00065033976,0.000019012641,0.064400144,0.00011431496,0.0037035954,0.00028953786,0.00001822536,0.00013459816],"genre_scores_gemma":[0.99131817,0.00075038045,0.00043086873,0.0056419685,0.00008638033,0.0012806321,0.00034473022,0.000056171564,0.00009071586],"study_design_codex":"observational","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9970128,0.00031542883,0.001228878,0.00055612274,0.00048709373,0.00039968852],"domain_scores_gemma":[0.99506366,0.0021742089,0.0016838944,0.0008064261,0.00023421102,0.000037574242],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004745177,0.00045875052,0.0015134542,0.0002175429,0.00013793008,0.000013674578,0.00019884911,0.00050458824,0.00004356084],"category_scores_gemma":[0.00037469898,0.00022864531,0.00037163714,0.00042803967,0.00019929261,0.000067062836,0.000056317465,0.00095765904,6.645692e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.016196907,0.0032430743,0.36123046,0.0445997,0.0075178626,0.30948415,0.021407172,0.0011581837,0.02900149,0.0003297961,0.2011883,0.0046429113],"study_design_scores_gemma":[0.019306786,0.008725868,0.024390455,0.026318861,0.006855602,0.16179845,0.001043951,0.0010488237,0.72962695,0.00024739545,0.019061156,0.0015757154],"about_ca_topic_score_codex":0.0003286694,"about_ca_topic_score_gemma":0.00022761164,"teacher_disagreement_score":0.7006254,"about_ca_system_score_codex":0.00031929262,"about_ca_system_score_gemma":0.0005564234,"threshold_uncertainty_score":0.9323885},"labels":[],"label_agreement":null},{"id":"W2997252988","doi":"10.5045/br.2019.54.4.284","title":"Retrospective screening for Philadelphia-negative myeloproliferative neoplasms in patients with cerebral infarctions as revealed using the revised 2016 World Health Organization diagnostic criteria","year":2019,"lang":"en","type":"article","venue":"Blood Research","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Retrospective cohort study; Family medicine; Pediatrics; Pathology","score_opus":0.04364501023164914,"score_gpt":0.36284318001258575,"score_spread":0.3191981697809366,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2997252988","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9769094,0.00020890372,0.00026428825,0.011896368,0.00010426251,0.010128599,0.000125779,0.000046782334,0.00031560112],"genre_scores_gemma":[0.99353004,0.00013421092,0.0039050162,0.0006296858,0.00021559713,0.00064749026,0.00022257636,0.00008914973,0.0006262623],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99618524,0.0006826837,0.00055735087,0.00076741,0.0009936534,0.00081362994],"domain_scores_gemma":[0.99481595,0.001999692,0.0002340962,0.000527134,0.0021621583,0.00026099698],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011317894,0.000335965,0.00068594527,0.00060697197,0.0007505891,0.00014012137,0.0001720823,0.000103214275,0.00043425008],"category_scores_gemma":[0.0032374223,0.00021597033,0.000078731515,0.002331893,0.00020429766,0.00027614826,0.000122007645,0.0007029126,0.000047534944],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0010356012,0.0010741802,0.992302,0.00014589397,0.00035328508,0.0000097783495,0.0019757745,0.00006680528,0.00007558664,0.0014446449,0.001334264,0.00018219136],"study_design_scores_gemma":[0.014218332,0.004083825,0.97610176,0.0018821947,0.0001274801,0.000016303165,0.00069160905,0.0004933167,0.0015952429,0.0003393094,0.00018477024,0.00026587097],"about_ca_topic_score_codex":0.0004970832,"about_ca_topic_score_gemma":0.00037721466,"teacher_disagreement_score":0.016620595,"about_ca_system_score_codex":0.0006286144,"about_ca_system_score_gemma":0.0010135405,"threshold_uncertainty_score":0.8807014},"labels":[],"label_agreement":null},{"id":"W2998157188","doi":"10.5045/br.2019.54.4.282","title":"EBV reactivation mimicking a lymphoproliferative disorder associated with ruxolitinib therapy for myelofibrosis","year":2019,"lang":"en","type":"article","venue":"Blood Research","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Ruxolitinib; Myelofibrosis; Lymphoproliferative disorders; Immunology; Virology; Dermatology; Bone marrow; Lymphoma","score_opus":0.06566128036117909,"score_gpt":0.3623600202648464,"score_spread":0.29669873990366735,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2998157188","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98878753,0.00032694603,0.000041484498,0.0025723046,0.000041552263,0.0042428817,0.000048622285,0.000066922956,0.0038717703],"genre_scores_gemma":[0.99353987,0.0002433926,0.00066284806,0.0002775123,0.00014229259,0.0017766145,0.00027295787,0.000069200796,0.0030152868],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9973375,0.00023734008,0.00027362423,0.0005918841,0.00087924255,0.0006804104],"domain_scores_gemma":[0.9969791,0.0012747607,0.000101980586,0.00037886578,0.0010944171,0.00017086457],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008545613,0.00024867774,0.00046420755,0.00027065622,0.00031529786,0.00009096889,0.00010425117,0.00015956399,0.00021877396],"category_scores_gemma":[0.00047439468,0.00016713067,0.00011953065,0.00056227535,0.000105421095,0.00014291117,0.000039095692,0.00028843762,0.000057056674],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0034807264,0.0043437146,0.95213073,0.0001254666,0.0016530995,0.000026663616,0.0019310754,0.000010785206,0.024495857,0.0026034925,0.00095814693,0.00824023],"study_design_scores_gemma":[0.041741516,0.014629228,0.68399674,0.0011659791,0.00021677962,0.000049600443,0.001468521,0.0006302157,0.24594538,0.0006518043,0.008944932,0.0005593157],"about_ca_topic_score_codex":0.00013268023,"about_ca_topic_score_gemma":0.000051568757,"teacher_disagreement_score":0.268134,"about_ca_system_score_codex":0.00020975113,"about_ca_system_score_gemma":0.00047781662,"threshold_uncertainty_score":0.6815391},"labels":[],"label_agreement":null},{"id":"W3004366031","doi":"10.1111/jth.14731","title":"Hemostasis and thrombosis 101—A challenge to energize","year":2020,"lang":"en","type":"editorial","venue":"Journal of Thrombosis and Haemostasis","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen's University","funders":"","keywords":"Hemostasis; Thrombosis; Medicine; Cardiology; Internal medicine","score_opus":0.05565347957751811,"score_gpt":0.3461972685966618,"score_spread":0.2905437890191437,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3004366031","genre_codex":"editorial","genre_gemma":"editorial","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"editorial","genre_consensus":"editorial","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.18732719,0.041911732,0.00012631931,0.19426586,0.5652467,0.0037392667,0.0027677207,0.00018022319,0.004435005],"genre_scores_gemma":[0.09798947,0.29453817,0.012577599,0.0043029115,0.58942366,0.00014811767,0.00025919682,0.00044289537,0.0003179781],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9955535,0.00015652955,0.0013483813,0.00083020993,0.0015563684,0.000555037],"domain_scores_gemma":[0.9953894,0.0009395596,0.0009381477,0.00044328542,0.0009797843,0.0013098439],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00053503463,0.0008869458,0.0030492845,0.0004579615,0.00027428407,0.00023661835,0.0002504642,0.00083391625,0.00035567133],"category_scores_gemma":[0.0009706585,0.00067202473,0.0005639941,0.000364783,0.00016965941,0.00022480793,0.00031018353,0.0011985952,0.000028094571],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0005258683,0.0006399196,0.0018545305,0.00059643615,0.0032106396,0.00015865729,0.0013441596,0.0000011367007,0.00013692147,0.000071904156,0.9710124,0.020447392],"study_design_scores_gemma":[0.004842249,0.0059132418,0.0058049005,0.0018410309,0.004128176,0.000080850776,0.00050258427,0.0000062519357,0.0018667164,0.000113596805,0.9742239,0.0006764906],"about_ca_topic_score_codex":0.00008323294,"about_ca_topic_score_gemma":0.000047474263,"teacher_disagreement_score":0.25262645,"about_ca_system_score_codex":0.00029567318,"about_ca_system_score_gemma":0.0005242811,"threshold_uncertainty_score":0.9995731},"labels":[],"label_agreement":null},{"id":"W3004714210","doi":"10.1111/bjh.16462","title":"Primary analysis of JUMP, a phase 3b, expanded‐access study evaluating the safety and efficacy of ruxolitinib in patients with myelofibrosis, including those with low platelet counts","year":2020,"lang":"en","type":"article","venue":"British Journal of Haematology","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":113,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; St. Paul's Hospital; University of British Columbia","funders":"AOP Orphan; Incyte; Baxalta; Pfizer; Novartis Pharmaceuticals Corporation; Celgene; Alexion Pharmaceuticals; Amgen; Ariad Pharmaceuticals; Teva Pharmaceutical Industries; Gilead Sciences; Sanofi; Bristol-Myers Squibb","keywords":"Ruxolitinib; Medicine; Myelofibrosis; Discontinuation; Internal medicine; Cohort; Adverse effect; Bone marrow","score_opus":0.04091387740162374,"score_gpt":0.35841570427673825,"score_spread":0.3175018268751145,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3004714210","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99839467,0.00068375346,0.000042184085,0.00016660799,0.000016534323,0.00057357247,0.000035575307,0.0000031018199,0.000084020045],"genre_scores_gemma":[0.9992554,0.00020046669,0.00034038513,0.00014573858,0.000016033384,0.000009110701,0.000019059655,0.000012069397,0.0000017166617],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99835527,0.0002024115,0.0007027248,0.00017577317,0.0004184175,0.00014541985],"domain_scores_gemma":[0.9984869,0.00035091452,0.00063861994,0.00010198517,0.00033053444,0.000091054295],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00037337505,0.0001268501,0.001097293,0.00016551884,0.000056962275,0.000018296912,0.000100965946,0.0000411332,0.000058203754],"category_scores_gemma":[0.00019380465,0.00008320615,0.00007152757,0.00046423246,0.000113398404,0.00009360556,0.00005668812,0.00018920563,2.8229414e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0059372084,0.00249704,0.9706956,0.00015172649,0.0020316988,0.0018460938,0.0013904584,0.000108658234,0.000028440234,0.000009967633,0.00003819806,0.015264875],"study_design_scores_gemma":[0.022793058,0.0065348553,0.9657765,0.00097456976,0.0016921153,0.0011540216,0.00041767387,0.0001658,0.0003936437,0.000003696993,0.000006305396,0.0000877791],"about_ca_topic_score_codex":0.00004162349,"about_ca_topic_score_gemma":0.000053422053,"teacher_disagreement_score":0.016855849,"about_ca_system_score_codex":0.000030267289,"about_ca_system_score_gemma":0.00014570307,"threshold_uncertainty_score":0.33930483},"labels":[],"label_agreement":null},{"id":"W3005061455","doi":"10.1097/hs9.0000000000000327","title":"Modifiable Lifestyle and Medical Risk Factors Associated With Myeloproliferative Neoplasms","year":2020,"lang":"en","type":"article","venue":"HemaSphere","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":32,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"National Cancer Institute; Cancer Council Western Australia; National Health and Medical Research Council; Queen's University; Queen's University Belfast; Medical Research Council; National Institute for Health and Care Research","keywords":"Medicine; Odds ratio; Confidence interval; Internal medicine; Population; Cohort study; Cohort; Essential thrombocythemia; Demography; Pediatrics; Polycythemia vera; Environmental health","score_opus":0.025835282769332987,"score_gpt":0.24792468086158065,"score_spread":0.22208939809224765,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3005061455","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9903975,0.0006282151,0.00016127127,0.004288035,0.000040635307,0.00066776806,0.00006309194,0.00016871098,0.0035847821],"genre_scores_gemma":[0.9967194,0.00034431618,0.00053363596,0.0015345139,0.00013874109,0.000095153286,0.00010256098,0.000052470456,0.00047920414],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99791944,0.00011593951,0.0003055304,0.0005621406,0.00070360786,0.00039336036],"domain_scores_gemma":[0.99819726,0.00039870842,0.00014864224,0.00018941771,0.00015198327,0.00091397733],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00013115775,0.00036848127,0.0006686024,0.000025744273,0.00021689682,0.000048081518,0.00007361449,0.00022556314,0.0017158652],"category_scores_gemma":[0.0009929698,0.00023850298,0.000081838,0.00028651292,0.0001489096,0.000113625094,0.0000622478,0.00045292504,0.000056417033],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00029498228,0.0004900783,0.98952,0.000067430476,0.0008518469,0.0003209792,0.002428131,0.00007051335,0.00005120729,0.0007856766,0.004202378,0.000916734],"study_design_scores_gemma":[0.0340329,0.013365898,0.8469813,0.001947358,0.0024262497,0.0002612629,0.005737524,0.04269196,0.035201352,0.0004038906,0.014753048,0.0021972517],"about_ca_topic_score_codex":0.000119345816,"about_ca_topic_score_gemma":0.00013837487,"teacher_disagreement_score":0.14253874,"about_ca_system_score_codex":0.00007784728,"about_ca_system_score_gemma":0.0002991214,"threshold_uncertainty_score":0.9991967},"labels":[],"label_agreement":null},{"id":"W3005887319","doi":"10.1097/01.hs9.0000560956.60646.c2","title":"PF668 RESULTS FROM ONGOING PHASE 1/2 CLINICAL TRIAL OF TAGRAXOFUSP (SL‐401) IN PATIENTS WITH INTERMEDIATE, OR HIGH RISK, RELAPSED/REFRACTORY MYELOFIBROSIS","year":2019,"lang":"en","type":"article","venue":"HemaSphere","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta Hospital; Alberta Hospital Edmonton; Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Myelofibrosis; Monocytosis; Refractory (planetary science); Internal medicine; Interleukin-3 receptor; Oncology; Phases of clinical research; Ruxolitinib; Myeloid; Clinical trial; Gastroenterology; Bone marrow","score_opus":0.024210525989180925,"score_gpt":0.3103908181273837,"score_spread":0.2861802921382028,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3005887319","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9954799,0.000075278556,0.000007670422,0.00011685973,0.0006292518,0.0021821982,0.0005427192,0.00004574174,0.00092041714],"genre_scores_gemma":[0.99614924,0.00023599528,0.0016951495,0.00015738874,0.0002710489,0.00009987439,0.000601596,0.00005843273,0.00073130114],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99656624,0.00029156197,0.0013862589,0.0007895162,0.0005908783,0.00037552128],"domain_scores_gemma":[0.9964856,0.0015370122,0.00074875396,0.0007789685,0.000194194,0.00025549662],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00042292156,0.00038244133,0.0012068716,0.00009231034,0.000046544617,0.000020726719,0.00013933632,0.00029323268,0.0012603853],"category_scores_gemma":[0.0007718987,0.00024357847,0.00020509712,0.00028764884,0.00011705286,0.00016513708,0.00007802845,0.0005546053,0.00017823387],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.2562397,0.008233009,0.713201,0.00006131294,0.00035431157,0.00006174321,0.00039867614,0.000005495787,0.000026001595,0.000012837037,0.0018093794,0.019596528],"study_design_scores_gemma":[0.39301857,0.023355758,0.5790825,0.0009851656,0.00026990726,8.7965344e-7,0.00018547816,0.00003822006,0.0012945933,0.000020265346,0.0014891871,0.00025950017],"about_ca_topic_score_codex":0.0007881827,"about_ca_topic_score_gemma":0.0006946308,"teacher_disagreement_score":0.13677886,"about_ca_system_score_codex":0.00015281118,"about_ca_system_score_gemma":0.0002868932,"threshold_uncertainty_score":0.9996526},"labels":[],"label_agreement":null},{"id":"W3007882742","doi":"10.1111/bjh.16533","title":"Anti‐myeloma potential of ruxolitinib in co‐existing <i>JAK2V617F</i>‐positive smouldering myeloma and polycythaemia vera","year":2020,"lang":"en","type":"letter","venue":"British Journal of Haematology","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Foothills Medical Centre; University of Calgary","funders":"","keywords":"Polycythaemia; Polycythemia vera; Multiple myeloma; Ruxolitinib; Medicine; Internal medicine; Oncology; Cancer research; Dermatology; Myelofibrosis; Bone marrow","score_opus":0.020054852191899845,"score_gpt":0.2821120807715569,"score_spread":0.2620572285796571,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3007882742","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.85908896,0.0071258415,0.0000692586,0.13134494,0.0005110739,0.00058411603,0.00023021841,0.000021848895,0.0010237453],"genre_scores_gemma":[0.9140998,0.0025953383,0.001817649,0.079237565,0.0018208546,0.000023690027,0.0002065366,0.00012060742,0.00007793015],"study_design_codex":"case_report","study_design_gemma":"case_report","domain_scores_codex":[0.9960103,0.00038709186,0.0017935043,0.0005462441,0.0006212732,0.00064159976],"domain_scores_gemma":[0.9972801,0.0004970769,0.0013927224,0.00018736396,0.00039902952,0.00024366392],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.0002704002,0.00050340715,0.0030822514,0.00046126946,0.000121792276,0.00007367284,0.00021105213,0.00075303065,0.00012341634],"category_scores_gemma":[0.00043109158,0.0005398595,0.00040176,0.00021222352,0.00040199744,0.00014584865,0.000121892146,0.0026625104,0.0000070799747],"study_design_candidate":"case_report","study_design_consensus":"case_report","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0004646651,0.00027789283,0.02288155,0.0015500374,0.001096973,0.8369761,0.00044536524,0.0000037045563,0.0008740898,0.000078223566,0.12623107,0.009120309],"study_design_scores_gemma":[0.008550452,0.0018551686,0.07366087,0.01005743,0.0011337335,0.87145907,0.00031230552,0.00004736803,0.01174738,0.00030839298,0.020167882,0.0006999445],"about_ca_topic_score_codex":0.00018854711,"about_ca_topic_score_gemma":0.000032671658,"teacher_disagreement_score":0.10606319,"about_ca_system_score_codex":0.00013912942,"about_ca_system_score_gemma":0.00042856706,"threshold_uncertainty_score":0.9997053},"labels":[],"label_agreement":null},{"id":"W3010448637","doi":"10.1200/jop.19.00506","title":"Patterns of Ruxolitinib Therapy Failure and Its Management in Myelofibrosis: Perspectives of the Canadian Myeloproliferative Neoplasm Group","year":2020,"lang":"en","type":"review","venue":"JCO Oncology Practice","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":32,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Jewish General Hospital; Memorial University of Newfoundland; Juravinski Cancer Centre; University of British Columbia; Windsor Regional Hospital; University of Calgary; McMaster University; St. Paul's Hospital; Princess Margaret Cancer Centre; Dalhousie University; University of Toronto","funders":"","keywords":"Ruxolitinib; Myelofibrosis; Medicine; Myeloproliferative neoplasm; Splenectomy; Clinical trial; Extramedullary hematopoiesis; Internal medicine; Transplantation; Oncology; Intensive care medicine; Surgery; Stem cell; Bone marrow; Spleen","score_opus":0.04523296266087844,"score_gpt":0.3649477534339695,"score_spread":0.31971479077309106,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3010448637","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0015057072,0.9734981,0.0000013902537,0.012006539,0.00017232132,0.005130093,0.00028028604,0.000016410866,0.0073891715],"genre_scores_gemma":[0.018806713,0.9782735,0.00077535876,0.000821922,0.00012254756,0.0009192944,0.000067472705,0.000058823898,0.00015437514],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.996273,0.001193893,0.0009692406,0.0007400747,0.00040057182,0.00042323922],"domain_scores_gemma":[0.99645895,0.0013853443,0.0011347921,0.00043849045,0.0002994133,0.00028303973],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00052103726,0.0005832613,0.0025507868,0.0003838355,0.00014509374,0.000025530335,0.00026654647,0.0005511554,0.00008472054],"category_scores_gemma":[0.0005266311,0.000379412,0.00035785732,0.0005553613,0.00013910067,0.00017285958,0.00016953725,0.0009843857,0.0000150561045],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0007518499,0.0032043857,0.007003674,0.015207045,0.008568219,0.0018130029,0.016807325,0.0000011450517,0.000004964386,0.038916804,0.0008120355,0.9069095],"study_design_scores_gemma":[0.0024335503,0.0013244951,0.0056518987,0.0047144447,0.0021202161,0.0004509044,0.005628535,0.0000033147728,0.000023817434,0.00002256734,0.9773521,0.00027417523],"about_ca_topic_score_codex":0.0042024064,"about_ca_topic_score_gemma":0.040851627,"teacher_disagreement_score":0.97654,"about_ca_system_score_codex":0.0010968491,"about_ca_system_score_gemma":0.0018454234,"threshold_uncertainty_score":0.9998658},"labels":[],"label_agreement":null},{"id":"W3011365044","doi":"10.3324/haematol.2019.244160","title":"Low incidence of &lt;i&gt;EPOR&lt;/i&gt; mutations in idiopathic erythrocytosis","year":2020,"lang":"en","type":"letter","venue":"Haematologica","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":13,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Stollery Children's Hospital; University of Alberta","funders":"Université de Recherche Paris Sciences et Lettres; Centre Hospitalier Universitaire de Nantes; Centre National de la Recherche Scientifique; Alberta Health Services; Université de Bourgogne; Institut National de la Santé et de la Recherche Médicale; Agence Nationale de la Recherche; University of Alberta","keywords":"Erythropoietin receptor; Incidence (geometry); Proband; Medicine; Mutation; Internal medicine; Genetics; Biology; Erythropoietin; Gene","score_opus":0.027471021382167452,"score_gpt":0.2705137380996264,"score_spread":0.24304271671745897,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3011365044","genre_codex":"commentary","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.21715681,0.006110394,0.00018677591,0.7663305,0.00045019604,0.0031192251,0.00024819456,0.00028137327,0.0061165174],"genre_scores_gemma":[0.8310754,0.0012304742,0.0014184134,0.16409224,0.00042832934,0.0008883997,0.00051876873,0.00007301601,0.00027498687],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9959693,0.00031055644,0.0013002201,0.0009964289,0.00082960323,0.00059389864],"domain_scores_gemma":[0.9974887,0.00061685627,0.0007169153,0.00070217624,0.00029491985,0.00018042774],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00020535817,0.000674936,0.0023902673,0.00038985355,0.00012488518,0.00003219091,0.00030553716,0.0009596689,0.00055690535],"category_scores_gemma":[0.0009826345,0.0005245153,0.00042229763,0.00066588225,0.00036000757,0.0000897739,0.0001643204,0.001309023,0.00036782929],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00031277022,0.0015422839,0.027067687,0.005213721,0.0007984406,0.072191045,0.0017332331,0.000026358512,0.0032568623,0.0025344365,0.88405573,0.0012674452],"study_design_scores_gemma":[0.014482742,0.009648421,0.09895772,0.026543401,0.004862216,0.012987192,0.00031831246,0.0008760767,0.089866236,0.008537847,0.7280595,0.0048603727],"about_ca_topic_score_codex":0.000023050987,"about_ca_topic_score_gemma":0.00010832103,"teacher_disagreement_score":0.61391854,"about_ca_system_score_codex":0.00021964226,"about_ca_system_score_gemma":0.0004793724,"threshold_uncertainty_score":0.99972063},"labels":[],"label_agreement":null},{"id":"W3014880052","doi":"10.1080/13543784.2020.1751121","title":"Investigational non-JAK inhibitors for chronic phase myelofibrosis","year":2020,"lang":"en","type":"review","venue":"Expert Opinion on Investigational Drugs","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":16,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"Princess Margaret Cancer Foundation","keywords":"Myelofibrosis; Ruxolitinib; Medicine; Clinical trial; Phases of clinical research; Tofacitinib; Pharmacology; Internal medicine; Oncology; Bone marrow","score_opus":0.08566006386425828,"score_gpt":0.41308605949262,"score_spread":0.3274259956283617,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3014880052","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000020390864,0.98106766,0.00011778667,0.010445269,0.0014967626,0.004869463,0.001099442,0.00015834448,0.00072485727],"genre_scores_gemma":[0.00003670474,0.9598016,0.0057015554,0.0038329165,0.006342826,0.0076426403,0.016120648,0.00020358343,0.00031749596],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99533695,0.00017809715,0.0014471745,0.0013552259,0.0011439217,0.0005386286],"domain_scores_gemma":[0.9963454,0.0010950029,0.0007010503,0.0005074431,0.00032292778,0.0010281886],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00024711562,0.0011013494,0.0023227502,0.00045168374,0.00039676513,0.00010568407,0.00026734459,0.00056601956,0.00033684325],"category_scores_gemma":[0.0005675917,0.0008958563,0.0011468236,0.0006319278,0.0004032136,0.00018283055,0.00009734107,0.0006009189,0.0005474523],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00014453327,0.00096994836,0.000019760564,0.0075718663,0.0011296972,0.0000149880125,0.0007429563,0.000011577842,0.000038689523,0.019313948,0.2587409,0.71130115],"study_design_scores_gemma":[0.0040597455,0.0018589229,0.000014054095,0.022930669,0.000182532,0.000040304767,0.00002420402,0.00035295903,0.0006406146,0.00058259984,0.96859473,0.00071865466],"about_ca_topic_score_codex":0.000015087048,"about_ca_topic_score_gemma":8.461382e-7,"teacher_disagreement_score":0.7105825,"about_ca_system_score_codex":0.0013786147,"about_ca_system_score_gemma":0.004733,"threshold_uncertainty_score":0.99934924},"labels":[],"label_agreement":null},{"id":"W3017829147","doi":"10.1016/j.clml.2020.04.010","title":"No Differences in Outcomes Between JAK2 V617F–Positive Patients with Variant Allele Fraction &lt; 2% Versus 2-10%: A 6-Year Province-wide Retrospective Analysis","year":2020,"lang":"en","type":"article","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; St. Paul's Hospital; Canada's Michael Smith Genome Sciences Centre","funders":"Novartis","keywords":"Medicine; Internal medicine; Incidence (geometry); Gastroenterology; JAK2 V617F; Thrombosis; Retrospective cohort study; Hematology; Myelofibrosis; Bone marrow","score_opus":0.03235531661503044,"score_gpt":0.2941142322710267,"score_spread":0.26175891565599624,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3017829147","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99289995,0.00002961943,0.00016017327,0.0012686711,0.00014205917,0.0014541878,0.00017940869,0.00010899654,0.0037569162],"genre_scores_gemma":[0.9963001,0.000063539905,0.0012467505,0.0008814747,0.00035390994,0.00022404839,0.00057036825,0.00005292842,0.0003068747],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99564433,0.00035690967,0.0012258055,0.0013136838,0.0008843282,0.0005749386],"domain_scores_gemma":[0.99569803,0.0020937403,0.00054274965,0.00052008807,0.000510068,0.0006353325],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00031334328,0.00057877286,0.0021231514,0.0002192368,0.00016484126,0.00008163733,0.00022818928,0.00038235035,0.0005064248],"category_scores_gemma":[0.0020608916,0.0004095287,0.0005586891,0.0009650246,0.0002509277,0.00025202948,0.00013821779,0.00043034062,0.00041935104],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.005406822,0.0008990506,0.9740467,0.000025770332,0.0040316186,0.0002963068,0.00015492665,0.0000048910383,0.0000014942932,0.00013108048,0.00056994037,0.0144314],"study_design_scores_gemma":[0.01781027,0.005991708,0.97206515,0.000094319614,0.0022948426,0.0000010946725,0.000070873226,0.00034892347,0.000057287958,0.000031547195,0.0008072304,0.00042672968],"about_ca_topic_score_codex":0.000285891,"about_ca_topic_score_gemma":0.0003093516,"teacher_disagreement_score":0.014004671,"about_ca_system_score_codex":0.001905226,"about_ca_system_score_gemma":0.0008738706,"threshold_uncertainty_score":0.99983567},"labels":[],"label_agreement":null},{"id":"W3018152860","doi":"10.14740/jh591","title":"Emergence of <i>BCR-ABL1</i> Chronic Myeloid Leukemia in a <i>JAK2</i>-V617F Polycythemia Vera","year":2020,"lang":"he","type":"article","venue":"Journal of Hematology","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":16,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Polycythemia vera; Myeloid leukemia; Myeloproliferative neoplasm; clone (Java method); Medicine; Myeloproliferative Disorders; Myeloid; Janus kinase 2; Concomitant; Cancer research; Immunology; Internal medicine; Myelofibrosis; Biology; Genetics; Bone marrow; Gene; Receptor","score_opus":0.021183222857253978,"score_gpt":0.2777495846759793,"score_spread":0.25656636181872533,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3018152860","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.91347104,0.062440176,0.00018225888,0.020094134,0.0011616396,0.00063493854,0.000037522805,0.000014741253,0.0019635637],"genre_scores_gemma":[0.982943,0.013561666,0.0008189711,0.0017479507,0.00076205237,0.000017112914,0.0000068267314,0.00005497343,0.00008743824],"study_design_codex":"observational","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9952735,0.0003071704,0.0025206744,0.0004730368,0.0006752422,0.0007504065],"domain_scores_gemma":[0.9964475,0.0005066925,0.0017024702,0.00037097768,0.00039450882,0.00057785434],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0004958074,0.00053198956,0.0025015979,0.00033187086,0.000072091665,0.00001559646,0.00042476712,0.00042788754,0.0032822238],"category_scores_gemma":[0.0005766289,0.0004304308,0.0005255912,0.00068877894,0.000267538,0.00018250835,0.00014455599,0.0011793898,0.00018328567],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.008915047,0.0033937588,0.65277,0.0064567,0.0046507423,0.021423046,0.014753419,0.0011945224,0.079414986,0.011623227,0.1834734,0.011931156],"study_design_scores_gemma":[0.04956464,0.03174956,0.026766561,0.010301964,0.003385539,0.018683076,0.0060874685,0.004827274,0.7889782,0.0010687992,0.056725297,0.0018616095],"about_ca_topic_score_codex":0.00008427394,"about_ca_topic_score_gemma":0.000086172426,"teacher_disagreement_score":0.7095632,"about_ca_system_score_codex":0.00057951675,"about_ca_system_score_gemma":0.003124104,"threshold_uncertainty_score":0.99981475},"labels":[],"label_agreement":null},{"id":"W3019193608","doi":"10.3390/cancers12041021","title":"STAT5 is Expressed in CD34+/CD38− Stem Cells and Serves as a Potential Molecular Target in Ph-Negative Myeloproliferative Neoplasms","year":2020,"lang":"en","type":"article","venue":"Cancers","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":16,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"Oesterreichische Nationalbank; Austrian Science Fund","keywords":"Cancer research; Stem cell; STAT5; CD38; Biology; Essential thrombocythemia; Janus kinase 2; Flow cytometry; CD34; Molecular biology; Chemistry; Polycythemia vera; Signal transduction; Immunology; Cell biology","score_opus":0.014091386147656898,"score_gpt":0.2532661724250303,"score_spread":0.2391747862773734,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3019193608","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9913111,0.001288856,0.00010635279,0.0049301963,0.000103359365,0.0013296728,0.00020878288,0.000036837217,0.0006848515],"genre_scores_gemma":[0.9922888,0.00073080475,0.0010293317,0.005266736,0.00007719175,0.00037689242,0.00002437783,0.000043790285,0.00016202556],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99790144,0.00014033899,0.000421011,0.00074052735,0.000353364,0.00044331656],"domain_scores_gemma":[0.9991086,0.00010582125,0.00012187982,0.00019264634,0.0001033807,0.00036767946],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0000949501,0.00037800698,0.00068727945,0.00013903683,0.000058713023,0.000049568356,0.00009168344,0.00013270987,0.00024565938],"category_scores_gemma":[0.000038885806,0.0003371405,0.00009239488,0.0003985043,0.00012239642,0.00016560475,0.00006954774,0.00033248306,0.00003685788],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.013581807,0.0012410219,0.2936546,0.0019482429,0.002580053,0.015172319,0.1965164,0.02249892,0.42345256,0.0021843775,0.013098087,0.014071614],"study_design_scores_gemma":[0.0107770525,0.0015253446,0.00942657,0.0003996033,0.000108602864,0.000018195784,0.005570813,0.008898323,0.96079004,0.00044728877,0.001520799,0.00051737763],"about_ca_topic_score_codex":0.00071451033,"about_ca_topic_score_gemma":0.00020742902,"teacher_disagreement_score":0.5373375,"about_ca_system_score_codex":0.00069290155,"about_ca_system_score_gemma":0.00073717115,"threshold_uncertainty_score":0.9999081},"labels":[],"label_agreement":null},{"id":"W3020183939","doi":"10.1007/s12325-020-01314-0","title":"The Myeloproliferative Neoplasm Landscape: A Patient’s Eye View","year":2020,"lang":"en","type":"review","venue":"Advances in Therapy","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":22,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Canadian Foundation for Healthcare Improvement","funders":"Novartis Pharmaceuticals Corporation","keywords":"Medicine; Polycythaemia; Quality of life (healthcare); Myelofibrosis; Myeloproliferative neoplasm; Psychosocial; Anxiety; Palliative care; Depression (economics); Physical therapy; Disease; Intensive care medicine; Internal medicine; Psychiatry; Nursing","score_opus":0.026338501614843735,"score_gpt":0.3577173501751318,"score_spread":0.33137884856028804,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3020183939","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000027854896,0.9907696,0.0000061473734,0.0010652402,0.00049166183,0.0035240483,0.0000557967,0.00007070058,0.0039889216],"genre_scores_gemma":[0.00005515531,0.995001,0.00028061375,0.00089130644,0.000342764,0.00291703,0.00013541848,0.0001047715,0.0002719087],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9967874,0.0003891007,0.0010062942,0.0008029475,0.00047391417,0.00054032006],"domain_scores_gemma":[0.99771744,0.00088453904,0.00048082415,0.0006037528,0.00010676687,0.0002066945],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00018856546,0.00083170814,0.0026168413,0.00013240929,0.00024376792,0.00008263943,0.00029416115,0.0002488765,0.0001427787],"category_scores_gemma":[0.00012470986,0.00042911363,0.00057937985,0.0006904043,0.0001419344,0.0001681244,0.00007287098,0.00077427976,0.00023470323],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00013110161,0.00022379494,0.00039653547,0.0013292287,0.00040202148,0.0002040841,0.00039304534,0.0000010539529,7.398034e-8,0.00056359696,0.00044081386,0.99591464],"study_design_scores_gemma":[0.0013975337,0.0008886759,0.000040891988,0.006323505,0.00020732683,0.000077381104,0.00007121319,0.0000060312013,0.000011694489,0.00022320433,0.9903644,0.00038815817],"about_ca_topic_score_codex":0.0000039576694,"about_ca_topic_score_gemma":0.000051476447,"teacher_disagreement_score":0.9955265,"about_ca_system_score_codex":0.00021983826,"about_ca_system_score_gemma":0.0004995546,"threshold_uncertainty_score":0.99981606},"labels":[],"label_agreement":null},{"id":"W3020462214","doi":"10.1080/10428194.2020.1749607","title":"Healthcare resource utilization in myeloproliferative neoplasms: a population-based study from Ontario, Canada","year":2020,"lang":"en","type":"article","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":20,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Sunnybrook Health Science Centre; Health Sciences Centre; Entomological Society of Canada; Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Polycythemia vera; Myelofibrosis; Population; Cohort; Health care; Comorbidity; Venous thrombosis; Internal medicine; Essential thrombocythemia; Thrombosis; Emergency medicine; Surgery; Environmental health","score_opus":0.02424562514465522,"score_gpt":0.25278177620426145,"score_spread":0.22853615105960623,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3020462214","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99269664,0.00091484486,0.000028211942,0.0032021066,0.00015332541,0.0021576327,0.00015438756,0.00013957552,0.00055325736],"genre_scores_gemma":[0.9861825,0.000049837057,0.00041677855,0.011190306,0.0002509237,0.0004219938,0.001187267,0.00009497696,0.0002054122],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9954166,0.0003402374,0.0010976007,0.0014231933,0.0009674202,0.00075495365],"domain_scores_gemma":[0.99756473,0.00045721227,0.00032171592,0.00056755723,0.0001941359,0.000894666],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00017355567,0.000791407,0.001280559,0.00020522584,0.00038212354,0.000121687524,0.00020768766,0.00032226765,0.00024304629],"category_scores_gemma":[0.00019836103,0.0007273669,0.0001397674,0.0007427171,0.000062178406,0.0001947751,0.00010794133,0.00024290466,0.000017208846],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.0017116889,0.00046403447,0.9707844,0.0001112873,0.00022798472,0.0010244849,0.0066646244,0.0005246477,0.000031974545,0.00017073078,0.0016236228,0.016660478],"study_design_scores_gemma":[0.022310447,0.0011212266,0.9545682,0.00029354973,0.00022233583,0.000039246515,0.0025282083,0.0101399645,0.00084321806,0.000057012996,0.0072481823,0.00062837533],"about_ca_topic_score_codex":0.9590221,"about_ca_topic_score_gemma":0.97026104,"teacher_disagreement_score":0.020598758,"about_ca_system_score_codex":0.020615583,"about_ca_system_score_gemma":0.016462846,"threshold_uncertainty_score":0.99951774},"labels":[],"label_agreement":null},{"id":"W3021578901","doi":"10.1182/blood.2020004897","title":"MDS/MPN-U with persistent monocytosis, del(20q), and CALR mutation, the great masquerader","year":2020,"lang":"en","type":"article","venue":"Blood","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Royal Jubilee Hospital","funders":"","keywords":"Monocytosis; Genetics; Mutation; Biology; Medicine; Gene; Internal medicine; Bone marrow","score_opus":0.023451608979030526,"score_gpt":0.23241138344701753,"score_spread":0.208959774467987,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3021578901","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9687388,0.0021524332,0.000060022237,0.026960464,0.000017382137,0.0006293394,0.000009979894,0.000045697576,0.0013858787],"genre_scores_gemma":[0.9948249,0.00019111355,0.00090337335,0.0035901421,0.00012902045,0.00013726766,0.000024244391,0.000021446082,0.00017851597],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99912864,0.000038452687,0.0001471503,0.000293347,0.00021878968,0.00017361787],"domain_scores_gemma":[0.9994345,0.000071078604,0.000046277863,0.00016684872,0.00008834463,0.00019298136],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000043054126,0.00017369069,0.00023340693,0.00002229325,0.00014337336,0.00005038059,0.00004500524,0.000044576485,0.00011364491],"category_scores_gemma":[0.000035946832,0.00009298963,0.00006855006,0.00011883128,0.00007179993,0.000059998394,0.00002586933,0.000115345305,0.00002966002],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0006397394,0.0016582811,0.96478117,0.00027356145,0.0035033638,0.0012057243,0.013439762,0.000076765165,0.0007513283,0.0011886654,0.0058163297,0.006665285],"study_design_scores_gemma":[0.038842652,0.010566789,0.85473937,0.00041179627,0.008488496,0.0030368036,0.00686546,0.0015744444,0.047713254,0.00011978017,0.026696894,0.00094423804],"about_ca_topic_score_codex":0.000049367285,"about_ca_topic_score_gemma":0.000023612823,"teacher_disagreement_score":0.1100418,"about_ca_system_score_codex":0.000021572441,"about_ca_system_score_gemma":0.000058252335,"threshold_uncertainty_score":0.3792007},"labels":[],"label_agreement":null},{"id":"W3022959153","doi":"10.1182/bloodadvances.2019001084","title":"Survival following allogeneic transplant in patients with myelofibrosis","year":2020,"lang":"en","type":"article","venue":"Blood Advances","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":97,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; University Health Network","funders":"National Institute of Allergy and Infectious Diseases; Office of Naval Research; Astellas Pharma US; University of Texas MD Anderson Cancer Center; Adaptive Biotechnologies; Janssen Scientific Affairs; Health Resources and Services Administration; Biomedical Advanced Research and Development Authority; Astellas Pharma; Swedish Orphan Biovitrum; Karyopharm Therapeutics; Omeros Corporation; bluebird bio; Atara Biotherapeutics; Medac; Jazz Pharmaceuticals; National Institutes of Health; Regeneron Pharmaceuticals; Actinium Pharmaceuticals; University of Pittsburgh; U.S. Department of Defense; Medical College of Wisconsin; Daiichi Sankyo Europe; University of Wisconsin-Madison; Takeda Oncology; University of Minnesota; Memorial Sloan-Kettering Cancer Center; Mundipharma EDO; U.S. Navy; Celgene; Sanofi; GlaxoSmithKline; Novartis Pharmaceuticals Corporation; National Center for Advancing Translational Sciences; Janssen Biotech; HistoGenetics; Janssen Pharmaceuticals; Sanofi Genzyme; Incyte; Patient-Centered Outcomes Research Institute; CSL Behring; Bristol-Myers Squibb; Spectrum Pharmaceuticals; Amgen; National Heart, Lung, and Blood Institute; Pfizer; Be The Match Foundation; National Cancer Institute; Gilead Sciences","keywords":"Myelofibrosis; Medicine; Oncology; Internal medicine; Immunology; Bone marrow","score_opus":0.010111506304074607,"score_gpt":0.2263255340203082,"score_spread":0.21621402771623358,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3022959153","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99672,0.0009973113,0.000029311199,0.0009321831,0.000079109384,0.0004590325,0.000026565118,0.00004037178,0.00071611453],"genre_scores_gemma":[0.9975253,0.00019808969,0.001544716,0.0005008395,0.000059989914,0.00006670489,0.000067088724,0.00002020443,0.000017078712],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99893516,0.000029487588,0.00019484578,0.0003226603,0.00029087128,0.00022695397],"domain_scores_gemma":[0.99961513,0.000057419067,0.000043341137,0.000103367056,0.000028513914,0.00015224132],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00003537581,0.00018064432,0.0003679384,0.000037523158,0.000044512915,0.000011416207,0.000051699895,0.000035696474,0.000038509825],"category_scores_gemma":[0.000019340461,0.00012295417,0.000077788514,0.0001935464,0.000021168049,0.00011876389,0.000010206961,0.00008453666,0.000014082071],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00041868977,0.0005940708,0.9948313,0.000053961543,0.00015966101,0.00012455051,0.0003515469,0.00002603199,0.0002490777,0.000044807945,0.000007021922,0.003139268],"study_design_scores_gemma":[0.008704268,0.0018312784,0.9767909,0.00022707444,0.00027975507,0.0000015695051,0.0000632524,0.0000053469357,0.010166905,0.0000088692705,0.0017419778,0.00017881017],"about_ca_topic_score_codex":0.000009368247,"about_ca_topic_score_gemma":0.000060906088,"teacher_disagreement_score":0.018040419,"about_ca_system_score_codex":0.000016117898,"about_ca_system_score_gemma":0.000035024867,"threshold_uncertainty_score":0.50139254},"labels":[],"label_agreement":null},{"id":"W3025325957","doi":"10.1182/blood.2020005335","title":"DLBCL subclassification: divide and conquer?","year":2020,"lang":"en","type":"letter","venue":"Blood","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":12,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Spinal Cord Injury BC; Canada's Michael Smith Genome Sciences Centre","funders":"Genentech; Celgene","keywords":"Medicine; Ruxolitinib; Immunology; Clinical trial; Intensive care medicine; Internal medicine; Bone marrow; Myelofibrosis","score_opus":0.03211092465470565,"score_gpt":0.25524510404347345,"score_spread":0.22313417938876778,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3025325957","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0068696127,0.0016671262,0.0000122792335,0.98495406,0.00012775819,0.00067970203,0.00010686527,0.000099280616,0.0054832934],"genre_scores_gemma":[0.052630164,0.001005413,0.00053551357,0.93631786,0.0049648667,0.0003405093,0.0013552869,0.000081136095,0.0027692483],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9986273,0.000051243827,0.00025696744,0.0005276666,0.0003029988,0.00023383302],"domain_scores_gemma":[0.99915993,0.00016773233,0.000116581046,0.00033064897,0.00008142159,0.00014366322],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00003423289,0.00031306242,0.000565177,0.000064369015,0.000080153826,0.00005021054,0.000066573186,0.000332659,0.00020646841],"category_scores_gemma":[0.000070177106,0.00024735692,0.00010392664,0.00008392549,0.00008694805,0.000029431774,0.00004668523,0.00072692434,0.00022210443],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000014831907,0.00034882146,0.03140606,0.00031976638,0.0005778307,0.002737424,0.00010295957,5.9659535e-9,0.00008710262,0.0001390304,0.96342546,0.0008407368],"study_design_scores_gemma":[0.0038262017,0.00038328784,0.012338091,0.00017958642,0.0012915612,0.0002743706,0.0000069564967,0.000002524355,0.0022146262,0.00012617491,0.9791222,0.00023438585],"about_ca_topic_score_codex":0.000011717534,"about_ca_topic_score_gemma":0.000003087923,"teacher_disagreement_score":0.04863622,"about_ca_system_score_codex":0.000029642695,"about_ca_system_score_gemma":0.00011921439,"threshold_uncertainty_score":0.99999785},"labels":[],"label_agreement":null},{"id":"W3025728373","doi":"10.22374/cjgim.v14i4.311","title":"Extensive Arterial and Venous Thromboses as the Initial Presentation of Polycythemia Vera","year":2019,"lang":"en","type":"article","venue":"Canadian Journal of General Internal Medicine","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"St. Paul's Hospital; University of British Columbia","funders":"","keywords":"Medicine; Polycythemia vera; Neutrophilia; Vasculitis; Gastroenterology; Internal medicine; Surgery; Gynecology","score_opus":0.024237964947717794,"score_gpt":0.3131775191010659,"score_spread":0.2889395541533481,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3025728373","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9863125,0.0014046862,0.00001804194,0.008097262,0.0012189244,0.00024136381,0.000011017577,0.0000015917517,0.0026946256],"genre_scores_gemma":[0.9961283,0.00016713732,0.00009181556,0.0016212332,0.0014036659,0.0000029734142,0.0000065779427,0.0000129809205,0.00056528166],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99897695,0.000056680157,0.00042003414,0.00011222186,0.00025969118,0.00017443168],"domain_scores_gemma":[0.9987532,0.00011689728,0.00027460462,0.00012631722,0.00034933025,0.00037967434],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00015490521,0.00013405588,0.00044399986,0.00017084932,0.000048853002,0.00001518856,0.000091760165,0.000050123133,0.0008928554],"category_scores_gemma":[0.00019584858,0.00007587224,0.00007247163,0.00007020575,0.00022810727,0.00007272283,0.000010266653,0.00019883175,0.000010204346],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.008658194,0.0006745217,0.524507,0.00045539002,0.0052980795,0.008162227,0.04000719,0.00015367917,0.26605278,0.008823197,0.079635434,0.057572294],"study_design_scores_gemma":[0.021103837,0.030043732,0.768076,0.0038592091,0.0014254468,0.017835367,0.0042092456,0.00024436027,0.12786697,0.0021799905,0.022742921,0.00041292427],"about_ca_topic_score_codex":0.009445693,"about_ca_topic_score_gemma":0.0016105397,"teacher_disagreement_score":0.24356897,"about_ca_system_score_codex":0.00009464271,"about_ca_system_score_gemma":0.00053592224,"threshold_uncertainty_score":0.9971505},"labels":[],"label_agreement":null},{"id":"W3029322331","doi":"10.1016/j.clml.2020.05.018","title":"Interferon Therapy in Myelofibrosis: Systematic Review and Meta-analysis","year":2020,"lang":"en","type":"review","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":21,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"National Center for Advancing Translational Sciences; National Cancer Institute; MedImmune; Takeda Canada; Sunesis; Daiichi-Sankyo; CTI Biopharma; National Institutes of Health; Arog Pharmaceuticals; Genentech; Acceleron; Astex Pharmaceuticals; Boehringer Ingelheim; AbbVie; Otsuka America; Memorial Sloan-Kettering Cancer Center; LAM Therapeutics; Novartis; Celgene; Jazz Pharmaceuticals; Takeda Pharmaceuticals U.S.A.; Pfizer; Astellas Pharma US; Astellas Pharma; Constellation Energy Group","keywords":"Medicine; Myelofibrosis; Meta-analysis; Oncology; Internal medicine; Intensive care medicine; Bone marrow","score_opus":0.1528373252975107,"score_gpt":0.41745414368467365,"score_spread":0.26461681838716294,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3029322331","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000033877768,0.9885717,0.00000638578,0.0009810562,0.00008735663,0.009713247,0.0001458818,0.000109485685,0.00035098652],"genre_scores_gemma":[0.00021664245,0.98601574,0.0002998216,0.0051062647,0.00014635306,0.0071610287,0.00033728132,0.00015504893,0.00056179817],"study_design_codex":"systematic_review","study_design_gemma":"meta_analysis","domain_scores_codex":[0.9886173,0.0023227376,0.005708905,0.0020564457,0.0006636289,0.0006310015],"domain_scores_gemma":[0.9926642,0.00280677,0.0018192661,0.0017297785,0.0001981947,0.00078178087],"candidate_categories":["metaepi_narrow","metaepi_broad"],"consensus_categories":["metaepi_narrow"],"category_scores_codex":[0.0018220602,0.001593774,0.03261614,0.00052456406,0.00008991427,0.00011711923,0.0005172396,0.00093675987,0.0005832099],"category_scores_gemma":[0.00129709,0.0009381074,0.0094566075,0.0019739785,0.0002557343,0.000115925235,0.000287047,0.0007583075,0.00046514388],"study_design_candidate":"meta_analysis","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000054641718,0.00030084848,0.00006909079,0.457806,0.22042626,0.00044805033,0.000027046946,5.1688126e-8,1.6240861e-8,0.00006923117,0.0005215024,0.32027724],"study_design_scores_gemma":[0.0011536946,0.0011134422,0.0010971961,0.07867712,0.77789986,0.00020362576,0.000008437184,0.000008431479,5.4591567e-7,0.0000141281935,0.13917881,0.0006447324],"about_ca_topic_score_codex":0.000046901638,"about_ca_topic_score_gemma":0.000030561492,"teacher_disagreement_score":0.55747354,"about_ca_system_score_codex":0.0012048822,"about_ca_system_score_gemma":0.0014126404,"threshold_uncertainty_score":0.999681},"labels":[],"label_agreement":null},{"id":"W3030535343","doi":"10.1016/j.blre.2020.100710","title":"Germline genetic factors in the pathogenesis of myeloproliferative neoplasms","year":2020,"lang":"en","type":"review","venue":"Blood Reviews","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":32,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Institute of Cancer Research; Agence Nationale de la Recherche; MPN Research Foundation; Institut National Du Cancer; Association pour la Recherche sur le Cancer","keywords":"Germline; Biology; Genetics; Myeloproliferative neoplasm; Allele; Germline mutation; Penetrance; Disease; Phenotype; Myeloid; Population; Mutation; Gene; Cancer research; Myelofibrosis; Immunology; Medicine; Bone marrow; Pathology","score_opus":0.08513582315563431,"score_gpt":0.3524276194796198,"score_spread":0.2672917963239855,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3030535343","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0005390526,0.9913946,0.000004909946,0.00017230172,0.000114368675,0.00719677,0.00016802731,0.000021834738,0.00038817708],"genre_scores_gemma":[0.000088012166,0.9954772,0.0012576391,0.00033922648,0.00030869487,0.0020360376,0.00032020587,0.000089079964,0.00008391963],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9946141,0.0012512311,0.0023519297,0.0008435504,0.0005197327,0.00041943922],"domain_scores_gemma":[0.9969738,0.0006504741,0.0011110096,0.0009550424,0.00010045809,0.0002092249],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0005492453,0.001017828,0.0064885155,0.0002428138,0.000073315896,0.000030406149,0.00042150868,0.0003534838,0.00023577928],"category_scores_gemma":[0.0005457765,0.0004898074,0.0016547793,0.0010982001,0.00009952427,0.0000374765,0.00009554,0.00062001246,0.00016495674],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000013780369,0.0011403323,0.0030146162,0.030818654,0.0007414705,0.0004653054,0.00096528075,1.3035985e-7,0.0000035147536,0.00012427723,0.00057431974,0.9621383],"study_design_scores_gemma":[0.0008045922,0.0006489072,0.0018958461,0.019732524,0.007546376,0.00030766233,0.000042171505,0.0000011941183,0.000029785573,0.0000060541042,0.9686057,0.00037918217],"about_ca_topic_score_codex":0.000021456199,"about_ca_topic_score_gemma":0.00003375791,"teacher_disagreement_score":0.9680314,"about_ca_system_score_codex":0.00008288795,"about_ca_system_score_gemma":0.00055444863,"threshold_uncertainty_score":0.9997554},"labels":[],"label_agreement":null},{"id":"W3039230543","doi":"10.1182/bloodadvances.2019001212","title":"Safety and efficacy of the combination of sonidegib and ruxolitinib in myelofibrosis: a phase 1b/2 dose-finding study","year":2020,"lang":"en","type":"article","venue":"Blood Advances","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Ruxolitinib; Myelofibrosis; Medicine; Oncology; Internal medicine; Phases of clinical research; Phase (matter); Clinical trial; Bone marrow; Chemistry","score_opus":0.025519984638298777,"score_gpt":0.3188262696074818,"score_spread":0.293306284969183,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3039230543","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99540585,0.0023101182,0.000004017464,0.0010983454,0.00002105845,0.00088679144,0.000016650121,0.0000081503085,0.00024902166],"genre_scores_gemma":[0.9990657,0.00058541505,0.00020449105,0.00007667541,0.000019373507,0.000029047169,0.0000036169542,0.0000071446593,0.000008519049],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9991636,0.00006475594,0.00030520186,0.00020005928,0.00016652793,0.00009981268],"domain_scores_gemma":[0.9994412,0.00021240328,0.00014786464,0.00009856033,0.000040791492,0.000059149814],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00010918881,0.000107930275,0.00034870952,0.000040678402,0.00004685833,0.0000063610387,0.000038396985,0.000023317578,0.0000067022124],"category_scores_gemma":[0.00018259592,0.00007034398,0.00003172752,0.00018297804,0.00007768812,0.000076830445,0.000043459764,0.00006918998,2.4117392e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00075223215,0.005900609,0.96703523,0.00022523718,0.0001300095,0.00001119908,0.0051068817,0.0000066150997,0.0025622172,0.0010708118,0.0000033941503,0.017195567],"study_design_scores_gemma":[0.036723733,0.003380069,0.9278944,0.0003315975,0.0002640973,0.0000070057185,0.0021150003,0.00006698481,0.028823722,0.00007749299,0.00023720144,0.00007868392],"about_ca_topic_score_codex":0.000018150176,"about_ca_topic_score_gemma":0.000026304304,"teacher_disagreement_score":0.039140813,"about_ca_system_score_codex":0.000008665382,"about_ca_system_score_gemma":0.000030216424,"threshold_uncertainty_score":0.28685442},"labels":[],"label_agreement":null},{"id":"W3040782867","doi":"10.1038/s41375-020-0979-6","title":"Spliceosome mutations are common in persons with myeloproliferative neoplasm-associated myelofibrosis with RBC-transfusion-dependence and correlate with response to pomalidomide","year":2020,"lang":"en","type":"letter","venue":"Leukemia","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Vancouver General Hospital; Ontario Institute for Cancer Research; Princess Margaret Cancer Centre","funders":"Rosetrees Trust; National Cancer Institute; Medical Research Council; National Institute for Health and Care Research; Cancer Research UK","keywords":"Pomalidomide; Myelofibrosis; Myeloproliferative neoplasm; Medicine; Polycythemia vera; Hematology; Spliceosome; Neoplasm; Myeloproliferative Disorders; Internal medicine; Pathology; Bone marrow; Biology; Genetics; Multiple myeloma; Gene","score_opus":0.011972133214173054,"score_gpt":0.23844778537906933,"score_spread":0.22647565216489626,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3040782867","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.7110295,0.00010725368,0.00007317975,0.28418085,0.000049036513,0.0034826174,0.0004926506,0.00015538395,0.00042951814],"genre_scores_gemma":[0.7505658,0.00015713823,0.003134212,0.2384503,0.00032333907,0.003044559,0.0009570147,0.00033196594,0.0030356674],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9952383,0.00050333125,0.0006404404,0.0015877086,0.0011302994,0.0008999171],"domain_scores_gemma":[0.9967977,0.0012445685,0.00044910275,0.00062210776,0.0003447117,0.0005418367],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.00017954133,0.0011683094,0.0018772366,0.0005658519,0.0004132683,0.0001826566,0.00021820147,0.00071336835,0.00007502866],"category_scores_gemma":[0.00016716887,0.0008000745,0.000121576966,0.0012677868,0.00033423147,0.00021828363,0.00008134138,0.002696497,0.00006762745],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.05850556,0.0006998647,0.757716,0.0008617442,0.0036548027,0.067048185,0.024389133,0.0012167395,0.0011770584,0.00004386345,0.08394771,0.0007393152],"study_design_scores_gemma":[0.02964258,0.015437096,0.90561116,0.01250192,0.0029106622,0.0027608608,0.0031555833,0.0006608809,0.0016977988,0.000048647686,0.022786623,0.0027861698],"about_ca_topic_score_codex":0.0012695659,"about_ca_topic_score_gemma":0.007849155,"teacher_disagreement_score":0.14789516,"about_ca_system_score_codex":0.0018149938,"about_ca_system_score_gemma":0.0016850837,"threshold_uncertainty_score":0.99960434},"labels":[],"label_agreement":null},{"id":"W3042058544","doi":"10.1212/wnl.0000000000009926","title":"Teaching NeuroImages: Intracranial extramedullary hematopoiesis","year":2020,"lang":"en","type":"article","venue":"Neurology","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"Medicine; Headaches; Extramedullary hematopoiesis; Biopsy; Papilledema; Weakness; Polycythemia vera; Magnetic resonance imaging; Radiology; Surgery; Haematopoiesis; Internal medicine","score_opus":0.025195661019837015,"score_gpt":0.2752296217812505,"score_spread":0.2500339607614135,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3042058544","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.87399703,0.000120555924,0.00017120363,0.12077029,0.00016586916,0.00031738935,0.0000067010633,0.00014892867,0.0043020067],"genre_scores_gemma":[0.9367935,0.000055172408,0.0008811919,0.06163655,0.0005041242,0.000042003532,0.000012918997,0.00003399104,0.000040511983],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99868995,0.00014982182,0.00024737773,0.00044701368,0.00017389959,0.00029194492],"domain_scores_gemma":[0.9992288,0.00020753084,0.00005824941,0.00020616973,0.000033927496,0.0002653217],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00006493796,0.00019762752,0.00039730262,0.000049044742,0.00010226314,0.00001668337,0.00008628603,0.000113456386,0.00043409408],"category_scores_gemma":[0.00024644253,0.00016519015,0.000110446024,0.00008577435,0.0000717506,0.000053670312,0.00006148164,0.00055910944,0.0002582687],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.010588072,0.003952232,0.6969407,0.00082661863,0.00092405477,0.038888276,0.006758405,0.00007676711,0.07085837,0.017075893,0.04614662,0.106963985],"study_design_scores_gemma":[0.014747395,0.031319432,0.58603084,0.00006826181,0.0009668269,0.008839696,0.00012116234,0.008078504,0.012991903,0.001015148,0.334738,0.0010828283],"about_ca_topic_score_codex":0.0000398219,"about_ca_topic_score_gemma":0.0000069947337,"teacher_disagreement_score":0.28859138,"about_ca_system_score_codex":0.000009126731,"about_ca_system_score_gemma":0.000049375754,"threshold_uncertainty_score":0.6736259},"labels":[],"label_agreement":null},{"id":"W3048012000","doi":"10.1503/cmaj.191587","title":"Investigation and management of erythrocytosis","year":2020,"lang":"en","type":"review","venue":"Canadian Medical Association Journal","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":88,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"McMaster University","funders":"Canadian Institutes of Health Research","keywords":"Hemoconcentration; Plasma volume; Internal medicine; Hematocrit; Endocrinology; Medicine; Chemistry","score_opus":0.03443674539649303,"score_gpt":0.2958217250853511,"score_spread":0.26138497968885804,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3048012000","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00008656537,0.98810804,0.000004971079,0.009578815,0.0002136179,0.00049008016,0.000049276154,0.0000081388625,0.0014605052],"genre_scores_gemma":[0.00005467701,0.99727374,0.00034500958,0.0015521792,0.00050092087,0.000040709427,0.000054944412,0.000023147206,0.00015467501],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99768513,0.00015680361,0.000706004,0.00020616554,0.0009985258,0.0002473581],"domain_scores_gemma":[0.997193,0.00014441693,0.00050936313,0.00008438214,0.00018602169,0.001882821],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000522478,0.00021936477,0.0011821854,0.00020873794,0.00010372612,0.000036806436,0.00008205108,0.00045726803,0.0007626866],"category_scores_gemma":[0.00031164248,0.00016874849,0.00024048035,0.00027479313,0.00004110406,0.000041065876,0.000021757769,0.0006935046,0.00006084917],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0000020351436,0.000015125127,0.002048088,0.0040312884,0.0013748908,0.0008839096,0.000066595676,1.13828165e-8,1.3291136e-8,0.00042582394,0.019455625,0.9716966],"study_design_scores_gemma":[0.00057960645,0.00010498057,0.00078715803,0.012174753,0.0014833795,0.0006354956,0.00004229766,0.000003872436,7.978625e-7,0.000028595483,0.9840458,0.0001132369],"about_ca_topic_score_codex":0.00020837334,"about_ca_topic_score_gemma":0.0008219705,"teacher_disagreement_score":0.97158337,"about_ca_system_score_codex":0.0011822265,"about_ca_system_score_gemma":0.0030453082,"threshold_uncertainty_score":0.8350883},"labels":[],"label_agreement":null},{"id":"W3085980128","doi":"10.1182/bloodadvances.2020002662","title":"ACVR1/JAK1/JAK2 inhibitor momelotinib reverses transfusion dependency and suppresses hepcidin in myelofibrosis phase 2 trial","year":2020,"lang":"en","type":"article","venue":"Blood Advances","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":123,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sierra Wireless (Canada); Princess Margaret Cancer Centre","funders":"National Cancer Institute","keywords":"Hepcidin; Anemia; Myelofibrosis; Medicine; Erythropoiesis; Internal medicine; Neutropenia; Gastroenterology; Ruxolitinib; Ineffective erythropoiesis; Bone marrow; Immunology; Chemotherapy","score_opus":0.025583402700213535,"score_gpt":0.3067703012933573,"score_spread":0.2811868985931438,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3085980128","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9867166,0.0071495613,0.000019780271,0.003784227,0.00019378979,0.001446551,0.00008219732,0.00007750531,0.00052975887],"genre_scores_gemma":[0.9862211,0.010657067,0.001791824,0.00046880805,0.00046766704,0.0002480156,0.00004928407,0.00003017764,0.00006610962],"study_design_codex":"observational","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99817973,0.00008586994,0.00047063694,0.00060674653,0.0003433063,0.00031373368],"domain_scores_gemma":[0.99915373,0.00023547777,0.00010110309,0.00016495895,0.000057960122,0.0002867688],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000100132704,0.00030656144,0.00063925044,0.000100116624,0.00010511959,0.00003911714,0.000076050695,0.00010487213,0.00026165816],"category_scores_gemma":[0.00027706922,0.00024209126,0.00010826042,0.00028860397,0.00007644391,0.00035477625,0.000041714342,0.00019089243,0.00001533566],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.12369395,0.017515186,0.45148894,0.0022491692,0.00077000656,0.0019987242,0.008979547,0.000042989646,0.24220227,0.00060018955,0.0021084717,0.14835055],"study_design_scores_gemma":[0.24520493,0.012059277,0.010308466,0.00065789925,0.0006607542,0.00007504999,0.0010233577,0.000058270623,0.70110494,0.00018254727,0.028071655,0.0005928402],"about_ca_topic_score_codex":0.00004655989,"about_ca_topic_score_gemma":0.00013674513,"teacher_disagreement_score":0.4589027,"about_ca_system_score_codex":0.000022098202,"about_ca_system_score_gemma":0.00008814046,"threshold_uncertainty_score":0.9872195},"labels":[],"label_agreement":null},{"id":"W3087464372","doi":"10.3390/cancers12092669","title":"Modification of the Histone Landscape with JAK Inhibition in Myeloproliferative Neoplasms","year":2020,"lang":"en","type":"article","venue":"Cancers","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Medical Research Council; Sierra Oncology; Health Service Executive; Wellcome Trust; Canadian Institute for Theoretical Astrophysics; Health Research Board; Celgene","keywords":"H3K4me3; Ruxolitinib; Histone; Cancer research; Chromatin immunoprecipitation; Epigenetics; EZH2; Histone methyltransferase; Histone methylation; Biology; Histone H3; Genetics; Gene expression; DNA methylation; Promoter; Gene; Immunology","score_opus":0.024672336464410197,"score_gpt":0.27460888761306756,"score_spread":0.24993655114865737,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3087464372","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98941165,0.0003131636,0.00008033598,0.0070881615,0.00004218825,0.00063608494,0.000017457327,0.0000161326,0.002394812],"genre_scores_gemma":[0.99817663,0.00010867766,0.00020905482,0.0011688449,0.000056974517,0.00016362261,0.000025409146,0.000012150538,0.000078605386],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9992542,0.000033763714,0.00018615715,0.00021089928,0.00019786214,0.00011708285],"domain_scores_gemma":[0.99955726,0.00003069758,0.00010389471,0.00014231833,0.000089503024,0.00007632232],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000040928397,0.0001146749,0.00023188928,0.00003721885,0.000039273298,0.000005342705,0.000030341695,0.000043096486,0.000078268175],"category_scores_gemma":[0.00003815548,0.00006880182,0.0000419816,0.0003287239,0.000077959274,0.00005152938,0.000012531247,0.00012080169,0.0000075144453],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.004502977,0.0003986976,0.89780086,0.00052651664,0.00041240617,0.00012498397,0.027051583,0.019757709,0.026397392,0.008017773,0.009102484,0.0059066154],"study_design_scores_gemma":[0.012434119,0.0023698295,0.5353372,0.0008695635,0.0002746414,0.000050851388,0.0023154106,0.012390497,0.4301428,0.0001365171,0.0032793577,0.0003991999],"about_ca_topic_score_codex":0.00011017639,"about_ca_topic_score_gemma":0.00021912191,"teacher_disagreement_score":0.4037454,"about_ca_system_score_codex":0.0004641745,"about_ca_system_score_gemma":0.00046095654,"threshold_uncertainty_score":0.28056568},"labels":[],"label_agreement":null},{"id":"W3093044960","doi":"10.1038/s41586-020-2786-7","title":"Inherited myeloproliferative neoplasm risk affects haematopoietic stem cells","year":2020,"lang":"en","type":"article","venue":"Nature","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":148,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; University Health Network","funders":"National Institute of Diabetes and Digestive and Kidney Diseases; National Heart, Lung, and Blood Institute; National Institutes of Health; U.S. Department of Veterans Affairs; Howard Hughes Medical Institute","keywords":"Haematopoiesis; Biology; Stem cell; Myeloproliferative neoplasm; Genetics; Myeloid; Somatic cell; Cancer research; Immunology; Gene; Bone marrow; Myelofibrosis","score_opus":0.013998981970451303,"score_gpt":0.25678130965672463,"score_spread":0.24278232768627334,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3093044960","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9764422,0.0026020715,0.000080399535,0.014939849,0.0003751503,0.0015678552,0.00011465662,0.00027053335,0.0036072473],"genre_scores_gemma":[0.9859862,0.0003938003,0.0012601275,0.011125503,0.0004296562,0.00013287507,0.000047288635,0.00006136769,0.0005631917],"study_design_codex":"observational","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99797153,0.00016202239,0.00027775875,0.00065760466,0.0005266484,0.00040444577],"domain_scores_gemma":[0.9985629,0.00023056005,0.00016287806,0.0003306076,0.00019871315,0.00051434344],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.00011253131,0.00042147416,0.00070369337,0.0000804069,0.00017678515,0.0000601487,0.00012704471,0.0011325136,0.00027019106],"category_scores_gemma":[0.00012332805,0.00031395603,0.00021256636,0.0005064288,0.00006649762,0.00010068122,0.000072229945,0.0027676702,0.00046859248],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0035284248,0.002870926,0.5672933,0.0020629128,0.0038461161,0.006151584,0.021568142,0.00025272893,0.03521559,0.0065689962,0.30513105,0.045510214],"study_design_scores_gemma":[0.015576978,0.004371506,0.13183343,0.00075745105,0.0014364875,0.00038074155,0.0012409233,0.0031308227,0.6934969,0.00025064166,0.14607811,0.0014459798],"about_ca_topic_score_codex":0.000008351994,"about_ca_topic_score_gemma":0.000015595966,"teacher_disagreement_score":0.6582813,"about_ca_system_score_codex":0.000102788305,"about_ca_system_score_gemma":0.00015638169,"threshold_uncertainty_score":0.9999313},"labels":[],"label_agreement":null},{"id":"W3093975417","doi":"10.1182/bloodadvances.2020002119","title":"Phase 2 study of ruxolitinib and decitabine in patients with myeloproliferative neoplasm in accelerated and blast phase","year":2020,"lang":"en","type":"article","venue":"Blood Advances","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":72,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"National Cancer Institute; Genentech; National Institutes of Health; Astellas Pharma; MacroGenics; Galecto; Sierra Oncology; CTI Biopharma; Incyte; Memorial Sloan-Kettering Cancer Center; Gilead Sciences; Cardinal Health; Amgen; Pfizer; PTC Therapeutics; Celgene; Eli Lilly and Company; AstraZeneca; Agios Pharmaceuticals","keywords":"Ruxolitinib; Decitabine; Medicine; Myeloproliferative neoplasm; Internal medicine; Phases of clinical research; Confidence interval; Population; Clinical endpoint; Oncology; Gastroenterology; Clinical trial; Myelofibrosis; Surgery; Bone marrow","score_opus":0.019484069314681895,"score_gpt":0.3019457263841157,"score_spread":0.2824616570694338,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3093975417","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99704975,0.0007063018,0.0000035661137,0.0003029663,0.000013397221,0.0017117116,0.000052744326,0.000016168435,0.00014338738],"genre_scores_gemma":[0.99895513,0.00020648379,0.00040651477,0.00018291552,0.000026594249,0.00015896592,0.000038893006,0.000018373414,0.000006129419],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99859023,0.00006842171,0.0004224383,0.0004555101,0.00024008645,0.00022330771],"domain_scores_gemma":[0.99932486,0.00012341498,0.00013183712,0.000109786706,0.00012239446,0.000187736],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000062596955,0.00025322684,0.0006397184,0.00013066902,0.000041149327,0.000018445855,0.000039416576,0.000040515846,0.000021278267],"category_scores_gemma":[0.00009133528,0.00018107762,0.000015204746,0.00038893567,0.00008318498,0.00022900604,0.00003873626,0.0001497126,8.883671e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.003572174,0.019160178,0.9592923,0.00009324877,0.00013438535,0.00013986624,0.0052215834,0.000010461697,0.00018582192,0.000025189232,0.0000037122886,0.012161088],"study_design_scores_gemma":[0.18705201,0.034474373,0.7664463,0.00026642892,0.00020123596,0.000008891214,0.0028996011,0.00017435908,0.008070604,0.000018062468,0.00013962231,0.00024854572],"about_ca_topic_score_codex":0.000029056602,"about_ca_topic_score_gemma":0.00028143983,"teacher_disagreement_score":0.19284603,"about_ca_system_score_codex":0.000016034082,"about_ca_system_score_gemma":0.000053868698,"threshold_uncertainty_score":0.7384131},"labels":[],"label_agreement":null},{"id":"W3094089270","doi":"10.1002/ajh.26034","title":"Splenectomy before allogeneic hematopoietic cell transplantation for myelofibrosis: A French nationwide study","year":2020,"lang":"en","type":"article","venue":"American Journal of Hematology","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":23,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hotel Dieu Hospital","funders":"Université de Lille","keywords":"Splenectomy; Medicine; Myelofibrosis; Hazard ratio; Transplantation; Incidence (geometry); Surgery; Hematopoietic cell; Internal medicine; Hematopoietic stem cell transplantation; Confidence interval; Bone marrow; Haematopoiesis; Spleen; Stem cell","score_opus":0.014417830692706574,"score_gpt":0.2808319163925815,"score_spread":0.2664140856998749,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3094089270","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9883154,0.0004308896,0.0035529872,0.006747713,0.000078895835,0.0007563807,0.000016373173,0.000018025832,0.00008332543],"genre_scores_gemma":[0.990803,0.000092676,0.00761126,0.0012229856,0.00011865353,0.00009625291,0.000016150165,0.000026593198,0.000012427606],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9984864,0.00010524035,0.0006752137,0.00023610586,0.00026395073,0.0002330783],"domain_scores_gemma":[0.99853516,0.00024520676,0.0005539244,0.00011778173,0.00030431183,0.0002436431],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00014620366,0.00020037216,0.0008935669,0.00014130774,0.00007193414,0.000012599851,0.000107077554,0.000042992684,0.00007693212],"category_scores_gemma":[0.00008300291,0.0001506567,0.00021978107,0.00024983782,0.00009455689,0.000066156674,0.000010772545,0.00014846162,0.00001200184],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0010738233,0.0017509487,0.9743026,0.00038243315,0.0007762501,0.00071652746,0.012429786,0.000039715214,0.0014993815,0.0003916989,0.00090852176,0.005728325],"study_design_scores_gemma":[0.026742617,0.09069215,0.76294535,0.00045284475,0.0042886212,0.010955848,0.015229441,0.0002339836,0.08476291,0.0006690959,0.002310575,0.00071656174],"about_ca_topic_score_codex":0.000017289822,"about_ca_topic_score_gemma":0.000027141185,"teacher_disagreement_score":0.21135724,"about_ca_system_score_codex":0.000037299225,"about_ca_system_score_gemma":0.00018387882,"threshold_uncertainty_score":0.6143602},"labels":[],"label_agreement":null},{"id":"W3094350415","doi":"10.1097/wno.0000000000001096","title":"Papilledema and Extensive Dural Sinus Thrombosis Due to JAK2 Mutation","year":2020,"lang":"en","type":"article","venue":"Journal of Neuro-Ophthalmology","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"","keywords":"Medicine; Papilledema; Optic nerve; Fundus (uterus); Optic disc; Headaches; Intracranial pressure; Ophthalmology; Subarachnoid space; Anatomy; Glaucoma; Surgery; Pathology; Cerebrospinal fluid","score_opus":0.04953454244734873,"score_gpt":0.31857662655930546,"score_spread":0.26904208411195674,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3094350415","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9549674,0.00026793557,0.000030411473,0.043593325,0.0002550074,0.00029177658,0.000006343335,0.0000086562495,0.0005791663],"genre_scores_gemma":[0.99215096,0.00006289722,0.0011498061,0.0062160604,0.00035014874,0.000009668836,0.0000029663736,0.000022809425,0.0000346651],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9986815,0.00013781685,0.0004792039,0.00024864924,0.00023946185,0.0002133959],"domain_scores_gemma":[0.99849486,0.00037282356,0.00026934053,0.0001065626,0.00034243256,0.0004140035],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00009407473,0.00019098852,0.00067160244,0.00012374623,0.00006671741,0.000019735042,0.00006317792,0.00008537503,0.00027954785],"category_scores_gemma":[0.00080296776,0.00014205977,0.00012899165,0.00016499257,0.000057889407,0.000089559144,0.000048799047,0.0002458023,0.000045088364],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0051138992,0.0016899642,0.442822,0.00033006078,0.0016710949,0.37991232,0.0073965755,0.00029085355,0.1288936,0.0006123426,0.023650538,0.007616753],"study_design_scores_gemma":[0.0027149138,0.01003155,0.8028367,0.000065669614,0.000274399,0.1759763,0.00025617637,0.000085233536,0.006748054,0.00017488531,0.0006959543,0.00014013122],"about_ca_topic_score_codex":0.0000069792363,"about_ca_topic_score_gemma":4.6837454e-7,"teacher_disagreement_score":0.36001474,"about_ca_system_score_codex":0.000039977826,"about_ca_system_score_gemma":0.000077180244,"threshold_uncertainty_score":0.5793029},"labels":[],"label_agreement":null},{"id":"W3094714150","doi":"10.1182/blood-2020-136135","title":"Molecular Response Patterns in Hydroxyurea (HU)-Resistant or Intolerant Polycythemia Vera (PV) during Treatment with Idasanutlin: Results of an Open-Label, Single-Arm Phase 2 Study","year":2020,"lang":"en","type":"article","venue":"Blood","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Polycythemia vera; Medicine; Open label; Internal medicine; Gastroenterology; Immunology; Clinical trial","score_opus":0.05130384645611689,"score_gpt":0.3253553041844848,"score_spread":0.27405145772836786,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3094714150","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9950115,0.00018265018,0.000006452078,0.0012751516,0.000018421988,0.003081825,0.00022990479,0.000054857213,0.00013924914],"genre_scores_gemma":[0.9983642,0.000038081762,0.000694971,0.00022570971,0.000055574405,0.0004177466,0.000085249834,0.0000689507,0.000049481096],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9971631,0.00032999107,0.0007690892,0.0008422504,0.0004940368,0.0004015288],"domain_scores_gemma":[0.9984263,0.00015261862,0.0002432807,0.0006750091,0.00009495498,0.00040782025],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0002418313,0.00046988463,0.000952478,0.00016198853,0.000088015535,0.00006924944,0.00023073603,0.00008484881,0.00005262634],"category_scores_gemma":[0.00012410792,0.0003085014,0.0000527875,0.00040431082,0.00005009902,0.00013770415,0.00011452772,0.00017057444,0.000005899824],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.31239226,0.20654541,0.03950842,0.00015681409,0.0015673921,0.028451936,0.013698819,0.000041597086,0.39541215,0.000006343761,0.0000067576775,0.0022121011],"study_design_scores_gemma":[0.209625,0.16363728,0.020173347,0.000478052,0.00078590657,0.000093311995,0.0012063059,0.0001204734,0.6034437,0.0000016061438,0.00010410683,0.0003309313],"about_ca_topic_score_codex":0.00047882102,"about_ca_topic_score_gemma":0.000503627,"teacher_disagreement_score":0.20803154,"about_ca_system_score_codex":0.00020302883,"about_ca_system_score_gemma":0.00029070603,"threshold_uncertainty_score":0.9999367},"labels":[],"label_agreement":null},{"id":"W3094835149","doi":"10.1182/blood-2020-139229","title":"Direct Oral Anticoagulants for Myeloproliferative Neoplasms (MPN-DOACs): Results from an International Study on 442 Patients","year":2020,"lang":"en","type":"article","venue":"Blood","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Medicine; Polycythemia vera; Hematologic Neoplasms; Internal medicine; Myelofibrosis; Intensive care medicine; Cancer; Bone marrow","score_opus":0.051685985827309974,"score_gpt":0.3246730739206457,"score_spread":0.2729870880933357,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3094835149","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99106747,0.00001932796,0.000018749151,0.0018187888,0.0003173267,0.0023862459,0.0021545684,0.00010782653,0.0021097113],"genre_scores_gemma":[0.9940164,0.000024455803,0.0010807257,0.0017901788,0.0005835288,0.0003229378,0.0020452086,0.000048032703,0.00008851165],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9976372,0.000118756885,0.0005079076,0.0008565915,0.0005729064,0.00030660382],"domain_scores_gemma":[0.9985254,0.00030998047,0.00017239997,0.00034268675,0.0002932981,0.0003562464],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00012915002,0.00035697027,0.0006791825,0.00008352648,0.00014433965,0.000080064136,0.00017821317,0.00009266612,0.00008352046],"category_scores_gemma":[0.0005853571,0.00027599224,0.00012856153,0.00014004002,0.000033009084,0.00016761973,0.00006145916,0.0001617822,0.000116059964],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0056149126,0.019181775,0.9630958,0.000012837834,0.0019837092,0.0001534199,0.005872942,0.000015085925,0.0003725834,0.00009038301,0.0016774414,0.0019291338],"study_design_scores_gemma":[0.04878186,0.012126735,0.89468116,0.000089824,0.00080915523,0.0000032519283,0.00051075063,0.00046528428,0.040468093,0.000031156218,0.0016727094,0.0003600259],"about_ca_topic_score_codex":0.0000894558,"about_ca_topic_score_gemma":0.00007173733,"teacher_disagreement_score":0.06841462,"about_ca_system_score_codex":0.00005416666,"about_ca_system_score_gemma":0.00008801202,"threshold_uncertainty_score":0.99996924},"labels":[],"label_agreement":null},{"id":"W3094933225","doi":"10.1111/ejh.13543","title":"Prevalence and risk factors for Pulmonary Hypertension associated with chronic Myeloproliferative Neoplasms","year":2020,"lang":"en","type":"review","venue":"European Journal Of Haematology","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":20,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Essential thrombocythemia; Polycythemia vera; Myelofibrosis; Pulmonary hypertension; Internal medicine; Myeloproliferative neoplasm; Bone marrow","score_opus":0.044727797251144424,"score_gpt":0.2880866734117881,"score_spread":0.2433588761606437,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3094933225","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.023301631,0.9743348,0.00010898799,0.00022972815,0.00020510882,0.0015169079,0.00013449645,0.000027144832,0.00014120752],"genre_scores_gemma":[0.010385027,0.9883896,0.0005776522,0.000062246916,0.00025411128,0.000031976688,0.00007471544,0.00013452265,0.000090140995],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9962696,0.0013408919,0.001199239,0.00051753427,0.00030234494,0.00037040198],"domain_scores_gemma":[0.9953134,0.0015305062,0.0021254215,0.00022927813,0.00042305986,0.00037833527],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0005402779,0.0006708074,0.0038399564,0.00024054205,0.0001762434,0.000034475455,0.00018262671,0.00016167667,0.000034717916],"category_scores_gemma":[0.0011488287,0.00037639966,0.0005199461,0.00019398228,0.00019927823,0.00009238897,0.00008053383,0.00087031367,0.000018105837],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0015250824,0.0017292546,0.04787832,0.039737917,0.018154832,0.10383291,0.0010905382,0.000008158012,0.0000048231364,0.00032429214,0.003238517,0.78247535],"study_design_scores_gemma":[0.00731747,0.02276563,0.015186869,0.07462522,0.030356614,0.12558638,0.00009116028,0.00012667288,0.00005398184,0.00002903838,0.7226934,0.0011675552],"about_ca_topic_score_codex":0.0000015396188,"about_ca_topic_score_gemma":0.0000035976639,"teacher_disagreement_score":0.7813078,"about_ca_system_score_codex":0.00020664581,"about_ca_system_score_gemma":0.0006799394,"threshold_uncertainty_score":0.9998688},"labels":[],"label_agreement":null},{"id":"W3094956814","doi":"10.1182/blood-2020-136746","title":"Incidence, Outcomes and Predictors of Acute Kidney Injury Post Allogeneic Stem Cell Transplant","year":2020,"lang":"en","type":"article","venue":"Blood","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Medicine; Internal medicine; Hazard ratio; Incidence (geometry); Proportional hazards model; Hematopoietic stem cell transplantation; Univariate analysis; Acute kidney injury; Transplantation; Graft-versus-host disease; Multivariate analysis; Cohort; Oncology; Confidence interval","score_opus":0.01053403100205351,"score_gpt":0.23570796655876727,"score_spread":0.22517393555671378,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3094956814","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9954269,0.00022773504,0.00000574712,0.0026414467,0.000050082515,0.00040840803,0.00073979405,0.000035818106,0.00046405272],"genre_scores_gemma":[0.9966954,0.000596559,0.00021731277,0.0022154632,0.00005095534,0.000033426924,0.000075746655,0.000017197366,0.000097965574],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.999075,0.000029460214,0.0002665956,0.00025452106,0.0002164884,0.00015793002],"domain_scores_gemma":[0.999315,0.00004342158,0.00007529781,0.0001398025,0.00005789578,0.00036853953],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000044469114,0.00017462918,0.00042027695,0.000047322777,0.000034707366,0.000007969648,0.000057988833,0.00007092292,0.00005912233],"category_scores_gemma":[0.000012072356,0.00012236237,0.000091490714,0.000093336515,0.00004740889,0.000042489886,0.000027965472,0.0000905992,0.000012234533],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00016220959,0.0005769226,0.97050345,0.00017330314,0.00076876546,0.00015741766,0.0015104663,9.9747496e-8,0.025459524,0.000034918936,0.0004875014,0.00016539355],"study_design_scores_gemma":[0.004788368,0.002204375,0.648068,0.00010895818,0.0020896948,0.00004477381,0.00006463837,0.0000062978324,0.34187016,0.0000035687553,0.00061307853,0.00013808522],"about_ca_topic_score_codex":0.000017214661,"about_ca_topic_score_gemma":0.0000022687072,"teacher_disagreement_score":0.32243547,"about_ca_system_score_codex":0.000008124065,"about_ca_system_score_gemma":0.0001152881,"threshold_uncertainty_score":0.49897924},"labels":[],"label_agreement":null},{"id":"W3095151225","doi":"10.1182/blood-2020-140408","title":"Adore: A Randomized, Open-Label, Phase 1/2 Open-Platform Study Evaluating Safety and Efficacy of Novel Ruxolitinib Combinations in Patients with Myelofibrosis","year":2020,"lang":"en","type":"article","venue":"Blood","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Ruxolitinib; Myelofibrosis; Open label; Medicine; Phases of clinical research; Randomized controlled trial; Internal medicine; Clinical trial; Oncology; Surgery; Bone marrow","score_opus":0.07703137770199205,"score_gpt":0.3677363953716987,"score_spread":0.2907050176697067,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3095151225","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9885199,0.00005915461,0.00003589083,0.0005203739,0.000016186377,0.009465485,0.00011649016,0.000012568824,0.0012539566],"genre_scores_gemma":[0.99503684,0.000020373072,0.00393368,0.0002739332,0.00001539326,0.0005279135,0.0001396919,0.000027520273,0.000024680108],"study_design_codex":"observational","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9981021,0.0001271659,0.00068728765,0.00045510335,0.0004110965,0.00021719279],"domain_scores_gemma":[0.9984136,0.0006120775,0.00027472794,0.0002467384,0.00025118337,0.00020164848],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00060354546,0.00024539244,0.0011395998,0.0000810553,0.00012627123,0.00008174837,0.00019863872,0.00004726735,0.00009098157],"category_scores_gemma":[0.00072769204,0.00017239635,0.000035029418,0.00036908442,0.0000851534,0.00022795539,0.0003086859,0.00014477943,0.000004116176],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.20485109,0.19663236,0.58002377,0.0001380083,0.0014825851,0.000030580213,0.005666021,0.000010465959,0.00020407914,0.0022441929,0.000028917751,0.008687953],"study_design_scores_gemma":[0.79320735,0.013546567,0.19059409,0.00028252564,0.0009603699,0.0000030343047,0.0002556564,0.0003941483,0.00058724696,0.00001099519,0.000009217331,0.00014882241],"about_ca_topic_score_codex":0.00017683773,"about_ca_topic_score_gemma":0.000049958355,"teacher_disagreement_score":0.58835626,"about_ca_system_score_codex":0.00003339517,"about_ca_system_score_gemma":0.00015692282,"threshold_uncertainty_score":0.70301193},"labels":[],"label_agreement":null},{"id":"W3095176799","doi":"10.1182/blood-2020-139936","title":"Clinical Significance of Emergent Leukocytosis in Patients with Myelofibrosis Receiving JAK Inhibitor Therapy","year":2020,"lang":"en","type":"article","venue":"Blood","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network; Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Leukocytosis; Ruxolitinib; Medicine; Myelofibrosis; Internal medicine; Clinical significance; Constitutional symptoms; Gastroenterology; Apheresis; Immunology; Bone marrow; Disease","score_opus":0.03236018264559547,"score_gpt":0.279762470930096,"score_spread":0.2474022882845005,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3095176799","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9974529,0.00024410052,0.000009355611,0.0011005311,0.00005439626,0.0008454117,0.000020080626,0.000024968302,0.00024827066],"genre_scores_gemma":[0.99718624,0.00049920374,0.0014552479,0.00055758597,0.00012980925,0.00010656603,0.000023672565,0.000026636733,0.000015014326],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99844456,0.00008960709,0.00054679054,0.00038709497,0.00033153332,0.00020041152],"domain_scores_gemma":[0.9991907,0.000120736855,0.0001662377,0.00020567658,0.00012772359,0.00018894461],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00011899436,0.00018523443,0.00053980236,0.000048617276,0.000029542942,0.00000700599,0.0000664316,0.00007812251,0.00014286724],"category_scores_gemma":[0.00011101228,0.00012979258,0.000112849666,0.00028989246,0.00005585775,0.00005127058,0.00002676135,0.00015145734,0.000014309674],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000945653,0.0039417045,0.9850051,0.000051274015,0.00023268466,0.000011409664,0.00042623276,0.0000031412937,0.00074418535,0.000011455818,0.00025175622,0.008375448],"study_design_scores_gemma":[0.013310714,0.004508836,0.927115,0.00020766942,0.00010933022,4.2913362e-7,0.000045046047,0.000008464132,0.054118104,0.0000023517816,0.00044979833,0.00012423082],"about_ca_topic_score_codex":0.000032016284,"about_ca_topic_score_gemma":0.000014280813,"teacher_disagreement_score":0.057890028,"about_ca_system_score_codex":0.000025607322,"about_ca_system_score_gemma":0.00009268042,"threshold_uncertainty_score":0.52927876},"labels":[],"label_agreement":null},{"id":"W3095676398","doi":"10.1182/blood-2020-138654","title":"Identifying Myeloid Mutations By NGS in Patients with Unexplained Erythrocytosis","year":2020,"lang":"en","type":"article","venue":"Blood","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Western University; London Health Sciences Centre","funders":"","keywords":"Medicine; Myeloid; Internal medicine; Population; Hematology; Myeloproliferative neoplasm; Polycythemia vera; Immunology; Myelofibrosis; Bone marrow","score_opus":0.013268459106144373,"score_gpt":0.23176066976435036,"score_spread":0.21849221065820598,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3095676398","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9961535,0.00012619591,0.000068613816,0.0023543856,0.000018984723,0.0005621157,0.00004470987,0.000049582122,0.0006219276],"genre_scores_gemma":[0.9972943,0.000027056756,0.0011981946,0.0009734238,0.000036382764,0.0001326788,0.00026674187,0.000023482555,0.000047754693],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9990223,0.000024427965,0.00021177565,0.00028907607,0.00025905063,0.00019335338],"domain_scores_gemma":[0.99953437,0.00004944085,0.000060790855,0.00011810289,0.00007389,0.00016342933],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00002895222,0.0001537366,0.0002638907,0.000057602054,0.000067759865,0.000025322654,0.00004327026,0.000044475168,0.00012435472],"category_scores_gemma":[0.000058315163,0.00011869714,0.000042049163,0.00029431496,0.000027848626,0.00009482234,0.000022022337,0.000109817935,0.00006367416],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00014981742,0.0017712929,0.9948043,0.000051110397,0.00019027131,0.00004566296,0.0011547717,0.0000033323183,0.0005334893,0.0000606198,0.00078233,0.00045300258],"study_design_scores_gemma":[0.024561772,0.0016719365,0.9371514,0.00018017128,0.00043920486,0.0000054846455,0.00031612962,0.00002820297,0.034574106,0.000023486527,0.0008136069,0.0002345024],"about_ca_topic_score_codex":0.000032152522,"about_ca_topic_score_gemma":0.000027232449,"teacher_disagreement_score":0.0576529,"about_ca_system_score_codex":0.000037224527,"about_ca_system_score_gemma":0.00004692281,"threshold_uncertainty_score":0.4840329},"labels":[],"label_agreement":null},{"id":"W3095758083","doi":"10.1182/blood-2020-139281","title":"Long-Term Effect of Ruxolitinib (RUX) in Inadequately Controlled Polycythemia Vera (PV) without Splenomegaly: 5-Year Results from the Phase 3 Response-2 Study","year":2020,"lang":"en","type":"article","venue":"Blood","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":12,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Health Sciences Centre; Sunnybrook Health Science Centre","funders":"","keywords":"Medicine; Ruxolitinib; Internal medicine; Polycythemia vera; Randomization; Phlebotomy; Gastroenterology; Myelofibrosis; Randomized controlled trial; Bone marrow","score_opus":0.027180894296659902,"score_gpt":0.3156119923488506,"score_spread":0.2884310980521907,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3095758083","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99116266,0.0004205887,0.000002500126,0.003841274,0.000054158016,0.0037328904,0.00029684856,0.000047345722,0.0004417643],"genre_scores_gemma":[0.9986926,0.000042409756,0.000048502694,0.0004338104,0.00023767822,0.00033878392,0.0000981115,0.000039999777,0.000068139736],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99696845,0.0009050559,0.0007818461,0.0005550631,0.00045827424,0.00033129178],"domain_scores_gemma":[0.9961422,0.0027553802,0.0002690657,0.00054617226,0.000070714355,0.00021646041],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009143311,0.0003509791,0.0012487359,0.00008350628,0.00007323196,0.00003266028,0.00018957359,0.000097280616,0.00011229961],"category_scores_gemma":[0.0019059236,0.00020796747,0.00020221573,0.00025837414,0.00008085481,0.000052557094,0.00007464767,0.0003245841,0.00005586215],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.19038525,0.005415663,0.7918174,0.00003892055,0.0011440163,0.00077346474,0.0046281484,0.000002242221,0.0049951235,0.000013267774,0.00012939578,0.0006570892],"study_design_scores_gemma":[0.35875934,0.016837737,0.56351995,0.0002600486,0.0014609977,0.000012600125,0.0003342962,0.000040024643,0.058463853,0.0000050845633,0.00010438703,0.00020166227],"about_ca_topic_score_codex":0.00023165262,"about_ca_topic_score_gemma":0.000087050925,"teacher_disagreement_score":0.22829744,"about_ca_system_score_codex":0.000054170203,"about_ca_system_score_gemma":0.0001775921,"threshold_uncertainty_score":0.84806675},"labels":[],"label_agreement":null},{"id":"W3096039995","doi":"10.1182/blood-2020-136673","title":"Real-World Clinical Outcomes of Patients with Myelofibrosis Treated with Ruxolitinib: Evidence from a Multinational Medical Record Review","year":2020,"lang":"en","type":"article","venue":"Blood","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Ruxolitinib; Medicine; Myelofibrosis; Cytopenia; Internal medicine; Myeloproliferative neoplasm; Constitutional symptoms; Transplantation; International Prognostic Scoring System; Pediatrics; Bone marrow; Myelodysplastic syndromes","score_opus":0.05009325928629455,"score_gpt":0.33947530763554246,"score_spread":0.2893820483492479,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3096039995","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99062246,0.00075065065,0.000015999942,0.0069837705,0.000021668753,0.0010388232,0.00014712183,0.00005838059,0.00036110004],"genre_scores_gemma":[0.97961396,0.006766364,0.009446708,0.0033821687,0.00013448637,0.00019415411,0.0003623854,0.00003850685,0.00006125117],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99733096,0.00017075535,0.00079079455,0.00051613175,0.0009843638,0.00020701082],"domain_scores_gemma":[0.99724835,0.0012337754,0.000337733,0.00029757508,0.0004152547,0.0004672846],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0001949051,0.00025592023,0.0010454657,0.000044992063,0.000042143623,0.0000085338,0.00012226617,0.00008399905,0.00094206474],"category_scores_gemma":[0.0013522271,0.00015048748,0.00016221737,0.00032897326,0.0001336605,0.00008373728,0.00004873922,0.00021175164,0.000035507946],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00070873555,0.0024154051,0.98851514,0.00029456525,0.00078371586,0.00007079658,0.000058887577,8.0631054e-8,0.000002969987,0.000026174226,0.0005483847,0.006575171],"study_design_scores_gemma":[0.009566598,0.0028568085,0.9778076,0.007210951,0.0014692979,0.0000020624582,0.000007238217,0.000015260537,0.000491391,0.0000026142295,0.00041484038,0.00015538509],"about_ca_topic_score_codex":0.00041480016,"about_ca_topic_score_gemma":0.00023761965,"teacher_disagreement_score":0.0110085085,"about_ca_system_score_codex":0.000026715441,"about_ca_system_score_gemma":0.00027333674,"threshold_uncertainty_score":0.9999712},"labels":[],"label_agreement":null},{"id":"W3096383113","doi":"10.1182/blood-2020-137572","title":"A Multicenter Phase 1/2 Clinical Trial of Tagraxofusp, a CD123-Targeted Therapy, in Patients with Poor-Risk Primary and Secondary Myelofibrosis","year":2020,"lang":"en","type":"article","venue":"Blood","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta Hospital; Alberta Hospital Edmonton; Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Myelofibrosis; Internal medicine; Ruxolitinib; Oncology; Phases of clinical research; Clinical trial; Gastroenterology; Bone marrow","score_opus":0.02269525113218795,"score_gpt":0.2888989259235585,"score_spread":0.2662036747913705,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3096383113","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99688876,0.00032952934,0.0000049017162,0.0004536935,0.000047414633,0.001882965,0.00015444921,0.000018553901,0.00021975643],"genre_scores_gemma":[0.9965704,0.00048882555,0.0014382914,0.001138833,0.00010786583,0.00010177844,0.000117380565,0.000025663652,0.000010936312],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9983725,0.00016299417,0.0005812692,0.00041319357,0.00027144406,0.00019861548],"domain_scores_gemma":[0.9990704,0.00020046385,0.00022334578,0.00018339016,0.00009429131,0.00022807327],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00015906939,0.00021664497,0.00068358897,0.000065426706,0.000033239183,0.000012327032,0.000051664127,0.00010113158,0.000119131204],"category_scores_gemma":[0.00013722926,0.00014493923,0.00011347846,0.0001607869,0.00009388088,0.00007001663,0.000040254694,0.00024983377,0.0000063149714],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.104800016,0.015325717,0.8501441,0.00006301053,0.0005146817,0.000032160126,0.0003789544,1.09789895e-7,0.0001679908,0.000002352703,0.00015459167,0.028416302],"study_design_scores_gemma":[0.37120265,0.025151303,0.6005174,0.00006677232,0.0002453547,9.349341e-7,0.000016428878,0.00001300658,0.0023719887,0.0000012028631,0.0003153003,0.00009768009],"about_ca_topic_score_codex":0.00004019558,"about_ca_topic_score_gemma":0.000018099465,"teacher_disagreement_score":0.26640263,"about_ca_system_score_codex":0.000014315362,"about_ca_system_score_gemma":0.00012583705,"threshold_uncertainty_score":0.591045},"labels":[],"label_agreement":null},{"id":"W3096573094","doi":"10.1182/blood-2020-135872","title":"Robust Overall Survival and Sustained Efficacy Outcomes during Long Term Exposure to Momelotinib in JAK Inhibitor Naïve and Previously JAK Inhibitor Treated Intermediate/High Risk Myelofibrosis Patients","year":2020,"lang":"en","type":"article","venue":"Blood","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":15,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sierra Wireless (Canada)","funders":"","keywords":"Ruxolitinib; Medicine; Myelofibrosis; Internal medicine; Randomized controlled trial; Clinical endpoint; Dosing; Clinical trial; Phases of clinical research; Oncology; Anemia; Gastroenterology; Bone marrow","score_opus":0.013179630735183334,"score_gpt":0.23065253924799684,"score_spread":0.2174729085128135,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3096573094","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99625015,0.0002701557,0.0000022411937,0.00087017677,0.00012593257,0.0022121603,0.0001240591,0.000108008,0.00003712682],"genre_scores_gemma":[0.9984663,0.00031367797,0.00023005427,0.00020984838,0.00028663664,0.00019831868,0.00013976195,0.000075786156,0.00007959255],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99727285,0.00016200989,0.0006971537,0.0008791144,0.0004082641,0.0005806305],"domain_scores_gemma":[0.9984435,0.00026056534,0.00019641628,0.00028433057,0.00014909904,0.00066611794],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00013287005,0.0005492638,0.0010139702,0.00022425049,0.00014121334,0.000107470696,0.00009396402,0.00018399859,0.000036681125],"category_scores_gemma":[0.00061605027,0.00043754137,0.00011831285,0.0003070925,0.00007169157,0.00017468205,0.0002470871,0.00030857124,0.000014134301],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0009634403,0.0019243954,0.99111044,0.00034078816,0.0003682784,0.0002424804,0.0028699709,0.000010549896,0.00063524925,0.0000073398032,0.000050328716,0.0014767081],"study_design_scores_gemma":[0.03315927,0.0030610624,0.95156705,0.00044637016,0.00043369862,0.0000075962207,0.00021006852,0.000009140831,0.010717345,0.0000020962982,0.000009870938,0.0003763983],"about_ca_topic_score_codex":0.00017739266,"about_ca_topic_score_gemma":0.00020154283,"teacher_disagreement_score":0.03954339,"about_ca_system_score_codex":0.00011327887,"about_ca_system_score_gemma":0.00005885147,"threshold_uncertainty_score":0.99980766},"labels":[],"label_agreement":null},{"id":"W3096605023","doi":"10.1182/blood-2020-138953","title":"Impact of COVID19 Pandemic on an International MPN Patient Population: Survey Results from 1560 MPN Patients","year":2020,"lang":"en","type":"article","venue":"Blood","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Pandemic; Medicine; Coronavirus disease 2019 (COVID-19); Population; Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2); 2019-20 coronavirus outbreak; Virology; Internal medicine; Outbreak; Environmental health; Disease","score_opus":0.04748348636769403,"score_gpt":0.320918894982484,"score_spread":0.27343540861479,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3096605023","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9957159,0.000020596264,0.0000028433249,0.00019719986,0.00012733098,0.0004139127,0.0030405654,0.000034804754,0.00044683623],"genre_scores_gemma":[0.9923942,0.00004499957,0.00016202625,0.0003737477,0.0001503107,0.000017964785,0.006830384,0.000018567076,0.000007786599],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99846995,0.00012528384,0.0004490804,0.00037580088,0.000438011,0.0001418669],"domain_scores_gemma":[0.9988655,0.00021762292,0.0002190558,0.0002500633,0.00022044253,0.00022733494],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0000867682,0.0001818523,0.00032748224,0.000054756572,0.00003606241,0.00001587385,0.00008568842,0.0000762472,0.00017559172],"category_scores_gemma":[0.0005712614,0.00013477894,0.000117301584,0.00011396418,0.000017725126,0.00008825738,0.000034184246,0.0001133427,0.000034993318],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0017085862,0.0031699352,0.9910155,0.0000050849712,0.0004125806,0.000013945188,0.000624664,0.000058915222,0.00010576331,0.000009941405,0.0004177387,0.0024573412],"study_design_scores_gemma":[0.010307583,0.0046258583,0.9832579,0.000057430196,0.000102123224,0.000001272473,0.0000126961295,0.00012993343,0.0013115585,0.000010925106,0.000072968476,0.0001097853],"about_ca_topic_score_codex":0.002150303,"about_ca_topic_score_gemma":0.00013926267,"teacher_disagreement_score":0.008598997,"about_ca_system_score_codex":0.000086156215,"about_ca_system_score_gemma":0.0000681037,"threshold_uncertainty_score":0.5496126},"labels":[],"label_agreement":null},{"id":"W3096623906","doi":"10.1182/blood-2020-141835","title":"Secondary Erythrocytosis Is Phenotypically Distinct from Polycythemia Vera but Associated with Comparable Rates of Thrombosis at Diagnosis","year":2020,"lang":"en","type":"article","venue":"Blood","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Centre Hospitalier de l’Université de Montréal; McGill University; Quebec - Clinical Research Organization in Cancer; Jewish General Hospital; Cégep de Saint-Laurent; Université de Montréal; Hôpital du Sacré-Cœur de Montréal; Hôpital Maisonneuve-Rosemont","funders":"","keywords":"Medicine; Polycythemia vera; Hematocrit; Internal medicine; Gastroenterology; Erythropoietin; Phlebotomy; Red blood cell distribution width","score_opus":0.036821682752452074,"score_gpt":0.26430781523983243,"score_spread":0.22748613248738037,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3096623906","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99089056,0.0009734497,0.0000146915145,0.004311711,0.000034783567,0.0005540156,0.0010524606,0.000087174405,0.0020811525],"genre_scores_gemma":[0.99597734,0.00025156606,0.0008701335,0.0020354674,0.000118172786,0.00015503948,0.00043471556,0.00005356903,0.00010401213],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9980737,0.00007420187,0.00046387254,0.0005787448,0.00045389257,0.00035559587],"domain_scores_gemma":[0.99826455,0.00063077617,0.00026339432,0.00032822782,0.00017207935,0.00034094646],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.000056645054,0.0003760414,0.0010267504,0.000041891577,0.00014607627,0.000028898683,0.00013314643,0.00014224774,0.003630437],"category_scores_gemma":[0.00017136165,0.00028064774,0.00019424268,0.00028776444,0.00014675701,0.00008495519,0.00010350886,0.00023052581,0.00012257214],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0005426184,0.0027412006,0.98061347,0.00007687644,0.002775389,0.00006156232,0.0011166154,0.0000018012162,0.00541455,0.00002559419,0.0063862004,0.00024411765],"study_design_scores_gemma":[0.007905099,0.001339482,0.5691644,0.0002867664,0.0015198071,0.000004618617,0.00009211156,0.00004310477,0.41885167,0.000028362103,0.0005367739,0.00022779111],"about_ca_topic_score_codex":0.00033236452,"about_ca_topic_score_gemma":0.00017674986,"teacher_disagreement_score":0.4134371,"about_ca_system_score_codex":0.00010553236,"about_ca_system_score_gemma":0.00016733866,"threshold_uncertainty_score":0.9999646},"labels":[],"label_agreement":null},{"id":"W3097237398","doi":"10.1182/blood-2020-141790","title":"Role of Allogeneic Hematopoietic Cell Transplant in Patients with Myelofibrosis in the JAK Inhibitor Era","year":2020,"lang":"en","type":"article","venue":"Blood","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Queen Elizabeth II Health Sciences Centre; Jewish General Hospital; University Health Network; University of Toronto; Dalhousie University; University of Calgary; St. Paul's Hospital; Alberta Health Services; University of British Columbia; Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Myelofibrosis; Ruxolitinib; Transplantation; Internal medicine; Hematopoietic cell; Hematopoietic stem cell transplantation; Pediatrics; Haematopoiesis; Bone marrow; Stem cell","score_opus":0.00635036303415021,"score_gpt":0.1918222657558316,"score_spread":0.1854719027216814,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3097237398","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99754304,0.00034541843,0.0000011781776,0.00081799855,0.000007400388,0.0006829755,0.00002983392,0.000008252445,0.00056392385],"genre_scores_gemma":[0.9990866,0.00004609481,0.00023337062,0.00045534052,0.000025957117,0.00009674465,0.00003807302,0.000014277745,0.0000035337735],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99904644,0.000053875425,0.000252432,0.000212322,0.0002662348,0.00016871441],"domain_scores_gemma":[0.9996352,0.000060667546,0.000055421104,0.00014890303,0.000030138212,0.00006967969],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000056102006,0.00014353379,0.00030353732,0.00004788289,0.000017618086,0.000006599247,0.00007100831,0.000049395145,0.000045939265],"category_scores_gemma":[0.0000081931075,0.00008300884,0.000050084946,0.00020785512,0.0000272203,0.000027604356,0.000010531532,0.00012382431,0.000013691834],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0002827966,0.003304417,0.9876416,0.00012016647,0.000040779592,0.00003909737,0.005486413,0.000006255911,0.0028240473,0.0000364169,0.000022688931,0.00019534324],"study_design_scores_gemma":[0.009614409,0.0016896074,0.87460685,0.00020443845,0.00016003348,0.000004274585,0.00030503882,0.000005945568,0.113245055,0.000010434162,0.00006240626,0.00009148552],"about_ca_topic_score_codex":0.000028990857,"about_ca_topic_score_gemma":0.00004168477,"teacher_disagreement_score":0.11303471,"about_ca_system_score_codex":0.000012166728,"about_ca_system_score_gemma":0.00004622571,"threshold_uncertainty_score":0.33850023},"labels":[],"label_agreement":null},{"id":"W3097627722","doi":"10.1182/blood-2020-136622","title":"Haploidentical Allogeneic Hematopoietic Cell Transplantation with Post-Transplant Cyclophosphamide in Patients with Myelofibrosis: A Multi-Institutional Experience","year":2020,"lang":"en","type":"article","venue":"Blood","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Medicine; Myelofibrosis; Internal medicine; Transplantation; Univariate analysis; Fludarabine; Graft-versus-host disease; Cyclophosphamide; Gastroenterology; Surgery; Oncology; Bone marrow; Chemotherapy; Multivariate analysis","score_opus":0.009634928572227752,"score_gpt":0.21735753878847927,"score_spread":0.20772261021625152,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3097627722","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9973183,0.00017699882,0.0009280017,0.00047655054,0.00001987817,0.00087645766,0.00007419549,0.000051109248,0.00007846495],"genre_scores_gemma":[0.99345845,0.00010177921,0.0052118464,0.0006839427,0.000023242928,0.00024475262,0.00024112251,0.00002527993,0.000009574292],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99848896,0.000030264486,0.00028530217,0.00045883984,0.0004521844,0.00028441966],"domain_scores_gemma":[0.99940383,0.000038260012,0.000058079193,0.00013649098,0.00010787377,0.0002554351],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000028771692,0.0002734829,0.0003494199,0.000058924663,0.00008446035,0.00002436792,0.00007203984,0.00007020919,0.00005799719],"category_scores_gemma":[0.000010550856,0.00017625152,0.000056047265,0.000215316,0.00010505047,0.00012646268,0.000008830107,0.00013985447,0.000031741933],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0016648904,0.0033941711,0.98774916,0.00024467727,0.000090812035,0.000618015,0.004451596,0.000047003883,0.0016041959,0.000075549666,0.000001498726,0.000058439502],"study_design_scores_gemma":[0.017043915,0.0018335904,0.9353522,0.0004238626,0.00036409352,0.000074591524,0.00015223592,0.000013995112,0.044512853,0.0000010374149,0.000013120133,0.00021450993],"about_ca_topic_score_codex":0.00004380514,"about_ca_topic_score_gemma":0.00008655223,"teacher_disagreement_score":0.052396953,"about_ca_system_score_codex":0.000034617344,"about_ca_system_score_gemma":0.00013640677,"threshold_uncertainty_score":0.71873283},"labels":[],"label_agreement":null},{"id":"W3097655634","doi":"10.1182/blood-2020-135868","title":"Safety and Efficacy of Idasanutlin in Patients (pts) with Hydroxyurea (HU)-Resistant/Intolerant Polycythemia Vera (PV): Results of an International Phase II Study","year":2020,"lang":"en","type":"article","venue":"Blood","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Roche (Canada); Princess Margaret Cancer Centre","funders":"","keywords":"Polycythemia vera; Medicine; Internal medicine; Maximum tolerated dose; Phases of clinical research; Gastroenterology; Adverse effect; Clinical trial","score_opus":0.012919549952461046,"score_gpt":0.2745294814535199,"score_spread":0.2616099315010589,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3097655634","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9977759,0.000049465267,0.0000028431805,0.00042281527,0.000021316097,0.00094339653,0.00021802985,0.000014202945,0.0005519903],"genre_scores_gemma":[0.99934167,0.000026956452,0.00031356307,0.00007606617,0.00004482575,0.00001988628,0.0001483066,0.000016404932,0.000012325521],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99848306,0.000058928195,0.0005526946,0.0003583288,0.0004097487,0.00013721157],"domain_scores_gemma":[0.99922305,0.000086165914,0.00019754093,0.00022116843,0.00011937596,0.00015269806],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001225147,0.00018142238,0.00047757282,0.000090400354,0.00003754502,0.000007572453,0.00008828463,0.00004435035,0.000029336612],"category_scores_gemma":[0.00013018512,0.00013228947,0.000040166055,0.00016660633,0.000055128072,0.00007814074,0.000056152145,0.000114030394,0.0000010696369],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.06712721,0.07943507,0.8288434,0.00008646489,0.0010821694,0.00021471099,0.011800208,0.000035081084,0.0028226094,0.00005884356,0.000030688847,0.008463515],"study_design_scores_gemma":[0.17643349,0.034314245,0.76588994,0.0002278011,0.00034759296,0.000003857155,0.0003012204,0.00019008938,0.022011764,0.0000023888383,0.00014025407,0.00013735091],"about_ca_topic_score_codex":0.00012183221,"about_ca_topic_score_gemma":0.00007166113,"teacher_disagreement_score":0.10930628,"about_ca_system_score_codex":0.000028219854,"about_ca_system_score_gemma":0.000065799635,"threshold_uncertainty_score":0.5394608},"labels":[],"label_agreement":null},{"id":"W3097677520","doi":"10.1182/blood-2020-135880","title":"Momelotinib's Spleen, Symptom and Anemia Efficacy Is Maintained in Intermediate/High Risk Myelofibrosis Patients with Thrombocytopenia","year":2020,"lang":"en","type":"article","venue":"Blood","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sierra Wireless (Canada)","funders":"","keywords":"Myelofibrosis; Medicine; Anemia; Spleen; Romiplostim; Splenectomy; Internal medicine; Gastroenterology; Thrombopoietin; Bone marrow; Haematopoiesis","score_opus":0.007611426859306224,"score_gpt":0.21804324498162156,"score_spread":0.21043181812231534,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3097677520","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99660003,0.00011259369,0.000007977176,0.0018108343,0.000032733933,0.0010499939,0.0001221919,0.000061103936,0.0002025198],"genre_scores_gemma":[0.99714804,0.00023310335,0.0010086466,0.0012351477,0.00009833785,0.00008357678,0.00012708463,0.000045286426,0.000020785112],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9983439,0.00006751367,0.0003468776,0.00057917123,0.000315409,0.00034713544],"domain_scores_gemma":[0.99902415,0.00015685447,0.00013642223,0.00025066675,0.000089171845,0.00034273852],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00007046022,0.0003227568,0.0006432096,0.00009059642,0.00007646618,0.000044782133,0.000088308065,0.00010339701,0.00023934418],"category_scores_gemma":[0.00012878962,0.00023044898,0.000058748778,0.00029099378,0.000089992405,0.00009589425,0.00009606439,0.00024316079,0.00006325017],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00060933275,0.0015275679,0.9935088,0.000088409615,0.0002538093,0.0000976136,0.0017813345,0.0000017933446,0.00009840868,0.000059900383,0.00029274853,0.0016802514],"study_design_scores_gemma":[0.02672047,0.0031639887,0.96158093,0.00020191497,0.0004943286,0.0000079298725,0.00009628939,0.000025332085,0.007269392,0.000019061854,0.00018628074,0.00023410808],"about_ca_topic_score_codex":0.00014694929,"about_ca_topic_score_gemma":0.000050222607,"teacher_disagreement_score":0.031927925,"about_ca_system_score_codex":0.000047763577,"about_ca_system_score_gemma":0.00007159924,"threshold_uncertainty_score":0.93974364},"labels":[],"label_agreement":null},{"id":"W3100562823","doi":"10.14740/jh642","title":"Unexpected Neurological Symptoms of Ruxolitinib: A Case Report","year":2020,"lang":"en","type":"article","venue":"Journal of Hematology","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Ruxolitinib; Medicine; Myelofibrosis; Polycythemia vera; Essential thrombocythemia; Adverse effect; Internal medicine; Pediatrics; Dermatology","score_opus":0.03114568655213267,"score_gpt":0.304929963944045,"score_spread":0.2737842773919123,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3100562823","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9855688,0.000548084,0.00014110323,0.012832471,0.000112166344,0.00014603397,0.0000034403129,0.000013039778,0.0006348549],"genre_scores_gemma":[0.99723244,0.000025849435,0.0012042471,0.0013636848,0.000140364,0.00000497085,0.000002737353,0.000010761742,0.000014976726],"study_design_codex":"case_report","study_design_gemma":"case_report","domain_scores_codex":[0.99851084,0.00009443775,0.000873228,0.00015450818,0.00020155976,0.00016540203],"domain_scores_gemma":[0.99841523,0.00024241285,0.0006380431,0.00013211934,0.00031523398,0.00025696002],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00012626107,0.00012650197,0.0008503136,0.00008126747,0.000026118654,0.0000038286485,0.00005453308,0.00010730104,0.00026839718],"category_scores_gemma":[0.00081432506,0.00008209847,0.00021276949,0.00013754872,0.00008487224,0.000033584536,0.000029825664,0.0002642054,0.000009098176],"study_design_candidate":"case_report","study_design_consensus":"case_report","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0007652298,0.00061034027,0.26202494,0.00009001941,0.00037073958,0.7295547,0.00038343167,0.0000060171706,0.00059393485,0.0030692325,0.0020417932,0.0004895991],"study_design_scores_gemma":[0.0027247898,0.0056680324,0.015937572,0.00005257669,0.00027991674,0.96402884,0.0001278811,0.00012700626,0.009058163,0.00014488224,0.0017810588,0.00006927535],"about_ca_topic_score_codex":0.000004270656,"about_ca_topic_score_gemma":0.000001609942,"teacher_disagreement_score":0.24608737,"about_ca_system_score_codex":0.000013581951,"about_ca_system_score_gemma":0.00014111973,"threshold_uncertainty_score":0.33478785},"labels":[],"label_agreement":null},{"id":"W3102505760","doi":"10.1182/blood-2020-138752","title":"The BET Inhibitor, CPI-0610, Promotes Myeloid Differentiation in Myelofibrosis Patient Bone Marrow and Peripheral CD34+ Hematopoietic Stem Cells","year":2020,"lang":"en","type":"article","venue":"Blood","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Myelofibrosis; CD34; Haematopoiesis; Bone marrow; Stem cell; Medicine; Myeloid; Cancer research; Immunology; Biology; Cell biology","score_opus":0.011218679323022007,"score_gpt":0.20972733454213277,"score_spread":0.19850865521911076,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3102505760","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99104935,0.0019727456,0.000009106632,0.0056053377,0.0000915343,0.0010395987,0.000021259488,0.00004780181,0.00016324001],"genre_scores_gemma":[0.9984517,0.00039334092,0.00025650015,0.00040707114,0.000121272446,0.00022905754,0.000022968243,0.000030326692,0.0000877498],"study_design_codex":"observational","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99844164,0.00009722391,0.00041158154,0.0004107249,0.00033454254,0.00030427062],"domain_scores_gemma":[0.9992797,0.0001211725,0.000120476536,0.00020749502,0.00006111883,0.0002100635],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000087302156,0.0002572257,0.00039759418,0.000040324918,0.00016199418,0.00009082843,0.00005445724,0.00008959935,0.000046145997],"category_scores_gemma":[0.000027610835,0.00016895344,0.00008598943,0.00016072397,0.000063500185,0.00007186227,0.00007751414,0.00017277965,0.000018577332],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00067355455,0.0044734,0.8141515,0.00086775626,0.0005902436,0.0002849402,0.021510132,0.000009080633,0.12849133,0.00061312335,0.0017257697,0.026609125],"study_design_scores_gemma":[0.012787071,0.004197691,0.20521154,0.0006006472,0.0005819536,0.00008913167,0.0018534876,0.0006664219,0.7709751,0.00014595494,0.0023111054,0.00057987846],"about_ca_topic_score_codex":0.000017757744,"about_ca_topic_score_gemma":0.000034791454,"teacher_disagreement_score":0.6424838,"about_ca_system_score_codex":0.00004925739,"about_ca_system_score_gemma":0.00004898767,"threshold_uncertainty_score":0.6889721},"labels":[],"label_agreement":null},{"id":"W3102785656","doi":"10.1182/bloodadvances.2020002727","title":"Genetic factors rather than blast reduction determine outcomes of allogeneic HCT in <i>BCR-ABL</i>–negative MPN in blast phase","year":2020,"lang":"en","type":"article","venue":"Blood Advances","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":45,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network; Princess Margaret Cancer Centre","funders":"National Institute of Allergy and Infectious Diseases; National Cancer Institute; National Heart, Lung, and Blood Institute","keywords":"Hazard ratio; Cumulative incidence; Internal medicine; Medicine; Oncology; Transplantation; Incidence (geometry); Proportional hazards model; Gastroenterology; Confidence interval","score_opus":0.025070125697652934,"score_gpt":0.29864880761343404,"score_spread":0.2735786819157811,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3102785656","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9965552,0.0015033197,0.000016415188,0.0007865566,0.000092021495,0.0007535577,0.000047479807,0.00002562608,0.00021978923],"genre_scores_gemma":[0.9974723,0.00073604233,0.0013280205,0.00014874882,0.00008681948,0.000115846924,0.000020014188,0.000027963966,0.00006428379],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99844605,0.00008259802,0.0005135588,0.00044025574,0.0002467779,0.00027075774],"domain_scores_gemma":[0.9992856,0.00014705854,0.00019083411,0.00017631821,0.000058175996,0.00014201281],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000057520225,0.00029136724,0.0006856729,0.00014237297,0.000030369858,0.000009460838,0.00008369134,0.00006902245,0.00012188142],"category_scores_gemma":[0.00016586599,0.0002151758,0.00011458335,0.000331301,0.00010123487,0.00014245156,0.00003197259,0.00014727195,0.000011545477],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00030345086,0.001988131,0.96676683,0.00008672596,0.00016653603,0.00011824448,0.0022882947,0.00021147306,0.023432085,0.000010808744,0.000014209175,0.0046132314],"study_design_scores_gemma":[0.0105414335,0.0023299651,0.60866237,0.00018962336,0.00019493308,0.000021004196,0.0011139895,0.00008788568,0.37607545,0.000063604384,0.00048065273,0.00023910993],"about_ca_topic_score_codex":0.00007737165,"about_ca_topic_score_gemma":0.00049557834,"teacher_disagreement_score":0.35810447,"about_ca_system_score_codex":0.00004258262,"about_ca_system_score_gemma":0.00007077394,"threshold_uncertainty_score":0.87746143},"labels":[],"label_agreement":null},{"id":"W3104232645","doi":"10.1080/10428194.2020.1845334","title":"Analysis of predictors of response to ruxolitinib in patients with myelofibrosis in the phase 3b expanded-access JUMP study","year":2020,"lang":"en","type":"article","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":36,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"St. Paul's Hospital; Princess Margaret Cancer Centre","funders":"AOP Orphan; Incyte; Sierra Oncology; European Hematology Association; Celgene; Novartis Pharmaceuticals Corporation; Pfizer","keywords":"Ruxolitinib; Myelofibrosis; Medicine; Internal medicine; Jump; Phase (matter); Oncology; Physics; Bone marrow","score_opus":0.016623192033264837,"score_gpt":0.2876019261148819,"score_spread":0.27097873408161705,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3104232645","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9967818,0.00012856707,0.00001234827,0.00032548665,0.000040203056,0.0022545499,0.0001962599,0.000031663094,0.00022910851],"genre_scores_gemma":[0.99823296,0.00004730084,0.00009543065,0.0010046201,0.00004369291,0.00039159931,0.00011838204,0.000044713146,0.000021296655],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9959838,0.0005041272,0.0011634137,0.0008617679,0.00096646504,0.00052046386],"domain_scores_gemma":[0.9976572,0.0006698964,0.00037255994,0.0006886199,0.00022475724,0.0003870103],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0005803132,0.0005245319,0.0015758448,0.00091011345,0.00008795926,0.000056726858,0.0003977921,0.0001664489,0.000050267605],"category_scores_gemma":[0.0003015074,0.00035072863,0.00021824936,0.0035041568,0.00017525871,0.0002157636,0.00016970541,0.00010221526,0.0000035371154],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.022985958,0.003299906,0.9462074,0.00011160181,0.0010988347,0.00016180756,0.015000885,0.00023902072,0.00024015612,0.000021601572,0.00012751286,0.01050534],"study_design_scores_gemma":[0.048444927,0.006975145,0.9363012,0.00023209851,0.0015129461,0.000006594626,0.002812458,0.00076716964,0.0024418975,0.0000035434925,0.00020339664,0.00029863892],"about_ca_topic_score_codex":0.0015461154,"about_ca_topic_score_gemma":0.00037595414,"teacher_disagreement_score":0.025458971,"about_ca_system_score_codex":0.0015729901,"about_ca_system_score_gemma":0.0012339149,"threshold_uncertainty_score":0.9998945},"labels":[],"label_agreement":null},{"id":"W3107792394","doi":"10.1182/bloodadvances.2020003314","title":"Determining the recommended dose of pacritinib: results from the PAC203 dose-finding trial in advanced myelofibrosis","year":2020,"lang":"en","type":"article","venue":"Blood Advances","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":87,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"National Cancer Institute; Galecto; Sierra Oncology; CTI Biopharma; Incyte; Astex Pharmaceuticals; Jazz Pharmaceuticals; Medical Research Council; Celgene; Gilead Sciences; Alexion Pharmaceuticals; Astellas Pharma; TG Therapeutics; Pfizer; Agios Pharmaceuticals; Bristol-Myers Squibb","keywords":"Medicine; Ruxolitinib; Myelofibrosis; Adverse effect; Anemia; Pharmacokinetics; Internal medicine; Randomized controlled trial; Pharmacodynamics; Gastroenterology; Bone marrow","score_opus":0.05893450828529068,"score_gpt":0.3189789532074175,"score_spread":0.2600444449221268,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3107792394","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9801775,0.0014893454,0.0000041290214,0.015240115,0.00021313004,0.0013104916,0.00020557603,0.000039841412,0.0013198435],"genre_scores_gemma":[0.994329,0.0011767166,0.0022850197,0.0014735663,0.00039918904,0.00021243238,0.0000784174,0.000025275194,0.000020383693],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9979958,0.0001981663,0.0007072455,0.00046244136,0.0003338506,0.00030251005],"domain_scores_gemma":[0.99679625,0.0023447953,0.00031852943,0.0003564349,0.00007291125,0.000111097375],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00027585577,0.00025491766,0.00055984734,0.000036223,0.00015469868,0.000031711286,0.0002041258,0.00006746389,0.00004212636],"category_scores_gemma":[0.0014956251,0.00013783504,0.00015388403,0.0003287671,0.000084217005,0.00017066264,0.00007710478,0.0002604698,0.000008033016],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.12209039,0.0031525637,0.48968896,0.00017917245,0.0008501784,0.00018132557,0.019375974,0.00014600367,0.007875241,0.00051067595,0.0012739644,0.35467556],"study_design_scores_gemma":[0.40207574,0.0098751495,0.40721557,0.0016933893,0.0009865235,0.0000118605785,0.007905834,0.00019097488,0.12891997,0.0006759202,0.0397156,0.00073349226],"about_ca_topic_score_codex":0.000039898165,"about_ca_topic_score_gemma":0.00015755492,"teacher_disagreement_score":0.35394207,"about_ca_system_score_codex":0.000027236187,"about_ca_system_score_gemma":0.00007629508,"threshold_uncertainty_score":0.562075},"labels":[],"label_agreement":null},{"id":"W3109220255","doi":"10.3389/fimmu.2020.604142","title":"Metabolic Vulnerabilities and Epigenetic Dysregulation in Myeloproliferative Neoplasms","year":2020,"lang":"en","type":"review","venue":"Frontiers in Immunology","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":12,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Epigenetics; Cancer research; Biology; Myelopoiesis; Haematopoiesis; Myeloid; Phenotype; Stem cell; Cell biology; Genetics; Gene","score_opus":0.022498601340378864,"score_gpt":0.29410171632034326,"score_spread":0.2716031149799644,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3109220255","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.001530091,0.99427986,0.000106673775,0.0004819348,0.00080057513,0.0024218855,0.00004117326,0.000040233506,0.00029754906],"genre_scores_gemma":[0.00063629216,0.9929767,0.0042370427,0.00010793751,0.0001244576,0.0013393476,0.00024253746,0.00007571975,0.00025991965],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99660766,0.00068253576,0.0010985659,0.00090378587,0.00018554261,0.0005219142],"domain_scores_gemma":[0.99883485,0.00029284504,0.00028945366,0.00040671945,0.00005952295,0.000116581294],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00023320313,0.0007031685,0.0041250535,0.00090918754,0.00006993718,0.000032001226,0.00014533999,0.00065490796,0.00006473084],"category_scores_gemma":[0.00029109593,0.0005756517,0.00025453037,0.000671916,0.00033661764,0.00008877705,0.00012305021,0.0009050457,0.000029370533],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00014371313,0.00023000843,0.013035106,0.0024763858,0.00092292874,0.0002283395,0.0012164185,0.0000033316855,0.0000011027737,0.0016670238,0.00036459084,0.97971106],"study_design_scores_gemma":[0.002535077,0.0006192297,0.012788639,0.0043324432,0.00090910506,0.00023622892,0.00037483833,0.00010197473,0.00003508398,0.00096017553,0.9765614,0.00054576184],"about_ca_topic_score_codex":0.00007173025,"about_ca_topic_score_gemma":0.000100315454,"teacher_disagreement_score":0.9791653,"about_ca_system_score_codex":0.0004385841,"about_ca_system_score_gemma":0.00056473806,"threshold_uncertainty_score":0.9996695},"labels":[],"label_agreement":null},{"id":"W3112812421","doi":"10.1016/s2152-2650(20)30993-9","title":"MPN-149: Long-Term Safety of Momelotinib in JAK Inhibitor-Naïve and Previously JAK Inhibitor-Treated Intermediate-/High-Risk Myelofibrosis Patients","year":2020,"lang":"en","type":"article","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sierra Wireless (Canada)","funders":"","keywords":"Ruxolitinib; Myelofibrosis; Medicine; Internal medicine; Anemia; Randomized controlled trial; Gastroenterology; Bone marrow","score_opus":0.019220719240198473,"score_gpt":0.28417587199586775,"score_spread":0.2649551527556693,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3112812421","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9948512,0.0007107514,0.000013048478,0.0005278272,0.00047779825,0.00256143,0.00029075026,0.00016161906,0.00040563053],"genre_scores_gemma":[0.9936397,0.0030815417,0.00043417083,0.0010356649,0.0007131885,0.00028399113,0.00058088877,0.00013814634,0.00009269438],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99269056,0.0006335998,0.0032461039,0.001664973,0.00083719083,0.0009275532],"domain_scores_gemma":[0.9948644,0.0015516195,0.0010704857,0.000800055,0.0004527652,0.0012606558],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0006859612,0.00092086685,0.00252373,0.00027240257,0.0001647373,0.00006804871,0.00033873343,0.0007881306,0.00017621244],"category_scores_gemma":[0.0023550985,0.00076948036,0.00057410327,0.0008083523,0.000714165,0.00030048602,0.0005213377,0.0006588536,0.00017862028],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0035736049,0.0013234039,0.7614133,0.0003395645,0.00038656374,0.0002494269,0.0005395269,0.00000441466,0.00016113429,0.00004352194,0.00075138616,0.23121415],"study_design_scores_gemma":[0.023681128,0.005484374,0.9608016,0.0013577425,0.0005525182,0.000021771251,0.00007046588,0.00017060337,0.00681832,0.000048250415,0.00037838347,0.0006148615],"about_ca_topic_score_codex":0.00031043278,"about_ca_topic_score_gemma":0.00015162438,"teacher_disagreement_score":0.2305993,"about_ca_system_score_codex":0.0009963242,"about_ca_system_score_gemma":0.0007626622,"threshold_uncertainty_score":0.9994756},"labels":[],"label_agreement":null},{"id":"W3113542088","doi":"10.1182/blood.v130.suppl_1.203.203","title":"SETBP1 and NRAS Mutations Are Frequent Events in Post-Myeloproliferative Neoplasm Acute Myeloid Leukemia (post-MPN AML) Lacking JAK-STAT Activating Mutations","year":2017,"lang":"en","type":"article","venue":"Blood","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Princess Margaret Cancer Centre","funders":"","keywords":"Essential thrombocythemia; Myelofibrosis; Polycythemia vera; Neuroblastoma RAS viral oncogene homolog; Medicine; Myeloproliferative neoplasm; Ruxolitinib; Myeloid; Cancer research; Oncology; Mutation; Cancer; Myeloid leukemia; Internal medicine; KRAS; Immunology; Gene; Biology; Genetics; Bone marrow","score_opus":0.019077214798341294,"score_gpt":0.2934034473382868,"score_spread":0.27432623253994554,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3113542088","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9925811,0.00022357353,0.000051571795,0.0037392667,0.00015699105,0.0015170862,0.00032787552,0.000085405176,0.0013170857],"genre_scores_gemma":[0.9943241,0.00022458304,0.0032035855,0.0006581253,0.00016837288,0.0005747614,0.00043592296,0.00006973491,0.00034081252],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9974255,0.00012969864,0.00061455905,0.0007632513,0.0004768297,0.0005901588],"domain_scores_gemma":[0.99765384,0.0003753247,0.0005473641,0.000621254,0.0004740958,0.00032814324],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00023023882,0.0004993165,0.00070897234,0.00029838365,0.0011304618,0.00018151884,0.0001926277,0.00020291586,0.0000750657],"category_scores_gemma":[0.00084795227,0.00044100801,0.00014364594,0.00018699825,0.00018334875,0.0006028927,0.00016321869,0.0004996597,0.000050236566],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00018401572,0.0013311454,0.97029155,0.00013178588,0.0013761749,0.0008463941,0.007923023,0.00006258408,0.010251448,0.00064229977,0.000046155634,0.006913426],"study_design_scores_gemma":[0.009368316,0.0005438535,0.95423496,0.00067624403,0.0006367368,0.00032185751,0.002201731,0.00020313745,0.030786375,0.00048729448,0.000108584,0.00043090736],"about_ca_topic_score_codex":0.0006530487,"about_ca_topic_score_gemma":0.0024184762,"teacher_disagreement_score":0.020534927,"about_ca_system_score_codex":0.00037391478,"about_ca_system_score_gemma":0.0005817292,"threshold_uncertainty_score":0.9998042},"labels":[],"label_agreement":null},{"id":"W3113745509","doi":"10.1016/j.atherosclerosis.2020.10.254","title":"Aging causes alterations in level and expression pattern of von Willebrand factor in an organ-specific manner","year":2020,"lang":"en","type":"article","venue":"Atherosclerosis","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"","keywords":"Von Willebrand factor; Thrombus; Thrombosis; Medicine; Internal medicine; Von Willebrand disease; Risk factor; Immunology; Endocrinology; Platelet","score_opus":0.09509513389150487,"score_gpt":0.29322121669948265,"score_spread":0.19812608280797778,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3113745509","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.997983,0.00021336101,0.00012824596,0.001206259,0.000025858762,0.00034638232,0.000058675014,0.000016134081,0.000022113396],"genre_scores_gemma":[0.9985566,0.00048076405,0.00034209245,0.0004566785,0.00004561884,0.000052951757,0.000026805104,0.000023739945,0.000014762655],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9990582,0.000058725465,0.0002808001,0.0003047018,0.00014371413,0.0001538897],"domain_scores_gemma":[0.99957484,0.00006689625,0.000060233608,0.00014705119,0.000035681103,0.0001152738],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00004449706,0.00015237083,0.00031383743,0.000081628685,0.000039747516,0.000025038129,0.000041386236,0.000059765014,0.00017033255],"category_scores_gemma":[0.000018310679,0.00012038213,0.000031898104,0.00015709555,0.000034118097,0.00015024928,0.00003139987,0.00010603379,0.0000060579637],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00003529449,0.00023450099,0.8020849,0.00003404966,0.000010223198,0.000004778286,0.006310369,0.0000085368,0.18901719,0.000014833911,0.000046323563,0.0021989779],"study_design_scores_gemma":[0.0019731682,0.00025886897,0.82367533,0.00032411478,0.0000103328275,9.610983e-7,0.0003485173,0.00012288998,0.17309399,0.0000051639886,0.00009297578,0.0000936605],"about_ca_topic_score_codex":0.00011212261,"about_ca_topic_score_gemma":0.00032173778,"teacher_disagreement_score":0.021590425,"about_ca_system_score_codex":0.00003669933,"about_ca_system_score_gemma":0.000018234385,"threshold_uncertainty_score":0.4909041},"labels":[],"label_agreement":null},{"id":"W3119071615","doi":"10.2217/fon-2020-1048","title":"MOMENTUM: Momelotinib Vs Danazol in Patients with Myelofibrosis Previously Treated with JAKi Who Are Symptomatic and Anemic","year":2021,"lang":"en","type":"article","venue":"Future Oncology","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":38,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sierra Wireless (Canada); Princess Margaret Cancer Centre","funders":"Medical Research Council; Cancer Research UK","keywords":"Myelofibrosis; Medicine; Ruxolitinib; Anemia; Constitutional symptoms; Internal medicine; Bone marrow","score_opus":0.005068712736830131,"score_gpt":0.23042734607706353,"score_spread":0.2253586333402334,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3119071615","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9933943,0.00066046196,0.0000026728671,0.0031219753,0.0000623553,0.0012214462,0.000030435018,0.000049142414,0.0014572127],"genre_scores_gemma":[0.99644923,0.00045194526,0.00093128486,0.00087011314,0.0001236921,0.00036909978,0.00025727597,0.000046534395,0.0005008243],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9982703,0.00014308063,0.0003318794,0.00057062507,0.0002698331,0.00041428691],"domain_scores_gemma":[0.9989155,0.00012299661,0.00019354693,0.00032636742,0.00021778207,0.00022380691],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00007215623,0.0003420924,0.0009685581,0.00014720624,0.00008330367,0.000024406687,0.00005485377,0.000203524,0.00018651297],"category_scores_gemma":[0.000029376748,0.0002201206,0.000042216907,0.00042497853,0.000091675254,0.000080230624,0.00004501418,0.00023157788,0.00001449291],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0015119945,0.0015159528,0.98887336,0.00022972956,0.0002930254,0.00062730146,0.00084060594,0.000003500581,0.00004273865,0.00009363507,0.0011906727,0.0047774767],"study_design_scores_gemma":[0.014857665,0.0067542754,0.97137296,0.0009168236,0.0003685386,0.00015853217,0.0005917839,0.000020560788,0.0009031663,0.000007978944,0.003811434,0.00023628066],"about_ca_topic_score_codex":0.00003203894,"about_ca_topic_score_gemma":0.0006445913,"teacher_disagreement_score":0.017500406,"about_ca_system_score_codex":0.0003696101,"about_ca_system_score_gemma":0.00024878734,"threshold_uncertainty_score":0.8976257},"labels":[],"label_agreement":null},{"id":"W3119565724","doi":"10.1097/der.0000000000000658","title":"Off-label Studies on the Use of Ruxolitinib in Dermatology","year":2021,"lang":"en","type":"article","venue":"Dermatitis","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":14,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Ruxolitinib; Medicine; Alopecia areata; Dermatology; Clinical trial; Myelofibrosis; Atopic dermatitis; Randomized controlled trial; MEDLINE; Psoriasis; Vitiligo; Off-label use; Internal medicine","score_opus":0.12800951551950393,"score_gpt":0.337551709338844,"score_spread":0.20954219381934006,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3119565724","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.95916426,0.0015326409,0.000002962756,0.03765074,0.00010043187,0.00024235091,0.000027934528,0.000011801202,0.0012668603],"genre_scores_gemma":[0.9850254,0.0019382457,0.0005823123,0.012063599,0.000021017684,0.0001059923,0.000025277044,0.000009545854,0.00022862175],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99909806,0.00013752047,0.0003171467,0.00014517368,0.00015181887,0.00015027306],"domain_scores_gemma":[0.99865216,0.0008390962,0.000074482334,0.00024130731,0.00015494073,0.000038035905],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000046502108,0.00011094169,0.000366117,0.00005883692,0.00004274196,0.000009835838,0.000032091928,0.0000451864,0.0001455417],"category_scores_gemma":[0.0005610753,0.00007050279,0.00005059561,0.00015762322,0.00008303139,0.000044463428,0.000036484696,0.00010441046,0.00005367803],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00004634232,0.0023859476,0.72543913,0.0005192345,0.0010774616,0.0053811767,0.0073368913,0.000051101397,0.00037575958,0.099980585,0.14499146,0.01241489],"study_design_scores_gemma":[0.005009167,0.0003307107,0.6986315,0.0012520199,0.00018864934,0.0014645577,0.0019685237,0.0008214664,0.1845272,0.00092756405,0.104629666,0.0002489633],"about_ca_topic_score_codex":0.000023949598,"about_ca_topic_score_gemma":0.00023169149,"teacher_disagreement_score":0.18415144,"about_ca_system_score_codex":0.00004237932,"about_ca_system_score_gemma":0.000073495845,"threshold_uncertainty_score":0.28750202},"labels":[],"label_agreement":null},{"id":"W3120229701","doi":"10.1002/jbmr.4245","title":"Severity of Megakaryocyte-Driven Osteosclerosis in Mpig6b-Deficient Mice Is Sex-Linked","year":2020,"lang":"en","type":"article","venue":"Journal of Bone and Mineral Research","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":14,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal; McGill University; Montreal Heart Institute; Shriners Hospitals for Children - Canada","funders":"Canadian Institutes of Health Research; British Heart Foundation","keywords":"Osteosclerosis; Medullary cavity; Megakaryocyte; Myelofibrosis; Bone marrow; Medicine; Extramedullary hematopoiesis; Internal medicine; Osteoclast; Endocrinology; Pathology; Osteopetrosis; Cortical bone; Biology; Haematopoiesis; Receptor; Stem cell","score_opus":0.11233650974319655,"score_gpt":0.3700696124166719,"score_spread":0.2577331026734754,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3120229701","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9807206,0.0013530063,0.000003610178,0.017067079,0.000025141904,0.00027317097,0.000016117976,0.0000026798207,0.00053863454],"genre_scores_gemma":[0.9958028,0.002218341,0.0008926329,0.00063224416,0.00013248624,0.0000075323937,0.0000024203687,0.000012227923,0.0002992935],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.99795866,0.0001570905,0.0006144833,0.00019504623,0.00079149165,0.0002832452],"domain_scores_gemma":[0.9986209,0.0002703896,0.00016132538,0.00010935232,0.00050679245,0.000331232],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00076615415,0.00012421467,0.00062643486,0.0002805813,0.000051257663,0.00002095482,0.00006644001,0.00008169269,0.00011106525],"category_scores_gemma":[0.00043274098,0.00008911259,0.0001345605,0.00040589503,0.00011007177,0.00009259195,0.00008997338,0.00053771376,0.0000070016386],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0037365283,0.0017804748,0.4654008,0.000533738,0.00032711093,0.00097256975,0.009284256,0.000023789962,0.48915628,0.0001309852,0.018371558,0.01028192],"study_design_scores_gemma":[0.014223569,0.012596042,0.82517034,0.0011545251,0.00019325272,0.0003567041,0.0028686381,0.0018633049,0.12862067,0.00010390893,0.012567981,0.0002810927],"about_ca_topic_score_codex":0.00015258012,"about_ca_topic_score_gemma":0.000033537017,"teacher_disagreement_score":0.3605356,"about_ca_system_score_codex":0.00008940104,"about_ca_system_score_gemma":0.00023641848,"threshold_uncertainty_score":0.3633906},"labels":[],"label_agreement":null},{"id":"W3124166282","doi":"10.1242/dmm.048915","title":"From its roots come branches and growth for Disease Models &amp; Mechanisms","year":2021,"lang":"en","type":"editorial","venue":"Disease Models & Mechanisms","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"SickKids Foundation; Hospital for Sick Children; University of Toronto","funders":"","keywords":"Biology","score_opus":0.031186556879148526,"score_gpt":0.284539320038888,"score_spread":0.2533527631597395,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3124166282","genre_codex":"methods","genre_gemma":"editorial","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"editorial","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0041805166,0.016597506,0.6783638,0.0025205002,0.24899255,0.0064359605,0.042268913,0.00048054155,0.00015968244],"genre_scores_gemma":[0.2712279,0.008201111,0.039315287,0.0025031627,0.5572875,0.013926056,0.10085375,0.0014181559,0.0052670836],"study_design_codex":"not_applicable","study_design_gemma":"theoretical_or_conceptual","domain_scores_codex":[0.99294484,0.0002137508,0.0009563946,0.0026188684,0.002193324,0.0010728149],"domain_scores_gemma":[0.9930902,0.0010209115,0.0004183865,0.0013157665,0.0013859824,0.0027687596],"candidate_categories":["metaepi_narrow"],"consensus_categories":["metaepi_narrow"],"category_scores_codex":[0.0003353474,0.001546058,0.0021453386,0.00031112783,0.0004427401,0.00033841017,0.00038655376,0.00093565567,0.0003144448],"category_scores_gemma":[0.00062389136,0.0014249578,0.00094425835,0.00022241342,0.000080738435,0.00051516347,0.00037114098,0.0007035347,0.000043730735],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0098879505,0.005530503,0.00004465925,0.005817701,0.004687426,0.0019883767,0.0010524148,0.0011792337,0.0013368642,0.2365144,0.7301912,0.0017692969],"study_design_scores_gemma":[0.009208419,0.0005113793,0.00003849693,0.0024893275,0.0071622003,0.0000033198226,0.000063552136,0.061886646,0.001664991,0.90372366,0.011432322,0.0018156703],"about_ca_topic_score_codex":0.00016259728,"about_ca_topic_score_gemma":0.0000766959,"teacher_disagreement_score":0.7187588,"about_ca_system_score_codex":0.0003712827,"about_ca_system_score_gemma":0.0017213814,"threshold_uncertainty_score":0.9997288},"labels":[],"label_agreement":null},{"id":"W3126854039","doi":"10.1016/j.hoc.2020.12.004","title":"Application of Stem Cell Therapy in Myelofibrosis","year":2021,"lang":"en","type":"review","venue":"Hematology/Oncology Clinics of North America","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; University Health Network; Princess Margaret Cancer Centre","funders":"Princess Margaret Cancer Foundation","keywords":"Myelofibrosis; Stem cell; Medicine; Transplantation; Ruxolitinib; Risk stratification; Oncology; Hematopoietic stem cell transplantation; Disease; Internal medicine; Haematopoiesis; Immunology; Biology; Bone marrow; Genetics","score_opus":0.054655732312037165,"score_gpt":0.38746404529954276,"score_spread":0.3328083129875056,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3126854039","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0052160453,0.9913747,0.00009732738,0.00014694365,0.00016677887,0.0022219557,0.0001121674,0.000025011599,0.0006390955],"genre_scores_gemma":[0.0029952577,0.9921716,0.0026582766,0.00024795503,0.000045948032,0.0011278959,0.00063057203,0.00006581561,0.000056691424],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9952909,0.0006154435,0.0026138423,0.0008310565,0.00025122514,0.00039757328],"domain_scores_gemma":[0.99335754,0.0025924307,0.0026342645,0.0009154945,0.0003421903,0.00015809298],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00028670582,0.0005664988,0.007407672,0.00041380894,0.000034670797,0.0000028011423,0.00027234686,0.000805981,0.00007835512],"category_scores_gemma":[0.00007307172,0.00045126682,0.0009616351,0.0009310783,0.00045508318,0.000028767794,0.00012279538,0.0006574265,0.000059659058],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000095185824,0.0028118757,0.08547567,0.0065271882,0.00052534894,0.00011831466,0.00010405965,0.0000018496823,4.045866e-7,0.000103243365,0.00031092545,0.90392596],"study_design_scores_gemma":[0.0020765825,0.003148031,0.0023889248,0.0031234506,0.0012013015,0.00018324469,0.00008441915,0.000015765007,0.00005114572,0.000009818248,0.9873969,0.00032043655],"about_ca_topic_score_codex":0.00004273002,"about_ca_topic_score_gemma":0.00006834272,"teacher_disagreement_score":0.98708594,"about_ca_system_score_codex":0.00017967167,"about_ca_system_score_gemma":0.0017204139,"threshold_uncertainty_score":0.9997939},"labels":[],"label_agreement":null},{"id":"W3127681212","doi":"10.1002/ajh.26114","title":"Young platelet millionaires with essential thrombocythemia","year":2021,"lang":"en","type":"article","venue":"American Journal of Hematology","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":21,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal","funders":"","keywords":"Essential thrombocythemia; Medicine; Thrombocytosis; Context (archaeology); Incidence (geometry); Aspirin; Internal medicine; Thrombosis; Young adult; Platelet","score_opus":0.006870433168835954,"score_gpt":0.2670210640124645,"score_spread":0.26015063084362855,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3127681212","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9928596,0.0010389846,0.00041132848,0.0045778863,0.00012509723,0.0000681957,0.000002702505,0.000008737766,0.0009074435],"genre_scores_gemma":[0.99207854,0.00038913536,0.00674848,0.0005747385,0.00011517432,0.0000054657553,0.000006358426,0.000017673245,0.00006443182],"study_design_codex":"observational","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9989502,0.00007425168,0.0003558076,0.00016079067,0.00024817933,0.00021078555],"domain_scores_gemma":[0.9988432,0.00014380198,0.00035123766,0.00015695964,0.00034890606,0.00015590744],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00007016756,0.0001452149,0.00078980776,0.000091118345,0.000051737417,0.000011009532,0.000055113465,0.0000358315,0.000288569],"category_scores_gemma":[0.000059384784,0.00009343074,0.00012587651,0.00021311671,0.000274706,0.000049118156,0.000019928553,0.00020104667,0.000016350383],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0021818567,0.0017821743,0.908863,0.00010128062,0.0032911543,0.04350885,0.0016440162,0.000029660325,0.0064033833,0.007363088,0.0073258705,0.017505674],"study_design_scores_gemma":[0.008348755,0.00816238,0.13159138,0.00069446414,0.00082472374,0.37999022,0.0038459937,0.000027372867,0.45981658,0.00042280904,0.005887693,0.00038764527],"about_ca_topic_score_codex":0.000018170338,"about_ca_topic_score_gemma":0.000033360073,"teacher_disagreement_score":0.7772716,"about_ca_system_score_codex":0.00004805707,"about_ca_system_score_gemma":0.0003958569,"threshold_uncertainty_score":0.3809995},"labels":[],"label_agreement":null},{"id":"W3138379858","doi":"10.1002/ajh.26159","title":"Risk of infection in <scp>MPN</scp> patients in the era of <scp>C</scp>ovid‐<scp>19</scp>: A prospective multicenter study of <scp>257</scp> patients from the <scp>CML‐MPN Q</scp>uebec <scp>R</scp>esearch <scp>G</scp>roup","year":2021,"lang":"en","type":"letter","venue":"American Journal of Hematology","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Hôpital Maisonneuve-Rosemont; Université du Québec; Jewish General Hospital; McGill University; Centre Hospitalier de l’Université de Montréal; McGill University Health Centre; Université de Montréal","funders":"","keywords":"Medicine; Ruxolitinib; Internal medicine; Population; Cohort; Essential thrombocythemia; Prospective cohort study; Myelofibrosis; Polycythemia vera; Concordance; Immunology","score_opus":0.01385321085323726,"score_gpt":0.27859430188749085,"score_spread":0.2647410910342536,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3138379858","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97835827,0.0043114433,0.00018294997,0.0018078071,0.0021669026,0.009750544,0.001661333,0.00013460964,0.0016261148],"genre_scores_gemma":[0.97432977,0.0055997185,0.0009176521,0.012179704,0.0018436239,0.0018461071,0.0013244933,0.0007816763,0.0011772825],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9660738,0.009810948,0.008784493,0.003909699,0.006756368,0.0046646823],"domain_scores_gemma":[0.90751684,0.06786506,0.014054663,0.003630589,0.0056232098,0.0013096345],"candidate_categories":["metaresearch","metaepi_narrow","sts","research_integrity"],"consensus_categories":["metaepi_narrow","research_integrity"],"category_scores_codex":[0.004443605,0.004039604,0.010694488,0.003768801,0.0009007975,0.00041725277,0.0033470436,0.0024683764,0.00004575386],"category_scores_gemma":[0.0557643,0.0029837617,0.0028043776,0.005680203,0.0029633543,0.0011312253,0.0016739115,0.013011022,0.00015666276],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00006519121,0.0160682,0.7537246,0.0008108475,0.006395117,0.0020359848,0.054080695,0.0002390744,0.00014266557,0.00004643609,0.16547823,0.0009129917],"study_design_scores_gemma":[0.027058648,0.018702371,0.8172393,0.003767967,0.0043732715,0.00078746694,0.07899041,0.0002339235,0.0053144363,0.00050338113,0.042808935,0.00021988992],"about_ca_topic_score_codex":0.01242612,"about_ca_topic_score_gemma":0.0050518843,"teacher_disagreement_score":0.12266929,"about_ca_system_score_codex":0.0024985832,"about_ca_system_score_gemma":0.002499583,"threshold_uncertainty_score":0.99975},"labels":[],"label_agreement":null},{"id":"W3141737467","doi":"10.1016/j.jtct.2021.03.027","title":"Association of Factors Influencing Selection of Upfront Hematopoietic Cell Transplantation versus Nontransplantation Therapies in Myelofibrosis","year":2021,"lang":"en","type":"article","venue":"Transplantation and Cellular Therapy","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"Princess Margaret Cancer Foundation; Pfizer","keywords":"Myelofibrosis; Hematopoietic stem cell transplantation; Hematopoietic cell; Medicine; Selection (genetic algorithm); Oncology; Transplantation; Internal medicine; Haematopoiesis; Biology; Stem cell; Genetics; Computer science; Bone marrow","score_opus":0.014824591476890104,"score_gpt":0.24446419568533495,"score_spread":0.22963960420844484,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3141737467","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99655193,0.00110586,0.0013709797,0.00014025152,0.000082161896,0.00037295508,0.000055320845,0.000020581521,0.0002999559],"genre_scores_gemma":[0.98195404,0.01685087,0.00059456786,0.00003361776,0.000014446035,0.000028300636,0.00044841095,0.000017971666,0.000057768622],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9985739,0.00014532711,0.000544499,0.00024633488,0.0003243105,0.0001656154],"domain_scores_gemma":[0.9992184,0.00022572835,0.00024286794,0.00008452908,0.00017444529,0.000054018732],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001802868,0.00018956873,0.00039669528,0.00016392833,0.000053216034,0.000013282664,0.000027272266,0.00013898546,0.0001229086],"category_scores_gemma":[0.000005794694,0.00017108076,0.000104569524,0.00027744914,0.000026870362,0.00013647116,0.0000011814251,0.00010726213,0.0000012052539],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0020755413,0.00040055008,0.4446209,0.000758953,0.00020607526,0.000021184369,0.016535405,0.00008029462,0.53403485,0.00014908651,0.0000021097571,0.0011150236],"study_design_scores_gemma":[0.006541456,0.00034818254,0.3061546,0.00016696424,0.00022174866,0.000009007814,0.0007966328,0.00004948996,0.6855727,0.000024940284,0.000014059585,0.000100244804],"about_ca_topic_score_codex":0.00016830044,"about_ca_topic_score_gemma":0.00032234937,"teacher_disagreement_score":0.1515378,"about_ca_system_score_codex":0.000079887825,"about_ca_system_score_gemma":0.00009217626,"threshold_uncertainty_score":0.69764704},"labels":[],"label_agreement":null},{"id":"W3141847896","doi":"10.1002/jha2.194","title":"A case of multiple myeloma with plasma cell cannibalism and cytophagocytosis","year":2021,"lang":"en","type":"article","venue":"eJHaem","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Fraser Health; University of British Columbia","funders":"","keywords":"Plasma cell; Pathology; Medicine; Bone marrow; Biopsy; Multiple myeloma; Plasma cell leukemia; Nuclear medicine; Internal medicine","score_opus":0.01657346320460847,"score_gpt":0.24704454494764697,"score_spread":0.2304710817430385,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3141847896","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9958265,0.00066162244,0.000017630286,0.00055603514,0.000039695027,0.0002660599,0.000055264,0.000021818709,0.002555371],"genre_scores_gemma":[0.9953113,0.00010225664,0.003243668,0.00019625036,0.000050195806,0.000057669156,0.000025861913,0.000020847414,0.0009919496],"study_design_codex":"observational","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9991698,0.00003499162,0.00018212337,0.0002872645,0.00014807415,0.00017772923],"domain_scores_gemma":[0.9992254,0.00014914878,0.0000662212,0.00023828486,0.00015399615,0.00016699177],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000045396166,0.0001616638,0.00036106445,0.000048854374,0.00007104591,0.000013309662,0.000020929956,0.00005894009,0.00016259446],"category_scores_gemma":[0.000044238233,0.00011740746,0.000052001917,0.0001489959,0.00006992218,0.00003947392,0.000035869427,0.00008952794,0.000010063795],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0011874152,0.0025900102,0.77386606,0.00086476246,0.000935892,0.14620739,0.009843573,0.000029548979,0.037128203,0.00081734447,0.003113579,0.023416212],"study_design_scores_gemma":[0.0070104976,0.00085309806,0.042149622,0.00015683101,0.00031919207,0.014980166,0.0013340529,0.00034392122,0.92980295,0.000011463657,0.0028504366,0.00018776239],"about_ca_topic_score_codex":0.00028261048,"about_ca_topic_score_gemma":0.00083026674,"teacher_disagreement_score":0.89267474,"about_ca_system_score_codex":0.00004715375,"about_ca_system_score_gemma":0.00016356149,"threshold_uncertainty_score":0.4787737},"labels":[],"label_agreement":null},{"id":"W3142056325","doi":"10.4021/jem31w","title":"Myelofibrosis and Antiphospholipid Syndrome Presenting With Adrenal Insufficiency Due to Bilateral Adrenal Hemorrhage: A Case Series","year":2011,"lang":"en","type":"article","venue":"Journal of Endocrinology and Metabolism","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Medicine; Adrenal Hemorrhage; Adrenal insufficiency; Splenectomy; Abdominal pain; Antiphospholipid syndrome; Nausea; Vomiting; Myelofibrosis; Adrenal disorder; Warfarin; Surgery; Thrombosis; Internal medicine; Insulin; Atrial fibrillation; Glucose homeostasis; Spleen","score_opus":0.01898796220890688,"score_gpt":0.24775073134511189,"score_spread":0.228762769136205,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3142056325","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99515253,0.003266979,0.000060449915,0.0006472797,0.00024803937,0.00026031313,0.0000131664865,0.000014519562,0.00033672515],"genre_scores_gemma":[0.98716027,0.00042587906,0.011771641,0.00026673605,0.0001462243,0.000018261455,0.0000014302938,0.000018656194,0.00019093145],"study_design_codex":"observational","study_design_gemma":"case_report","domain_scores_codex":[0.99860567,0.00007400702,0.0004504067,0.0002706271,0.00018368041,0.00041560316],"domain_scores_gemma":[0.9990011,0.00005508035,0.00023141407,0.00014884083,0.00021430763,0.0003492749],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001367707,0.0002544367,0.00074746954,0.0003032509,0.00017584984,0.000030451025,0.000063009924,0.00007249965,0.000118864264],"category_scores_gemma":[0.00007340004,0.00016122125,0.00008125623,0.00017534918,0.00019727023,0.00027195556,0.00008594711,0.00030957934,0.000003906148],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.004658829,0.0023429925,0.5508758,0.00030116134,0.0016401759,0.40342882,0.008610226,0.000004622155,0.003703513,0.005020289,0.00031657834,0.019097],"study_design_scores_gemma":[0.002342148,0.0019626108,0.4319205,0.00006442202,0.000450078,0.5497108,0.00027673683,0.000003960256,0.01213713,0.000073327115,0.00092843594,0.00012987627],"about_ca_topic_score_codex":0.0000727755,"about_ca_topic_score_gemma":0.000023722165,"teacher_disagreement_score":0.14628197,"about_ca_system_score_codex":0.000014070018,"about_ca_system_score_gemma":0.00009243098,"threshold_uncertainty_score":0.6574412},"labels":[],"label_agreement":null},{"id":"W3146326314","doi":"10.33667/2078-5631-2021-3-58-62","title":"Clinical and neuroimaging features of chronic cerebral ischemia in polycythemia vera","year":2021,"lang":"en","type":"article","venue":"Medical alphabet","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Neuroimaging; Internal medicine; Cardiology; Montreal Cognitive Assessment; Polycythemia vera; Cognitive impairment; Disease; Psychiatry","score_opus":0.016020192107575677,"score_gpt":0.32759542810783915,"score_spread":0.3115752360002635,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3146326314","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.979482,0.004698317,0.000011571467,0.01237374,0.00018447431,0.00015185252,0.0000071879285,0.00001876688,0.0030720795],"genre_scores_gemma":[0.99627435,0.0009265328,0.000495751,0.0015666872,0.000321646,0.000018458039,0.000031508676,0.000016191992,0.00034888918],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9983434,0.00009901662,0.0004592362,0.00038274433,0.0004556262,0.0002599519],"domain_scores_gemma":[0.99899614,0.00033661583,0.00005714077,0.00022932499,0.000053290485,0.00032748116],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00030436055,0.00015493331,0.00054995774,0.000051977535,0.000026665439,0.000010118581,0.00006368438,0.00015350668,0.001074358],"category_scores_gemma":[0.00078563456,0.00011831684,0.00010240368,0.0001664287,0.0002515723,0.000039221813,0.00011116319,0.00049636484,0.000010712905],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00008464095,0.000662759,0.94263667,0.00012712083,0.00008739883,0.0010667808,0.00009534541,1.6593357e-7,0.00063260976,0.00043826835,0.004637902,0.049530342],"study_design_scores_gemma":[0.007155064,0.00042079506,0.9523565,0.0005752344,0.00008087559,0.00038515255,0.00004492015,0.00025047688,0.029071866,0.00011278218,0.009413146,0.00013315926],"about_ca_topic_score_codex":0.000029895264,"about_ca_topic_score_gemma":0.00006566628,"teacher_disagreement_score":0.04939718,"about_ca_system_score_codex":0.000042597392,"about_ca_system_score_gemma":0.0004976705,"threshold_uncertainty_score":0.99983877},"labels":[],"label_agreement":null},{"id":"W3152992904","doi":"10.3390/curroncol28020146","title":"The Epidemiology of Myeloproliferative Neoplasms in New Zealand between 2010 and 2017: Insights from the New Zealand Cancer Registry","year":2021,"lang":"en","type":"article","venue":"Current Oncology","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":15,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"Leukaemia and Blood Cancer New Zealand; Auckland Medical Research Foundation","keywords":"Medicine; Epidemiology; Cancer; Cancer registry; Epidemiology of cancer; Family medicine; Breast cancer; Pathology; Internal medicine","score_opus":0.11719238906021853,"score_gpt":0.4065566169179948,"score_spread":0.28936422785777627,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3152992904","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8656784,0.061604887,0.000031648997,0.070579454,0.0011497528,0.0006374788,0.00009050808,0.000013657327,0.00021417801],"genre_scores_gemma":[0.85149586,0.120759994,0.0014737097,0.0029092329,0.005347071,0.00044091334,0.0008106664,0.00008079644,0.01668175],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.997561,0.00063792005,0.00070200866,0.0005330883,0.0001686667,0.00039734415],"domain_scores_gemma":[0.9934983,0.005188613,0.0003828855,0.00046826783,0.00015937725,0.00030251924],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00030511286,0.00028524463,0.0010211891,0.00004983593,0.00014897113,0.0000133529575,0.00016142553,0.00025968024,0.000108171924],"category_scores_gemma":[0.0009740961,0.00015227076,0.00010429944,0.00020559844,0.00033109565,0.000050514434,0.0001407089,0.00063440733,0.000013332744],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0002179959,0.00015294518,0.8218766,0.000011646437,0.00024576412,0.00003845581,0.0017268934,0.0000036956123,0.00004604033,0.00067533675,0.1363228,0.038681846],"study_design_scores_gemma":[0.003213589,0.00032796318,0.67824167,0.00018098325,0.00019053534,0.00003076553,0.0001674274,0.000021370342,0.0005484079,0.0037363316,0.31323645,0.000104517225],"about_ca_topic_score_codex":0.0035644283,"about_ca_topic_score_gemma":0.023975058,"teacher_disagreement_score":0.17691365,"about_ca_system_score_codex":0.0001823516,"about_ca_system_score_gemma":0.0021744883,"threshold_uncertainty_score":0.99383485},"labels":[],"label_agreement":null},{"id":"W3154723827","doi":"10.1159/000516471","title":"Antithrombotic Management in Ischemic Stroke with Essential Thrombocythemia: Current Evidence and Dilemmas","year":2021,"lang":"en","type":"review","venue":"Medical Principles and Practice","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"","keywords":"Medicine; Antithrombotic; Aspirin; Essential thrombocythemia; Stroke (engine); Thrombosis; Warfarin; Internal medicine; Venous thrombosis; Cardiology; Atrial fibrillation; Population; Fibrinolytic agent; Platelet","score_opus":0.1179633548377117,"score_gpt":0.424338016083712,"score_spread":0.3063746612460003,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3154723827","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00076599914,0.9928742,0.000082409104,0.0015256508,0.0001457983,0.001353572,0.000012173673,0.00002306059,0.0032171074],"genre_scores_gemma":[0.0005148966,0.9966425,0.0018956964,0.00017899222,0.00020339772,0.00027444874,0.00007015939,0.000044060296,0.00017590779],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99660724,0.00042256087,0.0007029185,0.0009036754,0.00097461906,0.00038895765],"domain_scores_gemma":[0.99613684,0.0025680042,0.00035327,0.00041177275,0.00008688129,0.0004432325],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.001014264,0.000527314,0.0019546538,0.00014135185,0.00009649133,0.00009770673,0.00012373523,0.00028399876,0.00029710474],"category_scores_gemma":[0.0013170168,0.0003372018,0.00013344675,0.00027320487,0.00024037754,0.00022097948,0.00038909735,0.0011265714,0.000017803462],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00010306347,0.001023815,0.00083777285,0.025037691,0.0011600755,0.003780565,0.00013299742,2.3693113e-7,3.3824105e-7,0.0014908427,0.00046908247,0.96596354],"study_design_scores_gemma":[0.0012233333,0.00027159724,0.00040755072,0.068584755,0.0043059057,0.002548615,0.00011453745,0.000018012299,0.000003256407,0.0000019449424,0.92221844,0.0003020461],"about_ca_topic_score_codex":0.00003879269,"about_ca_topic_score_gemma":0.000046767174,"teacher_disagreement_score":0.96566147,"about_ca_system_score_codex":0.00014848758,"about_ca_system_score_gemma":0.0006657137,"threshold_uncertainty_score":0.99990803},"labels":[],"label_agreement":null},{"id":"W3154921500","doi":"10.1038/s41408-021-00463-x","title":"Phenotypical differences and thrombosis rates in secondary erythrocytosis versus polycythemia vera","year":2021,"lang":"en","type":"letter","venue":"Blood Cancer Journal","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":35,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Micropharma (Canada); McGill University Health Centre; McGill University; Jewish General Hospital; Hôpital Maisonneuve-Rosemont; Hôpital du Sacré-Cœur de Montréal; Université de Montréal","funders":"","keywords":"Polycythemia vera; Thrombosis; Hematology; Medicine; Internal medicine; Phenotype; Gastroenterology; Immunology; Biology; Genetics","score_opus":0.048162946961059695,"score_gpt":0.3147656740675299,"score_spread":0.2666027271064702,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3154921500","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.5999117,0.030656362,0.0000018938614,0.3666224,0.0012722606,0.00032768253,0.0001248637,0.000021497985,0.0010613705],"genre_scores_gemma":[0.50827134,0.10567311,0.001278829,0.3625448,0.019827072,0.00060456624,0.00028325358,0.00024491805,0.001272075],"study_design_codex":"not_applicable","study_design_gemma":"observational","domain_scores_codex":[0.9974985,0.00017046292,0.0005725304,0.00060093537,0.00057740643,0.0005801479],"domain_scores_gemma":[0.9987048,0.00039180423,0.0002694948,0.00025130497,0.0001532565,0.00022932499],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.000115795156,0.0005459551,0.0012536262,0.00023251823,0.00019979583,0.00021003591,0.0001354734,0.0006075638,0.0029989805],"category_scores_gemma":[0.00006280172,0.00041395114,0.00024800788,0.00020067385,0.00014535522,0.000116229145,0.00008600609,0.0031745692,0.000008538802],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0009816135,0.00087961345,0.38663244,0.00070763926,0.0058253994,0.007192076,0.00097472285,7.2446227e-7,0.00034438932,0.000026840247,0.5781273,0.018307185],"study_design_scores_gemma":[0.04237162,0.0032440426,0.71124613,0.006847692,0.007073366,0.003236165,0.0005922759,0.000015092842,0.011542537,0.00032369068,0.21179494,0.0017124321],"about_ca_topic_score_codex":0.00018499815,"about_ca_topic_score_gemma":0.00026449564,"teacher_disagreement_score":0.3663324,"about_ca_system_score_codex":0.00030991854,"about_ca_system_score_gemma":0.001087728,"threshold_uncertainty_score":0.99983126},"labels":[],"label_agreement":null},{"id":"W3157098966","doi":"10.1097/hs9.0000000000000562","title":"Fedratinib Improves Myelofibrosis-related Symptoms and Health-related Quality of Life in Patients with Myelofibrosis Previously Treated with Ruxolitinib: Patient-reported Outcomes from the Phase II JAKARTA2 Trial","year":2021,"lang":"en","type":"article","venue":"HemaSphere","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":25,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Sierra Oncology; Incyte; Gilead Sciences; CTI Biopharma; Celgene; Sanofi; Bristol-Myers Squibb","keywords":"Myelofibrosis; Ruxolitinib; Medicine; Quality of life (healthcare); Internal medicine; Clinical trial; Population; Physical therapy; Bone marrow","score_opus":0.027292318968595786,"score_gpt":0.2889486548959623,"score_spread":0.2616563359273665,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3157098966","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9918093,0.0016389708,0.000002777063,0.0018605731,0.00008724246,0.003950311,0.00022358906,0.00009952437,0.0003276883],"genre_scores_gemma":[0.9969534,0.00008638597,0.0005362889,0.0005680089,0.000026562358,0.00040314492,0.0011187962,0.00007964791,0.00022772205],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9949413,0.00051230204,0.002187576,0.00094840757,0.0008076667,0.0006027814],"domain_scores_gemma":[0.99629617,0.0005898773,0.0013369689,0.000848365,0.00048689733,0.00044170168],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00035908056,0.000638513,0.0019932233,0.00006525981,0.00030365077,0.000057291876,0.00010064188,0.00025556405,0.0004583766],"category_scores_gemma":[0.00040930064,0.00036303094,0.00020397152,0.0007001377,0.00025259968,0.0001816634,0.00009988011,0.00038050787,0.0000047530184],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.025965609,0.0061881486,0.9517774,0.00014541393,0.001781077,0.000045804467,0.002882026,0.000004674799,0.00016120532,0.000121346646,0.00018371797,0.010743592],"study_design_scores_gemma":[0.16700606,0.013119464,0.81549877,0.0009466852,0.00042733806,0.00000851997,0.00081389875,0.000023015475,0.0017210706,0.00002820985,0.00005522185,0.00035172192],"about_ca_topic_score_codex":0.0029139975,"about_ca_topic_score_gemma":0.0010834069,"teacher_disagreement_score":0.14104044,"about_ca_system_score_codex":0.00016717173,"about_ca_system_score_gemma":0.00075931934,"threshold_uncertainty_score":0.99988216},"labels":[],"label_agreement":null},{"id":"W3160777207","doi":"10.1038/s41375-021-01290-6","title":"JAK2 unmutated erythrocytosis: current diagnostic approach and therapeutic views","year":2021,"lang":"en","type":"review","venue":"Leukemia","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":56,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal","funders":"","keywords":"Polycythemia vera; Phlebotomy; Erythropoietin; Medicine; Erythropoietin receptor; Erythropoiesis; Thrombocytosis; Internal medicine; Anemia","score_opus":0.09408255662853951,"score_gpt":0.36896144369121614,"score_spread":0.2748788870626766,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3160777207","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000082539635,0.99448144,0.000052288895,0.000053099957,0.00031595305,0.003181121,0.00006772801,0.00009537177,0.001670469],"genre_scores_gemma":[0.00011457715,0.99364746,0.00041304654,0.0002516524,0.00037565414,0.0035824613,0.0011252312,0.0001238696,0.00036606728],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9967951,0.00036227168,0.0008691171,0.0010602309,0.00040906577,0.00050418254],"domain_scores_gemma":[0.99748147,0.0010199065,0.000339968,0.00069120043,0.00012140931,0.0003460349],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00020182374,0.00090968766,0.0037316508,0.00019939934,0.00014102922,0.0000961502,0.00013908348,0.0004052515,0.00016646553],"category_scores_gemma":[0.00024330035,0.0006141615,0.0006821252,0.0004988461,0.00011857701,0.00004025562,0.00013402423,0.00084840215,0.00016271874],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0000065195422,0.00038169284,0.00018819042,0.017696125,0.0010425367,0.0001720851,0.000120376855,7.674272e-7,1.5203676e-7,0.00043319818,0.0016185206,0.97833985],"study_design_scores_gemma":[0.0011316494,0.00020093704,0.00016514423,0.026946828,0.0065934034,0.00064330664,0.000027008544,0.00002367189,0.0000067349324,0.00001804492,0.96374184,0.00050140335],"about_ca_topic_score_codex":0.000018582603,"about_ca_topic_score_gemma":0.000006318081,"teacher_disagreement_score":0.97783846,"about_ca_system_score_codex":0.0010689395,"about_ca_system_score_gemma":0.0014214087,"threshold_uncertainty_score":0.999631},"labels":[],"label_agreement":null},{"id":"W3161357565","doi":"10.1038/s41375-021-01279-1","title":"Direct oral anticoagulants for myeloproliferative neoplasms: results from an international study on 442 patients","year":2021,"lang":"en","type":"article","venue":"Leukemia","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":59,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"Associazione Italiana per la Ricerca sul Cancro","keywords":"Medicine; Myeloproliferative Disorders; Polycythemia vera; Hematology; Hematologic Neoplasms; Myelofibrosis; Internal medicine; Cancer; Bone marrow","score_opus":0.03891481730790351,"score_gpt":0.33515257241971297,"score_spread":0.29623775511180944,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3161357565","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99083763,0.000024377547,0.000024403313,0.00056772155,0.00072612514,0.0016211636,0.0015028961,0.00007770841,0.004617986],"genre_scores_gemma":[0.99153703,0.000039411265,0.0014373983,0.0013057587,0.0004136362,0.00046943288,0.0038823604,0.00004302484,0.0008719256],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.997643,0.00014549145,0.000490402,0.00085506664,0.00055241084,0.00031366487],"domain_scores_gemma":[0.9981528,0.00043209482,0.00014790882,0.0005146391,0.0005286715,0.00022387988],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00015584413,0.0003270634,0.000640914,0.000097005875,0.00015992511,0.000094628675,0.00013216372,0.00011585031,0.00014494387],"category_scores_gemma":[0.0006687988,0.00026212275,0.00013088493,0.00014845094,0.00003337009,0.00017597764,0.00006204445,0.00017963586,0.00011136589],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.005053611,0.0066669458,0.9669101,0.000013323125,0.0015772986,0.00043523803,0.003860838,0.000081169004,0.00041326345,0.0002760862,0.0051230784,0.009589006],"study_design_scores_gemma":[0.022327026,0.0028946411,0.93112236,0.00014151084,0.0003033387,0.0000066921857,0.0006459388,0.00083789206,0.036112446,0.000091197646,0.005209157,0.00030781902],"about_ca_topic_score_codex":0.0002087955,"about_ca_topic_score_gemma":0.00037830128,"teacher_disagreement_score":0.035787802,"about_ca_system_score_codex":0.0005761909,"about_ca_system_score_gemma":0.00037141936,"threshold_uncertainty_score":0.9999831},"labels":[],"label_agreement":null},{"id":"W3161919645","doi":"10.1038/s41375-021-01261-x","title":"Efficacy and safety of a novel dosing strategy for ruxolitinib in the treatment of patients with myelofibrosis and anemia: the REALISE phase 2 study","year":2021,"lang":"en","type":"article","venue":"Leukemia","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":66,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"St. Paul's Hospital; University of British Columbia","funders":"Novartis Pharmaceuticals Corporation","keywords":"Myelofibrosis; Ruxolitinib; Medicine; Anemia; Adverse effect; Dosing; Internal medicine; Polycythemia vera; Gastroenterology; Hemoglobin; Phases of clinical research; Surgery; Clinical trial; Bone marrow","score_opus":0.03425455265126314,"score_gpt":0.31733399499282644,"score_spread":0.2830794423415633,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3161919645","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99661744,0.0003627973,0.000016046259,0.00022060206,0.000009939057,0.0024563596,0.00016991826,0.0000037423758,0.00014314192],"genre_scores_gemma":[0.99894077,0.00022804974,0.00033670172,0.00006281876,0.000022203314,0.00028743834,0.00009060017,0.00001129504,0.000020140706],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9990974,0.00006433661,0.00028662698,0.00023455606,0.00017508144,0.00014200213],"domain_scores_gemma":[0.9989435,0.0005381292,0.00011203914,0.00024835696,0.00011247012,0.000045474553],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000112623486,0.00015504748,0.00036830295,0.00003282074,0.000077363606,0.000016024833,0.000032780492,0.000039642007,0.0000061367186],"category_scores_gemma":[0.000037398833,0.00007247412,0.0000368535,0.00014347902,0.00008839529,0.000030251535,0.000012504552,0.00005314359,6.044079e-8],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.011636969,0.028718725,0.8505425,0.00032863117,0.0006452035,0.00006732638,0.023899881,0.00009157462,0.00091198116,0.0010857022,0.000063170475,0.08200836],"study_design_scores_gemma":[0.06397943,0.011647944,0.91571045,0.00018030485,0.0005366632,0.000012450725,0.0031829309,0.00009149886,0.0042889547,0.000012779238,0.00027205003,0.000084516396],"about_ca_topic_score_codex":0.00020360855,"about_ca_topic_score_gemma":0.00017268136,"teacher_disagreement_score":0.08192384,"about_ca_system_score_codex":0.00011689821,"about_ca_system_score_gemma":0.00015431049,"threshold_uncertainty_score":0.2955409},"labels":[],"label_agreement":null},{"id":"W3168576198","doi":"10.1111/bjh.17617","title":"Association of frailty with clinical outcomes in myelofibrosis: a retrospective cohort study","year":2021,"lang":"en","type":"article","venue":"British Journal of Haematology","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Sciences Centre; Sunnybrook Health Science Centre; Toronto General Hospital; Princess Margaret Cancer Centre","funders":"Princess Margaret Cancer Foundation","keywords":"Medicine; Hazard ratio; Internal medicine; Myelofibrosis; Retrospective cohort study; Cohort; Proportional hazards model; Incidence (geometry); Cumulative incidence; Cohort study; Confidence interval; Surgery; Bone marrow","score_opus":0.02073554156395444,"score_gpt":0.3295500093735605,"score_spread":0.30881446780960603,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3168576198","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99734515,0.0005340515,0.000021199054,0.0011937508,0.00019837554,0.00036429905,0.000011832192,0.0000050469785,0.0003262822],"genre_scores_gemma":[0.9980914,0.0005368801,0.0009825623,0.00014040087,0.000045073994,0.00002144619,0.000004376724,0.000012602397,0.00016524956],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99767053,0.00041379198,0.0010645767,0.00021446025,0.0004587198,0.00017792014],"domain_scores_gemma":[0.9975673,0.0005387744,0.00076094415,0.00012922162,0.00091033825,0.0000934007],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008870792,0.00011467892,0.0016633972,0.00009623216,0.000031362724,0.000015893793,0.000055448734,0.00013029328,0.00014009958],"category_scores_gemma":[0.0019366947,0.00009752783,0.000191605,0.00020068929,0.00005449678,0.000074049756,0.000027974545,0.0004070388,0.000003147607],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00021919938,0.0038789704,0.9591286,0.000021731197,0.0017454297,0.033459924,0.00015171412,0.0000013649815,0.000008140198,0.00005019647,0.00078459736,0.000550098],"study_design_scores_gemma":[0.006821424,0.0020421178,0.96737355,0.00037389214,0.0005014413,0.02190838,0.00046378066,0.0000019109968,0.0003094935,0.000079136524,0.000053185202,0.00007167849],"about_ca_topic_score_codex":0.00012221503,"about_ca_topic_score_gemma":0.002273477,"teacher_disagreement_score":0.011551544,"about_ca_system_score_codex":0.00019834905,"about_ca_system_score_gemma":0.00030825057,"threshold_uncertainty_score":0.39770696},"labels":[],"label_agreement":null},{"id":"W3169177304","doi":"10.1200/jco.2021.39.15_suppl.7046","title":"Association of transfusion independence with improved overall survival in myelofibrosis patients receiving momelotinib.","year":2021,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sierra Wireless (Canada); Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Ruxolitinib; Myelofibrosis; Internal medicine; Anemia; Randomized controlled trial; Clinical trial; Gastroenterology; Phases of clinical research; Oncology; Bone marrow","score_opus":0.04754202071381504,"score_gpt":0.38199009167777626,"score_spread":0.33444807096396123,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3169177304","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9935792,0.00007519711,0.00006923432,0.0041836253,0.0005683751,0.00019663518,0.000005074264,0.0000031892198,0.0013194613],"genre_scores_gemma":[0.9948204,0.0014233983,0.0029515834,0.00040329868,0.00018270302,0.0000051428387,0.000006376633,0.000011990343,0.00019510258],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.996482,0.00059932563,0.0019247758,0.00020092462,0.0006036958,0.00018925898],"domain_scores_gemma":[0.9939915,0.002701286,0.0017077101,0.00011816537,0.0013039977,0.00017736113],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0023301695,0.00012476913,0.0013998586,0.000097268334,0.000022772187,0.000006845742,0.0000655566,0.00037319813,0.00012512985],"category_scores_gemma":[0.00438711,0.000085376814,0.00026349426,0.0001953037,0.000038918406,0.00012426234,0.000025679761,0.0007273763,0.0000021221463],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.002972168,0.0039182054,0.9568414,0.00003375115,0.00035221595,0.00015340932,0.000186887,0.000015362135,0.0007944517,0.000023098986,0.00012805889,0.034580957],"study_design_scores_gemma":[0.0168553,0.011098638,0.96749073,0.00030098882,0.00025077714,0.000023029927,0.00008012302,0.000045256344,0.002888513,0.000056169174,0.0008389442,0.00007150379],"about_ca_topic_score_codex":0.000057010824,"about_ca_topic_score_gemma":0.0010541667,"teacher_disagreement_score":0.034509454,"about_ca_system_score_codex":0.0003584155,"about_ca_system_score_gemma":0.0014544401,"threshold_uncertainty_score":0.5252097},"labels":[],"label_agreement":null},{"id":"W3169602208","doi":"10.1200/jco.2021.39.15_suppl.e19040","title":"Longitudinal and individual symptom analyses of momelotinib and ruxolitinib treated myelofibrosis patients from SIMPLIFY-1.","year":2021,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sierra Wireless (Canada); University of British Columbia; St. Paul's Hospital; Princess Margaret Cancer Centre","funders":"","keywords":"Ruxolitinib; Medicine; Myelofibrosis; Repeated measures design; Population; Clinical endpoint; Internal medicine; Clinical trial; Gee; Generalized estimating equation; Statistics; Mathematics; Bone marrow","score_opus":0.22903750908956824,"score_gpt":0.47981538160230097,"score_spread":0.25077787251273276,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3169602208","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9954866,0.0014200741,0.000011053158,0.002131884,0.0002164413,0.00014090493,0.0001052032,0.0000051326588,0.00048267338],"genre_scores_gemma":[0.993727,0.0021859296,0.0029057201,0.00073334645,0.00033254817,0.0000042197576,0.000057037792,0.000014308456,0.000039887604],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99654037,0.00042637126,0.0021142939,0.00030601796,0.00040918594,0.00020376845],"domain_scores_gemma":[0.993193,0.0039131544,0.0014171946,0.00016178806,0.0008466369,0.000468244],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00066075893,0.00019737055,0.0020261614,0.00012765237,0.000049476635,0.00001887108,0.0000674677,0.00031782055,0.00022184735],"category_scores_gemma":[0.0027413655,0.00013528409,0.00032221002,0.00016358949,0.0002698838,0.000100824844,0.00010388812,0.00042326015,0.000002954363],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0012886046,0.002976053,0.9494602,0.000028303013,0.0020071885,0.00035105256,0.00012368803,0.0000013581678,0.00023080742,0.000066074645,0.0005195871,0.0429471],"study_design_scores_gemma":[0.01232827,0.00943509,0.9701323,0.0001750447,0.0020760396,0.00011785296,0.00012453742,0.000014073916,0.0037280247,0.0002449561,0.001525516,0.00009828775],"about_ca_topic_score_codex":0.00007835995,"about_ca_topic_score_gemma":0.000042132375,"teacher_disagreement_score":0.04284881,"about_ca_system_score_codex":0.000049648286,"about_ca_system_score_gemma":0.0005919377,"threshold_uncertainty_score":0.5516725},"labels":[],"label_agreement":null},{"id":"W3169681939","doi":"10.1016/j.jval.2021.04.111","title":"PCN19 Beyond a Binary Endpoint: Longitudinal and Individual Symptom Analyses from the Simplify-1 Study Demonstrate Clinically Comparable Symptomatic Benefit of Momelotinib to Ruxolitinib in JAK Inhibitor Naive Myelofibrosis Patients","year":2021,"lang":"en","type":"article","venue":"Value in Health","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sierra Wireless (Canada); St. Paul's Hospital; University of Toronto; University of British Columbia; University Health Network","funders":"","keywords":"Ruxolitinib; Repeated measures design; Myelofibrosis; Medicine; Population; Clinical endpoint; Random effects model; Clinical trial; Internal medicine; Statistics; Mathematics; Meta-analysis","score_opus":0.0983970036572504,"score_gpt":0.3711097913004383,"score_spread":0.2727127876431879,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3169681939","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9931984,0.0010930585,0.000004092586,0.0026814872,0.00012521361,0.0022855818,0.00051773025,0.000021416345,0.00007299941],"genre_scores_gemma":[0.99647903,0.0002773197,0.0015768777,0.0011087822,0.000075259544,0.00022275055,0.0002185196,0.000031232816,0.000010212034],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99535686,0.00073924963,0.0018602195,0.0007891461,0.0006924262,0.00056209386],"domain_scores_gemma":[0.99593246,0.002503525,0.00044693224,0.0005116174,0.00022421368,0.00038125974],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0010212787,0.00037059846,0.0013558926,0.00027905294,0.00015588832,0.000056250155,0.00016139886,0.000113219176,0.00006115939],"category_scores_gemma":[0.0004942902,0.0002772785,0.00012421508,0.00092115987,0.00010478968,0.00009942672,0.00023334891,0.00037402578,0.000012234793],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00042092215,0.0049237073,0.98573065,0.00019387495,0.00031491098,0.00007592698,0.0058089592,0.0006348587,0.000041689487,0.00012859555,0.000129009,0.001596906],"study_design_scores_gemma":[0.0059193396,0.0041071437,0.9835155,0.0013674876,0.00018501151,0.00000771379,0.0032383823,0.00057364715,0.0005434185,0.0003268608,0.000017301678,0.00019817529],"about_ca_topic_score_codex":0.0072007016,"about_ca_topic_score_gemma":0.0014881394,"teacher_disagreement_score":0.0057125622,"about_ca_system_score_codex":0.00023130262,"about_ca_system_score_gemma":0.0006062649,"threshold_uncertainty_score":0.99996793},"labels":[],"label_agreement":null},{"id":"W3170873716","doi":"10.1182/blood.v130.suppl_1.1138.1138","title":"Gene-Specific Lineage Involvement of Age-Related Clonal Hematopoiesis","year":2017,"lang":"en","type":"article","venue":"Blood","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal; Centre Intégré Universitaire de Santé et de Services Sociaux du Centre-Sud-de-l'Île-de-Montréal; Hôpital Maisonneuve-Rosemont","funders":"","keywords":"Biology; Haematopoiesis; Lineage (genetic); Gene; Genetics; Immunology; Stem cell","score_opus":0.035200292817024754,"score_gpt":0.279304779419367,"score_spread":0.24410448660234224,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3170873716","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9906121,0.0011409821,0.000008303476,0.0006823998,0.00013944446,0.00041901442,0.0000296359,0.000029711538,0.0069384216],"genre_scores_gemma":[0.9959308,0.0005937755,0.0022605371,0.000098883036,0.00014608086,0.00006873914,0.00005813029,0.00002126939,0.0008218024],"study_design_codex":"observational","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9988585,0.000021533127,0.00035911426,0.0002711467,0.00029312234,0.00019659224],"domain_scores_gemma":[0.9988063,0.000047648526,0.00022326487,0.00068803877,0.00010629012,0.0001284445],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001312112,0.00017213997,0.00041712425,0.00006163827,0.00018657606,0.000033645105,0.00013286347,0.0000899327,0.00041313912],"category_scores_gemma":[0.00005114629,0.00013329943,0.00016122361,0.000043355863,0.00013344525,0.0000510528,0.000077308796,0.00010349628,0.00007948103],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00025795092,0.012472643,0.89713514,0.00036965345,0.0028882914,0.002229324,0.0015241777,0.00000456813,0.06407608,0.010194102,0.005450963,0.003397093],"study_design_scores_gemma":[0.0070931404,0.00046869356,0.3034447,0.0001839086,0.0003526978,0.00005414475,0.00004247762,0.0000078036655,0.6844673,0.00015569775,0.0035915663,0.00013784457],"about_ca_topic_score_codex":0.000039880335,"about_ca_topic_score_gemma":0.000021291917,"teacher_disagreement_score":0.6203912,"about_ca_system_score_codex":0.000025474277,"about_ca_system_score_gemma":0.000054424007,"threshold_uncertainty_score":0.54357934},"labels":[],"label_agreement":null},{"id":"W3171302195","doi":"10.14740/jh822","title":"Essential Thrombocythemia in Children: A Retrospective Study","year":2021,"lang":"en","type":"article","venue":"Journal of Hematology","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Medicine; Essential thrombocythemia; Anagrelide; Pediatrics; Thrombocytosis; Family history; Internal medicine; Incidence (geometry); Polycythemia vera; Platelet","score_opus":0.009817770609000654,"score_gpt":0.3007626874091444,"score_spread":0.2909449168001438,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3171302195","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99661946,0.0009827502,0.000021846983,0.0014045925,0.0001510282,0.0002291308,0.000001543202,0.0000046415385,0.00058499957],"genre_scores_gemma":[0.99902445,0.00010797993,0.00050697796,0.00016312156,0.00012615939,0.000008196164,0.0000022115,0.000010557167,0.000050356884],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99884874,0.00010866829,0.0004829826,0.00016551097,0.00022922945,0.00016486525],"domain_scores_gemma":[0.99923366,0.000053064894,0.00021860104,0.00014864856,0.00026389255,0.000082144725],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00017101112,0.000117283395,0.0007602992,0.00013562314,0.000029315757,0.000009653399,0.000047879672,0.00007040574,0.00034679237],"category_scores_gemma":[0.00018120336,0.000086023036,0.00012889948,0.00019092122,0.000035834102,0.00005020764,0.000032577027,0.00030739894,0.000013878888],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00014597316,0.0029544455,0.9889035,0.000008862835,0.00051160983,0.004679865,0.0005643741,0.000001597591,0.00044854416,0.0011285973,0.000548967,0.00010365365],"study_design_scores_gemma":[0.005766372,0.0013123619,0.9516738,0.0000847402,0.00018874292,0.020776683,0.00062494294,0.000003372493,0.019042615,0.0004267592,0.000035512676,0.00006408238],"about_ca_topic_score_codex":0.000008675893,"about_ca_topic_score_gemma":0.00005883003,"teacher_disagreement_score":0.037229694,"about_ca_system_score_codex":0.00012541095,"about_ca_system_score_gemma":0.0002640897,"threshold_uncertainty_score":0.37971333},"labels":[],"label_agreement":null},{"id":"W3172015782","doi":"10.1200/jco.2021.39.15_suppl.e19039","title":"Improved transfusion independence rates for momelotinib versus ruxolitinib in anemic JAKi naïve myelofibrosis patients independent of baseline platelet or transfusion status.","year":2021,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sierra Wireless (Canada)","funders":"","keywords":"Myelofibrosis; Ruxolitinib; Medicine; Anemia; Internal medicine; Phases of clinical research; Gastroenterology; Clinical trial; Surgery; Bone marrow","score_opus":0.09036830015533458,"score_gpt":0.4395758205238465,"score_spread":0.34920752036851194,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3172015782","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99436903,0.00034887076,0.00038266383,0.0021238555,0.0014365152,0.0010059279,0.00013370703,0.000008081427,0.00019134529],"genre_scores_gemma":[0.9840977,0.008121959,0.0066045215,0.0005618477,0.000350914,0.000050239087,0.00009068567,0.000034539145,0.00008760266],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99390733,0.000647641,0.003811399,0.00046965678,0.0006833433,0.00048064417],"domain_scores_gemma":[0.9883531,0.0077198716,0.0015022487,0.00023990696,0.0016858339,0.0004990479],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002717943,0.0003030767,0.002306971,0.00024533254,0.000059588234,0.000011996426,0.00015153758,0.00072414055,0.0004981999],"category_scores_gemma":[0.0070968214,0.00020939093,0.00066361524,0.0003317246,0.00013552372,0.00017294838,0.00004530249,0.0010381881,0.0000030857123],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.15373601,0.017556699,0.5035872,0.00041190902,0.0009089591,0.0009850705,0.0009813433,0.00007797703,0.008260508,0.000078727455,0.0005279792,0.31288767],"study_design_scores_gemma":[0.17073983,0.08412476,0.65839064,0.0010153081,0.0009699785,0.00019889863,0.0012657227,0.0009426756,0.07239118,0.00014983647,0.009394335,0.0004168045],"about_ca_topic_score_codex":0.00011690133,"about_ca_topic_score_gemma":0.0013451561,"teacher_disagreement_score":0.31247085,"about_ca_system_score_codex":0.0003462859,"about_ca_system_score_gemma":0.0037227238,"threshold_uncertainty_score":0.8538714},"labels":[],"label_agreement":null},{"id":"W3174383320","doi":"10.1186/s13045-021-01116-z","title":"Molecular pathogenesis of the myeloproliferative neoplasms","year":2021,"lang":"en","type":"review","venue":"Journal of Hematology & Oncology","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":114,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Health Research Board; Canadian Institute for Theoretical Astrophysics; Health Service Executive; Wellcome Trust; Wellcome","keywords":"Epigenetics; Disease; Biology; Myeloid; Myeloproliferative Disorders; Genetics; Bioinformatics; Cancer research; Medicine; Immunology; Gene; Internal medicine","score_opus":0.04123789998553555,"score_gpt":0.3755260178493881,"score_spread":0.33428811786385254,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3174383320","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0032813023,0.99214506,0.00003465909,0.0017077667,0.0010122873,0.000947442,0.000030751013,0.000006826991,0.0008339305],"genre_scores_gemma":[0.0007979954,0.99622434,0.001922662,0.0005405744,0.00020108742,0.0001114926,0.000019078576,0.000064491214,0.000118252865],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9948091,0.0015158993,0.0023775648,0.0004034303,0.0004900458,0.00040395497],"domain_scores_gemma":[0.9934127,0.001390679,0.0033681695,0.00060464366,0.0009976303,0.00022618473],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0005981313,0.0005946953,0.0075595793,0.00036581597,0.00009450314,0.000010199172,0.00039307072,0.0010060573,0.00023823237],"category_scores_gemma":[0.00084241014,0.0003232866,0.0024439765,0.0005381707,0.00035945716,0.000042556185,0.00020096613,0.0011214127,0.00001885348],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0003470874,0.005103,0.0042722556,0.017560385,0.017680895,0.02819164,0.0008039777,0.00001112237,0.00016076997,0.029644893,0.008065068,0.8881589],"study_design_scores_gemma":[0.0017518593,0.0021100338,0.00014289076,0.012501944,0.009391084,0.07283054,0.00011930807,0.0000011899724,0.0016111349,0.00010208462,0.8991933,0.000244643],"about_ca_topic_score_codex":0.0000032295397,"about_ca_topic_score_gemma":0.000012887961,"teacher_disagreement_score":0.89112824,"about_ca_system_score_codex":0.00045222195,"about_ca_system_score_gemma":0.005506819,"threshold_uncertainty_score":0.9999219},"labels":[],"label_agreement":null},{"id":"W3176781225","doi":"10.1182/blood.v130.suppl_1.4207.4207","title":"Platelet Function Tests and Inflammatory Markers for the Differentiation of Primary Thrombocytosis and Secondary Thrombocytosis","year":2017,"lang":"en","type":"article","venue":"Blood","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University","funders":"","keywords":"Thrombocytosis; Medicine; Platelet; Internal medicine; Erythrocyte sedimentation rate; Gastroenterology; C-reactive protein; Von Willebrand factor; Immunology; Inflammation","score_opus":0.01891405940328669,"score_gpt":0.2511722046933629,"score_spread":0.23225814529007618,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3176781225","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9963982,0.0010549846,0.00004335686,0.0005766603,0.00008924999,0.00088769034,0.000043787917,0.000016537319,0.0008895166],"genre_scores_gemma":[0.9981358,0.0010681131,0.00031131733,0.00013165029,0.000084363084,0.00016993114,0.000033461107,0.000016583379,0.000048774196],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9992928,0.000021040487,0.00019731416,0.00022217682,0.00013629,0.00013039],"domain_scores_gemma":[0.99905396,0.00029528572,0.00019976863,0.0003159247,0.00007307891,0.00006200709],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001466574,0.00014633284,0.0003221108,0.00004041174,0.00037543912,0.00005322891,0.000051031842,0.00007956764,0.000036058398],"category_scores_gemma":[0.00008811649,0.00009445997,0.00006233551,0.000018381563,0.00014427934,0.00013158147,0.000059163773,0.0000818913,0.00000104392],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00041822103,0.000478541,0.9499277,0.0005137018,0.001201551,0.0000040661453,0.0002623094,2.2889084e-7,0.014037194,0.00047134073,0.0004071797,0.032277964],"study_design_scores_gemma":[0.005803075,0.00062204665,0.9630421,0.00011546367,0.00091144355,0.000019415378,0.000056356366,0.000034765217,0.028804483,0.00017843593,0.00032700272,0.00008541413],"about_ca_topic_score_codex":0.000025640482,"about_ca_topic_score_gemma":0.00004651935,"teacher_disagreement_score":0.032192547,"about_ca_system_score_codex":0.000019258576,"about_ca_system_score_gemma":0.000055145192,"threshold_uncertainty_score":0.38519657},"labels":[],"label_agreement":null},{"id":"W3178291929","doi":"10.1101/gr.270066.120","title":"Hydroxycarbamide effects on DNA methylation and gene expression in myeloproliferative neoplasms","year":2021,"lang":"en","type":"article","venue":"Genome Research","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Comisión Nacional de Investigación Científica y Tecnológica; Medical Research Council; Agencia Nacional de Investigación y Desarrollo; Medical Research Council Canada; King's Health Partners; King's College London; National Institute for Health and Care Research; European Hematology Association","keywords":"Biology; DNA methylation; Transcriptome; RUNX1; Methylation; Haematopoiesis; Gene; Transcription factor; Cell cycle; Gene expression profiling; Gene expression; Genetics; Transcription (linguistics); Cancer research; Stem cell; Cell biology","score_opus":0.04670132125271869,"score_gpt":0.3575508120768331,"score_spread":0.3108494908241144,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3178291929","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9897365,0.0034573677,0.00003307433,0.0023373575,0.000056291003,0.0010453811,0.000009953252,0.000025129368,0.0032989415],"genre_scores_gemma":[0.9944568,0.0015612305,0.001857724,0.00023782326,0.00019652695,0.00042658468,0.00010301879,0.000033225133,0.0011270382],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9970756,0.00065730995,0.0002776366,0.0006744278,0.00078036205,0.0005346608],"domain_scores_gemma":[0.9979735,0.0010325564,0.000038208942,0.00038096268,0.00030071498,0.00027405174],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00084630225,0.00021475874,0.0004321358,0.00041305536,0.00020516093,0.00006506737,0.000060684368,0.0001487263,0.000113986935],"category_scores_gemma":[0.00057865854,0.00017231161,0.000059531812,0.0006399793,0.00008072172,0.000083647676,0.00013894381,0.00053399696,0.00011561864],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0005617553,0.00066286133,0.04432416,0.0002539621,0.00011401415,0.0017906276,0.0019362835,0.00006557473,0.9345082,0.0007013946,0.00020095268,0.014880194],"study_design_scores_gemma":[0.0022455032,0.0007792561,0.24479748,0.00023496203,0.000014776131,0.000049600872,0.00013087904,0.00010324359,0.75000066,0.0006057229,0.00091626076,0.00012167216],"about_ca_topic_score_codex":0.000021557515,"about_ca_topic_score_gemma":0.000041410825,"teacher_disagreement_score":0.20047332,"about_ca_system_score_codex":0.0003282893,"about_ca_system_score_gemma":0.00028225433,"threshold_uncertainty_score":0.70266634},"labels":[],"label_agreement":null},{"id":"W3178904653","doi":"10.1002/hon.2898","title":"Comparing the safety and efficacy of ruxolitinib in patients with Dynamic International Prognostic Scoring System low‐, intermediate‐1‐, intermediate‐2‐, and high‐risk myelofibrosis in JUMP, a Phase 3b, expanded‐access study","year":2021,"lang":"en","type":"article","venue":"Hematological Oncology","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":15,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; St. Paul's Hospital; Princess Margaret Cancer Centre","funders":"Novartis Pharma; Celgene","keywords":"Ruxolitinib; International Prognostic Scoring System; Medicine; Myelofibrosis; Internal medicine; Adverse effect; Anemia; Clinical endpoint; Janus kinase inhibitor; Gastroenterology; Surgery; Clinical trial; Bone marrow; Janus kinase; Myelodysplastic syndromes","score_opus":0.02074939354465334,"score_gpt":0.3252005367022574,"score_spread":0.3044511431576041,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3178904653","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99763507,0.00016033946,0.000046164587,0.0002344565,0.00017408926,0.0015612663,0.000020871117,0.00002553055,0.00014222127],"genre_scores_gemma":[0.99926406,0.00015159184,0.00015101586,0.00005278561,0.000021990998,0.00027420817,0.00006582587,0.0000148946765,0.0000035974488],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9976913,0.0003983811,0.0008050645,0.0005417803,0.00025853323,0.00030499275],"domain_scores_gemma":[0.9978818,0.0013300662,0.00030625594,0.00020262966,0.0001518396,0.0001273943],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00033330708,0.00025634907,0.001094641,0.00017936323,0.00006420617,0.00003564326,0.00014021907,0.00012619336,0.000025514493],"category_scores_gemma":[0.0005372397,0.00015253574,0.000045792895,0.0002523076,0.00025067735,0.00009395486,0.00034910828,0.0003664008,0.0000020020627],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0032594341,0.0064201537,0.9823825,0.00020422823,0.0001914593,0.00065623043,0.0010977119,0.00001409887,0.000010688374,0.00032776655,0.0000018955785,0.0054338854],"study_design_scores_gemma":[0.028150467,0.0031835441,0.9644592,0.00092751224,0.0001562379,0.00011659233,0.0016780786,0.0010298796,0.00014011211,0.000021137197,0.000005947181,0.00013131494],"about_ca_topic_score_codex":0.000076211276,"about_ca_topic_score_gemma":0.0006983683,"teacher_disagreement_score":0.024891034,"about_ca_system_score_codex":0.00029005215,"about_ca_system_score_gemma":0.000109684224,"threshold_uncertainty_score":0.6220227},"labels":[],"label_agreement":null},{"id":"W3179168710","doi":"10.1158/1538-7445.am2021-ct252","title":"Abstract CT252: A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Ruxolitinib Plus Parsaclisib in Patients with JAK- and PI3K-Inhibitor Treatment-Naïve Myelofibrosis","year":2021,"lang":"en","type":"article","venue":"Cancer Research","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Ruxolitinib; Medicine; Myelofibrosis; Internal medicine; Gastroenterology; Placebo; International Prognostic Scoring System; Polycythemia vera; Randomization; Anemia; Randomized controlled trial; Surgery; Bone marrow; Myelodysplastic syndromes; Pathology","score_opus":0.08149661003398903,"score_gpt":0.41382205842461756,"score_spread":0.3323254483906285,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3179168710","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98588395,0.001724224,0.0000011539188,0.00044871765,0.00006927748,0.010845875,0.00009892022,0.000018105118,0.0009098033],"genre_scores_gemma":[0.9906363,0.0009267111,0.00005931137,0.000033058368,0.00012833021,0.007515948,0.00009920191,0.000049216374,0.00055194466],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9961386,0.00052967307,0.00078046275,0.00078685675,0.0011159014,0.0006485478],"domain_scores_gemma":[0.9966955,0.0013218023,0.00018911042,0.0004983729,0.00093908666,0.00035611153],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00089420367,0.0003780664,0.0019586263,0.00041799774,0.0001613912,0.00008425528,0.000088159024,0.00012228072,0.0004822071],"category_scores_gemma":[0.0002523629,0.00024050378,0.00016751171,0.000609411,0.00025847138,0.00012954346,0.00007874163,0.00035661954,0.000010447613],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.85227823,0.011565437,0.12719405,0.00014274818,0.0015874723,0.00028000734,0.0029037131,0.000025705545,0.00026402314,0.00004462504,0.00010075442,0.0036132182],"study_design_scores_gemma":[0.95851046,0.0058446033,0.022763021,0.0005504054,0.00047767695,0.0000036629656,0.0016262195,0.000037380036,0.009881003,0.000012006811,0.0000998222,0.00019374753],"about_ca_topic_score_codex":0.0020062025,"about_ca_topic_score_gemma":0.0018667959,"teacher_disagreement_score":0.1062322,"about_ca_system_score_codex":0.0006951799,"about_ca_system_score_gemma":0.0011162605,"threshold_uncertainty_score":0.980746},"labels":[],"label_agreement":null},{"id":"W3182316807","doi":"10.1111/ejh.13689","title":"Effect of pre‐transplant JAK1/2 inhibitors and CD34 dose on transplant outcomes in myelofibrosis","year":2021,"lang":"en","type":"article","venue":"European Journal Of Haematology","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Medicine; Cumulative incidence; Myelofibrosis; Incidence (geometry); Internal medicine; CD34; Gastroenterology; Transplantation; Calcineurin; Tacrolimus; Surgery; Stem cell; Bone marrow","score_opus":0.009999089130386468,"score_gpt":0.2669885512672627,"score_spread":0.25698946213687623,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3182316807","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99584115,0.0010069256,0.000020018764,0.0018050205,0.00019772889,0.00019791281,0.000017032835,0.0000064002043,0.00090781425],"genre_scores_gemma":[0.99859935,0.00080282986,0.00024412856,0.00022980681,0.000041468185,0.0000032303158,0.000006998919,0.000024752528,0.00004745813],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9976612,0.0009374267,0.0007614443,0.00020230796,0.00022660366,0.00021103842],"domain_scores_gemma":[0.9987339,0.000616791,0.00026182234,0.00015862007,0.000079527206,0.00014936952],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00066035736,0.00021818835,0.0011002299,0.00022049353,0.000029070898,0.0000090301455,0.00006602239,0.000047915226,0.00005602782],"category_scores_gemma":[0.00011698126,0.00013942849,0.00019136711,0.000112552436,0.000085732114,0.00004556567,0.000017059325,0.000282444,0.00001028443],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0034726425,0.00085609616,0.9176264,0.00063681614,0.0005529502,0.06202194,0.0021344703,0.00001982112,0.006887554,0.00028955447,0.00025006876,0.0052516866],"study_design_scores_gemma":[0.012512344,0.010081479,0.6461679,0.002617193,0.0005909267,0.023056742,0.000067211695,0.000011863771,0.30421865,0.000020029962,0.00046537057,0.00019031488],"about_ca_topic_score_codex":0.0000049394434,"about_ca_topic_score_gemma":0.0000100204925,"teacher_disagreement_score":0.2973311,"about_ca_system_score_codex":0.000025453603,"about_ca_system_score_gemma":0.000059890684,"threshold_uncertainty_score":0.5685729},"labels":[],"label_agreement":null},{"id":"W3187131292","doi":"10.1172/jci.insight.145651","title":"TGF-β1 protein trap AVID200 beneficially affects hematopoiesis and bone marrow fibrosis in myelofibrosis","year":2021,"lang":"en","type":"article","venue":"JCI Insight","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":52,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Cégep de Saint-Laurent","funders":"National Cancer Institute; Istituto Superiore di Sanità","keywords":"Myelofibrosis; Bone marrow; Haematopoiesis; Trap (plumbing); Fibrosis; Medicine; Transforming growth factor; Internal medicine; Cancer research; Pathology; Cell biology; Biology; Stem cell; Physics","score_opus":0.013961953226851453,"score_gpt":0.24604710602370353,"score_spread":0.23208515279685207,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3187131292","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9835021,0.0037957774,0.00001237709,0.005033593,0.00009304821,0.0010575101,0.00003116506,0.000072041345,0.0064024166],"genre_scores_gemma":[0.9935498,0.00045467407,0.003081529,0.00067546,0.00013717522,0.00047453825,0.00007698335,0.0000538494,0.0014959535],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9979422,0.0001214244,0.00042026528,0.0006680868,0.00040347697,0.00044454582],"domain_scores_gemma":[0.99891716,0.00017627126,0.00010422583,0.00041594365,0.00012548624,0.0002609343],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00014019897,0.00037456825,0.0007987924,0.00021840692,0.0001364444,0.000086369284,0.00005740453,0.0002223327,0.000517008],"category_scores_gemma":[0.00015749328,0.00031747072,0.00015927928,0.0005454144,0.00007270617,0.00015519909,0.00008415367,0.00022729089,0.000053183907],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0014029233,0.0063517797,0.31574428,0.0024810897,0.0008109646,0.0060991626,0.0070311893,0.00001873524,0.61272466,0.012957083,0.0056616087,0.028716492],"study_design_scores_gemma":[0.0046673496,0.0009935971,0.24974704,0.0014601991,0.00020714225,0.00022299003,0.00027681686,0.00006379836,0.72784656,0.00038477764,0.013619275,0.00051045587],"about_ca_topic_score_codex":0.00009450505,"about_ca_topic_score_gemma":0.0007832638,"teacher_disagreement_score":0.11512187,"about_ca_system_score_codex":0.00016219304,"about_ca_system_score_gemma":0.00023041124,"threshold_uncertainty_score":0.99992776},"labels":[],"label_agreement":null},{"id":"W3196694240","doi":"10.1007/s00277-021-04657-y","title":"A rare de novo pure erythroid leukemia with JAK2 R683S mutation","year":2021,"lang":"en","type":"letter","venue":"Annals of Hematology","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Genome British Columbia; Royal Jubilee Hospital; University of British Columbia","funders":"","keywords":"Hematology; Mutation; Cancer research; Medicine; Leukemia; Internal medicine; Genetics; Biology; Gene","score_opus":0.04394175270848683,"score_gpt":0.3145461106660042,"score_spread":0.27060435795751736,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3196694240","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.27775615,0.004802247,0.000086098866,0.7142248,0.00012028232,0.0006531929,0.000100138604,0.000048224203,0.0022088494],"genre_scores_gemma":[0.23265399,0.001365482,0.0027092951,0.7574759,0.0009327865,0.00045503507,0.0030641512,0.00012785225,0.0012155095],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9979366,0.00015062977,0.0004892027,0.0005502066,0.00035836457,0.00051496254],"domain_scores_gemma":[0.99827176,0.00031428272,0.00036151017,0.0004998683,0.00044807245,0.000104524785],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00008672007,0.000417433,0.0013977626,0.0002065746,0.00006018098,0.000016510201,0.00010591605,0.0008757542,0.0004885486],"category_scores_gemma":[0.00013491856,0.00031474815,0.00024065824,0.00019147484,0.0001670859,0.000047615846,0.00004186343,0.0008657156,0.000039220507],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00022048017,0.00023432098,0.022842644,0.0016748754,0.0012799622,0.03875467,0.00044071957,0.0000061248797,0.00010143226,0.0006558745,0.93327206,0.00051685027],"study_design_scores_gemma":[0.007629465,0.004797028,0.007945214,0.005469332,0.0018688879,0.07322143,0.00044055408,0.000042855867,0.19788514,0.0012824073,0.69813275,0.0012849148],"about_ca_topic_score_codex":0.000048123977,"about_ca_topic_score_gemma":0.00006089021,"teacher_disagreement_score":0.23513928,"about_ca_system_score_codex":0.000070092734,"about_ca_system_score_gemma":0.001023962,"threshold_uncertainty_score":0.99993044},"labels":[],"label_agreement":null},{"id":"W3201223031","doi":"10.3899/jrheum.210455","title":"Abatacept as Adjunctive Therapy in Refractory Polymyalgia Rheumatica","year":2021,"lang":"en","type":"article","venue":"The Journal of Rheumatology","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Medicine; Polymyalgia rheumatica; Abatacept; Refractory (planetary science); Larrea; Internal medicine; Surgery; Giant cell arteritis; Rituximab; Vasculitis","score_opus":0.01743531549345923,"score_gpt":0.2879351550187901,"score_spread":0.27049983952533085,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3201223031","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98231554,0.00752536,0.000036282912,0.00818179,0.000282194,0.00016622985,0.0000023788687,0.000007387164,0.0014828325],"genre_scores_gemma":[0.9787584,0.020083714,0.00028882353,0.00062325853,0.0000113153255,0.000007899738,0.0000042365054,0.00001825675,0.00020407984],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99830854,0.00042143426,0.0006238644,0.00012676843,0.00027784705,0.00024156921],"domain_scores_gemma":[0.99810797,0.00082960067,0.00036761002,0.00027734405,0.0003004041,0.00011705428],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0004665445,0.00017167423,0.00069733773,0.00014013622,0.00006520326,0.000010707205,0.00012276266,0.00010659884,0.0010860714],"category_scores_gemma":[0.00042871313,0.00009693462,0.00014161636,0.00020775698,0.00011754631,0.00008212334,0.000035854388,0.00044810685,0.00007041326],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0034293658,0.0023168498,0.9472027,0.00008289454,0.0014144394,0.0009682421,0.008189587,0.000020061103,0.002309654,0.0050363904,0.0064476607,0.022582186],"study_design_scores_gemma":[0.03315325,0.010392256,0.75832915,0.0026578244,0.00050527777,0.12810242,0.008589605,0.00012702972,0.034867723,0.0074327663,0.015223349,0.0006193337],"about_ca_topic_score_codex":0.0001565099,"about_ca_topic_score_gemma":0.00009086463,"teacher_disagreement_score":0.1888735,"about_ca_system_score_codex":0.00010895899,"about_ca_system_score_gemma":0.00053843943,"threshold_uncertainty_score":0.9998271},"labels":[],"label_agreement":null},{"id":"W3202459519","doi":"10.1002/jha2.309","title":"Hydroxycarbamide‐related cutaneous ulcer complicated by osteomyelitis","year":2021,"lang":"en","type":"article","venue":"eJHaem","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Hydroxycarbamide; Thrombocytosis; Osteomyelitis; Surgery; White blood cell; Amputation; Internal medicine; Dermatology; Chemotherapy; Platelet","score_opus":0.008171183667236324,"score_gpt":0.24949338338643917,"score_spread":0.24132219971920285,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3202459519","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.93089706,0.002546247,0.000026494052,0.012435095,0.00022819685,0.00050192984,0.000112530026,0.00022085692,0.053031582],"genre_scores_gemma":[0.98164535,0.00031757395,0.0003317223,0.0015140763,0.00012451147,0.000082892846,0.0007688972,0.00004601297,0.0151689565],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99842334,0.00007359176,0.0003514476,0.0004959267,0.00029927705,0.00035639634],"domain_scores_gemma":[0.99888,0.00013494796,0.00007267618,0.00044379194,0.0002073574,0.0002611987],"candidate_categories":["insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.00004922634,0.00024935446,0.00047108298,0.00004655632,0.00011655281,0.000035010064,0.000064404056,0.00014025066,0.0032946512],"category_scores_gemma":[0.00009432205,0.00021461089,0.00013286901,0.00033826954,0.00007161398,0.00004191626,0.000054874316,0.00022908348,0.0010336131],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0005707034,0.0038409354,0.2141743,0.00036408647,0.0042542103,0.034670845,0.0029972873,0.000090641945,0.13862382,0.008613202,0.42515615,0.16664383],"study_design_scores_gemma":[0.007560274,0.0010279596,0.043369476,0.0003871557,0.00067003985,0.01010729,0.00031546087,0.00073110324,0.35684016,0.0006850003,0.5775213,0.0007847658],"about_ca_topic_score_codex":0.000080060905,"about_ca_topic_score_gemma":0.000027793796,"teacher_disagreement_score":0.21821636,"about_ca_system_score_codex":0.00014992351,"about_ca_system_score_gemma":0.00013009377,"threshold_uncertainty_score":0.9997442},"labels":[],"label_agreement":null},{"id":"W3203076204","doi":"10.1002/ccr3.4907","title":"Hereditary hemochromatosis and JAK2‐positive polycythemia vera","year":2021,"lang":"en","type":"article","venue":"Clinical Case Reports","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Saskatchewan Cancer Agency; University of Saskatchewan","funders":"","keywords":"Polycythemia vera; Medicine; Transferrin saturation; Hereditary hemochromatosis; Hemochromatosis; Phlebotomy; Gastroenterology; Ferritin; Genetic testing; Internal medicine; Mutation; Compound heterozygosity; Genetics; Gene; Serum ferritin","score_opus":0.034267658403063804,"score_gpt":0.35833731045260686,"score_spread":0.3240696520495431,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3203076204","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98936665,0.0019465442,0.000014190186,0.002994185,0.0005159733,0.00029682662,0.000018829856,0.00005294634,0.004793865],"genre_scores_gemma":[0.9949239,0.0004757252,0.0014598562,0.0017641694,0.00048378317,0.00004205269,0.00008791591,0.000026034322,0.0007365727],"study_design_codex":"case_report","study_design_gemma":"case_report","domain_scores_codex":[0.99796367,0.000106955566,0.00080850767,0.00065362727,0.00023364807,0.00023360591],"domain_scores_gemma":[0.9980148,0.00065893796,0.00017930918,0.00048138623,0.00020678835,0.0004587477],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00034144128,0.00020587926,0.00063055754,0.000031114163,0.00012165869,0.00002972703,0.000011256683,0.00018526774,0.0004183131],"category_scores_gemma":[0.0008482398,0.0001655745,0.00023818326,0.00012222903,0.0001449508,0.00006040594,0.00008797235,0.0002738867,0.000023083596],"study_design_candidate":"case_report","study_design_consensus":"case_report","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000077514625,0.0007222092,0.21540362,0.000042928397,0.00030954625,0.77032834,0.00006655457,1.5345351e-7,0.00008517808,0.000061085644,0.004632282,0.0082705775],"study_design_scores_gemma":[0.0017613767,0.0007080766,0.17384282,0.00026884757,0.0005975984,0.80010366,0.00017610448,0.000029337225,0.016156435,0.0002562157,0.005864256,0.00023526953],"about_ca_topic_score_codex":0.000048648944,"about_ca_topic_score_gemma":0.000022371283,"teacher_disagreement_score":0.041560806,"about_ca_system_score_codex":0.000057240428,"about_ca_system_score_gemma":0.00028674913,"threshold_uncertainty_score":0.6751932},"labels":[],"label_agreement":null},{"id":"W3205845588","doi":"10.1002/ajh.26377","title":"A population‐based study of outcomes in polycythemia vera, essential thrombocythemia, and primary myelofibrosis in the United States from 2001 to 2015: Comparison with data from a Mayo Clinic single institutional series","year":2021,"lang":"en","type":"letter","venue":"American Journal of Hematology","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":13,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal; Hôpital Maisonneuve-Rosemont","funders":"","keywords":"Myelofibrosis; Polycythemia vera; Essential thrombocythemia; Medicine; Population; Internal medicine; Oncology; Relative survival; Myeloproliferative neoplasm; Myeloid leukemia; Immunology; Epidemiology; Bone marrow; Cancer registry","score_opus":0.049623567506686936,"score_gpt":0.34078069779412856,"score_spread":0.2911571302874416,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3205845588","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.90674734,0.00036579082,0.000060999842,0.091859765,0.000083777726,0.00047441424,0.00039624813,0.00000428047,0.0000073617102],"genre_scores_gemma":[0.9515143,0.0000762956,0.0058764126,0.037835382,0.00016395346,0.00003486702,0.004457313,0.000031856882,0.000009606488],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99691206,0.0006003587,0.0012024603,0.00044327983,0.00056834973,0.00027350523],"domain_scores_gemma":[0.996514,0.0015858052,0.0010686785,0.0005831884,0.00016717734,0.000081120335],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00023714278,0.00035035875,0.0023545434,0.0005020152,0.000052513522,0.000031590887,0.0003241774,0.000145068,0.00014239145],"category_scores_gemma":[0.00013800208,0.00022159996,0.00007588833,0.0005088129,0.0002697999,0.00011219816,0.00012522459,0.00088154734,0.0000018664324],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0015762985,0.0023403415,0.97174543,0.00004940606,0.000895552,0.0016536377,0.0020794289,0.00007082897,0.000040110026,0.0000016670284,0.01945647,0.000090803085],"study_design_scores_gemma":[0.0075230785,0.006156316,0.9716677,0.0012396623,0.0009995353,0.00049031724,0.008483615,0.00005707922,0.00022435297,0.0000361512,0.0028019971,0.0003202082],"about_ca_topic_score_codex":0.009765232,"about_ca_topic_score_gemma":0.0045602815,"teacher_disagreement_score":0.05402438,"about_ca_system_score_codex":0.00016589709,"about_ca_system_score_gemma":0.000466878,"threshold_uncertainty_score":0.99682885},"labels":[],"label_agreement":null},{"id":"W3206289367","doi":"10.1038/s41375-021-01449-1","title":"Allogeneic blood or marrow transplantation with haploidentical donor and post-transplantation cyclophosphamide in patients with myelofibrosis: a multicenter study","year":2021,"lang":"en","type":"article","venue":"Leukemia","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":41,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"Daiichi Sankyo Europe; National Cancer Institute; Genentech; Cardinal Health; Sierra Oncology; CTI Biopharma; Incyte; Gilead Sciences; Actinium Pharmaceuticals; Helsinn; Bristol-Myers Squibb; AstraZeneca; Celgene; Pfizer; Constellation Pharmaceuticals; Agios Pharmaceuticals","keywords":"Medicine; Myelofibrosis; Cumulative incidence; Cyclophosphamide; Internal medicine; Transplantation; Gastroenterology; Bone marrow; Incidence (geometry); Surgery; Splenectomy; Graft-versus-host disease; Busulfan; Total body irradiation; Chemotherapy; Spleen","score_opus":0.00641380598825172,"score_gpt":0.22876650480061012,"score_spread":0.2223526988123584,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3206289367","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9979493,0.00010059551,0.000053749758,0.00017046284,0.000028170021,0.001541175,0.000051752377,0.00003162339,0.00007317436],"genre_scores_gemma":[0.99628663,0.00030653356,0.0021182701,0.0003693276,0.000021823858,0.0003682792,0.00036303123,0.000034462144,0.00013163434],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99846923,0.000085964566,0.00030610748,0.00050274935,0.00037205484,0.0002638939],"domain_scores_gemma":[0.99931043,0.000102635,0.00006556695,0.00018571159,0.00018959025,0.00014605893],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000065098575,0.00026130083,0.00036552598,0.00009412903,0.00007432823,0.000050744864,0.000036917176,0.00007612021,0.00007711335],"category_scores_gemma":[0.000017996472,0.00016698823,0.0000318307,0.00022041591,0.000047505255,0.00015632794,0.000010066356,0.00015262415,0.000007666354],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.008907476,0.0020242846,0.9821815,0.00026979335,0.00033340172,0.0023050096,0.0021823,0.000020450561,0.00083575194,0.0000130991175,0.0000028946092,0.00092405797],"study_design_scores_gemma":[0.029021224,0.0033112061,0.9548495,0.0005475498,0.0011987017,0.00012387338,0.00059048,0.000020522975,0.010127006,0.0000015546664,0.000007241907,0.00020114255],"about_ca_topic_score_codex":0.00023052271,"about_ca_topic_score_gemma":0.0039314795,"teacher_disagreement_score":0.027331984,"about_ca_system_score_codex":0.00014736247,"about_ca_system_score_gemma":0.00023103862,"threshold_uncertainty_score":0.6809582},"labels":[],"label_agreement":null},{"id":"W3209978954","doi":"10.1159/000519468","title":"Association of Polycythemia with Outcomes of Acute Coronary Syndrome","year":2021,"lang":"en","type":"article","venue":"Cardiology","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Heart and Stroke Foundation; Health Sciences Centre; University of Toronto; Sunnybrook Health Science Centre","funders":"","keywords":"Medicine; Mace; Internal medicine; Acute coronary syndrome; Hemoglobin; Propensity score matching; Anemia; Stroke (engine); Cardiology; Myocardial infarction; Percutaneous coronary intervention","score_opus":0.010339697328360174,"score_gpt":0.26195072476837755,"score_spread":0.2516110274400174,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3209978954","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9964393,0.0002521902,0.000039782648,0.0013147063,0.000083893196,0.0001278398,0.000057512116,0.000009010554,0.0016757883],"genre_scores_gemma":[0.9978068,0.00015673114,0.000477663,0.00015151913,0.000015555323,0.000023556944,0.00007309287,0.000008091683,0.001286989],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9993842,0.00006136806,0.00017477485,0.00014075253,0.0001241865,0.00011470315],"domain_scores_gemma":[0.99932563,0.00016258264,0.00011517166,0.00017857461,0.00018029491,0.00003771905],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000069407884,0.00008443072,0.00066880375,0.000031713793,0.0000132683035,9.070642e-7,0.000022913611,0.0000885121,0.00007215799],"category_scores_gemma":[0.00005551742,0.000057957506,0.00012238974,0.00007586111,0.000041789797,0.0000143512225,0.000020528954,0.000063170744,0.0000065341105],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000069828755,0.00006857763,0.99199104,0.00002229418,0.003984341,0.0007785009,0.000050512077,0.0000046333384,0.0021232106,0.00023981495,0.0005014846,0.00016572994],"study_design_scores_gemma":[0.0015086951,0.0006243043,0.97826374,0.000027340115,0.0008610187,0.001112308,0.000054802047,0.0000012397783,0.01717259,0.000028658615,0.0003002623,0.0000450289],"about_ca_topic_score_codex":0.0000064730243,"about_ca_topic_score_gemma":0.000003546687,"teacher_disagreement_score":0.015049379,"about_ca_system_score_codex":0.000075321776,"about_ca_system_score_gemma":0.00011484713,"threshold_uncertainty_score":0.23634385},"labels":[],"label_agreement":null},{"id":"W3210348916","doi":"10.14740/jh914","title":"Validation of a Modified Version of the Myeloproliferative Neoplasm Symptom Assessment Form Total Symptom Score","year":2021,"lang":"en","type":"article","venue":"Journal of Hematology","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":13,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"National Cancer Institute","keywords":"Myeloproliferative neoplasm; Medicine; Myelofibrosis; Essential thrombocythemia; Quality of life (healthcare); Cronbach's alpha; Physical therapy; Polycythemia vera; Distress; Internal medicine; Psychometrics; Clinical psychology","score_opus":0.016299848502045036,"score_gpt":0.29061294719938296,"score_spread":0.27431309869733794,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3210348916","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9943191,0.00037020803,0.00034179204,0.0029544907,0.00039287822,0.00030214933,0.000015327325,0.0000043332166,0.0012997685],"genre_scores_gemma":[0.99798775,0.00013538098,0.0015407107,0.00012832237,0.0000627557,0.000011284277,0.000012899178,0.000013122174,0.00010775022],"study_design_codex":"observational","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9980737,0.00017199315,0.0008846254,0.00016701836,0.0005198675,0.00018281394],"domain_scores_gemma":[0.99735963,0.0003341346,0.0009516928,0.00026298675,0.0009931779,0.000098373166],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00025887619,0.00017556816,0.00087384635,0.00013671703,0.00007402461,0.000009122557,0.00010081724,0.00013842374,0.00014106884],"category_scores_gemma":[0.0002278775,0.000107790765,0.00033641027,0.00023997985,0.00010461266,0.0001135124,0.000079651945,0.00027334274,0.0000028414206],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0009902028,0.0029365788,0.91603136,0.00066025154,0.0021969872,0.000519075,0.0027321307,0.0005289326,0.03853485,0.031255003,0.001863485,0.0017511653],"study_design_scores_gemma":[0.005713689,0.0013338989,0.2036087,0.0009549206,0.0006071215,0.0059464416,0.00073485734,0.00038019524,0.7794047,0.0010718025,0.00012362821,0.000120019424],"about_ca_topic_score_codex":0.000006117314,"about_ca_topic_score_gemma":0.000005954092,"teacher_disagreement_score":0.7408699,"about_ca_system_score_codex":0.00014777236,"about_ca_system_score_gemma":0.00082885084,"threshold_uncertainty_score":0.43955797},"labels":[],"label_agreement":null},{"id":"W3211450144","doi":"10.1182/blood-2021-148254","title":"Characteristics of High-Risk Polycythemia Vera Patients with Suboptimal Response to First-Line Therapy Who Switched to Ruxolitinib Vs Those Who Did Not Switch: Findings from PV-Switch, a Multinational, Retrospective Chart Review Study","year":2021,"lang":"en","type":"article","venue":"Blood","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hôpital Maisonneuve-Rosemont","funders":"","keywords":"Medicine; Polycythemia vera; Internal medicine; Ruxolitinib; Pediatrics; Myelofibrosis; Bone marrow","score_opus":0.01568797078002976,"score_gpt":0.27255795313385495,"score_spread":0.2568699823538252,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3211450144","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9893769,0.0005372364,0.000033015458,0.00458724,0.00009660205,0.0036139155,0.0016770702,0.00005311944,0.000024892113],"genre_scores_gemma":[0.99133444,0.0025944407,0.0018324547,0.0024962872,0.00018604627,0.000771254,0.00044041913,0.00008788861,0.00025674695],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9963452,0.00025976103,0.000871095,0.0010116453,0.0010514898,0.00046078354],"domain_scores_gemma":[0.99638087,0.0006493095,0.0003993757,0.00084556756,0.0013143804,0.0004105048],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0004999012,0.0005565879,0.0015496823,0.00017325176,0.00020165282,0.000049891434,0.00018559623,0.000104674684,0.00037800334],"category_scores_gemma":[0.0016661301,0.00042685185,0.00018215114,0.00064608606,0.000041228486,0.00010266177,0.00014433626,0.00033118736,0.000054253782],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.013918406,0.01106336,0.9664405,0.00012588104,0.0011266824,0.00022396739,0.004522583,0.0000014900768,0.0011402828,0.000023363425,0.00035223382,0.0010612794],"study_design_scores_gemma":[0.018813934,0.009587029,0.9314897,0.002943119,0.00083314034,0.00000832908,0.000122024394,0.000005843974,0.035122544,0.000008649589,0.0006777284,0.00038793692],"about_ca_topic_score_codex":0.00024128504,"about_ca_topic_score_gemma":0.00008379068,"teacher_disagreement_score":0.034950748,"about_ca_system_score_codex":0.00020619012,"about_ca_system_score_gemma":0.00028799038,"threshold_uncertainty_score":0.9998183},"labels":[],"label_agreement":null},{"id":"W3211871096","doi":"10.1182/blood-2021-147614","title":"A Randomized, Phase 3 Trial of Fedratinib Versus Best Available Therapy in Patients with Intermediate-2 or High-Risk Myelofibrosis Previously Treated with Ruxolitinib (FREEDOM2)","year":2021,"lang":"en","type":"article","venue":"Blood","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Ruxolitinib; Myelofibrosis; Internal medicine; Adverse effect; Population; Clinical trial; Phases of clinical research; Surgery; Pediatrics; Bone marrow","score_opus":0.02224321597315307,"score_gpt":0.2714861247213994,"score_spread":0.2492429087482463,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3211871096","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99414873,0.00036663224,0.00000498037,0.000075484255,0.00010248775,0.004146278,0.00017217967,0.00003927217,0.000943955],"genre_scores_gemma":[0.99489164,0.001444162,0.0012151175,0.00006253539,0.00012219297,0.0011754221,0.00047315625,0.00006132053,0.0005544252],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99731344,0.0003952482,0.0007416706,0.00059137936,0.0005354903,0.0004227425],"domain_scores_gemma":[0.9976186,0.0007764554,0.00042485917,0.0005217317,0.0004502028,0.00020816232],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00027492,0.00043325618,0.0016217798,0.00015949982,0.000074991534,0.00004237246,0.000091786664,0.00012913754,0.0008387648],"category_scores_gemma":[0.00042664734,0.0002386779,0.0001732056,0.0005038531,0.00021791682,0.00011558743,0.000031816824,0.00021270046,0.00003199731],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.8187262,0.023392437,0.15312453,0.00006306403,0.0018302317,0.00021784232,0.0004190532,0.0000019212773,0.000036313468,0.00002379388,0.00009496218,0.0020696868],"study_design_scores_gemma":[0.9226359,0.04542717,0.0067878426,0.0006006011,0.001752214,0.000009422188,0.000115212686,0.000008728799,0.022300826,0.0000034034824,0.00011108795,0.00024757234],"about_ca_topic_score_codex":0.00060204725,"about_ca_topic_score_gemma":0.00053405756,"teacher_disagreement_score":0.14633667,"about_ca_system_score_codex":0.00006596734,"about_ca_system_score_gemma":0.0005278706,"threshold_uncertainty_score":0.9733002},"labels":[],"label_agreement":null},{"id":"W3211995673","doi":"10.1182/blood-2021-151458","title":"Dynamic Stromal Changes in Myelofibrosis Patients Pre/Post JAK Inhibition Is Revealed in Clinically Archived Bone Marrow Biopsies By Smooth Muscle Actin (SMA)-CD34 Dual Immunohistochemistry","year":2021,"lang":"en","type":"article","venue":"Blood","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; Queen's University; University Health Network; Health Sciences Centre; Sunnybrook Health Science Centre","funders":"","keywords":"Medicine; Myelofibrosis; Pathology; Stromal cell; CD34; Bone marrow; Pulmonary fibrosis; Fibrosis; Cancer research; Internal medicine; Oncology; Stem cell; Biology","score_opus":0.007572596675188288,"score_gpt":0.258740802648175,"score_spread":0.2511682059729867,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3211995673","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9958313,0.0005776148,0.0000015460528,0.0018505121,0.00007131353,0.00069330464,0.0005367592,0.00004022144,0.0003974433],"genre_scores_gemma":[0.99512523,0.00053055363,0.0012088376,0.00049125624,0.000045217024,0.0003338683,0.0017131659,0.0000439323,0.0005079101],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.997644,0.00014335451,0.00070901436,0.00068529724,0.0003739853,0.0004443361],"domain_scores_gemma":[0.9988322,0.00022001176,0.00023350134,0.0004037941,0.00015454885,0.00015589123],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00018179904,0.00033745618,0.00064062135,0.0001397705,0.00007602892,0.000036489004,0.00006308598,0.00021067288,0.00022938747],"category_scores_gemma":[0.00033527784,0.00032826496,0.00014176437,0.00024533444,0.000095357915,0.00008262002,0.000115147806,0.00037189436,0.0000173149],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00053442724,0.0067528253,0.431268,0.00021553617,0.00010535591,0.00030873853,0.0012859805,4.848462e-7,0.55593944,0.0000024555993,0.0002830572,0.0033037062],"study_design_scores_gemma":[0.012391313,0.0011266011,0.84682584,0.00082135224,0.00015694641,0.000023760285,0.00032406815,0.000023519131,0.1378775,0.000019964384,0.00012880372,0.0002803381],"about_ca_topic_score_codex":0.00015420953,"about_ca_topic_score_gemma":0.00050399394,"teacher_disagreement_score":0.41806194,"about_ca_system_score_codex":0.00018085787,"about_ca_system_score_gemma":0.00018271967,"threshold_uncertainty_score":0.9999169},"labels":[],"label_agreement":null},{"id":"W3212160629","doi":"10.1182/blood-2021-150172","title":"Pelabresib (CPI-0610) Monotherapy in Patients with Myelofibrosis - Update of Clinical and Translational Data from the Ongoing Manifest Trial","year":2021,"lang":"en","type":"article","venue":"Blood","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":20,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Medicine; Myelofibrosis; Clinical trial; Internal medicine; Pediatrics","score_opus":0.054030964309501016,"score_gpt":0.3240995657734011,"score_spread":0.2700686014639001,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3212160629","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99696153,0.0004877085,0.000014984695,0.0014104415,0.00005585963,0.00052935054,0.00040017694,0.0000070268607,0.00013290011],"genre_scores_gemma":[0.99549055,0.0003629371,0.0027198454,0.0003155381,0.00017220466,0.000021966462,0.000886863,0.000015165172,0.000014954886],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99866986,0.00013597753,0.00044183934,0.0003627893,0.00027750112,0.00011202342],"domain_scores_gemma":[0.99883825,0.00048147075,0.00010476473,0.00044294388,0.00007194399,0.000060638195],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00020917381,0.00012274842,0.00037391778,0.000022272869,0.000043133787,0.000019475414,0.000088100685,0.000064887485,0.00017870513],"category_scores_gemma":[0.00007961356,0.00007458564,0.000045370318,0.00010373946,0.00007091326,0.0000793722,0.00003978725,0.00012835488,0.0000042591437],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0080233915,0.002792713,0.9842324,0.0000096518725,0.00036008656,0.000021735901,0.0001591817,7.243244e-7,0.000016752781,0.00009268308,0.00011215785,0.004178523],"study_design_scores_gemma":[0.114817254,0.00058593025,0.882983,0.0001240223,0.00027993735,0.0000024585793,0.000029075636,0.00003619772,0.00052501925,0.00004740221,0.0005014272,0.000068250454],"about_ca_topic_score_codex":0.00008699122,"about_ca_topic_score_gemma":0.00045212737,"teacher_disagreement_score":0.10679386,"about_ca_system_score_codex":0.0000031714242,"about_ca_system_score_gemma":0.00015217056,"threshold_uncertainty_score":0.30415142},"labels":[],"label_agreement":null},{"id":"W3212249039","doi":"10.1182/blood-2021-146623","title":"Baseline Serum Ferritin Differentially Predicts W24 Transfusion Independence Response for Momelotinib and Ruxolitinib in Patients with Myelofibrosis","year":2021,"lang":"en","type":"article","venue":"Blood","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Ruxolitinib; Myelofibrosis; Medicine; Ferritin; Internal medicine; Serum ferritin; Bone marrow","score_opus":0.00922556990859842,"score_gpt":0.2329814678827612,"score_spread":0.2237558979741628,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3212249039","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9965457,0.0001682171,0.00013465581,0.0013375569,0.00004738956,0.0012209791,0.00043566103,0.000030782547,0.00007911357],"genre_scores_gemma":[0.9965303,0.00014160694,0.002091798,0.0003155971,0.000057115907,0.00027935344,0.00027539834,0.00003667632,0.00027216855],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9982042,0.00017009751,0.0003444842,0.00053879956,0.00040221057,0.00034025067],"domain_scores_gemma":[0.9988201,0.00038377848,0.000064581815,0.00024488007,0.0002799489,0.00020667762],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00027841577,0.0002502689,0.000440351,0.00011548952,0.00009594482,0.000036525318,0.000045686254,0.00013503165,0.00013674574],"category_scores_gemma":[0.000295105,0.00019493891,0.00006607188,0.0001913701,0.000044929115,0.000082039114,0.00003669964,0.00016153489,0.000003633686],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.005546098,0.0039151595,0.98407507,0.00018498533,0.000127921,0.00011599206,0.00034077564,0.0000015875277,0.0024967818,0.000073586445,0.000025286146,0.003096762],"study_design_scores_gemma":[0.028113127,0.0023733259,0.9010906,0.0005377174,0.0002876987,0.000029352861,0.00006769805,0.0000418051,0.06714944,0.000030361427,0.00010311853,0.00017573535],"about_ca_topic_score_codex":0.000027070797,"about_ca_topic_score_gemma":0.00031600724,"teacher_disagreement_score":0.08298444,"about_ca_system_score_codex":0.000035945926,"about_ca_system_score_gemma":0.000219577,"threshold_uncertainty_score":0.7949378},"labels":[],"label_agreement":null},{"id":"W3212267000","doi":"10.1182/blood-2021-148922","title":"Patterns of Care and Outcomes in Adolescents and Young Adults with Myeloproliferative Neoplasms: A Multicenter Population-Based Study","year":2021,"lang":"en","type":"article","venue":"Blood","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Quebec - Clinical Research Organization in Cancer; Université de Montréal; Hôpital Maisonneuve-Rosemont","funders":"","keywords":"Medicine; Population; Myelofibrosis; Essential thrombocythemia; Polycythemia vera; Pediatrics; Young adult; Myeloproliferative neoplasm; Internal medicine; Bone marrow","score_opus":0.0074473887807283284,"score_gpt":0.25330578447427543,"score_spread":0.24585839569354712,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3212267000","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9981781,0.0004911311,0.000003874334,0.0001023865,0.000025959054,0.0011179829,0.000049691655,0.000012358447,0.000018479299],"genre_scores_gemma":[0.99916524,0.000039892664,0.00044747838,0.00011001434,0.000013685996,0.00013472368,0.000056906065,0.000018195384,0.000013864625],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99890023,0.00007529925,0.00026758437,0.00036622878,0.00023327963,0.00015739199],"domain_scores_gemma":[0.99941415,0.00005134494,0.00008002443,0.00017906974,0.00017999789,0.00009539999],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000036060417,0.00020036317,0.00047165668,0.0000901347,0.000044016626,0.000019603935,0.000021846357,0.000046887726,0.000011247636],"category_scores_gemma":[0.000054199107,0.00014306372,0.00003290312,0.00009441526,0.000014014637,0.00005031562,0.000030246014,0.000100243364,5.812856e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00044424197,0.0039218217,0.98765457,0.00044147673,0.00020368755,0.00031299744,0.00649692,0.0000032813198,0.000022531513,0.000005974944,2.706909e-7,0.0004922353],"study_design_scores_gemma":[0.026355436,0.0014940827,0.96140605,0.0012925846,0.00030014926,0.000018296923,0.006196683,0.00004712137,0.002765394,8.1179167e-7,6.3080194e-7,0.00012277126],"about_ca_topic_score_codex":0.000516327,"about_ca_topic_score_gemma":0.01115387,"teacher_disagreement_score":0.026248522,"about_ca_system_score_codex":0.00002978808,"about_ca_system_score_gemma":0.000065938024,"threshold_uncertainty_score":0.62241215},"labels":[],"label_agreement":null},{"id":"W3212466623","doi":"10.1182/blood-2021-146675","title":"A Retrospective Head-to-Head Comparison between Pacritinib and Ruxolitinib in Patients with Myelofibrosis and Moderate to Severe Thrombocytopenia","year":2021,"lang":"en","type":"article","venue":"Blood","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Ruxolitinib; Medicine; Myelofibrosis; Dosing; Internal medicine; Surgery; Gastroenterology; Bone marrow","score_opus":0.021375848778062534,"score_gpt":0.29120746873472725,"score_spread":0.2698316199566647,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3212466623","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9961619,0.00016966535,0.00001622546,0.0015446795,0.000017717239,0.0010224455,0.00019187482,0.000027350588,0.0008481858],"genre_scores_gemma":[0.9948862,0.000025469773,0.004084033,0.00062309095,0.00005804679,0.00012838178,0.000094405885,0.00003156844,0.00006879355],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.998357,0.00007299685,0.00029982868,0.0006252283,0.0002933563,0.0003516026],"domain_scores_gemma":[0.99902695,0.00008345422,0.000049290524,0.00024365273,0.00021980375,0.00037684102],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00008029369,0.00026657834,0.0008459139,0.00009921319,0.00010758153,0.000073821626,0.000035150875,0.00008295572,0.000037403905],"category_scores_gemma":[0.00008288031,0.00021569648,0.000031163243,0.00030278706,0.000039102273,0.000082778446,0.00009802294,0.00017429757,0.000013009923],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0004101467,0.0011478914,0.9947885,0.00005522686,0.00017742894,0.000066257286,0.0013581571,0.0000021459484,0.00010064502,0.000113572656,0.000071063034,0.0017089634],"study_design_scores_gemma":[0.012083798,0.002466667,0.9769159,0.00050379825,0.00024527733,0.000021804568,0.00019643772,0.000008003699,0.007135773,0.00006753055,0.000117083735,0.00023790098],"about_ca_topic_score_codex":0.000112860806,"about_ca_topic_score_gemma":0.00057234167,"teacher_disagreement_score":0.017872576,"about_ca_system_score_codex":0.000075451295,"about_ca_system_score_gemma":0.00008143332,"threshold_uncertainty_score":0.8795847},"labels":[],"label_agreement":null},{"id":"W3212628307","doi":"10.1182/blood-2021-147455","title":"DUSP6 Mediates Resistance to JAK2 Inhibition and Drives Myeloproliferative Neoplasm Disease Progression","year":2021,"lang":"en","type":"article","venue":"Blood","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; McGill University Health Centre","funders":"","keywords":"Biology; Cancer research; Myeloproliferative neoplasm; Myeloid; Myelofibrosis; Gene expression profiling; Transcriptome; Progenitor cell; Bone marrow; Stem cell; Immunology; Gene expression; Gene; Cell biology; Genetics","score_opus":0.010122875962954695,"score_gpt":0.2705913397530173,"score_spread":0.2604684637900626,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3212628307","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98313314,0.0034118153,0.000024027808,0.010195358,0.0000744799,0.00077816396,0.000059720118,0.00006293013,0.002260379],"genre_scores_gemma":[0.9908152,0.0007285222,0.0051429947,0.0010804805,0.00022873317,0.0004745117,0.00016230324,0.000029258968,0.0013379578],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99846506,0.00008558938,0.00026175164,0.00056199677,0.00034413158,0.00028149135],"domain_scores_gemma":[0.99870354,0.00015980254,0.00006819402,0.0002659732,0.0002407896,0.00056170044],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00008033835,0.00024647693,0.00035055354,0.000083297215,0.00018696362,0.000066002205,0.000028407138,0.000073875366,0.00011570754],"category_scores_gemma":[0.00043825625,0.00019392693,0.00006878844,0.00024944573,0.00006917344,0.000108787615,0.00007780839,0.00012786877,0.00005513645],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00095510605,0.0051667616,0.9473617,0.00061371515,0.0005155049,0.003787976,0.0033703793,0.00000311581,0.023126215,0.0054595293,0.0035981142,0.0060419017],"study_design_scores_gemma":[0.006320764,0.0004567367,0.6132578,0.0013458685,0.0006131732,0.00009297271,0.00026234318,0.00001176478,0.37111777,0.0006475993,0.0055318545,0.0003413015],"about_ca_topic_score_codex":0.0000018560756,"about_ca_topic_score_gemma":0.000091930626,"teacher_disagreement_score":0.34799156,"about_ca_system_score_codex":0.000037631962,"about_ca_system_score_gemma":0.00021650572,"threshold_uncertainty_score":0.79081106},"labels":[],"label_agreement":null},{"id":"W3212689194","doi":"10.1182/blood-2021-150634","title":"Germline-Somatic Interactions in Myelofibrosis Susceptibility","year":2021,"lang":"en","type":"article","venue":"Blood","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Biology; Myelofibrosis; Genome-wide association study; Genetics; Loss of heterozygosity; Genotyping; SNP array; Myeloid; Bone marrow; Single-nucleotide polymorphism; Cancer research; Immunology; Genotype; Allele; Gene","score_opus":0.025621913766289816,"score_gpt":0.3042765106407568,"score_spread":0.278654596874467,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3212689194","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99211586,0.00031557752,0.00001563988,0.0018888401,0.000094816896,0.00025484513,0.000012259157,0.00003982715,0.005262319],"genre_scores_gemma":[0.9959831,0.00009083061,0.0025494867,0.00028523649,0.00008684364,0.00010570845,0.000056136872,0.000013269083,0.00082939165],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99903494,0.00006063483,0.00028185532,0.0002927061,0.00014683454,0.00018301852],"domain_scores_gemma":[0.9992767,0.0001500904,0.000041030704,0.00032840113,0.00010106014,0.0001027058],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00007692682,0.00012648676,0.00029032526,0.00006937888,0.000044306158,0.00002044284,0.000029769892,0.00003611711,0.0010751977],"category_scores_gemma":[0.00020541374,0.000107302556,0.00010834536,0.00024980473,0.000023416862,0.000060982893,0.000034447345,0.00013755859,0.0001417621],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000024315324,0.004566851,0.9794136,0.00009258261,0.00013299331,0.00034635921,0.00031323638,0.0000022052561,0.01355262,0.00020622782,0.00020434831,0.0011446265],"study_design_scores_gemma":[0.0035316958,0.00014099757,0.875788,0.0002238955,0.00020263018,0.00018579187,0.00019241744,0.00005208823,0.11840271,0.00017261587,0.0009999991,0.00010716908],"about_ca_topic_score_codex":0.000056224995,"about_ca_topic_score_gemma":0.00094905496,"teacher_disagreement_score":0.10485009,"about_ca_system_score_codex":0.000067353,"about_ca_system_score_gemma":0.00012939524,"threshold_uncertainty_score":0.99983793},"labels":[],"label_agreement":null},{"id":"W3212899144","doi":"10.1182/blood-2021-147376","title":"Decision Analysis of Allogeneic Stem Cell Transplantation for Primary Myelofibrosis","year":2021,"lang":"en","type":"article","venue":"Blood","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Hospital; University of Ottawa","funders":"","keywords":"Myelofibrosis; Medicine; Cohort; Transplantation; Ruxolitinib; Natural history; Internal medicine; Pediatrics; Oncology; Bone marrow","score_opus":0.014712208037197852,"score_gpt":0.2605849413601725,"score_spread":0.24587273332297466,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3212899144","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9948002,0.0010408963,0.0026927725,0.000088461,0.000037071924,0.0003086081,0.00017572695,0.000010526091,0.00084572844],"genre_scores_gemma":[0.98644185,0.0010640016,0.011341426,0.00015087679,0.000026932457,0.000095750336,0.00052896846,0.000012694886,0.00033750295],"study_design_codex":"observational","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99911284,0.000026684922,0.00027921167,0.0002544056,0.00020419752,0.00012267428],"domain_scores_gemma":[0.9991809,0.0002801488,0.00007981704,0.00020563052,0.00018350124,0.0000699943],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000077209166,0.000110590445,0.000428212,0.00013681506,0.000040115385,0.000008362451,0.000030935273,0.00006453782,0.00015643881],"category_scores_gemma":[0.0000085447155,0.000090576235,0.00029992402,0.00037618788,0.0000125912375,0.000028239678,0.00000833611,0.000030408875,0.000008045106],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000475759,0.0036495037,0.8196643,0.0005948229,0.004291139,0.00011095612,0.0004885317,0.00012670201,0.14738439,0.00015685185,0.000115804796,0.022941232],"study_design_scores_gemma":[0.0028003207,0.00026122015,0.49286732,0.00005106944,0.009082159,0.000009938499,0.000028329277,0.000028595186,0.49463525,0.0000117072705,0.00016512415,0.000058970578],"about_ca_topic_score_codex":0.0000068732843,"about_ca_topic_score_gemma":0.000053165233,"teacher_disagreement_score":0.34725088,"about_ca_system_score_codex":0.00002301623,"about_ca_system_score_gemma":0.00009611365,"threshold_uncertainty_score":0.36935917},"labels":[],"label_agreement":null},{"id":"W3213271038","doi":"10.1182/blood-2021-149696","title":"Safety and Efficacy of JAK Inhibitor Therapy in <i>BCR-ABL</i> Negative MPN Patients with Underlying Portal Hypertension","year":2021,"lang":"en","type":"article","venue":"Blood","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Medicine; Myelofibrosis; Internal medicine; Gastroenterology; Esophageal varices; Population; Esophagogastroduodenoscopy; Polycythemia vera; Portal hypertension; Portal hypertensive gastropathy; Clinical endpoint; Surgery; Clinical trial; Cirrhosis","score_opus":0.01884720862864479,"score_gpt":0.24555464846014396,"score_spread":0.22670743983149919,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3213271038","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9978412,0.0005713109,0.000003361743,0.00032475806,0.00003235735,0.000476371,0.000016701619,0.000011410552,0.0007225214],"genre_scores_gemma":[0.99839514,0.0005086912,0.00067840004,0.00026654164,0.000025031037,0.000016812684,0.00005962054,0.000017448097,0.00003233009],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9990602,0.00004683106,0.00024330625,0.00027559182,0.00022334167,0.00015069595],"domain_scores_gemma":[0.9993295,0.0001738622,0.000082620325,0.00015644966,0.00017639021,0.00008114216],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000050875267,0.00015155654,0.00037368463,0.000052418378,0.00004646521,0.000008861054,0.000018590164,0.00005745616,0.00004185437],"category_scores_gemma":[0.00007127757,0.00010282888,0.000039956416,0.00018201064,0.00004984134,0.00005350049,0.000022716526,0.0001033626,0.0000017777933],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0008220155,0.00557127,0.9815865,0.00003492479,0.00028973416,0.00036478665,0.0006736123,0.0000031354562,0.002586127,0.00008186169,0.00003413649,0.007951862],"study_design_scores_gemma":[0.030540908,0.0014795617,0.9080931,0.00034669478,0.00012267628,0.000046991376,0.00018911039,0.0000059692775,0.058945846,0.00001578048,0.000106426654,0.00010696445],"about_ca_topic_score_codex":0.000044090993,"about_ca_topic_score_gemma":0.000080180485,"teacher_disagreement_score":0.073493466,"about_ca_system_score_codex":0.000017134413,"about_ca_system_score_gemma":0.00010289832,"threshold_uncertainty_score":0.419324},"labels":[],"label_agreement":null},{"id":"W3213296385","doi":"10.1182/blood-2021-152549","title":"Cytogenetics in Essential Thrombocythemia: Phenotype and Molecular Correlates and Prognostic Relevance in 818 Informative Cases","year":2021,"lang":"en","type":"article","venue":"Blood","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hôpital Maisonneuve-Rosemont","funders":"","keywords":"Essential thrombocythemia; Medicine; Trisomy 8; Anagrelide; Cytogenetics; Internal medicine; Trisomy; Clinical significance; Polycythemia vera; Cohort; Myelofibrosis; Anemia; Gastroenterology; Karyotype; Pathology; Pediatrics; Biology; Bone marrow; Chromosome; Genetics","score_opus":0.009637452859286466,"score_gpt":0.2554097320558072,"score_spread":0.24577227919652073,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3213296385","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9926942,0.006224333,0.000016488566,0.00025635673,0.00002389175,0.00033682422,0.000009534142,0.000010048298,0.00042830224],"genre_scores_gemma":[0.99641204,0.0021525687,0.0011589663,0.000156087,0.000016020222,0.000052715048,0.000024272294,0.0000108847025,0.000016455257],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9992837,0.000032457803,0.00020695696,0.00020237884,0.00011121615,0.00016330706],"domain_scores_gemma":[0.9994508,0.0002755255,0.000041349394,0.00010686552,0.00005976451,0.00006568871],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000046107132,0.00013188628,0.00026802026,0.00005565859,0.000026556045,0.000020082642,0.00001697865,0.000071912524,0.000015529324],"category_scores_gemma":[0.0003857248,0.000114338785,0.000018397195,0.00015903136,0.0000628622,0.000050078223,0.000050772545,0.00013682686,0.000003988659],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000060763905,0.00081012165,0.9900347,0.00013757592,0.000094733914,0.0029767933,0.001405965,0.0000138227415,0.0024616586,0.0005235974,0.000009793455,0.0014704951],"study_design_scores_gemma":[0.010581108,0.0009055483,0.72950244,0.00081786345,0.00039108057,0.0012826254,0.000699222,0.0003716636,0.25449473,0.00058637676,0.000100659134,0.00026664816],"about_ca_topic_score_codex":0.000022287415,"about_ca_topic_score_gemma":0.00018987797,"teacher_disagreement_score":0.2605322,"about_ca_system_score_codex":0.000019058407,"about_ca_system_score_gemma":0.00008819162,"threshold_uncertainty_score":0.46626002},"labels":[],"label_agreement":null},{"id":"W3213306989","doi":"10.1182/blood-2021-145276","title":"A Phase 1/2 Study of Single Agent Tagraxofusp, a First-in-Class CD123-Targeted Therapy, in Patients with Myelofibrosis That Is Relapsed/Refractory Following JAK Inhibitor Therapy","year":2021,"lang":"en","type":"article","venue":"Blood","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta Hospital; Alberta Hospital Edmonton; Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Myelofibrosis; Internal medicine; Constitutional symptoms; Refractory (planetary science); Ruxolitinib; Gastroenterology; Myeloid; Myeloproliferative neoplasm; Oncology; Bone marrow; Disease","score_opus":0.02370567160200735,"score_gpt":0.2601668068438865,"score_spread":0.23646113524187914,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3213306989","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9953718,0.0018895076,0.0000011413438,0.00028902723,0.00013571033,0.0020799858,0.00003605545,0.0000330245,0.00016375798],"genre_scores_gemma":[0.99847347,0.0003425528,0.000195292,0.00034301085,0.000044736575,0.00038168847,0.00008119135,0.00006304434,0.00007503409],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9974706,0.00017479947,0.00055635744,0.00066680793,0.00071987807,0.00041152202],"domain_scores_gemma":[0.99876404,0.0001691169,0.00021245428,0.00053983484,0.00016290904,0.000151625],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0001508649,0.0004053306,0.00084555167,0.00025412228,0.00008562787,0.000032922893,0.00009465212,0.00012853612,0.00016919382],"category_scores_gemma":[0.000048760212,0.00029766117,0.00019102998,0.00064653927,0.00003535358,0.00014549073,0.000045814788,0.00022494739,0.0000060871453],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0015393979,0.12522952,0.8550024,0.000032973894,0.00091011985,0.00044424902,0.0069429115,0.0000023155799,0.0046197004,0.000001316591,0.00009222093,0.005182886],"study_design_scores_gemma":[0.1399269,0.02353268,0.67188185,0.0005563847,0.0002416837,0.0000035601079,0.0014430092,0.0000054927095,0.1615347,0.0000046752925,0.00056680857,0.00030229436],"about_ca_topic_score_codex":0.00018996242,"about_ca_topic_score_gemma":0.0004727335,"teacher_disagreement_score":0.18312055,"about_ca_system_score_codex":0.00014773026,"about_ca_system_score_gemma":0.00015283453,"threshold_uncertainty_score":0.99994755},"labels":[],"label_agreement":null},{"id":"W3213308040","doi":"10.1182/blood-2021-149223","title":"The 1.5 Million Platelet Count Threshold in Essential Thrombocythemia: Phenotype and Genotype Correlates and Relevance to Vascular Events","year":2021,"lang":"en","type":"article","venue":"Blood","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hôpital Maisonneuve-Rosemont","funders":"","keywords":"Medicine; Essential thrombocythemia; Leukocytosis; Thrombocytosis; Internal medicine; Gastroenterology; Context (archaeology); Anemia; Platelet","score_opus":0.008706644511585376,"score_gpt":0.2457494269999107,"score_spread":0.23704278248832533,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3213308040","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98263925,0.015250717,0.000016559688,0.0013185015,0.00010287638,0.00041647087,0.000007170077,0.000014550925,0.00023389143],"genre_scores_gemma":[0.98874795,0.010314276,0.00030292379,0.0003562787,0.0000678565,0.00005767044,0.000017406996,0.000018285595,0.00011735792],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9990175,0.000032438827,0.00019096426,0.00033007475,0.00020998785,0.00021904193],"domain_scores_gemma":[0.999369,0.00017763891,0.00003638622,0.0002293292,0.00008056426,0.00010707807],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00013451179,0.000153192,0.00026859975,0.000030736566,0.00013312744,0.000031266198,0.000037196547,0.00008256311,0.00002428741],"category_scores_gemma":[0.00012240998,0.00010448167,0.000035495155,0.00014912596,0.0000407829,0.00004281919,0.000071511364,0.00015528302,0.000018527413],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00057797914,0.0022059674,0.96276385,0.00020576951,0.0011169002,0.0011837722,0.002133207,0.00005184062,0.015074172,0.004239882,0.0006655405,0.009781119],"study_design_scores_gemma":[0.014909798,0.0010403779,0.8729005,0.00071311306,0.00073479157,0.00043453576,0.00034503487,0.00033096064,0.094655134,0.0019425931,0.011522867,0.00047029532],"about_ca_topic_score_codex":0.000023697723,"about_ca_topic_score_gemma":0.00024283095,"teacher_disagreement_score":0.08986335,"about_ca_system_score_codex":0.000029142982,"about_ca_system_score_gemma":0.00006530459,"threshold_uncertainty_score":0.42606387},"labels":[],"label_agreement":null},{"id":"W3213514829","doi":"10.1182/blood-2021-145131","title":"Very Elderly Patients with Myeloproliferative Neoplasms: Phenotypic Distinctions and Prognostic Determinants of Complications and Mortality","year":2021,"lang":"en","type":"article","venue":"Blood","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Jewish General Hospital; Hôpital de l'Enfant-Jésus; Centre Hospitalier de l’Université de Montréal; McGill University; Quebec - Clinical Research Organization in Cancer; McGill University Health Centre; Université de Montréal; Hôpital Maisonneuve-Rosemont","funders":"","keywords":"Medicine; Thrombocytosis; Leukocytosis; Myelofibrosis; Internal medicine; Polycythemia vera; Incidence (geometry); Population; Gastroenterology; Surgery; Pediatrics; Bone marrow; Platelet","score_opus":0.014934982506050255,"score_gpt":0.2589592871307675,"score_spread":0.24402430462471725,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3213514829","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.998071,0.00041080007,0.000043287495,0.00012961017,0.000022951988,0.0006339471,0.00012463146,0.000021422567,0.0005423408],"genre_scores_gemma":[0.9979157,0.00009389401,0.0015621755,0.00007740048,0.000018718505,0.0001810772,0.000108809014,0.0000146852835,0.000027571297],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9990324,0.000043945904,0.0002493365,0.00033681432,0.00018175654,0.00015575191],"domain_scores_gemma":[0.99901843,0.000169199,0.000104699604,0.00023219104,0.00033578498,0.00013967733],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000037446924,0.00016865616,0.000338262,0.000042647283,0.00015114014,0.000023480685,0.000023598239,0.00004907533,0.00002141996],"category_scores_gemma":[0.00013031726,0.00012729222,0.000030395197,0.00014496536,0.00015292787,0.00007193168,0.0000391936,0.000085573636,0.0000025438592],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000038346647,0.0021865778,0.9943731,0.000113499395,0.00027739073,0.000027401133,0.0002791639,4.2685338e-7,0.00007521625,0.00039468103,0.000009456324,0.0022247701],"study_design_scores_gemma":[0.0041101417,0.0009238135,0.9894667,0.00020146609,0.00076515554,0.00007171569,0.000088038854,0.000029860228,0.004055301,0.00013183177,0.000038837363,0.00011712357],"about_ca_topic_score_codex":0.000024694054,"about_ca_topic_score_gemma":0.00027789857,"teacher_disagreement_score":0.004906355,"about_ca_system_score_codex":0.0000133824915,"about_ca_system_score_gemma":0.00013289538,"threshold_uncertainty_score":0.51908267},"labels":[],"label_agreement":null},{"id":"W3213674796","doi":"10.1182/blood-2021-148706","title":"Clinical Features and Long-Term Outcomes in a Molecularly-Annotated Cohort of Adolescents and Young Adults with Myeloproliferative Neoplasms","year":2021,"lang":"en","type":"article","venue":"Blood","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sunnybrook Health Science Centre; Royal Victoria Regional Health Centre; Princess Margaret Cancer Centre; Health Sciences Centre; University of Toronto; University Health Network","funders":"","keywords":"Medicine; Essential thrombocythemia; Internal medicine; Myelofibrosis; Polycythemia vera; Population; Oncology; Cohort; Hazard ratio; Bone marrow; Confidence interval","score_opus":0.01201167451677876,"score_gpt":0.2898668418790969,"score_spread":0.27785516736231813,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3213674796","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9967618,0.0018675259,0.000009918994,0.00028265404,0.000045481826,0.00085138914,0.000027742513,0.000018855146,0.00013465942],"genre_scores_gemma":[0.9972611,0.0011938614,0.00097250345,0.00025268187,0.000026016518,0.000087116394,0.000060249957,0.000024326322,0.00012213548],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99836236,0.00012673618,0.0004482012,0.0005362803,0.00029061458,0.00023581774],"domain_scores_gemma":[0.99911445,0.000099785684,0.00012512326,0.00024044253,0.00023054304,0.00018966624],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00013185522,0.0002634855,0.00080576603,0.00008684669,0.000043463275,0.000030444944,0.000037188816,0.0001342216,0.000012140015],"category_scores_gemma":[0.00016285376,0.00018495067,0.000070607704,0.00018240332,0.0001475725,0.00006542637,0.00006360413,0.00025471882,0.0000014526946],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0006482847,0.002745576,0.9918997,0.00021651828,0.00076748437,0.0018813444,0.00062654045,2.3956628e-7,0.00025800453,0.000048043534,0.000008726452,0.0008995277],"study_design_scores_gemma":[0.01683668,0.0010204376,0.96723825,0.0011063674,0.00052639877,0.00067820854,0.000112905116,0.0000082519755,0.012296012,0.000008122017,0.0000014620068,0.00016688739],"about_ca_topic_score_codex":0.000049676557,"about_ca_topic_score_gemma":0.00085260835,"teacher_disagreement_score":0.024661444,"about_ca_system_score_codex":0.00001637046,"about_ca_system_score_gemma":0.0001406868,"threshold_uncertainty_score":0.75420696},"labels":[],"label_agreement":null},{"id":"W3213696764","doi":"10.1182/blood-2021-147607","title":"Safety and Tolerability of Fedratinib (FEDR), an Oral Inhibitor of Janus Kinase 2 (JAK2), in Patients with Intermediate- or High-Risk Myelofibrosis (MF) Previously Treated with Ruxolitinib (RUX): Results from the Phase 3b FREEDOM Trial","year":2021,"lang":"en","type":"article","venue":"Blood","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":14,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; St. Paul's Hospital; Princess Margaret Cancer Centre","funders":"","keywords":"Ruxolitinib; Myelofibrosis; Janus kinase inhibitor; Medicine; Tolerability; Internal medicine; Janus kinase 2; Extramedullary hematopoiesis; Phases of clinical research; Janus kinase; Adverse effect; Clinical trial; Bone marrow; Haematopoiesis","score_opus":0.013457521453542209,"score_gpt":0.2540983390556299,"score_spread":0.2406408176020877,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3213696764","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9934708,0.00012998328,0.0000057836614,0.00018552787,0.00007210369,0.002447709,0.00360984,0.00002632097,0.00005194367],"genre_scores_gemma":[0.99613905,0.00012313551,0.0017214016,0.000058029233,0.00014278904,0.00014411531,0.0016085658,0.000036571942,0.000026346712],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99669075,0.0005533999,0.0011323997,0.00077019783,0.00051619305,0.00033707346],"domain_scores_gemma":[0.9970805,0.0008394175,0.0005842477,0.00079738314,0.00045671474,0.00024174052],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00038358304,0.00040265717,0.0011974297,0.00007351882,0.00009946327,0.00003624629,0.000113071386,0.00014853336,0.00009530695],"category_scores_gemma":[0.0007776008,0.00021242682,0.000091232665,0.0003949898,0.00031843164,0.00015088209,0.00007459654,0.00026113752,0.0000011482135],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.25162646,0.017264755,0.7236097,0.00007413539,0.0005495147,0.0001203604,0.0018606208,0.000006272999,0.00016701543,0.000009917984,0.000038646853,0.004672586],"study_design_scores_gemma":[0.32665864,0.022524795,0.61785585,0.0006359123,0.0010014551,0.0000052407154,0.00029873705,0.000023667879,0.03074688,0.000008369662,0.000047151367,0.00019332727],"about_ca_topic_score_codex":0.0030303919,"about_ca_topic_score_gemma":0.0052800295,"teacher_disagreement_score":0.105753876,"about_ca_system_score_codex":0.000063444844,"about_ca_system_score_gemma":0.0004085535,"threshold_uncertainty_score":0.86625147},"labels":[],"label_agreement":null},{"id":"W3213815301","doi":"10.1182/blood-2021-154267","title":"Clinical Features Associated with Long-Term Ruxolitinib Exposure in Myelofibrosis and Predictive Role of Neutrophils","year":2021,"lang":"en","type":"article","venue":"Blood","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Ruxolitinib; Myelofibrosis; Term (time); Medicine; Immunology; Internal medicine; Bone marrow","score_opus":0.012904061510805705,"score_gpt":0.27611957133891113,"score_spread":0.26321550982810543,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3213815301","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99526775,0.0030105042,0.0000012173407,0.00028734503,0.00002531623,0.00035493224,0.00009131269,0.000019047147,0.0009425477],"genre_scores_gemma":[0.99858683,0.00061211345,0.00025825534,0.00012796443,0.00007967104,0.00006342766,0.00013459673,0.000018966679,0.00011816704],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.998728,0.00013979827,0.0003477658,0.00035450753,0.00022143495,0.00020848698],"domain_scores_gemma":[0.99904495,0.00029897882,0.000125436,0.00020797043,0.00018434737,0.00013834158],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00013218213,0.00016757517,0.00055929297,0.0000567935,0.000032855674,0.000014493608,0.000034331846,0.0001527563,0.00004013466],"category_scores_gemma":[0.00021847965,0.00012372492,0.00008293873,0.0001829061,0.00009899264,0.000045339704,0.000040549516,0.00020849096,0.0000012939734],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0002869227,0.0034610901,0.99243176,0.00004525874,0.00064466393,0.00041715245,0.00033348484,0.00000118074,0.0010841785,0.00011046549,0.000021586939,0.0011622797],"study_design_scores_gemma":[0.009128003,0.0022615355,0.95916814,0.0005918873,0.0005578267,0.0000899565,0.00013765434,0.000002787546,0.027910113,0.00004332038,0.00001012848,0.00009865778],"about_ca_topic_score_codex":0.000012646175,"about_ca_topic_score_gemma":0.0001452611,"teacher_disagreement_score":0.03326361,"about_ca_system_score_codex":0.000022429684,"about_ca_system_score_gemma":0.00014848914,"threshold_uncertainty_score":0.5045356},"labels":[],"label_agreement":null},{"id":"W3214159399","doi":"10.1182/blood-2021-149140","title":"A Globally Applicable \"Triple AAA\" Risk Model for Essential Thrombocythemia Based on Age, Absolute Neutrophil Count, and Absolute Lymphocyte Count","year":2021,"lang":"en","type":"article","venue":"Blood","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hôpital Maisonneuve-Rosemont","funders":"","keywords":"Leukocytosis; Myelofibrosis; Essential thrombocythemia; Medicine; Internal medicine; Absolute neutrophil count; Polycythemia vera; Gastroenterology; Thrombocytosis; Complete blood count; Interquartile range; White blood cell; Immunology; Neutropenia; Bone marrow; Platelet; Chemotherapy","score_opus":0.015004159258327989,"score_gpt":0.26343599843894383,"score_spread":0.24843183918061584,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3214159399","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9827638,0.0020038646,0.006198453,0.0011728628,0.00019045183,0.0020510675,0.0011550926,0.0001474029,0.0043169674],"genre_scores_gemma":[0.9825812,0.001612349,0.011021658,0.0021450773,0.00034733137,0.0007868498,0.00035700898,0.00008318039,0.0010653445],"study_design_codex":"not_applicable","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.99779934,0.000039432503,0.0003825952,0.0007751018,0.00048621115,0.0005173297],"domain_scores_gemma":[0.9985558,0.00016564359,0.0001636919,0.0005744718,0.0002647472,0.00027565713],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00020109814,0.0003867409,0.00068288884,0.00006333478,0.0002788826,0.000109836416,0.00010230509,0.000176839,0.000071940965],"category_scores_gemma":[0.00007329947,0.00033399055,0.00021501238,0.0001794254,0.00009145228,0.00006344878,0.00006530679,0.00015960819,0.00002964149],"study_design_candidate":"simulation_or_modeling","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.03634663,0.13864346,0.16709167,0.009756203,0.028612211,0.017612966,0.0055358433,0.100904904,0.16809553,0.07225595,0.22773992,0.02740473],"study_design_scores_gemma":[0.10929128,0.0030874042,0.05553959,0.00080496306,0.00678157,0.00043924362,0.000090914094,0.70447516,0.08692753,0.002689307,0.028338555,0.0015344566],"about_ca_topic_score_codex":0.00013025229,"about_ca_topic_score_gemma":0.00020002293,"teacher_disagreement_score":0.6035703,"about_ca_system_score_codex":0.00020435204,"about_ca_system_score_gemma":0.0006737251,"threshold_uncertainty_score":0.9999112},"labels":[],"label_agreement":null},{"id":"W3214579091","doi":"10.1182/blood-2021-147417","title":"Surpass-ET Trial: A Phase 3, Open-Label, Multicenter, Randomized, Active-Controlled Study to Assess Pharmacokinetics and Compare the Efficacy, Safety, and Tolerability of P1101 Vs Anagrelide As Second Line Therapy for Essential Thrombocythemia","year":2021,"lang":"en","type":"article","venue":"Blood","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Tolerability; Anagrelide; Internal medicine; Clinical endpoint; Essential thrombocythemia; Randomized controlled trial; Hydroxycarbamide; Clinical trial; Surgery; Adverse effect; Polycythemia vera; Oncology; Chemotherapy","score_opus":0.06692123825267011,"score_gpt":0.41784009619556883,"score_spread":0.35091885794289873,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3214579091","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97530293,0.001039212,0.00016177191,0.002259342,0.00016291553,0.020648057,0.00023690573,0.000018986815,0.00016987661],"genre_scores_gemma":[0.9954924,0.0010853861,0.0009931842,0.0008227267,0.0001389996,0.0012371655,0.000086878026,0.00003489914,0.00010837247],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99705255,0.0009058895,0.00086656114,0.0006125108,0.00030198795,0.00026049066],"domain_scores_gemma":[0.99454904,0.0040428583,0.00030993024,0.00043384815,0.0004606765,0.00020364109],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0014118642,0.00035734786,0.0023021006,0.000057162346,0.00017040367,0.00013183818,0.00015600181,0.00005055172,0.00020157437],"category_scores_gemma":[0.0009010318,0.00021667207,0.00016510472,0.0001550785,0.00013186142,0.00008429692,0.00020162783,0.00017925004,0.0000010570886],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.91937894,0.061011147,0.003039707,0.00008819625,0.004311381,0.000050557686,0.0020122633,0.0000057542175,0.0073690605,0.00006862919,0.00014342257,0.0025209754],"study_design_scores_gemma":[0.90852934,0.006633385,0.004876882,0.00009255374,0.0023927276,0.000022195953,0.000525707,0.00041645672,0.075842574,0.000029767521,0.0004599446,0.00017844244],"about_ca_topic_score_codex":0.000065363885,"about_ca_topic_score_gemma":0.00019627146,"teacher_disagreement_score":0.06847352,"about_ca_system_score_codex":0.000026070022,"about_ca_system_score_gemma":0.00022224172,"threshold_uncertainty_score":0.88356304},"labels":[],"label_agreement":null},{"id":"W3214624665","doi":"10.1182/blood-2021-145750","title":"A Pilot Study of the Anti-SLAMF7 Monoclonal Antibody, Elotuzumab, in Myelofibrosis","year":2021,"lang":"en","type":"article","venue":"Blood","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Myelofibrosis; Medicine; Bone marrow; Cancer research; Internal medicine; Immunology; Oncology","score_opus":0.027626342156516416,"score_gpt":0.29195359031333695,"score_spread":0.2643272481568205,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3214624665","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99583346,0.00042076097,0.0000012054927,0.00053473294,0.000085885906,0.00064757245,0.000014294054,0.0000123916725,0.0024496908],"genre_scores_gemma":[0.9989997,0.0001117074,0.0002610147,0.00014258875,0.000049260674,0.000076176846,0.000012595305,0.00001790857,0.00032900664],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9986715,0.000116659656,0.0003409016,0.00031859748,0.00034469977,0.00020766712],"domain_scores_gemma":[0.9991912,0.0001064044,0.00008649224,0.00043529205,0.000117932905,0.000062648665],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00010449444,0.00016587714,0.00042758934,0.000066349516,0.00006377955,0.000014008849,0.00008892366,0.000028466671,0.00018924549],"category_scores_gemma":[0.00009472291,0.00010905619,0.00008571088,0.00042663934,0.000040532286,0.00003505119,0.00010898605,0.0001461092,0.000018172286],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00007130498,0.02073747,0.94544196,0.000042852844,0.00028192915,0.00023382976,0.00046296764,0.0000067983387,0.03228576,0.000199728,0.000067117806,0.0001682877],"study_design_scores_gemma":[0.008251486,0.0024214752,0.89041144,0.00017305334,0.00027916837,0.000072014554,0.000311284,0.000008573537,0.0978666,0.000025867685,0.00009173881,0.000087305816],"about_ca_topic_score_codex":0.00038018991,"about_ca_topic_score_gemma":0.0011272014,"teacher_disagreement_score":0.06558084,"about_ca_system_score_codex":0.000031451265,"about_ca_system_score_gemma":0.00021107396,"threshold_uncertainty_score":0.44471824},"labels":[],"label_agreement":null},{"id":"W3215514790","doi":"10.1182/blood-2021-149241","title":"A Prediction Rule to Guide <i>JAK2</i> Testing in Patients with Suspected Polycythemia Vera","year":2021,"lang":"en","type":"article","venue":"Blood","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Western University; London Health Sciences Centre","funders":"","keywords":"Medicine; Polycythemia vera; Mean corpuscular volume; Hematocrit; Internal medicine; Logistic regression; Cohort; Complete blood count; Mean corpuscular hemoglobin; Hemoglobin; Phlebotomy; Gastroenterology","score_opus":0.012007550937879492,"score_gpt":0.22649583093170797,"score_spread":0.21448827999382847,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3215514790","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9931901,0.00006729006,0.000011507467,0.00045519302,0.0000440694,0.00044173945,0.000031642412,0.000061695995,0.005696758],"genre_scores_gemma":[0.99169034,0.000005249524,0.0071623023,0.00047124783,0.000087532644,0.00010855778,0.000117649404,0.00002252502,0.00033457362],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99898934,0.000024745901,0.00021201542,0.00030707786,0.0002499682,0.0002168654],"domain_scores_gemma":[0.99932265,0.00006693834,0.000039038252,0.00021802924,0.00022262729,0.00013070411],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000047432564,0.00013732904,0.0002217609,0.000070911134,0.00004969017,0.000018824205,0.000028898618,0.000045628156,0.00007194372],"category_scores_gemma":[0.0002603306,0.00010790046,0.000026210857,0.00044218646,0.000010899597,0.000042667256,0.000031430074,0.00010223933,0.000029578361],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00011255032,0.0021771397,0.9942102,0.000018166127,0.00008875365,0.00019588498,0.00016828737,0.000007508716,0.0015957905,0.000020869335,0.00044694814,0.0009579363],"study_design_scores_gemma":[0.009071615,0.0008876587,0.94186354,0.00030248557,0.0001405943,0.000034416757,0.000036789315,0.000012545502,0.046881687,0.000009145129,0.0006629802,0.000096517135],"about_ca_topic_score_codex":0.00006380488,"about_ca_topic_score_gemma":0.000079341036,"teacher_disagreement_score":0.052346602,"about_ca_system_score_codex":0.000098442935,"about_ca_system_score_gemma":0.00016711147,"threshold_uncertainty_score":0.4400053},"labels":[],"label_agreement":null},{"id":"W3215728887","doi":"10.1182/blood-2021-153887","title":"Pregnancy Management and Outcomes in Patients with Myeloproliferative Neoplasms","year":2021,"lang":"en","type":"article","venue":"Blood","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Mount Sinai Hospital; Princess Margaret Cancer Centre; Sinai Health System; University of Toronto","funders":"","keywords":"Medicine; Pregnancy; Essential thrombocythemia; Obstetrics; Retrospective cohort study; Preeclampsia; Pediatrics; Polycythemia vera; Internal medicine","score_opus":0.006603631693702869,"score_gpt":0.22401754236660204,"score_spread":0.21741391067289917,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3215728887","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.993956,0.0007157452,0.0000069781104,0.0004869392,0.000033156735,0.00079972314,0.000014754261,0.000025544545,0.003961103],"genre_scores_gemma":[0.99394494,0.00027795305,0.0037631518,0.00031327887,0.0000123179825,0.00023559522,0.00005764359,0.000020793803,0.0013743417],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99888813,0.00003544162,0.0002012363,0.000386247,0.00026044337,0.00022851452],"domain_scores_gemma":[0.9994668,0.000047187124,0.000045265864,0.00022858409,0.00010169577,0.000110466506],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00002867865,0.00020294356,0.00037453463,0.00008019926,0.00005401556,0.000027825523,0.000027998321,0.00004754217,0.0000707573],"category_scores_gemma":[0.000022078313,0.00013885085,0.00003625907,0.00017391711,0.000033493314,0.00006922356,0.00005513607,0.0000987749,0.000014921148],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00007924632,0.0035969247,0.9909933,0.00008756152,0.00048774361,0.00061860005,0.00030429784,8.7942163e-7,0.0000038921175,0.0012692919,0.000023341152,0.0025348722],"study_design_scores_gemma":[0.016748562,0.00062962377,0.9786633,0.00045933854,0.00027150102,0.000018626493,0.000094314775,0.000002586099,0.002749519,0.00007542563,0.0001412191,0.00014597728],"about_ca_topic_score_codex":0.0000057639954,"about_ca_topic_score_gemma":0.00006996914,"teacher_disagreement_score":0.016669316,"about_ca_system_score_codex":0.00003130192,"about_ca_system_score_gemma":0.0000464459,"threshold_uncertainty_score":0.56621736},"labels":[],"label_agreement":null},{"id":"W3216627495","doi":"10.1182/blood-2021-147626","title":"Investigating Erythrocytosis: Changing Practice Patterns in the Era of Molecular Diagnostics","year":2021,"lang":"en","type":"article","venue":"Blood","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Western University; London Health Sciences Centre","funders":"","keywords":"Medicine; Molecular diagnostics; Polycythemia vera; Clinical Practice; Internal medicine; Diagnostic test; Retrospective cohort study; Pediatrics; Family medicine; Bioinformatics; Biology","score_opus":0.0172013780386173,"score_gpt":0.2815299753066155,"score_spread":0.2643285972679982,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3216627495","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9893037,0.0024434784,0.00010722395,0.0067021903,0.000036130026,0.00028846684,0.000011699834,0.000011778929,0.0010953206],"genre_scores_gemma":[0.9914963,0.0009115841,0.0033627353,0.0039900374,0.00007071248,0.000117594915,0.000029977571,0.000014610353,0.0000063977827],"study_design_codex":"observational","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9989162,0.0001515898,0.00024539293,0.00019640394,0.0002891051,0.00020131808],"domain_scores_gemma":[0.9986813,0.0007502705,0.00010427188,0.00026566433,0.00014512421,0.000053367756],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002397726,0.00011921866,0.00023426033,0.000048577556,0.000047509195,0.00002046672,0.00005542309,0.00004801104,0.000027969485],"category_scores_gemma":[0.0018281944,0.00008611941,0.0000639699,0.00033457062,0.000026741804,0.000055438533,0.000046828674,0.00022418775,0.000005558101],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000013346369,0.00482586,0.9628958,0.00031447873,0.00049749255,0.0036593047,0.00980003,0.000027717151,0.010541957,0.0040360983,0.00011347198,0.0032744303],"study_design_scores_gemma":[0.0056271125,0.00054338935,0.17514691,0.001858724,0.0013031793,0.0008162723,0.008122124,0.00006163841,0.8053751,0.00024394233,0.0006818337,0.00021980886],"about_ca_topic_score_codex":0.000048618524,"about_ca_topic_score_gemma":0.00003400418,"teacher_disagreement_score":0.7948331,"about_ca_system_score_codex":0.00001794292,"about_ca_system_score_gemma":0.00011731249,"threshold_uncertainty_score":0.35118476},"labels":[],"label_agreement":null},{"id":"W3217476733","doi":"10.1182/blood-2021-151696","title":"Rate of Clonal Hematopoiesis in Patients with Venous Thromboembolism","year":2021,"lang":"en","type":"article","venue":"Blood","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Hospital","funders":"","keywords":"Medicine; Internal medicine; Venous thrombosis; Incidence (geometry); Thrombosis; Oncology","score_opus":0.006218967977257774,"score_gpt":0.21679264152922237,"score_spread":0.2105736735519646,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3217476733","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9977305,0.00026141218,0.0000018816851,0.00024503068,0.000028188011,0.00021781934,0.000020017655,0.000009213093,0.001485953],"genre_scores_gemma":[0.9988279,0.000036561338,0.0007649577,0.00019073437,0.000023520017,0.000031025134,0.00005531326,0.000012625981,0.00005736186],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99931586,0.000034047123,0.00017596367,0.00017954307,0.00015583308,0.00013876127],"domain_scores_gemma":[0.999518,0.00005171326,0.000053488144,0.0001757334,0.00014419512,0.00005687514],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000044623433,0.0001032044,0.00039070306,0.000043813943,0.000020718984,0.0000052260007,0.000024266474,0.000039509225,0.00016864628],"category_scores_gemma":[0.000037936155,0.00007482871,0.000042624983,0.00016062894,0.000028674407,0.000027574377,0.000019934987,0.00006469987,0.000012184779],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00009392034,0.009049258,0.9886583,0.00008013632,0.00028553916,0.00020851055,0.00031738917,0.0000018035255,0.00028964417,0.000678129,0.000064966596,0.00027236983],"study_design_scores_gemma":[0.007854268,0.0006372452,0.9164788,0.00017480901,0.00019504002,0.000015373142,0.000038889488,9.358865e-7,0.07435808,0.0000853558,0.00009447704,0.00006672368],"about_ca_topic_score_codex":0.00002371625,"about_ca_topic_score_gemma":0.000040476025,"teacher_disagreement_score":0.07406844,"about_ca_system_score_codex":0.00001749133,"about_ca_system_score_gemma":0.00012568479,"threshold_uncertainty_score":0.30514264},"labels":[],"label_agreement":null},{"id":"W3217566107","doi":"10.1182/blood-2021-149585","title":"Environmental, Lifestyle Risk Factors and Host Characteristics Associated with Philadelphia Negative Myeloproliferative Neoplasm: A Systematic Review","year":2021,"lang":"en","type":"review","venue":"Blood","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Essential thrombocythemia; Systematic review; Myelofibrosis; Epidemiology; Etiology; MEDLINE; Polycythemia vera; Internal medicine","score_opus":0.02055970374362189,"score_gpt":0.26819965749094193,"score_spread":0.24763995374732004,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3217566107","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0032247105,0.9864706,0.0000028468742,0.00010424988,0.00006774645,0.007928718,0.0020402074,0.00007980851,0.00008111326],"genre_scores_gemma":[0.0027250713,0.9923556,0.00010894369,0.0002573788,0.00011640639,0.002143479,0.0019376505,0.0001817913,0.00017369486],"study_design_codex":"systematic_review","study_design_gemma":"systematic_review","domain_scores_codex":[0.99485534,0.0011264429,0.0015580124,0.001156869,0.0007421306,0.0005612025],"domain_scores_gemma":[0.99481004,0.0017306693,0.0020277968,0.0007889976,0.00015304926,0.0004894181],"candidate_categories":["metaepi_narrow"],"consensus_categories":["metaepi_narrow"],"category_scores_codex":[0.00038431952,0.0014136336,0.00850036,0.00018202227,0.00030746084,0.00012016157,0.00016211497,0.00047615127,0.00013360189],"category_scores_gemma":[0.0017933347,0.0008738085,0.0006752056,0.00045799263,0.00020648244,0.00011223988,0.00014481257,0.00095388456,0.000063100066],"study_design_candidate":"systematic_review","study_design_consensus":"systematic_review","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000017310407,0.004497981,0.019747812,0.9464167,0.024039267,0.0015143189,0.0008181728,2.281557e-8,4.860698e-7,0.000032688957,0.00020126227,0.002713974],"study_design_scores_gemma":[0.0024185216,0.0010775406,0.004593166,0.88662386,0.09688557,0.00090441096,0.00013438004,0.0000017094607,0.000021623111,0.0000012788188,0.006336646,0.0010012882],"about_ca_topic_score_codex":0.000014870026,"about_ca_topic_score_gemma":0.000016140279,"teacher_disagreement_score":0.0728463,"about_ca_system_score_codex":0.00031736383,"about_ca_system_score_gemma":0.00054239045,"threshold_uncertainty_score":0.99986136},"labels":[],"label_agreement":null},{"id":"W4200029008","doi":"10.1016/j.jcjo.2021.11.011","title":"Unilateral vision loss in a patient with essential thrombocythemia","year":2021,"lang":"en","type":"letter","venue":"Canadian Journal of Ophthalmology","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"University of British Columbia; University of British Columbia Hospital","funders":"","keywords":"Essential thrombocythemia; Medicine; Internal medicine; Polycythemia vera","score_opus":0.01562347386739426,"score_gpt":0.2714533778237678,"score_spread":0.25582990395637356,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4200029008","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.826533,0.00079663895,0.0000016643762,0.16748384,0.0006159168,0.00027041303,0.000038439757,0.0000016521936,0.0042584045],"genre_scores_gemma":[0.9674057,0.000021603923,0.0003836276,0.030107068,0.0010683702,0.000016342781,0.00019014535,0.00006209723,0.000745042],"study_design_codex":"case_report","study_design_gemma":"case_report","domain_scores_codex":[0.99796385,0.00019297481,0.0006259624,0.00033642614,0.0003065716,0.00057424325],"domain_scores_gemma":[0.9983602,0.00010334645,0.00039359857,0.00028503302,0.00040169977,0.0004560942],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00010605263,0.00036163797,0.0011049267,0.0006249788,0.000062709616,0.000042297157,0.00013875702,0.0006390367,0.0028543437],"category_scores_gemma":[0.000049290116,0.0002637732,0.00020187405,0.00022734272,0.00021142316,0.000067378925,0.00001783826,0.0017674102,0.000013772952],"study_design_candidate":"case_report","study_design_consensus":"case_report","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000109935805,0.00007829581,0.07277414,0.00008429606,0.00032157794,0.83815104,0.00030523507,0.000014982201,0.000012398645,0.000011722621,0.088029236,0.00010715567],"study_design_scores_gemma":[0.0024422426,0.003979523,0.028361237,0.0015014549,0.00025508477,0.9117462,0.00005359842,0.0000032348087,0.00047970784,0.00007413266,0.05080998,0.00029358504],"about_ca_topic_score_codex":0.0022250568,"about_ca_topic_score_gemma":0.00081582856,"teacher_disagreement_score":0.14087267,"about_ca_system_score_codex":0.00070711586,"about_ca_system_score_gemma":0.0041884906,"threshold_uncertainty_score":0.99998146},"labels":[],"label_agreement":null},{"id":"W4200053736","doi":"10.1016/s2152-2650(21)01829-2","title":"MPN-303: Longitudinal and Individual Symptom Analyses from the SIMPLIFY-1 Study Demonstrate Clinically Comparable Symptomatic Benefit of Momelotinib to Ruxolitinib in JAK Inhibitor-Naive Myelofibrosis Patients","year":2021,"lang":"en","type":"article","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"St. Paul's Hospital; University of Toronto; University of British Columbia; University Health Network","funders":"","keywords":"Ruxolitinib; Myelofibrosis; Medicine; Internal medicine; Longitudinal study; Oncology; Pathology; Bone marrow","score_opus":0.08829957035055626,"score_gpt":0.3818298745004986,"score_spread":0.29353030414994236,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4200053736","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99499923,0.0004909872,0.0000129266455,0.0009201717,0.00034939367,0.002289132,0.0004803121,0.00006885146,0.0003889786],"genre_scores_gemma":[0.9951671,0.00021664,0.0017141977,0.0016299579,0.00034656908,0.00038303508,0.0004085782,0.00007321564,0.000060725175],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9917378,0.00087237364,0.0037826519,0.0016252227,0.0011542917,0.00082766835],"domain_scores_gemma":[0.9888859,0.0075018173,0.0008450448,0.0012104592,0.00075269246,0.0008041124],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0013426103,0.00075460214,0.0025867734,0.00021139746,0.0002652718,0.00017461347,0.00046125925,0.00042634475,0.0001531511],"category_scores_gemma":[0.0025834555,0.00055655546,0.0005476512,0.0010704106,0.00048871123,0.00019496761,0.0006778902,0.00050205673,0.00009719358],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.001040876,0.004759716,0.92462534,0.00006123743,0.0013853606,0.00023712186,0.0009174338,0.000033799843,0.000094236246,0.0001041246,0.0005229962,0.06621776],"study_design_scores_gemma":[0.01343458,0.0037946347,0.9762831,0.0008608659,0.0012883398,0.000028066266,0.0014332248,0.00020145059,0.0017092195,0.00033160998,0.00014475537,0.0004901939],"about_ca_topic_score_codex":0.0009810259,"about_ca_topic_score_gemma":0.00070467696,"teacher_disagreement_score":0.06572756,"about_ca_system_score_codex":0.00047067582,"about_ca_system_score_gemma":0.0012201287,"threshold_uncertainty_score":0.99968857},"labels":[],"label_agreement":null},{"id":"W4200116858","doi":"10.1182/blood-2021-147618","title":"Spleen and Symptom Responses with Fedratinib (FEDR) in Patients with Myelofibrosis (MF) and Substantial Splenomegaly","year":2021,"lang":"en","type":"article","venue":"Blood","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Myelofibrosis; Ruxolitinib; Internal medicine; Gastroenterology; Placebo; Clinical trial; Spleen; Phases of clinical research; Surgery; Bone marrow; Pathology","score_opus":0.0063409982194134774,"score_gpt":0.21234891591118035,"score_spread":0.20600791769176688,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4200116858","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99763024,0.000630041,0.000003122305,0.00051088515,0.000015436204,0.0004549282,0.000077794684,0.00002216808,0.00065535755],"genre_scores_gemma":[0.9974385,0.0001833206,0.001858184,0.00016258028,0.00003175523,0.000057908266,0.00009066515,0.000022511693,0.0001546064],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9987862,0.00006793129,0.00020135035,0.00045115955,0.000257449,0.0002358714],"domain_scores_gemma":[0.99929214,0.00014204324,0.00006296571,0.0002191026,0.000129488,0.00015424419],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00007221098,0.00021741525,0.00039400285,0.0000930259,0.00008708973,0.00006290639,0.000024934943,0.00006264238,0.00006695295],"category_scores_gemma":[0.000043975386,0.00014732874,0.000021184413,0.00019546584,0.000088539215,0.00009288265,0.0000364931,0.000108882836,0.000004486488],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0015933058,0.0012607853,0.9947455,0.00006112945,0.00022475922,0.0003108519,0.00047439913,3.069922e-7,0.00030094569,0.00013183133,0.000027831995,0.0008683313],"study_design_scores_gemma":[0.017478894,0.002374387,0.9660774,0.00028454707,0.00032266096,0.000086225606,0.0001222029,0.0000024015803,0.012790309,0.0000075012795,0.00027481915,0.00017867328],"about_ca_topic_score_codex":0.00003779319,"about_ca_topic_score_gemma":0.00033591146,"teacher_disagreement_score":0.028668145,"about_ca_system_score_codex":0.000022485998,"about_ca_system_score_gemma":0.0001439361,"threshold_uncertainty_score":0.6007892},"labels":[],"label_agreement":null},{"id":"W4200216722","doi":"10.1016/j.htct.2021.11.011","title":"The tale of two organs: allogeneic hematopoietic stem cell transplantation following liver transplantation in a myelofibrosis patient","year":2021,"lang":"en","type":"article","venue":"Hematology Transfusion and Cell Therapy","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"London Health Sciences Centre; Windsor Regional Hospital; Western University","funders":"","keywords":"Myelofibrosis; Transplantation; Stem cell; Medicine; Hematopoietic stem cell transplantation; Haematopoiesis; Biology; Pathology; Surgery; Bone marrow; Cell biology","score_opus":0.011388322681602538,"score_gpt":0.24325754438128386,"score_spread":0.23186922169968133,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4200216722","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9830066,0.0147338975,0.0004978837,0.00048820407,0.000097161515,0.00061535276,0.000012275958,0.000019763445,0.0005288423],"genre_scores_gemma":[0.88224524,0.11700012,0.0002809471,0.00023310867,0.0000063667444,0.000104314415,0.000043194468,0.00002063531,0.000066097964],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9985297,0.00020524328,0.0004668036,0.00034664577,0.00021583725,0.00023580025],"domain_scores_gemma":[0.99932057,0.00027531598,0.00008128697,0.00018022853,0.00006166987,0.00008091527],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00013010358,0.0002157597,0.00045699356,0.0000788829,0.00015863267,0.000014620966,0.000045342756,0.00012321174,0.00010652394],"category_scores_gemma":[0.0000011971867,0.00015057193,0.00016434863,0.00021768776,0.000067312634,0.00005193387,0.000004155906,0.00013161828,0.0000046250316],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0031720942,0.003837795,0.21905755,0.0023440334,0.0003414792,0.004761609,0.059676953,0.00004304153,0.65425295,0.0020577016,0.000044888373,0.05040992],"study_design_scores_gemma":[0.007723261,0.0005392437,0.012340412,0.0002456536,0.00017871626,0.00078710774,0.0016106422,0.000047354595,0.9760796,0.00009290716,0.00019516007,0.00015998335],"about_ca_topic_score_codex":0.000050242143,"about_ca_topic_score_gemma":0.00030961985,"teacher_disagreement_score":0.32182664,"about_ca_system_score_codex":0.000021594005,"about_ca_system_score_gemma":0.000085838365,"threshold_uncertainty_score":0.6140145},"labels":[],"label_agreement":null},{"id":"W4200222349","doi":"10.1017/s0266462321001549","title":"PP409 Cost-Effectiveness Of Ruxolitinib For Patients With Myelofibrosis: A Review Of The Literature","year":2021,"lang":"en","type":"review","venue":"International Journal of Technology Assessment in Health Care","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Ruxolitinib; Medicine; Myelofibrosis; Cost effectiveness; Systematic review; Cochrane Library; MEDLINE; Checklist; Intensive care medicine; Internal medicine; Randomized controlled trial","score_opus":0.024714801639483114,"score_gpt":0.4318778615580482,"score_spread":0.40716305991856505,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4200222349","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0004787173,0.9925024,0.00002596068,0.0020564578,0.0005013303,0.0038983116,0.00049557805,0.00000541135,0.000035842822],"genre_scores_gemma":[0.004093525,0.9923899,0.0021214788,0.00022413734,0.000057505426,0.0005980774,0.00048085328,0.00002954812,0.0000049321284],"study_design_codex":"design_other","study_design_gemma":"systematic_review","domain_scores_codex":[0.9967864,0.00038235416,0.0016853798,0.00025884915,0.0006940173,0.000192997],"domain_scores_gemma":[0.9924005,0.0005525505,0.0028911603,0.00032737132,0.0037666375,0.0000617795],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00062135974,0.0003039884,0.0025685052,0.00059963425,0.00003304404,0.000009829216,0.00044405807,0.00028938302,0.000019280184],"category_scores_gemma":[0.00045689437,0.00016962664,0.00064509653,0.000586824,0.00009138142,0.000057579306,0.00010819123,0.0007716081,1.8627577e-7],"study_design_candidate":"systematic_review","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00019810522,0.0012327483,0.025910854,0.29038534,0.001570891,0.0000537468,0.00007941681,0.0000013629968,2.3092387e-7,0.0035201563,0.00020107074,0.6768461],"study_design_scores_gemma":[0.0024130356,0.0017484623,0.0049952623,0.778396,0.00055954704,0.00020564525,0.000110594985,1.8621147e-7,0.000028643617,0.000040136405,0.21139802,0.00010445868],"about_ca_topic_score_codex":0.0000042787574,"about_ca_topic_score_gemma":0.0000034732554,"teacher_disagreement_score":0.6767416,"about_ca_system_score_codex":0.0011923262,"about_ca_system_score_gemma":0.0028058097,"threshold_uncertainty_score":0.6917174},"labels":[],"label_agreement":null},{"id":"W4200223513","doi":"10.14740/jmc3784","title":"Successful Treatment of Thrombocytopenia, Anasarca, Fever, Reticulin Myelofibrosis/Renal Insufficiency, and Organomegaly Syndrome Using Plasma Exchange Followed by Rituximab in the Intensive Care Unit","year":2021,"lang":"en","type":"article","venue":"Journal of Medical Cases","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Medicine; Anasarca; Organomegaly; Rituximab; Myelofibrosis; Internal medicine; Surgery; Polyneuropathy; Lymphoma","score_opus":0.04851628832003806,"score_gpt":0.3285713427448742,"score_spread":0.28005505442483614,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4200223513","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97732085,0.01786281,0.000015282936,0.0042434093,0.00013360243,0.00029757738,0.00006377663,0.000003922908,0.00005879329],"genre_scores_gemma":[0.99427104,0.0046361657,0.0003276241,0.0006002993,0.00008870544,0.000010839582,0.00003043637,0.00001717076,0.000017690081],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99726546,0.00027490544,0.0007630345,0.0002546569,0.0011666352,0.00027529895],"domain_scores_gemma":[0.9976784,0.0006313736,0.00034663104,0.00020848596,0.00083308533,0.0003020407],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00034564655,0.0002577017,0.00107688,0.0001807162,0.000099588695,0.00004258228,0.00014837737,0.0001693832,0.00059087196],"category_scores_gemma":[0.0010545461,0.00014919633,0.00019047876,0.00044255363,0.00025133544,0.00011379258,0.00006633558,0.0002886856,0.0000020566906],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0017275086,0.014312373,0.794234,0.00080651947,0.0011275671,0.14216736,0.02214026,0.000014302162,0.004489784,0.00013259932,0.0035712547,0.015276487],"study_design_scores_gemma":[0.09624765,0.04432294,0.38898298,0.008015238,0.0041250694,0.18654881,0.16811255,0.00074657233,0.09003287,0.00005496813,0.011749721,0.0010606104],"about_ca_topic_score_codex":0.00036567208,"about_ca_topic_score_gemma":0.0003132879,"teacher_disagreement_score":0.405251,"about_ca_system_score_codex":0.00026282706,"about_ca_system_score_gemma":0.0008915358,"threshold_uncertainty_score":0.64696336},"labels":[],"label_agreement":null},{"id":"W4200275091","doi":"10.1182/blood-2021-148230","title":"Spectrum of Myeloid Mutations in Patients with Elevated Hemoglobin","year":2021,"lang":"en","type":"article","venue":"Blood","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Western University; London Health Sciences Centre","funders":"","keywords":"Medicine; Internal medicine; Genetic testing; Population; Hemoglobin; Incidence (geometry); Oncology; Genetics; Biology","score_opus":0.006602397248185671,"score_gpt":0.22132343824818843,"score_spread":0.21472104100000275,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4200275091","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9975186,0.0000846439,0.000005384536,0.00048471126,0.0000182937,0.00027314946,0.000025432644,0.000012685249,0.0015770892],"genre_scores_gemma":[0.9985031,0.000015895559,0.0010142992,0.00009196708,0.00001429714,0.000031567084,0.00017285871,0.000010696515,0.00014533092],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99933237,0.00002351854,0.00017541123,0.00016694846,0.00017335181,0.00012839962],"domain_scores_gemma":[0.99958575,0.00003671937,0.000048586535,0.00015861575,0.000116130774,0.00005421178],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000026497817,0.00008985012,0.00021963498,0.000060064645,0.000019133204,0.0000049491655,0.000020079642,0.000031910913,0.00020459245],"category_scores_gemma":[0.000044355023,0.000068069996,0.000031720392,0.00029403338,0.000023127242,0.000027172924,0.000012452726,0.00006363261,0.000014666904],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00006972972,0.004180284,0.9942069,0.000028082508,0.0001445758,0.000107857886,0.00013821763,0.000005044525,0.0006175219,0.00029608922,0.000026663298,0.00017902696],"study_design_scores_gemma":[0.009181234,0.0004960128,0.825781,0.00009945073,0.00012985201,0.000009972031,0.000039333743,0.0000036462393,0.16409464,0.00005361013,0.000056099343,0.000055183707],"about_ca_topic_score_codex":0.000020783367,"about_ca_topic_score_gemma":0.00013432764,"teacher_disagreement_score":0.16842595,"about_ca_system_score_codex":0.000026993781,"about_ca_system_score_gemma":0.00012741386,"threshold_uncertainty_score":0.2775814},"labels":[],"label_agreement":null},{"id":"W4200311759","doi":"10.1017/cjn.2021.512","title":"Dural Venous Sinus Thrombosis and Papilledema Related to <i>JAK2</i> Mutation: A Case Series","year":2021,"lang":"en","type":"article","venue":"Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"","keywords":"Papilledema; Medicine; Thrombosis; Thrombocytosis; Mutation; Polycythemia vera; Gene mutation; Venous thrombosis; Surgery; Pediatrics; Internal medicine; Gene; Platelet; Genetics","score_opus":0.037588186064037445,"score_gpt":0.29357734825060605,"score_spread":0.2559891621865686,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4200311759","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9629672,0.0014349973,0.000004248273,0.033041846,0.0005079884,0.00019562556,0.000014185045,0.000015369948,0.0018185149],"genre_scores_gemma":[0.9897187,0.00055929215,0.0031580145,0.0063524996,0.00012567989,0.0000055961864,5.8289544e-7,0.000011123876,0.00006852839],"study_design_codex":"observational","study_design_gemma":"case_report","domain_scores_codex":[0.99655086,0.0006053495,0.00077396317,0.00055206765,0.0005755316,0.00094223296],"domain_scores_gemma":[0.9959083,0.00043027606,0.00037313325,0.00013335842,0.0006909616,0.0024639624],"candidate_categories":["sts"],"consensus_categories":["sts"],"category_scores_codex":[0.0015348513,0.00030799204,0.00064099167,0.00052794104,0.0025146701,0.0005969317,0.0003658596,0.00015926985,0.00027011064],"category_scores_gemma":[0.0018744428,0.00020420525,0.00018519495,0.0013401723,0.0029188434,0.000641617,0.00006222871,0.0007195034,0.0000049001424],"study_design_candidate":"case_report","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00009051767,0.00010237894,0.581846,0.000013273648,0.00006151364,0.41071916,0.0013929193,0.0006043477,0.00007814603,0.0013174298,0.0007557034,0.0030186137],"study_design_scores_gemma":[0.00047996125,0.06292867,0.12034216,0.000063746775,0.000102826736,0.8086707,0.0007660834,0.00012537626,0.00034397864,0.00442552,0.0015369186,0.0002140592],"about_ca_topic_score_codex":0.0006414848,"about_ca_topic_score_gemma":0.05774362,"teacher_disagreement_score":0.46150383,"about_ca_system_score_codex":0.00020351852,"about_ca_system_score_gemma":0.003216817,"threshold_uncertainty_score":0.99979466},"labels":[],"label_agreement":null},{"id":"W4200393847","doi":"10.1152/ajpcell.00328.2021","title":"Megakaryocyte-bone cell interactions: lessons from mouse models of experimental myelofibrosis and related disorders","year":2021,"lang":"en","type":"review","venue":"American Journal of Physiology-Cell Physiology","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Shriners Hospitals for Children - Canada","funders":"Canadian Institutes of Health Research; Government of Canada","keywords":"Megakaryocyte; Osteosclerosis; Bone marrow; Myelofibrosis; Osteoclast; Osteoblast; Haematopoiesis; Cell biology; Progenitor cell; Biology; Cancer research; Immunology; Chemistry; In vitro; Pathology; Stem cell; Medicine","score_opus":0.026389735264008764,"score_gpt":0.32428101131625847,"score_spread":0.2978912760522497,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4200393847","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.17380443,0.82489735,0.0000067029587,0.00013119045,0.00030379105,0.00045099808,0.00016161343,0.000015578342,0.0002283426],"genre_scores_gemma":[0.23487999,0.7632352,0.0010410973,0.000087622815,0.0001587141,0.00007134168,0.00031929894,0.000081781756,0.00012495756],"study_design_codex":"bench_or_experimental","study_design_gemma":"not_applicable","domain_scores_codex":[0.9959369,0.00086766685,0.0017137412,0.0007978196,0.00023988199,0.00044402602],"domain_scores_gemma":[0.99482906,0.0009995669,0.003040751,0.0005892171,0.0002463887,0.00029503385],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00012086704,0.0007914693,0.0057930765,0.00039788013,0.000104813094,0.0000117546415,0.00025543524,0.0002863266,0.00035703494],"category_scores_gemma":[0.000037177626,0.0005895132,0.001341908,0.00040255347,0.00093012914,0.00015942295,0.00022476971,0.0010132658,0.000016358794],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0013228743,0.0086520845,0.000025461188,0.0032960277,0.006902503,0.0001002171,0.0015712974,0.00021922508,0.7446175,0.0002105985,0.0018487566,0.23123345],"study_design_scores_gemma":[0.038227435,0.06663252,0.0028315492,0.05297779,0.042588916,0.0030333211,0.018030126,0.00071817165,0.27342343,0.0052281353,0.48851934,0.007789272],"about_ca_topic_score_codex":0.00020741929,"about_ca_topic_score_gemma":0.000005172815,"teacher_disagreement_score":0.48667058,"about_ca_system_score_codex":0.00020435684,"about_ca_system_score_gemma":0.00044930386,"threshold_uncertainty_score":0.9996556},"labels":[],"label_agreement":null},{"id":"W4200536979","doi":"10.1182/bloodadvances.2021006043","title":"The MDM2 antagonist idasanutlin in patients with polycythemia vera: results from a single-arm phase 2 study","year":2021,"lang":"en","type":"article","venue":"Blood Advances","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":25,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Roche (Canada); Princess Margaret Cancer Centre","funders":"F. Hoffmann-La Roche","keywords":"Medicine; Hematocrit; Nausea; Internal medicine; Gastroenterology; Vomiting; Ruxolitinib; Adverse effect; Polycythemia vera; Phlebotomy; Clinical endpoint; Regimen; Anemia; Surgery; Myelofibrosis; Clinical trial","score_opus":0.012022650763287865,"score_gpt":0.27513504460580723,"score_spread":0.2631123938425194,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4200536979","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99445117,0.0025342838,0.0000027552571,0.0008575064,0.0001356944,0.0008048966,0.00018124342,0.000030247931,0.0010022045],"genre_scores_gemma":[0.9982797,0.00025377647,0.0006186708,0.00017165241,0.00011762643,0.00011713008,0.0002362336,0.000021587095,0.00018364827],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9983447,0.00009235315,0.00038509566,0.0005006314,0.000399217,0.00027798093],"domain_scores_gemma":[0.9988124,0.00038875375,0.00013601486,0.00042047998,0.00013672742,0.000105620136],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00009636404,0.00022892063,0.00036906765,0.000036674082,0.00020057938,0.00006799517,0.000081830316,0.000036005466,0.000028153685],"category_scores_gemma":[0.00019421376,0.00013233071,0.000048676127,0.00024995554,0.000072375595,0.00011134906,0.000043475935,0.00016103417,0.000011353897],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.005317831,0.04109919,0.92524964,0.000010686097,0.00040895626,0.0007705717,0.0011943664,0.0000067922997,0.0002511779,0.000024556724,0.00009297741,0.025573272],"study_design_scores_gemma":[0.1439122,0.018021297,0.7306985,0.0005149235,0.00074525736,0.00001752228,0.003560129,0.000017659378,0.08194978,0.00014361048,0.019938366,0.00048070593],"about_ca_topic_score_codex":0.00008256426,"about_ca_topic_score_gemma":0.001064004,"teacher_disagreement_score":0.19455107,"about_ca_system_score_codex":0.00006142629,"about_ca_system_score_gemma":0.00011633181,"threshold_uncertainty_score":0.539629},"labels":[],"label_agreement":null},{"id":"W4200625806","doi":"10.1182/hematology.2021000279","title":"Novel therapies vs hematopoietic cell transplantation in myelofibrosis: who, when, how?","year":2021,"lang":"en","type":"review","venue":"Hematology","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":15,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Myelofibrosis; Medicine; Tolerability; Transplantation; Hematopoietic stem cell transplantation; Disease; Clinical trial; Oncology; Stem cell; Internal medicine; Intensive care medicine; Immunology; Bone marrow; Adverse effect; Biology","score_opus":0.044771631549249645,"score_gpt":0.31648119483142395,"score_spread":0.2717095632821743,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4200625806","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00022040823,0.99574035,0.00024071545,0.0011894119,0.00020535372,0.0014564977,0.00006813772,0.00005560024,0.0008235166],"genre_scores_gemma":[0.00041419372,0.99459136,0.0020108847,0.00029673884,0.00007886463,0.0011848173,0.00063545746,0.00009620989,0.0006914824],"study_design_codex":"systematic_review","study_design_gemma":"not_applicable","domain_scores_codex":[0.99737453,0.00024775602,0.00081139023,0.0008061934,0.00027075145,0.0004893927],"domain_scores_gemma":[0.9983986,0.00050492544,0.0003341643,0.00051681994,0.000099456716,0.00014605306],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00015080205,0.00068536017,0.004139187,0.00036916012,0.00006510462,0.00004393179,0.00013674292,0.0006680328,0.00038674986],"category_scores_gemma":[0.000036460257,0.0005186858,0.00059132144,0.00032799467,0.000093726805,0.00006365877,0.00003584662,0.00047986838,0.00010735089],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00032700595,0.0077115465,0.008148558,0.45549542,0.003562781,0.010018145,0.011803452,0.0000012488347,0.000056659832,0.044804066,0.013767869,0.44430324],"study_design_scores_gemma":[0.0033660063,0.00044829492,0.0002607423,0.066662386,0.0029858132,0.009108479,0.0003114942,0.000003145739,0.000603515,0.0001030498,0.9153825,0.00076459587],"about_ca_topic_score_codex":0.000024973517,"about_ca_topic_score_gemma":0.000089569985,"teacher_disagreement_score":0.9016146,"about_ca_system_score_codex":0.00014598381,"about_ca_system_score_gemma":0.00045163324,"threshold_uncertainty_score":0.9997265},"labels":[],"label_agreement":null},{"id":"W4205185159","doi":"10.51731/cjht.2021.124","title":"Fedratinib (Inrebic)","year":2021,"lang":"en","type":"article","venue":"Canadian Journal of Health Technologies","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Myelofibrosis; Reimbursement; Medicine; Ruxolitinib; Polycythemia vera; Disease; Essential thrombocythemia; Family medicine; Intensive care medicine; Internal medicine; Health care; Political science","score_opus":0.0371294891938039,"score_gpt":0.3059198913794901,"score_spread":0.26879040218568623,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4205185159","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.44549826,0.16855292,0.00022261468,0.38123494,0.0007067123,0.00039208026,0.000032273892,0.00011786744,0.0032423148],"genre_scores_gemma":[0.9936349,0.0016055969,0.002668516,0.0018255324,0.000019395711,0.000007510065,0.0000055595624,0.000011648976,0.00022134562],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9988577,0.000045554403,0.000471544,0.00012884675,0.00014866018,0.0003477382],"domain_scores_gemma":[0.99896795,0.00005832223,0.00023135092,0.00022390114,0.00035745173,0.00016102029],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00025493198,0.00011517404,0.00044684415,0.0002867216,0.00019430152,0.000031170668,0.000093041446,0.00010959683,0.00015273111],"category_scores_gemma":[0.00074804755,0.000088566034,0.00009937466,0.000288265,0.000104019644,0.000055714627,0.000011883635,0.0003420368,0.000019392324],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000023927667,0.00013448096,0.110453315,0.00017106153,0.00022545847,0.0051901178,0.0004644308,0.000005986684,0.00011987424,0.007217847,0.028658008,0.8473355],"study_design_scores_gemma":[0.0027444013,0.002123719,0.11593555,0.0011178018,0.000085957516,0.0072244913,0.00680695,0.000010564974,0.024507292,0.005135916,0.8340577,0.00024966605],"about_ca_topic_score_codex":0.0006990108,"about_ca_topic_score_gemma":0.0041388725,"teacher_disagreement_score":0.84708583,"about_ca_system_score_codex":0.00038142584,"about_ca_system_score_gemma":0.0066669225,"threshold_uncertainty_score":0.99896437},"labels":[],"label_agreement":null},{"id":"W4205527069","doi":"10.1182/blood.2021012743","title":"A randomized phase 3 trial of interferon-α vs hydroxyurea in polycythemia vera and essential thrombocythemia","year":2022,"lang":"en","type":"article","venue":"Blood","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":129,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"National Cancer Institute; NYU Grossman School of Medicine; Genentech; National Institutes of Health; Italfarmaco; Astellas Pharma; Rosetrees Trust; Cancer Research UK; Sierra Oncology; CTI Biopharma; Incyte; Tizona Therapeutics; Constellation Pharmaceuticals; Jazz Pharmaceuticals; Memorial Sloan-Kettering Cancer Center; Medical Research Council; Celgene; Gilead Sciences; Amgen","keywords":"Essential thrombocythemia; Polycythemia vera; Hydroxycarbamide; Adverse effect; Clinical endpoint; Phases of clinical research; Myelofibrosis; Randomized controlled trial","score_opus":0.013426965618761739,"score_gpt":0.29497064113746935,"score_spread":0.2815436755187076,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4205527069","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9958895,0.00049818953,0.0000086127375,0.00063385826,0.00013383768,0.0015566448,0.000033752458,0.000018867675,0.0012267544],"genre_scores_gemma":[0.9987274,0.00014432344,0.00012349336,0.00012566865,0.000108438144,0.0006018399,0.000047892732,0.000018742225,0.000102192185],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9986203,0.00018680678,0.00044927123,0.00027547445,0.0002816419,0.00018655388],"domain_scores_gemma":[0.99927247,0.0002722324,0.0001379239,0.00021003243,0.00002376471,0.00008358103],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00040576473,0.0001727409,0.0009187681,0.00014142646,0.00006237647,0.000009875399,0.0000613619,0.000046562236,0.0005158972],"category_scores_gemma":[0.000109197244,0.00013768305,0.0001618406,0.00014278175,0.00010476817,0.000034705306,0.00010155923,0.00020451436,0.0000025606294],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9751378,0.009914804,0.0022293606,0.000060043323,0.00064237666,0.00018367196,0.0014905343,0.0000028297352,0.009227145,0.00044111404,0.00021088921,0.00045942722],"study_design_scores_gemma":[0.93316823,0.0035022476,0.000120115285,0.0000563582,0.0005770213,0.000080220976,0.000119518845,0.00011973892,0.061855383,0.0001266769,0.00016965334,0.00010483467],"about_ca_topic_score_codex":0.00007967601,"about_ca_topic_score_gemma":0.000010655406,"teacher_disagreement_score":0.052628238,"about_ca_system_score_codex":0.00004727572,"about_ca_system_score_gemma":0.000115450566,"threshold_uncertainty_score":0.56487125},"labels":[],"label_agreement":null},{"id":"W4206049855","doi":"10.1016/j.leukres.2022.106788","title":"Characterizing Frailty In Myeloproliferative Neoplasms: results from the ORCHID study","year":2022,"lang":"en","type":"letter","venue":"Leukemia Research","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University; Population Health Research Institute; University of Ottawa; Queen's University","funders":"","keywords":"Medicine; Grip strength; Internal medicine; Gerontology; Physical therapy","score_opus":0.1357372759358897,"score_gpt":0.38400832411243013,"score_spread":0.24827104817654044,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4206049855","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.46454546,0.00047225863,4.967621e-7,0.52171135,0.0004151475,0.00589494,0.0012996261,0.00008188186,0.005578862],"genre_scores_gemma":[0.42524424,0.0015391636,0.00026450047,0.51486254,0.013250914,0.012085353,0.012914459,0.00048485142,0.019353949],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9871048,0.0038514875,0.0013272443,0.0021504627,0.0039086672,0.001657392],"domain_scores_gemma":[0.9885152,0.008231792,0.00031726537,0.0022323504,0.00047216855,0.00023125081],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.003333991,0.0008537315,0.0015112638,0.0007395694,0.0010177494,0.00033011462,0.0010508773,0.0007687737,0.0021286458],"category_scores_gemma":[0.002068776,0.00057248375,0.00030149962,0.0015241657,0.00035042883,0.00015118853,0.0011023483,0.01500738,0.00050994055],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0033699558,0.00093478383,0.031742174,0.000083805455,0.0009425458,0.01594847,0.01757714,0.00001135008,0.00010661132,0.000034406374,0.926897,0.0023517667],"study_design_scores_gemma":[0.011564992,0.0032703718,0.102082506,0.00056530454,0.00017853477,0.00006951599,0.0044888915,0.00017600626,0.000511138,0.00020396442,0.876251,0.00063780526],"about_ca_topic_score_codex":0.010766029,"about_ca_topic_score_gemma":0.0020286515,"teacher_disagreement_score":0.070340335,"about_ca_system_score_codex":0.005467833,"about_ca_system_score_gemma":0.0034392998,"threshold_uncertainty_score":0.99967265},"labels":[],"label_agreement":null},{"id":"W4206183925","doi":"10.22541/au.162845186.63975031/v1","title":"HEREDITARY HEMOCHROMATOSIS AND JAK2-POSITIVE POLYCYTHEMIA VERA","year":2021,"lang":"en","type":"preprint","venue":"","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Saskatchewan","funders":"","keywords":"Polycythemia vera; Transferrin saturation; Hemochromatosis; Hereditary hemochromatosis; Medicine; Gastroenterology; Phlebotomy; Ferritin; Genetic testing; Internal medicine; Bloodletting; Mutation; Genetics; Gene; Pathology; Serum ferritin; Biology","score_opus":0.013111481693719696,"score_gpt":0.2657244088654796,"score_spread":0.2526129271717599,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4206183925","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9644709,0.005367294,0.00009570318,0.0062641855,0.0005003583,0.00092270254,0.00010482003,0.000118706674,0.022155335],"genre_scores_gemma":[0.9860647,0.0018337307,0.006948772,0.0019152687,0.00043017685,0.00026240936,0.000785099,0.000057540456,0.0017023381],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9980567,0.00006396248,0.00035489604,0.0008601222,0.0003568237,0.00030751442],"domain_scores_gemma":[0.9986863,0.00016916633,0.00010396093,0.000540387,0.00018207783,0.00031810842],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00008115497,0.00049166207,0.0009130541,0.00010461982,0.000100127836,0.00010542264,0.0000711911,0.00038892828,0.0013999245],"category_scores_gemma":[0.000049033977,0.00039090574,0.00024028157,0.00008718831,0.00009592204,0.00005585243,0.00052838324,0.0005514859,0.00003780886],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0022832341,0.011221155,0.6633908,0.0071379035,0.025863148,0.033110306,0.013413439,0.00005144718,0.009406336,0.005507847,0.13869286,0.08992153],"study_design_scores_gemma":[0.009373442,0.0017740476,0.60564697,0.0068489583,0.003889541,0.0042535933,0.0025777055,0.00085210206,0.35913074,0.00080615573,0.0027156027,0.00213113],"about_ca_topic_score_codex":0.00041204324,"about_ca_topic_score_gemma":0.00006170077,"teacher_disagreement_score":0.34972438,"about_ca_system_score_codex":0.00019716988,"about_ca_system_score_gemma":0.00035638126,"threshold_uncertainty_score":0.99985427},"labels":[],"label_agreement":null},{"id":"W4206909017","doi":"10.1148/cases.20203809","title":"Extramedullary hematopoiesis","year":2020,"lang":"fr","type":"standard","venue":"","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"","keywords":"Extramedullary hematopoiesis; Haematopoiesis; Biology; Genetics; Stem cell","score_opus":0.026996753588650266,"score_gpt":0.2914812655125202,"score_spread":0.2644845119238699,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4206909017","genre_codex":"other","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"other","genre_consensus":"other","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0025927902,0.20035651,0.0016955488,0.08140043,0.0108394185,0.00386743,0.0027183346,0.00046178125,0.69606775],"genre_scores_gemma":[0.10572121,0.2741001,0.03404567,0.042513527,0.030853068,0.0020028886,0.007472061,0.0010272348,0.50226426],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99532443,0.00019307689,0.0010052812,0.0012752285,0.0011455856,0.0010563855],"domain_scores_gemma":[0.99669445,0.00074458146,0.00026953232,0.000741539,0.00032686765,0.0012230389],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.00021552792,0.0011553273,0.002240857,0.00017793731,0.00026974635,0.00012830188,0.00026256547,0.0008689791,0.062416602],"category_scores_gemma":[0.0004753819,0.00091632357,0.0008003668,0.0004276418,0.00032066516,0.000098475604,0.00020512071,0.0010572427,0.009338421],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00035602768,0.001193183,0.012272143,0.0033871478,0.0032922495,0.0049647638,0.0011785505,0.000004073408,0.000053821623,0.04560461,0.8773717,0.050321724],"study_design_scores_gemma":[0.002960265,0.0017245736,0.0020399452,0.00282074,0.0020825197,0.00032857762,0.0007258517,0.00013447217,0.004851032,0.00047339415,0.9810505,0.00080815435],"about_ca_topic_score_codex":0.00015324548,"about_ca_topic_score_gemma":0.0001261827,"teacher_disagreement_score":0.1938035,"about_ca_system_score_codex":0.00095317175,"about_ca_system_score_gemma":0.0013920008,"threshold_uncertainty_score":0.99932873},"labels":[],"label_agreement":null},{"id":"W4206925700","doi":"10.1016/j.jtct.2022.01.018","title":"Optimal Timing of Allogeneic Stem Cell Transplantation for Primary Myelofibrosis","year":2022,"lang":"en","type":"article","venue":"Transplantation and Cellular Therapy","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":16,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Hospital; University of Ottawa","funders":"","keywords":"Myelofibrosis; Medicine; Transplantation; Ruxolitinib; Cohort; Life expectancy; Internal medicine; International Prognostic Scoring System; Confidence interval; Clinical trial; Pediatrics; Myelodysplastic syndromes; Population; Bone marrow","score_opus":0.024606021570595098,"score_gpt":0.25110888320272856,"score_spread":0.22650286163213346,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4206925700","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9866166,0.001915789,0.009541214,0.00019638415,0.000060357866,0.00092643854,0.0002507061,0.000027660179,0.00046481483],"genre_scores_gemma":[0.9891227,0.006419515,0.002467215,0.0003038336,0.000024977546,0.00035547995,0.0010049095,0.000026171889,0.00027518894],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99903417,0.00006984482,0.0002740552,0.00024327346,0.00022769181,0.00015097178],"domain_scores_gemma":[0.9996004,0.000098489356,0.00009428649,0.00009677742,0.00004373118,0.000066292974],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00015149689,0.00015364945,0.00026944836,0.00009176016,0.00019226741,0.000009548563,0.000042387244,0.0000415331,0.00020977197],"category_scores_gemma":[2.3165738e-7,0.00013856312,0.00011565308,0.000083792176,0.00002994062,0.000049223323,0.0000030116414,0.000072807874,0.0000015363828],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00908252,0.0011674309,0.021381278,0.0018670037,0.00035978554,0.00009187515,0.012603193,0.0011046011,0.8993603,0.0005207381,0.000073225216,0.052388024],"study_design_scores_gemma":[0.009552226,0.0022179612,0.028072715,0.000049976174,0.00039280966,0.00009440325,0.00056236424,0.00037749135,0.9569634,0.000023169645,0.0014797432,0.00021373208],"about_ca_topic_score_codex":0.000010734005,"about_ca_topic_score_gemma":0.0000012093645,"teacher_disagreement_score":0.057603084,"about_ca_system_score_codex":0.00003350705,"about_ca_system_score_gemma":0.00005412314,"threshold_uncertainty_score":0.565044},"labels":[],"label_agreement":null},{"id":"W4206949196","doi":"10.1182/blood-2019-131217","title":"Results from a Phase 1/2 Clinical Trial of Tagraxofusp (SL-401) in Patients with Intermediate, or High Risk, Relapsed/Refractory Myelofibrosis","year":2019,"lang":"en","type":"article","venue":"Blood","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":23,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta; Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Medicine; Monocytosis; Myelofibrosis; Refractory (planetary science); Internal medicine; Ruxolitinib; Phases of clinical research; Myeloid; Oncology; Regimen; Gastroenterology; Clinical trial; Bone marrow","score_opus":0.021539292520514345,"score_gpt":0.3020193437126692,"score_spread":0.28048005119215486,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4206949196","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9958882,0.000037917533,0.000001913279,0.000078983045,0.00045167483,0.0020469625,0.0011302237,0.000026298487,0.00033783377],"genre_scores_gemma":[0.9974808,0.0002284132,0.00087020115,0.00011874782,0.00023892007,0.00010831167,0.0006638851,0.000038685983,0.0002520104],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9970932,0.0002705941,0.0011767907,0.00065857964,0.0005041676,0.00029667458],"domain_scores_gemma":[0.997106,0.0012348031,0.00061284046,0.000673032,0.00015983095,0.00021349551],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00038248274,0.00030306805,0.0010122036,0.0001513095,0.000030185487,0.000014833165,0.00012504234,0.00023067146,0.00043596886],"category_scores_gemma":[0.00076646055,0.00018695075,0.00016926302,0.00023822898,0.000100166806,0.00010807891,0.00006164417,0.00042080204,0.00013071882],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.22816496,0.027661419,0.7375626,0.000023964676,0.00049460155,0.00005089478,0.00023446893,6.792856e-7,0.000029053104,0.0000054004017,0.0003827367,0.0053892285],"study_design_scores_gemma":[0.41723725,0.02754056,0.55255723,0.00029999125,0.00042942676,5.8026336e-7,0.000027380043,0.0000044492763,0.0013814126,0.000009517396,0.00037752764,0.00013469024],"about_ca_topic_score_codex":0.0006633217,"about_ca_topic_score_gemma":0.00038193978,"teacher_disagreement_score":0.1890723,"about_ca_system_score_codex":0.000055422188,"about_ca_system_score_gemma":0.00023312849,"threshold_uncertainty_score":0.7623631},"labels":[],"label_agreement":null},{"id":"W4207082494","doi":"10.1182/blood.v128.22.2595.2595","title":"The Risk of Venous Thromboembolism in Pregnant Women with Essential Thrombocythemia: A Systematic Review and Meta-Analysis","year":2016,"lang":"en","type":"review","venue":"Blood","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Ottawa Hospital; University of Ottawa","funders":"","keywords":"Medicine; Pregnancy; Essential thrombocythemia; Absolute risk reduction; Obstetrics; Thrombophilia; Aspirin; Low molecular weight heparin; Meta-analysis; Relative risk; Venous thromboembolism; Cohort study; Confidence interval; Thrombosis; Surgery; Internal medicine; Polycythemia vera","score_opus":0.026959144689271436,"score_gpt":0.3053683838241388,"score_spread":0.27840923913486737,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4207082494","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00015141843,0.99372745,0.0000032397918,0.000081378086,0.000010211323,0.00568412,0.00020079498,0.000012900328,0.00012847959],"genre_scores_gemma":[0.00042006906,0.9944327,0.000057034962,0.00003553498,0.000021847429,0.00479742,0.000018153347,0.000046045858,0.00017122518],"study_design_codex":"systematic_review","study_design_gemma":"meta_analysis","domain_scores_codex":[0.99664515,0.0007177487,0.0012813945,0.00054581894,0.00044601734,0.00036385065],"domain_scores_gemma":[0.99646395,0.0008925757,0.0013393029,0.0010440414,0.00012912544,0.0001309941],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00091904536,0.00059157156,0.014074948,0.00018442639,0.00009286988,0.0000279287,0.00018944971,0.00016714384,0.00011574014],"category_scores_gemma":[0.00020025334,0.00020238424,0.0012520392,0.00061151304,0.00014675509,0.000034203007,0.000076022094,0.00027611616,0.000014043307],"study_design_candidate":"meta_analysis","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000005877187,0.0009051414,0.000023979037,0.5656124,0.4317924,0.000057396177,0.00014620203,3.1314144e-8,6.1649295e-8,0.00007351028,0.000008309342,0.0013747247],"study_design_scores_gemma":[0.0007098728,0.0004291368,0.00003754966,0.13812928,0.8590019,0.0001342722,0.000018217743,8.352667e-8,0.0000048661313,0.000017887829,0.0013379406,0.00017903536],"about_ca_topic_score_codex":0.000029459832,"about_ca_topic_score_gemma":0.00006221316,"teacher_disagreement_score":0.42748308,"about_ca_system_score_codex":0.00008830217,"about_ca_system_score_gemma":0.00027874942,"threshold_uncertainty_score":0.9621353},"labels":[],"label_agreement":null},{"id":"W4210289504","doi":"10.1002/ajh.26481","title":"Chronic neutrophilic leukemia: 2022 update on diagnosis, genomic landscape, prognosis, and management","year":2022,"lang":"en","type":"article","venue":"American Journal of Hematology","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":26,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hôpital Maisonneuve-Rosemont","funders":"","keywords":"Medicine; Leukocytosis; Ruxolitinib; Monocytosis; Chronic myelomonocytic leukemia; Immunology; Oncology; Disease; Myelodysplastic syndromes; Cancer research; Bioinformatics; Myelofibrosis; Bone marrow; Internal medicine; Biology","score_opus":0.00728513728808696,"score_gpt":0.24919690401785277,"score_spread":0.2419117667297658,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4210289504","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97905934,0.00868192,0.000009276753,0.011139521,0.00018313465,0.00044920176,0.000013311413,0.000014909491,0.00044937935],"genre_scores_gemma":[0.98559713,0.011359305,0.0004842846,0.0019778905,0.00014238073,0.00035100884,0.000013494515,0.00003014145,0.00004437377],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9983733,0.00018793537,0.00049689715,0.00029403198,0.00031892635,0.0003288744],"domain_scores_gemma":[0.9988884,0.00015278059,0.0004972123,0.00021079877,0.000056411198,0.00019445266],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00022103709,0.00021787877,0.00079449045,0.00033072903,0.0001917611,0.000013698064,0.00014068582,0.00002615101,0.00053446414],"category_scores_gemma":[0.000013889755,0.00017355537,0.00014308633,0.0002646987,0.00016881146,0.000037735474,0.00015170666,0.00042981614,0.000019672598],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0012396611,0.0013383355,0.85272497,0.00019918887,0.002013195,0.0066224905,0.00033363674,0.00034753617,0.00016700079,0.012647181,0.025314424,0.09705239],"study_design_scores_gemma":[0.017343104,0.052767422,0.5822427,0.00042902355,0.002105205,0.042676676,0.002810697,0.00021264082,0.004229535,0.00065099914,0.29363456,0.0008973684],"about_ca_topic_score_codex":0.00001150118,"about_ca_topic_score_gemma":0.0000074183,"teacher_disagreement_score":0.2704822,"about_ca_system_score_codex":0.0004506289,"about_ca_system_score_gemma":0.00019151716,"threshold_uncertainty_score":0.7077383},"labels":[],"label_agreement":null},{"id":"W4213450385","doi":"10.1681/asn.2021060774","title":"Association of Clonal Hematopoiesis of Indeterminate Potential with Worse Kidney Function and Anemia in Two Cohorts of Patients with Advanced Chronic Kidney Disease","year":2022,"lang":"en","type":"article","venue":"Journal of the American Society of Nephrology","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":104,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; St. Joseph’s Healthcare Hamilton; Impact; Hamilton Health Sciences; St. Paul's Hospital; Queen's University; McMaster University; Population Health Research Institute; Thrombosis and Atherosclerosis Research Institute","funders":"Institute of Genetics; Physicians' Services Incorporated Foundation; Kidney Foundation of Canada; U.S. Department of Veterans Affairs","keywords":"Kidney disease; Medicine; Internal medicine; Renal function; Oncology; Population; Anemia","score_opus":0.0035371054996781556,"score_gpt":0.23171794228506756,"score_spread":0.22818083678538942,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4213450385","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99703175,0.00009179068,0.00003070489,0.002433607,0.000038584592,0.0002804897,0.000086577194,0.0000014567017,0.0000050411795],"genre_scores_gemma":[0.9979031,0.00012190112,0.0006589238,0.0012374644,0.000026649477,0.00001361615,0.0000137835605,0.00001069921,0.000013824079],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99856526,0.00017101692,0.00048361399,0.00012215116,0.00051866303,0.00013930329],"domain_scores_gemma":[0.9970131,0.00009605371,0.0023379691,0.00013471508,0.00029741597,0.00012073101],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00024026362,0.00011857299,0.00067827344,0.000072846975,0.000046651807,0.0000013889854,0.00007532854,0.000022741215,0.000052442694],"category_scores_gemma":[0.00005358058,0.00007655242,0.00017415266,0.00028014774,0.000341148,0.00005889944,0.000061409846,0.00021583666,2.9662802e-8],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.006613674,0.00088420924,0.9821309,0.00014853562,0.000718507,0.0000065295685,0.00039504629,0.00066662504,0.0059894645,0.0000060610437,0.0015929992,0.00084743847],"study_design_scores_gemma":[0.0074334815,0.005290102,0.98479867,0.0001381129,0.0006853644,0.000021842778,0.00031434884,0.00011812496,0.0008911992,0.0000458079,0.00020453826,0.000058379617],"about_ca_topic_score_codex":0.0000606641,"about_ca_topic_score_gemma":0.000011826254,"teacher_disagreement_score":0.0050982656,"about_ca_system_score_codex":0.0002450528,"about_ca_system_score_gemma":0.00052628363,"threshold_uncertainty_score":0.3121717},"labels":[],"label_agreement":null},{"id":"W4220835528","doi":"10.1038/s41375-022-01544-x","title":"Clinical and molecular correlates of JAK-inhibitor therapy failure in myelofibrosis: long-term data from a molecularly annotated cohort","year":2022,"lang":"en","type":"letter","venue":"Leukemia","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Toronto General Hospital; University Health Network; Health Sciences Centre; Sunnybrook Health Science Centre; Princess Margaret Cancer Centre","funders":"Princess Margaret Cancer Foundation","keywords":"Myelofibrosis; Cohort; Medicine; Internal medicine; Oncology; Ruxolitinib; Term (time); Bone marrow","score_opus":0.030032981912128946,"score_gpt":0.30582845099942824,"score_spread":0.2757954690872993,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4220835528","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9487062,0.0067461897,0.000036662837,0.040052414,0.00037539966,0.0024003189,0.001505345,0.00006307049,0.00011436757],"genre_scores_gemma":[0.60397923,0.011166507,0.002908233,0.30833974,0.0023070266,0.0018215053,0.068311416,0.00052136014,0.00064498826],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9954654,0.0004931435,0.0012142779,0.0015486374,0.00080879347,0.0004697385],"domain_scores_gemma":[0.9969494,0.00051921245,0.000459469,0.0017829492,0.00012825642,0.00016071032],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.00035445826,0.0006742262,0.0017416739,0.0002563253,0.00006627058,0.00006257359,0.00049202284,0.0010415904,0.00073708204],"category_scores_gemma":[0.00015184087,0.00057631475,0.00026061613,0.0003291307,0.00027256345,0.00011717058,0.00047569704,0.0025063218,0.000022560813],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00048770173,0.00027201328,0.81681347,0.00014674611,0.0014968795,0.0072195353,0.00010507874,0.0000026312637,0.00061864953,0.0000037969003,0.17129065,0.0015428492],"study_design_scores_gemma":[0.013097947,0.0021906893,0.88990813,0.0017350862,0.0014489779,0.00014660262,0.000039022572,0.00036519236,0.0025117046,0.00007914901,0.087503746,0.0009737616],"about_ca_topic_score_codex":0.0005592369,"about_ca_topic_score_gemma":0.00008339318,"teacher_disagreement_score":0.344727,"about_ca_system_score_codex":0.00032470463,"about_ca_system_score_gemma":0.0007111862,"threshold_uncertainty_score":0.99979496},"labels":[],"label_agreement":null},{"id":"W4220837067","doi":"10.1182/bloodadvances.2022007023","title":"1.5 million platelet count limit at essential thrombocythemia diagnosis: correlations and relevance to vascular events","year":2022,"lang":"en","type":"article","venue":"Blood Advances","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal","funders":"","keywords":"Essential thrombocythemia; Platelet; Limit (mathematics); Relevance (law); Medicine; Internal medicine; Mathematics; Political science","score_opus":0.01017278419129375,"score_gpt":0.2616825523304963,"score_spread":0.25150976813920256,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4220837067","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98201734,0.014690863,0.00005268974,0.0015347134,0.00030574828,0.00092594046,0.0001071724,0.000059349517,0.00030618845],"genre_scores_gemma":[0.98618466,0.0094063515,0.0013209621,0.0006954171,0.0001369627,0.0016063649,0.00011467815,0.000031716045,0.0005028962],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.9984248,0.00006093767,0.0002671205,0.0004858177,0.0004876383,0.00027365622],"domain_scores_gemma":[0.9991129,0.00027176682,0.000100588135,0.00026783094,0.00006475609,0.00018215957],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000115556,0.00021721181,0.00036561748,0.000087353445,0.00053450855,0.000014441802,0.00007633983,0.000040278224,0.000448717],"category_scores_gemma":[0.00012347518,0.00019173422,0.000092974515,0.00023522908,0.000040142862,0.00012435167,0.00017026278,0.00016248484,0.000047987643],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00046462563,0.0027466556,0.97081953,0.00016616166,0.0008571299,0.00032064645,0.0014857915,0.003008326,0.0020386232,0.0009796781,0.0047761486,0.0123367],"study_design_scores_gemma":[0.008736616,0.0028116202,0.25176215,0.00037883112,0.0011032256,0.00040877357,0.0004914599,0.0001975158,0.049825273,0.00058929285,0.68302387,0.0006713508],"about_ca_topic_score_codex":0.000019102032,"about_ca_topic_score_gemma":0.00006874502,"teacher_disagreement_score":0.7190574,"about_ca_system_score_codex":0.00014880652,"about_ca_system_score_gemma":0.000049541668,"threshold_uncertainty_score":0.7818694},"labels":[],"label_agreement":null},{"id":"W4220863985","doi":"10.1038/s41408-022-00639-z","title":"Cytogenetic abnormalities in essential thrombocythemia: Clinical and molecular correlates and prognostic relevance in 809 informative cases","year":2022,"lang":"en","type":"article","venue":"Blood Cancer Journal","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":17,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal","funders":"","keywords":"Karyotype; Leukocytosis; Essential thrombocythemia; Internal medicine; Gastroenterology; Medicine; Clinical significance; Biology; Pathology; Chromosome; Genetics; Polycythemia vera; Gene","score_opus":0.019627244049158665,"score_gpt":0.3221583252107662,"score_spread":0.30253108116160754,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4220863985","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9812419,0.017339481,0.0000073652327,0.00074498804,0.00013833618,0.00038595818,0.000026056381,0.000007047253,0.00010891319],"genre_scores_gemma":[0.98781115,0.011239826,0.00022204156,0.0004055293,0.00008197403,0.00019537816,0.0000058097785,0.000013527328,0.000024792571],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99858403,0.00016432047,0.0005450397,0.00019459304,0.00026087897,0.00025114988],"domain_scores_gemma":[0.9991904,0.0003811136,0.00015813866,0.0000817922,0.00005469234,0.00013388398],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00034921902,0.00016013312,0.00040886726,0.00013622762,0.00014609858,0.000040060604,0.000047094767,0.00005253329,0.00011975055],"category_scores_gemma":[0.00020234259,0.00013447397,0.000051882627,0.00015362201,0.00014010559,0.000110817884,0.0000945302,0.0006608574,7.1802833e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00030362673,0.00040233528,0.9908928,0.00006280437,0.00016244625,0.0026010766,0.0017469611,0.00019677376,0.0000759396,0.0001339145,0.00006778754,0.0033534968],"study_design_scores_gemma":[0.0144758485,0.0031599833,0.95879394,0.0006812997,0.0005308242,0.013680518,0.0029229652,0.0006192282,0.0037101593,0.00063624355,0.0004716722,0.0003173226],"about_ca_topic_score_codex":0.000106021456,"about_ca_topic_score_gemma":0.00017271965,"teacher_disagreement_score":0.0320989,"about_ca_system_score_codex":0.00008047718,"about_ca_system_score_gemma":0.00027927884,"threshold_uncertainty_score":0.54836893},"labels":[],"label_agreement":null},{"id":"W4220986315","doi":"10.1038/s41467-022-29381-7","title":"Discovery of a signaling feedback circuit that defines interferon responses in myeloproliferative neoplasms","year":2022,"lang":"en","type":"article","venue":"Nature Communications","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":25,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Toronto General Hospital; University of Toronto; University Health Network","funders":"National Institute of General Medical Sciences; Robert H. Lurie Comprehensive Cancer Center; National Cancer Institute; National Institutes of Health; U.S. Department of Health and Human Services; MPN Research Foundation; Northwestern University; Memorial Sloan-Kettering Cancer Center; U.S. Department of Veterans Affairs","keywords":"Interferon; Signal transduction; Myeloproliferative Disorders; Cancer research; Computer science; Biology; Computational biology; Immunology; Cell biology","score_opus":0.0513206644624859,"score_gpt":0.3186964757747004,"score_spread":0.2673758113122145,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4220986315","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97892094,0.009785214,0.000025954232,0.0074847126,0.00012625444,0.0008324992,0.00018242498,0.00003958876,0.0026024396],"genre_scores_gemma":[0.9953062,0.00084528327,0.0015411279,0.00082835706,0.000023928409,0.0006927359,0.00026968753,0.000028487877,0.0004642022],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99819374,0.0004905648,0.00042487527,0.0002976613,0.00037216413,0.00022099513],"domain_scores_gemma":[0.9971618,0.0012018181,0.00020577596,0.0012247876,0.00014808678,0.000057697733],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003841039,0.00021348681,0.00046599514,0.00034869288,0.00031890144,0.000031234933,0.00049875,0.00013132107,0.0000947554],"category_scores_gemma":[0.0003076124,0.00018920706,0.00014628774,0.0006093235,0.00015207217,0.00016281958,0.0005290047,0.0012386014,0.0000063218704],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0019632182,0.0032515011,0.89600796,0.00008937359,0.00043032237,0.000047975092,0.0067141564,0.00014232786,0.014730525,0.07339958,0.0016447456,0.0015783344],"study_design_scores_gemma":[0.010047624,0.003620085,0.82221204,0.001013749,0.00057402445,0.00043028235,0.011828736,0.0009267833,0.121859916,0.0035028497,0.022955934,0.0010279693],"about_ca_topic_score_codex":0.00006918576,"about_ca_topic_score_gemma":0.0006236462,"teacher_disagreement_score":0.10712939,"about_ca_system_score_codex":0.00030955562,"about_ca_system_score_gemma":0.0003123718,"threshold_uncertainty_score":0.77156395},"labels":[],"label_agreement":null},{"id":"W4221017287","doi":"10.1182/blood.2021013113","title":"CRLF3 plays a key role in the final stage of platelet genesis and is a potential therapeutic target for thrombocythemia","year":2022,"lang":"en","type":"article","venue":"Blood","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":26,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sinai Health System; Lunenfeld-Tanenbaum Research Institute","funders":"Medical Research Council; Deutsche Forschungsgemeinschaft; UK Research and Innovation; British Heart Foundation; Wellcome Trust","keywords":"Platelet; Megakaryocyte; Thrombopoietin; Haematopoiesis; Cell biology; Biology; Stem cell; Thrombopoiesis; Essential thrombocythemia; Immunology","score_opus":0.02347596223597036,"score_gpt":0.268012092046979,"score_spread":0.24453612981100864,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4221017287","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9954316,0.0022729612,0.00003593715,0.00085252814,0.000021779193,0.00083354744,0.000311009,0.000008008505,0.0002326217],"genre_scores_gemma":[0.9976561,0.000109436645,0.00073007465,0.00067385467,0.000041734635,0.00055622484,0.000039382303,0.0000152699,0.0001778865],"study_design_codex":"observational","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9991324,0.000060596994,0.00018888673,0.00020951289,0.0002301945,0.00017842864],"domain_scores_gemma":[0.9995808,0.00011546023,0.00006984671,0.00017271392,0.000027055767,0.00003410829],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001942776,0.00012380122,0.00028237505,0.000059133752,0.00012541543,0.000011360515,0.0000765378,0.000034135588,0.00038517136],"category_scores_gemma":[0.000010943971,0.00008389147,0.00008225923,0.00010238385,0.000033531807,0.00002194462,0.000042481486,0.00010435224,0.0000011893156],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0050359247,0.02365763,0.77708656,0.0009903013,0.0037928158,0.000956641,0.057110976,0.00041782527,0.10651049,0.006736789,0.0031113438,0.014592731],"study_design_scores_gemma":[0.06878733,0.015254951,0.4086595,0.00012674942,0.0020860964,0.0010004333,0.0148960985,0.003186874,0.43908563,0.0030342469,0.04309583,0.0007862846],"about_ca_topic_score_codex":0.00007457607,"about_ca_topic_score_gemma":0.000012439981,"teacher_disagreement_score":0.36842704,"about_ca_system_score_codex":0.00002067635,"about_ca_system_score_gemma":0.00007605752,"threshold_uncertainty_score":0.4217356},"labels":[],"label_agreement":null},{"id":"W4221052812","doi":"10.1002/jha2.420","title":"Osteolytic lesion in polycythemia vera: First report and review of literature","year":2022,"lang":"en","type":"article","venue":"eJHaem","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Medicine; Polycythemia vera; Myelofibrosis; Internal medicine; Myeloproliferative neoplasm; Thrombocytosis; Bone pain; Essential thrombocythemia; Gastroenterology; Myeloid; Bone marrow; Surgery; Platelet","score_opus":0.015955295414443425,"score_gpt":0.2853901931935242,"score_spread":0.2694348977790808,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4221052812","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.873316,0.11373703,9.715359e-7,0.0091877375,0.000106022744,0.00067682954,0.000022892405,0.000015244594,0.002937297],"genre_scores_gemma":[0.98161197,0.015593981,0.00018065925,0.0010592315,0.00004200197,0.00022563606,0.00009861777,0.000012423338,0.0011754623],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.999138,0.000039156213,0.00028283263,0.00021317526,0.00021993044,0.00010689656],"domain_scores_gemma":[0.99949443,0.00006351353,0.00012559655,0.00022438985,0.00003684791,0.000055235705],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00022347906,0.00010219223,0.0003348828,0.00006898512,0.00006000919,0.0000044851577,0.000031339823,0.000026454094,0.00041712978],"category_scores_gemma":[0.00013283193,0.00007915096,0.000054542244,0.00024087797,0.000020561474,0.000027906568,0.000071684684,0.00016617343,0.000003040384],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0005424063,0.0014420721,0.8841812,0.013191269,0.00019343798,0.018960275,0.0041686576,0.0000063013367,0.0007780021,0.0011190184,0.056967456,0.01844992],"study_design_scores_gemma":[0.007889294,0.0028407497,0.6143709,0.042592034,0.00044437294,0.013708401,0.00037611445,0.00008210625,0.01091144,0.00024143602,0.3060112,0.00053199887],"about_ca_topic_score_codex":0.0000267331,"about_ca_topic_score_gemma":0.000012697358,"teacher_disagreement_score":0.26981032,"about_ca_system_score_codex":0.000102479484,"about_ca_system_score_gemma":0.0000647038,"threshold_uncertainty_score":0.45672783},"labels":[],"label_agreement":null},{"id":"W4221096818","doi":"10.1080/10428194.2022.2043304","title":"Momelotinib reduces transfusion requirements in patients with myelofibrosis","year":2022,"lang":"en","type":"letter","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":21,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"Sierra Oncology","keywords":"Myelofibrosis; Medicine; Blood transfusion; Intensive care medicine; Hematologic Neoplasms; Internal medicine; Cancer; Bone marrow","score_opus":0.011677659078381407,"score_gpt":0.22856058992765435,"score_spread":0.21688293084927293,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4221096818","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9670621,0.0010769828,0.0000030692468,0.023578376,0.0005950111,0.0030464078,0.0004066826,0.00023045648,0.0040008724],"genre_scores_gemma":[0.73067254,0.0037801785,0.0009889635,0.24206066,0.0020695026,0.0031599153,0.009720476,0.0008272232,0.0067205196],"study_design_codex":"not_applicable","study_design_gemma":"observational","domain_scores_codex":[0.99191236,0.00037312307,0.0014587402,0.00242021,0.0022275744,0.0016080054],"domain_scores_gemma":[0.9970912,0.0003601413,0.0006343816,0.0011937367,0.00025293115,0.00046763773],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":["metaepi_narrow"],"category_scores_codex":[0.00032642388,0.0017318543,0.0023504228,0.0010072631,0.0006143797,0.0001968367,0.0004799145,0.0013671679,0.0009649613],"category_scores_gemma":[0.000062671694,0.0014191485,0.000423304,0.0010305205,0.00036593864,0.0003818221,0.0002947982,0.0008969331,0.000065387125],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.008458223,0.0022170956,0.36199465,0.0017462798,0.0018608843,0.0059683435,0.002381618,0.00003230581,0.0001842553,0.00006781811,0.44317406,0.17191446],"study_design_scores_gemma":[0.05404688,0.0048483396,0.52793866,0.0020392684,0.0011707023,0.0003347117,0.0002130162,0.00010721676,0.0018842164,0.000057627487,0.40537775,0.0019816041],"about_ca_topic_score_codex":0.0016668394,"about_ca_topic_score_gemma":0.00008321286,"teacher_disagreement_score":0.23638959,"about_ca_system_score_codex":0.015226315,"about_ca_system_score_gemma":0.003578403,"threshold_uncertainty_score":0.99994826},"labels":[],"label_agreement":null},{"id":"W4223938136","doi":"10.1002/cncr.34195","title":"Real‐world analysis of main clinical outcomes in patients with polycythemia vera treated with ruxolitinib or best available therapy after developing resistance/intolerance to hydroxyurea","year":2022,"lang":"en","type":"article","venue":"Cancer","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":32,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Instituto de Salud Carlos III; Sierra Oncology; Sociedad Española de Hematología y Hemoterapia; Astellas Pharma; Incyte; AstraZeneca; Celgene; Sanofi","keywords":"Medicine; Ruxolitinib; Polycythemia vera; Internal medicine; Myelofibrosis; Intensive care medicine; Bone marrow","score_opus":0.03460510078697988,"score_gpt":0.3338272260981437,"score_spread":0.2992221253111638,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4223938136","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99649495,0.0002084944,0.000006508091,0.00078876683,0.000042884756,0.000985949,0.0003316409,0.000020493511,0.0011203401],"genre_scores_gemma":[0.9866192,0.00028147877,0.0012642831,0.0014766504,0.000029294075,0.0016994845,0.00010734255,0.000040261784,0.008482046],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99791193,0.0001141107,0.00057822146,0.0005532908,0.00048695036,0.00035547995],"domain_scores_gemma":[0.9988874,0.00018481167,0.00019819105,0.0004270978,0.0001511884,0.00015127732],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00019102951,0.0002814191,0.0010777301,0.00039457786,0.0000884887,0.000013675755,0.00010430366,0.000042477663,0.0022044168],"category_scores_gemma":[0.000019700341,0.00017124208,0.00012554904,0.0017953055,0.0000690922,0.000055547578,0.00003887202,0.00019727272,0.0000075475505],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.016759738,0.0008109125,0.9784084,0.000024381081,0.0019642264,0.00009200274,0.00037454837,0.0001279403,0.0000043216623,0.000025025038,0.00058192655,0.0008265981],"study_design_scores_gemma":[0.0063113626,0.0012646207,0.98475665,0.0002481016,0.00057487923,4.208243e-7,0.000064311505,0.000017399856,0.0004169885,0.0000019661447,0.0061142347,0.00022906523],"about_ca_topic_score_codex":0.0011335263,"about_ca_topic_score_gemma":0.015480412,"teacher_disagreement_score":0.0143468855,"about_ca_system_score_codex":0.000698147,"about_ca_system_score_gemma":0.0004785172,"threshold_uncertainty_score":0.9987077},"labels":[],"label_agreement":null},{"id":"W4225014393","doi":"10.1111/bjh.18213","title":"Myeloproliferative neoplasms – a global view","year":2022,"lang":"en","type":"letter","venue":"British Journal of Haematology","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hôpital Maisonneuve-Rosemont","funders":"","keywords":"Phlebotomy; Presentation (obstetrics); Medicine; Disease; Schedule; Intensive care medicine; Surgery; Pathology; Management; Economics","score_opus":0.017986190241884616,"score_gpt":0.2806940402939551,"score_spread":0.2627078500520705,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4225014393","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0716541,0.057182033,0.00008425526,0.86003554,0.003164144,0.0015608616,0.0006576541,0.000070266506,0.0055911453],"genre_scores_gemma":[0.013743703,0.016079117,0.0031800359,0.9588329,0.0049378416,0.0003288991,0.00067969796,0.00018161828,0.0020361813],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9954002,0.000663629,0.0015729966,0.0005684945,0.0010754095,0.0007192714],"domain_scores_gemma":[0.99694425,0.0003748023,0.0013578318,0.00034502574,0.0007096027,0.0002685021],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00040205815,0.00057557935,0.0030831813,0.0002454853,0.00027738695,0.00011002757,0.00038372233,0.00080945017,0.0052376594],"category_scores_gemma":[0.00039877364,0.00056655746,0.0008729336,0.00035578074,0.00023911039,0.00012978898,0.00017262985,0.0036613543,0.000095788746],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00016725501,0.00025257742,0.001494482,0.00028244194,0.0010740722,0.40434012,0.00005032336,0.0000016378032,6.258685e-7,0.00018493785,0.58791286,0.0042386474],"study_design_scores_gemma":[0.0018843585,0.0013083302,0.00053330127,0.0007366391,0.00063612347,0.4917506,0.000038056693,0.0000025887978,0.000027124315,0.0005060419,0.5023483,0.00022852911],"about_ca_topic_score_codex":0.000090282185,"about_ca_topic_score_gemma":0.0000770105,"teacher_disagreement_score":0.09879737,"about_ca_system_score_codex":0.00063384115,"about_ca_system_score_gemma":0.0012965517,"threshold_uncertainty_score":0.9996786},"labels":[],"label_agreement":null},{"id":"W4225268854","doi":"10.1002/cncr.34205","title":"Defining disease modification in myelofibrosis in the era of targeted therapy","year":2022,"lang":"en","type":"review","venue":"Cancer","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":58,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"Medical Research Council; Cancer Research UK; Rosetrees Trust; AbbVie","keywords":"Medicine; Myelofibrosis; Clinical trial; Disease; Intensive care medicine; Drug development; Bone marrow; Drug; Internal medicine; Pharmacology","score_opus":0.09511411791858394,"score_gpt":0.38955132555919575,"score_spread":0.2944372076406118,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4225268854","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0014867417,0.99610645,7.4475884e-7,0.00037760971,0.0000817266,0.0014971525,0.00019150722,0.00000740477,0.0002506727],"genre_scores_gemma":[0.004585306,0.98836833,0.000035420908,0.00025275696,0.000047717705,0.0061605065,0.00049063604,0.000028607887,0.000030742776],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99859494,0.00025412845,0.00043965917,0.00029885754,0.0002534807,0.00015891957],"domain_scores_gemma":[0.9990869,0.00028875415,0.00021083528,0.0003405318,0.000023335242,0.000049653452],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00021834917,0.00022457035,0.0009170189,0.00013596255,0.000036553363,0.000008672182,0.00012509727,0.000068058354,0.0008001419],"category_scores_gemma":[0.000055271867,0.00013344536,0.0002245494,0.0005362092,0.000030492492,0.00002566275,0.00001946535,0.00036332433,0.000006062018],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000067464585,0.00033031375,0.008287795,0.0022112585,0.0000962397,0.000025473993,0.00054627296,0.000011781555,4.248607e-7,0.00037452934,0.00032129267,0.98772717],"study_design_scores_gemma":[0.00078328385,0.00011256595,0.026453657,0.006599613,0.00032465174,0.0000024229778,0.00006357167,0.000018732415,0.000007340273,0.000028696164,0.96544963,0.00015581677],"about_ca_topic_score_codex":0.00022028251,"about_ca_topic_score_gemma":0.000044912238,"teacher_disagreement_score":0.98757136,"about_ca_system_score_codex":0.0003757334,"about_ca_system_score_gemma":0.00063865236,"threshold_uncertainty_score":0.8760993},"labels":[],"label_agreement":null},{"id":"W4225657301","doi":"10.55519/jamc-02-9227","title":"DIFFERENT SHAPES OF MEGAKARYOCYTES IN ESSENTIAL THROMBOCYTHEMIA","year":2022,"lang":"en","type":"article","venue":"Journal of Ayub Medical College Abbottabad","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University","funders":"","keywords":"Essential thrombocythemia; Medicine; Myeloproliferative neoplasm; Biopsy; Pathology; Bone marrow; Myeloproliferative Disorders; Megakaryocyte; Myelofibrosis; Platelet; Neoplasm; Internal medicine; Haematopoiesis; Stem cell","score_opus":0.010789093814883632,"score_gpt":0.2833429085470271,"score_spread":0.27255381473214346,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4225657301","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9903668,0.0021384198,0.000038962655,0.005796058,0.0003737321,0.00031802827,0.00004304017,0.000007791144,0.00091717445],"genre_scores_gemma":[0.9980001,0.0005777955,0.00045221782,0.0005034107,0.00024333049,0.0000290531,0.000007787855,0.00002185941,0.00016448945],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9961209,0.00021853902,0.0011266939,0.00020298533,0.0020396619,0.00029121854],"domain_scores_gemma":[0.9983309,0.0004670385,0.00048454883,0.00015449736,0.0001829204,0.00038010752],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0007950903,0.00021639837,0.0010590081,0.0003533486,0.000101309764,0.000007153796,0.00024704073,0.00009966076,0.0057845544],"category_scores_gemma":[0.00050754356,0.00015034099,0.00034142614,0.0003899844,0.00012546626,0.00008149255,0.00017159538,0.0008237858,0.0000032874398],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.01017269,0.030661685,0.805625,0.00092730054,0.0039041399,0.02947457,0.0050684744,0.00030735132,0.022337211,0.01917136,0.060225487,0.012124696],"study_design_scores_gemma":[0.058873847,0.019227589,0.77948546,0.0025976577,0.0015707953,0.011252864,0.0071538975,0.0032805982,0.08823039,0.0019797483,0.025394319,0.000952853],"about_ca_topic_score_codex":0.00002395386,"about_ca_topic_score_gemma":0.000047908485,"teacher_disagreement_score":0.06589317,"about_ca_system_score_codex":0.0003076212,"about_ca_system_score_gemma":0.0007322814,"threshold_uncertainty_score":0.9951243},"labels":[],"label_agreement":null},{"id":"W4230800436","doi":"10.1002/ajh.25128","title":"Issue Information – Table of Contents","year":2018,"lang":"en","type":"paratext","venue":"American Journal of Hematology","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Table (database); Citation; Information retrieval; Computer science; Table of contents; World Wide Web; Library science; Database","score_opus":0.012158247047930275,"score_gpt":0.29746320147343985,"score_spread":0.28530495442550957,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4230800436","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.7173594,0.016102506,0.002758543,0.015258723,0.014400245,0.0024097173,0.0005914297,0.000030666703,0.23108874],"genre_scores_gemma":[0.9702319,0.0050404053,0.005505543,0.003057515,0.00097111566,0.000038127368,0.00026880056,0.000060294966,0.014826321],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99812996,0.00009320539,0.001111443,0.00011217555,0.00032051225,0.00023270807],"domain_scores_gemma":[0.995711,0.00015942927,0.0026289416,0.00021892154,0.001120433,0.00016125606],"candidate_categories":["insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.00014409063,0.00024096614,0.0018588263,0.00037524203,0.000032756623,0.000009442054,0.00013640583,0.0001397294,0.0035221614],"category_scores_gemma":[0.00015601795,0.00017023864,0.0002105091,0.0002084012,0.00041572336,0.00013351008,0.000033424112,0.00030292163,0.0019102488],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00083423953,0.00038864397,0.0075355787,0.00033426384,0.0014167282,0.00008203731,0.0005573465,0.0000038695002,0.000059883245,0.00018340637,0.9796249,0.008979047],"study_design_scores_gemma":[0.0030670464,0.010135679,0.0011639645,0.0012531277,0.00059836806,0.0052836156,0.0009604969,0.000009195697,0.014845833,0.00002412384,0.9624495,0.000209045],"about_ca_topic_score_codex":0.000089733694,"about_ca_topic_score_gemma":0.0000034144098,"teacher_disagreement_score":0.25287244,"about_ca_system_score_codex":0.000082033526,"about_ca_system_score_gemma":0.00039700768,"threshold_uncertainty_score":0.99886686},"labels":[],"label_agreement":null},{"id":"W4237747876","doi":"10.1182/blood.v128.22.4263.4263","title":"Impact of Genomic Alterations on Outcomes in Myelofibrosis Patients Undergoing JAK1/2 Inhibitor Therapy","year":2016,"lang":"en","type":"article","venue":"Blood","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University Health Network; Princess Margaret Cancer Centre; Ontario Institute for Cancer Research; University of Toronto","funders":"","keywords":"Myelofibrosis; Ruxolitinib; Medicine; International Prognostic Scoring System; Oncology; Internal medicine; Population; Myeloid; Bone marrow; Myelodysplastic syndromes","score_opus":0.01812504723493484,"score_gpt":0.28604574830719215,"score_spread":0.2679207010722573,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4237747876","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99845177,0.00006405041,0.000004161955,0.00044595535,0.00004923417,0.00050162734,0.000062021434,0.00001556961,0.00040563318],"genre_scores_gemma":[0.9992199,0.00023274121,0.00017964885,0.00009919127,0.000045263158,0.00007482835,0.000016371958,0.000019390924,0.00011268368],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99912274,0.000038587346,0.00028253175,0.0002084495,0.00016832682,0.00017937146],"domain_scores_gemma":[0.99929655,0.00025837737,0.00008796808,0.00021704944,0.000062347026,0.000077688586],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000046064633,0.0001618087,0.00032132326,0.00014509812,0.000035604236,0.000008911916,0.0000390692,0.000051186194,0.00016915839],"category_scores_gemma":[0.000068966816,0.000085570035,0.0001518783,0.00007753616,0.00002368737,0.000059084352,0.000014825803,0.00004468543,0.000052254563],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00012995466,0.0039692977,0.979401,0.0000078457215,0.0002731802,0.000004517566,0.00017191337,0.0000026937605,0.012926273,0.00008768604,0.00008024269,0.0029454075],"study_design_scores_gemma":[0.013466055,0.003111432,0.94146484,0.00017311447,0.0000397174,0.0000012735167,0.000005900038,0.0000010594923,0.04159084,0.000040191273,0.000021298014,0.00008427704],"about_ca_topic_score_codex":0.00005188263,"about_ca_topic_score_gemma":0.00004990519,"teacher_disagreement_score":0.037936144,"about_ca_system_score_codex":0.00012744512,"about_ca_system_score_gemma":0.00011260644,"threshold_uncertainty_score":0.34894446},"labels":[],"label_agreement":null},{"id":"W4239376504","doi":"10.1182/blood-2019-122506","title":"Dynamic and Time-to-Event Analyses Demonstrate Marked Reduction in Transfusion Requirements for Janus Kinase Inhibitor-Naïve Myelofibrosis Patients Treated with Momelotinib Compared Head to Head with Ruxolitinib","year":2019,"lang":"en","type":"article","venue":"Blood","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sierra Wireless (Canada)","funders":"","keywords":"Ruxolitinib; Anemia; Myelofibrosis; Medicine; Hepcidin; Internal medicine; Gastroenterology; Bone marrow","score_opus":0.022464254339492215,"score_gpt":0.30306630699863457,"score_spread":0.28060205265914234,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4239376504","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9937907,0.000053939144,0.000034054,0.00045174157,0.000033560602,0.0050949617,0.0001465002,0.000051423125,0.00034311364],"genre_scores_gemma":[0.99564224,0.000023651806,0.0026667546,0.00009439564,0.00002390779,0.00066293986,0.0004473454,0.00005133701,0.00038741893],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9978613,0.00008724912,0.00047629754,0.0007405192,0.00038338357,0.00045124625],"domain_scores_gemma":[0.9989381,0.00006747107,0.000121818266,0.00029653707,0.00022713175,0.00034894628],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0001341798,0.0003977392,0.0007148176,0.00034668497,0.000101406054,0.000041220803,0.000054671505,0.000089333895,0.00005983351],"category_scores_gemma":[0.000020733407,0.00028758653,0.000073929565,0.00051202124,0.000042213418,0.00012018386,0.000022291728,0.00009975748,0.00004113842],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.011250871,0.00524652,0.9253787,0.00023909817,0.00056852505,0.000036356323,0.00061848434,0.00014500131,0.05200816,0.000004089072,0.00007336888,0.0044308244],"study_design_scores_gemma":[0.032645963,0.013173289,0.8790168,0.0017309673,0.0007175668,0.000036545658,0.00019774369,0.0004400452,0.07153517,0.000004647646,0.00009288758,0.0004083372],"about_ca_topic_score_codex":0.00028692553,"about_ca_topic_score_gemma":0.00038042726,"teacher_disagreement_score":0.046361867,"about_ca_system_score_codex":0.00017784578,"about_ca_system_score_gemma":0.00009306447,"threshold_uncertainty_score":0.9999576},"labels":[],"label_agreement":null},{"id":"W4240441585","doi":"10.1038/s41375-021-01396-x","title":"Correction: Efficacy and safety of a novel dosing strategy for ruxolitinib in the treatment of patients with myelofibrosis and anemia: the REALISE phase 2 study","year":2021,"lang":"en","type":"erratum","venue":"Leukemia","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"St. Paul's Hospital; University of British Columbia","funders":"","keywords":"Ruxolitinib; Myelofibrosis; Dosing; Anemia; Medicine; Internal medicine; Intensive care medicine; Bone marrow","score_opus":0.029868034284706118,"score_gpt":0.3113404190433497,"score_spread":0.28147238475864356,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4240441585","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9894061,0.0017895474,0.000014760422,0.0001823909,0.000699758,0.0060772416,0.0006035872,0.000008878966,0.0012177255],"genre_scores_gemma":[0.99223775,0.0022067076,0.00016573496,0.00008716643,0.00032395445,0.0011605696,0.0015168922,0.000051084575,0.002250124],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99831456,0.00011820813,0.00053528947,0.0004653248,0.00034465818,0.00022193798],"domain_scores_gemma":[0.99812186,0.0007933202,0.00035545367,0.0004340506,0.00022624366,0.00006908758],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00016643085,0.00038190396,0.0009075518,0.00009105818,0.0001402976,0.000035709163,0.000068625806,0.00018896819,0.000012650799],"category_scores_gemma":[0.000069366135,0.00018668838,0.00008982488,0.00023437016,0.00015538513,0.000035940513,0.000022166956,0.0002549671,7.848835e-8],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.045849044,0.10805702,0.3948362,0.0038944483,0.005833689,0.00032297333,0.07009809,0.00023731244,0.000115648065,0.00049325026,0.09937355,0.2708888],"study_design_scores_gemma":[0.10061203,0.04442054,0.8214852,0.002459423,0.0035028066,0.000057541576,0.007188332,0.00031593366,0.00046818727,0.000007022647,0.019075785,0.0004072005],"about_ca_topic_score_codex":0.0006064051,"about_ca_topic_score_gemma":0.0005375994,"teacher_disagreement_score":0.42664903,"about_ca_system_score_codex":0.00036118677,"about_ca_system_score_gemma":0.00052718946,"threshold_uncertainty_score":0.7612931},"labels":[],"label_agreement":null},{"id":"W4241096387","doi":"10.3324/haematol.2013.092155","title":"Efficacy, safety and survival with ruxolitinib in patients with myelofibrosis: results of a median 2-year follow-up of COMFORT-I","year":2013,"lang":"en","type":"article","venue":"Haematologica","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":162,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"Incyte","keywords":"Ruxolitinib; Myelofibrosis; Medicine; Hazard ratio; Placebo; Internal medicine; Randomized controlled trial; Confidence interval; Janus kinase 2; Myeloproliferative neoplasm; Anemia; Surgery; Gastroenterology; Bone marrow; Pathology","score_opus":0.012935383039976026,"score_gpt":0.23148396466348847,"score_spread":0.21854858162351246,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4241096387","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9948586,0.000045006193,0.000006080428,0.00043224462,0.000025303512,0.0012542229,0.00007461903,0.000019831798,0.0032840655],"genre_scores_gemma":[0.9977701,0.00008117505,0.0018402023,0.000039328912,0.000007167125,0.00008072748,0.000103306695,0.000015830123,0.000062199935],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99843997,0.00008031667,0.0005347045,0.0003234472,0.00036040452,0.0002611691],"domain_scores_gemma":[0.99877197,0.0003075204,0.00026213698,0.00029418955,0.00021381353,0.00015039933],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00013840027,0.00021760724,0.0009064147,0.000103088605,0.00003601157,0.000007613349,0.00006599456,0.000100723555,0.00010961078],"category_scores_gemma":[0.00014335552,0.00012023922,0.000047332134,0.00020908364,0.0002320722,0.00006210508,0.000042244646,0.000109168446,0.00000958961],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.009075544,0.0008751877,0.987075,0.00013620137,0.00016027251,0.000032902175,0.00053707475,0.0000018588769,0.00001172262,0.00081734447,0.00013803534,0.0011388697],"study_design_scores_gemma":[0.02726137,0.003688028,0.9662166,0.00063485344,0.00009803639,0.000017348006,0.00030019772,0.00000937794,0.0015085173,0.000032899658,0.00010437411,0.00012835773],"about_ca_topic_score_codex":0.00032933953,"about_ca_topic_score_gemma":0.00030237573,"teacher_disagreement_score":0.020858347,"about_ca_system_score_codex":0.000024218556,"about_ca_system_score_gemma":0.000059869926,"threshold_uncertainty_score":0.4903213},"labels":[],"label_agreement":null},{"id":"W4244094686","doi":"10.4274/tjh.2018.0267","title":"A case of SF3B1 positive myelodysplastic/myeloproliferative neoplasm with ring sideroblasts and thrombocytosis","year":2018,"lang":"en","type":"article","venue":"Turkish Journal of Hematology","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Western University","funders":"","keywords":"Medicine; Thrombocytosis; Myeloproliferative neoplasm; Myelodysplastic syndromes; Internal medicine; Pathology; Myelofibrosis; Bone marrow; Platelet","score_opus":0.01506314087287462,"score_gpt":0.2774147001245811,"score_spread":0.26235155925170645,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4244094686","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99604124,0.000583473,0.00065208727,0.0009715409,0.00012359025,0.00035489377,0.000017288863,0.000012865066,0.0012430057],"genre_scores_gemma":[0.99177635,0.00012027506,0.007600349,0.00026571006,0.00016502368,0.000012725137,0.0000027132473,0.000030801588,0.000026079873],"study_design_codex":"observational","study_design_gemma":"case_report","domain_scores_codex":[0.9982202,0.0001289535,0.0007548035,0.00028579173,0.00027186805,0.0003383842],"domain_scores_gemma":[0.9972187,0.00060963636,0.0006833347,0.0001812161,0.0010251644,0.000281927],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00022066214,0.00031432512,0.0012419224,0.00029354246,0.00015215164,0.000022625516,0.000069278394,0.00014450582,0.00010681277],"category_scores_gemma":[0.00021267401,0.00020751149,0.00011113915,0.00021641207,0.0005903357,0.00017395796,0.00005869325,0.00031718562,0.000009996879],"study_design_candidate":"case_report","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.017400227,0.0046274285,0.68745035,0.0015088777,0.012821447,0.16595304,0.038531005,0.000054070293,0.017678717,0.039407067,0.0027179595,0.011849803],"study_design_scores_gemma":[0.008954521,0.012631667,0.044653818,0.0015814094,0.0011769035,0.6590523,0.0019239605,0.00020389157,0.26886144,0.0005364938,0.00009829785,0.00032529037],"about_ca_topic_score_codex":0.000029112964,"about_ca_topic_score_gemma":0.0001434715,"teacher_disagreement_score":0.6427965,"about_ca_system_score_codex":0.00006833517,"about_ca_system_score_gemma":0.00025989112,"threshold_uncertainty_score":0.84620726},"labels":[],"label_agreement":null},{"id":"W4245093480","doi":"10.1007/s12288-017-0893-x","title":"58th Annual Conference of Indian Society of Hematology &amp; Blood Transfusion (ISHBT) November 2017, Guwahati, India","year":2017,"lang":"en","type":"article","venue":"Indian Journal of Hematology and Blood Transfusion","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"All-India Institute of Medical Sciences","keywords":"Hematology; Medicine; Internal medicine; Transfusion medicine; Human genetics; Blood transfusion; Biology","score_opus":0.022577315394585924,"score_gpt":0.28137077742444244,"score_spread":0.25879346202985654,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4245093480","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9934087,0.0020902324,0.00011559469,0.0030455235,0.00024027062,0.0005349657,0.00009577447,0.000009867118,0.0004591055],"genre_scores_gemma":[0.9895865,0.007872777,0.0021756187,0.00017479347,0.0000796505,0.000013081004,0.000021100803,0.000027482096,0.000049011847],"study_design_codex":"observational","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9972807,0.00018383804,0.0012777478,0.00039397855,0.0004382033,0.00042553377],"domain_scores_gemma":[0.9969792,0.00030855212,0.0012112408,0.00048822103,0.000659655,0.00035316826],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00066001294,0.0003961364,0.0016976277,0.0002972234,0.00038732594,0.000029036411,0.00031547496,0.00061900273,0.00041401715],"category_scores_gemma":[0.00014112951,0.0003026274,0.00048129246,0.00012438098,0.0007964852,0.00033199982,0.000041739444,0.00067613344,0.0000044323547],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0016071665,0.004298881,0.9401447,0.0016841599,0.0024735688,0.0022061062,0.028216707,0.0000018046911,0.013747329,0.0014119325,0.0005387229,0.0036688852],"study_design_scores_gemma":[0.031405803,0.006540618,0.40388325,0.003940133,0.0031014767,0.052376747,0.002603509,0.0000058546775,0.49368662,0.001263262,0.0005821362,0.00061059947],"about_ca_topic_score_codex":0.00012588386,"about_ca_topic_score_gemma":0.00037807334,"teacher_disagreement_score":0.5362615,"about_ca_system_score_codex":0.000014427711,"about_ca_system_score_gemma":0.00043711485,"threshold_uncertainty_score":0.9999426},"labels":[],"label_agreement":null},{"id":"W4247176307","doi":"10.1016/j.jaad.2018.05.209","title":"Analysis of incidence and geographic distribution of myeloproliferative neoplasms in Canada","year":2018,"lang":"en","type":"article","venue":"Journal of the American Academy of Dermatology","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Incidence (geometry); Distribution (mathematics); Dermatology","score_opus":0.009336622356722732,"score_gpt":0.2829380887523283,"score_spread":0.27360146639560556,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4247176307","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99330884,0.0004913417,0.000034856126,0.005951723,0.000030992767,0.0001234274,0.00004154943,8.21082e-7,0.00001647378],"genre_scores_gemma":[0.99864036,0.0007202652,0.0002041733,0.00040761495,0.000016192149,0.000002931442,0.0000022756194,0.0000043833193,0.0000017925659],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9983432,0.00019824285,0.00086004444,0.000116975854,0.0003242489,0.00015727218],"domain_scores_gemma":[0.99746925,0.0003343362,0.0017765098,0.00010325564,0.00023276587,0.00008388535],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00015774288,0.00012119169,0.0011812617,0.00032851603,0.00002902867,0.0000015049884,0.00014901593,0.000047970527,0.0000126822315],"category_scores_gemma":[0.00021691062,0.00007687713,0.00016313951,0.0011555081,0.00079882104,0.000051818508,0.00005423356,0.00024337236,1.0977839e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00034751339,0.00009077908,0.99574596,0.000029961848,0.0011384485,0.000017336724,0.00025599444,0.00003805585,0.0011409434,0.00022511014,0.00013691776,0.0008329843],"study_design_scores_gemma":[0.0006932191,0.0003219681,0.9600072,0.000114220726,0.00094621134,0.0005430723,0.0003693757,0.00047120164,0.03633005,0.00009069811,0.000061714025,0.000051079674],"about_ca_topic_score_codex":0.048778754,"about_ca_topic_score_gemma":0.06326695,"teacher_disagreement_score":0.035738766,"about_ca_system_score_codex":0.0001109134,"about_ca_system_score_gemma":0.00049351226,"threshold_uncertainty_score":0.95755553},"labels":[],"label_agreement":null},{"id":"W4248769741","doi":"10.1007/978-1-349-94186-5_567","title":"Honda Foundation","year":2018,"lang":"en","type":"book-chapter","venue":"Palgrave Macmillan UK eBooks","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Australian National University; John Simon Guggenheim Memorial Foundation; Harry Frank Guggenheim Foundation; Heart and Stroke Foundation of Canada","keywords":"Foundation (evidence); Geology; Computer science; History; Archaeology","score_opus":0.027361073924686907,"score_gpt":0.26991686662405895,"score_spread":0.24255579269937205,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4248769741","genre_codex":"other","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"other","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0016069188,0.0005220533,0.000050650033,0.00019844594,0.00050242076,0.0013071988,0.000089947884,0.00013660875,0.99558574],"genre_scores_gemma":[0.9098965,0.00026618404,0.00074639305,0.0007322825,0.0012981842,0.0001180542,0.0005732494,0.00015256362,0.08621657],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"theoretical_or_conceptual","domain_scores_codex":[0.99772316,0.000022445598,0.0005350204,0.00075340143,0.0005668893,0.00039908694],"domain_scores_gemma":[0.9981595,0.00010288126,0.00029907716,0.0007846636,0.00034182952,0.0003120316],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.00013002077,0.00069064385,0.00088122324,0.00026912827,0.00016288146,0.00006000924,0.00012871316,0.00044636507,0.009991212],"category_scores_gemma":[0.00003529516,0.00056311983,0.00038607564,0.000016049951,0.00023996572,5.08266e-7,0.000096072494,0.00032359202,0.0040101963],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":"theoretical_or_conceptual","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00027080148,0.0000036648707,0.0017704262,0.00019645119,0.0011384587,0.00040525282,0.00050190516,8.336953e-8,0.0001588441,0.950152,0.0010061837,0.044395953],"study_design_scores_gemma":[0.0027905675,0.0016611982,0.002906894,0.000997212,0.0010922882,0.00027775168,0.00002400312,0.000015656933,0.0028854376,0.8882587,0.09815783,0.0009324796],"about_ca_topic_score_codex":0.000026329355,"about_ca_topic_score_gemma":0.00012317336,"teacher_disagreement_score":0.9093692,"about_ca_system_score_codex":0.00025890436,"about_ca_system_score_gemma":0.0002236772,"threshold_uncertainty_score":0.999682},"labels":[],"label_agreement":null},{"id":"W4249803865","doi":"10.1111/ijlh.12506","title":"Congenital erythrocytosis","year":2016,"lang":"en","type":"review","venue":"International Journal of Laboratory Hematology","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":20,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Queen's University; Queen's University Belfast","keywords":"Erythropoietin; Medicine; Internal medicine","score_opus":0.035126517426067316,"score_gpt":0.38054218684600755,"score_spread":0.34541566941994023,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4249803865","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00027151004,0.9955654,0.00003829044,0.00089380704,0.002157156,0.00026586835,0.00023399205,0.000014603938,0.0005593307],"genre_scores_gemma":[0.00046209956,0.99752057,0.00044914644,0.00030411582,0.0009923116,0.000038162725,0.000028100307,0.000048603037,0.00015690475],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99752384,0.00016899627,0.0012908878,0.00024467285,0.0005626594,0.00020895683],"domain_scores_gemma":[0.99592346,0.0005085496,0.0013457596,0.00020417671,0.001798781,0.00021926832],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00021892024,0.00037175303,0.0022818658,0.00056147756,0.000029413428,0.000029805584,0.00033891323,0.0003451857,0.0009488316],"category_scores_gemma":[0.00035548236,0.00022015926,0.000703686,0.00014198749,0.00012384879,0.0001271333,0.00007163706,0.0003941977,0.0003591327],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00034960386,0.0013056166,0.0025166532,0.0033123717,0.019360203,0.017999232,0.0001124372,6.656524e-8,0.000011091313,0.013652338,0.02658517,0.9147952],"study_design_scores_gemma":[0.0013363446,0.00031487131,0.00001948644,0.011138188,0.001131271,0.013347615,0.0000115473695,9.881091e-8,0.00014132966,0.000066934546,0.97232294,0.00016935419],"about_ca_topic_score_codex":9.941891e-7,"about_ca_topic_score_gemma":0.0000025326374,"teacher_disagreement_score":0.9457378,"about_ca_system_score_codex":0.00040971424,"about_ca_system_score_gemma":0.0016027653,"threshold_uncertainty_score":0.9999644},"labels":[],"label_agreement":null},{"id":"W4250695549","doi":"10.1182/blood.v106.11.117.117","title":"X-Linked Clonality Analysis and Quantitative JAK2V617F Assessment Reveals a Strong Association between Clonality and JAK2V617F in PV but Not in ET/MMM, and Identifies a Subset of JAK2V617F Negative ET and MMM Patients with Clonal Hematopoiesis.","year":2005,"lang":"en","type":"article","venue":"Blood","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hôpital Maisonneuve-Rosemont","funders":"","keywords":"Biology; Myelofibrosis; Essential thrombocythemia; Allele; Polycythemia vera; Myeloid; Immunology; Genetics; Gene; Bone marrow","score_opus":0.02157559065515803,"score_gpt":0.32370485578322117,"score_spread":0.30212926512806315,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4250695549","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99568325,0.00045044994,0.000055863926,0.0017940389,0.000010556633,0.0010848049,0.00079896895,0.000014690342,0.000107371925],"genre_scores_gemma":[0.9937209,0.00047045437,0.005055132,0.00021900624,0.000023992328,0.00014124544,0.0003105409,0.000021354954,0.000037404512],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9966169,0.0006576938,0.00089697633,0.0007505688,0.0007163926,0.0003614933],"domain_scores_gemma":[0.9968351,0.0018092892,0.00060596655,0.00021933259,0.0003304624,0.00019985925],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0015115226,0.00039891814,0.0013525286,0.0003999421,0.0001041077,0.00009015807,0.00005551058,0.00018752775,0.000019783372],"category_scores_gemma":[0.0004373859,0.00032993435,0.00008692266,0.000547905,0.00021954958,0.00038966295,0.00011780331,0.00037432314,5.2557476e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00035403288,0.0014671956,0.99168533,0.00021864744,0.002179266,0.000015974494,0.0024646309,0.000008211142,0.00021911289,0.0011416905,0.000012311199,0.0002336027],"study_design_scores_gemma":[0.010882367,0.00071279623,0.9826659,0.0003133925,0.0019866584,0.0000045936854,0.0006781035,0.0001087043,0.0019768449,0.0003884603,0.000006424207,0.00027576348],"about_ca_topic_score_codex":0.0013711314,"about_ca_topic_score_gemma":0.007763957,"teacher_disagreement_score":0.010528334,"about_ca_system_score_codex":0.00019329894,"about_ca_system_score_gemma":0.00014533995,"threshold_uncertainty_score":0.99991524},"labels":[],"label_agreement":null},{"id":"W4254953115","doi":"10.3410/f.735422952.793580850","title":"Faculty Opinions recommendation of PTENα promotes neutrophil chemotaxis through regulation of cell deformability.","year":2020,"lang":"en","type":"dataset","venue":"Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"","keywords":"PTEN; Chemotaxis; Pseudopodia; Cell biology; Moesin; Biology; Immune system; Inflammation; Immunology; Cell; Signal transduction; Ezrin; Actin; Cytoskeleton; Receptor; Genetics; PI3K/AKT/mTOR pathway","score_opus":0.03644845062542982,"score_gpt":0.34056347790395486,"score_spread":0.304115027278525,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4254953115","genre_codex":"dataset","genre_gemma":"dataset","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"dataset","genre_consensus":"dataset","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00001198361,0.0005890635,0.000022294724,0.1975996,0.0003291713,0.0026105586,0.7986986,0.000029396562,0.00010931873],"genre_scores_gemma":[0.0002475652,0.0007079424,0.0026186868,0.0028892485,0.0002603505,0.0003582379,0.9926025,0.000033854656,0.00028161306],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99465334,0.00037831994,0.0022597732,0.0007820057,0.0016018738,0.00032468635],"domain_scores_gemma":[0.989057,0.00019143712,0.0023324764,0.0014682434,0.006644423,0.00030642594],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.000731224,0.0006351897,0.0016682561,0.00022862335,0.00016546735,0.000048896134,0.00071430416,0.00069456286,0.00052230986],"category_scores_gemma":[0.004528861,0.00038909077,0.00093393604,0.0018515405,0.00040532096,0.00033650416,0.00035206735,0.0008744554,0.00004446734],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0000653162,0.001511398,0.000059198956,0.021554569,0.0002724768,3.624612e-7,0.0002751986,1.3939233e-7,0.000031676074,0.00019051429,0.9747666,0.0012725358],"study_design_scores_gemma":[0.0016013937,0.00072120264,0.007147488,0.010710286,0.0006155523,0.00003440961,0.000032374744,0.000015855776,0.001756475,0.000052051237,0.9770362,0.00027671072],"about_ca_topic_score_codex":0.000063679756,"about_ca_topic_score_gemma":0.0000037653535,"teacher_disagreement_score":0.19471036,"about_ca_system_score_codex":0.00018862465,"about_ca_system_score_gemma":0.00072525855,"threshold_uncertainty_score":0.9998561},"labels":[],"label_agreement":null},{"id":"W4255393706","doi":"10.1111/j.1538-7836.2004.00715.x","title":"Talking About...","year":2004,"lang":"en","type":"article","venue":"Journal of Thrombosis and Haemostasis","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"World Federation of Science Journalists","funders":"","keywords":"Medicine; Aspirin; Contraindication; Polycythemia vera; Antithrombotic; Thrombosis; Internal medicine; Placebo; Population; Pulmonary embolism; Stroke (engine); Surgery; Myocardial infarction; Deep vein; Randomized controlled trial","score_opus":0.04669083122871979,"score_gpt":0.33485163727257783,"score_spread":0.288160806043858,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4255393706","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98697644,0.0021913678,0.00015745686,0.008971061,0.00015272529,0.00013581786,0.0000065892937,0.000008616527,0.0013999422],"genre_scores_gemma":[0.98724467,0.0056144535,0.0059745666,0.00093089725,0.00018945461,0.0000036588528,0.0000019502704,0.000015228927,0.000025098829],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.999014,0.000018086785,0.00038888457,0.00012498195,0.00028683068,0.00016720775],"domain_scores_gemma":[0.99920505,0.000048448437,0.0002378899,0.00011336096,0.0001895865,0.00020568236],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00018680381,0.00014287909,0.0004848479,0.00012453103,0.000111234796,0.000045959277,0.00004623054,0.00006151288,0.00017909044],"category_scores_gemma":[0.000055813405,0.00009634984,0.00017865696,0.00011800456,0.000060787213,0.00013616952,0.000025180962,0.00016536094,0.000009839548],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0009822444,0.004508582,0.7311554,0.0004463116,0.00533778,0.0010538712,0.0058984538,0.00014947931,0.009020228,0.012606255,0.01607421,0.21276717],"study_design_scores_gemma":[0.01003089,0.0025101213,0.920619,0.001211488,0.0011342264,0.0013560891,0.0006302608,0.000006887876,0.043101702,0.0017324943,0.017415356,0.00025147066],"about_ca_topic_score_codex":0.000026165279,"about_ca_topic_score_gemma":0.000008480782,"teacher_disagreement_score":0.2125157,"about_ca_system_score_codex":0.00010699218,"about_ca_system_score_gemma":0.00010488407,"threshold_uncertainty_score":0.39290324},"labels":[],"label_agreement":null},{"id":"W4256282437","doi":"10.1182/blood.v112.11.5245.5245","title":"Enhancment of SCA1 Positive Hematopoietic Progenitors in Polycythemic Mice Inhibits Leukemogenesis","year":2008,"lang":"en","type":"article","venue":"Blood","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Sciences Centre; Women's College Hospital; Sunnybrook Health Science Centre","funders":"","keywords":"Haematopoiesis; Biology; Progenitor cell; Erythropoietin; Cancer research; Immunology; Cell culture; Leukemia; Molecular biology; Stem cell; Cell biology; Endocrinology; Genetics","score_opus":0.013014085090796634,"score_gpt":0.2402509545131229,"score_spread":0.22723686942232627,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4256282437","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99631107,0.001415832,0.0000046701625,0.00024936863,0.000045879664,0.00075594586,0.00001684392,0.000023815119,0.001176598],"genre_scores_gemma":[0.9983354,0.00028306062,0.0008014319,0.00011408689,0.00007291211,0.00015977788,0.00001997728,0.000024441968,0.00018891384],"study_design_codex":"observational","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9987377,0.000043559754,0.0003755119,0.00029936957,0.0002866159,0.00025724413],"domain_scores_gemma":[0.99940705,0.00007664737,0.00010447775,0.00020183787,0.00009000125,0.000119977],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00007020273,0.00020025125,0.00043804076,0.00015358187,0.000050686303,0.000003382858,0.000053408403,0.0000819537,0.000056906494],"category_scores_gemma":[0.00003540727,0.00016648142,0.000119480625,0.00026257092,0.00007874698,0.000039975228,0.000034797802,0.00008964308,0.00003982918],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00027627827,0.0071520363,0.77051914,0.00017910526,0.00045292024,0.00065268326,0.0033419381,0.0000024189767,0.21658368,0.00013221486,0.00012682355,0.0005807922],"study_design_scores_gemma":[0.0044225133,0.0005234773,0.113313064,0.0002908306,0.00018468797,0.0006173748,0.00011196536,0.0000022684671,0.88037694,0.0000146948005,0.000023585493,0.000118627504],"about_ca_topic_score_codex":0.00009007603,"about_ca_topic_score_gemma":0.000023329414,"teacher_disagreement_score":0.6637932,"about_ca_system_score_codex":0.00009482166,"about_ca_system_score_gemma":0.00019324839,"threshold_uncertainty_score":0.6788915},"labels":[],"label_agreement":null},{"id":"W4256287645","doi":"10.4021/jmc1158e","title":"Reactive Thrombocytosis","year":2013,"lang":"en","type":"article","venue":"Journal of Medical Cases","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Medicine; Thrombocytosis; Malignancy; Surgery; Platelet; Internal medicine","score_opus":0.03716876728120244,"score_gpt":0.3320541931923071,"score_spread":0.29488542591110467,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4256287645","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9731798,0.0009358845,0.00004583567,0.02327045,0.00020760405,0.00016070328,0.0000019529848,0.000008422483,0.0021893103],"genre_scores_gemma":[0.9959045,0.00063850073,0.00062095444,0.0021437716,0.0005806046,0.000013757604,0.0000018062871,0.000010164424,0.000085911415],"study_design_codex":"not_applicable","study_design_gemma":"observational","domain_scores_codex":[0.99816376,0.00005100632,0.0003983121,0.00009313914,0.0011374919,0.00015627457],"domain_scores_gemma":[0.9984168,0.00041749468,0.00019468273,0.00010449793,0.00033062746,0.00053589855],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0002844398,0.00011016302,0.0004251982,0.000088276436,0.000039937597,0.00002108357,0.00007967509,0.00010716881,0.010125254],"category_scores_gemma":[0.0015889413,0.0000628657,0.00016924113,0.0000891841,0.00008011197,0.00012876629,0.000024921037,0.00032189555,0.00014166615],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000598343,0.0049901856,0.3315264,0.0001609778,0.0013670058,0.020715224,0.0010211631,0.0000013260982,0.002236089,0.0016127916,0.5154841,0.1202864],"study_design_scores_gemma":[0.012729748,0.011754218,0.8123385,0.0022960985,0.0011558031,0.055240333,0.0036696186,0.00014675163,0.043327514,0.0012193375,0.055708185,0.00041390306],"about_ca_topic_score_codex":0.0001003435,"about_ca_topic_score_gemma":0.000006092027,"teacher_disagreement_score":0.4808121,"about_ca_system_score_codex":0.000089346584,"about_ca_system_score_gemma":0.00029049095,"threshold_uncertainty_score":0.99077964},"labels":[],"label_agreement":null},{"id":"W4280581414","doi":"10.1016/j.leukres.2022.106858","title":"Genetic changes during leukemic transformation to secondary acute myeloid leukemia from myeloproliferative neoplasms","year":2022,"lang":"en","type":"article","venue":"Leukemia Research","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Princess Margaret Cancer Centre","funders":"National Research Foundation of Korea; Ministry of Health and Welfare; Ministry of Science, ICT and Future Planning; National Natural Science Foundation of China; Natural Sciences and Engineering Research Council of Canada; Princess Margaret Cancer Foundation","keywords":"Myeloid leukemia; Cancer research; Myeloid; Biology; Allele; Mutation; Myeloproliferative Disorders; Gene; Spliceosome; Malignant transformation; Internal medicine; Genetics; Oncology; Immunology; Medicine; RNA splicing","score_opus":0.03371642877177031,"score_gpt":0.32196012770747157,"score_spread":0.28824369893570123,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4280581414","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.985166,0.0008289377,0.00006948295,0.0056862948,0.00028683495,0.003019279,0.0005716137,0.00018379923,0.004187767],"genre_scores_gemma":[0.9865021,0.00091301964,0.0015783128,0.0015142513,0.00058314775,0.004390759,0.00055424985,0.00012357034,0.003840589],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.99393564,0.00063680334,0.00066321925,0.0011674194,0.0022444883,0.0013524219],"domain_scores_gemma":[0.9974187,0.00045843463,0.00011487016,0.0008434219,0.00041858578,0.0007459943],"candidate_categories":["metaepi_narrow","sts","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00078072195,0.00053060043,0.0008014223,0.00096055435,0.0016565868,0.00015998643,0.00048708674,0.0001984869,0.0034625735],"category_scores_gemma":[0.00011148795,0.00049862213,0.00020495607,0.0014136716,0.00016156642,0.00022511811,0.0005174529,0.002078163,0.0006349076],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.019733401,0.0015399689,0.051128153,0.0010865649,0.005263323,0.007545834,0.09586547,0.008894278,0.62384343,0.003030107,0.043749783,0.13831967],"study_design_scores_gemma":[0.02079792,0.0069884663,0.47272903,0.00040035284,0.00048065902,0.0012297049,0.007937194,0.005371836,0.42710462,0.0011710544,0.054189134,0.0016000137],"about_ca_topic_score_codex":0.0015681874,"about_ca_topic_score_gemma":0.0006637296,"teacher_disagreement_score":0.42160088,"about_ca_system_score_codex":0.011740739,"about_ca_system_score_gemma":0.003378478,"threshold_uncertainty_score":0.99974656},"labels":[],"label_agreement":null},{"id":"W4280594357","doi":"10.1016/s2352-3026(22)00102-8","title":"Ruxolitinib versus best available therapy in inadequately controlled polycythaemia vera without splenomegaly (RESPONSE-2): 5-year follow up of a randomised, phase 3b study","year":2022,"lang":"en","type":"article","venue":"The Lancet Haematology","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":47,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Kingston Health Sciences Centre; Queen's University","funders":"Novartis Pharmaceuticals Corporation; Novartis","keywords":"Ruxolitinib; Medicine; Polycythaemia; Clinical endpoint; Internal medicine; Phlebotomy; Myelofibrosis; Polycythemia vera; Clinical trial; Randomized controlled trial; Pediatrics; Surgery; Bone marrow","score_opus":0.08405562557028219,"score_gpt":0.35526130428884,"score_spread":0.27120567871855783,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4280594357","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9869192,0.0012691626,0.0000031321015,0.0040841126,0.00043356078,0.0048103905,0.000081747596,0.00004469843,0.0023539695],"genre_scores_gemma":[0.99502504,0.00032283104,0.00007706755,0.00054353714,0.000102751765,0.0028542199,0.00003309102,0.00004317455,0.0009982677],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9960715,0.0016831205,0.0007735683,0.00046158605,0.00043283566,0.0005773871],"domain_scores_gemma":[0.996712,0.0019814898,0.00036253937,0.000743754,0.00009227395,0.00010789857],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0018028829,0.00033951266,0.002819989,0.00024269425,0.0002463966,0.0000127147905,0.0003181986,0.0000792102,0.0015979465],"category_scores_gemma":[0.00045833224,0.00022485925,0.00023552145,0.00035058922,0.00015361693,0.000046421355,0.00012074798,0.00047261966,0.00009207233],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.86730206,0.004748012,0.117960855,0.00003802914,0.0011194696,0.0010336905,0.003957473,0.000026237632,0.0005437927,0.0011660433,0.0017116292,0.0003926802],"study_design_scores_gemma":[0.9655591,0.016280118,0.004872672,0.00004816578,0.0005099179,0.0003856628,0.0038413492,0.00021601352,0.0021899184,0.00011108754,0.005705856,0.00028013403],"about_ca_topic_score_codex":0.000486632,"about_ca_topic_score_gemma":0.00018386525,"teacher_disagreement_score":0.11308818,"about_ca_system_score_codex":0.00017964869,"about_ca_system_score_gemma":0.00039045146,"threshold_uncertainty_score":0.9993147},"labels":[],"label_agreement":null},{"id":"W4281722646","doi":"10.1200/jco.2022.40.16_suppl.7061","title":"Thrombocytopenic myelofibrosis (MF) patients previously treated with a JAK inhibitor in a phase 3 randomized study of momelotinib (MMB) versus danazol (DAN) [MOMENTUM].","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sierra Wireless (Canada); Princess Margaret Cancer Centre","funders":"Sierra Oncology","keywords":"Medicine; Myelofibrosis; Gastroenterology; Internal medicine; Placebo; Clinical endpoint; Anemia; Danazol; Randomization; Randomized controlled trial; Surgery; Bone marrow; Pathology","score_opus":0.09404202623910829,"score_gpt":0.4406790425051299,"score_spread":0.3466370162660216,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4281722646","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99474365,0.00020893116,0.0000039323513,0.0007095386,0.00058641454,0.0032152694,0.000016166945,0.00000981532,0.00050631014],"genre_scores_gemma":[0.99848175,0.00028282253,0.00034764115,0.00024087692,0.00017391876,0.00035612678,0.000020814683,0.000033435514,0.00006263707],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99160784,0.0025299375,0.0041092196,0.00040688814,0.0009910351,0.00035507287],"domain_scores_gemma":[0.99068445,0.0048270863,0.003252943,0.00031503726,0.00054220017,0.0003782602],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0036868497,0.00031267863,0.004740037,0.00036383735,0.00009650925,0.000011107631,0.00022222291,0.00015605423,0.00037273127],"category_scores_gemma":[0.0024794561,0.00019742569,0.00060638716,0.0005182681,0.00021167984,0.0001259032,0.00015921074,0.0009770854,0.000003412883],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.53540313,0.07599532,0.3725564,0.000031372067,0.0024146975,0.00083112955,0.0012632404,0.00006512914,0.00004259235,0.000022451664,0.00038388322,0.010990667],"study_design_scores_gemma":[0.68933207,0.19761914,0.108056284,0.00012351312,0.0018988793,0.0000486694,0.0013716877,0.00006929527,0.0002015845,0.000009666782,0.0011279254,0.0001412613],"about_ca_topic_score_codex":0.00013383097,"about_ca_topic_score_gemma":0.0002136555,"teacher_disagreement_score":0.26450008,"about_ca_system_score_codex":0.0006405068,"about_ca_system_score_gemma":0.0014536559,"threshold_uncertainty_score":0.80507857},"labels":[],"label_agreement":null},{"id":"W4281780011","doi":"10.1200/jco.2022.40.16_suppl.7058","title":"Risk-adjusted safety analysis of pacritinib (PAC) in patients (pts) with myelofibrosis (MF).","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"CTI Biopharma","keywords":"Medicine; Adverse effect; Internal medicine; Ruxolitinib; Myelofibrosis; Gastroenterology","score_opus":0.0631261125869471,"score_gpt":0.40426387406868175,"score_spread":0.34113776148173464,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4281780011","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9951143,0.00014533113,0.00003714346,0.0024867237,0.00028038566,0.00031186477,0.00012352705,0.0000048200113,0.0014958702],"genre_scores_gemma":[0.99618554,0.00056971866,0.0020840121,0.00088837167,0.000118780874,0.00001922732,0.00004344002,0.00001588009,0.00007503825],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9945131,0.0012565418,0.0029670869,0.00026352087,0.00075465883,0.0002450687],"domain_scores_gemma":[0.992902,0.0031576105,0.0027927884,0.00025045866,0.0006028746,0.0002942926],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.002948321,0.00017485174,0.00263214,0.00057577516,0.00008060869,0.0000043539635,0.00014973075,0.00016853845,0.0011319059],"category_scores_gemma":[0.0020657547,0.00011665452,0.00073808734,0.0011031386,0.00014774232,0.00006936301,0.000090546135,0.0010649866,0.000003245541],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.011747872,0.008658776,0.9109757,0.000014023541,0.0036865233,0.0002537821,0.00021758825,0.0007241698,0.0000033949125,0.00006285664,0.0007579986,0.062897295],"study_design_scores_gemma":[0.018974092,0.03171677,0.9311275,0.000051371135,0.004931451,0.000022523975,0.0003535115,0.00021504008,0.000030409716,0.000024226707,0.012458451,0.00009468943],"about_ca_topic_score_codex":0.00011822521,"about_ca_topic_score_gemma":0.00034554838,"teacher_disagreement_score":0.062802605,"about_ca_system_score_codex":0.0004014559,"about_ca_system_score_gemma":0.0008274943,"threshold_uncertainty_score":0.9997812},"labels":[],"label_agreement":null},{"id":"W4282913926","doi":"10.1152/ajpcell.00187.2022","title":"Platelets and osteoblasts: secretome connections","year":2022,"lang":"en","type":"editorial","venue":"American Journal of Physiology-Cell Physiology","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Shriners Hospitals for Children - Canada","funders":"Canadian Institutes of Health Research; Canadian Network for Research and Innovation in Machining Technology, Natural Sciences and Engineering Research Council of Canada; Government of Canada","keywords":"Platelet; Proteomics; Megakaryocyte; Osteoblast; Lysyl oxidase; Cell biology; Extracellular matrix; Bone marrow; Biology; Chemistry; Biochemistry; Immunology; Haematopoiesis; Gene; Stem cell","score_opus":0.006179010608252318,"score_gpt":0.25809970611679844,"score_spread":0.2519206955085461,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4282913926","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.7698784,0.0012898126,0.000002924492,0.0007027442,0.22689126,0.00045149404,0.0003089243,0.000037992322,0.00043644448],"genre_scores_gemma":[0.6298678,0.006112943,0.000508274,0.0007512859,0.36118272,0.000137983,0.00072791625,0.0001548495,0.00055623613],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9964929,0.00060191477,0.0010044201,0.00077738875,0.00052209746,0.00060125993],"domain_scores_gemma":[0.9941204,0.0024162421,0.0019927798,0.0004970781,0.0005907054,0.00038276808],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00027907567,0.0006725824,0.0027515,0.00046599878,0.00027116042,0.000017438097,0.00030485445,0.0004021259,0.0013186656],"category_scores_gemma":[0.00035957302,0.0005311096,0.0005298299,0.0003614473,0.0010192092,0.00008833479,0.00025924278,0.0023817827,0.000037529575],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.002913619,0.0010638516,0.000092289745,0.00021517996,0.0015921,0.00016971187,0.00038985105,0.00009241922,0.20501344,0.000036099787,0.78718466,0.0012367517],"study_design_scores_gemma":[0.006178776,0.02975465,0.0058216676,0.00020121528,0.0011719058,0.00052201684,0.0012933277,0.000019025123,0.0030293665,0.0005343021,0.950788,0.0006857191],"about_ca_topic_score_codex":0.00010448044,"about_ca_topic_score_gemma":0.000007187483,"teacher_disagreement_score":0.20198408,"about_ca_system_score_codex":0.00032177256,"about_ca_system_score_gemma":0.0008873856,"threshold_uncertainty_score":0.9999198},"labels":[],"label_agreement":null},{"id":"W4283319043","doi":"10.1002/ejhf.2588","title":"Clonal haematopoiesis is associated with higher mortality in patients with cardiogenic shock","year":2022,"lang":"en","type":"article","venue":"European Journal of Heart Failure","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":59,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network; University of Toronto; Toronto General Hospital; Ontario Institute for Cancer Research; Ted Rogers Centre for Heart Research","funders":"Department of Medicine, University of Toronto; Canada First Research Excellence Fund; Canadian Institutes of Health Research; Terry Fox Foundation; Heart and Stroke Foundation of Canada","keywords":"Medicine; Hazard ratio; Internal medicine; Cardiogenic shock; Odds ratio; Heart failure; Gastroenterology; Population; Confidence interval; Ejection fraction; Myocardial infarction","score_opus":0.012861700758917082,"score_gpt":0.22691434007347677,"score_spread":0.2140526393145597,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4283319043","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9944478,0.00015486951,0.0000030162062,0.004536229,0.000077933204,0.0002649834,0.00004997629,0.000011140142,0.0004540145],"genre_scores_gemma":[0.9979667,0.0000047757203,0.0006811878,0.0009894663,0.00007596769,0.0000075896064,0.000029127325,0.000042940606,0.00020221111],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9976742,0.0005575014,0.00043026675,0.00020656097,0.00089171313,0.0002397385],"domain_scores_gemma":[0.99898845,0.000051861858,0.00033742122,0.00020165219,0.00025151498,0.00016910568],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0005563774,0.00019633514,0.0005588215,0.00014375646,0.00014099333,0.000022581919,0.00009241826,0.000017369903,0.0009541113],"category_scores_gemma":[0.000031055628,0.00012763165,0.00015451243,0.00030508297,0.000044455905,0.00008845228,0.00005352303,0.0004643485,0.000014115872],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0005829685,0.00075743726,0.9659626,0.000010547735,0.00076505635,0.0015393742,0.0002979534,0.00009559171,0.000011905821,0.000009683079,0.029911954,0.000054958513],"study_design_scores_gemma":[0.0068432256,0.0033374967,0.9641344,0.00015941514,0.00026023455,0.00021854343,0.00009992441,0.0000019198642,0.00009448028,0.000002794414,0.024714667,0.00013291913],"about_ca_topic_score_codex":0.000007767774,"about_ca_topic_score_gemma":0.000016645665,"teacher_disagreement_score":0.0062602567,"about_ca_system_score_codex":0.00022995369,"about_ca_system_score_gemma":0.00014842044,"threshold_uncertainty_score":0.9999592},"labels":[],"label_agreement":null},{"id":"W4283326697","doi":"10.1097/01.hs9.0000843684.97625.7e","title":"S198: BET INHIBITOR PELABRESIB (CPI-0610) COMBINED WITH RUXOLITINIB IN PATIENTS WITH MYELOFIBROSIS — JAK INHIBITOR-NAÏVE OR WITH SUBOPTIMAL RESPONSE TO RUXOLITINIB — PRELIMINARY DATA FROM THE MANIFEST STUDY","year":2022,"lang":"en","type":"article","venue":"HemaSphere","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Ruxolitinib; Medicine; Myelofibrosis; Internal medicine; Myeloproliferative neoplasm; Oncology; Bone marrow","score_opus":0.02699854354408923,"score_gpt":0.26657649225316404,"score_spread":0.2395779487090748,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4283326697","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98752,0.00011078471,0.000005093715,0.0027386944,0.00011482267,0.006965617,0.0019793937,0.00012546184,0.00044016395],"genre_scores_gemma":[0.99109644,0.0000051599577,0.0023340075,0.0010078531,0.00022036218,0.0022394436,0.0018130752,0.0001828154,0.0011008229],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99417955,0.00081450475,0.0007667155,0.0016132231,0.0017482511,0.0008777338],"domain_scores_gemma":[0.99543154,0.0012228308,0.00032095492,0.0022619562,0.00029390608,0.0004687997],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00065035885,0.0008062852,0.001041142,0.00013744773,0.00063385186,0.00013145221,0.000660127,0.00009377904,0.0016918296],"category_scores_gemma":[0.00018774562,0.0004491476,0.00006787417,0.0010141908,0.00017857764,0.0003120188,0.00096469064,0.0007424924,0.000077378056],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.2107571,0.008112353,0.7674115,0.00005605328,0.00047840737,0.0015802385,0.004011159,0.00008258043,0.000028945791,0.000023798055,0.0070805685,0.00037730098],"study_design_scores_gemma":[0.030587645,0.06890293,0.87971586,0.00068278133,0.0005612932,0.00009069586,0.015555069,0.0000559539,0.0003623497,0.0000042050915,0.0028492848,0.0006319398],"about_ca_topic_score_codex":0.00091009523,"about_ca_topic_score_gemma":0.0027712246,"teacher_disagreement_score":0.18016945,"about_ca_system_score_codex":0.00045555652,"about_ca_system_score_gemma":0.00076880405,"threshold_uncertainty_score":0.99979603},"labels":[],"label_agreement":null},{"id":"W4283381234","doi":"10.1097/01.hs9.0000846956.81764.f3","title":"P1022: OUTCOMES IN MYELOPROLIFERATIVE NEOPLASM PATIENTS WITH OR WITHOUT PRIOR HISTORY OF CANCER: A POPULATION-BASED STUDY FROM ONTARIO","year":2022,"lang":"en","type":"article","venue":"HemaSphere","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Health Sciences Centre; Sunnybrook Health Science Centre; Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Myeloproliferative neoplasm; Polycythemia vera; Internal medicine; Cancer; Essential thrombocythemia; Oncology; Myelofibrosis; Population; Radiation therapy; Cohort; Retrospective cohort study; Hormonal therapy; Bone marrow; Breast cancer","score_opus":0.01836061546473317,"score_gpt":0.2678379448957078,"score_spread":0.24947732943097461,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4283381234","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9961114,0.00022760156,0.0000031052264,0.0001519874,0.00020545133,0.002759572,0.00011317614,0.00003436211,0.00039336568],"genre_scores_gemma":[0.9920178,0.0000014273045,0.00094691233,0.0005075209,0.000020742164,0.0019046634,0.00020563747,0.00004458033,0.004350693],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9978123,0.00014225965,0.00051836984,0.0005167621,0.00075662014,0.00025370435],"domain_scores_gemma":[0.998878,0.00018650491,0.00029220994,0.0003788586,0.00014646446,0.000117980715],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00008806646,0.00032482058,0.00092850457,0.00010388418,0.00010823321,0.0000075916037,0.00009985512,0.00004971954,0.00612372],"category_scores_gemma":[0.000036599053,0.00022243398,0.00008504826,0.00019753336,0.000030179115,0.000071986055,0.00005688596,0.0003152511,0.0000040894797],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0028872497,0.0056987097,0.98072773,0.000033713397,0.00039761522,0.00007901537,0.0086042695,0.00039142897,0.0000032477012,0.000008174776,0.00021851384,0.0009503171],"study_design_scores_gemma":[0.015322177,0.0027183755,0.9784696,0.00011040229,0.0002555509,8.401099e-7,0.0011184437,0.000108917986,0.000048576716,0.0000056762274,0.0016095011,0.00023193502],"about_ca_topic_score_codex":0.13021606,"about_ca_topic_score_gemma":0.58880913,"teacher_disagreement_score":0.45859307,"about_ca_system_score_codex":0.004086388,"about_ca_system_score_gemma":0.0018862733,"threshold_uncertainty_score":0.9997367},"labels":[],"label_agreement":null},{"id":"W4283516342","doi":"10.1111/bjh.18329","title":"Quality of life independently predicts overall survival in myelofibrosis: Key insights from the COntrolled MyeloFibrosis Study with ORal Janus kinase inhibitor Treatment <scp>(COMFORT)‐I</scp> study","year":2022,"lang":"en","type":"letter","venue":"British Journal of Haematology","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Myelofibrosis; Ruxolitinib; Medicine; Janus; Quality of life (healthcare); Janus kinase 2; Oncology; Internal medicine; Key (lock); Cancer research; Biology; Nanotechnology; Materials science","score_opus":0.03137900389653403,"score_gpt":0.2793989253585921,"score_spread":0.2480199214620581,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4283516342","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9747208,0.007243893,0.000005844054,0.009729809,0.0010651214,0.0064650476,0.0005740795,0.000033223252,0.00016223501],"genre_scores_gemma":[0.9851122,0.00075079803,0.00013106514,0.011094001,0.0011117198,0.0011473319,0.00031762134,0.00014940387,0.00018589669],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9861765,0.005274213,0.0039835586,0.0010878124,0.002646923,0.0008310154],"domain_scores_gemma":[0.98927826,0.005214478,0.0035374733,0.0008942872,0.0006966963,0.00037878484],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.0013048378,0.0011044053,0.0075018494,0.0005944561,0.00033597497,0.00017719339,0.0006824324,0.0006720405,0.00020945257],"category_scores_gemma":[0.0012945397,0.00075422437,0.0009024209,0.00040387938,0.00030918085,0.00024055665,0.00029498583,0.0028364283,0.000005519029],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.008586106,0.019878132,0.76166236,0.00019364816,0.012477073,0.14858821,0.006288309,0.000044447417,0.000022911012,0.000012852846,0.041788895,0.00045705147],"study_design_scores_gemma":[0.15607162,0.045904186,0.7601773,0.001707432,0.004936457,0.009081952,0.0126501145,0.00001021477,0.00015163505,0.000103739134,0.008686656,0.00051870075],"about_ca_topic_score_codex":0.010096279,"about_ca_topic_score_gemma":0.014958841,"teacher_disagreement_score":0.14748552,"about_ca_system_score_codex":0.00073092093,"about_ca_system_score_gemma":0.0015099646,"threshold_uncertainty_score":0.99949086},"labels":[],"label_agreement":null},{"id":"W4283578547","doi":"10.14740/jh981","title":"Non-Hepatosplenic Extramedullary Hematopoiesis Masquerading as Metastatic Malignant Melanoma","year":2022,"lang":"en","type":"article","venue":"Journal of Hematology","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Medicine; Extramedullary hematopoiesis; Pathology; Bone marrow; Biopsy; Haematopoiesis; Melanoma; Spleen; Internal medicine; Stem cell; Cancer research","score_opus":0.01842137032251001,"score_gpt":0.2901533227007369,"score_spread":0.2717319523782269,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4283578547","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9876002,0.004209284,0.00016154342,0.0060240505,0.00046549825,0.0003635144,0.0000093940625,0.0000154198,0.0011510884],"genre_scores_gemma":[0.99412817,0.0002671838,0.0038705852,0.0011981404,0.000080089514,0.00008795654,0.000008558229,0.000035883862,0.0003234506],"study_design_codex":"observational","study_design_gemma":"case_report","domain_scores_codex":[0.9977414,0.00018319998,0.00091521407,0.00023494248,0.0005582342,0.0003670253],"domain_scores_gemma":[0.9983649,0.0003384246,0.00062674255,0.00025920224,0.00016174401,0.00024898132],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00052978686,0.00024095224,0.0011348957,0.00036686438,0.00022548936,0.000017163016,0.00017043187,0.000054200274,0.002556862],"category_scores_gemma":[0.00012685807,0.00018269161,0.00037428102,0.00024751024,0.00006288796,0.00009021699,0.00010576144,0.00047212734,0.000054973287],"study_design_candidate":"case_report","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0032422284,0.007268263,0.7209437,0.0011709199,0.0074839145,0.11202838,0.0054016854,0.00018492648,0.009634319,0.072927795,0.056450564,0.0032632954],"study_design_scores_gemma":[0.01732239,0.016410515,0.022966983,0.00080182735,0.0035128002,0.75344706,0.007565588,0.00094390847,0.1239384,0.011402505,0.040746126,0.0009419113],"about_ca_topic_score_codex":0.00001577345,"about_ca_topic_score_gemma":0.0000034535751,"teacher_disagreement_score":0.6979767,"about_ca_system_score_codex":0.00022940245,"about_ca_system_score_gemma":0.0004196993,"threshold_uncertainty_score":0.9983549},"labels":[],"label_agreement":null},{"id":"W4283733969","doi":"10.1097/01.hs9.0000846900.48214.5b","title":"P1008: ASSOCIATION BETWEEN FRAILTY AND CLINICAL OUTCOMES IN MYELOPROLIFERATIVE NEOPLAMS: A POPULATION-BASED STUDY FROM ONTARIO, CANADA","year":2022,"lang":"en","type":"article","venue":"HemaSphere","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Toronto General Hospital; Sunnybrook Health Science Centre; Health Sciences Centre; University Health Network; Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Hazard ratio; Confidence interval; Proportional hazards model; Population; Cumulative incidence; Internal medicine; Cohort; Environmental health","score_opus":0.029322913248741055,"score_gpt":0.3064895132019538,"score_spread":0.27716659995321274,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4283733969","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9960236,0.000060952512,0.0000040818495,0.0017995076,0.00018837268,0.0013635978,0.00019819544,0.000028320334,0.00033338732],"genre_scores_gemma":[0.9964623,0.0000022324232,0.00033022882,0.0010312835,0.00009159101,0.0003744776,0.00046595652,0.000023784718,0.0012181379],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9974418,0.0003619302,0.00067324046,0.00052286644,0.00072687137,0.00027326142],"domain_scores_gemma":[0.9979771,0.0012731554,0.00024191322,0.00025720955,0.0000752139,0.00017545126],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00036388045,0.00025123972,0.0008201144,0.00004547907,0.00024547632,0.000027899356,0.00006963816,0.00008894766,0.002232241],"category_scores_gemma":[0.00026398007,0.00022059339,0.00009426607,0.00017352571,0.000009728103,0.000055533455,0.00007942258,0.0005507201,0.000004597939],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000120127,0.001006981,0.9954661,0.000006243724,0.00058641133,0.00013358038,0.00091871165,0.000051429968,4.6575659e-7,0.000011069099,0.00086875533,0.0008300905],"study_design_scores_gemma":[0.0056871474,0.00073384796,0.99054545,0.000022721622,0.0002750191,9.038055e-7,0.0013548834,0.00007799405,0.000013327142,0.000058505233,0.0010384324,0.00019175213],"about_ca_topic_score_codex":0.9507717,"about_ca_topic_score_gemma":0.99540955,"teacher_disagreement_score":0.044637833,"about_ca_system_score_codex":0.0031892501,"about_ca_system_score_gemma":0.0014767324,"threshold_uncertainty_score":0.9986799},"labels":[],"label_agreement":null},{"id":"W4284895899","doi":"10.1002/ajh.26654","title":"Innovative strategies to improve hematopoietic stem cell transplant outcomes in myelofibrosis","year":2022,"lang":"en","type":"review","venue":"American Journal of Hematology","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":16,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Myelofibrosis; Medicine; Disease; Transplantation; Hematopoietic stem cell transplantation; Ruxolitinib; Stem cell; Oncology; Immunology; Internal medicine; Bone marrow; Biology","score_opus":0.028133156894663783,"score_gpt":0.32871746541423763,"score_spread":0.30058430851957385,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4284895899","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.015879383,0.9804995,0.000106922074,0.0008410651,0.00041535628,0.0014480993,0.000113251735,0.000019955132,0.0006764354],"genre_scores_gemma":[0.028387895,0.9696611,0.0009575192,0.0003847561,0.000048941896,0.0003584874,0.000025983078,0.00008563032,0.00008966628],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99605507,0.0004596144,0.002043676,0.00046720737,0.00046459073,0.00050981593],"domain_scores_gemma":[0.99636495,0.0010641005,0.0017664857,0.00036804212,0.00017193433,0.00026446386],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00036395612,0.00065718975,0.006575029,0.001085847,0.000062611885,0.000028330638,0.0003157666,0.00013796373,0.00026168508],"category_scores_gemma":[0.000029966955,0.00044150156,0.0006778216,0.0013164965,0.0001875665,0.00008279197,0.00007740435,0.0009901128,0.000031128737],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0004766116,0.0024134603,0.010002068,0.013297397,0.0028666165,0.0076911324,0.0060937693,0.0000057926813,0.000010320114,0.003047302,0.0005263398,0.9535692],"study_design_scores_gemma":[0.0047210003,0.023685442,0.000843462,0.01785743,0.0044995733,0.02484102,0.01725403,0.0000013880422,0.00040899706,0.000134694,0.9041889,0.0015640853],"about_ca_topic_score_codex":0.000042700634,"about_ca_topic_score_gemma":0.000015034643,"teacher_disagreement_score":0.9520051,"about_ca_system_score_codex":0.00041354602,"about_ca_system_score_gemma":0.0015110641,"threshold_uncertainty_score":0.99980366},"labels":[],"label_agreement":null},{"id":"W4284967068","doi":"10.1038/s41598-022-16151-0","title":"Author Correction: Increased prevalence of clonal hematopoiesis of indeterminate potential amongst people living with HIV","year":2022,"lang":"en","type":"erratum","venue":"Scientific Reports","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Manitoba; Public Health Agency of Canada","funders":"Boston Scientific Corporation; XBiotech; National Heart, Lung, and Blood Institute; Brigham and Women's Hospital; AstraZeneca; Amgen","keywords":"Indeterminate; Human immunodeficiency virus (HIV); Haematopoiesis; Medicine; Virology; Biology; Gerontology; Environmental health; Genetics; Stem cell; Mathematics","score_opus":0.009301462370544574,"score_gpt":0.2475238906587806,"score_spread":0.23822242828823603,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4284967068","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.88365823,0.0013107415,0.00007987094,0.0003718478,0.10079463,0.002403313,0.00024283663,0.000117751944,0.011020754],"genre_scores_gemma":[0.63463604,0.0000462579,0.00024465934,0.000011364938,0.0002370439,0.00027620708,0.0006244449,0.00005367933,0.36387032],"study_design_codex":"not_applicable","study_design_gemma":"observational","domain_scores_codex":[0.9947649,0.00017305069,0.0012404429,0.00131207,0.0021118755,0.00039766196],"domain_scores_gemma":[0.99541825,0.00016546773,0.002059054,0.0013288764,0.0007890097,0.00023933017],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0013522527,0.0004537002,0.0012031986,0.000563622,0.00038921167,0.00007961778,0.00018199465,0.0002543044,0.0047295196],"category_scores_gemma":[0.00053239835,0.00036224307,0.00038258758,0.00086668,0.00047438333,0.00012850696,0.0002468032,0.0006132317,0.0000052493615],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00013481281,0.0011502758,0.26717517,0.0031909277,0.000381267,0.0018486643,0.0009835353,0.000030306262,0.00044372282,0.0000069897355,0.7243991,0.00025520532],"study_design_scores_gemma":[0.0015122829,0.0024088891,0.8575773,0.011785169,0.0043224622,0.013233143,0.0012094824,0.000892404,0.022894667,0.00012595317,0.08277039,0.0012678526],"about_ca_topic_score_codex":0.00024428032,"about_ca_topic_score_gemma":0.00012471864,"teacher_disagreement_score":0.64162874,"about_ca_system_score_codex":0.00022283068,"about_ca_system_score_gemma":0.0018613458,"threshold_uncertainty_score":0.99988294},"labels":[],"label_agreement":null},{"id":"W4285733939","doi":"10.3390/curroncol29070395","title":"Management of Myelofibrosis during Treatment with Ruxolitinib: A Real-World Perspective in Case of Resistance and/or Intolerance","year":2022,"lang":"en","type":"article","venue":"Current Oncology","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Ruxolitinib; Myelofibrosis; Medicine; Myeloproliferative neoplasm; Quality of life (healthcare); Internal medicine; Intensive care medicine; Family medicine; Oncology; Bone marrow","score_opus":0.06097810189943391,"score_gpt":0.39146625107298527,"score_spread":0.33048814917355135,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4285733939","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99133325,0.0023332785,0.0000037689435,0.0006310394,0.00007801183,0.0010086407,0.0000854611,0.000013726591,0.0045128134],"genre_scores_gemma":[0.99448365,0.0025488532,0.001166665,0.000009937534,0.000022740305,0.0010474949,0.000013442569,0.000015626563,0.00069157453],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9987197,0.00013200071,0.00037429735,0.00038651776,0.00016522469,0.0002222682],"domain_scores_gemma":[0.9992658,0.00012458538,0.00021367261,0.00022479951,0.00009093456,0.000080209466],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000115172195,0.00018357209,0.00061995257,0.00023628434,0.00008841521,0.00000255509,0.000043959466,0.000023007551,0.00014905533],"category_scores_gemma":[0.000007013015,0.00013423986,0.000057432906,0.0003989284,0.00013801178,0.000028607095,0.000081716076,0.0001254435,5.657786e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.02525107,0.016581329,0.81387,0.0026189848,0.0014049481,0.027468964,0.024715124,0.00008894296,0.0003552105,0.028875481,0.00013414952,0.058635786],"study_design_scores_gemma":[0.04212343,0.021970391,0.8631305,0.0019585823,0.0011617101,0.002583909,0.037500557,0.00012518588,0.0074103195,0.00039041412,0.021083195,0.0005617798],"about_ca_topic_score_codex":0.00044627237,"about_ca_topic_score_gemma":0.0032108757,"teacher_disagreement_score":0.058074005,"about_ca_system_score_codex":0.0014341157,"about_ca_system_score_gemma":0.00014886797,"threshold_uncertainty_score":0.54741424},"labels":[],"label_agreement":null},{"id":"W4286295706","doi":"10.1200/jco.2022.40.16_suppl.7002","title":"MOMENTUM: Phase 3 randomized study of momelotinib (MMB) versus danazol (DAN) in symptomatic and anemic myelofibrosis (MF) patients previously treated with a JAK inhibitor.","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":22,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sierra Wireless (Canada); Princess Margaret Cancer Centre","funders":"Sierra Oncology","keywords":"Medicine; Anemia; Clinical endpoint; Placebo; Myelofibrosis; Gastroenterology; Internal medicine; Randomization; Hematocrit; Ruxolitinib; Randomized controlled trial; Surgery; Urology; Bone marrow; Pathology","score_opus":0.061160090670637865,"score_gpt":0.4143125339813228,"score_spread":0.3531524433106849,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4286295706","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99615157,0.0002900054,0.0000022214629,0.0005810744,0.0003259734,0.00243022,0.000010126339,0.000008470971,0.00020035279],"genre_scores_gemma":[0.99881256,0.00035276616,0.00027859467,0.00015647519,0.000099026685,0.00022792896,0.000013658273,0.000024753866,0.00003422266],"study_design_codex":"observational","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9936061,0.0018526996,0.0032379234,0.0003212004,0.0007121553,0.0002699226],"domain_scores_gemma":[0.99194205,0.0047149924,0.0024606674,0.00021550198,0.00033941437,0.00032738416],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0027843784,0.00025940148,0.0034673973,0.00033421983,0.00007826463,0.000009455363,0.00012414067,0.00012780579,0.00011512467],"category_scores_gemma":[0.0017959683,0.00016523615,0.0002995209,0.00035473544,0.0002000903,0.0000948885,0.000107897904,0.00067741214,0.0000011838358],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.36749178,0.042409264,0.57435334,0.00006183586,0.0016701281,0.00056763645,0.001408526,0.00004755302,0.000032346707,0.000011552297,0.00020706932,0.011739011],"study_design_scores_gemma":[0.70441246,0.15326704,0.13808747,0.00018171115,0.0018671291,0.000085676955,0.0014156094,0.0002126894,0.00009781309,0.0000134348875,0.00023155971,0.00012740734],"about_ca_topic_score_codex":0.00007340449,"about_ca_topic_score_gemma":0.00008098542,"teacher_disagreement_score":0.43626583,"about_ca_system_score_codex":0.00036180232,"about_ca_system_score_gemma":0.0006292471,"threshold_uncertainty_score":0.67381346},"labels":[],"label_agreement":null},{"id":"W4286299145","doi":"10.1200/jco.2022.40.16_suppl.7015","title":"Navitoclax plus ruxolitinib in JAK inhibitor-naive patients with myelofibrosis: Preliminary safety and efficacy in a multicenter, open-label phase 2 study.","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre; Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Medicine; Ruxolitinib; Myelofibrosis; Clinical endpoint; Internal medicine; Adverse effect; Phases of clinical research; Anemia; Gastroenterology; Clinical trial; Oncology; Bone marrow","score_opus":0.0949849504133424,"score_gpt":0.45899286883157475,"score_spread":0.3640079184182323,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4286299145","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99361604,0.0002808326,0.0000025387012,0.0028043478,0.0004529088,0.0024941782,0.000029533358,0.0000050280664,0.00031456005],"genre_scores_gemma":[0.99677837,0.00020239042,0.0011224836,0.0014636323,0.00018712046,0.00014893325,0.000018793939,0.000025486894,0.000052803505],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9946886,0.0013523006,0.0026605565,0.00042165318,0.0005489859,0.00032791053],"domain_scores_gemma":[0.9950601,0.00274861,0.0013436121,0.00021213802,0.00025571638,0.0003798489],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0024838634,0.00024271556,0.001977098,0.0002468962,0.00011111498,0.000021684593,0.00022878704,0.00014797898,0.00010136903],"category_scores_gemma":[0.0013586583,0.00017015336,0.000103243336,0.00028176184,0.0001408452,0.00019273302,0.000447562,0.001391714,0.0000030157262],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.12820071,0.10281509,0.7060651,0.000021647924,0.0002924073,0.0025055762,0.0015836828,0.000042088093,0.000004412832,0.000018427198,0.0003612416,0.05808963],"study_design_scores_gemma":[0.22082601,0.13646834,0.63745403,0.00024027248,0.00021469795,0.000073176634,0.0011733723,0.00014787201,0.000006848206,0.000007659313,0.003279232,0.000108482294],"about_ca_topic_score_codex":0.000111882386,"about_ca_topic_score_gemma":0.00014325586,"teacher_disagreement_score":0.092625305,"about_ca_system_score_codex":0.00076043856,"about_ca_system_score_gemma":0.001279585,"threshold_uncertainty_score":0.6938653},"labels":[],"label_agreement":null},{"id":"W4286562026","doi":"10.1038/s41375-022-01637-7","title":"Overall survival in the SIMPLIFY-1 and SIMPLIFY-2 phase 3 trials of momelotinib in patients with myelofibrosis","year":2022,"lang":"en","type":"article","venue":"Leukemia","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":63,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"Sierra Oncology","keywords":"Ruxolitinib; Myelofibrosis; Internal medicine; Medicine; Anemia; Phases of clinical research; Survival analysis; Clinical trial; Randomized controlled trial; Gastroenterology; Oncology; Bone marrow","score_opus":0.030805311245682452,"score_gpt":0.3067301174061303,"score_spread":0.27592480616044784,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4286562026","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9970007,0.00012171972,0.0000035830678,0.0005228944,0.000052749292,0.0014988763,0.00017655501,0.000009639937,0.0006132747],"genre_scores_gemma":[0.9985932,0.000037863134,0.000104863146,0.00054362556,0.000032093038,0.00047502277,0.00015345242,0.000019052959,0.00004081036],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9979404,0.00043430447,0.00059304707,0.0002974661,0.0004939612,0.00024078863],"domain_scores_gemma":[0.99865645,0.00075208175,0.00021186352,0.00026979053,0.00004480668,0.00006501336],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009756904,0.00019004417,0.0007369639,0.00015800563,0.00007579969,0.000015148946,0.000096763215,0.00004463821,0.00023161662],"category_scores_gemma":[0.0002012834,0.00011569882,0.00007182205,0.00032043425,0.000052274827,0.000055280292,0.000071827024,0.00024609666,0.0000018019333],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0030863027,0.0016854439,0.98464316,0.000059218593,0.00008903425,0.000046466143,0.0014305108,0.00014639721,0.0001603129,0.00064251217,0.00052923383,0.0074814097],"study_design_scores_gemma":[0.03245121,0.0030897358,0.96080273,0.00007200361,0.00009628789,0.0000058499418,0.00041666324,0.00008761639,0.0006629967,0.00015593773,0.0020203115,0.00013865814],"about_ca_topic_score_codex":0.00035451117,"about_ca_topic_score_gemma":0.00010010668,"teacher_disagreement_score":0.029364908,"about_ca_system_score_codex":0.00033361683,"about_ca_system_score_gemma":0.00017921269,"threshold_uncertainty_score":0.4718061},"labels":[],"label_agreement":null},{"id":"W4288067172","doi":"10.1111/jth.15834","title":"Site‐specific venous thrombosis in essential thrombocythemia: Impact on subsequent vascular events and survival","year":2022,"lang":"en","type":"letter","venue":"Journal of Thrombosis and Haemostasis","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal","funders":"","keywords":"Essential thrombocythemia; Medicine; Venous thrombosis; Antithrombotic; Thrombosis; Internal medicine; Incidence (geometry); Myelofibrosis; Polycythemia vera; Gastroenterology; Surgery; Bone marrow","score_opus":0.05252022141408907,"score_gpt":0.3322102962374395,"score_spread":0.2796900748233504,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4288067172","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8921407,0.004941944,0.0000040770537,0.10073671,0.00073223974,0.00080345577,0.0003402229,0.000016760061,0.00028389072],"genre_scores_gemma":[0.85097384,0.09873366,0.0004921337,0.04596405,0.002879904,0.00010757789,0.00048456443,0.000282147,0.0000821336],"study_design_codex":"not_applicable","study_design_gemma":"observational","domain_scores_codex":[0.99513996,0.00046430883,0.001275835,0.0007866042,0.0016151698,0.00071813894],"domain_scores_gemma":[0.99741405,0.0004886803,0.00096022116,0.00056731794,0.00024207043,0.00032763352],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.000848651,0.00090486027,0.0029644924,0.00076744886,0.00030194302,0.00013741544,0.00023245462,0.0006450567,0.0021734543],"category_scores_gemma":[0.000058649308,0.0006583104,0.0009586893,0.00036769643,0.00017575422,0.00016360104,0.00019874441,0.002829321,0.000013941863],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0015452757,0.00539392,0.20928457,0.0010045137,0.010821822,0.0042693345,0.002923821,0.000082703766,0.00077282084,0.00006829386,0.75943524,0.004397663],"study_design_scores_gemma":[0.016729927,0.015136908,0.74434674,0.0029518863,0.005346485,0.0013104455,0.0006920418,0.000022672264,0.0018959176,0.00040231275,0.20951186,0.0016528199],"about_ca_topic_score_codex":0.0002460964,"about_ca_topic_score_gemma":0.000029383174,"teacher_disagreement_score":0.5499234,"about_ca_system_score_codex":0.0011186989,"about_ca_system_score_gemma":0.00031800172,"threshold_uncertainty_score":0.9995868},"labels":[],"label_agreement":null},{"id":"W4291019728","doi":"10.2217/fon-2022-0484","title":"Phase III MANIFEST-2: Pelabresib + Ruxolitinib vs Placebo + Ruxolitinib in JAK Inhibitor Treatment-Naive Myelofibrosis","year":2022,"lang":"en","type":"article","venue":"Future Oncology","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":39,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"Medical Research Council; Rosetrees Trust; Cancer Research UK","keywords":"Ruxolitinib; Medicine; Myelofibrosis; Myeloproliferative neoplasm; Internal medicine; Placebo; Clinical trial; Oncology; Extramedullary hematopoiesis; Bone marrow; Haematopoiesis; Pathology; Stem cell","score_opus":0.02084345738915811,"score_gpt":0.3262002128301859,"score_spread":0.3053567554410278,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4291019728","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.94326353,0.001172837,0.0000036118875,0.015247025,0.0016189918,0.0028257342,0.0005351236,0.000161153,0.035172023],"genre_scores_gemma":[0.9817665,0.0006236355,0.0009754239,0.0033319762,0.0027219963,0.004087188,0.0010539826,0.0000996196,0.0053396653],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9961163,0.0005958824,0.0008407882,0.000981,0.00050574285,0.00096029113],"domain_scores_gemma":[0.99801105,0.00053539267,0.00031392032,0.0005697068,0.00011924007,0.00045065922],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0003557414,0.0006118029,0.0013653517,0.00046090354,0.00045668113,0.000029824658,0.00019688132,0.00032753334,0.0054972027],"category_scores_gemma":[0.00006628998,0.0005244421,0.00032842296,0.000514619,0.00013921194,0.00010900999,0.00019981612,0.00067820033,0.00021178547],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.1144464,0.11777818,0.19429514,0.0005935633,0.0037199643,0.027421007,0.040070064,0.00012372225,0.010716173,0.054642033,0.22458397,0.2116098],"study_design_scores_gemma":[0.091035835,0.031529568,0.017857026,0.000078013676,0.0004604751,0.0011088797,0.006282044,0.00006997532,0.0037759277,0.0001703223,0.84708345,0.00054849946],"about_ca_topic_score_codex":0.00037313107,"about_ca_topic_score_gemma":0.00049600116,"teacher_disagreement_score":0.62249947,"about_ca_system_score_codex":0.0028865614,"about_ca_system_score_gemma":0.0010342001,"threshold_uncertainty_score":0.9997207},"labels":[],"label_agreement":null},{"id":"W4291178118","doi":"10.1080/16078454.2022.2109346","title":"Prevalence of elevated hemoglobin and hematocrit levels in patients with obstructive sleep apnea and the impact of treatment with continuous positive airway pressure: a meta-analysis","year":2022,"lang":"en","type":"review","venue":"Hematology","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":22,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network; Toronto General Hospital; Women's College Hospital; Toronto Rehabilitation Institute; University of Toronto","funders":"","keywords":"Medicine; Hematocrit; Continuous positive airway pressure; Internal medicine; Meta-analysis; Obstructive sleep apnea; Hemoglobin; Subgroup analysis; Randomized controlled trial; Sleep apnea; Blood pressure; Gastroenterology","score_opus":0.034857259617766125,"score_gpt":0.311181579502665,"score_spread":0.27632431988489886,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4291178118","genre_codex":"review","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.05808963,0.93530005,0.000011803887,0.000036979858,0.0000070470446,0.0051809363,0.0012890993,0.000008883211,0.00007556685],"genre_scores_gemma":[0.52391744,0.47317556,0.00029462777,0.000013277325,0.0000040189675,0.0022547573,0.0001940641,0.000051363266,0.00009486324],"study_design_codex":"meta_analysis","study_design_gemma":"meta_analysis","domain_scores_codex":[0.9970988,0.0007547445,0.000863058,0.00069344445,0.00029744185,0.0002925129],"domain_scores_gemma":[0.9968072,0.0012886762,0.0010611798,0.0005247929,0.00021634426,0.00010177771],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00019807214,0.0006645319,0.0077174874,0.00035478317,0.000060345592,0.000008858403,0.00010209822,0.00015885022,0.0003507023],"category_scores_gemma":[0.00006210127,0.00028024142,0.0008717095,0.0006705969,0.000535274,0.000046337842,0.00008332458,0.00022836501,4.4581196e-7],"study_design_candidate":"meta_analysis","study_design_consensus":"meta_analysis","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0035295954,0.0025475407,0.29481742,0.014263732,0.6629019,0.00020519416,0.0022634435,0.000023617396,2.0726634e-7,0.001279047,0.00000771949,0.018160634],"study_design_scores_gemma":[0.016873788,0.0127181,0.0522141,0.0013936321,0.9143382,0.0009792931,0.00016196296,0.000065485314,0.000096616954,0.000039666047,0.0005577238,0.00056146394],"about_ca_topic_score_codex":0.00041605983,"about_ca_topic_score_gemma":0.000045385983,"teacher_disagreement_score":0.46582782,"about_ca_system_score_codex":0.00016226158,"about_ca_system_score_gemma":0.00024741256,"threshold_uncertainty_score":0.99996495},"labels":[],"label_agreement":null},{"id":"W4292263075","doi":"10.1177/2050313x221117643","title":"Extramedullary hematopoiesis secondary to COVID-19: A first case report in a newborn","year":2022,"lang":"en","type":"article","venue":"SAGE Open Medical Case Reports","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal; Centre Hospitalier Universitaire Sainte-Justine","funders":"","keywords":"Medicine; Extramedullary hematopoiesis; Coronavirus disease 2019 (COVID-19); Rash; Pregnancy; Dermatology; Pandemic; Skin biopsy; Biopsy; Haematopoiesis; Pathology; Stem cell; Infectious disease (medical specialty)","score_opus":0.03024810347232539,"score_gpt":0.3506642501358043,"score_spread":0.32041614666347895,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4292263075","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9472541,0.0016571153,0.0003177667,0.03466793,0.0005369232,0.004574303,0.00009882852,0.00010016855,0.010792828],"genre_scores_gemma":[0.9741913,0.00007618638,0.0024659145,0.017483298,0.0001540009,0.003605356,0.00020503874,0.000067127956,0.0017517664],"study_design_codex":"case_report","study_design_gemma":"case_report","domain_scores_codex":[0.99487025,0.00028703868,0.0015386597,0.0012298204,0.0014627073,0.0006115423],"domain_scores_gemma":[0.9949969,0.00056525273,0.0003732618,0.0012103644,0.00007821773,0.002775975],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0035071962,0.000385245,0.0010209573,0.0003039762,0.00071656285,0.00009581709,0.00015550622,0.0001707015,0.03747133],"category_scores_gemma":[0.005768587,0.00033814722,0.00019931694,0.0008134544,0.00011262842,0.00013923012,0.0012049604,0.0008674695,0.000024486464],"study_design_candidate":"case_report","study_design_consensus":"case_report","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00023262767,0.0012887372,0.02157959,0.00017990646,0.00013375955,0.9384536,0.0015634497,0.000027362132,0.000002929677,0.000029156923,0.022762952,0.013745942],"study_design_scores_gemma":[0.0017149441,0.0004269546,0.0007079871,0.00014599648,0.00009819702,0.7384717,0.0017513592,0.00004132175,0.00006258471,0.000118176715,0.25622037,0.00024042498],"about_ca_topic_score_codex":0.011037199,"about_ca_topic_score_gemma":0.013536742,"teacher_disagreement_score":0.23345743,"about_ca_system_score_codex":0.0011160237,"about_ca_system_score_gemma":0.004403538,"threshold_uncertainty_score":0.9999071},"labels":[],"label_agreement":null},{"id":"W4292457542","doi":"10.21203/rs.3.rs-1929377/v1","title":"Targeting PP2A-dependent autophagy enhances sensitivity to ruxolitinib in JAK2V617F myeloproliferative neoplasms","year":2022,"lang":"en","type":"preprint","venue":"Research Square","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Hospital","funders":"Fondation Toulouse Cancer Santé; Institut Carnot Santé Animale; Ligue Contre le Cancer","keywords":"Ruxolitinib; Autophagy; Sensitivity (control systems); Myelofibrosis; Myeloproliferative neoplasm; Cancer research; Medicine; Internal medicine; Biology; Genetics; Engineering; Apoptosis; Bone marrow","score_opus":0.06047930332577097,"score_gpt":0.41411588601614957,"score_spread":0.3536365826903786,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4292457542","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.973232,0.0022465237,0.00011700897,0.007220301,0.0006768331,0.008059134,0.00077735895,0.00020315533,0.007467689],"genre_scores_gemma":[0.98510444,0.001527004,0.001793251,0.0005358922,0.00081362156,0.006377858,0.00097648316,0.00014729805,0.0027241218],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9880632,0.0029708745,0.001128631,0.0023629037,0.003517651,0.0019567376],"domain_scores_gemma":[0.99410987,0.0023236296,0.00024286998,0.0012244921,0.001168142,0.0009309761],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.005392522,0.00088680245,0.0017400241,0.0015049033,0.00069887936,0.00029030882,0.00040282775,0.00052091415,0.002871147],"category_scores_gemma":[0.0028888143,0.00081158517,0.00038452182,0.0011808488,0.00020422804,0.0001389591,0.0030497883,0.004741149,0.00043710374],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.011090336,0.019065056,0.6973451,0.013483005,0.0035682882,0.04872399,0.06360878,0.036762945,0.023994505,0.014506736,0.031381324,0.036469974],"study_design_scores_gemma":[0.016090622,0.012805353,0.5937278,0.0124433525,0.00043143437,0.00036625698,0.038868397,0.013205918,0.2557584,0.005048553,0.045999695,0.005254199],"about_ca_topic_score_codex":0.002027563,"about_ca_topic_score_gemma":0.0015964024,"teacher_disagreement_score":0.23176388,"about_ca_system_score_codex":0.0029239394,"about_ca_system_score_gemma":0.002400499,"threshold_uncertainty_score":0.9994335},"labels":[],"label_agreement":null},{"id":"W4295004843","doi":"10.1038/s41467-022-32986-7","title":"Germline-somatic JAK2 interactions are associated with clonal expansion in myelofibrosis","year":2022,"lang":"en","type":"article","venue":"Nature Communications","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":12,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"Division of Cancer Epidemiology and Genetics, National Cancer Institute; Federal Office of Rural Health Policy; Office of Naval Research; Medical Research Council; U.S. Public Health Service; National Cancer Institute; National Institutes of Health; U.S. Department of Health and Human Services; British Heart Foundation; Wellcome Trust; U.S. Department of Defense","keywords":"Myelofibrosis; Germline; Myeloproliferative neoplasm; Biology; Germline mutation; Somatic cell; Genetics; Myeloid; Mutation; Essential thrombocythemia; Cancer research; Gene; Bone marrow; Immunology; Polycythemia vera","score_opus":0.026531949712830953,"score_gpt":0.31412676717835164,"score_spread":0.2875948174655207,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4295004843","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.969894,0.0018354125,0.000010281278,0.024133071,0.00011347926,0.0007651784,0.00014259254,0.00009693979,0.0030090294],"genre_scores_gemma":[0.99409086,0.00015671532,0.002253019,0.0011461035,0.00002125527,0.0010551735,0.0008113298,0.000025813193,0.00043973507],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9986838,0.00027462133,0.00029111974,0.00022618752,0.00034078985,0.00018346586],"domain_scores_gemma":[0.997935,0.00058450113,0.00018673991,0.0010441557,0.00016728735,0.0000823175],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00017807099,0.00016130613,0.00029875545,0.00023760517,0.0005510435,0.00002107269,0.00029514646,0.00009243302,0.0003004178],"category_scores_gemma":[0.000246229,0.000134258,0.00008546548,0.0007405158,0.000063453495,0.00008498699,0.000268518,0.0014109506,0.000013535403],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0001638843,0.00364406,0.9852809,0.000018483866,0.0002892163,0.000041061423,0.0013042471,0.00015865748,0.0006137608,0.0021065616,0.005527376,0.000851795],"study_design_scores_gemma":[0.0019278934,0.00028772885,0.9807055,0.00027935268,0.00014679194,0.000069693386,0.0010676737,0.0015373932,0.00026788548,0.00007185873,0.013472713,0.00016549596],"about_ca_topic_score_codex":0.0000374088,"about_ca_topic_score_gemma":0.0021050635,"teacher_disagreement_score":0.02419684,"about_ca_system_score_codex":0.0005325353,"about_ca_system_score_gemma":0.00015172562,"threshold_uncertainty_score":0.6129957},"labels":[],"label_agreement":null},{"id":"W4295256640","doi":"10.1016/j.jaad.2022.06.723","title":"31924 Hydroxyurea-induced ulcers: Anagrelide as a treatment option after hydroxyurea discontinuation","year":2022,"lang":"en","type":"article","venue":"Journal of the American Academy of Dermatology","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université Laval","funders":"","keywords":"Discontinuation; Medicine; Anagrelide; Hydroxycarbamide; Dermatology; Surgery; Chemotherapy; Internal medicine; Essential thrombocythemia; Polycythemia vera","score_opus":0.01721270540044,"score_gpt":0.3159962406476453,"score_spread":0.2987835352472053,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4295256640","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.95187384,0.00051863,0.000017142413,0.046703752,0.00014604168,0.00042473985,0.000013850894,0.000009768467,0.0002922138],"genre_scores_gemma":[0.9963729,0.00042165892,0.0003491365,0.0024816524,0.00011692705,0.000097018594,0.0000045901334,0.000023658526,0.00013245989],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99779105,0.00043155346,0.000773514,0.00020813092,0.0005294332,0.00026630276],"domain_scores_gemma":[0.9978677,0.00017397782,0.0015678698,0.00018445347,0.000062784566,0.00014321068],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00016071048,0.00023457197,0.00090997224,0.00027879243,0.0001401541,0.000009527627,0.00021058587,0.000060924613,0.0001521656],"category_scores_gemma":[0.00007499487,0.00014576169,0.00045536365,0.00037877224,0.00018788537,0.00010918576,0.00009765952,0.00046355158,0.000011406302],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.008254618,0.004882882,0.8968532,0.00007425527,0.0040889024,0.0012312783,0.0048314207,0.0005919961,0.037563868,0.0015278421,0.005333202,0.034766536],"study_design_scores_gemma":[0.01023959,0.00976108,0.8071167,0.00024954515,0.002635508,0.026096448,0.0032175912,0.00057298725,0.114968866,0.0017521557,0.022896187,0.0004933694],"about_ca_topic_score_codex":0.00007884081,"about_ca_topic_score_gemma":0.000006446209,"teacher_disagreement_score":0.08973653,"about_ca_system_score_codex":0.00041297817,"about_ca_system_score_gemma":0.00018466357,"threshold_uncertainty_score":0.5943989},"labels":[],"label_agreement":null},{"id":"W4295725642","doi":"10.1155/2022/9343951","title":"[Retracted] The Predictive Value of Neutrophil‐Lymphocyte Ratio in Patients with Polycythemia Vera at the Time of Initial Diagnosis for Thrombotic Events","year":2022,"lang":"en","type":"article","venue":"BioMed Research International","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":3,"is_retracted":true,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Waterloo","funders":"National Natural Science Foundation of China","keywords":"Polycythemia vera; Medicine; Predictive value; Neutrophil to lymphocyte ratio; Value (mathematics); Immunology; Lymphocyte; Gastroenterology; Internal medicine; Statistics; Mathematics","score_opus":0.029312553644641873,"score_gpt":0.3557763888284769,"score_spread":0.32646383518383504,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4295725642","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99171734,0.00008295712,0.000013860579,0.00473791,0.00024056497,0.0019582063,0.000935725,0.000005273703,0.00030816725],"genre_scores_gemma":[0.99714607,0.000044324755,0.000056427172,0.00009890186,0.00012646716,0.0017212183,0.00047833944,0.000018400015,0.00030985917],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99728024,0.0002987742,0.00032896083,0.0002447686,0.0016054158,0.00024185129],"domain_scores_gemma":[0.9978435,0.0011664501,0.00015588825,0.00024062053,0.00053526013,0.00005826636],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00072420744,0.000118615164,0.00022710278,0.00027099057,0.00022787378,0.000010246823,0.00029490874,0.000042823074,0.00075620046],"category_scores_gemma":[0.0003004876,0.000064851054,0.0000900763,0.0004081461,0.00029066633,0.00006099463,0.0002533652,0.00026501148,0.000006600245],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.012960987,0.004882077,0.96511394,0.00006944224,0.0014980076,0.000019205696,0.0021264018,0.00058552483,0.0016640066,0.0014328025,0.0075633344,0.0020842555],"study_design_scores_gemma":[0.008025493,0.0035465388,0.96799845,0.00011208851,0.00005639523,0.000006597729,0.00016916645,0.0017965877,0.016256437,0.00017248034,0.001787384,0.00007240718],"about_ca_topic_score_codex":0.00012847788,"about_ca_topic_score_gemma":0.000015062734,"teacher_disagreement_score":0.014592431,"about_ca_system_score_codex":0.0008777181,"about_ca_system_score_gemma":0.000358547,"threshold_uncertainty_score":0.8279864},"labels":[],"label_agreement":null},{"id":"W4295903721","doi":"10.1177/20406207221118429","title":"Efficacy and safety of ruxolitinib in patients with myelofibrosis and low platelet count (50 × 10 <sup>9</sup> /L to &lt;100 × 10 <sup>9</sup> /L) at baseline: the final analysis of EXPAND","year":2022,"lang":"en","type":"article","venue":"Therapeutic Advances in Hematology","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Genentech; AOP Orphan; Sierra Oncology; CTI Biopharma; Incyte; FibroGen; Gilead Sciences; BeiGene; Sanofi; MorphoSys; Celgene; AstraZeneca; Novartis; Pfizer; Amgen","keywords":"Ruxolitinib; Medicine; Myelofibrosis; Adverse effect; Internal medicine; Clinical endpoint; Anemia; Phases of clinical research; Gastroenterology; Discontinuation; International Prognostic Scoring System; Clinical trial; Bone marrow; Myelodysplastic syndromes","score_opus":0.013257384808473436,"score_gpt":0.2773913357063457,"score_spread":0.2641339508978723,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4295903721","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99319696,0.0046262243,0.000055799104,0.0005415898,0.000016401791,0.0012247754,0.00019880122,0.000012390969,0.00012708272],"genre_scores_gemma":[0.9976799,0.00085202686,0.0004474908,0.00042579323,0.00001173931,0.00031163002,0.0001551063,0.000027553557,0.000088796885],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9973565,0.00037101278,0.0008302462,0.0005792908,0.00044743047,0.00041551993],"domain_scores_gemma":[0.99745077,0.0015733248,0.00028028272,0.00045282082,0.00012893938,0.000113853544],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00045390075,0.00034427765,0.0013527428,0.00045010596,0.00014821593,0.0000069989424,0.00015254066,0.000088696346,0.0010335492],"category_scores_gemma":[0.00008779063,0.00023283839,0.00008634811,0.00090577564,0.00035187832,0.0000825902,0.00017644269,0.00021479369,0.0000030369324],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.017990177,0.0017379302,0.9229407,0.0002697856,0.0010986137,0.00004851326,0.0051185885,0.027113907,0.00002821303,0.0008638612,0.00004565844,0.022744106],"study_design_scores_gemma":[0.041015144,0.009886449,0.8957158,0.0007160172,0.0025121032,0.00020271032,0.003909707,0.022156896,0.0031344874,0.0003659642,0.01945017,0.00093459024],"about_ca_topic_score_codex":0.000045681303,"about_ca_topic_score_gemma":0.00011472839,"teacher_disagreement_score":0.027224889,"about_ca_system_score_codex":0.00015088361,"about_ca_system_score_gemma":0.00007780828,"threshold_uncertainty_score":0.99987966},"labels":[],"label_agreement":null},{"id":"W4296468442","doi":"10.1016/s2152-2650(22)01463-x","title":"MPN-478 MOMENTUM: Phase 3 Randomized Study of Momelotinib (MMB) versus Danazol (DAN) in Symptomatic and Anemic Myelofibrosis (MF) Patients Previously Treated With a JAK Inhibitor","year":2022,"lang":"en","type":"article","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Myelofibrosis; Ruxolitinib; Placebo; Gastroenterology; Anemia; Internal medicine; Danazol; Clinical endpoint; Hematocrit; Randomized controlled trial; Surgery; Bone marrow; Pathology","score_opus":0.023011113189529718,"score_gpt":0.31756661395067076,"score_spread":0.29455550076114106,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4296468442","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99055123,0.000381048,0.0000021576143,0.00011777054,0.00026275482,0.00819472,0.00007910399,0.000109327855,0.00030189264],"genre_scores_gemma":[0.994979,0.0002215731,0.00019370856,0.00016632878,0.000094630384,0.0038420355,0.00027076135,0.00010152387,0.00013039788],"study_design_codex":"observational","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99294823,0.0013798997,0.0025954763,0.0012564842,0.0011193833,0.00070050906],"domain_scores_gemma":[0.99458903,0.0028340502,0.0009519384,0.0008437582,0.00024989073,0.00053131365],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0012928903,0.0007263953,0.0031019903,0.0004335463,0.00027483696,0.00004821827,0.00026584812,0.0001984845,0.0001645696],"category_scores_gemma":[0.0008877609,0.00055235834,0.00037874092,0.0009266505,0.00043881574,0.00016420319,0.00034922382,0.00038955896,0.000013127708],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.25058454,0.021826468,0.6492174,0.00024854537,0.0017854591,0.00052368024,0.0020648318,0.00003789882,0.00010270177,0.000050996925,0.0003093778,0.07324809],"study_design_scores_gemma":[0.52414936,0.021792945,0.44938183,0.00031688454,0.0012796863,0.00003968623,0.0010969203,0.00096111937,0.00044949437,0.000013855269,0.00012061788,0.000397583],"about_ca_topic_score_codex":0.00041461037,"about_ca_topic_score_gemma":0.000099440156,"teacher_disagreement_score":0.27356485,"about_ca_system_score_codex":0.0015519907,"about_ca_system_score_gemma":0.0007377359,"threshold_uncertainty_score":0.9996928},"labels":[],"label_agreement":null},{"id":"W4296468477","doi":"10.1016/s2152-2650(22)01464-1","title":"MPN-483 Thrombocytopenic Myelofibrosis (MF) Patients Previously Treated With a JAK Inhibitor in a Phase 3 Randomized Study of Momelotinib (MMB) versus Danazol (DAN) [MOMENTUM]","year":2022,"lang":"en","type":"article","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Gastroenterology; Internal medicine; Danazol; Placebo; Myelofibrosis; Ruxolitinib; Anemia; Hematocrit; Clinical endpoint; Randomized controlled trial; Surgery; Bone marrow; Pathology","score_opus":0.033995052927979164,"score_gpt":0.337825457765041,"score_spread":0.30383040483706186,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4296468477","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98776096,0.000289443,0.0000033274055,0.00017873528,0.00044360047,0.010423585,0.00011271564,0.00012881748,0.0006587854],"genre_scores_gemma":[0.9927237,0.00019202242,0.00022024123,0.00029677086,0.00014943362,0.005640023,0.0004157492,0.00013427743,0.0002277947],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9908878,0.001923673,0.0031897337,0.0015720549,0.0015213226,0.0009053777],"domain_scores_gemma":[0.99377203,0.0028414521,0.0011959014,0.0012175072,0.00038034804,0.0005927671],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0017126206,0.000864241,0.004085836,0.00045828428,0.00034065545,0.00005612451,0.00045789249,0.0002414141,0.0004730005],"category_scores_gemma":[0.0010811945,0.00065515976,0.0007237552,0.001338916,0.0004622957,0.00021319324,0.0005031758,0.000550899,0.000039198832],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.44045648,0.041603252,0.43480453,0.00014117533,0.0027591002,0.0008323912,0.0021517833,0.00006392181,0.00013964418,0.000095765645,0.00071847026,0.076233506],"study_design_scores_gemma":[0.56181175,0.030000687,0.40303254,0.00023737962,0.0013777128,0.000025212452,0.0011388467,0.0003609758,0.0009206008,0.0000114187005,0.00061183685,0.00047105178],"about_ca_topic_score_codex":0.00079309667,"about_ca_topic_score_gemma":0.00025303575,"teacher_disagreement_score":0.121355265,"about_ca_system_score_codex":0.002738378,"about_ca_system_score_gemma":0.0015922254,"threshold_uncertainty_score":0.99959},"labels":[],"label_agreement":null},{"id":"W4296533666","doi":"10.1016/s2152-2650(22)01457-4","title":"MPN-379 Matching-Adjusted Indirect Comparison (MAIC) of Pelabresib (CPI-0610) in Combination With Ruxolitinib vs. JAK Inhibitor Monotherapy in Patients With Intermediate or High-Risk Myelofibrosis","year":2022,"lang":"en","type":"article","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Ruxolitinib; Medicine; Myelofibrosis; Internal medicine; Phases of clinical research; Clinical trial","score_opus":0.01947532067221452,"score_gpt":0.2836838542439213,"score_spread":0.26420853357170676,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4296533666","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99616593,0.00010166206,0.000021851574,0.0003251657,0.000315814,0.0025602537,0.00025626307,0.000099237324,0.00015382981],"genre_scores_gemma":[0.9958949,0.00014759185,0.001314621,0.0006244223,0.000109127,0.0009594143,0.0006909357,0.00012665759,0.00013233152],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99385226,0.0009994752,0.002201896,0.0010931109,0.0011513832,0.00070184824],"domain_scores_gemma":[0.9959693,0.0014808065,0.0012142354,0.0007187998,0.00027706276,0.0003397919],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0009494406,0.0006499367,0.0021412182,0.0006250033,0.00020511173,0.0000457835,0.00033661255,0.00029532457,0.00031388042],"category_scores_gemma":[0.00028830286,0.00047310296,0.00021940387,0.0012400756,0.0003553139,0.0002229066,0.00021325104,0.00078039785,0.000023471819],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.033256304,0.0053057764,0.8514604,0.00011483348,0.0003378533,0.00015847108,0.0012867902,0.00019513782,0.000019058467,0.000113526,0.00037565804,0.1073762],"study_design_scores_gemma":[0.056193314,0.016779622,0.9230623,0.00067211007,0.00022256424,0.00001587364,0.00051281706,0.0004737716,0.0009465838,0.000110247965,0.00052202697,0.00048877386],"about_ca_topic_score_codex":0.0015500414,"about_ca_topic_score_gemma":0.0013657309,"teacher_disagreement_score":0.10688743,"about_ca_system_score_codex":0.0022357253,"about_ca_system_score_gemma":0.0012391694,"threshold_uncertainty_score":0.9997721},"labels":[],"label_agreement":null},{"id":"W4296613459","doi":"10.1016/s2152-2650(22)00982-x","title":"Poster: MPN-375 BET Inhibitor Pelabresib (CPI-0610) Combined With Ruxolitinib in Patients With Myelofibrosis-JAK Inhibitor-Naïve or With Suboptimal Response to Ruxolitinib-Preliminary Data From the MANIFEST Study","year":2022,"lang":"en","type":"article","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Ruxolitinib; Medicine; Myelofibrosis; Myeloproliferative neoplasm; Internal medicine; Oncology; Bone marrow","score_opus":0.03944203951438547,"score_gpt":0.31124101279108096,"score_spread":0.2717989732766955,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4296613459","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98532975,0.000092709444,0.0000033999256,0.0031010585,0.0003790416,0.008124683,0.0024538857,0.00020982722,0.00030564534],"genre_scores_gemma":[0.9884316,0.0000131059605,0.0014036418,0.0036150087,0.00062080065,0.0023033977,0.0027811823,0.00028058572,0.0005507245],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9887131,0.0023564294,0.0022510504,0.0028789025,0.0023992693,0.0014012365],"domain_scores_gemma":[0.9881185,0.0056981323,0.0007783375,0.0038374038,0.0005128935,0.0010546957],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0021968053,0.0012713319,0.0021219691,0.00032477762,0.00088634586,0.0002414572,0.0014941621,0.00026675285,0.0005030886],"category_scores_gemma":[0.0010005271,0.00074181875,0.00021023939,0.0013671936,0.0006031556,0.00046195474,0.0021835985,0.0011108689,0.0001769103],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.29528677,0.007580502,0.67962396,0.000034516546,0.000660954,0.003601906,0.0012896232,0.000027843582,0.000014436337,0.000019493247,0.004060095,0.0077999225],"study_design_scores_gemma":[0.052841354,0.094455466,0.84351355,0.00070206734,0.0008059695,0.00023763615,0.003327853,0.0000899073,0.00011768324,0.000008367907,0.0029992643,0.00090089266],"about_ca_topic_score_codex":0.00092398195,"about_ca_topic_score_gemma":0.0011827868,"teacher_disagreement_score":0.24244541,"about_ca_system_score_codex":0.0018685589,"about_ca_system_score_gemma":0.0033554551,"threshold_uncertainty_score":0.9995033},"labels":[],"label_agreement":null},{"id":"W4296613467","doi":"10.1016/s2152-2650(22)00950-8","title":"Poster: MPN-478 MOMENTUM: Phase 3 Randomized Study of Momelotinib (MMB) versus Danazol (DAN) in Symptomatic and Anemic Myelofibrosis (MF) Patients Previously Treated With a JAK Inhibitor","year":2022,"lang":"en","type":"article","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Myelofibrosis; Danazol; Ruxolitinib; Medicine; Internal medicine; Randomized controlled trial; Gastroenterology; Bone marrow; Endometriosis","score_opus":0.022196037003589065,"score_gpt":0.31451704398633307,"score_spread":0.292321006982744,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4296613467","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9902462,0.00038813,0.0000012127788,0.0001414602,0.00027089473,0.008433399,0.00009377913,0.00010787273,0.00031710253],"genre_scores_gemma":[0.99548084,0.0001991298,0.00012668931,0.0002054108,0.000090524256,0.0033630957,0.00030628862,0.00010448926,0.00012356242],"study_design_codex":"observational","study_design_gemma":"randomized_trial","domain_scores_codex":[0.992862,0.001415184,0.0026412953,0.0012668271,0.0011070811,0.0007076019],"domain_scores_gemma":[0.9946725,0.0027039442,0.000969519,0.00086007826,0.00025987346,0.00053410133],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0012246793,0.0007432366,0.0030986888,0.00044454535,0.00026824384,0.000053107768,0.0002729555,0.00020147044,0.00015064499],"category_scores_gemma":[0.0007669171,0.0005651964,0.00038555005,0.0008663375,0.00041795612,0.0001753301,0.00038214016,0.0003840501,0.000013513389],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.250626,0.018944189,0.6645393,0.00023568046,0.0016338925,0.00052297977,0.0021211335,0.000018673174,0.000107876935,0.000028715946,0.00022627017,0.060995344],"study_design_scores_gemma":[0.5018189,0.024135938,0.46997842,0.0003331838,0.001250754,0.00005124014,0.0009058953,0.00052368507,0.0005101009,0.000010074341,0.00008974203,0.00039207964],"about_ca_topic_score_codex":0.00040230204,"about_ca_topic_score_gemma":0.00009946969,"teacher_disagreement_score":0.2511929,"about_ca_system_score_codex":0.001510782,"about_ca_system_score_gemma":0.0006962846,"threshold_uncertainty_score":0.9996799},"labels":[],"label_agreement":null},{"id":"W4296614337","doi":"10.1016/s2152-2650(22)00973-9","title":"Poster: MPN-379 Matching-Adjusted Indirect Comparison (MAIC) of Pelabresib (CPI-0610) in Combination With Ruxolitinib vs. JAK Inhibitor Monotherapy in Patients With Intermediate or High-Risk Myelofibrosis","year":2022,"lang":"en","type":"article","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Myelofibrosis; Ruxolitinib; Medicine; Matching (statistics); Internal medicine; Pathology","score_opus":0.01883409622815097,"score_gpt":0.28202109503869616,"score_spread":0.2631869988105452,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4296614337","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9959401,0.000105129504,0.00001235348,0.000386293,0.000325898,0.002669772,0.0002990002,0.000098498116,0.00016297813],"genre_scores_gemma":[0.9962528,0.00013370768,0.00086486613,0.0007592222,0.000104597755,0.0008560975,0.0007726271,0.00013050988,0.00012557991],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9937593,0.0010310636,0.0022493901,0.0011067876,0.0011423719,0.0007111306],"domain_scores_gemma":[0.9959701,0.001424274,0.001236987,0.00073570415,0.00028884056,0.0003441333],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0009069108,0.0006673786,0.0021513752,0.0006415625,0.00020169599,0.000050529852,0.0003458895,0.00029931954,0.00028616737],"category_scores_gemma":[0.00025279282,0.00048633892,0.00022511613,0.0011621767,0.0003412625,0.00023798671,0.00023516062,0.0007677595,0.000024020812],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.037628952,0.005115843,0.8559647,0.000119778124,0.00034325063,0.00017436956,0.0014480896,0.00010602313,0.00002220873,0.00007154959,0.00030100322,0.09870423],"study_design_scores_gemma":[0.056611195,0.019279018,0.92033386,0.0007229852,0.00022895419,0.000021378659,0.0004479893,0.0002768786,0.0010935906,0.000082538856,0.00040237838,0.0004992212],"about_ca_topic_score_codex":0.0014892991,"about_ca_topic_score_gemma":0.0013330587,"teacher_disagreement_score":0.098205,"about_ca_system_score_codex":0.0021714875,"about_ca_system_score_gemma":0.0011661547,"threshold_uncertainty_score":0.99975884},"labels":[],"label_agreement":null},{"id":"W4296965070","doi":"10.1016/s2152-2650(22)00954-5","title":"Poster: MPN-145 Retrospective Analysis of Anemia Benefit of Pacritinib From the PERSIST-2 Trial","year":2022,"lang":"en","type":"article","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Anemia; Medicine; Internal medicine","score_opus":0.034934633993297694,"score_gpt":0.327188234025527,"score_spread":0.2922536000322293,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4296965070","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9919247,0.00071617786,0.0000045876973,0.0015247859,0.00048221127,0.0012177302,0.0014500989,0.00004276941,0.0026369395],"genre_scores_gemma":[0.9963346,0.00021715609,0.0002273376,0.0014432571,0.00045728963,0.00033070703,0.0006108023,0.000042143965,0.0003366991],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9952776,0.0005187318,0.0018599896,0.0008774863,0.0010654392,0.0004007561],"domain_scores_gemma":[0.99409056,0.0031884888,0.0008486804,0.0012115497,0.000401782,0.00025896193],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.001083277,0.00037882308,0.0020404384,0.00021319889,0.0003045668,0.000023066785,0.0004481461,0.00022458528,0.0022538693],"category_scores_gemma":[0.0011253873,0.00027500483,0.0017789354,0.0013008822,0.00047699994,0.000063854364,0.00037233683,0.00040418646,0.000018664465],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.02708091,0.0019124966,0.89746284,0.000025994008,0.0069739944,0.00016470408,0.0009129932,0.00004089855,0.00022965489,0.001215967,0.0029239021,0.061055616],"study_design_scores_gemma":[0.033825308,0.0041663987,0.95126957,0.00005438717,0.006254466,0.000016847182,0.0007253456,0.00024269622,0.00097203726,0.0002966177,0.0019471316,0.00022918911],"about_ca_topic_score_codex":0.00097406417,"about_ca_topic_score_gemma":0.00016871038,"teacher_disagreement_score":0.060826425,"about_ca_system_score_codex":0.0011613664,"about_ca_system_score_gemma":0.00086234324,"threshold_uncertainty_score":0.9999702},"labels":[],"label_agreement":null},{"id":"W4296965454","doi":"10.1016/s2152-2650(22)00951-x","title":"Poster: MPN-483 Thrombocytopenic Myelofibrosis (MF) Patients Previously Treated With a JAK Inhibitor in a Phase 3 Randomized Study of Momelotinib (MMB) versus Danazol (DAN) [MOMENTUM]","year":2022,"lang":"en","type":"article","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Myelofibrosis; Danazol; Ruxolitinib; Medicine; Internal medicine; Gastroenterology; Bone marrow; Endometriosis","score_opus":0.03254762962863671,"score_gpt":0.3342227044601921,"score_spread":0.30167507483155537,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4296965454","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9873743,0.00029658613,0.0000018444007,0.00021475927,0.0004556081,0.0107075,0.00013368276,0.00012697378,0.00068872015],"genre_scores_gemma":[0.99344045,0.00017339172,0.0001427336,0.00036600308,0.00014249505,0.004912663,0.00046931766,0.00013808275,0.00021489331],"study_design_codex":"observational","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9907916,0.001968787,0.0032416538,0.0015838693,0.0015006855,0.00091337267],"domain_scores_gemma":[0.9938435,0.0027120516,0.0012161441,0.0012378049,0.00039440277,0.00059611903],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0016183004,0.0008841965,0.004074021,0.00047000527,0.0003322141,0.00006194412,0.00046827126,0.00024506042,0.00042839564],"category_scores_gemma":[0.0009321975,0.0006703958,0.0007328037,0.0012465463,0.00044064815,0.00022761758,0.0005506201,0.0005420305,0.000040000887],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.42968395,0.03565824,0.4652577,0.00013406452,0.0025036072,0.0008246549,0.0022034578,0.000030734882,0.0001458152,0.000053037482,0.0005167216,0.06298801],"study_design_scores_gemma":[0.53687507,0.033036236,0.42537367,0.00025031215,0.00134411,0.00003279222,0.00093437405,0.00019551202,0.0010398306,0.000008280673,0.00044635477,0.0004634561],"about_ca_topic_score_codex":0.00076617236,"about_ca_topic_score_gemma":0.0002515273,"teacher_disagreement_score":0.1071911,"about_ca_system_score_codex":0.0026513997,"about_ca_system_score_gemma":0.0014911728,"threshold_uncertainty_score":0.9995747},"labels":[],"label_agreement":null},{"id":"W4306639578","doi":"10.1080/14656566.2022.2135989","title":"Fedratinib: a pharmacotherapeutic option for JAK-inhibitor naïve and exposed patients with myelofibrosis","year":2022,"lang":"en","type":"review","venue":"Expert Opinion on Pharmacotherapy","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Ruxolitinib; Medicine; Myelofibrosis; Extramedullary hematopoiesis; Clinical trial; Internal medicine; Bone marrow; Haematopoiesis","score_opus":0.10124681455615386,"score_gpt":0.4063206045908273,"score_spread":0.30507379003467344,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4306639578","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00031086823,0.98819464,0.00008844312,0.00041095976,0.0012333423,0.00897686,0.00046706162,0.00017052781,0.0001472698],"genre_scores_gemma":[0.00007085528,0.9819113,0.0012178809,0.0030936215,0.0010373557,0.010400792,0.0016942781,0.00034025774,0.00023366505],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9964196,0.00031443598,0.0008020282,0.001199504,0.0007240518,0.0005403705],"domain_scores_gemma":[0.99796087,0.0005852123,0.0005446464,0.00042495562,0.00012720774,0.0003571098],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0001874692,0.0010880088,0.0020315533,0.00039263326,0.00045009528,0.00010009012,0.00017266325,0.00022333574,0.0014698181],"category_scores_gemma":[0.000013603855,0.0007521397,0.00057415204,0.00034369604,0.00008673533,0.0001404291,0.000036667316,0.00044499597,0.000022800054],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.002212585,0.0021167225,0.0000794622,0.001977919,0.0014130848,0.000006569223,0.0005041795,5.7589216e-7,0.00008540697,0.00008556511,0.005615981,0.98590195],"study_design_scores_gemma":[0.0124280555,0.0052524284,0.000021341917,0.0039375783,0.0003029276,0.000022426218,0.000031604675,0.000035949528,0.0013517065,0.000004888026,0.97587043,0.0007406361],"about_ca_topic_score_codex":0.0000053020353,"about_ca_topic_score_gemma":3.3870373e-7,"teacher_disagreement_score":0.9851613,"about_ca_system_score_codex":0.0004656863,"about_ca_system_score_gemma":0.00029448123,"threshold_uncertainty_score":0.99949294},"labels":[],"label_agreement":null},{"id":"W4306921860","doi":"10.1002/jha2.591","title":"Risk‐adjusted safety analysis of the oral JAK2/IRAK1 inhibitor pacritinib in patients with myelofibrosis","year":2022,"lang":"en","type":"article","venue":"eJHaem","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":15,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Myelofibrosis; Medicine; Ruxolitinib; Adverse effect; Internal medicine","score_opus":0.008993993547951244,"score_gpt":0.22962069161456786,"score_spread":0.2206266980666166,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4306921860","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9972619,0.00007286615,0.000005320683,0.0005770094,0.00009201431,0.00070418586,0.00054312986,0.00001810383,0.00072548207],"genre_scores_gemma":[0.99889773,0.000016088272,0.00024507247,0.00022024581,0.000022410146,0.00015124118,0.00020373639,0.000019804731,0.00022365035],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99817675,0.00026052736,0.00039357052,0.00031832032,0.0006160169,0.00023481475],"domain_scores_gemma":[0.9990407,0.00013284339,0.00020126003,0.00042571742,0.00012001726,0.000079433274],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00022213403,0.00018280162,0.0005660461,0.00024950615,0.00020190705,0.000008295795,0.000108049986,0.000039357994,0.0009798608],"category_scores_gemma":[0.00008152575,0.0001120769,0.0002112336,0.001777648,0.00007227756,0.000043771026,0.00013308895,0.00025748814,0.0000040588534],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0007409644,0.0011058272,0.9917632,0.000014080631,0.0008799247,0.000010019343,0.00089573214,0.00039607962,0.000016240398,0.00008068552,0.0004506102,0.0036466508],"study_design_scores_gemma":[0.004523396,0.0007777386,0.98964393,0.000046930007,0.0015453945,0.000001095034,0.00044363725,0.00018942294,0.0010622157,0.0000056019007,0.0016443513,0.000116285395],"about_ca_topic_score_codex":0.00046028293,"about_ca_topic_score_gemma":0.0006569908,"teacher_disagreement_score":0.0037824316,"about_ca_system_score_codex":0.000230973,"about_ca_system_score_gemma":0.00008069168,"threshold_uncertainty_score":0.99993336},"labels":[],"label_agreement":null},{"id":"W4308525293","doi":"10.9778/cmajo.20210322","title":"Secondary causes of elevated hemoglobin in patients undergoing molecular testing for suspected polycythemia vera in southwestern Ontario: a chart review","year":2022,"lang":"en","type":"review","venue":"CMAJ Open","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":18,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":true,"ca_institutions":"London Health Sciences Centre; Western University","funders":"","keywords":"Polycythemia vera; Medicine; Hemoglobin; Internal medicine","score_opus":0.06964767738263312,"score_gpt":0.3417167477090578,"score_spread":0.2720690703264247,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4308525293","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.016636666,0.96903867,7.348076e-7,0.00006263022,0.00010526929,0.012719748,0.0002517295,0.000020137639,0.0011644145],"genre_scores_gemma":[0.0012121544,0.9899993,0.000610855,0.00050597946,0.000022393024,0.0042441394,0.0028762098,0.00013004508,0.00039893866],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9969789,0.00023770989,0.0013441413,0.0007158934,0.00031230805,0.00041108928],"domain_scores_gemma":[0.9978701,0.00067590753,0.00068322587,0.0005404801,0.00011700364,0.00011328894],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00044241862,0.0005430455,0.0031680488,0.0002823933,0.00005998119,0.00003720621,0.00036616996,0.00015692331,0.0010449281],"category_scores_gemma":[0.00067960797,0.0004602014,0.00030565495,0.0007247807,0.000026793377,0.00009614863,0.00040833262,0.00056258513,0.000012036896],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00044633634,0.002909169,0.2900248,0.16429944,0.0014086702,0.0007436786,0.00080843363,0.0000017710156,0.00000789027,0.000091914255,0.0010363413,0.53822154],"study_design_scores_gemma":[0.014313617,0.0027837139,0.030582802,0.36344153,0.0026478583,0.0000808209,0.000065930384,0.000002530934,0.00008602959,0.00004314299,0.5848499,0.0011021547],"about_ca_topic_score_codex":0.009711042,"about_ca_topic_score_gemma":0.025337731,"teacher_disagreement_score":0.58381355,"about_ca_system_score_codex":0.001564029,"about_ca_system_score_gemma":0.0028270218,"threshold_uncertainty_score":0.9998683},"labels":[],"label_agreement":null},{"id":"W4309350238","doi":"10.1002/jha2.611","title":"Improved donor chimerism in relapse myelofibrosis post allogenic stem cell transplant with azacitidine and oral decitabine—First case report","year":2022,"lang":"en","type":"article","venue":"eJHaem","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network; Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Decitabine; Medicine; Azacitidine; Myelofibrosis; Context (archaeology); Oncology; Internal medicine; Stem cell; Myeloid leukemia; Bone marrow","score_opus":0.010410219276091015,"score_gpt":0.22342727244906854,"score_spread":0.21301705317297753,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4309350238","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.995597,0.0007905615,0.000023442739,0.001715827,0.00010680853,0.0010926994,0.00018206243,0.000057769965,0.00043382347],"genre_scores_gemma":[0.9964627,0.00014570823,0.00096690515,0.0003292154,0.000046454734,0.00062614377,0.00021385544,0.000055188455,0.0011538173],"study_design_codex":"case_report","study_design_gemma":"case_report","domain_scores_codex":[0.9980953,0.00008609131,0.0004868328,0.00064054993,0.0002903617,0.0004008839],"domain_scores_gemma":[0.9990166,0.00012396662,0.00015113456,0.00039100836,0.000063097,0.00025421515],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00026866767,0.00033536853,0.0005763868,0.00017380467,0.00030317134,0.00002679786,0.000064659915,0.00006883012,0.00027239072],"category_scores_gemma":[0.000009246691,0.00025811556,0.00009869463,0.0002945654,0.00007167483,0.00008633264,0.00006959999,0.00033375167,0.000005659427],"study_design_candidate":"case_report","study_design_consensus":"case_report","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0048181103,0.002754988,0.47495496,0.00035064828,0.00061868643,0.4849945,0.0104556205,0.00010027471,0.0157337,0.000119756194,0.00060929824,0.004489458],"study_design_scores_gemma":[0.044151556,0.019781005,0.23138067,0.00049116253,0.0019157581,0.5981793,0.008890294,0.0015122265,0.07234044,0.000022914312,0.019275157,0.0020595232],"about_ca_topic_score_codex":0.0012735637,"about_ca_topic_score_gemma":0.0022866237,"teacher_disagreement_score":0.24357429,"about_ca_system_score_codex":0.00020127522,"about_ca_system_score_gemma":0.00014754287,"threshold_uncertainty_score":0.9999871},"labels":[],"label_agreement":null},{"id":"W4310093492","doi":"10.1182/blood-2022-168675","title":"The Empower Study - Design of a Randomized Clinical Trial to Assess the Efficacy and Safety of a Plasma-Derived Von Willebrand Factor / Factor VIII Concentrate for Heavy Menstrual Bleeding in Women with Von Willebrand Disease","year":2022,"lang":"en","type":"article","venue":"Blood","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Hospital for Sick Children; Queen Elizabeth II Health Sciences Centre; University of Alberta; Queen's University; St. Paul's Hospital; Health Sciences Centre; University of Toronto; St. Michael's Hospital","funders":"","keywords":"Medicine; Von Willebrand disease; Von Willebrand factor; Randomized controlled trial; Placebo; Crossover study; Menstruation; Clinical trial; Pediatrics; Internal medicine; Obstetrics","score_opus":0.0504650170704808,"score_gpt":0.331584281593129,"score_spread":0.28111926452264824,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4310093492","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9834502,0.00021942335,0.00014881162,0.0005562133,0.00016359847,0.015241804,0.00019576398,0.000013419457,0.000010812275],"genre_scores_gemma":[0.9963855,0.00016281684,0.00016773194,0.000084312014,0.00007424868,0.0030667945,0.00000871374,0.000030176672,0.00001967403],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99615794,0.0014085424,0.0010731682,0.00045608266,0.000537543,0.00036673938],"domain_scores_gemma":[0.99058205,0.008329643,0.00039964815,0.00030862016,0.00012434222,0.00025570428],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002231739,0.00029270552,0.0014577878,0.00007432488,0.00031895397,0.000040863557,0.00014732666,0.00004602173,0.00005228323],"category_scores_gemma":[0.0012871447,0.00014550783,0.00015579871,0.00020059219,0.00024723055,0.000052676114,0.00009873272,0.00022581436,2.2341284e-7],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9097616,0.005727325,0.07389743,0.00004008081,0.0020468829,0.000024609073,0.0070434394,0.000083141866,0.00044741464,0.000036525824,0.000019931575,0.0008716024],"study_design_scores_gemma":[0.91437966,0.015024581,0.06417157,0.00012219317,0.0010321344,0.0000053732456,0.003143339,0.00023276819,0.0015813246,0.000014137937,0.00010846067,0.00018446552],"about_ca_topic_score_codex":0.000013913526,"about_ca_topic_score_gemma":0.000016044798,"teacher_disagreement_score":0.012935378,"about_ca_system_score_codex":0.000067521294,"about_ca_system_score_gemma":0.00036095307,"threshold_uncertainty_score":0.59336376},"labels":[],"label_agreement":null},{"id":"W4310106458","doi":"10.1182/blood-2022-163734","title":"<i>JAK2 V617F</i> Mutation and Associated Chromosomal Alterations Involving <i>JAK2</i> in Pre-HCT Blood Samples and Transplant Outcomes in Myelofibrosis Subtypes","year":2022,"lang":"en","type":"article","venue":"Blood","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network","funders":"","keywords":"Myelofibrosis; Essential thrombocythemia; Medicine; Polycythemia vera; Internal medicine; Hazard ratio; Oncology; Myeloproliferative neoplasm; Cumulative incidence; Transplantation; Proportional hazards model; Immunology; Bone marrow; Gastroenterology; Confidence interval","score_opus":0.015120145523409054,"score_gpt":0.24247031211100306,"score_spread":0.227350166587594,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4310106458","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9961104,0.0016802844,0.0000037270995,0.0009198553,0.000046377343,0.0008086809,0.00029183552,0.000047756545,0.00009111682],"genre_scores_gemma":[0.9975664,0.0005898774,0.00050753687,0.00035206994,0.000025102629,0.00053225615,0.00034844567,0.000026982727,0.000051323907],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9983666,0.00017547503,0.0004309898,0.0004368066,0.00029094866,0.00029916147],"domain_scores_gemma":[0.99924725,0.0003633388,0.00010370113,0.00014724367,0.000035311285,0.000103152444],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00025120034,0.00023985383,0.00050063356,0.00022762807,0.00022896298,0.00005269761,0.0000506344,0.00007440834,0.00005997187],"category_scores_gemma":[0.000105235005,0.00022036258,0.00005697709,0.00030081204,0.000048675534,0.00013880977,0.000053783566,0.00024017876,0.0000010288745],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00007295313,0.002563734,0.9856729,0.000069543625,0.00023398797,0.00030087927,0.0040645455,0.000037032547,0.0064706667,0.00028073732,0.000017129989,0.00021591097],"study_design_scores_gemma":[0.010144327,0.0008943822,0.9734407,0.00016926392,0.00047008984,0.00018492572,0.000299363,0.0002006913,0.013793407,0.00013050121,0.000049547936,0.00022280328],"about_ca_topic_score_codex":0.0007118454,"about_ca_topic_score_gemma":0.0033395882,"teacher_disagreement_score":0.012232181,"about_ca_system_score_codex":0.000072419636,"about_ca_system_score_gemma":0.00009271499,"threshold_uncertainty_score":0.8986125},"labels":[],"label_agreement":null},{"id":"W4310107696","doi":"10.1182/blood-2022-157949","title":"The Combination of Navitoclax and Ruxolitinib in JAK Inhibitor-Naïve Patients with Myelofibrosis Mediates Responses Suggestive of Disease Modification","year":2022,"lang":"en","type":"article","venue":"Blood","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":14,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; McGill University; University Health Network","funders":"","keywords":"Ruxolitinib; Myelofibrosis; Medicine; Disease; Polycythemia vera; Internal medicine; Cancer research; Bone marrow","score_opus":0.009447585481964296,"score_gpt":0.2412132125914176,"score_spread":0.2317656271094533,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4310107696","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9981059,0.0003816353,6.4792397e-7,0.00046992188,0.000024527204,0.00076086755,0.00018994907,0.000006995234,0.000059552276],"genre_scores_gemma":[0.9992495,0.000079526304,0.00007101175,0.000019400015,0.000009970167,0.0003861604,0.00014832181,0.000010020904,0.000026092304],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9990008,0.00014564859,0.00024286605,0.00016678528,0.0003403056,0.00010363045],"domain_scores_gemma":[0.99897516,0.00047638264,0.00017005269,0.00015440001,0.00015995913,0.00006405883],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00016340284,0.0000949893,0.00018744382,0.00008933544,0.00010637481,0.0000061108394,0.00003929562,0.000018455848,0.000009324159],"category_scores_gemma":[0.00020728089,0.00006302181,0.000026265274,0.00018399942,0.00010788881,0.000041767744,0.00004152257,0.00007439328,3.3455052e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0020400737,0.002470922,0.992143,0.000053246007,0.000061790124,0.00000380706,0.000729255,0.0000056135823,0.00043276377,0.0010692704,0.000029844558,0.0009604515],"study_design_scores_gemma":[0.006112384,0.0016844645,0.9712929,0.00009949381,0.00014660394,9.952207e-7,0.0003704994,0.00002636188,0.01999721,0.00018083623,0.000031225984,0.00005702877],"about_ca_topic_score_codex":0.000048908718,"about_ca_topic_score_gemma":0.000012938401,"teacher_disagreement_score":0.020850066,"about_ca_system_score_codex":0.000045149212,"about_ca_system_score_gemma":0.00010278974,"threshold_uncertainty_score":0.2569955},"labels":[],"label_agreement":null},{"id":"W4310119420","doi":"10.1182/blood-2022-159389","title":"Improvement in Individual Symptoms and Total Symptom Score (TSS) and Matching-Adjusted Indirect Comparison (MAIC) Analysis to Compare TSS As a Continuous Endpoint in Patients with Myelofibrosis Treated with Pelabresib in Combination with Ruxolitinib Versus Janus Kinase Inhibitor Monotherapy","year":2022,"lang":"en","type":"article","venue":"Blood","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network","funders":"","keywords":"Medicine; Clinical endpoint; Ruxolitinib; Internal medicine; Clinical trial; Phases of clinical research; Myelofibrosis; Surrogate endpoint; Surgery","score_opus":0.011811782464268646,"score_gpt":0.23882372616238914,"score_spread":0.2270119436981205,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4310119420","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9964486,0.00013281633,0.0000037504853,0.00014506963,0.000019303177,0.002926291,0.00022044021,0.00004087951,0.00006288505],"genre_scores_gemma":[0.99769115,0.000009447164,0.00029195118,0.0001066994,0.000011539109,0.0010493544,0.0007777794,0.000047266287,0.000014792746],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9972453,0.00020626272,0.0005627676,0.00078367506,0.00073546625,0.00046650303],"domain_scores_gemma":[0.9989803,0.00016016747,0.00025039713,0.0002686707,0.000108501816,0.00023198954],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0002157969,0.0004677691,0.0011352956,0.0010743524,0.00014066315,0.000074159245,0.00008197018,0.000061295235,0.00004125493],"category_scores_gemma":[0.000012465419,0.00035935963,0.00004613481,0.0015327493,0.00007671298,0.00012392944,0.00010364169,0.00033297617,9.008341e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0140408715,0.007141197,0.96791595,0.000052140018,0.001393137,0.00019059853,0.0062691728,0.0003796118,0.00006806237,0.000033600038,0.0000032774444,0.0025123917],"study_design_scores_gemma":[0.07379985,0.017952261,0.9012813,0.00029434683,0.0010745171,0.000013345079,0.0024957876,0.0001687649,0.0025344202,0.0000028682325,0.000005744941,0.00037680953],"about_ca_topic_score_codex":0.0025892754,"about_ca_topic_score_gemma":0.006161011,"teacher_disagreement_score":0.066634655,"about_ca_system_score_codex":0.00034773236,"about_ca_system_score_gemma":0.000113842594,"threshold_uncertainty_score":0.99988586},"labels":[],"label_agreement":null},{"id":"W4310159140","doi":"10.1182/blood-2022-163785","title":"Prognostic Impact of High Calreticulin Variant Allele Frequency in Patients with Myeloproliferative Neoplasms","year":2022,"lang":"en","type":"article","venue":"Blood","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Quebec - Clinical Research Organization in Cancer; Université de Montréal; Hôpital Maisonneuve-Rosemont","funders":"","keywords":"Calreticulin; Myelofibrosis; Allele; JAK2 V617F; Allele frequency; Medicine; Hematologic Neoplasms; Immunology; Myeloproliferative neoplasm; Biology; Internal medicine; Cancer research; Genetics; Bone marrow; Cancer; Gene","score_opus":0.005725406112724976,"score_gpt":0.22480384174292192,"score_spread":0.21907843563019694,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4310159140","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99720407,0.00015371972,0.00001458936,0.00020753626,0.000038746686,0.0017062549,0.00020225819,0.000028516652,0.00044433423],"genre_scores_gemma":[0.9969156,0.000012875112,0.0018423181,0.00008192481,0.000031338768,0.0006696475,0.00036709293,0.000035636855,0.00004357739],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9980832,0.00014688047,0.00042153857,0.00041855744,0.0005686519,0.00036122557],"domain_scores_gemma":[0.9990311,0.00013131076,0.00018069212,0.00030564095,0.000192085,0.00015913283],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000136758,0.000283144,0.0005914472,0.00018249749,0.000113507485,0.0000120940995,0.00009801903,0.000055064065,0.00091197714],"category_scores_gemma":[0.00010852419,0.00019469282,0.00011619386,0.00045737962,0.00006325268,0.000066303415,0.000073988085,0.00029417672,0.000011013246],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00064566487,0.009226457,0.98639077,0.000036710408,0.00062792754,0.00038477004,0.0008571036,0.00038508684,0.00006382152,0.0011247244,0.000081923994,0.00017504871],"study_design_scores_gemma":[0.015753381,0.010867368,0.97132146,0.00007219602,0.00033843768,0.00007068658,0.00007299286,0.0000518974,0.0009968239,0.00024454255,0.000010235038,0.00019997775],"about_ca_topic_score_codex":0.0007153213,"about_ca_topic_score_gemma":0.000102465616,"teacher_disagreement_score":0.0151077155,"about_ca_system_score_codex":0.00021677265,"about_ca_system_score_gemma":0.00045220283,"threshold_uncertainty_score":0.998551},"labels":[],"label_agreement":null},{"id":"W4310161034","doi":"10.1182/blood-2022-171047","title":"Evaluation of Bleeding and Thrombocytopenia in Older Adults with Acute Myeloid Leukemia Treated with Hypomethylating Agents: A Systematic Review and Meta-Analysis","year":2022,"lang":"en","type":"review","venue":"Blood","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen's University; University of Toronto; University of British Columbia; University of Manitoba; BC Cancer Agency; Health Sciences Centre; CancerCare Manitoba; Sunnybrook Health Science Centre","funders":"","keywords":"Hypomethylating agent; Medicine; Myeloid leukemia; Meta-analysis; Internal medicine; Oncology","score_opus":0.09200793101125183,"score_gpt":0.3518450314302243,"score_spread":0.25983710041897246,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4310161034","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.005715357,0.9843599,0.0000021603319,0.00002473239,0.0000028766124,0.009601145,0.00008833884,0.000014992561,0.00019047788],"genre_scores_gemma":[0.004224078,0.9892303,0.00047818635,0.000053322645,0.0000065906715,0.005631073,0.0002706062,0.000053609383,0.00005223191],"study_design_codex":"systematic_review","study_design_gemma":"meta_analysis","domain_scores_codex":[0.99579036,0.0009634003,0.0011781274,0.00074174005,0.0010982306,0.00022811086],"domain_scores_gemma":[0.9974791,0.00043270382,0.0011851323,0.00049376674,0.0002939239,0.00011537246],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0019922329,0.0006173303,0.009529286,0.0005342528,0.00008055071,0.000032666678,0.00008693707,0.000110638284,0.0004730218],"category_scores_gemma":[0.00021410013,0.00032064362,0.0005314232,0.0016506815,0.000047889353,0.00009094654,0.000069489346,0.00027428864,0.00000114779],"study_design_candidate":"meta_analysis","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000019796531,0.0004254905,0.0003671005,0.5853482,0.40855604,0.00013399565,0.00034014165,0.0000024980966,1.7429862e-7,0.0000045449083,0.000002903915,0.0047991253],"study_design_scores_gemma":[0.00326026,0.00057360297,0.00020210518,0.081325725,0.9138271,0.0003416043,0.00009487946,0.00003234207,0.0000053774997,6.0131555e-7,0.000079211364,0.00025715373],"about_ca_topic_score_codex":0.000107760796,"about_ca_topic_score_gemma":0.00010873535,"teacher_disagreement_score":0.5052711,"about_ca_system_score_codex":0.0003011955,"about_ca_system_score_gemma":0.00042329382,"threshold_uncertainty_score":0.99992454},"labels":[],"label_agreement":null},{"id":"W4310161917","doi":"10.1182/blood-2022-170026","title":"Higher Rates of Perioperative Thrombosis and Distinct Management Practices in Secondary Erythrocytosis Versus Polycythemia Vera","year":2022,"lang":"en","type":"article","venue":"Blood","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Jewish General Hospital; Université Laval; Quebec - Clinical Research Organization in Cancer; Université de Montréal; Hôpital Maisonneuve-Rosemont","funders":"","keywords":"Polycythemia vera; Medicine; Thrombosis; Internal medicine; Gastroenterology; Intensive care medicine","score_opus":0.05142106782183492,"score_gpt":0.33286534946577107,"score_spread":0.28144428164393614,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4310161917","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9747973,0.0011232352,4.1190623e-7,0.0015338452,0.00011642288,0.0005161697,0.000055913093,0.000015864272,0.021840835],"genre_scores_gemma":[0.99784803,0.0005034469,0.00059264776,0.00014634684,0.00003624975,0.00040105006,0.000043003583,0.000017929764,0.0004112839],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9989133,0.000092518305,0.00023990918,0.00032876368,0.0002498267,0.00017570819],"domain_scores_gemma":[0.99933565,0.00019915,0.000180652,0.00018910367,0.00003121566,0.000064242275],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00012871396,0.00016990812,0.00035380005,0.00010421605,0.00014377662,0.000019474583,0.00005838666,0.000029595605,0.0014988341],"category_scores_gemma":[0.000027477203,0.00014328815,0.000053250216,0.00019885482,0.00006580608,0.00009264429,0.00016063631,0.00018376393,0.0000047210824],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0019820556,0.007637583,0.9712774,0.0004331244,0.0027083422,0.00035617145,0.0040397937,0.000005972989,0.003137755,0.0042773164,0.00069278566,0.0034516642],"study_design_scores_gemma":[0.018454634,0.0024078877,0.94606215,0.0000811216,0.00082044926,0.000024889936,0.002638924,0.000010927238,0.021403654,0.000023339944,0.007870574,0.0002014508],"about_ca_topic_score_codex":0.00014157787,"about_ca_topic_score_gemma":0.0000661599,"teacher_disagreement_score":0.025215287,"about_ca_system_score_codex":0.000084010375,"about_ca_system_score_gemma":0.00006324829,"threshold_uncertainty_score":0.9994139},"labels":[],"label_agreement":null},{"id":"W4310565668","doi":"10.1007/s11606-022-07963-x","title":"A Rational Approach to JAK2 Mutation Testing in Patients with Elevated Hemoglobin: Results from the JAK2 Prediction Cohort (JAKPOT) Study","year":2022,"lang":"en","type":"article","venue":"Journal of General Internal Medicine","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":15,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"London Health Sciences Centre; Western University","funders":"","keywords":"Medicine; Cohort; Mutation; Cohort study; Hemoglobin; Internal medicine; Genetic testing; Genetics; Gene","score_opus":0.025076011177822086,"score_gpt":0.26783862764012367,"score_spread":0.24276261646230157,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4310565668","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99401486,0.000063633684,0.00029753215,0.0029436543,0.00041196798,0.0013033177,0.000078737445,0.000010815888,0.00087549764],"genre_scores_gemma":[0.9953883,0.000004235697,0.0018740731,0.0012027818,0.0008683557,0.00011356445,0.00022494009,0.000020883273,0.0003028178],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99675983,0.0002838196,0.0010501707,0.0002983135,0.001417162,0.0001906978],"domain_scores_gemma":[0.998074,0.00034634004,0.0005752126,0.00019006802,0.00064391986,0.00017045677],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010335109,0.00021007103,0.00049162825,0.00024371954,0.00015880789,0.000021536307,0.00016656643,0.000029796096,0.00008806823],"category_scores_gemma":[0.0007840481,0.00011454806,0.000052652616,0.0005264308,0.000042072676,0.000107541055,0.00006601224,0.0005464674,0.0000020655882],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.006799968,0.0023127978,0.97405094,0.0000045697857,0.00048696433,0.00018982134,0.0027213118,0.0050732233,0.00035111612,0.000010265884,0.006587678,0.0014113664],"study_design_scores_gemma":[0.018320905,0.013595793,0.96269506,0.00025803558,0.00029597819,0.00021210044,0.0012396639,0.0027736998,0.00015875262,0.000020586627,0.00033893806,0.000090468064],"about_ca_topic_score_codex":0.0011077466,"about_ca_topic_score_gemma":0.00005828775,"teacher_disagreement_score":0.011520937,"about_ca_system_score_codex":0.00055281154,"about_ca_system_score_gemma":0.0001624656,"threshold_uncertainty_score":0.4671134},"labels":[],"label_agreement":null},{"id":"W4311816595","doi":"10.1002/jha2.622","title":"Impact of mutations on pregnancy outcome in patients with myeloproliferative neoplasms","year":2022,"lang":"en","type":"article","venue":"eJHaem","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Lunenfeld-Tanenbaum Research Institute; Mount Sinai Hospital; Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Pregnancy; Medicine; Essential thrombocythemia; Cohort; Obstetrics; Early Pregnancy Loss; Aspirin; Antiphospholipid syndrome; Thrombosis; Gynecology; Internal medicine; Abortion; Polycythemia vera; Biology; Genetics","score_opus":0.018943475649943357,"score_gpt":0.3028540981848966,"score_spread":0.28391062253495325,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4311816595","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.996533,0.000058832073,0.000004991635,0.00023078753,0.000058502737,0.0011668409,0.00016130114,0.000022482802,0.0017632716],"genre_scores_gemma":[0.99853826,0.0000046646855,0.0002875515,0.000108772976,0.000013725145,0.0004902975,0.00020348642,0.000025694793,0.00032756536],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99859524,0.000085890904,0.00033995506,0.0002889907,0.00045848216,0.00023142259],"domain_scores_gemma":[0.9992678,0.0001224982,0.00014264575,0.0002565658,0.000112814894,0.000097632605],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00006430942,0.00020432816,0.00042552798,0.0002224329,0.00011726947,0.00000740319,0.00006358122,0.000030050911,0.0007248776],"category_scores_gemma":[0.000055575787,0.00013917976,0.0001156171,0.00039408565,0.0000445823,0.00006101013,0.000041605137,0.00023745043,0.000019865238],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0008122343,0.0026313998,0.99111396,0.00001824776,0.00019081835,0.000062335086,0.0016521006,0.0012251595,0.0000070379124,0.0005836928,0.00011473189,0.001588302],"study_design_scores_gemma":[0.006571405,0.0078470595,0.9846293,0.00012049549,0.000056304438,0.000006655885,0.00013576845,0.00006417742,0.00035373936,0.000047029916,0.000040483344,0.0001275888],"about_ca_topic_score_codex":0.00009164584,"about_ca_topic_score_gemma":0.000039117618,"teacher_disagreement_score":0.0064846477,"about_ca_system_score_codex":0.00040537753,"about_ca_system_score_gemma":0.00018068333,"threshold_uncertainty_score":0.79369015},"labels":[],"label_agreement":null},{"id":"W4313379780","doi":"10.1016/j.trsl.2022.12.009","title":"Emerging evidence on the role of clonal hematopoiesis of indeterminate potential in chronic kidney disease","year":2022,"lang":"en","type":"review","venue":"Translational research","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen's University","funders":"National Institute of Diabetes and Digestive and Kidney Diseases; National Institutes of Health; U.S. Department of Veterans Affairs","keywords":"Kidney disease; Disease; Medicine; Population; Renal function; Internal medicine; Bioinformatics; Immunology; Biology; Environmental health","score_opus":0.18135825911121917,"score_gpt":0.4586645270930837,"score_spread":0.27730626798186453,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4313379780","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0017014139,0.994172,0.0000028128754,0.0013713577,0.000028259132,0.001746955,0.0002819855,0.0000048259058,0.00069042685],"genre_scores_gemma":[0.0733514,0.9253518,0.000026463224,0.00001729946,0.000082142185,0.0008528798,0.00018281142,0.000029847233,0.000105332816],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9958729,0.0007631191,0.00066973205,0.00038196772,0.0020024907,0.00030978824],"domain_scores_gemma":[0.99620205,0.0029245494,0.00015801794,0.00037142527,0.00016068538,0.00018324742],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0013963721,0.00022604107,0.00087697414,0.0005589897,0.00012798309,0.000010423116,0.00026955345,0.00008709797,0.003955875],"category_scores_gemma":[0.00060597894,0.00014740159,0.00043954942,0.0007137623,0.00019992239,0.000050519757,0.00007007976,0.00079081603,0.000017741448],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0007119644,0.0010879859,0.0032265678,0.026876269,0.0005723016,0.00021974371,0.00040331812,0.00007922085,0.000046153782,0.015041733,0.00023980995,0.95149493],"study_design_scores_gemma":[0.0018162704,0.0011914192,0.009913615,0.07461532,0.0010297522,0.000031527914,0.00010280505,0.00097302266,0.00040737746,0.003174443,0.90632373,0.00042074],"about_ca_topic_score_codex":0.00007258404,"about_ca_topic_score_gemma":0.000011997503,"teacher_disagreement_score":0.9510742,"about_ca_system_score_codex":0.0003527257,"about_ca_system_score_gemma":0.0041485685,"threshold_uncertainty_score":0.9969546},"labels":[],"label_agreement":null},{"id":"W4317867940","doi":"10.1002/ajh.26861","title":"Screening for signs of portal hypertension by esophagogastroduodenoscopy in patients with <i>BCR‐ABL</i> negative myeloproliferative neoplasms","year":2023,"lang":"en","type":"letter","venue":"American Journal of Hematology","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Queen's University; University Health Network; Kingston Health Sciences Centre; Princess Margaret Cancer Centre","funders":"Princess Margaret Cancer Foundation","keywords":"Esophagogastroduodenoscopy; Medicine; Myeloproliferative Disorders; Portal hypertension; Internal medicine; Myelofibrosis; Gastroenterology; Endoscopy; Bone marrow; Cirrhosis","score_opus":0.013368725638416056,"score_gpt":0.25538521505860007,"score_spread":0.242016489420184,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4317867940","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8509018,0.0005330109,0.0013799254,0.14367864,0.0004321314,0.0023808354,0.0005954358,0.000033619475,0.00006461516],"genre_scores_gemma":[0.85957897,0.00026035128,0.031774648,0.105526604,0.0009192563,0.00029286704,0.001070214,0.00035027714,0.00022678895],"study_design_codex":"not_applicable","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.996396,0.00024575178,0.001408635,0.00055734994,0.00073690485,0.00065536797],"domain_scores_gemma":[0.9945213,0.0014248062,0.0024997392,0.00030708782,0.0010664768,0.00018058855],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00023663616,0.0006230145,0.0032085867,0.00064897264,0.00007538156,0.000014704635,0.00020340586,0.0003221389,0.000039685732],"category_scores_gemma":[0.0003203358,0.00043793514,0.00034395442,0.0005119617,0.00056373194,0.00011971762,0.000048413614,0.001316642,0.0000048967568],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.006890096,0.0011214975,0.375278,0.00032128894,0.002889288,0.0044591506,0.0007990332,0.000054050815,0.00010002122,0.00004851099,0.6063246,0.0017144752],"study_design_scores_gemma":[0.16949588,0.44381782,0.18408196,0.02417341,0.01292105,0.021161575,0.009868416,0.00049817975,0.076227464,0.00096136256,0.050477635,0.006315271],"about_ca_topic_score_codex":0.000082443585,"about_ca_topic_score_gemma":0.00002473618,"teacher_disagreement_score":0.555847,"about_ca_system_score_codex":0.00012070673,"about_ca_system_score_gemma":0.0004519639,"threshold_uncertainty_score":0.99980724},"labels":[],"label_agreement":null},{"id":"W4318159227","doi":"10.1016/s0140-6736(22)02036-0","title":"Momelotinib versus danazol in symptomatic patients with anaemia and myelofibrosis (MOMENTUM): results from an international, double-blind, randomised, controlled, phase 3 study","year":2023,"lang":"en","type":"article","venue":"The Lancet","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":185,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Myelofibrosis; Danazol; Medicine; Double blind; Internal medicine; Gastroenterology; Placebo; Pathology; Bone marrow; Alternative medicine; Endometriosis","score_opus":0.054584232529998125,"score_gpt":0.3514086913066433,"score_spread":0.2968244587766452,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4318159227","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99185115,0.00003753625,0.0000013669586,0.0024533346,0.00020097844,0.004316919,0.0002506703,0.00008163336,0.00080643763],"genre_scores_gemma":[0.9975213,0.00016398316,0.000057610403,0.000158625,0.00024183573,0.00097644574,0.00077040103,0.000024615138,0.00008518685],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99825263,0.000145336,0.00045320432,0.00041537816,0.00045525504,0.00027819697],"domain_scores_gemma":[0.998287,0.0007943729,0.00017571183,0.000529378,0.0000940635,0.00011948009],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00047992438,0.00023594261,0.0008478268,0.00015989426,0.000100758116,0.00008425517,0.00018248611,0.00004449015,0.00004874252],"category_scores_gemma":[0.0001860925,0.00013055115,0.000046956513,0.0003014796,0.000054424017,0.00014730694,0.00006270673,0.00014705198,0.000033832435],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.6206911,0.0023035319,0.37030533,0.000011919168,0.0010198094,0.00006029146,0.0032243568,0.000034641864,0.00001816972,0.000037321355,0.0007290742,0.0015644657],"study_design_scores_gemma":[0.6898896,0.0020474768,0.30593678,0.000090399095,0.0002583935,6.120094e-7,0.0007239738,0.0007007253,0.00008533605,0.000014660569,0.00014372733,0.00010828229],"about_ca_topic_score_codex":0.00025009774,"about_ca_topic_score_gemma":0.00027702493,"teacher_disagreement_score":0.069198534,"about_ca_system_score_codex":0.00010363542,"about_ca_system_score_gemma":0.000043100208,"threshold_uncertainty_score":0.5323722},"labels":[],"label_agreement":null},{"id":"W4318833487","doi":"10.1016/j.jtha.2023.01.021","title":"Corrigendum to GoldVariants, a resource for sharing rare genetic variants detected in bleeding, thrombotic, and platelet disorders: Communication from the ISTH SSC Subcommittee on Genomics in Thrombosis and Hemostasis [J Thromb Haemost. 2021 Oct;19(10):2612-2617]","year":2023,"lang":"en","type":"erratum","venue":"Journal of Thrombosis and Haemostasis","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"St. Lawrence College; Queen's University","funders":"European Hematology Association","keywords":"Blood Platelet Disorders; Platelet disorder; Genetic variants; Medicine; Hemostasis; Thrombosis; Bioinformatics; Gene; Genetics; Platelet; Biology; Internal medicine; Platelet aggregation; Genotype","score_opus":0.07584238165262659,"score_gpt":0.3242577789150123,"score_spread":0.2484153972623857,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4318833487","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9307734,0.016988754,0.00012742731,0.040644918,0.0029117854,0.005191639,0.002540118,0.000059490427,0.0007624634],"genre_scores_gemma":[0.4956028,0.47668424,0.014578743,0.0050379387,0.0020765916,0.000796877,0.002126282,0.00091509643,0.0021814485],"study_design_codex":"not_applicable","study_design_gemma":"observational","domain_scores_codex":[0.9948872,0.00037832386,0.0018824814,0.0012194731,0.0007637845,0.0008687774],"domain_scores_gemma":[0.9953978,0.001455003,0.0011981633,0.0010900728,0.00031842667,0.00054050644],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0011048678,0.0010487236,0.002703691,0.00082831946,0.000628277,0.00049063645,0.00066290627,0.000817116,0.00023545713],"category_scores_gemma":[0.0007849203,0.0008104763,0.00031657342,0.00093180843,0.00028909356,0.0002599719,0.0006713154,0.0016521947,0.000009909513],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0018072415,0.0016131263,0.1373162,0.00076769484,0.0041456544,0.00017311455,0.012798795,0.00007183917,0.00027993997,0.00015011741,0.8070028,0.033873513],"study_design_scores_gemma":[0.009629838,0.0026827245,0.89652324,0.006965585,0.0021078794,0.00012299481,0.005249576,0.0012894205,0.00032069872,0.0010656741,0.07292339,0.0011190004],"about_ca_topic_score_codex":0.0023064483,"about_ca_topic_score_gemma":0.008064583,"teacher_disagreement_score":0.759207,"about_ca_system_score_codex":0.000706051,"about_ca_system_score_gemma":0.00040589433,"threshold_uncertainty_score":0.9994346},"labels":[],"label_agreement":null},{"id":"W4319786746","doi":"10.3324/haematol.2022.281958","title":"Association between the choice of the conditioning regimen and outcomes of allogeneic hematopoietic cell transplantation for myelofibrosis","year":2023,"lang":"en","type":"article","venue":"Haematologica","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":33,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"National Institute of Allergy and Infectious Diseases; Office of Naval Research; Legend Biotech; Pharmacyclics; Kite Pharma; Sanofi Genzyme; Takeda Oncology; Health Resources and Services Administration; National Institutes of Health; MorphoSys; Daiichi-Sankyo; Omeros Corporation; Astellas Pharma; Adaptive Biotechnologies; Pfizer; Incyte; Kiadis Pharma; bluebird bio; TG Therapeutics; Medical College of Wisconsin; StemCyte; HistoGenetics; Karyopharm Therapeutics; CareDx; Actinium Pharmaceuticals; Daiichi Sankyo Europe; National Cancer Institute; Gilead Sciences; Amgen; Accenture; Sanofi; GlaxoSmithKline; CSL Behring; Bristol-Myers Squibb; Astellas Pharma US; National Heart, Lung, and Blood Institute; Novartis Pharmaceuticals Corporation; Medac; Jazz Pharmaceuticals; Seagen; Be The Match Foundation","keywords":"Busulfan; Fludarabine; Medicine; Hazard ratio; Internal medicine; Melphalan; Cyclophosphamide; Myelofibrosis; Transplantation; Gastroenterology; Regimen; Surgery; Hematopoietic stem cell transplantation; Hematopoietic cell; Proportional hazards model; Oncology; Chemotherapy; Confidence interval; Bone marrow; Haematopoiesis; Stem cell","score_opus":0.03062084220648969,"score_gpt":0.2970089551485368,"score_spread":0.2663881129420471,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4319786746","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99354684,0.00010651155,0.00004287798,0.0051428,0.000032554413,0.00076112064,0.00008754489,0.000021662807,0.00025809932],"genre_scores_gemma":[0.9990121,0.00014829516,0.0002238055,0.00011206689,0.000012364961,0.00017531286,0.000059613438,0.000007201177,0.0002492439],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99923784,0.00006884857,0.00026264557,0.00013107483,0.00017787017,0.00012173882],"domain_scores_gemma":[0.99794036,0.0015577169,0.00026346804,0.00013559603,0.000079388396,0.00002346505],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00021159461,0.00009184289,0.00035655967,0.000033309258,0.00012728645,0.000006580199,0.000056483528,0.00007487294,0.000019887257],"category_scores_gemma":[0.00017121127,0.000045405395,0.00010748873,0.00013723239,0.000054851138,0.000022718068,0.000016665084,0.00004796756,0.000004135651],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000017744089,0.000040811734,0.9969261,0.00029046545,0.00019295175,0.0000011701063,0.0005334293,0.000006659056,0.0006941223,0.0005896103,0.0005924383,0.00011447637],"study_design_scores_gemma":[0.0008168264,0.00013541112,0.9296177,0.00007878923,0.00051368924,0.0000042718,0.00014483956,0.000012806812,0.06802641,0.0004826654,0.00012515797,0.000041435753],"about_ca_topic_score_codex":0.00001640043,"about_ca_topic_score_gemma":0.00000892269,"teacher_disagreement_score":0.06733228,"about_ca_system_score_codex":0.000020942169,"about_ca_system_score_gemma":0.00002052103,"threshold_uncertainty_score":0.18515782},"labels":[],"label_agreement":null},{"id":"W4320733022","doi":"10.22541/au.167635647.75089299/v1","title":"A case of synchronous dual hematological malignancy: effects of multiple myeloma therapy on essential thrombocythemia and vice versa","year":2023,"lang":"en","type":"preprint","venue":"","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Royal Victoria Hospital; Royal Victoria Regional Health Centre; Western University","funders":"","keywords":"Multiple myeloma; Thrombocytosis; Essential thrombocythemia; Hematologic malignancy; Medicine; Concomitant; Bone marrow; Malignancy; Internal medicine; Hematology; Polycythemia vera; Platelet","score_opus":0.0296770239288361,"score_gpt":0.3015479398088681,"score_spread":0.27187091588003204,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4320733022","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99585825,0.0008713649,0.0000913477,0.00030386262,0.0002860751,0.0020014127,0.00008220911,0.000094562856,0.0004109049],"genre_scores_gemma":[0.99655837,0.0014917774,0.0012214914,0.00009902926,0.000092791546,0.0003177985,0.00007834932,0.000048294238,0.00009209307],"study_design_codex":"observational","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99800897,0.00011918967,0.00055042736,0.0007129891,0.00032809516,0.00028034236],"domain_scores_gemma":[0.9974862,0.0013636561,0.00030508835,0.00053547736,0.00015293014,0.0001566527],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00013701088,0.00047206672,0.0014589767,0.0001570666,0.00005776121,0.000014406335,0.00007304916,0.0004320183,0.0001420181],"category_scores_gemma":[0.00018650596,0.0003197097,0.00026256996,0.00011181684,0.00019747522,0.000020361962,0.00026262578,0.0003450147,0.000019081868],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.018199544,0.03484759,0.42756775,0.049826693,0.025596023,0.24775733,0.023805743,0.00046032824,0.09889945,0.020071056,0.0075619677,0.04540654],"study_design_scores_gemma":[0.013362066,0.005329607,0.07199121,0.003516107,0.00080977316,0.0035616418,0.00027092415,0.0007450798,0.8993251,0.00049254374,0.000040969055,0.0005549915],"about_ca_topic_score_codex":0.00056130934,"about_ca_topic_score_gemma":0.000114039394,"teacher_disagreement_score":0.80042565,"about_ca_system_score_codex":0.00007829122,"about_ca_system_score_gemma":0.00018564083,"threshold_uncertainty_score":0.9999255},"labels":[],"label_agreement":null},{"id":"W4321184903","doi":"10.1159/000529123","title":"Pericardial Extramedullary Hematopoiesis Associated with Metastatic Adenocarcinoma of Gastrointestinal or Pancreaticobiliary Origin: A Case Report","year":2023,"lang":"en","type":"article","venue":"Case Reports in Oncology","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Western University","funders":"","keywords":"Medicine; Extramedullary hematopoiesis; Pericardium; Pericardial effusion; Pathology; Haematopoiesis; Internal medicine; Stem cell","score_opus":0.05685606529908406,"score_gpt":0.35500155942847733,"score_spread":0.2981454941293933,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4321184903","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9966191,0.00018858069,0.00004475382,0.0004498603,0.000147728,0.0011710041,0.000027418413,0.00010908332,0.0012424489],"genre_scores_gemma":[0.99327064,0.000033172346,0.0052443007,0.00009296263,0.000067988585,0.0005879735,0.00012896118,0.000048823156,0.00052516477],"study_design_codex":"case_report","study_design_gemma":"case_report","domain_scores_codex":[0.9969234,0.00027671494,0.0012678041,0.000657246,0.00036840598,0.00050642824],"domain_scores_gemma":[0.99641585,0.0016263981,0.00076046336,0.00059990614,0.00032647786,0.0002708737],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010797635,0.0003319283,0.0014311641,0.00035359594,0.00009455613,0.0000109300645,0.000029029881,0.00011472324,0.0002684813],"category_scores_gemma":[0.0031745138,0.00022913363,0.00017530697,0.0009256466,0.0002936933,0.000063311905,0.00006361263,0.000304318,0.0000065780678],"study_design_candidate":"case_report","study_design_consensus":"case_report","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00040661203,0.0007573251,0.34371102,0.00011439256,0.00031283282,0.6532468,0.0003522664,0.000027470822,0.000043930933,0.000018632221,0.0005426322,0.0004660725],"study_design_scores_gemma":[0.0021034747,0.0034157871,0.054727074,0.00043319975,0.0008316435,0.9354548,0.002018511,0.00018772169,0.0003471987,0.00004296311,0.00025596583,0.000181659],"about_ca_topic_score_codex":0.00046439288,"about_ca_topic_score_gemma":0.00084173837,"teacher_disagreement_score":0.28898394,"about_ca_system_score_codex":0.00061142776,"about_ca_system_score_gemma":0.0017560003,"threshold_uncertainty_score":0.9343798},"labels":[],"label_agreement":null},{"id":"W4321485511","doi":"10.1017/9781108975780.064","title":"Thrombocytopenia in Pregnancy","year":2023,"lang":"en","type":"book-chapter","venue":"Cambridge University Press eBooks","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University","funders":"","keywords":"Medicine; Obstetrics; Pregnancy; Gestation; Singleton; Anemia; Center (category theory); Fetus; Blood count; Complete blood count; Pediatrics; Gynecology; Internal medicine","score_opus":0.04623967968003105,"score_gpt":0.2446455047641711,"score_spread":0.19840582508414006,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4321485511","genre_codex":"other","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"other","genre_consensus":"other","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0010609907,0.000281476,0.0000070229216,0.00008418834,0.00018641628,0.001272462,0.00022067118,0.0001674059,0.99671936],"genre_scores_gemma":[0.003381311,0.001080168,0.000071526694,0.00007425127,0.00008027984,0.000007862085,0.00015441937,0.00008497206,0.9950652],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","domain_scores_codex":[0.9984498,0.000027602215,0.0002442808,0.00064025767,0.00031314814,0.0003249175],"domain_scores_gemma":[0.9988892,0.00009770516,0.00014389861,0.00054629426,0.000119434386,0.00020344986],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0000537768,0.0004344696,0.0008382228,0.00030567913,0.00009025489,0.000021572894,0.00018446875,0.00039624513,0.000023728531],"category_scores_gemma":[0.000013935337,0.00044650788,0.0002501249,0.000016981818,0.00013460865,0.000050247047,0.00024327882,0.00050599733,0.00016096536],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00023383679,0.000081757986,0.0005410698,0.00030934924,0.00046082924,0.008693015,0.000097461234,0.0000011934765,0.000026902524,0.96390903,0.023007609,0.0026379388],"study_design_scores_gemma":[0.0055337823,0.00049337925,0.00563635,0.0056233895,0.00088972494,0.00007615283,0.000045397832,0.000029708304,0.0010742581,0.000034128494,0.97977555,0.00078818825],"about_ca_topic_score_codex":0.00015727691,"about_ca_topic_score_gemma":0.000030241881,"teacher_disagreement_score":0.96387494,"about_ca_system_score_codex":0.0004141351,"about_ca_system_score_gemma":0.00021297576,"threshold_uncertainty_score":0.99979866},"labels":[],"label_agreement":null},{"id":"W4321488444","doi":"10.1017/9781108975780.060","title":"Hematologic Conditions in Pregnancy","year":2023,"lang":"en","type":"book-chapter","venue":"Cambridge University Press eBooks","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University","funders":"","keywords":"Pregnancy; Content (measure theory); Computer science; Information retrieval; Mathematics; Biology","score_opus":0.043539377591675435,"score_gpt":0.24962640844205372,"score_spread":0.20608703085037827,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4321488444","genre_codex":"other","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"other","genre_consensus":"other","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0014143483,0.00022016751,0.000008311572,0.00010669074,0.00014280246,0.0011325483,0.0004640972,0.0001951996,0.99631584],"genre_scores_gemma":[0.008659297,0.0006414685,0.000047671278,0.000076782795,0.000042540414,0.0000140268485,0.000346891,0.00005418204,0.99011713],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","domain_scores_codex":[0.9987113,0.00002672571,0.00022695045,0.000528319,0.00022895438,0.00027773873],"domain_scores_gemma":[0.99900323,0.00013422874,0.00014158397,0.00042959783,0.00011489884,0.00017644952],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.000037487807,0.00036234714,0.0006700364,0.00032739007,0.000107574815,0.000014372844,0.00013445059,0.00037266497,0.000027701977],"category_scores_gemma":[0.000018050456,0.000369536,0.00023453815,0.000016647953,0.0001626084,0.000037940412,0.0001541851,0.0004275981,0.00014390527],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00007630041,0.0000737188,0.0005159855,0.00024486188,0.00028710518,0.007837206,0.00004443489,0.0000011994107,0.000012332471,0.9698894,0.020767823,0.0002496141],"study_design_scores_gemma":[0.008729452,0.00076388696,0.0074905986,0.010556082,0.0017571133,0.00038721302,0.00013453525,0.00006418151,0.0015251109,0.00024541083,0.96697694,0.0013695032],"about_ca_topic_score_codex":0.000072478,"about_ca_topic_score_gemma":0.000016861924,"teacher_disagreement_score":0.969644,"about_ca_system_score_codex":0.00030186356,"about_ca_system_score_gemma":0.00015698097,"threshold_uncertainty_score":0.99987566},"labels":[],"label_agreement":null},{"id":"W4321600787","doi":"10.1002/ajh.26890","title":"Comparison of clinical outcomes between transplant and nontransplant therapies in myelofibrosis following failure of first‐line JAK‐inhibitor","year":2023,"lang":"en","type":"letter","venue":"American Journal of Hematology","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Sunnybrook Health Science Centre; Health Sciences Centre; University Health Network; Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Myelofibrosis; Medicine; Ruxolitinib; Internal medicine; Oncology; Second line; Surgery; First line; Bone marrow","score_opus":0.04967768675891962,"score_gpt":0.37728214272357113,"score_spread":0.3276044559646515,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4321600787","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.83113724,0.0010716938,0.000088573885,0.16698015,0.00026384738,0.0003021011,0.00013751126,0.000009117331,0.000009752559],"genre_scores_gemma":[0.9909821,0.0013386591,0.001868541,0.005231122,0.0004173133,0.000015069564,0.0000759294,0.000056755187,0.000014522915],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.995432,0.00036317317,0.002973046,0.00033798028,0.0005183283,0.00037546616],"domain_scores_gemma":[0.99345076,0.003932961,0.0020810205,0.00025029152,0.0001507121,0.00013423983],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00055047247,0.00042827826,0.005952395,0.00053046277,0.00003548566,0.0000066998714,0.00018002847,0.00043777225,0.000020144498],"category_scores_gemma":[0.00013271545,0.00029084206,0.0008901715,0.00025468727,0.00049489306,0.00004615287,0.000023829713,0.0013701712,0.0000019818729],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00042261952,0.00033306822,0.9823049,0.00057835603,0.0030816395,0.0018310831,0.0014254145,0.0000022084762,0.00002577579,0.000008747654,0.008098347,0.0018878944],"study_design_scores_gemma":[0.010044127,0.012134164,0.95090985,0.0068046465,0.004177592,0.001064294,0.0012555753,0.000018341067,0.0030893204,0.000082914084,0.009885919,0.00053323136],"about_ca_topic_score_codex":0.00016910511,"about_ca_topic_score_gemma":0.00022195795,"teacher_disagreement_score":0.16174902,"about_ca_system_score_codex":0.000032930133,"about_ca_system_score_gemma":0.00017274181,"threshold_uncertainty_score":0.99995434},"labels":[],"label_agreement":null},{"id":"W4321787519","doi":"10.1038/s41375-023-01837-9","title":"Clinicohematologic and molecular response of essential thrombocythemia patients treated with pegylated interferon-α: a multi-center study of the German Study Group-Myeloproliferative Neoplasms (GSG-MPN)","year":2023,"lang":"en","type":"article","venue":"Leukemia","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"AOP Orphan; Swedish Orphan Biovitrum; RWTH Aachen University; Astellas Pharma; Deutsche Forschungsgemeinschaft; Syndax Pharmaceuticals; Sierra Oncology; Incyte; Agios Pharmaceuticals; Jazz Pharmaceuticals; Gilead Sciences; Celgene; AstraZeneca; Ariad Pharmaceuticals; Amgen; Pfizer; Alexion Pharmaceuticals","keywords":"Essential thrombocythemia; Pegylated interferon; Medicine; Myeloproliferative Disorders; Internal medicine; Hematology; Oncology; Polycythemia vera; Immunology; Ribavirin","score_opus":0.019057850718400677,"score_gpt":0.30487386581736764,"score_spread":0.285816015098967,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4321787519","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9950277,0.000026665208,0.0000061436804,0.00006800786,0.00007282163,0.0046531837,0.00004187051,0.00007447404,0.000029137496],"genre_scores_gemma":[0.99915075,0.000017525264,0.00007231581,0.000072362855,0.00001255254,0.00048062787,0.000050645125,0.00005207021,0.000091129805],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9969531,0.00065716467,0.00081207574,0.0006509352,0.0005753007,0.00035138946],"domain_scores_gemma":[0.9981172,0.00033096096,0.0004346592,0.0006602772,0.00032401277,0.00013286942],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0003572636,0.00043559005,0.0010235187,0.00021078585,0.00013783498,0.000022323065,0.00018484774,0.00013619543,0.000026346408],"category_scores_gemma":[0.00017216214,0.00024951945,0.00012696961,0.0007069361,0.00022184031,0.00007894641,0.0002466262,0.00030649672,0.000011200402],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.008430203,0.009716017,0.9649584,0.000075642085,0.0012161271,0.00024147154,0.0120217465,0.000017399201,0.0031011917,0.000013683059,0.000063625004,0.00014448662],"study_design_scores_gemma":[0.033997934,0.014462463,0.9227008,0.00027512442,0.0006090225,0.000030881416,0.0033877287,0.00049998524,0.023806542,0.0000064756255,0.000005567177,0.00021745046],"about_ca_topic_score_codex":0.00016367246,"about_ca_topic_score_gemma":0.00021419115,"teacher_disagreement_score":0.04225758,"about_ca_system_score_codex":0.0002056973,"about_ca_system_score_gemma":0.00016608759,"threshold_uncertainty_score":0.9999957},"labels":[],"label_agreement":null},{"id":"W4322502657","doi":"10.3390/cancers15051479","title":"CRP/Albumin Ratio and Glasgow Prognostic Score Provide Prognostic Information in Myelofibrosis Independently of MIPSS70—A Retrospective Study","year":2023,"lang":"en","type":"article","venue":"Cancers","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"Novartis Stiftung für Medizinisch-Biologische Forschung; Krebsliga Schweiz; Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung","keywords":"Medicine; Internal medicine; Proportional hazards model; Gastroenterology; Retrospective cohort study; Albumin; Myelofibrosis; Hazard ratio; Surgery; Confidence interval; Bone marrow","score_opus":0.019070914943113512,"score_gpt":0.2740113714834523,"score_spread":0.25494045654033876,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4322502657","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.995118,0.00013883857,0.00001798508,0.0002857887,0.000109112014,0.003886495,0.000042498967,0.00006834241,0.00033292783],"genre_scores_gemma":[0.9981914,0.000110297115,0.00012063087,0.000081771905,0.00004242315,0.0012483214,0.000084170526,0.000018572684,0.00010241457],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99843013,0.000060074446,0.00047299298,0.00031344083,0.0004361712,0.00028718458],"domain_scores_gemma":[0.99913245,0.00013532618,0.00018890722,0.00020813475,0.00020981216,0.0001253595],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00023860656,0.00021845996,0.00045336565,0.00036480522,0.000071501854,0.00004070541,0.00006165893,0.00008216079,0.000030336616],"category_scores_gemma":[0.0006214853,0.00018444237,0.000049194317,0.000777824,0.000092371156,0.0003323932,0.000055357938,0.00017465558,0.000026053334],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0002578239,0.00015211619,0.98909676,0.00025068998,0.00012958919,0.000042167518,0.0053262613,0.00017908277,0.00017600044,0.00010496042,0.00032744056,0.0039571007],"study_design_scores_gemma":[0.0036334586,0.0019999945,0.9879613,0.00042947312,0.00015567373,0.000008796025,0.0025082824,0.0014615149,0.0015389196,0.000061027065,0.000091371556,0.00015021906],"about_ca_topic_score_codex":0.0005390923,"about_ca_topic_score_gemma":0.0008772547,"teacher_disagreement_score":0.0038068814,"about_ca_system_score_codex":0.00090689724,"about_ca_system_score_gemma":0.00064142735,"threshold_uncertainty_score":0.75213414},"labels":[],"label_agreement":null},{"id":"W4323352826","doi":"10.1200/jco.22.01972","title":"MANIFEST: Pelabresib in Combination With Ruxolitinib for Janus Kinase Inhibitor Treatment-Naïve Myelofibrosis","year":2023,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":85,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"National Cancer Institute; Medical Research Council; Cancer Research UK","keywords":"Medicine; Ruxolitinib; Myelofibrosis; Discontinuation; Internal medicine; Gastroenterology; Cohort; Clinical endpoint; Surgery; Clinical trial; Bone marrow","score_opus":0.14049935953026033,"score_gpt":0.4583511375790651,"score_spread":0.31785177804880477,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4323352826","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98164636,0.00015200909,0.00003281108,0.015162467,0.00060353114,0.0008716294,0.00002073539,0.000020877489,0.0014896026],"genre_scores_gemma":[0.99301624,0.000928675,0.0033226584,0.0007485406,0.00089379225,0.00013492264,0.000038650676,0.000030123829,0.0008863791],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.997063,0.0002715342,0.0017502886,0.0002673285,0.0003176848,0.00033019422],"domain_scores_gemma":[0.9942204,0.0038453087,0.000967496,0.00016269648,0.00046331502,0.00034079998],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0014386531,0.00020786865,0.0014662857,0.00031142533,0.000058653986,0.000015171501,0.000077154604,0.0003047253,0.00006358646],"category_scores_gemma":[0.0014972105,0.00012959274,0.0003976636,0.00030203332,0.00011575332,0.000115836825,0.000021952002,0.00033685047,0.000047260553],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.017730035,0.012121985,0.7355753,0.000107011714,0.0008944557,0.004008695,0.0004892224,0.000040915613,0.00019007073,0.0019966594,0.0070071537,0.2198385],"study_design_scores_gemma":[0.04648079,0.08596678,0.810272,0.00033171065,0.0005440967,0.0003142065,0.00034164827,0.00020479404,0.0012529936,0.00074012415,0.053400885,0.00015002108],"about_ca_topic_score_codex":0.0000343841,"about_ca_topic_score_gemma":0.00020287812,"teacher_disagreement_score":0.21968849,"about_ca_system_score_codex":0.00042967667,"about_ca_system_score_gemma":0.0012058775,"threshold_uncertainty_score":0.52846384},"labels":[],"label_agreement":null},{"id":"W4327618758","doi":"10.3390/cancers15061785","title":"Use of Next Generation Sequencing to Define the Origin of Primary Myelofibrosis","year":2023,"lang":"en","type":"article","venue":"Cancers","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hospital for Sick Children","funders":"Ministero della Salute","keywords":"Myelofibrosis; DNA sequencing; Primary (astronomy); Computational biology; Medicine; Biology; Computer science; Genetics; Pathology; DNA; Bone marrow","score_opus":0.1876444967423714,"score_gpt":0.31371917473062527,"score_spread":0.12607467798825386,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4327618758","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9976139,0.00019171563,0.000057590267,0.0011547251,0.00013383204,0.00040893396,0.000032634056,0.000021558339,0.000385086],"genre_scores_gemma":[0.9967072,0.00050030753,0.001267171,0.0008133275,0.00011009333,0.00012112783,0.000059357506,0.000013663896,0.00040777022],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99931073,0.000024568753,0.00020153985,0.00014687452,0.00019017329,0.00012612269],"domain_scores_gemma":[0.9994374,0.00011199492,0.0000707741,0.0002110893,0.00010851231,0.00006023029],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00009726296,0.00008695638,0.00022687009,0.00007836025,0.000042407682,0.000009017841,0.000038178303,0.000029752257,0.000057842986],"category_scores_gemma":[0.00007472556,0.00005660446,0.00005989276,0.0004020254,0.000039418795,0.000058420163,0.000021650276,0.00004297082,0.000018551897],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0002292647,0.000035865698,0.088177204,0.00025524417,0.0003214749,0.000020215377,0.0026516549,0.01492825,0.8181507,0.0014754721,0.0454758,0.028278828],"study_design_scores_gemma":[0.0013598962,0.0009985368,0.14820921,0.00046712975,0.00030102598,0.00001012253,0.0004471548,0.005314738,0.8194986,0.000032440134,0.02315632,0.00020478813],"about_ca_topic_score_codex":0.0009904972,"about_ca_topic_score_gemma":0.00017348147,"teacher_disagreement_score":0.060032014,"about_ca_system_score_codex":0.00081760634,"about_ca_system_score_gemma":0.00054828904,"threshold_uncertainty_score":0.23082627},"labels":[],"label_agreement":null},{"id":"W4327698183","doi":"10.5306/wjco.v14.i3.99","title":"Budd-Chiari syndrome in myeloproliferative neoplasms: A review of literature","year":2023,"lang":"en","type":"review","venue":"World Journal of Clinical Oncology","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":12,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Northern College","funders":"National Institute for Health and Care Research","keywords":"Medicine; Essential thrombocythemia; Budd–Chiari syndrome; Myelofibrosis; Pathogenesis; Pathology; Polycythemia vera; Stem cell; Myeloproliferative Disorders; Haematopoiesis; Gene mutation; Immunology; Mutation; Internal medicine; Bone marrow; Gene; Biology","score_opus":0.18841427085542872,"score_gpt":0.5227852446199168,"score_spread":0.3343709737644881,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4327698183","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000052375286,0.98844546,0.0000021285034,0.004335358,0.0016137046,0.001997096,0.00007491266,0.000017385715,0.003461586],"genre_scores_gemma":[0.000024381192,0.99250126,0.0016149316,0.0020236294,0.00093291095,0.00016487202,0.00009481693,0.00009843576,0.0025447642],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9856933,0.0024772955,0.00985368,0.000646301,0.0008117268,0.0005177156],"domain_scores_gemma":[0.981302,0.009439363,0.007043476,0.0005964634,0.0010153794,0.0006033147],"candidate_categories":["metaepi_narrow","metaepi_broad","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.0060370723,0.00078236987,0.016063076,0.00140036,0.000040746585,0.000020158288,0.00046330548,0.0010301385,0.00048495852],"category_scores_gemma":[0.0067851706,0.00048551042,0.0034843525,0.002409096,0.00029038687,0.00012144357,0.00016857912,0.004248745,0.0001409368],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00045860425,0.0027132514,0.0011722366,0.12050532,0.003300005,0.01761885,0.0000912765,6.2939404e-7,3.023365e-8,0.0013320238,0.015585101,0.8372227],"study_design_scores_gemma":[0.002299583,0.0038969868,0.00077364437,0.36781698,0.0031336346,0.0038929794,0.0000065933527,8.351807e-7,2.2433171e-7,0.0001288916,0.6178489,0.0002008046],"about_ca_topic_score_codex":0.0000053629174,"about_ca_topic_score_gemma":0.00012289222,"teacher_disagreement_score":0.8370219,"about_ca_system_score_codex":0.0004839977,"about_ca_system_score_gemma":0.005817317,"threshold_uncertainty_score":0.9998188},"labels":[],"label_agreement":null},{"id":"W4360983730","doi":"10.1002/ajh.26920","title":"<i>JAK2</i> unmutated erythrocytosis: 2023 Update on diagnosis and management","year":2023,"lang":"en","type":"article","venue":"American Journal of Hematology","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":48,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal","funders":"","keywords":"Medicine; Internal medicine","score_opus":0.015402661478499939,"score_gpt":0.29491209372074717,"score_spread":0.2795094322422472,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4360983730","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97781485,0.0006439571,0.000029361316,0.01999423,0.0001672227,0.00027283028,0.0000093380995,0.00003951909,0.0010286955],"genre_scores_gemma":[0.9792962,0.016298788,0.0012324054,0.0028819423,0.000058153917,0.0000864236,0.000010609989,0.0000262472,0.000109238936],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9986368,0.000094204624,0.00046765132,0.00023031468,0.00026301303,0.0003080453],"domain_scores_gemma":[0.9988562,0.000296067,0.00034942402,0.00017970048,0.000103206905,0.00021544339],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00020023926,0.00019533465,0.00080852566,0.00040640202,0.00007430622,0.0000143794805,0.00007893472,0.00003897221,0.00009705426],"category_scores_gemma":[0.000056512785,0.000142132,0.00012507272,0.00056054804,0.0002248334,0.000047281057,0.00005333625,0.00018100573,0.00020331709],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0021151674,0.001909045,0.6391939,0.00038451244,0.004791165,0.020410921,0.0007819651,0.000077793746,0.000132112,0.020053437,0.14489493,0.16525507],"study_design_scores_gemma":[0.023921775,0.037816223,0.62002075,0.003878797,0.003963424,0.02733027,0.008607542,0.00025592156,0.042616803,0.0030109466,0.22708766,0.0014899154],"about_ca_topic_score_codex":0.0000111957315,"about_ca_topic_score_gemma":0.000006581089,"teacher_disagreement_score":0.16376516,"about_ca_system_score_codex":0.00005356046,"about_ca_system_score_gemma":0.000038092454,"threshold_uncertainty_score":0.57959753},"labels":[],"label_agreement":null},{"id":"W4361227860","doi":"10.21203/rs.3.rs-2687765/v1","title":"Tamoxifen reduces mitochondrial respiration, oncogenic signaling and mutant allele burden in a myeloproliferative neoplasm subset","year":2023,"lang":"en","type":"preprint","venue":"Research Square","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Blood Cancer UK; Associazione Italiana per la Ricerca sul Cancro; National Institute for Health and Care Research; Cancer Research UK; Sierra Oncology; Incyte; AstraZeneca; UK Research and Innovation; Cambridge Trust; Wellcome Trust; European Commission; China Scholarship Council; Japan Agency for Medical Research and Development; Medical Research Council; Celgene; Gilead Sciences; NHS Blood and Transplant","keywords":"Tamoxifen; Myeloproliferative neoplasm; Allele; Mutant; Cancer research; Biology; Neoplasm; Genetics; Respiration; Internal medicine; Gene; Cancer; Medicine; Myelofibrosis; Breast cancer; Botany","score_opus":0.10739029337668063,"score_gpt":0.4076504864187123,"score_spread":0.30026019304203166,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4361227860","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98278916,0.0014306945,0.000022147738,0.00880505,0.000357254,0.0055311257,0.00031511037,0.00013893314,0.00061050215],"genre_scores_gemma":[0.98830444,0.00215446,0.0010707284,0.00008249258,0.0022367036,0.0035121618,0.0010948768,0.00014945795,0.0013946643],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.992742,0.0011804681,0.0010530537,0.0018030866,0.0019784349,0.001242949],"domain_scores_gemma":[0.9958499,0.0013341861,0.00022967938,0.0008450952,0.0011386715,0.00060243084],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.0020826226,0.0006733964,0.0013054961,0.001326606,0.0004584028,0.0003334084,0.0003160477,0.00075173174,0.00017046848],"category_scores_gemma":[0.00223593,0.0005755818,0.00026188628,0.0009427412,0.000356186,0.00013848007,0.0009871516,0.0024718482,0.00019545936],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.017173363,0.0058926768,0.5273144,0.013035811,0.0069943042,0.020135447,0.15401885,0.008545834,0.17297599,0.0037982976,0.03158342,0.03853159],"study_design_scores_gemma":[0.046199676,0.0157271,0.4426844,0.035135187,0.001245886,0.00064981123,0.023585174,0.01394477,0.354854,0.02671939,0.033367082,0.005887509],"about_ca_topic_score_codex":0.0031292092,"about_ca_topic_score_gemma":0.0037965176,"teacher_disagreement_score":0.181878,"about_ca_system_score_codex":0.0013574477,"about_ca_system_score_gemma":0.00339354,"threshold_uncertainty_score":0.9998295},"labels":[],"label_agreement":null},{"id":"W4361302933","doi":"10.1097/moh.0000000000000761","title":"Editorial: Current Opinion in Hematology: new editor announcement","year":2023,"lang":"en","type":"editorial","venue":"Current Opinion in Hematology","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Political science; Law; Medicine; Library science; Family medicine; Computer science","score_opus":0.06186317321446142,"score_gpt":0.39825926750276536,"score_spread":0.3363960942883039,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4361302933","genre_codex":"editorial","genre_gemma":"editorial","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"editorial","genre_consensus":"editorial","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000048091326,0.03421738,0.000054096698,0.0018709202,0.9605242,0.0025914467,0.0003982539,0.0002521266,0.000043455813],"genre_scores_gemma":[0.000030951276,0.047266517,0.00009246123,0.000010180402,0.94183713,0.0020093757,0.00848641,0.0001821807,0.0000848112],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9911873,0.00048831216,0.0025773162,0.0021777207,0.0019826384,0.0015867371],"domain_scores_gemma":[0.9937009,0.0030083486,0.00092773396,0.0011262329,0.00060058467,0.00063616614],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":["metaepi_narrow","research_integrity"],"category_scores_codex":[0.0009114785,0.0013688342,0.0033769878,0.0015135844,0.00012795418,0.00007583861,0.0005728752,0.002331426,0.00019475436],"category_scores_gemma":[0.00346747,0.001263136,0.00047026933,0.0010733175,0.00022401472,0.00017598842,0.00048510672,0.003465686,0.0009101033],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0005105383,0.002109799,0.014466,0.005830076,0.00015471787,0.000018807768,0.0003591686,0.000006766418,8.5117347e-7,0.0016137611,0.97263145,0.0022980596],"study_design_scores_gemma":[0.008413185,0.0007551794,0.0003917685,0.012701462,0.00008921072,0.00002790571,0.00006494146,0.000050756127,0.000019534946,0.00070138107,0.9759269,0.00085779227],"about_ca_topic_score_codex":0.0002497769,"about_ca_topic_score_gemma":0.00010469468,"teacher_disagreement_score":0.018687118,"about_ca_system_score_codex":0.0013614447,"about_ca_system_score_gemma":0.0032541796,"threshold_uncertainty_score":0.99990624},"labels":[],"label_agreement":null},{"id":"W4362657072","doi":"10.1002/cam4.5799","title":"Symptomatic benefit of momelotinib in patients with myelofibrosis: Results from the <scp>SIMPLIFY</scp> phase <scp>III</scp> studies","year":2023,"lang":"en","type":"article","venue":"Cancer Medicine","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":16,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"St. Paul's Hospital; University of Toronto; University of British Columbia; University Health Network","funders":"Genentech; Italfarmaco; Cancer Research UK; Galecto; Sierra Oncology; Incyte; CTI Biopharma; Gilead Sciences; Medical Research Council; Celgene; Bristol-Myers Squibb; AstraZeneca; Amgen; Pfizer","keywords":"Repeated measures design; Medicine; Generalized estimating equation; Myelofibrosis; Clinical trial; Odds ratio; Odds; Quality of life (healthcare); Confidence interval; Longitudinal study; Physical therapy; Logistic regression; Internal medicine; Mathematics; Statistics","score_opus":0.03805187361331621,"score_gpt":0.33125315601867766,"score_spread":0.2932012824053615,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4362657072","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.987592,0.0063261273,0.0000032237103,0.0027728376,0.00041680064,0.0016866614,0.00053166563,0.00011222891,0.00055844587],"genre_scores_gemma":[0.9923123,0.003837213,0.000068672365,0.0011212383,0.00046224447,0.00075861794,0.00060853024,0.00006555626,0.00076562923],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9966003,0.00008850575,0.0010422338,0.00068051607,0.0009906788,0.0005978126],"domain_scores_gemma":[0.9943021,0.003729744,0.00050512067,0.00071742706,0.0004909139,0.00025468608],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00044825138,0.0004884729,0.0013602908,0.00027383133,0.00013958086,0.000012139656,0.0002269212,0.00011930109,0.000023215005],"category_scores_gemma":[0.001987802,0.0002616447,0.0000959242,0.0012886972,0.0004146477,0.00009894398,0.00010447633,0.00028943596,0.0000341354],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00042865548,0.001269216,0.8806983,0.0004162648,0.002040726,0.00010050747,0.036472894,0.00014938033,0.00038321293,0.00015203917,0.06610368,0.011785121],"study_design_scores_gemma":[0.043678362,0.0031932017,0.927215,0.0059825224,0.00086287706,0.000002640454,0.01050812,0.00015049825,0.0046774666,0.00018017713,0.0034823304,0.00006679764],"about_ca_topic_score_codex":0.0007361917,"about_ca_topic_score_gemma":0.0004891976,"teacher_disagreement_score":0.06262135,"about_ca_system_score_codex":0.00026693835,"about_ca_system_score_gemma":0.00017764281,"threshold_uncertainty_score":0.99998355},"labels":[],"label_agreement":null},{"id":"W4365136161","doi":"10.1182/bloodadvances.2022009311","title":"Momelotinib long-term safety and survival in myelofibrosis: integrated analysis of phase 3 randomized controlled trials","year":2023,"lang":"en","type":"article","venue":"Blood Advances","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":48,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"National Cancer Institute; Genentech; AOP Orphan; Italfarmaco; Angelini Pharma; Galecto; Sierra Oncology; CTI Biopharma; Incyte; Jazz Pharmaceuticals; Gilead Sciences; MorphoSys; Celgene; Bristol-Myers Squibb; AstraZeneca; Amgen; Pfizer; Constellation Pharmaceuticals","keywords":"Ruxolitinib; Discontinuation; Medicine; Anemia; Internal medicine; Randomized controlled trial; Myelofibrosis; Neutropenia; Adverse effect; Gastroenterology; Bone marrow; Chemotherapy","score_opus":0.029112969208309653,"score_gpt":0.359403814225357,"score_spread":0.33029084501704736,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4365136161","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9876208,0.0084625585,0.00011619464,0.00047254213,0.00012609492,0.0025604533,0.00016496472,0.00006614363,0.0004102915],"genre_scores_gemma":[0.98043877,0.018006358,0.0002507927,0.00003988844,0.000048289352,0.00053581706,0.00036076334,0.00001689998,0.00030242436],"study_design_codex":"observational","study_design_gemma":"randomized_trial","domain_scores_codex":[0.996275,0.0009844875,0.0017330337,0.0003996829,0.0003461133,0.00026169998],"domain_scores_gemma":[0.9930919,0.0058003273,0.00060404395,0.00021622612,0.00016324995,0.00012430102],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0036453686,0.00029508237,0.0070193466,0.0008947507,0.000050086815,0.000023169678,0.000060978033,0.000081813916,0.00019844383],"category_scores_gemma":[0.0039289966,0.00017101491,0.0008287543,0.0016289881,0.0001530622,0.00010459459,0.000028533032,0.00010456667,0.0000047075814],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.41976205,0.0026349195,0.5288193,0.00020398352,0.026690194,0.00018496944,0.0006382072,0.0002079544,0.0029558863,0.0006630491,0.000011665994,0.017227795],"study_design_scores_gemma":[0.8304512,0.00057550217,0.14026639,0.00036694534,0.01995399,0.0000035829842,0.00025122357,0.0012849056,0.006526733,0.00005725297,0.00007337953,0.00018889585],"about_ca_topic_score_codex":0.000049543876,"about_ca_topic_score_gemma":0.00029490123,"teacher_disagreement_score":0.41068918,"about_ca_system_score_codex":0.000022966438,"about_ca_system_score_gemma":0.00008233074,"threshold_uncertainty_score":0.6973786},"labels":[],"label_agreement":null},{"id":"W4366603286","doi":"10.1080/10428194.2023.2196593","title":"Ten years after ruxolitinib approval for myelofibrosis: a review of clinical efficacy","year":2023,"lang":"en","type":"review","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":46,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Genentech; Servier; Astellas Pharma; Galecto; Sierra Oncology; CTI Biopharma; Incyte; Pfizer; CareDx; MorphoSys; Celgene; Bristol-Myers Squibb; AstraZeneca; Constellation Pharmaceuticals; Italfarmaco; Menarini Group; Astellas Pharma US; Gilead Sciences; U.S. Department of Defense","keywords":"Ruxolitinib; Myelofibrosis; Medicine; Myeloproliferative neoplasm; Clinical trial; Janus kinase; Expanded access; Internal medicine; Oncology; Bone marrow; Cytokine","score_opus":0.07429801613504322,"score_gpt":0.3947768205150981,"score_spread":0.3204788043800549,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4366603286","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0043822373,0.9857004,0.000010702919,0.0000989379,0.00070005393,0.006910394,0.0009315882,0.00027310275,0.0009925355],"genre_scores_gemma":[0.00021552572,0.9868562,0.0015957502,0.0013319356,0.0013728781,0.004525268,0.0014410024,0.00044215773,0.0022192674],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9905502,0.00052073237,0.0044938894,0.002179992,0.0009978822,0.0012572865],"domain_scores_gemma":[0.99229276,0.00286446,0.0018294487,0.0016574179,0.00040948286,0.0009464098],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":["metaepi_narrow"],"category_scores_codex":[0.0016464419,0.0016585216,0.0092240535,0.0005261546,0.0001702774,0.00009072254,0.0005286557,0.0015377235,0.00012012762],"category_scores_gemma":[0.0013684003,0.0012810609,0.0037372366,0.0010030215,0.0005361746,0.00014326318,0.0004004289,0.00034973875,0.00030429015],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000472957,0.000456357,0.0002899837,0.17733824,0.0019694972,0.00039129687,0.00008152606,1.05700316e-7,2.4249437e-7,0.00029454278,0.009355881,0.80934936],"study_design_scores_gemma":[0.011060884,0.0009835447,0.008070043,0.20461702,0.008270303,0.00068850163,0.00002688489,0.000029022403,0.000007514735,0.000043418633,0.76527584,0.0009270119],"about_ca_topic_score_codex":0.00016908108,"about_ca_topic_score_gemma":0.000010922465,"teacher_disagreement_score":0.8084223,"about_ca_system_score_codex":0.0032015715,"about_ca_system_score_gemma":0.010749343,"threshold_uncertainty_score":0.9997585},"labels":[],"label_agreement":null},{"id":"W4366726224","doi":"10.1212/wnl.0000000000207014","title":"Teaching NeuroImages: Intracranial extramedullary hematopoiesis","year":2023,"lang":"en","type":"article","venue":"Neurology","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"Medicine; Headaches; Extramedullary hematopoiesis; Papilledema; Biopsy; Weakness; Polycythemia vera; Radiology; Surgery; Haematopoiesis; Internal medicine","score_opus":0.022335062336056418,"score_gpt":0.2955230315319611,"score_spread":0.27318796919590466,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4366726224","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.960408,0.000056850087,0.000029174204,0.03373446,0.0004035299,0.0003265115,0.000007940111,0.00035920556,0.0046743373],"genre_scores_gemma":[0.9890338,0.00013110075,0.00030864606,0.009529639,0.00036876122,0.00009996861,0.000035331537,0.000043267297,0.00044945875],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99859184,0.00015336917,0.00024143765,0.0004219616,0.00019745705,0.00039391938],"domain_scores_gemma":[0.99908507,0.0003722131,0.000050916067,0.00030762973,0.00003492231,0.0001492739],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00016109149,0.00019066062,0.00035860966,0.0001810736,0.00014681926,0.000017088263,0.00008205631,0.0001270301,0.00027459915],"category_scores_gemma":[0.00020713531,0.00015915284,0.00011069425,0.0001921748,0.00007774306,0.000050646944,0.00007172467,0.00046822723,0.00082715525],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0036410452,0.0027452307,0.70058256,0.00050326565,0.0006880997,0.0465768,0.002625916,0.00009338895,0.035349593,0.01634823,0.07577591,0.11506994],"study_design_scores_gemma":[0.004187754,0.005339969,0.88638055,0.00003810959,0.00025389454,0.004179327,0.000049737293,0.0025025674,0.0024829493,0.001464427,0.09275042,0.0003702867],"about_ca_topic_score_codex":0.000069231806,"about_ca_topic_score_gemma":0.000020345895,"teacher_disagreement_score":0.18579797,"about_ca_system_score_codex":0.0000126752175,"about_ca_system_score_gemma":0.000047673824,"threshold_uncertainty_score":0.9999508},"labels":[],"label_agreement":null},{"id":"W4367856691","doi":"10.1182/bloodadvances.2023009886","title":"A simple prognostic system in patients with myelofibrosis undergoing allogeneic stem cell transplantation: a CIBMTR/EBMT analysis","year":2023,"lang":"en","type":"article","venue":"Blood Advances","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":20,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Hospital; Princess Margaret Cancer Centre; University of Toronto","funders":"Cancer Moonshot; Moonshot Research and Development Program; National Institute of Allergy and Infectious Diseases; National Cancer Institute; Office of Naval Research; Legend Biotech; Adaptive Biotechnologies; Health Resources and Services Administration; Kite Pharma; Daiichi Sankyo Europe; Agios Pharmaceuticals; Takeda Oncology; AstraZeneca; Genentech; National Institutes of Health; MorphoSys; Invitae; Vertex Pharmaceuticals; Ono Pharmaceutical; Mazak Foundation; Cardinal Health; CareDx; BeiGene; Swedish Orphan Biovitrum; Astellas Pharma; GlaxoSmithKline; Kiadis Pharma; Pharmacyclics; bluebird bio; Sanofi; TG Therapeutics; Omeros Corporation; Medical College of Wisconsin; StemCyte; HistoGenetics; Atara Biotherapeutics; Actinium Pharmaceuticals; Gilead Sciences; Celgene; CSL Behring; Bristol-Myers Squibb; Mallinckrodt Pharmaceuticals; Sierra Oncology; Astellas Pharma US; Amgen; National Heart, Lung, and Blood Institute; Novartis Pharmaceuticals Corporation; Incyte; Pfizer; Medac; Jazz Pharmaceuticals; CTI Biopharma; Be The Match Foundation","keywords":"Transplantation; Medicine; Stem cell; Myelofibrosis; Oncology; Internal medicine; Biology; Bone marrow; Genetics","score_opus":0.008305577184414827,"score_gpt":0.23136967647607926,"score_spread":0.22306409929166443,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4367856691","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9974128,0.00071206264,0.00010992919,0.00006058749,0.00003651973,0.0009701999,0.00008204327,0.00015344843,0.00046242698],"genre_scores_gemma":[0.9979679,0.00044976265,0.00055279216,0.000042743526,0.000030937023,0.0004124555,0.000413254,0.000028759241,0.00010142571],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99828553,0.00007000536,0.00036800458,0.0004908679,0.0004237446,0.00036183014],"domain_scores_gemma":[0.9991021,0.00030693234,0.0001352315,0.00022906737,0.00009706579,0.00012960692],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00009633355,0.0002553899,0.0005445985,0.00040556016,0.000111526606,0.000032058982,0.0000691716,0.000056705605,0.000019865636],"category_scores_gemma":[0.000009028186,0.00018572659,0.00012009026,0.0017423199,0.000030397821,0.00015005434,0.0000150249925,0.0000802242,0.000036538746],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00023089253,0.0005683885,0.9937829,0.00082179107,0.00063915085,0.00021067545,0.00040584686,0.0016902064,0.000040343963,0.000051945826,0.000008061962,0.0015497985],"study_design_scores_gemma":[0.0055279317,0.0010707695,0.9854984,0.0004714789,0.0028869025,0.0000065767267,0.0006523745,0.00017861983,0.0033825515,0.00000699192,0.000102495476,0.00021486125],"about_ca_topic_score_codex":0.000023519604,"about_ca_topic_score_gemma":0.0005778505,"teacher_disagreement_score":0.008284451,"about_ca_system_score_codex":0.00007286773,"about_ca_system_score_gemma":0.000083143845,"threshold_uncertainty_score":0.75737107},"labels":[],"label_agreement":null},{"id":"W4376133764","doi":"10.3324/haematol.2022.282411","title":"Safety and efficacy of zinpentraxin alfa as monotherapy or in combination with ruxolitinib in myelofibrosis: stage I of a phase II trial","year":2023,"lang":"en","type":"article","venue":"Haematologica","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":17,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; University of British Columbia","funders":"National Cancer Institute; University of Texas MD Anderson Cancer Center; National Institutes of Health; F. Hoffmann-La Roche","keywords":"Ruxolitinib; Myelofibrosis; Medicine; Oncology; Internal medicine; Clinical trial; Stage (stratigraphy); Phases of clinical research; Pharmacology; Bone marrow; Biology","score_opus":0.03954079516253714,"score_gpt":0.34076388170347427,"score_spread":0.3012230865409371,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4376133764","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.996591,0.00013747781,0.000009853968,0.0009229773,0.0000213158,0.0017908822,0.000034943558,0.000028428443,0.00046314314],"genre_scores_gemma":[0.99829036,0.00076054904,0.00032644393,0.000067775065,0.0000067077817,0.00018426767,0.000052168096,0.000012211134,0.0002995066],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99867356,0.00011011789,0.00053983566,0.0002645094,0.00020872618,0.00020324803],"domain_scores_gemma":[0.9991092,0.0004156563,0.00019225222,0.00016947064,0.000049784194,0.000063606996],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00026815964,0.0001595148,0.00077337783,0.00023447847,0.00003596084,0.0000049607443,0.000047212165,0.000091593705,0.00028424186],"category_scores_gemma":[0.00019969018,0.00009827591,0.000045762863,0.0004954966,0.00010231315,0.000044755732,0.00002810049,0.00008897726,0.000004423417],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.6966456,0.03131032,0.19258364,0.0009738189,0.0004687144,0.0021277776,0.008946468,0.000056286375,0.0033523391,0.029904984,0.00019824665,0.033431813],"study_design_scores_gemma":[0.5875597,0.049545854,0.31620324,0.0012688092,0.00010154633,0.00009441722,0.0013654332,0.00047894535,0.041516725,0.00037460978,0.0012006265,0.00029008105],"about_ca_topic_score_codex":0.00013729976,"about_ca_topic_score_gemma":0.00011304806,"teacher_disagreement_score":0.12361961,"about_ca_system_score_codex":0.000034901444,"about_ca_system_score_gemma":0.000103015635,"threshold_uncertainty_score":0.40075752},"labels":[],"label_agreement":null},{"id":"W4376608692","doi":"10.1182/bloodadvances.2023009825","title":"Prevalence of frailty and its association with clinical outcomes in myeloproliferative neoplasms: a population-based study","year":2023,"lang":"en","type":"article","venue":"Blood Advances","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Health Sciences Centre; Toronto General Hospital; University of Toronto; Sunnybrook Health Science Centre; Institute for Clinical Evaluative Sciences; Princess Margaret Cancer Centre","funders":"Ontario Ministry of Health and Long-Term Care; Institute for Clinical Evaluative Sciences","keywords":"Medicine; Essential thrombocythemia; Confidence interval; Hazard ratio; Myelofibrosis; Internal medicine; Polycythemia vera; Proportional hazards model; Population; Gastroenterology; Bone marrow","score_opus":0.03246975683870799,"score_gpt":0.355246296950634,"score_spread":0.32277654011192597,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4376608692","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9974497,0.00047966835,0.0000024081123,0.00055906415,0.000055889454,0.0012984272,0.00004223054,0.000050474995,0.00006212657],"genre_scores_gemma":[0.99837595,0.0003958527,0.00045020494,0.00010052542,0.000031349744,0.0002726927,0.000020618947,0.000013819581,0.0003389687],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.998359,0.00015576312,0.0004971616,0.00037411932,0.00041936382,0.0001945931],"domain_scores_gemma":[0.99826014,0.0010965058,0.0002641896,0.00014489866,0.00015526658,0.000078993275],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00041480453,0.0001777856,0.0005610492,0.00014294044,0.00005742772,0.000011419525,0.0000447806,0.00006844265,0.000021768396],"category_scores_gemma":[0.000764453,0.00012142492,0.000053397205,0.0003581855,0.000019517804,0.00014752866,0.000021253718,0.00013958593,0.000007296193],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00020254243,0.0017338545,0.9963767,0.00015628483,0.00023295959,0.0000399921,0.00039859087,0.00013288295,0.000010993064,0.000069265385,0.000005182059,0.00064075773],"study_design_scores_gemma":[0.0059437887,0.0020640807,0.98998135,0.00019193943,0.00026916922,0.0000015368007,0.00025983748,0.00025217177,0.00086034794,0.000044219534,0.00001703621,0.00011454139],"about_ca_topic_score_codex":0.000036709815,"about_ca_topic_score_gemma":0.0005188832,"teacher_disagreement_score":0.0063953637,"about_ca_system_score_codex":0.000046063346,"about_ca_system_score_gemma":0.00009964211,"threshold_uncertainty_score":0.49515647},"labels":[],"label_agreement":null},{"id":"W4376640934","doi":"10.1158/2767-9764.c.6649205","title":"Data from Targeting CHAF1B Enhances IFN Activity against Myeloproliferative Neoplasm Cells","year":2023,"lang":"en","type":"preprint","venue":"","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Toronto General Hospital; University of Toronto; University Health Network","funders":"","keywords":"Myeloproliferative neoplasm; Cancer research; Gene silencing; Targeted therapy; Biology; Transcription factor; Pharmacology; Immunology; Gene; Myelofibrosis; Cancer; Bone marrow; Genetics","score_opus":0.10749656750992162,"score_gpt":0.3461319227321471,"score_spread":0.23863535522222548,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4376640934","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9619517,0.00086506194,0.0017532777,0.0067127673,0.0033054992,0.00348251,0.0077793803,0.0009420038,0.013207839],"genre_scores_gemma":[0.9524076,0.005242473,0.013327601,0.0011031837,0.0024047506,0.0008723599,0.01665152,0.0002352127,0.007755306],"study_design_codex":"not_applicable","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9941012,0.00029750136,0.00092828536,0.0027887856,0.001018305,0.0008658825],"domain_scores_gemma":[0.99473995,0.0010699761,0.0006214726,0.0027133743,0.00034432745,0.00051089417],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00059873203,0.0011730725,0.001962418,0.0002701035,0.00036636615,0.00026907696,0.00088504696,0.00075227616,0.00085876783],"category_scores_gemma":[0.00045062366,0.00092600397,0.00035202052,0.00028600794,0.00016774437,0.00029385995,0.0035681596,0.0016798885,0.0020094581],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0032222231,0.010122236,0.09402564,0.0038382928,0.023751488,0.004976165,0.008776977,0.0018866902,0.14427537,0.0006071196,0.63105816,0.07345967],"study_design_scores_gemma":[0.00567029,0.00061254174,0.06915537,0.0032151234,0.001871216,0.000012300026,0.0013847984,0.02947906,0.85374326,0.0015656487,0.030373042,0.0029173335],"about_ca_topic_score_codex":0.0016605556,"about_ca_topic_score_gemma":0.0018810207,"teacher_disagreement_score":0.7094679,"about_ca_system_score_codex":0.00036800993,"about_ca_system_score_gemma":0.00093798264,"threshold_uncertainty_score":0.9993191},"labels":[],"label_agreement":null},{"id":"W4376956889","doi":"10.1158/2767-9764.crc-23-0010","title":"Targeting CHAF1B Enhances IFN Activity against Myeloproliferative Neoplasm Cells","year":2023,"lang":"en","type":"article","venue":"Cancer Research Communications","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network","funders":"National Cancer Institute; National Institutes of Health; MPN Research Foundation; Northwestern University; National Institute of General Medical Sciences; Robert H. Lurie Comprehensive Cancer Center; Weinberg College of Arts and Sciences, Northwestern University; U.S. Department of Veterans Affairs","keywords":"Myeloproliferative neoplasm; Neoplasm; Cancer research; Myeloproliferative Disorders; Immunology; Medicine; Myelofibrosis; Bone marrow; Pathology","score_opus":0.16180218825012613,"score_gpt":0.4612231435675354,"score_spread":0.2994209553174093,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4376956889","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.930618,0.0029715206,0.000059911712,0.03715751,0.00022856188,0.0023472502,0.00019537564,0.00036468287,0.026057174],"genre_scores_gemma":[0.95532686,0.035284683,0.00089855725,0.00026060425,0.0002090431,0.0036544888,0.00020282126,0.000048247515,0.0041147172],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9969416,0.00067437,0.0003281644,0.0004816104,0.0008044777,0.0007697441],"domain_scores_gemma":[0.9956751,0.0013851206,0.00010329704,0.0016119668,0.0008885763,0.00033596903],"candidate_categories":["sts","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0012058298,0.00024032753,0.0004209678,0.00041545677,0.0015249863,0.000108212196,0.00064484595,0.00011917565,0.00019935313],"category_scores_gemma":[0.00047743178,0.00020628468,0.00012319647,0.0016933663,0.00054719124,0.00021450264,0.00070775696,0.0010122588,0.0008743622],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00065974647,0.0031363221,0.03653516,0.0005906201,0.0016853013,0.00016580458,0.012632782,0.0006491966,0.6532643,0.0088063115,0.13499159,0.14688288],"study_design_scores_gemma":[0.0037284654,0.0007315038,0.06948252,0.0010951246,0.00013280846,0.000009622066,0.003597599,0.015312495,0.58755004,0.00084732653,0.31670904,0.00080345245],"about_ca_topic_score_codex":0.0003879788,"about_ca_topic_score_gemma":0.00055122183,"teacher_disagreement_score":0.18171744,"about_ca_system_score_codex":0.0005558123,"about_ca_system_score_gemma":0.00084726186,"threshold_uncertainty_score":0.99990356},"labels":[],"label_agreement":null},{"id":"W4377093091","doi":"10.1002/ajh.26935","title":"Comprehensive profiling of clinical <scp>JAK</scp> inhibitors in myeloproliferative neoplasms","year":2023,"lang":"en","type":"article","venue":"American Journal of Hematology","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":14,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"National Center for Advancing Translational Sciences; National Heart, Lung, and Blood Institute; National Cancer Institute; MPN Research Foundation; National Institutes of Health; Alvin J. Siteman Cancer Center; Institute of Clinical and Translational Sciences; Canadian Institutes of Health Research; Leukemia and Lymphoma Society","keywords":"Ruxolitinib; Myeloproliferative neoplasm; Cancer research; Janus kinase; STAT3; stat; Myelofibrosis; Biology; Medicine; Pharmacology; Cytokine; Signal transduction; Immunology; Bone marrow; Genetics","score_opus":0.04216840408838109,"score_gpt":0.3690324555668604,"score_spread":0.3268640514784793,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4377093091","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9967293,0.0006381957,0.000043678338,0.001341499,0.0004187271,0.00040290054,0.000008595841,0.000023123343,0.00039396517],"genre_scores_gemma":[0.99367654,0.0008990331,0.0046596294,0.00046797874,0.00018710655,0.000027186188,0.0000111978625,0.00003125798,0.000040049566],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9964171,0.00043939686,0.0019876645,0.00031208104,0.00041152106,0.00043221505],"domain_scores_gemma":[0.9945965,0.0028543754,0.0014437963,0.00022432464,0.00060714205,0.00027387647],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006419931,0.00026675442,0.0022103735,0.0006160015,0.000045321893,0.0000079552,0.00013849935,0.00012746445,0.000016427784],"category_scores_gemma":[0.0013331318,0.0001996181,0.00036609496,0.0009859191,0.0006251993,0.000086772925,0.0000712459,0.0006271787,0.000045912362],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00031808106,0.00063772855,0.98434424,0.00009529567,0.0005177826,0.0017633855,0.0014040114,0.000081860526,0.00072349067,0.0015339572,0.0018297819,0.006750353],"study_design_scores_gemma":[0.011459012,0.015428585,0.8311599,0.0012121416,0.00039809637,0.006624494,0.020194354,0.0006337463,0.108144216,0.0008398028,0.0036657322,0.00023990488],"about_ca_topic_score_codex":0.000031710668,"about_ca_topic_score_gemma":0.000017893175,"teacher_disagreement_score":0.15318435,"about_ca_system_score_codex":0.000058560454,"about_ca_system_score_gemma":0.00052305305,"threshold_uncertainty_score":0.81401896},"labels":[],"label_agreement":null},{"id":"W4377292146","doi":"10.3390/cancers15102859","title":"Benefit of Early Ruxolitinib Initiation Regardless of Fibrosis Grade in Patients with Primary Myelofibrosis: A Post Hoc Analysis of the Single-Arm Phase 3b JUMP Study","year":2023,"lang":"en","type":"article","venue":"Cancers","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":12,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"Novartis Pharmaceuticals Corporation","keywords":"Ruxolitinib; Myelofibrosis; Post-hoc analysis; Medicine; Internal medicine; Post hoc; Jump; Oncology; Physics; Bone marrow","score_opus":0.02314503416591296,"score_gpt":0.27907081930700117,"score_spread":0.2559257851410882,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4377292146","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9980386,0.000089300185,0.0000013531977,0.00009055551,0.000046315534,0.0010771889,0.00047262947,0.000013222184,0.00017081828],"genre_scores_gemma":[0.9994323,0.00003639077,0.00004800062,0.000060401828,0.000012267875,0.00014751779,0.00021743106,0.00001941064,0.000026239451],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99840564,0.00006974214,0.0005224249,0.00027727935,0.0005326744,0.00019222396],"domain_scores_gemma":[0.9986449,0.00013176166,0.00042177452,0.00037841182,0.00035928097,0.00006387723],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00012655303,0.00017219217,0.0006958598,0.00046953937,0.000037897516,0.0000064983587,0.00009984701,0.000052145664,0.00003068157],"category_scores_gemma":[0.00004482883,0.000115689065,0.00017052064,0.0021386375,0.00010231771,0.00007572474,0.000042236825,0.00008021068,7.369406e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0020178962,0.002334006,0.98603487,0.00016113045,0.0014793559,0.000003252652,0.004550706,0.00083143415,0.00073045556,0.000029114308,0.00002766238,0.0018001422],"study_design_scores_gemma":[0.008219382,0.008088248,0.972628,0.00043873306,0.0017314368,1.2250112e-7,0.0010715089,0.00006971678,0.007650171,0.00000583174,0.0000071447835,0.00008971465],"about_ca_topic_score_codex":0.000900893,"about_ca_topic_score_gemma":0.00069104286,"teacher_disagreement_score":0.013406853,"about_ca_system_score_codex":0.0005492969,"about_ca_system_score_gemma":0.00028088296,"threshold_uncertainty_score":0.47176632},"labels":[],"label_agreement":null},{"id":"W4378837736","doi":"10.1158/2767-9764.c.6649205.v2","title":"Data from Targeting CHAF1B Enhances IFN Activity against Myeloproliferative Neoplasm Cells","year":2023,"lang":"en","type":"preprint","venue":"","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Toronto General Hospital; University of Toronto; University Health Network","funders":"","keywords":"Myeloproliferative neoplasm; Cancer research; Gene silencing; Transcription factor; Biology; Targeted therapy; Immunology; Gene; Myelofibrosis; Cancer; Bone marrow; Genetics","score_opus":0.10749656750992162,"score_gpt":0.3461319227321471,"score_spread":0.23863535522222548,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4378837736","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9619517,0.00086506194,0.0017532777,0.0067127673,0.0033054992,0.00348251,0.0077793803,0.0009420038,0.013207839],"genre_scores_gemma":[0.9524076,0.005242473,0.013327601,0.0011031837,0.0024047506,0.0008723599,0.01665152,0.0002352127,0.007755306],"study_design_codex":"not_applicable","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9941012,0.00029750136,0.00092828536,0.0027887856,0.001018305,0.0008658825],"domain_scores_gemma":[0.99473995,0.0010699761,0.0006214726,0.0027133743,0.00034432745,0.00051089417],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00059873203,0.0011730725,0.001962418,0.0002701035,0.00036636615,0.00026907696,0.00088504696,0.00075227616,0.00085876783],"category_scores_gemma":[0.00045062366,0.00092600397,0.00035202052,0.00028600794,0.00016774437,0.00029385995,0.0035681596,0.0016798885,0.0020094581],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0032222231,0.010122236,0.09402564,0.0038382928,0.023751488,0.004976165,0.008776977,0.0018866902,0.14427537,0.0006071196,0.63105816,0.07345967],"study_design_scores_gemma":[0.00567029,0.00061254174,0.06915537,0.0032151234,0.001871216,0.000012300026,0.0013847984,0.02947906,0.85374326,0.0015656487,0.030373042,0.0029173335],"about_ca_topic_score_codex":0.0016605556,"about_ca_topic_score_gemma":0.0018810207,"teacher_disagreement_score":0.7094679,"about_ca_system_score_codex":0.00036800993,"about_ca_system_score_gemma":0.00093798264,"threshold_uncertainty_score":0.9993191},"labels":[],"label_agreement":null},{"id":"W4378952730","doi":"10.1002/ccr3.7409","title":"A case of <scp>MDS</scp>/<scp>MPN</scp> overlap syndrome with ring sideroblasts and thrombocytosis: Tackling the quandary of thrombosis versus hemorrhage","year":2023,"lang":"en","type":"article","venue":"Clinical Case Reports","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Fraser Health; University of British Columbia","funders":"","keywords":"Medicine; Thrombocytosis; Thrombosis; Internal medicine; Platelet","score_opus":0.07177739917314697,"score_gpt":0.3586473925629252,"score_spread":0.28686999338977826,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4378952730","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9964449,0.0007076029,0.000023529932,0.00016434901,0.00040401562,0.0010617973,0.000055076624,0.00011686064,0.0010218716],"genre_scores_gemma":[0.9982299,0.0005089346,0.00065484707,0.00011986657,0.00012575001,0.00012345999,0.000031168664,0.000074962365,0.00013109323],"study_design_codex":"case_report","study_design_gemma":"case_report","domain_scores_codex":[0.9958765,0.00023170665,0.001852913,0.0008910974,0.0006053491,0.0005424349],"domain_scores_gemma":[0.9885418,0.008574194,0.0011070792,0.001024525,0.0003219036,0.00043053456],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0016737814,0.0004605652,0.0015983181,0.00017131008,0.00027109362,0.000044237488,0.00006384577,0.00027648045,0.00002055875],"category_scores_gemma":[0.004750147,0.00029561715,0.00040201697,0.0006299573,0.00057650544,0.00014806291,0.00022843598,0.0005291618,0.00000971952],"study_design_candidate":"case_report","study_design_consensus":"case_report","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00009307524,0.0009832222,0.20278688,0.0008010851,0.0015003971,0.79029894,0.0014600721,0.00011690479,0.00019050983,0.00008339296,0.0008673572,0.0008181607],"study_design_scores_gemma":[0.0086024,0.0074940156,0.16136639,0.0017287185,0.003749822,0.79555726,0.009674495,0.0013027343,0.009644581,0.00018326807,0.0004886058,0.00020772839],"about_ca_topic_score_codex":0.00024289239,"about_ca_topic_score_gemma":0.00016933984,"teacher_disagreement_score":0.041420497,"about_ca_system_score_codex":0.000067990615,"about_ca_system_score_gemma":0.000318405,"threshold_uncertainty_score":0.9999496},"labels":[],"label_agreement":null},{"id":"W4378953442","doi":"10.3324/haematol.2023.283106","title":"Clinical outcomes of patients with myelofibrosis after immediate transition to momelotinib from ruxolitinib","year":2023,"lang":"en","type":"letter","venue":"Haematologica","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":13,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"National Cancer Institute; Genentech; Italfarmaco; Astellas Pharma; Sierra Oncology; CTI Biopharma; Incyte; Jazz Pharmaceuticals; Gilead Sciences; Celgene; Bristol-Myers Squibb; AstraZeneca; Amgen; Pfizer","keywords":"Ruxolitinib; Myelofibrosis; Medicine; Internal medicine; Oncology; Bone marrow","score_opus":0.029609548292402355,"score_gpt":0.29878744014817415,"score_spread":0.2691778918557718,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4378953442","genre_codex":"empirical","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.7545115,0.00005288137,0.000030908628,0.24026228,0.000418486,0.0018742264,0.002497559,0.00015522519,0.00019696004],"genre_scores_gemma":[0.48617712,0.00017125186,0.004089426,0.49856266,0.0011151902,0.0018442885,0.0073001273,0.00019782929,0.0005421195],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9960693,0.00023875714,0.0012544076,0.0010152785,0.00084207446,0.00058015855],"domain_scores_gemma":[0.99697566,0.0012790831,0.00043296567,0.00072665024,0.00033466323,0.00025094816],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0001581936,0.00066832895,0.002624571,0.00025315172,0.000058773563,0.000025585185,0.00017850214,0.0009840872,0.0007986449],"category_scores_gemma":[0.00023373359,0.00040768465,0.0005833924,0.00027820308,0.00017859763,0.0000511317,0.00008256871,0.00086866977,0.00073540694],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0011628739,0.0006664662,0.7378173,0.00026978523,0.0009901006,0.0015594063,0.0002882774,5.4096233e-7,5.4909674e-7,0.000008040263,0.2564248,0.0008118342],"study_design_scores_gemma":[0.0033602929,0.0021327562,0.9565197,0.0008392329,0.00096966483,0.000006419935,0.000029538398,0.0000015319525,0.00011808851,0.00009285043,0.035506923,0.00042296379],"about_ca_topic_score_codex":0.00010345214,"about_ca_topic_score_gemma":0.00002619772,"teacher_disagreement_score":0.26833436,"about_ca_system_score_codex":0.0000630743,"about_ca_system_score_gemma":0.000096664924,"threshold_uncertainty_score":0.9998375},"labels":[],"label_agreement":null},{"id":"W4379282483","doi":"10.1200/jco.2023.41.16_suppl.7068","title":"Consistency of pacritinib for spleen and symptom reduction in patients with myelofibrosis regardless of cytopenias.","year":2023,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"CTI Biopharma","keywords":"Medicine; Myelofibrosis; Ruxolitinib; Internal medicine; Gastroenterology; Exacerbation; Spleen; Bone marrow","score_opus":0.08983051127285616,"score_gpt":0.4316969737022216,"score_spread":0.34186646242936547,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4379282483","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9958977,0.00009015543,0.000011302299,0.0029422564,0.00022871832,0.0004518543,0.00002003483,0.0000029177584,0.00035502922],"genre_scores_gemma":[0.9953938,0.0005318013,0.0037640722,0.00009915082,0.00012263782,0.000015066967,0.000009362928,0.000010408244,0.000053697047],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99769187,0.00016049239,0.0016446136,0.00014470101,0.00022756873,0.00013073476],"domain_scores_gemma":[0.99618894,0.0017253837,0.0011693409,0.00010532824,0.00068074116,0.00013025572],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012137991,0.000094161805,0.0013392301,0.00016311574,0.000018324617,0.000002448249,0.00004598822,0.0001669,0.0000166066],"category_scores_gemma":[0.0015105755,0.00006053792,0.00017223207,0.00016827103,0.00020581167,0.00006262274,0.000023478986,0.00019500437,8.174656e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0075013544,0.0017665635,0.9417272,0.0001189177,0.00033689322,0.000027792388,0.00017942676,0.0000040734226,0.000082361774,0.00028578858,0.00090976583,0.047059823],"study_design_scores_gemma":[0.017132739,0.023890821,0.9557796,0.0003961879,0.0003306287,0.000029226578,0.00021851825,0.000012661444,0.0008138543,0.00019600595,0.0011491507,0.000050595714],"about_ca_topic_score_codex":0.000014091519,"about_ca_topic_score_gemma":0.000020754649,"teacher_disagreement_score":0.047009226,"about_ca_system_score_codex":0.00004649086,"about_ca_system_score_gemma":0.00045491676,"threshold_uncertainty_score":0.24686648},"labels":[],"label_agreement":null},{"id":"W4379335961","doi":"10.1200/jco.2023.41.16_suppl.7066","title":"Impact of transfusion burden on health-related quality of life (HRQOL) and functioning in patients (pts) with myelofibrosis (MF): Post hoc analysis of SIMPLIFY-1 (S1) and -2 (S2).","year":2023,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sierra Wireless (Canada)","funders":"GlaxoSmithKline","keywords":"Medicine; Quality of life (healthcare); Post-hoc analysis; Ruxolitinib; Anemia; Population; Myelofibrosis; Health related quality of life; Internal medicine; Bone marrow","score_opus":0.09369376429611907,"score_gpt":0.4527289621501644,"score_spread":0.3590351978540453,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4379335961","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9967223,0.00021560247,0.000008200439,0.00257269,0.00007510205,0.00028998716,0.00005106484,0.0000038842454,0.00006119858],"genre_scores_gemma":[0.9973146,0.0022212546,0.00020585812,0.00016656263,0.000038434016,0.0000030854621,0.000030512456,0.000010630144,0.000009082028],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99538565,0.0006540205,0.003138629,0.00022126918,0.00042261655,0.00017784159],"domain_scores_gemma":[0.993087,0.0033599744,0.0025254476,0.00014835878,0.0005573789,0.00032187227],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0023464586,0.00015568969,0.0027732097,0.0006012294,0.00003464239,0.000003342942,0.000048259124,0.00024068015,0.00008175282],"category_scores_gemma":[0.001722452,0.00009587736,0.0004303257,0.0007990358,0.00018979807,0.00006443316,0.00002496461,0.00039131808,8.714708e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.023988325,0.0020668143,0.9195051,0.00009907367,0.0028031731,0.00001314979,0.00068702275,0.00056994916,0.0001302745,0.000020762112,0.00009156994,0.050024793],"study_design_scores_gemma":[0.0142249605,0.07391656,0.9100956,0.00028758176,0.00087368255,0.000004186125,0.00025185864,0.00021006462,0.00003255319,0.00002069374,0.000022239523,0.0000600191],"about_ca_topic_score_codex":0.0011363508,"about_ca_topic_score_gemma":0.000594139,"teacher_disagreement_score":0.07184975,"about_ca_system_score_codex":0.00012895725,"about_ca_system_score_gemma":0.0007162453,"threshold_uncertainty_score":0.39097652},"labels":[],"label_agreement":null},{"id":"W4379337128","doi":"10.1200/jco.2023.41.16_suppl.tps7088","title":"EXCEED-ET: A single-arm multicenter study to assess the efficacy, safety, and tolerability of ropeginterferon alfa-2b-njft (P1101) in North American adults with essential thrombocythemia.","year":2023,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Essential thrombocythemia; Tolerability; Anagrelide; Myelofibrosis; Thrombocytosis; Internal medicine; Polycythemia vera; Interferon alfa; Myeloproliferative neoplasm; Oncology; Alpha interferon; Surgery; Gastroenterology; Immunology; Bone marrow; Adverse effect; Platelet; Interferon","score_opus":0.10602229858724463,"score_gpt":0.4481146316255874,"score_spread":0.34209233303834274,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4379337128","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9872147,0.000027647086,0.000053353153,0.011106453,0.00024676992,0.0011273273,0.000008244906,0.000009874661,0.00020561767],"genre_scores_gemma":[0.99793506,0.00026219056,0.0005129695,0.0010010798,0.00022368005,0.000019726951,0.0000038549997,0.000021264343,0.000020204745],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9960191,0.00083662703,0.0020599072,0.00034599542,0.00045814944,0.000280203],"domain_scores_gemma":[0.99344456,0.0043754512,0.0011749368,0.00028681877,0.00041902522,0.0002991817],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0025074568,0.00021687307,0.001955721,0.00014981726,0.00004536924,0.000016361808,0.00017724097,0.00007522312,0.000033977987],"category_scores_gemma":[0.0017976823,0.00011290112,0.00020496524,0.00044940066,0.00035787842,0.00007634315,0.00015883638,0.0007249058,0.0000075505936],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.026598,0.020246863,0.90738684,0.000031468855,0.00053617207,0.00043528504,0.003420762,0.00016490751,0.00003296999,0.0000081855205,0.00015160574,0.040986933],"study_design_scores_gemma":[0.015360177,0.065077536,0.9152491,0.00019346585,0.00031371458,0.000050277467,0.0027121787,0.00012320954,0.00010645402,0.0000035161033,0.0007172874,0.00009304862],"about_ca_topic_score_codex":0.0002258665,"about_ca_topic_score_gemma":0.012022797,"teacher_disagreement_score":0.044830672,"about_ca_system_score_codex":0.00017291216,"about_ca_system_score_gemma":0.0004458786,"threshold_uncertainty_score":0.6709003},"labels":[],"label_agreement":null},{"id":"W4379882764","doi":"10.3389/fonc.2023.1213942","title":"Case Report: Effects of multiple myeloma therapy on essential thrombocythemia and vice versa: a case of synchronous dual hematological malignancy","year":2023,"lang":"en","type":"article","venue":"Frontiers in Oncology","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Royal Victoria Regional Health Centre; Western University","funders":"","keywords":"Medicine; Multiple myeloma; Concomitant; Essential thrombocythemia; Melphalan; Internal medicine; Thrombocytosis; Bone marrow; Bortezomib; Serum protein electrophoresis; Plasmacytosis; Malignancy; Gastroenterology; Oncology; Immunology; Antibody; Platelet; Monoclonal","score_opus":0.017204162632703593,"score_gpt":0.3092797044649251,"score_spread":0.2920755418322215,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4379882764","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9967842,0.00087304745,0.00010090015,0.00032306986,0.00061277306,0.0009653682,0.000018472027,0.000036195743,0.00028597456],"genre_scores_gemma":[0.9962486,0.00060659565,0.0027320518,0.00008902485,0.000057575286,0.00018347069,0.00002588483,0.000019934545,0.00003685305],"study_design_codex":"case_report","study_design_gemma":"case_report","domain_scores_codex":[0.99847627,0.00017597467,0.0005005687,0.00041598838,0.00014192557,0.000289265],"domain_scores_gemma":[0.9984435,0.0008585276,0.00024450105,0.00027281136,0.00007172871,0.00010895414],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00022567759,0.00021440172,0.000996383,0.00023556838,0.00005873392,0.0000033930692,0.000037270896,0.0002626116,0.000027663895],"category_scores_gemma":[0.00036329025,0.00016553668,0.00009896775,0.00027975877,0.0002581856,0.000030317355,0.00005343385,0.00018141003,0.0000041794437],"study_design_candidate":"case_report","study_design_consensus":"case_report","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00126217,0.0014578045,0.13387512,0.00032751315,0.0003797871,0.8425575,0.0023286932,0.000013168254,0.0015491864,0.00016168838,0.0031066295,0.012980775],"study_design_scores_gemma":[0.03425917,0.017325876,0.08858215,0.0007012972,0.0005130444,0.65082186,0.0032187095,0.0017818945,0.2007122,0.00045114008,0.001106505,0.00052615],"about_ca_topic_score_codex":0.00020286533,"about_ca_topic_score_gemma":0.00013535273,"teacher_disagreement_score":0.19916302,"about_ca_system_score_codex":0.00016464737,"about_ca_system_score_gemma":0.00016560081,"threshold_uncertainty_score":0.675039},"labels":[],"label_agreement":null},{"id":"W4380148718","doi":"10.1016/j.clml.2023.06.004","title":"Cross-Study Comparisons of JAK2 Inhibitors in Myelofibrosis: Risks and Recommendations","year":2023,"lang":"en","type":"article","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Sierra Oncology; CTI Biopharma; Gilead Sciences","keywords":"Medicine; Myelofibrosis; Clinical trial; Spurious relationship; Janus kinase; Ruxolitinib; Oncology; Intensive care medicine; Internal medicine","score_opus":0.10245799520236465,"score_gpt":0.42278286234884843,"score_spread":0.3203248671464838,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4380148718","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.995123,0.00024028748,0.000005168916,0.0013423461,0.0004110196,0.0013922615,0.000076686665,0.00013974095,0.001269442],"genre_scores_gemma":[0.997304,0.00061237253,0.0006338726,0.00026167184,0.00019656013,0.00044854454,0.00013742763,0.000045977937,0.00035953167],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99631435,0.0003198694,0.0017580112,0.0007714608,0.0003734725,0.00046283627],"domain_scores_gemma":[0.9969136,0.0016390764,0.0003384483,0.00057684263,0.0001754474,0.00035658467],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0011687997,0.0003422004,0.0011587883,0.00034173467,0.0001722455,0.000052770447,0.0001483408,0.00028257273,0.00013358152],"category_scores_gemma":[0.0009182636,0.00029414322,0.00025426783,0.00094946864,0.00038387836,0.00013401435,0.00023851327,0.00028239744,0.00019119028],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00031542376,0.0013149362,0.8290703,0.00004619083,0.00017987732,0.000112524634,0.0003201613,0.000012557837,0.00005182825,0.00015530152,0.004676425,0.16374443],"study_design_scores_gemma":[0.008396063,0.001543365,0.98178416,0.0003058928,0.00015826084,0.000023166434,0.0008109304,0.0006400057,0.0005777908,0.00010236649,0.0054216343,0.00023637542],"about_ca_topic_score_codex":0.0005144142,"about_ca_topic_score_gemma":0.00027755668,"teacher_disagreement_score":0.16350806,"about_ca_system_score_codex":0.0003737434,"about_ca_system_score_gemma":0.0004945867,"threshold_uncertainty_score":0.99995106},"labels":[],"label_agreement":null},{"id":"W4381855175","doi":"10.1177/20406207231177282","title":"Treating accelerated and blast phase myeloproliferative neoplasms: progress and challenges","year":2023,"lang":"en","type":"review","venue":"Therapeutic Advances in Hematology","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Sierra Oncology; National Cancer Institute; Galecto; Incyte; Servier; Celgene","keywords":"Medicine; Myelofibrosis; Essential thrombocythemia; Polycythemia vera; Bone marrow; Internal medicine; Myeloid leukemia; Myeloproliferative neoplasm; Oncology; Population; Myeloid; Acute leukemia; Haematopoiesis; Leukemia; Immunology; Stem cell","score_opus":0.17094447341793698,"score_gpt":0.44510187801768714,"score_spread":0.27415740459975013,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4381855175","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00089353486,0.9952183,0.000008945384,0.0005460567,0.0001331734,0.0026875208,0.000036840258,0.00014885652,0.00032678898],"genre_scores_gemma":[0.00096777367,0.9957309,0.00056747627,0.00008028285,0.00010154797,0.0022660014,0.000096792784,0.00012513765,0.00006410274],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9967388,0.0003725153,0.0009922836,0.0010695452,0.00021199492,0.00061489036],"domain_scores_gemma":[0.99753714,0.0013687016,0.00045608936,0.00035485608,0.00008949718,0.00019371837],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0002499624,0.0008592476,0.0037959223,0.00046329424,0.00014028586,0.00003961061,0.000115293136,0.00047773606,0.000036088277],"category_scores_gemma":[0.00008550989,0.0006077031,0.00014479113,0.00043670644,0.00050943927,0.00016860379,0.000119595876,0.0005463269,0.000029599792],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00014877749,0.000455922,0.0005999783,0.02110151,0.0006296039,0.0005097332,0.00083289726,2.2605154e-7,1.3347162e-7,0.009505404,0.0000031109264,0.9662127],"study_design_scores_gemma":[0.010496671,0.0034327435,0.00016008464,0.04541438,0.0029795207,0.006226661,0.0012179966,0.0002501434,0.0000562539,0.0030739803,0.9252795,0.0014120605],"about_ca_topic_score_codex":0.0000032412056,"about_ca_topic_score_gemma":0.00009211721,"teacher_disagreement_score":0.96480066,"about_ca_system_score_codex":0.000113979026,"about_ca_system_score_gemma":0.00021196855,"threshold_uncertainty_score":0.9996374},"labels":[],"label_agreement":null},{"id":"W4382050159","doi":"10.22374/cjgim.v18i1.667","title":"Bilateral Asynchronous Adrenal Infarction in JAK2-Positive Essential Thrombocythemia","year":2023,"lang":"en","type":"article","venue":"Canadian Journal of General Internal Medicine","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"Centre Hospitalier Universitaire de Sherbrooke","funders":"","keywords":"Medicine; Essential thrombocythemia; Gynecology; Venous thrombosis; Thrombosis; Internal medicine; Polycythemia vera","score_opus":0.015667901356513952,"score_gpt":0.2907197342208417,"score_spread":0.2750518328643277,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4382050159","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98518395,0.0006515421,0.0000919263,0.009630824,0.0014045474,0.00022353318,0.00001880147,0.000011803888,0.002783052],"genre_scores_gemma":[0.9953475,0.00020418645,0.00020470003,0.0010996228,0.0020610238,0.000010286063,0.000047842033,0.000028761502,0.000996104],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99815196,0.000080392194,0.0007272998,0.0002194187,0.00037151243,0.00044941047],"domain_scores_gemma":[0.9983618,0.00007857543,0.00023901064,0.00014107369,0.00031581314,0.00086368335],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00036880258,0.00024094924,0.0006309804,0.0011145324,0.000079619334,0.000027130536,0.00013924734,0.00011175586,0.0010114659],"category_scores_gemma":[0.00017889761,0.00017302085,0.00018331794,0.0004721489,0.00019932032,0.0001386099,0.000016945172,0.00049318,0.00006359241],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0014118251,0.0002666192,0.8254936,0.00013113531,0.0018682186,0.032349985,0.006412859,0.0008027655,0.032620072,0.0016637126,0.0751623,0.02181692],"study_design_scores_gemma":[0.008734581,0.004685424,0.95135665,0.0029938244,0.00036904545,0.007067508,0.0004740983,0.0010639136,0.0183024,0.00064655044,0.003992897,0.00031310171],"about_ca_topic_score_codex":0.018190365,"about_ca_topic_score_gemma":0.019264339,"teacher_disagreement_score":0.12586308,"about_ca_system_score_codex":0.000710662,"about_ca_system_score_gemma":0.00091063045,"threshold_uncertainty_score":0.9999018},"labels":[],"label_agreement":null},{"id":"W4382987260","doi":"10.1038/s41586-023-06375-z","title":"Author Correction: Clonal haematopoiesis and risk of chronic liver disease","year":2023,"lang":"en","type":"erratum","venue":"Nature","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Ottawa; McGill University; University of Calgary; University of Saskatchewan; Université Laval; Université de Montréal; Providence Health Care","funders":"National Heart, Lung, and Blood Institute","keywords":"Haematopoiesis; Medicine; Biology; Internal medicine; Genetics; Stem cell","score_opus":0.01201849741101405,"score_gpt":0.2857340594997535,"score_spread":0.27371556208873943,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4382987260","genre_codex":"review","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"other","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.06607168,0.6524715,0.000048337486,0.024250044,0.21953836,0.0068258788,0.0076782666,0.0009294543,0.022186473],"genre_scores_gemma":[0.04237871,0.060500506,0.00020464181,0.00049500086,0.006742464,0.00033417562,0.0026690478,0.00016953106,0.8865059],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99833304,0.000076876626,0.00027813806,0.0005246808,0.0005507948,0.00023648642],"domain_scores_gemma":[0.99862593,0.00022466111,0.0002521337,0.0003797195,0.0002367875,0.0002807412],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":["research_integrity"],"category_scores_codex":[0.00012699302,0.00036671053,0.0007458831,0.00019862314,0.00012472151,0.000021154248,0.0000739633,0.002112972,0.0004928061],"category_scores_gemma":[0.00049012003,0.0002739984,0.00025784364,0.0002545233,0.000110897,0.000036385456,0.00007962376,0.00391936,0.000069344824],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00018507015,0.00022899205,0.026520569,0.0010570434,0.000821157,0.0005155894,0.00009349761,0.0000014569672,9.4602933e-7,0.00012859232,0.9656969,0.0047502248],"study_design_scores_gemma":[0.00091468176,0.00041438077,0.36413348,0.0017857617,0.0022036948,0.000066825225,0.000021387037,0.0005515904,0.00007940272,0.000078387835,0.62951106,0.0002393655],"about_ca_topic_score_codex":0.00009112194,"about_ca_topic_score_gemma":0.000356799,"teacher_disagreement_score":0.86431944,"about_ca_system_score_codex":0.00021429536,"about_ca_system_score_gemma":0.0006723456,"threshold_uncertainty_score":0.9999712},"labels":[],"label_agreement":null},{"id":"W4384197679","doi":"10.3389/fonc.2023.1206965","title":"Epigenetics in myeloproliferative neoplasms","year":2023,"lang":"en","type":"review","venue":"Frontiers in Oncology","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Health Service Executive; Wellcome Trust; Canadian Institute for Theoretical Astrophysics","keywords":"Epigenetics; Epigenome; DNA methylation; Histone; Biology; microRNA; Myelofibrosis; Cancer research; Bioinformatics; Epigenomics; Disease; Medicine; Genetics; Gene; Immunology; Internal medicine; Gene expression","score_opus":0.10534541548689019,"score_gpt":0.4279332036901433,"score_spread":0.3225877882032531,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4384197679","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00009703722,0.9895923,0.00005733523,0.00045454127,0.0023640047,0.0034174896,0.00007354637,0.000075054275,0.003868667],"genre_scores_gemma":[0.000008419971,0.9865913,0.007547141,0.00026123747,0.00033226694,0.0025007778,0.00037273444,0.00014181467,0.0022443049],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.995878,0.0005953584,0.0014482612,0.00097448035,0.00030424594,0.00079966884],"domain_scores_gemma":[0.99810666,0.0006755506,0.00039455725,0.0005079286,0.00007812055,0.00023720988],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00052308926,0.0007437944,0.00511193,0.0014632273,0.00005379358,0.000019654022,0.00024779522,0.0012275178,0.00010597334],"category_scores_gemma":[0.00039765885,0.00060133665,0.00045410846,0.0013218787,0.00018251037,0.000041349867,0.0001482325,0.0012320289,0.00036785298],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00009812044,0.00080902793,0.012286004,0.0052301195,0.00061614637,0.0034064204,0.0005249743,0.000008224583,4.2007713e-8,0.00031074224,0.02386316,0.952847],"study_design_scores_gemma":[0.0021994207,0.0010958366,0.0008520162,0.008626404,0.000680612,0.00014932203,0.00017881668,0.000059441758,0.0000024254912,0.00041203565,0.98530394,0.000439755],"about_ca_topic_score_codex":0.000056266064,"about_ca_topic_score_gemma":0.0007054276,"teacher_disagreement_score":0.96144074,"about_ca_system_score_codex":0.0027419208,"about_ca_system_score_gemma":0.0022634324,"threshold_uncertainty_score":0.9996438},"labels":[],"label_agreement":null},{"id":"W4384463907","doi":"10.58931/cht.2022.117","title":"Myeloproliferative neoplasms in 2022","year":2022,"lang":"en","type":"article","venue":"Canadian Hematology Today","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; Ottawa Hospital","funders":"","keywords":"Polycythemia vera; Essential thrombocythemia; Ruxolitinib; Myelofibrosis; Myeloid leukemia; Medicine; Janus kinase 2; Oncology; Disease; Janus kinase; Internal medicine; Stem cell; Haematopoiesis; Immunology; Myeloproliferative Disorders; Myeloproliferative neoplasm; Myeloid; Cancer research; Bone marrow; Biology; Cytokine; Receptor","score_opus":0.011950200826081201,"score_gpt":0.2499592666882276,"score_spread":0.2380090658621464,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4384463907","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9532465,0.0020069962,0.0000041442827,0.02284,0.0004832347,0.0010705132,0.00012973128,0.00004780782,0.020171072],"genre_scores_gemma":[0.9894357,0.00005480551,0.00020908636,0.006626368,0.000046329278,0.0011846654,0.0001559772,0.000032641565,0.002254427],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.9981008,0.00018452673,0.0003488359,0.00048618898,0.00022694418,0.00065271],"domain_scores_gemma":[0.9988347,0.00014479973,0.00006460136,0.00033534525,0.000057277113,0.0005632412],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00022362074,0.00023424877,0.0005673954,0.0005968115,0.00035906376,0.000012346176,0.00012904854,0.00010602622,0.007542676],"category_scores_gemma":[0.00010865372,0.0002310496,0.00009521121,0.0005374418,0.00008335093,0.000048562815,0.00006492033,0.00052669196,0.00018688111],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0001439951,0.0003277558,0.8743308,0.00003313816,0.00015476801,0.0070984745,0.0017756158,0.000069779606,0.00005599019,0.07565624,0.03898489,0.0013685455],"study_design_scores_gemma":[0.012622693,0.0027640886,0.41568783,0.00014524777,0.00022857162,0.013927517,0.004499954,0.0012606013,0.0074947164,0.0045981538,0.53537095,0.0013996578],"about_ca_topic_score_codex":0.01535621,"about_ca_topic_score_gemma":0.19727021,"teacher_disagreement_score":0.49638608,"about_ca_system_score_codex":0.0010642741,"about_ca_system_score_gemma":0.0015583631,"threshold_uncertainty_score":0.9933646},"labels":[],"label_agreement":null},{"id":"W4385212779","doi":"10.3390/cancers15143706","title":"Predictors of Response to Hydroxyurea and Switch to Ruxolitinib in HU-Resistant Polycythaemia VERA Patients: A Real-World PV-NET Study","year":2023,"lang":"en","type":"article","venue":"Cancers","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":14,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Grifols; AOP Orphan; Swedish Orphan Biovitrum; Pfizer; Ministero della Salute; Sierra Oncology; Incyte; Alexion Pharmaceuticals; Gilead Sciences; Sanofi; Celgene; AstraZeneca; Amgen; GlaxoSmithKline","keywords":"Polycythaemia; Ruxolitinib; Polycythemia vera; Medicine; Internal medicine; Myelofibrosis","score_opus":0.017448144012393564,"score_gpt":0.3075690887937115,"score_spread":0.2901209447813179,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4385212779","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9956359,0.0000411475,5.137367e-7,0.0010008587,0.00018644039,0.0020056772,0.00016762836,0.000051525814,0.00091029453],"genre_scores_gemma":[0.9978291,0.00006247346,0.000046042278,0.00046171813,0.000062280764,0.0006074452,0.00003493581,0.000031300064,0.00086471275],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9982569,0.000115815754,0.00042210228,0.00044839195,0.00039317893,0.0003636168],"domain_scores_gemma":[0.99887013,0.0002622166,0.00007412989,0.0003365559,0.000095028816,0.00036192665],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00034556145,0.00021623756,0.0005013685,0.0005356536,0.000051340186,0.00001320387,0.00007547181,0.000046791465,0.00005010658],"category_scores_gemma":[0.0003032375,0.00018351764,0.000046433295,0.0010638488,0.00003767214,0.000040858115,0.00007833689,0.00011037928,0.000023464403],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.007745879,0.00023071669,0.9778195,0.000046935158,0.00013873709,0.00012826572,0.006760204,0.00016679289,0.00063888176,0.000029358607,0.0057035447,0.00059119373],"study_design_scores_gemma":[0.0044861194,0.003681055,0.9844851,0.00030335417,0.0000768528,5.93575e-7,0.0013116252,0.000026569007,0.0017519748,0.000007857077,0.003719062,0.0001498371],"about_ca_topic_score_codex":0.0038987526,"about_ca_topic_score_gemma":0.004913253,"teacher_disagreement_score":0.006665609,"about_ca_system_score_codex":0.0012941335,"about_ca_system_score_gemma":0.0004510991,"threshold_uncertainty_score":0.7483632},"labels":[],"label_agreement":null},{"id":"W4385297552","doi":"10.1016/s2352-3026(23)00174-6","title":"Momelotinib versus danazol in symptomatic patients with anaemia and myelofibrosis previously treated with a JAK inhibitor (MOMENTUM): an updated analysis of an international, double-blind, randomised phase 3 study","year":2023,"lang":"en","type":"article","venue":"The Lancet Haematology","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":39,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Myelofibrosis; Internal medicine; Danazol; Clinical endpoint; Ruxolitinib; Anemia; Post-hoc analysis; Randomized controlled trial; Intention-to-treat analysis; Adverse effect; Placebo; Gastroenterology; Surgery; Bone marrow; Endometriosis","score_opus":0.04147677945176609,"score_gpt":0.34679700797642826,"score_spread":0.3053202285246622,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4385297552","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99603105,0.00001902653,0.0000030983579,0.00038593033,0.00004154422,0.0032765088,0.00006554041,0.00008824688,0.0000890565],"genre_scores_gemma":[0.99752325,0.000042456788,0.000096807205,0.000049103848,0.000026331094,0.00072298903,0.0014935537,0.00002927123,0.000016218128],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99796575,0.000286492,0.0005372072,0.0004938186,0.00036839768,0.00034831185],"domain_scores_gemma":[0.99853873,0.00024034668,0.00030261872,0.00058945926,0.00018743095,0.00014138677],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00035875663,0.00029409898,0.0016686575,0.0006743823,0.00007893373,0.00003340013,0.00018537529,0.0000753467,0.0000735849],"category_scores_gemma":[0.000037341837,0.00016396934,0.000056673893,0.0015646848,0.0001431413,0.00016991433,0.000053028834,0.0001347899,0.000004785885],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.15224214,0.003554035,0.8361516,0.00004896504,0.0043506883,0.00021677578,0.0027617372,0.00011835331,0.00003673295,0.00006263991,0.000041602758,0.0004147319],"study_design_scores_gemma":[0.4475587,0.0083770435,0.53403753,0.00010642411,0.0042388616,0.000019697685,0.0012707207,0.0032321557,0.0009332219,0.0000045398624,0.0000130289645,0.00020805618],"about_ca_topic_score_codex":0.00023342765,"about_ca_topic_score_gemma":0.0013985552,"teacher_disagreement_score":0.30211407,"about_ca_system_score_codex":0.000082694474,"about_ca_system_score_gemma":0.000063817264,"threshold_uncertainty_score":0.6686475},"labels":[],"label_agreement":null},{"id":"W4385477402","doi":"10.1182/bloodadvances.2023010628","title":"Matching-adjusted indirect comparison of the pelabresib-ruxolitinib combination vs JAKi monotherapy in myelofibrosis","year":2023,"lang":"en","type":"article","venue":"Blood Advances","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"National Cancer Institute; Celgene; MorphoSys; Astellas Pharma; Galecto; Sierra Oncology; Incyte; CTI Biopharma; Constellation Pharmaceuticals; Astex Pharmaceuticals; Jazz Pharmaceuticals; AOP Orphan; GlaxoSmithKline","keywords":"Ruxolitinib; Myelofibrosis; Matching (statistics); Medicine; Internal medicine; Pathology","score_opus":0.02895329108079735,"score_gpt":0.3213575054599074,"score_spread":0.29240421437911,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4385477402","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9946236,0.0015348067,0.000005164787,0.0016345158,0.00015919078,0.000688558,0.000024682888,0.000073966214,0.0012555238],"genre_scores_gemma":[0.99814504,0.0007735212,0.00032820785,0.00015183572,0.00004144734,0.00015000637,0.000040303854,0.000021741867,0.00034787518],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99865466,0.00010822902,0.0004031934,0.00025779585,0.00034228564,0.00023382845],"domain_scores_gemma":[0.9991458,0.00028166317,0.00020197175,0.00024579052,0.000073279494,0.000051464755],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00016240941,0.00017392068,0.000495748,0.00017147759,0.000091524336,0.000013800967,0.000111725596,0.000067443005,0.000049417653],"category_scores_gemma":[0.000057801502,0.00011708287,0.00010292608,0.0007179073,0.00006764669,0.00010354896,0.000036070196,0.00014245007,0.00002229271],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0002333225,0.0012076691,0.9796142,0.00014590885,0.00011959944,0.000008363925,0.002679546,0.0001833981,0.0029037856,0.0016023411,0.00017578035,0.011126083],"study_design_scores_gemma":[0.0040782634,0.0005283123,0.8613773,0.00035698854,0.00009314989,0.000004888989,0.0008123079,0.0001522944,0.12939477,0.0011387053,0.0019482542,0.00011478471],"about_ca_topic_score_codex":0.000113469905,"about_ca_topic_score_gemma":0.0003282086,"teacher_disagreement_score":0.12649098,"about_ca_system_score_codex":0.000039497358,"about_ca_system_score_gemma":0.00005750257,"threshold_uncertainty_score":0.4774501},"labels":[],"label_agreement":null},{"id":"W4385483571","doi":"10.57264/cer-2023-0066","title":"Cost–effectiveness of ropeginterferon alfa-2b-njft for the treatment of polycythemia vera","year":2023,"lang":"en","type":"article","venue":"Journal of Comparative Effectiveness Research","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Sierra Oncology; Incyte; Celgene","keywords":"Medicine; Polycythemia vera; Quality-adjusted life year; Myelofibrosis; Population; Internal medicine; Cost effectiveness; Cohort","score_opus":0.3315524533615838,"score_gpt":0.5218676901699087,"score_spread":0.19031523680832496,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4385483571","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9903619,0.002237307,0.0022029325,0.0003204591,0.00029637633,0.0041957838,0.00006269225,0.00001071613,0.00031181253],"genre_scores_gemma":[0.9974534,0.0012466813,0.000118706834,0.000004068132,0.00020238965,0.0007948035,0.00001752532,0.000032018186,0.00013038574],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9956924,0.0018825192,0.00066644774,0.00029168985,0.0010000584,0.0004669355],"domain_scores_gemma":[0.97714245,0.019543588,0.00038784716,0.00037536657,0.0023747387,0.00017601454],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0039956523,0.00029509122,0.0014935698,0.0006242161,0.00021345647,0.000027674383,0.00025220128,0.0001003278,0.000043050124],"category_scores_gemma":[0.0003446391,0.00016223382,0.0005718215,0.0009534046,0.00045455343,0.0001252437,0.000055858425,0.00033036922,0.000016739716],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.19168347,0.01883154,0.32036227,0.00574309,0.018768007,0.00047281897,0.0154301375,0.010109389,0.34189886,0.0081708655,0.003217793,0.06531176],"study_design_scores_gemma":[0.009271469,0.021250807,0.3539984,0.0013400192,0.00026191107,0.000052534644,0.00074964226,0.0008739931,0.60879457,0.00046504676,0.002833494,0.0001080983],"about_ca_topic_score_codex":0.00006810619,"about_ca_topic_score_gemma":0.000012997602,"teacher_disagreement_score":0.2668957,"about_ca_system_score_codex":0.00079059973,"about_ca_system_score_gemma":0.00056674535,"threshold_uncertainty_score":0.6615703},"labels":[],"label_agreement":null},{"id":"W4385644744","doi":"10.1182/bloodadvances.2023010151","title":"Pacritinib is a potent ACVR1 inhibitor with significant anemia benefit in patients with myelofibrosis","year":2023,"lang":"en","type":"article","venue":"Blood Advances","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":73,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"Genentech; Italfarmaco; Swedish Orphan Biovitrum; Grifols; Actuate Therapeutics; Galecto; Sierra Oncology; Pfizer; Incyte; CTI Biopharma; Bristol-Myers Squibb; Constellation Pharmaceuticals; Acceleron; Astellas Pharma; Ionis Pharmaceuticals; Jazz Pharmaceuticals; Alexion Pharmaceuticals; Karyopharm Therapeutics; National Cancer Institute; Gilead Sciences; Sanofi; MorphoSys; Celgene; AstraZeneca; Amgen","keywords":"Ruxolitinib; Anemia; Myelofibrosis; IC50; Medicine; Pharmacology; Cmax; Potency; Internal medicine; Chemistry; Pharmacokinetics; Bone marrow; Biochemistry; In vitro","score_opus":0.006939995416863052,"score_gpt":0.2316811282671716,"score_spread":0.22474113285030856,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4385644744","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9963855,0.00037486776,0.000002866639,0.0014080366,0.000049178136,0.00096236303,0.00011892403,0.00010660288,0.0005916665],"genre_scores_gemma":[0.9965414,0.00039303856,0.0016097974,0.00048630088,0.00008410983,0.00037950798,0.00014477374,0.00004364477,0.00031747328],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9981785,0.000020588372,0.0002852324,0.00053766934,0.000535743,0.00044229458],"domain_scores_gemma":[0.9991914,0.00009307701,0.00009967925,0.00027561028,0.00015578445,0.00018447122],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00006465087,0.00030134013,0.0004517245,0.00017607557,0.00009461165,0.000031165226,0.000067892215,0.000061927836,0.000070785376],"category_scores_gemma":[0.000025490614,0.00018772233,0.000053966538,0.0006321655,0.00007869083,0.00017941256,0.000033684966,0.00013795914,0.000058804515],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00077691826,0.0012633393,0.9866226,0.00013468489,0.00010588123,0.00020530909,0.00041545168,0.00003712559,0.00021021554,0.00005140471,0.00029276882,0.009884322],"study_design_scores_gemma":[0.009628319,0.00428787,0.9482215,0.00086321466,0.00021058328,0.000009087559,0.0003796231,0.0000081664875,0.033929598,0.000047776175,0.0021163167,0.00029796863],"about_ca_topic_score_codex":0.00003471857,"about_ca_topic_score_gemma":0.00009252498,"teacher_disagreement_score":0.0384011,"about_ca_system_score_codex":0.00005235692,"about_ca_system_score_gemma":0.00007033338,"threshold_uncertainty_score":0.7655094},"labels":[],"label_agreement":null},{"id":"W4385667045","doi":"10.1097/01.hs9.0000970976.05785.80","title":"P1018: UPDATED RESULTS FROM MANIFEST ARM 2: EFFICACY AND SAFETY OF PELABRESIB (CPI-0610) AS ADD-ON TO RUXOLITINIB IN MYELOFIBROSIS","year":2023,"lang":"en","type":"article","venue":"HemaSphere","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Ruxolitinib; Medicine; Myelofibrosis; Internal medicine; Discontinuation; Oncology; Gastroenterology; Bone marrow","score_opus":0.024068135180549254,"score_gpt":0.296001022558554,"score_spread":0.27193288737800475,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4385667045","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9724218,0.00015036263,0.0000014643683,0.0032842844,0.00009476075,0.0010479348,0.00057087734,0.00011254389,0.022315932],"genre_scores_gemma":[0.9948582,0.00028820985,0.00067981804,0.0006055505,0.00012479362,0.000085762666,0.00076252286,0.000048127116,0.0025469884],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99780613,0.000085575026,0.00064097234,0.0006638195,0.00039877734,0.0004047286],"domain_scores_gemma":[0.9982961,0.000666688,0.00012664402,0.0005055504,0.00009637475,0.00030867665],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.0002076688,0.00031066986,0.0006380856,0.00014079038,0.00007307336,0.000021810327,0.000093148,0.0001594986,0.0013417017],"category_scores_gemma":[0.00039873857,0.00025909086,0.0000819847,0.0006220039,0.000055864635,0.00005050781,0.000100120706,0.00019561176,0.00087742857],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.09214003,0.0129832765,0.43626285,0.0011224687,0.0024588602,0.0058515673,0.024027178,0.00087540946,0.029855115,0.018970396,0.2567039,0.11874894],"study_design_scores_gemma":[0.016695295,0.002447636,0.9211441,0.001530769,0.00013289896,0.000024331055,0.0010534871,0.00009833608,0.034436498,0.0002493192,0.021834502,0.00035278333],"about_ca_topic_score_codex":0.0008806901,"about_ca_topic_score_gemma":0.0005457924,"teacher_disagreement_score":0.4848813,"about_ca_system_score_codex":0.000103922626,"about_ca_system_score_gemma":0.00010029695,"threshold_uncertainty_score":0.9999861},"labels":[],"label_agreement":null},{"id":"W4385667605","doi":"10.1097/01.hs9.0000970892.97539.5e","title":"P997: FEDRATINIB IS EFFECTIVE IN RUXOLITINIB-RESISTANT CELLS: CLINICAL AND PRECLINICAL CORRELATIONS","year":2023,"lang":"en","type":"article","venue":"HemaSphere","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Ruxolitinib; Myelofibrosis; Myeloproliferative neoplasm; Medicine; Kinome; Cancer research; Dasatinib; Internal medicine; Janus kinase 2; Immunology; Oncology; Pharmacology; Bone marrow; Kinase; Biology; Tyrosine kinase; Receptor","score_opus":0.050313681724031015,"score_gpt":0.3819137140479928,"score_spread":0.3316000323239618,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4385667605","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98502207,0.00047480446,0.000015306101,0.0028438147,0.00026877093,0.0013251612,0.000058252695,0.00011816027,0.009873668],"genre_scores_gemma":[0.99430937,0.00053553836,0.0008003032,0.0007946595,0.00021100846,0.0003664155,0.000050592294,0.000032901884,0.002899203],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9980003,0.00020546542,0.00066816044,0.0005549612,0.00024297058,0.00032811824],"domain_scores_gemma":[0.99731123,0.0019463195,0.000100638405,0.00030089647,0.000083224666,0.00025768348],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005209483,0.00022014133,0.00059551996,0.000064431726,0.00010599547,0.000028216466,0.000047718266,0.0002270173,0.0007904048],"category_scores_gemma":[0.00047261908,0.00017599811,0.00015967523,0.0003205487,0.00016472713,0.00005994138,0.00007038045,0.00039208116,0.0007539097],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0004885822,0.0008700236,0.96108574,0.00013489866,0.00017438238,0.0003362235,0.0008193752,0.000006166289,0.00017428758,0.0020167322,0.021221215,0.012672378],"study_design_scores_gemma":[0.005209832,0.0011483296,0.9759866,0.0003518993,0.00013566457,0.000017814806,0.00046808674,0.0009559827,0.0013991775,0.0006821728,0.013441211,0.00020325747],"about_ca_topic_score_codex":0.000049587532,"about_ca_topic_score_gemma":0.00019830068,"teacher_disagreement_score":0.014900836,"about_ca_system_score_codex":0.000047764748,"about_ca_system_score_gemma":0.00013077873,"threshold_uncertainty_score":0.9690235},"labels":[],"label_agreement":null},{"id":"W4385667614","doi":"10.1097/01.hs9.0000971072.43107.6c","title":"P1044: REDUCTION IN RED BLOOD CELL TRANSFUSION BURDEN: A NOVEL LONGITUDINAL TIME-DEPENDENT ANALYSIS IN PATIENTS WITH TRANSFUSION-DEPENDENT MYELOFIBROSIS TREATED WITH MOMELOTINIB","year":2023,"lang":"en","type":"article","venue":"HemaSphere","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"","keywords":"Ruxolitinib; Medicine; Myelofibrosis; Anemia; Blood transfusion; Internal medicine; Bone marrow","score_opus":0.00935522102421016,"score_gpt":0.21967169838021455,"score_spread":0.2103164773560044,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4385667614","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9959582,0.00008230863,0.00009225664,0.0005307796,0.00003523604,0.002044872,0.00007080995,0.00016261834,0.0010229263],"genre_scores_gemma":[0.9960863,0.00030505273,0.000581565,0.000017964001,0.000052277366,0.00043660327,0.0005593578,0.00008569349,0.001875177],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99647486,0.00010329173,0.0006760375,0.0011034596,0.0010207592,0.0006215774],"domain_scores_gemma":[0.99879175,0.00007678484,0.00016043244,0.0005093477,0.00020916159,0.00025254214],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00023730715,0.0005502713,0.0010405831,0.0007083278,0.00013458064,0.000044108303,0.00011123443,0.00022726151,0.0010491692],"category_scores_gemma":[0.000012731252,0.0003977414,0.00019874527,0.0033669062,0.000062994724,0.00017587311,0.000028091663,0.00035009987,0.00007569513],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0041672587,0.0044851634,0.97557604,0.00014941323,0.00096512487,0.000370677,0.0013526987,0.0048447475,0.0068536093,0.000003827158,0.000048613725,0.0011828438],"study_design_scores_gemma":[0.02789403,0.0032884846,0.93790126,0.0005784603,0.002435642,0.000036169684,0.00075374555,0.0009810099,0.025601927,0.0000031938866,0.000020453132,0.00050564186],"about_ca_topic_score_codex":0.0017568849,"about_ca_topic_score_gemma":0.0031560776,"teacher_disagreement_score":0.03767478,"about_ca_system_score_codex":0.000297332,"about_ca_system_score_gemma":0.00013500443,"threshold_uncertainty_score":0.999864},"labels":[],"label_agreement":null},{"id":"W4385702799","doi":"10.1097/01.hs9.0000975724.65819.6e","title":"PB2248: BONE MARROW NECROSIS: RARE PRESENTATION OF CHRONIC MYELOID NEOPLASMS SYSTEMIC REVIEW AND CASE REPORT","year":2023,"lang":"en","type":"article","venue":"HemaSphere","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Myeloproliferative neoplasm; Medicine; Myelofibrosis; Pathology; Bone marrow; Essential thrombocythemia; Myeloid; Internal medicine; Polycythemia vera","score_opus":0.020819081014949736,"score_gpt":0.2954762781996693,"score_spread":0.2746571971847196,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4385702799","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.893169,0.09953657,0.000017364735,0.0025901708,0.00015906942,0.002204932,0.000052578504,0.00015896866,0.0021113856],"genre_scores_gemma":[0.9701319,0.023109386,0.00026941762,0.00022543097,0.00011491156,0.000523845,0.00021680843,0.00004412202,0.0053641805],"study_design_codex":"case_report","study_design_gemma":"case_report","domain_scores_codex":[0.9983121,0.00006958161,0.00063646317,0.0004249646,0.00029232746,0.00026451916],"domain_scores_gemma":[0.9987805,0.00012500524,0.00028602424,0.0004562276,0.0001813183,0.00017095936],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00026943552,0.00023374884,0.00073383935,0.000057659872,0.00009237084,0.000016418522,0.000036122008,0.0000986959,0.00064293947],"category_scores_gemma":[0.00017362591,0.00018599025,0.000123118,0.0004150267,0.000060825187,0.000094216164,0.000057166606,0.00012383421,0.000092456576],"study_design_candidate":"case_report","study_design_consensus":"case_report","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00037957967,0.0013558852,0.2125372,0.118808985,0.0020734333,0.33891112,0.0023624355,0.000087133834,0.014541123,0.0008770142,0.25509587,0.052970245],"study_design_scores_gemma":[0.014078027,0.0035622157,0.05007172,0.052216206,0.0068063927,0.790252,0.0034951686,0.0013409441,0.054782823,0.00022331206,0.021652605,0.0015186307],"about_ca_topic_score_codex":0.00014800634,"about_ca_topic_score_gemma":0.00012650424,"teacher_disagreement_score":0.45134085,"about_ca_system_score_codex":0.00012031372,"about_ca_system_score_gemma":0.00018106245,"threshold_uncertainty_score":0.7584463},"labels":[],"label_agreement":null},{"id":"W4386035313","doi":"10.1016/j.exphem.2023.08.005","title":"Complementary and countervailing actions of Jak2 and Ikk2 in hematopoiesis in mice","year":2023,"lang":"en","type":"article","venue":"Experimental Hematology","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"National Heart, Lung, and Blood Institute; National Cancer Institute; MPN Research Foundation; National Institutes of Health; Leukemia and Lymphoma Society; Canadian Institutes of Health Research; Alvin J. Siteman Cancer Center","keywords":"Haematopoiesis; Myeloid; Biology; Stem cell; Hematopoietic stem cell; JAK2 V617F; Cancer research; Janus kinase 2; Progenitor cell; Cell biology; Mutation; Genetics; Gene; Kinase","score_opus":0.04596417111803542,"score_gpt":0.36023279160905797,"score_spread":0.31426862049102255,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4386035313","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9948625,0.0033318112,0.0000010560706,0.0009900322,0.000047073023,0.0003310784,0.0000116615165,0.000017424258,0.00040734938],"genre_scores_gemma":[0.99904114,0.00019934778,0.00041612136,0.00015000725,0.000007451174,0.0001173425,0.000031461976,0.000009759047,0.000027362184],"study_design_codex":"observational","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99921143,0.00003614574,0.00028627555,0.00021666584,0.00007805542,0.00017140585],"domain_scores_gemma":[0.99966866,0.00014608714,0.00004324272,0.00007936369,0.000010970595,0.000051658866],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000080330894,0.000111139205,0.00038954997,0.00020750296,0.000032974833,0.0000038432513,0.000022592309,0.000047597972,0.000120184566],"category_scores_gemma":[0.000011235791,0.00010271196,0.000023493538,0.00016882455,0.000097795644,0.000046819867,0.00006757345,0.00006828226,0.000008897635],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00020088874,0.00080148765,0.9520044,0.00022593209,0.00007476543,0.00035184986,0.0047424757,0.0000014423658,0.024502903,0.016376298,0.0005290986,0.00018845862],"study_design_scores_gemma":[0.005730273,0.0005127763,0.21741775,0.0003758152,0.000026102778,0.0008061134,0.016817985,0.0004966159,0.75708365,0.0001917891,0.0003772542,0.00016387537],"about_ca_topic_score_codex":0.0002901449,"about_ca_topic_score_gemma":0.00039486948,"teacher_disagreement_score":0.73458666,"about_ca_system_score_codex":0.0000550134,"about_ca_system_score_gemma":0.000017096832,"threshold_uncertainty_score":0.4188472},"labels":[],"label_agreement":null},{"id":"W4386067267","doi":"10.1097/01.hs9.0000971056.91985.c2","title":"P1040: FACTORS ASSOCIATED WITH THROMBOSIS IN MYELOFIBROSIS","year":2023,"lang":"en","type":"article","venue":"HemaSphere","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Health Sciences Centre; Sunnybrook Health Science Centre; Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Myelofibrosis; Polycythemia vera; Internal medicine; Hazard ratio; Thrombosis; Population; Incidence (geometry); Diabetes mellitus; Proportional hazards model; Surgery; Confidence interval; Bone marrow","score_opus":0.06777147028570386,"score_gpt":0.29968683444939304,"score_spread":0.23191536416368919,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4386067267","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99049634,0.00008532175,0.000003802791,0.001095289,0.00005436985,0.00044915415,0.00002431914,0.0002153501,0.007576075],"genre_scores_gemma":[0.99726355,0.00008984297,0.000119864555,0.00018050277,0.000029912137,0.00013819657,0.0001806801,0.000042425923,0.0019550412],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9987029,0.00004233447,0.00021701929,0.00033516964,0.0003276454,0.00037493953],"domain_scores_gemma":[0.9992834,0.00022009989,0.00006421894,0.00022896488,0.00006584689,0.00013747714],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00009625801,0.00022626776,0.00045065433,0.00008802553,0.0000740303,0.00002179373,0.000050592913,0.00011670908,0.00097129465],"category_scores_gemma":[0.000116069226,0.00015303238,0.0000865113,0.00088512205,0.000044804503,0.00007058583,0.00003077381,0.00014742024,0.0002071104],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000034412722,0.00035576813,0.99288905,0.000037067486,0.0002145102,0.000084941086,0.0007195272,0.000022502063,0.0004490697,0.00022642703,0.0045520626,0.00041463866],"study_design_scores_gemma":[0.0020673436,0.00044817588,0.9871432,0.0004203486,0.00009158393,0.0000022255938,0.0008411756,0.00008892924,0.0077423365,0.000051821175,0.0009304649,0.00017235686],"about_ca_topic_score_codex":0.00012403452,"about_ca_topic_score_gemma":0.00081725715,"teacher_disagreement_score":0.0072932667,"about_ca_system_score_codex":0.00018232572,"about_ca_system_score_gemma":0.00008917686,"threshold_uncertainty_score":0.99994195},"labels":[],"label_agreement":null},{"id":"W4386071127","doi":"10.1097/01.hs9.0000971044.20101.d8","title":"P1037: CONSISTENCY OF PACRITINIB FOR SPLEEN AND SYMPTOM REDUCTION IN PATIENTS WITH MYELOFIBROSIS REGARDLESS OF CYTOPENIAS","year":2023,"lang":"en","type":"article","venue":"HemaSphere","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Myelofibrosis; Medicine; Ruxolitinib; Internal medicine; Exacerbation; Gastroenterology; Anemia; Bone marrow","score_opus":0.012963645255667799,"score_gpt":0.2547533797614052,"score_spread":0.24178973450573743,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4386071127","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9973342,0.00015347774,0.0000078483245,0.00035674454,0.000035630266,0.0010198163,0.00007134265,0.000017812865,0.0010031665],"genre_scores_gemma":[0.9973442,0.00009369574,0.0019357523,0.000018010835,0.000019959754,0.00015435825,0.000092075985,0.000019690942,0.00032225432],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99911714,0.000022859347,0.000295868,0.00022764568,0.00018231713,0.00015417383],"domain_scores_gemma":[0.9993396,0.0001094279,0.000114736504,0.00017362165,0.00020306098,0.00005954344],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000089750916,0.00012387882,0.0004255393,0.00006392772,0.000030688665,0.0000046031982,0.000025992336,0.00006123562,0.000054149157],"category_scores_gemma":[0.00006108895,0.00009282611,0.00004895837,0.00023653783,0.00008341991,0.00005156794,0.000021096095,0.00004476511,0.000002510846],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0009853087,0.00047162405,0.9873365,0.00068905135,0.00014495895,0.0000057159136,0.00067034725,0.000004143727,0.0006701293,0.0011751505,0.00092276203,0.0069242725],"study_design_scores_gemma":[0.007600584,0.0018070095,0.96072996,0.00093008793,0.00015370887,0.000006752213,0.0009225365,0.000025592191,0.0272898,0.00013348163,0.00028310245,0.00011738559],"about_ca_topic_score_codex":0.0000558004,"about_ca_topic_score_gemma":0.000040355306,"teacher_disagreement_score":0.02661967,"about_ca_system_score_codex":0.000028713139,"about_ca_system_score_gemma":0.00005813518,"threshold_uncertainty_score":0.37853387},"labels":[],"label_agreement":null},{"id":"W4386074702","doi":"10.1097/01.hs9.0000971004.26914.cb","title":"P1027: UPDATED DURABILITY OF RESPONSE AND SAFETY IN MANIFEST ARM 3: PELABRESIB (CPI-0610) COMBINED WITH RUXOLITINIB FOR JAK INHIBITOR TREATMENT-NAÏVE PATIENTS WITH MYELOFIBROSIS","year":2023,"lang":"en","type":"article","venue":"HemaSphere","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Ruxolitinib; Myelofibrosis; Internal medicine; Discontinuation; Phases of clinical research; Clinical endpoint; Gastroenterology; Oncology; Bone marrow; Clinical trial","score_opus":0.012602810886682003,"score_gpt":0.2505186048097666,"score_spread":0.23791579392308462,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4386074702","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9945327,0.00006485655,0.000004501986,0.001107321,0.000037946003,0.003261402,0.0004708402,0.00009066386,0.00042974585],"genre_scores_gemma":[0.99655014,0.00006477155,0.0010817377,0.00007121772,0.00003080164,0.0006307629,0.0006926198,0.00006201811,0.00081590324],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99791044,0.00014512421,0.0005295363,0.0006241206,0.00034382907,0.00044695343],"domain_scores_gemma":[0.9982225,0.0006318826,0.00019255714,0.00044036482,0.00028956847,0.00022313371],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0002451084,0.00040486341,0.00080926734,0.00011963129,0.0001204329,0.000020596115,0.000055753128,0.00013400408,0.00020808025],"category_scores_gemma":[0.00011942468,0.0002631165,0.00008851962,0.00051985716,0.00016894759,0.00010583806,0.00003863361,0.00010507849,0.000016046193],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.068550915,0.0028930127,0.92371345,0.00033699,0.00030963638,0.00008417242,0.0008722204,0.000011226671,0.00040225196,0.00026153197,0.0005400909,0.0020244974],"study_design_scores_gemma":[0.030546116,0.015814023,0.9389118,0.00061265274,0.00023527077,0.000013511083,0.000725039,0.0000868588,0.011822958,0.00005204246,0.0009140368,0.00026569684],"about_ca_topic_score_codex":0.0001324024,"about_ca_topic_score_gemma":0.0006513128,"teacher_disagreement_score":0.038004797,"about_ca_system_score_codex":0.00027019763,"about_ca_system_score_gemma":0.00022007793,"threshold_uncertainty_score":0.9999821},"labels":[],"label_agreement":null},{"id":"W4386143084","doi":"10.1097/01.hs9.0000977400.14880.93","title":"PB2681: GAPS IN THE ASSESSMENT AND MONITORING OF CARDIOVASCULAR RISK AND PSYCHOLOGICAL BURDEN IN POLYCYTHEMIA VERA: LANDMARK 2.0: A WORLDWIDE HEALTH SURVEY","year":2023,"lang":"en","type":"article","venue":"HemaSphere","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hôpital Maisonneuve-Rosemont; University of British Columbia","funders":"","keywords":"Medicine; Polycythemia vera; Phlebotomy; Quality of life (healthcare); Internal medicine","score_opus":0.05549516958441596,"score_gpt":0.36432288253758044,"score_spread":0.30882771295316447,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4386143084","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9913205,0.006797754,0.000008418711,0.0009035203,0.000049154427,0.0005303003,0.000021270534,0.00001612275,0.00035297076],"genre_scores_gemma":[0.9893913,0.009857806,0.00046824626,0.000046594145,0.00006596207,0.00010184728,0.000018810992,0.000011965413,0.00003743764],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9984542,0.00043149074,0.00028319232,0.00031054547,0.00027461848,0.0002459647],"domain_scores_gemma":[0.99908566,0.0004729649,0.000064222804,0.00027333433,0.000023140286,0.00008065746],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0014617352,0.00014666968,0.0005139019,0.00006559474,0.00005373191,0.000015481997,0.000049665698,0.000064161926,0.000017221784],"category_scores_gemma":[0.0000890057,0.000092500275,0.00006831089,0.0003988894,0.000046721074,0.000026195434,0.000040824303,0.00025316034,0.0000029598218],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00007336101,0.0001491494,0.9830756,0.000074908196,0.000117291536,0.00011784915,0.00085215917,0.000045573008,0.00001040559,0.00003112537,0.00031801272,0.015134549],"study_design_scores_gemma":[0.0022746476,0.0003338447,0.9954841,0.000267,0.00003780339,0.000024916186,0.00082884374,0.00005449404,0.0000514342,0.00006489754,0.0005051962,0.00007282511],"about_ca_topic_score_codex":0.002788545,"about_ca_topic_score_gemma":0.0006319549,"teacher_disagreement_score":0.015061724,"about_ca_system_score_codex":0.00007574504,"about_ca_system_score_gemma":0.000047981714,"threshold_uncertainty_score":0.42154646},"labels":[],"label_agreement":null},{"id":"W4386189225","doi":"10.1016/j.htct.2023.07.005","title":"Extramedullary haematopoiesis in patients with thalassemia: a cross-sectional description of its prevalence, clinical features and survival","year":2023,"lang":"en","type":"article","venue":"Hematology Transfusion and Cell Therapy","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Global Affairs Canada","funders":"Ministério da Saúde","keywords":"Medicine; Hazard ratio; Internal medicine; Confidence interval; Extramedullary hematopoiesis; Cross-sectional study; Thalassemia; Cohort; Gastroenterology; Magnetic resonance imaging; Pediatrics; Pathology; Radiology; Haematopoiesis","score_opus":0.0336181875670144,"score_gpt":0.3139517174565897,"score_spread":0.2803335298895753,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4386189225","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99584025,0.0029536341,0.000011267065,0.00019007376,0.000108271684,0.00060926203,0.000014516701,0.000030226354,0.00024248807],"genre_scores_gemma":[0.9586222,0.040871907,0.00009294001,0.00009285285,0.000013642453,0.00006128685,0.000029813265,0.000014119853,0.00020124216],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9987948,0.00012558152,0.00035774065,0.00034261085,0.00020648721,0.0001727667],"domain_scores_gemma":[0.9994083,0.00022927595,0.00006982729,0.00011014182,0.00009274424,0.00008971572],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00026194935,0.00016000391,0.00046046154,0.0001385246,0.00007351929,0.000012447901,0.000030408162,0.00021804747,0.00011030182],"category_scores_gemma":[0.000014749405,0.00010860038,0.000059350812,0.00018459486,0.00016649933,0.00006703204,0.000010359134,0.00018796428,0.0000030403553],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0018239921,0.0008480067,0.9950504,0.00036488162,0.000061728926,0.000034210592,0.0003128186,8.376884e-7,0.00027831536,0.00026779794,0.000068311485,0.00088871503],"study_design_scores_gemma":[0.0080865575,0.0010407331,0.9868824,0.0001497011,0.000025374951,0.000060284605,0.00006152432,0.000016972455,0.0034735962,0.000047954003,0.00006442716,0.00009049945],"about_ca_topic_score_codex":0.000008130746,"about_ca_topic_score_gemma":0.000040415227,"teacher_disagreement_score":0.037918273,"about_ca_system_score_codex":0.000011050948,"about_ca_system_score_gemma":0.00004396926,"threshold_uncertainty_score":0.44285953},"labels":[],"label_agreement":null},{"id":"W4386269952","doi":"10.1016/s2152-2650(23)00631-6","title":"POSTER: MPN-133 Reduction in Red Blood Cell Transfusion Burden: A Novel Longitudinal Time-Dependent Analysis in Patients With Transfusion-Dependent Myelofibrosis Treated With Momelotinib","year":2023,"lang":"en","type":"article","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"","keywords":"Myelofibrosis; Medicine; Red blood cell; Reduction (mathematics); Blood transfusion; Internal medicine; Bone marrow","score_opus":0.015510990277060228,"score_gpt":0.2628728778025586,"score_spread":0.24736188752549834,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4386269952","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9950871,0.00006792739,0.000038837916,0.00064965,0.00012523988,0.00295052,0.00014045596,0.0002660146,0.00067425735],"genre_scores_gemma":[0.99598813,0.0005946557,0.00040297088,0.00008694083,0.00017175497,0.0006209031,0.0010198357,0.00014349312,0.00097131514],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99299705,0.00037822605,0.0020617396,0.002074059,0.0014522081,0.0010367325],"domain_scores_gemma":[0.9970744,0.0004987202,0.0004359445,0.0009903206,0.00039379857,0.0006068143],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00089179614,0.0009076161,0.0021507656,0.0014429134,0.00021510603,0.00009050962,0.00028947016,0.0006177711,0.00032574745],"category_scores_gemma":[0.00009741574,0.00067512546,0.00056609826,0.0041346946,0.00024426603,0.00028697183,0.000090204856,0.0005420024,0.00017005844],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.012475789,0.005065728,0.9485361,0.00010714037,0.0014978495,0.0008941738,0.0005531671,0.0009934937,0.0019538393,0.0000038299468,0.00005160434,0.027867278],"study_design_scores_gemma":[0.045538727,0.0060068844,0.93726987,0.00058963976,0.0030281446,0.00007942248,0.00017928093,0.0010222673,0.0055539096,0.00000556396,0.000034067914,0.00069219613],"about_ca_topic_score_codex":0.0016638555,"about_ca_topic_score_gemma":0.001215275,"teacher_disagreement_score":0.03306294,"about_ca_system_score_codex":0.0012953737,"about_ca_system_score_gemma":0.0007355175,"threshold_uncertainty_score":0.99957},"labels":[],"label_agreement":null},{"id":"W4386270935","doi":"10.1016/s2152-2650(23)00654-7","title":"POSTER: MPN-574 Characteristics and Clinical Outcomes in Patients With Polycythemia Vera Receiving Ruxolitinib After Hydroxyurea: A Longitudinal Analysis From the Prospective Observational Study of Patients With Polycythemia Vera in US Clinical Practices Trial (REVEAL)","year":2023,"lang":"en","type":"article","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Polycythemia vera; Ruxolitinib; Observational study; Medicine; Internal medicine; Clinical trial; Pediatrics; Myelofibrosis","score_opus":0.05766674354178424,"score_gpt":0.3603647340024213,"score_spread":0.30269799046063706,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4386270935","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99413705,0.000037663754,0.0000012824145,0.00045559707,0.00040098384,0.004454539,0.00041325638,0.000059319093,0.00004032297],"genre_scores_gemma":[0.9970818,0.00010001028,0.00026134428,0.0005441336,0.00044239726,0.0006819386,0.000751495,0.0000818261,0.000055029064],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99081355,0.0013629254,0.003994501,0.0017455424,0.0013678173,0.0007156741],"domain_scores_gemma":[0.98399323,0.011468838,0.0024137278,0.0011204152,0.0005699974,0.00043381075],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.002313779,0.0007512311,0.0030464293,0.00034093362,0.00016868165,0.00010666877,0.0003620606,0.0005152239,0.00006377022],"category_scores_gemma":[0.005289295,0.0004621702,0.0005453455,0.0014997096,0.0005922317,0.0003716683,0.00035628327,0.00096984755,0.000022718126],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.106062695,0.0098027,0.8690649,0.000022237418,0.0038582932,0.0002209466,0.0005089789,0.0000025676613,1.2415626e-7,0.0000062955346,0.000039696533,0.010410544],"study_design_scores_gemma":[0.11181824,0.009838784,0.8746936,0.00030497866,0.002600316,0.000001814257,0.00016914132,0.00009480429,0.0000018616131,0.000024348714,0.00003132065,0.00042083932],"about_ca_topic_score_codex":0.0009886221,"about_ca_topic_score_gemma":0.0019763976,"teacher_disagreement_score":0.010105913,"about_ca_system_score_codex":0.0006827894,"about_ca_system_score_gemma":0.0010483176,"threshold_uncertainty_score":0.999783},"labels":[],"label_agreement":null},{"id":"W4386270936","doi":"10.1016/s2152-2650(23)00651-1","title":"POSTER: MPN-540 Disease Progression and Leukemic Transformation in Patients With Lower-Risk Myelofibrosis: An Analysis From the Myelofibrosis and Essential Thrombocythemia Observational Study (MOST)","year":2023,"lang":"en","type":"article","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Myelofibrosis; Essential thrombocythemia; Medicine; Observational study; Internal medicine; Disease; Oncology; Polycythemia vera; Bone marrow","score_opus":0.03200216297594318,"score_gpt":0.33100134329576514,"score_spread":0.298999180319822,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4386270936","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9956709,0.0002033207,0.000023040695,0.0007334827,0.00012884685,0.0027007272,0.00035639925,0.00014884955,0.00003439533],"genre_scores_gemma":[0.9960547,0.00040039638,0.00022912938,0.00039178628,0.00019252207,0.0005687528,0.0020770517,0.00006080722,0.00002484208],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9955316,0.0005950638,0.0011973574,0.0011983808,0.0009593865,0.00051821],"domain_scores_gemma":[0.996892,0.001064382,0.0004211361,0.00078028097,0.0002552157,0.0005870184],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0008028338,0.0005607449,0.0010928775,0.000267338,0.00045816146,0.00020044453,0.00021574092,0.00024781286,0.000058464273],"category_scores_gemma":[0.00031031822,0.00035556784,0.00023385283,0.0013888789,0.00038867362,0.0005676531,0.00015935242,0.00030916327,0.000024266585],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0044726324,0.0013107053,0.87481546,0.000032477958,0.0009133327,0.000056451714,0.0010560657,0.00004126643,0.000015786998,0.000028325641,0.000084241736,0.11717327],"study_design_scores_gemma":[0.013612059,0.0028250918,0.9740083,0.00029342974,0.0028590248,0.0000024890296,0.0005485192,0.005237586,0.000050519746,0.00009709338,0.00007524893,0.0003906133],"about_ca_topic_score_codex":0.0004519514,"about_ca_topic_score_gemma":0.0005156274,"teacher_disagreement_score":0.11678266,"about_ca_system_score_codex":0.00050704344,"about_ca_system_score_gemma":0.0006314978,"threshold_uncertainty_score":0.9998896},"labels":[],"label_agreement":null},{"id":"W4386270957","doi":"10.1016/s2152-2650(23)01220-x","title":"MPN-133 Reduction in Red Blood Cell Transfusion Burden: A Novel Longitudinal Time-Dependent Analysis in Patients With Transfusion-Dependent Myelofibrosis Treated With Momelotinib","year":2023,"lang":"en","type":"article","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"","keywords":"Myelofibrosis; Medicine; Blood transfusion; Reduction (mathematics); Red blood cell; Red Blood Cell Transfusion; Internal medicine; Bone marrow","score_opus":0.015933669431979786,"score_gpt":0.2642112244048966,"score_spread":0.2482775549729168,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4386270957","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9952948,0.00006575033,0.00006932075,0.00055468734,0.00012089419,0.0028518077,0.00012064747,0.0002732281,0.00064886914],"genre_scores_gemma":[0.99566036,0.00066581886,0.0006123199,0.00007101701,0.00018093784,0.00069583027,0.0009242268,0.00014067438,0.0010488366],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9930296,0.00036495322,0.0020264543,0.0020717715,0.0014728574,0.001034376],"domain_scores_gemma":[0.99709433,0.0005153215,0.00042602312,0.0009766265,0.00038149706,0.0006061698],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0009375705,0.0008925595,0.002151022,0.0014299544,0.00021967321,0.000083451734,0.00028339436,0.00061764073,0.00035728898],"category_scores_gemma":[0.0001101741,0.00066367397,0.00055971375,0.0044886344,0.0002549114,0.0002720406,0.000081904356,0.0005519002,0.00017129924],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.011024755,0.005311952,0.9464134,0.00010448958,0.0015182286,0.00084118947,0.0004942149,0.0018823007,0.0017867418,0.000006006815,0.00006423348,0.030552493],"study_design_scores_gemma":[0.04513752,0.0051752417,0.93847615,0.0005496812,0.00302359,0.000060511353,0.00020425438,0.0017763114,0.0048620407,0.0000072420785,0.000043330998,0.000684158],"about_ca_topic_score_codex":0.0017282473,"about_ca_topic_score_gemma":0.00124037,"teacher_disagreement_score":0.034112763,"about_ca_system_score_codex":0.0013296927,"about_ca_system_score_gemma":0.0007793456,"threshold_uncertainty_score":0.99958146},"labels":[],"label_agreement":null},{"id":"W4386270996","doi":"10.1016/s2152-2650(23)00655-9","title":"POSTER: MPN-346 INDEPENDENCE: Enrolling Phase III Trial to Study the Efficacy and Safety of Luspatercept versus Placebo in Patients With Myelofibrosis on JAK2 Inhibitor (JAK2i) Therapy Requiring Red Blood Cell Transfusions (RBCTs)","year":2023,"lang":"en","type":"article","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Myelofibrosis; Placebo; Medicine; Internal medicine; Phases of clinical research; Clinical trial; Bone marrow; Pathology; Alternative medicine","score_opus":0.042019637120578365,"score_gpt":0.3397200616766584,"score_spread":0.29770042455608003,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4386270996","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99018985,0.00005036057,0.0000040428117,0.0004875992,0.0005323818,0.008277566,0.000051787523,0.00009887993,0.00030753363],"genre_scores_gemma":[0.9980538,0.00038021282,0.00011776706,0.00027561677,0.00030114094,0.0006618802,0.000063528205,0.0000826395,0.00006343331],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.99487877,0.000624642,0.001700728,0.0011351341,0.0010372003,0.00062350987],"domain_scores_gemma":[0.99494076,0.0032075453,0.00035427467,0.00084232277,0.00020933838,0.00044574315],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0013668583,0.0005728257,0.0013133842,0.00031881942,0.00034258756,0.00005953462,0.00028803025,0.00033957485,0.00007605044],"category_scores_gemma":[0.00040776847,0.00036639406,0.00025102505,0.0009233163,0.0002113136,0.00011917771,0.00016391164,0.0004584073,0.000035046436],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.597486,0.010026901,0.14793003,0.000028948985,0.0007127746,0.00018261066,0.00368512,0.0000572269,0.0005162112,0.000007862419,0.00006380879,0.2393025],"study_design_scores_gemma":[0.40096635,0.030966083,0.5636506,0.00029415765,0.00032617783,0.000002075646,0.0004161213,0.00003357706,0.0030240992,0.0000027641781,0.0000757794,0.00024218834],"about_ca_topic_score_codex":0.000099747165,"about_ca_topic_score_gemma":0.00006864007,"teacher_disagreement_score":0.4157206,"about_ca_system_score_codex":0.00033593233,"about_ca_system_score_gemma":0.00046852077,"threshold_uncertainty_score":0.9998788},"labels":[],"label_agreement":null},{"id":"W4386271092","doi":"10.1016/s2152-2650(23)00628-6","title":"POSTER: MPN-093 Impact of Transfusion Burden on Health-Related Quality of Life and Functioning in Patients With Myelofibrosis: Post Hoc Analysis of SIMPLIFY-1 and -2","year":2023,"lang":"en","type":"article","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"","keywords":"Myelofibrosis; Post-hoc analysis; Medicine; Quality of life (healthcare); Health related quality of life; Quality-adjusted life year; Intensive care medicine; Internal medicine; Risk analysis (engineering); Disease; Cost effectiveness","score_opus":0.032754464477425915,"score_gpt":0.3414316607324285,"score_spread":0.30867719625500256,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4386271092","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9980476,0.00031691528,0.000002375693,0.00042463903,0.00004419665,0.00082209526,0.00023788033,0.000032216536,0.00007208513],"genre_scores_gemma":[0.99866503,0.0006892206,0.00006876758,0.00014576454,0.000021272766,0.000030959425,0.00033355603,0.000029102974,0.000016350572],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99608856,0.00039414957,0.0021057166,0.0005934223,0.00050018856,0.00031797847],"domain_scores_gemma":[0.9965817,0.0014743252,0.000831595,0.00042637915,0.00032339143,0.0003626355],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009650214,0.00031053345,0.0020491823,0.00060225144,0.00007144017,0.000010693792,0.00007246714,0.00025295315,0.000044278026],"category_scores_gemma":[0.00057345594,0.00022033212,0.00039839858,0.0012388672,0.00029218584,0.000085671134,0.00006005309,0.00016127042,0.0000031438808],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.010356386,0.0005588361,0.85644835,0.0002100138,0.0017918844,0.0000062534546,0.0006734978,0.00015061455,0.00014816738,0.00003404152,0.000028412727,0.12959354],"study_design_scores_gemma":[0.012954626,0.012511797,0.97246426,0.00057153875,0.0005738564,0.0000018399176,0.00018997442,0.00043693843,0.000106194224,0.000020327854,0.000004021836,0.0001646036],"about_ca_topic_score_codex":0.0028933703,"about_ca_topic_score_gemma":0.00035703176,"teacher_disagreement_score":0.12942892,"about_ca_system_score_codex":0.00031824366,"about_ca_system_score_gemma":0.00063181604,"threshold_uncertainty_score":0.8984883},"labels":[],"label_agreement":null},{"id":"W4386277475","doi":"10.1016/s2152-2650(23)01256-9","title":"MPN-551 Clinical Outcomes With Momelotinib vs Ruxolitinib in Patients With Myelofibrosis and Anemia: Subgroup Analysis of SIMPLIFY-1","year":2023,"lang":"en","type":"article","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Ruxolitinib; Myelofibrosis; Subgroup analysis; Medicine; Anemia; Internal medicine; Oncology; Bone marrow; Meta-analysis","score_opus":0.024545140548926824,"score_gpt":0.32648908092638934,"score_spread":0.3019439403774625,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4386277475","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99678767,0.00006123173,0.000011502663,0.0006633078,0.00014711864,0.0014127145,0.00020437843,0.0001706181,0.00054148195],"genre_scores_gemma":[0.99604577,0.0003643369,0.001139943,0.0010411426,0.00011886271,0.00025548544,0.00066032313,0.00009904979,0.0002751174],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99345887,0.0004288797,0.002714302,0.001507508,0.0009959866,0.0008944678],"domain_scores_gemma":[0.9926721,0.0041855373,0.00079018617,0.0011158857,0.0004559192,0.0007803834],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0013608757,0.0007182563,0.0034527578,0.00083209184,0.00013842221,0.000055483717,0.00026916288,0.00060719776,0.00012028144],"category_scores_gemma":[0.0011049173,0.00047717386,0.00070125685,0.0029317378,0.00088676915,0.00018993298,0.00023253619,0.00046070688,0.00007793722],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0044398303,0.0014891413,0.91719437,0.00012087735,0.0027091668,0.0002450815,0.00012808846,0.000031041745,0.0000021049436,0.00025693656,0.00040734076,0.07297605],"study_design_scores_gemma":[0.020289669,0.005223186,0.9694616,0.00031676423,0.0031548298,0.000009351063,0.00012127497,0.00037860835,0.00005416256,0.00004339636,0.00044556052,0.00050155225],"about_ca_topic_score_codex":0.000240032,"about_ca_topic_score_gemma":0.0003451431,"teacher_disagreement_score":0.0724745,"about_ca_system_score_codex":0.00040476874,"about_ca_system_score_gemma":0.00072692806,"threshold_uncertainty_score":0.999768},"labels":[],"label_agreement":null},{"id":"W4386278009","doi":"10.1016/s2152-2650(23)00652-3","title":"POSTER: MPN-551 Clinical Outcomes With Momelotinib vs Ruxolitinib in Patients With Myelofibrosis and Anemia: Subgroup Analysis of SIMPLIFY-1","year":2023,"lang":"en","type":"article","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Ruxolitinib; Myelofibrosis; Medicine; Anemia; Subgroup analysis; Internal medicine; Meta-analysis; Bone marrow","score_opus":0.023892048971928592,"score_gpt":0.323527816953411,"score_spread":0.2996357679814824,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4386278009","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99652207,0.00006407385,0.0000062852337,0.0007892799,0.00015366828,0.0014825371,0.00024145469,0.00016780807,0.0005728423],"genre_scores_gemma":[0.9962317,0.00032641133,0.0007217425,0.0012712302,0.00011440843,0.00023042764,0.00074181304,0.00010241114,0.0002598952],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99335784,0.00044812157,0.0027738854,0.0015239107,0.0009907999,0.00090547395],"domain_scores_gemma":[0.9927961,0.0039953045,0.00081077777,0.0011394459,0.00047315034,0.0007851776],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0012938947,0.0007382443,0.0034555313,0.0008475661,0.0001370637,0.00006143111,0.00027822438,0.00061235245,0.00011127337],"category_scores_gemma":[0.0009582262,0.00049151975,0.000712736,0.0027059347,0.0008420545,0.00020333096,0.00025789178,0.00045682245,0.000079172976],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.005216755,0.0014671516,0.92306554,0.00012726933,0.0027081785,0.00027256866,0.00014968423,0.000016654833,0.0000025297181,0.00015613866,0.00032765433,0.06648986],"study_design_scores_gemma":[0.020768384,0.006138282,0.96829605,0.00034584533,0.0031654693,0.000012865391,0.00010635774,0.00021235233,0.00006578016,0.000032527663,0.00034173785,0.0005143646],"about_ca_topic_score_codex":0.00023669467,"about_ca_topic_score_gemma":0.00034423487,"teacher_disagreement_score":0.065975495,"about_ca_system_score_codex":0.00040203644,"about_ca_system_score_gemma":0.00068912015,"threshold_uncertainty_score":0.99975365},"labels":[],"label_agreement":null},{"id":"W4386282152","doi":"10.1016/s2152-2650(23)01190-4","title":"MDS-460 Efficacy of Pacritinib for Spleen, Symptoms, and Anemia Benefit in Myelofibrosis Patients Across the Cytopenic Spectrum","year":2023,"lang":"en","type":"article","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Myelofibrosis; Ruxolitinib; Medicine; Anemia; Spleen; Pediatrics; Internal medicine; Bone marrow","score_opus":0.029721782192800052,"score_gpt":0.3497908632459027,"score_spread":0.32006908105310267,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4386282152","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9936874,0.00032912422,0.0000047761296,0.002349385,0.000349537,0.0025421528,0.00031024544,0.00010475568,0.00032263808],"genre_scores_gemma":[0.9960935,0.0009213928,0.00026404776,0.0009704349,0.00033986423,0.00060836785,0.0003201716,0.000082217215,0.00039999431],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99588513,0.00015098095,0.0016189193,0.0009551045,0.0004968422,0.00089303503],"domain_scores_gemma":[0.9941364,0.004116068,0.00037214812,0.00080410566,0.00021240259,0.00035891013],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0010493277,0.00047525147,0.0012703395,0.00013889806,0.00026122766,0.00006696036,0.00031037157,0.00039853744,0.00005375977],"category_scores_gemma":[0.001518841,0.00033547851,0.0004825078,0.0007262695,0.0005166825,0.00012176531,0.00031203812,0.00025994104,0.000095175645],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0014552741,0.0006234795,0.69612914,0.00015913411,0.00021293825,0.000051391504,0.00037132864,0.000008285677,0.00006758578,0.0008172942,0.0019247624,0.2981794],"study_design_scores_gemma":[0.017389774,0.0019654324,0.9721932,0.00035954808,0.00021117108,0.000022634382,0.00014560271,0.00033219322,0.0017952012,0.00055021193,0.004721911,0.0003131414],"about_ca_topic_score_codex":0.00016887953,"about_ca_topic_score_gemma":0.00018965399,"teacher_disagreement_score":0.29786626,"about_ca_system_score_codex":0.0004787521,"about_ca_system_score_gemma":0.0004151893,"threshold_uncertainty_score":0.9999097},"labels":[],"label_agreement":null},{"id":"W4386282232","doi":"10.1016/s2152-2650(23)00615-8","title":"POSTER: MDS-460 Efficacy of Pacritinib for Spleen, Symptoms, and Anemia Benefit in Myelofibrosis Patients Across the Cytopenic Spectrum","year":2023,"lang":"en","type":"article","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Myelofibrosis; Ruxolitinib; Medicine; Anemia; Internal medicine; Bone marrow","score_opus":0.028470738352065237,"score_gpt":0.34542074319377575,"score_spread":0.3169500048417105,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4386282232","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99305606,0.00033827036,0.0000025636925,0.002763797,0.00036210808,0.0026592964,0.00036914254,0.00010377888,0.00034498356],"genre_scores_gemma":[0.9961427,0.00081097655,0.00016690198,0.0011945256,0.00032129633,0.00053866435,0.00036539033,0.00008542197,0.0003741133],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99579453,0.00016065541,0.0016664083,0.00097299373,0.0004992042,0.00090621697],"domain_scores_gemma":[0.9942929,0.0039059634,0.00038592968,0.0008268098,0.00022315838,0.00036523506],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.000999104,0.00049265,0.0012886,0.0001452446,0.00025672163,0.00007461831,0.00032134017,0.000404511,0.000050309343],"category_scores_gemma":[0.0012941085,0.00034834983,0.00049308775,0.00068032375,0.00049273024,0.00013170899,0.00034725663,0.00026004275,0.00009686838],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0017033399,0.0006030581,0.72902894,0.00016262208,0.00021393195,0.00005717607,0.00042032226,0.000004267803,0.00007680301,0.00046424582,0.0014542444,0.26581106],"study_design_scores_gemma":[0.01790345,0.0023695263,0.9724441,0.0003960034,0.00021998367,0.000031465075,0.00012711166,0.00018151996,0.0021198427,0.00039258617,0.0034897819,0.00032462995],"about_ca_topic_score_codex":0.00016702626,"about_ca_topic_score_gemma":0.00019090979,"teacher_disagreement_score":0.26548645,"about_ca_system_score_codex":0.000475325,"about_ca_system_score_gemma":0.00039576722,"threshold_uncertainty_score":0.9998968},"labels":[],"label_agreement":null},{"id":"W4386282346","doi":"10.1016/s2152-2650(23)00629-8","title":"POSTER: MPN-111 SVR (Spleen Volume Reduction) Predicts OS (Overall Survival) in MF (Myelofibrosis) Patients on PAC (Pacritinib) but Not BAT (Best Available Therapy): PERSIST-2 Landmark OS Analysis","year":2023,"lang":"en","type":"article","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"","keywords":"Myelofibrosis; Medicine; Spleen; Internal medicine; Bone marrow","score_opus":0.049535927681756665,"score_gpt":0.31279730629499675,"score_spread":0.26326137861324006,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4386282346","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98605376,0.00021453312,0.000002743185,0.0021131402,0.0012082934,0.0020032069,0.0005774841,0.00035205783,0.0074747675],"genre_scores_gemma":[0.9805405,0.0023860808,0.0001448004,0.0016951549,0.00091379875,0.00067704916,0.0020852203,0.00015737681,0.011399985],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9920336,0.00084902113,0.002231602,0.0020748454,0.0014724744,0.0013384788],"domain_scores_gemma":[0.9948581,0.0015542671,0.0005443165,0.001558918,0.00056773465,0.0009166585],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.0014284746,0.00096050184,0.0023258133,0.0008795968,0.00039941448,0.00018284118,0.00047792657,0.00076918496,0.0017115447],"category_scores_gemma":[0.0011460085,0.00081837655,0.0013494637,0.0021047662,0.00036631533,0.00035377365,0.00025961644,0.0005944679,0.004535677],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0047962647,0.0025054659,0.8717947,0.00009597115,0.0022783906,0.00045955522,0.00033558725,0.000059715632,0.00013617701,0.000058537724,0.022272898,0.09520673],"study_design_scores_gemma":[0.01570947,0.0043278113,0.95742416,0.00038791832,0.0010893294,0.000028537137,0.00019523856,0.0010785826,0.0009865077,0.000031004005,0.018010002,0.00073143904],"about_ca_topic_score_codex":0.0012649848,"about_ca_topic_score_gemma":0.0002763611,"teacher_disagreement_score":0.09447529,"about_ca_system_score_codex":0.0018158283,"about_ca_system_score_gemma":0.00090367877,"threshold_uncertainty_score":0.9994267},"labels":[],"label_agreement":null},{"id":"W4386415343","doi":"10.1002/ajh.27079","title":"A globally applicable “triple <scp>A</scp>” risk model for essential thrombocythemia based on <scp>A</scp>ge, <scp>A</scp>bsolute neutrophil count, and <scp>A</scp>bsolute lymphocyte count","year":2023,"lang":"en","type":"article","venue":"American Journal of Hematology","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":38,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal","funders":"Associazione Italiana per la Ricerca sul Cancro; Università degli Studi di Firenze; Ministero della Salute","keywords":"Medicine; Myelofibrosis; Internal medicine; Essential thrombocythemia; Absolute neutrophil count; Gastroenterology; Akaike information criterion; International Prognostic Scoring System; Lymphocyte; Neutropenia; Myelodysplastic syndromes; Bone marrow; Platelet; Chemotherapy","score_opus":0.014006456477845966,"score_gpt":0.27438056488019474,"score_spread":0.26037410840234876,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4386415343","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9728652,0.00343054,0.014312897,0.0011198048,0.0009748263,0.0027368814,0.0011846669,0.00032707726,0.0030480826],"genre_scores_gemma":[0.9656832,0.009252416,0.013611437,0.0049519013,0.0012436019,0.0010384826,0.00035226325,0.0005409762,0.0033257147],"study_design_codex":"not_applicable","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.9896568,0.00056713726,0.0027751268,0.0019697533,0.0020523258,0.0029788574],"domain_scores_gemma":[0.98112476,0.010676772,0.0036325408,0.0014365817,0.0014312104,0.0016981313],"candidate_categories":["metaepi_narrow"],"consensus_categories":["metaepi_narrow"],"category_scores_codex":[0.0018253872,0.0017750782,0.0047181277,0.0012030021,0.0009568832,0.00030201167,0.0010515708,0.000706413,0.000017995175],"category_scores_gemma":[0.0044723647,0.0015306007,0.0012286224,0.0018826872,0.0014542058,0.0004420925,0.00037735832,0.0014473205,0.0002303723],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0011296505,0.007022245,0.09408377,0.0016880566,0.008997803,0.0055022915,0.0076140994,0.03072522,0.0065871566,0.009159508,0.8232318,0.0042583584],"study_design_scores_gemma":[0.07207309,0.027601441,0.033093896,0.0027215069,0.010099064,0.016900806,0.017669136,0.46085572,0.037067443,0.007786634,0.31316552,0.00096574036],"about_ca_topic_score_codex":0.0003535242,"about_ca_topic_score_gemma":0.00016336949,"teacher_disagreement_score":0.51006633,"about_ca_system_score_codex":0.0010616708,"about_ca_system_score_gemma":0.002365364,"threshold_uncertainty_score":0.9994995},"labels":[],"label_agreement":null},{"id":"W4386529949","doi":"10.1161/circulationaha.123.064170","title":"Clonal Hematopoiesis in Clinical and Experimental Heart Failure With Preserved Ejection Fraction","year":2023,"lang":"en","type":"article","venue":"Circulation","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":63,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Canadian Heart Research Centre; University of Alberta Hospital; University of Alberta","funders":"National Institute of General Medical Sciences; National Heart, Lung, and Blood Institute; National Institute on Aging; Japan Science and Technology Agency; National Institutes of Health; Alberta Innovates; Japanese Circulation Society; Nuclear Safety and Security Commission; Kowa Life Science Foundation; Alberta Heritage Foundation for Medical Research; Suzuken Memorial Foundation; Alberta Health Services; Kowa Company; National Aeronautics and Space Administration","keywords":"Medicine; Heart failure with preserved ejection fraction; Ejection fraction; Internal medicine; Cardiology; Cohort; Hazard ratio; Heart failure; Diastole; Blood pressure; Confidence interval","score_opus":0.03952104147993568,"score_gpt":0.33919051195187594,"score_spread":0.29966947047194026,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4386529949","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99794686,0.000056570487,0.000059301583,0.0012254596,0.00005311121,0.00042090687,0.0000014829816,0.00006123827,0.00017507836],"genre_scores_gemma":[0.9992165,0.000012145012,0.00036666397,0.00008376796,0.00009648709,0.00011151193,0.00007958283,0.0000114217955,0.000021928303],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9992315,0.000057376183,0.00020634232,0.00023444887,0.00016735385,0.000102975995],"domain_scores_gemma":[0.9996765,0.00008287559,0.000043480308,0.000100031015,0.000037489644,0.00005957286],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00016893202,0.000085201726,0.00018383922,0.00010601925,0.000059781178,0.00001804729,0.000009697796,0.00007824341,0.00007355105],"category_scores_gemma":[0.00004188367,0.00006967203,0.000036902908,0.00021496543,0.000034243145,0.00013188263,0.000010547568,0.00009455092,0.000041002044],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00013826576,0.00019244255,0.99677145,0.000021148444,0.000030578223,0.000011564786,0.000073530995,0.00008499406,0.0018952367,0.00012649578,0.00049242075,0.00016187048],"study_design_scores_gemma":[0.0019251163,0.00017107528,0.9894289,0.000070785616,0.000023949813,0.000027193299,0.00029473234,0.0025099071,0.004987401,0.00006196784,0.00043398698,0.000064993845],"about_ca_topic_score_codex":0.000037742422,"about_ca_topic_score_gemma":0.00004931908,"teacher_disagreement_score":0.007342561,"about_ca_system_score_codex":0.000064716274,"about_ca_system_score_gemma":0.000028602448,"threshold_uncertainty_score":0.2841143},"labels":[],"label_agreement":null},{"id":"W4386738396","doi":"10.21203/rs.3.rs-3342813/v1","title":"A Case Report of Gelatinous Transformation of Bone Marrow Following Lymphoma and a Novel, Potential Treatment","year":2023,"lang":"en","type":"preprint","venue":"Research Square","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Saskatchewan Cancer Agency; University of Saskatchewan","funders":"","keywords":"Medicine; Bone marrow; Lymphoma; Diffuse large B-cell lymphoma; Population; Bone marrow failure; Biopsy; Haematopoiesis; Surgery; Internal medicine; Stem cell","score_opus":0.09194119356274527,"score_gpt":0.3908894383955217,"score_spread":0.29894824483277643,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4386738396","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99413407,0.0008280715,0.00031444567,0.0008210182,0.00012392012,0.0028852122,0.00035486667,0.00004387102,0.00049451273],"genre_scores_gemma":[0.99659497,0.0006642328,0.0009980359,0.0000036829942,0.0000849224,0.00064365234,0.0005284244,0.00004895792,0.00043309605],"study_design_codex":"case_report","study_design_gemma":"observational","domain_scores_codex":[0.9968742,0.00016520898,0.00088659814,0.000555737,0.0011168374,0.00040139077],"domain_scores_gemma":[0.9980731,0.00031242103,0.00026300474,0.00058860367,0.0005363186,0.00022656651],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010191412,0.00030339166,0.000991809,0.00062015635,0.0001416646,0.000032658463,0.000051234867,0.00029604786,0.000037894675],"category_scores_gemma":[0.00028959473,0.00023926025,0.00043762045,0.00030243656,0.00012610163,0.000060388535,0.00016897995,0.00026375268,0.0000056959425],"study_design_candidate":"case_report","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0030531315,0.011642578,0.114187226,0.02112576,0.0077497195,0.734776,0.022082917,0.0006517833,0.014202583,0.0012761243,0.00045602646,0.06879614],"study_design_scores_gemma":[0.06849926,0.030171307,0.4172183,0.027765201,0.0062033264,0.25508797,0.016431216,0.020050101,0.15235493,0.0026825725,0.0012762038,0.0022596056],"about_ca_topic_score_codex":0.0029266858,"about_ca_topic_score_gemma":0.00030946155,"teacher_disagreement_score":0.47968805,"about_ca_system_score_codex":0.00044016796,"about_ca_system_score_gemma":0.0007696826,"threshold_uncertainty_score":0.975675},"labels":[],"label_agreement":null},{"id":"W4386850841","doi":"10.1111/bjh.19107","title":"Ratio of stemness to interferon signalling as a biomarker and therapeutic target of myeloproliferative neoplasm progression to acute myeloid leukaemia","year":2023,"lang":"en","type":"article","venue":"British Journal of Haematology","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Princess Margaret Cancer Centre; University Health Network","funders":"Instituto Nacional de Ciência e Tecnologia da Criosfera; Conselho Nacional de Desenvolvimento Científico e Tecnológico; Canadian Network for Research and Innovation in Machining Technology, Natural Sciences and Engineering Research Council of Canada; Fundação de Amparo à Pesquisa do Estado de São Paulo; Institute of Cancer Research; Ontario Institute for Cancer Research; World Health Organization","keywords":"Myeloproliferative neoplasm; Interferon; Cancer research; Biology; Myeloid; Biomarker; Immunology; Stem cell; Myelofibrosis; Bone marrow; Cell biology","score_opus":0.02302117307169929,"score_gpt":0.32677305605342655,"score_spread":0.3037518829817273,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4386850841","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99365073,0.0014939368,0.0013072656,0.0023119154,0.00020362639,0.00085767044,0.000026877977,0.00001817905,0.00012978293],"genre_scores_gemma":[0.9949261,0.0005591218,0.0038740945,0.00038354108,0.00004815611,0.000071102804,0.000010706363,0.000032604574,0.00009457301],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99773437,0.00021246726,0.0010393598,0.00028992762,0.00040527925,0.00031857207],"domain_scores_gemma":[0.99808997,0.00029266634,0.0005112372,0.00013595357,0.00067490916,0.00029526235],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00049341866,0.00022971956,0.0012911049,0.00046153605,0.00008447706,0.000030414792,0.00013389756,0.00014637271,0.00010059028],"category_scores_gemma":[0.0002112333,0.0001971556,0.0001516813,0.0004796157,0.000121694364,0.0000937437,0.0001046749,0.00022563161,0.000017117314],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.015691532,0.0026901965,0.18421085,0.0022517976,0.008231786,0.063222185,0.017147934,0.0003229231,0.41879126,0.0020349396,0.008394902,0.2770097],"study_design_scores_gemma":[0.008917556,0.013908269,0.111996815,0.009591376,0.000991575,0.11182699,0.0021657427,0.0007723934,0.7368455,0.0012470506,0.0011420873,0.00059465226],"about_ca_topic_score_codex":0.000035635534,"about_ca_topic_score_gemma":0.000045977973,"teacher_disagreement_score":0.31805423,"about_ca_system_score_codex":0.000059588514,"about_ca_system_score_gemma":0.00026382497,"threshold_uncertainty_score":0.80397725},"labels":[],"label_agreement":null},{"id":"W4386922381","doi":"10.4254/wjh.v15.i9.1021","title":"Toxicity of targeted anticancer treatments on the liver in myeloproliferative neoplasms","year":2023,"lang":"en","type":"review","venue":"World Journal of Hepatology","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"","keywords":"Medicine; Essential thrombocythemia; Polycythemia vera; Myelofibrosis; Myeloid leukemia; Drug; Myeloproliferative Disorders; Internal medicine; Pharmacology; Bone marrow","score_opus":0.10749203646912495,"score_gpt":0.37571981980578345,"score_spread":0.26822778333665853,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4386922381","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.014850143,0.9813249,0.0000021805017,0.0012190958,0.00047415667,0.0014642279,0.00007421898,0.000012209468,0.0005788704],"genre_scores_gemma":[0.010307632,0.98815036,0.00015512353,0.0003539684,0.00018146084,0.00014601283,0.000023742254,0.00006154227,0.0006201536],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9963247,0.0007151063,0.0017044354,0.00035785063,0.0004868105,0.00041106076],"domain_scores_gemma":[0.99566495,0.0020493427,0.0014930662,0.00037464045,0.00026290046,0.00015507688],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0005297187,0.00055776257,0.0039675008,0.001033084,0.00006937973,0.000012063789,0.00025010167,0.00025303397,0.00045057404],"category_scores_gemma":[0.00036698565,0.00028781797,0.0008336256,0.000993359,0.00020605898,0.00004735349,0.00006529004,0.00095741625,0.0000995295],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.002481914,0.0074610747,0.076416165,0.013066202,0.019970352,0.018108137,0.0017421189,0.000021536036,0.000011953963,0.017912129,0.020918502,0.82188994],"study_design_scores_gemma":[0.00785196,0.0073136953,0.009477811,0.062039502,0.009673872,0.0034134772,0.00013838103,0.00010228069,0.0012385669,0.00060626055,0.89718306,0.0009611477],"about_ca_topic_score_codex":0.000041873176,"about_ca_topic_score_gemma":0.00055193884,"teacher_disagreement_score":0.8762646,"about_ca_system_score_codex":0.0005340242,"about_ca_system_score_gemma":0.0010088963,"threshold_uncertainty_score":0.9999574},"labels":[],"label_agreement":null},{"id":"W4387337747","doi":"10.1016/j.cjca.2023.06.411","title":"BILATERAL ASYNCHRONOUS ADRENAL INFARCTION IN JAK2-POSITIVE ESSENTIAL THROMBOCYTHEMIA","year":2023,"lang":"en","type":"article","venue":"Canadian Journal of Cardiology","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Medicine; Essential thrombocythemia; Venous thrombosis; Infarction; Internal medicine; Thrombosis; Cardiology; Myeloproliferative neoplasm; Platelet; Myocardial infarction; Myelofibrosis; Bone marrow","score_opus":0.012925265688508863,"score_gpt":0.2642919335142326,"score_spread":0.2513666678257237,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4387337747","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99281436,0.00024707874,0.00011734471,0.0023719657,0.0006720653,0.00017769435,0.000026899841,0.000007849041,0.0035647447],"genre_scores_gemma":[0.99852645,0.0001191842,0.00007145858,0.0002083103,0.0009583405,0.000010523662,0.00003833559,0.000014760426,0.000052627405],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9989223,0.00011366368,0.00034667045,0.00014898297,0.000117936186,0.00035046504],"domain_scores_gemma":[0.9991342,0.0000807747,0.00010450484,0.00010598485,0.00017340128,0.0004011339],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00024539017,0.00013359105,0.00053893053,0.00059994264,0.00006678519,0.000015652005,0.00006280177,0.00013574708,0.00007894146],"category_scores_gemma":[0.00008977831,0.000109257504,0.00022193251,0.00027696812,0.00011227501,0.00006997156,0.000009259862,0.0002964765,0.00006168945],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00027932355,0.000015595684,0.96620595,0.000026193748,0.0010966484,0.007719314,0.0009166309,0.0032424948,0.0017611008,0.00066642754,0.011338137,0.0067321872],"study_design_scores_gemma":[0.0022365989,0.00083973585,0.9857388,0.0001343633,0.00015428592,0.0030981493,0.00014450419,0.000047624868,0.0017710935,0.00029157466,0.005429617,0.00011366217],"about_ca_topic_score_codex":0.0010938585,"about_ca_topic_score_gemma":0.0032626523,"teacher_disagreement_score":0.019532844,"about_ca_system_score_codex":0.0004470634,"about_ca_system_score_gemma":0.0012759406,"threshold_uncertainty_score":0.44553918},"labels":[],"label_agreement":null},{"id":"W4387459320","doi":"10.3389/flupu.2023.1219277","title":"Osteonecrosis is associated with APOL1 variants in African Americans with systemic lupus erythematosus","year":2023,"lang":"en","type":"article","venue":"Frontiers in Lupus","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"National Center for Advancing Translational Sciences; School of Medicine, New York University; National Institutes of Health; Georgia Clinical and Translational Science Alliance; York University; Rheumatology Research Foundation","keywords":"Medicine; Internal medicine; Cohort; Hazard ratio; Proportional hazards model; Medical record; Rheumatology; Genotype; Kidney disease; Confidence interval","score_opus":0.014140118999562495,"score_gpt":0.24139547632069575,"score_spread":0.22725535732113325,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4387459320","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9935893,0.0003852135,0.00025925125,0.0013043886,0.0008214373,0.0012605658,0.00009059809,0.00015640978,0.002132836],"genre_scores_gemma":[0.9931222,0.00032002,0.0017076588,0.00028746907,0.000027024156,0.00057516573,0.00009823855,0.00007582162,0.0037863974],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9975816,0.00012781558,0.00042744784,0.0006288024,0.00052921416,0.0007051131],"domain_scores_gemma":[0.9989351,0.00014121289,0.00020016184,0.0004236276,0.000094066076,0.00020583536],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00024505865,0.00038717536,0.0010354606,0.0005928222,0.00008516173,0.000040085877,0.00013346288,0.00014030504,0.000041444102],"category_scores_gemma":[0.000094794166,0.0002737073,0.00007604981,0.0021531747,0.00015973125,0.000104084735,0.00004125998,0.00028836651,0.00004374222],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00069357007,0.00039940985,0.9713824,0.00008715236,0.00042015297,0.0015775997,0.0049846764,0.000087598826,0.00003640072,0.000029582267,0.01939145,0.0009100116],"study_design_scores_gemma":[0.04257895,0.00564393,0.892837,0.007864244,0.00097097,0.0040557534,0.03539469,0.00469751,0.0012171612,0.00027502328,0.0027447175,0.0017200753],"about_ca_topic_score_codex":0.00056125177,"about_ca_topic_score_gemma":0.00096897606,"teacher_disagreement_score":0.07854542,"about_ca_system_score_codex":0.0007940969,"about_ca_system_score_gemma":0.00021462912,"threshold_uncertainty_score":0.9999715},"labels":[],"label_agreement":null},{"id":"W4387697629","doi":"10.3390/cancers15205027","title":"A Prognostic Model to Predict Ruxolitinib Discontinuation and Death in Patients with Myelofibrosis","year":2023,"lang":"en","type":"article","venue":"Cancers","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Sierra Oncology; Ministero della Salute; Incyte; Gilead Sciences; Sanofi; Celgene; AstraZeneca; Amgen; Pfizer; GlaxoSmithKline","keywords":"Ruxolitinib; Myelofibrosis; Discontinuation; Medicine; Prognostic model; Internal medicine; Oncology; Intensive care medicine; Overall survival; Bone marrow","score_opus":0.02099094039731565,"score_gpt":0.26897378582380294,"score_spread":0.2479828454264873,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4387697629","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99760073,0.000026280299,0.00006724474,0.0004937158,0.0000320163,0.00111567,0.000051323797,0.000046769626,0.0005662741],"genre_scores_gemma":[0.99822557,0.000033971537,0.00050816697,0.00020731152,0.000025806621,0.0006471492,0.000100460384,0.000017661006,0.00023392263],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9991991,0.000012061494,0.00012786571,0.00025605186,0.00019385014,0.00021110116],"domain_scores_gemma":[0.9996203,0.000042787382,0.000029171459,0.00010752544,0.000059014517,0.00014118718],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000050576116,0.00011712301,0.00019316732,0.00011754708,0.0000369035,0.000015268986,0.000021806833,0.000030093752,0.000009879697],"category_scores_gemma":[0.000060939386,0.00008476479,0.000016745777,0.0002567804,0.000017623199,0.00005889819,0.00001946848,0.000050123817,0.0000120458535],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00027362918,0.000047555004,0.99327326,0.000028082915,0.000030924013,0.000006584079,0.00067225803,0.0018690871,0.00000827773,0.00017201166,0.00034090117,0.0032774534],"study_design_scores_gemma":[0.0027048779,0.00086608395,0.98729116,0.0003451131,0.000056981564,3.7178646e-7,0.00007637859,0.008317952,0.00012563627,0.000036697234,0.00008838631,0.000090370355],"about_ca_topic_score_codex":0.00006942779,"about_ca_topic_score_gemma":0.0001086306,"teacher_disagreement_score":0.0064488654,"about_ca_system_score_codex":0.0003900864,"about_ca_system_score_gemma":0.0001871612,"threshold_uncertainty_score":0.34566078},"labels":[],"label_agreement":null},{"id":"W4387736032","doi":"10.21203/rs.3.rs-3443273/v1","title":"Small molecule STAT3/5 inhibitors exhibit therapeutic potential in acute myeloid leukemia and extra-nodal natural killer/T cell lymphoma","year":2023,"lang":"en","type":"preprint","venue":"Research Square","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"Austrian Science Fund; European Commission","keywords":"Cancer research; Biology; Tyrosine kinase; Myeloid; Myeloid leukemia; Viability assay; STAT3; PIM1; Oncogene; Cell cycle; Cell; Signal transduction; Cell biology; Genetics; Phosphorylation","score_opus":0.050529816005521304,"score_gpt":0.3428372149251989,"score_spread":0.2923073989196776,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4387736032","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9845169,0.00745869,0.000029326371,0.0030769203,0.0007408901,0.0033104885,0.00013299931,0.0001558054,0.0005779341],"genre_scores_gemma":[0.98534954,0.0075243325,0.00030418785,0.00014515102,0.00040859802,0.0010282414,0.00065005355,0.00017770065,0.0044122245],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9940695,0.00064590713,0.0007188124,0.0015689315,0.0016169354,0.0013798942],"domain_scores_gemma":[0.99758214,0.00047957274,0.0001511459,0.0008651886,0.00037661908,0.000545355],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0009844458,0.0007189902,0.0010244708,0.0011074672,0.00027545405,0.00027699218,0.00032306585,0.00066476077,0.00012197844],"category_scores_gemma":[0.000117386066,0.00059875153,0.00033738694,0.00064976927,0.00032471458,0.000083984894,0.0012466557,0.0021115674,0.00017068113],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.016833836,0.016434208,0.5104473,0.028314222,0.009977591,0.09393251,0.02291831,0.0021742885,0.07446368,0.0026096273,0.039271478,0.18262295],"study_design_scores_gemma":[0.029267639,0.0043287235,0.8561819,0.0074320827,0.00075083977,0.00032724047,0.002779262,0.009758755,0.07981014,0.003285513,0.0036737446,0.0024041436],"about_ca_topic_score_codex":0.0022976329,"about_ca_topic_score_gemma":0.0008260472,"teacher_disagreement_score":0.34573463,"about_ca_system_score_codex":0.0018085386,"about_ca_system_score_gemma":0.0018178757,"threshold_uncertainty_score":0.99964637},"labels":[],"label_agreement":null},{"id":"W4387899802","doi":"10.1097/hs9.0000000000000966","title":"Patient-reported Outcomes and Quality of Life in Anemic and Symptomatic Patients With Myelofibrosis: Results From the MOMENTUM Study","year":2023,"lang":"en","type":"article","venue":"HemaSphere","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":17,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; Princess Margaret Cancer Centre; University of Toronto","funders":"Sierra Oncology; MorphoSys; Cancer Research UK; Galecto; Incyte; Gilead Sciences; CTI Biopharma; Division of Materials Research; Celgene; Pfizer","keywords":"Myelofibrosis; Medicine; Quality of life (healthcare); Anemia; Ruxolitinib; Clinical endpoint; Danazol; Internal medicine; Physical therapy; Myeloproliferative neoplasm; Janus kinase 2; Clinical trial; Bone marrow","score_opus":0.027577465176416873,"score_gpt":0.2802369706173891,"score_spread":0.25265950544097227,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4387899802","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99747854,0.00017227628,3.0425335e-7,0.0005848573,0.000031426393,0.0014959548,0.00009223584,0.000038458275,0.0001059181],"genre_scores_gemma":[0.99941707,0.000050530827,0.00008365169,0.00012915042,0.000008196891,0.00014824873,0.00009320096,0.00001682425,0.0000531274],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99828404,0.00012763285,0.00066436833,0.00035110008,0.00039757456,0.00017525721],"domain_scores_gemma":[0.9985554,0.0006299366,0.0002699658,0.00035792426,0.00008138282,0.00010538478],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00019097717,0.00019169514,0.0005524053,0.00003864834,0.00006034641,0.000016890343,0.000035580695,0.000045854787,0.00002504243],"category_scores_gemma":[0.00038476245,0.0001035562,0.00003052971,0.00026108755,0.00006648348,0.000053653235,0.00006957778,0.00008935711,0.000004291983],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00060230226,0.0009108132,0.9920891,0.000067193534,0.0002991456,0.000015338983,0.0048061656,0.0000040446002,0.0000236189,0.0000104644605,0.00022162043,0.0009501867],"study_design_scores_gemma":[0.011567573,0.0009177771,0.9816148,0.0002838148,0.00011845787,5.962089e-7,0.005233482,0.000040875708,0.000089926376,0.000021102152,0.000009531583,0.000102009515],"about_ca_topic_score_codex":0.00104936,"about_ca_topic_score_gemma":0.0007942434,"teacher_disagreement_score":0.010965271,"about_ca_system_score_codex":0.000029554983,"about_ca_system_score_gemma":0.00004514523,"threshold_uncertainty_score":0.42228994},"labels":[],"label_agreement":null},{"id":"W4387936946","doi":"10.1101/2023.10.23.563619","title":"Platelet proteo-transcriptomic profiling validates mediators of thrombosis and proteostasis in patients with myeloproliferative neoplasms","year":2023,"lang":"en","type":"preprint","venue":"bioRxiv (Cold Spring Harbor Laboratory)","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"National Human Genome Research Institute; Università degli Studi di Milano-Bicocca; Canadian Institute for Theoretical Astrophysics; National Center for Advancing Translational Sciences; University College Dublin; Wellcome Trust; National Institutes of Health; MPN Research Foundation","keywords":"Transcriptome; Platelet; Essential thrombocythemia; Platelet activation; Immunology; Polycythemia vera; Medicine; Biology; Bioinformatics; Gene expression; Genetics","score_opus":0.01986058733052113,"score_gpt":0.2438934250313751,"score_spread":0.22403283770085397,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4387936946","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98987055,0.00029884942,0.00004433961,0.00045218936,0.00026861107,0.00803774,0.00078710145,0.00023760555,0.0000029871173],"genre_scores_gemma":[0.9869183,0.0005828915,0.009070578,0.000081230544,0.00010545339,0.0029965187,0.00001043677,0.00023254546,0.0000020794607],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9957376,0.00019726767,0.001038419,0.0014674452,0.0008411489,0.0007180923],"domain_scores_gemma":[0.9971242,0.00016480678,0.0006441356,0.00088654476,0.000804806,0.00037548575],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0005111465,0.00096269476,0.0017198412,0.0007081059,0.00013075302,0.00010732155,0.00023248933,0.0006077541,0.000025790208],"category_scores_gemma":[0.0002507999,0.00078589487,0.00015323624,0.00079883507,0.0002737274,0.00019694197,0.00025737053,0.00095758284,0.000017143682],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00063113996,0.00094889523,0.97398734,0.0020781355,0.001011043,0.000056728568,0.0001572627,0.00003670794,0.020854646,0.00019976187,0.00003469234,0.0000036259526],"study_design_scores_gemma":[0.0036368328,0.00061263796,0.60548747,0.0018164106,0.00027397985,1.8351345e-8,0.0000123653335,0.00007277504,0.38758206,0.0000032228318,0.0000173748,0.00048486597],"about_ca_topic_score_codex":0.00013564611,"about_ca_topic_score_gemma":0.000027609129,"teacher_disagreement_score":0.3684999,"about_ca_system_score_codex":0.0003778202,"about_ca_system_score_gemma":0.0009421341,"threshold_uncertainty_score":0.9994592},"labels":[],"label_agreement":null},{"id":"W4387969051","doi":"10.1097/hs9.0000000000000963","title":"Momelotinib in Myelofibrosis Patients With Thrombocytopenia: Post Hoc Analysis From Three Randomized Phase 3 Trials","year":2023,"lang":"en","type":"article","venue":"HemaSphere","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":22,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"National Cancer Institute; Genentech; Italfarmaco; Galecto; Sierra Oncology; CTI Biopharma; Incyte; Jazz Pharmaceuticals; Yuhan; Gilead Sciences; Celgene; Bristol-Myers Squibb; AstraZeneca; Amgen; Pfizer; Constellation Pharmaceuticals","keywords":"Ruxolitinib; Myelofibrosis; Medicine; Post-hoc analysis; Internal medicine; Population; Anemia; Gastroenterology; Bone marrow","score_opus":0.03576256372437367,"score_gpt":0.32653761267776016,"score_spread":0.29077504895338646,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4387969051","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9938114,0.00046490168,0.0001117662,0.0011280194,0.00009038929,0.002861096,0.00040967402,0.00013663332,0.0009860937],"genre_scores_gemma":[0.99458885,0.00023931748,0.0015125264,0.00026735157,0.000097008626,0.00077175215,0.0021587096,0.000052923373,0.00031156847],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9969019,0.0003882057,0.0009870962,0.0006702258,0.0006209246,0.00043162514],"domain_scores_gemma":[0.9968536,0.0018035652,0.00033607925,0.0005395802,0.00024189739,0.00022527485],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0008501992,0.00041299337,0.0034024601,0.00030665164,0.000099193705,0.000060507027,0.00011045724,0.0001541345,0.004374188],"category_scores_gemma":[0.00067189825,0.00025385135,0.0006320605,0.0018864737,0.00010150021,0.0001317576,0.000061639344,0.00018083234,0.00035275292],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.17459863,0.0026545927,0.7989403,0.00006746411,0.009269914,0.00025966452,0.0010061953,0.00009927675,0.00022915842,0.00017334762,0.0014977691,0.011203673],"study_design_scores_gemma":[0.49085742,0.0013130528,0.49892554,0.00024287483,0.005423375,0.0000010023931,0.00024353032,0.0005965973,0.0016429992,0.0001688166,0.00025422813,0.00033054917],"about_ca_topic_score_codex":0.00065543654,"about_ca_topic_score_gemma":0.0028776855,"teacher_disagreement_score":0.3162588,"about_ca_system_score_codex":0.00012750216,"about_ca_system_score_gemma":0.0001340249,"threshold_uncertainty_score":0.99999136},"labels":[],"label_agreement":null},{"id":"W4388204260","doi":"10.14740/jh1167","title":"A Rare Coexistence of Multiple Myeloma and Polycythemia Vera","year":2023,"lang":"en","type":"article","venue":"Journal of Hematology","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Medicine; Multiple myeloma; Polycythemia vera; Monoclonal gammopathy of undetermined significance; Anemia; Presentation (obstetrics); Pathophysiology; Pathology; Bone marrow; Gastroenterology; Internal medicine; Immunology; Monoclonal; Surgery","score_opus":0.026437579359055847,"score_gpt":0.299205100245193,"score_spread":0.27276752088613715,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4388204260","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99515724,0.0012322814,0.000015270176,0.003053911,0.000112237285,0.00010879585,0.000005480146,0.00000922172,0.00030557188],"genre_scores_gemma":[0.9982027,0.0004249819,0.0010478604,0.00015007959,0.000046800666,0.0000050472936,0.0000025223285,0.00000884222,0.00011120433],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.999184,0.000033725253,0.00038927508,0.000093957235,0.0001583946,0.00014066465],"domain_scores_gemma":[0.9990422,0.00034375017,0.00025588635,0.000102595724,0.00014996156,0.00010557769],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00013462422,0.00009185668,0.00053112087,0.00015875742,0.000031016207,0.0000037904788,0.000045102293,0.00006746995,0.000055883986],"category_scores_gemma":[0.00026847835,0.00006331681,0.00008910012,0.0001387426,0.000084443636,0.000039145765,0.00002918214,0.00012275623,0.000013960779],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00072123174,0.00026866083,0.9766153,0.00025794355,0.0003175619,0.0024636984,0.0010599698,0.0000031369457,0.007990061,0.0018830383,0.0061409893,0.0022783878],"study_design_scores_gemma":[0.011482045,0.0035753322,0.720789,0.0010791604,0.00038241566,0.031928733,0.0013284492,0.0003899269,0.22237572,0.0008968861,0.0055569126,0.00021543112],"about_ca_topic_score_codex":0.0000042477354,"about_ca_topic_score_gemma":0.0000057339107,"teacher_disagreement_score":0.25582632,"about_ca_system_score_codex":0.000020367017,"about_ca_system_score_gemma":0.000082107275,"threshold_uncertainty_score":0.25819847},"labels":[],"label_agreement":null},{"id":"W4388418018","doi":"10.1007/s00277-023-05535-5","title":"Safe utilization of ruxolitinib in simultaneous primary myelofibrosis and warm autoimmune hemolytic anemia","year":2023,"lang":"en","type":"letter","venue":"Annals of Hematology","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Victoria Hospital; London Health Sciences Centre; Western University","funders":"","keywords":"Ruxolitinib; Myelofibrosis; Medicine; Autoimmune hemolytic anemia; Hematology; Anemia; Internal medicine; Immunology; Bone marrow","score_opus":0.07482621262517429,"score_gpt":0.3393682397040566,"score_spread":0.2645420270788823,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4388418018","genre_codex":"commentary","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.47308293,0.010386848,0.000016611764,0.51084054,0.00031625296,0.0019225995,0.0003311487,0.00010516216,0.002997911],"genre_scores_gemma":[0.8340755,0.007901621,0.0005211919,0.15354465,0.00023585309,0.00018345991,0.0022293306,0.00014525809,0.0011631073],"study_design_codex":"not_applicable","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9975192,0.00014015452,0.0010420033,0.00051274453,0.0003281696,0.00045773006],"domain_scores_gemma":[0.9968186,0.0019506457,0.0005010054,0.0004413281,0.00022348286,0.00006494172],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00016919583,0.0003883908,0.0018909593,0.00050223706,0.000031299423,0.0000059123518,0.0001101549,0.00083121075,0.00009303397],"category_scores_gemma":[0.0005613082,0.00034071726,0.00017211272,0.00030507983,0.0002558869,0.000035360765,0.00009946487,0.00053971895,0.000020948371],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0019070911,0.0024648192,0.14328684,0.042428326,0.0021539677,0.01916988,0.0024572823,0.000097152086,0.0038111412,0.0028892842,0.7573703,0.02196394],"study_design_scores_gemma":[0.02170469,0.0121894665,0.18049866,0.023881348,0.0027762845,0.0067374893,0.0005636488,0.002447813,0.40276834,0.0066604763,0.3361354,0.003636368],"about_ca_topic_score_codex":0.000153006,"about_ca_topic_score_gemma":0.000016320015,"teacher_disagreement_score":0.42123488,"about_ca_system_score_codex":0.00003139183,"about_ca_system_score_gemma":0.00021902702,"threshold_uncertainty_score":0.9999045},"labels":[],"label_agreement":null},{"id":"W4388459786","doi":"10.1111/bjh.19164","title":"Diagnosis and evaluation of prognosis of myelofibrosis: A British Society for Haematology Guideline","year":2023,"lang":"en","type":"article","venue":"British Journal of Haematology","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Queen's University; Queen's University Belfast; Wellcome Trust; Academy of Medical Sciences; European Hematology Association; National Institute for Health and Care Research; Cancer Research UK","keywords":"Medicine; Guideline; Myelofibrosis; MEDLINE; Grading (engineering); Family medicine; Polycythaemia; Clinical trial; Internal medicine; Pathology","score_opus":0.04995317493433869,"score_gpt":0.34855145415029,"score_spread":0.2985982792159513,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4388459786","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98052907,0.014931875,0.00016591756,0.0028407865,0.00019071746,0.0011265086,0.00015375896,0.000018674278,0.000042696738],"genre_scores_gemma":[0.97823733,0.011124317,0.009811615,0.00020124746,0.00009757916,0.00040579677,0.00006931329,0.00003339277,0.000019379917],"study_design_codex":"observational","study_design_gemma":"case_report","domain_scores_codex":[0.997105,0.00018069307,0.0015804294,0.00027781865,0.00054263516,0.00031340448],"domain_scores_gemma":[0.99574465,0.0005954715,0.0009870981,0.00013230699,0.002394657,0.00014584733],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0017697432,0.00017054947,0.0015495778,0.00018644509,0.000091625734,0.000022267684,0.000105964864,0.00022212585,0.00013882277],"category_scores_gemma":[0.0012979674,0.00018808305,0.00053347094,0.00032932902,0.00028290178,0.00011515046,0.0000608797,0.0001563958,0.0000017519367],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0005923985,0.0028446198,0.39327887,0.0036616668,0.004393194,0.006039492,0.0011289517,0.00008794706,0.0012778562,0.0008652155,0.28717136,0.2986584],"study_design_scores_gemma":[0.0420671,0.0076413755,0.36926183,0.0130802,0.010907216,0.46389034,0.0030276212,0.006287422,0.06474643,0.008689346,0.009535053,0.0008660734],"about_ca_topic_score_codex":0.00016290869,"about_ca_topic_score_gemma":0.00022508929,"teacher_disagreement_score":0.45785084,"about_ca_system_score_codex":0.00005035695,"about_ca_system_score_gemma":0.00034036124,"threshold_uncertainty_score":0.7669804},"labels":[],"label_agreement":null},{"id":"W4388490413","doi":"10.1038/s41409-023-02146-6","title":"Upfront allogeneic transplantation versus JAK inhibitor therapy for patients with myelofibrosis: a North American collaborative study","year":2023,"lang":"en","type":"article","venue":"Bone Marrow Transplantation","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Public Health Ontario; University of Waterloo; Jewish General Hospital; McGill University; Princess Margaret Cancer Centre; University of Calgary; St. Paul's Hospital; Alberta Health Services; University of British Columbia; University Health Network; Dalhousie University; University of Toronto","funders":"","keywords":"Medicine; Myelofibrosis; Internal medicine; Retrospective cohort study; Transplantation; Ruxolitinib; Hematopoietic stem cell transplantation; Cohort; Observational study; Surgery; Cohort study; Bone marrow","score_opus":0.014628634487853254,"score_gpt":0.26797390285078504,"score_spread":0.2533452683629318,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4388490413","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99277544,0.00004931481,0.00023548784,0.0003485452,0.0001741943,0.0052030925,0.0009662657,0.00017726251,0.000070385366],"genre_scores_gemma":[0.98942006,0.0012306198,0.0010584022,0.000107250016,0.00008923697,0.002557811,0.0054220054,0.000062089006,0.000052505955],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9980316,0.00011547778,0.0004026827,0.00055704144,0.0005297489,0.00036342323],"domain_scores_gemma":[0.99885786,0.00025091993,0.00018351177,0.00019793022,0.00036202258,0.00014778248],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00012397942,0.00035866813,0.00049701316,0.0002475752,0.00022809205,0.000043370805,0.000055710316,0.000051578118,0.000014338613],"category_scores_gemma":[0.000012252767,0.00027423355,0.00008945336,0.0009102058,0.000072187286,0.00016618612,0.0000031952925,0.00009061474,0.000025150568],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.047622234,0.002247811,0.9253668,0.00019603045,0.00068477425,0.000119677665,0.008254621,0.0001333348,0.0006967147,0.000018549614,0.0002732418,0.014386197],"study_design_scores_gemma":[0.032723855,0.0153257735,0.9458282,0.00009063744,0.0007128464,0.0000049325495,0.0009744698,0.000048258567,0.003834183,0.0000030119666,0.00015565235,0.00029819188],"about_ca_topic_score_codex":0.000088336754,"about_ca_topic_score_gemma":0.0024354665,"teacher_disagreement_score":0.020461373,"about_ca_system_score_codex":0.000112983435,"about_ca_system_score_gemma":0.00014124032,"threshold_uncertainty_score":0.999971},"labels":[],"label_agreement":null},{"id":"W4388596429","doi":"10.1016/j.rpth.2023.101944","title":"PB1527 Sticky Platelet Syndrome and Pregnancy Complications - 18 Years' Experience in National Center of Hemostasis and Thrombosis in Slovak Republic","year":2023,"lang":"en","type":"article","venue":"Research and Practice in Thrombosis and Haemostasis","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"","keywords":"Hemostasis; Slovak; Medicine; Thrombosis; Pregnancy; Platelet; Center (category theory); Obstetrics; Surgery; Internal medicine; Biology; Czech","score_opus":0.3347988155364868,"score_gpt":0.49619577259190467,"score_spread":0.16139695705541784,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4388596429","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9858713,0.0024040407,0.0000013758312,0.009166519,0.000016322072,0.00086209003,0.00013681903,0.000013448813,0.0015280499],"genre_scores_gemma":[0.95205235,0.04665695,0.0007492514,0.00014143676,0.000007631817,0.00029242778,0.00005372856,0.000017415632,0.000028804101],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99762243,0.00032264338,0.00046693633,0.000575582,0.00058015576,0.0004322724],"domain_scores_gemma":[0.9960878,0.0031636409,0.000099251985,0.00021813838,0.0002355793,0.00019558404],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013296047,0.00017814837,0.0004942083,0.0007468906,0.00013431246,0.00010765153,0.000070721464,0.00012040766,0.00008908495],"category_scores_gemma":[0.0018191602,0.00016310097,0.000024081803,0.0011442517,0.00044115563,0.0005086678,0.00021252366,0.00037853487,0.0000045958895],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0003064385,0.0015621785,0.94010484,0.00045545623,0.00019890998,0.00022550348,0.011450011,0.0000032579142,0.0005249219,0.0030313435,0.0010725809,0.04106454],"study_design_scores_gemma":[0.0029380294,0.0005672108,0.9876057,0.0010507704,0.000020088131,0.00014496785,0.004584757,0.00021656923,0.00048281648,0.00091110147,0.001329002,0.0001490191],"about_ca_topic_score_codex":0.0010040668,"about_ca_topic_score_gemma":0.00041851544,"teacher_disagreement_score":0.04750081,"about_ca_system_score_codex":0.00010636794,"about_ca_system_score_gemma":0.00013194044,"threshold_uncertainty_score":0.6651064},"labels":[],"label_agreement":null},{"id":"W4388596712","doi":"10.1016/j.rpth.2023.101052","title":"PB1227 Lupus Anticoagulant in Acquired Hemophilia A Subjects in Quebec: Data from the Quebec Reference Center for Inhibitors","year":2023,"lang":"en","type":"article","venue":"Research and Practice in Thrombosis and Haemostasis","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Dalhousie University; Université de Montréal; Centre Hospitalier Universitaire Sainte-Justine","funders":"","keywords":"Lupus anticoagulant; Medicine; Center (category theory); Systemic lupus erythematosus; Internal medicine; Thrombosis; Chemistry; Disease","score_opus":0.3354164574006097,"score_gpt":0.4735859952723877,"score_spread":0.138169537871778,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4388596712","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.94438624,0.0017830898,0.0000010035667,0.051358387,0.00008270884,0.001551181,0.00047932306,0.000016854907,0.00034122245],"genre_scores_gemma":[0.9693265,0.02850168,0.00025872787,0.0004676898,0.00009943373,0.00029616168,0.0007832901,0.000025935973,0.00024058486],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9969698,0.0006421013,0.0004402342,0.00076771877,0.0005261524,0.000653995],"domain_scores_gemma":[0.99003524,0.008929842,0.000083293446,0.0006263366,0.00015399864,0.000171306],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0027356343,0.00022178309,0.0005207619,0.00033790164,0.0001973276,0.00024855134,0.00021496,0.00014865941,0.000049011585],"category_scores_gemma":[0.0034168453,0.00015086759,0.000028915236,0.00090580597,0.0002469908,0.0006239453,0.00042488697,0.0004142766,0.000020375006],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.002769807,0.0016629217,0.9057245,0.00022166365,0.00020888155,0.00035481443,0.006424851,0.0000013836859,0.00082294416,0.0006550233,0.02773339,0.05341982],"study_design_scores_gemma":[0.0071344255,0.0005833792,0.947129,0.0010938036,0.00007227155,0.00002931684,0.009889273,0.00048426638,0.0010969321,0.0006830701,0.031556245,0.00024803547],"about_ca_topic_score_codex":0.20230116,"about_ca_topic_score_gemma":0.4951087,"teacher_disagreement_score":0.29280755,"about_ca_system_score_codex":0.00017381595,"about_ca_system_score_gemma":0.00031016482,"threshold_uncertainty_score":0.80301076},"labels":[],"label_agreement":null},{"id":"W4388597123","doi":"10.1016/j.rpth.2023.101781","title":"PB0922 Predictive Scores of Thrombosis and Bleeding Complications in Newly-Diagnosed Acute Myeloid Leukemia Patients","year":2023,"lang":"en","type":"article","venue":"Research and Practice in Thrombosis and Haemostasis","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University; McGill University; Impact","funders":"","keywords":"Myeloid leukemia; Medicine; Thrombosis; Internal medicine","score_opus":0.16279815234739353,"score_gpt":0.4425294782483458,"score_spread":0.2797313259009523,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4388597123","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9850501,0.0008703454,0.000003955694,0.01043053,0.00002949569,0.0012791734,0.00017254149,0.000026404603,0.0021374465],"genre_scores_gemma":[0.9032415,0.09543526,0.00067098567,0.0001588421,0.000027182217,0.0003234969,0.00009992902,0.000024678515,0.00001813446],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.997433,0.00035734082,0.00047463423,0.00059045455,0.0006185482,0.0005260119],"domain_scores_gemma":[0.99350077,0.005380673,0.00014007151,0.00026253425,0.00044054585,0.00027539424],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013516382,0.00022723123,0.00059899705,0.00070396246,0.00028506873,0.00010162483,0.00008524588,0.00014473619,0.00003811717],"category_scores_gemma":[0.0016864098,0.00019368995,0.00004048722,0.0012639152,0.00045130803,0.00049889064,0.00024979486,0.00048404504,0.000008911241],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00057685666,0.0009862651,0.9721952,0.00023908354,0.00047318346,0.000032939144,0.0047915615,0.0000065178524,0.0008872329,0.0010181322,0.0026245045,0.016168501],"study_design_scores_gemma":[0.0045439806,0.001547481,0.98570305,0.00061122735,0.00016436502,0.000010434299,0.004041377,0.00037891825,0.0014096604,0.00058751996,0.0008477916,0.0001542181],"about_ca_topic_score_codex":0.0019411786,"about_ca_topic_score_gemma":0.00045986485,"teacher_disagreement_score":0.094564915,"about_ca_system_score_codex":0.00019576399,"about_ca_system_score_gemma":0.00019830544,"threshold_uncertainty_score":0.7898447},"labels":[],"label_agreement":null},{"id":"W4388597930","doi":"10.1016/j.rpth.2023.101422","title":"PB0290 Bleeding Complications in Children with Myeloproliferative Neoplasms and Thrombosis on Anticoagulation","year":2023,"lang":"en","type":"article","venue":"Research and Practice in Thrombosis and Haemostasis","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hospital for Sick Children","funders":"","keywords":"Medicine; Thrombosis; Myeloproliferative Disorders; Surgery; Internal medicine","score_opus":0.19376356998779712,"score_gpt":0.45383254851985994,"score_spread":0.2600689785320628,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4388597930","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96930593,0.0005499051,0.000005151721,0.02658498,0.000011390747,0.0013732065,0.000036161095,0.00003522841,0.0020980274],"genre_scores_gemma":[0.9691982,0.02906054,0.0009435797,0.00033528465,0.000038093796,0.00029175996,0.00008013502,0.000027527114,0.000024848765],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.997674,0.00033257925,0.00030748473,0.00064351485,0.0005417056,0.0005007187],"domain_scores_gemma":[0.99626917,0.002947918,0.000082275044,0.00023172057,0.00023136457,0.00023754756],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013387286,0.00023646154,0.00046697079,0.0006795104,0.0004318466,0.00020367558,0.000051814404,0.00011933708,0.000027626407],"category_scores_gemma":[0.00074112875,0.00018141486,0.00002174347,0.0012300801,0.00032385232,0.00044200398,0.000104196435,0.0005151624,0.000018548977],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00049733336,0.00070546946,0.975441,0.00006630534,0.0003008666,0.00002026915,0.0028065036,0.000015750411,0.00038573123,0.0056705824,0.00044186745,0.013648329],"study_design_scores_gemma":[0.002879289,0.0016177546,0.98968655,0.0004267827,0.000081329046,0.00009040788,0.00256975,0.0005474571,0.0009867037,0.0006166735,0.00031649708,0.00018082526],"about_ca_topic_score_codex":0.0007170728,"about_ca_topic_score_gemma":0.00038884845,"teacher_disagreement_score":0.028510636,"about_ca_system_score_codex":0.00009772797,"about_ca_system_score_gemma":0.00010465,"threshold_uncertainty_score":0.7397883},"labels":[],"label_agreement":null},{"id":"W4388598581","doi":"10.1016/j.rpth.2023.100417","title":"OC 33.1 Neutrophil Extracellular Traps Promote Gasdermin-D-Dependent Joint Damage in Hemophilia","year":2023,"lang":"en","type":"article","venue":"Research and Practice in Thrombosis and Haemostasis","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen's University","funders":"","keywords":"Neutrophil extracellular traps; Joint (building); Extracellular; Immunology; Medicine; Chemistry; Cell biology; Inflammation; Biology; Engineering","score_opus":0.23275539235276166,"score_gpt":0.44619402561594407,"score_spread":0.2134386332631824,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4388598581","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.950192,0.0028912444,0.0000018614617,0.04176468,0.00004822965,0.0014090254,0.000052436655,0.000041470987,0.0035990593],"genre_scores_gemma":[0.9404104,0.05774412,0.000543868,0.00022597334,0.00008305998,0.00028815673,0.000057362908,0.000042952794,0.0006041518],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99628484,0.00066964456,0.00053265534,0.0007828492,0.0008689406,0.0008610628],"domain_scores_gemma":[0.9970421,0.0018080805,0.00009510848,0.00040891976,0.00022893051,0.00041681662],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0035569402,0.00029479858,0.0006507332,0.0007635631,0.00028583093,0.00020026493,0.00009564795,0.00018440443,0.00022769731],"category_scores_gemma":[0.0014269475,0.00024569264,0.00006594098,0.0011648402,0.00027390398,0.0004439668,0.00020624064,0.0009086382,0.00010093209],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0074811424,0.016849041,0.34589106,0.0032974582,0.0016256776,0.024177732,0.029423062,0.000042856685,0.079956554,0.013885518,0.0273667,0.45000318],"study_design_scores_gemma":[0.013533724,0.004313155,0.87283695,0.0014247522,0.0002623859,0.00066036236,0.011507923,0.00112546,0.024495706,0.004314522,0.06468514,0.00083993044],"about_ca_topic_score_codex":0.00085721473,"about_ca_topic_score_gemma":0.0005547695,"teacher_disagreement_score":0.5269459,"about_ca_system_score_codex":0.000177809,"about_ca_system_score_gemma":0.00019906092,"threshold_uncertainty_score":0.9999995},"labels":[],"label_agreement":null},{"id":"W4388598652","doi":"10.1016/j.rpth.2023.100673","title":"OC 25.3 A Multicentre Cohort Study Evaluating Pregnancy Loss in Patients with Von Willebrand Disease and Unspecified Bleeding Disorders","year":2023,"lang":"en","type":"article","venue":"Research and Practice in Thrombosis and Haemostasis","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; St. Paul's Hospital; University of Ottawa; Queen's University; University of Calgary","funders":"","keywords":"Von Willebrand disease; Medicine; Cohort; Obstetrics; Disease; Pediatrics; Internal medicine; Gynecology; Von Willebrand factor; Platelet","score_opus":0.12271649333975351,"score_gpt":0.4396196658508293,"score_spread":0.3169031725110758,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4388598652","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9894703,0.0014906856,6.2944287e-7,0.0047338144,0.000020873973,0.0037383558,0.000029614617,0.000022341193,0.00049338565],"genre_scores_gemma":[0.9766982,0.02251233,0.00015897908,0.00004597479,0.000020281814,0.00044832987,0.00004736735,0.00002925381,0.000039236682],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9969127,0.00058913167,0.00033065103,0.00070640765,0.0009061585,0.000554915],"domain_scores_gemma":[0.9965767,0.002477672,0.00008944938,0.00023422852,0.0002603622,0.00036157484],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0017537221,0.00023896042,0.00047452547,0.00040576258,0.00034754022,0.00016266698,0.000050503448,0.000063604704,0.000042464133],"category_scores_gemma":[0.0019705903,0.00017750192,0.000021775071,0.00084383856,0.0002079205,0.00046809172,0.00015395044,0.00040636092,0.000005027138],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0025868264,0.002361159,0.96342194,0.00020395854,0.00029995822,0.00010763114,0.004130261,0.0000043678774,0.0000057725797,0.000054167846,0.00009006372,0.026733913],"study_design_scores_gemma":[0.011399409,0.0027570818,0.9770964,0.0010070006,0.00023253176,0.0000023122595,0.0067792446,0.00032572777,0.000011190269,0.000096478114,0.00011489298,0.0001777235],"about_ca_topic_score_codex":0.00052031415,"about_ca_topic_score_gemma":0.00084164157,"teacher_disagreement_score":0.02655619,"about_ca_system_score_codex":0.00009637846,"about_ca_system_score_gemma":0.0001026647,"threshold_uncertainty_score":0.72383183},"labels":[],"label_agreement":null},{"id":"W4388601525","doi":"10.1016/j.rpth.2023.101694","title":"PB1425 High Cell-free (cf)DNA in Patients with Myelofibrosis (MF) is Associated with Adverse Clinical Outcomes, Activation of the AIM2 Inflammasome and Elevated Levels of Inflammasome-Related Cytokine IL-18","year":2023,"lang":"en","type":"article","venue":"Research and Practice in Thrombosis and Haemostasis","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University; Thrombosis and Atherosclerosis Research Institute","funders":"","keywords":"Inflammasome; AIM2; Myelofibrosis; Cytokine; Medicine; Immunology; Inflammation; Bone marrow","score_opus":0.11107226291439205,"score_gpt":0.3911518890331012,"score_spread":0.2800796261187092,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4388601525","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9916118,0.00005263395,4.971334e-7,0.0062253587,0.000021501919,0.0014395374,0.00040154773,0.000016448092,0.00023066717],"genre_scores_gemma":[0.99661684,0.0028049042,0.00017632617,0.00012337921,0.000009995847,0.000076247925,0.0000822849,0.000033725886,0.000076314864],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99634516,0.0008062946,0.00082185405,0.00052915857,0.0010280379,0.00046946917],"domain_scores_gemma":[0.99260914,0.00559747,0.00039783685,0.00047060224,0.0007365482,0.00018840696],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0022678706,0.00028283792,0.000874181,0.00046405866,0.0001742088,0.000038390233,0.00012918569,0.00025185486,0.00007657279],"category_scores_gemma":[0.0039365306,0.00017272762,0.000058215282,0.0018750761,0.00055372436,0.00046437047,0.00025970466,0.00065543945,0.0000019633403],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0024243323,0.0014022314,0.98979855,0.00015527144,0.0006502254,0.000016948705,0.0011805209,0.0000062775375,0.0006453346,0.00009956766,0.00034369124,0.003277081],"study_design_scores_gemma":[0.014600055,0.0028319072,0.9672595,0.0008702958,0.00020430166,0.0000021583326,0.00081604096,0.00003706473,0.012918852,0.00014812927,0.000141453,0.00017024379],"about_ca_topic_score_codex":0.00083703804,"about_ca_topic_score_gemma":0.00040367065,"teacher_disagreement_score":0.02253902,"about_ca_system_score_codex":0.00011326418,"about_ca_system_score_gemma":0.00023548855,"threshold_uncertainty_score":0.7043628},"labels":[],"label_agreement":null},{"id":"W4389031270","doi":"10.1093/ofid/ofad500.004","title":"88. Fostamatinib for the Treatment of Hospitalized Patients With COVID-19 Who Required Oxygen Supplementation: Results of a Phase 3 Trial","year":2023,"lang":"en","type":"article","venue":"Open Forum Infectious Diseases","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Syk; Placebo; Clinical endpoint; Internal medicine; Randomization; Randomized controlled trial; Tyrosine kinase","score_opus":0.04173891059475748,"score_gpt":0.3767705047743755,"score_spread":0.33503159417961803,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4389031270","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9752788,0.00010225635,0.00007224407,0.0030812984,0.00015372992,0.013548785,0.007068211,0.00005559373,0.00063906243],"genre_scores_gemma":[0.9914743,0.00030615905,0.000085223954,0.00029948613,0.00005321599,0.0035990947,0.0036917296,0.000032009193,0.00045880696],"study_design_codex":"observational","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9983922,0.0000781728,0.00057895324,0.0003443363,0.00033749617,0.00026883068],"domain_scores_gemma":[0.99784416,0.0008222566,0.0004295034,0.00042433472,0.00026011103,0.00021965233],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00013085414,0.00023778965,0.000611851,0.000113139795,0.0002699168,0.000051297615,0.00012070629,0.00004042955,0.00019497517],"category_scores_gemma":[0.00042211864,0.00013555944,0.00022443787,0.0003584581,0.00010687327,0.0001361756,0.00005211547,0.00002116855,0.000006302735],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.29765505,0.02295998,0.6006473,0.00027749533,0.0030359062,0.000021927504,0.0025694785,0.00011369326,0.000017572138,0.0009331135,0.058770802,0.012997728],"study_design_scores_gemma":[0.7943396,0.07731338,0.09476049,0.00015802454,0.0021363983,0.0000021566002,0.0008605522,0.00017362594,0.0014446287,0.00057896064,0.027962158,0.0002700015],"about_ca_topic_score_codex":0.00057944824,"about_ca_topic_score_gemma":0.00024909762,"teacher_disagreement_score":0.50588673,"about_ca_system_score_codex":0.00020043475,"about_ca_system_score_gemma":0.00041826747,"threshold_uncertainty_score":0.55279535},"labels":[],"label_agreement":null},{"id":"W4389040648","doi":"10.1182/bloodadvances.2023010882","title":"<i>JAK2</i> <i>V617F</i> mutation and associated chromosomal alterations in primary and secondary myelofibrosis and post-HCT outcomes","year":2023,"lang":"en","type":"article","venue":"Blood Advances","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"National Institute of Allergy and Infectious Diseases; National Heart, Lung, and Blood Institute; Division of Cancer Epidemiology and Genetics, National Cancer Institute; Office of Naval Research; Health Resources and Services Administration; National Cancer Institute; U.S. Department of Health and Human Services; National Institutes of Health; Be The Match Foundation","keywords":"Hazard ratio; Medicine; Myelofibrosis; Internal medicine; Genotyping; Transplantation; International Prognostic Scoring System; Oncology; Hematopoietic stem cell transplantation; Confidence interval; Gastroenterology; Bone marrow; Genotype; Genetics; Myelodysplastic syndromes; Biology","score_opus":0.008063648788985196,"score_gpt":0.2547382195823869,"score_spread":0.24667457079340172,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4389040648","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9917246,0.00426908,0.0000018623273,0.0024437015,0.000055126977,0.00049042015,0.00013851827,0.00008005128,0.00079665385],"genre_scores_gemma":[0.994064,0.0032661033,0.00074066024,0.0010437358,0.000033852586,0.0001556308,0.00033520247,0.000019350644,0.0003415004],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.998981,0.00004760436,0.0002543948,0.0003434916,0.0001615401,0.00021194787],"domain_scores_gemma":[0.9993516,0.00031620273,0.00007743094,0.00009319435,0.000056253702,0.00010529847],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00011520659,0.00018702849,0.00037708564,0.00013982487,0.00014481788,0.000051674946,0.000021250791,0.000065793414,0.000013299506],"category_scores_gemma":[0.00011456969,0.00015213607,0.00003047492,0.00022190758,0.00008457646,0.00031480117,0.00004685,0.00011150071,0.000004618409],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0000647812,0.00032546607,0.97520113,0.00017650875,0.0001639619,0.00019236482,0.00088059733,0.000004584916,0.004813342,0.00015595146,0.00013260522,0.017888682],"study_design_scores_gemma":[0.003932401,0.00056641176,0.99012226,0.00015358898,0.00015132452,0.0000844646,0.00020063511,0.000058374924,0.0038914722,0.00014795808,0.0005380031,0.000153082],"about_ca_topic_score_codex":0.0000378291,"about_ca_topic_score_gemma":0.0002687268,"teacher_disagreement_score":0.0177356,"about_ca_system_score_codex":0.000027214703,"about_ca_system_score_gemma":0.000059460224,"threshold_uncertainty_score":0.62039286},"labels":[],"label_agreement":null},{"id":"W4389220419","doi":"10.1182/blood-2023-179596","title":"Sodium-Glucose Co-Transporter-2 Inhibitor Use in the Setting of Myeloproliferative Neoplasms: Impact on Hemoglobin/Hematocrit Levels and Thrombosis Risk","year":2023,"lang":"en","type":"article","venue":"Blood","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hôpital Maisonneuve-Rosemont","funders":"","keywords":"Medicine; Internal medicine; Polycythemia vera; Essential thrombocythemia; Gastroenterology; Myelofibrosis; Anagrelide; Myeloproliferative neoplasm; Hematocrit; Thrombosis; Diabetes mellitus; Surgery; Endocrinology; Bone marrow","score_opus":0.034838825285021836,"score_gpt":0.31634320086731366,"score_spread":0.2815043755822918,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4389220419","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99658495,0.000165979,0.000003836146,0.0009123915,0.00005464987,0.001414768,0.00054787175,0.00007267883,0.00024287189],"genre_scores_gemma":[0.9983755,0.00047359467,0.00030282693,0.00032471155,0.00010915949,0.0002412725,0.000104946,0.000041464784,0.000026560843],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9977415,0.00021634829,0.00056584284,0.0005001261,0.00051343034,0.00046272235],"domain_scores_gemma":[0.9980578,0.0010472003,0.00020741214,0.00042727694,0.00010804893,0.0001523021],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00057011336,0.0004010483,0.00075369194,0.00025294482,0.00016730004,0.00006412447,0.000107412256,0.00013984201,0.000058924918],"category_scores_gemma":[0.00023022304,0.00024262124,0.00019982728,0.00060779316,0.00011274294,0.00016902864,0.000030531763,0.0003638992,0.00004304198],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0002221876,0.0016664156,0.98635095,0.0001344151,0.00048522756,0.0002030102,0.0067517464,0.000018018882,0.0028011224,0.00020350091,0.00067128695,0.000492116],"study_design_scores_gemma":[0.006083392,0.0012788817,0.87961024,0.00043330292,0.00038846274,0.000058126087,0.0009057603,0.00009868257,0.11076487,0.00012460534,0.00005095395,0.00020270905],"about_ca_topic_score_codex":0.0002638449,"about_ca_topic_score_gemma":0.000243825,"teacher_disagreement_score":0.10796374,"about_ca_system_score_codex":0.000054256507,"about_ca_system_score_gemma":0.00013568897,"threshold_uncertainty_score":0.9893807},"labels":[],"label_agreement":null},{"id":"W4389221075","doi":"10.1182/blood-2023-182116","title":"Durable Clinical Benefits of Idasanutlin Therapy in Hydroxyurea-Refractory Polycythemia Vera","year":2023,"lang":"en","type":"article","venue":"Blood","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Phlebotomy; Medicine; Discontinuation; Clinical trial; Internal medicine; Polycythemia vera; Refractory (planetary science); Thrombocytosis; Surgery; Platelet","score_opus":0.04865075982292039,"score_gpt":0.33139214301040093,"score_spread":0.28274138318748054,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4389221075","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99516684,0.0012602331,3.5579436e-7,0.0008456269,0.00011833231,0.00043817548,0.000021521952,0.000068351146,0.0020805507],"genre_scores_gemma":[0.9938243,0.0050649075,0.00012881911,0.00027099348,0.00018137084,0.00008607829,0.000049005364,0.000028368362,0.0003661725],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9985556,0.00007041723,0.00051855354,0.00031615043,0.00026454587,0.00027472514],"domain_scores_gemma":[0.99903065,0.00034480356,0.000109039225,0.00033369003,0.00005746177,0.0001243802],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00034996815,0.00017247407,0.00051921984,0.0001611346,0.000032475662,0.0000072521543,0.00007862678,0.00014677088,0.00018535698],"category_scores_gemma":[0.0001306549,0.0001315786,0.00015628674,0.0003722781,0.000053525066,0.00004524088,0.00003076802,0.00021406457,0.00015248277],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0002729954,0.004166782,0.9822088,0.000032357257,0.00025271243,0.00012590161,0.00026936704,0.000012331503,0.0027612236,0.000211079,0.0009968086,0.008689673],"study_design_scores_gemma":[0.011621886,0.0015261765,0.92494744,0.00018850267,0.000077870434,0.000013386527,0.000045654604,0.000029927778,0.059681337,0.00009283247,0.0016530629,0.00012194892],"about_ca_topic_score_codex":0.00007846756,"about_ca_topic_score_gemma":0.00003600346,"teacher_disagreement_score":0.05726136,"about_ca_system_score_codex":0.000023979594,"about_ca_system_score_gemma":0.000117078875,"threshold_uncertainty_score":0.53656197},"labels":[],"label_agreement":null},{"id":"W4389222216","doi":"10.1182/blood-2023-173420","title":"Patient Characteristics, Treatment Patterns, and Health Outcomes in a Real-World Population of Patients with Myelofibrosis Treated with Fedratinib","year":2023,"lang":"en","type":"article","venue":"Blood","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"Swedish Orphan Biovitrum; Eisai; Gilead Sciences; Bristol-Myers Squibb","keywords":"Medicine; Myelofibrosis; Ruxolitinib; Discontinuation; Myeloproliferative neoplasm; Population; Constitutional symptoms; Internal medicine; Pediatrics; Anemia; International Prognostic Scoring System; Bone marrow; Myelodysplastic syndromes; Disease","score_opus":0.020519365206540977,"score_gpt":0.28103736685163716,"score_spread":0.2605180016450962,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4389222216","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9978004,0.000015068107,6.99723e-7,0.00040912477,0.000014497418,0.0013607581,0.00028822524,0.000052646184,0.00005856228],"genre_scores_gemma":[0.99767625,0.00023410455,0.00023339044,0.000076035474,0.000011952723,0.00024889954,0.0014035037,0.000030513758,0.00008533777],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9986895,0.000051064028,0.000416631,0.0003281566,0.0002665549,0.00024814397],"domain_scores_gemma":[0.9992801,0.000058291236,0.00023950252,0.00021309908,0.00007621063,0.00013278126],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000051943713,0.000249907,0.0006695948,0.0002536096,0.000058494174,0.000014444419,0.000018743953,0.000036232337,0.000016371916],"category_scores_gemma":[0.000008683882,0.0001479473,0.000037072386,0.0003129483,0.000024150997,0.00005048,0.000015602474,0.00004888869,0.0000030537512],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00033301068,0.0029673716,0.9871455,0.00010730603,0.00024116732,0.00003651659,0.0005730559,0.0000011292693,0.000004446149,0.000026605661,0.000007860395,0.008556069],"study_design_scores_gemma":[0.00977506,0.0069882,0.98168427,0.00043630585,0.00017317425,0.0000019256072,0.0000615259,0.000011635236,0.0007243732,0.0000019175336,0.0000144865435,0.00012711587],"about_ca_topic_score_codex":0.004737076,"about_ca_topic_score_gemma":0.004857751,"teacher_disagreement_score":0.009442049,"about_ca_system_score_codex":0.00012993084,"about_ca_system_score_gemma":0.0000563107,"threshold_uncertainty_score":0.71610737},"labels":[],"label_agreement":null},{"id":"W4389224369","doi":"10.1111/bjh.19186","title":"The management of myelofibrosis: A British Society for Haematology Guideline","year":2023,"lang":"en","type":"article","venue":"British Journal of Haematology","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":15,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Queen's University; Queen's University Belfast; Wellcome Trust; Academy of Medical Sciences; European Hematology Association; National Institute for Health and Care Research; Cancer Research UK","keywords":"Myelofibrosis; Guideline; Hematology; Medicine; Internal medicine; Intensive care medicine; Family medicine; Pathology","score_opus":0.018734447172604585,"score_gpt":0.3053347433035227,"score_spread":0.28660029613091814,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4389224369","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96671426,0.016794356,0.001717186,0.01217601,0.0007684707,0.0011565887,0.00010354302,0.000053218133,0.00051633565],"genre_scores_gemma":[0.8979995,0.054673657,0.04305016,0.0015218197,0.00041614083,0.0004111948,0.00011872962,0.000106159,0.0017026291],"study_design_codex":"not_applicable","study_design_gemma":"case_report","domain_scores_codex":[0.99755543,0.00007477956,0.0013571713,0.00023530025,0.00032732505,0.00044996353],"domain_scores_gemma":[0.99792403,0.0004026619,0.0006282826,0.00019946025,0.00070663315,0.00013893441],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008865488,0.00016164653,0.00106886,0.00007570252,0.00026526177,0.00004947461,0.00021629831,0.00014735604,0.00006989687],"category_scores_gemma":[0.0001474351,0.00014589677,0.0007324723,0.0002854017,0.00025910654,0.00006648651,0.000093591,0.00019831947,0.000012694512],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0005313545,0.00075939245,0.0054320088,0.0014757743,0.0055592707,0.056741357,0.00024830777,0.000029325125,0.0001408669,0.008564142,0.804001,0.116517216],"study_design_scores_gemma":[0.016434075,0.0023600375,0.026077054,0.0049470826,0.002377473,0.7123592,0.0032579426,0.0006569842,0.0032846145,0.00842842,0.21936624,0.00045087957],"about_ca_topic_score_codex":0.0000522746,"about_ca_topic_score_gemma":0.000122284,"teacher_disagreement_score":0.65561783,"about_ca_system_score_codex":0.000048122965,"about_ca_system_score_gemma":0.00013107248,"threshold_uncertainty_score":0.5949498},"labels":[],"label_agreement":null},{"id":"W4389229148","doi":"10.1182/blood-2023-174076","title":"<i>Calr</i> Variant Allele Frequency in Essential Thrombocythemia: Molecular Associations and Impact on Disease Phenotype and Outcome","year":2023,"lang":"en","type":"article","venue":"Blood","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Quebec - Clinical Research Organization in Cancer; Université de Montréal; MPB Technologies & Communications (Canada); Hôpital Maisonneuve-Rosemont","funders":"","keywords":"Essential thrombocythemia; Myelofibrosis; Medicine; Internal medicine; Leukocytosis; Gastroenterology; Thrombocytosis; Myeloproliferative neoplasm; Calreticulin; Myeloid; Myeloid leukemia; Allele; Polycythemia vera; Oncology; Genetics; Biology; Gene; Platelet; Bone marrow","score_opus":0.014999724719802302,"score_gpt":0.3041925289978127,"score_spread":0.28919280427801036,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4389229148","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99652696,0.0004374194,0.000009966086,0.0017851492,0.00002814676,0.0003754935,0.000102521495,0.000046764697,0.00068758044],"genre_scores_gemma":[0.9989992,0.00022146311,0.00017013215,0.00030457045,0.000049489903,0.00006513169,0.00012628874,0.00001887156,0.000044888642],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9991067,0.000041304545,0.00018413743,0.00026605994,0.00018524528,0.00021653967],"domain_scores_gemma":[0.9994619,0.00010872072,0.00004436437,0.00015963301,0.000029650722,0.0001957216],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000109190994,0.00015441544,0.000286887,0.000092176495,0.00006301197,0.00002640884,0.000026199623,0.00006197701,0.00004783678],"category_scores_gemma":[0.00014856453,0.0001146206,0.000059853202,0.0001865695,0.000028494527,0.0000389985,0.000031695523,0.00012179203,0.000029500143],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00005774323,0.0011920286,0.9914096,0.000039712482,0.00028258425,0.0012159073,0.00022928177,0.0000152523135,0.0019362386,0.0032347983,0.0001701711,0.00021668647],"study_design_scores_gemma":[0.0044234158,0.00027275793,0.9919887,0.000042595835,0.00032876342,0.000011262535,0.000019728726,0.000086515814,0.0011487511,0.0015496304,0.000016524687,0.000111311165],"about_ca_topic_score_codex":0.000108185166,"about_ca_topic_score_gemma":0.000026970787,"teacher_disagreement_score":0.004365673,"about_ca_system_score_codex":0.00004654147,"about_ca_system_score_gemma":0.00007258265,"threshold_uncertainty_score":0.46740922},"labels":[],"label_agreement":null},{"id":"W4389229912","doi":"10.1182/blood-2023-187775","title":"Morphologic and Genetic Features of Unclassifiable Chronic Myeloid Neoplasms: Five-Year Experience of a Canadian Provincial Referral Center","year":2023,"lang":"en","type":"article","venue":"Blood","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Canadian Electricity Association; Vancouver General Hospital; Ottawa Hospital; University of British Columbia","funders":"","keywords":"Medicine; Myeloproliferative neoplasm; Essential thrombocythemia; Myeloid; Myelodysplastic syndromes; Myelofibrosis; Bone marrow; Chronic myelomonocytic leukemia; Internal medicine; Thrombocytosis; Pathology; Oncology; Polycythemia vera","score_opus":0.02088657977640402,"score_gpt":0.2555580365971531,"score_spread":0.23467145682074908,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4389229912","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.994642,0.000448333,4.5328468e-7,0.0003917298,0.00006819795,0.00048367248,0.000115355,0.00002663139,0.00382359],"genre_scores_gemma":[0.99754345,0.00067327655,0.0005619307,0.000078092984,0.000079845064,0.000106725995,0.000047299673,0.000017050606,0.0008923136],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99890256,0.00003192985,0.00023915473,0.00029317435,0.0002054161,0.0003277899],"domain_scores_gemma":[0.99935716,0.00004378582,0.0000832478,0.00022990657,0.000082604085,0.000203293],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000050484963,0.00016067333,0.0003469643,0.0003204544,0.00006532219,0.000009727008,0.00007465864,0.000100458456,0.00013388108],"category_scores_gemma":[0.0000701155,0.0001247794,0.000061763625,0.0004166226,0.00013913361,0.000035353274,0.00004813236,0.00010035355,0.000016606478],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00018402265,0.0008823186,0.9629832,0.0004095212,0.00027732833,0.00069484214,0.003141137,0.000018080253,0.023047788,0.00071507547,0.0045695086,0.0030772062],"study_design_scores_gemma":[0.005114598,0.0016507063,0.92913604,0.000214947,0.00016568438,0.00019361767,0.00046304867,0.000048471124,0.061244838,0.000053316304,0.0015515557,0.0001632048],"about_ca_topic_score_codex":0.019628102,"about_ca_topic_score_gemma":0.03653909,"teacher_disagreement_score":0.03819705,"about_ca_system_score_codex":0.0000656503,"about_ca_system_score_gemma":0.0004233803,"threshold_uncertainty_score":0.98690027},"labels":[],"label_agreement":null},{"id":"W4389229953","doi":"10.1182/blood-2023-189318","title":"Impact of Kidney Dysfunction on Overall Survival in Myeloproliferative Neoplasms: A Single-Center Retrospective Study","year":2023,"lang":"en","type":"article","venue":"Blood","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; Queen's University; University Health Network","funders":"","keywords":"Medicine; Renal function; Internal medicine; Kidney disease; Gastroenterology; Myelofibrosis; Essential thrombocythemia; Urology; Pathology; Polycythemia vera; Oncology; Bone marrow","score_opus":0.028885551216120568,"score_gpt":0.3005566588834749,"score_spread":0.2716711076673543,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4389229953","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9940051,0.000016235857,0.0000020347795,0.00037192923,0.0002080015,0.0017776536,0.000125093,0.00009832893,0.003395634],"genre_scores_gemma":[0.998875,0.000039631872,0.000037500155,0.00014677588,0.0001443791,0.0002715674,0.000121198755,0.000042113148,0.00032181863],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9978578,0.00017647704,0.00045973592,0.00055835175,0.00055321655,0.00039443397],"domain_scores_gemma":[0.9988635,0.00014022473,0.00015157243,0.00036048092,0.00020605922,0.00027812336],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00027647696,0.0003390641,0.00073108164,0.00043183853,0.00006658315,0.000025295925,0.00006772214,0.00010654444,0.00018654202],"category_scores_gemma":[0.0006248677,0.0002531528,0.00022590667,0.00072217657,0.000044337325,0.000097940625,0.00005227699,0.0002651833,0.00011550409],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0012365998,0.019562887,0.9726843,0.000028480075,0.0009785896,0.00029994198,0.0022641993,0.000032259162,0.001587109,0.00018102487,0.0009926434,0.00015196366],"study_design_scores_gemma":[0.022529837,0.015006844,0.95798546,0.00022107456,0.00019051757,0.000023395267,0.00034074442,0.00006279896,0.0033384298,0.00008636582,0.00002927302,0.00018525642],"about_ca_topic_score_codex":0.00022606991,"about_ca_topic_score_gemma":0.00019353649,"teacher_disagreement_score":0.021293238,"about_ca_system_score_codex":0.00039619557,"about_ca_system_score_gemma":0.00028137473,"threshold_uncertainty_score":0.9999921},"labels":[],"label_agreement":null},{"id":"W4389229959","doi":"10.1182/blood-2023-185582","title":"Ruxolitinib Versus Best Available Therapy for Polycythemia Vera: A Systematic Review and Meta-Analysis","year":2023,"lang":"en","type":"review","venue":"Blood","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University","funders":"","keywords":"Ruxolitinib; Medicine; Internal medicine; Polycythemia vera; Population; Meta-analysis; Myelofibrosis; Myeloproliferative neoplasm; Randomized controlled trial; Anemia; Confidence interval; Bone marrow","score_opus":0.2569226833816552,"score_gpt":0.40872079641507186,"score_spread":0.15179811303341667,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4389229959","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0000015602011,0.9874356,0.0000020314133,0.0002318924,0.00004733097,0.010907008,0.00070971233,0.000069558766,0.00059530884],"genre_scores_gemma":[0.0000011957676,0.9743921,0.0003113002,0.0003124741,0.000091977105,0.015649326,0.0005973145,0.000110826615,0.008533447],"study_design_codex":"systematic_review","study_design_gemma":"meta_analysis","domain_scores_codex":[0.9969451,0.00024386418,0.0012344957,0.0008147757,0.00035911961,0.00040266517],"domain_scores_gemma":[0.9964834,0.001507213,0.0006590478,0.000955865,0.00016816531,0.00022631446],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0006251431,0.0007672498,0.012921355,0.00029764438,0.00012224849,0.00004698196,0.00015798214,0.0002389143,0.0006676027],"category_scores_gemma":[0.00037499162,0.00043189595,0.0043067923,0.00080701296,0.000040310933,0.000036139827,0.00005145819,0.00020770617,0.00056007213],"study_design_candidate":"meta_analysis","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000012609663,0.00039050108,0.0000015462012,0.59029406,0.40813398,0.000032690128,0.000009988038,7.1124084e-9,1.4735812e-8,0.00008061506,0.00071929797,0.0003246775],"study_design_scores_gemma":[0.0019663565,0.0005144261,1.766093e-7,0.04260523,0.83245075,0.000051169285,0.0000061888913,3.9124242e-7,0.0000031450302,0.0000036238216,0.12212681,0.0002717189],"about_ca_topic_score_codex":0.000026838927,"about_ca_topic_score_gemma":0.0000143189345,"teacher_disagreement_score":0.54768884,"about_ca_system_score_codex":0.00006862501,"about_ca_system_score_gemma":0.00027147777,"threshold_uncertainty_score":0.99981326},"labels":[],"label_agreement":null},{"id":"W4389231445","doi":"10.1182/blood-2023-190270","title":"Rates and Predictors of Prophylaxis in Women with Von Willebrand Disease and Heavy Menstrual Bleeding","year":2023,"lang":"en","type":"article","venue":"Blood","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Alberta","funders":"","keywords":"Medicine; Dilation and curettage; Desmopressin; Hysterectomy; Retrospective cohort study; Von Willebrand disease; Gynecology; Blood transfusion; Obstetrics; Internal medicine; Pediatrics; Von Willebrand factor; Surgery; Pregnancy","score_opus":0.008427221471121696,"score_gpt":0.2331476104958599,"score_spread":0.22472038902473823,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4389231445","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99863297,0.00046890217,2.1961013e-7,0.00031510714,0.000016195394,0.00042683442,0.000023241395,0.000024626508,0.000091909205],"genre_scores_gemma":[0.99923545,0.0004377335,0.000059717837,0.000026772215,0.000034917965,0.00013379616,0.000008753582,0.000012486646,0.000050364764],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99931115,0.000018705969,0.00013893333,0.00020896303,0.0001475932,0.00017465492],"domain_scores_gemma":[0.9996084,0.00007000839,0.000035441873,0.00008290251,0.000028102797,0.00017517542],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00009335227,0.00011415753,0.00024828373,0.00011764092,0.000034660567,0.000011608227,0.000015171729,0.000029696204,0.000011985093],"category_scores_gemma":[0.000040687573,0.000075849486,0.000010550372,0.00020756168,0.00008387877,0.000048602218,0.000026432286,0.000057371682,0.0000010773765],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0008491234,0.0003432912,0.9952589,0.00022964783,0.0001796775,0.00012924995,0.0015100078,0.0000016141927,0.0006128913,0.000038239934,0.000028310238,0.00081900554],"study_design_scores_gemma":[0.0063938154,0.0019750183,0.9824387,0.00030477424,0.00012538266,0.00001536931,0.00042715616,0.000027813134,0.008119656,0.000050569284,0.000042204065,0.000079562735],"about_ca_topic_score_codex":0.000016877239,"about_ca_topic_score_gemma":0.000012248916,"teacher_disagreement_score":0.012820262,"about_ca_system_score_codex":0.000014776349,"about_ca_system_score_gemma":0.000050042694,"threshold_uncertainty_score":0.30930522},"labels":[],"label_agreement":null},{"id":"W4389232085","doi":"10.1182/blood-2023-179141","title":"Pelabresib in Combination with Ruxolitinib for Janus Kinase Inhibitor Treatment-Naïve Patients with Myelofibrosis: Results of the MANIFEST-2 Randomized, Double-Blind, Phase 3 Study","year":2023,"lang":"en","type":"article","venue":"Blood","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":30,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Ruxolitinib; Myelofibrosis; Medicine; Clinical endpoint; Internal medicine; Phases of clinical research; Placebo; Polycythemia vera; Gastroenterology; Anemia; Essential thrombocythemia; Neutropenia; Janus kinase; Clinical trial; Oncology; Bone marrow; Chemotherapy; Pathology","score_opus":0.028040060228644307,"score_gpt":0.2989658824812911,"score_spread":0.2709258222526468,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4389232085","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9853006,0.000050971426,0.000002667294,0.00046865558,0.00007091901,0.013441094,0.00025513128,0.000049147628,0.00036079765],"genre_scores_gemma":[0.9946623,0.00002599219,0.00015897294,0.000030197865,0.00006027934,0.004212949,0.00043673354,0.00004302625,0.00036955616],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99791497,0.00017058446,0.0006104585,0.00047531587,0.0005039557,0.00032469563],"domain_scores_gemma":[0.9982953,0.00049434375,0.0003260643,0.00044685006,0.00033083005,0.00010661721],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00036189292,0.00033022478,0.00082028436,0.00023099725,0.00012607568,0.000028578239,0.00008814349,0.000073389005,0.0000068336885],"category_scores_gemma":[0.00012380375,0.00016775537,0.00014675138,0.00058240374,0.00010433806,0.00008991622,0.000033227305,0.00009224657,0.0000077555615],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.64941883,0.045365807,0.29947716,0.00010183668,0.0010138635,0.00008390059,0.0029152862,0.00001304033,0.00004629465,0.00020242322,0.00007624085,0.0012853344],"study_design_scores_gemma":[0.85739136,0.015228119,0.10800898,0.0004162326,0.0014894077,0.000005684633,0.00067313306,0.0000270752,0.016527977,0.000025111252,0.000048257683,0.00015868666],"about_ca_topic_score_codex":0.0002467466,"about_ca_topic_score_gemma":0.00040783786,"teacher_disagreement_score":0.20797253,"about_ca_system_score_codex":0.00009259255,"about_ca_system_score_gemma":0.0001587565,"threshold_uncertainty_score":0.6840865},"labels":[],"label_agreement":null},{"id":"W4389232132","doi":"10.1182/blood-2023-173942","title":"Meter: A Multi-Country, Real-World Chart Review Study to Explore Treatment Patterns, Effectiveness and Healthcare Resource Utilization for Patients with Myelofibrosis","year":2023,"lang":"en","type":"article","venue":"Blood","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Myelofibrosis; Ruxolitinib; Discontinuation; Extramedullary hematopoiesis; Constitutional symptoms; Internal medicine; Clinical trial; Oncology; Intensive care medicine; Bone marrow; Disease; Haematopoiesis","score_opus":0.08302500608640526,"score_gpt":0.3601961046844037,"score_spread":0.2771710985979985,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4389232132","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9878713,0.0009419028,0.00002447256,0.0006371622,0.000035716537,0.010165744,0.00021823672,0.00009065815,0.00001482126],"genre_scores_gemma":[0.98666185,0.0048991046,0.00028128046,0.00043451253,0.00005419833,0.006748261,0.000744535,0.000061068866,0.00011521729],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99835026,0.0001717923,0.00028961807,0.0005923964,0.0002921571,0.0003037762],"domain_scores_gemma":[0.9989394,0.00020978255,0.000093410534,0.0003452968,0.0001836431,0.00022850113],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00020130462,0.0003081459,0.0006543397,0.00016604463,0.00016446145,0.00002484796,0.00004310319,0.000032734242,0.000010568813],"category_scores_gemma":[0.00005440363,0.00020541505,0.00006508932,0.0004556264,0.000013525499,0.000048142192,0.0000394471,0.00004469681,0.000015016911],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00046501146,0.005205148,0.9773197,0.0023318527,0.00041119658,0.000023631572,0.0011614421,6.637757e-7,0.0000069805146,0.000005720494,0.00014469404,0.012923966],"study_design_scores_gemma":[0.014119107,0.011734803,0.96623313,0.003796242,0.0010233027,0.000002526532,0.00030183085,0.000008233706,0.0010514078,9.540067e-7,0.001542127,0.00018635708],"about_ca_topic_score_codex":0.0004228259,"about_ca_topic_score_gemma":0.0013503667,"teacher_disagreement_score":0.013654095,"about_ca_system_score_codex":0.0001260155,"about_ca_system_score_gemma":0.000043703472,"threshold_uncertainty_score":0.8376582},"labels":[],"label_agreement":null},{"id":"W4389233524","doi":"10.1182/blood-2023-179417","title":"Effect of New or Worsening Anemia on Clinical Outcomes in 2233 Patients with Myelofibrosis Treated with Ruxolitinib in the Expanded-Access Jump Study","year":2023,"lang":"en","type":"article","venue":"Blood","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Ruxolitinib; Medicine; Anemia; Myelofibrosis; Discontinuation; Internal medicine; Clinical trial; Pure red cell aplasia; Bone marrow","score_opus":0.04665425392825574,"score_gpt":0.3791412665114085,"score_spread":0.3324870125831528,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4389233524","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9970188,0.000008651236,2.2403513e-7,0.0001457881,0.000024879128,0.0025031245,0.0000123708005,0.00004256963,0.00024356126],"genre_scores_gemma":[0.99920547,0.00001598736,0.000038185033,0.00010783321,0.00003589361,0.00036499696,0.00004743131,0.000029466833,0.00015475116],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9979288,0.0003867437,0.000501264,0.00040756224,0.00047685285,0.00029880565],"domain_scores_gemma":[0.9977559,0.0015750587,0.00014760783,0.00037208988,0.00004716003,0.000102210564],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000500392,0.0002802782,0.00081434724,0.00022366636,0.000043474618,0.000028531254,0.00013650251,0.00007310848,0.00003341724],"category_scores_gemma":[0.00024161123,0.00011778921,0.00007385276,0.0008607333,0.000046431873,0.00006332595,0.000040158386,0.00022253637,0.000012736312],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0048157517,0.0062834974,0.9834508,0.000054713008,0.00026351959,0.00039454838,0.0011187706,0.000010041261,0.0000017585769,0.000002818159,0.00006324462,0.003540572],"study_design_scores_gemma":[0.04057423,0.028673327,0.92828363,0.000482379,0.00041458115,0.000004184956,0.00035336395,0.0000031507345,0.0010832838,0.000001161819,0.000007155912,0.00011957776],"about_ca_topic_score_codex":0.00044148866,"about_ca_topic_score_gemma":0.0008494827,"teacher_disagreement_score":0.05516716,"about_ca_system_score_codex":0.000028748605,"about_ca_system_score_gemma":0.00009059063,"threshold_uncertainty_score":0.48033047},"labels":[],"label_agreement":null},{"id":"W4389233533","doi":"10.1182/blood-2023-173509","title":"Transform-1: A Randomized, Double-Blind, Placebo-Controlled, Multicenter, International Phase 3 Study of Navitoclax in Combination with Ruxolitinib Versus Ruxolitinib Plus Placebo in Patients with Untreated Myelofibrosis","year":2023,"lang":"en","type":"article","venue":"Blood","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":37,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Juravinski Cancer Centre","funders":"","keywords":"Ruxolitinib; Myelofibrosis; Medicine; Placebo; Internal medicine; Phases of clinical research; Gastroenterology; Polycythemia vera; Anemia; Clinical trial; Surgery; Oncology; Bone marrow; Pathology","score_opus":0.02273215938856701,"score_gpt":0.3032064606300736,"score_spread":0.28047430124150663,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4389233533","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.984101,0.000020474728,0.000010207085,0.00023555063,0.00013476358,0.014080435,0.00008667526,0.00006360886,0.0012673148],"genre_scores_gemma":[0.9942858,0.00003525326,0.00012924362,0.00002174775,0.000036012934,0.004582998,0.000722674,0.000051176525,0.00013507495],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99690187,0.0002577369,0.00096508086,0.00056374003,0.00085524295,0.00045634346],"domain_scores_gemma":[0.99808884,0.0008018544,0.00032121604,0.0002843662,0.00034684307,0.00015689552],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00050994154,0.00043765598,0.0014914487,0.00079836603,0.00006411786,0.000032660024,0.00013966476,0.00012046349,0.000090322545],"category_scores_gemma":[0.00012429859,0.00029970365,0.00014127625,0.0007474894,0.00010308508,0.00019859047,0.000032880256,0.00025563655,0.000020403893],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.7525326,0.023468776,0.21863428,0.0000615385,0.0015884809,0.00021904029,0.0028884388,0.00024367635,0.000008343393,0.000095242256,0.0000052477762,0.000254351],"study_design_scores_gemma":[0.9405336,0.008775876,0.045202114,0.00049829116,0.0011035872,0.000006465303,0.0014684265,0.0013919879,0.0007520812,0.000005692011,0.0000076269184,0.00025424545],"about_ca_topic_score_codex":0.0007707814,"about_ca_topic_score_gemma":0.0017623719,"teacher_disagreement_score":0.18800102,"about_ca_system_score_codex":0.00025388887,"about_ca_system_score_gemma":0.00019920836,"threshold_uncertainty_score":0.9999455},"labels":[],"label_agreement":null},{"id":"W4389233604","doi":"10.1182/blood-2023-186571","title":"<i>SH2B3</i> Mutations in Patients with <i>JAK2</i>-Negative Erythrocytosis","year":2023,"lang":"en","type":"article","venue":"Blood","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Western University; London Health Sciences Centre","funders":"","keywords":"Medicine; Internal medicine; Population; Cohort; Hematology; Phlebotomy; Ruxolitinib; Gastroenterology; Myelofibrosis; Environmental health","score_opus":0.010408834904551724,"score_gpt":0.23868852320916417,"score_spread":0.22827968830461245,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4389233604","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9946776,0.000024994199,0.0000034660764,0.0007650118,0.00003512132,0.00071833964,0.00005661065,0.0001077575,0.0036110713],"genre_scores_gemma":[0.99797255,0.000039102488,0.0007976337,0.00034542402,0.000035697583,0.0003330189,0.00020328535,0.00002655409,0.00024673215],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99894804,0.000029063567,0.00019370495,0.000284736,0.00028636653,0.00025807944],"domain_scores_gemma":[0.99939084,0.00014663082,0.000053458047,0.0001918799,0.00011276649,0.000104421444],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000054854376,0.00016244949,0.0002690028,0.00017247794,0.00007736043,0.0000156351,0.000040334195,0.000051223455,0.000084748644],"category_scores_gemma":[0.00007228854,0.000118477445,0.000048250273,0.0007021228,0.000049721206,0.00007607722,0.000025963393,0.00011135498,0.00024218422],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00010196043,0.0021403898,0.99545723,0.000026295082,0.0001856229,0.00009011931,0.00061036664,0.00001441658,0.00004542217,0.00012305143,0.00065410306,0.0005510462],"study_design_scores_gemma":[0.013195214,0.0009267827,0.9722387,0.00014353322,0.00022349591,0.0000048184374,0.00014694611,0.00001175227,0.012516057,0.000110275534,0.00034495274,0.0001374528],"about_ca_topic_score_codex":0.00004511516,"about_ca_topic_score_gemma":0.000120103796,"teacher_disagreement_score":0.023218486,"about_ca_system_score_codex":0.00004476069,"about_ca_system_score_gemma":0.000074070595,"threshold_uncertainty_score":0.483137},"labels":[],"label_agreement":null},{"id":"W4389233783","doi":"10.1182/blood-2023-173441","title":"Clinical Factors but Not Somatic Mutations Predict for Survival in Patients with Myelofibrosis Undergoing Allogeneic Hematopoietic Cell Transplant: Analysis of the North American Myelofibrosis Transplant Outcome (NAMTO) Study","year":2023,"lang":"en","type":"article","venue":"Blood","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Medicine; Myelofibrosis; Internal medicine; Univariate analysis; Hazard ratio; Oncology; Hematopoietic stem cell transplantation; Proportional hazards model; Transplantation; Cumulative incidence; Graft-versus-host disease; Survival analysis; Multivariate analysis; Confidence interval; Bone marrow","score_opus":0.02903976474016231,"score_gpt":0.2890969394949203,"score_spread":0.26005717475475804,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4389233783","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9958168,0.000009880123,0.000090379195,0.00011565616,0.000077382036,0.0024760729,0.0013343127,0.00006436028,0.000015134996],"genre_scores_gemma":[0.99855477,0.000042138705,0.0002373273,0.000040652423,0.000017980783,0.0003723264,0.00065741147,0.00005010634,0.000027285858],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9968187,0.00026061837,0.0011870905,0.00058982335,0.00070136256,0.00044239845],"domain_scores_gemma":[0.99720347,0.0015945442,0.0003905686,0.0005239963,0.00011074615,0.00017667944],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00029945862,0.00038213772,0.0014061569,0.00044346548,0.00017716365,0.000021624239,0.00020118475,0.00007078463,0.00001437114],"category_scores_gemma":[0.000064966815,0.00023466637,0.0005666787,0.0018797112,0.00015644768,0.000055852957,0.000027813841,0.00017244613,0.000003842364],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00035800968,0.006259075,0.98552066,0.00025771628,0.0034994215,0.000013737656,0.003455054,0.00050807616,0.000040133124,0.0000038953863,0.000001447425,0.00008277621],"study_design_scores_gemma":[0.010059195,0.002808606,0.97083366,0.00013116293,0.0132282525,7.627662e-7,0.001301588,0.0001825862,0.0012278097,0.0000017193629,6.375625e-7,0.00022400903],"about_ca_topic_score_codex":0.00023285935,"about_ca_topic_score_gemma":0.0061892364,"teacher_disagreement_score":0.014686987,"about_ca_system_score_codex":0.000050680293,"about_ca_system_score_gemma":0.00014016985,"threshold_uncertainty_score":0.95694166},"labels":[],"label_agreement":null},{"id":"W4389235150","doi":"10.1182/blood-2023-178753","title":"Retrospective Analysis of the Relationship between Transfusion Independence and Bone Marrow Fibrosis Reduction in Patients with Myelofibrosis Treated with Pacritinib Versus Ruxolitinib","year":2023,"lang":"en","type":"article","venue":"Blood","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Myelofibrosis; Ruxolitinib; Medicine; Internal medicine; Anemia; Bone marrow; Gastroenterology; Fibrosis; Surgery","score_opus":0.02016026273135185,"score_gpt":0.2550750532538174,"score_spread":0.23491479052246556,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4389235150","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9985401,0.000025678497,0.000002350481,0.0002890516,0.0000150444,0.00071985956,0.00016752942,0.000038114908,0.0002022904],"genre_scores_gemma":[0.999377,0.000034291977,0.00015919082,0.0000052426003,0.000020181727,0.000094897085,0.00023602163,0.000019405144,0.000053762073],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99853504,0.00009889511,0.00028278417,0.00038359562,0.00049398135,0.00020569406],"domain_scores_gemma":[0.99910873,0.00023501118,0.00013052484,0.0002740814,0.00017059693,0.00008104892],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00014761118,0.00018346164,0.00047226145,0.0003841117,0.00012979258,0.000015018341,0.00004149524,0.00010839044,0.000019324225],"category_scores_gemma":[0.000120414414,0.0001127438,0.00008311919,0.002597497,0.00011593666,0.00009786776,0.000020271149,0.00018383397,0.0000015784279],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0010426755,0.00043068588,0.99669224,0.000035027504,0.0007416383,0.0000053065296,0.00058169774,0.000010539,0.00013857127,0.00009363571,0.000005581536,0.00022239446],"study_design_scores_gemma":[0.010729927,0.0017220554,0.97813594,0.0002935599,0.003696285,0.0000020856928,0.000237813,0.000008562013,0.0050363205,0.000020375017,0.0000012311549,0.000115834046],"about_ca_topic_score_codex":0.00024489695,"about_ca_topic_score_gemma":0.00026688614,"teacher_disagreement_score":0.018556295,"about_ca_system_score_codex":0.000076892684,"about_ca_system_score_gemma":0.00004819061,"threshold_uncertainty_score":0.4597559},"labels":[],"label_agreement":null},{"id":"W4389235188","doi":"10.1182/blood-2023-179924","title":"Assessment of Minimal Clinically Important Difference in Patient-Reported Myelofibrosis-Associated Symptoms Using an Anchor-Based Analysis Based on MANIFEST Arm 3 Data","year":2023,"lang":"en","type":"article","venue":"Blood","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Ruxolitinib; Medicine; Clinical endpoint; Myelofibrosis; Clinical trial; Internal medicine; Minimal clinically important difference; Phlebotomy; Surgery; Randomized controlled trial","score_opus":0.06707208395435149,"score_gpt":0.36133022280332344,"score_spread":0.29425813884897195,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4389235188","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99830544,0.000018696319,0.00006388663,0.00013174696,0.00006339972,0.0007223633,0.000470279,0.00008904833,0.00013511702],"genre_scores_gemma":[0.9936492,0.000021544594,0.0021486885,0.00024560795,0.000032472228,0.00008118941,0.0037762763,0.000036783116,0.000008235117],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99594736,0.0002576385,0.0016201156,0.00090950995,0.000827732,0.00043764483],"domain_scores_gemma":[0.99675786,0.00056727976,0.0008439213,0.0013819465,0.00020223207,0.00024673558],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00085634046,0.00034047887,0.0010523759,0.0006264577,0.00007969596,0.000033365282,0.00023215186,0.00017400757,0.000102071375],"category_scores_gemma":[0.00048497177,0.00028076014,0.000226651,0.0017488061,0.00006913052,0.00007045705,0.00009581822,0.00023552268,0.0000026568562],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000190527,0.01616751,0.9765743,0.000048641705,0.0013766353,0.0007791311,0.00005049912,0.0008167737,0.003612943,0.000010566851,0.000009343802,0.00036310198],"study_design_scores_gemma":[0.0059026657,0.0032452983,0.792143,0.00028973524,0.0028616479,0.000002957569,0.00005039481,0.19334991,0.0019513675,0.0000045645575,0.0000025687345,0.00019590053],"about_ca_topic_score_codex":0.00026683195,"about_ca_topic_score_gemma":0.00041474073,"teacher_disagreement_score":0.19253315,"about_ca_system_score_codex":0.00013377397,"about_ca_system_score_gemma":0.00061350723,"threshold_uncertainty_score":0.9999645},"labels":[],"label_agreement":null},{"id":"W4389235353","doi":"10.1182/blood-2023-178816","title":"Clinical Effectiveness and Safety of Momelotinib Compared with Continued Ruxolitinib or Best Available Therapy in Patients with Myelofibrosis Who Required RBC Transfusions: Subgroup Analysis of the Phase 3 Simplify-2 Study","year":2023,"lang":"en","type":"article","venue":"Blood","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University","funders":"","keywords":"Ruxolitinib; Medicine; Myelofibrosis; Anemia; Internal medicine; Clinical trial; Gastroenterology; Bone marrow","score_opus":0.03773473642772903,"score_gpt":0.3299724246593061,"score_spread":0.2922376882315771,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4389235353","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99589384,0.00007652185,0.000005009013,0.000052632935,0.000022021322,0.0035755907,0.0002708435,0.000024253686,0.00007929888],"genre_scores_gemma":[0.9991508,0.00028927135,0.00006935205,0.000028197292,0.00001234717,0.00028375513,0.000083973035,0.000029504476,0.000052772146],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9973965,0.0005359917,0.000798146,0.00051680737,0.0004816306,0.00027087043],"domain_scores_gemma":[0.99760675,0.0011627191,0.0002971769,0.00051787525,0.00029618028,0.00011930912],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000672217,0.0002771245,0.0015207872,0.00027290464,0.0001020642,0.000012908536,0.000113235415,0.000080770515,0.00008051201],"category_scores_gemma":[0.00011726015,0.0001401698,0.00016136674,0.0020819702,0.00022598916,0.0000647829,0.00003989504,0.00014344357,0.0000021334533],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.019037548,0.022495927,0.9507693,0.00009145224,0.0043954663,0.000021649646,0.001139904,0.000018008603,0.00023014107,0.000008902457,0.000009381878,0.0017823252],"study_design_scores_gemma":[0.08719953,0.013912961,0.89146847,0.0005466805,0.0032682868,0.0000011470934,0.0005677751,0.000057214518,0.0028191586,0.0000015599616,0.000019396117,0.00013785396],"about_ca_topic_score_codex":0.00027254532,"about_ca_topic_score_gemma":0.00073853927,"teacher_disagreement_score":0.06816198,"about_ca_system_score_codex":0.000023201768,"about_ca_system_score_gemma":0.00012167734,"threshold_uncertainty_score":0.57159585},"labels":[],"label_agreement":null},{"id":"W4389235357","doi":"10.1182/blood-2023-177774","title":"Longitudinal Assessment of Transfusion Intensity in Patients with JAK Inhibitor-Naive or -Experienced Myelofibrosis Treated with Momelotinib in the Phase 3 Simplify-1 and Momentum Trials","year":2023,"lang":"en","type":"article","venue":"Blood","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"St. Paul's Hospital; University of British Columbia","funders":"","keywords":"Medicine; Myelofibrosis; Ruxolitinib; Anemia; Internal medicine; Phases of clinical research; Clinical trial; Clinical endpoint; Gastroenterology; Bone marrow","score_opus":0.04069344640571948,"score_gpt":0.336656887551284,"score_spread":0.2959634411455645,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4389235357","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99724054,0.000019752006,0.0000071718696,0.00038306724,0.000020144449,0.0021723663,0.00005837657,0.00002482196,0.000073742114],"genre_scores_gemma":[0.9990436,0.00011312099,0.00017726632,0.00005702869,0.000021356891,0.00043231182,0.00012116123,0.00001819755,0.000015950687],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9981707,0.00015985241,0.00052149815,0.00040356608,0.00047580566,0.00026863272],"domain_scores_gemma":[0.9990638,0.00031363382,0.00016365857,0.00022491314,0.00014476487,0.000089245106],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004999056,0.00025324035,0.0008318424,0.00025429227,0.00006859087,0.000022586288,0.000059506685,0.000067818975,0.00003633458],"category_scores_gemma":[0.000080874976,0.000119697535,0.000052131494,0.0008638838,0.0001073687,0.00008948904,0.000025736572,0.00014556562,0.0000010549282],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0051398384,0.006101837,0.98357964,0.00006791957,0.00019262951,0.00014534986,0.0027894143,0.0000057548154,0.0012131379,0.000014208906,0.00003309075,0.00071720616],"study_design_scores_gemma":[0.047546845,0.0105729755,0.92019963,0.00043778852,0.0003083425,0.000011990692,0.0017167821,0.000055109354,0.019003602,0.000003649446,0.000011156638,0.00013210572],"about_ca_topic_score_codex":0.00027886935,"about_ca_topic_score_gemma":0.00028361488,"teacher_disagreement_score":0.06337996,"about_ca_system_score_codex":0.000056734287,"about_ca_system_score_gemma":0.000106878404,"threshold_uncertainty_score":0.4881124},"labels":[],"label_agreement":null},{"id":"W4389243157","doi":"10.1182/blood-2023-180776","title":"Development of a Combined Risk Assessment Model for Venous Thromboembolism and Bleeding in Hematopoietic Stem Cell Transplantation Patients","year":2023,"lang":"en","type":"article","venue":"Blood","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Western University","funders":"","keywords":"Medicine; Thrombosis; Pulmonary embolism; Population; Surgery; Retrospective cohort study; Transplantation; Venous thrombosis; Internal medicine; Hematopoietic stem cell transplantation; Deep vein","score_opus":0.022859686077006256,"score_gpt":0.27490560665943853,"score_spread":0.25204592058243225,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4389243157","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9981977,0.00004125623,0.00048415424,0.000042879765,0.000028931243,0.0009697713,0.000046306774,0.000024505096,0.00016453932],"genre_scores_gemma":[0.9926215,0.00024054895,0.00665223,0.000016282705,0.0000064775236,0.0003185816,0.00010879386,0.000016289952,0.000019293628],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99913186,0.000016024505,0.00031052515,0.00019567771,0.00017966842,0.00016622215],"domain_scores_gemma":[0.99962175,0.0000847969,0.000097542514,0.00007582657,0.0000630188,0.00005708057],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00014912292,0.000118775104,0.0003366277,0.000114795184,0.0000656337,0.0000079172305,0.000025394309,0.00004880744,0.000002373942],"category_scores_gemma":[0.0000042152637,0.000101687314,0.000034734003,0.000118483316,0.000012319223,0.00003593448,0.00001309068,0.00005671313,0.000001739745],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00026081022,0.010004527,0.9355742,0.0025816816,0.00041924944,0.000028728484,0.03851131,0.00037043402,0.004259396,0.00065028976,0.000036810274,0.007302569],"study_design_scores_gemma":[0.01995853,0.0008426193,0.9120767,0.00040018058,0.00056789507,0.0000032768369,0.00056821894,0.014803082,0.05038094,0.00022744945,0.0000065811837,0.00016449104],"about_ca_topic_score_codex":0.00000560983,"about_ca_topic_score_gemma":0.00001736067,"teacher_disagreement_score":0.046121545,"about_ca_system_score_codex":0.000035636338,"about_ca_system_score_gemma":0.00009949256,"threshold_uncertainty_score":0.41466883},"labels":[],"label_agreement":null},{"id":"W4389243191","doi":"10.1182/blood-2023-188259","title":"<i>Perioperative Outcomes and Management in Patients with Myeloproliferative Neoplasms: A Multicentric Retrospective Analysis of 354 Surgical Interventions</i>","year":2023,"lang":"en","type":"article","venue":"Blood","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Centre Hospitalier de l’Université de Montréal; McGill University; Jewish General Hospital; Concordia University; St Mary's Hospital Centre; Université de Montréal","funders":"","keywords":"Medicine; Essential thrombocythemia; Perioperative; Myelofibrosis; Population; Polycythemia vera; Surgery; Thrombosis; Myeloproliferative neoplasm; Venous thrombosis; Internal medicine","score_opus":0.011499135810078186,"score_gpt":0.27667086762581344,"score_spread":0.2651717318157353,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4389243191","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9972922,0.00013774284,0.0000079387755,0.00023135866,0.000025910163,0.0014084654,0.000098113545,0.00004389896,0.0007543709],"genre_scores_gemma":[0.9979641,0.00045192553,0.00068222167,0.000053982363,0.0000089618125,0.0003372317,0.00018571406,0.00001910918,0.00029674172],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99822325,0.00009667741,0.00048272507,0.00049242756,0.0004224502,0.0002824958],"domain_scores_gemma":[0.99913174,0.0001448463,0.00014405345,0.00024194608,0.00021692697,0.00012049069],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001675699,0.00026377922,0.0009008031,0.0009212861,0.000074770775,0.000025874393,0.00005479425,0.000064337924,0.00007577078],"category_scores_gemma":[0.000056729757,0.00017998532,0.00021858476,0.002296809,0.000100348494,0.000094779694,0.00008585121,0.0001330079,0.000011428545],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000341428,0.0032547617,0.9860798,0.000110914494,0.0072792284,0.00025438034,0.0011287495,0.000044594115,0.0000023483112,0.0011347544,0.000013518902,0.00035552555],"study_design_scores_gemma":[0.018471127,0.0010351854,0.97509784,0.0002057218,0.004006134,0.0000030112485,0.00037970967,0.00023611884,0.00036945855,0.000008927,0.000025245274,0.00016154174],"about_ca_topic_score_codex":0.00003819793,"about_ca_topic_score_gemma":0.00020330389,"teacher_disagreement_score":0.018129699,"about_ca_system_score_codex":0.000087555825,"about_ca_system_score_gemma":0.000028741764,"threshold_uncertainty_score":0.73395884},"labels":[],"label_agreement":null},{"id":"W4389243927","doi":"10.1182/blood-2023-190446","title":"British Columbia Experience in Allogeneic Stem Cell Transplantation for Myelofibrosis with or without Pre-Transplant Ruxolitinib","year":2023,"lang":"en","type":"article","venue":"Blood","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of British Columbia","funders":"","keywords":"Medicine; Transplantation; Myelofibrosis; Internal medicine; Cohort; Ruxolitinib; Log-rank test; Retrospective cohort study; Survival analysis; Pediatrics; Surgery; Bone marrow","score_opus":0.02448102470018347,"score_gpt":0.27531596360934785,"score_spread":0.25083493890916436,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4389243927","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99726945,0.00010460577,0.00008981058,0.00006966967,0.000060230912,0.0017765184,0.00020723087,0.000120117424,0.00030235405],"genre_scores_gemma":[0.9920627,0.0008241628,0.0010762344,0.000116708354,0.000053385444,0.002239466,0.0002834944,0.000041880652,0.003301994],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9985848,0.00003516151,0.0003000407,0.00044385312,0.00025120255,0.00038495913],"domain_scores_gemma":[0.9994097,0.00015714015,0.000062811065,0.00017080484,0.0000630107,0.00013657357],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00009709852,0.00016071617,0.0003865156,0.000061881685,0.00009117513,0.000086014275,0.00006889752,0.00008811486,0.00015165955],"category_scores_gemma":[0.0000053471795,0.0001606941,0.00006677084,0.00030011687,0.000046965626,0.00008116922,0.000006330161,0.0000754226,0.000009760075],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0007387006,0.0009524121,0.98793495,0.00050615537,0.00008888481,0.0006682621,0.0039331056,0.000013043749,0.0029425297,0.0000037633458,0.00029118505,0.001926984],"study_design_scores_gemma":[0.013678608,0.0020467062,0.92546135,0.001034132,0.0004351325,0.00045665598,0.00063533697,0.00013082898,0.055386707,0.0000063637967,0.00045537588,0.0002728187],"about_ca_topic_score_codex":0.0020434281,"about_ca_topic_score_gemma":0.034756936,"teacher_disagreement_score":0.062473644,"about_ca_system_score_codex":0.000029864657,"about_ca_system_score_gemma":0.00012922115,"threshold_uncertainty_score":0.9828562},"labels":[],"label_agreement":null},{"id":"W4389246822","doi":"10.1182/blood-2023-178584","title":"Consensus-Based Best Practice Recommendations for Myelofibrosis Management in Routine Clinical Practice with a Focus on Patients with Cytopenias: Systematic Literature Review and Clinical Practice Recommendations from a Global Consensus Group","year":2023,"lang":"en","type":"article","venue":"Blood","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Medicine; Myelofibrosis; Ruxolitinib; Myeloproliferative neoplasm; Clinical trial; Intensive care medicine; Clinical Practice; Family medicine; Internal medicine; Bone marrow","score_opus":0.039101100771556596,"score_gpt":0.3866391842533437,"score_spread":0.3475380834817871,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4389246822","genre_codex":"commentary","genre_gemma":"methods","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.12166423,0.019406691,0.00053857703,0.7940549,0.00083558704,0.04809738,0.005340652,0.0005279922,0.009533969],"genre_scores_gemma":[0.19718748,0.05733851,0.6815506,0.048243757,0.0004128336,0.0083413925,0.0063986494,0.00023469653,0.00029207164],"study_design_codex":"observational","study_design_gemma":"systematic_review","domain_scores_codex":[0.9941959,0.0018594544,0.0018396993,0.001078753,0.0005826468,0.00044358536],"domain_scores_gemma":[0.9776224,0.018821351,0.00130999,0.00076421665,0.0011439411,0.00033809984],"candidate_categories":["metaresearch","metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.002642342,0.0005014488,0.001382208,0.00015685051,0.00024455637,0.00016622515,0.00012505482,0.00020834195,0.000022056518],"category_scores_gemma":[0.012532963,0.00035134255,0.0001679497,0.0011005775,0.0001213682,0.00025859228,0.00008341034,0.0005364739,0.00006359493],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.05575816,0.2021707,0.47392717,0.0665024,0.038907506,0.007857283,0.0015131406,0.00001892557,0.0000016748613,0.011864665,0.10514438,0.036333993],"study_design_scores_gemma":[0.19824345,0.057254035,0.15013191,0.3219976,0.11893418,0.001438784,0.008282429,0.000470823,0.000022772372,0.00020704906,0.14051722,0.0024997306],"about_ca_topic_score_codex":0.00009412327,"about_ca_topic_score_gemma":0.0002391613,"teacher_disagreement_score":0.74581116,"about_ca_system_score_codex":0.00016931545,"about_ca_system_score_gemma":0.00022198397,"threshold_uncertainty_score":0.99989384},"labels":[],"label_agreement":null},{"id":"W4389246877","doi":"10.1182/blood-2023-183005","title":"<i>Prospective Symptom Burden Analysis in 784 Patients with Myeloproliferative Neoplasms: High Burden Correlates with Inflammatory/Genetic Biomarkers and Reduced Survival</i>","year":2023,"lang":"en","type":"article","venue":"Blood","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Hôpital Charles-Le Moyne; Université de Sherbrooke; Cegep de Saint Jerome; Université de Montréal; Université Laval; Jewish General Hospital; MPB Technologies & Communications (Canada); Hôpital du Sacré-Cœur de Montréal; Hôpital Maisonneuve-Rosemont","funders":"","keywords":"Medicine; Internal medicine; Thrombocytosis; Myelofibrosis; Prospective cohort study; Cohort; Population; Pediatrics; Bone marrow","score_opus":0.004731582304750719,"score_gpt":0.21062074301826408,"score_spread":0.20588916071351338,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4389246877","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99676275,0.0002265304,0.0000066602233,0.0004780912,0.00005556445,0.0017326521,0.00007678045,0.00015441519,0.00050653255],"genre_scores_gemma":[0.99794155,0.00026741726,0.000540928,0.000050159528,0.00009421688,0.00053491077,0.00028155753,0.00007077184,0.00021845738],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.997241,0.00013748283,0.00048107016,0.0009298225,0.0006492083,0.00056140445],"domain_scores_gemma":[0.9983848,0.00031432812,0.0002109354,0.0004462568,0.00034910336,0.00029462893],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00017642336,0.00053062267,0.0009646406,0.00072713644,0.0001758401,0.000081265236,0.00010509165,0.00016258111,0.000064491134],"category_scores_gemma":[0.00008503891,0.0003678353,0.00009718039,0.00242363,0.00020830406,0.00013870833,0.00008018334,0.00024822546,0.00004300448],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0009501955,0.00050148106,0.98808074,0.00005981693,0.0064687487,0.00039339674,0.002386005,0.00047366446,0.00020251471,0.000104912586,0.000046033958,0.0003325095],"study_design_scores_gemma":[0.016153611,0.0017157038,0.9750581,0.00027671567,0.0032822909,0.000020885942,0.00077669456,0.00036505502,0.0018346851,0.000057623376,0.000026263706,0.00043237922],"about_ca_topic_score_codex":0.0004624259,"about_ca_topic_score_gemma":0.0007838327,"teacher_disagreement_score":0.015203415,"about_ca_system_score_codex":0.00012496789,"about_ca_system_score_gemma":0.00019887008,"threshold_uncertainty_score":0.99987733},"labels":[],"label_agreement":null},{"id":"W4389247999","doi":"10.1182/blood-2023-178772","title":"Red Blood Cell Transfusion Independence Status Is an Independent Predictor of Survival: A Post Hoc Time-Dependent Analysis of the Phase 3 Simplify-1, Simplify-2, and Momentum Trials","year":2023,"lang":"en","type":"article","venue":"Blood","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Medicine; Ruxolitinib; Myelofibrosis; Anemia; Internal medicine; Blood transfusion; Post-hoc analysis; International Prognostic Scoring System; Oncology; Bone marrow; Myelodysplastic syndromes","score_opus":0.031653870898847254,"score_gpt":0.3116797957853737,"score_spread":0.28002592488652644,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4389247999","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9940118,0.0004645542,0.000019380586,0.00049254234,0.000119118195,0.0019162423,0.0026405202,0.00007940036,0.00025643918],"genre_scores_gemma":[0.99686384,0.0019981693,0.000084958105,0.00010143589,0.00006675983,0.00014055958,0.0003443428,0.000051654974,0.00034828333],"study_design_codex":"observational","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99525505,0.0005787295,0.0013241543,0.0007991215,0.0015078298,0.0005351002],"domain_scores_gemma":[0.9969437,0.0006158049,0.00066880346,0.0009361978,0.0004221404,0.0004133568],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.001584149,0.00043749987,0.001765818,0.0006343349,0.00015232604,0.00003873852,0.00025359177,0.0002724005,0.00064372626],"category_scores_gemma":[0.00032546296,0.0002957395,0.0005564208,0.001494787,0.00013157094,0.00013201276,0.0001632474,0.00029163458,0.000009242253],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0024519057,0.017860474,0.5664171,0.00044803292,0.011070019,0.00015441242,0.005863946,0.00012233546,0.39344347,0.000050813578,0.0002121289,0.0019053564],"study_design_scores_gemma":[0.049492456,0.006877735,0.28586504,0.00022017669,0.031030847,0.000026602655,0.0013160364,0.0011937639,0.6232292,0.000100166995,0.00018304601,0.0004649206],"about_ca_topic_score_codex":0.00040711882,"about_ca_topic_score_gemma":0.00027030124,"teacher_disagreement_score":0.2805521,"about_ca_system_score_codex":0.00004681301,"about_ca_system_score_gemma":0.00031375882,"threshold_uncertainty_score":0.99994946},"labels":[],"label_agreement":null},{"id":"W4389248398","doi":"10.1182/blood-2023-189912","title":"A Phase 3b, Randomized, Open-Label, Parallel Group, Multicenter Study to Assess Efficacy, Safety, and Tolerability of Two Dosing Regimens of Ropeginterferon Alfa-2b-Njft (P1101) in Adult Patients with Polycythemia Vera","year":2023,"lang":"en","type":"article","venue":"Blood","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Tolerability; Dosing; Polycythemia vera; Internal medicine; Regimen; Clinical trial; Surgery; Adverse effect","score_opus":0.03332096510326708,"score_gpt":0.3407370386707625,"score_spread":0.3074160735674954,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4389248398","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99257654,0.00004804857,0.00006119058,0.00031598713,0.00004798827,0.0066939336,0.00006391614,0.000026007421,0.00016638504],"genre_scores_gemma":[0.9977002,0.000051436145,0.0016515868,0.000100620135,0.000019530375,0.00032378413,0.000077335055,0.000035729805,0.000039762715],"study_design_codex":"observational","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9975503,0.0003127543,0.0008322129,0.00057274714,0.00040638575,0.0003256126],"domain_scores_gemma":[0.9983105,0.00052795024,0.00026481497,0.00047416383,0.00023768074,0.0001848645],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00064559816,0.00031598232,0.0014199857,0.00018664148,0.000061715946,0.000034514596,0.00015893242,0.000047606474,0.000024719477],"category_scores_gemma":[0.00026565895,0.00021650716,0.00006349908,0.00035350292,0.00010748087,0.00012698886,0.00025999578,0.00015821434,0.0000054201455],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.21911201,0.083112374,0.68889487,0.00016102746,0.000959352,0.00008119203,0.004931361,0.000030774372,0.00061535236,0.000064361295,0.000032786615,0.0020045408],"study_design_scores_gemma":[0.8182236,0.008768729,0.16717285,0.00085431704,0.00072138134,0.0000036057813,0.00044379864,0.00028472097,0.0033061223,0.000007343571,0.000010058603,0.00020346032],"about_ca_topic_score_codex":0.00076624466,"about_ca_topic_score_gemma":0.0005904739,"teacher_disagreement_score":0.5991116,"about_ca_system_score_codex":0.00007152611,"about_ca_system_score_gemma":0.000057698315,"threshold_uncertainty_score":0.8828906},"labels":[],"label_agreement":null},{"id":"W4389259069","doi":"10.1182/blood-2023-178822","title":"Oral Decitabine/Cedazuridine Is a Tolerable and Effective Ambulatory Regimen for Patients with Advanced Myeloproliferative Neoplasms","year":2023,"lang":"en","type":"article","venue":"Blood","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Silence Therapeutics; Swedish Orphan Biovitrum; Astellas Pharma; Karyopharm Therapeutics; Galecto; Sierra Oncology; Incyte; CTI Biopharma; Gilead Sciences; MorphoSys; Celgene; GlaxoSmithKline; Constellation Pharmaceuticals; Bristol-Myers Squibb","keywords":"Medicine; Decitabine; Internal medicine; Ruxolitinib; Myelofibrosis; Oncology; Bone marrow; Gastroenterology; Febrile neutropenia; Neutropenia; Chemotherapy","score_opus":0.007458680412565143,"score_gpt":0.2499339059953076,"score_spread":0.24247522558274245,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4389259069","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99454886,0.0002810458,0.000029618694,0.0006595064,0.000075676115,0.0036652146,0.00013195965,0.00014902107,0.00045912137],"genre_scores_gemma":[0.9927156,0.00015257961,0.0032946006,0.0005575031,0.00008725428,0.0022837322,0.00020557926,0.0000659109,0.0006372712],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99830866,0.00004327731,0.0002525771,0.0006224334,0.0003170803,0.00045594922],"domain_scores_gemma":[0.9986653,0.00035850157,0.00010947008,0.00028413924,0.00034008926,0.00024249768],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00013139259,0.00035663162,0.0006077244,0.00015665298,0.00022204682,0.000037609057,0.000053045947,0.00009938062,0.000035762405],"category_scores_gemma":[0.00013717911,0.00025409757,0.00008678338,0.0003599085,0.00007870277,0.00015655461,0.00005017016,0.00013031626,0.000038900776],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0035657107,0.0031704693,0.9717473,0.00033085153,0.0018568784,0.000109018496,0.0023858263,0.000024818672,0.000663525,0.00092562195,0.004135515,0.01108447],"study_design_scores_gemma":[0.051507227,0.011487656,0.87860596,0.00043756946,0.00096062367,0.000036717996,0.00021558469,0.00028616877,0.051017996,0.00035022385,0.0045381356,0.00055611454],"about_ca_topic_score_codex":0.000009869333,"about_ca_topic_score_gemma":0.000014302907,"teacher_disagreement_score":0.09314131,"about_ca_system_score_codex":0.00006258199,"about_ca_system_score_gemma":0.000103175254,"threshold_uncertainty_score":0.9999911},"labels":[],"label_agreement":null},{"id":"W4389259347","doi":"10.1182/blood-2023-175012","title":"Assessing the Feasibility of Thromboprophylaxis with Apixaban in JAK2-Positive Myeloproliferative Neoplasm Patients: The Airport-MPN Trial","year":2023,"lang":"en","type":"article","venue":"Blood","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Centre Hospitalier Universitaire de Sherbrooke; Ottawa Hospital","funders":"","keywords":"Medicine; Apixaban; Aspirin; Essential thrombocythemia; Internal medicine; Polycythemia vera; Myeloproliferative neoplasm; Surgery; Warfarin; Thrombosis; Randomized controlled trial; Gastroenterology; Myelofibrosis; Rivaroxaban; Atrial fibrillation","score_opus":0.04039808053858123,"score_gpt":0.3288473379887396,"score_spread":0.28844925745015837,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4389259347","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.991816,0.00008805279,0.00000819493,0.0015608056,0.0001393275,0.003732902,0.000059310078,0.00005415197,0.0025412643],"genre_scores_gemma":[0.9986155,0.00004026181,0.000165433,0.000266585,0.00014332056,0.00052158127,0.00013123214,0.000032456435,0.00008364228],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99747366,0.00034255345,0.0005797505,0.00051978003,0.000685172,0.0003990616],"domain_scores_gemma":[0.9978967,0.0007502021,0.00029381932,0.00060382887,0.0003596413,0.00009585295],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00064586004,0.00032584983,0.00063552696,0.00012671103,0.0002803786,0.000075510616,0.00016868477,0.00010691415,0.00003294604],"category_scores_gemma":[0.00037601645,0.00015100488,0.00015872411,0.0009630876,0.00033360496,0.00018792352,0.00008624632,0.00038129656,0.000025666144],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0032710372,0.004443316,0.9850723,0.00005934128,0.0005618138,0.000097500175,0.0042400374,0.000017385611,0.00019382595,0.00032713756,0.00018245987,0.0015338087],"study_design_scores_gemma":[0.048634745,0.0038598287,0.93653774,0.00022850746,0.00033667887,0.000017135571,0.0014493801,0.00004282068,0.008516328,0.00016646714,0.00004003675,0.00017032876],"about_ca_topic_score_codex":0.00013569351,"about_ca_topic_score_gemma":0.00026855976,"teacher_disagreement_score":0.048534594,"about_ca_system_score_codex":0.00010248355,"about_ca_system_score_gemma":0.00036071893,"threshold_uncertainty_score":0.61578},"labels":[],"label_agreement":null},{"id":"W4389304091","doi":"10.1016/s2352-3026(23)00305-8","title":"Indication and management of allogeneic haematopoietic stem-cell transplantation in myelofibrosis: updated recommendations by the EBMT/ELN International Working Group","year":2023,"lang":"en","type":"review","venue":"The Lancet Haematology","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":96,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Myelofibrosis; International Prognostic Scoring System; Transplantation; Hematopoietic stem cell transplantation; Internal medicine; Disease; Oncology; Intensive care medicine; Bone marrow; Myelodysplastic syndromes","score_opus":0.0847614625065938,"score_gpt":0.356447509342724,"score_spread":0.2716860468361302,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4389304091","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.006188285,0.9797915,0.00014609113,0.009052019,0.00036136393,0.0032143798,0.0001817817,0.00007014314,0.0009944419],"genre_scores_gemma":[0.008038856,0.9884518,0.00022978938,0.00018652009,0.000047933958,0.0011955026,0.0016322323,0.00003875037,0.00017865737],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9979761,0.00040508824,0.0007868649,0.00037314708,0.00020949134,0.00024930554],"domain_scores_gemma":[0.9985741,0.00043936798,0.00052949565,0.0003880457,0.00003072709,0.000038294453],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00052756385,0.00028911763,0.0015307099,0.0002008641,0.00009629644,0.000024821291,0.00030016003,0.00018233551,0.000055524717],"category_scores_gemma":[0.0000053911954,0.00016554556,0.00012498282,0.00038260373,0.0001233123,0.000033919285,0.00008463143,0.00029350942,0.000050178776],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00026897067,0.0009756515,0.010506365,0.056447513,0.0036997504,0.00046620026,0.0027401487,0.000006162136,0.000009122101,0.03310112,0.015903518,0.8758755],"study_design_scores_gemma":[0.0060725203,0.00033418898,0.0076351375,0.051219057,0.008438146,0.002586988,0.0011179814,0.000086048436,0.00012702234,0.001014629,0.92060256,0.0007657199],"about_ca_topic_score_codex":0.000026099618,"about_ca_topic_score_gemma":0.00008157297,"teacher_disagreement_score":0.904699,"about_ca_system_score_codex":0.000087125736,"about_ca_system_score_gemma":0.000039981624,"threshold_uncertainty_score":0.6750752},"labels":[],"label_agreement":null},{"id":"W4389381305","doi":"10.1097/moh.0000000000000790","title":"Editorial introductions","year":2023,"lang":"en","type":"article","venue":"Current Opinion in Hematology","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Hematologist; Editorial board; Medicine; Family medicine; Medical education; Library science; Internal medicine; Disease","score_opus":0.0649312495352651,"score_gpt":0.38954418725099954,"score_spread":0.3246129377157344,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4389381305","genre_codex":"editorial","genre_gemma":"editorial","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"editorial","genre_consensus":"editorial","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.061271798,0.0026367533,0.00005681599,0.010876,0.923662,0.0008028882,0.000019159927,0.00026270264,0.00041189897],"genre_scores_gemma":[0.37905785,0.013957237,0.0004444868,0.00010937101,0.60206753,0.0024215803,0.0014971182,0.00008620196,0.0003586028],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9990112,0.000047596786,0.00026370824,0.00027870084,0.00015833255,0.00024042213],"domain_scores_gemma":[0.999481,0.00013420332,0.00004273175,0.00019201779,0.00007010867,0.000079918515],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00010999638,0.00011320533,0.00029412284,0.00025846675,0.000046862307,0.0000056461236,0.000041701027,0.00008826391,0.00015753176],"category_scores_gemma":[0.00021719282,0.00009572326,0.000060076407,0.00043416824,0.00005099265,0.000034840654,0.00004065928,0.00019907908,0.0007519569],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00004821757,0.00033770842,0.1347723,0.00015495747,0.000021717036,0.0000016406397,0.00014019686,0.0000057731722,0.000018754685,0.018975342,0.8427745,0.002748872],"study_design_scores_gemma":[0.0020803574,0.00017906286,0.045724787,0.00021904796,0.000015229995,0.00009148384,0.00006792495,0.00012705245,0.00024098683,0.001208564,0.94993293,0.00011255531],"about_ca_topic_score_codex":0.0000062813583,"about_ca_topic_score_gemma":0.0000029152704,"teacher_disagreement_score":0.32159445,"about_ca_system_score_codex":0.000056883888,"about_ca_system_score_gemma":0.00008190742,"threshold_uncertainty_score":0.9665135},"labels":[],"label_agreement":null},{"id":"W4389608524","doi":"10.1111/bjh.19257","title":"Evidence creation for myelofibrosis: Challenges and opportunities","year":2023,"lang":"en","type":"article","venue":"British Journal of Haematology","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Myelofibrosis; Medicine; Hematology; Guideline; Intensive care medicine; Internal medicine; Pathology; Bone marrow","score_opus":0.17640818437281713,"score_gpt":0.34452391725671927,"score_spread":0.16811573288390214,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4389608524","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8858301,0.095157154,0.00008283868,0.018124172,0.00015129133,0.00027098774,0.000009380749,0.000023717612,0.0003503233],"genre_scores_gemma":[0.75057364,0.2480478,0.000777442,0.0002286412,0.00010273449,0.00005032535,0.000006175448,0.000012066616,0.00020118125],"study_design_codex":"design_other","study_design_gemma":"case_report","domain_scores_codex":[0.9991796,0.00006176709,0.00034076424,0.000121630175,0.0001368547,0.00015936652],"domain_scores_gemma":[0.99884677,0.0005102048,0.00018205374,0.00006017331,0.00028622424,0.000114602524],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00036351316,0.00008418881,0.00047265904,0.00014014998,0.00007601467,0.000023646202,0.000039087747,0.00007114543,0.000028630917],"category_scores_gemma":[0.00045549966,0.00007951554,0.00008490485,0.000040155508,0.00008514689,0.00013879078,0.0000192327,0.00008029342,0.000004627568],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00071800634,0.00035775802,0.0077265226,0.0014641867,0.00070561667,0.03691658,0.0016706017,0.0000037696068,0.0003919201,0.017403113,0.025674444,0.90696746],"study_design_scores_gemma":[0.0074060024,0.006056021,0.32320824,0.013258841,0.0010082498,0.5971375,0.0048157265,0.00021742216,0.0048271613,0.008949898,0.032712825,0.00040212504],"about_ca_topic_score_codex":0.0000060803295,"about_ca_topic_score_gemma":0.000023916831,"teacher_disagreement_score":0.90656537,"about_ca_system_score_codex":0.000019637773,"about_ca_system_score_gemma":0.00009078711,"threshold_uncertainty_score":0.32425496},"labels":[],"label_agreement":null},{"id":"W4390403997","doi":"10.1080/14740338.2023.2299391","title":"A safety evaluation of ruxolitinib for the treatment of polycythemia vera","year":2023,"lang":"en","type":"article","venue":"Expert Opinion on Drug Safety","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Associazione Italiana per la Ricerca sul Cancro; Ministry of Health, British Columbia","keywords":"Ruxolitinib; Polycythemia vera; Medicine; Myelofibrosis; Myeloproliferative neoplasm; Haematopoiesis; Disease; Immunology; Thrombocytosis; Stem cell; Internal medicine; Bone marrow; Platelet","score_opus":0.07678855501728588,"score_gpt":0.3890195278381949,"score_spread":0.312230972820909,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4390403997","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.80620706,0.028673194,0.00082058215,0.11020383,0.006071401,0.025131598,0.0021768468,0.00046057324,0.020254906],"genre_scores_gemma":[0.9770863,0.019469922,0.00032160967,0.00026041004,0.00045802273,0.001252421,0.0005440897,0.00003694361,0.0005702915],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9982669,0.000121577286,0.00049416727,0.0002889305,0.0006072311,0.00022120422],"domain_scores_gemma":[0.99786067,0.0011421671,0.00017882668,0.0004621968,0.00027847564,0.00007764299],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006158293,0.00020645311,0.00043817065,0.00010494902,0.00014212172,0.0000047681533,0.00007288566,0.00006385936,0.00025675312],"category_scores_gemma":[0.00015687305,0.000121346406,0.00028139178,0.00023315451,0.00007082492,0.000030300374,0.000014938579,0.00004387946,0.000027659924],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.015276053,0.00675284,0.009993894,0.00018093023,0.0023709666,0.000005444887,0.03018537,0.0018056153,0.002592446,0.024303934,0.036580097,0.8699524],"study_design_scores_gemma":[0.027291931,0.00481704,0.12580398,0.0005882,0.00023021479,0.000009870574,0.002835911,0.014367079,0.14101118,0.0003604782,0.6823662,0.00031795359],"about_ca_topic_score_codex":0.000089878464,"about_ca_topic_score_gemma":0.000009218809,"teacher_disagreement_score":0.86963445,"about_ca_system_score_codex":0.0003248953,"about_ca_system_score_gemma":0.00021861558,"threshold_uncertainty_score":0.4948363},"labels":[],"label_agreement":null},{"id":"W4390572101","doi":"10.1182/bloodadvances.2023011735","title":"Outcomes of intensive and nonintensive blast-reduction strategies in accelerated and blast-phase MPN","year":2024,"lang":"en","type":"article","venue":"Blood Advances","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":14,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network; Health Sciences Centre; Sunnybrook Health Science Centre; Princess Margaret Cancer Centre","funders":"Astellas Pharma; Leukemia and Lymphoma Society of Canada; Celgene; Sierra Oncology; Leukemia and Lymphoma Society; Princess Margaret Cancer Foundation; Amgen; Pfizer; Bristol-Myers Squibb","keywords":"Medicine; Cytarabine; Internal medicine; Daunorubicin; Gastroenterology; Myeloid leukemia; Confidence interval; Retrospective cohort study; Odds ratio; Myeloid; Hypomethylating agent; Oncology; Leukemia; Biology","score_opus":0.02021642297003689,"score_gpt":0.3423091176300899,"score_spread":0.322092694660053,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4390572101","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98513216,0.012414473,0.000018575634,0.0013990914,0.00017039444,0.00040505303,0.000029894682,0.000037542683,0.0003927955],"genre_scores_gemma":[0.9955124,0.0035104179,0.0005458463,0.00014451853,0.000049339433,0.000055725835,0.00001848557,0.00001461488,0.00014861659],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.999098,0.000024982117,0.00026799535,0.00032685482,0.00012416167,0.000158019],"domain_scores_gemma":[0.99928653,0.00012935276,0.000058129295,0.00009160789,0.00036107228,0.000073289564],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00005294466,0.00018932935,0.00044024794,0.000177226,0.00003221203,0.000047158857,0.000021721498,0.00005186626,0.000028511224],"category_scores_gemma":[0.00014024002,0.0001330772,0.00003958623,0.0001857255,0.00017263865,0.00031010856,0.000027326336,0.00012766979,0.0000030790866],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0023302096,0.004375698,0.7127512,0.0030179126,0.004033099,0.002963474,0.01915892,0.0001898559,0.102294594,0.018338041,0.0010007533,0.12954621],"study_design_scores_gemma":[0.021952547,0.008697722,0.4984402,0.003433398,0.0017428718,0.0017569255,0.06392435,0.0014105592,0.39050806,0.0032486792,0.004051049,0.0008336547],"about_ca_topic_score_codex":0.000051214392,"about_ca_topic_score_gemma":0.00009695332,"teacher_disagreement_score":0.28821346,"about_ca_system_score_codex":0.000016631206,"about_ca_system_score_gemma":0.00007966381,"threshold_uncertainty_score":0.54267305},"labels":[],"label_agreement":null},{"id":"W4390875111","doi":"10.1038/s41408-023-00974-9","title":"Driver mutation zygosity is a critical factor in predicting clonal hematopoiesis transformation risk","year":2024,"lang":"en","type":"article","venue":"Blood Cancer Journal","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen's University","funders":"National Institute for Occupational Safety and Health; National Institute of Diabetes and Digestive and Kidney Diseases; National Heart, Lung, and Blood Institute; National Institute on Aging; National Cancer Institute; National Institutes of Health; Alexander and Margaret Stewart Trust; Vanderbilt University Medical Center; Vanderbilt University; Canadian Institutes of Health Research; Leukemia and Lymphoma Society","keywords":"Zygosity; Loss of heterozygosity; Germline mutation; Biology; Internal medicine; Uniparental disomy; Mutation; Oncology; Genetics; Medicine; Allele; Chromosome; Gene; Karyotype","score_opus":0.017966603771226337,"score_gpt":0.3262525614460847,"score_spread":0.3082859576748584,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4390875111","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9897968,0.0033824916,0.00083985314,0.0048827976,0.00030281415,0.00024371113,0.00013484238,0.000039506085,0.00037715334],"genre_scores_gemma":[0.99705887,0.0016481958,0.00046404157,0.00026891814,0.000434575,0.00006803885,0.000008053308,0.000016559834,0.000032729517],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9987074,0.00007116086,0.00038308505,0.00019570663,0.0004063047,0.00023635691],"domain_scores_gemma":[0.99942344,0.00017041889,0.000055748675,0.000065375934,0.00012091239,0.00016407756],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00019877347,0.00015076238,0.00024425276,0.00017395851,0.00016046224,0.000119134886,0.000036300655,0.00008414461,0.0010922691],"category_scores_gemma":[0.00008304726,0.0001160208,0.00014223403,0.00018769324,0.000033428227,0.0003311278,0.000007560114,0.0004979005,0.000019262741],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0001808348,0.00064150203,0.95458233,0.00046272634,0.00069297745,0.001000075,0.012996421,0.000045970268,0.0006780008,0.00072447496,0.00091533875,0.027079348],"study_design_scores_gemma":[0.0055130315,0.0008045512,0.92708033,0.002872554,0.0015855709,0.0032649937,0.0008517131,0.0066419854,0.04816784,0.0012017558,0.0016961119,0.00031956652],"about_ca_topic_score_codex":0.00012478819,"about_ca_topic_score_gemma":0.000120937664,"teacher_disagreement_score":0.047489837,"about_ca_system_score_codex":0.00022529664,"about_ca_system_score_gemma":0.0002737377,"threshold_uncertainty_score":0.9998209},"labels":[],"label_agreement":null},{"id":"W4391091559","doi":"10.1182/blood.2023023428","title":"<i>CALR</i> mutation burden in essential thrombocythemia and disease outcome","year":2024,"lang":"en","type":"article","venue":"Blood","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":12,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal; MPB Technologies & Communications (Canada); Hôpital Maisonneuve-Rosemont","funders":"Associazione Italiana per la Ricerca sul Cancro; Ministero della Salute","keywords":"Essential thrombocythemia; Myelofibrosis; Calreticulin; Mutation; Polycythemia vera; Medicine; Internal medicine; Genetics; Biology; Gene; Bone marrow","score_opus":0.01326638004264136,"score_gpt":0.2955476349621177,"score_spread":0.28228125491947637,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4391091559","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99321854,0.0022160264,0.000026044501,0.0031181606,0.00008705033,0.0003171898,0.000017424509,0.00005484718,0.0009447425],"genre_scores_gemma":[0.9988599,0.00013713673,0.00023575981,0.00019158341,0.00018235965,0.00007700197,0.000039637776,0.000014953446,0.0002616832],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9993261,0.000016999673,0.00016168195,0.00023524727,0.0001358605,0.00012412114],"domain_scores_gemma":[0.99964875,0.00006449855,0.000013671114,0.0001025572,0.000016194885,0.00015432548],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000057461435,0.00010609264,0.00017458283,0.000070310634,0.000024907813,0.000039315037,0.000017914126,0.000035637335,0.000097341595],"category_scores_gemma":[0.000057106026,0.00008026552,0.00004467602,0.00010039904,0.000028371944,0.000056356777,0.00001928391,0.00008742734,0.000050901403],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00014001556,0.0013506231,0.97281516,0.00075950456,0.0003546131,0.0059144497,0.0015098788,0.0000093554445,0.0034250293,0.0048254947,0.000773053,0.008122808],"study_design_scores_gemma":[0.011718654,0.0005184271,0.9577007,0.0009410536,0.0017584846,0.0003163803,0.00020546108,0.0016524788,0.018827634,0.0027981903,0.0031682192,0.00039430385],"about_ca_topic_score_codex":0.000036647078,"about_ca_topic_score_gemma":0.000016091384,"teacher_disagreement_score":0.015402604,"about_ca_system_score_codex":0.000024691879,"about_ca_system_score_gemma":0.00007283112,"threshold_uncertainty_score":0.32731327},"labels":[],"label_agreement":null},{"id":"W4391239214","doi":"10.1017/9781009070256.022","title":"Disorders of Blood, Coagulation, and Bone Marrow","year":2024,"lang":"en","type":"book-chapter","venue":"Cambridge University Press eBooks","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"Bone marrow; Coagulation Disorder; Coagulation; Medicine; Pathology; Internal medicine","score_opus":0.01422985777077165,"score_gpt":0.2096570525780655,"score_spread":0.19542719480729384,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4391239214","genre_codex":"other","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"other","genre_consensus":"other","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.007026369,0.0021063033,0.00001268232,0.00013014191,0.00009593888,0.0006666194,0.0003186308,0.000060512397,0.9895828],"genre_scores_gemma":[0.04887548,0.0012451087,0.000090617774,0.00003461285,0.000058820275,0.0000018065573,0.0001041842,0.00004180255,0.9495476],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","domain_scores_codex":[0.99901533,0.000011420299,0.0001967057,0.00041213006,0.00022030673,0.00014411121],"domain_scores_gemma":[0.9992381,0.00006575849,0.00013394274,0.00029225482,0.000119858785,0.0001501157],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00004408216,0.0002979981,0.00054058473,0.00019270113,0.000067460016,0.000014006293,0.00005943644,0.00023345537,0.0000146324155],"category_scores_gemma":[0.0000064748424,0.00029440306,0.0001755556,0.00000848335,0.00023924299,0.000029625107,0.00013477684,0.00023562273,0.0000070304936],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00019000424,0.00005973084,0.00050758495,0.00070319447,0.0011563554,0.0004918807,0.0000827393,7.749224e-7,0.00012678915,0.9865001,0.008873598,0.0013072846],"study_design_scores_gemma":[0.0027609237,0.0004881255,0.0010606773,0.0012005512,0.005002752,0.000099180725,0.000041141004,0.00005176063,0.0016650573,0.00011456724,0.98709434,0.00042093045],"about_ca_topic_score_codex":0.00009977609,"about_ca_topic_score_gemma":0.000010848342,"teacher_disagreement_score":0.9863855,"about_ca_system_score_codex":0.000057370216,"about_ca_system_score_gemma":0.000080556085,"threshold_uncertainty_score":0.9999508},"labels":[],"label_agreement":null},{"id":"W4391260620","doi":"10.1038/s41409-023-02194-y","title":"Correction: Upfront allogeneic transplantation versus JAK inhibitor therapy for patients with myelofibrosis: a North American collaborative study","year":2024,"lang":"en","type":"erratum","venue":"Bone Marrow Transplantation","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Public Health Ontario; University of Waterloo; Jewish General Hospital; McGill University; Princess Margaret Cancer Centre; University of Calgary; St. Paul's Hospital; Alberta Health Services; University of British Columbia; University Health Network; Dalhousie University; University of Toronto","funders":"","keywords":"Medicine; Myelofibrosis; Ruxolitinib; Transplantation; Internal medicine; Oncology; Bone marrow","score_opus":0.010594761833712281,"score_gpt":0.2600338277664049,"score_spread":0.2494390659326926,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4391260620","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9518844,0.001683072,0.00038827967,0.00058020663,0.021760782,0.015558783,0.0060204915,0.0003753539,0.0017486168],"genre_scores_gemma":[0.9096083,0.012717887,0.0010824103,0.00024581366,0.0017560789,0.008665089,0.05537802,0.00035983807,0.010186582],"study_design_codex":"not_applicable","study_design_gemma":"observational","domain_scores_codex":[0.9963125,0.00019814196,0.0007830029,0.0012298131,0.0009753303,0.0005012405],"domain_scores_gemma":[0.99789643,0.0002898427,0.00045290368,0.00036002035,0.000774799,0.00022601068],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0001415541,0.00093627704,0.0012183086,0.00045554517,0.00029779956,0.00014379746,0.00010277985,0.0002575877,0.000040169332],"category_scores_gemma":[0.00001849499,0.00072340603,0.0002460258,0.0009069967,0.00012899442,0.00019158698,0.0000063495045,0.0005723883,0.00003283703],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.18641046,0.012104868,0.3289143,0.0040854258,0.008945239,0.0010163378,0.02381471,0.0001322591,0.00011143299,0.000022319395,0.3861233,0.048319336],"study_design_scores_gemma":[0.045471698,0.05568845,0.8579552,0.0021237866,0.009493203,0.000058475267,0.0015296364,0.00012561724,0.0009746521,0.0000047291223,0.025047787,0.0015267506],"about_ca_topic_score_codex":0.00020689555,"about_ca_topic_score_gemma":0.009208601,"teacher_disagreement_score":0.5290409,"about_ca_system_score_codex":0.00044401517,"about_ca_system_score_gemma":0.00073694665,"threshold_uncertainty_score":0.9995217},"labels":[],"label_agreement":null},{"id":"W4391337917","doi":"10.1182/bloodadvances.2023011620","title":"Phase 2 study of add-on parsaclisib for patients with myelofibrosis and suboptimal response to ruxolitinib: final results","year":2024,"lang":"en","type":"article","venue":"Blood Advances","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":13,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"University of Texas MD Anderson Cancer Center; Genentech; Swedish Orphan Biovitrum; Sierra Oncology; Pfizer; Incyte; CTI Biopharma; Syndax Pharmaceuticals; Bristol-Myers Squibb; Constellation Pharmaceuticals; Agios Pharmaceuticals; Cancer Center, University of Kansas; Astex Pharmaceuticals; Daiichi Sankyo Europe; National Cancer Institute; Gilead Sciences; Servier; Memorial Sloan-Kettering Cancer Center; Jazz Pharmaceuticals; Kite Pharma; Shionogi; Amgen; Ohio State University; Karyopharm Therapeutics; MorphoSys; Celgene; AstraZeneca; Astellas Pharma; TG Therapeutics","keywords":"Ruxolitinib; Myelofibrosis; Medicine; Internal medicine; Oncology; Bone marrow","score_opus":0.022074267639499635,"score_gpt":0.33314619034157544,"score_spread":0.3110719227020758,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4391337917","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99600613,0.00062128605,0.00001131479,0.00046298857,0.00006765675,0.0020017822,0.00064260024,0.000040753213,0.00014546036],"genre_scores_gemma":[0.99614275,0.000048972433,0.0028982544,0.00008843945,0.00006661088,0.00046437368,0.000058015004,0.000024860034,0.00020773524],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.9986502,0.00005399524,0.00031445676,0.00047559635,0.00029121432,0.00021454597],"domain_scores_gemma":[0.99868464,0.00074970536,0.00006787222,0.00020449984,0.00014319435,0.00015009742],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00017386729,0.00020395967,0.0003636633,0.00014319441,0.0000737939,0.000028758472,0.0000420002,0.000031322055,0.000011286695],"category_scores_gemma":[0.00025183617,0.0001330755,0.000045505596,0.0001868332,0.000040366445,0.000102728416,0.000021232996,0.00006428321,0.0000040949753],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.4259331,0.07191643,0.3312037,0.0010322559,0.001807226,0.0004110011,0.009823308,0.00011891502,0.001390842,0.00058149814,0.002063987,0.15371773],"study_design_scores_gemma":[0.118738204,0.35419822,0.45235717,0.0022765412,0.0016057725,0.000020909403,0.0014689617,0.000070013615,0.03362882,0.0000613741,0.035036385,0.0005376356],"about_ca_topic_score_codex":0.000007119462,"about_ca_topic_score_gemma":0.000018468032,"teacher_disagreement_score":0.3071949,"about_ca_system_score_codex":0.000019347128,"about_ca_system_score_gemma":0.000056205954,"threshold_uncertainty_score":0.54266614},"labels":[],"label_agreement":null},{"id":"W4391486916","doi":"10.1016/j.jval.2024.01.014","title":"Meaningful Symptomatic Change in Patients With Myelofibrosis From the SIMPLIFY Studies","year":2024,"lang":"en","type":"article","venue":"Value in Health","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"St. Paul's Hospital; Princess Margaret Cancer Centre; University of Toronto; University of British Columbia; University Health Network","funders":"Sierra Oncology; Cancer Research UK; GlaxoSmithKline","keywords":"Myelofibrosis; Medicine; Computer science; Internal medicine","score_opus":0.07058585056676162,"score_gpt":0.3383343008064327,"score_spread":0.2677484502396711,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4391486916","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.974417,0.010510487,0.0000025233967,0.013241782,0.00019227427,0.0014863494,0.00004222048,0.000050644507,0.00005671949],"genre_scores_gemma":[0.9955951,0.0012750401,0.00039025594,0.002104321,0.00012838292,0.00042414086,0.000041473846,0.000027209202,0.000014064293],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99848557,0.00017851702,0.00037637274,0.0003321724,0.00032032246,0.00030705234],"domain_scores_gemma":[0.9987911,0.0007783472,0.00006165615,0.00023841154,0.000043019023,0.00008746725],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00031962962,0.0001858588,0.00043673525,0.00011961639,0.000069074245,0.000025892805,0.00005747878,0.000042311993,0.000031737905],"category_scores_gemma":[0.00009016597,0.0000989322,0.000038761045,0.00041432132,0.000042527397,0.000073535404,0.000036497488,0.00019830243,0.000041622614],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00007660238,0.000281922,0.9721336,0.00043538772,0.00013348162,0.000028885246,0.01446265,0.000036686095,5.24441e-7,0.0006271854,0.00043063003,0.01135244],"study_design_scores_gemma":[0.0016317972,0.0010342584,0.98894703,0.00555904,0.00004210729,0.0000016815586,0.00052157027,0.0012617043,0.000022695305,0.00032230167,0.0005580626,0.0000977258],"about_ca_topic_score_codex":0.0045918818,"about_ca_topic_score_gemma":0.00065090257,"teacher_disagreement_score":0.021178111,"about_ca_system_score_codex":0.00047440268,"about_ca_system_score_gemma":0.00014177593,"threshold_uncertainty_score":0.6941582},"labels":[],"label_agreement":null},{"id":"W4391559562","doi":"10.1038/s41375-024-02155-4","title":"Clinical Features and Long-Term Outcomes of a Pan-Canadian Cohort of Adolescents and Young Adults with Myeloproliferative Neoplasms: A Canadian MPN Group Study","year":2024,"lang":"en","type":"article","venue":"Leukemia","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":14,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"McMaster University; Royal Victoria Regional Health Centre; London Health Sciences Centre; Princess Margaret Cancer Centre; University of Calgary; McGill University; University of Ottawa; Sunnybrook Health Science Centre; Jewish General Hospital; Université de Montréal; Hôpital Maisonneuve-Rosemont; Health Sciences Centre; University Health Network; Ottawa Hospital; Western University; University of Toronto; Newfoundland and Labrador Centre for Applied Health Research","funders":"Princess Margaret Cancer Foundation","keywords":"Medicine; Essential thrombocythemia; Myelofibrosis; Polycythemia vera; Internal medicine; Cohort; Population; Myeloproliferative neoplasm; Myeloid leukemia; Pediatrics; Bone marrow","score_opus":0.013928911740136649,"score_gpt":0.2933344691302155,"score_spread":0.27940555739007883,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4391559562","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9948847,0.0016685107,0.000002304486,0.00027038375,0.00016372549,0.0024689115,0.00013492144,0.000023855217,0.00038266252],"genre_scores_gemma":[0.9984249,0.0005311423,0.00016619463,0.0002874193,0.00006923082,0.00020901537,0.000053340544,0.00003933913,0.00021945674],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9980181,0.00010242873,0.0005342238,0.0006197254,0.00033423485,0.00039130694],"domain_scores_gemma":[0.9985515,0.00014507367,0.000100398014,0.0003022831,0.00015459114,0.0007461434],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00026265456,0.00034714938,0.0008972548,0.00034305226,0.000100253346,0.000054044867,0.000078251665,0.00017601102,0.000029356626],"category_scores_gemma":[0.00008858519,0.00023699632,0.000089834204,0.00023622859,0.00023468111,0.00010056555,0.000035895886,0.00036198934,0.0000045614483],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00036130854,0.00023432855,0.98598486,0.00038151088,0.0011837113,0.0009332488,0.0026717256,3.3084083e-7,0.0000057745538,0.00015788079,0.0002171489,0.007868173],"study_design_scores_gemma":[0.0039090435,0.0021971343,0.99058867,0.0014607247,0.0006434354,0.00020187418,0.00062396884,0.000043068972,0.00007507338,0.000008689938,0.000043978074,0.00020432836],"about_ca_topic_score_codex":0.36761352,"about_ca_topic_score_gemma":0.9451145,"teacher_disagreement_score":0.57750094,"about_ca_system_score_codex":0.00044320305,"about_ca_system_score_gemma":0.0014807655,"threshold_uncertainty_score":0.96644294},"labels":[],"label_agreement":null},{"id":"W4391611819","doi":"10.1002/jha2.854","title":"Changes in bone marrow fibrosis during momelotinib or ruxolitinib therapy do not correlate with efficacy outcomes in patients with myelofibrosis","year":2024,"lang":"en","type":"article","venue":"eJHaem","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":20,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"Sierra Oncology; Cancer Research UK","keywords":"Myelofibrosis; Ruxolitinib; Medicine; Bone marrow; Internal medicine; Fibrosis; Oncology","score_opus":0.016644996279522664,"score_gpt":0.2625453157424232,"score_spread":0.24590031946290053,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4391611819","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.994898,0.00046219543,0.0000014924889,0.0024586427,0.00013122888,0.0015625709,0.00006838802,0.0001308878,0.00028659607],"genre_scores_gemma":[0.99675435,0.00034108025,0.00049815315,0.0002854738,0.00006700549,0.00046744326,0.00007159887,0.00009509302,0.0014197933],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99777937,0.00006926875,0.0003952084,0.00067842007,0.00051802496,0.0005597268],"domain_scores_gemma":[0.99898994,0.00031614045,0.00008683571,0.00036305882,0.00007030256,0.00017371892],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00013447246,0.00045842334,0.00080572773,0.00044530001,0.00007546242,0.00009188982,0.00008513934,0.00012262113,0.0004137755],"category_scores_gemma":[0.000043213106,0.0002562387,0.00008186243,0.0006778715,0.00007884725,0.00014438835,0.000044546792,0.00032342924,0.00006969717],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0056469766,0.0012455562,0.97727203,0.00019134447,0.00025169816,0.00059936225,0.002475701,0.00002323937,0.0001669539,0.0000653166,0.000067458386,0.011994362],"study_design_scores_gemma":[0.014393417,0.0027874867,0.9733511,0.0020294888,0.00007045909,0.000022081684,0.00015826448,0.0000271636,0.0062324596,0.000004014374,0.00059369043,0.0003303517],"about_ca_topic_score_codex":0.00011738857,"about_ca_topic_score_gemma":0.0006420111,"teacher_disagreement_score":0.01166401,"about_ca_system_score_codex":0.00023544458,"about_ca_system_score_gemma":0.000103599414,"threshold_uncertainty_score":0.999989},"labels":[],"label_agreement":null},{"id":"W4391743666","doi":"10.1155/2024/3056216","title":"An Approach to the Investigation of Thrombocytosis: Differentiating between Essential Thrombocythemia and Secondary Thrombocytosis","year":2024,"lang":"en","type":"article","venue":"Advances in Hematology","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":13,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"London Health Sciences Centre","funders":"","keywords":"Thrombocytosis; Essential thrombocythemia; Medicine; Plateletpheresis; Platelet; Dermatology; Internal medicine","score_opus":0.018613721041102253,"score_gpt":0.3184044533163339,"score_spread":0.2997907322752316,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4391743666","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9879736,0.0077799684,0.0013789911,0.0009914243,0.0001524931,0.0006563771,0.000027356113,0.00005698523,0.0009828564],"genre_scores_gemma":[0.9941489,0.000728355,0.0044833114,0.00018402969,0.000116257404,0.00023075819,0.00007609168,0.000026839007,0.0000054628617],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99840933,0.00013789455,0.00047668177,0.0005151473,0.00019610203,0.0002648636],"domain_scores_gemma":[0.99900943,0.0004247582,0.000091087124,0.00031187187,0.00004763273,0.00011523766],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002177802,0.0002273319,0.0007114378,0.00016981103,0.00008915389,0.000030980027,0.000117915944,0.00012085468,0.00003535173],"category_scores_gemma":[0.00005360608,0.00014961325,0.0000643827,0.0003460641,0.00022766003,0.0002810718,0.00007253001,0.00026335436,0.0000067617],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000052188443,0.0002223098,0.94272995,0.0012761615,0.00027656773,0.000019245423,0.005709767,0.000047399695,0.0037936657,0.033318777,0.00009107665,0.012462915],"study_design_scores_gemma":[0.0017484799,0.0009919764,0.77501994,0.0012743318,0.0005670936,0.00030397996,0.0020170293,0.002005758,0.20573324,0.009379587,0.0005354432,0.00042314752],"about_ca_topic_score_codex":0.000031768683,"about_ca_topic_score_gemma":0.00006451673,"teacher_disagreement_score":0.20193958,"about_ca_system_score_codex":0.000053276784,"about_ca_system_score_gemma":0.00008994208,"threshold_uncertainty_score":0.6101051},"labels":[],"label_agreement":null},{"id":"W4392071562","doi":"10.1016/j.jdmv.2023.12.027","title":"Infarctus surrénaliens bilatéraux asynchrones menant au diagnostic d’une thrombocytose essentielle avec mutation JAK2 positive","year":2024,"lang":"fr","type":"article","venue":"JMV-Journal de Médecine Vasculaire","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Sherbrooke","funders":"","keywords":"Gynecology; Medicine","score_opus":0.010978758096148664,"score_gpt":0.28216899288186137,"score_spread":0.2711902347857127,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4392071562","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.780594,0.14440149,0.0033512907,0.05500388,0.010996107,0.0017833165,0.00028277622,0.00017135011,0.0034157985],"genre_scores_gemma":[0.95185304,0.03282528,0.0008145172,0.0005752536,0.0063145543,0.00018031045,0.00022576582,0.00021305063,0.006998219],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9934027,0.0006482088,0.0014757186,0.001133303,0.0014839509,0.0018560898],"domain_scores_gemma":[0.9941088,0.0025027797,0.00050680997,0.00086848065,0.000697044,0.0013161027],"candidate_categories":["metaepi_narrow","sts","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.0015685636,0.0011325079,0.0016198221,0.0006854143,0.0015342307,0.0009669529,0.00039246175,0.00053932663,0.0021935178],"category_scores_gemma":[0.0014945696,0.0008880818,0.0012987033,0.0009338156,0.0005730144,0.00090513687,0.00020797539,0.0015673798,0.001250294],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0007054288,0.008581635,0.25741503,0.0038742593,0.019482428,0.14210406,0.030592993,0.004530298,0.002155095,0.013998562,0.047215052,0.46934518],"study_design_scores_gemma":[0.012477667,0.004283808,0.8151487,0.025387563,0.009000337,0.038450766,0.002374903,0.012693486,0.011651343,0.006031939,0.060819253,0.0016801928],"about_ca_topic_score_codex":0.0013492765,"about_ca_topic_score_gemma":0.00069601845,"teacher_disagreement_score":0.5577337,"about_ca_system_score_codex":0.0035252303,"about_ca_system_score_gemma":0.0032937734,"threshold_uncertainty_score":0.99976563},"labels":[],"label_agreement":null},{"id":"W4392108373","doi":"10.15173/m.v1i35.2205","title":"Pacritinib: A novel therapeutic agent for treating myelofibrosis","year":2019,"lang":"en","type":"article","venue":"The Meducator","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Myelofibrosis; Medicine; Internal medicine","score_opus":0.03333689565152862,"score_gpt":0.31487950305037277,"score_spread":0.2815426073988441,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4392108373","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9815262,0.0008276592,0.00013970505,0.011999501,0.00043033998,0.0019470216,0.00003602709,0.00005357744,0.0030399852],"genre_scores_gemma":[0.9896664,0.00005620846,0.002036819,0.0030072236,0.00032683904,0.0008469121,0.00002946004,0.00004303791,0.003987105],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99895436,0.00003037074,0.00021687846,0.0002821538,0.00019994522,0.0003163082],"domain_scores_gemma":[0.99883896,0.0004891875,0.0000734066,0.0004122448,0.00008218336,0.000104024075],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00021160442,0.00019576054,0.0003246072,0.00004647623,0.00013966323,0.000031720094,0.00009631455,0.000050447477,0.0004717151],"category_scores_gemma":[0.00007382938,0.00010930065,0.00018971498,0.00011547647,0.00004348159,0.000035136458,0.000022881139,0.00009289717,0.00025608632],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0021268982,0.007663167,0.52394927,0.0013020525,0.0033099162,0.000012278048,0.02345752,0.000015143628,0.2448736,0.037690815,0.019489434,0.13610992],"study_design_scores_gemma":[0.017811446,0.005224616,0.44072002,0.0010927919,0.0021418014,0.00025867924,0.011136593,0.0008989382,0.2653067,0.0010535001,0.25330722,0.0010476696],"about_ca_topic_score_codex":0.000035590034,"about_ca_topic_score_gemma":0.0000059260005,"teacher_disagreement_score":0.23381779,"about_ca_system_score_codex":0.00010922893,"about_ca_system_score_gemma":0.0001729883,"threshold_uncertainty_score":0.5164949},"labels":[],"label_agreement":null},{"id":"W4392560887","doi":"10.1038/s41591-024-02854-6","title":"Clonal hematopoiesis of indeterminate potential is associated with acute kidney injury","year":2024,"lang":"en","type":"article","venue":"Nature Medicine","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":75,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"St. Joseph’s Healthcare Hamilton; McMaster University; Population Health Research Institute; Impact; Queen's University","funders":"CIHR Skin Research Training Centre; National Institute of Environmental Health Sciences; National Institute of Diabetes and Digestive and Kidney Diseases; National Human Genome Research Institute; National Heart, Lung, and Blood Institute; Gillings School of Public Health; National Institute on Aging; Government of Canada; Deutsche Forschungsgemeinschaft; National Institute on Minority Health and Health Disparities; Physicians' Services Incorporated Foundation; National Institutes of Health; U.S. Department of Health and Human Services; Broad Institute; Canadian Institutes of Health Research; U.S. Department of Veterans Affairs","keywords":"Acute kidney injury; Medicine; Mendelian randomization; Proinflammatory cytokine; Dialysis; Kidney disease; Population; Internal medicine; Oncology; Biology; Inflammation; Gene; Genetics; Genotype","score_opus":0.005648820251525019,"score_gpt":0.29042096260989336,"score_spread":0.28477214235836834,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4392560887","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.95739824,0.0029121095,0.00006946457,0.033356313,0.0008009423,0.00066949124,0.0004556559,0.00015385423,0.0041839196],"genre_scores_gemma":[0.9918199,0.00031091337,0.0002562711,0.004741431,0.0003891428,0.000046061225,0.0003397666,0.000043615757,0.0020528897],"study_design_codex":"not_applicable","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9980236,0.000043798223,0.00037913263,0.0004256294,0.00084370445,0.00028409535],"domain_scores_gemma":[0.9989145,0.000117297845,0.000115803494,0.00027360226,0.00028688158,0.00029195985],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00023609905,0.00030772598,0.00075040647,0.0002916901,0.000058010028,0.000012964372,0.00009115195,0.00039062576,0.0012071092],"category_scores_gemma":[0.0002509462,0.0001756904,0.00013109489,0.0005762731,0.00022087534,0.000073460644,0.000036132507,0.00078368944,0.00001929028],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.004616463,0.0023208663,0.06387018,0.0023257197,0.01862099,0.022647446,0.0057480233,8.9765945e-7,0.059772372,0.0070728813,0.7899942,0.023009982],"study_design_scores_gemma":[0.025007784,0.020077163,0.20706262,0.028779708,0.016623717,0.0047528045,0.0003774622,0.0015113985,0.6021064,0.002278868,0.089917734,0.0015043692],"about_ca_topic_score_codex":0.000019682846,"about_ca_topic_score_gemma":0.000003594594,"teacher_disagreement_score":0.70007646,"about_ca_system_score_codex":0.0001216715,"about_ca_system_score_gemma":0.00032668427,"threshold_uncertainty_score":0.9997059},"labels":[],"label_agreement":null},{"id":"W4392954109","doi":"10.1080/10428194.2024.2328800","title":"Momelotinib vs. ruxolitinib in myelofibrosis patient subgroups by baseline hemoglobin levels in the SIMPLIFY-1 trial","year":2024,"lang":"en","type":"article","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":15,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"GlaxoSmithKline","keywords":"Ruxolitinib; Myelofibrosis; Anemia; Post-hoc analysis; Medicine; Janus kinase; Internal medicine; Hemoglobin; Randomized controlled trial; Janus kinase 2; Clinical trial; Gastroenterology; Receptor; Bone marrow","score_opus":0.01462902550181141,"score_gpt":0.2639739017926614,"score_spread":0.24934487629084998,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4392954109","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9852715,0.00565842,0.000034798635,0.00246053,0.0005814413,0.0026495743,0.00039832518,0.00020565673,0.002739713],"genre_scores_gemma":[0.9911192,0.0012172803,0.00024209454,0.004470911,0.0004985373,0.0012968072,0.00047508083,0.00013389894,0.0005461816],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99395365,0.0005539847,0.0016025751,0.0015491545,0.0010394392,0.001301178],"domain_scores_gemma":[0.99677855,0.0015877285,0.00020532846,0.00086433254,0.000104896295,0.00045915783],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0011686056,0.0009957291,0.0013782027,0.00056812016,0.00024941744,0.00036548945,0.00036522964,0.00056375825,0.00022031706],"category_scores_gemma":[0.0002979469,0.00071083504,0.00039136427,0.0013981553,0.0002790781,0.00034998867,0.00017883163,0.00034655028,0.00014024686],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.040267143,0.005265865,0.061728626,0.0018046604,0.0009357252,0.00832267,0.016538573,0.00012601732,0.004178064,0.009392359,0.09127273,0.7601676],"study_design_scores_gemma":[0.32531413,0.008071561,0.3401714,0.0037059898,0.00090977695,0.0031315305,0.004126104,0.01745508,0.026210418,0.0016631957,0.26617387,0.0030669163],"about_ca_topic_score_codex":0.0026576198,"about_ca_topic_score_gemma":0.00033333892,"teacher_disagreement_score":0.75710064,"about_ca_system_score_codex":0.0066837603,"about_ca_system_score_gemma":0.0026987689,"threshold_uncertainty_score":0.99953425},"labels":[],"label_agreement":null},{"id":"W4394564034","doi":"10.1016/s2352-3026(24)00067-x","title":"Methodological challenges in the development of endpoints for myelofibrosis clinical trials","year":2024,"lang":"en","type":"article","venue":"The Lancet Haematology","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal","funders":"","keywords":"Myelofibrosis; Ruxolitinib; Medicine; Myeloproliferative neoplasm; Clinical trial; Myeloid; Oncology; Clinical endpoint; Janus kinase 2; Surrogate endpoint; Internal medicine; Myeloid leukemia; Bone marrow","score_opus":0.8278153183857964,"score_gpt":0.584567789265612,"score_spread":0.24324752912018432,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4394564034","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.85458,0.018015547,0.0024938623,0.11858418,0.0006745292,0.0027470044,0.00003071339,0.00007260161,0.0028016018],"genre_scores_gemma":[0.9659759,0.0033973702,0.028212465,0.00095787994,0.00038979185,0.0009931412,0.000017008393,0.000014858565,0.00004162912],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99554497,0.0026710865,0.0010486464,0.00030997497,0.00015640829,0.0002689009],"domain_scores_gemma":[0.97722554,0.02220941,0.00014548612,0.00033906027,0.00004336479,0.000037121543],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.016333688,0.0001518566,0.0019026793,0.0000631004,0.00005064748,0.000010973878,0.00019308008,0.000158062,0.00006762013],"category_scores_gemma":[0.003661953,0.00006113868,0.00024756457,0.0001076199,0.00015085281,0.000016989341,0.000048390608,0.00023702194,0.00002711667],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.004248204,0.0017614926,0.041262645,0.003117128,0.0019801953,0.00044920732,0.02338117,0.0000032018859,0.00062856916,0.42488518,0.015956908,0.4823261],"study_design_scores_gemma":[0.019314462,0.00478648,0.4936278,0.002700109,0.0023004925,0.002868936,0.0072394703,0.0006926561,0.045520052,0.10138297,0.31876037,0.0008062171],"about_ca_topic_score_codex":0.0000018696007,"about_ca_topic_score_gemma":0.000056004563,"teacher_disagreement_score":0.48151988,"about_ca_system_score_codex":0.000025022979,"about_ca_system_score_gemma":0.000141481,"threshold_uncertainty_score":0.56609625},"labels":[],"label_agreement":null},{"id":"W4394620901","doi":"10.14740/jh1245","title":"Effective Management of Polycythemia Vera With Ropeginterferon Alfa-2b Treatment","year":2024,"lang":"en","type":"article","venue":"Journal of Hematology","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":22,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Medicine; Polycythemia vera; Internal medicine; Gastroenterology; Myelofibrosis; Clinical endpoint; Surgery; Clinical trial; Bone marrow","score_opus":0.00964026921246559,"score_gpt":0.2894893436079517,"score_spread":0.2798490743954861,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4394620901","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9848291,0.007438452,0.0005399454,0.0029302302,0.00027849255,0.00052501395,0.0000049570335,0.000015970789,0.0034378301],"genre_scores_gemma":[0.99670935,0.00083177094,0.0018078864,0.00005887055,0.00007435129,0.000040318675,0.0000028457766,0.000020923668,0.00045368695],"study_design_codex":"design_other","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99902606,0.00004879683,0.00038514397,0.00016710686,0.00020084344,0.00017203162],"domain_scores_gemma":[0.9993312,0.00014827392,0.0001675626,0.000150965,0.00010066144,0.00010135932],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001007423,0.00018550496,0.00067353004,0.00018990732,0.000022880744,0.000011148707,0.000051224208,0.000056830067,0.00014499531],"category_scores_gemma":[0.000005551045,0.00009995846,0.00018087815,0.0001200878,0.000064810585,0.00005522744,0.000018293691,0.00013116973,0.000026665128],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.027795538,0.013180141,0.2686764,0.00790175,0.06469559,0.13115354,0.008928827,0.00017544451,0.0069477223,0.116597734,0.019163368,0.33478394],"study_design_scores_gemma":[0.029287493,0.08165832,0.07003382,0.0149052655,0.009144752,0.07972346,0.0019076295,0.0003453346,0.6610142,0.0013891198,0.04990679,0.00068380224],"about_ca_topic_score_codex":0.00000879689,"about_ca_topic_score_gemma":0.0000055330042,"teacher_disagreement_score":0.6540665,"about_ca_system_score_codex":0.00025446052,"about_ca_system_score_gemma":0.00008765885,"threshold_uncertainty_score":0.40761876},"labels":[],"label_agreement":null},{"id":"W4394770687","doi":"10.1182/bloodadvances.2023011510","title":"Clonal hematopoiesis and inflammation in the vasculature: CHIVE, a prospective, longitudinal clonal hematopoiesis cohort and biorepository","year":2024,"lang":"en","type":"article","venue":"Blood Advances","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":12,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen's University","funders":"National Heart, Lung, and Blood Institute","keywords":"Biorepository; Medicine; Malignancy; Internal medicine; Prospective cohort study; Disease; Hematologic malignancy; Cohort; Oncology; Bioinformatics; Biobank; Biology","score_opus":0.005859118181534548,"score_gpt":0.25333109554222416,"score_spread":0.2474719773606896,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4394770687","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96044415,0.03550765,0.000022080438,0.001687118,0.000099507546,0.0008744086,0.000019411389,0.000054753353,0.0012909444],"genre_scores_gemma":[0.9958714,0.0022252467,0.0010468272,0.00008368321,0.0002473171,0.000415669,0.000022917015,0.000016830036,0.000070074864],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9986227,0.000058210975,0.00027791137,0.00047642886,0.0003591025,0.00020564275],"domain_scores_gemma":[0.99936694,0.00028396677,0.000054220614,0.0001668347,0.000052626332,0.00007539389],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002158335,0.00023756284,0.00035483658,0.00012946152,0.00015426177,0.00013033865,0.000050616654,0.000072487695,0.00002225668],"category_scores_gemma":[0.000055367407,0.00014619378,0.0000800511,0.00024837963,0.00017424938,0.00029535565,0.000039303286,0.00020277713,0.000003838751],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000084661275,0.00024342317,0.98361444,0.0004901169,0.00041432658,0.00039544274,0.0009344122,0.0000027103238,0.0006199551,0.011412571,0.00010002103,0.0016878961],"study_design_scores_gemma":[0.0011921042,0.0002551576,0.9810833,0.00048257632,0.00049432804,0.00124622,0.00021583351,0.000075904405,0.010874349,0.0017504294,0.0021597554,0.00017003961],"about_ca_topic_score_codex":0.000021265214,"about_ca_topic_score_gemma":0.000100025325,"teacher_disagreement_score":0.03542731,"about_ca_system_score_codex":0.00003322356,"about_ca_system_score_gemma":0.000060216455,"threshold_uncertainty_score":0.59616095},"labels":[],"label_agreement":null},{"id":"W4394853841","doi":"10.1080/14656566.2024.2343780","title":"Momelotinib in myelofibrosis","year":2024,"lang":"en","type":"article","venue":"Expert Opinion on Pharmacotherapy","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Ministry of Health, British Columbia","keywords":"Ruxolitinib; Medicine; Myelofibrosis; Discontinuation; Anemia; Janus kinase; Bone marrow; Constitutional symptoms; Disease; Internal medicine; Immunology; Receptor","score_opus":0.041051992191448325,"score_gpt":0.4061195072751803,"score_spread":0.365067515083732,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4394853841","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.68533576,0.15151617,0.00035423346,0.10568771,0.010190661,0.004450312,0.00009988012,0.0015464772,0.040818818],"genre_scores_gemma":[0.9208278,0.063757814,0.0008063955,0.011324654,0.0011850205,0.00070154574,0.00006501399,0.00010092886,0.0012308244],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9986532,0.000058584894,0.00027357778,0.00045096505,0.0002889285,0.0002747762],"domain_scores_gemma":[0.99947387,0.00013880509,0.000023037666,0.00018942094,0.000025990425,0.0001488995],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00011923512,0.00024544608,0.00029581942,0.0002903279,0.000046215035,0.000051457984,0.000063987565,0.000072438146,0.0023955612],"category_scores_gemma":[0.000007818309,0.00018239256,0.0001402457,0.00033946644,0.00003150963,0.00009347235,0.00001019096,0.00019876745,0.00043762362],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0022023728,0.0033854125,0.018155346,0.00016810103,0.00067699834,0.00045731233,0.006737067,0.0000380154,0.13944292,0.012141386,0.2003996,0.61619544],"study_design_scores_gemma":[0.003326031,0.000718132,0.0054430487,0.0005354567,0.000003489927,0.000028464041,0.00005444682,0.0010351572,0.17092232,0.00008605212,0.81764144,0.00020597788],"about_ca_topic_score_codex":0.000035870235,"about_ca_topic_score_gemma":0.0000014796396,"teacher_disagreement_score":0.6172418,"about_ca_system_score_codex":0.0001749068,"about_ca_system_score_gemma":0.000085146836,"threshold_uncertainty_score":0.9985164},"labels":[],"label_agreement":null},{"id":"W4394873978","doi":"10.1002/ajh.27311","title":"Novel germline <scp><i>JAK2</i><sup>R715T</sup></scp> mutation causing <scp>PV</scp>‐like erythrocytosis in 3 generations. Amelioration by Ropeg‐Interferon","year":2024,"lang":"en","type":"article","venue":"American Journal of Hematology","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University","funders":"Walloon excellence in life sciences and biotechnology; Agentura Pro Zdravotnický Výzkum České Republiky; Fonds De La Recherche Scientifique - FNRS; NextGenerationEU; Grantová Agentura České Republiky; Ludwig Institute for Cancer Research; MPN Research Foundation","keywords":"Biology; Germline mutation; Polycythemia vera; Germline; Mutation; Janus kinase 2; Somatic cell; Myelopoiesis; Molecular biology; Exon; Haematopoiesis; Cancer research; Erythropoietin; Ruxolitinib; Genetics; Myelofibrosis; Immunology; Gene; Stem cell; Bone marrow","score_opus":0.014020668776503457,"score_gpt":0.28183050315371994,"score_spread":0.2678098343772165,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4394873978","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96795064,0.004626745,0.02344892,0.0027671715,0.00037839997,0.00043054906,0.000042108837,0.000058228215,0.00029724184],"genre_scores_gemma":[0.9888893,0.00092330185,0.007988697,0.0013382955,0.0003327546,0.00006896829,0.00013491823,0.000076217766,0.00024757438],"study_design_codex":"not_applicable","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99686515,0.00023220861,0.0013589308,0.00051094923,0.0004967791,0.00053599884],"domain_scores_gemma":[0.99729127,0.0010627545,0.00067055214,0.0002683167,0.00042993514,0.00027716294],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00045546622,0.0004308815,0.0012220509,0.0008010454,0.00013841146,0.00012530459,0.00012397817,0.00015794084,0.000038224545],"category_scores_gemma":[0.00052071974,0.00035708793,0.0002572813,0.0009054945,0.00028734407,0.00040882576,0.00004985282,0.0006221779,0.00005168677],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0008330031,0.01195317,0.20619774,0.0017550255,0.00797799,0.018755984,0.04687647,0.027563766,0.2726211,0.010978031,0.3058915,0.08859621],"study_design_scores_gemma":[0.026101578,0.036187354,0.026683677,0.0071485513,0.00505556,0.1292318,0.040533025,0.13115247,0.47126308,0.0011525087,0.124334104,0.0011562846],"about_ca_topic_score_codex":0.00015645784,"about_ca_topic_score_gemma":0.00011248413,"teacher_disagreement_score":0.19864202,"about_ca_system_score_codex":0.000435128,"about_ca_system_score_gemma":0.00044427012,"threshold_uncertainty_score":0.9998881},"labels":[],"label_agreement":null},{"id":"W4394920251","doi":"10.1111/cts.13799","title":"Clinical assessment of momelotinib drug–drug interactions via <scp>CYP3A</scp> metabolism and transporters","year":2024,"lang":"en","type":"article","venue":"Clinical and Translational Science","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Sierra Oncology; Gilead Sciences","keywords":"Cmax; Pharmacokinetics; Pharmacology; CYP3A; Area under the curve; Chemistry; CYP3A4; Ritonavir; Medicine; Cytochrome P450; Metabolism; Viral load; Biochemistry; Immunology","score_opus":0.04430249168122976,"score_gpt":0.4170789012942723,"score_spread":0.37277640961304254,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4394920251","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9887332,0.0012156139,0.0018246201,0.005099377,0.00063456123,0.00035138777,0.000059327405,0.00003576458,0.0020461516],"genre_scores_gemma":[0.9928741,0.0011234204,0.00514334,0.00031293993,0.00019820042,0.0000255192,0.00002158239,0.000009155017,0.00029175897],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9977272,0.000083073224,0.00089415663,0.0006087648,0.00048157416,0.00020519253],"domain_scores_gemma":[0.9970815,0.002188312,0.0000832919,0.00013673787,0.00014082823,0.00036930307],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0015700876,0.00015991819,0.00047454785,0.00013320202,0.00015343782,0.000049985723,0.00008175409,0.000045384615,0.00007140889],"category_scores_gemma":[0.00011605872,0.00011226396,0.00021370842,0.00037467983,0.0013763511,0.000274871,0.000018691075,0.00035404987,0.000006702434],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000023381912,0.0007234644,0.92896044,0.00008320073,0.00018047613,0.000025843801,0.00042587818,0.000008663103,0.00023137944,0.013981375,0.00020441084,0.055151496],"study_design_scores_gemma":[0.0011267602,0.0001217053,0.9810794,0.00015095873,0.0002796145,0.0000317709,0.000056575787,0.004868189,0.00021715507,0.0017942926,0.010219969,0.000053583783],"about_ca_topic_score_codex":0.000020909747,"about_ca_topic_score_gemma":0.000032132757,"teacher_disagreement_score":0.05509791,"about_ca_system_score_codex":0.000008232804,"about_ca_system_score_gemma":0.0003727311,"threshold_uncertainty_score":0.5071223},"labels":[],"label_agreement":null},{"id":"W4396993308","doi":"10.1681/asn.20213210s1584b","title":"Clonal Hematopoiesis of Indeterminate Potential Is Associated with Worse Kidney Function and Anemia in a Cohort of Patients with Advanced CKD","year":2021,"lang":"en","type":"article","venue":"Journal of the American Society of Nephrology","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University; Queen's University","funders":"","keywords":"Cohort; Medicine; Indeterminate; Anemia; Renal function; Kidney disease; Haematopoiesis; Internal medicine; Intensive care medicine; Stem cell; Biology","score_opus":0.004894922195378374,"score_gpt":0.22794426980623408,"score_spread":0.2230493476108557,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4396993308","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9977235,0.000080418075,0.00003457336,0.0019286961,0.000022579907,0.00016939141,0.000025746242,0.0000014680671,0.000013630203],"genre_scores_gemma":[0.9955509,0.00018344431,0.0016258939,0.0025853945,0.000015815225,0.0000045239085,0.000006949006,0.000010172905,0.000016946042],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99884284,0.000112246875,0.00043149246,0.00012885248,0.00034877472,0.00013581237],"domain_scores_gemma":[0.99778485,0.00010745874,0.0013551313,0.00013089231,0.00054720015,0.00007446437],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00015261192,0.00012299421,0.00077276095,0.000046419686,0.000028291592,0.0000021497247,0.00005504998,0.000055523913,0.00003898055],"category_scores_gemma":[0.00005845212,0.00007311986,0.00017008148,0.00032064438,0.00049772044,0.000050180945,0.000037658767,0.00019703615,5.7885426e-8],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0026821434,0.00084108725,0.98349786,0.00005824881,0.0011450598,0.000019721587,0.0006532959,0.00003157143,0.009140858,0.0000031231652,0.00094229064,0.0009847694],"study_design_scores_gemma":[0.0052287634,0.0035044765,0.9850941,0.00024477538,0.0005448647,0.00008663463,0.00056048686,0.000034375444,0.004544492,0.000032424028,0.00006784433,0.00005677461],"about_ca_topic_score_codex":0.000035241283,"about_ca_topic_score_gemma":0.000014768646,"teacher_disagreement_score":0.0045963665,"about_ca_system_score_codex":0.0000670573,"about_ca_system_score_gemma":0.00027733963,"threshold_uncertainty_score":0.2981741},"labels":[],"label_agreement":null},{"id":"W4397041788","doi":"10.1681/asn.20233411s1473c","title":"Clonal Hematopoiesis of Indeterminate Potential Is Associated with Kidney Disease Progression in a Multi-Cohort Meta-Analysis of Individuals with CKD","year":2023,"lang":"en","type":"article","venue":"Journal of the American Society of Nephrology","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"McMaster University; University of British Columbia; Queen's University","funders":"","keywords":"Meta-analysis; Indeterminate; Cohort; Kidney disease; Medicine; Internal medicine; Disease; Haematopoiesis; Cohort study; Oncology; Immunology; Biology; Stem cell; Genetics","score_opus":0.03719378794538453,"score_gpt":0.3282201334575187,"score_spread":0.2910263455121342,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4397041788","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99160707,0.00016177919,0.000041332816,0.00763686,0.000010678699,0.0003526856,0.00017985515,0.000005132466,0.000004615902],"genre_scores_gemma":[0.9942387,0.00017390051,0.0033159105,0.0021500012,0.000013544182,0.00003114901,0.000018906841,0.00001754665,0.000040376985],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9976232,0.00030354405,0.0007997112,0.00020894353,0.0008232872,0.00024130022],"domain_scores_gemma":[0.99609524,0.00025967773,0.0027345659,0.0002822312,0.0004545929,0.00017369946],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006971858,0.00021095388,0.0022687397,0.00029446595,0.000046461115,0.0000045774955,0.0001968748,0.00006877277,0.00007716558],"category_scores_gemma":[0.00011953936,0.00010601358,0.0015345418,0.0017888584,0.0008012443,0.00005710406,0.00008519009,0.00025118826,3.1222552e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0010558518,0.001253308,0.85253984,0.000056089444,0.13904974,0.00007456113,0.0012778315,0.00035898745,0.002411224,0.0000029993191,0.0017946106,0.00012496178],"study_design_scores_gemma":[0.0024794808,0.001519436,0.9037345,0.000097330514,0.08864418,0.000033050866,0.000494768,0.00080209214,0.0020555442,0.000015022034,0.00004202289,0.00008255382],"about_ca_topic_score_codex":0.000088795794,"about_ca_topic_score_gemma":0.000021613914,"teacher_disagreement_score":0.051194686,"about_ca_system_score_codex":0.00006751811,"about_ca_system_score_gemma":0.00040062898,"threshold_uncertainty_score":0.43231082},"labels":[],"label_agreement":null},{"id":"W4397041997","doi":"10.1681/asn.20233411s1432a","title":"Clonal Hematopoiesis of Indeterminate Potential Is Associated with AKI","year":2023,"lang":"en","type":"article","venue":"Journal of the American Society of Nephrology","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"McMaster University; Queen's University","funders":"","keywords":"Indeterminate; Haematopoiesis; Medicine; Intensive care medicine; Stem cell; Biology; Genetics","score_opus":0.016158088839418716,"score_gpt":0.27937806248659597,"score_spread":0.26321997364717725,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4397041997","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98482215,0.000061671744,0.000029012042,0.014835453,0.00005033304,0.00012473852,0.000023575094,0.00000749113,0.00004554453],"genre_scores_gemma":[0.9939741,0.00029421347,0.0009741777,0.004496705,0.00008710863,0.00000412204,0.000002480304,0.00001587272,0.00015123912],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9986232,0.00011319128,0.00047401094,0.00011578492,0.00045936316,0.00021442784],"domain_scores_gemma":[0.9976299,0.00023674221,0.0015071773,0.00018196307,0.0003702647,0.00007397665],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00031024826,0.00013769942,0.00082988705,0.000068312795,0.00006265986,0.0000035692467,0.00016020017,0.00006572605,0.00006381521],"category_scores_gemma":[0.000054285763,0.00007860998,0.0005903883,0.0005204556,0.00072646444,0.000037250415,0.0000687938,0.00024353286,0.0000024023157],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0036059797,0.0022640747,0.52683246,0.0002115186,0.01421977,0.00037652472,0.0072150393,0.00027005552,0.1779777,0.000092976166,0.25969234,0.007241546],"study_design_scores_gemma":[0.002808068,0.0036047602,0.97368073,0.0001640739,0.0007261755,0.0005836404,0.0011306981,0.0002907163,0.015372147,0.00018559121,0.0013613448,0.00009204045],"about_ca_topic_score_codex":0.000038823255,"about_ca_topic_score_gemma":0.000004734985,"teacher_disagreement_score":0.44684827,"about_ca_system_score_codex":0.0000672881,"about_ca_system_score_gemma":0.00020704181,"threshold_uncertainty_score":0.32056218},"labels":[],"label_agreement":null},{"id":"W4397044825","doi":"10.1681/asn.20233411s1772d","title":"Clonal Hematopoiesis of Indeterminate Potential Associates with Severe AKI","year":2023,"lang":"en","type":"article","venue":"Journal of the American Society of Nephrology","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen's University","funders":"","keywords":"Indeterminate; Medicine; Haematopoiesis; Immunology; Biology; Stem cell; Genetics","score_opus":0.012593619037076634,"score_gpt":0.27204721570022317,"score_spread":0.25945359666314655,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4397044825","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9869997,0.00008095924,0.000021908834,0.012621031,0.000052735813,0.00012428519,0.000018247314,0.0000073938913,0.00007374949],"genre_scores_gemma":[0.99416006,0.00039734688,0.0027498594,0.0024208494,0.00010545772,0.000004456831,0.0000020568023,0.000015582338,0.00014431929],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9986862,0.00010830137,0.0004448089,0.000112676695,0.0004339495,0.00021406473],"domain_scores_gemma":[0.99776757,0.00024843015,0.0014147627,0.00017169704,0.00032639978,0.000071125854],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002954187,0.00013754511,0.0008021684,0.000060205184,0.000065308384,0.0000039939573,0.00016104266,0.00006155777,0.00004348751],"category_scores_gemma":[0.000040692055,0.0000773582,0.00056988077,0.0004154,0.0006124138,0.000042264917,0.00007549289,0.00024376786,0.000002297461],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0029254598,0.0012740352,0.7599343,0.00025934057,0.008152683,0.00022116632,0.0037875534,0.00050679944,0.09880583,0.00012601008,0.11764591,0.0063608875],"study_design_scores_gemma":[0.0025067206,0.0031247996,0.98075205,0.00012559154,0.0006064738,0.0011240914,0.0016223388,0.00016944083,0.00794705,0.00024083698,0.0016887488,0.00009184646],"about_ca_topic_score_codex":0.00004789956,"about_ca_topic_score_gemma":0.000005879733,"teacher_disagreement_score":0.22081774,"about_ca_system_score_codex":0.00006639731,"about_ca_system_score_gemma":0.00020779506,"threshold_uncertainty_score":0.31545758},"labels":[],"label_agreement":null},{"id":"W4397045661","doi":"10.1681/asn.20233411s156a","title":"Associations Between Clonal Hematopoiesis of Indeterminate Potential and Cardiovascular Disease in Three Prospective CKD Patient Cohorts","year":2023,"lang":"en","type":"article","venue":"Journal of the American Society of Nephrology","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"McMaster University; University of British Columbia; Queen's University","funders":"","keywords":"Disease; Medicine; Prospective cohort study; Indeterminate; Internal medicine; Haematopoiesis; Intensive care medicine; Stem cell; Biology; Genetics","score_opus":0.014377802562641987,"score_gpt":0.2634790182776193,"score_spread":0.24910121571497734,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4397045661","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99578637,0.00033436564,0.000030204035,0.0034271753,0.000036449135,0.0002994946,0.000072822106,0.0000040767018,0.000009023456],"genre_scores_gemma":[0.9986684,0.00041540535,0.0004716202,0.00033280827,0.000081826896,0.000011409949,0.0000041707267,0.000010050428,0.000004334938],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9986676,0.00012655082,0.00047922693,0.00013702155,0.00042458758,0.00016500228],"domain_scores_gemma":[0.9986089,0.00018883782,0.00072085013,0.00017838806,0.00021433987,0.0000886956],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003491312,0.000112290494,0.0008826711,0.000075952696,0.000056868153,0.000003591589,0.00007845937,0.00004487231,0.0000058152445],"category_scores_gemma":[0.00007908892,0.00007588826,0.0006940777,0.00035647396,0.00042676306,0.000039457518,0.000090570305,0.00019690071,4.3758166e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00016482198,0.0001919644,0.9919307,0.000027573373,0.0027302622,0.000039844595,0.0008979965,0.00024146278,0.0007190708,0.0000147437595,0.0008838316,0.0021576812],"study_design_scores_gemma":[0.0011541988,0.00068763463,0.9955241,0.000055259174,0.00081646646,0.000030258832,0.00032299783,0.00012881658,0.00049532705,0.00063511817,0.00009704949,0.00005273887],"about_ca_topic_score_codex":0.0001593072,"about_ca_topic_score_gemma":0.000009990059,"teacher_disagreement_score":0.003593387,"about_ca_system_score_codex":0.00009245556,"about_ca_system_score_gemma":0.00014351764,"threshold_uncertainty_score":0.30946332},"labels":[],"label_agreement":null},{"id":"W4397046247","doi":"10.1681/asn.20223311s11a","title":"Clonal Hematopoiesis of Indeterminate Potential Is Associated With a Higher Risk of Incident AKI","year":2022,"lang":"en","type":"article","venue":"Journal of the American Society of Nephrology","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University; Queen's University","funders":"","keywords":"Indeterminate; Medicine; Haematopoiesis; Intensive care medicine; Internal medicine; Stem cell; Biology; Genetics","score_opus":0.010976131359244223,"score_gpt":0.2574947141265915,"score_spread":0.24651858276734726,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4397046247","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9938691,0.00019081298,0.000027977538,0.005563194,0.00006627971,0.00016484791,0.00008266023,0.0000028623108,0.000032216158],"genre_scores_gemma":[0.99523014,0.00022362609,0.0012294684,0.0031345629,0.000057965884,0.000009749884,0.0000021550898,0.000015956652,0.00009634769],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9979864,0.00033579403,0.0006562145,0.00012910194,0.00070774456,0.00018475723],"domain_scores_gemma":[0.9954666,0.00025527683,0.0036157079,0.00021818519,0.0003778459,0.000066419096],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00047217697,0.00014895745,0.0010083334,0.00006650972,0.000104169165,0.0000022381978,0.00021874391,0.000045658042,0.00030279823],"category_scores_gemma":[0.000042225816,0.000091727146,0.0007220797,0.00036213527,0.0007025689,0.000032758177,0.00016167568,0.00041286365,2.681365e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0045339856,0.0034069333,0.8688019,0.00009877445,0.012134471,0.00012130107,0.0056384564,0.0006148888,0.058938198,0.000054044885,0.043664403,0.001992651],"study_design_scores_gemma":[0.0033670522,0.0064685727,0.97671777,0.000066653585,0.0013804819,0.00047605607,0.0013254187,0.0001171491,0.008564966,0.00016904275,0.0012608551,0.000085973814],"about_ca_topic_score_codex":0.00021751237,"about_ca_topic_score_gemma":0.000007243931,"teacher_disagreement_score":0.107915886,"about_ca_system_score_codex":0.00015999192,"about_ca_system_score_gemma":0.00026753903,"threshold_uncertainty_score":0.37405246},"labels":[],"label_agreement":null},{"id":"W4399203533","doi":"10.1182/bloodadvances.2024012939","title":"Safety and efficacy of luspatercept for the treatment of anemia in patients with myelofibrosis","year":2024,"lang":"en","type":"article","venue":"Blood Advances","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":43,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"AOP Orphan; Agence Nationale de la Recherche; Relay Therapeutics; Galecto; Sierra Oncology; CTI Biopharma; Incyte; Astex Pharmaceuticals; MEI Pharma; Jazz Pharmaceuticals; Gilead Sciences; GlaxoSmithKline; MorphoSys; Celgene; Bristol-Myers Squibb; AstraZeneca; Pfizer","keywords":"Myelofibrosis; Anemia; Medicine; Internal medicine; Gastroenterology; Bone marrow","score_opus":0.008121336556417046,"score_gpt":0.2615354574995308,"score_spread":0.2534141209431137,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399203533","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9888312,0.00966134,0.000028156894,0.00023042473,0.000038230948,0.0010182493,0.00008071349,0.000009048459,0.00010262432],"genre_scores_gemma":[0.99454033,0.004172734,0.00103587,0.000012429185,0.000023614246,0.000107005064,0.000026594895,0.000010700879,0.000070709204],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9994154,0.000011080176,0.00019106826,0.00017423532,0.00010865992,0.000099571604],"domain_scores_gemma":[0.9993842,0.0003830183,0.000045569956,0.00011539384,0.000042215986,0.000029567937],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000031366275,0.00011363784,0.00027401967,0.00004681747,0.000025873207,0.0000055674714,0.000021845468,0.000022307619,0.000016122332],"category_scores_gemma":[0.000011972971,0.00005344145,0.00004638789,0.00010162591,0.00006856344,0.000044457705,0.000005625839,0.000020254867,4.537367e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0016426721,0.0019033459,0.81624556,0.00032020325,0.00026740503,0.0000045434153,0.0011982954,0.000036284997,0.00011597487,0.00021186723,0.000008156708,0.17804568],"study_design_scores_gemma":[0.009329599,0.0073497845,0.9554879,0.00048311186,0.0005363018,0.0000020219718,0.00009316677,0.00003452738,0.021373177,0.000020764683,0.0052214325,0.00006819351],"about_ca_topic_score_codex":0.000020419362,"about_ca_topic_score_gemma":0.000044481207,"teacher_disagreement_score":0.17797749,"about_ca_system_score_codex":0.000022530543,"about_ca_system_score_gemma":0.000026227952,"threshold_uncertainty_score":0.21792792},"labels":[],"label_agreement":null},{"id":"W4399367500","doi":"10.1080/10428194.2024.2346733","title":"Safety and efficacy of fedratinib in patients with myelofibrosis previously treated with ruxolitinib: primary analysis of FREEDOM trial","year":2024,"lang":"en","type":"article","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":18,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; Princess Margaret Cancer Centre","funders":"Agence Nationale de la Recherche","keywords":"Ruxolitinib; Medicine; Myelofibrosis; Clinical endpoint; Adverse effect; Internal medicine; Confidence interval; Randomized controlled trial; Population; Anemia; Phases of clinical research; Clinical trial; Gastroenterology; Bone marrow","score_opus":0.006397220163147106,"score_gpt":0.22620042659871015,"score_spread":0.21980320643556303,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399367500","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99437183,0.0016138214,0.000026962929,0.00005161286,0.000053733493,0.0019544272,0.00023152001,0.00008794012,0.0016081341],"genre_scores_gemma":[0.9971135,0.00073243433,0.0009161156,0.000092932176,0.00006864727,0.00015568158,0.0006428639,0.00008110849,0.00019671598],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9963251,0.00016345322,0.0011867008,0.0010244672,0.0007367214,0.00056359946],"domain_scores_gemma":[0.99771184,0.00074131624,0.00037172518,0.00059408264,0.0002355299,0.0003455375],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00029370293,0.00066893036,0.0020699052,0.0008826162,0.00011234738,0.00007659344,0.00012887351,0.00029671588,0.00005310867],"category_scores_gemma":[0.00007255829,0.00044975654,0.0002662396,0.0019080063,0.00047310995,0.00022764153,0.00008762252,0.00011256306,0.0000025935253],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.107914165,0.0016865461,0.79665774,0.00097552437,0.005723298,0.00022074713,0.0019291207,0.00023603473,0.00015746831,0.0007017792,0.00009524341,0.08370234],"study_design_scores_gemma":[0.1466865,0.00514274,0.83848006,0.0013570035,0.0047041955,0.00003765227,0.000109989465,0.001736252,0.0010043626,0.000006100937,0.00033675504,0.00039838607],"about_ca_topic_score_codex":0.0014880267,"about_ca_topic_score_gemma":0.00020971062,"teacher_disagreement_score":0.08330396,"about_ca_system_score_codex":0.002297065,"about_ca_system_score_gemma":0.0019843215,"threshold_uncertainty_score":0.99979544},"labels":[],"label_agreement":null},{"id":"W4399481122","doi":"10.1200/jco.2024.42.16_suppl.tps6592","title":"VERIFY: A randomized controlled phase 3 study of the hepcidin mimetic rusfertide (PTG-300) in patients with polycythemia vera (PV).","year":2024,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Polycythemia vera; Medicine; Hepcidin; Internal medicine; Gastroenterology; Oncology; Anemia","score_opus":0.04344162385569494,"score_gpt":0.4286534419399107,"score_spread":0.38521181808421573,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399481122","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99134225,0.0007518679,0.000014618138,0.0038331167,0.00093904434,0.002558531,0.0000043237765,0.0000063842467,0.0005498793],"genre_scores_gemma":[0.9985033,0.00017940394,0.0002217551,0.00062436867,0.00023984739,0.00008758829,0.000001407816,0.000020225165,0.00012206179],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9938577,0.0017466989,0.0033316354,0.00023348123,0.00062122865,0.00020927646],"domain_scores_gemma":[0.989414,0.008488558,0.0012860498,0.0002460477,0.00035825997,0.00020707835],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0040342933,0.00021907133,0.00450781,0.00018690257,0.00003312851,0.000014561959,0.00014886247,0.00018892772,0.00017146197],"category_scores_gemma":[0.0050111967,0.00009168141,0.0008733756,0.0002519397,0.0002148886,0.00006939558,0.00004427334,0.000890737,0.000007200905],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.6463149,0.02260033,0.31757993,0.000029251227,0.0032705276,0.00054367294,0.0005885609,0.000013818298,0.000017905364,0.00007570099,0.0004239967,0.008541406],"study_design_scores_gemma":[0.7802082,0.03549036,0.17987373,0.00043352137,0.0025362608,0.000034181547,0.00014443381,0.00022139886,0.00010657601,0.000075959746,0.00079794443,0.00007746531],"about_ca_topic_score_codex":0.000037494185,"about_ca_topic_score_gemma":0.00006004985,"teacher_disagreement_score":0.1377062,"about_ca_system_score_codex":0.00018756131,"about_ca_system_score_gemma":0.0012919578,"threshold_uncertainty_score":0.59992325},"labels":[],"label_agreement":null},{"id":"W4399514809","doi":"10.1111/bjh.19566","title":"A sinister case of pseudothrombocytosis","year":2024,"lang":"en","type":"article","venue":"British Journal of Haematology","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Children's Hospital; University of British Columbia","funders":"","keywords":"Medicine","score_opus":0.018063261334557216,"score_gpt":0.31474170711812055,"score_spread":0.29667844578356334,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399514809","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.982625,0.013092873,0.0001977508,0.002249715,0.0003600259,0.00012808066,0.000021326488,0.000012169014,0.0013130311],"genre_scores_gemma":[0.9968501,0.0010664783,0.001587808,0.00026980552,0.00009057179,0.000006340536,0.000002276016,0.000017677547,0.000108961656],"study_design_codex":"case_report","study_design_gemma":"case_report","domain_scores_codex":[0.99890983,0.00007004435,0.00059018226,0.00013222914,0.00014381824,0.0001538663],"domain_scores_gemma":[0.99922603,0.00020066305,0.00015208637,0.00009153136,0.00020965266,0.00012005031],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001909438,0.00010091224,0.00071844796,0.0001551839,0.000036164176,0.00003072651,0.00004462175,0.00008724722,0.00050007366],"category_scores_gemma":[0.00011200541,0.00008837421,0.00024071621,0.00012503276,0.000114644085,0.000078924655,0.000020120551,0.00021830133,0.000021365202],"study_design_candidate":"case_report","study_design_consensus":"case_report","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000090313355,0.0004435873,0.00532416,0.0004190461,0.0006788717,0.9562082,0.00029042407,0.0000013818676,0.0003693229,0.0021770906,0.01441762,0.019579947],"study_design_scores_gemma":[0.0010929345,0.00077636354,0.001589652,0.0013795652,0.00036368732,0.982269,0.0001410549,0.000044384884,0.007980169,0.00035236604,0.0039464133,0.000064449516],"about_ca_topic_score_codex":0.000059044403,"about_ca_topic_score_gemma":0.000067211105,"teacher_disagreement_score":0.026060725,"about_ca_system_score_codex":0.000037620805,"about_ca_system_score_gemma":0.00017007325,"threshold_uncertainty_score":0.5475456},"labels":[],"label_agreement":null},{"id":"W4399519971","doi":"10.1200/jco.2024.42.16_suppl.6502","title":"Updated safety and efficacy data from the phase 3 MANIFEST-2 study of pelabresib in combination with ruxolitinib for JAK inhibitor treatment-naïve patients with myelofibrosis.","year":2024,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Ruxolitinib; Medicine; Myelofibrosis; Internal medicine; Phases of clinical research; Oncology; Clinical trial; Surgery; Bone marrow","score_opus":0.11759710885495724,"score_gpt":0.45585084155277766,"score_spread":0.33825373269782044,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399519971","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99390554,0.00030319873,0.00003735308,0.0034762556,0.00022739192,0.0017008398,0.00026244464,0.000006678023,0.000080292455],"genre_scores_gemma":[0.9978517,0.000286923,0.001004573,0.00020170315,0.0002678582,0.000025048937,0.00030883393,0.000020805644,0.00003254114],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99725366,0.00038942823,0.0015447511,0.0003340988,0.00031983762,0.0001582093],"domain_scores_gemma":[0.99283004,0.0056066634,0.00075682584,0.00030403538,0.00034587597,0.00015656138],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009997074,0.00018746076,0.0011931113,0.00009219015,0.000050994564,0.000021947984,0.00013077872,0.0001326934,0.00003955276],"category_scores_gemma":[0.00061750796,0.000085618216,0.00008448885,0.00015688634,0.00013801524,0.00016092957,0.000052941272,0.0003181867,0.0000018660328],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.056461908,0.048936322,0.75299186,0.000033088956,0.0021293354,0.0003509622,0.0010764509,0.000007927966,0.000010203873,0.00013010752,0.0013906637,0.1364812],"study_design_scores_gemma":[0.10168175,0.12524395,0.761454,0.0003638704,0.0014686146,0.00002369156,0.00051539566,0.00023740201,0.00004066906,0.000034480076,0.008859866,0.00007632912],"about_ca_topic_score_codex":0.000099865465,"about_ca_topic_score_gemma":0.000608657,"teacher_disagreement_score":0.13640487,"about_ca_system_score_codex":0.00013921614,"about_ca_system_score_gemma":0.0006474849,"threshold_uncertainty_score":0.34914094},"labels":[],"label_agreement":null},{"id":"W4399662838","doi":"10.1007/s00428-024-03844-2","title":"Obliteration of liver sinusoids through platelet aggregates associated to extramedullary haematopoiesis in myeloid neoplasms","year":2024,"lang":"en","type":"article","venue":"Archiv für Pathologische Anatomie und Physiologie und für Klinische Medicin","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hotel Dieu Hospital","funders":"","keywords":"Myelofibrosis; Medicine; Myeloproliferative neoplasm; Extramedullary hematopoiesis; Pathology; Liver biopsy; Haematopoiesis; Myeloid; Biopsy; Gastroenterology; Portal hypertension; Myeloproliferative Disorders; Internal medicine; Bone marrow; Cirrhosis; Stem cell","score_opus":0.03422847173954512,"score_gpt":0.3675421348647228,"score_spread":0.3333136631251777,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399662838","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9746117,0.014623882,0.0008728441,0.003419318,0.00045930594,0.0016567587,0.00021254519,0.00031865633,0.003824965],"genre_scores_gemma":[0.98313737,0.0054379366,0.007779007,0.0020314443,0.00023769731,0.0002840347,0.0007124495,0.0000869117,0.00029314644],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9950404,0.0006293479,0.0013803982,0.001300979,0.00069260894,0.0009562251],"domain_scores_gemma":[0.9957516,0.0026163615,0.00030015234,0.0007926069,0.00020133494,0.00033791678],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0010665258,0.0007784393,0.0016764799,0.00065913005,0.00016073091,0.000082204184,0.00038821754,0.0005105349,0.0002098439],"category_scores_gemma":[0.0019390681,0.0005639876,0.00041861838,0.0013538768,0.00063555886,0.00032015552,0.00027926674,0.0010676088,0.00018504351],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0068908636,0.014324608,0.21835627,0.0057633966,0.010134546,0.028212713,0.0663129,0.0036209766,0.26288897,0.08205067,0.030492214,0.27095187],"study_design_scores_gemma":[0.014896204,0.015934704,0.5900681,0.013484196,0.0029353423,0.0004934973,0.0035598786,0.017422935,0.27095404,0.03288446,0.03398119,0.0033854633],"about_ca_topic_score_codex":0.0004101516,"about_ca_topic_score_gemma":0.00021566042,"teacher_disagreement_score":0.37171182,"about_ca_system_score_codex":0.00020942204,"about_ca_system_score_gemma":0.000515259,"threshold_uncertainty_score":0.9996812},"labels":[],"label_agreement":null},{"id":"W4400018844","doi":"10.1182/bloodadvances.2024013451","title":"Donor types and outcomes of transplantation in myelofibrosis: a CIBMTR study","year":2024,"lang":"en","type":"article","venue":"Blood Advances","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":13,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary; University of British Columbia; Ottawa Hospital; Princess Margaret Cancer Centre","funders":"Cancer Moonshot; National Institute of Environmental Health Sciences; National Institute of Allergy and Infectious Diseases; Office of Naval Research; Legend Biotech; Pharmacyclics; Takeda Oncology; Health Resources and Services Administration; National Institutes of Health; MorphoSys; Seagen; Astellas Pharma; Adaptive Biotechnologies; Pfizer; Incyte; Kiadis Pharma; bluebird bio; Medac; Jazz Pharmaceuticals; BeiGene; HistoGenetics; Atara Biotherapeutics; CareDx; Actinium Pharmaceuticals; National Cancer Institute; Gilead Sciences; Moonshot Research and Development Program; Sanofi; GlaxoSmithKline; CSL Behring; Bristol-Myers Squibb; AstraZeneca; Gateway for Cancer Research; Swedish Orphan Biovitrum; Omeros Corporation; Vertex Pharmaceuticals; Alexion Pharmaceuticals; Mallinckrodt Pharmaceuticals; Astellas Pharma US; Amgen; National Heart, Lung, and Blood Institute; Novartis Pharmaceuticals Corporation","keywords":"Medicine; Hazard ratio; Internal medicine; Confidence interval; Myelofibrosis; Transplantation; Gastroenterology; Surgery; Hematopoietic cell; Bone marrow; Haematopoiesis; Stem cell","score_opus":0.010134579352549945,"score_gpt":0.29850450830052117,"score_spread":0.2883699289479712,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4400018844","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.986221,0.012383169,0.0000069744897,0.00035593644,0.000060746177,0.00044210427,0.000017593404,0.000025347805,0.0004871353],"genre_scores_gemma":[0.9964357,0.0027595896,0.0005319134,0.00003298125,0.000019708228,0.00010395868,0.0000069918656,0.00000798023,0.0001011805],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99941015,0.000021023026,0.00018236453,0.0001892228,0.0001133738,0.000083888866],"domain_scores_gemma":[0.99973345,0.00012586336,0.000022128397,0.00006905369,0.000017879196,0.000031604268],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00006450436,0.00009646691,0.0002517618,0.000100005935,0.00001597946,0.000012027405,0.000018308401,0.0000205992,0.000021196198],"category_scores_gemma":[0.000014692754,0.000064476706,0.000030375983,0.0001248065,0.000023895125,0.00010215679,0.0000056207728,0.000045871424,0.0000035847956],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00007561978,0.00075762294,0.984474,0.00033274584,0.00019028089,0.00012019497,0.0018620875,0.0000050543936,0.0004252887,0.00035075142,0.0000042212187,0.011402149],"study_design_scores_gemma":[0.0020490256,0.0009731693,0.9866241,0.00031632054,0.00040886074,0.00002118707,0.0005727,0.000017489067,0.008436049,0.00014719031,0.00036453578,0.00006933845],"about_ca_topic_score_codex":0.000041236337,"about_ca_topic_score_gemma":0.0003077383,"teacher_disagreement_score":0.01133281,"about_ca_system_score_codex":0.000007554885,"about_ca_system_score_gemma":0.000023858265,"threshold_uncertainty_score":0.26292837},"labels":[],"label_agreement":null},{"id":"W4400108991","doi":"10.1200/jco.2024.42.16_suppl.6571","title":"Long-term survival adjusted for treatment crossover in patients (pts) with myelofibrosis (MF) treated with momelotinib (MMB) vs danazol (DAN) in the MOMENTUM trial.","year":2024,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Medicine; Anemia; Ruxolitinib; Internal medicine; Gastroenterology; Crossover study; Proportional hazards model; Myelofibrosis; Surgery; Placebo; Bone marrow; Pathology","score_opus":0.10952433892141154,"score_gpt":0.4284397066555723,"score_spread":0.31891536773416074,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4400108991","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99142176,0.00028843794,0.00002665005,0.0044981767,0.0005919336,0.0026829904,0.000033458236,0.000014752919,0.00044182845],"genre_scores_gemma":[0.9973557,0.0004921088,0.00035984252,0.00050103816,0.00053358555,0.0003446632,0.00005273138,0.000046318262,0.00031403586],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9956006,0.0006236477,0.0022457386,0.00046540576,0.00061208045,0.0004525354],"domain_scores_gemma":[0.99396676,0.004302266,0.0008161189,0.00029021868,0.00035227308,0.00027238688],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0015039496,0.0003823871,0.0022057493,0.00029744438,0.00006124561,0.00006485456,0.00017422918,0.00032833955,0.0000695846],"category_scores_gemma":[0.0005090038,0.00017352712,0.00045787735,0.0004739663,0.0001867387,0.0001675975,0.000024038614,0.0005090254,0.000008419974],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.18719412,0.01234815,0.76565194,0.000067661575,0.0010577955,0.001402072,0.00033511498,0.000033378776,0.0000030448318,0.00009320329,0.0002835675,0.03152995],"study_design_scores_gemma":[0.1859646,0.118309386,0.69150186,0.00048336602,0.0008876579,0.00006096087,0.0001002841,0.000088286615,0.00008182866,0.000011544509,0.0023736274,0.00013659718],"about_ca_topic_score_codex":0.00007786136,"about_ca_topic_score_gemma":0.0013767147,"teacher_disagreement_score":0.10596124,"about_ca_system_score_codex":0.0008069697,"about_ca_system_score_gemma":0.0012393881,"threshold_uncertainty_score":0.70762306},"labels":[],"label_agreement":null},{"id":"W4400109015","doi":"10.1200/jco.2024.42.16_suppl.6578","title":"Efficacy of pacritinib in patients with myelofibrosis who have both thrombocytopenia and anemia.","year":2024,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Medicine; Myelofibrosis; Anemia; Ruxolitinib; Internal medicine; Population; Randomized controlled trial; Gastroenterology; Surgery; Bone marrow","score_opus":0.05868376799624149,"score_gpt":0.422944571031209,"score_spread":0.36426080303496755,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4400109015","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99351674,0.0006823132,0.0000099810695,0.0033536155,0.0002085781,0.0003082921,0.000009103377,0.0000046438627,0.0019067312],"genre_scores_gemma":[0.9963657,0.00088974467,0.0018615123,0.00053237577,0.00022991444,0.0000048528836,0.000003914844,0.000016394935,0.00009557763],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99752533,0.00021697831,0.0015568553,0.00021218818,0.00031670943,0.00017191774],"domain_scores_gemma":[0.9962363,0.0026851348,0.0004860329,0.00012130936,0.00023208582,0.0002390886],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009854021,0.0001444316,0.001576647,0.00014471804,0.000018204026,0.000013554971,0.000061485545,0.00022184453,0.000107933854],"category_scores_gemma":[0.0009333632,0.00008401574,0.00018728006,0.00012458506,0.00021404616,0.00010577024,0.000035802783,0.0005799666,0.0000042448137],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0046736905,0.0024742845,0.89914304,0.00009858979,0.0002895136,0.00045832797,0.00023894424,0.0000022764832,0.000012942511,0.00020177582,0.0015682954,0.09083832],"study_design_scores_gemma":[0.015408722,0.024149334,0.952669,0.0009719607,0.000359202,0.00006561043,0.00006157155,0.00002163797,0.00017108608,0.00006877441,0.0059797936,0.00007327673],"about_ca_topic_score_codex":0.00001316889,"about_ca_topic_score_gemma":0.000033569988,"teacher_disagreement_score":0.090765044,"about_ca_system_score_codex":0.000093310104,"about_ca_system_score_gemma":0.0006546862,"threshold_uncertainty_score":0.34260622},"labels":[],"label_agreement":null},{"id":"W4400136091","doi":"10.3389/jpps.2024.12905","title":"Development and validation of an LC-MS/MS method for ruxolitinib quantification: advancing personalized therapy in hematologic malignancies","year":2024,"lang":"en","type":"article","venue":"Journal of Pharmacy & Pharmaceutical Sciences","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Ruxolitinib; Medicine; Oncology; Internal medicine; Myelofibrosis; Bone marrow","score_opus":0.16659831611030693,"score_gpt":0.48098282308813695,"score_spread":0.31438450697783005,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4400136091","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9847019,0.007249487,0.0031854108,0.004057851,0.00020270846,0.0004778162,0.000006178039,0.00001326333,0.000105422216],"genre_scores_gemma":[0.9094755,0.002302084,0.0876636,0.0003791177,0.000104598075,0.00004563737,0.0000037495886,0.000008297011,0.000017411952],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99818563,0.00015153222,0.0006800172,0.0002664228,0.00046016858,0.00025622902],"domain_scores_gemma":[0.9987278,0.00062923314,0.00019153701,0.000050014296,0.0001993533,0.00020207891],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0024803088,0.0001539346,0.00040428364,0.000242624,0.00011590443,0.00007072671,0.00010996813,0.000029705718,0.00018360816],"category_scores_gemma":[0.00013771142,0.00009805392,0.00009968429,0.0003645438,0.00019130496,0.0003901281,0.00001718731,0.0001518333,0.0000013660141],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0018657562,0.0017434615,0.05906425,0.0008708657,0.00035552264,0.00020665275,0.006754024,0.00015566667,0.5091546,0.0147340875,0.00021552268,0.40487957],"study_design_scores_gemma":[0.0035201102,0.00057145266,0.0029418014,0.00035107878,0.00010163921,0.0004333534,0.0006026196,0.015012887,0.9062423,0.0004398203,0.06965439,0.00012852391],"about_ca_topic_score_codex":0.000008557233,"about_ca_topic_score_gemma":0.0000028461352,"teacher_disagreement_score":0.40475103,"about_ca_system_score_codex":0.000084932464,"about_ca_system_score_gemma":0.00041646077,"threshold_uncertainty_score":0.39985228},"labels":[],"label_agreement":null},{"id":"W4400231709","doi":"10.1016/j.clml.2024.06.012","title":"Consistency of Spleen and Symptom Reduction Regardless of Cytopenia in Patients With Myelofibrosis Treated With Pacritinib","year":2024,"lang":"en","type":"article","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"Swedish Orphan Biovitrum; CTI Biopharma","keywords":"Medicine; Myelofibrosis; Cytopenia; Consistency (knowledge bases); Internal medicine; Bone marrow","score_opus":0.013909071689812024,"score_gpt":0.28155096078063574,"score_spread":0.2676418890908237,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4400231709","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9965064,0.00052546355,0.000005622894,0.00024605947,0.000082691266,0.0010715247,0.000080931015,0.0000532333,0.0014280784],"genre_scores_gemma":[0.9979912,0.00026464436,0.0011563378,0.00005289647,0.00006873418,0.00012338787,0.000117234216,0.000051790837,0.00017375],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99732214,0.0001548948,0.001103042,0.0007020908,0.00042227653,0.000295539],"domain_scores_gemma":[0.9982256,0.00053232536,0.00024605295,0.00043774056,0.0003357324,0.00022249497],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003043686,0.00034002986,0.0011626454,0.00021243471,0.000047522753,0.00002839876,0.00008166211,0.00023114354,0.000048164708],"category_scores_gemma":[0.00014301,0.0002236713,0.00014482895,0.0005273124,0.0006164345,0.00015157482,0.000052265194,0.00016549249,0.000008224309],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0034293488,0.00070059916,0.8562763,0.00040611625,0.0004331081,0.00012433167,0.00018077358,0.0000017236792,0.0001629795,0.00066367234,0.00015402595,0.13746704],"study_design_scores_gemma":[0.009679407,0.0049163285,0.97554374,0.0030287595,0.0005168572,0.00008453106,0.00012109502,0.00006530327,0.0055016573,0.000044229262,0.00027175882,0.00022630607],"about_ca_topic_score_codex":0.00021046435,"about_ca_topic_score_gemma":0.00004148334,"teacher_disagreement_score":0.13724074,"about_ca_system_score_codex":0.00032093932,"about_ca_system_score_gemma":0.0006828151,"threshold_uncertainty_score":0.91210514},"labels":[],"label_agreement":null},{"id":"W4400322351","doi":"10.1101/2024.07.02.601518","title":"HIF-1 activated by PIM1 assembles a pathological transcription complex and regulon that drives JAK2V617F MPN disease","year":2024,"lang":"en","type":"preprint","venue":"bioRxiv (Cold Spring Harbor Laboratory)","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Regulon; Transcription factor; Hypoxia (environmental); Cancer research; PIM1; Transcription (linguistics); Chemistry; Biology; Cell biology; Gene; Biochemistry; Oxygen","score_opus":0.02975351721571846,"score_gpt":0.2556407288314251,"score_spread":0.22588721161570663,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4400322351","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98510396,0.0071664285,0.00013885036,0.0038056558,0.0004629487,0.0017042534,0.0010107846,0.0005826276,0.000024485496],"genre_scores_gemma":[0.99404824,0.002818091,0.0014315454,0.00049821794,0.0002869302,0.0007264692,0.000015498534,0.00014970337,0.00002527771],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.99652845,0.00022390053,0.0005142941,0.0016022726,0.00056338694,0.00056768756],"domain_scores_gemma":[0.99778956,0.00011694728,0.00023688337,0.00085938734,0.00024969393,0.00074750924],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00029147518,0.0008705087,0.0010468938,0.0002539726,0.00021438935,0.00029771612,0.00018522785,0.0005699625,0.00017150656],"category_scores_gemma":[0.00012832964,0.0007178679,0.00028467778,0.00031840778,0.00023747703,0.00011173488,0.00031727637,0.00094080635,0.000054634485],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00037151563,0.00096235314,0.06491439,0.001410496,0.00060062075,0.0008197254,0.00003661205,0.0000030487968,0.9261251,0.00074099004,0.0039940025,0.00002114704],"study_design_scores_gemma":[0.0015542256,0.0002989109,0.7282902,0.0016746911,0.0010795378,2.5082855e-7,0.000008990997,0.0002608476,0.26175737,0.000022362497,0.004290816,0.00076181785],"about_ca_topic_score_codex":0.000035905283,"about_ca_topic_score_gemma":0.0000023748667,"teacher_disagreement_score":0.66436774,"about_ca_system_score_codex":0.00036363042,"about_ca_system_score_gemma":0.00036546378,"threshold_uncertainty_score":0.9995272},"labels":[],"label_agreement":null},{"id":"W4400452962","doi":"10.1038/s41375-024-02330-7","title":"Myelofibrosis management in routine clinical practice with a focus on patients with cytopenias: recommendations from a global consensus group","year":2024,"lang":"en","type":"article","venue":"Leukemia","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"GlaxoSmithKline","keywords":"Myelofibrosis; Ruxolitinib; Medicine; Myeloproliferative neoplasm; Context (archaeology); Extramedullary hematopoiesis; Anemia; Clinical trial; Population; Internal medicine; Intensive care medicine; Bone marrow; Haematopoiesis; Stem cell","score_opus":0.019302411383895744,"score_gpt":0.3254109324200806,"score_spread":0.30610852103618486,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4400452962","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.95487267,0.00020750858,0.00018982863,0.012470221,0.00023073042,0.002007874,0.0002483037,0.0001290327,0.029643824],"genre_scores_gemma":[0.97027475,0.00014671168,0.026694711,0.0017892547,0.00010655491,0.00044239496,0.00033218617,0.000032430296,0.00018098761],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9980285,0.00015719171,0.00046888407,0.00065653166,0.00040877805,0.00028008915],"domain_scores_gemma":[0.99856067,0.000714728,0.00010506008,0.00036026887,0.00009144701,0.00016783108],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002122673,0.00027543996,0.00041481477,0.00008449291,0.00006593479,0.00008382854,0.00006919849,0.0000944875,0.00013983411],"category_scores_gemma":[0.000095413154,0.00017803056,0.000070214235,0.0004371505,0.00006422865,0.000100327474,0.000051992665,0.0003014611,0.00018197218],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.008549584,0.0030419999,0.7860738,0.00008962157,0.0022368182,0.0027218345,0.0004102256,0.00003378456,0.0000015171752,0.011490053,0.01145068,0.17390007],"study_design_scores_gemma":[0.01609789,0.0047956933,0.9293211,0.0019095755,0.0010352274,0.00004154353,0.00046055164,0.00033902007,0.000044618675,0.00030575646,0.04531032,0.0003386896],"about_ca_topic_score_codex":0.00077193003,"about_ca_topic_score_gemma":0.0008035175,"teacher_disagreement_score":0.17356136,"about_ca_system_score_codex":0.0011898844,"about_ca_system_score_gemma":0.00019547706,"threshold_uncertainty_score":0.72598755},"labels":[],"label_agreement":null},{"id":"W4400490882","doi":"10.1101/2024.07.09.24310101","title":"Stem Cell-Derived Gene Expression Scores Predict Survival and Blastic Transformation in Myelofibrosis","year":2024,"lang":"en","type":"preprint","venue":"medRxiv","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sunnybrook Health Science Centre; Princess Margaret Cancer Centre; Health Sciences Centre; Sunnybrook Hospital; University of Toronto; University Health Network","funders":"","keywords":"Myelofibrosis; Transformation (genetics); Gene; Gene expression; Cancer research; Biology; Stem cell; Oncology; Internal medicine; Medicine; Computational biology; Genetics; Bone marrow","score_opus":0.02243060103179512,"score_gpt":0.2605837581716398,"score_spread":0.2381531571398447,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4400490882","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99239147,0.003283352,0.0002640793,0.0006835219,0.0006202529,0.001398508,0.00014313363,0.0001176656,0.0010980229],"genre_scores_gemma":[0.9957246,0.002506937,0.0005738922,0.000033116972,0.00016977159,0.0005420328,0.00022047541,0.000058587615,0.00017058956],"study_design_codex":"observational","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99779475,0.00014410312,0.00058776536,0.0007080548,0.00045999413,0.0003053211],"domain_scores_gemma":[0.9990736,0.00017625536,0.00011904444,0.00035373212,0.00007332901,0.00020401354],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00027641223,0.0004529817,0.00073245453,0.00031103002,0.00006175466,0.000084092324,0.000093638286,0.00032426542,0.000076310534],"category_scores_gemma":[0.000017218223,0.00034109587,0.00014495025,0.0001504289,0.00006949212,0.000058071295,0.00023779043,0.0006143387,0.000043765274],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0010562973,0.0011537328,0.7210832,0.010038097,0.0004478136,0.0005823895,0.011032076,0.0006706177,0.24183297,0.00019551776,0.00041751488,0.01148975],"study_design_scores_gemma":[0.0028014984,0.00049732684,0.4367167,0.004532626,0.00050332776,0.000026368361,0.00034152495,0.002983241,0.5506312,0.00034716673,0.0001786496,0.00044031913],"about_ca_topic_score_codex":0.000055376524,"about_ca_topic_score_gemma":0.00005418631,"teacher_disagreement_score":0.30879828,"about_ca_system_score_codex":0.00014857942,"about_ca_system_score_gemma":0.00016979236,"threshold_uncertainty_score":0.9999041},"labels":[],"label_agreement":null},{"id":"W4400496774","doi":"10.1053/j.ajkd.2024.06.007","title":"Clonal Hematopoiesis and Acute Kidney Injury Risk: Inflammatory Macrophages Implicated","year":2024,"lang":"en","type":"letter","venue":"American Journal of Kidney Diseases","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"National Institute of Diabetes and Digestive and Kidney Diseases; Chinook Therapeutics; Pfizer","keywords":"Medicine; Acute kidney injury; Haematopoiesis; Kidney; Immunology; Inflammation; Pathology; Internal medicine; Stem cell; Cell biology","score_opus":0.005050144858255479,"score_gpt":0.26363666305306105,"score_spread":0.25858651819480555,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4400496774","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.13984595,0.004573842,0.000012925148,0.8414605,0.0006752324,0.0006600366,0.012426034,0.00010980869,0.00023566176],"genre_scores_gemma":[0.050324954,0.012363303,0.00094716536,0.92802364,0.0057224166,0.00014640605,0.0011433909,0.00028180593,0.0010469169],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9966883,0.0002571983,0.0010437345,0.0005970344,0.00086782273,0.000545909],"domain_scores_gemma":[0.9949619,0.00027992507,0.0013356032,0.00047685934,0.00040803282,0.0025376857],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00014981655,0.0007473368,0.0018137506,0.0006108815,0.00014931239,0.00015638903,0.00024547792,0.00023687327,0.00044119105],"category_scores_gemma":[0.0010342638,0.0005319332,0.0007633438,0.00038425438,0.00075042807,0.00014845633,0.0001429443,0.0017516447,0.00008131318],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0005347093,0.00020853174,0.05609174,0.00056504627,0.0052127237,0.008948908,0.000111462796,7.223126e-8,0.00011843784,0.000009932302,0.92391175,0.004286713],"study_design_scores_gemma":[0.0018151427,0.0028164554,0.03346962,0.0025984438,0.012982616,0.003289828,0.00008239752,0.0000062028657,0.0009850146,0.0003101289,0.9409633,0.0006808231],"about_ca_topic_score_codex":0.000039296567,"about_ca_topic_score_gemma":2.0879824e-7,"teacher_disagreement_score":0.089521,"about_ca_system_score_codex":0.00023444781,"about_ca_system_score_gemma":0.002712169,"threshold_uncertainty_score":0.99971324},"labels":[],"label_agreement":null},{"id":"W4400533986","doi":"10.1007/s12325-024-02928-4","title":"Momelotinib versus Continued Ruxolitinib or Best Available Therapy in JAK Inhibitor-Experienced Patients with Myelofibrosis and Anemia: Subgroup Analysis of SIMPLIFY-2","year":2024,"lang":"en","type":"article","venue":"Advances in Therapy","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":15,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Jewish General Hospital","funders":"","keywords":"Ruxolitinib; Medicine; Myelofibrosis; Anemia; Post-hoc analysis; Internal medicine; Gastroenterology; Subgroup analysis; Randomized controlled trial; Surgery; Meta-analysis; Bone marrow","score_opus":0.022127148808323633,"score_gpt":0.31237314423471757,"score_spread":0.29024599542639395,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4400533986","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98283935,0.015115685,0.000007209006,0.00012159759,0.00015054467,0.0008816673,0.000057029734,0.000034640543,0.0007922593],"genre_scores_gemma":[0.9752518,0.023439478,0.0005076354,0.00012364725,0.000040723302,0.00033770665,0.000094344585,0.00003470029,0.00016995994],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99810743,0.000073070376,0.00050624384,0.00059858937,0.000356457,0.00035823535],"domain_scores_gemma":[0.9987708,0.00059201464,0.00012091409,0.00029357593,0.00011931703,0.000103424194],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00015293015,0.00032094377,0.0008240299,0.00051846367,0.00004707758,0.000040490006,0.000087230175,0.000106521475,0.00039494716],"category_scores_gemma":[0.00004729065,0.00020360404,0.00009426741,0.0016575665,0.00019299204,0.00035487534,0.000020502732,0.00017833621,0.000006777817],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.010125301,0.0011724666,0.90358883,0.00008040456,0.0005681997,0.000060858645,0.0028463062,0.000050000173,0.00074677827,0.00019046773,0.00003849888,0.08053186],"study_design_scores_gemma":[0.05785365,0.022766959,0.83296144,0.0015514232,0.0005849292,0.000007134528,0.0025556346,0.0005773493,0.053150028,0.00012623591,0.026842527,0.0010227002],"about_ca_topic_score_codex":0.00013767194,"about_ca_topic_score_gemma":0.0005373243,"teacher_disagreement_score":0.07950916,"about_ca_system_score_codex":0.00012493804,"about_ca_system_score_gemma":0.00009698027,"threshold_uncertainty_score":0.83027315},"labels":[],"label_agreement":null},{"id":"W4401413268","doi":"10.1182/blood.2024025802","title":"Proposals for revised International Working Group–European LeukemiaNet criteria for anemia response in myelofibrosis","year":2024,"lang":"en","type":"article","venue":"Blood","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":24,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal; Hôpital Maisonneuve-Rosemont; McGill University; Jewish General Hospital; Princess Margaret Cancer Centre","funders":"Daiichi Sankyo Europe; National Cancer Institute; Genentech; National Institutes of Health; AOP Orphan; Swedish Orphan Biovitrum; Servier; Astellas Pharma; Galecto; Sierra Oncology; Incyte; CTI Biopharma; Astex Pharmaceuticals; Jazz Pharmaceuticals; Celgene; Amgen; Ariad Pharmaceuticals; Gilead Sciences; Bristol-Myers Squibb; American Society of Clinical Oncology; Pfizer; Constellation Pharmaceuticals; Agios Pharmaceuticals","keywords":"Medicine; Myelofibrosis; Anemia; Internal medicine; Bone marrow","score_opus":0.0340283563664436,"score_gpt":0.3251509218668734,"score_spread":0.2911225655004298,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4401413268","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9887252,0.0011455263,0.00054759905,0.0040754266,0.00050532044,0.0023553462,0.0001572307,0.00010963301,0.0023787345],"genre_scores_gemma":[0.98489815,0.00011322699,0.012111687,0.00038118492,0.0005962615,0.000783572,0.00024386421,0.000058274443,0.0008137815],"study_design_codex":"bench_or_experimental","study_design_gemma":"not_applicable","domain_scores_codex":[0.9987219,0.000107511354,0.0003481841,0.00042050882,0.00015545754,0.00024641235],"domain_scores_gemma":[0.9990899,0.000539762,0.000044066444,0.00017581528,0.000065143926,0.000085296044],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007323386,0.00018305113,0.00027249186,0.00018843627,0.000054099335,0.00011934777,0.0000886693,0.000061884486,0.00014506972],"category_scores_gemma":[0.0003330226,0.00014899498,0.0001403225,0.0001361039,0.000025619587,0.00007080836,0.00003312437,0.000094101786,0.000035116624],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0469308,0.008158671,0.26197368,0.0068753213,0.0030558133,0.0036209112,0.0068256143,0.000020667207,0.41064364,0.01402195,0.06693545,0.17093746],"study_design_scores_gemma":[0.046187084,0.008343312,0.34464732,0.011367051,0.0016889727,0.0005408047,0.0002734739,0.0031352504,0.1009587,0.0008855147,0.48075792,0.0012145938],"about_ca_topic_score_codex":0.00000648276,"about_ca_topic_score_gemma":0.000011584405,"teacher_disagreement_score":0.41382247,"about_ca_system_score_codex":0.00014371851,"about_ca_system_score_gemma":0.00011060747,"threshold_uncertainty_score":0.6075839},"labels":[],"label_agreement":null},{"id":"W4401876264","doi":"10.1016/s2152-2650(24)01436-8","title":"MPN-470 Efficacy of Pacritinib in Patients With Myelofibrosis Who Have Both Thrombocytopenia and Anemia","year":2024,"lang":"en","type":"article","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Medicine; Myelofibrosis; Ruxolitinib; Anemia; Internal medicine; Oncology; Bone marrow","score_opus":0.019116769765462005,"score_gpt":0.3116485406359668,"score_spread":0.2925317708705048,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4401876264","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9936696,0.0009707049,0.0000111342415,0.0004905417,0.00018022566,0.0013828988,0.00009051498,0.0000958245,0.0031085],"genre_scores_gemma":[0.9968838,0.00054130395,0.0010744289,0.0005174752,0.00020800349,0.00014080817,0.0001276385,0.00008946329,0.00041705123],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9962604,0.00019306791,0.0013336074,0.001073923,0.00058517855,0.00055379246],"domain_scores_gemma":[0.9969616,0.0016008377,0.00019307598,0.00062283326,0.00017910586,0.00044258195],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00047549134,0.0005134444,0.0015295466,0.00022222617,0.00008781761,0.00009214425,0.00016142784,0.00038124956,0.00017459832],"category_scores_gemma":[0.000427269,0.00036971422,0.00026697974,0.00042505728,0.0005512859,0.00021318813,0.0001507334,0.00033995227,0.00006158446],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0015258798,0.0007767235,0.7086819,0.00029779755,0.00022175566,0.00027589474,0.0002592032,0.000001640004,0.000030213321,0.00058810716,0.0014327166,0.28590816],"study_design_scores_gemma":[0.013481006,0.003223553,0.9760342,0.00225563,0.00034943005,0.000039679384,0.00006953766,0.00020738058,0.001007388,0.000096918266,0.0028652304,0.00037004266],"about_ca_topic_score_codex":0.00011398808,"about_ca_topic_score_gemma":0.00005058406,"teacher_disagreement_score":0.28553814,"about_ca_system_score_codex":0.0005700209,"about_ca_system_score_gemma":0.0008238249,"threshold_uncertainty_score":0.9998755},"labels":[],"label_agreement":null},{"id":"W4401878210","doi":"10.1016/s2152-2650(24)00689-x","title":"The Impact of New or Worsening Anemia on Clinical Outcomes in 2233 Patients With Myelofibrosis Treated With Ruxolitinib: Results From the Expanded-Access JUMP Study","year":2024,"lang":"en","type":"article","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Ruxolitinib; Myelofibrosis; Anemia; Internal medicine; Oncology; Intensive care medicine; Bone marrow","score_opus":0.0710747234573941,"score_gpt":0.40867704013906925,"score_spread":0.3376023166816752,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4401878210","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99481285,0.00014845864,0.0000035097537,0.0007678593,0.00028558733,0.0029931373,0.00027428512,0.00014245015,0.00057184504],"genre_scores_gemma":[0.9974236,0.00023499377,0.00017630126,0.0003636139,0.000456257,0.00027512744,0.00020294831,0.00011245966,0.0007546841],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99327826,0.0008467232,0.0027458214,0.0014091935,0.0009838744,0.0007361296],"domain_scores_gemma":[0.97969645,0.017325887,0.00064159016,0.0015035536,0.0002771892,0.00055532466],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0013822871,0.000783637,0.0018420751,0.00014272142,0.00026967272,0.0003017262,0.0005989066,0.00035003593,0.00008788623],"category_scores_gemma":[0.002336352,0.00029290965,0.00065887393,0.0009694852,0.0005531593,0.00022148054,0.00020743675,0.00070472865,0.00006294914],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.028642097,0.0021782233,0.7642855,0.000012109443,0.00150007,0.0004513841,0.00051127473,0.00002955708,6.7688865e-7,0.000017870861,0.0022865804,0.20008467],"study_design_scores_gemma":[0.028251046,0.017594932,0.95075727,0.0013155502,0.0006545936,0.000013525957,0.00040781428,0.00015308255,0.00005828145,0.000038683185,0.00039691897,0.00035833567],"about_ca_topic_score_codex":0.004907187,"about_ca_topic_score_gemma":0.0016433349,"teacher_disagreement_score":0.19972634,"about_ca_system_score_codex":0.0008871921,"about_ca_system_score_gemma":0.0026816623,"threshold_uncertainty_score":0.9999523},"labels":[],"label_agreement":null},{"id":"W4401897346","doi":"10.1016/s2152-2650(24)00705-5","title":"Pelabresib Plus Ruxolitinib Combination Therapy in JAK Inhibitor-Naïve Patients With Myelofibrosis in the Phase 3 MANIFEST-2 Study: Preliminary Evidence of Bone Marrow Recovery","year":2024,"lang":"en","type":"article","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Ruxolitinib; Myelofibrosis; Internal medicine; Oncology; Bone marrow","score_opus":0.04308279592004458,"score_gpt":0.35312180724785097,"score_spread":0.31003901132780637,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4401897346","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9918587,0.0022128362,0.000005621032,0.0008970036,0.00036375804,0.0041709687,0.00004063226,0.00006610809,0.0003843608],"genre_scores_gemma":[0.9967338,0.0010018843,0.00018416054,0.000535204,0.00020079107,0.0010105219,0.00011148806,0.00006782988,0.00015433325],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99481803,0.0008777751,0.0018099828,0.0009922639,0.0010043042,0.0004976307],"domain_scores_gemma":[0.9945956,0.003816499,0.0003503278,0.0007826879,0.000272922,0.00018199529],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0018035199,0.0004978457,0.0011479246,0.00038160657,0.000093457755,0.000097637174,0.00027105495,0.0002908756,0.00007749974],"category_scores_gemma":[0.0006842679,0.00032051047,0.00029053545,0.0009663153,0.0002774719,0.00042654955,0.00010916876,0.00045128068,0.00005255936],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.015155568,0.00915976,0.52629256,0.00030096242,0.00022487168,0.0011478954,0.0021335816,0.000011904665,0.000051470146,0.00024386868,0.00075807865,0.44451946],"study_design_scores_gemma":[0.025474025,0.029417679,0.93911386,0.0034535215,0.00018955786,0.000052357333,0.0006615672,0.00041824862,0.0004374192,0.00018745958,0.00029188322,0.0003024299],"about_ca_topic_score_codex":0.0003261023,"about_ca_topic_score_gemma":0.0001359271,"teacher_disagreement_score":0.44421703,"about_ca_system_score_codex":0.0012552636,"about_ca_system_score_gemma":0.0012413402,"threshold_uncertainty_score":0.9999247},"labels":[],"label_agreement":null},{"id":"W4401909908","doi":"10.1111/cts.70018","title":"Momelotinib: Mechanism of action, clinical, and translational science","year":2024,"lang":"en","type":"review","venue":"Clinical and Translational Science","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":12,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Gilead Sciences; Sierra Oncology; GlaxoSmithKline","keywords":"Ruxolitinib; Myelofibrosis; Medicine; Anemia; Internal medicine; Pharmacology; Bone marrow; Oncology","score_opus":0.24746458064651866,"score_gpt":0.5133993228606166,"score_spread":0.26593474221409796,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4401909908","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0044412185,0.9896144,0.00029633468,0.0018665737,0.0009700804,0.0012968881,0.00021043573,0.000049071255,0.0012549632],"genre_scores_gemma":[0.039176095,0.9575079,0.0026456944,0.000114486604,0.00032299323,0.000051199386,0.00003576127,0.000020694059,0.00012514234],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9953679,0.00011333807,0.0017894241,0.0012839289,0.0011164958,0.0003289492],"domain_scores_gemma":[0.9972585,0.0012554488,0.00028795743,0.00026851974,0.00037545693,0.0005541143],"candidate_categories":["sts"],"consensus_categories":[],"category_scores_codex":[0.003591031,0.00036398167,0.0015736105,0.0003809945,0.00037314906,0.00010308262,0.00024003159,0.0002730955,0.00009793635],"category_scores_gemma":[0.0004089552,0.00023611642,0.00047929844,0.0012741503,0.0063809664,0.0002921384,0.000067898814,0.0006029189,0.000032394764],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000040622974,0.00049255334,0.0112924,0.00281923,0.00018888814,0.00001404478,0.00007123496,3.7054647e-7,0.0000037232417,0.09284732,0.00005230426,0.8921773],"study_design_scores_gemma":[0.004928615,0.0023011507,0.1475634,0.019812504,0.008214833,0.00063133327,0.000048067966,0.0015533094,0.00006963164,0.048393473,0.7650979,0.0013857683],"about_ca_topic_score_codex":0.0000061984765,"about_ca_topic_score_gemma":0.0000071539457,"teacher_disagreement_score":0.89079154,"about_ca_system_score_codex":0.000013200397,"about_ca_system_score_gemma":0.0030683714,"threshold_uncertainty_score":0.9963231},"labels":[],"label_agreement":null},{"id":"W4402112177","doi":"10.14740/jh1297","title":"A Case of Autoimmune Myelofibrosis Associated With Autoimmune Hepatitis","year":2024,"lang":"en","type":"article","venue":"Journal of Hematology","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"Royal University Hospital; Saskatchewan Cancer Agency; University of Saskatchewan","funders":"","keywords":"Autoimmune hepatitis; Medicine; Myelofibrosis; Immunology; Autoimmune disease; Hepatitis; Antibody; Bone marrow","score_opus":0.015809365511717556,"score_gpt":0.2786786834832257,"score_spread":0.26286931797150814,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4402112177","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9882665,0.008006691,0.00019321167,0.0024592918,0.00027191825,0.00019155497,0.00001695172,0.000030105077,0.0005637686],"genre_scores_gemma":[0.9977144,0.00042979565,0.0013595911,0.00009441989,0.000037874754,0.00001304635,0.000007965234,0.00002745312,0.00031544385],"study_design_codex":"observational","study_design_gemma":"case_report","domain_scores_codex":[0.9985193,0.00009681075,0.00077859964,0.00015144121,0.0002371802,0.00021667236],"domain_scores_gemma":[0.9985157,0.00044783726,0.00040597515,0.00017138192,0.000361589,0.0000975174],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00028555476,0.00018295593,0.0010031452,0.00029295814,0.000051512005,0.000017694809,0.00005999586,0.00013098463,0.00034514267],"category_scores_gemma":[0.00021086336,0.00011554339,0.00023159594,0.00031329176,0.00011928325,0.00009680354,0.000024466484,0.00029600324,0.000013239852],"study_design_candidate":"case_report","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0015527955,0.0038595558,0.5302839,0.0014980155,0.012322798,0.38037682,0.004602872,0.000045321023,0.008976388,0.030019777,0.010446569,0.016015181],"study_design_scores_gemma":[0.008403547,0.011990224,0.27356234,0.0071477084,0.0030185066,0.64717644,0.00047268058,0.0017246973,0.041826118,0.0006735868,0.0035865423,0.0004176009],"about_ca_topic_score_codex":0.0000873015,"about_ca_topic_score_gemma":0.000063001426,"teacher_disagreement_score":0.26679963,"about_ca_system_score_codex":0.00012954965,"about_ca_system_score_gemma":0.00036072367,"threshold_uncertainty_score":0.47117227},"labels":[],"label_agreement":null},{"id":"W4402242201","doi":"10.1016/j.exphem.2024.104636","title":"Involvement of CREB3L1 in erythropoiesis induced by JAK2 exon 12 mutation","year":2024,"lang":"en","type":"article","venue":"Experimental Hematology","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Daiichi Sankyo Company; Bayer Canada; Chugai Pharmaceutical; Dainippon Sumitomo Pharma; Taiho Pharmaceutical; Meiji Seika Pharma; Kyowa Hakko Kirin; Takeda Pharmaceutical Company; Bayer Corporation; AbbVie","keywords":"Erythropoiesis; Mutation; Exon; Genetics; Internal medicine; Medicine; Biology; Gene; Anemia","score_opus":0.02760894213571821,"score_gpt":0.33175626679645415,"score_spread":0.30414732466073596,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4402242201","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98207116,0.014000989,0.000022241287,0.00096444704,0.00025503116,0.00053260446,0.000010709149,0.000045757708,0.002097041],"genre_scores_gemma":[0.9987233,0.00007482779,0.00041498954,0.00020771635,0.00002587733,0.0003101522,0.00009792923,0.000022177432,0.0001230287],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9988406,0.000053059975,0.00039234787,0.00032203845,0.0001834671,0.0002085404],"domain_scores_gemma":[0.9996104,0.000089631874,0.00005153277,0.0001527649,0.000021806783,0.00007384261],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00007500137,0.00017535785,0.00042512975,0.00017354534,0.000028057932,0.00000997323,0.000040670457,0.00011018272,0.00069699035],"category_scores_gemma":[0.000014210211,0.00014804323,0.00007843349,0.00015460246,0.00007491316,0.000073662326,0.000037938164,0.00010495105,0.000067762674],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0011359097,0.011543281,0.14471985,0.001607555,0.0011934306,0.002384635,0.026897218,0.000004738036,0.5976984,0.17847401,0.027220042,0.007120957],"study_design_scores_gemma":[0.0015496473,0.001004688,0.00326833,0.00026110542,0.000030268608,0.00014263215,0.0023155673,0.00013604063,0.990409,0.000119090386,0.0006499472,0.00011365181],"about_ca_topic_score_codex":0.00029059115,"about_ca_topic_score_gemma":0.00007249737,"teacher_disagreement_score":0.39271066,"about_ca_system_score_codex":0.0002172859,"about_ca_system_score_gemma":0.000063151034,"threshold_uncertainty_score":0.7631556},"labels":[],"label_agreement":null},{"id":"W4402312879","doi":"10.1007/s11899-024-00742-x","title":"Advances in Stem Cell Transplantation for Myelofibrosis","year":2024,"lang":"en","type":"review","venue":"Current Hematologic Malignancy Reports","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Myelofibrosis; Medicine; Transplantation; Hematology; Stem cell; Internal medicine; Oncology; Intensive care medicine; Biology; Bone marrow; Genetics","score_opus":0.06258721104371225,"score_gpt":0.38268654524185536,"score_spread":0.3200993341981431,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4402312879","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00009298301,0.99121815,0.00013416725,0.00003168032,0.001640487,0.0051465146,0.00013151752,0.00013367015,0.0014708301],"genre_scores_gemma":[0.0005580872,0.99160904,0.00030224182,0.000010509767,0.00012423554,0.005950626,0.0010561218,0.00008039326,0.00030876993],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9959655,0.00009178255,0.0018735512,0.0012275217,0.00034071566,0.00050095946],"domain_scores_gemma":[0.9981958,0.00025513297,0.0007974488,0.00049491704,0.0000959568,0.00016071611],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00028670923,0.00080549845,0.0031443401,0.00040271884,0.00006512912,0.00004626353,0.000088750654,0.0003677018,0.000052381718],"category_scores_gemma":[0.000026320557,0.00052283134,0.0009828836,0.00044564166,0.00004558665,0.000110893205,0.000032059066,0.0003650797,0.000060694216],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000018857143,0.0004652299,0.00081239216,0.26745886,0.000069244044,0.0040860143,0.00007997743,2.7984916e-7,2.0904322e-7,0.00067183777,0.000805203,0.7255319],"study_design_scores_gemma":[0.00039766825,0.00023012125,0.000015823425,0.10112011,0.0036912863,0.005273693,0.000014804796,0.0000027207534,0.00009067977,0.0005207482,0.8881725,0.0004698425],"about_ca_topic_score_codex":0.0000016816971,"about_ca_topic_score_gemma":0.0000065727445,"teacher_disagreement_score":0.8873673,"about_ca_system_score_codex":0.00023691557,"about_ca_system_score_gemma":0.00043656415,"threshold_uncertainty_score":0.9997223},"labels":[],"label_agreement":null},{"id":"W4402590252","doi":"10.1182/bloodadvances.2024013777","title":"Risk of bleeding in patients with essential thrombocythemia and extreme thrombocytosis","year":2024,"lang":"en","type":"article","venue":"Blood Advances","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"National Cancer Institute; MorphoSys; Swedish Orphan Biovitrum; Sierra Oncology; Incyte; bluebird bio; Sarepta Therapeutics; Jazz Pharmaceuticals; Vertex Pharmaceuticals; Gilead Sciences; GlaxoSmithKline; Massachusetts General Hospital; Servier; Pfizer; Amgen","keywords":"Medicine; Thrombocytosis; Bleed; Internal medicine; Essential thrombocythemia; Incidence (geometry); Cumulative incidence; Gastroenterology; Thrombosis; Platelet; Von Willebrand factor; Surgery; Cohort","score_opus":0.007852097513491925,"score_gpt":0.24457378985571063,"score_spread":0.2367216923422187,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4402590252","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9924449,0.0061733606,0.00002097865,0.000086970394,0.00006789007,0.00032964468,0.000030208756,0.00002966823,0.0008163929],"genre_scores_gemma":[0.99596685,0.0022229757,0.0016519382,0.00001552497,0.000050585317,0.000035019657,0.000013363194,0.000016857119,0.000026856786],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99912316,0.000018894476,0.00019818757,0.00028723845,0.00021724346,0.00015528359],"domain_scores_gemma":[0.9996113,0.00011466244,0.00005996666,0.00010847956,0.00004898446,0.000056595043],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00006490915,0.00014916298,0.0003391207,0.00010037804,0.000036026773,0.000018765968,0.000028450846,0.00003721267,0.000054830623],"category_scores_gemma":[0.000026843887,0.00009599983,0.00003784478,0.00019080838,0.00008129415,0.0001755131,0.000022947777,0.00010493638,0.0000028692875],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00011760415,0.0005136376,0.9917242,0.00022714506,0.00029680337,0.000024982233,0.0003693554,0.000007229047,0.00050243904,0.00035355994,0.00001499209,0.0058480725],"study_design_scores_gemma":[0.0037194535,0.0010831198,0.95220697,0.0010333457,0.00066892756,0.0000083809955,0.0001253403,0.000051194074,0.04040342,0.0002291024,0.00033680993,0.00013396658],"about_ca_topic_score_codex":0.000030387682,"about_ca_topic_score_gemma":0.00005768853,"teacher_disagreement_score":0.039900977,"about_ca_system_score_codex":0.000020812153,"about_ca_system_score_gemma":0.00003714668,"threshold_uncertainty_score":0.39147595},"labels":[],"label_agreement":null},{"id":"W4402775481","doi":"10.1016/j.bvth.2024.100026","title":"Perioperative outcomes in patients with myeloproliferative neoplasms: a multicentric analysis of 354 surgical procedures","year":2024,"lang":"en","type":"article","venue":"Blood Vessels Thrombosis & Hemostasis","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Jewish General Hospital; Hôpital Maisonneuve-Rosemont; St Mary's Hospital Centre; McGill University Health Centre; Université de Montréal; Leukemia & Lymphoma Society of Canada","funders":"","keywords":"Medicine; Perioperative; General surgery; Surgery","score_opus":0.01213494145538686,"score_gpt":0.2901237554948247,"score_spread":0.27798881403943787,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4402775481","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9945102,0.0013491284,0.00001272949,0.0010201976,0.0000741175,0.0019071401,0.00036923363,0.000114504684,0.0006427639],"genre_scores_gemma":[0.99668366,0.00062436605,0.0014234402,0.00020001981,0.000035877212,0.0004838268,0.00033750405,0.00007204893,0.00013928846],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99623317,0.00017625887,0.0009515556,0.0010702066,0.0009504342,0.00061840087],"domain_scores_gemma":[0.99784803,0.0006441885,0.00019724216,0.0004998482,0.0005222731,0.00028844242],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00022209492,0.00067378837,0.002086502,0.001245132,0.00013756735,0.00012337197,0.00015501109,0.00020682013,0.0005289616],"category_scores_gemma":[0.00021199803,0.00044307864,0.00046324357,0.0037804798,0.00021888792,0.00032300476,0.000079455225,0.00035702676,0.000024610717],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00049524865,0.00605025,0.9700003,0.00037557542,0.015569373,0.00021658005,0.0048410567,0.00012688336,0.00008072695,0.0008481131,0.000053253232,0.0013426399],"study_design_scores_gemma":[0.0076576606,0.001715566,0.9648501,0.00064690324,0.011063094,0.000011253911,0.00064688735,0.0006350483,0.012096897,0.000008513738,0.00019254432,0.0004754792],"about_ca_topic_score_codex":0.00011651301,"about_ca_topic_score_gemma":0.00036772623,"teacher_disagreement_score":0.01201617,"about_ca_system_score_codex":0.0002123473,"about_ca_system_score_gemma":0.0005364297,"threshold_uncertainty_score":0.9998021},"labels":[],"label_agreement":null},{"id":"W4403037895","doi":"10.1080/14796694.2024.2406597","title":"Treatment of the blood cancer polycythemia vera with ruxolitinib in the MAJIC-PV study: a plain language summary","year":2024,"lang":"en","type":"article","venue":"Future Oncology","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen's University","funders":"AOP Orphan; Cancer Research UK; Galecto; Incyte; Gilead Sciences; CTI Biopharma; Constellation Pharmaceuticals; Celgene","keywords":"Medicine; Ruxolitinib; Polycythemia vera; Internal medicine; Cancer; Oncology; Myelofibrosis; Bone marrow","score_opus":0.01271030447566842,"score_gpt":0.3285629588500332,"score_spread":0.3158526543743648,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4403037895","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96668947,0.006203141,3.3025773e-7,0.018662395,0.00032292702,0.001524624,0.00007612036,0.000023614664,0.0064973845],"genre_scores_gemma":[0.9957142,0.0005216493,0.00005822522,0.0007094592,0.0007682389,0.000964567,0.00002128131,0.000021474254,0.0012209273],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99883074,0.00022013437,0.0002138014,0.0002822142,0.00021838446,0.0002347332],"domain_scores_gemma":[0.99922526,0.0003005213,0.000057100857,0.00034348344,0.000025962825,0.000047683687],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00011945757,0.00020441541,0.00041478284,0.00006963366,0.00006007375,0.000012890955,0.00010621288,0.000102318365,0.00019920482],"category_scores_gemma":[0.000009739003,0.000081235106,0.000098316676,0.000284437,0.000077208824,0.000021108097,0.00002339396,0.00020239907,0.0000075563457],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.002643037,0.015162669,0.7768756,0.000264102,0.0030389768,0.01026959,0.121518664,0.000013324586,0.0012890921,0.005849013,0.0069953213,0.056080572],"study_design_scores_gemma":[0.02184495,0.026420003,0.604346,0.00062365504,0.0030824498,0.0013501488,0.036133416,0.00004454724,0.007889744,0.00005700718,0.29786724,0.00034084969],"about_ca_topic_score_codex":0.0008051505,"about_ca_topic_score_gemma":0.0060238657,"teacher_disagreement_score":0.29087192,"about_ca_system_score_codex":0.00029644903,"about_ca_system_score_gemma":0.00048492238,"threshold_uncertainty_score":0.33614585},"labels":[],"label_agreement":null},{"id":"W4403083778","doi":"10.1177/10668969241283742","title":"Case Report: Extramedullary Hematopoiesis in the Prostate","year":2024,"lang":"en","type":"article","venue":"International Journal of Surgical Pathology","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Saskatchewan","funders":"","keywords":"Extramedullary hematopoiesis; Prostate; Medicine; Rectal examination; Nodule (geology); Haematopoiesis; Pathology; Internal medicine; Biology; Stem cell","score_opus":0.023572722172666885,"score_gpt":0.3384296850850618,"score_spread":0.31485696291239496,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4403083778","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96415234,0.0019786356,0.0000526739,0.030732624,0.0008173773,0.00013221851,0.000009604405,0.000008638513,0.002115891],"genre_scores_gemma":[0.99798745,0.0005654042,0.0003686355,0.00045482325,0.0004130908,0.000016627722,0.000009184954,0.0000084003495,0.00017639865],"study_design_codex":"case_report","study_design_gemma":"case_report","domain_scores_codex":[0.9986856,0.000118041964,0.0005551512,0.00014047073,0.0003810952,0.00011965823],"domain_scores_gemma":[0.9990056,0.0005065959,0.000118789576,0.00009426491,0.00021434214,0.00006038138],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007368725,0.000097300646,0.00024273245,0.00021013607,0.00001961219,0.0000463004,0.00009829702,0.000063496045,0.00022913056],"category_scores_gemma":[0.00013275337,0.000052240113,0.00017027395,0.00011287068,0.00007646033,0.000082502214,0.000024645256,0.00033856332,0.000021305712],"study_design_candidate":"case_report","study_design_consensus":"case_report","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00019092897,0.00031646548,0.011344903,0.000015426458,0.00013738211,0.97745776,0.0007905913,0.000008064048,0.000056890378,0.00325742,0.001216551,0.005207641],"study_design_scores_gemma":[0.0009761677,0.00026266882,0.0047998074,0.00016046937,0.00004967806,0.96304154,0.00022163618,0.000047563044,0.0002579085,0.0012078923,0.028929343,0.00004533355],"about_ca_topic_score_codex":0.000007518865,"about_ca_topic_score_gemma":0.0000074727404,"teacher_disagreement_score":0.0338351,"about_ca_system_score_codex":0.00008060372,"about_ca_system_score_gemma":0.00011668233,"threshold_uncertainty_score":0.2508819},"labels":[],"label_agreement":null},{"id":"W4403201995","doi":"10.3389/frhem.2024.1473920","title":"Clonal evolution: a landmark of MPN evolution","year":2024,"lang":"en","type":"article","venue":"Frontiers in Hematology","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Institute of Cancer Research; Institut National Du Cancer; Ligue Contre le Cancer","keywords":"Landmark; Evolutionary biology; Biology; Geography; Cartography","score_opus":0.008516954567374009,"score_gpt":0.2648572700703742,"score_spread":0.2563403155030002,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4403201995","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.88331234,0.059570514,0.03862028,0.004936816,0.0035769271,0.0009202352,0.000045029192,0.00013847767,0.00887938],"genre_scores_gemma":[0.9925532,0.00013610958,0.0067104558,0.000050338105,0.0000792969,0.000094816285,0.000028034587,0.0000124051,0.00033538937],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99904156,0.000054274424,0.00030010738,0.00025880348,0.00014126062,0.00020401766],"domain_scores_gemma":[0.99962217,0.00007787574,0.000038458656,0.00015406706,0.0000478195,0.00005960855],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00012087058,0.000120799465,0.00044096392,0.00028220683,0.000022762695,0.0000047071276,0.000042352574,0.00013467259,0.00012786587],"category_scores_gemma":[0.0000656262,0.00009811369,0.000095268995,0.00027885207,0.00010126196,0.000045144367,0.000020972111,0.00014738094,0.000032415137],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0001717083,0.00021732434,0.87511116,0.00032397747,0.00016861339,0.00030283706,0.000190701,0.000007336879,0.000047893693,0.08127878,0.04110728,0.0010723621],"study_design_scores_gemma":[0.006972606,0.0017659622,0.858109,0.0024514867,0.00061629474,0.0033637036,0.0011032084,0.018908443,0.005820231,0.0585867,0.041714422,0.0005879211],"about_ca_topic_score_codex":0.00004587046,"about_ca_topic_score_gemma":0.000029024008,"teacher_disagreement_score":0.109240815,"about_ca_system_score_codex":0.0002670052,"about_ca_system_score_gemma":0.00018749776,"threshold_uncertainty_score":0.40009603},"labels":[],"label_agreement":null},{"id":"W4403467786","doi":"10.1016/j.clml.2024.10.001","title":"Longitudinal Assessment of Transfusion Intensity in Patients With JAK Inhibitor–Naive or –Experienced Myelofibrosis Treated With Momelotinib","year":2024,"lang":"en","type":"article","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; University of Toronto","funders":"GlaxoSmithKline","keywords":"Medicine; Myelofibrosis; Ruxolitinib; Internal medicine; Oncology; Bone marrow","score_opus":0.02601167438967047,"score_gpt":0.32898140265542736,"score_spread":0.3029697282657569,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4403467786","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99659294,0.00009002223,0.00007868477,0.00029098542,0.00022413183,0.0017902282,0.00005603463,0.0001385449,0.00073843624],"genre_scores_gemma":[0.99656683,0.00016562568,0.002120512,0.0002122159,0.00013385172,0.00036312532,0.00016972153,0.000077563076,0.00019054723],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99593484,0.00014713303,0.0013328879,0.0011886886,0.0008566315,0.0005397999],"domain_scores_gemma":[0.9976469,0.0006457063,0.00023090742,0.0005660513,0.0005050837,0.00040534747],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0003819292,0.0005811265,0.0015115071,0.0002979634,0.00010808707,0.00006291645,0.0001564105,0.00032919866,0.0002217112],"category_scores_gemma":[0.00012365209,0.0003346709,0.0002766626,0.001066223,0.0005300481,0.00024683698,0.00007924717,0.00037220342,0.000023005674],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.010225465,0.0019098521,0.91231996,0.00020221507,0.00046586743,0.00068002206,0.00041098872,0.000011006011,0.0001350095,0.00010284379,0.00020374333,0.07333304],"study_design_scores_gemma":[0.0133582065,0.01272618,0.9652447,0.00238831,0.00040472246,0.000063559644,0.00023138484,0.0007404911,0.004137201,0.000008903306,0.0003064077,0.0003899033],"about_ca_topic_score_codex":0.0004238504,"about_ca_topic_score_gemma":0.00026777503,"teacher_disagreement_score":0.072943136,"about_ca_system_score_codex":0.0012764618,"about_ca_system_score_gemma":0.0016614472,"threshold_uncertainty_score":0.99991053},"labels":[],"label_agreement":null},{"id":"W4403526311","doi":"10.1101/2024.10.17.24315679","title":"Reduction of clonal hematopoiesis mutation burden in coronary patients treated with low-dose colchicine","year":2024,"lang":"en","type":"preprint","venue":"medRxiv","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hôpital Maisonneuve-Rosemont; Université de Montréal; Cegep regional de Lanaudiere; Health Care Foundation; Montreal Heart Institute","funders":"Canadian Institutes of Health Research; Institut de Cardiologie de Montréal; Fondation Institut de Cardiologie de Montréal; AstraZeneca; Canada Research Chairs; Sanofi; Singulex","keywords":"Colchicine; Reduction (mathematics); Haematopoiesis; Mutation; Medicine; Internal medicine; Genetics; Biology; Stem cell; Mathematics","score_opus":0.012925276003924829,"score_gpt":0.2670815661167419,"score_spread":0.25415629011281704,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4403526311","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9958052,0.00048242163,0.000002831794,0.0008437074,0.00024210713,0.0017368719,0.0001000298,0.000059357575,0.00072748],"genre_scores_gemma":[0.9973994,0.00016779799,0.0003284289,0.000027327003,0.0001304322,0.00048379326,0.0010068761,0.000056504243,0.00039945627],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9979673,0.000092949085,0.0006068732,0.00061661546,0.0005059263,0.00021034197],"domain_scores_gemma":[0.99889964,0.00007096997,0.000255052,0.00036209682,0.00030512403,0.00010709176],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0001534339,0.00037656337,0.000787449,0.00038808776,0.00003003782,0.00001585843,0.000071114024,0.00022613716,0.00015124497],"category_scores_gemma":[0.000054426087,0.00027327432,0.00012299814,0.00032500253,0.000096732954,0.00003335551,0.00012977442,0.00046366255,0.00003241127],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0018403715,0.0015743212,0.9872598,0.0020657205,0.00066746416,0.00066765293,0.001499724,0.00043310004,0.0008206699,0.00012700597,0.0002701553,0.0027740153],"study_design_scores_gemma":[0.004249175,0.0014407829,0.96989524,0.004288564,0.0006484258,0.0001094464,0.00015595148,0.00044263477,0.018139623,0.00033769832,0.00003880538,0.0002536513],"about_ca_topic_score_codex":0.00039096113,"about_ca_topic_score_gemma":0.00008213401,"teacher_disagreement_score":0.017364558,"about_ca_system_score_codex":0.00029991748,"about_ca_system_score_gemma":0.00025093948,"threshold_uncertainty_score":0.9999719},"labels":[],"label_agreement":null},{"id":"W4403528674","doi":"10.1002/9781394244843.ch5","title":"MYELOPROLIFERATIVE AND MYELODYSPLASTIC/MYELOPROLIFERATIVE NEOPLASMS AND RELATED CONDITIONS","year":2024,"lang":"en","type":"other","venue":"","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"St. Thomas Hospital","funders":"","keywords":"Myeloproliferative Disorders; Myelodysplastic syndromes; Medicine; Internal medicine; Bone marrow","score_opus":0.008250050501089611,"score_gpt":0.2763914297994051,"score_spread":0.2681413792983155,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4403528674","genre_codex":"other","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"other","genre_consensus":"other","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.004363359,0.015486373,0.00003834328,0.004736248,0.00078829646,0.003339626,0.0007966843,0.0010095026,0.9694416],"genre_scores_gemma":[0.038431633,0.0067465478,0.001992079,0.0009116066,0.00046300798,0.0007957864,0.0005898567,0.0010267686,0.94904274],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9967119,0.000111680536,0.0006496624,0.0014776685,0.00047313285,0.00057594606],"domain_scores_gemma":[0.99828976,0.00025536568,0.00022309902,0.00045453312,0.00014692881,0.0006303037],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.0001454077,0.0010790449,0.0014755229,0.00077598967,0.00017487284,0.0001994556,0.00007562759,0.000818698,0.008249309],"category_scores_gemma":[0.00014264548,0.00080105313,0.0001724594,0.00038540724,0.0006017386,0.000097960234,0.00017946452,0.0008318338,0.0016973094],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0001807684,0.00043436803,0.004197775,0.0011748024,0.004827362,0.001494574,0.001732912,6.7879915e-7,0.00012246841,0.0911325,0.893133,0.0015687806],"study_design_scores_gemma":[0.014167854,0.0048095253,0.016823703,0.010017955,0.007933948,0.007963633,0.001737016,0.0010023018,0.0021806075,0.014852928,0.91459507,0.003915465],"about_ca_topic_score_codex":0.00010486687,"about_ca_topic_score_gemma":0.00027817223,"teacher_disagreement_score":0.07627957,"about_ca_system_score_codex":0.00012806666,"about_ca_system_score_gemma":0.0002860638,"threshold_uncertainty_score":0.999444},"labels":[],"label_agreement":null},{"id":"W4404186521","doi":"10.1038/s41409-024-02464-3","title":"Fedratinib as an alternative to splenectomy for refractory splenomegaly prior to transplant for myelofibrosis","year":2024,"lang":"en","type":"letter","venue":"Bone Marrow Transplantation","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Women's College Hospital; Princess Margaret Cancer Centre; Health Sciences Centre; Sunnybrook Health Science Centre","funders":"","keywords":"Medicine; Myelofibrosis; Splenectomy; Refractory (planetary science); Surgery; Internal medicine; Spleen; Bone marrow","score_opus":0.028043798873074427,"score_gpt":0.3129004296434697,"score_spread":0.28485663077039525,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4404186521","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.19530916,0.0006754852,0.018014394,0.7177249,0.002509837,0.029508132,0.033495173,0.00060709513,0.0021558073],"genre_scores_gemma":[0.17819017,0.0012510791,0.05545727,0.6413055,0.010980532,0.033677965,0.06500978,0.001034189,0.013093501],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9957738,0.00010655963,0.0009536355,0.001626524,0.0007182398,0.00082124776],"domain_scores_gemma":[0.99774057,0.0006801066,0.00020306668,0.00053023786,0.00038407967,0.00046196146],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00032429947,0.0009404335,0.0012985788,0.0007573341,0.00024460503,0.00020278161,0.00021671962,0.0006833155,0.00014495266],"category_scores_gemma":[0.00005233925,0.00083139254,0.0005765239,0.00029576433,0.000038479666,0.00021060507,0.000011938751,0.0006237786,0.00024215931],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.024813605,0.0013790369,0.00057177397,0.021078305,0.0032858665,0.0037566535,0.025932744,0.00012258459,0.023745583,0.0016272448,0.8711794,0.022507174],"study_design_scores_gemma":[0.008174863,0.013838058,0.0017162184,0.0040953835,0.0051379255,0.0004527219,0.00013119659,0.00016843439,0.04952433,0.00090030255,0.9142193,0.001641236],"about_ca_topic_score_codex":0.00025510814,"about_ca_topic_score_gemma":0.00046411407,"teacher_disagreement_score":0.076419406,"about_ca_system_score_codex":0.00044172307,"about_ca_system_score_gemma":0.0004380798,"threshold_uncertainty_score":0.99941367},"labels":[],"label_agreement":null},{"id":"W4404467705","doi":"10.1001/jama.2024.20377","title":"Diagnosis and Treatment of Polycythemia Vera","year":2024,"lang":"en","type":"review","venue":"JAMA","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":30,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Sierra Oncology; MorphoSys; Swedish Orphan Biovitrum; Astellas Pharma; National Cancer Institute; National Institutes of Health; Galecto; Genentech; Celgene; Gilead Sciences","keywords":"Medicine; Thrombocytosis; Polycythemia vera; Internal medicine; Gastroenterology; Hematocrit; Thrombosis; Phlebotomy; Erythromelalgia; Aspirin; Leukocytosis; Myeloproliferative neoplasm; Venous thrombosis; Surgery; Platelet; Myelofibrosis; Anesthesia","score_opus":0.06695132079187116,"score_gpt":0.367966762477603,"score_spread":0.30101544168573185,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4404467705","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00049643073,0.995737,1.9308598e-7,0.00053792284,0.0001642322,0.0012543515,0.00022364971,0.000035533158,0.0015506622],"genre_scores_gemma":[0.00015374307,0.99606615,0.00015850531,0.000044155237,0.00040613592,0.0013329921,0.00016081815,0.00006110372,0.0016163767],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.998684,0.00004588238,0.00045410942,0.00044044663,0.00018549229,0.00019009484],"domain_scores_gemma":[0.99904317,0.00027740758,0.00014130579,0.00034049636,0.00004144549,0.00015615189],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00004820443,0.00045779702,0.0020793849,0.00018731254,0.000029116096,0.000035334702,0.000042211595,0.00026672735,0.00019878526],"category_scores_gemma":[0.000038928105,0.0002584162,0.0005431392,0.00018040482,0.00005835863,0.000026361226,0.00003796422,0.00013770793,0.00015580696],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00001789171,0.0004818653,0.00051252136,0.011139943,0.0014039804,0.00027019167,0.00013101028,5.379567e-9,1.1511458e-7,0.00025239962,0.003976781,0.9818133],"study_design_scores_gemma":[0.0010056687,0.0010311872,0.00017711724,0.01891012,0.008150468,0.0001766087,0.000008310804,8.070405e-7,0.00006560012,0.000018276683,0.97029144,0.00016438829],"about_ca_topic_score_codex":0.00005237781,"about_ca_topic_score_gemma":0.000008018032,"teacher_disagreement_score":0.9816489,"about_ca_system_score_codex":0.00027782566,"about_ca_system_score_gemma":0.00022558714,"threshold_uncertainty_score":0.9999868},"labels":[],"label_agreement":null},{"id":"W4405034490","doi":"10.1182/blood-2024-193193","title":"Updated Results from the Phase 3 Manifest-2 Study of Pelabresib in Combination with Ruxolitinib for Janus Kinase Inhibitor-Naïve Patients with Myelofibrosis","year":2024,"lang":"en","type":"article","venue":"Blood","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Ruxolitinib; Myelofibrosis; Janus kinase inhibitor; Medicine; Internal medicine; Janus kinase 2; Janus; Janus kinase; Phases of clinical research; Janus kinase 1; Phase (matter); Oncology; Clinical trial; Chemistry; Bone marrow; Computer science; Receptor","score_opus":0.01474007386459411,"score_gpt":0.26935648544036855,"score_spread":0.25461641157577447,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4405034490","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99500906,0.000113750626,0.0000070568635,0.0004541765,0.000060870952,0.0032445467,0.00084522733,0.000033384847,0.00023193152],"genre_scores_gemma":[0.9977727,0.00000877554,0.00033308883,0.000058051817,0.000068379,0.00045093163,0.0011995101,0.0000341044,0.00007446751],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9984736,0.00008039306,0.00041012996,0.00043792214,0.00039391025,0.00020407826],"domain_scores_gemma":[0.99882716,0.00041787614,0.00012032393,0.0003229403,0.00023738989,0.000074324664],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00015111416,0.0002243337,0.00034391863,0.00010735953,0.00007150753,0.0000428045,0.000069993745,0.000056313722,0.000024546325],"category_scores_gemma":[0.00007158738,0.0001226373,0.00004322883,0.00032870632,0.000045907942,0.00009259555,0.000025073477,0.00012993885,0.0000075016537],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.011218402,0.051473845,0.92285115,0.00013067551,0.0011460395,0.0002987668,0.007130261,0.000009459385,0.000268337,0.00031781857,0.0008822287,0.004273025],"study_design_scores_gemma":[0.123124756,0.021427257,0.83597773,0.00092647586,0.0012282259,0.000006172115,0.0012202441,0.000089013934,0.015391637,0.000049773353,0.0003619515,0.00019674533],"about_ca_topic_score_codex":0.00059499405,"about_ca_topic_score_gemma":0.00087744754,"teacher_disagreement_score":0.11190636,"about_ca_system_score_codex":0.000050310235,"about_ca_system_score_gemma":0.00009948312,"threshold_uncertainty_score":0.5001004},"labels":[],"label_agreement":null},{"id":"W4405034526","doi":"10.1182/blood-2024-200881","title":"A Phase 3, Randomized, Double-Blind, Active-Comparator-Controlled Study of Bomedemstat Versus Hydroxyurea in Patients with Essential Thrombocythemia Naïve to Cytoreductive Therapy","year":2024,"lang":"en","type":"article","venue":"Blood","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Swedish Orphan Biovitrum; RWTH Aachen University; Daiichi-Sankyo; Novartis Pharma; Galecto; Sierra Oncology; Incyte; Baxalta; Novartis Foundation; Astellas Pharma; Nippon Shinyaku; Bristol-Myers Squibb; AstraZeneca; Active Biotech; MorphoSys; Celgene; Alexion Pharmaceuticals; Ariad Pharmaceuticals","keywords":"Medicine; Essential thrombocythemia; Thrombocytosis; Internal medicine; Myelofibrosis; Anagrelide; Myeloproliferative neoplasm; Gastroenterology; Hydroxycarbamide; Oncology; Bone marrow; Surgery; Polycythemia vera; Chemotherapy; Platelet","score_opus":0.0260369682254912,"score_gpt":0.33580788874330114,"score_spread":0.30977092051780997,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4405034526","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9876541,0.0004083889,0.000010460685,0.00012470644,0.00025834542,0.010907036,0.000039878094,0.000050832106,0.0005462823],"genre_scores_gemma":[0.9970627,0.00004258011,0.00009369777,0.000027968174,0.0001377201,0.002493645,0.00006048392,0.000048005848,0.00003321074],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9976625,0.00018295553,0.0005920332,0.0006102422,0.00062235317,0.0003299239],"domain_scores_gemma":[0.99865454,0.00045730663,0.00014656379,0.00033596752,0.00021700705,0.00018860986],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00025926757,0.00040923335,0.0017754771,0.00037765008,0.000057798556,0.000046029596,0.00009961535,0.00008383174,0.0000998963],"category_scores_gemma":[0.000047336245,0.0002510444,0.00021692184,0.0005392225,0.00009296621,0.00013792052,0.000032160046,0.00023090863,0.000021573822],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.92055345,0.048329055,0.013736834,0.000032176606,0.0070560225,0.00012907166,0.009028641,0.000019276713,0.00043627914,0.00009798255,0.000051602838,0.000529611],"study_design_scores_gemma":[0.95007616,0.014339208,0.0050077327,0.00018406635,0.0016305227,0.0000038857906,0.0009930502,0.000031631247,0.027481828,0.000012597892,0.000018544662,0.00022075532],"about_ca_topic_score_codex":0.00014828617,"about_ca_topic_score_gemma":0.00009714449,"teacher_disagreement_score":0.033989847,"about_ca_system_score_codex":0.00012333127,"about_ca_system_score_gemma":0.00023063843,"threshold_uncertainty_score":0.99999416},"labels":[],"label_agreement":null},{"id":"W4405037693","doi":"10.1182/blood-2024-204140","title":"Haploidentical and Mismatched Unrelated Donor Allogeneic Hematopoietic Cell Transplantation in Patients with Myelofibrosis: A Retrospective Cohort Study","year":2024,"lang":"en","type":"article","venue":"Blood","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; University Health Network","funders":"","keywords":"Hematopoietic cell; Myelofibrosis; Medicine; Retrospective cohort study; Hematopoietic stem cell transplantation; Transplantation; Cohort; Graft-versus-host disease; Internal medicine; Oncology; Immunology; Haematopoiesis; Stem cell; Biology; Bone marrow; Genetics","score_opus":0.004580391393654998,"score_gpt":0.21856394297392626,"score_spread":0.21398355158027127,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4405037693","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9971229,0.0004327928,0.000015505515,0.00011563074,0.00004128625,0.0019574736,0.000019418228,0.00006911671,0.00022589149],"genre_scores_gemma":[0.9991638,0.00011756188,0.0001986393,0.000032474025,0.000017458242,0.00029820137,0.00006736158,0.00003120557,0.00007330853],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9986788,0.000056909696,0.00026300494,0.0004759017,0.00032736376,0.0001980428],"domain_scores_gemma":[0.9995841,0.000062546984,0.00003135239,0.00014710502,0.000066909284,0.000107981745],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000116701754,0.00020778377,0.000380254,0.0001326191,0.000044804478,0.00005307695,0.00002898438,0.00007699208,0.00004404144],"category_scores_gemma":[0.0000104044075,0.00014777025,0.000040079874,0.00025947153,0.000038283622,0.00007423301,0.000011693923,0.00016201122,0.000021555812],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00028454335,0.0045488887,0.9913983,0.00020367898,0.0004384089,0.00039794313,0.0023904939,0.0000010437591,0.00022348868,0.000043984754,0.00000908696,0.000060143957],"study_design_scores_gemma":[0.0102505395,0.0022178905,0.98076653,0.00038910654,0.0016046757,0.0000336899,0.00018432249,0.000014368818,0.0043555894,0.000034025343,0.0000020469272,0.00014721113],"about_ca_topic_score_codex":0.00005883776,"about_ca_topic_score_gemma":0.000086435146,"teacher_disagreement_score":0.0106317615,"about_ca_system_score_codex":0.00007009709,"about_ca_system_score_gemma":0.000047481983,"threshold_uncertainty_score":0.60258955},"labels":[],"label_agreement":null},{"id":"W4405038536","doi":"10.1182/blood-2024-206260","title":"Diagnostic Accuracy of Erythropoietin and Jakpot in Predicting JAK2-Postiive Erythrocytosis: A Retrospective Cohort Study","year":2024,"lang":"en","type":"article","venue":"Blood","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"St. Joseph's Hospital; McMaster University","funders":"","keywords":"Erythropoietin; Medicine; Retrospective cohort study; Cohort; Internal medicine","score_opus":0.009680853439043081,"score_gpt":0.2768538329675442,"score_spread":0.2671729795285011,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4405038536","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99150217,0.004044902,0.000006859436,0.00046276578,0.00012923166,0.0025337425,0.00005126083,0.000091101785,0.0011779682],"genre_scores_gemma":[0.99782425,0.001059157,0.00023180604,0.000044370554,0.00013634433,0.0005980614,0.000017511993,0.000038190843,0.000050323226],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9981111,0.000095996955,0.00049136725,0.0006209151,0.00040229017,0.00027828052],"domain_scores_gemma":[0.9979592,0.0014208792,0.0000978183,0.00027423038,0.0001255449,0.0001223328],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00036282264,0.00026653137,0.0006693806,0.00022074793,0.00006689461,0.00004534403,0.00005684199,0.00008811955,0.00009226848],"category_scores_gemma":[0.0018685733,0.00021380774,0.00008174924,0.0004242681,0.00010192785,0.00011931505,0.000093635615,0.0002983577,0.000015715856],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00006971494,0.0036632402,0.9895984,0.00022101485,0.0008858993,0.0008336744,0.003563639,0.000002141726,0.00023432293,0.00018607633,0.00010752008,0.0006343639],"study_design_scores_gemma":[0.00435378,0.0026220048,0.9833923,0.0012716772,0.0012649222,0.00014479182,0.0015386752,0.00008941648,0.005028832,0.00010151299,0.0000310572,0.00016102343],"about_ca_topic_score_codex":0.00040741442,"about_ca_topic_score_gemma":0.000277844,"teacher_disagreement_score":0.006322067,"about_ca_system_score_codex":0.00011577651,"about_ca_system_score_gemma":0.00013209585,"threshold_uncertainty_score":0.8718827},"labels":[],"label_agreement":null},{"id":"W4405038688","doi":"10.1182/blood-2024-206911","title":"Phase I Safety Study of Anti-Transferrin Receptor 1 Antibody (PPMX-T003) in Patients with Polycythemia Vera and Erythrocythemia","year":2024,"lang":"en","type":"article","venue":"Blood","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Daiichi Sankyo Europe; Chugai Pharmaceutical; Teijin Pharma; Eisai; Sierra Oncology; Novartis Pharma; Otsuka Pharmaceutical; JCR Pharmaceuticals","keywords":"Polycythemia vera; Medicine; Transferrin receptor; Antibody; Internal medicine; Transferrin; Soluble transferrin receptor; Immunology; Anemia; Iron deficiency; Iron status","score_opus":0.007775493434966133,"score_gpt":0.2774428740026725,"score_spread":0.26966738056770634,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4405038688","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9976386,0.00044399672,0.000008290522,0.0001796024,0.00006906866,0.0012636362,0.00009168394,0.000042929296,0.0002621816],"genre_scores_gemma":[0.999295,0.00021150618,0.00017312496,0.000030828585,0.000045435554,0.00005279233,0.00010066671,0.000034121855,0.00005649794],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99865305,0.00004348936,0.0003494867,0.00042337802,0.00030925736,0.00022132958],"domain_scores_gemma":[0.99947256,0.00007689743,0.000037812737,0.00023618563,0.000063682455,0.00011285156],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00010212138,0.00023846538,0.0005015695,0.00015818652,0.000044203673,0.000021629849,0.00004581424,0.000067049754,0.0001122808],"category_scores_gemma":[0.000015973847,0.00015004599,0.000043485277,0.00030177046,0.000055810804,0.000085972446,0.00002472236,0.00017722482,0.000008863842],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0011819242,0.024396164,0.96490014,0.00021017726,0.0006149357,0.00016002511,0.002111426,0.0000010162619,0.0032018367,0.000049254468,0.00006244832,0.0031106512],"study_design_scores_gemma":[0.08153884,0.017946567,0.8524576,0.0011285124,0.00092188903,0.000030903288,0.0005619725,0.000023484374,0.04427992,0.000006637518,0.00079156604,0.00031212321],"about_ca_topic_score_codex":0.000071494345,"about_ca_topic_score_gemma":0.000040571424,"teacher_disagreement_score":0.11244256,"about_ca_system_score_codex":0.00004244203,"about_ca_system_score_gemma":0.000090938345,"threshold_uncertainty_score":0.6118698},"labels":[],"label_agreement":null},{"id":"W4405039268","doi":"10.1182/blood-2024-199378","title":"Findings from a Longitudinal Series of Continuing Education and Quality Improvement Programs in Myelofibrosis","year":2024,"lang":"en","type":"article","venue":"Blood","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Sierra Oncology; Swedish Orphan Biovitrum; Incyte; AOP Orphan; GlaxoSmithKline; Exelixis; Celgene; CTI Biopharma; Gilead Sciences; Bristol-Myers Squibb","keywords":"Myelofibrosis; Series (stratigraphy); Medicine; Quality (philosophy); Internal medicine; Biology; Bone marrow","score_opus":0.030046561866453988,"score_gpt":0.2960412193980795,"score_spread":0.2659946575316255,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4405039268","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9965722,0.0022767703,0.0000047772705,0.00038722678,0.00007457154,0.00044975357,0.000018711386,0.000020383588,0.00019558312],"genre_scores_gemma":[0.9978123,0.00021569605,0.0014406851,0.000021344735,0.000054156833,0.00020534113,0.00004857424,0.0000093237895,0.0001925965],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99923295,0.000018500874,0.00025654968,0.00024705875,0.00013150647,0.00011341217],"domain_scores_gemma":[0.99970734,0.00005697396,0.000036261314,0.00010407032,0.000043342192,0.00005198842],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000114677794,0.0001064338,0.00024463903,0.0000677664,0.000016208733,0.00003953936,0.000019710233,0.00004310425,0.000040207244],"category_scores_gemma":[0.00003217568,0.00008432931,0.000043660853,0.00012099585,0.000038738563,0.00008330864,0.00002432752,0.0000662015,0.0000035440046],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00005088699,0.0012395683,0.91705906,0.00027776332,0.00012707885,0.00000977315,0.0018839196,2.7710312e-8,0.0153185455,0.0008828001,0.000014238821,0.06313633],"study_design_scores_gemma":[0.0012783682,0.0006713427,0.899731,0.0012136734,0.00020193182,0.000009407294,0.00071721215,0.0000036439674,0.09568998,0.00018450928,0.00021919752,0.00007974254],"about_ca_topic_score_codex":0.0008133178,"about_ca_topic_score_gemma":0.00040081982,"teacher_disagreement_score":0.08037144,"about_ca_system_score_codex":0.000030586874,"about_ca_system_score_gemma":0.00006285886,"threshold_uncertainty_score":0.34388494},"labels":[],"label_agreement":null},{"id":"W4405041653","doi":"10.1182/blood-2024-210900","title":"Predictive Modeling of Clonal Hematopoiesis across Diverse Cohorts","year":2024,"lang":"en","type":"article","venue":"Blood","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen's University","funders":"","keywords":"Biology; Haematopoiesis; Immunology; Computational biology; Medicine; Genetics; Stem cell","score_opus":0.022145515399113178,"score_gpt":0.29845280279792136,"score_spread":0.27630728739880817,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4405041653","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.994426,0.0018243167,0.00038603166,0.00023862209,0.00012727556,0.00032493658,0.0001594747,0.00007908033,0.0024342407],"genre_scores_gemma":[0.9987103,0.00019208562,0.0006072668,0.000054249376,0.00012891406,0.00007241053,0.000033563738,0.000017761935,0.00018349853],"study_design_codex":"observational","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9990539,0.000015424393,0.00021496248,0.00026073944,0.000269626,0.00018532426],"domain_scores_gemma":[0.9995467,0.00007597267,0.00002702203,0.00015949667,0.000095879834,0.00009491954],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000099949124,0.0001330036,0.00030183408,0.000047784408,0.000057864418,0.000018736158,0.000036269124,0.00006453416,0.0001481629],"category_scores_gemma":[0.000035880246,0.00010036328,0.00013468208,0.00012689774,0.000047042504,0.00006248121,0.000049614457,0.000099766505,0.00003633474],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0007060797,0.0087567195,0.93658173,0.0024087164,0.008488621,0.0035658898,0.016317176,0.001750319,0.0044114203,0.009175199,0.0030998313,0.0047382787],"study_design_scores_gemma":[0.031515058,0.007403867,0.19469035,0.009403192,0.012610327,0.002482963,0.008512949,0.23475695,0.488433,0.004341415,0.0041035605,0.0017463814],"about_ca_topic_score_codex":0.00004320341,"about_ca_topic_score_gemma":0.000010799848,"teacher_disagreement_score":0.7418914,"about_ca_system_score_codex":0.0000301182,"about_ca_system_score_gemma":0.00008429884,"threshold_uncertainty_score":0.40926957},"labels":[],"label_agreement":null},{"id":"W4405043227","doi":"10.1182/blood-2024-206225","title":"<i>Understanding the Lived Experience of Fatigue in Adolescents and Young Adults with Myeloproliferative Neoplasms: A Mixed Methods Study</i>","year":2024,"lang":"en","type":"article","venue":"Blood","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Université de Sherbrooke; Cegep de Saint Jerome; Centre Hospitalier de l’Université de Montréal; Hôpital Charles-Le Moyne; McGill University; Jewish General Hospital; Hôpital du Sacré-Cœur de Montréal; Hôpital Maisonneuve-Rosemont; Concordia University; Université Laval; Université de Montréal","funders":"","keywords":"Medicine; Pediatrics; Polycythemia vera; Psychology; Gerontology; Internal medicine","score_opus":0.06620166686141943,"score_gpt":0.34359963880992206,"score_spread":0.27739797194850263,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4405043227","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9943469,0.0018879654,0.0014520108,0.00020299671,0.00010865972,0.0016693121,0.000006565155,0.000039499548,0.00028609153],"genre_scores_gemma":[0.9969423,0.00021636329,0.002215976,0.00006361761,0.000037991194,0.0004675524,0.0000035372236,0.000026170621,0.00002652971],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9983533,0.00026144303,0.00034840335,0.00046918515,0.00031975322,0.00024789385],"domain_scores_gemma":[0.9992866,0.00022808628,0.00007369754,0.00024342877,0.00006995785,0.000098226585],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003468383,0.00025460206,0.00043982998,0.00013842818,0.000100773614,0.000059879436,0.00007609484,0.00005779612,0.000011743849],"category_scores_gemma":[0.00009163479,0.00014313009,0.000049826183,0.00043141027,0.00015681575,0.00010527765,0.000060813618,0.00023056084,0.0000014479205],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0005708556,0.0021030062,0.8772239,0.00032254917,0.00044720565,0.00036984275,0.11615572,0.000004998163,0.0006925751,0.00044478607,0.000017204711,0.0016473768],"study_design_scores_gemma":[0.01952703,0.005452581,0.7358833,0.008100347,0.0010394874,0.00046097607,0.17945905,0.001705242,0.047660917,0.00019234768,0.00002725455,0.00049149024],"about_ca_topic_score_codex":0.00015087168,"about_ca_topic_score_gemma":0.0006658653,"teacher_disagreement_score":0.1413406,"about_ca_system_score_codex":0.000068794434,"about_ca_system_score_gemma":0.00010742498,"threshold_uncertainty_score":0.5836676},"labels":[],"label_agreement":null},{"id":"W4405044516","doi":"10.1182/blood-2024-203719","title":"A Phase 1b Study of DISC-0974, an Anti-Hemojuvelin Antibody, in Patients with Myelofibrosis and Anemia","year":2024,"lang":"en","type":"article","venue":"Blood","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Servier; Ionis Pharmaceuticals; Astellas Pharma; Karyopharm Therapeutics; Galecto; Sierra Oncology; CTI Biopharma; Incyte; Agios Pharmaceuticals; Jazz Pharmaceuticals; Gilead Sciences; MorphoSys; Celgene","keywords":"Myelofibrosis; Medicine; Anemia; Antibody; Internal medicine; Immunology; Bone marrow","score_opus":0.009992879252824242,"score_gpt":0.29898833286682747,"score_spread":0.28899545361400325,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4405044516","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9982786,0.0003560844,0.000003939529,0.000083884705,0.000033394947,0.0010394126,0.00005520348,0.00003564603,0.000113804395],"genre_scores_gemma":[0.9993644,0.000057280806,0.00030429932,0.000028029166,0.00003393916,0.00005803262,0.000103794606,0.000027337934,0.000022899478],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99880725,0.00004644882,0.0002781964,0.00040743224,0.00027588836,0.00018480982],"domain_scores_gemma":[0.9994779,0.000050148177,0.000046587586,0.0002399322,0.000063453386,0.00012193373],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00008762283,0.00019733251,0.00042049776,0.00017115063,0.000036373007,0.00003549616,0.0000414433,0.000049990584,0.000031842643],"category_scores_gemma":[0.000016162427,0.00013000934,0.000028987837,0.00028489545,0.000045991477,0.00013035603,0.0000327151,0.0001104485,0.0000039601236],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00028557755,0.05229355,0.93972385,0.00017590962,0.0002003652,0.00020002674,0.0020814228,6.6447325e-7,0.0009567064,0.00002922596,0.000019731648,0.0040329625],"study_design_scores_gemma":[0.041160643,0.016007762,0.9347738,0.00047681294,0.00055492553,0.000013428851,0.0004961634,0.00005143993,0.0062827487,0.000007402459,0.000027874714,0.0001469733],"about_ca_topic_score_codex":0.0001107268,"about_ca_topic_score_gemma":0.00009360237,"teacher_disagreement_score":0.040875062,"about_ca_system_score_codex":0.000017730254,"about_ca_system_score_gemma":0.00005507971,"threshold_uncertainty_score":0.5301627},"labels":[],"label_agreement":null},{"id":"W4405045134","doi":"10.1182/blood-2024-199107","title":"Anticoagulation Management of Splanchnic Vein Thrombosis in Myeloproliferative Neoplasms: A Global Abdominal/Splanchnic Thrombosis Retrospective Observational Study in 486 MPN Patients (GASTRO-MPN)","year":2024,"lang":"en","type":"article","venue":"Blood","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"ZonMw; Sierra Oncology; Regeneron Pharmaceuticals; Gilead Sciences; Incyte; Swedish Orphan Biovitrum; CSL Behring; GlaxoSmithKline","keywords":"Medicine; Thrombosis; Splanchnic Circulation; Retrospective cohort study; Internal medicine; Portal vein thrombosis; Splanchnic; Surgery; Radiology; Hemodynamics","score_opus":0.0473868436243069,"score_gpt":0.3367112398238378,"score_spread":0.28932439619953093,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4405045134","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.994115,0.0004007472,0.00003900824,0.00032090343,0.00025912462,0.0033593578,0.00021143549,0.000075890624,0.0012185532],"genre_scores_gemma":[0.99675417,0.0003067158,0.0017069851,0.00007459188,0.00009408222,0.00072343607,0.00026336632,0.00004054406,0.00003608152],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99643815,0.00018038541,0.0010108954,0.0009291131,0.0009345695,0.0005068619],"domain_scores_gemma":[0.9988923,0.00014912365,0.00020202022,0.00040916723,0.00022441539,0.00012298227],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00040828562,0.0004845846,0.0010001587,0.0003552268,0.00007634423,0.00006312549,0.00015343106,0.00015513304,0.00012282681],"category_scores_gemma":[0.00006374633,0.00042867835,0.00017356395,0.0014660214,0.00008151832,0.00030835677,0.00012236545,0.00031300524,0.000040882038],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0002639245,0.010452566,0.98260546,0.00036421596,0.0011829379,0.0002046042,0.0014693956,0.00005543776,0.0001477334,0.002587151,0.00012196371,0.0005445926],"study_design_scores_gemma":[0.01018968,0.0022899744,0.9822067,0.0015296408,0.00080406404,0.000011400881,0.00066021836,0.0004992662,0.0009030062,0.00059983955,0.000014723906,0.0002914837],"about_ca_topic_score_codex":0.00022913315,"about_ca_topic_score_gemma":0.0007698078,"teacher_disagreement_score":0.009925756,"about_ca_system_score_codex":0.0007964533,"about_ca_system_score_gemma":0.0001840515,"threshold_uncertainty_score":0.9998165},"labels":[],"label_agreement":null},{"id":"W4405045446","doi":"10.1182/blood-2024-200925","title":"Safety and Efficacy of Bromodomain and Extra-Terminal Inhibitor INCB057643 in Patients with Relapsed or Refractory Myelofibrosis and Other Advanced Myeloid Neoplasms: A Phase 1 Study","year":2024,"lang":"en","type":"article","venue":"Blood","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Tolerability; Myelofibrosis; Internal medicine; Anemia; Phases of clinical research; Gastroenterology; Neutropenia; Ruxolitinib; Oncology; Adverse effect; Clinical trial; Chemotherapy; Bone marrow","score_opus":0.010356650701533321,"score_gpt":0.2722896965138336,"score_spread":0.2619330458123003,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4405045446","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9967864,0.0012537803,0.000005416543,0.00006425356,0.00003556656,0.0016293353,0.00009296371,0.000034361892,0.000097884935],"genre_scores_gemma":[0.99852234,0.00018977563,0.0009642324,0.000051841682,0.000034956323,0.00009506403,0.000016433636,0.000043870456,0.00008148366],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9984481,0.000091554386,0.00041886148,0.0005478038,0.00027242224,0.00022129898],"domain_scores_gemma":[0.9991162,0.00036889373,0.000089603185,0.00020958408,0.000047188496,0.00016857366],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00016434942,0.00029071304,0.0005630908,0.00018818023,0.00006287448,0.0000351231,0.00003226927,0.000084203464,0.000041317006],"category_scores_gemma":[0.000070406204,0.0001894856,0.000029308592,0.00022662208,0.00013366962,0.0001373736,0.00006577948,0.00017614901,0.0000014354632],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.014783088,0.014319678,0.90210575,0.00047252353,0.0005490449,0.00048930437,0.0051673055,6.6690114e-7,0.0016441328,0.000034177574,0.000016569304,0.060417764],"study_design_scores_gemma":[0.09615148,0.023253707,0.87345135,0.0016054257,0.0007570289,0.00009694243,0.00062574644,0.00002729874,0.003169693,0.000012250091,0.0005536835,0.0002953821],"about_ca_topic_score_codex":0.000035405777,"about_ca_topic_score_gemma":0.00010324209,"teacher_disagreement_score":0.08136839,"about_ca_system_score_codex":0.00003923384,"about_ca_system_score_gemma":0.000092110546,"threshold_uncertainty_score":0.77269983},"labels":[],"label_agreement":null},{"id":"W4405045833","doi":"10.1182/blood-2024-200966","title":"POIESIS: A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Global Phase 3 Study of Navtemadlin As Add-on to Ruxolitinib in JAK Inhibitor-Naïve Patients with Myelofibrosis Who Have a Suboptimal Response to Ruxolitinib","year":2024,"lang":"en","type":"article","venue":"Blood","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Daiichi Sankyo Europe; Genentech; Swedish Orphan Biovitrum; Servier; Astellas Pharma; Galecto; Sierra Oncology; CTI Biopharma; Incyte; Astex Pharmaceuticals; Jazz Pharmaceuticals; MorphoSys; Celgene; Amgen; Ariad Pharmaceuticals; Alexion Pharmaceuticals; Gilead Sciences; Constellation Pharmaceuticals; Bristol-Myers Squibb","keywords":"Ruxolitinib; Myelofibrosis; Medicine; Placebo; Internal medicine; Phases of clinical research; Double blind; Tofacitinib; Clinical trial; Oncology; Bone marrow; Pathology","score_opus":0.017571251566661904,"score_gpt":0.32326592481535626,"score_spread":0.30569467324869437,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4405045833","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9760438,0.00028939816,0.000010430657,0.0010928594,0.0001772262,0.020648403,0.000460293,0.00010583681,0.0011717048],"genre_scores_gemma":[0.9906962,0.000014470494,0.0005785507,0.00050025515,0.00019000747,0.007463613,0.00008342513,0.00008877693,0.00038468567],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99431944,0.00084331975,0.0015209062,0.0012431614,0.0012461073,0.00082703854],"domain_scores_gemma":[0.9962554,0.0016069186,0.0002518101,0.0006988781,0.00046884926,0.00071814156],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.001334931,0.0007981939,0.0025470355,0.0007453613,0.000111948975,0.00014941947,0.00020705326,0.00019423568,0.00015341122],"category_scores_gemma":[0.0010442714,0.00055956526,0.00041725233,0.0008350417,0.00009302094,0.00015567582,0.00014754642,0.00034096674,0.00017351542],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9110835,0.03264518,0.04581409,0.00017439044,0.0020640881,0.000706,0.0063258354,0.00006213118,0.00009743978,0.00016505549,0.0002846039,0.0005776946],"study_design_scores_gemma":[0.94910866,0.02548262,0.011615344,0.0030709978,0.0021135947,0.000025542051,0.002208235,0.00011772951,0.005569899,0.000007991296,0.00019229083,0.00048709975],"about_ca_topic_score_codex":0.00057283195,"about_ca_topic_score_gemma":0.00041627596,"teacher_disagreement_score":0.038025163,"about_ca_system_score_codex":0.00035569363,"about_ca_system_score_gemma":0.0003922314,"threshold_uncertainty_score":0.9996856},"labels":[],"label_agreement":null},{"id":"W4405045956","doi":"10.1182/blood-2024-209001","title":"Burden of Anemia in Myelofibrosis Patients in Japan, South Korea, Taiwan, and Canada: A Real-World Survey and Multinational Database Analysis","year":2024,"lang":"en","type":"article","venue":"Blood","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Myelofibrosis; Multinational corporation; Medicine; Anemia; Database; Political science; Internal medicine; Bone marrow; Computer science","score_opus":0.013716439286719367,"score_gpt":0.25886145044872333,"score_spread":0.24514501116200396,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4405045956","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99800736,0.00037458376,8.849492e-7,0.00019696227,0.000018969235,0.0002954533,0.0009449647,0.0000071739114,0.00015366316],"genre_scores_gemma":[0.9984566,0.00014141948,0.00024608927,0.00002881621,0.000018846431,0.000043935153,0.000942303,0.00001119528,0.00011082092],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9988102,0.00007562268,0.00032922594,0.00035059013,0.00027280097,0.00016159307],"domain_scores_gemma":[0.99938893,0.00021762551,0.00005490691,0.00014571981,0.00008939916,0.0001034009],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00023249301,0.00014601847,0.0003947161,0.0004764074,0.00002226255,0.000017011029,0.00003116565,0.000038850794,0.000040912477],"category_scores_gemma":[0.0001390348,0.00012135254,0.000030127061,0.0007266259,0.00004093403,0.000054245862,0.000048452275,0.00010085893,5.536473e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000054926222,0.0003393741,0.9975625,0.00013734118,0.0003133608,0.000060890925,0.0007506147,0.000009926372,0.000056504672,0.000055647193,0.00009732275,0.00056155457],"study_design_scores_gemma":[0.002832367,0.000098882876,0.9951528,0.00017854721,0.00045399216,0.0000018129557,0.00013161667,0.0005420434,0.00047795003,0.00000399838,0.000028047169,0.00009795747],"about_ca_topic_score_codex":0.72600996,"about_ca_topic_score_gemma":0.9538131,"teacher_disagreement_score":0.22780313,"about_ca_system_score_codex":0.000095239106,"about_ca_system_score_gemma":0.00028121835,"threshold_uncertainty_score":0.4948613},"labels":[],"label_agreement":null},{"id":"W4405045962","doi":"10.1182/blood-2024-197898","title":"Outcomes of Patients with <i>IDH1/2</i> Mutated Accelerated/Blast-Phase Myeloproliferative Neoplasms in the Era of IDH Inhibitors","year":2024,"lang":"en","type":"article","venue":"Blood","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; University Health Network","funders":"","keywords":"Hematologic Neoplasms; Medicine; IDH1; Cancer research; Internal medicine; Oncology; Mutation; Genetics; Biology; Gene; Cancer","score_opus":0.012591655478528673,"score_gpt":0.2781960324993265,"score_spread":0.2656043770207978,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4405045962","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99632937,0.0004979896,0.000007568029,0.0008620749,0.000104135965,0.0014026796,0.00019336026,0.000042207972,0.00056061766],"genre_scores_gemma":[0.99886024,0.00007645791,0.00025999223,0.0002969717,0.000043961216,0.00021288818,0.00017555188,0.000036973557,0.00003696793],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99799305,0.000117638665,0.0006309984,0.0003863231,0.0005847541,0.00028722288],"domain_scores_gemma":[0.9987893,0.0003696051,0.00015266717,0.00031975703,0.0002779449,0.000090742615],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00018917394,0.00033091576,0.00068492006,0.00018740355,0.000050696308,0.000036346897,0.000119090015,0.000101437305,0.00009059235],"category_scores_gemma":[0.000087568325,0.0001743353,0.00013264696,0.00077868137,0.00013747414,0.00014115579,0.00003434472,0.00035560204,0.000013945176],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00057540735,0.008846758,0.9811382,0.00023283785,0.001057523,0.0002562312,0.004205795,0.000018600958,0.00075786427,0.000526599,0.00034782942,0.0020363224],"study_design_scores_gemma":[0.024974596,0.005446034,0.7558708,0.00095410406,0.0009600857,0.0000337868,0.0005582124,0.00011019516,0.21039094,0.00007618646,0.0003208775,0.00030416483],"about_ca_topic_score_codex":0.0000758546,"about_ca_topic_score_gemma":0.000096745185,"teacher_disagreement_score":0.22526741,"about_ca_system_score_codex":0.00003754292,"about_ca_system_score_gemma":0.0002434621,"threshold_uncertainty_score":0.7109187},"labels":[],"label_agreement":null},{"id":"W4405047419","doi":"10.1182/blood-2024-204138","title":"Thrombosis Risk Assessment in Polycythemia Vera (TRAP): A 4,636-Patient-Year Analysis of Arterial and Venous Thrombosis in Low-Risk Patients","year":2024,"lang":"en","type":"article","venue":"Blood","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal","funders":"","keywords":"Polycythemia vera; Thrombosis; Medicine; Venous thrombosis; Internal medicine; Cardiology","score_opus":0.008621146025015554,"score_gpt":0.2732172179531038,"score_spread":0.2645960719280882,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4405047419","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99798167,0.00035402444,0.000007837245,0.000101053796,0.00013350672,0.0006482901,0.00039458563,0.000027211456,0.00035181682],"genre_scores_gemma":[0.9976237,0.0013466653,0.0006566238,0.00003793978,0.0000395213,0.0001367637,0.00012760877,0.000027806398,0.0000034155241],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9980589,0.00014588766,0.0005843541,0.0005244765,0.00038649552,0.0002998581],"domain_scores_gemma":[0.99916416,0.00019922227,0.00015556566,0.00030194118,0.00006407905,0.00011501219],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00018951752,0.00026325946,0.0008574089,0.00067763915,0.00004823452,0.000044782624,0.00005870719,0.00012547174,0.00017596642],"category_scores_gemma":[0.000065852735,0.00021659164,0.00020100409,0.0010239583,0.00006485214,0.00010040839,0.000055290002,0.00028688417,0.000007847988],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00011329045,0.006508187,0.9848453,0.000113892165,0.0029237894,0.000036048506,0.0025298588,0.00002567213,0.00040358794,0.000055789646,0.000029038696,0.0024155453],"study_design_scores_gemma":[0.005676363,0.0015937227,0.98278964,0.00041724398,0.0045303814,0.0000013487784,0.00022697069,0.0005258561,0.003979488,0.000055627606,0.000031514097,0.00017187293],"about_ca_topic_score_codex":0.0011014219,"about_ca_topic_score_gemma":0.00063921243,"teacher_disagreement_score":0.005563073,"about_ca_system_score_codex":0.00014281926,"about_ca_system_score_gemma":0.000120259465,"threshold_uncertainty_score":0.88323504},"labels":[],"label_agreement":null},{"id":"W4405047640","doi":"10.1182/blood-2024-208908","title":"Impact of Cooperating Myeloid Gene Mutations on Disease Progression and Survival in Japanese MPN Patients: A Multicenter Study","year":2024,"lang":"en","type":"article","venue":"Blood","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Chugai Pharmaceutical; Sierra Oncology; Eisai","keywords":"Myelofibrosis; Essential thrombocythemia; Internal medicine; Myeloid leukemia; Polycythemia vera; Medicine; Myeloid; Oncology; Gene mutation; Immunology; Gastroenterology; Mutation; Biology; Bone marrow; Genetics; Gene","score_opus":0.015254960949132115,"score_gpt":0.32894043992126243,"score_spread":0.31368547897213034,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4405047640","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99804765,0.00037937818,4.6393237e-7,0.00007421735,0.00004998367,0.0012634033,0.00006671677,0.000023143253,0.00009504399],"genre_scores_gemma":[0.9995089,0.00002909979,0.00008753376,0.000015349426,0.000037296875,0.00020229195,0.00008302231,0.000017306993,0.000019164185],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99908245,0.000077410856,0.0002325874,0.0002628699,0.00021154658,0.00013312316],"domain_scores_gemma":[0.9994978,0.00012651696,0.00003328952,0.00012958406,0.00008199086,0.00013086434],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00008882768,0.00014243324,0.00022215252,0.00011660361,0.00004123996,0.000028947226,0.000021062622,0.000023949538,0.00003448733],"category_scores_gemma":[0.00014715033,0.00009035209,0.000055308694,0.00015803262,0.000024675788,0.000057170302,0.000025336138,0.000087611785,0.0000065801655],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00030224,0.012870909,0.98074645,0.00008729299,0.00023163122,0.00020180136,0.0031964928,0.000017623031,0.00036355658,0.000007973587,0.000006226044,0.0019677968],"study_design_scores_gemma":[0.0074636065,0.0027553008,0.9874456,0.00047401123,0.00025985428,0.0000017483719,0.0002627814,0.00045251145,0.0008043942,0.0000016866015,0.0000023525577,0.00007615178],"about_ca_topic_score_codex":0.00007935704,"about_ca_topic_score_gemma":0.00004930077,"teacher_disagreement_score":0.010115608,"about_ca_system_score_codex":0.000042254032,"about_ca_system_score_gemma":0.000073743766,"threshold_uncertainty_score":0.36844516},"labels":[],"label_agreement":null},{"id":"W4405047980","doi":"10.1182/blood-2024-193118","title":"Revised International Working Group Risk Model for Survival in Polycythemia Vera","year":2024,"lang":"en","type":"article","venue":"Blood","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal","funders":"","keywords":"Medicine; Polycythemia vera; Internal medicine; Receiver operating characteristic; Venous thrombosis; Cohort; Leukocytosis; Thrombosis; Gastroenterology; Surgery","score_opus":0.03004400889671403,"score_gpt":0.2971240487684494,"score_spread":0.26708003987173534,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4405047980","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98717856,0.0019893157,0.003398826,0.0017543421,0.0005155827,0.0007152467,0.00007252873,0.00008998133,0.004285624],"genre_scores_gemma":[0.9945431,0.00046933576,0.0036669096,0.0001186749,0.0003524056,0.00022713543,0.00007594394,0.000023683402,0.0005228523],"study_design_codex":"observational","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.9992085,0.00001730961,0.00019035477,0.0002629427,0.00016352898,0.00015735108],"domain_scores_gemma":[0.99960387,0.00017162856,0.000027973592,0.00011545524,0.000025155363,0.000055919754],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001829628,0.00011702403,0.00019288377,0.00009962937,0.000031562628,0.0000411714,0.000051032763,0.00005294469,0.000051486837],"category_scores_gemma":[0.00007380494,0.0000936013,0.00010407544,0.00009542003,0.000012357261,0.000042094674,0.000022040274,0.00012996608,0.000017617971],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0007769396,0.0032539768,0.912749,0.00033010734,0.0015970157,0.00041774326,0.0020385247,0.00031987342,0.0020939764,0.024663411,0.0020059003,0.049753524],"study_design_scores_gemma":[0.046469554,0.0013644713,0.1697733,0.0052862396,0.0024294937,0.0001565779,0.00023469349,0.70985687,0.015261627,0.007879697,0.040224086,0.0010633975],"about_ca_topic_score_codex":0.000020806894,"about_ca_topic_score_gemma":0.00004983315,"teacher_disagreement_score":0.7429757,"about_ca_system_score_codex":0.0000684613,"about_ca_system_score_gemma":0.00005692892,"threshold_uncertainty_score":0.38169503},"labels":[],"label_agreement":null},{"id":"W4405049155","doi":"10.1182/blood-2024-207623","title":"Addressing Unmet Needs in the Management of Drug-Induced Secondary Erythrocytosis: Results from an International Physician Survey","year":2024,"lang":"en","type":"article","venue":"Blood","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Jewish General Hospital; McGill University; Centre Hospitalier de l’Université de Montréal; Université de Montréal; Hôpital Maisonneuve-Rosemont","funders":"","keywords":"Medicine; Referral; Family medicine; Hematocrit; Internal medicine; Hematology; Drug; Intensive care medicine; Pharmacology","score_opus":0.061377999420227515,"score_gpt":0.33675321064106517,"score_spread":0.27537521122083763,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4405049155","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9871162,0.0004219912,0.0000030896492,0.0011868088,0.00022385753,0.00033539205,0.0004233799,0.000028378774,0.010260903],"genre_scores_gemma":[0.9980781,0.00015473923,0.00030849208,0.00042601296,0.00018221795,0.00006354252,0.0007043998,0.000016618595,0.00006588349],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9988039,0.0001421262,0.00031290218,0.0002770074,0.00032553964,0.00013850101],"domain_scores_gemma":[0.99932617,0.00022333494,0.000060596165,0.00030190634,0.000046190355,0.000041780415],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004117879,0.00014146128,0.00022353392,0.00014557979,0.000035803238,0.00006265257,0.00014457642,0.000038968723,0.0000408003],"category_scores_gemma":[0.000015791205,0.00009573898,0.00006633317,0.00031094023,0.000024461357,0.00013073653,0.000043680524,0.00016697409,0.000015968826],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0031705042,0.033161584,0.47664198,0.0014133464,0.018489415,0.0055081807,0.077341355,0.00005455646,0.014931857,0.010770936,0.008433847,0.35008246],"study_design_scores_gemma":[0.0055744476,0.00022784398,0.9581877,0.0012522391,0.000415728,0.000009242791,0.0022460502,0.00013188043,0.030786041,0.00016688523,0.000867608,0.00013433168],"about_ca_topic_score_codex":0.0005990164,"about_ca_topic_score_gemma":0.0003977715,"teacher_disagreement_score":0.48154575,"about_ca_system_score_codex":0.000038273254,"about_ca_system_score_gemma":0.00005625864,"threshold_uncertainty_score":0.3904122},"labels":[],"label_agreement":null},{"id":"W4405049238","doi":"10.1182/blood-2024-193373","title":"Polycythemia Vera Vs. <i>JAK2</i> Mutated or Wild-Type Essential Thrombocythemia: Clinical and Molecular Comparisons and Long-Term Outcome Among 2,010 Patients","year":2024,"lang":"en","type":"article","venue":"Blood","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal","funders":"","keywords":"Essential thrombocythemia; Polycythemia vera; Myelofibrosis; Medicine; Leukocytosis; Internal medicine; Gastroenterology; Myeloproliferative neoplasm; Bone marrow","score_opus":0.024476581753653182,"score_gpt":0.3361209585768312,"score_spread":0.311644376823178,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4405049238","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99672055,0.001281818,0.00003332046,0.00055980106,0.00034819168,0.00068678695,0.000037808608,0.00012405244,0.00020766667],"genre_scores_gemma":[0.99813193,0.00048900465,0.00041668213,0.00043950035,0.00014354032,0.000040283943,0.00013698291,0.000052623003,0.00014947445],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99811983,0.000069952686,0.00056201435,0.0006223057,0.00030159415,0.00032433163],"domain_scores_gemma":[0.99901927,0.00020067146,0.00008092843,0.00029066164,0.00008835528,0.00032014452],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00013726696,0.00032851685,0.0007121263,0.00008870191,0.000104034785,0.000104508756,0.00006644431,0.00022062098,0.00012187788],"category_scores_gemma":[0.00010630307,0.00023148504,0.00012469114,0.00019793802,0.0003336212,0.00009621527,0.00011681526,0.00041302346,0.0000333426],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00034186008,0.0016180164,0.9935961,0.0001912858,0.0008544847,0.001164188,0.00016459062,2.2984736e-7,0.00037914087,0.00006970833,0.0008781427,0.0007423029],"study_design_scores_gemma":[0.00922148,0.0015076073,0.97170174,0.00038607145,0.0018802127,0.00016365456,0.000022531363,0.000096553136,0.014419321,0.000014815563,0.00031051217,0.00027549546],"about_ca_topic_score_codex":0.000028256065,"about_ca_topic_score_gemma":0.000039211995,"teacher_disagreement_score":0.021894304,"about_ca_system_score_codex":0.000025173154,"about_ca_system_score_gemma":0.000103967875,"threshold_uncertainty_score":0.94396865},"labels":[],"label_agreement":null},{"id":"W4405049622","doi":"10.1182/blood-2024-205639","title":"The Role of JAK2 Allele Burden on Muscle Strength and Physical Functioning in Patients with Myeloproliferative Neoplasm: A Systematic Review and Prospective Cohort Analysis","year":2024,"lang":"en","type":"review","venue":"Blood","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Juravinski Cancer Centre; McMaster University; Population Health Research Institute","funders":"","keywords":"Myeloproliferative neoplasm; Medicine; Cohort; Prospective cohort study; Internal medicine; Cohort study; Hematologic Neoplasms; Allele; Oncology; Physical therapy; Myelofibrosis; Gerontology; Genetics; Cancer; Biology; Bone marrow; Gene","score_opus":0.006366189304538765,"score_gpt":0.2560722394649221,"score_spread":0.2497060501603833,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4405049622","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.023058476,0.96970564,3.3570382e-7,0.00003352615,0.00001225252,0.0066549233,0.0000748806,0.000017535216,0.0004424516],"genre_scores_gemma":[0.04161046,0.95545495,0.000025857176,0.000017135866,0.00005483854,0.0025553596,0.00014130223,0.000043336266,0.00009677013],"study_design_codex":"systematic_review","study_design_gemma":"systematic_review","domain_scores_codex":[0.9977599,0.00024971497,0.00067847123,0.00064423674,0.0004290453,0.00023865074],"domain_scores_gemma":[0.99845695,0.0004573137,0.0004060539,0.00039922347,0.00016868502,0.000111747344],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00027466388,0.0005161594,0.0035919975,0.00022709221,0.00011951565,0.000053108957,0.00006877225,0.00010082646,0.0000044687667],"category_scores_gemma":[0.00017073887,0.0002441747,0.00028458794,0.0008034847,0.000099190256,0.000042367734,0.0000643695,0.0003711179,0.000007452993],"study_design_candidate":"systematic_review","study_design_consensus":"systematic_review","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00008881684,0.0029832697,0.15034606,0.76595885,0.046280112,0.000047930956,0.0018947478,0.000001579429,6.808909e-8,0.00081429404,0.000020815014,0.031563472],"study_design_scores_gemma":[0.0035997548,0.0032130077,0.051995687,0.55574036,0.38161433,0.00003763714,0.0003839241,0.000053803487,0.000007087255,0.000051037838,0.0026389358,0.0006644752],"about_ca_topic_score_codex":0.000048098416,"about_ca_topic_score_gemma":0.00011206449,"teacher_disagreement_score":0.3353342,"about_ca_system_score_codex":0.00014219122,"about_ca_system_score_gemma":0.00020006973,"threshold_uncertainty_score":0.9957155},"labels":[],"label_agreement":null},{"id":"W4405054112","doi":"10.1182/blood-2024-199839","title":"Beyond Bleeding: Unpacking Gender Disparities in Von Willebrand Disease Clinical Trials of the Past Half-Century","year":2024,"lang":"en","type":"article","venue":"Blood","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Unpacking; Medicine; Von Willebrand disease; Von Willebrand factor; Clinical trial; Disease; Internal medicine; Platelet","score_opus":0.07835661219272597,"score_gpt":0.37022684736031647,"score_spread":0.2918702351675905,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4405054112","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9812139,0.011492003,0.000004794746,0.0040415507,0.0006683191,0.0007177273,0.00006660386,0.000031189957,0.0017638884],"genre_scores_gemma":[0.99711406,0.0016773688,0.00006428468,0.00029937353,0.00056114065,0.00008315379,0.000023082355,0.000022610491,0.00015493356],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99803406,0.00030934156,0.0008206261,0.0003173463,0.00030890413,0.00020974074],"domain_scores_gemma":[0.99840367,0.0010185364,0.00011596345,0.00025637858,0.00004571001,0.00015973252],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012418071,0.0001733758,0.0006309832,0.000094347895,0.000051235773,0.000044768665,0.0000750816,0.000085749656,0.00011668169],"category_scores_gemma":[0.00080919435,0.00009730876,0.00038083803,0.00020254095,0.00010977286,0.000062503655,0.00006236696,0.00023721391,0.000008679358],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00017490209,0.0014920945,0.98808235,0.00038313822,0.00046122013,0.0001371247,0.0003029685,0.0000026340626,0.00014910025,0.005921188,0.0011900367,0.0017032466],"study_design_scores_gemma":[0.007884778,0.00022382036,0.9792513,0.0013492996,0.0021701981,0.00002103999,0.00016945842,0.00010604991,0.0025429572,0.0016632947,0.004441461,0.00017629488],"about_ca_topic_score_codex":0.000018939709,"about_ca_topic_score_gemma":0.0000170287,"teacher_disagreement_score":0.015900128,"about_ca_system_score_codex":0.000027721762,"about_ca_system_score_gemma":0.00016801285,"threshold_uncertainty_score":0.3968136},"labels":[],"label_agreement":null},{"id":"W4405096042","doi":"10.1182/blood-2024-200319","title":"HOPE-PMF: A Randomized, Double-Blind, Placebo-Controlled Phase 3 Study to Assess Efficacy and Safety of Ropeginterferon Alfa-2b in Patients with Early/Lower-Risk Primary Myelofibrosis","year":2024,"lang":"en","type":"article","venue":"Blood","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Daiichi Sankyo Europe; Chugai Pharmaceutical; Genentech; Swedish Orphan Biovitrum; Eisai; Sierra Oncology; CTI Biopharma; Incyte; Novartis Pharma; Otsuka Pharmaceutical; Astellas Pharma; Ariad Pharmaceuticals; MorphoSys; Celgene; Gilead Sciences; Meiji Seika Pharma; AOP Orphan; Torii Pharmaceutical; Bristol-Myers Squibb","keywords":"Myelofibrosis; Medicine; Placebo; Internal medicine; Randomized controlled trial; Phases of clinical research; Double blind; Clinical trial; Oncology; Alternative medicine; Pathology; Bone marrow","score_opus":0.01651577286164992,"score_gpt":0.2874387472039899,"score_spread":0.27092297434234,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4405096042","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9848089,0.0005559139,0.000079625446,0.00018820835,0.0001157382,0.013485694,0.000064570944,0.0000481821,0.0006531171],"genre_scores_gemma":[0.99763274,0.00013248214,0.00042496828,0.000060417555,0.000062516156,0.0013549865,0.000047429432,0.000057310805,0.0002271542],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9973477,0.0003403497,0.0007327262,0.0006945982,0.0005434944,0.00034114695],"domain_scores_gemma":[0.99816924,0.0008437096,0.00016985176,0.00040093798,0.00016927168,0.00024696154],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0007974536,0.00043163483,0.0018414714,0.0003850612,0.00007103582,0.000093373295,0.00009869089,0.00007852823,0.000081386046],"category_scores_gemma":[0.0001333064,0.00026771773,0.00017528744,0.00040204742,0.00007796815,0.00013833947,0.000098623794,0.00027165472,0.000025671956],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.7478186,0.019397719,0.22595686,0.00011995767,0.0025256332,0.000118733995,0.0016512455,0.0000116061265,0.000058988368,0.000018281318,0.000034080862,0.0022882903],"study_design_scores_gemma":[0.8401021,0.012320053,0.14256577,0.00076143065,0.0029889036,0.0000052456703,0.000077231605,0.00002547485,0.00088123884,0.0000017154307,0.000043688648,0.00022718613],"about_ca_topic_score_codex":0.00022112983,"about_ca_topic_score_gemma":0.00013497107,"teacher_disagreement_score":0.09228345,"about_ca_system_score_codex":0.00009659545,"about_ca_system_score_gemma":0.0001450496,"threshold_uncertainty_score":0.9999775},"labels":[],"label_agreement":null},{"id":"W4405096106","doi":"10.1182/blood-2024-205767","title":"Odyssey: A Phase 2 Open-Label Study of Momelotinib in Combination with Luspatercept in Patients with Transfusion-Dependent Myelofibrosis","year":2024,"lang":"en","type":"article","venue":"Blood","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Myelofibrosis; Medicine; Open label; Phases of clinical research; Ruxolitinib; Surgery; Internal medicine; Clinical trial; Bone marrow","score_opus":0.02033822022441533,"score_gpt":0.29750628624004904,"score_spread":0.2771680660156337,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4405096106","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99586195,0.000064390115,0.000010838991,0.00015791375,0.00003456434,0.0034385857,0.000030957377,0.000020596332,0.00038019096],"genre_scores_gemma":[0.9989643,0.000033344997,0.00023734153,0.000030350473,0.000008460356,0.00054161064,0.00006633487,0.00003350927,0.00008472607],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99847454,0.00007861659,0.00037017683,0.00043570352,0.00044364872,0.00019729172],"domain_scores_gemma":[0.9994806,0.0000619668,0.000057433066,0.00022248134,0.00009903379,0.000078476376],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00015205685,0.00021486702,0.0004678797,0.00029843653,0.0000323899,0.00004644644,0.00009402551,0.0000518543,0.00009924308],"category_scores_gemma":[0.000009927926,0.00013989343,0.00001719276,0.0005371919,0.000025858788,0.00016471608,0.000039030598,0.00015247498,0.000009044213],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0019092065,0.12564565,0.8630315,0.00013273688,0.00025555876,0.00022885976,0.0046271603,0.0000065702843,0.00023100372,0.000049788676,0.0000084596495,0.0038734963],"study_design_scores_gemma":[0.15977271,0.028509082,0.80568683,0.0009391488,0.0003461992,0.0000069191906,0.0006313322,0.00006742562,0.0038605835,0.000010574455,0.000009708373,0.00015950855],"about_ca_topic_score_codex":0.0007540432,"about_ca_topic_score_gemma":0.0032784438,"teacher_disagreement_score":0.1578635,"about_ca_system_score_codex":0.00007656544,"about_ca_system_score_gemma":0.00010843732,"threshold_uncertainty_score":0.5704688},"labels":[],"label_agreement":null},{"id":"W4405096216","doi":"10.1182/blood-2024-193907","title":"Monocytosis Is an Independent Risk Factor for Survival in Essential Thrombocythemia - a Revised Triple-a Prognostic Score (AAA+A) Based on Age and Absolute Monocyte, Neutrophil, and Lymphocyte Counts","year":2024,"lang":"en","type":"article","venue":"Blood","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal","funders":"","keywords":"Monocytosis; Medicine; Internal medicine; Essential thrombocythemia; Absolute neutrophil count; Lymphocyte; Immunology; Gastroenterology; Platelet; Neutropenia","score_opus":0.03477717518231871,"score_gpt":0.29505890667816126,"score_spread":0.26028173149584255,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4405096216","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9950589,0.0021069525,0.000054078628,0.00019504516,0.00015864683,0.0015145545,0.00058493216,0.000060545623,0.00026632397],"genre_scores_gemma":[0.9972611,0.0015432023,0.0003975861,0.00014970651,0.00015369365,0.00027371617,0.00006072095,0.000048176295,0.000112088426],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9985885,0.000059491027,0.0002658189,0.0005710703,0.00024958418,0.00026554853],"domain_scores_gemma":[0.9992623,0.0002289399,0.0000616326,0.00023247319,0.000042054748,0.00017264072],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00014445397,0.00027091222,0.00045310776,0.00016953918,0.000078934936,0.000115114985,0.00005068781,0.00012735397,0.00009246233],"category_scores_gemma":[0.00006746881,0.00021519708,0.00008513698,0.00014265368,0.00005289068,0.00008012067,0.000026828504,0.00015541141,0.000012074441],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.006590087,0.010860181,0.82039046,0.0053468673,0.003420828,0.004837129,0.0049829655,0.000055496588,0.008061858,0.0014702929,0.0016298447,0.132354],"study_design_scores_gemma":[0.030672822,0.003763719,0.92373383,0.0016617266,0.0018788854,0.00006948475,0.000074116506,0.017820325,0.01753459,0.00024977696,0.0018902019,0.0006504992],"about_ca_topic_score_codex":0.00007485178,"about_ca_topic_score_gemma":0.00006922,"teacher_disagreement_score":0.1317035,"about_ca_system_score_codex":0.00009902229,"about_ca_system_score_gemma":0.00016983155,"threshold_uncertainty_score":0.8775483},"labels":[],"label_agreement":null},{"id":"W4405367959","doi":"10.1159/000538206","title":"Hemostasis and Its Regulation","year":2024,"lang":"en","type":"book-chapter","venue":"","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Research Institute in Oncology and Hematology; Children's Hospital Research Institute of Manitoba; CancerCare Manitoba; Hospital for Sick Children","funders":"","keywords":"Hemostasis; Medicine; Internal medicine","score_opus":0.03013514456647138,"score_gpt":0.2754049817119563,"score_spread":0.24526983714548495,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4405367959","genre_codex":"other","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"other","genre_consensus":"other","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00070129044,0.006757635,0.0000036736847,0.0038801776,0.00011535354,0.0005276152,0.000037878268,0.00008276491,0.98789364],"genre_scores_gemma":[0.026975645,0.0021373106,0.00020100888,0.00043512537,0.00019649035,0.000024558996,0.00014052687,0.00004861221,0.9698407],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","domain_scores_codex":[0.9992018,0.0000021554802,0.0001783314,0.0003361721,0.00018760124,0.000093967115],"domain_scores_gemma":[0.9995941,0.000042312826,0.00003852671,0.00014480673,0.000074417774,0.00010581591],"candidate_categories":["insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.00003594084,0.00023296937,0.00033386188,0.00010531499,0.000032750424,0.000024458652,0.0000143419065,0.0001928525,0.004112015],"category_scores_gemma":[0.000007539526,0.00016329273,0.00008645831,0.000013649537,0.000019739815,0.000023751625,0.00003327425,0.00014301273,0.0008730769],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000037468242,0.000027025348,0.0001337581,0.00028551626,0.00046624147,0.00016137818,0.000057360736,1.5829733e-7,0.000033368975,0.9630525,0.018099613,0.017645601],"study_design_scores_gemma":[0.00087084516,0.00047911596,0.0012520368,0.0011906184,0.0011753532,0.00022373091,0.000008161904,0.00015847832,0.0032738585,0.031711023,0.9593248,0.00033197485],"about_ca_topic_score_codex":0.000003214543,"about_ca_topic_score_gemma":0.000012287525,"teacher_disagreement_score":0.9412252,"about_ca_system_score_codex":0.00007214383,"about_ca_system_score_gemma":0.000040884395,"threshold_uncertainty_score":0.9999049},"labels":[],"label_agreement":null},{"id":"W4405585460","doi":"10.1111/bjh.19944","title":"Olutasidenib demonstrates significant clinical activity in mutated <i>IDH1</i> acute myeloid leukaemia arising from a prior myeloproliferative neoplasm","year":2024,"lang":"en","type":"article","venue":"British Journal of Haematology","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Medicine; Internal medicine; Myeloproliferative neoplasm; Gastroenterology; IDH1; Myeloid; Refractory (planetary science); Confidence interval; Adverse effect; Azacitidine; Myeloid leukaemia; Surgery; Oncology; Myelofibrosis; Bone marrow; Biology","score_opus":0.023683305550631133,"score_gpt":0.3325004295931669,"score_spread":0.30881712404253575,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4405585460","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9879293,0.0062389,0.00061924494,0.0033101777,0.0007814223,0.0006467599,0.00011881124,0.0000674274,0.00028797204],"genre_scores_gemma":[0.9901832,0.0046105594,0.004206907,0.0004553239,0.0003538259,0.000042898642,0.000032765132,0.000060472794,0.000054098706],"study_design_codex":"case_report","study_design_gemma":"case_report","domain_scores_codex":[0.9957589,0.00066223764,0.0018244827,0.0006788938,0.00047638282,0.0005991218],"domain_scores_gemma":[0.9967664,0.0017133768,0.0005276405,0.00022063061,0.00034665293,0.0004253125],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00088858197,0.0004127762,0.0020744647,0.0002949525,0.00014357975,0.00022726241,0.00019498449,0.00044995395,0.00015802849],"category_scores_gemma":[0.00059824524,0.00038047513,0.0004958062,0.0004602992,0.0003596804,0.0004142591,0.00007694606,0.0017505501,0.000066378394],"study_design_candidate":"case_report","study_design_consensus":"case_report","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0017666003,0.0018182294,0.22730361,0.00020390165,0.0035528976,0.61552316,0.00086205517,0.00004725795,0.007560525,0.0002926164,0.004429532,0.1366396],"study_design_scores_gemma":[0.0134484405,0.0028323082,0.43242273,0.007332523,0.0021783118,0.45505124,0.0006480375,0.002616539,0.07750918,0.003333847,0.0016780578,0.00094876834],"about_ca_topic_score_codex":0.00038031046,"about_ca_topic_score_gemma":0.0007507143,"teacher_disagreement_score":0.20511913,"about_ca_system_score_codex":0.0002763617,"about_ca_system_score_gemma":0.0014279074,"threshold_uncertainty_score":0.9998647},"labels":[],"label_agreement":null},{"id":"W4405751065","doi":"10.1016/j.jval.2024.10.3708","title":"RWD150 First Patient Enrolled in Pilot Phase of the Economics and Patient Outcomes in China in Hemophilia (EPOCH) Study","year":2024,"lang":"en","type":"article","venue":"Value in Health","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University","funders":"","keywords":"Epoch (astronomy); China; Medicine; Phase (matter); Pediatrics; Family medicine; Political science; Astronomy; Physics; Quantum mechanics","score_opus":0.03346837752971393,"score_gpt":0.3145139233185352,"score_spread":0.2810455457888213,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4405751065","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9864976,0.0014898456,1.641774e-7,0.008724603,0.00021713407,0.0029544234,0.000030117473,0.000008029,0.000078112986],"genre_scores_gemma":[0.9984665,0.0008396163,0.000048585665,0.0003276379,0.000009614918,0.000272808,0.0000046792024,0.000018019957,0.000012562012],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9980506,0.00024450055,0.00092400145,0.00036176635,0.0001545181,0.00026464232],"domain_scores_gemma":[0.9992768,0.00025879493,0.00011703696,0.0002500438,0.0000120156865,0.00008528633],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00043757755,0.00018935143,0.00064801244,0.00034610266,0.000031891002,0.000012465635,0.000054854983,0.00004005334,0.000015272248],"category_scores_gemma":[0.00011169006,0.0001258245,0.000046519446,0.0003381213,0.00003250815,0.000044371485,0.00006834328,0.00025258222,0.0000028430195],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00034774485,0.0071588242,0.9644554,0.0002649414,0.000030386364,0.00009155138,0.01834925,0.002357487,0.0000021578792,0.00042208476,0.0000351458,0.006485008],"study_design_scores_gemma":[0.010047722,0.005640538,0.97544223,0.0009385349,0.000010514917,0.000007681169,0.0009843248,0.0061076423,0.000094549025,0.00042399432,0.00019153622,0.00011075559],"about_ca_topic_score_codex":0.010819277,"about_ca_topic_score_gemma":0.0101220375,"teacher_disagreement_score":0.017364925,"about_ca_system_score_codex":0.00061346526,"about_ca_system_score_gemma":0.00028372498,"threshold_uncertainty_score":0.9957678},"labels":[],"label_agreement":null},{"id":"W4405760701","doi":"10.1016/j.jbior.2024.101072","title":"Molecular basis of JAK kinase regulation guiding therapeutic approaches: Evaluating the JAK3 pseudokinase domain as a drug target","year":2024,"lang":"en","type":"review","venue":"Advances in Biological Regulation","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Syöpäsäätiö; Paulon Säätiö; Tampereen Tuberkuloosisäätiö; Syöpäjärjestöt; Tays; Sigrid Juséliuksen Säätiö; Structural Genomics Consortium; Academy of Finland","keywords":"Kinase; Janus kinase; Cancer research; Computational biology; Biology; Tofacitinib; Drug development; Cell biology; Drug; Pharmacology; Immunology","score_opus":0.15704109790465737,"score_gpt":0.4137394905043695,"score_spread":0.2566983925997121,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4405760701","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.011329985,0.98357403,0.00047515018,0.00038607328,0.00016430215,0.0028292725,0.000023828801,0.00005051648,0.0011668539],"genre_scores_gemma":[0.10339825,0.8903137,0.004315104,0.00008048799,0.00014962736,0.0010643388,0.00054258,0.000048755828,0.00008716387],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99613374,0.000971813,0.0011781139,0.00084308087,0.00053291273,0.00034035355],"domain_scores_gemma":[0.99775386,0.0008834894,0.00062303274,0.00054890185,0.000110332105,0.00008036083],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0014349989,0.00057460397,0.0015339334,0.0002565198,0.00011222449,0.00003450159,0.0001930943,0.0003658851,0.00011574173],"category_scores_gemma":[0.0005269101,0.00029244096,0.0005633571,0.0008532253,0.00022380233,0.00012631797,0.00010283734,0.00033170125,0.00002462603],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00013563724,0.0002762964,0.0004525892,0.003959568,0.0002668261,0.00003554611,0.00021944488,0.00041415085,0.00017801861,0.026263706,0.000018045532,0.9677802],"study_design_scores_gemma":[0.0030405184,0.0038872932,0.0026248,0.05569015,0.0055030547,0.00030058075,0.00064955506,0.008849017,0.0025664102,0.16633089,0.74875265,0.0018050498],"about_ca_topic_score_codex":0.000008697037,"about_ca_topic_score_gemma":0.0000041788644,"teacher_disagreement_score":0.9659751,"about_ca_system_score_codex":0.00038802443,"about_ca_system_score_gemma":0.00017721282,"threshold_uncertainty_score":0.9999528},"labels":[],"label_agreement":null},{"id":"W4405837485","doi":"10.1182/bloodadvances.2024014625","title":"Real-world treatment patterns and health care resource use for patients with myelofibrosis: results from the METER study","year":2024,"lang":"en","type":"article","venue":"Blood Advances","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"Astellas Pharma; Incyte; CSL Behring; Gilead Sciences; Division of Materials Research; Celgene; BeiGene; Daiichi Sankyo Europe; Sanofi; Chugai Pharmaceutical; Pfizer; Amgen","keywords":"Medicine; Myelofibrosis; Ruxolitinib; Transplantation; Observational study; Internal medicine; Retrospective cohort study; Pediatrics; Intensive care unit; Bone marrow","score_opus":0.028132859133466397,"score_gpt":0.3150878821616425,"score_spread":0.2869550230281761,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4405837485","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9883457,0.004123951,0.0000068264185,0.0022555154,0.000080292026,0.003116616,0.001897637,0.00007396135,0.00009951385],"genre_scores_gemma":[0.9949436,0.001296617,0.0014207575,0.0003493835,0.00017690053,0.00081834,0.00066045934,0.000037657584,0.00029627501],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9985523,0.00007364822,0.00029579864,0.0005899192,0.00024626055,0.00024207408],"domain_scores_gemma":[0.99868363,0.0006928345,0.00008674192,0.00034227545,0.00007135584,0.00012317867],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00007549976,0.00026619068,0.00038470156,0.000056377045,0.0002042855,0.000113547474,0.00004756366,0.000022616412,0.0000056316576],"category_scores_gemma":[0.000022842389,0.00012732847,0.00006643483,0.000119231205,0.000034358294,0.00013734003,0.000025450425,0.00006588989,0.0000020775012],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00087960385,0.0012618682,0.946579,0.00007341528,0.00071331573,0.00002682851,0.008160647,0.0000029371288,0.0000010156631,0.0000268546,0.0004123773,0.04186213],"study_design_scores_gemma":[0.009216625,0.010236249,0.9327945,0.00066667795,0.00085833744,0.0000015167684,0.0024810373,0.0000054518305,0.00036869018,0.000008357026,0.04321699,0.00014554091],"about_ca_topic_score_codex":0.0023633419,"about_ca_topic_score_gemma":0.013021837,"teacher_disagreement_score":0.04280461,"about_ca_system_score_codex":0.00011408538,"about_ca_system_score_gemma":0.00007314953,"threshold_uncertainty_score":0.72664905},"labels":[],"label_agreement":null},{"id":"W4406091233","doi":"10.58931/cht.2024.3357","title":"Treatment of Philadelphia Chromosome-negative Myeloproliferative Neoplasms in 2024: A Concise Review","year":2024,"lang":"en","type":"review","venue":"Canadian Hematology Today","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Philadelphia chromosome; Genetics; Chromosome; Genealogy; Biology; Medicine; History; Chromosomal translocation; Gene","score_opus":0.05218010246034125,"score_gpt":0.3594279745392955,"score_spread":0.3072478720789542,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4406091233","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000038086557,0.9833996,3.27886e-7,0.004294265,0.0005890281,0.006506403,0.0009823471,0.00004241119,0.0041475263],"genre_scores_gemma":[0.00038182104,0.99146545,0.00012695738,0.0006402259,0.00016548601,0.0043265224,0.00067738624,0.00014804525,0.0020680996],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99507177,0.00041101367,0.0019319915,0.0013064075,0.00031150365,0.0009673332],"domain_scores_gemma":[0.9966758,0.0006603446,0.00052256096,0.0008916029,0.00023493104,0.001014744],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":["metaepi_narrow","insufficient_payload"],"category_scores_codex":[0.00018574233,0.0013396316,0.0080974605,0.0013433484,0.00008743186,0.000023254013,0.00022768517,0.0008752146,0.0019723496],"category_scores_gemma":[0.00030793456,0.0009253179,0.0011783673,0.0013719359,0.0003473054,0.000067191686,0.00004731524,0.0006915337,0.001047997],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00013315646,0.0020856133,0.001663873,0.3686253,0.011755977,0.046843674,0.0028908465,8.2917876e-7,4.6994887e-7,0.027813315,0.11313799,0.42504895],"study_design_scores_gemma":[0.0013284561,0.0010913468,0.00002098199,0.12253442,0.0063991267,0.0036727097,0.00004878418,0.0000061254323,0.000029180332,0.000119097815,0.86415666,0.0005931321],"about_ca_topic_score_codex":0.0073793638,"about_ca_topic_score_gemma":0.061950866,"teacher_disagreement_score":0.75101864,"about_ca_system_score_codex":0.0029218723,"about_ca_system_score_gemma":0.009106553,"threshold_uncertainty_score":0.9999355},"labels":[],"label_agreement":null},{"id":"W4406390902","doi":"10.1016/s1155-1984(95)13215-x","title":"10.1016/s1155-1984(95)13215-x","year":2000,"lang":"en","type":"article","venue":"Time to knit","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Physics","score_opus":0.0077078644785394295,"score_gpt":0.20378326216886805,"score_spread":0.1960753976903286,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4406390902","genre_codex":"other","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"other","genre_consensus":"other","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0077088135,0.0002557407,3.6432755e-7,0.0018627039,0.0000020988527,0.0005651234,0.000028623026,0.00012736184,0.98944914],"genre_scores_gemma":[0.0014626781,0.0000047275835,0.00030131664,0.0003249906,0.00022261977,0.00014287361,0.00006595694,0.00003541589,0.99743944],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9988321,0.00003452054,0.00022317797,0.00033395592,0.00025682335,0.00031941975],"domain_scores_gemma":[0.9991485,0.00007227601,0.000028174418,0.00035725356,0.000070586626,0.00032322804],"candidate_categories":["insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.000085659376,0.00021662204,0.00034596687,0.00006517341,0.00008520012,0.000026947224,0.00008123773,0.00007688174,0.99775755],"category_scores_gemma":[0.00004212688,0.00017301933,0.00010828251,0.00018937093,0.00003157815,0.000053903823,0.000024512789,0.000117374606,0.9941653],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00031314488,0.00042531636,0.000018873154,0.000014274494,0.000111311914,0.000078280784,0.000035214387,0.000012719779,0.00005572203,0.0000035277562,0.5011546,0.49777701],"study_design_scores_gemma":[0.0012753971,0.0009062017,0.0011358209,0.0000733735,0.00010874362,0.000051394476,0.0000013421127,0.00007745967,0.0011168844,0.0000052029,0.9950763,0.00017188201],"about_ca_topic_score_codex":0.000028328845,"about_ca_topic_score_gemma":4.7235437e-7,"teacher_disagreement_score":0.49760514,"about_ca_system_score_codex":0.00008454959,"about_ca_system_score_gemma":0.000063307394,"threshold_uncertainty_score":0.7055524},"labels":[],"label_agreement":null},{"id":"W4406412484","doi":"10.1016/s2211-9698(16)59084-0","title":"10.1016/s2211-9698(16)59084-0","year":2000,"lang":"en","type":"article","venue":"Time to knit","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Philosophy","score_opus":0.007607357722860121,"score_gpt":0.2035666330413411,"score_spread":0.19595927531848098,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4406412484","genre_codex":"other","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"other","genre_consensus":"other","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.007611962,0.00017595722,5.9576143e-7,0.0020689575,0.0000021681176,0.0005483366,0.000023889059,0.00012250687,0.9894456],"genre_scores_gemma":[0.002437255,0.000003030556,0.00024107698,0.0003220331,0.00023654346,0.00013640466,0.000064636755,0.00003556292,0.99652344],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99882233,0.000034911955,0.00022395953,0.00033355993,0.00026413676,0.00032110684],"domain_scores_gemma":[0.99915254,0.000068818415,0.000028327106,0.0003605036,0.000072240815,0.00031759116],"candidate_categories":["insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.00009008227,0.00021760217,0.00034768303,0.000082301194,0.000087163324,0.000028193499,0.00008090955,0.00007763065,0.9979615],"category_scores_gemma":[0.00004140131,0.00017328661,0.00011061982,0.0001886778,0.000031773066,0.00005367797,0.000024510802,0.000117580865,0.99436307],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00026391709,0.00040946616,0.000023417686,0.000012830682,0.00011076129,0.000058355625,0.00002665508,0.000007935924,0.000030759267,0.000004658155,0.45334494,0.54570633],"study_design_scores_gemma":[0.0012835643,0.0008453524,0.0011832396,0.00006810241,0.00011139584,0.000052455092,0.0000015016814,0.000040284922,0.0011880342,0.000007418212,0.99504733,0.00017133146],"about_ca_topic_score_codex":0.000037816837,"about_ca_topic_score_gemma":0.0000011018046,"teacher_disagreement_score":0.54553497,"about_ca_system_score_codex":0.00012738688,"about_ca_system_score_gemma":0.000060995677,"threshold_uncertainty_score":0.7066423},"labels":[],"label_agreement":null},{"id":"W4406443449","doi":"10.1016/s0246-0521(21)44704-2","title":"10.1016/s0246-0521(21)44704-2","year":2000,"lang":"en","type":"article","venue":"Time to knit","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Medicine","score_opus":0.008717493563180924,"score_gpt":0.2101723023293971,"score_spread":0.2014548087662162,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4406443449","genre_codex":"other","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"other","genre_consensus":"other","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0045736027,0.00016522665,4.4634325e-7,0.0022397093,0.0000018825843,0.0005587569,0.000023774595,0.0001253957,0.9923112],"genre_scores_gemma":[0.0017977222,0.000003465004,0.00029904465,0.00029538383,0.00022370114,0.00012444542,0.000057016987,0.00003574996,0.9971635],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99881333,0.000035748828,0.00022212106,0.00033425604,0.00027001894,0.00032451475],"domain_scores_gemma":[0.9991389,0.000078602476,0.00002706179,0.0003551327,0.0000755738,0.0003247415],"candidate_categories":["insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.00009706878,0.00021491812,0.00034230467,0.0000843175,0.00008343362,0.000029190065,0.000081485894,0.000078399986,0.99789137],"category_scores_gemma":[0.00004617598,0.00017056022,0.00010715622,0.00018912082,0.000032323027,0.000053303418,0.000025085228,0.00012346903,0.99457544],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00026544547,0.00037566732,0.000017680444,0.000015045495,0.000101823796,0.00007601887,0.0000356141,0.00000910256,0.000047458583,0.000002148031,0.6732623,0.3257917],"study_design_scores_gemma":[0.0011887881,0.0008635455,0.0011620147,0.00008231111,0.00010176408,0.000051294104,0.0000014153886,0.000057170844,0.0014088884,0.000006814334,0.99490744,0.00016856476],"about_ca_topic_score_codex":0.000030388406,"about_ca_topic_score_gemma":5.969049e-7,"teacher_disagreement_score":0.32562312,"about_ca_system_score_codex":0.000091431204,"about_ca_system_score_gemma":0.000068944995,"threshold_uncertainty_score":0.6955244},"labels":[],"label_agreement":null},{"id":"W4406472220","doi":"10.1038/s41467-024-55643-7","title":"RSK1 is an exploitable dependency in myeloproliferative neoplasms and secondary acute myeloid leukemia","year":2025,"lang":"en","type":"article","venue":"Nature Communications","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":14,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"National Center for Advancing Translational Sciences; National Institute of Arthritis and Musculoskeletal and Skin Diseases; National Institute of General Medical Sciences; National Cancer Institute; National Heart, Lung, and Blood Institute; Edward P. Evans Foundation; U.S. Department of Health and Human Services; National Institutes of Health; Alvin J. Siteman Cancer Center; Institute of Clinical and Translational Sciences; Memorial Sloan-Kettering Cancer Center; Hyundai Hope On Wheels; Canadian Institutes of Health Research; Leukemia and Lymphoma Society; MPN Research Foundation; McGill University; U.S. Department of Defense","keywords":"Myeloid leukemia; Dependency (UML); Myeloid; Leukemia; Cancer research; Medicine; Biology; Computer science; Immunology","score_opus":0.019371731891371792,"score_gpt":0.32308257496370985,"score_spread":0.30371084307233803,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4406472220","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9179459,0.024833148,0.000042993295,0.02433771,0.00018373888,0.0014970343,0.0001486067,0.00013218011,0.030878684],"genre_scores_gemma":[0.97148794,0.009883334,0.01045881,0.0055849697,0.000032269312,0.00054192083,0.00032354274,0.00002570635,0.0016614884],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99840903,0.00017396068,0.00041387184,0.0004809047,0.00020904206,0.00031319694],"domain_scores_gemma":[0.9974743,0.00035968487,0.000090329915,0.0016532365,0.00025082822,0.00017160934],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00022110004,0.00029498333,0.0004895979,0.00035274605,0.00039890438,0.000077346434,0.0004265541,0.0004330804,0.00013242652],"category_scores_gemma":[0.00012426589,0.0002593085,0.00007841931,0.0006277624,0.00016769771,0.0003531059,0.0003416561,0.0015811322,0.000024418468],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00044383682,0.0021993278,0.7771536,0.00016001881,0.0013383889,0.00010631178,0.008552906,0.000007937438,0.002980444,0.14980449,0.018053109,0.039199628],"study_design_scores_gemma":[0.00834383,0.0007837847,0.87780046,0.00068942795,0.0007294088,0.00019904335,0.0025686203,0.0020273686,0.022512069,0.00708452,0.076512724,0.00074876234],"about_ca_topic_score_codex":0.00013815862,"about_ca_topic_score_gemma":0.0030908496,"teacher_disagreement_score":0.14271997,"about_ca_system_score_codex":0.0003843655,"about_ca_system_score_gemma":0.0007707387,"threshold_uncertainty_score":0.99998593},"labels":[],"label_agreement":null},{"id":"W4406574032","doi":"10.1016/s1634-6939(20)30318-5","title":"10.1016/s1634-6939(20)30318-5","year":2000,"lang":"en","type":"article","venue":"Time to knit","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Computer science","score_opus":0.007430796912036011,"score_gpt":0.20285926658972478,"score_spread":0.19542846967768876,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4406574032","genre_codex":"other","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"other","genre_consensus":"other","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.006729296,0.00017142837,4.1647664e-7,0.0024124426,0.000002074856,0.0005490985,0.000029662391,0.00012525158,0.98998034],"genre_scores_gemma":[0.0013323026,0.0000025107793,0.00029691093,0.00031063744,0.00023553551,0.0001358617,0.00007436263,0.000035642326,0.99757624],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9988153,0.000034596404,0.00022417612,0.00033533055,0.00026561687,0.00032495253],"domain_scores_gemma":[0.99915016,0.00007030025,0.000028143857,0.00036174452,0.000072364375,0.00031728455],"candidate_categories":["insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.000089052686,0.00021813778,0.00034849078,0.00008280608,0.00008744113,0.000027983348,0.00008182766,0.00007735952,0.9977577],"category_scores_gemma":[0.000037169128,0.00017363383,0.00010740867,0.00018808332,0.000032783693,0.00005410515,0.000024601815,0.00011230687,0.99416983],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0003058381,0.00044219647,0.000019346422,0.000014413122,0.00011773592,0.00008661593,0.000036462465,0.000015168098,0.00006360256,0.0000032297892,0.502898,0.49599743],"study_design_scores_gemma":[0.0012744756,0.0008704598,0.0008763566,0.00006788686,0.00011029646,0.000054725337,0.0000013147069,0.00006682314,0.0011310681,0.000005948941,0.9953687,0.00017195367],"about_ca_topic_score_codex":0.00002317563,"about_ca_topic_score_gemma":7.1834546e-7,"teacher_disagreement_score":0.49582547,"about_ca_system_score_codex":0.00008918458,"about_ca_system_score_gemma":0.0000617215,"threshold_uncertainty_score":0.7080582},"labels":[],"label_agreement":null},{"id":"W4406578853","doi":"10.1016/s1541-9800(07)70509-4","title":"10.1016/s1541-9800(07)70509-4","year":2000,"lang":"en","type":"article","venue":"Time to knit","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Medicine; Computer science; Internal medicine","score_opus":0.007943441495525836,"score_gpt":0.20540275862871674,"score_spread":0.1974593171331909,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4406578853","genre_codex":"other","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"other","genre_consensus":"other","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00905086,0.0001678231,3.813009e-7,0.0021442268,0.000002058187,0.00054845866,0.000024759971,0.000121888,0.98793954],"genre_scores_gemma":[0.0019201604,0.0000030946205,0.00031272706,0.00031787323,0.00022750322,0.00013279454,0.000061248174,0.000035264085,0.9969893],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99881834,0.00003461674,0.00022438246,0.00033518302,0.00026535767,0.0003221035],"domain_scores_gemma":[0.9991503,0.0000716123,0.000028164184,0.00035972078,0.00007168761,0.00031854757],"candidate_categories":["insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.00008903515,0.0002180835,0.0003490131,0.0000781762,0.00008715382,0.00002821956,0.00008142822,0.00007720406,0.9985705],"category_scores_gemma":[0.000041198175,0.00017358766,0.00010856923,0.00016990423,0.000031800373,0.000054236036,0.000024310875,0.000117714495,0.99699694],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000315525,0.0004658385,0.000022094067,0.000015300444,0.00012321999,0.00009559382,0.000042086496,0.000012592759,0.00004594725,0.000003886298,0.48915458,0.50970334],"study_design_scores_gemma":[0.0012790114,0.0008620854,0.0014753315,0.00006943356,0.00010836992,0.000055450044,0.0000013988271,0.000058161942,0.0010425942,0.0000066688476,0.9948695,0.00017203695],"about_ca_topic_score_codex":0.000028230303,"about_ca_topic_score_gemma":4.937274e-7,"teacher_disagreement_score":0.5095313,"about_ca_system_score_codex":0.00008731221,"about_ca_system_score_gemma":0.00005924039,"threshold_uncertainty_score":0.7078699},"labels":[],"label_agreement":null},{"id":"W4406640906","doi":"10.1016/b978-2-294-08855-1.50063-2","title":"10.1016/b978-2-294-08855-1.50063-2","year":2000,"lang":"en","type":"book-chapter","venue":"Time to knit","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Computer science","score_opus":0.012036156488337326,"score_gpt":0.20413320986353706,"score_spread":0.19209705337519972,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4406640906","genre_codex":"other","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"other","genre_consensus":"other","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000007906956,0.0008384413,3.0171364e-7,0.001022521,0.000006806786,0.0013138702,0.00023617453,0.00018557368,0.9963884],"genre_scores_gemma":[0.000006755046,0.000013476977,0.00018612054,0.00031811357,0.0007869368,0.00015765353,0.0005724403,0.00018667907,0.9977718],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.997638,0.000021976488,0.0005218075,0.0007811675,0.0005756367,0.00046145427],"domain_scores_gemma":[0.9982571,0.00012843475,0.00014404436,0.00078045455,0.0001645483,0.0005254452],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.000105045554,0.0007378839,0.001107312,0.0003059764,0.00011247418,0.00004807719,0.00017237295,0.00045920195,0.9980707],"category_scores_gemma":[0.000031742118,0.0006270797,0.00038157732,0.000057948837,0.00008112848,0.000048034864,0.000086096785,0.00045949325,0.99617916],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00040912826,0.00020600273,6.2371754e-7,0.00005546288,0.00057968916,0.00037186654,0.00001950283,0.000003143027,0.000004511038,0.00020430336,0.44174975,0.556396],"study_design_scores_gemma":[0.0012574063,0.0012732649,0.000025371524,0.0006015734,0.0006299389,0.00011785647,3.2651525e-7,0.000006754759,0.000102205355,0.0001527088,0.9952903,0.0005423353],"about_ca_topic_score_codex":0.000020111758,"about_ca_topic_score_gemma":0.0000011872149,"teacher_disagreement_score":0.55585366,"about_ca_system_score_codex":0.00026212778,"about_ca_system_score_gemma":0.00020489492,"threshold_uncertainty_score":0.99961805},"labels":[],"label_agreement":null},{"id":"W4406643207","doi":"10.1016/b978-2-294-76306-9.50348-3","title":"10.1016/b978-2-294-76306-9.50348-3","year":2000,"lang":"en","type":"book-chapter","venue":"Time to knit","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Computer science","score_opus":0.012122343585305,"score_gpt":0.20428506017428733,"score_spread":0.19216271658898232,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4406643207","genre_codex":"other","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"other","genre_consensus":"other","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000007924213,0.00076267077,2.9796456e-7,0.0010498073,0.0000068864792,0.001321733,0.00022072151,0.00018572858,0.9964442],"genre_scores_gemma":[0.000007190462,0.000013158956,0.00018124246,0.00032550705,0.0008043688,0.00015827252,0.0005535922,0.00018901209,0.9977676],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99763894,0.000022023647,0.0005209567,0.0007808993,0.0005776426,0.00045951013],"domain_scores_gemma":[0.99824286,0.00013087771,0.00014376006,0.0007812557,0.00016547229,0.00053576403],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.00010478098,0.0007391762,0.0011158093,0.00030612218,0.00011256607,0.000047903723,0.0001737063,0.0004603086,0.9981284],"category_scores_gemma":[0.000032417855,0.0006282572,0.00038190014,0.000058168185,0.000081489896,0.000048437825,0.00008590843,0.0004632331,0.9961304],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00042598482,0.00021184876,6.5604047e-7,0.000057725112,0.0006070953,0.00041180497,0.000022470153,0.0000033396234,0.0000046404525,0.00021498372,0.4271263,0.5709132],"study_design_scores_gemma":[0.0012648049,0.001262627,0.000025562926,0.0006151937,0.0006271155,0.00012262187,3.3518486e-7,0.0000070454166,0.000099103185,0.00015109414,0.99528044,0.00054402795],"about_ca_topic_score_codex":0.000019183239,"about_ca_topic_score_gemma":0.0000010874297,"teacher_disagreement_score":0.5703691,"about_ca_system_score_codex":0.0002639836,"about_ca_system_score_gemma":0.00020543108,"threshold_uncertainty_score":0.99961686},"labels":[],"label_agreement":null},{"id":"W4406852237","doi":"10.1080/14796694.2025.2454895","title":"Real-world treatment patterns and health outcomes for patients with myelofibrosis treated with fedratinib","year":2025,"lang":"en","type":"article","venue":"Future Oncology","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"Bristol-Myers Squibb","keywords":"Medicine; Myelofibrosis; Ruxolitinib; Discontinuation; Internal medicine; Oncology; Pediatrics; Intensive care medicine","score_opus":0.017927463657704014,"score_gpt":0.3361532998949089,"score_spread":0.31822583623720485,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4406852237","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9652815,0.00009380472,0.000061784354,0.027131166,0.00014502901,0.0034198416,0.00021143389,0.00007866312,0.003576795],"genre_scores_gemma":[0.9841292,0.0005662822,0.005901867,0.0029709209,0.00015879369,0.0017356813,0.00074058474,0.00004059283,0.003756115],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99867415,0.00006452886,0.00029446618,0.00048214168,0.00013031873,0.00035440666],"domain_scores_gemma":[0.99904007,0.00020635013,0.00015956564,0.00025654858,0.00015130853,0.00018616373],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00006163743,0.00034292173,0.0009151633,0.0001782673,0.00020564544,0.000020321799,0.000037448095,0.0001084147,0.0000459656],"category_scores_gemma":[0.0000064975675,0.0001812224,0.00007058346,0.00019613758,0.00005854318,0.000040026647,0.000016788079,0.00008477251,0.0000025561026],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0016695153,0.0017760328,0.947758,0.00010871468,0.00069684925,0.000018753992,0.0002775065,5.1063216e-7,0.0000014651201,0.0012889424,0.0018775025,0.04452619],"study_design_scores_gemma":[0.016922144,0.021063652,0.9218842,0.00017437455,0.00039422035,0.0000053221956,0.00016518179,0.0000053197377,0.00019396732,0.000011744247,0.03904074,0.00013917056],"about_ca_topic_score_codex":0.0010158356,"about_ca_topic_score_gemma":0.014797576,"teacher_disagreement_score":0.044387016,"about_ca_system_score_codex":0.0007186507,"about_ca_system_score_gemma":0.000424812,"threshold_uncertainty_score":0.82573944},"labels":[],"label_agreement":null},{"id":"W4406866321","doi":"10.1001/jama.2024.25349","title":"Essential Thrombocythemia","year":2025,"lang":"en","type":"review","venue":"JAMA","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":26,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal","funders":"","keywords":"Essential thrombocythemia; Medicine; Myeloproliferative neoplasm; Polycythemia vera; Internal medicine; Myelofibrosis; Thrombocytosis; Gastroenterology; Janus kinase 2; Venous thrombosis; Thrombosis; Immunology; Platelet; Bone marrow","score_opus":0.03171265118798724,"score_gpt":0.3696623690021248,"score_spread":0.3379497178141376,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4406866321","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0000061300593,0.9621578,0.000010237601,0.00035124706,0.00033910424,0.001120335,0.00007129263,0.00006268979,0.035881188],"genre_scores_gemma":[0.0000067774085,0.9884372,0.00029179873,0.0002729182,0.0007421368,0.0004377981,0.00042793193,0.000035098798,0.009348382],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9986076,0.00006942042,0.00041503043,0.0004383707,0.0002320767,0.00023752876],"domain_scores_gemma":[0.99889195,0.00029108103,0.00014755774,0.00046755318,0.00008468842,0.00011717147],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00008315184,0.00039665407,0.0020486524,0.00015879248,0.00006122294,0.000049201597,0.0001063099,0.00038715592,0.00086464436],"category_scores_gemma":[0.00015554778,0.000259572,0.0006746099,0.0002505415,0.000037575664,0.0000321553,0.000081291015,0.00038329166,0.00055250246],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000009179042,0.00020202839,0.000029255243,0.022817116,0.00062858313,0.00016769483,0.000015388096,1.27707125e-8,1.0980558e-7,0.0010149024,0.031017521,0.94409823],"study_design_scores_gemma":[0.00085342815,0.000090953174,0.000038155773,0.033985496,0.0030717542,0.00009433283,0.0000030512022,4.604936e-7,0.000024717005,0.000028503744,0.96164,0.00016916684],"about_ca_topic_score_codex":0.000011029297,"about_ca_topic_score_gemma":0.0000037845275,"teacher_disagreement_score":0.943929,"about_ca_system_score_codex":0.0001951268,"about_ca_system_score_gemma":0.0007606719,"threshold_uncertainty_score":0.99998564},"labels":[],"label_agreement":null},{"id":"W4407414901","doi":"10.1002/jha2.70000","title":"Treatment of Myeloproliferative Neoplasms With Janus Kinase Inhibitors: A Meta‐Analysis of Cardiovascular Safety","year":2025,"lang":"en","type":"article","venue":"eJHaem","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université Laval","funders":"","keywords":"Medicine; Ruxolitinib; Subgroup analysis; Meta-analysis; Internal medicine; Myelofibrosis; Adverse effect; Population; Incidence (geometry); Surgery","score_opus":0.027578270535772765,"score_gpt":0.28464209403928714,"score_spread":0.25706382350351437,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4407414901","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9354287,0.047247123,0.0011677673,0.0017881548,0.00012488154,0.0027532831,0.00036329252,0.00007380082,0.011053036],"genre_scores_gemma":[0.9951317,0.0011768945,0.0021400894,0.00008073187,0.00004017575,0.00042844977,0.00012138862,0.000021243246,0.00085933186],"study_design_codex":"meta_analysis","study_design_gemma":"meta_analysis","domain_scores_codex":[0.99789035,0.00013658304,0.00063939183,0.0005447476,0.0005165659,0.0002723516],"domain_scores_gemma":[0.99816036,0.0002750733,0.00020063494,0.0008135947,0.00041312093,0.00013722085],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0001624681,0.00040992917,0.002903082,0.0005913178,0.00008476298,0.000011282025,0.00007348067,0.000110398425,0.00020377756],"category_scores_gemma":[0.00003981499,0.0002480154,0.0022373914,0.0015851259,0.00017103524,0.000060985618,0.000025387837,0.0000832643,0.000005924587],"study_design_candidate":"meta_analysis","study_design_consensus":"meta_analysis","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0015331671,0.0025674247,0.05313752,0.00017594876,0.9275243,0.00028125648,0.0023278976,0.003119761,0.00019813055,0.0032068111,0.00008342778,0.0058443383],"study_design_scores_gemma":[0.0074092993,0.003865839,0.036641914,0.00011389734,0.7408294,0.000024314075,0.00066990213,0.000495113,0.1991568,0.000035768157,0.0104486,0.0003091079],"about_ca_topic_score_codex":0.0007423981,"about_ca_topic_score_gemma":0.00030516458,"teacher_disagreement_score":0.19895868,"about_ca_system_score_codex":0.00021472987,"about_ca_system_score_gemma":0.0003156988,"threshold_uncertainty_score":0.9999972},"labels":[],"label_agreement":null},{"id":"W4407563556","doi":"10.51731/cjht.2025.1075","title":"Momelotinib (Ojjaara)","year":2025,"lang":"en","type":"article","venue":"Canadian Journal of Health Technologies","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Myelofibrosis; Medicine; Polycythemia vera; Essential thrombocythemia; Anemia; Drug; Internal medicine; Surgery; Pharmacology; Bone marrow","score_opus":0.02145489802086633,"score_gpt":0.31894452950270036,"score_spread":0.29748963148183405,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4407563556","genre_codex":"commentary","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.40491423,0.13978265,0.00040624934,0.4464148,0.0009447339,0.00074590783,0.000022693224,0.00016892499,0.0065997904],"genre_scores_gemma":[0.9955826,0.0010198444,0.0010097303,0.0019819906,0.000008619914,0.000011980081,0.0000019799247,0.000007370484,0.00037588444],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9989148,0.000029798564,0.0004789945,0.00011675746,0.000109484026,0.00035018395],"domain_scores_gemma":[0.9992164,0.00006585998,0.00020468865,0.00020845968,0.0002019123,0.00010272338],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00031747675,0.00011702856,0.00045491487,0.00084036385,0.00018784261,0.000021298707,0.00014136812,0.000114332186,0.000047739002],"category_scores_gemma":[0.000525624,0.00008740795,0.00009148457,0.00040378625,0.00013529224,0.000045899404,0.000012087862,0.00033268682,0.000009456342],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000033996683,0.00008426049,0.2209355,0.00019498664,0.00022425386,0.00047824316,0.00017458784,0.00000522579,0.000021183543,0.017194727,0.041386206,0.71926683],"study_design_scores_gemma":[0.0021439495,0.0014183401,0.23830163,0.0013797315,0.000079681595,0.00052666274,0.0024053352,0.000010008619,0.0045380844,0.0068592597,0.74218804,0.00014927995],"about_ca_topic_score_codex":0.0012216121,"about_ca_topic_score_gemma":0.0019166368,"teacher_disagreement_score":0.7191176,"about_ca_system_score_codex":0.0004893959,"about_ca_system_score_gemma":0.0045011495,"threshold_uncertainty_score":0.7984846},"labels":[],"label_agreement":null},{"id":"W4407685617","doi":"10.1055/a-2471-6729","title":"Hydroxyurea-resistente, primäre Erythrozytose bei einer juvenilen Mischlingshündin","year":2025,"lang":"de","type":"article","venue":"Tierärztliche Praxis Ausgabe K Kleintiere / Heimtiere","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Gynecology; Medicine","score_opus":0.011087672327153889,"score_gpt":0.2845935520429487,"score_spread":0.2735058797157948,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4407685617","genre_codex":"review","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.27034608,0.51498234,0.0007578213,0.047862913,0.015103951,0.011619887,0.0014339193,0.0015788637,0.13631424],"genre_scores_gemma":[0.7653674,0.03697795,0.0039938213,0.007890346,0.004632522,0.0019193023,0.0021762569,0.00077135337,0.17627108],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.98589784,0.0010203434,0.0035746868,0.0038368185,0.0022274996,0.0034427934],"domain_scores_gemma":[0.9905952,0.0010104158,0.0013974867,0.0038811527,0.0014173656,0.0016983461],"candidate_categories":["metaepi_narrow","sts","research_integrity","insufficient_payload"],"consensus_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"category_scores_codex":[0.0016295487,0.0031512163,0.004368194,0.001498542,0.0015386547,0.0007668604,0.0015874808,0.002202456,0.0034903728],"category_scores_gemma":[0.0015489538,0.0028471348,0.0019125709,0.0027355903,0.0010929499,0.00069617596,0.0012530292,0.0031016513,0.0049947803],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.004997885,0.010096936,0.17820872,0.0052077784,0.030861152,0.0019623684,0.0036249235,0.00013415748,0.001121345,0.0180822,0.6702112,0.07549133],"study_design_scores_gemma":[0.012252893,0.0028808715,0.018059067,0.005476581,0.011715101,0.000040832223,0.0010866255,0.0010463542,0.014896707,0.0013317193,0.928658,0.0025552325],"about_ca_topic_score_codex":0.0005559556,"about_ca_topic_score_gemma":0.00019019883,"teacher_disagreement_score":0.4950213,"about_ca_system_score_codex":0.0018387183,"about_ca_system_score_gemma":0.0027052427,"threshold_uncertainty_score":0.9997612},"labels":[],"label_agreement":null},{"id":"W4407744262","doi":"10.1182/bloodadvances.2024015712","title":"Assessing AML-based risk criteria in patients with accelerated/blast-phase MPN treated with less-intensive therapy","year":2025,"lang":"en","type":"article","venue":"Blood Advances","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"National Cancer Institute","keywords":"Medicine; Oncology; Internal medicine; Intensive care medicine","score_opus":0.024151143343204076,"score_gpt":0.33969388413691126,"score_spread":0.3155427407937072,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4407744262","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9963763,0.001197913,0.00016298713,0.0003669773,0.00005344721,0.0010749265,0.000043534295,0.00007349422,0.0006504328],"genre_scores_gemma":[0.99699485,0.0002546704,0.0013100901,0.0008838795,0.000029007118,0.0002494714,0.00017354082,0.000031331387,0.00007318085],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99847,0.00010976,0.00030380566,0.000521718,0.00026385486,0.00033086736],"domain_scores_gemma":[0.9986245,0.00018125081,0.00018036424,0.00027858187,0.0006353598,0.00009993342],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00006673937,0.0003687874,0.0005969723,0.00022465018,0.00014701382,0.00010776118,0.00007090633,0.000067587025,0.00006400208],"category_scores_gemma":[0.00007341208,0.00021368507,0.000051582316,0.00055618584,0.00011087007,0.0003539394,0.000012640923,0.0001945105,0.0000030539463],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00311492,0.003846395,0.9645855,0.000048224647,0.00031465763,0.00012894369,0.000101769496,0.000090860805,0.00019346444,0.00001488053,0.000045527,0.027514854],"study_design_scores_gemma":[0.049133968,0.004732439,0.87604886,0.0011713459,0.0003750775,0.0000027968465,0.0004357775,0.00014296662,0.06702173,0.000018822171,0.00064132735,0.00027490288],"about_ca_topic_score_codex":0.00008626409,"about_ca_topic_score_gemma":0.00019710159,"teacher_disagreement_score":0.08853666,"about_ca_system_score_codex":0.0000714263,"about_ca_system_score_gemma":0.00020630879,"threshold_uncertainty_score":0.8713824},"labels":[],"label_agreement":null},{"id":"W4407947794","doi":"10.5737/2368807635153","title":"Impact of the clinical nurse specialist role for the myeloproliferative neoplasm program: Part One – From timeliness of triage to cost-saving","year":2025,"lang":"en","type":"article","venue":"Canadian Oncology Nursing Journal","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"Association canadienne des infirmières en oncologie","keywords":"Triage; Myeloproliferative neoplasm; Medicine; Clinical nurse specialist; Health care; Myeloid leukemia; Shared care; Nursing; Family medicine; Medical emergency; Primary care; Internal medicine","score_opus":0.05833597860401225,"score_gpt":0.4367443024306502,"score_spread":0.37840832382663797,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4407947794","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9330235,0.0014940996,0.00068623415,0.048645593,0.004248732,0.005756472,0.00053584133,0.000016759594,0.005592772],"genre_scores_gemma":[0.99201584,0.00014544808,0.003457642,0.0015243035,0.0019943402,0.0002783181,0.00003408654,0.0000303275,0.0005196945],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99771047,0.00034971075,0.000954134,0.00028291496,0.0002197143,0.00048304116],"domain_scores_gemma":[0.9962969,0.0013930864,0.00043598554,0.00038396553,0.000927492,0.0005626061],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008299241,0.0002323279,0.0009021327,0.00021155471,0.0004642221,0.000045446704,0.0002862088,0.00024139625,0.00017978245],"category_scores_gemma":[0.0019483096,0.00013509412,0.0005361285,0.00040400407,0.00044981285,0.000047304515,0.000016875823,0.0005649732,0.000004132641],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.001923847,0.0016611267,0.21255243,0.000012472725,0.0016134168,0.000029600977,0.0020649985,0.000106602034,0.00015728036,0.0004646326,0.052287463,0.7271261],"study_design_scores_gemma":[0.008205274,0.0036833629,0.91781247,0.0024285805,0.0017061407,0.00007541338,0.0011382813,0.00080563594,0.001457342,0.0008519435,0.06164528,0.00019029363],"about_ca_topic_score_codex":0.0030874992,"about_ca_topic_score_gemma":0.029821757,"teacher_disagreement_score":0.72693586,"about_ca_system_score_codex":0.002249635,"about_ca_system_score_gemma":0.009727749,"threshold_uncertainty_score":0.99588615},"labels":[],"label_agreement":null},{"id":"W4407964925","doi":"10.5737/2368807635171","title":"Impact of the clinical nurse specialist role for the myeloproliferative neoplasm program: Part Two – The team and patient care experiences","year":2025,"lang":"en","type":"article","venue":"Canadian Oncology Nursing Journal","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":true,"route_about_ca":true,"ca_institutions":"Princess Margaret Cancer Centre","funders":"Association canadienne des infirmières en oncologie","keywords":"Clinical nurse specialist; Medicine; Myeloproliferative neoplasm; Triage; Shared care; Health care; Nursing; Myeloid leukemia; Family medicine; Medical emergency; Primary care; Internal medicine","score_opus":0.024932074591139785,"score_gpt":0.40926905274437836,"score_spread":0.3843369781532386,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4407964925","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9538513,0.00565345,0.000015014491,0.027997233,0.0022672326,0.0024690933,0.000050609102,0.000009091918,0.007686979],"genre_scores_gemma":[0.9970112,0.00020861847,0.00023486302,0.0013977798,0.0006005137,0.0003904813,0.000005013689,0.000012935495,0.0001386218],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99829817,0.00032832424,0.0005244871,0.00024022484,0.00017790233,0.00043088652],"domain_scores_gemma":[0.99796,0.0007263504,0.00027156709,0.0002771362,0.00040638924,0.0003585978],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00035001396,0.0002059317,0.00044448394,0.0000907331,0.0012672858,0.00008942765,0.00020581477,0.00013568529,0.000053145708],"category_scores_gemma":[0.0003924855,0.00008879136,0.00032834685,0.00021267254,0.0011653646,0.000047005607,0.00001567518,0.0005195202,9.2403263e-7],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00038970207,0.0004233186,0.19145618,0.000007256474,0.0005361624,0.00002279801,0.04656136,0.000021048823,0.000005171084,0.0008628321,0.05205707,0.7076571],"study_design_scores_gemma":[0.0062072133,0.009154399,0.5364549,0.0012706192,0.0011774445,0.0009433695,0.16593039,0.00043897307,0.0004132512,0.00077847304,0.2769827,0.00024826365],"about_ca_topic_score_codex":0.001301602,"about_ca_topic_score_gemma":0.017783111,"teacher_disagreement_score":0.70740885,"about_ca_system_score_codex":0.001598,"about_ca_system_score_gemma":0.0069601303,"threshold_uncertainty_score":0.9986695},"labels":[],"label_agreement":null},{"id":"W4407976465","doi":"10.1016/j.jtct.2025.01.520","title":"REMOVED: Genetic Landscape in Myelofibrosis Impacts Post-Hematopoietic Cell Transplantation Outcomes","year":2025,"lang":"en","type":"article","venue":"Transplantation and Cellular Therapy","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Myelofibrosis; Hematopoietic cell; Hematopoietic stem cell transplantation; Transplantation; Medicine; Haematopoiesis; Oncology; Biology; Internal medicine; Stem cell; Genetics; Bone marrow","score_opus":0.008553491637657184,"score_gpt":0.25208421759104016,"score_spread":0.243530725953383,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4407976465","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9919219,0.0027447918,0.0010227067,0.0013002331,0.00007550353,0.00067834003,0.000036681024,0.000046687484,0.002173153],"genre_scores_gemma":[0.97541946,0.021946808,0.00064419454,0.0012386566,0.000013759987,0.00007320439,0.00026751246,0.000019512974,0.00037690956],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9988159,0.00008291029,0.00035947183,0.00032127093,0.00018705758,0.00023341487],"domain_scores_gemma":[0.9995164,0.00011522991,0.00005638606,0.0001581306,0.00005260303,0.000101243655],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00010794746,0.0002460449,0.000369431,0.00025640256,0.000082325554,0.000037562375,0.00004652106,0.0001164339,0.00014671],"category_scores_gemma":[0.0000027757294,0.00019259677,0.00009939986,0.00021905606,0.00003386672,0.00007460597,0.0000022661673,0.00011822701,0.000015212029],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0015955286,0.00063994084,0.90077895,0.00090297434,0.00014206051,0.00030723118,0.0045457194,0.000025406553,0.081758484,0.0004277736,0.000029753126,0.008846152],"study_design_scores_gemma":[0.008388278,0.00028392253,0.835634,0.00022486331,0.00016763403,0.000046409124,0.00022617396,0.00006173541,0.15454794,0.00013333095,0.00011626565,0.00016946727],"about_ca_topic_score_codex":0.000085937936,"about_ca_topic_score_gemma":0.000064432075,"teacher_disagreement_score":0.07278947,"about_ca_system_score_codex":0.000028358289,"about_ca_system_score_gemma":0.00007225408,"threshold_uncertainty_score":0.7853868},"labels":[],"label_agreement":null},{"id":"W4408187558","doi":"10.1159/000544818","title":"ECLIPSE-PV: A Randomized, Multicenter Study to Assess Efficacy, Safety, and Tolerability of Two Dosing Regimens of Ropeginterferon Alfa-2b-Njft in Polycythemia Vera","year":2025,"lang":"en","type":"article","venue":"Acta Haematologica","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Institute of Cancer Research; University of Ottawa; Jewish General Hospital; St. Michael's Hospital; University of British Columbia; McGill University; University of Calgary; McMaster University; St. Paul's Hospital; Princess Margaret Cancer Centre","funders":"","keywords":"Tolerability; Dosing; Polycythemia vera; Medicine; Multicenter study; Randomized controlled trial; Internal medicine; Adverse effect","score_opus":0.03175080926879111,"score_gpt":0.3492806947068883,"score_spread":0.3175298854380972,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4408187558","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9913911,0.00018791259,0.000095701755,0.0028774207,0.000109573855,0.0034414777,0.000011836229,0.000024984849,0.0018599482],"genre_scores_gemma":[0.99830073,0.000095175084,0.0010903587,0.00024640266,0.000018208542,0.00013520646,0.000008257747,0.000012870849,0.000092805174],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9975153,0.0004482744,0.0009941281,0.00052523124,0.0002340116,0.00028304095],"domain_scores_gemma":[0.9973996,0.0015897087,0.00024761478,0.00051995035,0.00013527759,0.00010784788],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00076100643,0.00029063248,0.0020260466,0.00021984355,0.0000571039,0.000018045346,0.00013737219,0.000083341794,0.00008615055],"category_scores_gemma":[0.0008715929,0.00019445931,0.00016235349,0.0002728263,0.00018070135,0.000060200487,0.00022412189,0.00019896969,0.0000033751608],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.13884048,0.010131021,0.83796465,0.0004578184,0.00094410405,0.00019126323,0.005456867,0.000038841812,0.0019893846,0.0014274362,0.00033077627,0.002227377],"study_design_scores_gemma":[0.43694216,0.0036036973,0.48437467,0.0032567196,0.0013465328,0.00008225894,0.0027444707,0.00078676397,0.065521725,0.00038410796,0.00043583437,0.00052107795],"about_ca_topic_score_codex":0.00031038106,"about_ca_topic_score_gemma":0.00022710669,"teacher_disagreement_score":0.35358998,"about_ca_system_score_codex":0.000116807045,"about_ca_system_score_gemma":0.00007615858,"threshold_uncertainty_score":0.7929821},"labels":[],"label_agreement":null},{"id":"W4408195654","doi":"10.1016/j.jtha.2024.11.017","title":"“Discrepant low von Willebrand factor activity results on the ACL TOP analyzer are frequent in unselected patients with myeloproliferative neoplasms and show no correlation with high-molecular-weight multimer loss or bleeding phenotype”: comment from Al Sharif et al.","year":2025,"lang":"en","type":"letter","venue":"Journal of Thrombosis and Haemostasis","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University; Memorial University of Newfoundland","funders":"Princess Nourah Bint Abdulrahman University; McMaster University; King Abdulaziz University Hospital","keywords":"Von Willebrand factor; Medicine; Gastroenterology; Internal medicine; Platelet","score_opus":0.022433705580100154,"score_gpt":0.27760221845930283,"score_spread":0.25516851287920267,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4408195654","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.62553144,0.00012661309,0.00007236362,0.37197933,0.00014422995,0.0010915926,0.0010031739,0.000010371366,0.000040886443],"genre_scores_gemma":[0.770276,0.0020334919,0.0012268443,0.22520596,0.00018535281,0.000081915525,0.0008508523,0.00007840069,0.00006115702],"study_design_codex":"not_applicable","study_design_gemma":"observational","domain_scores_codex":[0.9962835,0.00043959293,0.0008600754,0.00081576424,0.0011519707,0.0004491333],"domain_scores_gemma":[0.996046,0.0012446989,0.001311742,0.0004139333,0.0007918059,0.00019180679],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00031260645,0.0008160096,0.0016597772,0.00037495166,0.0002771279,0.0002290822,0.00015365172,0.00039550543,0.00017961905],"category_scores_gemma":[0.00020906786,0.00040218138,0.0001623042,0.0003779725,0.00017920964,0.00028568786,0.00008033205,0.0020586958,0.0000024541441],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.029965717,0.0030382108,0.40169019,0.00027299635,0.013334912,0.0011746287,0.0031840745,0.00017141206,0.0002581528,0.000043336546,0.54345256,0.0034138085],"study_design_scores_gemma":[0.041448206,0.009796796,0.8737859,0.014215423,0.004502395,0.000057283803,0.00030106702,0.0011509428,0.011009658,0.00004482582,0.042215373,0.0014721465],"about_ca_topic_score_codex":0.00051474606,"about_ca_topic_score_gemma":0.00039926847,"teacher_disagreement_score":0.50123715,"about_ca_system_score_codex":0.00042256332,"about_ca_system_score_gemma":0.00030529377,"threshold_uncertainty_score":0.999843},"labels":[],"label_agreement":null},{"id":"W4408275933","doi":"10.1038/s41591-025-03572-3","title":"Pelabresib plus ruxolitinib for JAK inhibitor-naive myelofibrosis: a randomized phase 3 trial","year":2025,"lang":"en","type":"article","venue":"Nature Medicine","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":35,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"University of Texas MD Anderson Cancer Center; National Institutes of Health; Grifols; National Cancer Institute; Gilead Sciences; Servier; Astellas Pharma; Sierra Oncology; Pfizer; Incyte; CTI Biopharma; BeiGene; Bristol-Myers Squibb; Constellation Pharmaceuticals; Agios Pharmaceuticals; Swedish Orphan Biovitrum; MPN Research Foundation; Leukemia and Lymphoma Society; Alexion Pharmaceuticals; Sanofi; MorphoSys; Celgene; AstraZeneca; Amgen; GlaxoSmithKline","keywords":"Ruxolitinib; Myelofibrosis; Medicine; Randomized controlled trial; Internal medicine; Oncology; Pharmacology; Bone marrow","score_opus":0.016416539408772177,"score_gpt":0.37238304536340383,"score_spread":0.35596650595463164,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4408275933","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.6145938,0.05499052,0.004264311,0.20949547,0.012410868,0.041290905,0.00040252495,0.00068418484,0.0618674],"genre_scores_gemma":[0.9646684,0.00071911386,0.0019286285,0.013204447,0.004585099,0.003990148,0.00071822206,0.000063227504,0.010122715],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9969105,0.00021387136,0.00096842385,0.0007250192,0.0006477129,0.0005344706],"domain_scores_gemma":[0.9959182,0.0023978427,0.00026197947,0.0005149287,0.0005957789,0.00031127472],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0011627799,0.00051836116,0.0022927925,0.00046633187,0.00021302671,0.000025966676,0.00015016827,0.0006234483,0.00039844905],"category_scores_gemma":[0.004828567,0.00032279507,0.00051639613,0.00053934025,0.00037882567,0.00007205316,0.00005062537,0.0007982719,0.00001856822],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.8369434,0.0010502132,0.00008914793,0.00038860485,0.0011257627,0.00006452127,0.00063532806,6.2987806e-7,0.0011381572,0.020395134,0.13223329,0.0059357896],"study_design_scores_gemma":[0.87150604,0.0035603715,0.000119043005,0.0015098578,0.002129842,0.000022266413,0.00026208072,0.0002847197,0.010346467,0.0015469778,0.10849443,0.00021792662],"about_ca_topic_score_codex":0.000059046226,"about_ca_topic_score_gemma":0.000017327964,"teacher_disagreement_score":0.3500746,"about_ca_system_score_codex":0.00031554722,"about_ca_system_score_gemma":0.0006025581,"threshold_uncertainty_score":0.9999224},"labels":[],"label_agreement":null},{"id":"W4408301977","doi":"10.1038/s41375-025-02550-5","title":"Loss of Socs2 improves molecular responses to IFNα in a mouse model of myeloproliferative neoplasms driven by JAK2-V617F","year":2025,"lang":"en","type":"article","venue":"Leukemia","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Swiss Cancer Research Foundation; European Federation of Pharmaceutical Industries and Associations; Universität Basel; Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung; McGill University; European Commission; Amgen; Cancer Prevention and Research Institute of Texas; National Science Foundation","keywords":"JAK2 V617F; Myeloproliferative Disorders; Hematology; SOCS2; Polycythemia vera; Ruxolitinib; Cancer research; Biology; Leukemia; Janus kinase 2; Immunology; Myelofibrosis; Medicine; Genetics; Bone marrow; Receptor; Gene; Suppressor","score_opus":0.011048397314771523,"score_gpt":0.2797456143309054,"score_spread":0.26869721701613386,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4408301977","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9939395,0.00031590904,0.0012332894,0.0014460551,0.00004200331,0.0013812482,0.00020783927,0.00003060894,0.0014035429],"genre_scores_gemma":[0.988948,0.00014978166,0.0045823674,0.0011500214,0.000012992291,0.00048286188,0.000037913986,0.000031117757,0.0046049766],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99801415,0.000108097236,0.0006734983,0.00049510057,0.00035358034,0.0003555437],"domain_scores_gemma":[0.9987568,0.00024428213,0.00016005166,0.00042851767,0.00025324023,0.00015708857],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00017957926,0.0003218872,0.0008506018,0.0003762442,0.00004260722,0.000013420294,0.00015652213,0.00018768078,0.000022943474],"category_scores_gemma":[0.00033178853,0.00027650266,0.00016425959,0.00046728985,0.00013500765,0.00007506946,0.00011832889,0.00023609574,0.000009912023],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.003465277,0.0009686173,0.11946176,0.00040980813,0.00055225356,0.00006595199,0.0024956102,0.003649785,0.85723704,0.006314008,0.0029263773,0.0024534974],"study_design_scores_gemma":[0.0040884386,0.0008303907,0.010070346,0.00040706122,0.00012159045,0.0000035205294,0.00022521766,0.009197201,0.9741357,0.00049593434,0.00020320475,0.00022140727],"about_ca_topic_score_codex":0.00026783944,"about_ca_topic_score_gemma":0.00010719517,"teacher_disagreement_score":0.11689863,"about_ca_system_score_codex":0.00056773337,"about_ca_system_score_gemma":0.0010661857,"threshold_uncertainty_score":0.9999687},"labels":[],"label_agreement":null},{"id":"W4408460398","doi":"10.1002/ajh.27665","title":"Topics of Interest in Women With Myeloproliferative Neoplasms","year":2025,"lang":"en","type":"review","venue":"American Journal of Hematology","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal","funders":"","keywords":"Essential thrombocythemia; Polycythemia vera; Medicine; Myelofibrosis; Internal medicine; Myeloproliferative neoplasm; Disease; Oncology; Gynecology; Bone marrow","score_opus":0.040912619085824165,"score_gpt":0.3393716473534898,"score_spread":0.2984590282676656,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4408460398","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.02181625,0.9762118,0.000037885537,0.00065563933,0.00013996213,0.00064137555,0.00001650968,0.0000059061626,0.00047470382],"genre_scores_gemma":[0.006369452,0.99134266,0.0017439999,0.00021461013,0.000072735274,0.0001074913,0.000006896214,0.000028605444,0.00011352514],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99748343,0.0003115776,0.0014361708,0.0002712731,0.00016003297,0.00033748537],"domain_scores_gemma":[0.99675393,0.0007158408,0.0017744454,0.00028198786,0.0003019677,0.0001718329],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00023032115,0.00041919562,0.0055178404,0.0007841416,0.000020399373,0.000007844367,0.00019586056,0.00014783013,0.00007141653],"category_scores_gemma":[0.00021438622,0.00025112007,0.0002904038,0.00068526797,0.00037942312,0.000043575812,0.000055512097,0.0006740265,0.000004764939],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0008040822,0.0007043698,0.0040216176,0.008868688,0.0019118877,0.0017219007,0.0008422704,8.977204e-7,2.186049e-7,0.00318042,0.0002781265,0.97766554],"study_design_scores_gemma":[0.007327287,0.034162324,0.0014085978,0.18224844,0.004269087,0.03258787,0.0035827768,0.0000026295575,0.0001993329,0.0005001307,0.73273444,0.0009770991],"about_ca_topic_score_codex":0.000015609938,"about_ca_topic_score_gemma":0.000053505835,"teacher_disagreement_score":0.97668844,"about_ca_system_score_codex":0.00031190924,"about_ca_system_score_gemma":0.0017198545,"threshold_uncertainty_score":0.9999941},"labels":[],"label_agreement":null},{"id":"W4408507497","doi":"10.58931/cht.2025.4s0262","title":"Momelotinib Usage Within Our Current Canadian Myelofibrosis Armamentarium","year":2025,"lang":"en","type":"article","venue":"Canadian Hematology Today","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Calgary","funders":"","keywords":"Myelofibrosis; Current (fluid); Medicine; Internal medicine; Engineering","score_opus":0.018587110024780217,"score_gpt":0.3005025020663963,"score_spread":0.2819153920416161,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4408507497","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.803213,0.0062918966,0.000043668977,0.12505768,0.005027831,0.0027763224,0.0005576064,0.00017223845,0.056859776],"genre_scores_gemma":[0.98841953,0.00009961694,0.0003933745,0.0075444235,0.00009137073,0.00030145864,0.00021816228,0.0000339892,0.002898064],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.997634,0.00009388739,0.000496004,0.0006118219,0.0001647805,0.0009995118],"domain_scores_gemma":[0.99729186,0.00007421612,0.00008565401,0.00052761455,0.00015700415,0.0018636511],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00018712372,0.00038025324,0.00071726314,0.0009855352,0.00037373026,0.00004860365,0.00018544169,0.00024918918,0.0006036412],"category_scores_gemma":[0.000154015,0.0003513485,0.00015591228,0.0005096198,0.000087900065,0.00006883043,0.00003096685,0.00041356965,0.0004649591],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00003868191,0.00014685419,0.7960323,0.00016864594,0.0003971618,0.0008747377,0.0005495481,0.000007082044,0.00004023381,0.03668605,0.16168094,0.0033777312],"study_design_scores_gemma":[0.00451598,0.0003860105,0.2782722,0.0010561324,0.0007041101,0.00071876094,0.0012284681,0.00020915303,0.012143285,0.0010285069,0.6988402,0.00089718634],"about_ca_topic_score_codex":0.6105027,"about_ca_topic_score_gemma":0.9691964,"teacher_disagreement_score":0.53715926,"about_ca_system_score_codex":0.0016422684,"about_ca_system_score_gemma":0.0058957343,"threshold_uncertainty_score":0.99989384},"labels":[],"label_agreement":null},{"id":"W4408845598","doi":"10.1002/hem3.70106","title":"Patient and physician perceptions regarding treatment expectations and symptomatology in polycythemia vera: Insights from the Landmark 2.0 global health survey","year":2025,"lang":"en","type":"article","venue":"HemaSphere","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal; Hôpital Maisonneuve-Rosemont; University of British Columbia","funders":"AOP Orphan; Astellas Pharma; Galecto; Sierra Oncology; Incyte; CTI Biopharma; BeiGene; Bristol-Myers Squibb; AstraZeneca; CSL Behring; MPN Research Foundation; Alexion Pharmaceuticals; Gilead Sciences; Sanofi; GlaxoSmithKline; Pfizer; Novartis Pharmaceuticals Corporation; Celgene","keywords":"Medicine; Depression (economics); Myeloproliferative neoplasm; Quality of life (healthcare); Polycythemia vera; Family medicine; Disease; Physical therapy; Emergency medicine; Internal medicine; Myelofibrosis","score_opus":0.01158140979650688,"score_gpt":0.3007316178053178,"score_spread":0.2891502080088109,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4408845598","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98877627,0.0055581336,0.000026918946,0.003437937,0.00006517922,0.00052651105,0.00009977931,0.000022741255,0.0014865216],"genre_scores_gemma":[0.9979233,0.00058678957,0.0001997894,0.00092467933,0.000026736363,0.00013584741,0.00013694621,0.000006731915,0.000059138973],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9990907,0.00016695664,0.00020947405,0.00028828258,0.0000807819,0.00016385669],"domain_scores_gemma":[0.9993276,0.0003249229,0.000051666288,0.0001836546,0.000033150678,0.00007900317],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000029559365,0.0001606056,0.0003469761,0.000022914059,0.00020205029,0.000025904637,0.000022252767,0.000053472228,0.000020977717],"category_scores_gemma":[0.00003141784,0.000100309604,0.000037111688,0.00017814248,0.000061744075,0.000036351717,0.000030320896,0.00006712091,0.0000056254007],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000082792474,0.0003132424,0.9787941,0.000012507524,0.00016227465,0.00001246047,0.0037636491,0.0000020348455,0.0000129855225,0.0018968205,0.0012741325,0.013672984],"study_design_scores_gemma":[0.0021299087,0.00029026592,0.9916593,0.00021647509,0.000054009073,0.000011429792,0.004514679,0.00010142439,0.00008689332,0.0003544183,0.00050784025,0.00007334928],"about_ca_topic_score_codex":0.003554589,"about_ca_topic_score_gemma":0.02862161,"teacher_disagreement_score":0.02506702,"about_ca_system_score_codex":0.00025713182,"about_ca_system_score_gemma":0.000151997,"threshold_uncertainty_score":0.9891035},"labels":[],"label_agreement":null},{"id":"W4409083304","doi":"10.1038/s41408-025-01234-8","title":"Symptom burden in myeloproliferative neoplasms: clinical correlates, dynamics, and survival impact—a study of 784 patients from the Quebec MPN research group","year":2025,"lang":"en","type":"letter","venue":"Blood Cancer Journal","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Bell (Canada); Hôpital Charles-Le Moyne; Université de Sherbrooke; Bausch Health (Canada); Cegep de Saint Jerome; Centre Hospitalier Universitaire de Sherbrooke; Centre hospitalier de l'Université Laval; Montreal Heart Institute; St. Jerome's University; Cégep de Lévis; Centre hospitalier universitaire de Québec; Hôpital du Sacré-Cœur de Montréal; McGill University; Jewish General Hospital; Centre Hospitalier de l’Université de Montréal; Université Laval; Université de Montréal; McGill-Queen's University Press; Hôpital Maisonneuve-Rosemont","funders":"","keywords":"Internal medicine; Medicine; Hematology; Oncology; Gerontology","score_opus":0.04317865656157713,"score_gpt":0.3873996564677468,"score_spread":0.3442209999061697,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4409083304","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.89491063,0.004571527,0.0000028594452,0.09580835,0.0013621771,0.002455933,0.0007023708,0.000013899131,0.00017224507],"genre_scores_gemma":[0.9469686,0.014584562,0.000086125525,0.026428286,0.008281954,0.00063989044,0.00091389514,0.00015387381,0.0019427723],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9919318,0.0026461326,0.0018544012,0.000947131,0.0017853357,0.0008352288],"domain_scores_gemma":[0.9929784,0.004085688,0.00078897394,0.00067365705,0.0011959402,0.0002773403],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.0019206061,0.0006977516,0.0019937656,0.0004826976,0.00038488966,0.00022227442,0.0004917999,0.0008724133,0.00028190835],"category_scores_gemma":[0.00067722984,0.00042956902,0.00036316304,0.00057828694,0.0003796795,0.00013818151,0.0003371101,0.0077431714,0.000006062225],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0007555755,0.002264608,0.82326627,0.0000732304,0.0038965603,0.00082997995,0.0025931576,0.000011046505,6.696244e-7,0.000015504622,0.1600017,0.006291673],"study_design_scores_gemma":[0.021444771,0.005204741,0.95906,0.0028670873,0.0020116093,0.000054335083,0.0021787742,0.0001990069,0.000007994688,0.00015236126,0.006404905,0.0004144268],"about_ca_topic_score_codex":0.06732217,"about_ca_topic_score_gemma":0.10118493,"teacher_disagreement_score":0.1535968,"about_ca_system_score_codex":0.001086375,"about_ca_system_score_gemma":0.0021803363,"threshold_uncertainty_score":0.9998156},"labels":[],"label_agreement":null},{"id":"W4409290429","doi":"10.1681/asn.0000000671","title":"Association of Clonal Hematopoiesis of Indeterminate Potential with Cardiovascular Events in Patients with CKD","year":2025,"lang":"en","type":"article","venue":"Journal of the American Society of Nephrology","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen's University; McMaster University; Population Health Research Institute; Impact; St. Joseph’s Healthcare Hamilton; University of British Columbia","funders":"National Institute of Diabetes and Digestive and Kidney Diseases; National Human Genome Research Institute; Canadian Institutes of Health Research; National Institutes of Health","keywords":"Medicine; Internal medicine; Prospective cohort study; Stroke (engine); Population; Myocardial infarction; Heart failure; Cardiology; Disease; Oncology","score_opus":0.004018477805930322,"score_gpt":0.22634854144168381,"score_spread":0.2223300636357535,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4409290429","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99756116,0.00011187908,0.00011378469,0.0019311259,0.000032465912,0.00021630214,0.000008994009,0.0000011647537,0.000023137272],"genre_scores_gemma":[0.99753684,0.00011551896,0.0016948277,0.0005870358,0.00002098077,0.0000044736244,0.0000015347476,0.00000718724,0.00003163128],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99858373,0.00016184697,0.0004726783,0.00010118777,0.0005435749,0.00013695937],"domain_scores_gemma":[0.9977972,0.000112862144,0.0013782228,0.0001847664,0.0004970244,0.000029918494],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00034086782,0.000111772824,0.00091900816,0.00007809084,0.000024595405,0.0000010542714,0.00011163714,0.00005630181,0.000007108634],"category_scores_gemma":[0.000035415505,0.00006383537,0.0005150165,0.00034287848,0.00023536652,0.000038789123,0.000040486404,0.00018522961,9.811906e-8],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0014786446,0.000702352,0.98954225,0.00008026844,0.004987121,0.0000034332777,0.00031506954,0.00027192975,0.00077487313,0.000006169852,0.00073128403,0.0011065867],"study_design_scores_gemma":[0.005101209,0.0020638981,0.9886317,0.0002134238,0.0009742243,0.00001593271,0.00023651989,0.00002265906,0.0024770903,0.000039619514,0.00018077841,0.000042947406],"about_ca_topic_score_codex":0.000098150806,"about_ca_topic_score_gemma":0.000011657906,"teacher_disagreement_score":0.0040128967,"about_ca_system_score_codex":0.0001566094,"about_ca_system_score_gemma":0.00020740405,"threshold_uncertainty_score":0.26031306},"labels":[],"label_agreement":null},{"id":"W4409290870","doi":"10.1681/asn.0000000680","title":"Clonal Hematopoiesis of Indeterminate Potential and Progression of CKD","year":2025,"lang":"en","type":"article","venue":"Journal of the American Society of Nephrology","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":16,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of British Columbia; Queen's University; McMaster University; Population Health Research Institute; Impact; Thrombosis and Atherosclerosis Research Institute","funders":"National Institute of Diabetes and Digestive and Kidney Diseases; National Human Genome Research Institute","keywords":"Hazard ratio; Medicine; Kidney disease; Internal medicine; Renal function; Dialysis; Oncology; Population; Cohort; Proportional hazards model; Confidence interval","score_opus":0.008733124313821118,"score_gpt":0.30522491639928384,"score_spread":0.2964917920854627,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4409290870","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9902903,0.00059572665,0.000091022914,0.008771659,0.00005111061,0.00013447006,0.000006239677,0.0000015459393,0.000057919733],"genre_scores_gemma":[0.99255866,0.0006721361,0.0052964357,0.0013821224,0.00004212378,0.0000027714586,4.404471e-7,0.0000051023076,0.00004021061],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9989905,0.00009302759,0.0004915207,0.00008704029,0.00022788225,0.00011005377],"domain_scores_gemma":[0.9982204,0.00014932273,0.0011931446,0.00013868418,0.00025685676,0.000041597294],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00021917827,0.00009675487,0.00070366065,0.00005697366,0.00003703096,0.000001846031,0.00010481833,0.000053525724,0.000016180602],"category_scores_gemma":[0.000036907815,0.000056446395,0.0003829301,0.00018683396,0.00089631055,0.00002666117,0.000090334,0.0001617716,8.9217835e-8],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0029688445,0.0016819829,0.46541744,0.00064651936,0.0032881403,0.000028725712,0.0017853512,0.000025761998,0.45556685,0.00034153237,0.02032489,0.047923945],"study_design_scores_gemma":[0.0025065579,0.00295274,0.91057795,0.00040050113,0.0006490123,0.0003400824,0.00081876596,0.00014236513,0.079679586,0.00050404324,0.0013726711,0.00005570315],"about_ca_topic_score_codex":0.000023631788,"about_ca_topic_score_gemma":0.000001339301,"teacher_disagreement_score":0.4451605,"about_ca_system_score_codex":0.000026612759,"about_ca_system_score_gemma":0.0001618312,"threshold_uncertainty_score":0.33024934},"labels":[],"label_agreement":null},{"id":"W4409404594","doi":"10.1007/7651_2025_625","title":"Multiplex PCR for the Rapid Diagnosis of Myeloproliferative Neoplasms","year":2025,"lang":"en","type":"article","venue":"Methods in molecular biology","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Kingston Health Sciences Centre; Queen's University","funders":"","keywords":"Multiplex; Multiplex polymerase chain reaction; Myeloproliferative Disorders; Medicine; Pathology; Biology; Polymerase chain reaction; Genetics; Gene","score_opus":0.035138011327321486,"score_gpt":0.42360521834836184,"score_spread":0.3884672070210404,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4409404594","genre_codex":"methods","genre_gemma":"methods","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"methods","genre_consensus":"methods","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.05254674,0.009988357,0.923256,0.008544432,0.0005158136,0.0034282552,0.000060137492,0.000032861266,0.00162745],"genre_scores_gemma":[0.15344982,0.0014693562,0.8374575,0.0029017767,0.00005098252,0.0043832706,0.00005130719,0.000026890879,0.00020909769],"study_design_codex":"design_other","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99791706,0.0007281481,0.0005110732,0.00044153025,0.000080030695,0.00032214043],"domain_scores_gemma":[0.9952304,0.0039196066,0.00012717454,0.00044460795,0.0002267101,0.00005152846],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010286013,0.0002448006,0.00069831824,0.00023033064,0.000083543746,0.0000082248935,0.00016580151,0.00021294584,0.0000961934],"category_scores_gemma":[0.0023851977,0.00015359218,0.00022726836,0.00046561728,0.00024823518,0.0000148937925,0.000088966124,0.00020066144,0.0000020994325],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0010823552,0.001140918,0.36155972,0.00024899543,0.0016846239,0.00003562223,0.0007066826,0.00013609482,0.13720347,0.09264639,0.000933367,0.40262178],"study_design_scores_gemma":[0.00439169,0.0010377263,0.03140998,0.00014123433,0.00033370574,0.000009754044,0.00017781931,0.0017778623,0.9311129,0.0067445845,0.022682805,0.00017995984],"about_ca_topic_score_codex":0.00006696559,"about_ca_topic_score_gemma":0.000039669227,"teacher_disagreement_score":0.79390943,"about_ca_system_score_codex":0.00007310486,"about_ca_system_score_gemma":0.00016965682,"threshold_uncertainty_score":0.62633073},"labels":[],"label_agreement":null},{"id":"W4409448575","doi":"10.1681/asn.0000000739","title":"Deciphering Clonal Hematopoiesis of Indeterminate Potential","year":2025,"lang":"en","type":"article","venue":"Journal of the American Society of Nephrology","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen's University","funders":"National Institute of Diabetes and Digestive and Kidney Diseases; National Human Genome Research Institute","keywords":"Indeterminate; Haematopoiesis; Medicine; Biology; Genetics; Stem cell; Mathematics","score_opus":0.010472138972424851,"score_gpt":0.29011657641409144,"score_spread":0.2796444374416666,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4409448575","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9887476,0.00030288455,0.0004971057,0.010080879,0.000107011314,0.0001062659,0.000004294703,0.000002819191,0.00015117112],"genre_scores_gemma":[0.988212,0.00038647966,0.0070408517,0.0041610315,0.00008746962,0.0000030851309,3.454782e-7,0.000007356112,0.00010140199],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9988936,0.00008459981,0.00052917865,0.00009581821,0.0002448602,0.00015190843],"domain_scores_gemma":[0.99834675,0.00017819238,0.0009815175,0.00018715857,0.0002577446,0.000048669273],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00021881048,0.00011320219,0.0007214271,0.000053162166,0.000051476014,0.0000031531295,0.00017235786,0.000052509236,0.00004020554],"category_scores_gemma":[0.000044015993,0.000071059425,0.00069539,0.0002607409,0.00059333054,0.000031302177,0.00009460621,0.00021490664,5.0720695e-7],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0029877392,0.0018853402,0.37311497,0.00042717767,0.007219894,0.00008186233,0.0020260732,0.0003910269,0.5169423,0.00059000135,0.05990196,0.03443166],"study_design_scores_gemma":[0.002595337,0.0015975154,0.9366035,0.00024963307,0.0007690559,0.00051912025,0.0010114812,0.00026131456,0.050022587,0.0006195794,0.005668074,0.00008279276],"about_ca_topic_score_codex":0.000039649665,"about_ca_topic_score_gemma":0.0000030998717,"teacher_disagreement_score":0.56348854,"about_ca_system_score_codex":0.000065585125,"about_ca_system_score_gemma":0.00022131448,"threshold_uncertainty_score":0.2897719},"labels":[],"label_agreement":null},{"id":"W4409546702","doi":"10.3389/fmed.2025.1548590","title":"A multicenter study to assess efficacy, safety, and tolerability of ropeginterferon alfa-2b-njft in patients with essential thrombocythemia in the US and Canada: EXCEED-ET trial","year":2025,"lang":"en","type":"article","venue":"Frontiers in Medicine","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Custom Security Industries (Canada); University of Calgary; University of Toronto; Princess Margaret Cancer Centre; McMaster University; St. Paul's Hospital; University of British Columbia","funders":"Italfarmaco; Kiadis Pharma; Association of Community Cancer Centers; Incyte; CTI Biopharma; Genentech; Janssen Scientific Affairs; MEI Pharma; Arog Pharmaceuticals; Astex Pharmaceuticals; FibroGen; Gilead Sciences; Sanofi; MorphoSys; Celgene; Bristol-Myers Squibb; AstraZeneca; Amgen; Pfizer","keywords":"Tolerability; Medicine; Discontinuation; Essential thrombocythemia; Internal medicine; Adverse effect; Polycythemia vera; Regimen; Clinical endpoint; Anagrelide; Dosing; Clinical trial; Surgery","score_opus":0.012431943863849538,"score_gpt":0.2929638078176176,"score_spread":0.28053186395376806,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4409546702","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.991538,0.00016167719,0.00014507948,0.0038066267,0.00034035978,0.0037645746,0.000010875678,0.000003752596,0.00022906478],"genre_scores_gemma":[0.9986964,0.000050128674,0.00030874528,0.00076114485,0.000031420477,0.000097378754,0.000021461623,0.000009600455,0.000023740853],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9981441,0.00026650517,0.0005705683,0.00039215534,0.0004023837,0.00022431275],"domain_scores_gemma":[0.999256,0.00023208848,0.000086886575,0.00027312466,0.0000730613,0.00007884164],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007297597,0.00021522409,0.0009429363,0.0002253556,0.000030808424,0.000008796755,0.00009936515,0.00004485902,0.000012332572],"category_scores_gemma":[0.00028358065,0.00012243111,0.00001668723,0.00028859806,0.00013516449,0.000044509154,0.00006946041,0.00025259814,6.556842e-8],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.031291038,0.0024858296,0.9589805,0.00007417846,0.00011679921,0.000040514977,0.0042747515,0.00001861783,0.000004545102,0.0000122411175,0.0012762259,0.0014247533],"study_design_scores_gemma":[0.0971605,0.0030975817,0.895419,0.0006380471,0.00012927047,7.052614e-7,0.0031734551,0.000088191046,0.000038901682,0.000008007678,0.00016468864,0.0000816534],"about_ca_topic_score_codex":0.09076721,"about_ca_topic_score_gemma":0.3782684,"teacher_disagreement_score":0.2875012,"about_ca_system_score_codex":0.00032489846,"about_ca_system_score_gemma":0.0002262396,"threshold_uncertainty_score":0.91528744},"labels":[],"label_agreement":null},{"id":"W4410151754","doi":"10.1182/bloodadvances.2025015860","title":"ADORE: an open platform study of ruxolitinib in combination with other novel therapies in patients with myelofibrosis","year":2025,"lang":"en","type":"article","venue":"Blood Advances","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"Daiichi Sankyo Europe; Servier; Blood Cancer UK; AOP Orphan; Swedish Orphan Biovitrum; Galecto; Novartis Pharma; Astellas Pharma; Incyte; Celgene; AstraZeneca; Pfizer","keywords":"Ruxolitinib; Myelofibrosis; Medicine; Internal medicine; Anemia; Neutropenia; Adverse effect; International Prognostic Scoring System; Phases of clinical research; Clinical trial; Gastroenterology; Surgery; Toxicity; Bone marrow; Myelodysplastic syndromes","score_opus":0.01639570833985633,"score_gpt":0.29476738531813995,"score_spread":0.27837167697828363,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410151754","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9963479,0.00016936412,0.000009751251,0.00010762627,0.000016812039,0.0020740358,0.000016212007,0.0000107123,0.0012475777],"genre_scores_gemma":[0.9977754,0.000021831644,0.0016122614,0.000116336334,0.000005084961,0.0003662897,0.000026181027,0.000013876675,0.00006276126],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9990748,0.000026201138,0.0002567541,0.0002754499,0.00021989312,0.00014687648],"domain_scores_gemma":[0.99948305,0.00006537705,0.000110777306,0.00020222375,0.000105820334,0.00003277082],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00008980823,0.00015732636,0.00038469327,0.0001682077,0.000035968016,0.000022021844,0.000108393215,0.000029808663,0.000017994636],"category_scores_gemma":[0.000013109388,0.00009695435,0.000010588617,0.00036600928,0.000042327963,0.00036380618,0.000033679327,0.00007175789,4.4968505e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0016331873,0.020884775,0.967976,0.00004761856,0.0001389757,0.0000038062624,0.001963254,0.000026357826,0.000039562212,0.0012287323,0.0000012335524,0.006056525],"study_design_scores_gemma":[0.03218023,0.0097152805,0.9526167,0.0005592392,0.000080645994,5.232431e-7,0.002396339,0.0000060905268,0.0020795877,0.000119566306,0.00014495793,0.00010082207],"about_ca_topic_score_codex":0.00040458565,"about_ca_topic_score_gemma":0.004235385,"teacher_disagreement_score":0.030547043,"about_ca_system_score_codex":0.000035329624,"about_ca_system_score_gemma":0.00006115684,"threshold_uncertainty_score":0.39536834},"labels":[],"label_agreement":null},{"id":"W4410443435","doi":"10.21203/rs.3.rs-6622364/v1","title":"Clonal megakaryocyte dysplasia with normal blood values (CMD-NBV): an unique form of early myeloproliferative neoplasm","year":2025,"lang":"en","type":"preprint","venue":"Research Square","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Hospital Foundation","funders":"Associazione Italiana per la Ricerca sul Cancro","keywords":"Megakaryocyte; Myeloproliferative neoplasm; Dysplasia; Neoplasm; Pathology; Myeloproliferative Disorders; Medicine; Polycythemia vera; Bone marrow; Internal medicine; Biology; Myelofibrosis; Haematopoiesis; Genetics","score_opus":0.043679813563949454,"score_gpt":0.3819419718664984,"score_spread":0.33826215830254897,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410443435","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97607344,0.0009619769,0.00015374311,0.001486386,0.0001567669,0.005500286,0.0011030618,0.00015357819,0.014410767],"genre_scores_gemma":[0.98361045,0.0015452824,0.0062615834,0.00015952198,0.00047529532,0.0023749874,0.0012310636,0.00011310193,0.0042287167],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.992199,0.0009774544,0.001008048,0.0016121138,0.00287178,0.0013315959],"domain_scores_gemma":[0.99177885,0.0009465465,0.00035337688,0.0016383706,0.0044566025,0.00082622416],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.0015608928,0.00094861886,0.0017894557,0.0012357819,0.00048724297,0.00020237817,0.00063098175,0.0008499158,0.00031485918],"category_scores_gemma":[0.0004348538,0.00070731016,0.00040623854,0.0009486599,0.00069172576,0.00031929766,0.0010375127,0.0031770421,0.000034826295],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.012429885,0.009020118,0.91453046,0.010623947,0.0073965453,0.002821552,0.01565391,0.0004447962,0.0006475765,0.017112268,0.001919479,0.0073994617],"study_design_scores_gemma":[0.01856782,0.036732737,0.7314056,0.020087078,0.002191128,0.00051118067,0.0026056292,0.001979008,0.17455073,0.0070854775,0.002261465,0.00202212],"about_ca_topic_score_codex":0.0014251114,"about_ca_topic_score_gemma":0.0010608813,"teacher_disagreement_score":0.18312484,"about_ca_system_score_codex":0.0005618182,"about_ca_system_score_gemma":0.0053854426,"threshold_uncertainty_score":0.9995378},"labels":[],"label_agreement":null},{"id":"W4410485253","doi":"10.1101/2025.05.14.654143","title":"Classical Myelo-Proliferative Neoplasms emergence and development based on real life incidence and mathematical modeling","year":2025,"lang":"en","type":"preprint","venue":"bioRxiv (Cold Spring Harbor Laboratory)","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Polytechnique Montréal","funders":"Institut National de la Santé et de la Recherche Médicale; Institut National Du Cancer; European Commission","keywords":"Incidence (geometry); Development (topology); Computer science; Mathematics; Mathematical analysis","score_opus":0.026152544358530986,"score_gpt":0.2644018191827291,"score_spread":0.2382492748241981,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410485253","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98183984,0.00070778775,0.012839313,0.0018126114,0.0002685259,0.0020052155,0.000118607175,0.00027029376,0.00013781452],"genre_scores_gemma":[0.9678047,0.00064352725,0.029534403,0.00082502415,0.00018738405,0.00090856175,0.0000015394854,0.000071519586,0.000023396173],"study_design_codex":"observational","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.9960886,0.00017053205,0.0008880569,0.0015409554,0.0007222056,0.0005896319],"domain_scores_gemma":[0.9972362,0.00035139304,0.00025770132,0.0008367124,0.0005245467,0.0007934784],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0005489413,0.0008749257,0.0012304782,0.0003539002,0.0003297848,0.00017198923,0.00019645454,0.0005948834,0.00012366366],"category_scores_gemma":[0.00068485725,0.00076635793,0.000111350855,0.00027742915,0.00019331569,0.00009587533,0.00046964723,0.00096255296,0.000052604282],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.010182278,0.016923299,0.77212894,0.033948395,0.011043168,0.003872777,0.0024087788,0.02636774,0.055838764,0.0626785,0.0039548827,0.0006524729],"study_design_scores_gemma":[0.0059904717,0.0013032806,0.17479195,0.010709627,0.0012976275,4.965919e-7,0.000043643162,0.7216618,0.08031522,0.0000325769,0.0011411703,0.0027121233],"about_ca_topic_score_codex":0.000020890611,"about_ca_topic_score_gemma":0.0000064926608,"teacher_disagreement_score":0.6952941,"about_ca_system_score_codex":0.00032651567,"about_ca_system_score_gemma":0.0024524138,"threshold_uncertainty_score":0.99947876},"labels":[],"label_agreement":null},{"id":"W4410706903","doi":"10.51731/cjht.2025.1134","title":"Ruxolitinib (Opzelura)","year":2025,"lang":"en","type":"article","venue":"Canadian Journal of Health Technologies","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Ruxolitinib; Business; Medicine; Internal medicine; Myelofibrosis; Bone marrow","score_opus":0.022036681065779235,"score_gpt":0.32141706921339325,"score_spread":0.29938038814761403,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410706903","genre_codex":"commentary","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.32978648,0.12349658,0.00033469166,0.534721,0.00086939003,0.0007084862,0.00002894005,0.00016384569,0.009890573],"genre_scores_gemma":[0.9951569,0.0009333462,0.0010343102,0.0024105096,0.000010255925,0.0000121915145,0.0000024570277,0.000007133806,0.00043293694],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99888647,0.000034138808,0.00048408433,0.00011469822,0.00010755739,0.00037307778],"domain_scores_gemma":[0.9991974,0.00007186558,0.0002021726,0.0002095,0.00020982893,0.000109193505],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00033136632,0.000116494004,0.00044329368,0.0007216039,0.00019234569,0.000022402464,0.00013680974,0.000114428476,0.000048815084],"category_scores_gemma":[0.00057766424,0.00008713464,0.00009286518,0.00033244299,0.00014679323,0.000052413117,0.0000117615455,0.00033360397,0.000011382763],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000033794127,0.000081274346,0.17882514,0.00021643723,0.00021167772,0.00053237623,0.000166315,0.0000028807137,0.000017323875,0.03531114,0.05199786,0.7326038],"study_design_scores_gemma":[0.001819708,0.0011133272,0.16638508,0.0012772323,0.0000681083,0.00055690715,0.002734528,0.0000063190614,0.0035389012,0.009326371,0.8130457,0.00012784115],"about_ca_topic_score_codex":0.00145734,"about_ca_topic_score_gemma":0.0017756864,"teacher_disagreement_score":0.7610478,"about_ca_system_score_codex":0.000510549,"about_ca_system_score_gemma":0.0046444917,"threshold_uncertainty_score":0.8239129},"labels":[],"label_agreement":null},{"id":"W4410809556","doi":"10.1200/jco.2025.43.16_suppl.6500","title":"Ropeginterferon alfa-2b versus anagrelide for the treatment of essential thrombocythemia: Topline results of the phase 3 SURPASS-ET trial.","year":2025,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Medicine; Anagrelide; Essential thrombocythemia; Internal medicine; Oncology; Pediatrics; Polycythemia vera","score_opus":0.19727298350660116,"score_gpt":0.5520955850902599,"score_spread":0.35482260158365875,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410809556","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.94202214,0.0011068883,0.0004242921,0.048528478,0.0043839714,0.0014980074,0.00006949736,0.0000040265927,0.0019626888],"genre_scores_gemma":[0.99216473,0.004683616,0.00090521894,0.0005496274,0.0008594566,0.000041504805,0.000008307634,0.000011098395,0.00077641406],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.996287,0.00043066958,0.002628634,0.00019831014,0.00028131795,0.00017406639],"domain_scores_gemma":[0.98443115,0.012339453,0.0021153053,0.00040074976,0.00060970924,0.00010365942],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0020640942,0.00017564483,0.0017177465,0.00007410286,0.000059557,0.0000066598936,0.00020794033,0.00023514168,0.000042501404],"category_scores_gemma":[0.0038830824,0.00007534818,0.0011450689,0.000151941,0.00028333,0.00003766681,0.000043734985,0.00031820862,0.0000011808529],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.77993995,0.029289287,0.0026908945,0.000058443584,0.0056966995,0.000069413305,0.00037406592,0.000101517864,0.0005571016,0.0013376409,0.021714948,0.15817004],"study_design_scores_gemma":[0.5937814,0.15843998,0.014366659,0.00029515574,0.0046642656,0.00002509046,0.0002602189,0.00026093345,0.021232339,0.000292024,0.20629093,0.000090961694],"about_ca_topic_score_codex":0.000056764206,"about_ca_topic_score_gemma":0.0002776775,"teacher_disagreement_score":0.18615852,"about_ca_system_score_codex":0.00021737997,"about_ca_system_score_gemma":0.0015511767,"threshold_uncertainty_score":0.46486926},"labels":[],"label_agreement":null},{"id":"W4411027625","doi":"10.1200/jco.2025.43.17_suppl.lba3","title":"Results from VERIFY, a phase 3, double-blind, placebo (PBO)-controlled study of rusfertide for treatment of polycythemia vera (PV).","year":2025,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"Protagonist Therapeutics","keywords":"Medicine; Polycythemia vera; Placebo; Double blind; Internal medicine; Pharmacology; Pathology; Alternative medicine","score_opus":0.21537154448924106,"score_gpt":0.5330535497673295,"score_spread":0.3176820052780885,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4411027625","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98884916,0.00063417706,0.00010821274,0.004733449,0.000955161,0.0029159146,0.000096042655,0.000006923165,0.0017009609],"genre_scores_gemma":[0.9957947,0.0006633118,0.0019204991,0.0003366991,0.00057038997,0.0001793264,0.000023330142,0.000016737133,0.0004950199],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9937341,0.00042622705,0.004874138,0.00034370786,0.0003788169,0.00024300018],"domain_scores_gemma":[0.9850428,0.010674645,0.0028737187,0.00039347238,0.0007404146,0.00027494197],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0017178549,0.00027501694,0.00434899,0.00025516734,0.00005060868,0.000007629466,0.00015941207,0.00035715743,0.00007436743],"category_scores_gemma":[0.0026886011,0.00016868605,0.0010735311,0.00016914097,0.00013124653,0.000058607173,0.000035062854,0.00026977286,0.0000032011499],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.85262066,0.06857661,0.022068342,0.00002665216,0.0077085,0.0002743592,0.0007493606,0.000037615624,0.00050769764,0.00011482053,0.0016495186,0.045665864],"study_design_scores_gemma":[0.80845207,0.1516121,0.015446204,0.00020837685,0.0048655677,0.000016589092,0.00058885413,0.00017588913,0.007059988,0.00016943594,0.0113051655,0.000099730874],"about_ca_topic_score_codex":0.00022360065,"about_ca_topic_score_gemma":0.00024024653,"teacher_disagreement_score":0.083035484,"about_ca_system_score_codex":0.00030061943,"about_ca_system_score_gemma":0.0020578385,"threshold_uncertainty_score":0.68788177},"labels":[],"label_agreement":null},{"id":"W4411156465","doi":"10.3390/curroncol32060339","title":"Myelofibrosis: Treatment Options After Ruxolitinib Failure","year":2025,"lang":"en","type":"review","venue":"Current Oncology","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Ruxolitinib; Myelofibrosis; Medicine; Internal medicine; Bioinformatics; Intensive care medicine; Bone marrow","score_opus":0.15068883873976952,"score_gpt":0.47485392960050815,"score_spread":0.32416509086073864,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4411156465","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000022595683,0.9887441,0.000013773669,0.0007118225,0.0015472594,0.0034497455,0.0006167699,0.00011905304,0.0047749267],"genre_scores_gemma":[0.000016774098,0.9807245,0.0006372972,0.00009933762,0.0008556978,0.012502998,0.0017465121,0.000059443508,0.003357447],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9968453,0.0003842429,0.0009615308,0.00096137816,0.00023095147,0.00061656535],"domain_scores_gemma":[0.9977824,0.0006145683,0.00033289418,0.0007315781,0.0001765734,0.00036198745],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.000111215624,0.00092121674,0.0037886288,0.00049741264,0.00013192889,0.000037311547,0.00015211506,0.00066454243,0.0011307658],"category_scores_gemma":[0.000094775736,0.0006168871,0.0013966496,0.00041343097,0.0001341988,0.000044185013,0.00012581598,0.00053206884,0.0008359064],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000050337752,0.0028139753,0.00039393004,0.013864853,0.0009512077,0.00017796615,0.000083843624,6.891553e-8,3.5120355e-8,0.00092555303,0.0076325727,0.97310567],"study_design_scores_gemma":[0.0017247498,0.0016737136,0.00016332316,0.02376446,0.00821606,0.00019160386,0.000023824943,8.210863e-7,0.00000169266,0.0000337621,0.9638374,0.00036859664],"about_ca_topic_score_codex":0.000007819592,"about_ca_topic_score_gemma":0.00005701324,"teacher_disagreement_score":0.9727371,"about_ca_system_score_codex":0.0022959583,"about_ca_system_score_gemma":0.002736554,"threshold_uncertainty_score":0.99994206},"labels":[],"label_agreement":null},{"id":"W4411159569","doi":"10.1002/bcp.70118","title":"Exposure–response relationship of fedratinib in patients with intermediate‐2 or high‐risk myelofibrosis","year":2025,"lang":"en","type":"article","venue":"British Journal of Clinical Pharmacology","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Bristol-Myers Squibb Canada","keywords":"Medicine; Ruxolitinib; Internal medicine; Confidence interval; Myelofibrosis; Anemia; Gastroenterology; Adverse effect; Population; Odds ratio; Nausea; Incidence (geometry); Janus kinase inhibitor; Bone marrow; Tofacitinib","score_opus":0.027148559165148137,"score_gpt":0.3787313259327033,"score_spread":0.3515827667675552,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4411159569","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9968256,0.0003124128,0.000050045634,0.0011886018,0.00100241,0.0004699692,0.000045396613,0.000006960559,0.00009861907],"genre_scores_gemma":[0.9963768,0.0007601992,0.0012968637,0.0011245921,0.0001887906,0.00002349308,0.000010296295,0.000014383756,0.00020458845],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99613786,0.0012097508,0.0019422453,0.00022188119,0.00028084387,0.00020740803],"domain_scores_gemma":[0.9931973,0.0049633924,0.00096141995,0.0001058105,0.000584693,0.0001873884],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0016225216,0.00014886455,0.0010278994,0.00025088195,0.000055791337,0.000014655664,0.00012785946,0.00018326362,0.0004284124],"category_scores_gemma":[0.0038427166,0.00011457921,0.00019816663,0.0003280456,0.00023396718,0.00011570812,0.000044585337,0.00081007264,0.000005252321],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.045437876,0.003233545,0.9134039,0.00004618622,0.00049618154,0.000540269,0.000050105584,0.000027478824,0.000020664707,0.00001264016,0.0072474107,0.029483737],"study_design_scores_gemma":[0.0327205,0.008237541,0.9563007,0.00072422944,0.0005245294,0.00007102869,0.00003305607,0.000009707375,0.00050986925,0.00007088928,0.0007134029,0.00008454604],"about_ca_topic_score_codex":0.000031911284,"about_ca_topic_score_gemma":0.00007895126,"teacher_disagreement_score":0.0428968,"about_ca_system_score_codex":0.00007993207,"about_ca_system_score_gemma":0.0006922901,"threshold_uncertainty_score":0.46908152},"labels":[],"label_agreement":null},{"id":"W4412014975","doi":"10.1177/20406207251342199","title":"Clinical outcomes of high-risk patients with polycythemia vera after suboptimal response to first-line therapy who switched to ruxolitinib versus nonswitchers: results from the PV-Switch study","year":2025,"lang":"en","type":"article","venue":"Therapeutic Advances in Hematology","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hôpital Maisonneuve-Rosemont","funders":"AOP Orphan; Swedish Orphan Biovitrum; Novartis Pharma; Galecto; Sierra Oncology; CTI Biopharma; Incyte; Celgene; Alexion Pharmaceuticals; Ariad Pharmaceuticals; Gilead Sciences; RWTH Aachen University; Pfizer; Bristol-Myers Squibb","keywords":"Medicine; Ruxolitinib; Phlebotomy; Internal medicine; Polycythemia vera; Thrombosis; Hematology; Retrospective cohort study; Myelofibrosis; Gastroenterology; Surgery; Bone marrow","score_opus":0.025718908178229527,"score_gpt":0.3605291126465878,"score_spread":0.3348102044683583,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4412014975","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9871146,0.00125775,0.00042087716,0.007382772,0.00042827832,0.00313346,0.00015469067,0.00004199068,0.00006555186],"genre_scores_gemma":[0.99408096,0.0004923532,0.002047064,0.00243129,0.000051450057,0.0007591841,0.000026858883,0.000041249878,0.000069616304],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9962878,0.0006604139,0.0012471935,0.0008747062,0.00042176215,0.0005081185],"domain_scores_gemma":[0.9895106,0.008629901,0.00032081275,0.0011248733,0.0002471432,0.00016669981],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00080430706,0.00047922475,0.0015144108,0.00020239768,0.000108735374,0.000013542084,0.00033251394,0.00018039142,0.000061897146],"category_scores_gemma":[0.00085348624,0.0002757427,0.00015591767,0.00059308886,0.00019562677,0.000091782225,0.00013152263,0.00042428283,0.000025160289],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.20870245,0.0025959713,0.7724775,0.000009043789,0.00085992884,0.000044016717,0.0027540077,0.00009693016,0.0000031713287,0.000116878124,0.000020542835,0.012319564],"study_design_scores_gemma":[0.040305708,0.008209321,0.9470092,0.00022172088,0.00032239896,0.000001752699,0.00093672477,0.000017164719,0.00062941655,0.00031784573,0.0017842875,0.0002444728],"about_ca_topic_score_codex":0.00041713283,"about_ca_topic_score_gemma":0.0016562429,"teacher_disagreement_score":0.17453168,"about_ca_system_score_codex":0.00013767928,"about_ca_system_score_gemma":0.00019971804,"threshold_uncertainty_score":0.9999695},"labels":[],"label_agreement":null},{"id":"W4412123572","doi":"10.1681/asn.0000000790","title":"Authors' Reply: Clonal Hematopoiesis of Indeterminate Potential and Cardiovascular Events: Issues to Be Further Explored","year":2025,"lang":"en","type":"article","venue":"Journal of the American Society of Nephrology","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"St. Joseph’s Healthcare Hamilton; McMaster University; Population Health Research Institute; Impact; Queen's University","funders":"","keywords":"Indeterminate; Intensive care medicine; Medicine; Haematopoiesis; Biology; Stem cell; Genetics","score_opus":0.016607308877155093,"score_gpt":0.2974330448033454,"score_spread":0.2808257359261903,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4412123572","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9402574,0.0013982743,0.0002814089,0.057712022,0.000099197074,0.0002153913,0.000008811743,0.0000038112382,0.00002371836],"genre_scores_gemma":[0.98225737,0.0011739859,0.006192737,0.010092942,0.00011526346,0.000010946059,6.6961735e-7,0.000012160582,0.00014392425],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9985825,0.00019625007,0.0005213025,0.00016951944,0.0003592317,0.00017123236],"domain_scores_gemma":[0.9986625,0.00010611253,0.00053496833,0.000320175,0.0002884628,0.00008779481],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00046595663,0.00014815835,0.0010160533,0.000081177735,0.00005584732,0.000004132569,0.00015390043,0.000058863643,0.000025811401],"category_scores_gemma":[0.00007778158,0.00009513583,0.0009362293,0.00026857114,0.00041674744,0.000040979245,0.00013140633,0.00019306425,4.063472e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.007940997,0.0033276428,0.33285156,0.00096577045,0.057924964,0.00021395583,0.03224441,0.0006588109,0.21364091,0.00043343334,0.2811104,0.06868713],"study_design_scores_gemma":[0.0044046165,0.0035145357,0.8925714,0.00040197847,0.00285679,0.0006888492,0.008157862,0.00009913068,0.029005028,0.00089062226,0.057210434,0.00019877497],"about_ca_topic_score_codex":0.000111055844,"about_ca_topic_score_gemma":0.0000025549216,"teacher_disagreement_score":0.5597198,"about_ca_system_score_codex":0.000046274825,"about_ca_system_score_gemma":0.00012286834,"threshold_uncertainty_score":0.38795266},"labels":[],"label_agreement":null},{"id":"W4412366154","doi":"10.1159/000546585","title":"Impact of Early-Onset or Worsening Anemia in Patients with Myelofibrosis Treated with Ruxolitinib: A post hoc Analysis of the JUMP Study","year":2025,"lang":"en","type":"article","venue":"Acta Haematologica","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"Incyte","keywords":"Ruxolitinib; Myelofibrosis; Medicine; Anemia; Internal medicine; Post-hoc analysis; Discontinuation; Gastroenterology; Bone marrow","score_opus":0.01209793266619165,"score_gpt":0.28963655441350117,"score_spread":0.27753862174730953,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4412366154","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99795777,0.000025408464,8.860211e-7,0.0001257473,0.0000074828095,0.0014599853,0.00011027306,0.000021664011,0.00029077224],"genre_scores_gemma":[0.99951816,0.000008651105,0.0001580076,0.00004950707,0.000001873027,0.0001232498,0.00006104881,0.000012841991,0.00006668152],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9983188,0.00018624662,0.00050126534,0.00037652868,0.0003393379,0.00027783817],"domain_scores_gemma":[0.99833274,0.0003720118,0.0003351649,0.0005664586,0.00032208377,0.00007156474],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001097868,0.00028872536,0.0012470314,0.0004743245,0.00007501777,0.000014377158,0.00014768541,0.00009057285,0.00014975767],"category_scores_gemma":[0.00014682338,0.000117142896,0.00020840688,0.0026452062,0.00014035494,0.00005589074,0.00006955986,0.00014742096,9.629653e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.01036153,0.0033363379,0.9811949,0.00004936121,0.0035263863,0.00006965506,0.001110714,0.000020820502,0.00002079283,0.0000090718295,0.00004079432,0.00025960917],"study_design_scores_gemma":[0.005372191,0.011082767,0.97873366,0.00041783933,0.0030252398,0.000007467708,0.0006263652,0.000017906417,0.0005993364,0.000001679393,0.0000012114962,0.00011432288],"about_ca_topic_score_codex":0.0010261772,"about_ca_topic_score_gemma":0.00080008723,"teacher_disagreement_score":0.0077464283,"about_ca_system_score_codex":0.00010510323,"about_ca_system_score_gemma":0.00020334186,"threshold_uncertainty_score":0.47769487},"labels":[],"label_agreement":null},{"id":"W4412535392","doi":"10.1007/s12185-025-04037-6","title":"Efficacy and safety of momelotinib in Janus kinase inhibitor-experienced Asian patients with myelofibrosis and anemia","year":2025,"lang":"en","type":"article","venue":"International Journal of Hematology","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Sierra Oncology; Seoul National University Hospital","keywords":"Danazol; Anemia; Internal medicine; Medicine; Adverse effect; Placebo; Clinical endpoint; Gastroenterology; Randomized controlled trial; Endometriosis; Pathology","score_opus":0.005437242787894735,"score_gpt":0.2727625705534311,"score_spread":0.26732532776553636,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4412535392","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9962894,0.00036108628,0.00004218008,0.0024271745,0.00013777899,0.00017881507,0.000006702385,0.0000023171817,0.00055459247],"genre_scores_gemma":[0.9987614,0.00010221891,0.00093519426,0.00014526327,0.00001902591,0.000006436823,0.000006006736,0.0000047735857,0.000019689282],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9990765,0.000034701785,0.00045635263,0.00012645923,0.00021332818,0.00009265024],"domain_scores_gemma":[0.99916714,0.00016213185,0.00022049178,0.000059153226,0.00032750113,0.000063604886],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0000801928,0.00010212421,0.00037979623,0.0003008729,0.000018453045,0.000009072989,0.000060307524,0.000056546836,0.000025200803],"category_scores_gemma":[0.0001495987,0.000071239236,0.000029751884,0.00009281642,0.000119247816,0.00007099636,0.000039606926,0.00011352874,4.072134e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0031928292,0.00067059085,0.9831132,0.0000412838,0.00017340203,0.00019012502,0.0006421043,0.0000029507003,0.00030562098,0.0024135928,0.00007033115,0.009183931],"study_design_scores_gemma":[0.0113689825,0.0009311705,0.9732887,0.0008009097,0.000047683865,0.0003386401,0.00020603534,0.000008876744,0.0125596365,0.00011618091,0.00027789475,0.00005528894],"about_ca_topic_score_codex":0.0000113637225,"about_ca_topic_score_gemma":0.000014240774,"teacher_disagreement_score":0.012254016,"about_ca_system_score_codex":0.0000564512,"about_ca_system_score_gemma":0.000087650056,"threshold_uncertainty_score":0.29050517},"labels":[],"label_agreement":null},{"id":"W4412578317","doi":"10.3390/jcm14155173","title":"External Validation of the JAKPOT Score for Diagnosing JAK2-Positive Erythrocytosis: A Retrospective Cohort Study","year":2025,"lang":"en","type":"article","venue":"Journal of Clinical Medicine","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"McMaster University","funders":"American Society of Hematology","keywords":"Medicine; Cohort; Erythropoietin; Internal medicine; Logistic regression; Retrospective cohort study; Multivariate analysis; Gastroenterology; Demographics; Demography","score_opus":0.05691252617997373,"score_gpt":0.42853294595245117,"score_spread":0.37162041977247745,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4412578317","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98325133,0.00068571547,0.001369953,0.009897446,0.0015897974,0.0021737078,0.0000104852725,0.0000068133522,0.0010147478],"genre_scores_gemma":[0.99648255,0.0004514776,0.00059296505,0.0010943634,0.0011036145,0.00007459594,0.0000028077015,0.000015388221,0.0001822314],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9962051,0.00033103823,0.0021766,0.0002839526,0.00081952557,0.00018376882],"domain_scores_gemma":[0.99339277,0.0030847488,0.0014842546,0.00032064176,0.0015607252,0.00015689388],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.0029432469,0.00020925452,0.0016013795,0.00017423056,0.000119634366,0.000011339851,0.00017863864,0.000120840436,0.000068217705],"category_scores_gemma":[0.009087726,0.00010875145,0.00047702997,0.00035599293,0.0002877496,0.00008948244,0.0000567241,0.0005323315,0.0000010310363],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0017013652,0.0024584187,0.9863506,0.000066149994,0.0013718724,0.00003809803,0.0003974151,0.000006678448,0.00019469584,0.00038757906,0.0021647785,0.0048623504],"study_design_scores_gemma":[0.011883184,0.009526453,0.96174634,0.004209565,0.0028655464,0.000048357426,0.0004949224,0.000031535954,0.007961481,0.0009959731,0.00016547443,0.00007117766],"about_ca_topic_score_codex":0.000028707344,"about_ca_topic_score_gemma":0.0000139591175,"teacher_disagreement_score":0.024604268,"about_ca_system_score_codex":0.00019263693,"about_ca_system_score_gemma":0.00036310026,"threshold_uncertainty_score":0.9992592},"labels":[],"label_agreement":null},{"id":"W4412820305","doi":"10.1002/pbc.31946","title":"Complications at Diagnosis of Pediatric Chronic Myeloid Leukemia in Chronic Phase","year":2025,"lang":"en","type":"review","venue":"Pediatric Blood & Cancer","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University; Ontario Clinical Oncology Group","funders":"","keywords":"Medicine; Leukostasis; Thrombocytosis; Surgery; Anagrelide; Asymptomatic; Leukemia; Internal medicine; Platelet; Essential thrombocythemia","score_opus":0.04023888368529648,"score_gpt":0.3733000008212411,"score_spread":0.3330611171359446,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4412820305","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0027100558,0.989976,0.0000033011042,0.00014871523,0.00044082114,0.0040559634,0.0015459865,0.000075631164,0.001043565],"genre_scores_gemma":[0.0010897953,0.97997534,0.0000803045,0.0000784337,0.0034605362,0.013570058,0.0008451165,0.00010857858,0.0007918533],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99538684,0.00020281802,0.0018012498,0.0012336181,0.00058471184,0.00079077977],"domain_scores_gemma":[0.99618757,0.0011683537,0.0010468741,0.0010453798,0.00023569596,0.00031615433],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00023400663,0.0009660995,0.003693528,0.001310025,0.00015249186,0.00002314367,0.00041178273,0.0005783186,0.001006341],"category_scores_gemma":[0.00014665801,0.0008113767,0.0010210233,0.0027980134,0.00008512889,0.000078526944,0.00027519278,0.00078057515,0.00013624718],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.000055051492,0.002763979,0.06725457,0.21682584,0.0016412257,0.0001490408,0.00009788103,0.000047644546,9.3206677e-7,0.000117484575,0.02100834,0.690038],"study_design_scores_gemma":[0.009225392,0.0012797368,0.003239147,0.0123941265,0.045636036,0.000046278332,0.0000036456922,0.000020667201,0.00005991883,0.000012978196,0.92704654,0.0010355671],"about_ca_topic_score_codex":0.0005691759,"about_ca_topic_score_gemma":0.0009115837,"teacher_disagreement_score":0.90603817,"about_ca_system_score_codex":0.008462412,"about_ca_system_score_gemma":0.015568244,"threshold_uncertainty_score":0.9999069},"labels":[],"label_agreement":null},{"id":"W4412934716","doi":"10.1186/s12920-025-02159-8","title":"Molecular landscape of non-driver genes in myeloproliferative neoplasms through 333 cancer genes panel: Insights to reveal in Pakistan","year":2025,"lang":"en","type":"article","venue":"BMC Medical Genomics","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université du Québec à Trois-Rivières; Innovation and Economic Development Trois Rivières","funders":"University of Texas MD Anderson Cancer Center; University of Karachi","keywords":"Gene; Human genetics; Biology; Genetics; Myeloproliferative Disorders; Computational biology; Cancer; DNA microarray; Bioinformatics; Cancer research; Immunology; Gene expression","score_opus":0.02270431221568463,"score_gpt":0.3359220866536142,"score_spread":0.3132177744379296,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4412934716","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98933494,0.005203795,0.0013526651,0.00094756525,0.00022886274,0.0012464392,0.000032128315,0.000019579702,0.0016339937],"genre_scores_gemma":[0.98603815,0.0045784567,0.006491073,0.0018782892,0.00013077763,0.00051895453,0.00004885427,0.000035500652,0.0002799481],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99739945,0.00015052778,0.0009308722,0.00056002475,0.00051440136,0.0004447176],"domain_scores_gemma":[0.99871355,0.00032764583,0.0001281581,0.00038372842,0.00015745846,0.00028943855],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00025190864,0.00035613176,0.00095478597,0.0003206669,0.000047916517,0.000016913627,0.00021646495,0.0002967764,0.00018881552],"category_scores_gemma":[0.00015096957,0.0002821949,0.00015762578,0.0007162065,0.00012034829,0.00005505595,0.00015952456,0.00029805154,0.000019647405],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0010254682,0.0010155644,0.96433145,0.00043712265,0.0003174624,0.0005999018,0.0055826665,0.0024154151,0.008509519,0.0024109508,0.00060621125,0.012748255],"study_design_scores_gemma":[0.015157779,0.0011193661,0.86236405,0.002609551,0.00027996645,0.000044610853,0.001838792,0.006605487,0.09956028,0.00083711353,0.008777198,0.0008057703],"about_ca_topic_score_codex":0.0009762873,"about_ca_topic_score_gemma":0.0077614263,"teacher_disagreement_score":0.10196738,"about_ca_system_score_codex":0.00043881134,"about_ca_system_score_gemma":0.0021141076,"threshold_uncertainty_score":0.99996305},"labels":[],"label_agreement":null},{"id":"W4413605538","doi":"10.1016/j.bneo.2025.100165","title":"Final safety and efficacy results from a phase 1/2 study of tagraxofusp, a CD123-targeted therapy, for myelofibrosis","year":2025,"lang":"en","type":"article","venue":"Blood Neoplasia","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta Hospital; Princess Margaret Cancer Centre","funders":"Menarini Group","keywords":"Myelofibrosis; Medicine; Phase (matter); Targeted therapy; Oncology; Internal medicine; Chemistry; Bone marrow; Cancer","score_opus":0.026818573508397035,"score_gpt":0.31592032229977934,"score_spread":0.2891017487913823,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4413605538","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99249303,0.0012971922,0.00007070301,0.0010358937,0.00011248179,0.0034515625,0.0009102393,0.000061436076,0.0005674824],"genre_scores_gemma":[0.99639237,0.00046145305,0.0016898887,0.00023960856,0.00008309472,0.00031699287,0.00034605854,0.000026591384,0.00044391767],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99798566,0.00009569864,0.00070706656,0.000661359,0.00025645542,0.0002937348],"domain_scores_gemma":[0.99791193,0.0010862491,0.00020237338,0.00047753178,0.00017568424,0.00014622693],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00019495412,0.00033463378,0.00082432735,0.0001899682,0.0001702046,0.000029421275,0.00009711242,0.00012403248,0.000050054106],"category_scores_gemma":[0.00030781562,0.00025884263,0.0001520012,0.00033862854,0.00006803891,0.000051194987,0.000054362892,0.00013523255,0.0000030783926],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.17903572,0.1287212,0.37002057,0.00040402857,0.013545693,0.00030742618,0.01703064,0.000030889703,0.036974106,0.001080431,0.008329569,0.24451971],"study_design_scores_gemma":[0.2824469,0.021251984,0.5943384,0.0004974927,0.0023393165,0.000018859859,0.0011159474,0.00023538418,0.087528795,0.0001317975,0.009721906,0.00037320922],"about_ca_topic_score_codex":0.00033778627,"about_ca_topic_score_gemma":0.00015421728,"teacher_disagreement_score":0.24414651,"about_ca_system_score_codex":0.000030852138,"about_ca_system_score_gemma":0.00018056211,"threshold_uncertainty_score":0.99998635},"labels":[],"label_agreement":null},{"id":"W4413684499","doi":"10.51731/cjht.2025.1204","title":"Ruxolitinib (Opzelura)","year":2025,"lang":"en","type":"article","venue":"Canadian Journal of Health Technologies","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Ruxolitinib; Computer science; Medicine; Internal medicine; Myelofibrosis; Bone marrow","score_opus":0.022036681065779235,"score_gpt":0.32141706921339325,"score_spread":0.29938038814761403,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4413684499","genre_codex":"commentary","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.32978648,0.12349658,0.00033469166,0.534721,0.00086939003,0.0007084862,0.00002894005,0.00016384569,0.009890573],"genre_scores_gemma":[0.9951569,0.0009333462,0.0010343102,0.0024105096,0.000010255925,0.0000121915145,0.0000024570277,0.000007133806,0.00043293694],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99888647,0.000034138808,0.00048408433,0.00011469822,0.00010755739,0.00037307778],"domain_scores_gemma":[0.9991974,0.00007186558,0.0002021726,0.0002095,0.00020982893,0.000109193505],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00033136632,0.000116494004,0.00044329368,0.0007216039,0.00019234569,0.000022402464,0.00013680974,0.000114428476,0.000048815084],"category_scores_gemma":[0.00057766424,0.00008713464,0.00009286518,0.00033244299,0.00014679323,0.000052413117,0.0000117615455,0.00033360397,0.000011382763],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000033794127,0.000081274346,0.17882514,0.00021643723,0.00021167772,0.00053237623,0.000166315,0.0000028807137,0.000017323875,0.03531114,0.05199786,0.7326038],"study_design_scores_gemma":[0.001819708,0.0011133272,0.16638508,0.0012772323,0.0000681083,0.00055690715,0.002734528,0.0000063190614,0.0035389012,0.009326371,0.8130457,0.00012784115],"about_ca_topic_score_codex":0.00145734,"about_ca_topic_score_gemma":0.0017756864,"teacher_disagreement_score":0.7610478,"about_ca_system_score_codex":0.000510549,"about_ca_system_score_gemma":0.0046444917,"threshold_uncertainty_score":0.8239129},"labels":[],"label_agreement":null},{"id":"W4413789824","doi":"10.1016/s2152-2650(25)02141-x","title":"MPN-785: Results From VERIFY, an International, Randomized, Phase 3, Double-Blind, Placebo-Controlled Study of Rusfertide (First-in-Class Hepcidin Mimetic) for Treatment of Polycythemia Vera (PV)","year":2025,"lang":"en","type":"article","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Polycythemia vera; Hepcidin; Double blind; Placebo; Internal medicine; Gastroenterology; Anemia; Pathology; Alternative medicine","score_opus":0.06723351044361701,"score_gpt":0.40402092516422355,"score_spread":0.3367874147206065,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4413789824","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9833893,0.00051869545,0.000084194086,0.0010816255,0.0009137867,0.011499164,0.00039561858,0.000060553437,0.0020570303],"genre_scores_gemma":[0.9919823,0.0008679323,0.0011511393,0.00022489758,0.00035143897,0.004109714,0.0005930538,0.00005836975,0.00066118373],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99285054,0.0005945175,0.0041469187,0.001295137,0.00061016233,0.0005027081],"domain_scores_gemma":[0.9872778,0.009602971,0.0010578666,0.0012464806,0.00047213054,0.00034271742],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0015985797,0.0006857066,0.004408838,0.00047440847,0.00012007673,0.000049561677,0.00041905805,0.00043803582,0.00009955152],"category_scores_gemma":[0.0022113703,0.00050732447,0.001192165,0.0003770996,0.0003406451,0.00017107534,0.00010328285,0.00014420012,0.000015993875],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.897613,0.02264292,0.021624172,0.000046676792,0.005143255,0.00015212875,0.00094725465,0.000083585364,0.000273197,0.0005330813,0.00028761962,0.050653096],"study_design_scores_gemma":[0.91706127,0.009078598,0.049474128,0.00042774924,0.0025713118,0.0000061560163,0.00045982425,0.005530715,0.013069062,0.00022380413,0.001778435,0.00031894678],"about_ca_topic_score_codex":0.0023719051,"about_ca_topic_score_gemma":0.00092509715,"teacher_disagreement_score":0.050334148,"about_ca_system_score_codex":0.0015125539,"about_ca_system_score_gemma":0.0012837203,"threshold_uncertainty_score":0.99973786},"labels":[],"label_agreement":null},{"id":"W4413791759","doi":"10.1016/s2152-2650(25)01744-6","title":"AML-886: Demographics, Management, and Outcomes of Active Acute Myeloid Leukemia Patients Admitted for Acute Pulmonary Embolism: A Propensity Score-Matched Study From the United States","year":2025,"lang":"en","type":"article","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Red Deer Regional Hospital","funders":"","keywords":"Medicine; Pulmonary embolism; Propensity score matching; Demographics; Myeloid leukemia; Internal medicine; Intensive care medicine; Oncology; Demography","score_opus":0.032062653653082224,"score_gpt":0.32782600224960656,"score_spread":0.2957633485965243,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4413791759","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9895791,0.0001740626,0.00007021681,0.0010766174,0.00043146373,0.0074937814,0.00080575043,0.00012634491,0.00024265914],"genre_scores_gemma":[0.99051917,0.0018430882,0.00078479835,0.0033808209,0.00009304216,0.0012574233,0.0015061457,0.00007210812,0.0005433857],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9952637,0.00047982598,0.0017161333,0.0012937951,0.00060372014,0.00064285507],"domain_scores_gemma":[0.99428266,0.0027845278,0.00068635365,0.0011455467,0.00074364385,0.00035726945],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0005846546,0.00074855087,0.0020966353,0.00033420953,0.00044048484,0.00008848217,0.00048969913,0.0003661368,0.000018604293],"category_scores_gemma":[0.0004707598,0.0004861903,0.0005672243,0.0009943085,0.00065233296,0.00018494594,0.0006178203,0.0003664513,0.000010623024],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0049677966,0.0022812157,0.84160984,0.000077985715,0.013501607,0.00017838998,0.00042352662,0.0000030459,0.00001920615,0.0003335865,0.0010646373,0.13553916],"study_design_scores_gemma":[0.017446736,0.0016132427,0.9686526,0.0003340375,0.0075527867,0.0000066816183,0.0008609254,0.00063309487,0.00040391824,0.0007854272,0.0013114309,0.00039913907],"about_ca_topic_score_codex":0.00092623616,"about_ca_topic_score_gemma":0.00015670496,"teacher_disagreement_score":0.13514002,"about_ca_system_score_codex":0.00069818454,"about_ca_system_score_gemma":0.000656922,"threshold_uncertainty_score":0.99975896},"labels":[],"label_agreement":null},{"id":"W4413806112","doi":"10.1016/j.jacc.2025.08.025","title":"Colchicine and Longitudinal Dynamics of Clonal Hematopoiesis","year":2025,"lang":"en","type":"article","venue":"Journal of the American College of Cardiology","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":24,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University","funders":"National Heart, Lung, and Blood Institute; American Heart Association","keywords":"Medicine; Colchicine; Internal medicine; Oncology; Cardiology","score_opus":0.009838546534647847,"score_gpt":0.28100614374658,"score_spread":0.2711675972119322,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4413806112","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9874467,0.00071522436,0.00030065383,0.0093503455,0.00017561216,0.00017212711,0.00007345707,0.000001753167,0.00176413],"genre_scores_gemma":[0.9980289,0.00046848043,0.0010098346,0.00022082013,0.00007528619,0.0000035913902,8.966346e-7,0.0000057974175,0.0001864369],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99895775,0.00013658601,0.00050349045,0.00009978371,0.00018781406,0.000114575705],"domain_scores_gemma":[0.99837583,0.0003809124,0.00064020854,0.00018811478,0.00036189312,0.000053055635],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00026153252,0.000112462425,0.0011828414,0.00016142285,0.000041048424,0.0000014045821,0.00010687319,0.000036561734,0.0000073118194],"category_scores_gemma":[0.00021233501,0.000066043096,0.00028611108,0.00032537014,0.000595376,0.00001852976,0.000072600895,0.00015375091,1.6486479e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.001244074,0.00010273225,0.9835019,0.000090973925,0.0016024178,0.00013179751,0.000018573433,0.00008772951,0.0007442518,0.007728594,0.00406313,0.000683795],"study_design_scores_gemma":[0.0021752624,0.0019725382,0.986484,0.0002738108,0.0009024829,0.0023631216,0.00045352828,0.000094545125,0.0031447643,0.00091640814,0.0011602252,0.00005932],"about_ca_topic_score_codex":0.000013635241,"about_ca_topic_score_gemma":0.000017039687,"teacher_disagreement_score":0.010582159,"about_ca_system_score_codex":0.000086978005,"about_ca_system_score_gemma":0.00026830874,"threshold_uncertainty_score":0.26931593},"labels":[],"label_agreement":null},{"id":"W4413954079","doi":"10.1002/ajh.70065","title":"Triple A Plus ( <scp>AAA</scp> <sup>+</sup> ) Survival Prediction Model for Essential Thrombocythemia: Analysis Involving 7308 Patients","year":2025,"lang":"en","type":"article","venue":"American Journal of Hematology","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal","funders":"Associazione Italiana per la Ricerca sul Cancro","keywords":"Medicine; Internal medicine; Essential thrombocythemia; Gastroenterology; Confidence interval; Cohort; Survival analysis; Platelet","score_opus":0.012702881087114148,"score_gpt":0.28619297085756173,"score_spread":0.2734900897704476,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4413954079","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.94222033,0.00040981005,0.055600677,0.00069979933,0.00022775354,0.00046299578,0.000061007424,0.000023145773,0.000294512],"genre_scores_gemma":[0.993978,0.00023832727,0.0048775454,0.00040635376,0.000105388026,0.00007052638,0.000071835224,0.000023695407,0.00022828784],"study_design_codex":"observational","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.9978085,0.0001453785,0.0009456202,0.00033820458,0.00036029043,0.00040196942],"domain_scores_gemma":[0.9973464,0.00074753875,0.00074375776,0.00025953096,0.00070567324,0.00019710198],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00031722095,0.0002714648,0.0016665822,0.00069096574,0.0001556103,0.000024206716,0.00014708492,0.00011618432,0.000018972267],"category_scores_gemma":[0.00064568873,0.00021438624,0.00058922695,0.0008187282,0.00022461302,0.00011773455,0.000051721236,0.00029236157,0.0000029565765],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00086508295,0.0017789279,0.95164275,0.00017969985,0.010467981,0.00008442537,0.0029060012,0.0165253,0.0001548172,0.0033245147,0.009486791,0.0025836937],"study_design_scores_gemma":[0.029501975,0.0077772406,0.090744406,0.0006112767,0.01997175,0.00047440888,0.008072902,0.83089566,0.008274363,0.0020064167,0.0013281497,0.0003414434],"about_ca_topic_score_codex":0.00004286988,"about_ca_topic_score_gemma":0.000031263015,"teacher_disagreement_score":0.8608984,"about_ca_system_score_codex":0.0002741143,"about_ca_system_score_gemma":0.0005175981,"threshold_uncertainty_score":0.8742417},"labels":[],"label_agreement":null},{"id":"W4414003325","doi":"10.14740/jh2094","title":"Efficacy and Safety of Momelotinib in Myelofibrosis: A Systematic Review and Meta-Analysis With a Focus on Anemia Outcomes","year":2025,"lang":"en","type":"article","venue":"Journal of Hematology","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Myelofibrosis; Medicine; Anemia; Meta-analysis; Focus (optics); Intensive care medicine; Internal medicine; Bone marrow","score_opus":0.022358392343143157,"score_gpt":0.31793696645086,"score_spread":0.2955785741077168,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4414003325","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.65837085,0.29516307,0.00014611792,0.042848144,0.000025732223,0.0028216827,0.000016215066,0.000009417405,0.00059878075],"genre_scores_gemma":[0.9946028,0.0036119025,0.00075987866,0.0008865107,0.0000018491897,0.00004982449,9.1084416e-7,0.000006320586,0.00007999423],"study_design_codex":"observational","study_design_gemma":"meta_analysis","domain_scores_codex":[0.9982603,0.00020604263,0.0010671598,0.00016289565,0.00018285234,0.00012075048],"domain_scores_gemma":[0.99809813,0.0008506747,0.0006223266,0.00020311346,0.00015160468,0.00007412937],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00047651664,0.00018114272,0.004481149,0.00047446828,0.0000223518,0.0000062287877,0.00004999024,0.00006149603,0.000039212337],"category_scores_gemma":[0.00034857384,0.00008834104,0.00031576157,0.00042117864,0.00006294138,0.000032397005,0.000020672633,0.00014965472,6.802137e-7],"study_design_candidate":"meta_analysis","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0020739017,0.0019871567,0.46115008,0.21330306,0.30560806,0.0008576064,0.0005673727,0.000020980744,0.000026892085,0.01404842,0.0002758747,0.00008059017],"study_design_scores_gemma":[0.006976246,0.001986534,0.1577775,0.01535045,0.81493866,0.0016166584,0.00015377716,0.000009192648,0.0008326817,0.0002031557,0.000011116889,0.00014404558],"about_ca_topic_score_codex":0.0000101494325,"about_ca_topic_score_gemma":0.00004212324,"teacher_disagreement_score":0.5093306,"about_ca_system_score_codex":0.00003247284,"about_ca_system_score_gemma":0.00007154907,"threshold_uncertainty_score":0.3602443},"labels":[],"label_agreement":null},{"id":"W4414016490","doi":"10.51731/cjht.2025.1215","title":"Ruxolitinib (Opzelura)","year":2025,"lang":"en","type":"article","venue":"Canadian Journal of Health Technologies","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Ruxolitinib; Medicine; Internal medicine; Myelofibrosis","score_opus":0.022036681065779235,"score_gpt":0.32141706921339325,"score_spread":0.29938038814761403,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4414016490","genre_codex":"commentary","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.32978648,0.12349658,0.00033469166,0.534721,0.00086939003,0.0007084862,0.00002894005,0.00016384569,0.009890573],"genre_scores_gemma":[0.9951569,0.0009333462,0.0010343102,0.0024105096,0.000010255925,0.0000121915145,0.0000024570277,0.000007133806,0.00043293694],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99888647,0.000034138808,0.00048408433,0.00011469822,0.00010755739,0.00037307778],"domain_scores_gemma":[0.9991974,0.00007186558,0.0002021726,0.0002095,0.00020982893,0.000109193505],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00033136632,0.000116494004,0.00044329368,0.0007216039,0.00019234569,0.000022402464,0.00013680974,0.000114428476,0.000048815084],"category_scores_gemma":[0.00057766424,0.00008713464,0.00009286518,0.00033244299,0.00014679323,0.000052413117,0.0000117615455,0.00033360397,0.000011382763],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000033794127,0.000081274346,0.17882514,0.00021643723,0.00021167772,0.00053237623,0.000166315,0.0000028807137,0.000017323875,0.03531114,0.05199786,0.7326038],"study_design_scores_gemma":[0.001819708,0.0011133272,0.16638508,0.0012772323,0.0000681083,0.00055690715,0.002734528,0.0000063190614,0.0035389012,0.009326371,0.8130457,0.00012784115],"about_ca_topic_score_codex":0.00145734,"about_ca_topic_score_gemma":0.0017756864,"teacher_disagreement_score":0.7610478,"about_ca_system_score_codex":0.000510549,"about_ca_system_score_gemma":0.0046444917,"threshold_uncertainty_score":0.8239129},"labels":[],"label_agreement":null},{"id":"W4415100934","doi":"10.1038/s41375-025-02754-9","title":"Defining remission following hematopoietic cell transplant for myelofibrosis: an international expert panel consensus","year":2025,"lang":"en","type":"review","venue":"Leukemia","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"National Cancer Institute","keywords":"Hematopoietic cell; MEDLINE; Hematology; Haematopoiesis; Hematopoietic stem cell transplantation; Transplantation","score_opus":0.04881192111003129,"score_gpt":0.35144795871386036,"score_spread":0.30263603760382907,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4415100934","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00026766502,0.99199176,0.0001353882,0.00013823582,0.000901708,0.0022549827,0.00025776034,0.00011694787,0.003935547],"genre_scores_gemma":[0.000737676,0.9870761,0.005434091,0.0003141263,0.00025559092,0.0021994796,0.0021177027,0.00008660714,0.0017786025],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99750596,0.000100758494,0.0008304234,0.00080648845,0.00036114678,0.00039522402],"domain_scores_gemma":[0.99809307,0.000827348,0.00025769672,0.00048907055,0.00008431837,0.0002484925],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00020242203,0.0006230028,0.001936968,0.00023889927,0.0001698871,0.000064049775,0.00022504706,0.00046805758,0.00007508013],"category_scores_gemma":[0.000111668305,0.0004655868,0.0010504986,0.00015958158,0.000029558933,0.000051394138,0.000042248834,0.0003294681,0.000033208245],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00025651624,0.00054834905,0.00039612895,0.041731,0.0015463389,0.0006934109,0.001094492,0.000004144309,0.00005066789,0.0011912935,0.0064006327,0.946087],"study_design_scores_gemma":[0.002550939,0.0003270335,0.00001804211,0.07616932,0.0027163432,0.00020907712,0.000097410826,0.000066586574,0.00047308925,0.000034984303,0.91684306,0.00049410627],"about_ca_topic_score_codex":0.000033681816,"about_ca_topic_score_gemma":0.0000041520666,"teacher_disagreement_score":0.94559294,"about_ca_system_score_codex":0.00094709673,"about_ca_system_score_gemma":0.0015772771,"threshold_uncertainty_score":0.9997796},"labels":[],"label_agreement":null},{"id":"W4415432833","doi":"10.1002/ajh.70118","title":"<i>JAK2</i> Unmutated Erythrocytosis: 2026 Update on Diagnosis and Management","year":2025,"lang":"en","type":"review","venue":"American Journal of Hematology","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal","funders":"","keywords":"Hematology; MEDLINE; Prospective cohort study; Hematologic tests","score_opus":0.02068847504912243,"score_gpt":0.3436894408646349,"score_spread":0.32300096581551246,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4415432833","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00033100904,0.99488276,0.000026734455,0.0022456292,0.00025986342,0.0009071989,0.00003424796,0.000020067338,0.0012924597],"genre_scores_gemma":[0.00030647955,0.99589705,0.001613891,0.0015892783,0.00007832645,0.00030453652,0.000032982593,0.000046237932,0.00013123942],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99728674,0.00032081545,0.0012448928,0.00045483053,0.00031467644,0.00037805687],"domain_scores_gemma":[0.9969853,0.0008560971,0.0013712011,0.0003672645,0.00015260724,0.000267494],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00022171525,0.0005800748,0.004810022,0.0007870156,0.000081206665,0.000025384421,0.00018690508,0.00014891532,0.000099356024],"category_scores_gemma":[0.00009766451,0.00038692553,0.00062494265,0.0005930136,0.0003046741,0.000040471106,0.00010957324,0.000549108,0.000054571854],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00013746838,0.0006360557,0.0008364536,0.010640186,0.0039993245,0.0033317641,0.000031047686,4.0139233e-7,1.8694038e-8,0.0029255787,0.012887278,0.9645744],"study_design_scores_gemma":[0.0012482642,0.002667756,0.00006868816,0.041105185,0.007104033,0.006146709,0.00009423993,3.901347e-7,0.00002137314,0.000055753742,0.94121265,0.00027496045],"about_ca_topic_score_codex":0.000006809872,"about_ca_topic_score_gemma":0.000003581395,"teacher_disagreement_score":0.96429944,"about_ca_system_score_codex":0.00018253701,"about_ca_system_score_gemma":0.00029232257,"threshold_uncertainty_score":0.99985826},"labels":[],"label_agreement":null},{"id":"W4415434980","doi":"10.1016/j.jaccas.2025.105731","title":"Massive Anterior STEMI Due to Essential Thrombocythemia Leading to Urgent Thrombocytapheresis","year":2025,"lang":"en","type":"article","venue":"JACC Case Reports","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre hospitalier universitaire de Québec; Institut universitaire de cardiologie et de pneumologie de Québec","funders":"","keywords":"Essential thrombocythemia; Myocardial infarction; Disease; MEDLINE; Fibrinolytic therapy; Fibrinolytic agent","score_opus":0.015175534324555286,"score_gpt":0.32187819898298475,"score_spread":0.3067026646584295,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4415434980","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9844238,0.00034989556,0.00078380224,0.0040111933,0.00088825804,0.0018852182,0.00001979403,0.000114963856,0.007523046],"genre_scores_gemma":[0.99218714,0.000036476078,0.0017843421,0.002098248,0.00023429673,0.0004953354,0.000018266013,0.000040857034,0.0031050479],"study_design_codex":"case_report","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99744076,0.000054431814,0.0007932488,0.00084498053,0.00038221123,0.0004843479],"domain_scores_gemma":[0.9980444,0.00012849519,0.0001952515,0.0007697741,0.0002472428,0.0006148717],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0002575715,0.00037207027,0.00096990954,0.00029304903,0.00022527404,0.00008749303,0.000045596105,0.00013623881,0.0010200145],"category_scores_gemma":[0.0004216666,0.00030773447,0.00026289737,0.0005298007,0.00003411995,0.000079117395,0.00017196858,0.0001613017,0.00012976537],"study_design_candidate":"case_report","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00044111148,0.0010650514,0.05036928,0.00041466588,0.0013461763,0.8080991,0.001793357,0.00009536387,0.05320896,0.00043156813,0.06860225,0.0141331395],"study_design_scores_gemma":[0.0027712223,0.0012862297,0.05318935,0.0037409149,0.0016145402,0.16037093,0.0018802367,0.00006519372,0.7303948,0.00020816358,0.04340584,0.0010726274],"about_ca_topic_score_codex":0.00034386726,"about_ca_topic_score_gemma":0.00031604408,"teacher_disagreement_score":0.6771858,"about_ca_system_score_codex":0.00050800387,"about_ca_system_score_gemma":0.0004276631,"threshold_uncertainty_score":0.9999375},"labels":[],"label_agreement":null},{"id":"W4415668966","doi":"10.1016/j.htct.2025.104457","title":"RESULTS FROM VERIFY, A PHASE 3, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF RUSFERTIDE FOR THE TREATMENT OF POLYCYTHEMIA VERA","year":2025,"lang":"en","type":"article","venue":"Hematology Transfusion and Cell Therapy","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Phlebotomy; Polycythemia vera; Clinical endpoint; Hematocrit; Placebo; Clinical trial; Randomized controlled trial","score_opus":0.04133502875619269,"score_gpt":0.3419187682989942,"score_spread":0.3005837395428015,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4415668966","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98631525,0.005676622,0.00020224303,0.0014666133,0.00012337153,0.0055931085,0.000064245934,0.000016843564,0.00054172165],"genre_scores_gemma":[0.9842864,0.013914589,0.000101445374,0.00014825586,0.000020607222,0.0011427145,0.000038014507,0.000013297016,0.00033463511],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9986857,0.000083251056,0.00059383665,0.00034530746,0.00012663823,0.0001652709],"domain_scores_gemma":[0.9982273,0.0011483226,0.00013090328,0.00035374323,0.00008175306,0.000057969602],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00013225878,0.00023828639,0.0010110558,0.00010293768,0.00013123523,0.000006654876,0.00006367446,0.00011910461,0.0000834923],"category_scores_gemma":[0.000007716098,0.00012771763,0.00021366175,0.00011625659,0.00008652179,0.000016130882,0.0000051048005,0.00006635217,8.1136596e-7],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9153709,0.025910664,0.007145382,0.000054530603,0.002359327,0.000022118113,0.009769784,0.000005081454,0.019390509,0.00046630765,0.00016159273,0.019343827],"study_design_scores_gemma":[0.63037544,0.009993737,0.00081628567,0.000058445738,0.00073468994,0.000005325201,0.0014902139,0.00017777618,0.35410732,0.00006432608,0.0020942667,0.00008217785],"about_ca_topic_score_codex":0.00042588744,"about_ca_topic_score_gemma":0.00021039006,"teacher_disagreement_score":0.33471683,"about_ca_system_score_codex":0.000022946164,"about_ca_system_score_gemma":0.00008557522,"threshold_uncertainty_score":0.5208174},"labels":[],"label_agreement":null},{"id":"W4415900074","doi":"10.1016/s2352-3026(25)00264-9","title":"Ropeginterferon alfa-2b in hydroxyurea-intolerant or hydroxyurea-refractory essential thrombocythaemia (SURPASS ET): a multicentre, open-label, randomised, active-controlled, phase 3 study","year":2025,"lang":"en","type":"article","venue":"The Lancet Haematology","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Phase (matter); Clinical trial; Phases of clinical research; MEDLINE","score_opus":0.05743628741329941,"score_gpt":0.4161781471176606,"score_spread":0.3587418597043612,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4415900074","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9681416,0.0009835789,0.00014288741,0.012799998,0.00062957115,0.01079567,0.000037779177,0.00011083884,0.006358091],"genre_scores_gemma":[0.99174845,0.00049398065,0.0002402838,0.0030487052,0.00018493077,0.0028896995,0.00006371364,0.000058811605,0.0012713949],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99490714,0.0016295321,0.001157771,0.0009955785,0.00038885715,0.0009211074],"domain_scores_gemma":[0.9961169,0.0019144536,0.0004267751,0.0011967358,0.00016475725,0.00018040398],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0012231865,0.0007020744,0.004523632,0.0003091112,0.00025746907,0.00013244404,0.0007828618,0.00025601397,0.0005724908],"category_scores_gemma":[0.0006190625,0.00039430906,0.00019191434,0.00047234056,0.00025433267,0.00024066141,0.00045133414,0.0009090685,0.00011820417],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.80850655,0.066887215,0.05176089,0.00066064135,0.008194263,0.01279076,0.013422751,0.00009032237,0.005394163,0.004897799,0.015479263,0.011915358],"study_design_scores_gemma":[0.9645314,0.004085801,0.009714996,0.00092438614,0.0022169605,0.0005187921,0.0019118472,0.0029263105,0.008360059,0.0004290421,0.0037487582,0.000631625],"about_ca_topic_score_codex":0.00087337545,"about_ca_topic_score_gemma":0.0045086485,"teacher_disagreement_score":0.15602484,"about_ca_system_score_codex":0.0003358798,"about_ca_system_score_gemma":0.0005244573,"threshold_uncertainty_score":0.99985087},"labels":[],"label_agreement":null},{"id":"W4416397923","doi":"10.3324/haematol.2025.288654","title":"JAK inhibitor selection in challenging scenarios of myelofibrosis: a review","year":2025,"lang":"en","type":"article","venue":"Haematologica","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"MorphoSys; Swedish Orphan Biovitrum; Sierra Oncology; Incyte; Celgene","keywords":"Ruxolitinib; Myelofibrosis; Janus kinase; Context (archaeology); Clinical trial; Constitutional symptoms; Venetoclax; Selection (genetic algorithm)","score_opus":0.015796766915338285,"score_gpt":0.30762751780376535,"score_spread":0.2918307508884271,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4416397923","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.76083946,0.19491059,0.00019602042,0.025722213,0.00017421009,0.003085553,0.000008048905,0.00016581021,0.014898078],"genre_scores_gemma":[0.9759256,0.020944018,0.0007661283,0.0018222677,0.000014603533,0.0003040834,0.000008017877,0.000006637585,0.00020861335],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99896586,0.000066281034,0.00040657335,0.000251979,0.00013002488,0.0001792755],"domain_scores_gemma":[0.9995506,0.000095238975,0.00009406075,0.00013159278,0.000086618864,0.000041907377],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00015767211,0.00014205149,0.00066272996,0.00015904152,0.00004349302,0.00000448996,0.000043255488,0.00008994968,0.00022455025],"category_scores_gemma":[0.00020819333,0.000101568636,0.00009969075,0.00045935382,0.000033416854,0.00003304721,0.000032365988,0.0001275346,0.000020473753],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0008699382,0.0053984784,0.8067948,0.036652923,0.00074790366,0.00060205976,0.00078286504,0.000042329702,0.0059908433,0.036802355,0.06991195,0.035403512],"study_design_scores_gemma":[0.010510879,0.0030517797,0.6149482,0.13304037,0.0012064653,0.00077520806,0.000554387,0.0012144018,0.14683755,0.001259212,0.085727975,0.00087354606],"about_ca_topic_score_codex":0.000023494282,"about_ca_topic_score_gemma":0.000026210124,"teacher_disagreement_score":0.21508615,"about_ca_system_score_codex":0.00007180961,"about_ca_system_score_gemma":0.00007585283,"threshold_uncertainty_score":0.4141849},"labels":[],"label_agreement":null},{"id":"W4416439541","doi":"10.5858/arpa.2025-0207-le","title":"Machine Learning for JAK2 Mutation Prediction in Erythrocytosis: Context Matters","year":2025,"lang":"en","type":"article","venue":"Archives of Pathology & Laboratory Medicine","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"London Health Sciences Centre; Western University","funders":"","keywords":"Limiting; Context (archaeology); Population; Erythropoietin; Classifier (UML); Turnaround time; Hematology","score_opus":0.011988862396732164,"score_gpt":0.2858450090116038,"score_spread":0.2738561466148717,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4416439541","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9671775,0.005093739,0.004537903,0.019187104,0.00040654629,0.0014588267,0.000120823286,0.00007487215,0.0019426524],"genre_scores_gemma":[0.99391913,0.00050467695,0.001235313,0.0032891156,0.00007945528,0.00034245566,0.0002787183,0.000018255147,0.00033287608],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9985656,0.00019649825,0.0005362452,0.00035045904,0.000127713,0.00022345013],"domain_scores_gemma":[0.9986898,0.0007591942,0.00016958635,0.00019368989,0.00011630322,0.000071483904],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00030196222,0.00019320495,0.0006118511,0.00050249713,0.00007595896,0.0000024314174,0.00006127011,0.000088702385,0.000061987834],"category_scores_gemma":[0.00051294814,0.0001540836,0.00006434015,0.00029910155,0.0003810301,0.000051888437,0.00002511116,0.00023264329,0.000003820473],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0023469105,0.00084469916,0.87196916,0.00089698145,0.0004306552,0.00045542527,0.00741236,0.00014999355,0.06957622,0.0065981373,0.0028265605,0.03649287],"study_design_scores_gemma":[0.029035846,0.006397311,0.88601875,0.0032340153,0.00087856635,0.00011979086,0.004371189,0.0039781835,0.043396298,0.0023481618,0.019939627,0.00028224636],"about_ca_topic_score_codex":0.000042758104,"about_ca_topic_score_gemma":0.00010732988,"teacher_disagreement_score":0.036210623,"about_ca_system_score_codex":0.000056321576,"about_ca_system_score_gemma":0.00015814968,"threshold_uncertainty_score":0.6283347},"labels":[],"label_agreement":null},{"id":"W4417001683","doi":"10.1182/blood-2025-81","title":"Rusfertide or placebo plus current standard-of-care therapy for polycythemia vera: Durability of response and safety results through week 52 from the randomized controlled phase 3 VERIFY study","year":2025,"lang":"en","type":"article","venue":"Blood","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Phlebotomy; Placebo; Randomized controlled trial; Hematocrit; Randomization; Polycythemia vera","score_opus":0.02675687638169033,"score_gpt":0.3520523992182334,"score_spread":0.32529552283654306,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4417001683","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9715349,0.009551756,0.0001606691,0.0019461002,0.00017964681,0.014755681,0.001706085,0.000025324427,0.00013982884],"genre_scores_gemma":[0.9957735,0.0017676045,0.00042976238,0.000110473586,0.000058109457,0.00171884,0.000076740136,0.000017622448,0.000047338337],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99671143,0.0010875778,0.0011392487,0.00046548614,0.0003841715,0.00021210803],"domain_scores_gemma":[0.9850714,0.0135951815,0.00027567684,0.00058857596,0.00040298735,0.00006617956],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0018746234,0.0003158533,0.0023833218,0.000053345473,0.00017086096,0.000020372812,0.00011515604,0.00008229327,0.000038328875],"category_scores_gemma":[0.0043884204,0.00015388402,0.00039544617,0.00015451384,0.00023460109,0.000042672164,0.0000491997,0.00017801899,4.2191218e-7],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.97421825,0.0055954126,0.0033844712,0.000095215655,0.003177018,0.0000113334,0.009533219,0.0000022899978,0.0005286999,0.000088601875,0.00022210964,0.003143399],"study_design_scores_gemma":[0.9373734,0.0072630206,0.010359274,0.0004302739,0.002423666,0.0000016235907,0.0030051197,0.000033262553,0.037867766,0.00011631224,0.0010042688,0.00012198739],"about_ca_topic_score_codex":0.0001313231,"about_ca_topic_score_gemma":0.000097188095,"teacher_disagreement_score":0.037339065,"about_ca_system_score_codex":0.000097211916,"about_ca_system_score_gemma":0.000771162,"threshold_uncertainty_score":0.6275208},"labels":[],"label_agreement":null},{"id":"W4417001702","doi":"10.1182/blood-2025-82","title":"Evaluation of the novel TMPRSS6 antisense inhibitor sapablursen for treatment of polycythemia vera: Results of the imprssion clinical trial","year":2025,"lang":"en","type":"article","venue":"Blood","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Royal Victoria Hospital","funders":"","keywords":"Phlebotomy; Polycythemia vera; Hematocrit; Cohort; TMPRSS6; Ferritin; Clinical trial; Clinical endpoint","score_opus":0.09594355595731972,"score_gpt":0.4079281348573382,"score_spread":0.31198457890001846,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4417001702","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9932447,0.00039675715,0.000009319197,0.0014313005,0.0006648147,0.0033820206,0.00022652758,0.0000052997157,0.00063925405],"genre_scores_gemma":[0.99886453,0.00010485667,0.00032051923,0.00003767464,0.00021300961,0.00016075533,0.000016557655,0.000009099548,0.00027302516],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9981002,0.00020041071,0.00082745415,0.00024202759,0.00050934625,0.00012055656],"domain_scores_gemma":[0.9978815,0.0006303764,0.00045237434,0.0005410041,0.0004603439,0.000034407305],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000926443,0.0001414035,0.00051516335,0.00004537533,0.000063054365,0.0000032105652,0.000077300065,0.00012041277,0.0000067544247],"category_scores_gemma":[0.0013114741,0.00006716941,0.00043272687,0.00018936548,0.00011487675,0.000016510465,0.000038325445,0.00004876542,4.013311e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.14703742,0.089022234,0.18827282,0.00051097537,0.0073032314,0.000003648298,0.0021633732,0.000048669404,0.4089701,0.002323973,0.004462327,0.14988124],"study_design_scores_gemma":[0.2053284,0.0031095142,0.08820522,0.0003785512,0.0033366738,0.0000023816406,0.000045644658,0.00014502495,0.69872934,0.00007992216,0.0005942047,0.000045139313],"about_ca_topic_score_codex":0.000056793673,"about_ca_topic_score_gemma":0.000040093273,"teacher_disagreement_score":0.28975922,"about_ca_system_score_codex":0.00007434546,"about_ca_system_score_gemma":0.00070787285,"threshold_uncertainty_score":0.27390888},"labels":[],"label_agreement":null},{"id":"W4417002423","doi":"10.1182/blood-2025-6434","title":"Diagnosis, management, and outcomes of tumor-associated erythrocytosis: A systematic review","year":2025,"lang":"en","type":"article","venue":"Blood","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"London Health Sciences Centre; Western University","funders":"","keywords":"Systematic review; Renal cell carcinoma; Cohort; Retrospective cohort study; MEDLINE; Clear cell; Cohort study","score_opus":0.010060352941037883,"score_gpt":0.27333480496208185,"score_spread":0.26327445202104394,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4417002423","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.76954895,0.21555522,0.0000073195974,0.0031547432,0.00008330153,0.005464294,0.000042005533,0.0000987321,0.0060454123],"genre_scores_gemma":[0.94822747,0.04607679,0.00027291002,0.0027839637,0.0000055499236,0.0017967515,0.00001642944,0.000013438641,0.0008066894],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9988612,0.000075241296,0.0004875172,0.00022797906,0.00019452952,0.00015354181],"domain_scores_gemma":[0.9991739,0.00021420605,0.0001761467,0.00029440966,0.0000820187,0.000059350114],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00019589298,0.00016913262,0.0010782406,0.000105098974,0.00004650658,0.000010791405,0.00005786763,0.00003478806,0.000029420966],"category_scores_gemma":[0.00032817727,0.000121275596,0.00013070476,0.00025186114,0.00003229002,0.000029119976,0.000058948277,0.000058447586,0.000009505761],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0000067616784,0.0022277914,0.72111094,0.26997814,0.0035071883,0.00007943045,0.000037931815,2.5942407e-8,0.000006043782,0.001601234,0.0013440057,0.0001005081],"study_design_scores_gemma":[0.0064052097,0.00027421792,0.67071116,0.3004013,0.018528974,0.000024687804,0.000096698146,0.0000022522286,0.00310602,0.0001670728,0.00011081021,0.00017158686],"about_ca_topic_score_codex":0.000014322515,"about_ca_topic_score_gemma":0.0000130881745,"teacher_disagreement_score":0.17867851,"about_ca_system_score_codex":0.000031578675,"about_ca_system_score_gemma":0.000026730655,"threshold_uncertainty_score":0.49454755},"labels":[],"label_agreement":null},{"id":"W4417004887","doi":"10.1182/blood-2025-1026","title":"Cytoreductive therapy reduces recurrent thrombosis in patients with myeloproliferative neoplasm-associated splanchnic vein thrombosis: A global abdominal/splanchnic thrombosis retrospective observational study (GASTRO-MPN) study of 757 patients","year":2025,"lang":"en","type":"article","venue":"Blood","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University; McMaster University Medical Centre","funders":"","keywords":"Thrombosis; Discontinuation; Retrospective cohort study; Hazard ratio; Portal vein thrombosis; Transjugular intrahepatic portosystemic shunt; Proportional hazards model; Asymptomatic","score_opus":0.033037452227772754,"score_gpt":0.31220677108044764,"score_spread":0.2791693188526749,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4417004887","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.988964,0.00016026667,0.0000030541528,0.00017835839,0.00038250408,0.009151321,0.0005596505,0.00009847092,0.0005023826],"genre_scores_gemma":[0.9969078,0.00013332423,0.00027271116,0.00012150607,0.00007985623,0.0019587504,0.000445701,0.00006070408,0.000019695923],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9939185,0.0006681423,0.0014086151,0.0015320904,0.0016709433,0.00080170843],"domain_scores_gemma":[0.99626696,0.00026320366,0.00087174756,0.000731544,0.0016581108,0.0002084257],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00044702092,0.0009704962,0.0021510983,0.0004193086,0.00032567096,0.00007822998,0.0003630844,0.00024832602,0.000063694104],"category_scores_gemma":[0.00032897334,0.0007537377,0.00022966902,0.00222707,0.00020808597,0.0003896248,0.0001739827,0.00057767215,0.00000860991],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.002124295,0.12260455,0.8629024,0.000040024355,0.0057536815,0.000009826483,0.0058227675,0.00001386502,0.00005670066,0.00006474304,0.00020452774,0.00040262955],"study_design_scores_gemma":[0.052652013,0.027134618,0.9120693,0.00088428747,0.0015710795,8.855429e-7,0.0040760916,0.000009719471,0.0010048747,0.00010366223,0.000003420035,0.00049000414],"about_ca_topic_score_codex":0.00043899784,"about_ca_topic_score_gemma":0.0012886563,"teacher_disagreement_score":0.09546994,"about_ca_system_score_codex":0.0013811277,"about_ca_system_score_gemma":0.00063125347,"threshold_uncertainty_score":0.99949133},"labels":[],"label_agreement":null},{"id":"W4417004955","doi":"10.1182/blood-2025-1024","title":"Safety and efficacy of INCA033989, a novel first in class mutant calreticulin-specific monoclonal antibody, in patients with essential thrombocythemia","year":2025,"lang":"en","type":"article","venue":"Blood","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hôpital Maisonneuve-Rosemont; Princess Margaret Cancer Centre","funders":"","keywords":"Essential thrombocythemia; Anagrelide; Myelofibrosis; Calreticulin; Hematology; Thrombocytosis; Thrombopoietin receptor; Polycythemia vera; Platelet","score_opus":0.006471341317987652,"score_gpt":0.2467173859262837,"score_spread":0.24024604460829604,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4417004955","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9977315,0.00024191684,0.000062161715,0.00042255636,0.000037473237,0.00079083786,0.00004490303,0.000010559199,0.00065806095],"genre_scores_gemma":[0.9988459,0.00026608264,0.00068208,0.00005156942,0.000020344112,0.000026590096,0.000079381796,0.000013119127,0.00001493016],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9987607,0.000024090472,0.00041376994,0.00035542238,0.00022770897,0.0002183315],"domain_scores_gemma":[0.99939096,0.00016905055,0.00008578746,0.00020821695,0.00007938375,0.00006658319],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00008848557,0.00019691099,0.0005249244,0.00018118213,0.00004107265,0.000010671665,0.000053517797,0.000095074574,0.000033150678],"category_scores_gemma":[0.00003936814,0.0001451298,0.000043170854,0.00034434666,0.000119087716,0.00003872714,0.000060637183,0.00017171552,0.0000018075802],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0015157425,0.007344115,0.98747253,0.00010343984,0.00017565615,0.0000557537,0.0003694021,0.000019313518,0.0013073909,0.0012323688,0.000011708009,0.00039255977],"study_design_scores_gemma":[0.03750247,0.00054030283,0.9488088,0.0007560367,0.00012808885,0.000006948431,0.00003815744,0.00006970302,0.011775582,0.00001144096,0.0002470085,0.00011547593],"about_ca_topic_score_codex":0.00009445202,"about_ca_topic_score_gemma":0.0002713423,"teacher_disagreement_score":0.038663764,"about_ca_system_score_codex":0.00007138048,"about_ca_system_score_gemma":0.00011441353,"threshold_uncertainty_score":0.59182215},"labels":[],"label_agreement":null},{"id":"W4417007088","doi":"10.1182/blood-2025-2046","title":"Clonal persistence and early cooperative mutations shape transformation in myelofibrosis","year":2025,"lang":"en","type":"article","venue":"Blood","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Myelofibrosis; Loss of heterozygosity; Mutation; Point mutation; Somatic cell; Myeloid; Gene; Copy-number variation; Somatic evolution in cancer","score_opus":0.016289167920287062,"score_gpt":0.2623000399633939,"score_spread":0.24601087204310684,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4417007088","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9908276,0.0004101032,0.000051566385,0.0017351509,0.000021308253,0.00042983258,0.0000149547495,0.000013840709,0.0064956225],"genre_scores_gemma":[0.9985218,0.00014448616,0.0006455386,0.00024227763,0.000011966249,0.00014654377,0.000022125483,0.000004244128,0.00026098377],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99943215,0.00002018909,0.00017392753,0.00016332993,0.00009766464,0.000112744994],"domain_scores_gemma":[0.99971515,0.00007759363,0.000019785624,0.00006617768,0.00007273642,0.000048586346],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000055322973,0.00009603292,0.0001736655,0.00012115575,0.000083585546,0.000023268869,0.000021019086,0.000046664107,0.00007575491],"category_scores_gemma":[0.00003316315,0.000079784244,0.00003628446,0.0002213678,0.0000483552,0.00009872788,0.000007929987,0.00007964097,0.000012526441],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00009529678,0.0010256935,0.97927094,0.00009278201,0.00018780028,0.000026300151,0.0046807015,0.000008453794,0.0020485972,0.0078994725,0.00003990262,0.00462404],"study_design_scores_gemma":[0.004246346,0.0003700098,0.9784923,0.00020023607,0.00019471424,0.000017056143,0.00042610275,0.00027421024,0.015421609,0.00010591937,0.0001770086,0.00007448575],"about_ca_topic_score_codex":0.000044017488,"about_ca_topic_score_gemma":0.00011810894,"teacher_disagreement_score":0.013373012,"about_ca_system_score_codex":0.000028946892,"about_ca_system_score_gemma":0.00008295867,"threshold_uncertainty_score":0.3253507},"labels":[],"label_agreement":null},{"id":"W4417008341","doi":"10.1182/blood-2025-7342","title":"Real-world hematologic response and treatment patterns among patients with polycythemia vera (PV) treated with ropeginterferon alfa-2b (ropeg)","year":2025,"lang":"en","type":"article","venue":"Blood","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Forming Technologies (Canada)","funders":"","keywords":"Polycythemia vera; Hematocrit; Hematology; Medical prescription; Retrospective cohort study; Observational study; Clinical trial; Myeloproliferative neoplasm; Guideline","score_opus":0.008347005931708583,"score_gpt":0.23960370287153207,"score_spread":0.23125669693982348,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4417008341","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99535114,0.00012738952,0.000010628494,0.0007255213,0.000023720842,0.0012909686,0.00005823113,0.00010820741,0.0023041817],"genre_scores_gemma":[0.9949541,0.00025446506,0.0002758246,0.00014029612,0.000021410631,0.0003536726,0.00011949107,0.000040565545,0.0038401762],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99838644,0.00013163143,0.0002816252,0.00060197397,0.00023375593,0.00036454995],"domain_scores_gemma":[0.9989367,0.00017150085,0.000115836505,0.00046338252,0.000115648996,0.00019690843],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00006977485,0.0004458318,0.00064635265,0.00023597814,0.00014245205,0.000052360683,0.00006380266,0.00008179438,0.000080576436],"category_scores_gemma":[0.000017214365,0.00024753052,0.00006465161,0.00024631905,0.000118339034,0.00007582053,0.000041778552,0.000117531636,0.000010655653],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.008110803,0.003352812,0.9849966,0.000049296475,0.0011325342,0.0005982788,0.00020946862,0.0000014263635,0.00010036278,0.000073678195,0.00010232925,0.0012723852],"study_design_scores_gemma":[0.021046456,0.0069174515,0.9421382,0.0007856556,0.0012173248,0.00003548569,0.00007438594,0.000009948777,0.02718782,0.0000035519117,0.00035242003,0.0002313066],"about_ca_topic_score_codex":0.00082764943,"about_ca_topic_score_gemma":0.0012027678,"teacher_disagreement_score":0.042858433,"about_ca_system_score_codex":0.00023044532,"about_ca_system_score_gemma":0.00012127009,"threshold_uncertainty_score":0.9999977},"labels":[],"label_agreement":null},{"id":"W4417010141","doi":"10.1182/blood-2025-8202","title":"Estimating incidence and prevalence of polycythemia vera and associated eligibility for cytoreductive therapies in major US health plans","year":2025,"lang":"en","type":"article","venue":"Blood","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Theratechnologies (Canada); Forming Technologies (Canada)","funders":"","keywords":"Polycythemia vera; Incidence (geometry); Cumulative incidence; Myeloproliferative neoplasm; Epidemiology; Myelofibrosis; Cancer","score_opus":0.013651752186808237,"score_gpt":0.3255977372001084,"score_spread":0.3119459850133001,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4417010141","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9949265,0.0030301805,0.000057265835,0.000981526,0.000026318936,0.000816204,0.00010375206,0.000012149634,0.000046113164],"genre_scores_gemma":[0.99479425,0.00028613882,0.0045883595,0.00015080908,0.000013022863,0.00011711394,0.0000079683305,0.000005110834,0.000037232785],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99925303,0.000046458314,0.00023503968,0.00024008425,0.00008513465,0.00014026012],"domain_scores_gemma":[0.9993429,0.00034514582,0.00010118122,0.000106654166,0.00005977779,0.000044295484],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00027427744,0.00010233197,0.0003142229,0.000057787787,0.000059561607,0.000008114477,0.000026600519,0.000044605487,0.0000030303502],"category_scores_gemma":[0.00037995982,0.000082630315,0.000023102995,0.00009377349,0.00007341643,0.000040228388,0.000023996483,0.00006832092,8.998847e-8],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00013574741,0.0005659121,0.9940493,0.0006649688,0.00014248428,0.0000025262968,0.0018003243,0.000001417434,0.00089983316,0.00020295658,0.00002009428,0.0015144323],"study_design_scores_gemma":[0.004149714,0.0005644006,0.9791706,0.00089794165,0.00011793697,0.0000073788806,0.0001436049,0.00024270447,0.013884078,0.00076287845,0.0000036605804,0.000055059543],"about_ca_topic_score_codex":0.00026369403,"about_ca_topic_score_gemma":0.00018825219,"teacher_disagreement_score":0.01487866,"about_ca_system_score_codex":0.000058782218,"about_ca_system_score_gemma":0.00016474878,"threshold_uncertainty_score":0.33695665},"labels":[],"label_agreement":null},{"id":"W4417010151","doi":"10.1182/blood-2025-8199","title":"Estimating incident and prevalent essential thrombocythemia patients eligible for cytoreductive therapies in the US and Canada","year":2025,"lang":"en","type":"article","venue":"Blood","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Theratechnologies (Canada); Forming Technologies (Canada)","funders":"","keywords":"Essential thrombocythemia; Epidemiology; Medical prescription; Anagrelide; Population; Incidence (geometry); MEDLINE; Myelofibrosis","score_opus":0.006760433327555526,"score_gpt":0.266591384883312,"score_spread":0.2598309515557565,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4417010151","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99683493,0.0009460744,0.000020265803,0.0008848182,0.00007860804,0.0010076308,0.000020614807,0.00000550887,0.00020154983],"genre_scores_gemma":[0.99808264,0.000099565965,0.0010883261,0.0003371732,0.00004677653,0.00029331027,0.000015656617,0.0000060817883,0.000030455461],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.999358,0.000030014367,0.00015000779,0.00019163,0.00013582992,0.0001345312],"domain_scores_gemma":[0.99959695,0.00016656937,0.000044173656,0.00010237839,0.000059219463,0.00003070885],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000090288944,0.00011116,0.00019012057,0.00003470892,0.00010360451,0.000026843094,0.000033936984,0.000027594413,0.0000038832472],"category_scores_gemma":[0.00007884576,0.000069534515,0.000019356945,0.00005229389,0.00003796892,0.00003046952,0.000028146365,0.00005923517,1.09138504e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000066155335,0.00062879635,0.9944941,0.00016835611,0.00022588306,0.000008881726,0.0019320052,0.0000053142076,0.00019490262,0.00041613088,0.0004925966,0.0013668721],"study_design_scores_gemma":[0.0058218976,0.00030789236,0.98091316,0.0002290531,0.00032193243,0.000011073354,0.00050057116,0.00012483314,0.011003438,0.0004305982,0.0002512049,0.00008432782],"about_ca_topic_score_codex":0.03315535,"about_ca_topic_score_gemma":0.06300976,"teacher_disagreement_score":0.029854413,"about_ca_system_score_codex":0.000057256253,"about_ca_system_score_gemma":0.00018475427,"threshold_uncertainty_score":0.97328293},"labels":[],"label_agreement":null},{"id":"W4417011691","doi":"10.1182/blood-2025-910","title":"Durable efficacy and long-term safety with pelabresib plus ruxolitinib in JAK Inhibitor–Naive myelofibrosis: 96-week Results from the Phase III MANIFEST-2 study","year":2025,"lang":"en","type":"article","venue":"Blood","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Ruxolitinib; Discontinuation; Clinical endpoint; Adverse effect; Phases of clinical research; Myelofibrosis; Placebo; Clinical trial","score_opus":0.017388750860584338,"score_gpt":0.2848147305685922,"score_spread":0.26742597970800785,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4417011691","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99054974,0.0012778194,0.0000068618738,0.0026127035,0.00008854081,0.0030008256,0.00021478868,0.00006316918,0.0021855645],"genre_scores_gemma":[0.9977132,0.00031675826,0.00013728102,0.00045548752,0.00017903667,0.00029729016,0.0001962667,0.000030125208,0.0006745281],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99760437,0.00019513314,0.0006479357,0.00076867477,0.00037251145,0.00041134536],"domain_scores_gemma":[0.998015,0.0009139109,0.00015763329,0.0006329847,0.00011631072,0.00016416116],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00031234897,0.0003892605,0.0006813431,0.00012185427,0.0002632019,0.00009455174,0.00014054884,0.00010615935,0.00004429692],"category_scores_gemma":[0.00017711452,0.00024011369,0.00006235475,0.0003724981,0.00012344318,0.00010068806,0.00012516772,0.00033344634,0.000017560575],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.019283723,0.02503329,0.9396165,0.000088043496,0.0015527142,0.0018492813,0.008262033,0.00000917552,0.00043969112,0.00021918905,0.0008870233,0.0027593537],"study_design_scores_gemma":[0.14745498,0.0033875143,0.84089935,0.0010943322,0.0010705041,0.0000440629,0.0017512962,0.000012928168,0.0038289777,0.000018107348,0.0002270197,0.0002109507],"about_ca_topic_score_codex":0.0011541845,"about_ca_topic_score_gemma":0.0018542326,"teacher_disagreement_score":0.12817125,"about_ca_system_score_codex":0.00011085637,"about_ca_system_score_gemma":0.00029182222,"threshold_uncertainty_score":0.97915524},"labels":[],"label_agreement":null},{"id":"W4417012694","doi":"10.1182/blood-2025-5596","title":"Aspirin therapy in myelofibrosis: Real-world clinical practice and outcomes in 215 consecutive patients","year":2025,"lang":"en","type":"article","venue":"Blood","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Jewish General Hospital; MPB Technologies & Communications (Canada); Université de Montréal","funders":"","keywords":"Thrombocytosis; Clinical Practice; Aspirin; Polycythemia vera; Anagrelide; Myelofibrosis; Medical record; Thrombosis","score_opus":0.02464276871906311,"score_gpt":0.37115303027883007,"score_spread":0.34651026155976694,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4417012694","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9815112,0.00048098754,7.159358e-7,0.0033033274,0.00010153824,0.0009351872,0.000012339444,0.000021068037,0.013633665],"genre_scores_gemma":[0.993194,0.0023471983,0.00086885487,0.0028839004,0.00002211515,0.00019212044,0.000018700355,0.000011682066,0.00046141684],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99847686,0.00021653667,0.00054622773,0.00037674262,0.00017238635,0.00021126895],"domain_scores_gemma":[0.9982901,0.0012050438,0.00010505146,0.00021091383,0.000105589934,0.00008328808],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00034852786,0.00018039066,0.000546324,0.00022933273,0.000032877873,0.00002035657,0.00004503835,0.00009476757,0.000019767607],"category_scores_gemma":[0.0006236431,0.00013560026,0.000065461056,0.00030883536,0.000073834446,0.00008414923,0.00004617324,0.00023491585,0.000010764007],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0004683161,0.0072268303,0.9811803,0.000023005834,0.0002825436,0.00009576207,0.0003089017,1.4495733e-7,0.000009630641,0.0009580867,0.00022942142,0.0092170555],"study_design_scores_gemma":[0.019494578,0.0009509746,0.9754012,0.00026708157,0.000122817,0.0000023249088,0.00016132773,0.0000032870767,0.00077142584,0.00012721021,0.0025957376,0.00010200804],"about_ca_topic_score_codex":0.00059128966,"about_ca_topic_score_gemma":0.0013427995,"teacher_disagreement_score":0.01902626,"about_ca_system_score_codex":0.000052760413,"about_ca_system_score_gemma":0.0001653914,"threshold_uncertainty_score":0.5529618},"labels":[],"label_agreement":null},{"id":"W4417012851","doi":"10.1182/blood-2025-7317","title":"Clinical characteristics and outcomes in patients with SH2B3-mutated erythrocytosis: A retrospective cohort study","year":2025,"lang":"en","type":"article","venue":"Blood","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Western University","funders":"","keywords":"Retrospective cohort study; Polycythemia vera; Myeloid; Cohort; Etiology; Phlebotomy; Cohort study; Hematology","score_opus":0.008668864416354465,"score_gpt":0.2928568483438678,"score_spread":0.2841879839275134,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4417012851","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99721754,0.000031639185,0.000002379758,0.00020493442,0.00006919227,0.0019526111,0.000028085831,0.00003260937,0.00046100855],"genre_scores_gemma":[0.9991145,0.000045738474,0.00014542168,0.00026990115,0.000018174338,0.00022541085,0.000035152152,0.000013017387,0.0001326469],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9987088,0.00007573005,0.00040531694,0.00041339544,0.00022568008,0.00017106498],"domain_scores_gemma":[0.9993247,0.00011997841,0.000086449494,0.0002321363,0.00015600119,0.000080782345],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00018231834,0.00018568788,0.0007488789,0.00010603161,0.000052435713,0.000021928057,0.000035378318,0.00006771153,0.000018701961],"category_scores_gemma":[0.00019964686,0.00012372353,0.000040170722,0.00019439761,0.000058487796,0.00003812594,0.00004601211,0.00018803625,0.0000053788885],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00036071203,0.014584792,0.9830474,0.000018099558,0.00121254,0.00007826458,0.00016762572,2.5985495e-8,6.7643833e-7,0.000041843476,0.000025470408,0.00046252194],"study_design_scores_gemma":[0.020585679,0.0029011504,0.9752029,0.0001274523,0.0009215612,0.0000014735161,0.00008534827,0.0000028540283,0.00004171405,0.000012538634,0.000012990569,0.00010432031],"about_ca_topic_score_codex":0.000039224116,"about_ca_topic_score_gemma":0.0000977676,"teacher_disagreement_score":0.020224968,"about_ca_system_score_codex":0.00006494687,"about_ca_system_score_gemma":0.000070558875,"threshold_uncertainty_score":0.5045299},"labels":[],"label_agreement":null},{"id":"W4417016053","doi":"10.1182/blood-2025-723","title":"Sex-based disparities in MPN treatment patterns: A study of 1167 patients from the Quebec MPN registry","year":2025,"lang":"en","type":"article","venue":"Blood","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Louisiana-Pacific (Canada); Université de Montréal; Hôpital Maisonneuve-Rosemont","funders":"","keywords":"Polycythemia vera; Medical record; Demographics; Essential thrombocythemia; Disease; Myelofibrosis; Epidemiology","score_opus":0.013023588258969057,"score_gpt":0.2639429333610009,"score_spread":0.25091934510203184,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4417016053","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99679357,0.00032124016,0.0000046462433,0.00086934044,0.00007023807,0.0014419563,0.00013781569,0.0000195109,0.00034168255],"genre_scores_gemma":[0.9981804,0.000052404946,0.000036780115,0.00039162557,0.000037008584,0.0006272495,0.00013453346,0.000012039797,0.0005279713],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99880326,0.00012404795,0.0003506693,0.00030953577,0.00023597646,0.00017651348],"domain_scores_gemma":[0.998938,0.00035712522,0.00009671008,0.00050138275,0.00006038978,0.000046367666],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00005819239,0.00020759481,0.00044781843,0.000067146764,0.00006025998,0.000021341997,0.00009164549,0.000058605125,0.000048639387],"category_scores_gemma":[0.00006013163,0.00012391883,0.000085283056,0.00013361532,0.000039388477,0.00002561306,0.000033511158,0.0000908097,0.0000039393353],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00014574997,0.023198424,0.9721275,0.00004129496,0.0005208071,0.00005486849,0.0014033259,0.0000054256557,0.000012683215,0.00003603271,0.00019023557,0.00226363],"study_design_scores_gemma":[0.019784478,0.001557534,0.9689848,0.00035115177,0.0005705928,3.4420873e-7,0.001294667,0.0000147117735,0.007146966,0.000023857983,0.00018559986,0.00008528861],"about_ca_topic_score_codex":0.068867415,"about_ca_topic_score_gemma":0.0704983,"teacher_disagreement_score":0.02164089,"about_ca_system_score_codex":0.00012959307,"about_ca_system_score_gemma":0.0001658112,"threshold_uncertainty_score":0.9464627},"labels":[],"label_agreement":null},{"id":"W4417017876","doi":"10.1182/blood-2025-383","title":"Development of a JAK2V617F-targeting lipid nanoparticle-siRNA as a novel gene therapy for myeloproliferative neoplasms","year":2025,"lang":"en","type":"article","venue":"Blood","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"iCo Therapeutics (Canada)","funders":"","keywords":"Bone marrow; Myelofibrosis; Myeloproliferative neoplasm; Essential thrombocythemia; Gene knockdown; Polycythemia vera; In vivo; Genetic enhancement","score_opus":0.022917169300661098,"score_gpt":0.2934784122967103,"score_spread":0.27056124299604917,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4417017876","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9931434,0.0011645665,0.001066431,0.0010704729,0.00016465224,0.0020250347,0.00002972828,0.000065567656,0.0012701805],"genre_scores_gemma":[0.90711296,0.000162835,0.08976667,0.00092386623,0.00013767782,0.0012590238,0.00006323966,0.000035345987,0.0005383663],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99804205,0.000030282637,0.0006984427,0.0004988127,0.00030135922,0.00042906325],"domain_scores_gemma":[0.9987333,0.0002641275,0.0001888247,0.00028193957,0.00038258836,0.0001492095],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0003081619,0.00032828932,0.0006394694,0.0001641224,0.00024029972,0.000029453062,0.00011360631,0.00012156305,0.000062959625],"category_scores_gemma":[0.00024330031,0.00025695103,0.00018338775,0.0003289436,0.00006112528,0.000064991014,0.000058250476,0.00011795048,0.000017719642],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0017463055,0.00959887,0.052807022,0.0003013417,0.0028468736,0.000021526399,0.005243096,0.000013155572,0.9024855,0.006738601,0.0006178753,0.01757987],"study_design_scores_gemma":[0.015936105,0.00086711865,0.011220611,0.00024141185,0.00026188188,0.00002099663,0.00028734482,0.000117091746,0.96215737,0.00014617053,0.00852907,0.00021485187],"about_ca_topic_score_codex":0.000014772115,"about_ca_topic_score_gemma":0.000023956381,"teacher_disagreement_score":0.088700235,"about_ca_system_score_codex":0.00007667253,"about_ca_system_score_gemma":0.0008437235,"threshold_uncertainty_score":0.99998826},"labels":[],"label_agreement":null},{"id":"W4417018938","doi":"10.1182/blood-2025-1386","title":"A pre-NGS screening strategy to identify populations with high-risk clonal hematopoiesis","year":2025,"lang":"en","type":"article","venue":"Blood","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen's University","funders":"","keywords":"Overdiagnosis; Haematopoiesis; Population; Cohort; Myeloid; Bone marrow; Malignancy; Clinical trial; Mutation","score_opus":0.022725663312884153,"score_gpt":0.3222930530622046,"score_spread":0.29956738974932046,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4417018938","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9932398,0.00021191122,0.0026250877,0.001359681,0.000046936486,0.0007027715,0.000048997266,0.00007706609,0.0016877152],"genre_scores_gemma":[0.9807896,0.000018581584,0.017310686,0.00030554022,0.00007187027,0.00026774235,0.00006387772,0.000017375036,0.0011547544],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99890894,0.00003740545,0.00024029744,0.00033341735,0.00025314957,0.00022679151],"domain_scores_gemma":[0.99930817,0.00007584415,0.0000651468,0.0002824493,0.00012247721,0.00014589421],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0000846574,0.00018052106,0.00031126157,0.00015834536,0.00018808397,0.000056470242,0.000060505834,0.00006201122,0.00015369472],"category_scores_gemma":[0.000063892134,0.00013466069,0.00007083925,0.0003659396,0.000025641995,0.000065755725,0.000040124996,0.00012862925,0.0000346979],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00020745855,0.0012906203,0.9812043,0.00006862236,0.0007969404,0.00010116794,0.00018419864,0.00018904683,0.00037327854,0.010992748,0.0016712238,0.0029204122],"study_design_scores_gemma":[0.0040382766,0.0009365337,0.97998405,0.0003573844,0.0010649844,0.000039710394,0.0001151018,0.000024748535,0.012438335,0.0004606112,0.00040450584,0.00013574757],"about_ca_topic_score_codex":0.00066152774,"about_ca_topic_score_gemma":0.0005630743,"teacher_disagreement_score":0.014685598,"about_ca_system_score_codex":0.000028969018,"about_ca_system_score_gemma":0.000107488726,"threshold_uncertainty_score":0.5491303},"labels":[],"label_agreement":null},{"id":"W4417021412","doi":"10.1182/blood-2025-3803","title":"Preliminary experience from the ODYSSEY trial: Efficacy and safety of momelotinib in combination with luspatercept in patients with transfusion-dependent myelofibrosis","year":2025,"lang":"en","type":"article","venue":"Blood","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Ruxolitinib; Myelofibrosis; Anemia; Phases of clinical research; Clinical trial; Randomized controlled trial; Deferasirox","score_opus":0.00808731145729626,"score_gpt":0.23912464614956824,"score_spread":0.23103733469227197,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4417021412","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99692434,0.0001147924,0.000021732356,0.0004990293,0.000029979119,0.00218592,0.00001925174,0.000008638398,0.00019633313],"genre_scores_gemma":[0.9992188,0.00014736244,0.00021252857,0.00007394919,0.0000069574194,0.00025649322,0.000045092485,0.000010175566,0.00002861243],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99892694,0.00008855291,0.00030822874,0.00028987136,0.0002545595,0.00013182749],"domain_scores_gemma":[0.9993218,0.0002938206,0.000072371666,0.00021136134,0.00006263052,0.00003802609],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00009597619,0.00015152359,0.0003304634,0.00009107358,0.000047852598,0.000011328613,0.000061031653,0.00005566691,0.00003465352],"category_scores_gemma":[0.000039070663,0.00008470865,0.000020555814,0.00025358607,0.00007368798,0.000059553568,0.000026815054,0.00010476389,7.547309e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.03810086,0.006090945,0.94781405,0.000029674988,0.000084430634,0.000009526088,0.0046267286,0.000008708074,0.00010910917,0.000050400893,0.000003924027,0.0030716439],"study_design_scores_gemma":[0.14560635,0.003969344,0.8442994,0.0006753395,0.000133863,7.3962906e-7,0.0003642213,0.000009117872,0.0048532216,0.000010695907,0.000007672098,0.00007005103],"about_ca_topic_score_codex":0.00060980074,"about_ca_topic_score_gemma":0.00063252676,"teacher_disagreement_score":0.10750549,"about_ca_system_score_codex":0.000035330566,"about_ca_system_score_gemma":0.00006486683,"threshold_uncertainty_score":0.34543186},"labels":[],"label_agreement":null},{"id":"W4417021539","doi":"10.1182/blood-2025-3809","title":"Impact of new or worsening anemia and thrombocytopenia on clinical outcomes in JAK inhibitor–naive myelofibrosis patients treated with ruxolitinib","year":2025,"lang":"en","type":"article","venue":"Blood","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Ruxolitinib; Myelofibrosis; Anemia; Platelet; Post-hoc analysis; Spleen; Hemoglobin; Subgroup analysis","score_opus":0.03194674096498619,"score_gpt":0.3559187528937559,"score_spread":0.32397201192876973,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4417021539","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9976697,0.000054111682,7.5585615e-7,0.00020127099,0.000031798478,0.0007681467,0.000035490775,0.000023182467,0.0012155275],"genre_scores_gemma":[0.9985255,0.000085503816,0.000546815,0.00018047872,0.000035257126,0.00003571082,0.000039921008,0.00001807653,0.0005327186],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99857706,0.000073137155,0.000520039,0.00038162674,0.00020088941,0.0002472257],"domain_scores_gemma":[0.9989146,0.000436671,0.0001420283,0.0002424296,0.000091498,0.00017274737],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000093849405,0.00026243587,0.0008885447,0.00017573981,0.000040851435,0.00001882051,0.000046748366,0.00012753466,0.0000686058],"category_scores_gemma":[0.00023479386,0.00014643207,0.00012778903,0.00029838228,0.000073808464,0.000055869674,0.000041070725,0.00017882996,0.000005304324],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00195072,0.003471696,0.9905149,0.000041535495,0.00058741774,0.000060714883,0.00023092983,0.0000011538649,0.000049750273,0.00004003447,0.00035222902,0.002698943],"study_design_scores_gemma":[0.02386281,0.007838487,0.9629698,0.0007861129,0.00043572666,0.0000054798934,0.00004958874,0.0000026950374,0.0038864538,0.000010723189,0.000028536691,0.00012361577],"about_ca_topic_score_codex":0.0006814097,"about_ca_topic_score_gemma":0.00020179684,"teacher_disagreement_score":0.027545106,"about_ca_system_score_codex":0.00007170634,"about_ca_system_score_gemma":0.000308612,"threshold_uncertainty_score":0.5971327},"labels":[],"label_agreement":null},{"id":"W4417021721","doi":"10.1182/blood-2025-3795","title":"The activin receptor-like kinase-2 inhibitor zilurgisertib (INCB000928) as monotherapy or with ruxolitinib in patients with anemia due to myelofibrosis: Phase 1/2 study final results","year":2025,"lang":"en","type":"article","venue":"Blood","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Ruxolitinib; Myelofibrosis; Anemia; Pharmacokinetics; Hepcidin; Phases of clinical research; Regimen; Toxicity","score_opus":0.012428506558766855,"score_gpt":0.2869146319855738,"score_spread":0.27448612542680695,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4417021721","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9911201,0.00009506327,0.0000044234666,0.0022541166,0.00010713295,0.0053857057,0.00007091484,0.00006781231,0.00089470757],"genre_scores_gemma":[0.99453217,0.000030184961,0.00049916544,0.0007745034,0.000096478914,0.0018372926,0.000064067666,0.000049157876,0.002116965],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99739367,0.00017642126,0.00056160847,0.00075704535,0.00058621424,0.00052506325],"domain_scores_gemma":[0.9982998,0.00035799405,0.00015888002,0.0007167108,0.00023399624,0.00023263115],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002639513,0.00044433412,0.00061329175,0.00020747326,0.0002881799,0.00010538539,0.00017510557,0.00009805049,0.000058894748],"category_scores_gemma":[0.0001507529,0.00023192953,0.000059074406,0.0007679521,0.00006896711,0.0001094124,0.00005753775,0.00027891513,0.000037661554],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.5238595,0.060480975,0.38947764,0.00007753276,0.0010364424,0.00054805074,0.0031110859,0.000010117287,0.0002565592,0.000075412194,0.0031558005,0.017910877],"study_design_scores_gemma":[0.45736033,0.06844202,0.43740416,0.001218277,0.00047211387,0.000013626586,0.0013424882,0.0000038593594,0.02440432,0.000012372793,0.008861136,0.00046532534],"about_ca_topic_score_codex":0.00028930654,"about_ca_topic_score_gemma":0.0011017915,"teacher_disagreement_score":0.066499196,"about_ca_system_score_codex":0.00020470678,"about_ca_system_score_gemma":0.00053057575,"threshold_uncertainty_score":0.9457812},"labels":[],"label_agreement":null},{"id":"W4417023440","doi":"10.1182/blood-2025-5579","title":"Survival outcomes in ruxolitinib-treated patients with myelofibrosis following crossover to momelotinib: Application of the response to ruxolitinib at 6 months (RR6) prognostic model to SIMPLIFY-1","year":2025,"lang":"en","type":"article","venue":"Blood","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Ruxolitinib; Myelofibrosis; Discontinuation; Post-hoc analysis; Survival analysis; Population; Clinical trial; Phases of clinical research","score_opus":0.009425352301015117,"score_gpt":0.27461878846563686,"score_spread":0.26519343616462177,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4417023440","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9908307,0.000018320417,0.00016820473,0.0026584552,0.00007471166,0.005173594,0.00025659305,0.000060167964,0.0007592474],"genre_scores_gemma":[0.99461854,0.0000012473377,0.0013130719,0.0010724562,0.000017604645,0.0018922961,0.000049649236,0.000048701168,0.0009864566],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9974402,0.00014572735,0.0006196568,0.0006624309,0.00060838356,0.00052356475],"domain_scores_gemma":[0.9979142,0.0006262465,0.00012087636,0.0007696862,0.00027871015,0.0002902773],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00029230828,0.0003799233,0.0007824617,0.00029393766,0.00015948586,0.000033570068,0.00022160883,0.00011374905,0.000009743424],"category_scores_gemma":[0.0009497441,0.0002526423,0.00018104113,0.0009977886,0.000035162535,0.000058800997,0.00026161625,0.00012410092,0.000035239624],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.003749411,0.002369738,0.98881245,0.000055373315,0.0002664074,0.000007125499,0.0008838013,0.0007994009,0.0023117773,0.00026102562,0.00009041462,0.0003930559],"study_design_scores_gemma":[0.009022432,0.0008257077,0.96316564,0.0004382428,0.00036641324,5.732134e-7,0.00009468453,0.00010609274,0.025505155,0.000032110176,0.00021610066,0.0002268618],"about_ca_topic_score_codex":0.00025577482,"about_ca_topic_score_gemma":0.0004640652,"teacher_disagreement_score":0.025646843,"about_ca_system_score_codex":0.00026241504,"about_ca_system_score_gemma":0.00019069725,"threshold_uncertainty_score":0.9999926},"labels":[],"label_agreement":null},{"id":"W4417023442","doi":"10.1182/blood-2025-5581","title":"Impact of hemoglobin improvement with momelotinib on survival in patients with myelofibrosis and anemia: Post hoc analyses of the simplify-1 and momentum trials","year":2025,"lang":"en","type":"article","venue":"Blood","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Post-hoc analysis; Ruxolitinib; Myelofibrosis; Anemia; Hazard ratio; Survival analysis; Clinical trial; Clinical endpoint","score_opus":0.018701950883845655,"score_gpt":0.312995108099779,"score_spread":0.29429315721593335,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4417023442","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9979888,0.00018116231,0.0000011614273,0.00023701864,0.000017421095,0.0012227184,0.0001642377,0.000005274292,0.00018219018],"genre_scores_gemma":[0.9996578,0.00007834509,0.00008819771,0.00005200145,0.00000807991,0.000050543775,0.000023660636,0.000010893041,0.00003046358],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9987602,0.00009760305,0.00041765423,0.0002699221,0.00028645637,0.00016815911],"domain_scores_gemma":[0.9990028,0.00027084432,0.0002473329,0.0002605379,0.00015241586,0.00006607083],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00021899382,0.00021360158,0.00077664683,0.00015253537,0.00003864823,0.000012410699,0.00004738165,0.000054610744,0.000013260764],"category_scores_gemma":[0.00011060105,0.00009863601,0.000080312195,0.00032065235,0.00009603417,0.000033943168,0.000048725822,0.000084385065,1.366897e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0028862301,0.0027215139,0.98584914,0.00015092366,0.0008720435,0.0000028734225,0.00012882614,0.000010238315,0.0055989437,0.000047618603,0.00001795514,0.0017136954],"study_design_scores_gemma":[0.01972156,0.010087106,0.8922783,0.00046277736,0.0007435166,0.000001033343,0.00008906619,0.0000025545257,0.07652548,0.000009960407,0.0000017608581,0.000076847],"about_ca_topic_score_codex":0.00032709658,"about_ca_topic_score_gemma":0.00007971286,"teacher_disagreement_score":0.0935708,"about_ca_system_score_codex":0.000049675553,"about_ca_system_score_gemma":0.00013667838,"threshold_uncertainty_score":0.40222597},"labels":[],"label_agreement":null},{"id":"W4417023476","doi":"10.1182/blood-2025-5574","title":"INCB057643, a bromodomain and extra-terminal protein inhibitor, in combination with ruxolitinib in patients with myelofibrosis: A phase 1 study of safety and efficacy","year":2025,"lang":"en","type":"article","venue":"Blood","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Ruxolitinib; Myelofibrosis; Tolerability; Anemia; Myeloproliferative neoplasm; Bromodomain; Phases of clinical research; Phlebotomy; Adverse effect","score_opus":0.0070089788861592605,"score_gpt":0.2553300017353423,"score_spread":0.24832102284918306,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4417023476","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99628496,0.00010145407,0.000006582773,0.000094931085,0.0000053493873,0.00334463,0.0000136563485,0.000010453272,0.00013799687],"genre_scores_gemma":[0.9992476,0.000008822907,0.00037414112,0.000021643335,0.000005192998,0.00028537647,0.0000230449,0.000011651036,0.000022487051],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9988628,0.00009895285,0.00033596827,0.00032212865,0.00021835728,0.00016177619],"domain_scores_gemma":[0.99953866,0.00007946256,0.00009481686,0.00014929286,0.00007422472,0.000063519874],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00013713507,0.00017972122,0.00042525772,0.00023325454,0.0000403924,0.000014812662,0.000027036833,0.000049918584,0.000004053653],"category_scores_gemma":[0.00004002342,0.00012739419,0.0000117192585,0.00030649005,0.000068537396,0.000073506526,0.00003229633,0.00011663759,1.833958e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.005656309,0.039668404,0.94621277,0.00017902986,0.00011536149,0.000089897214,0.0017749219,6.361507e-7,0.0001933971,0.00017645846,0.0000011719385,0.0059316745],"study_design_scores_gemma":[0.13982998,0.014055015,0.84077,0.0014717191,0.00016898436,0.0000070600277,0.00041588146,0.000011926443,0.0031467052,0.000019425974,0.0000057619873,0.000097539116],"about_ca_topic_score_codex":0.00012372462,"about_ca_topic_score_gemma":0.00029921852,"teacher_disagreement_score":0.13417368,"about_ca_system_score_codex":0.000039160615,"about_ca_system_score_gemma":0.0000839982,"threshold_uncertainty_score":0.51949847},"labels":[],"label_agreement":null},{"id":"W4417023485","doi":"10.1182/blood-2025-5588","title":"Comprehensive analyses of patient-reported outcomes from the phase 3 VERIFY study of rusfertide or placebo plus current standard of care for polycythemia vera","year":2025,"lang":"en","type":"article","venue":"Blood","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Phlebotomy; Polycythemia vera; Placebo; Clinical endpoint; Myeloproliferative neoplasm; Hematocrit; Ruxolitinib; Clinical trial","score_opus":0.06118410426330739,"score_gpt":0.3977018425519126,"score_spread":0.3365177382886052,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4417023485","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9938312,0.002491434,0.000031356587,0.00010259104,0.00013740864,0.0024792226,0.0008560758,0.000012089752,0.000058591108],"genre_scores_gemma":[0.99923146,0.000082665705,0.00025047245,0.00004680044,0.00001798704,0.00023123974,0.00011771321,0.00001222641,0.0000094286215],"study_design_codex":"observational","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9984436,0.00007272774,0.0007090313,0.00025503128,0.00038111184,0.00013850104],"domain_scores_gemma":[0.99771005,0.00088697905,0.00028630006,0.0004569138,0.00061015104,0.00004958939],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00004732774,0.00020515647,0.0010073157,0.00008845267,0.000062254694,0.0000054486254,0.00008964684,0.000043934288,0.000048077072],"category_scores_gemma":[0.00026392832,0.00011260929,0.00020731988,0.00019367982,0.00006749274,0.000020740401,0.000056887402,0.00009335805,2.5620074e-7],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.03399708,0.017483234,0.8952089,0.00091985223,0.012898062,0.000059191916,0.019073118,0.00006737415,0.0071060415,0.000049290265,0.00069760554,0.012440231],"study_design_scores_gemma":[0.09821758,0.011915304,0.18353033,0.0007875155,0.008359785,0.0000022682186,0.024330698,0.000027572418,0.6718777,0.00001862037,0.0007692418,0.00016343904],"about_ca_topic_score_codex":0.0004692516,"about_ca_topic_score_gemma":0.00018329007,"teacher_disagreement_score":0.7116786,"about_ca_system_score_codex":0.0000532889,"about_ca_system_score_gemma":0.000354897,"threshold_uncertainty_score":0.45920736},"labels":[],"label_agreement":null},{"id":"W4417023492","doi":"10.1182/blood-2025-5580","title":"Association between momelotinib exposure and hemoglobin improvement in patients with myelofibrosis and anemia: An exposure-response and time-to-event analysis","year":2025,"lang":"en","type":"article","venue":"Blood","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Anemia; Myelofibrosis; Post-hoc analysis; Randomized controlled trial; Hemoglobin; Ruxolitinib; Prospective cohort study; Clinical trial","score_opus":0.003761307535390847,"score_gpt":0.22601530291703,"score_spread":0.22225399538163917,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4417023492","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99759084,0.00019610187,0.000011123815,0.0010605262,0.000009122677,0.0009629997,0.00008785696,0.00002317849,0.000058251488],"genre_scores_gemma":[0.9984222,0.00003362086,0.00055863475,0.00024051167,0.000018888975,0.00013043698,0.000103538885,0.000013634983,0.00047855324],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99853605,0.00012999188,0.0003217096,0.000487574,0.00028035717,0.00024430986],"domain_scores_gemma":[0.9991516,0.00021260759,0.000110129506,0.00020937536,0.00011357776,0.0002027068],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00038955305,0.00022826121,0.00054826506,0.00036207587,0.00008738646,0.000057264606,0.000034153683,0.00012204283,0.00002648303],"category_scores_gemma":[0.000099982804,0.00018032223,0.00003705295,0.0005202493,0.000024919946,0.00008569052,0.00006309337,0.00010658991,0.0000026884882],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000793881,0.0010020215,0.98880816,0.000048739344,0.0012378489,0.0000072119087,0.00038316887,0.0000035036567,0.0006797908,0.0000046055347,0.000039750725,0.006991313],"study_design_scores_gemma":[0.010468464,0.0042128344,0.9770407,0.00010851505,0.002736922,6.246485e-7,0.000065112195,0.000014306248,0.0051294994,0.000008418287,0.00005876083,0.00015585138],"about_ca_topic_score_codex":0.000058130925,"about_ca_topic_score_gemma":0.00006857281,"teacher_disagreement_score":0.011767473,"about_ca_system_score_codex":0.00012291293,"about_ca_system_score_gemma":0.000052582946,"threshold_uncertainty_score":0.73533267},"labels":[],"label_agreement":null},{"id":"W4417023493","doi":"10.1182/blood-2025-5587","title":"Should dermatologic examinations become routine standard of care in patients with polycythemia vera? Observations from the phase 3 VERIFY study prior to rusfertide exposure","year":2025,"lang":"en","type":"article","venue":"Blood","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Phlebotomy; Randomization; Placebo; Hematocrit; Polycythemia vera; Stage (stratigraphy); Randomized controlled trial","score_opus":0.02118794865231098,"score_gpt":0.29643712669220745,"score_spread":0.27524917803989646,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4417023493","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9949848,0.00028028453,0.000022644663,0.0020521893,0.000041573086,0.0020911316,0.0003713309,0.000023906377,0.00013214268],"genre_scores_gemma":[0.9981329,0.0000076134565,0.0006843241,0.0005389371,0.000014119782,0.00037655677,0.00020126828,0.00001191114,0.000032375174],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99886334,0.000077771554,0.0003424522,0.0002605244,0.0002954796,0.00016044038],"domain_scores_gemma":[0.99900347,0.00023260257,0.00006997552,0.00038437647,0.00024991788,0.00005967202],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00006685631,0.00017033437,0.00039536293,0.00009599259,0.00011615175,0.000017103786,0.000106756765,0.00005383543,0.00003765045],"category_scores_gemma":[0.0001654045,0.000104024984,0.000042958323,0.0004181219,0.000028700879,0.00004621344,0.000053544667,0.00013721811,0.0000023076489],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00103071,0.0053871064,0.9886731,0.000021891909,0.00028501512,0.000018931752,0.0035174799,0.000006881045,0.000038254126,0.00008839026,0.000106602674,0.0008256571],"study_design_scores_gemma":[0.023749685,0.0045114793,0.9630494,0.00021045914,0.00050528167,5.1000166e-7,0.001941991,0.0000021138471,0.005676145,0.000009442581,0.000257834,0.00008562873],"about_ca_topic_score_codex":0.00017425207,"about_ca_topic_score_gemma":0.0015120504,"teacher_disagreement_score":0.025623651,"about_ca_system_score_codex":0.000091431706,"about_ca_system_score_gemma":0.00016612012,"threshold_uncertainty_score":0.42420155},"labels":[],"label_agreement":null},{"id":"W4417042330","doi":"10.1182/hematology.2025000704","title":"<i>JAK2</i> wild-type erythrocytosis: concept, differential diagnosis, diagnostic steps, and treatment approaches","year":2025,"lang":"en","type":"article","venue":"Hematology","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal","funders":"","keywords":"Erythropoietin; Phlebotomy; Hyperviscosity; Polycythemia vera; Thrombocytosis; Aspirin; Erythropoietin receptor; Germline","score_opus":0.03560577312526011,"score_gpt":0.28218990243611797,"score_spread":0.24658412931085785,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4417042330","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97291577,0.016713317,0.00016698196,0.006146472,0.00044221204,0.0014711218,0.000027163778,0.00013439737,0.001982592],"genre_scores_gemma":[0.9909725,0.0055864016,0.00048241267,0.00088060525,0.00009699846,0.0012997072,0.00012708934,0.000028336912,0.0005259173],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9981915,0.00011737807,0.0004259307,0.00066413,0.00015479293,0.00044629507],"domain_scores_gemma":[0.99804956,0.0011620738,0.000099307996,0.00040899747,0.00008133291,0.00019870965],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00004480442,0.00042135292,0.0010345582,0.00016534959,0.00018612781,0.000038463608,0.00007519411,0.00023298936,0.00023945537],"category_scores_gemma":[0.00026810425,0.00031165016,0.00013713422,0.00022644512,0.00028109027,0.000056210945,0.00009127836,0.000149863,0.000046730496],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00031795347,0.002718064,0.9306876,0.00022165429,0.0013288498,0.00035522075,0.00084200245,0.0000032688904,0.000051554427,0.03417437,0.010278719,0.019020746],"study_design_scores_gemma":[0.04029915,0.0103729805,0.62018085,0.0025180094,0.007518299,0.0024514212,0.0026132886,0.0006519309,0.197493,0.0028994558,0.11110791,0.0018936917],"about_ca_topic_score_codex":0.00007670953,"about_ca_topic_score_gemma":0.00010702707,"teacher_disagreement_score":0.31050673,"about_ca_system_score_codex":0.00015067088,"about_ca_system_score_gemma":0.00016313669,"threshold_uncertainty_score":0.99993354},"labels":[],"label_agreement":null},{"id":"W4417207098","doi":"10.1016/j.rpth.2025.103104","title":"HTRS2025.P2.85 Sociodemographic disparities in thrombosis and bleeding rates in patients with myeloproliferative neoplasms: a real-world study from the Quebec MPN Research Group","year":2025,"lang":"en","type":"article","venue":"Research and Practice in Thrombosis and Haemostasis","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Jewish General Hospital; Centre Hospitalier de l’Université de Montréal; McGill-Queen's University Press; Hôpital Maisonneuve-Rosemont; Université de Montréal","funders":"","keywords":"Thrombosis; Epidemiology; Major bleeding; Population; Myeloproliferative Disorders; Incidence (geometry)","score_opus":0.13795322088253098,"score_gpt":0.4554123663913899,"score_spread":0.3174591455088589,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4417207098","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9585148,0.0030533068,0.0000010864005,0.033298023,0.000037301663,0.0035442759,0.00006883075,0.000018086905,0.0014642645],"genre_scores_gemma":[0.95761734,0.040428974,0.0002964381,0.00038727798,0.000046577836,0.0010286827,0.000059357364,0.00003451309,0.000100834804],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.993039,0.002844387,0.00069137005,0.0011455585,0.0012602578,0.0010194288],"domain_scores_gemma":[0.9819087,0.016611595,0.00012442766,0.0004619134,0.00064260454,0.00025080817],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.005769156,0.00043244034,0.000997677,0.001342223,0.00091921596,0.00066743995,0.00019413908,0.00019251178,0.000050776853],"category_scores_gemma":[0.0018516687,0.00028766698,0.00004598566,0.0029931644,0.0013190209,0.0008435408,0.000461752,0.0019012538,0.000002837657],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0024715087,0.003567211,0.9712744,0.00014219157,0.0006219122,0.00004384508,0.0120919915,0.0000010760702,0.000019259809,0.0039224024,0.0009007866,0.0049434095],"study_design_scores_gemma":[0.0077749407,0.0020547004,0.9491712,0.0013338722,0.00014979798,0.000001435752,0.03687812,0.00006401297,0.000087098015,0.0017950836,0.00044662104,0.0002431445],"about_ca_topic_score_codex":0.15617096,"about_ca_topic_score_gemma":0.3637838,"teacher_disagreement_score":0.20761286,"about_ca_system_score_codex":0.0004122939,"about_ca_system_score_gemma":0.00040699705,"threshold_uncertainty_score":0.99995756},"labels":[],"label_agreement":null},{"id":"W4417424232","doi":"10.1182/blood-2025-482","title":"Preliminary data from the Phase I/II study of nuvisertib, an oral investigational selective PIM1 inhibitor, in combination with momelotinib showed clinical responses in patients with relapsed/refractory myelofibrosis","year":2025,"lang":"en","type":"article","venue":"Blood","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Ruxolitinib; Myelofibrosis; PIM1; Phases of clinical research; Bone marrow; Combination therapy; Janus kinase inhibitor","score_opus":0.04823130709713899,"score_gpt":0.34450074179795664,"score_spread":0.2962694347008177,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4417424232","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9971156,0.000057908255,0.0000034848006,0.00041755443,0.00004562185,0.002125543,0.00017365019,0.000017757176,0.00004286987],"genre_scores_gemma":[0.997956,0.000009622776,0.0006182712,0.00019967719,0.000026686403,0.00019875048,0.0009362231,0.000020295352,0.000034491877],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9973982,0.00070431345,0.0006392948,0.0006106164,0.00046973513,0.00017786674],"domain_scores_gemma":[0.9977762,0.0009930405,0.00021948769,0.0006661322,0.0002580206,0.00008713686],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005165848,0.00022745092,0.0005031441,0.00018761944,0.00010818125,0.000018164063,0.0002034442,0.000100098325,0.000018888348],"category_scores_gemma":[0.00047844797,0.00014152576,0.000024929965,0.0006039409,0.0001544881,0.00028310675,0.00014167409,0.0003374236,0.0000015272008],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.018514594,0.08679854,0.8908018,0.000014203804,0.00037763576,0.000022366414,0.0018914365,0.000007100571,0.000069315254,0.000025105986,0.00020383354,0.0012740579],"study_design_scores_gemma":[0.07297636,0.04685674,0.8771374,0.00042027442,0.00043654448,7.1518195e-7,0.0006932777,0.00011631741,0.0011819376,0.00004561803,0.000016014694,0.00011880803],"about_ca_topic_score_codex":0.00049657346,"about_ca_topic_score_gemma":0.0025644116,"teacher_disagreement_score":0.054461762,"about_ca_system_score_codex":0.00007102447,"about_ca_system_score_gemma":0.0005132631,"threshold_uncertainty_score":0.5771253},"labels":[],"label_agreement":null},{"id":"W655017083","doi":"10.1182/blood.v124.21.3197.3197","title":"Safety and Efficacy of Ruxolitinib in an Open-Label, Multicenter, Single-Arm, Expanded-Access Study in Patients with Myelofibrosis (MF): An 1144-Patient Update","year":2014,"lang":"en","type":"article","venue":"Blood","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":32,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; St. Paul's Hospital; University of British Columbia","funders":"","keywords":"Ruxolitinib; Medicine; Myelofibrosis; Internal medicine; Clinical endpoint; Tolerability; Discontinuation; Clinical trial; Phases of clinical research; Placebo; Surgery; Adverse effect; Bone marrow; Pathology","score_opus":0.03038952331248791,"score_gpt":0.30902278592985855,"score_spread":0.27863326261737065,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W655017083","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99668616,0.000036341906,0.000003819058,0.000059338756,0.00004340042,0.00289886,0.000041899115,0.00002042636,0.000209757],"genre_scores_gemma":[0.99847776,0.000020984462,0.0009666088,0.00016454191,0.000020966434,0.0001554006,0.00015034243,0.000038541708,0.00000483366],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9977984,0.0002819056,0.000614721,0.0006205426,0.00035107287,0.00033335394],"domain_scores_gemma":[0.9987937,0.00010686524,0.00021304975,0.00049759896,0.00014873395,0.00024005043],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002261075,0.00029835355,0.0006983979,0.00018886189,0.00006637697,0.00008894416,0.00020963902,0.00006694511,0.00003744672],"category_scores_gemma":[0.00007459806,0.00022358946,0.00001642713,0.0002477009,0.00006583097,0.00043213431,0.00021146087,0.00013384757,0.0000024236022],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.003384125,0.113624915,0.8694467,0.00004280733,0.00008974813,0.000019559604,0.001811371,0.000006225536,0.00013716416,0.000028718488,0.0000022602874,0.011406406],"study_design_scores_gemma":[0.08599223,0.028401453,0.88066167,0.000339679,0.00017665299,0.0000019849017,0.00029624414,0.00005703443,0.0038251902,0.000005361042,0.00003518673,0.00020729615],"about_ca_topic_score_codex":0.00036868895,"about_ca_topic_score_gemma":0.0012793136,"teacher_disagreement_score":0.08522346,"about_ca_system_score_codex":0.000057605463,"about_ca_system_score_gemma":0.000043914417,"threshold_uncertainty_score":0.91177136},"labels":[],"label_agreement":null},{"id":"W68963654","doi":"10.1182/blood.v96.10.3310.h8003310_3310_3321","title":"Hypersensitivity of circulating progenitor cells to megakaryocyte growth and development factor (PEG-rHu MGDF) in essential thrombocythemia","year":2000,"lang":"en","type":"article","venue":"Blood","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":94,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Mount Sinai Hospital","funders":"","keywords":"Thrombopoietin; Megakaryocyte; Progenitor cell; Immunology; Biology; Haematopoiesis; Myeloid; Interleukin 3; Stem cell factor; Stem cell; Cell biology; T cell; Antigen-presenting cell","score_opus":0.014273951780636278,"score_gpt":0.24738974098751318,"score_spread":0.2331157892068769,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W68963654","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99789697,0.00014780722,0.00000922443,0.00011032328,0.00003597701,0.00071509084,0.000017696806,0.000024679366,0.0010422196],"genre_scores_gemma":[0.99537575,0.00005274842,0.0042850254,0.00008878279,0.000064028645,0.000058191847,0.000012329652,0.000021214877,0.000041937565],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9987597,0.000044079254,0.00032797514,0.00034765198,0.0002598989,0.00026073612],"domain_scores_gemma":[0.9995213,0.00007745531,0.000056617973,0.00014739709,0.00005728562,0.00013992867],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00008083058,0.00020233201,0.00044397326,0.0000926131,0.0000590772,0.000014031561,0.000034727007,0.00007691533,0.00013367762],"category_scores_gemma":[0.000031276148,0.00016998708,0.000049232964,0.00014878441,0.000037406204,0.000052126245,0.000032575233,0.00010223475,0.000026039399],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00026490074,0.003340748,0.4634095,0.00038879277,0.0004977873,0.00046858983,0.005677756,0.000008696604,0.5019795,0.000040631698,0.000016251211,0.023906851],"study_design_scores_gemma":[0.0028331818,0.00016883478,0.27231845,0.000153895,0.000075776494,0.000059589354,0.00007205035,0.000010406578,0.72407377,0.0000033942638,0.00009945719,0.00013116012],"about_ca_topic_score_codex":0.00008637706,"about_ca_topic_score_gemma":0.00003862599,"teacher_disagreement_score":0.2220943,"about_ca_system_score_codex":0.000048061764,"about_ca_system_score_gemma":0.00014035558,"threshold_uncertainty_score":0.6931872},"labels":[],"label_agreement":null},{"id":"W6920984560","doi":"10.6084/m9.figshare.20652344.v1","title":"Prevalence of elevated hemoglobin and hematocrit levels in patients with obstructive sleep apnea and the impact of treatment with continuous positive airway pressure: a meta-analysis","year":2022,"lang":"en","type":"article","venue":"Figshare","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Toronto General Hospital","funders":"","keywords":"Hematocrit; Hemoglobin; Continuous positive airway pressure; Obstructive sleep apnea; Randomized controlled trial; Subgroup analysis; Sleep apnea","score_opus":0.023062829393685147,"score_gpt":0.26318534227003204,"score_spread":0.2401225128763469,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W6920984560","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8308584,0.0019141282,7.5088184e-7,0.000062200335,0.0000013603968,0.0020987317,0.1649859,0.000006169613,0.00007237771],"genre_scores_gemma":[0.9952176,0.000005122867,0.00006838901,0.000018841152,0.0000022674024,0.0012706657,0.0032994992,0.000013538169,0.00010405389],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99875915,0.00018931403,0.0002659547,0.00033110633,0.0002960104,0.00015847581],"domain_scores_gemma":[0.9987962,0.00032394187,0.00029548438,0.00025185564,0.00026495673,0.0000675137],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.000059184164,0.0002427012,0.0011051595,0.000118551994,0.000068750225,0.0000102838485,0.000056562723,0.000027851478,0.010003764],"category_scores_gemma":[0.00006711944,0.00011233747,0.00022770226,0.00041618876,0.000057732403,0.000061258885,0.00006506175,0.00009294495,6.617522e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0053055543,0.0014922766,0.84297025,0.00039876142,0.14370061,0.000045600133,0.004433751,0.00094156037,0.00001681298,0.000024282956,0.00014669968,0.0005238559],"study_design_scores_gemma":[0.009835898,0.0064651244,0.9413594,0.00011184375,0.039399855,0.000019519679,0.00017839714,0.00049005134,0.0019934375,0.000006358021,0.000009593461,0.00013049335],"about_ca_topic_score_codex":0.0002697317,"about_ca_topic_score_gemma":0.000027147913,"teacher_disagreement_score":0.16435924,"about_ca_system_score_codex":0.00010412641,"about_ca_system_score_gemma":0.00007856251,"threshold_uncertainty_score":0.99090123},"labels":[],"label_agreement":null},{"id":"W6921030266","doi":"10.6084/m9.figshare.28283588","title":"Real-world treatment patterns and health outcomes for patients with myelofibrosis treated with fedratinib","year":2025,"lang":"en","type":"article","venue":"Figshare","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Ruxolitinib; Myelofibrosis; Discontinuation; Medical record; Population; Incidence (geometry); Anemia","score_opus":0.03749849712892124,"score_gpt":0.323720691071694,"score_spread":0.28622219394277276,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W6921030266","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.75151986,0.00013748207,0.0000068861464,0.00532862,0.000032653636,0.008419357,0.23098725,0.00022465792,0.0033432266],"genre_scores_gemma":[0.8849838,0.000045786495,0.00081102236,0.00097388565,0.00002776818,0.0040573096,0.10588053,0.000042882555,0.003177027],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9988533,0.00002304607,0.00023108789,0.00042937312,0.00016461867,0.00029852256],"domain_scores_gemma":[0.9990824,0.00018042557,0.000121894125,0.00026197138,0.00017821792,0.00017510343],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.000017617862,0.00032145478,0.00057610957,0.00013657198,0.00018657686,0.000049314393,0.00003646758,0.000045937384,0.0026363449],"category_scores_gemma":[0.00003056281,0.00017765828,0.00006739904,0.00018632812,0.000009146983,0.000059642603,0.000019951829,0.00005023672,0.00001854035],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0003676637,0.00074389036,0.971638,0.00034021912,0.0004186211,0.000008475344,0.00010596731,8.3541914e-7,2.472807e-7,0.000036698355,0.015704835,0.010634546],"study_design_scores_gemma":[0.008750343,0.00505525,0.97320217,0.0031015573,0.00015102845,0.0000013074084,0.00003041343,0.000016825823,0.00048764827,0.0000026352807,0.009044844,0.00015599559],"about_ca_topic_score_codex":0.0005051053,"about_ca_topic_score_gemma":0.0027892704,"teacher_disagreement_score":0.13346392,"about_ca_system_score_codex":0.00029109433,"about_ca_system_score_gemma":0.00020416315,"threshold_uncertainty_score":0.9982754},"labels":[],"label_agreement":null},{"id":"W6929128546","doi":"10.4224/23002744","title":"L'éthique, base de la science du comportement au Centre de recherche en construction du CNRC","year":2017,"lang":"fr","type":"other","venue":"NPARC","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"National Research Council Canada","funders":"","keywords":"Base (topology); Context (archaeology); Work (physics); Field (mathematics)","score_opus":0.06965546489796819,"score_gpt":0.3546327467213055,"score_spread":0.2849772818233373,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W6929128546","genre_codex":"other","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"other","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.045463156,0.0005203406,0.0009174642,0.0091251675,0.0013482083,0.0013915165,0.00008470161,0.00007573871,0.9410737],"genre_scores_gemma":[0.6572171,0.0126685845,0.11446201,0.0023701766,0.0058358214,0.0006066664,0.00013477422,0.00031862714,0.20638627],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.99581945,0.0015880534,0.00037694714,0.0007615334,0.0005828794,0.0008711329],"domain_scores_gemma":[0.9966491,0.001271877,0.0004286696,0.00073080446,0.00025297105,0.0006665698],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0047816453,0.00051996746,0.00066950754,0.00021666393,0.00056102057,0.00015209295,0.00040445535,0.00093460194,0.018531714],"category_scores_gemma":[0.0029010153,0.00045103396,0.00017297422,0.00015515035,0.0018141872,0.0001076359,0.00015172624,0.0010690294,0.000474733],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00012966033,0.0015032324,0.64201856,0.00046428773,0.0005415152,0.0012370865,0.002748855,0.000010985926,0.013321302,0.12579727,0.04482577,0.1674015],"study_design_scores_gemma":[0.005978579,0.00055052864,0.12755449,0.0053485013,0.001155325,0.0013609345,0.00097191444,0.0014475349,0.05480511,0.007378416,0.7925603,0.00088840816],"about_ca_topic_score_codex":0.0008460563,"about_ca_topic_score_gemma":0.00041490796,"teacher_disagreement_score":0.7477345,"about_ca_system_score_codex":0.006958948,"about_ca_system_score_gemma":0.005331629,"threshold_uncertainty_score":0.9997941},"labels":[],"label_agreement":null},{"id":"W6931332962","doi":"10.5281/zenodo.4036798","title":"The Babysitter: Killer Queen Streaming Complet Gratuit VF HD","year":2020,"lang":"fr","type":"article","venue":"Zenodo (CERN European Organization for Nuclear Research)","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Context (archaeology); Ideal (ethics); Population","score_opus":0.04766819736848914,"score_gpt":0.2650160731697461,"score_spread":0.21734787580125697,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W6931332962","genre_codex":"commentary","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.053222626,0.014752314,0.0044045714,0.52811146,0.003035034,0.0057910713,0.002343431,0.002297924,0.38604155],"genre_scores_gemma":[0.9605825,0.0062129684,0.00044473403,0.0052818963,0.0030368087,5.7005605e-7,0.0038733373,0.0034348944,0.017132303],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99665207,0.00075466017,0.00048357353,0.0006562466,0.00066372997,0.00078969816],"domain_scores_gemma":[0.99779975,0.0001871738,0.00017165027,0.0005546933,0.00065415405,0.0006325799],"candidate_categories":["metaepi_narrow","sts","scholarly_communication","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.00056276255,0.00033332894,0.00037908243,0.000089576366,0.0039569275,0.0011370451,0.0007666812,0.000114467046,0.025387743],"category_scores_gemma":[0.0011062121,0.0002698686,0.00014529651,0.00061572256,0.00040482334,0.00020956375,0.0010895818,0.0005846795,0.02820573],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00021441816,0.0003966703,0.00020890379,0.0001967127,0.0004535868,0.00018467187,0.0036518613,0.000046277542,0.0006187059,0.021721529,0.73984957,0.2324571],"study_design_scores_gemma":[0.0015334999,0.0010421464,0.0042724023,0.0002027147,0.00014390223,0.000104550534,0.0011118408,0.0010242981,0.00054489204,0.00009977734,0.98967254,0.00024745564],"about_ca_topic_score_codex":0.00007963458,"about_ca_topic_score_gemma":0.0000018741783,"teacher_disagreement_score":0.90735984,"about_ca_system_score_codex":0.0003493626,"about_ca_system_score_gemma":0.000016263695,"threshold_uncertainty_score":0.9999753},"labels":[],"label_agreement":null},{"id":"W6939255164","doi":"10.60692/wpz3g-3k925","title":"HSP27 is a partner of JAK2-STAT5 and a potential therapeutic target in myelofibrosis","year":2018,"lang":"en","type":"article","venue":"Greater South Information System","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"Hsp27; Myelofibrosis; Myeloproliferative Disorders; Megakaryocyte; Heat shock protein; Spleen; Bone marrow; Disease","score_opus":0.027527654482688693,"score_gpt":0.24496877916775808,"score_spread":0.21744112468506938,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W6939255164","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99491173,0.000021464342,0.0013639083,0.0002319927,0.00010322329,0.0006133394,0.000084668376,0.000036993377,0.0026326852],"genre_scores_gemma":[0.9987204,0.0000014300153,0.0005908275,0.0004209496,0.000057216916,0.00009729975,0.000017103024,0.000008647195,0.00008610399],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9988303,0.000042134125,0.00054337195,0.00013792462,0.00025462802,0.0001916381],"domain_scores_gemma":[0.9993088,0.000007549895,0.000193658,0.0002133235,0.00018993526,0.00008670532],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00017358173,0.00016192054,0.0003512501,0.00023449364,0.000057959245,0.00004194384,0.000040112755,0.000087635,0.000104765415],"category_scores_gemma":[0.0000076546185,0.00011382659,0.00006169638,0.0001747651,0.00006801947,0.00024092874,0.000029360754,0.000054502114,0.00018207985],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0002905483,0.000015125307,0.9370293,0.0004207783,0.00012781387,0.000005053867,0.06095176,0.0000028724178,0.000021263006,0.00018199222,0.00012744522,0.0008260424],"study_design_scores_gemma":[0.0056652916,0.00083181437,0.9635778,0.0005947032,0.00014774766,0.00011190077,0.007388891,0.0032818743,0.017397461,0.000010968498,0.00076716504,0.00022436434],"about_ca_topic_score_codex":0.000018398057,"about_ca_topic_score_gemma":3.428778e-7,"teacher_disagreement_score":0.05356287,"about_ca_system_score_codex":0.00006159272,"about_ca_system_score_gemma":0.00004397273,"threshold_uncertainty_score":0.46417135},"labels":[],"label_agreement":null},{"id":"W6976604446","doi":"10.60692/n058f-x9b63","title":"HSP27 is a partner of JAK2-STAT5 and a potential therapeutic target in myelofibrosis","year":2018,"lang":"en","type":"article","venue":"Greater South Information System","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"Hsp27; Myelofibrosis; Myeloproliferative Disorders; Megakaryocyte; Heat shock protein; Spleen; Bone marrow; Disease","score_opus":0.027527654482688693,"score_gpt":0.24496877916775808,"score_spread":0.21744112468506938,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W6976604446","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99491173,0.000021464342,0.0013639083,0.0002319927,0.00010322329,0.0006133394,0.000084668376,0.000036993377,0.0026326852],"genre_scores_gemma":[0.9987204,0.0000014300153,0.0005908275,0.0004209496,0.000057216916,0.00009729975,0.000017103024,0.000008647195,0.00008610399],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9988303,0.000042134125,0.00054337195,0.00013792462,0.00025462802,0.0001916381],"domain_scores_gemma":[0.9993088,0.000007549895,0.000193658,0.0002133235,0.00018993526,0.00008670532],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00017358173,0.00016192054,0.0003512501,0.00023449364,0.000057959245,0.00004194384,0.000040112755,0.000087635,0.000104765415],"category_scores_gemma":[0.0000076546185,0.00011382659,0.00006169638,0.0001747651,0.00006801947,0.00024092874,0.000029360754,0.000054502114,0.00018207985],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0002905483,0.000015125307,0.9370293,0.0004207783,0.00012781387,0.000005053867,0.06095176,0.0000028724178,0.000021263006,0.00018199222,0.00012744522,0.0008260424],"study_design_scores_gemma":[0.0056652916,0.00083181437,0.9635778,0.0005947032,0.00014774766,0.00011190077,0.007388891,0.0032818743,0.017397461,0.000010968498,0.00076716504,0.00022436434],"about_ca_topic_score_codex":0.000018398057,"about_ca_topic_score_gemma":3.428778e-7,"teacher_disagreement_score":0.05356287,"about_ca_system_score_codex":0.00006159272,"about_ca_system_score_gemma":0.00004397273,"threshold_uncertainty_score":0.46417135},"labels":[],"label_agreement":null},{"id":"W6977150076","doi":"10.6084/m9.figshare.28283588.v1","title":"Real-world treatment patterns and health outcomes for patients with myelofibrosis treated with fedratinib","year":2025,"lang":"en","type":"article","venue":"Figshare","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Ruxolitinib; Myelofibrosis; Discontinuation; Medical record; Population; Incidence (geometry); Anemia","score_opus":0.03749849712892124,"score_gpt":0.323720691071694,"score_spread":0.28622219394277276,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W6977150076","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.75151986,0.00013748207,0.0000068861464,0.00532862,0.000032653636,0.008419357,0.23098725,0.00022465792,0.0033432266],"genre_scores_gemma":[0.8849838,0.000045786495,0.00081102236,0.00097388565,0.00002776818,0.0040573096,0.10588053,0.000042882555,0.003177027],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9988533,0.00002304607,0.00023108789,0.00042937312,0.00016461867,0.00029852256],"domain_scores_gemma":[0.9990824,0.00018042557,0.000121894125,0.00026197138,0.00017821792,0.00017510343],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.000017617862,0.00032145478,0.00057610957,0.00013657198,0.00018657686,0.000049314393,0.00003646758,0.000045937384,0.0026363449],"category_scores_gemma":[0.00003056281,0.00017765828,0.00006739904,0.00018632812,0.000009146983,0.000059642603,0.000019951829,0.00005023672,0.00001854035],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0003676637,0.00074389036,0.971638,0.00034021912,0.0004186211,0.000008475344,0.00010596731,8.3541914e-7,2.472807e-7,0.000036698355,0.015704835,0.010634546],"study_design_scores_gemma":[0.008750343,0.00505525,0.97320217,0.0031015573,0.00015102845,0.0000013074084,0.00003041343,0.000016825823,0.00048764827,0.0000026352807,0.009044844,0.00015599559],"about_ca_topic_score_codex":0.0005051053,"about_ca_topic_score_gemma":0.0027892704,"teacher_disagreement_score":0.13346392,"about_ca_system_score_codex":0.00029109433,"about_ca_system_score_gemma":0.00020416315,"threshold_uncertainty_score":0.9982754},"labels":[],"label_agreement":null},{"id":"W6977301564","doi":"10.6084/m9.figshare.20652344","title":"Prevalence of elevated hemoglobin and hematocrit levels in patients with obstructive sleep apnea and the impact of treatment with continuous positive airway pressure: a meta-analysis","year":2022,"lang":"en","type":"article","venue":"Figshare","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Toronto General Hospital","funders":"","keywords":"Hematocrit; Hemoglobin; Continuous positive airway pressure; Obstructive sleep apnea; Randomized controlled trial; Subgroup analysis; Sleep apnea","score_opus":0.023062829393685147,"score_gpt":0.26318534227003204,"score_spread":0.2401225128763469,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W6977301564","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8308584,0.0019141282,7.5088184e-7,0.000062200335,0.0000013603968,0.0020987317,0.1649859,0.000006169613,0.00007237771],"genre_scores_gemma":[0.9952176,0.000005122867,0.00006838901,0.000018841152,0.0000022674024,0.0012706657,0.0032994992,0.000013538169,0.00010405389],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99875915,0.00018931403,0.0002659547,0.00033110633,0.0002960104,0.00015847581],"domain_scores_gemma":[0.9987962,0.00032394187,0.00029548438,0.00025185564,0.00026495673,0.0000675137],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.000059184164,0.0002427012,0.0011051595,0.000118551994,0.000068750225,0.0000102838485,0.000056562723,0.000027851478,0.010003764],"category_scores_gemma":[0.00006711944,0.00011233747,0.00022770226,0.00041618876,0.000057732403,0.000061258885,0.00006506175,0.00009294495,6.617522e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0053055543,0.0014922766,0.84297025,0.00039876142,0.14370061,0.000045600133,0.004433751,0.00094156037,0.00001681298,0.000024282956,0.00014669968,0.0005238559],"study_design_scores_gemma":[0.009835898,0.0064651244,0.9413594,0.00011184375,0.039399855,0.000019519679,0.00017839714,0.00049005134,0.0019934375,0.000006358021,0.000009593461,0.00013049335],"about_ca_topic_score_codex":0.0002697317,"about_ca_topic_score_gemma":0.000027147913,"teacher_disagreement_score":0.16435924,"about_ca_system_score_codex":0.00010412641,"about_ca_system_score_gemma":0.00007856251,"threshold_uncertainty_score":0.99090123},"labels":[],"label_agreement":null},{"id":"W6981034512","doi":"","title":"Destination-Based Taxation in the House Republican Blueprint","year":2016,"lang":"en","type":"article","venue":"eYLS (Yale Law School)","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"Blueprint; Tax reform; Incentive; Aside; Value-added tax; Tax avoidance; State income tax; Tax policy; Direct tax","score_opus":0.02125418018493521,"score_gpt":0.272381614488303,"score_spread":0.2511274343033678,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W6981034512","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9678749,0.00006690405,0.00041612957,0.025387565,0.00007003401,0.00075005984,0.000009787814,0.00011191226,0.005312703],"genre_scores_gemma":[0.9942758,0.000022765198,0.0011086466,0.003700559,0.00012872991,0.0004100043,0.000014322666,0.000022989798,0.00031615418],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99872434,0.00014198307,0.00026669647,0.00030438646,0.0003386092,0.00022400978],"domain_scores_gemma":[0.9987071,0.00041252677,0.00014962096,0.00046710164,0.00013577519,0.00012786654],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00044643186,0.00014807019,0.00018888131,0.000081154394,0.00010160353,0.000051459207,0.00011204677,0.00006438878,0.00061306765],"category_scores_gemma":[0.000913948,0.00007595648,0.00007094211,0.00021707991,0.00007354206,0.0001184087,0.000017778211,0.0001310544,0.00021001462],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00014577013,0.0009602737,0.8985255,0.000029434443,0.00004619525,0.00009895452,0.00024257222,0.000026116035,0.0016952339,0.08331223,0.003286791,0.011630969],"study_design_scores_gemma":[0.0042200694,0.00038684104,0.94643563,0.0002515671,0.00004787352,0.000022235547,0.000062225205,0.00009633618,0.016121084,0.0011417415,0.031044085,0.00017029203],"about_ca_topic_score_codex":0.00045205737,"about_ca_topic_score_gemma":0.0012988228,"teacher_disagreement_score":0.08217049,"about_ca_system_score_codex":0.0002014809,"about_ca_system_score_gemma":0.00014972521,"threshold_uncertainty_score":0.6712661},"labels":[],"label_agreement":null},{"id":"W6981215280","doi":"","title":"Do Patent Terms Impact Domestic R&amp;D Spending in the Pharmaceutical Industry?","year":2007,"lang":"en","type":"article","venue":"PubMed Central","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Control (management); Positive correlation; Drug prices; Impression","score_opus":0.10070358402054964,"score_gpt":0.37167938185551264,"score_spread":0.270975797834963,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W6981215280","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9929505,0.00026398586,0.00004878407,0.0015971384,0.00036037722,0.0011354191,0.000012947201,0.000028987615,0.0036018682],"genre_scores_gemma":[0.9982383,0.00010152513,0.00011188249,0.0006734563,0.0005712202,0.00015016248,0.00003710128,0.000018836983,0.00009750321],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9971654,0.00008172112,0.00033180392,0.0002975225,0.00043343435,0.0016901636],"domain_scores_gemma":[0.99873537,0.00026664426,0.000057855064,0.0002496713,0.000016645541,0.00067379803],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010759002,0.00023414016,0.00029055466,0.00012790936,0.00007159737,0.00006672422,0.00011974982,0.00015770468,0.00049121765],"category_scores_gemma":[0.0002316763,0.00013094621,0.00014360486,0.00029969963,0.00007003473,0.00007466807,0.000030216292,0.0006975089,0.000049807557],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00025403447,0.0007399122,0.9693233,0.000017758068,0.00010064398,0.0008388433,0.0008305596,0.00001598242,0.000064483276,0.0004909456,0.00046624267,0.026857305],"study_design_scores_gemma":[0.002697119,0.00010011207,0.9911167,0.00005064887,0.000113919625,0.00042678238,0.00014785993,0.000024445317,0.00096414343,0.00008454505,0.0041403538,0.00013334685],"about_ca_topic_score_codex":0.00005354971,"about_ca_topic_score_gemma":0.00005731767,"teacher_disagreement_score":0.026723959,"about_ca_system_score_codex":0.0007115507,"about_ca_system_score_gemma":0.000078179764,"threshold_uncertainty_score":0.5378489},"labels":[],"label_agreement":null},{"id":"W7033857367","doi":"","title":"Rethinking innovation labs for complex adaptive systems going through release and reorganization","year":2020,"lang":"en","type":"other","venue":"OCAD University Open Research Repository (OCAD University)","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Variety (cybernetics); Situated; Living lab; Social innovation; Social system; Work (physics); Phase (matter)","score_opus":0.15934283696197557,"score_gpt":0.3322672052256861,"score_spread":0.17292436826371052,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W7033857367","genre_codex":"other","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"other","genre_consensus":"other","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0025624535,0.00023953899,0.0023306264,0.0010855912,0.00016660662,0.0042389138,0.0001865815,0.00017403252,0.98901564],"genre_scores_gemma":[0.04882933,0.0010767671,0.0057284585,0.00012504985,0.0003563492,0.000005336621,0.0006929471,0.00026162626,0.94292414],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","domain_scores_codex":[0.9969867,0.0006393465,0.00025496192,0.0010105992,0.0006547529,0.0004536799],"domain_scores_gemma":[0.9976764,0.00026721242,0.00038006474,0.00047093327,0.0009368619,0.00026857323],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00041137333,0.00038268126,0.0007472842,0.0008356756,0.0011238958,0.00021683413,0.0004904967,0.0005074988,0.000010636964],"category_scores_gemma":[0.00015066411,0.00042886936,0.00009140151,0.0017696952,0.0003639289,0.0004496427,0.00048349818,0.0006978625,0.000025368316],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0013381745,0.00017307233,0.0019493907,0.00047011618,0.0006671904,0.0010901175,0.00092751585,0.000006051624,0.0006918007,0.92371607,0.06876583,0.00020465322],"study_design_scores_gemma":[0.0046115243,0.0012288688,0.00072108855,0.0014555741,0.00042353035,0.00005079082,0.0025262546,0.00081056246,0.0005495957,0.00010181895,0.9870735,0.00044691656],"about_ca_topic_score_codex":0.0022144208,"about_ca_topic_score_gemma":0.00025843972,"teacher_disagreement_score":0.92361426,"about_ca_system_score_codex":0.0011800912,"about_ca_system_score_gemma":0.00085029745,"threshold_uncertainty_score":0.9998163},"labels":[],"label_agreement":null},{"id":"W7093121852","doi":"","title":"C052 | OUTCOMES OF IMETELSTAT THERAPY IN PATIENTS WITH RING SIDEROBLAST–NEGATIVE LOWER-RISK MYELODYSPLASTIC SYNDROMES FROM THE POOLED IMERGE STUDY POPULATIONS","year":2025,"lang":"en","type":"article","venue":"DOAJ (DOAJ: Directory of Open Access Journals)","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Sciences Centre; Sunnybrook Health Science Centre","funders":"","keywords":"Anemia; Myelodysplastic syndromes; Erythropoietin; Placebo; Phases of clinical research; Refractory (planetary science); Clinical trial","score_opus":0.14451314286955588,"score_gpt":0.5015166410672763,"score_spread":0.3570034981977205,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W7093121852","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9940742,0.0022006875,0.00006739089,0.00024806545,0.0002876493,0.0025504064,0.00019854192,0.00001922626,0.00035383584],"genre_scores_gemma":[0.998032,0.0011938136,0.00024139907,0.00016662473,0.000022155973,0.0001922486,0.000035354748,0.000042130367,0.00007431917],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99678683,0.0005163188,0.0010601681,0.0005053835,0.00080601574,0.00032530498],"domain_scores_gemma":[0.9959754,0.0018848475,0.0009415385,0.0005947979,0.0004658605,0.00013756724],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0005227731,0.00044971314,0.0014219409,0.0006702255,0.0002716684,0.00025340336,0.000762779,0.000075537595,0.002100833],"category_scores_gemma":[0.00058419607,0.00026236582,0.00019318015,0.0011876427,0.00013136867,0.0006948449,0.00034135417,0.00042135,0.0000049519767],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0014274059,0.0036694366,0.98500043,0.000022271493,0.0028977906,0.000033010292,0.00076122227,0.00036734657,0.00022339176,0.000027937542,0.0007339609,0.00483582],"study_design_scores_gemma":[0.0072219763,0.0003063591,0.98705554,0.0007086707,0.00068234093,7.8174133e-7,0.0004329352,0.000042441123,0.002315853,0.0009804622,0.000027641057,0.00022499825],"about_ca_topic_score_codex":0.0038810398,"about_ca_topic_score_gemma":0.0012056383,"teacher_disagreement_score":0.0057945703,"about_ca_system_score_codex":0.00015535539,"about_ca_system_score_gemma":0.00018420194,"threshold_uncertainty_score":0.99998283},"labels":[],"label_agreement":null},{"id":"W7093123291","doi":"","title":"B03 | PELABRESIB IN COMBINATION WITH RUXOLITINIB FOR JANUS KINASE INHIBITOR-NAIVE PATIENTS WITH MYELOFIBROSIS: 72-WEEK FOLLOW-UP WITH LONG-TERM EFFICACY OUTCOMES OF THE PHASE III MANIFEST-2","year":2025,"lang":"en","type":"article","venue":"DOAJ (DOAJ: Directory of Open Access Journals)","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Ruxolitinib; Myelofibrosis; Anemia; Adverse effect; Placebo; Bone marrow; Randomization; Hemoglobin; Phases of clinical research","score_opus":0.0935858793037303,"score_gpt":0.47228855912226564,"score_spread":0.37870267981853534,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W7093123291","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9921977,0.0011492356,0.00014762022,0.0005805653,0.00026036677,0.0048180046,0.00014327074,0.000021923735,0.00068131485],"genre_scores_gemma":[0.9977851,0.00030968033,0.00024625688,0.00038936688,0.00003684961,0.0005746901,0.000119448225,0.00006374429,0.00047484622],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99668366,0.00021536736,0.0010309226,0.00060886773,0.00097008265,0.0004911061],"domain_scores_gemma":[0.99635893,0.00066571357,0.001115356,0.00062776223,0.0010137743,0.00021848526],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00048093344,0.000550806,0.0014285529,0.0007338821,0.0002911727,0.000298409,0.0007791517,0.00011922508,0.0003030144],"category_scores_gemma":[0.00022731337,0.00031072868,0.00021619085,0.0011027672,0.00024995982,0.00084350497,0.00028412926,0.0003441287,0.0000014471512],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.012978915,0.0077808197,0.96872854,0.0003674193,0.0010862405,0.000061757695,0.00041644025,0.000024841283,0.00055518904,0.0002046003,0.0012948021,0.0065004136],"study_design_scores_gemma":[0.051964097,0.00096836616,0.9144602,0.004130692,0.0008451358,0.000008514208,0.00013063646,0.000011484637,0.026909882,0.00014195412,0.00011075333,0.00031827623],"about_ca_topic_score_codex":0.0004268018,"about_ca_topic_score_gemma":0.0004418886,"teacher_disagreement_score":0.054268353,"about_ca_system_score_codex":0.00025883538,"about_ca_system_score_gemma":0.0004625136,"threshold_uncertainty_score":0.9999345},"labels":[],"label_agreement":null},{"id":"W7099277464","doi":"","title":"National Library of Canada to","year":2015,"lang":"en","type":"article","venue":"","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"","score_opus":0.03192616190075579,"score_gpt":0.269730805945331,"score_spread":0.23780464404457521,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W7099277464","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.50060856,0.00004823149,0.0000164751,0.018957185,0.00007255521,0.00018332708,0.00001960736,0.0000141786,0.48007986],"genre_scores_gemma":[0.9808188,0.0000017985037,0.002862226,0.0038697408,0.0000501551,0.000016037331,0.000015921889,0.000004335456,0.012360995],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99954706,0.0000053009744,0.000078537654,0.00006309394,0.00024757633,0.00005840958],"domain_scores_gemma":[0.9996467,0.000028439079,0.000011188947,0.00004851355,0.000090886904,0.00017426573],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000026451758,0.000037944752,0.00008887398,0.000024676652,0.0000074862205,0.0000022780873,0.000016972122,0.000010377926,0.0006204474],"category_scores_gemma":[0.00005790374,0.00002586647,0.000011818063,0.0000672994,0.0000044862245,0.000026780039,0.000013509706,0.00001569286,0.000016362188],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000052340827,0.00011121537,0.13973635,0.000006953011,0.000040504638,0.000016681553,0.00007234553,0.000022356475,0.000034322322,0.012199072,0.84726113,0.00044670713],"study_design_scores_gemma":[0.0029659572,0.00090850645,0.3878884,0.00006413494,0.000032894684,0.000035240806,0.00027110634,0.00018492382,0.108045734,0.0009846485,0.49846208,0.00015638863],"about_ca_topic_score_codex":0.023991322,"about_ca_topic_score_gemma":0.051061194,"teacher_disagreement_score":0.4802102,"about_ca_system_score_codex":0.000056051045,"about_ca_system_score_gemma":0.0016104763,"threshold_uncertainty_score":0.982508},"labels":[],"label_agreement":null},{"id":"W7101391442","doi":"10.1136/bmj.320.7239.0/c","title":"Income inequality and mortality are not associated in Canada","year":2000,"lang":"en","type":"article","venue":"BMJ","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Metropolitan area; Inequality; Economic inequality; State (computer science); Population; Social inequality; Mortality rate","score_opus":0.03478081143199115,"score_gpt":0.31324519673532536,"score_spread":0.2784643853033342,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W7101391442","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99445796,0.00006349443,1.5647593e-7,0.0029479458,0.000034847908,0.00036466785,0.00006787715,0.000011768129,0.0020513074],"genre_scores_gemma":[0.9983551,0.000050167026,0.000025399668,0.001165913,0.000038094637,0.000062382256,0.000028737895,0.0000065127015,0.00026772052],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9991087,0.00007829819,0.00025627782,0.00017931817,0.0002171104,0.00016034905],"domain_scores_gemma":[0.9995561,0.00008705693,0.00005868543,0.0001584478,0.00003310494,0.00010655936],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00021316754,0.000101382895,0.00029864107,0.000021230364,0.000030992083,0.0000071706622,0.000022532984,0.000041476083,0.0005204559],"category_scores_gemma":[0.00013525345,0.00008143087,0.00002157601,0.00010232089,0.00001588323,0.000026647842,0.000011990327,0.00009636455,0.000009810321],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000042968866,0.00013470186,0.9969756,0.000020524376,0.000058230464,0.00023372042,0.000059100075,0.000005014993,0.000005954985,0.00002202938,0.000850241,0.0015919141],"study_design_scores_gemma":[0.0013732227,0.000046154102,0.99749607,0.00008879912,0.000028574803,0.0000069239836,0.000036429832,0.000103920764,0.00027170902,0.000032259133,0.0004344451,0.000081506776],"about_ca_topic_score_codex":0.7819498,"about_ca_topic_score_gemma":0.9626888,"teacher_disagreement_score":0.18073902,"about_ca_system_score_codex":0.00044142202,"about_ca_system_score_gemma":0.0003779091,"threshold_uncertainty_score":0.56986266},"labels":[],"label_agreement":null},{"id":"W7108479951","doi":"10.1182/blood-2025-484","title":"Safety and efficacy of the mutant calreticulin-specific monoclonal antibody INCA033989 as monotherapy or in combination with ruxolitinib in patients (pts) with myelofibrosis (MF): Preliminary results from dose escalation of two global Phase 1 studies","year":2025,"lang":"en","type":"article","venue":"Blood","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Ruxolitinib; Myelofibrosis; Anemia; Phases of clinical research; Monoclonal; Thrombopoietin; Clinical endpoint; Essential thrombocythemia","score_opus":0.015249921125697511,"score_gpt":0.3173373087987922,"score_spread":0.3020873876730947,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W7108479951","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99700046,0.00047523,0.000017894065,0.0005778311,0.000028867316,0.0014935646,0.00025468704,0.000009129307,0.0001423461],"genre_scores_gemma":[0.9983603,0.0005933502,0.00074872724,0.000045945122,0.000010993976,0.00004602702,0.00017293046,0.00000987534,0.000011861335],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99846715,0.00013132127,0.00058681093,0.0003527906,0.0003115634,0.00015035391],"domain_scores_gemma":[0.9988381,0.00041996717,0.00025489036,0.0002489746,0.00019643163,0.000041593816],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00013995141,0.00020587503,0.00051334105,0.00009797165,0.00005235212,0.000008564663,0.000060243314,0.000062266445,0.0000059962517],"category_scores_gemma":[0.00010464699,0.0001138049,0.00003685809,0.00049340294,0.0001719932,0.0000623735,0.000043859498,0.00010072007,3.4993974e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.065340675,0.012960807,0.9086344,0.000068906396,0.00043228175,0.000029859171,0.00202299,0.00006830718,0.0005168244,0.00072561996,0.0000069486955,0.009192364],"study_design_scores_gemma":[0.1201049,0.0062360913,0.8549553,0.001525309,0.00021094481,0.0000034911957,0.00026885056,0.00013953022,0.016345458,0.00010021794,0.000016579737,0.000093310475],"about_ca_topic_score_codex":0.00032387124,"about_ca_topic_score_gemma":0.00022651804,"teacher_disagreement_score":0.054764226,"about_ca_system_score_codex":0.000112494796,"about_ca_system_score_gemma":0.00013545266,"threshold_uncertainty_score":0.4640829},"labels":[],"label_agreement":null},{"id":"W7111615820","doi":"","title":"Diagnosis and evaluation of prognosis of myelofibrosis: A British Society for Haematology Guideline","year":2023,"lang":"en","type":"article","venue":"Oxford University Research Archive (ORA) (University of Oxford)","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Queen's University; Queen's University Belfast","keywords":"Guideline; Myelofibrosis; Health professionals; Primary care; Hematology; MEDLINE","score_opus":0.0658777972847748,"score_gpt":0.3278972594251324,"score_spread":0.26201946214035765,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W7111615820","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9908172,0.0002444927,0.00096536556,0.0027656148,0.00002707811,0.00230606,0.0011402145,0.000042480286,0.0016915093],"genre_scores_gemma":[0.9666419,0.011104123,0.021053696,0.000020284833,0.000023286597,0.000012480558,0.0005724169,0.000024763705,0.00054705935],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9973747,0.00031398542,0.00030567468,0.00052890903,0.0009824845,0.00049420435],"domain_scores_gemma":[0.99623394,0.0008960157,0.00026910266,0.00032080492,0.0020319542,0.00024819042],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0017102718,0.00018310815,0.00076121994,0.00064138265,0.0004273325,0.000010491398,0.00030755985,0.00015518788,0.00018592825],"category_scores_gemma":[0.00032831315,0.00023127536,0.00046755775,0.0010817861,0.001063232,0.00022640984,0.0004983917,0.00022195489,0.0000015810538],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0037484518,0.0026231944,0.7572654,0.0033693134,0.0033643618,0.00025249974,0.007798436,0.00015833828,0.0035346514,0.008063596,0.08238927,0.12743247],"study_design_scores_gemma":[0.02773218,0.007490864,0.7121132,0.0023813457,0.0032262297,0.00010121201,0.05380145,0.041826885,0.0065084253,0.0058303764,0.1382462,0.0007416248],"about_ca_topic_score_codex":0.001150699,"about_ca_topic_score_gemma":0.0014460043,"teacher_disagreement_score":0.12669085,"about_ca_system_score_codex":0.00016934761,"about_ca_system_score_gemma":0.0005751474,"threshold_uncertainty_score":0.94311357},"labels":[],"label_agreement":null},{"id":"W7112798601","doi":"","title":"The management of myelofibrosis: A British Society for Haematology Guideline","year":2023,"lang":"en","type":"article","venue":"Research Portal (Queen's University Belfast)","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Queen's University; Queen's University Belfast","keywords":"Guideline; MEDLINE; Work (physics); Legislation","score_opus":0.03212846401344273,"score_gpt":0.32777244170472347,"score_spread":0.29564397769128076,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W7112798601","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9086388,0.00039205624,0.00074408174,0.056935634,0.0002652171,0.0067422064,0.00074362836,0.00037903205,0.02515937],"genre_scores_gemma":[0.8791877,0.014400448,0.008129701,0.00020269128,0.00016762842,0.00015593787,0.00078944385,0.000075879085,0.09689054],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99784225,0.0000909442,0.00030975664,0.0004050936,0.00069280376,0.0006591478],"domain_scores_gemma":[0.9982519,0.0003702627,0.000090553396,0.00037541107,0.00070443325,0.00020741881],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00097512436,0.00014367036,0.00036955904,0.00014504614,0.00071296707,0.000032686272,0.00024120568,0.000110673514,0.00014899144],"category_scores_gemma":[0.000058677146,0.00012716874,0.00038686045,0.0008293904,0.00037650415,0.000079671096,0.0003309382,0.00022064935,0.000044327742],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0009072563,0.0008891109,0.021020293,0.001251101,0.004013284,0.0050280252,0.00045292312,0.000027156526,0.00012692463,0.08580918,0.86426055,0.01621418],"study_design_scores_gemma":[0.008918528,0.0019432507,0.090776294,0.0009427974,0.00061149045,0.00012975624,0.01883787,0.0006796647,0.0022089898,0.0012907952,0.8732645,0.00039608034],"about_ca_topic_score_codex":0.00058879226,"about_ca_topic_score_gemma":0.00007551319,"teacher_disagreement_score":0.08451838,"about_ca_system_score_codex":0.00012666447,"about_ca_system_score_gemma":0.00021060108,"threshold_uncertainty_score":0.5483638},"labels":[],"label_agreement":null},{"id":"W7117694170","doi":"10.1038/s41408-025-01444-0","title":"Effect of prior therapy on the clinical activity of imetelstat in patients with transfusion-dependent, ESA-relapsed or -refractory/-ineligible LR-MDS","year":2025,"lang":"en","type":"article","venue":"Blood Cancer Journal","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Sciences Centre; Sunnybrook Health Science Centre","funders":"","keywords":"Hematology; Clinical trial; MEDLINE; Chemotherapy; Text mining","score_opus":0.019761591039750934,"score_gpt":0.34972406755008556,"score_spread":0.3299624765103346,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W7117694170","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9970745,0.00053435465,0.000012986507,0.0007347273,0.0002435401,0.0011312541,0.00002768275,0.0000061733504,0.00023479729],"genre_scores_gemma":[0.99520475,0.0042585665,0.000035174216,0.0002191722,0.000071391325,0.00009166877,0.0000018459895,0.000017390708,0.00010001713],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99804306,0.000464652,0.0005410621,0.0002375056,0.0005007223,0.00021301722],"domain_scores_gemma":[0.99799603,0.0011448521,0.0003205116,0.00025580268,0.00018768225,0.000095143245],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00080700376,0.00022394507,0.000727188,0.00016016295,0.000087636945,0.000013844843,0.00012157455,0.00010087694,0.0003326914],"category_scores_gemma":[0.00014151401,0.00009734578,0.00019348437,0.00030032385,0.000086464024,0.00006118524,0.000014730959,0.0005606652,0.0000011143286],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.025087968,0.0041029295,0.8681308,0.000080633945,0.0009980189,0.000026018404,0.00017179076,0.000018363917,0.0007865455,0.00001044562,0.0001786029,0.100407876],"study_design_scores_gemma":[0.03858728,0.017155048,0.76847696,0.0011257854,0.00048056635,0.0000063625503,0.000013423098,0.000009237654,0.17386949,0.000011558396,0.0001697947,0.00009447685],"about_ca_topic_score_codex":0.00018915437,"about_ca_topic_score_gemma":0.00020624307,"teacher_disagreement_score":0.17308295,"about_ca_system_score_codex":0.000088919114,"about_ca_system_score_gemma":0.000563289,"threshold_uncertainty_score":0.39696455},"labels":[],"label_agreement":null},{"id":"W7133016465","doi":"","title":"TEL-JAK2 chromosomal translocations and the PI 3&apos; kinase and PKB signalling pathway","year":2000,"lang":"en","type":"dissertation","venue":"TSpace","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Chromosomal translocation; Signalling; Signal transduction; Kinase; Hedgehog signaling pathway; Protein kinase A; Proto-Oncogenes; MAP kinase kinase kinase","score_opus":0.022520160607627484,"score_gpt":0.32905080967813666,"score_spread":0.3065306490705092,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W7133016465","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96895903,0.011566389,0.00001532992,0.0031953591,0.000101435704,0.0012527052,0.000026688347,0.000049318845,0.014833756],"genre_scores_gemma":[0.9792124,0.0051978407,0.00026871092,0.0002703347,0.00020636454,0.0003726496,0.0006539845,0.000050401086,0.013767339],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9987859,0.00007844238,0.00025208277,0.00040877442,0.00025131356,0.00022346857],"domain_scores_gemma":[0.99916613,0.00026403583,0.0001014274,0.00022538491,0.00008800201,0.00015501615],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00012964694,0.00033665186,0.0005209479,0.00008621579,0.00028346473,0.000068326146,0.000053486903,0.0001989895,0.00049983774],"category_scores_gemma":[0.00003866241,0.00021733734,0.00010233274,0.00011992352,0.00011882298,0.000040862258,0.0000064480478,0.00031443065,0.000024023526],"study_design_candidate":"qualitative","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.02175071,0.0047657834,0.013833285,0.005911156,0.006219508,0.0016449561,0.4141973,0.0001337085,0.02975616,0.034737863,0.0065603633,0.4604892],"study_design_scores_gemma":[0.0947276,0.0070446455,0.32341063,0.013516981,0.015914671,0.0011645859,0.07259692,0.0036413816,0.30367148,0.0037605315,0.1550188,0.005531764],"about_ca_topic_score_codex":0.0002273875,"about_ca_topic_score_gemma":0.00063408917,"teacher_disagreement_score":0.45495746,"about_ca_system_score_codex":0.000042485022,"about_ca_system_score_gemma":0.00019658,"threshold_uncertainty_score":0.8862759},"labels":[],"label_agreement":null},{"id":"W7133016467","doi":"","title":"Association of Frailty with Clinical Outcomes in Myeloproliferative Neoplasms: A Population-based Study from Ontario, Canada","year":2022,"lang":"","type":"dissertation","venue":"TSpace","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Institute of Health Services and Policy Research","funders":"","keywords":"Proportional hazards model; Hazard ratio; Thrombosis; Frailty Index; Risk of mortality; Epidemiology; Confidence interval; Stroke (engine)","score_opus":0.02705204463043093,"score_gpt":0.3583822559445256,"score_spread":0.3313302113140947,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W7133016467","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99015355,0.0002137184,0.0000048696397,0.0012778981,0.0014365708,0.0057393536,0.0004943918,0.000029746743,0.0006498824],"genre_scores_gemma":[0.97464484,0.000040918356,0.00037377788,0.00047050352,0.00012964076,0.0015230267,0.007389947,0.00012167032,0.015305662],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9902927,0.00154096,0.0027430663,0.0016587089,0.0029872216,0.000777339],"domain_scores_gemma":[0.98990613,0.004974992,0.003032053,0.00091777206,0.00077364023,0.00039538465],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0010590529,0.0012214262,0.0037531701,0.00041852845,0.000377619,0.00006436688,0.0003257043,0.0005684399,0.011098364],"category_scores_gemma":[0.0013152047,0.0010466094,0.00040280333,0.0007840393,0.000034037253,0.00012469455,0.000069235626,0.002099142,0.0000110784495],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.0040938333,0.0075646653,0.9509487,0.00009460801,0.004858045,0.00033008656,0.0298677,0.0013781607,0.000002911272,0.000020954187,0.0005500925,0.00029024473],"study_design_scores_gemma":[0.016053924,0.0041660783,0.9376446,0.0004928384,0.0025229482,6.399047e-7,0.0375002,0.00027357784,0.00013565244,0.000013543185,0.00041937624,0.0007766088],"about_ca_topic_score_codex":0.9966791,"about_ca_topic_score_gemma":0.99986905,"teacher_disagreement_score":0.015508715,"about_ca_system_score_codex":0.0111186635,"about_ca_system_score_gemma":0.016832747,"threshold_uncertainty_score":0.99919844},"labels":[],"label_agreement":null},{"id":"W7160089738","doi":"10.5281/zenodo.17533192","title":"Фізико-хімічний стан мембран лейкоцитів крові хворих на гострий ішемічний інсульт в залежності від тяжкості захворювання","year":2025,"lang":"uk","type":"article","venue":"Zenodo (CERN European Organization for Nuclear Research)","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Stroke (engine); Acute stroke; MEDLINE; Disease","score_opus":0.0317154080035808,"score_gpt":0.2834336718775146,"score_spread":0.2517182638739338,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W7160089738","genre_codex":"other","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.08837338,0.0066760504,0.0025306502,0.024544226,0.0025577615,0.0063775848,0.0021270458,0.0027961887,0.8640171],"genre_scores_gemma":[0.93448013,0.0045278026,0.0006181051,0.0023996755,0.001343498,0.00000285702,0.0055446047,0.0040244116,0.04705891],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99143356,0.0013982514,0.0014981023,0.0021549007,0.0015951148,0.0019200499],"domain_scores_gemma":[0.9936976,0.00031132656,0.0005083829,0.0021707113,0.002199781,0.0011122441],"candidate_categories":["metaepi_narrow","sts","scholarly_communication","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.0015349722,0.00110342,0.0013235001,0.0012330873,0.005574815,0.0021047457,0.0020555155,0.0005495439,0.062341806],"category_scores_gemma":[0.002502849,0.0010976406,0.00049479015,0.002672385,0.00078807224,0.0005740564,0.002995931,0.0015103167,0.042859454],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0011890297,0.0037393128,0.0010634587,0.0012105405,0.0020949927,0.0007398249,0.0034259157,0.000079734455,0.0026266314,0.054287076,0.76910436,0.1604391],"study_design_scores_gemma":[0.0059750415,0.0017701103,0.010901054,0.0011602087,0.0007169624,0.0002959545,0.0013336842,0.000669983,0.004439553,0.00072668307,0.97109956,0.0009112265],"about_ca_topic_score_codex":0.00019682311,"about_ca_topic_score_gemma":0.000009715653,"teacher_disagreement_score":0.84610677,"about_ca_system_score_codex":0.0014536701,"about_ca_system_score_gemma":0.00017195471,"threshold_uncertainty_score":0.99914736},"labels":[],"label_agreement":null},{"id":"W7160195591","doi":"10.5281/zenodo.17533191","title":"Фізико-хімічний стан мембран лейкоцитів крові хворих на гострий ішемічний інсульт в залежності від тяжкості захворювання","year":2025,"lang":"uk","type":"article","venue":"Zenodo (CERN European Organization for Nuclear Research)","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Stroke (engine); Acute stroke; MEDLINE; Disease","score_opus":0.0317154080035808,"score_gpt":0.2834336718775146,"score_spread":0.2517182638739338,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W7160195591","genre_codex":"other","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.08837338,0.0066760504,0.0025306502,0.024544226,0.0025577615,0.0063775848,0.0021270458,0.0027961887,0.8640171],"genre_scores_gemma":[0.93448013,0.0045278026,0.0006181051,0.0023996755,0.001343498,0.00000285702,0.0055446047,0.0040244116,0.04705891],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99143356,0.0013982514,0.0014981023,0.0021549007,0.0015951148,0.0019200499],"domain_scores_gemma":[0.9936976,0.00031132656,0.0005083829,0.0021707113,0.002199781,0.0011122441],"candidate_categories":["metaepi_narrow","sts","scholarly_communication","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.0015349722,0.00110342,0.0013235001,0.0012330873,0.005574815,0.0021047457,0.0020555155,0.0005495439,0.062341806],"category_scores_gemma":[0.002502849,0.0010976406,0.00049479015,0.002672385,0.00078807224,0.0005740564,0.002995931,0.0015103167,0.042859454],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0011890297,0.0037393128,0.0010634587,0.0012105405,0.0020949927,0.0007398249,0.0034259157,0.000079734455,0.0026266314,0.054287076,0.76910436,0.1604391],"study_design_scores_gemma":[0.0059750415,0.0017701103,0.010901054,0.0011602087,0.0007169624,0.0002959545,0.0013336842,0.000669983,0.004439553,0.00072668307,0.97109956,0.0009112265],"about_ca_topic_score_codex":0.00019682311,"about_ca_topic_score_gemma":0.000009715653,"teacher_disagreement_score":0.84610677,"about_ca_system_score_codex":0.0014536701,"about_ca_system_score_gemma":0.00017195471,"threshold_uncertainty_score":0.99914736},"labels":[],"label_agreement":null},{"id":"W84221740","doi":"10.1182/blood.v122.21.661.661","title":"Efficacy and Safety Of Fedratinib (SAR302503/TG101348) In Patients With Intermediate- Or High-Risk Myelofibrosis (MF), Post-Polycythemia Vera (PV) MF, Or Post-Essential Thrombocythemia (ET) MF Previously Treated With Ruxolitinib: Interim Results From a Phase II Study (JAKARTA-2)","year":2013,"lang":"en","type":"article","venue":"Blood","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":16,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Ruxolitinib; Medicine; Myelofibrosis; Internal medicine; Clinical endpoint; Polycythemia vera; Essential thrombocythemia; Phases of clinical research; Gastroenterology; Clinical trial; Bone marrow","score_opus":0.00992980083170512,"score_gpt":0.2635124977117351,"score_spread":0.25358269688003,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W84221740","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99072635,0.00007249322,0.0000048395736,0.00030538175,0.00006311927,0.00645944,0.002161592,0.0001082814,0.00009850349],"genre_scores_gemma":[0.99585193,0.00013205143,0.00094304036,0.00020323879,0.000103841696,0.000636832,0.0018606271,0.0001232057,0.00014522551],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9956284,0.0003575195,0.0013834337,0.0012187507,0.0007214174,0.0006904816],"domain_scores_gemma":[0.99635345,0.00087787124,0.0007670543,0.00089142274,0.0006691199,0.0004410962],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00023229077,0.00086931133,0.0016741782,0.00027954957,0.0002185145,0.000113920774,0.0002341868,0.00021733358,0.0005571568],"category_scores_gemma":[0.00053789647,0.0004910501,0.000112888294,0.00046195177,0.00029038097,0.0003775269,0.00023112193,0.00047954643,0.000025670342],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.19840413,0.060697276,0.7049523,0.00018345934,0.003913534,0.00039300957,0.021642003,0.0000060556154,0.002997325,0.000007889089,0.00019628783,0.006606725],"study_design_scores_gemma":[0.1791366,0.07592501,0.7161519,0.0013628935,0.0018420495,0.000026225951,0.0014674433,0.000019446607,0.023559805,0.0000028920942,0.000022395408,0.00048335906],"about_ca_topic_score_codex":0.0061759595,"about_ca_topic_score_gemma":0.002223491,"teacher_disagreement_score":0.020562481,"about_ca_system_score_codex":0.00013720528,"about_ca_system_score_gemma":0.00042853673,"threshold_uncertainty_score":0.99975413},"labels":[],"label_agreement":null},{"id":"W96046762","doi":"10.4137/cmt.s9566","title":"Review of Treatment Options for Myelofibrosis: Focus on Ruxolitinib","year":2013,"lang":"en","type":"article","venue":"Clinical Medicine Insights Therapeutics","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Ruxolitinib; Myelofibrosis; Polycythaemia; Medicine; Food and drug administration; Clinical trial; Janus kinase; Janus kinase 2; Internal medicine; Pharmacology; Bone marrow","score_opus":0.15977028268133486,"score_gpt":0.4327420877786614,"score_spread":0.27297180509732655,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W96046762","genre_codex":"review","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.28784496,0.3647003,0.0010856655,0.2743152,0.003007551,0.026074855,0.00016481844,0.00041188556,0.042394776],"genre_scores_gemma":[0.5271199,0.41870755,0.003402041,0.04502639,0.0017942014,0.0024750337,0.0001912273,0.000093215975,0.0011904696],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9973589,0.00017144604,0.0014292743,0.00046318115,0.0002748898,0.0003022866],"domain_scores_gemma":[0.9956258,0.002403573,0.0003679517,0.0006880891,0.0005829849,0.00033161486],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00028752824,0.0003590624,0.0013947284,0.00010800274,0.000091814516,0.0000069313096,0.000112749156,0.00018458809,0.00055700145],"category_scores_gemma":[0.00039367707,0.00019299526,0.0004547017,0.000199461,0.0003707437,0.000047660622,0.00001792357,0.000180863,0.00012598645],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0014988757,0.01488151,0.018890895,0.007568026,0.005868421,0.00003071299,0.0013112823,0.0000029030164,0.0018803129,0.0835445,0.055021953,0.80950063],"study_design_scores_gemma":[0.024410311,0.0950009,0.044477504,0.043404553,0.0056543644,0.000047282574,0.00030793552,0.00033283056,0.009847821,0.018047111,0.7577847,0.0006846518],"about_ca_topic_score_codex":0.00004327562,"about_ca_topic_score_gemma":0.0000054982484,"teacher_disagreement_score":0.80881596,"about_ca_system_score_codex":0.00013800967,"about_ca_system_score_gemma":0.00019984951,"threshold_uncertainty_score":0.7870118},"labels":[],"label_agreement":null}]}